false	2	16	the dt fluoroquinolones nn are vbp a dt rapidly rb growing vbg class nn of inpos antibiotics nn with inpos a dt broad jj spectrum nn of inpos activity nn against inpos gram_negative jj and cc some dt gram_positive jj aerobic jj bacteria nns
false	24	44	in inpos order nn to topos provide vb information nn for inpos the dt appropriate jj package nn insert nn labeling nn of inpos progestin_only_oral_contraceptives nn in inpos the dt us nnp a dt comprehensive jj review nn was vbd made vbn of inpos norgestrel nn and cc norethindrone nn with inpos the dt clinical jj differences nns indicated vbd where wrb applicable jj
false	24	48	in inpos order nn to topos provide vb information nn for inpos the dt appropriate jj package nn insert nn labeling nn of inpos progestin_only_oral_contraceptives nn in inpos the dt us nnp a dt comprehensive jj review nn was vbd made vbn of inpos norgestrel nn and cc norethindrone nn with inpos the dt clinical jj differences nns indicated vbd where wrb applicable jj
false	24	44	in inpos order nn to topos provide vb information nn for inpos the dt appropriate jj package nn insert nn labeling nn of inpos poc nn in inpos the dt us nnp a dt comprehensive jj review nn was vbd made vbn of inpos norgestrel nn and cc norethindrone nn with inpos the dt clinical jj differences nns indicated vbd where wrb applicable jj
false	24	48	in inpos order nn to topos provide vb information nn for inpos the dt appropriate jj package nn insert nn labeling nn of inpos poc nn in inpos the dt us nnp a dt comprehensive jj review nn was vbd made vbn of inpos norgestrel nn and cc norethindrone nn with inpos the dt clinical jj differences nns indicated vbd where wrb applicable jj
false	44	48	in inpos order nn to topos provide vb information nn for inpos the dt appropriate jj package nn insert nn labeling nn of inpos progestin_only_oral_contraceptives nns in inpos the dt us nnp a dt comprehensive jj review nn was vbd made vbn of inpos norgestrel nn and cc norethindrone nn with inpos the dt clinical jj differences nns indicated vbd where wrb applicable jj
false	6	20	antimicrobial jj activity nn of inpos ganoderma_lucidum_extract nn alone rb and cc in inpos combination nn with inpos some dt antibiotics nn
false	16	26	to topos investigate vb the dt effects nns of inpos antimicrobial jj combinations nns of inpos gl nn with inpos num cd kinds nns of inpos antibiotics nn the dt fractional jj inhibitory jj concentration nn index nn was vbd determined vbn by inpos checkerboard nn assay nn for inpos each dt strain nn
false	16	26	to topos investigate vb the dt effects nns of inpos antimicrobial jj combinations nns of inpos gl nn with inpos num cd kinds nns of inpos ampicillin nn the dt fractional jj inhibitory jj concentration nn index nn was vbd determined vbn by inpos checkerboard nn assay nn for inpos each dt strain nn
false	16	26	to topos investigate vb the dt effects nns of inpos antimicrobial jj combinations nns of inpos gl nn with inpos num cd kinds nns of inpos cefazolin nn the dt fractional jj inhibitory jj concentration nn index nn was vbd determined vbn by inpos checkerboard nn assay nn for inpos each dt strain nn
false	16	26	to topos investigate vb the dt effects nns of inpos antimicrobial jj combinations nns of inpos gl nn with inpos num cd kinds nns of inpos oxytetracycline nn the dt fractional jj inhibitory jj concentration nn index nn was vbd determined vbn by inpos checkerboard nn assay nn for inpos each dt strain nn
false	16	26	to topos investigate vb the dt effects nns of inpos antimicrobial jj combinations nns of inpos gl nn with inpos num cd kinds nns of inpos chloramphenicol nn the dt fractional jj inhibitory jj concentration nn index nn was vbd determined vbn by inpos checkerboard nn assay nn for inpos each dt strain nn
effect	8	14	the dt antimicrobial jj combinations nns of inpos gl nn with inpos num cd antibiotics nn resulted vbd in inpos additive jj effect nn in inpos most jjs instances nns synergism nn in inpos num cd instances nns and cc antagonism nn in inpos num cd instances nns
effect	8	16	synergism nn was vbd observed vbn when wrb gl nn was vbd combined vbn with inpos cefazolin nn against inpos bacillus nnp subtilis nn and cc klebsiella nnp oxytoca nn
false	24	90	on inpos the dt basis nn of inpos the dt estimated vbn number nn of inpos regular jj users nns of inpos intravenous jj amphetamine nn in inpos ontario nnp the dt mortality nn rate nn in inpos such jj users nns is vbz at inpos least jjs num cd times nns as rb high jj as inpos in inpos the dt general jj population nn of inpos the dt same jj age nn and cc is vbz comparable jj to topos that dt in inpos alcoholics nns and cc heroin nn addicts nns
false	10	34	however rb the dt absolute jj number nn of inpos alcohol nn related jj deaths nns is vbz far rb greater jjr than inpos the dt number nn of inpos deaths nns in inpos amphetamine nn or cc heroin nn users nns
false	10	38	however rb the dt absolute jj number nn of inpos alcohol nn related jj deaths nns is vbz far rb greater jjr than inpos the dt number nn of inpos deaths nns in inpos amphetamine nn or cc heroin nn users nns
false	32	36	however rb the dt absolute jj number nn of inpos alcohol_related jj deaths nns is vbz far rb greater jjr than inpos the dt number nn of inpos deaths nns in inpos amphetamine nn or cc heroin nn users nns
false	18	30	differential jj regulation nn of inpos tyrosine nn phosphorylation nn in inpos tumor nn cells nns by inpos contortrostatin nn a dt homodimeric jj disintegrin nn monomeric jj disintegrins nns echistatin nn flavoridin nn
false	18	32	differential jj regulation nn of inpos tyrosine nn phosphorylation nn in inpos tumor nn cells nns by inpos contortrostatin nn a dt homodimeric jj disintegrin nn monomeric jj disintegrins nns echistatin nn flavoridin nn
false	30	32	differential jj regulation nn of inpos tyrosine nn phosphorylation nn in inpos tumor nn cells nns by inpos contortrostatin nn a dt homodimeric jj disintegrin nn monomeric jj disintegrins nns echistatin nn flavoridin nn
false	6	22	the dt homodimeric jj disintegrin nn contortrostatin nn was vbd compared vbn directly rb to topos the dt monomeric jj disintegrins nns echistatin nn and cc flavoridin nn for inpos the dt ability nn to topos affect vb protein nn tyrosine nn phosphorylation nn in inpos tumor nn cells nns
false	6	26	the dt homodimeric jj disintegrin nn contortrostatin nn was vbd compared vbn directly rb to topos the dt monomeric jj disintegrins nns echistatin nn and cc flavoridin nn for inpos the dt ability nn to topos affect vb protein nn tyrosine nn phosphorylation nn in inpos tumor nn cells nns
false	22	26	the dt homodimeric jj disintegrin nn contortrostatin nn was vbd compared vbn directly rb to topos the dt monomeric jj disintegrins nns echistatin nn and cc flavoridin nn for inpos the dt ability nn to topos affect vb protein nn tyrosine nn phosphorylation nn in inpos tumor nn cells nns
effect	0	34	echistatin nn alone rb had vbd no dt effect nn on inpos tyrosine nn phosphorylation nn in inpos t24 nn cells nns but cc dose_dependently rb inhibits vbz the dt effects nns of inpos contortrostatin nn when wrb both dt are vbp added vbn simultaneously rb
effect	0	28	flavoridin nn alone rb was vbd found vbn to topos have vb no dt effect nn on inpos cas nn but cc can md completely rb block vb contortrostatin nn induced jj phosphorylation nn of inpos this dt protein nn in inpos mda_mb_num nn cells nns
false	0	26	diethyl_pyrocarbonate nn at inpos ph nn float cd was vbd used vbn to topos chemically rb modify vb exposed vbn histidine nn residues nns on inpos toxin_a nn
false	4	8	modification nn of inpos toxin_a nn with inpos diethyl_pyrocarbonate nn abolished vbd both cc its prp cytotoxic jj activity nn and cc the dt ability nn of inpos the dt toxin nn to topos bind vb zn_sepharose nn gel nn
false	4	10	treatment nn of inpos toxin_a nn with inpos lrb_c nn rrb_hyph_diethyl_pyrocarbonate nn revealed vbd concentration nn dependent jj labelling nn of inpos histidine nn residues nns on inpos the dt toxin nn molecules nns
false	6	16	the dt effects nns of inpos diethyl_pyrocarbonate nn could md be vb reversed vbn by inpos hydroxylamine nn treatment nn
false	6	14	exposed vbn histidines nns on inpos toxin_a nn are vbp available jj for inpos zinc nn chelation nn and cc these dt have vbp been vbn exploited vbn in inpos the dt development nn of inpos a dt novel jj purification nn protocol nn for inpos toxin_a nn using vbg zinc_chelating jj chromatography nn
false	6	14	exposed vbn histidines nns on inpos toxin_a nn are vbp available jj for inpos zinc nn chelation nn and cc these dt have vbp been vbn exploited vbn in inpos the dt development nn of inpos a dt novel jj purification nn protocol nn for inpos toxin_a nn using vbg zinc nn chelating jj chromatography nn
false	14	6	exposed vbn histidines nns on inpos toxin_a nn are vbp available jj for inpos zinc nn chelation nn and cc these dt have vbp been vbn exploited vbn in inpos the dt development nn of inpos a dt novel jj purification nn protocol nn for inpos toxin_a nn using vbg zinc_chelating jj chromatography nn
false	6	14	exposed vbn histidines nns on inpos toxin_a nn are vbp available jj for inpos zinc nn chelation nn and cc these dt have vbp been vbn exploited vbn in inpos the dt development nn of inpos a dt novel jj purification nn protocol nn for inpos toxin_a nn using vbg zinc nn chelating jj chromatography nn
false	12	16	note nnp dissolution nn of inpos aerosol nn particles nns of inpos budesonide nn in inpos survanta nn a dt model nn lung_surfactant nn
false	12	22	note nnp dissolution nn of inpos aerosol nn particles nns of inpos budesonide nn in inpos survanta nnp a dt model nn lung_surfactant nn
false	16	22	note nnp dissolution nn of inpos aerosol nn particles nns of inpos budesonide nn in inpos survanta nn a dt model nn lung_surfactant nn
false	8	18	the dt effect nn of inpos a dt pulmonary_surfactant nn extract nn from inpos bovine jj lung nn survanta nn on inpos the dt dissolution nn rate nn of inpos aerosol nn particles nns of inpos budesonide nn was vbd determined vbn
false	8	36	the dt effect nn of inpos a dt pulmonary_surfactant nn extract nn from inpos bovine jj lung nn survanta nnp on inpos the dt dissolution nn rate nn of inpos aerosol nn particles nns of inpos budesonide nn was vbd determined vbn
false	18	36	the dt effect nn of inpos a dt pulmonary_surfactant jj extract nn from inpos bovine jj lung nn survanta nn on inpos the dt dissolution nn rate nn of inpos aerosol nn particles nns of inpos budesonide nn was vbd determined vbn
false	6	16	aerosol nn particles nns of inpos budesonide nn were vbd generated vbn from inpos an dt ethanol nn solution nn dried vbn collected vbn by inpos a dt cascade nn impactor nn for inpos characterization nn or cc by inpos a dt liquid jj impinger nn for inpos dissolution nn experiments nns
false	0	14	survanta nn increased vbd the dt extent nn of inpos dissolution nn of inpos budesonide nn in inpos proportion nn to topos the dt added vbn concentration nn which wdt was vbd also rb verified vbn by inpos equilibrium nn solubilization nn studies nns
false	0	22	survanta nn also rb increased vbd rate nn of inpos dissolution nn in inpos a dt manner nn similar jj to topos sodium_dodecyl_sulfate nn
false	10	36	analysis nn of inpos the dt concentration nn of inpos budesonide nn following vbg ultracentrifugation nn indicated vbd that inpos there ex is vbz rapid jj equilibration nn of inpos budesonide nn between inpos the dt survanta nn and cc aqueous jj phase nn
false	10	36	analysis nn of inpos the dt concentration nn of inpos budesonide nn following vbg ultracentrifugation nn indicated vbd that inpos there ex is vbz rapid jj equilibration nn of inpos budesonide nn between inpos the dt survanta nn and cc aqueous jj phase nn
effect	14	72	using vbg in fw situ fw hybridization nn we prp observed vbd that inpos meth nn caused vbd a dt rapid jj and cc transient jj dose_dependent jj increase nn in inpos arc nn mrna nn level nn in inpos the dt striatum nn and cc cortex nn that wdt was vbd abolished vbn by inpos pretreatment nn with inpos the dt specific jj dopamine nn d1 nn receptor nn antagonist nn sch_num nn but cc not rb by inpos an dt atypical_neuroleptic jj clozapine nn
false	14	82	using vbg in fw situ fw hybridization nn we prp observed vbd that inpos meth nn caused vbd a dt rapid jj and cc transient jj dose_dependent jj increase nn in inpos arc nn mrna nn level nn in inpos the dt striatum nn and cc cortex nn that wdt was vbd abolished vbn by inpos pretreatment nn with inpos the dt specific jj dopamine nn d1 nn receptor nn antagonist nn sch_num nn but cc not rb by inpos an dt atypical_neuroleptic nn clozapine nn
false	14	84	using vbg in fw situ fw hybridization nn we prp observed vbd that inpos meth nn caused vbd a dt rapid jj and cc transient jj dose_dependent jj increase nn in inpos arc nn mrna nn level nn in inpos the dt striatum nn and cc cortex nn that wdt was vbd abolished vbn by inpos pretreatment nn with inpos the dt specific jj dopamine nn d1 nn receptor nn antagonist nn sch_num nn but cc not rb by inpos an dt atypical_neuroleptic jj clozapine nn
false	72	82	using vbg in fw situ fw hybridization nn we prp observed vbd that inpos meth nn caused vbd a dt rapid jj and cc transient jj dose_dependent jj increase nn in inpos arc nn mrna nn level nn in inpos the dt striatum nn and cc cortex nn that wdt was vbd abolished vbn by inpos pretreatment nn with inpos the dt specific jj dopamine nn d1 nn receptor nn antagonist nn sch_num nn but cc not rb by inpos an dt atypical_neuroleptic nn clozapine nn
false	72	84	using vbg in fw situ fw hybridization nn we prp observed vbd that inpos meth nn caused vbd a dt rapid jj and cc transient jj dose_dependent jj increase nn in inpos arc nn mrna nn level nn in inpos the dt striatum nn and cc cortex nn that wdt was vbd abolished vbn by inpos pretreatment nn with inpos the dt specific jj dopamine nn d1 nn receptor nn antagonist nn sch_num nn but cc not rb by inpos an dt atypical_neuroleptic jj clozapine nn
false	82	84	using vbg in fw situ fw hybridization nn we prp observed vbd that inpos meth nn caused vbd a dt rapid jj and cc transient jj dose_dependent jj increase nn in inpos arc nn mrna nn level nn in inpos the dt striatum nn and cc cortex nn that wdt was vbd abolished vbn by inpos pretreatment nn with inpos the dt specific jj dopamine nn d1 nn receptor nn antagonist nn sch_num nn but cc not rb by inpos an dt atypical_neuroleptic nn clozapine nn
false	6	10	the dt effects nns of inpos dcg_iv nn and cc l_ccg_num nn upon inpos phencyclidine nn induced jj locomotion nn and cc behavioral jj changes nns in inpos mice nns
false	6	14	the dt effects nns of inpos dcg_iv nn and cc l_ccg_num nn upon inpos phencyclidine nn induced jj locomotion nn and cc behavioral jj changes nns in inpos mice nns
false	6	14	the dt effects nns of inpos dcg_iv nn and cc l_ccg_num nn upon inpos pcp nn induced jj locomotion nn and cc behavioral jj changes nns in inpos mice nns
false	10	14	the dt effects nns of inpos dcg_iv nn and cc l_ccg_num nn upon inpos phencyclidine nn induced jj locomotion nn and cc behavioral jj changes nns in inpos mice nns
false	10	14	the dt effects nns of inpos dcg_iv nn and cc l_ccg_num nn upon inpos pcp nn induced jj locomotion nn and cc behavioral jj changes nns in inpos mice nns
false	16	20	then rb the dt effects nns of inpos metabotropic jj glutamate nn receptor nn agonists nns dcg_iv nn and cc l_ccg_num nn on inpos the dt above jj behavioral jj changes nns induced vbn by inpos pcp nn were vbd found vbn
false	16	36	then rb the dt effects nns of inpos metabotropic jj glutamate nn receptor nn agonists nns dcg_iv nn and cc l_ccg_num nn on inpos the dt above jj behavioral jj changes nns induced vbn by inpos pcp nn were vbd found vbn
false	20	36	then rb the dt effects nns of inpos metabotropic jj glutamate nn receptor nn agonists nns dcg_iv nn and cc l_ccg_num nn on inpos the dt above jj behavioral jj changes nns induced vbn by inpos pcp nn were vbd found vbn
effect	6	22	the dt effects nns of inpos dcg_iv nn were vbd very rb strong jj and cc completely rb depressed vbd the dt pcp nn induced jj hyperlocomotion nn
false	8	28	behavioral jj responses nns to topos repeated vbn cocaine nn exposure nn in inpos mice nns selectively rb bred vbn for inpos differential jj sensitivity nn to topos pentobarbital nn
false	26	60	mice nns from inpos the dt 20th jj generation nn of inpos num cd lines nns divergently rb selected vbn for inpos response nn to topos pentobarbital nn induced jj sedation nn times nns lrb_long_sedation nn time nn short jj sedation nn time nn and cc randomly rb bred vbd control nn rrb_were vbd used vbn to topos study vb cocaine nn induced jj behavioral nn sensitization nn
false	0	4	num_methoxycoronaridine nn and cc ibogaine nn comparison nn of inpos antiaddictive jj efficacy nn toxicity nn mechanisms nns of inpos action nn
false	0	4	num_mc nn and cc ibogaine nn comparison nn of inpos antiaddictive jj efficacy nn toxicity nn mechanisms nns of inpos action nn
false	2	4	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	2	16	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	2	20	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	2	32	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	2	36	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	4	16	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	4	20	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	4	32	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	4	36	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	16	20	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	16	32	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	16	36	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	20	32	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	20	36	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	32	36	like inpos ibogaine nn num_mc nn decreases vbz the dt intravenous jj self_administration nn of inpos morphine nn and cc cocaine nn and cc the dt oral jj self_administration nn of inpos ethanol nn and cc nicotine nn in inpos rats nns
false	2	4	unlike inpos ibogaine nn num_mc nn does vbz not rb affect vb responding vbg for inpos a dt nondrug jj reinforcer nn
false	2	6	both cc ibogaine nn and cc num_mc nn ameliorate vbp opioid jj withdrawal nn signs nns
false	2	10	both cc ibogaine nn and cc num_mc nn ameliorate vbp opioid nn withdrawal nn signs nns
false	6	10	both cc ibogaine nn and cc num_mc nn ameliorate vbp opioid nn withdrawal nn signs nns
false	2	6	both cc ibogaine nn and cc num_mc nn decrease vbp extracellular jj levels nns of inpos dopamine nn in inpos the dt nucleus nn accumbens vbz but cc only rb ibogaine nn increases vbz extracellular jj levels nns of inpos serotonin nn in inpos the dt nucleus nn accumbens vbz
false	6	2	both cc ibogaine nn and cc num_mc nn decrease vbp extracellular jj levels nns of inpos dopamine nn in inpos the dt nucleus nn accumbens vbz but cc only rb ibogaine nn increases vbz extracellular jj levels nns of inpos serotonin nn in inpos the dt nucleus nn accumbens vbz
false	2	6	both cc ibogaine nn and cc num_mc nn block vbp morphine_induced jj and cc nicotine_induced jj dopamine nn release nn in inpos the dt nucleus nn accumbens vbz
effect	2	10	both cc ibogaine nn and cc num_mc nn block vbp morphine nn induced jj and cc nicotine_induced jj dopamine nn release nn in inpos the dt nucleus nn accumbens vbz
effect	2	14	both cc ibogaine nn and cc num_mc nn block vbp morphine_induced jj and cc nicotine nn induced jj dopamine nn release nn in inpos the dt nucleus nn accumbens vbz
effect	6	10	both cc ibogaine nn and cc num_mc nn block vbp morphine nn induced jj and cc nicotine_induced jj dopamine nn release nn in inpos the dt nucleus nn accumbens vbz
effect	6	14	both cc ibogaine nn and cc num_mc nn block vbp morphine_induced jj and cc nicotine nn induced jj dopamine nn release nn in inpos the dt nucleus nn accumbens vbz
false	10	16	both cc ibogaine nn and cc num_mc nn block vbp morphine nn induced jj and cc nicotine nn induced jj dopamine nn release nn in inpos the dt nucleus nn accumbens vbz
effect	2	6	only rb ibogaine nn enhances vbz cocaine nn induced jj increases nns in inpos accumbal jj dopamine nn
false	2	6	both cc ibogaine nn and cc num_mc nn enhance vbp the dt locomotor nn and_or cc stereotypic jj effects nns of inpos stimulants nns
false	0	6	ibogaine nn attenuates vbz but cc num_mc nn potentiates nns the dt acute jj locomotor jj effects nns of inpos morphine nn
effect	0	20	ibogaine nn attenuates vbz but cc num_mc nn potentiates nns the dt acute jj locomotor jj effects nns of inpos morphine nn
effect	6	20	ibogaine nn attenuates vbz but cc num_mc nn potentiates nns the dt acute jj locomotor jj effects nns of inpos morphine nn
false	0	6	ibogaine nn but cc not rb num_mc nn decreases vbz heart nn rate nn at inpos high jj doses nns
false	2	6	while inpos num_mc nn and cc ibogaine nn have vbp similar jj affinities nns for inpos k nn opioid jj and cc possibly rb nicotinic jj receptors nns num_mc nn has vbz much rb lower jjr affinities nns than inpos ibogaine nn for inpos nmda nn and cc s_num nn receptors nns sodium nn channels nns and cc the dt num_ht nn transporter nn
false	2	6	while inpos num_mc nn and cc ibogaine nn have vbp similar jj affinities nns for inpos k nn opioid jj and cc possibly rb nicotinic jj receptors nns num_mc nn has vbz much rb lower jjr affinities nns than inpos ibogaine nn for inpos nmda nn and cc s_num nn receptors nns sodium nn channels nns and cc the dt num_ht nn transporter nn
false	6	2	while inpos num_mc nn and cc ibogaine nn have vbp similar jj affinities nns for inpos k nn opioid jj and cc possibly rb nicotinic jj receptors nns num_mc nn has vbz much rb lower jjr affinities nns than inpos ibogaine nn for inpos nmda nn and cc s_num nn receptors nns sodium nn channels nns and cc the dt num_ht nn transporter nn
false	2	6	while inpos num_mc nn and cc ibogaine nn have vbp similar jj affinities nns for inpos k nn opioid jj and cc possibly rb nicotinic jj receptors nns num_mc nn has vbz much rb lower jjr affinities nns than inpos ibogaine nn for inpos nmda nn and cc s_num nn receptors nns sodium nn channels nns and cc the dt num_ht nn transporter nn
false	2	6	both cc num_mc nn and cc ibogaine nn are vbp sequestered vbn in inpos fat nn and cc like inpos ibogaine nn num_mc nn probably rb has vbz an dt active jj metabolite nn
false	2	6	both cc num_mc nn and cc ibogaine nn are vbp sequestered vbn in inpos fat nn and cc like inpos ibogaine nn num_mc nn probably rb has vbz an dt active jj metabolite nn
false	6	2	both cc num_mc nn and cc ibogaine nn are vbp sequestered vbn in inpos fat nn and cc like inpos ibogaine nn num_mc nn probably rb has vbz an dt active jj metabolite nn
false	6	2	both cc num_mc nn and cc ibogaine nn are vbp sequestered vbn in inpos fat nn and cc like inpos ibogaine nn num_mc nn probably rb has vbz an dt active jj metabolite nn
false	8	40	the dt data nns suggest vbp that inpos num_mc nn has vbz a dt narrower jjr spectrum nn of inpos actions nns and cc will md have vb a dt substantially rb greater jjr therapeutic jj index nn than inpos ibogaine nn
int	6	14	clinical jj implications nns of inpos warfarin nn interactions nns with inpos num cd sedatives nn
false	12	18	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant nn interference nn by inpos phenobarbital nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	12	18	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant nn interference nn by inpos secobarbital nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	12	18	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant nn interference nn by inpos glutethimide nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	12	18	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant nn interference nn by inpos chloral_hydrate nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	12	18	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant nn interference nn by inpos methaqualone nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	12	42	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant nn interference nn by inpos phenobarbital nn secobarbital nn glutethimide nn chloral_hydrate nn methaqualone nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	18	34	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant jj interference nn by inpos phenobarbital nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	18	34	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant jj interference nn by inpos secobarbital nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	18	34	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant jj interference nn by inpos glutethimide nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	18	34	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant jj interference nn by inpos chloral_hydrate nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	18	34	the dt intensity nn uniformity nn time nn course nn of inpos anticoagulant jj interference nn by inpos methaqualone nn were vbd systematically rb investigated vbn in inpos num cd patients nns receiving vbg coumarin nn therapy nn
false	26	30	there ex was vbd no dt significant jj change nn in inpos prothrombin nn test nn results nns during inpos the dt trials nns of inpos chloral_hydrate nn and cc methaqualone nn
false	0	4	barbiturates nn and cc glutethimide nn should md not rb be vb administered vbn to topos patients nns receiving vbg coumarin_drugs nns
advise	0	20	barbiturates nn and cc glutethimide nn should md not rb be vb administered vbn to topos patients nns receiving vbg coumarin_drugs nn
advise	4	20	barbiturates nns and cc glutethimide nn should md not rb be vb administered vbn to topos patients nns receiving vbg coumarin_drugs nn
false	0	4	chloral_hydrate nn and cc methaqualone nn interact vbp pharmacologically rb with inpos orally rb administered vbn anticoagulant_agents nns but cc the dt effect nn is vbz not rb clinically rb significant jj
int	0	16	chloral_hydrate nn and cc methaqualone nn interact vbp pharmacologically rb with inpos orally rb administered vbn anticoagulant_agents nn but cc the dt effect nn is vbz not rb clinically rb significant jj
int	4	16	chloral_hydrate nn and cc methaqualone nn interact vbp pharmacologically rb with inpos orally rb administered vbn anticoagulant_agents nn but cc the dt effect nn is vbz not rb clinically rb significant jj
false	8	12	it prp is vbz concluded vbn that inpos chloral_hydrate nn and cc methaqualone nn may md be vb administered vbn safely rb without inpos additional jj caution nn in inpos prothrombin nn test nn monitoring nn during inpos oral jj anticoagulant jj therapy nn
false	8	40	it prp is vbz concluded vbn that inpos chloral_hydrate nn and cc methaqualone nn may md be vb administered vbn safely rb without inpos additional jj caution nn in inpos prothrombin nn test nn monitoring nn during inpos oral jj anticoagulant nn therapy nn
false	12	40	it prp is vbz concluded vbn that inpos chloral_hydrate nn and cc methaqualone nn may md be vb administered vbn safely rb without inpos additional jj caution nn in inpos prothrombin nn test nn monitoring nn during inpos oral jj anticoagulant nn therapy nn
false	4	26	concomitantly rb given vbn thiazide_diuretics nn did vbd not rb interfere vb with inpos the dt absorption nn of inpos a dt tablet nn of inpos digoxin nn
false	4	8	combinations nns of inpos clozapine nn and cc phencyclidine nn effects nns on inpos drug nn discrimination nn and cc behavioral jj inhibition nn in inpos rats nns
false	10	12	in inpos the dt present jj study nn the dt atypical_antipsychotic nn clozapine nn was vbd tested vbn in inpos combination nn with inpos an dt active jj dose nn of inpos pcp nn in inpos two_lever jj drug nn discrimination nn and cc mixed jj signalled_unsignalled jj differential_reinforcement_of_low_rates nns procedures nns
false	10	32	in inpos the dt present jj study nn the dt atypical_antipsychotic nn clozapine nn was vbd tested vbn in inpos combination nn with inpos an dt active jj dose nn of inpos pcp nn in inpos two_lever jj drug nn discrimination nn and cc mixed jj signalled_unsignalled jj differential_reinforcement_of_low_rates nns procedures nns
false	12	32	in inpos the dt present jj study nn the dt atypical_antipsychotic jj clozapine nn was vbd tested vbn in inpos combination nn with inpos an dt active jj dose nn of inpos pcp nn in inpos two_lever jj drug nn discrimination nn and cc mixed jj signalled_unsignalled jj differential_reinforcement_of_low_rates nns procedures nns
false	6	22	acute jj dosing nn with inpos clozapine nn failed vbd to topos alter vb the dt behavioral jj effects nns of inpos pcp nn in inpos either cc procedure nn even rb when wrb tested vbn up rp to topos doses nns that wdt produced vbd pharmacological jj effects nns alone rb
false	14	32	these dt results nns suggest vbp that inpos acute jj dosing nn with inpos clozapine nn would md not rb affect vb behaviors nns most rbs closely rb associated vbn with inpos pcp nn intoxication nn
false	18	52	since inpos chronic jj dosing nn is vbz required vbn for inpos therapeutic jj efficacy nn of inpos antipsychotics nn future jj studies nns should md focus vb on inpos investigation nn of inpos chronic jj dosing nn effects nns of inpos these dt drugs nns in inpos combination nn with inpos pcp nn
false	0	18	resveratrol nn induced vbd concentration_dependent jj relaxation nn of inpos mesenteric jj arteries nns preconstricted vbn with inpos noradrenaline nn or cc kcl nn from inpos both cc lean jj and cc dietary_obese jj rats nns
false	0	22	resveratrol nn induced vbd concentration_dependent jj relaxation nn of inpos mesenteric jj arteries nns preconstricted vbn with inpos noradrenaline nn or cc kcl nn from inpos both cc lean jj and cc dietary_obese jj rats nns
false	18	22	resveratrol nn induced vbd concentration_dependent jj relaxation nn of inpos mesenteric jj arteries nns preconstricted vbn with inpos noradrenaline nn or cc kcl nn from inpos both cc lean jj and cc dietary_obese jj rats nns
false	2	16	however rb l_name nn did vbd not rb alter vb the dt effects nns of inpos reseveratrol nn on inpos arteries nns from inpos dietary_obese jj rats nns giving vbg superimposed vbn concentration_responses nns curves nns
false	0	12	indomethacin nn was vbd also rb ineffective jj in inpos altering vbg resveratrol nn activity nn in inpos arteries nns from inpos both cc lean jj and cc dietary_obese jj rats nns
false	2	18	in inpos noradrenaline nn precontracted jj arteries nns from inpos dietary_obese jj rats nns responses nns to topos resveratrol nn were vbd not rb attenuated vbn by inpos endothelial jj denudation nn indicating vbg an dt action nn independent jj of inpos the dt endothelium nn
false	10	12	if inpos taken vbn num cd hour nn before inpos indinavir nn didanosine nn does vbz not rb affect vb idv nn exposure nn despite inpos persistent jj buffering nn effects nns
false	10	20	if inpos taken vbn num cd hour nn before inpos indinavir nn didanosine nn does vbz not rb affect vb idv nn exposure nn despite inpos persistent jj buffering nn effects nns
false	10	12	if inpos taken vbn num cd hour nn before inpos idv nn didanosine nn does vbz not rb affect vb idv nn exposure nn despite inpos persistent jj buffering nn effects nns
false	12	20	if inpos taken vbn num cd hour nn before inpos indinavir nn didanosine nn does vbz not rb affect vb idv nn exposure nn despite inpos persistent jj buffering nn effects nns
mechanism	6	10	concurrent jj administration nn of inpos indinavir nn and cc didanosine nn significantly rb reduces vbz the dt level nn of inpos exposure nn to topos indinavir nn but cc it prp is vbz unclear jj how wrb soon rb after inpos didanosine nn administration nn indinavir nn may md be vb given vbn safely rb
false	6	10	concurrent jj administration nn of inpos indinavir nn and cc didanosine nn significantly rb reduces vbz the dt level nn of inpos exposure nn to topos indinavir nn but cc it prp is vbz unclear jj how wrb soon rb after inpos didanosine nn administration nn indinavir nn may md be vb given vbn safely rb
false	10	6	concurrent jj administration nn of inpos indinavir nn and cc didanosine nn significantly rb reduces vbz the dt level nn of inpos exposure nn to topos indinavir nn but cc it prp is vbz unclear jj how wrb soon rb after inpos didanosine nn administration nn indinavir nn may md be vb given vbn safely rb
false	10	6	concurrent jj administration nn of inpos indinavir nn and cc didanosine nn significantly rb reduces vbz the dt level nn of inpos exposure nn to topos indinavir nn but cc it prp is vbz unclear jj how wrb soon rb after inpos didanosine nn administration nn indinavir nn may md be vb given vbn safely rb
false	6	10	concurrent jj administration nn of inpos indinavir nn and cc didanosine nn significantly rb reduces vbz the dt level nn of inpos exposure nn to topos indinavir nn but cc it prp is vbz unclear jj how wrb soon rb after inpos didanosine nn administration nn indinavir nn may md be vb given vbn safely rb
false	10	6	concurrent jj administration nn of inpos indinavir nn and cc didanosine nn significantly rb reduces vbz the dt level nn of inpos exposure nn to topos indinavir nn but cc it prp is vbz unclear jj how wrb soon rb after inpos didanosine nn administration nn indinavir nn may md be vb given vbn safely rb
false	4	60	we prp compared vbd indinavir nn pharmacokinetics nns and cc gastric jj ph nn in inpos num cd human jj immunodeficiency nn virus_positive jj patients nns by inpos use nn of inpos num cd mg nn of inpos indinavir nn alone rb versus inpos num cd mg nn of inpos indinavir nn administered vbn num cd h nn after inpos didanosine nn administration nn
false	4	60	we prp compared vbd indinavir nn pharmacokinetics nns and cc gastric jj ph nn in inpos num cd human jj immunodeficiency nn virus_positive jj patients nns by inpos use nn of inpos num cd mg nn of inpos indinavir nn alone rb versus inpos num cd mg nn of inpos indinavir nn administered vbn num cd h nn after inpos didanosine nn administration nn
false	4	60	we prp compared vbd indinavir nn pharmacokinetics nns and cc gastric jj ph nn in inpos num cd human jj immunodeficiency nn virus_positive jj patients nns by inpos use nn of inpos num cd mg nn of inpos indinavir nn alone rb versus inpos num cd mg nn of inpos indinavir nn administered vbn num cd h nn after inpos didanosine nn administration nn
mechanism	14	22	median jj gastric jj ph nn was vbd significantly rb higher jjr when wrb indinavir nn was vbd taken vbn after inpos didanosine nn administration nn
advise	0	34	indinavir nn may md be vb taken vbn with inpos a dt light jj meal nn num cd h nn following vbg the dt administration nn of inpos num cd mg nn of inpos didanosine nn
effect	0	20	cytochalasin_d nn at inpos num cd microm nn preferentially rb blocked vbd the dt secretory jj effect nn of inpos carbachol nn and cc its prp synergism nn with inpos camp nn whereas inpos it prp had vbd no dt effect nn on inpos histamine nn or cc camp_stimulated jj acid nn secretion nn within inpos num cd min nn
effect	0	6	cytochalasin_d nn inhibited vbd the dt carbachol nn stimulated jj intracellular jj ca nn concentration nn rrb_rrb_increase vbp due jj to topos release vb from inpos the dt ca nn store nn
false	12	14	the dt percentage nn of inpos neurons nns hyperpolarized vbn by inpos m nn d_num nn and cc k nn bbbbbcom_selective_opioids_eeeeecom nn was vbd significantly rb reduced vbn when wrb num cd but cc not rb
effect	4	8	suppression nn by inpos verapamil nn of inpos bombesin nn enhanced jj peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn in inpos wistar nn rats nns
false	4	24	suppression nn by inpos verapamil nn of inpos bombesin_enhanced jj peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn in inpos wistar nn rats nns
false	8	26	suppression nn by inpos verapamil nn of inpos bombesin nn enhanced jj peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn in inpos wistar nn rats nns
false	12	16	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	12	16	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	12	20	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	12	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	12	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos aom nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	16	20	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	16	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	16	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos aom nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	16	20	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	16	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	16	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos aom nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	20	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos azoxymethane nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	20	44	the dt effects nns of inpos combined vbn administration nn of inpos bombesin nn and cc verapamil_hydrochloride nn a dt calcium_channel_blocker nn on inpos the dt incidence nn of inpos peritoneal jj metastasis nn of inpos intestinal jj adenocarcinomas nns induced vbn by inpos aom nn and cc the dt labeling nn index nn of inpos intestinal jj cancers nns were vbd investigated vbn in inpos male jj wistar nnp rats nns
false	28	38	from inpos the dt beginning nn of inpos the dt experiment nn rats nns were vbd given vbn num cd weekly jj subcutaneous jj injections nns of inpos aom nn and cc subcutaneous jj injections nns of inpos bombesin nn every dt other jj day nn and cc from inpos week nn num cd intraperitoneal jj injections nns of inpos verapamil nn every dt other jj day nn until inpos the dt end nn fo nn the dt experiment nn in inpos week nn num cd
false	28	60	from inpos the dt beginning nn of inpos the dt experiment nn rats nns were vbd given vbn num cd weekly jj subcutaneous jj injections nns of inpos aom nn and cc subcutaneous jj injections nns of inpos bombesin nn every dt other jj day nn and cc from inpos week nn num cd intraperitoneal jj injections nns of inpos verapamil nn every dt other jj day nn until inpos the dt end nn fo nn the dt experiment nn in inpos week nn num cd
false	38	60	from inpos the dt beginning nn of inpos the dt experiment nn rats nns were vbd given vbn num cd weekly jj subcutaneous jj injections nns of inpos aom nn and cc subcutaneous jj injections nns of inpos bombesin nn every dt other jj day nn and cc from inpos week nn num cd intraperitoneal jj injections nns of inpos verapamil nn every dt other jj day nn until inpos the dt end nn fo nn the dt experiment nn in inpos week nn num cd
false	2	36	although inpos verapamil nn administered vbn at inpos either cc dose nn had vbd little jj or cc no dt effect nn on inpos the dt enhancement nn of inpos intestinal jj carcinogenesis nn by inpos bombesin nn or cc on inpos the dt location nn histologic jj type nn depth nn of inpos involvement nn labeling vbg index nn apoptotic jj index nn tumor nn vascularity nn of inpos intestinal jj cancers nns it prp significantly rb decreased vbd the dt incidence nn of inpos cancer nn metastasis nn
effect	0	30	verapamil nn also rb significantly rb decreased vbd the dt incidence nn of inpos lymphatic jj invasion nn of inpos adenocarcinomas nns which wdt was vbd enhanced vbn by inpos bombesin nn
int	8	12	in fw vitro fw interaction nn of inpos prostaglandin_f2ap nn and cc oxytocin nn in inpos placental jj vessels nns
false	6	12	the dt interaction nn of inpos prostaglandin_f2ap nn and cc synthetic jj oxytocin nn on inpos placental jj vessels nns was vbd studied vbn in fw vitro fw
false	10	14	in inpos num cd experiments nns reactions nns to topos norepinephrine nn and cc oxytocin nn were vbd pgf2ap nn
false	10	18	in inpos num cd experiments nns reactions nns to topos norepinephrine nn and cc oxytocin nn were vbd pgf2ap nn
false	14	18	in inpos num cd experiments nns reactions nns to topos norepinephrine nn and cc oxytocin nn were vbd pgf2ap nn
effect	0	20	pgf2ap nn produced vbd significantly rb increased vbn vasoconstriction nn after inpos a dt single jj administration nn of inpos oxytocin nn
effect	14	30	there ex is vbz thus rb an dt enhancement nn effect nn of inpos pgf2ap nn upon inpos the dt reaction nn of inpos placental jj vessels nns to topos oxytocin nn in fw vitro fw
false	0	10	carbamazepine nn overdose nn recognized vbn by inpos a dt tricyclic_antidepressant nn assay nn
effect	24	34	we prp report vbp the dt case nn of inpos an dt adolescent jj with inpos altered vbn consciousness nn caused vbn by inpos carbamazepine nn overdose nn with inpos a dt positive jj tricyclic_antidepressant nn level nn to topos alert vb clinicians nns to topos the dt cross_reactivity nn of inpos carbamazepine nn with inpos a dt toxicology nn screen nn for inpos tricyclic_antidepressants nns
false	24	64	we prp report vbp the dt case nn of inpos an dt adolescent jj with inpos altered vbn consciousness nn caused vbn by inpos carbamazepine nn overdose nn with inpos a dt positive jj tricyclic_antidepressant nn level nn to topos alert vb clinicians nns to topos the dt cross_reactivity nn of inpos carbamazepine nn with inpos a dt toxicology nn screen nn for inpos tricyclic_antidepressants nn
false	34	24	we prp report vbp the dt case nn of inpos an dt adolescent jj with inpos altered vbn consciousness nn caused vbn by inpos carbamazepine nn overdose nn with inpos a dt positive jj tricyclic_antidepressant nn level nn to topos alert vb clinicians nns to topos the dt cross_reactivity nn of inpos carbamazepine nn with inpos a dt toxicology nn screen nn for inpos tricyclic_antidepressants nns
advise	24	64	we prp report vbp the dt case nn of inpos an dt adolescent jj with inpos altered vbn consciousness nn caused vbn by inpos carbamazepine nn overdose nn with inpos a dt positive jj tricyclic_antidepressant nn level nn to topos alert vb clinicians nns to topos the dt cross_reactivity nn of inpos carbamazepine nn with inpos a dt toxicology nn screen nn for inpos tricyclic_antidepressants nn
effect	0	24	cypermethrin nn induced jj oxidative jj stress nn in inpos rat nn brain nn and cc liver nn is vbz prevented vbn by inpos vitamin_e nn or cc allopurinol nn
effect	0	28	cypermethrin nn induced jj oxidative jj stress nn in inpos rat nn brain nn and cc liver nn is vbz prevented vbn by inpos vitamin_e nn or cc allopurinol nn
false	22	26	cypermethrin_induced jj oxidative jj stress nn in inpos rat nn brain nn and cc liver nn is vbz prevented vbn by inpos vitamin_e nn or cc allopurinol nn
false	60	64	considering vbg that inpos the dt involvement nn of inpos reactive jj oxygen nn species nns has vbz been vbn implicated vbn in inpos the dt toxicity nn of inpos various jj pesticides nns this dt study nn was vbd designed vbn to topos investigate vb the dt possibility nn of inpos oxidative jj stress nn induction nn by inpos cypermethrin nn a dt type_ii_pyrethroid nn
false	8	12	pretreatment nn of inpos rats nns with inpos allopurinol nn or cc vitamin_e nn provided vbd significant jj protection nn against inpos the dt elevation nn of inpos tbars nn levels nns in inpos cerebral jj and cc hepatic jj tissues nns induced vbn by inpos single jj high jj dose nn of inpos oral jj cypermethrin nn administration nn within inpos num cd h nn
effect	8	56	pretreatment nn of inpos rats nns with inpos allopurinol nn or cc vitamin_e nn provided vbd significant jj protection nn against inpos the dt elevation nn of inpos tbars nn levels nns in inpos cerebral jj and cc hepatic jj tissues nns induced vbn by inpos single jj high jj dose nn of inpos oral jj cypermethrin nn administration nn within inpos num cd h nn
effect	12	56	pretreatment nn of inpos rats nns with inpos allopurinol nn or cc vitamin_e nn provided vbd significant jj protection nn against inpos the dt elevation nn of inpos tbars nn levels nns in inpos cerebral jj and cc hepatic jj tissues nns induced vbn by inpos single jj high jj dose nn of inpos oral jj cypermethrin nn administration nn within inpos num cd h nn
effect	10	56	thus rb the dt results nns suggest vbp that inpos cypermethrin nn exposure nn of inpos rats nns results vbz in inpos free jj radical_mediated jj tissue nn damage nn as inpos indicated vbn by inpos elevated vbn cerebral jj and cc hepatic jj lipid nn peroxidation nn which wdt was vbd prevented vbn by inpos allopurinol nn and cc vitamin_e nn
effect	10	60	thus rb the dt results nns suggest vbp that inpos cypermethrin nn exposure nn of inpos rats nns results vbz in inpos free jj radical_mediated jj tissue nn damage nn as inpos indicated vbn by inpos elevated vbn cerebral jj and cc hepatic jj lipid nn peroxidation nn which wdt was vbd prevented vbn by inpos allopurinol nn and cc vitamin_e nn
false	56	60	thus rb the dt results nns suggest vbp that inpos cypermethrin nn exposure nn of inpos rats nns results vbz in inpos free jj radical_mediated jj tissue nn damage nn as inpos indicated vbn by inpos elevated vbn cerebral jj and cc hepatic jj lipid nn peroxidation nn which wdt was vbd prevented vbn by inpos allopurinol nn and cc vitamin_e nn
false	16	36	in inpos this dt study nn we prp investigated vbd the dt effect nn of inpos ginsenosides nn on inpos high jj threshold nn voltage_dependent jj ca nn channel nn subtypes nns using vbg their prp selective_ca_2+_channel_blockers nn nimodipine nn o_conotoxin_gvia nn o_agatoxin_iva nn in inpos bovine jj chromaffin nn cells nns
false	16	38	in inpos this dt study nn we prp investigated vbd the dt effect nn of inpos ginsenosides nn on inpos high jj threshold nn voltage_dependent jj ca nn channel nn subtypes nns using vbg their prp selective_ca_2+_channel_blockers nns nimodipine nn in inpos bovine jj chromaffin nn cells nns
false	16	38	in inpos this dt study nn we prp investigated vbd the dt effect nn of inpos ginsenosides nn on inpos high jj threshold nn voltage_dependent jj ca nn channel nn subtypes nns using vbg their prp selective_ca_2+_channel_blockers nns o_conotoxin_gvia nn in inpos bovine jj chromaffin nn cells nns
false	16	38	in inpos this dt study nn we prp investigated vbd the dt effect nn of inpos ginsenosides nn on inpos high jj threshold nn voltage_dependent jj ca nn channel nn subtypes nns using vbg their prp selective_ca_2+_channel_blockers nns o_agatoxin_iva nn in inpos bovine jj chromaffin nn cells nns
false	36	38	in inpos this dt study nn we prp investigated vbd the dt effect nn of inpos ginsenosides nns on inpos high jj threshold nn voltage_dependent jj ca nn channel nn subtypes nns using vbg their prp selective_ca_2+_channel_blockers nn nimodipine nn in inpos bovine jj chromaffin nn cells nns
false	36	38	in inpos this dt study nn we prp investigated vbd the dt effect nn of inpos ginsenosides nns on inpos high jj threshold nn voltage_dependent jj ca nn channel nn subtypes nns using vbg their prp selective_ca_2+_channel_blockers nn o_conotoxin_gvia nn in inpos bovine jj chromaffin nn cells nns
false	36	38	in inpos this dt study nn we prp investigated vbd the dt effect nn of inpos ginsenosides nns on inpos high jj threshold nn voltage_dependent jj ca nn channel nn subtypes nns using vbg their prp selective_ca_2+_channel_blockers nn o_agatoxin_iva nn in inpos bovine jj chromaffin nn cells nns
false	0	10	nimodipine nn had vbd no dt effect nn on inpos ginsenosides nn response nn
false	8	40	these dt data nns suggest vbp that inpos ginsenosides nn are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia nn sensitive jj channel nn an dt o_agatoxin_iva_sensitive jj channel nn and cc o_conotoxin_gvia nn channel nn
false	8	46	these dt data nns suggest vbp that inpos ginsenosides nn are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia_sensitive jj channel nn an dt o_agatoxin_iva nn sensitive jj channel nn and cc o_agatoxin_via_resistant jj channel nn
false	8	52	these dt data nns suggest vbp that inpos ginsenosides nn are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia_sensitive jj channel nn an dt o_agatoxin_iva_sensitive jj channel nn and cc nimodipine nn channel nn
false	8	40	these dt data nns suggest vbp that inpos ginsenosides nn are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia_sensitive jj channel nn an dt o_agatoxin_iva_sensitive jj channel nn and cc o_conotoxin_gvia nn channel nn
false	8	52	these dt data nns suggest vbp that inpos ginsenosides nn are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia_sensitive jj channel nn an dt o_agatoxin_iva_sensitive jj channel nn and cc o_agatoxin_via nn resistant jj channel nn
false	40	48	these dt data nns suggest vbp that inpos ginsenosides nns are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia nn sensitive jj channel nn an dt o_agatoxin_iva nn sensitive jj channel nn and cc o_agatoxin_via_resistant jj channel nn
false	40	54	these dt data nns suggest vbp that inpos ginsenosides nns are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia nn sensitive jj channel nn an dt o_agatoxin_iva_sensitive jj channel nn and cc nimodipine nn channel nn
false	40	54	these dt data nns suggest vbp that inpos ginsenosides nns are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia nn sensitive jj channel nn an dt o_agatoxin_iva_sensitive jj channel nn and cc o_agatoxin_via nn resistant jj channel nn
false	46	54	these dt data nns suggest vbp that inpos ginsenosides nns are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia_sensitive jj channel nn an dt o_agatoxin_iva nn sensitive jj channel nn and cc nimodipine nn channel nn
false	46	40	these dt data nns suggest vbp that inpos ginsenosides nns are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia_sensitive jj channel nn an dt o_agatoxin_iva nn sensitive jj channel nn and cc o_conotoxin_gvia nn channel nn
false	46	54	these dt data nns suggest vbp that inpos ginsenosides nns are vbp negatively rb coupled vbn to topos num cd types nns of inpos calcium nn channels nns in inpos bovine jj chromaffin nn cell nn including vbg an dt o_conotoxin_gvia_sensitive jj channel nn an dt o_agatoxin_iva nn sensitive jj channel nn and cc o_agatoxin_via nn resistant jj channel nn
false	18	48	thus rb the dt selective jj regulation nn of inpos voltage_dependent jj ca nn subtypes nns by inpos ginsenosides nn in inpos bovine jj chromaffin nn cell nn could md be vb the dt cellular jj basis nn of inpos antistress nn effects nns induced vbn by inpos ginseng nn
false	8	22	in fw vitro fw activity nn of inpos krm_num nn either cc singly rb or cc in inpos combination nn with inpos ofloxacin nn against inpos mycobacterium nn ulcerans nns
false	10	12	the dt antimicrobial jj effect nn of inpos a dt benzoxazinorifamycin nn krm_num nn either cc alone rb or cc in inpos combination nn with inpos ofloxacin nn was vbd evaluated vbn in fw vitro fw against inpos num cd type nn strains nns and cc num cd clinical jj isolates nns of inpos mycobacterium nn ulcerans nns
false	10	26	the dt antimicrobial jj effect nn of inpos a dt benzoxazinorifamycin nn krm_num nn either cc alone rb or cc in inpos combination nn with inpos ofloxacin nn was vbd evaluated vbn in fw vitro fw against inpos num cd type nn strains nns and cc num cd clinical jj isolates nns of inpos mycobacterium nn ulcerans nns
false	12	26	the dt antimicrobial jj effect nn of inpos a dt benzoxazinorifamycin nn krm_num nn either cc alone rb or cc in inpos combination nn with inpos ofloxacin nn was vbd evaluated vbn in fw vitro fw against inpos num cd type nn strains nns and cc num cd clinical jj isolates nns of inpos mycobacterium nn ulcerans nns
false	22	26	ulcerans nns was vbd between inpos float cd and cc float cd mg_l nn while inpos corresponding vbg values nns for inpos rifampicin nn and cc rifabutin nn were vbd in inpos the dt range nn of inpos float cd mg_l nn and cc float cd mg_l nn respectively rb
effect	6	8	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifampicin nn and cc ofloxacin nn
false	6	38	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifampicin nn and cc ofloxacin nn
false	6	38	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifabutin nn and cc ofloxacin nn
false	8	38	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifampicin nn and cc ofloxacin nn
false	8	38	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifabutin nn and cc ofloxacin nn
false	8	6	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifampicin nn and cc ofloxacin nn
effect	38	6	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifampicin nn and cc ofloxacin nn
effect	38	6	when wrb combined vbn with inpos ofloxacin nn krm_num nn exhibited vbd strong jj synergistic jj activity nn while inpos only rb additive jj effects nns were vbd observed vbn with inpos the dt combination nn of inpos rifabutin nn and cc ofloxacin nn
false	6	10	the dt effects nns of inpos ruthenium_red nn on inpos inositol_nums_trisphosphate nn induced jj responses nns were vbd studied vbn in inpos rat nn bone nn marrow nn megakaryocytes nns with inpos the dt patch_clamp jj whole_cell jj recording nn technique nn in inpos combination nn with inpos fura_num nn microfluorometry nn
false	6	10	the dt effects nns of inpos ruthenium_red nn on inpos insp_num nn induced jj responses nns were vbd studied vbn in inpos rat nn bone nn marrow nn megakaryocytes nns with inpos the dt patch_clamp jj whole_cell jj recording nn technique nn in inpos combination nn with inpos fura_num nn microfluorometry nn
false	6	10	the dt effects nns of inpos rr nn on inpos inositol_nums_trisphosphate nn induced jj responses nns were vbd studied vbn in inpos rat nn bone nn marrow nn megakaryocytes nns with inpos the dt patch_clamp jj whole_cell jj recording nn technique nn in inpos combination nn with inpos fura_num nn microfluorometry nn
false	6	10	the dt effects nns of inpos rr nn on inpos insp_num nn induced jj responses nns were vbd studied vbn in inpos rat nn bone nn marrow nn megakaryocytes nns with inpos the dt patch_clamp jj whole_cell jj recording nn technique nn in inpos combination nn with inpos fura_num nn microfluorometry nn
effect	2	8	administering vbg insp_num nn together rb with inpos rr nn inhibited vbd insp nn induced jj responses nns and cc current jj responses nns rrb_in inpos a dt dose_dependent jj fashion nn
effect	10	16	pretreatment nn of inpos megakaryocytes nns with inpos extracellular jj rr nn also rb inhibited vbd insp_num nn induced jj responses nns
false	16	26	in inpos contrast nn in inpos isolated vbn single jj pancreatic jj acinar jj cells nns rr nn had vbd no dt effect nn on inpos insp_num nn induced jj responses nns
false	12	34	in inpos addition nn we prp have vbp shown vbn that inpos rr nn is vbz a dt useful jj pharmacological jj tool nn with inpos which wdt to topos examine vb the dt insp_num nn mediated jj responses nns of inpos megakaryocytes nns
false	4	14	effect nn of inpos rofecoxib nn on inpos the dt pharmacokinetics nns of inpos digoxin nn in inpos healthy jj volunteers nns
false	18	34	the dt authors nns examined vbd the dt effect nn of inpos the dt cyclooxygenase_num nn inhibitor nn rofecoxib nn at inpos steady jj state nn on inpos the dt pharmacokinetics nns of inpos digoxin nn following vbg a dt single jj dose nn in inpos healthy jj subjects nns
false	2	18	for inpos digoxin nn auc nn auc nn cmax nn the dt geometric jj mean jj ratios nns rofecoxib nn were vbd float cd float cd float cd respectively rb
false	2	4	for inpos rofecoxib nn +_digoxin nn +_digoxin nn
false	22	24	the dt harmonic jj mean jj elimination nn half_life nn was vbd float cd and cc float cd hours nns for inpos rofecoxib nn +_digoxin nn and cc placebo nn +_digoxin nn treatments nns respectively rb
false	22	24	the dt harmonic jj mean jj elimination nn half_life nn was vbd float cd and cc float cd hours nns for inpos rofecoxib nn +_digoxin nn and cc placebo nn +_digoxin nn treatments nns respectively rb
false	14	24	the dt mean jj cumulative jj urinary jj excretion nn of inpos immunoreactive jj digoxin nn after inpos concurrent jj treatment nn with inpos rofecoxib nn or cc placebo nn was vbd float cd and cc float cd micrograms_num nn hours nns respectively rb
false	0	32	rofecoxib nn did vbd not rb influence vb the dt plasma nn pharmacokinetics nns or cc renal jj elimination nn of inpos a dt single jj oral jj dose nn of inpos digoxin nn
false	2	4	concomitant jj cyclophosphamide nn prednisone nn chemotherapy nn plus cc highly_active_antiretroviral jj therapy nn in inpos patients nns with inpos human jj immunodeficiency nn virus_related jj non_hodgkin jj lymphoma nn
false	2	10	concomitant jj cyclophosphamide nn prednisone nn chemotherapy nn plus cc highly_active_antiretroviral nn therapy nn in inpos patients nns with inpos human jj immunodeficiency nn virus_related jj non_hodgkin jj lymphoma nn
false	2	4	concomitant jj doxorubicin nn prednisone nn chemotherapy nn plus cc highly_active_antiretroviral jj therapy nn in inpos patients nns with inpos human jj immunodeficiency nn virus_related jj non_hodgkin jj lymphoma nn
false	2	10	concomitant jj doxorubicin nn prednisone nn chemotherapy nn plus cc highly_active_antiretroviral nn therapy nn in inpos patients nns with inpos human jj immunodeficiency nn virus_related jj non_hodgkin jj lymphoma nn
false	2	4	concomitant jj vincristine nn prednisone nn chemotherapy nn plus cc highly_active_antiretroviral jj therapy nn in inpos patients nns with inpos human jj immunodeficiency nn virus_related jj non_hodgkin jj lymphoma nn
false	2	10	concomitant jj vincristine nn prednisone nn chemotherapy nn plus cc highly_active_antiretroviral nn therapy nn in inpos patients nns with inpos human jj immunodeficiency nn virus_related jj non_hodgkin jj lymphoma nn
false	8	14	concomitant jj cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn plus cc highly_active_antiretroviral nn therapy nn in inpos patients nns with inpos human jj immunodeficiency nn virus_related jj non_hodgkin jj lymphoma nn
false	70	72	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj regimen nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj doxorubicin nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj teniposide nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	72	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj prednisone nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj vincristine nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj bleomycin nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	118	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj regimen nn without inpos receiving vbg antiretroviral nn therapy nn
false	70	72	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt doxorubicin nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj regimen nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt doxorubicin nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj cyclophosphamide nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt doxorubicin nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj teniposide nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	72	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt doxorubicin nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj prednisone nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt doxorubicin nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj vincristine nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt doxorubicin nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj bleomycin nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	118	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt doxorubicin nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj regimen nn without inpos receiving vbg antiretroviral nn therapy nn
false	70	72	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj regimen nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj cyclophosphamide nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj doxorubicin nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj teniposide nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	72	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj prednisone nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	112	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj bleomycin nn without inpos receiving vbg antiretroviral jj therapy nn
false	70	118	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj regimen nn without inpos receiving vbg antiretroviral nn therapy nn
false	76	70	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj cyclophosphamide nn without inpos receiving vbg antiretroviral jj therapy nn
false	76	72	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj doxorubicin nn without inpos receiving vbg antiretroviral jj therapy nn
false	76	116	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj teniposide nn without inpos receiving vbg antiretroviral jj therapy nn
false	76	74	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj vincristine nn without inpos receiving vbg antiretroviral jj therapy nn
false	76	116	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj bleomycin nn without inpos receiving vbg antiretroviral jj therapy nn
false	76	122	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj regimen nn without inpos receiving vbg antiretroviral nn therapy nn
false	70	122	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj cyclophosphamide nn without inpos receiving vbg antiretroviral nn therapy nn
false	72	122	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj doxorubicin nn without inpos receiving vbg antiretroviral nn therapy nn
false	116	122	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj teniposide nn without inpos receiving vbg antiretroviral nn therapy nn
false	76	122	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj prednisone nn without inpos receiving vbg antiretroviral nn therapy nn
false	74	122	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj vincristine nn without inpos receiving vbg antiretroviral nn therapy nn
false	116	122	to topos evaluate vb the dt impact nn of inpos chemotherapy nn plus cc haart nn on inpos the dt clinical jj course nn of inpos patients nns with inpos hiv_related jj systemic jj non_hodgkin jj lymphoma nn the dt authors nns compared vbd retrospectively rb a dt group nn of inpos num cd patients nns with inpos hiv_nhl nn who wp were vbd treated vbn with inpos the dt cyclophosphamide nn doxorubicin nn vincristine nn prednisone nn chemotherapy nn regimen nn plus cc haart nn with inpos a dt group nn of inpos num cd patients nns who wp were vbd treated vbn with inpos chop nn chemotherapy nn or cc a dt chop_like jj bleomycin nn without inpos receiving vbg antiretroviral nn therapy nn
false	0	10	antiretroviral nn regimens nns consisted vbd of inpos num cd reverse_transcriptase_inhibitors nn and cc num cd protease_inhibitor nn
false	0	16	antiretroviral nn regimens nns consisted vbd of inpos num cd reverse_transcriptase_inhibitors nns and cc num cd protease_inhibitor nn
false	10	16	antiretroviral jj regimens nns consisted vbd of inpos num cd reverse_transcriptase_inhibitors nn and cc num cd protease_inhibitor nn
advise	28	32	however rb careful jj attention nn must md be vb directed vbn to topos cross vb toxicity nn and cc possible jj pharmacokinetic jj interactions nns between inpos antiretroviral nn and cc antineoplastic nn bbbbbcom_drugs_eeeeecom nn
int	4	28	treatment nn with inpos antidepressant_drugs nn can md directly rb interfere vb with inpos blood nn glucose nn levels nns or cc may md interact vb with inpos hypoglycemic_agents nn
false	0	4	imipramine nn and cc clonazepam nn did vbd not rb change vb fasting nn or cc overload nn glycemia nn
false	0	4	fluoxetine nn and cc moclobemide nn increased vbd blood nn glucose nn at inpos different jj times nns after inpos the dt glucose nn overload nn
false	0	10	fluoxetine nn and cc moclobemide nn increased vbd blood nn glucose nn at inpos different jj times nns after inpos the dt glucose nn overload nn
false	4	10	fluoxetine nn and cc moclobemide nn increased vbd blood nn glucose nn at inpos different jj times nns after inpos the dt glucose nn overload nn
false	0	18	sertraline nn neutralized vbd the dt increase nn of inpos glycemia nn induced vbn by inpos oral jj glucose nn overload nn
false	2	16	again rb sertraline nn neutralized vbd the dt increase nn in inpos glycemia nn after inpos glucose nn overload nn both cc in inpos diabetic jj and cc non_diabetic jj rats nns
false	4	16	activity nn of inpos buforin_ii nn alone rb and cc in inpos combination nn with inpos azithromycin nn and cc minocycline nn against inpos cryptosporidium nn parvum nn in inpos cell nn culture nn
false	4	20	activity nn of inpos buforin_ii nn alone rb and cc in inpos combination nn with inpos azithromycin nn and cc minocycline nn against inpos cryptosporidium nn parvum nn in inpos cell nn culture nn
false	16	20	activity nn of inpos buforin_ii nn alone rb and cc in inpos combination nn with inpos azithromycin nn and cc minocycline nn against inpos cryptosporidium nn parvum nn in inpos cell nn culture nn
false	12	24	the dt in fw vitro fw anti_cryptosporidial jj activity nn of inpos buforin_ii nn alone rb and cc in inpos combination nn with inpos azithromycin nn and cc minocycline nn was vbd investigated vbn
false	12	28	the dt in fw vitro fw anti_cryptosporidial jj activity nn of inpos buforin_ii nn alone rb and cc in inpos combination nn with inpos azithromycin nn and cc minocycline nn was vbd investigated vbn
false	24	28	the dt in fw vitro fw anti_cryptosporidial jj activity nn of inpos buforin_ii nn alone rb and cc in inpos combination nn with inpos azithromycin nn and cc minocycline nn was vbd investigated vbn
false	22	26	moreover rb its prp activity nn was vbd enhanced vbn when wrb it prp was vbd combined vbn with inpos either cc azithromycin nn or cc minocycline nn with inpos num cd parasite nn reduction nn at inpos the dt highest jjs concentration nn tested vbn
effect	0	30	buforin_ii nn may md be vb active jj in inpos inhibiting vbg cryptosporidium nn parvum nn growth nn in fw vitro fw upon inpos combination nn with inpos either cc azithromycin nn or cc minocycline nn
effect	0	34	buforin_ii nn may md be vb active jj in inpos inhibiting vbg cryptosporidium nn parvum nn growth nn in fw vitro fw upon inpos combination nn with inpos either cc azithromycin nn or cc minocycline nn
false	30	34	buforin_ii nn may md be vb active jj in inpos inhibiting vbg cryptosporidium nn parvum nn growth nn in fw vitro fw upon inpos combination nn with inpos either cc azithromycin nn or cc minocycline nn
false	4	14	effect nn of inpos dofetillide nn on inpos the dt pharmacokinetics nns of inpos digoxin nn
false	6	18	the dt effect nn of inpos dofetilide nn on inpos the dt steady_state jj pharmacokinetics nns of inpos digoxin nn was vbd evaluated vbn in inpos a dt randomized vbn double_blind jj study nn
false	6	26	num cd days nns of inpos dofetilide nn treatment nn did vbd not rb significantly rb affect vb steady_state jj pharmacokinetic jj variables nns of inpos digoxin nn compared vbn with inpos placebo nn
false	8	22	therefore rb the dt use nn of inpos dofetilide nn does vbz not rb necessitate vb an dt adjustment nn in inpos digoxin nn dose nn to topos maintain vb therapeutic jj digoxin nn levels nns
false	14	20	numerous jj drug nn interactions nns are vbp possible jj with inpos some dt anticonvulsant_agents nn such jj as inpos phenobarbitone nn and cc phenytoin nn which wdt affect vbp hepatic jj microsomal jj enzyme nn systems nns
false	14	24	numerous jj drug nn interactions nns are vbp possible jj with inpos some dt anticonvulsant_agents nn such jj as inpos phenobarbitone nn and cc phenytoin nn which wdt affect vbp hepatic jj microsomal jj enzyme nn systems nns
false	20	24	numerous jj drug nn interactions nns are vbp possible jj with inpos some dt anticonvulsant_agents nns such jj as inpos phenobarbitone nn and cc phenytoin nn which wdt affect vbp hepatic jj microsomal jj enzyme nn systems nns
int	4	8	interaction nn of inpos ketamine nn and cc halothane nn in inpos rats nns
false	10	22	the dt interaction nn of inpos intramuscularly rb injected vbn ketamine nn and cc its prp n_demethylated vbn metabolite nn with inpos halothane nn was vbd evaluated vbn in inpos rats nns
mechanism	2	50	however rb halothane nn anesthetic jj requirement nn was vbd depressed vbn in inpos a dt dose_dependent jj fashion nn as rb much jj as inpos num cd num cd hours nns as rb much jj as inpos num cd num cd hours nns after inpos injection nn of inpos ketamine nn num cd mg_kg nn im rb
mechanism	6	28	the dt half_life nn of inpos ketamine nn in inpos plasma nn and cc brain nn was vbd longer rbr in inpos the dt presence nn of inpos halothane nn than inpos when wrb ketamine nn was vbd given vbn alone rb
false	28	6	the dt half_life nn of inpos ketamine nn in inpos plasma nn and cc brain nn was vbd longer rbr in inpos the dt presence nn of inpos halothane nn than inpos when wrb ketamine nn was vbd given vbn alone rb
effect	8	30	it prp is vbz concluded vbn that inpos ketamine nn is vbz not rb a dt short_acting jj drug nn and cc that inpos concomitant jj use nn with inpos halothane nn would md be vb expected vbn to topos prolong vb further rbr the dt duration nn of inpos its prp action nn on inpos the dt central jj nervous jj system nn
int	0	4	rifampin nn and cc warfarin nn a dt drug nn interaction nn
int	8	12	the dt drug nn interaction nn between inpos warfarin nn and cc rifampin nn is vbz not rb well rb known vbn
mechanism	0	14	rifampin nn has vbz been vbn reported vbn to topos increase vb the dt warfarin nn requirements nns in inpos human jj subjects nns ingesting vbg these dt agents nns simultaneously rb
mechanism	8	12	the dt concomitant jj administration nn of inpos rifampin nn and cc warfarin nn resulted vbd in inpos the dt need nn for inpos an dt unusually rb high jj maintenance nn dose nn of inpos warfarin nn in inpos order nn to topos produce vb a dt therapeutic jj effect nn
false	8	12	the dt concomitant jj administration nn of inpos rifampin nn and cc warfarin nn resulted vbd in inpos the dt need nn for inpos an dt unusually rb high jj maintenance nn dose nn of inpos warfarin nn in inpos order nn to topos produce vb a dt therapeutic jj effect nn
mechanism	4	10	withdrawal nn of inpos rifampin nn decreased vbd the dt warfarin nn requirement nn by inpos num cd
mechanism	18	38	this dt effect nn may md be vb mediated vbn by inpos the dt ability nn of inpos rifampin nn to topos induce vb microsomal jj enzymes nns and cc thus rb the dt catabolism nn of inpos warfarin nn
effect	6	12	the dt effect nn of inpos rifampin nn on inpos the dt warfarin nn requirement nn of inpos our prp patient nn appeared vbd to topos be vb maximal jj num cd to topos num cd days nns after inpos the dt initiation nn of inpos rifampin nn and cc extended vbd a dt similar jj length nn of inpos time nn after inpos rifampin nn withdrawal nn
false	12	6	the dt effect nn of inpos rifampin nn on inpos the dt warfarin nn requirement nn of inpos our prp patient nn appeared vbd to topos be vb maximal jj num cd to topos num cd days nns after inpos the dt initiation nn of inpos rifampin nn and cc extended vbd a dt similar jj length nn of inpos time nn after inpos rifampin nn withdrawal nn
false	12	6	the dt effect nn of inpos rifampin nn on inpos the dt warfarin nn requirement nn of inpos our prp patient nn appeared vbd to topos be vb maximal jj num cd to topos num cd days nns after inpos the dt initiation nn of inpos rifampin nn and cc extended vbd a dt similar jj length nn of inpos time nn after inpos rifampin nn withdrawal nn
false	22	26	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	26	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc cmc_cys nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos naflu nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	50	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	54	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	26	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos nacmc nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	26	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos nacmc nn and cc cmc_cys nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos nacmc nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos nacmc nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos naflu nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	50	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos nacmc nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	22	54	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos nacmc nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos naflu nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	50	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	54	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc cmc_cys nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	40	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc cmc_cys nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos naflu nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	50	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc cmc_cys nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	26	54	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc cmc_cys nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	40	50	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	40	54	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	40	50	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos naflu nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	40	54	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos naflu nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	50	54	the dt purpose nn of inpos this dt study nn was vbd to topos evaluate vb the dt effect nn of inpos sodium_carboxymethylcellulose nn and cc carboxymethylcellulose_cysteine nn conjugates nns on inpos the dt intestinal jj permeation nn of inpos sodium_fluorescein nn and cc model nn peptide nn drugs nns bacitracin nn and cc insulin nn
false	0	14	cysteine nn was vbd covalently rb linked vbn to topos carbodiimide nn activated vbd nacmc nn
false	2	20	unmodified jj nacmc nn significantly rb improved vbd the dt transport nn ratio nn polymer nn control nn rrb_of inpos naflu nn to topos float cd and cc num cd nacmc nn conjugated vbn with inpos cysteine nn further rbr enhanced vbd the dt permeation nn
false	2	36	unmodified jj nacmc nn significantly rb improved vbd the dt transport nn ratio nn polymer nn control nn rrb_of inpos naflu nn to topos float cd and cc num cd nacmc nn conjugated vbn with inpos cysteine nn further rbr enhanced vbd the dt permeation nn
false	20	2	unmodified jj nacmc nnp significantly rb improved vbd the dt transport nn ratio nn polymer nn control nn rrb_of inpos naflu nn to topos float cd and cc num cd nacmc nn conjugated vbn with inpos cysteine nn further rbr enhanced vbd the dt permeation nn
false	20	36	unmodified jj nacmc nnp significantly rb improved vbd the dt transport nn ratio nn p nn control nn rrb_of inpos naflu nn to topos float cd and cc num cd nacmc nn conjugated vbn with inpos cysteine nn further rbr enhanced vbd the dt permeation nn
false	2	36	unmodified jj nacmc nnp significantly rb improved vbd the dt transport nn ratio nn polymer nn control nn rrb_of inpos naflu nn to topos float cd and cc num cd nacmc nn conjugated vbn with inpos cysteine nn further rbr enhanced vbd the dt permeation nn
false	8	18	decreasing vbg the dt concentration nn of inpos cmc_cys nn exhibiting vbg float cd of inpos immobilised jj cysteine nn from inpos num cd to topos float cd decreased vbd the dt r_value nn of inpos naflu nnp from inpos float cd to topos float cd
false	8	36	decreasing vbg the dt concentration nn of inpos cmc_cys nn exhibiting vbg float cd of inpos immobilised jj cysteine nn from inpos num cd to topos float cd decreased vbd the dt r_value nn of inpos naflu nn from inpos float cd to topos float cd
false	18	36	decreasing vbg the dt concentration nn of inpos cmc_cys nn exhibiting vbg float cd of inpos immobilised jj cysteine nn from inpos num cd to topos float cd decreased vbd the dt r_value nn of inpos naflu nn from inpos float cd to topos float cd
false	0	16	nacmc nn at inpos num cd in inpos the dt presence nn of inpos free jj cysteine nn had vbd no dt significant jj effect nn on inpos the dt r_value nn of inpos naflu nn compared vbn to topos nacmc nn alone rb
false	0	34	nacmc nn at inpos num cd in inpos the dt presence nn of inpos free jj cysteine nn had vbd no dt significant jj effect nn on inpos the dt r_value nn of inpos naflu nn compared vbn to topos nacmc nn alone rb
false	16	34	nacmc nn at inpos num cd in inpos the dt presence nn of inpos free jj cysteine nn had vbd no dt significant jj effect nn on inpos the dt r_value nn of inpos naflu nn compared vbn to topos nacmc nn alone rb
false	16	0	nacmc nn at inpos num cd in inpos the dt presence nn of inpos free jj cysteine nn had vbd no dt significant jj effect nn on inpos the dt r_value nn of inpos naflu nn compared vbn to topos nacmc nn alone rb
false	34	0	nacmc nn at inpos num cd in inpos the dt presence nn of inpos free jj cysteine nn had vbd no dt significant jj effect nn on inpos the dt r_value nn of inpos naflu nn compared vbn to topos nacmc nn alone rb
false	8	12	formulation nn of inpos fluorescence nn labelled vbn bacitracin nn and cc insulin nn in inpos unconjugated jj nacmc nn did vbd not rb significantly rb improve vb the dt permeation nn however rb in inpos the dt presence nn of inpos num cd cmc_cys7.3 nn a dt significantly rb improved vbn permeation nn was vbd observed vbn
false	8	18	formulation nn of inpos fluorescence nn labelled vbn bacitracin nn and cc insulin nn in inpos unconjugated jj nacmc nn did vbd not rb significantly rb improve vb the dt permeation nn however rb in inpos the dt presence nn of inpos num cd cmc_cys7.3 nn a dt significantly rb improved vbn permeation nn was vbd observed vbn
false	8	44	formulation nn of inpos fluorescence nn labelled vbn bacitracin nn and cc insulin nn in inpos unconjugated jj nacmc nn did vbd not rb significantly rb improve vb the dt permeation nn however rb in inpos the dt presence nn of inpos num cd cmc_cys nn float cd a dt significantly rb improved vbn permeation nn was vbd observed vbn
false	12	18	formulation nn of inpos fluorescence nn labelled vbn bacitracin nn and cc insulin nn in inpos unconjugated jj nacmc nn did vbd not rb significantly rb improve vb the dt permeation nn however rb in inpos the dt presence nn of inpos num cd cmc_cys7.3 nn a dt significantly rb improved vbn permeation nn was vbd observed vbn
false	12	44	formulation nn of inpos fluorescence nn labelled vbn bacitracin nn and cc insulin nn in inpos unconjugated jj nacmc nn did vbd not rb significantly rb improve vb the dt permeation nn however rb in inpos the dt presence nn of inpos num cd cmc_cys nn float cd a dt significantly rb improved vbn permeation nn was vbd observed vbn
false	18	44	formulation nn of inpos fluorescence nn labelled vbn bacitracin nn and cc insulin nn in inpos unconjugated jj nacmc nn did vbd not rb significantly rb improve vb the dt permeation nn however rb in inpos the dt presence nn of inpos num cd cmc_cys nn float cd a dt significantly rb improved vbn permeation nn was vbd observed vbn
false	4	8	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	4	30	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	4	40	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	4	42	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	8	30	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	8	40	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	8	42	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	30	40	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	30	42	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	40	42	conjugation nn at inpos nacmc nn with inpos cysteine nn moieties nns significantly rb improves vbz the dt intestinal jj permeation nn of inpos the dt hydrophilic jj molecule nn naflu nn the dt model nn peptide nn drugs nns bacitracin nn insulin nn in fw vitro fw therefore rb this dt conjugated vbn system nn maybe rb useful jj for inpos peroral jj administration nn of inpos peptide nn drugs nns in inpos the dt future nn
false	30	38	the dt objective nn of inpos this dt study nn was vbd to topos determine vb if inpos there ex is vbz a dt pharmacokinetic jj interaction nn when wrb amprenavir nn is vbz given vbn with inpos rifabutin nn or cc rifampin nn and cc to topos determine vb the dt effects nns of inpos these dt drugs nns on inpos the dt erythromycin nn breath nn test nn
false	30	42	the dt objective nn of inpos this dt study nn was vbd to topos determine vb if inpos there ex is vbz a dt pharmacokinetic jj interaction nn when wrb amprenavir nn is vbz given vbn with inpos rifabutin nn or cc rifampin nn and cc to topos determine vb the dt effects nns of inpos these dt drugs nns on inpos the dt erythromycin nn breath nn test nn
false	38	42	the dt objective nn of inpos this dt study nn was vbd to topos determine vb if inpos there ex is vbz a dt pharmacokinetic jj interaction nn when wrb amprenavir nn is vbz given vbn with inpos rifabutin nn or cc rifampin nn and cc to topos determine vb the dt effects nns of inpos these dt drugs nns on inpos the dt erythromycin nn breath nn test nn
false	6	32	all dt subjects nns received vbd amprenavir nn for inpos num cd days nns followed vbn by inpos a dt num_day jj washout nn period nn followed vbn by inpos either cc rifabutin nn or cc rifampin nn for inpos num cd days nns
false	6	36	all dt subjects nns received vbd amprenavir nn for inpos num cd days nns followed vbn by inpos a dt num_day jj washout nn period nn followed vbn by inpos either cc rifabutin nn or cc rifampin nn for inpos num cd days nns
false	32	36	all dt subjects nns received vbd amprenavir nn for inpos num cd days nns followed vbn by inpos a dt num_day jj washout nn period nn followed vbn by inpos either cc rifabutin nn or cc rifampin nn for inpos num cd days nns
false	8	12	cohort nnp num cd then rb received vbd amprenavir nn plus cc rifabutin nn for inpos num cd days nns and cc cohort jj num cd received vbd amprenavir nn plus cc rifampin nn for inpos num cd days nns
false	8	32	cohort nnp num cd then rb received vbd amprenavir nn plus cc rifabutin nn for inpos num cd days nns and cc cohort jj num cd received vbd amprenavir nn plus cc rifampin nn for inpos num cd days nns
false	12	8	cohort nnp num cd then rb received vbd amprenavir nn plus cc rifabutin nn for inpos num cd days nns and cc cohort jj num cd received vbd amprenavir nn plus cc rifampin nn for inpos num cd days nns
false	12	32	cohort nnp num cd then rb received vbd amprenavir nn plus cc rifabutin nn for inpos num cd days nns and cc cohort jj num cd received vbd amprenavir nn plus cc rifampin nn for inpos num cd days nns
false	8	32	cohort nnp num cd then rb received vbd amprenavir nn plus cc rifabutin nn for inpos num cd days nns and cc cohort jj num cd received vbd amprenavir nn plus cc rifampin nn for inpos num cd days nns
false	0	10	rifabutin nn did vbd not rb significantly rb affect vb amprenavir nn s pos pharmacokinetics nns
mechanism	0	24	amprenavir nn significantly rb increased vbd the dt area nn under inpos the dt curve nn at inpos steady jj state nn rrb_of inpos rifabutin nn by inpos float_fold jj and cc the dt auc nn of inpos num_o_desacetylrifabutin nn by inpos float_fold jj
mechanism	0	38	amprenavir nn significantly rb increased vbd the dt area nn under inpos the dt curve nn at inpos steady jj state nn rrb_of inpos rifabutin nn by inpos float_fold jj and cc the dt auc nn of inpos num_o_desacetylrifabutin nn by inpos float_fold jj
mechanism	0	12	rifampin nn significantly rb decreased vbd the dt auc nn of inpos amprenavir nn by inpos num cd but cc amprenavir nn had vbd no dt effect nn on inpos rifampin nn pharmacokinetics nns
false	0	12	rifampin nn significantly rb decreased vbd the dt auc nn of inpos amprenavir nn by inpos num cd but cc amprenavir nn had vbd no dt effect nn on inpos rifampin nn pharmacokinetics nns
false	12	0	rifampin nn significantly rb decreased vbd the dt auc nn of inpos amprenavir nn by inpos num cd but cc amprenavir nn had vbd no dt effect nn on inpos rifampin nn pharmacokinetics nns
false	12	0	rifampin nn significantly rb decreased vbd the dt auc nn of inpos amprenavir nn by inpos num cd but cc amprenavir nn had vbd no dt effect nn on inpos rifampin nn pharmacokinetics nns
false	18	22	the dt results nns of inpos the dt ermbt nn after inpos num cd weeks nns of inpos rifabutin nn and cc rifampin nn therapy nn were vbd increased vbn num cd and cc num cd respectively rb
false	0	4	amprenavir nn plus cc rifampin nn was vbd well rb tolerated vbn
effect	0	4	amprenavir nn plus cc rifabutin nn was vbd poorly rb tolerated vbn and cc num cd of inpos num cd subjects nns discontinued vbd therapy nn
mechanism	0	14	rifampin nn markedly rb increases vbz the dt metabolic jj clearance nn of inpos amprenavir nn and cc coadministration nn is vbz contraindicated vbn
mechanism	0	10	amprenavir nn significantly rb decreases vbz clearance nn of inpos rifabutin nn and cc num_o_desacetylrifabutin nn and cc the dt combination nn is vbz poorly rb tolerated vbn
mechanism	0	14	amprenavir nn significantly rb decreases vbz clearance nn of inpos rifabutin nn and cc num_o_desacetylrifabutin nn and cc the dt combination nn is vbz poorly rb tolerated vbn
false	0	10	amprenavir nn inhibits vbz the dt ermbt nn and cc rifampin nn and cc rifabutin nn are vbp equipotent jj inducers nns of inpos the dt ermbt nn
false	0	14	amprenavir nn inhibits vbz the dt ermbt nn and cc rifampin nn and cc rifabutin nn are vbp equipotent jj inducers nns of inpos the dt ermbt nn
false	10	14	amprenavir nn inhibits vbz the dt ermbt nn and cc rifampin nn and cc rifabutin nn are vbp equipotent jj inducers nns of inpos the dt ermbt nn
false	2	14	the dt thiazolidinediones nn a dt new jj class nn of inpos oral jj antidiabetic_agents nn are vbp insulin nn sensitizers nns
false	2	14	the dt rosiglitazone nn a dt new jj class nn of inpos oral jj antidiabetic_agents nn are vbp insulin nn sensitizers nns
false	2	14	the dt pioglitazone nn a dt new jj class nn of inpos oral jj antidiabetic_agents nn are vbp insulin nn sensitizers nns
false	0	14	glucose nn alone rb and cc in inpos the dt presence nn of inpos theophylline nn caused vbd subnormal jj insulin nn release nn and cc less jjr suppression nn of inpos glucagon nn release nn in inpos the dt diabectics nns than inpos in inpos the dt normals nns
false	0	10	arginine nn in inpos the dt presence nn of inpos glucose nn and cc theophylline nn caused vbd excessive jj glucagon nn release nn but cc nearly rb normal jj insulin nn release nn in inpos the dt diabetics nns
false	0	14	arginine nn in inpos the dt presence nn of inpos glucose nn and cc theophylline nn caused vbd excessive jj glucagon nn release nn but cc nearly rb normal jj insulin nn release nn in inpos the dt diabetics nns
false	10	14	arginine nn in inpos the dt presence nn of inpos glucose nn and cc theophylline nn caused vbd excessive jj glucagon nn release nn but cc nearly rb normal jj insulin nn release nn in inpos the dt diabetics nns
false	0	10	arginine nn in inpos the dt absence nn of inpos glucose nn or cc theophylline nn caused vbd excessive jj glucagon nn release nn in inpos the dt diabetics nns and cc undetectable jj insulin nn release nn in inpos either cc diabetics nns or cc normals nns
false	0	14	arginine nn in inpos the dt absence nn of inpos glucose nn or cc theophylline nn caused vbd excessive jj glucagon nn release nn in inpos the dt diabetics nns and cc undetectable jj insulin nn release nn in inpos either cc diabetics nns or cc normals nns
false	10	14	arginine nn in inpos the dt absence nn of inpos glucose nn or cc theophylline nn caused vbd excessive jj glucagon nn release nn in inpos the dt diabetics nns and cc undetectable jj insulin nn release nn in inpos either cc diabetics nns or cc normals nns
false	34	46	further rb these dt results nns confirm vbp that inpos the dt diabetic jj chinese jj hamster nn s pos ap nn and cc b nn cells nns respond vbp normally rb to topos theophylline nn but cc are vbp relatively rb insensitive jj to topos glucose nn
effect	0	12	etofibrate nn elicited vbd num cd enhancement nn of inpos post jj heparin nn lipolytic jj activity nn and cc num cd increase nn of inpos 3h_triglyceride nn fractional jj clearance nn rate nn compared vbn with inpos placebo nn treatment nn
false	16	24	the dt mode nn of inpos toxic jj action nn of inpos the dt pesticide nn gliftor nn the dt metabolism nn of inpos nums_difluoroacetone nn to topos erythro_fluorocitrate vb
false	16	28	the dt mode nn of inpos toxic jj action nn of inpos the dt pesticide nn gliftor nn the dt metabolism nn of inpos nums_difluoroacetone nn to topos erythro_fluorocitrate nn
false	24	28	the dt mode nn of inpos toxic jj action nn of inpos the dt pesticide nn gliftor nn the dt metabolism nn of inpos nums_difluoroacetone nn to topos erythro_fluorocitrate nn
false	8	30	the dt biochemical jj toxicology nn of inpos nums_difluoroacetone nn a dt known jj metabolite nn of inpos the dt major jj ingredient nn of inpos the dt pesticide nn gliftor nn was vbd investigated vbn in fw vivo fw and cc in fw vitro fw
false	8	30	the dt biochemical jj toxicology nn of inpos nums_difluoroacetone nn a dt known jj metabolite nn of inpos the dt major jj ingredient nn of inpos the dt pesticide nn nums_difluoro_num_propanol nn was vbd investigated vbn in fw vivo fw and cc in fw vitro fw
false	22	26	rat nn kidney nn homogenates nns supplemented vbn with inpos coenzyme nn a nn atp nn oxaloacetate nn mg2+ nn converted vbd nums_difluoroacetone nn to topos erythro_fluorocitrate nn in fw vitro fw
false	4	22	administration nn of inpos nums_difluoroacetone nn body nn weight nn rrb_to topos rats nns in fw vivo fw resulted vbd in inpos erythro_fluorocitrate nn synthesis nn in inpos the dt kidney nn which wdt was vbd preceded vbn by inpos an dt elevation nn in inpos fluoride nn levels nns and cc followed vbn by inpos citrate nn accumulation nn
false	6	28	animals nns dosed vbn with inpos nums_difluoroacetone nn did vbd not rb display vb the dt num cd hour nn lag nn phase nn in inpos either cc erythro_fluorocitrate nn synthesis nn or cc in inpos citrate nn and cc fluoride nn accumulation nn characteristic jj of inpos animals nns dosed vbn with inpos nums_difluoro_num_propanol nn
false	6	54	animals nns dosed vbn with inpos nums_difluoroacetone nn did vbd not rb display vb the dt num cd hour nn lag nn phase nn in inpos either cc erythro_fluorocitrate jj synthesis nn or cc in inpos citrate nn and cc fluoride nn accumulation nn characteristic jj of inpos animals nns dosed vbn with inpos nums_difluoro_num_propanol nn
false	28	54	animals nns dosed vbn with inpos nums_difluoroacetone nn did vbd not rb display vb the dt num cd hour nn lag nn phase nn in inpos either cc erythro_fluorocitrate nn synthesis nn or cc in inpos citrate nn and cc fluoride nn accumulation nn characteristic jj of inpos animals nns dosed vbn with inpos nums_difluoro_num_propanol nn
false	12	16	we prp demonstrate vbp that inpos the dt conversion nn of inpos nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn by inpos an dt nad+_dependent jj oxidation nn is vbz the dt rate_limiting jj step nn in inpos the dt synthesis nn of inpos the dt toxic jj product nn erythro_fluorocitrate jj from inpos nums_difluoro_num_propanol nn
false	12	48	we prp demonstrate vbp that inpos the dt conversion nn of inpos nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn by inpos an dt nad+_dependent jj oxidation nn is vbz the dt rate_limiting jj step nn in inpos the dt synthesis nn of inpos the dt toxic jj product nn erythro_fluorocitrate nn from inpos nums_difluoro_num_propanol nn
false	16	48	we prp demonstrate vbp that inpos the dt conversion nn of inpos nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn by inpos an dt nad+_dependent jj oxidation nn is vbz the dt rate_limiting jj step nn in inpos the dt synthesis nn of inpos the dt toxic jj product nn erythro_fluorocitrate nn from inpos nums_difluoro_num_propanol nn
false	16	12	we prp demonstrate vbp that inpos the dt conversion nn of inpos nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn by inpos an dt nad+_dependent jj oxidation nn is vbz the dt rate_limiting jj step nn in inpos the dt synthesis nn of inpos the dt toxic jj product nn erythro_fluorocitrate jj from inpos nums_difluoro_num_propanol nn
false	48	12	we prp demonstrate vbp that inpos the dt conversion nn of inpos nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn by inpos an dt nad+_dependent jj oxidation nn is vbz the dt rate_limiting jj step nn in inpos the dt synthesis nn of inpos the dt toxic jj product nn erythro_fluorocitrate nn from inpos nums_difluoro_num_propanol nn
effect	6	26	prior jj administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_was vbd shown vbn to topos prevent vb the dt conversion nn of inpos nums_difluoro_num_propanol nn body nn weight nn rrb_to topos erythro_fluorocitrate vb in fw vivo fw and cc to topos eliminate vb the dt fluoride nn and cc citrate nn elevations nns seen vbn in inpos nums_difluoro_num_propanol_intoxicated jj animals nns
false	6	34	prior jj administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_was vbd shown vbn to topos prevent vb the dt conversion nn of inpos nums_difluoro_num_propanol nn body nn weight nn rrb_to topos erythro_fluorocitrate nn in fw vivo fw and cc to topos eliminate vb the dt fluoride nn and cc citrate nn elevations nns seen vbn in inpos nums_difluoro_num_propanol_intoxicated jj animals nns
false	6	26	prior jj administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_was vbd shown vbn to topos prevent vb the dt conversion nn of inpos nums_difluoro_num_propanol nn body nn weight nn rrb_to topos erythro_fluorocitrate vb in fw vivo fw and cc to topos eliminate vb the dt fluoride nn and cc citrate nn elevations nns seen vbn in inpos nums_difluoro_num_propanol nn intoxicated jj animals nns
false	26	34	prior jj administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_was vbd shown vbn to topos prevent vb the dt conversion nn of inpos nums_difluoro_num_propanol nn body nn weight nn rrb_to topos erythro_fluorocitrate nn in fw vivo fw and cc to topos eliminate vb the dt fluoride nn and cc citrate nn elevations nns seen vbn in inpos nums_difluoro_num_propanol_intoxicated jj animals nns
false	34	26	prior jj administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_was vbd shown vbn to topos prevent vb the dt conversion nn of inpos nums_difluoro_num_propanol nn body nn weight nn rrb_to topos erythro_fluorocitrate nn in fw vivo fw and cc to topos eliminate vb the dt fluoride nn and cc citrate nn elevations nns seen vbn in inpos nums_difluoro_num_propanol nn intoxicated jj animals nns
false	6	24	however rb administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_to topos rats nns num cd hours nns prior rb to topos nums_difluoroacetone nn body nn weight nn rrb_was vbd ineffective jj in inpos preventing vbg erythro_fluorocitrate jj synthesis nn and cc did vbd not rb diminish vb fluoride nn or cc citrate nn accumulation nn in fw vivo fw
false	6	38	however rb administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_to topos rats nns num cd hours nns prior rb to topos nums_difluoroacetone nn body nn weight nn rrb_was vbd ineffective jj in inpos preventing vbg erythro_fluorocitrate nn synthesis nn and cc did vbd not rb diminish vb fluoride nn or cc citrate nn accumulation nn in fw vivo fw
false	24	38	however rb administration nn of inpos num_methylpyrazole nn body nn weight nn rrb_to topos rats nns num cd hours nns prior rb to topos nums_difluoroacetone nn body nn weight nn rrb_was vbd ineffective jj in inpos preventing vbg erythro_fluorocitrate nn synthesis nn and cc did vbd not rb diminish vb fluoride nn or cc citrate nn accumulation nn in fw vivo fw
effect	18	30	we prp conclude vbp that inpos the dt prophylactic jj and cc antidotal jj properties nns of inpos num_methylpyrazole nn seen vbn in inpos animals nns treated vbn with inpos nums_difluoro_num_propanol nn derive vbp from inpos its prp capacity nn to topos inhibit vb the dt nad+_dependent jj oxidation nn responsible jj for inpos converting vbg nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn in inpos the dt committed jj step nn of inpos the dt toxic jj pathway nn
false	18	30	we prp conclude vbp that inpos the dt prophylactic jj and cc antidotal jj properties nns of inpos num_methylpyrazole nn seen vbn in inpos animals nns treated vbn with inpos nums_difluoro_num_propanol nn derive vbp from inpos its prp capacity nn to topos inhibit vb the dt nad+_dependent jj oxidation nn responsible jj for inpos converting vbg nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn in inpos the dt committed jj step nn of inpos the dt toxic jj pathway nn
false	18	60	we prp conclude vbp that inpos the dt prophylactic jj and cc antidotal jj properties nns of inpos num_methylpyrazole nn seen vbn in inpos animals nns treated vbn with inpos nums_difluoro_num_propanol nn derive vbp from inpos its prp capacity nn to topos inhibit vb the dt nad+_dependent jj oxidation nn responsible jj for inpos converting vbg nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn in inpos the dt committed jj step nn of inpos the dt toxic jj pathway nn
false	30	60	we prp conclude vbp that inpos the dt prophylactic jj and cc antidotal jj properties nns of inpos num_methylpyrazole nn seen vbn in inpos animals nns treated vbn with inpos nums_difluoro_num_propanol nn derive vbp from inpos its prp capacity nn to topos inhibit vb the dt nad+_dependent jj oxidation nn responsible jj for inpos converting vbg nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn in inpos the dt committed jj step nn of inpos the dt toxic jj pathway nn
false	30	60	we prp conclude vbp that inpos the dt prophylactic jj and cc antidotal jj properties nns of inpos num_methylpyrazole nn seen vbn in inpos animals nns treated vbn with inpos nums_difluoro_num_propanol nn derive vbp from inpos its prp capacity nn to topos inhibit vb the dt nad+_dependent jj oxidation nn responsible jj for inpos converting vbg nums_difluoro_num_propanol nn to topos nums_difluoroacetone nn in inpos the dt committed jj step nn of inpos the dt toxic jj pathway nn
false	0	6	green_tea_polyphenols nn as inpos potent jj enhancers nn of inpos glucocorticoid_induced jj mouse nn mammary jj tumor nn virus nn gene nn expression nn
false	0	30	n_dodecyl_gallate nn showed vbd the dt most rbs potent jj inhibition nn which wdt was vbd far rb more rbr potent jj than inpos that dt of inpos crude jj tannic_acid nn
mechanism	14	18	pharmacokinetic jj interaction nn between inpos single jj oral jj doses nns of inpos diltiazem nn and cc sirolimus nn in inpos healthy jj volunteers nns
false	8	12	the dt pharmacokinetic jj interaction nn between inpos sirolimus nn a dt macrolide_immunosuppressant nn metabolized vbn by inpos cyp3a4 nn and cc the dt calcium_channel_blocker nn diltiazem nn was vbd studied vbn in inpos num cd healthy jj subjects nns
false	8	24	the dt pharmacokinetic jj interaction nn between inpos sirolimus nn a dt macrolide_immunosuppressant nn metabolized vbn by inpos cyp3a4 nn and cc the dt calcium_channel_blocker nn diltiazem nn was vbd studied vbn in inpos num cd healthy jj subjects nns
false	8	26	the dt pharmacokinetic jj interaction nn between inpos sirolimus nn a dt macrolide_immunosuppressant nn metabolized vbn by inpos cyp3a4 nn and cc the dt calcium_channel_blocker nn diltiazem nn was vbd studied vbn in inpos num cd healthy jj subjects nns
false	12	24	the dt pharmacokinetic jj interaction nn between inpos sirolimus nn a dt macrolide_immunosuppressant nn metabolized vbn by inpos cyp3a4 nn and cc the dt calcium_channel_blocker nn diltiazem nn was vbd studied vbn in inpos num cd healthy jj subjects nns
false	12	26	the dt pharmacokinetic jj interaction nn between inpos sirolimus nn a dt macrolide_immunosuppressant nn metabolized vbn by inpos cyp3a4 nn and cc the dt calcium_channel_blocker nn diltiazem nn was vbd studied vbn in inpos num cd healthy jj subjects nns
false	24	26	the dt pharmacokinetic jj interaction nn between inpos sirolimus nn a dt macrolide_immunosuppressant nn metabolized vbn by inpos cyp3a4 nn and cc the dt calcium_channel_blocker nn diltiazem nn was vbd studied vbn in inpos num cd healthy jj subjects nns
false	20	40	several jj clinically rb important jj interactions nns have vbp previously rb been vbn reported vbn for inpos other jj immunosuppressive_drugs nn that wdt are vbp metabolized vbn by inpos the dt same jj enzyme nn and cc for inpos calcium_antagonists nn
false	54	68	healthy jj subjects nns who wp were vbd num cd to topos num cd years nns old jj participated vbn in inpos an dt open jj three_period jj randomized vbn crossover nn study nn of inpos the dt pharmacokinetics nns of inpos a dt single jj num_mg jj oral jj dose nn of inpos sirolimus nn a dt single jj oral jj num_mg nn dose nn of inpos diltiazem nn and cc the dt num cd drugs nns given vbn together rb
mechanism	10	62	the dt geometric jj mean jj whole jj blood nn sirolimus nn area nn under inpos the dt plasma nn concentration nn time_curve nn increased vbd num cd from inpos num cd to topos num cd ng nn x_h_ml nn and cc maximum jj concentration nn increased vbd num cd from inpos num cd to topos num cd ng_ml nn with inpos diltiazem nn coadministration nn whereas inpos the dt mean jj elimination nn half_life nn of inpos sirolimus nn decreased vbd slightly rb from inpos num cd to topos num cd hours nns
false	62	10	the dt geometric jj mean jj whole jj blood nn sirolimus nn area nn under inpos the dt plasma nn concentration nn time_curve nn increased vbd num cd from inpos num cd to topos num cd ng nn x_h_ml nn and cc maximum jj concentration nn increased vbd num cd from inpos num cd to topos num cd ng_ml nn with inpos diltiazem nn coadministration nn whereas inpos the dt mean jj elimination nn half_life nn of inpos sirolimus nn decreased vbd slightly rb from inpos num cd to topos num cd hours nns
false	16	40	apparent jj oral jj clearance nn and cc volume nn of inpos distribution nn of inpos sirolimus nn decreased vbd with inpos num cd and cc num cd respectively rb when wrb sirolimus nn was vbd given vbn with inpos diltiazem nn
mechanism	16	40	apparent jj oral jj clearance nn and cc volume nn of inpos distribution nn of inpos sirolimus nn decreased vbd with inpos num cd and cc num cd respectively rb when wrb sirolimus nn was vbd given vbn with inpos diltiazem nn
false	24	36	the dt plasma nn maximum nn concentration nn and cc area nn under inpos the dt plasma nn concentration_time jj curve nn of inpos diltiazem nn were vbd unchanged jj after inpos coadministration nn of inpos sirolimus nn and cc no dt potentiation nn of inpos the dt effects nns of inpos diltiazem nn on inpos diastolic jj or cc systolic jj blood nn pressure nn or cc on inpos the dt electrocardiographic jj parameters nns was vbd seen vbn
false	24	36	the dt plasma nn maximum nn concentration nn and cc area nn under inpos the dt plasma nn concentration_time jj curve nn of inpos desacetyldiltiazem nn were vbd unchanged jj after inpos coadministration nn of inpos sirolimus nn and cc no dt potentiation nn of inpos the dt effects nns of inpos diltiazem nn on inpos diastolic jj or cc systolic jj blood nn pressure nn or cc on inpos the dt electrocardiographic jj parameters nns was vbd seen vbn
false	24	36	the dt plasma nn maximum nn concentration nn and cc area nn under inpos the dt plasma nn concentration_time jj curve nn of inpos desmethyldiltiazem nn were vbd unchanged jj after inpos coadministration nn of inpos sirolimus nn and cc no dt potentiation nn of inpos the dt effects nns of inpos diltiazem nn on inpos diastolic jj or cc systolic jj blood nn pressure nn or cc on inpos the dt electrocardiographic jj parameters nns was vbd seen vbn
false	40	24	the dt plasma nn maximum nn concentration nn and cc area nn under inpos the dt plasma nn concentration_time jj curve nn of inpos diltiazem nn desacetyldiltiazem nn desmethyldiltiazem nn were vbd unchanged jj after inpos coadministration nn of inpos sirolimus nn and cc no dt potentiation nn of inpos the dt effects nns of inpos diltiazem nn on inpos diastolic jj or cc systolic jj blood nn pressure nn or cc on inpos the dt electrocardiographic jj parameters nns was vbd seen vbn
mechanism	2	12	single_dose jj diltiazem nn coadministration nn leads vbz to topos higher jjr sirolimus nn exposure nn presumably rb by inpos inhibition nn of inpos the dt first_pass jj metabolism nn of inpos sirolimus nn
false	2	12	single_dose jj diltiazem nn coadministration nn leads vbz to topos higher jjr sirolimus nn exposure nn presumably rb by inpos inhibition nn of inpos the dt first_pass jj metabolism nn of inpos sirolimus nn
advise	22	24	because inpos of inpos the dt pronounced jj intersubject jj variability nn in inpos the dt extent nn of inpos the dt sirolimus nn hyph_diltiazem nn interaction nn whole jj blood nn sirolimus nn concentrations nns should md be vb monitored vbn closely rb in inpos patients nns treated vbn with inpos the dt num cd drugs nns
false	24	22	because inpos of inpos the dt pronounced jj intersubject jj variability nn in inpos the dt extent nn of inpos the dt sirolimus jj diltiazem nn interaction nn whole jj blood nn sirolimus nn concentrations nns should md be vb monitored vbn closely rb in inpos patients nns treated vbn with inpos the dt num cd drugs nns
mechanism	0	14	fluvoxamine nn inhibits vbz the dt cyp2c9 nn catalyzed vbd biotransformation nn of inpos tolbutamide nn
false	16	20	our prp objective nn was vbd to topos examine vb the dt interaction nn between inpos fluvoxamine nn and cc tolbutamide nn to topos confirm vb that inpos fluvoxamine nn inhibits vbz cyp2c9 nn
false	20	16	our prp objective nn was vbd to topos examine vb the dt interaction nn between inpos fluvoxamine nn and cc tolbutamide nn to topos confirm vb that inpos fluvoxamine nn inhibits vbz cyp2c9 nn
false	30	34	plasma nn was vbd analyzed vbn for inpos tolbutamide nn and cc urine nn was vbd analyzed vbn for inpos tolbutamide nn and cc its prp num cd metabolites nns num_hydroxytolbutamide nn and cc carboxytolbutamide nn by inpos means nns of inpos hplc nn
mechanism	8	38	results nns during inpos treatment nn with inpos fluvoxamine nn there ex was vbd a dt statistically rb significant jj decrease nn in inpos the dt median nn of inpos the dt total jj clearance nn of inpos tolbutamide nn from inpos num cd ml_h nn to topos num cd ml_h nn among inpos the dt volunteers nns who wp received vbd num cd mg_d nn
false	10	14	the dt clearance nn by inpos means nns of inpos num_hydroxytolbutamide nn and cc carboxytolbutamide nn was vbd significantly rb reduced vbn in inpos both dt groups nns
false	6	40	longitudinal jj assessment nn of inpos everolimus nn in inpos de fw novo fw renal jj transplant nn recipients nns over inpos the dt first jj post_transplant jj year nn pharmacokinetics nns exposure_response jj relationships nns influence nn on inpos cyclosporine nn
false	18	22	our prp objective nn was vbd to topos characterize vb the dt steady_state jj pharmacokinetics nns of inpos everolimus nn and cc cyclosporine nn when wrb coadministered vbn in inpos de fw novo fw kidney nn allograft nn recipients nns during inpos the dt first jj year nn after inpos transplantation nn
false	18	22	our prp objective nn was vbd to topos characterize vb the dt steady_state jj pharmacokinetics nns of inpos everolimus nn and cc ciclosporin nn when wrb coadministered vbn in inpos de fw novo fw kidney nn allograft nn recipients nns during inpos the dt first jj year nn after inpos transplantation nn
false	40	68	this dt study nn was vbd a dt multicenter jj randomized vbn double_blind jj study nn of inpos num cd patients nns who wp were vbd randomly rb assigned vbn num cd num cd num cd to topos receive vb everolimus nn tablets nns at inpos doses nns of inpos float cd mg nn num cd mg nn num cd mg nn twice rb daily rb with inpos cyclosporine nn and cc prednisone nn
false	40	72	this dt study nn was vbd a dt multicenter jj randomized vbn double_blind jj study nn of inpos num cd patients nns who wp were vbd randomly rb assigned vbn num cd num cd num cd to topos receive vb everolimus nn tablets nns at inpos doses nns of inpos float cd mg nn num cd mg nn num cd mg nn twice rb daily rb with inpos cyclosporine nn and cc prednisone nn
false	68	72	this dt study nn was vbd a dt multicenter jj randomized vbn double_blind jj study nn of inpos num cd patients nns who wp were vbd randomly rb assigned vbn num cd num cd num cd to topos receive vb everolimus nn tablets nns at inpos doses nns of inpos float cd mg nn num cd mg nn num cd mg nn twice rb daily rb with inpos cyclosporine nn and cc prednisone nn
false	12	16	blood nn sampling vbg for inpos the dt pharmacokinetics nns of inpos everolimus nn and cc cyclosporine nn was vbd performed vbn on inpos day nn num cd on inpos weeks nns num cd num cd num cd num cd and cc on inpos months nns num cd num cd num cd num cd num cd
false	6	22	potential jj differences nns in inpos cyclosporine nn dosing nn and cc pharmacokinetics nns at inpos different jj levels nns of inpos everolimus nn exposure nn were vbd assessed vbn in inpos the dt context nn of inpos anova nn
false	0	38	cyclosporine nn doses nns trough nn concentrations nns auc nn exhibited vbd similar jj temporal jj patterns nns during inpos the dt course nn of inpos the dt study nn regardless rb of inpos the dt co_administered vbn everolimus nn dose nn level nn
false	10	26	for inpos a dt num_fold jj range nn of inpos everolimus nn doses nns there ex were vbd no dt differential jj effects nns on inpos cyclosporine nn dosing nn or cc pharmacokinetics nns
effect	0	18	adl_num_num nn a dt trans_nums_dimethyl_num nn piperidine nn prevents vbz gastrointestinal jj effects nns of inpos intravenous jj morphine nn without inpos affecting vbg analgesia nn
false	0	8	adl_num_num nn is vbz a dt novel jj peripherally_restricted_opioid_antagonist nn that wdt may md selectively rb prevent vb opioid_induced jj gastrointestinal jj effects nns without inpos reversing vbg analgesia nn
effect	0	8	adl_num_num nn is vbz a dt novel jj peripherally_restricted_opioid_antagonist nn that wdt may md selectively rb prevent vb opioid nn induced jj gastrointestinal jj effects nns without inpos reversing vbg analgesia nn
false	34	38	gastrointestinal jj transit nn time nn was vbd measured vbn in inpos num cd volunteers nns with inpos oral jj and cc intravenous jj placebo nn oral jj placebo nn and cc intravenous jj morphine nn rrb_oral jj adl_num_num nn intravenous jj morphine nn rrb_in inpos a dt double jj blind jj cross_over jj study nn
false	38	34	gastrointestinal jj transit nn time nn was vbd measured vbn in inpos num cd volunteers nns with inpos oral jj and cc intravenous jj placebo nn oral jj placebo nn and cc intravenous jj morphine nn rrb_oral jj adl_num_num nn intravenous jj morphine nn rrb_in inpos a dt double jj blind jj cross_over jj study nn
effect	0	28	morphine nn prolonged vbd gastrointestinal jj transit nn time nn from inpos num cd to topos num cd minutes nns this dt was vbd prevented vbn by inpos adl_num_num nn
false	0	16	morphine nn analgesia nn and cc pupil nn constriction nn were vbd unaffected jj by inpos adl_num_num nn and cc differed vbd from inpos placebo nn
effect	6	10	we prp conclude vbp that inpos adl_num_num nn prevents vbz morphine nn induced jj increases nns in inpos gastrointestinal jj transit nn time nn by inpos means nns of inpos selective jj peripheral jj opioid jj anitagonism nn without inpos affecting vbg central jj opioid jj analgesia nn
effect	14	18	rhabdomyolysis nn secondary jj to topos a dt drug nn interaction nn between inpos simvastatin nn and cc clarithromycin nn
false	22	26	to topos report vb a dt case nn of inpos rhabdomyolysis nn resulting vbg from inpos concomitant jj use nn of inpos clarithromycin nn and cc simvastatin nn
mechanism	0	24	clarithromycin nn is vbz a dt potent jj inhibitor nn of inpos cyp3a4 nn the dt major jj enzyme nn responsible jj for inpos simvastatin nn metabolism nn
effect	8	14	the dt concomitant jj administration nn of inpos macrolide_antibiotics nn and cc other jj hydroxymethylglutaryl_coenzyme_a_hmg_coa_reductase_inhibitors nn have vbp resulted vbn in inpos previous jj reports nns of inpos rhabdomyolysis nn
false	0	10	macrolide_antibiotics nn inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nn that wdt are vbp metabolized vbn by inpos cyp3a4 nn
mechanism	0	20	macrolide_antibiotics nn inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nns that wdt are vbp metabolized vbn by inpos atorvastatin nn
mechanism	0	20	macrolide_antibiotics nn inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nns that wdt are vbp metabolized vbn by inpos cerivastatin nn
mechanism	0	20	macrolide_antibiotics nn inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nns that wdt are vbp metabolized vbn by inpos lovastatin nn
mechanism	0	20	macrolide_antibiotics nn inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nns that wdt are vbp metabolized vbn by inpos simvastatin nn
false	10	20	macrolide_antibiotics nns inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nn that wdt are vbp metabolized vbn by inpos atorvastatin nn
false	10	20	macrolide_antibiotics nns inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nn that wdt are vbp metabolized vbn by inpos cerivastatin nn
false	10	20	macrolide_antibiotics nns inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nn that wdt are vbp metabolized vbn by inpos lovastatin nn
false	10	20	macrolide_antibiotics nns inhibit vbp the dt metabolism nn of inpos hmg_coa_reductase_inhibitors nn that wdt are vbp metabolized vbn by inpos simvastatin nn
false	8	22	the dt effects nns of inpos concomitant jj phenytoin nn administration nn on inpos the dt steady_state jj pharmacokinetics nns of inpos quetiapine nn
false	0	10	quetiapine_fumarate nn is vbz a dt newly rb introduced vbn atypical_antipsychotic nn with inpos demonstrated vbn efficacy nn in inpos the dt treatment nn of inpos positive jj and cc negative jj symptoms nns of inpos schizophrenia nn
false	0	10	seroquel nn is vbz a dt newly rb introduced vbn atypical_antipsychotic nn with inpos demonstrated vbn efficacy nn in inpos the dt treatment nn of inpos positive jj and cc negative jj symptoms nns of inpos schizophrenia nn
mechanism	18	40	this dt study nn demonstrated vbd that inpos the dt potent jj cytochrome nn p450 nn enzyme_inducer nn phenytoin nn did vbd indeed rb have vb a dt marked jj effect nn on inpos the dt metabolism nn of inpos quetiapine nn resulting vbg in inpos a dt num_fold jj increase nn in inpos clearance nn when wrb administered vbn concomitantly rb to topos patients nns with inpos dsm_iv_diagnosed jj schizophrenia nn schizoaffective jj disorder nn bipolar jj disorder nn
false	0	2	acetaminophen nn theophylline nn
false	0	2	acetaminophen nn lidocaine nn
false	0	2	acetaminophen nn quinidine nn
false	0	2	acetaminophen nn phenobarbital nn
false	0	2	acetaminophen nn phenobarbital nn
false	0	2	acetaminophen nn valproic_acid nn
false	0	2	acetaminophen nn quinidine nn
false	0	2	acetaminophen nn lidocaine nn
false	0	2	acetaminophen nn theophylline nn
false	0	2	acetaminophen nn valproic_acid nn
false	0	2	acetaminophen nn phenobarbital nn
false	6	26	similarly rb dialyzed vbn were vbd phenobarbital nn both dt alone rb at inpos therapeutic jj concentrations nns in inpos serum nn and cc with inpos ethanol nn at inpos num cd different jj concentrations nns in inpos serum nn
false	6	26	similarly rb dialyzed vbn were vbd quinidine nn both dt alone rb at inpos therapeutic jj concentrations nns in inpos serum nn and cc with inpos ethanol nn at inpos num cd different jj concentrations nns in inpos serum nn
false	6	26	similarly rb dialyzed vbn were vbd theophylline nn both dt alone rb at inpos therapeutic jj concentrations nns in inpos serum nn and cc with inpos ethanol nn at inpos num cd different jj concentrations nns in inpos serum nn
mechanism	0	10	acetaminophen nn diminished vbd the dt binding nn of inpos theophylline nn to topos human jj serum nn by inpos a dt net jj change nn of inpos float cd at inpos num cd micromol_l nn and cc by inpos a dt net jj change nn of inpos float cd at inpos num cd micromol_l nn
mechanism	0	10	theophylline nn decreased vbd the dt binding nn of inpos acetaminophen nn by inpos a dt net jj change nn of inpos float cd at inpos float cd micromol_l nn
mechanism	0	8	valproic_acid nn diminished vbd binding nn of inpos phenobarbital nn by inpos a dt net jj change nn of inpos float cd at inpos num cd micromol_l nn
effect	4	8	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	4	10	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	4	16	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	4	10	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	8	10	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	8	4	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	8	16	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	8	10	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
effect	10	4	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	10	16	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	4	16	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	4	10	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
effect	16	10	coingestion nn of inpos acetaminophen nn with inpos theophylline nn phenobarbital nn with inpos acetaminophen nn valproic_acid nn with inpos phenobarbital nn at inpos high jj to topos toxic jj concentrations nns decreases vbz the dt binding nn of inpos the dt target nn drug nn
false	8	26	the dt serum nn concentration nn of inpos phenytoin nn increased vbd dramatically rb from inpos float cd to topos float cd microg_ml nn when wrb fluvoxamine nn was vbd coadministered vbn although inpos the dt daily jj dosage nn of inpos phenytoin nn and cc other jj drugs nns had vbd not rb changed vbn
false	8	48	the dt serum nn concentration nn of inpos phenytoin nn increased vbd dramatically rb from inpos float cd to topos float cd microg_ml nn when wrb fluvoxamine nn was vbd coadministered vbn although inpos the dt daily jj dosage nn of inpos phenytoin nn and cc other jj drugs nn had vbd not rb changed vbn
false	26	8	the dt serum nn concentration nn of inpos phenytoin nn increased vbd dramatically rb from inpos float cd to topos float cd microg_ml nn when wrb fluvoxamine nn was vbd coadministered vbn although inpos the dt daily jj dosage nn of inpos phenytoin nn and cc other jj drugs nns had vbd not rb changed vbn
false	26	48	the dt serum nn concentration nn of inpos phenytoin nn increased vbd dramatically rb from inpos float cd to topos float cd microg_ml nn when wrb fluvoxamine nn was vbd coadministered vbn although inpos the dt daily jj dosage nn of inpos phenytoin nn and cc other jj drugs nn had vbd not rb changed vbn
false	8	48	the dt serum nn concentration nn of inpos phenytoin nn increased vbd dramatically rb from inpos float cd to topos float cd microg_ml nn when wrb fluvoxamine nn was vbd coadministered vbn although inpos the dt daily jj dosage nn of inpos phenytoin nn and cc other jj drugs nn had vbd not rb changed vbn
false	20	28	the dt interaction nn may md be vb a dt result nn of inpos inhibition nn of inpos both cc cyp2c9 nn and cc 2c19 nn by inpos fluvoxamine nn
false	14	22	here rb we prp show vbp that inpos a dt combination nn of inpos galangin nn or cc nums_dihydroxyflavone nn with inpos vancomycin nn may md be vb used vbn to topos sensitize vb resistant jj strains nns of inpos enterococcus nnp faecalis nn and cc enterococcus nnp faecium nn to topos the dt level nn of inpos vancomycin_sensitive jj strains nns
false	0	4	glucose nn and cc insulin nn exert vbp additive jj ocular jj and cc renal jj vasodilator nn effects nns on inpos healthy jj humans nns
false	8	12	there ex is vbz evidence nn that inpos insulin nn and cc glucose nn cause vbp renal jj and cc ocular jj vasodilation nn
false	6	10	haemodynamic jj effects nns of inpos glucose nn and cc insulin nn were vbd additive jj when wrb somatostatin nn was vbd co_administered vbn but cc not rb under inpos basal jj conditions nns
false	6	18	haemodynamic jj effects nns of inpos glucose nn and cc insulin nn were vbd additive jj when wrb somatostatin nn was vbd co_administered vbn but cc not rb under inpos basal jj conditions nns
false	10	18	haemodynamic jj effects nns of inpos glucose nn and cc insulin nn were vbd additive jj when wrb somatostatin nn was vbd co_administered vbn but cc not rb under inpos basal jj conditions nns
false	0	4	glucose nn and cc insulin nn can md exert vb additive jj vasodilator nn properties nns on inpos renal jj and cc ocular jj circulation nn
false	8	12	lack nn of inpos interaction nn between inpos levofloxacin nn and cc oxycodone nn pharmacokinetics nns and cc drug nn disposition nn
false	24	28	previous jj studies nns have vbp demonstrated vbn a dt significant jj reduction nn in inpos the dt oral jj bioavailability nn of inpos trovafloxacin nn and cc ciprofloxacin nn when wrb administered vbn concomitantly rb with inpos an dt intravenous jj opiate nn such jj as inpos morphine nn
mechanism	24	42	previous jj studies nns have vbp demonstrated vbn a dt significant jj reduction nn in inpos the dt oral jj bioavailability nn of inpos trovafloxacin nn and cc ciprofloxacin nn when wrb administered vbn concomitantly rb with inpos an dt intravenous jj opiate nn such jj as inpos morphine nn
mechanism	24	48	previous jj studies nns have vbp demonstrated vbn a dt significant jj reduction nn in inpos the dt oral jj bioavailability nn of inpos trovafloxacin nn and cc ciprofloxacin nn when wrb administered vbn concomitantly rb with inpos an dt intravenous jj opiate nn such jj as inpos morphine nn
mechanism	28	42	previous jj studies nns have vbp demonstrated vbn a dt significant jj reduction nn in inpos the dt oral jj bioavailability nn of inpos trovafloxacin nn and cc ciprofloxacin nn when wrb administered vbn concomitantly rb with inpos an dt intravenous jj opiate nn such jj as inpos morphine nn
mechanism	28	48	previous jj studies nns have vbp demonstrated vbn a dt significant jj reduction nn in inpos the dt oral jj bioavailability nn of inpos trovafloxacin nn and cc ciprofloxacin nn when wrb administered vbn concomitantly rb with inpos an dt intravenous jj opiate nn such jj as inpos morphine nn
false	42	48	previous jj studies nns have vbp demonstrated vbn a dt significant jj reduction nn in inpos the dt oral jj bioavailability nn of inpos trovafloxacin nn and cc ciprofloxacin nn when wrb administered vbn concomitantly rb with inpos an dt intravenous jj opiate nn such jj as inpos morphine nn
false	26	30	this dt decrease nn in inpos absorption nn results vbz in inpos a dt num cd and cc num cd lower jjr auc nn for inpos trovafloxacin nn and cc ciprofloxacin nn respectively rb which wdt could md cause vb clinical jj failures nns
false	20	24	the dt authors nns investigated vbd the dt possibility nn of inpos a dt similar jj interaction nn between inpos oxycodone nn and cc levofloxacin nn
false	10	14	num cd hour nn after inpos starting vbg the dt oxycodone nn or cc levofloxacin nn num cd mg nn p.o nn
false	22	26	there ex was vbd not rb a dt significant jj difference nn in inpos auc nn cmax nn tmax nn for inpos levofloxacin nn versus inpos oxycodone nn regimens nns
false	10	14	it prp was vbd concluded vbn that inpos oral jj oxycodone nn and cc levofloxacin nn can md be vb administered vbn concomitantly rb without inpos a dt significant jj decrease nn in inpos auc nn cmax nn tmax nn
false	10	20	lack nn of inpos an dt effect nn of inpos azithromycin nn on inpos the dt disposition nn of inpos zidovudine nn and cc dideoxyinosine nn in inpos hiv_infected jj patients nns
false	10	24	lack nn of inpos an dt effect nn of inpos azithromycin nn on inpos the dt disposition nn of inpos zidovudine nn and cc dideoxyinosine nn in inpos hiv_infected jj patients nns
false	20	24	lack nn of inpos an dt effect nn of inpos azithromycin nn on inpos the dt disposition nn of inpos zidovudine nn and cc dideoxyinosine nn in inpos hiv_infected jj patients nns
false	24	32	num cd studies nns were vbd conducted vbn in inpos hiv_infected jj subjects nns to topos assess vb the dt potential nn for inpos azithromycin nn to topos interact vb with inpos zidovudine nn and cc dideoxyinosine nn
false	24	36	num cd studies nns were vbd conducted vbn in inpos hiv_infected jj subjects nns to topos assess vb the dt potential nn for inpos azithromycin nn to topos interact vb with inpos zidovudine nn and cc dideoxyinosine nn
false	32	36	num cd studies nns were vbd conducted vbn in inpos hiv_infected jj subjects nns to topos assess vb the dt potential nn for inpos azithromycin nn to topos interact vb with inpos zidovudine nn and cc dideoxyinosine nn
false	2	18	the dt zidovudine nn study nn dosed vbd subjects nns with inpos num cd mg_day nn of inpos azithromycin nn for inpos days nns num cd to topos num cd of inpos a dt num_day jj course nn of inpos num cd mg nn num cd times_day nn of inpos zidovudine nn
false	18	2	the dt zidovudine nn study nn dosed vbd subjects nns with inpos num cd mg_day nn of inpos azithromycin nn for inpos days nns num cd to topos num cd of inpos a dt num_day jj course nn of inpos num cd mg nn num cd times_day nn of inpos zidovudine nn
false	12	32	subjects nns treated vbn with inpos num cd mg nn of inpos dideoxyinosine nn twice rb daily rb for inpos num cd days nns received vbd num cd mg nn of inpos azithromycin nn or cc an dt equivalent jj amount nn of inpos placebo_day nn for inpos days nns num cd to topos num cd
false	0	22	azithromycin nn had vbd no dt significant jj impact nn on inpos the dt cmax nn and cc auc nn of inpos zidovudine nn although inpos it prp significantly rb decreased vbd the dt zidovudine nn tmax nn by inpos num cd and cc increased vbd the dt intracellular jj exposure nn to topos phosphorylated vbn zidovudine nn by inpos num cd
mechanism	0	22	azithromycin nn had vbd no dt significant jj impact nn on inpos the dt cmax nn and cc auc nn of inpos zidovudine nn although inpos it prp significantly rb decreased vbd the dt zidovudine nn tmax nn by inpos num cd and cc increased vbd the dt intracellular jj exposure nn to topos phosphorylated vbn zidovudine nn by inpos num cd
mechanism	0	22	azithromycin nn had vbd no dt significant jj impact nn on inpos the dt cmax nn and cc auc nn of inpos zidovudine nn although inpos it prp significantly rb decreased vbd the dt zidovudine nn tmax nn by inpos num cd and cc increased vbd the dt intracellular jj exposure nn to topos phosphorylated vbn zidovudine nn by inpos num cd
false	0	12	azithromycin nn had vbd no dt significant jj effect nn on inpos dideoxyinosine nn pharmacokinetics nns
false	22	36	based vbn on inpos the dt results nns of inpos these dt studies nns it prp is vbz concluded vbn that inpos azithromycin nn may md be vb safely rb coadministered vbn with inpos both cc zidovudine nn and cc dideoxyinosine nn
false	22	40	based vbn on inpos the dt results nns of inpos these dt studies nns it prp is vbz concluded vbn that inpos azithromycin nn may md be vb safely rb coadministered vbn with inpos both cc zidovudine nn and cc dideoxyinosine nn
false	36	40	based vbn on inpos the dt results nns of inpos these dt studies nns it prp is vbz concluded vbn that inpos azithromycin nn may md be vb safely rb coadministered vbn with inpos both cc zidovudine nn and cc dideoxyinosine nn
false	4	8	effect nn of inpos diazepam nn and cc midazolam nn on inpos the dt antinociceptive jj effect nn of inpos morphine nn metamizol nn indomethacin nn in inpos mice nns
false	4	20	effect nn of inpos diazepam nn and cc midazolam nn on inpos the dt antinociceptive jj effect nn of inpos morphine nn in inpos mice nns
false	4	20	effect nn of inpos diazepam nn and cc midazolam nn on inpos the dt antinociceptive jj effect nn of inpos metamizol nn in inpos mice nns
false	4	20	effect nn of inpos diazepam nn and cc midazolam nn on inpos the dt antinociceptive jj effect nn of inpos indomethacin nn in inpos mice nns
false	8	20	effect nn of inpos diazepam nn and cc midazolam nn on inpos the dt antinociceptive jj effect nn of inpos morphine nn in inpos mice nns
false	8	20	effect nn of inpos diazepam nn and cc midazolam nn on inpos the dt antinociceptive jj effect nn of inpos metamizol nn in inpos mice nns
false	8	20	effect nn of inpos diazepam nn and cc midazolam nn on inpos the dt antinociceptive jj effect nn of inpos indomethacin nn in inpos mice nns
false	6	10	the dt influence nn of inpos midazolam nn and cc diazepam nn on inpos antinociceptive jj effect nn of inpos morphine nn metamizol nn indomethacin nn was vbd investigated vbn in inpos a dt mouse nn model nn using vbg the dt tail_flick jj and cc hot_plate jj tests nns
false	6	20	the dt influence nn of inpos midazolam nn and cc diazepam nn on inpos antinociceptive jj effect nn of inpos morphine nn was vbd investigated vbn in inpos a dt mouse nn model nn using vbg the dt tail_flick jj and cc hot_plate jj tests nns
false	6	20	the dt influence nn of inpos midazolam nn and cc diazepam nn on inpos antinociceptive jj effect nn of inpos metamizol nn was vbd investigated vbn in inpos a dt mouse nn model nn using vbg the dt tail_flick jj and cc hot_plate jj tests nns
false	6	20	the dt influence nn of inpos midazolam nn and cc diazepam nn on inpos antinociceptive jj effect nn of inpos indomethacin nn was vbd investigated vbn in inpos a dt mouse nn model nn using vbg the dt tail_flick jj and cc hot_plate jj tests nns
false	10	20	the dt influence nn of inpos midazolam nn and cc diazepam nn on inpos antinociceptive jj effect nn of inpos morphine nn was vbd investigated vbn in inpos a dt mouse nn model nn using vbg the dt tail_flick jj and cc hot_plate jj tests nns
false	10	20	the dt influence nn of inpos midazolam nn and cc diazepam nn on inpos antinociceptive jj effect nn of inpos metamizol nn was vbd investigated vbn in inpos a dt mouse nn model nn using vbg the dt tail_flick jj and cc hot_plate jj tests nns
false	10	20	the dt influence nn of inpos midazolam nn and cc diazepam nn on inpos antinociceptive jj effect nn of inpos indomethacin nn was vbd investigated vbn in inpos a dt mouse nn model nn using vbg the dt tail_flick jj and cc hot_plate jj tests nns
false	0	20	benzodiazepines nn were vbd administered vbn to topos mice nns num cd min nn before inpos applying vbg the dt analgesic_drugs nn
effect	0	22	diazepam nn at inpos doses nns of inpos float cd mg_kg nn and cc float cd mg_kg nn injected vbn with inpos morphine nn was vbd found vbn to topos decrease vb the dt antinociceptive jj effect nn of inpos morphine nn
false	0	22	diazepam nn at inpos doses nns of inpos float cd mg_kg nn and cc float cd mg_kg nn injected vbn with inpos morphine nn was vbd found vbn to topos decrease vb the dt antinociceptive jj effect nn of inpos morphine nn
effect	2	14	similarly rb diazepam nn decreased vbd the dt antinociceptive jj effect nn of inpos metamizol nn and cc indomethacin nn
effect	2	18	similarly rb diazepam nn decreased vbd the dt antinociceptive jj effect nn of inpos metamizol nn and cc indomethacin nn
false	14	18	similarly rb diazepam nn decreased vbd the dt antinociceptive jj effect nn of inpos metamizol nn and cc indomethacin nn
effect	0	30	midazolam nn used vbn at inpos doses nns of inpos float cd mg_kg nn and cc float cd mg_kg nn decreased vbd the dt antinociceptive jj effect nn of inpos morphine nn
effect	0	30	midazolam nn used vbn at inpos doses nns of inpos float cd mg_kg nn and cc float cd mg_kg nn decreased vbd the dt antinociceptive jj effect nn of inpos metamizol nn
effect	0	30	midazolam nn used vbn at inpos doses nns of inpos float cd mg_kg nn and cc float cd mg_kg nn decreased vbd the dt antinociceptive jj effect nn of inpos indomethacin nn
false	4	8	influence nn of inpos estradiol nn and cc progesterone nn on inpos the dt sensitivity nn of inpos rat nn thoracic jj aorta nn to topos noradrenaline nn
false	4	26	influence nn of inpos estradiol nn and cc progesterone nn on inpos the dt sensitivity nn of inpos rat nn thoracic jj aorta nn to topos noradrenaline nn
false	8	26	influence nn of inpos estradiol nn and cc progesterone nn on inpos the dt sensitivity nn of inpos rat nn thoracic jj aorta nn to topos noradrenaline nn
false	32	38	the dt aim nn of inpos this dt study nn was vbd to topos investigate vb the dt effects nns of inpos low jj and cc high jj doses nns of inpos estradiol nn and cc of inpos progesterone nn on inpos the dt response nn to topos noradrenaline nn in inpos rat nn thoracic jj aorta nn
false	32	48	the dt aim nn of inpos this dt study nn was vbd to topos investigate vb the dt effects nns of inpos low jj and cc high jj doses nns of inpos estradiol nn and cc of inpos progesterone nn on inpos the dt response nn to topos noradrenaline nn in inpos rat nn thoracic jj aorta nn
false	38	48	the dt aim nn of inpos this dt study nn was vbd to topos investigate vb the dt effects nns of inpos low jj and cc high jj doses nns of inpos estradiol nn and cc of inpos progesterone nn on inpos the dt response nn to topos noradrenaline nn in inpos rat nn thoracic jj aorta nn
false	6	10	injection nn of inpos vehicle nn estradiol nn and_or cc progesterone nn for inpos num cd days nns
effect	16	26	aortic jj rings nns with inpos intact jj endothelium nn from inpos the dt high_dose jj estradiol nn group nn were vbd supersensitive jj to topos noradrenaline nn compared vbn to topos the dt vehicle nn or cc low_dose jj estradiol nn groups nns
effect	10	20	endothelium_intact jj aortic jj rings nns from inpos high jj estradiol nn rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn progesterone nn +_high_estradiol_treated jj rats nns
false	10	30	endothelium_intact jj aortic jj rings nns from inpos high jj estradiol nn rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn hyph_progesterone nn +_high_estradiol_treated jj rats nns
false	10	30	endothelium_intact jj aortic jj rings nns from inpos high jj estradiol nn rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn progesterone nn +_high_estradiol_treated jj rats nns
false	18	28	endothelium_intact jj aortic jj rings nns from inpos high_estradiol jj rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn hyph_progesterone nn +_high_estradiol_treated jj rats nns
false	18	28	endothelium_intact jj aortic jj rings nns from inpos high_estradiol jj rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn progesterone nn +_high_estradiol_treated jj rats nns
false	18	8	endothelium_intact jj aortic jj rings nns from inpos high_estradiol jj rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn progesterone nn +_high jj estradiol nn treated jj rats nns
false	28	8	endothelium_intact jj aortic jj rings nns from inpos high_estradiol jj rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn hyph_and cc progesterone nn +_high jj estradiol nn treated jj rats nns
false	28	8	endothelium_intact jj aortic jj rings nns from inpos high_estradiol jj rats nns were vbd supersensitive jj to topos noradrenaline nn when wrb compared vbn to topos vehicle nn progesterone nn progesterone nn +_high jj estradiol nn treated jj rats nns
advise	0	12	sildenafil nn is vbz contraindicated vbn in inpos patients nns using vbg long_acting_nitrates nn or cc who wp may md need vb to topos use vb short_acting_nitrates nns because inpos the dt combination nn may md cause vb a dt sharp jj fall nn of inpos the dt blood nn pressure nn
advise	0	26	sildenafil nn is vbz contraindicated vbn in inpos patients nns using vbg long_acting_nitrates nns or cc who wp may md need vb to topos use vb short_acting_nitrates nn because inpos the dt combination nn may md cause vb a dt sharp jj fall nn of inpos the dt blood nn pressure nn
false	12	26	sildenafil nn is vbz contraindicated vbn in inpos patients nns using vbg long_acting_nitrates nn or cc who wp may md need vb to topos use vb short_acting_nitrates nn because inpos the dt combination nn may md cause vb a dt sharp jj fall nn of inpos the dt blood nn pressure nn
false	12	14	no dt interactions nns have vbp been vbn observed vbn with inpos b_receptor_blockers nn loop_diuretics nn ace_inhibitors nns
false	12	16	no dt interactions nns have vbp been vbn observed vbn with inpos b_receptor_blockers nn loop_diuretics nns ace_inhibitors nn
false	14	16	no dt interactions nns have vbp been vbn observed vbn with inpos b_receptor_blockers nns calcium_antagonists nn loop_diuretics nns
false	12	16	no dt interactions nns have vbp been vbn observed vbn with inpos calcium_antagonists nn loop_diuretics nns ace_inhibitors nn
false	16	20	no dt interactions nns have vbp been vbn observed vbn with inpos b_receptor_blockers nns calcium_antagonists nns thiazide nn and cc loop nn bbbbbcom_diuretics_eeeeecom nn and cc ace_inhibitors nns
false	12	18	no dt interactions nns have vbp been vbn observed vbn with inpos thiazide nn loop nn bbbbb12_diuretics_eeeee12 nn ace_inhibitors nn
false	18	20	no dt interactions nns have vbp been vbn observed vbn with inpos b_receptor_blockers nns calcium_antagonists nns thiazide nn loop_diuretics nn ace_inhibitors nn
false	8	12	influence nn of inpos coadministration nn of inpos fluoxetine nn on inpos cisapride nn pharmacokinetics nns and cc qtc nn intervals nns in inpos healthy jj volunteers nns
false	10	26	to topos evaluate vb the dt effect nn of inpos fluoxetine nn on inpos the dt pharmacokinetics nns and cc cardiovascular jj safety nn of inpos cisapride nn at inpos steady jj state nn in inpos healthy jj men nns
false	6	18	and cc phase nn num cd cisapride nn num cd mg nn num cd times_day nn plus cc fluoxetine nn num cd mg_day nn
mechanism	4	10	coadministration nn of inpos fluoxetine nn significantly rb decreased vbd cisapride nn plasma nn concentrations nns
false	26	34	there ex were vbd no dt clinically rb significant jj changes nns in inpos corrected vbn qt nn intervals nns during inpos administration nn of inpos cisapride nn alone rb or cc with inpos fluoxetine nn
false	0	18	cisapride nn was vbd well rb tolerated vbn when wrb administered vbn alone rb or cc with inpos fluoxetine nn
false	0	24	cisapride nn can md be vb administered vbn safely rb to topos patients nns receiving vbg low jj therapeutic jj dosages nns of inpos fluoxetine nn
false	0	4	olanzapine nn a dt thienobenzodiazepine_derivative nn is vbz a dt second_generation_atypical_antipsychotic_agent nn which wdt has vbz proven vbn efficacy nn against inpos the dt positive jj and cc negative jj symptoms nns of inpos schizophrenia nn
false	0	10	olanzapine nn a dt thienobenzodiazepine_derivative nn is vbz a dt second_generation_atypical_antipsychotic_agent nn which wdt has vbz proven vbn efficacy nn against inpos the dt positive jj and cc negative jj symptoms nns of inpos schizophrenia nn
false	4	10	olanzapine nn a dt thienobenzodiazepine_derivative nn is vbz a dt second_generation_atypical_antipsychotic_agent nn which wdt has vbz proven vbn efficacy nn against inpos the dt positive jj and cc negative jj symptoms nns of inpos schizophrenia nn
false	24	42	in inpos large jj well rb controlled vbn trials nns in inpos patients nns with inpos schizophrenia nn or cc related jj psychoses nns olanzapine nn num cd to topos num cd mg_day nn was vbd significantly rb superior jj to topos haloperidol nn num cd to topos num cd mg_day nn in inpos overall jj improvements nns in inpos psychopathology nn rating nn scales nns and cc in inpos the dt treatment nn of inpos depressive jj and cc negative jj symptoms nns and cc was vbd comparable jj in inpos effects nns on inpos positive jj psychotic jj symptoms nns
false	18	24	the dt num_year jj risk nn of inpos relapse nn was vbd significantly rb lower jjr with inpos olanzapine nn than inpos with inpos haloperidol nn treatment nn
false	14	18	in inpos the dt first jj double_blind jj comparative jj study nn of inpos olanzapine nn and cc risperidone nn olanzapine nn num cd to topos num cd mg_day nn proved vbd to topos be vb significantly rb more rbr effective jj than inpos risperidone nn num cd to topos num cd mg_day nn in inpos the dt treatment nn of inpos negative jj and cc depressive jj symptoms nns but cc not rb on inpos overall jj psychopathology nn symptoms nns
false	14	18	in inpos the dt first jj double_blind jj comparative jj study nn of inpos olanzapine nn and cc risperidone nn olanzapine nn num cd to topos num cd mg_day nn proved vbd to topos be vb significantly rb more rbr effective jj than inpos risperidone nn num cd to topos num cd mg_day nn in inpos the dt treatment nn of inpos negative jj and cc depressive jj symptoms nns but cc not rb on inpos overall jj psychopathology nn symptoms nns
false	18	14	in inpos the dt first jj double_blind jj comparative jj study nn of inpos olanzapine nn and cc risperidone nn olanzapine nn num cd to topos num cd mg_day nn proved vbd to topos be vb significantly rb more rbr effective jj than inpos risperidone nn num cd to topos num cd mg_day nn in inpos the dt treatment nn of inpos negative jj and cc depressive jj symptoms nns but cc not rb on inpos overall jj psychopathology nn symptoms nns
false	14	18	in inpos the dt first jj double_blind jj comparative jj study nn of inpos olanzapine nn and cc risperidone nn olanzapine nn num cd to topos num cd mg_day nn proved vbd to topos be vb significantly rb more rbr effective jj than inpos risperidone nn num cd to topos num cd mg_day nn in inpos the dt treatment nn of inpos negative jj and cc depressive jj symptoms nns but cc not rb on inpos overall jj psychopathology nn symptoms nns
false	20	36	in inpos contrast nn preliminary jj results nns from inpos an dt num_week jj controlled jj study nn suggested vbd risperidone nn num cd to topos num cd mg_day nn was vbd superior jj to topos olanzapine nn num cd to topos num cd mg_day nn against inpos positive jj and cc anxiety nn symptoms nns although inpos consistent jj with inpos the dt first jj study nn both dt agents nns demonstrated vbd similar jj efficacy nn on inpos measures nns of inpos overall jj psychopathology nn
false	14	54	improvements nns in inpos general jj cognitive jj function nn seen vbn with inpos olanzapine nn treatment nn in inpos a dt num_year jj controlled jj study nn of inpos patients nns with inpos early_phase jj schizophrenia nn were vbd significantly rb greater jjr than inpos changes nns seen vbn with inpos either cc risperidone nn or cc haloperidol nn
false	14	58	improvements nns in inpos general jj cognitive jj function nn seen vbn with inpos olanzapine nn treatment nn in inpos a dt num_year jj controlled jj study nn of inpos patients nns with inpos early_phase jj schizophrenia nn were vbd significantly rb greater jjr than inpos changes nns seen vbn with inpos either cc risperidone nn or cc haloperidol nn
false	54	58	improvements nns in inpos general jj cognitive jj function nn seen vbn with inpos olanzapine nn treatment nn in inpos a dt num_year jj controlled jj study nn of inpos patients nns with inpos early_phase jj schizophrenia nn were vbd significantly rb greater jjr than inpos changes nns seen vbn with inpos either cc risperidone nn or cc haloperidol nn
false	26	30	however rb preliminary jj results nns from inpos an dt num_week jj trial nn showed vbd comparable jj cognitive jj enhancing vbg effects nns of inpos olanzapine nn and cc risperidone nn treatment nn in inpos patients nns with inpos schizophrenia nn or cc schizoaffective jj disorder nn
false	0	18	olanzapine nn is vbz associated vbn with inpos significantly rb fewer jjr extrapyramidal jj symptoms nns than inpos haloperidol nn and cc risperidone nn
false	0	22	olanzapine nn is vbz associated vbn with inpos significantly rb fewer jjr extrapyramidal jj symptoms nns than inpos haloperidol nn and cc risperidone nn
false	18	22	olanzapine nn is vbz associated vbn with inpos significantly rb fewer jjr extrapyramidal jj symptoms nns than inpos haloperidol nn and cc risperidone nn
false	4	28	in inpos addition nn olanzapine nn is vbz not rb associated vbn with inpos a dt risk nn of inpos agranulocytosis nn as inpos seen vbn with inpos clozapine nn or cc clinically rb significant jj hyperprolactinaemia nn as inpos seen vbn with inpos risperidone nn or cc prolongation nn of inpos the dt qt nn interval nn
false	4	44	in inpos addition nn olanzapine nn is vbz not rb associated vbn with inpos a dt risk nn of inpos agranulocytosis nn as inpos seen vbn with inpos clozapine nn or cc clinically rb significant jj hyperprolactinaemia nn as inpos seen vbn with inpos risperidone nn or cc prolongation nn of inpos the dt qt nn interval nn
false	28	44	in inpos addition nn olanzapine nn is vbz not rb associated vbn with inpos a dt risk nn of inpos agranulocytosis nn as inpos seen vbn with inpos clozapine nn or cc clinically rb significant jj hyperprolactinaemia nn as inpos seen vbn with inpos risperidone nn or cc prolongation nn of inpos the dt qt nn interval nn
false	6	24	in inpos comparison nn with inpos haloperidol nn the dt adverse jj events nns reported vbd significantly rb more rbr frequently rb with inpos olanzapine nn in inpos or cc float cd of inpos patients nns were vbd dry jj mouth nn bodyweight nn gain nn increased vbd appetite nn compared vbn with inpos risperidone nn only rb bodyweight jj gain nn occurred vbd significantly rb more rbr frequently rb with inpos olanzapine nn
false	6	54	in inpos comparison nn with inpos haloperidol nn the dt adverse jj events nns reported vbd significantly rb more rbr frequently rb with inpos olanzapine nn in inpos or cc float cd of inpos patients nns were vbd dry jj mouth nn bodyweight nn gain nn increased vbd appetite nn compared vbn with inpos risperidone nn only rb bodyweight jj gain nn occurred vbd significantly rb more rbr frequently rb with inpos olanzapine nn
false	6	24	in inpos comparison nn with inpos haloperidol nn the dt adverse jj events nns reported vbd significantly rb more rbr frequently rb with inpos olanzapine nn in inpos or cc float cd of inpos patients nns were vbd dry jj mouth nn bodyweight nn gain nn increased vbd appetite nn compared vbn with inpos risperidone nn only rb bodyweight jj gain nn occurred vbd significantly rb more rbr frequently rb with inpos olanzapine nn
false	24	54	in inpos comparison nn with inpos haloperidol nn the dt adverse jj events nns reported vbd significantly rb more rbr frequently rb with inpos olanzapine nn in inpos or cc float cd of inpos patients nns were vbd dry jj mouth nn bodyweight nn gain nn increased vbd appetite nn compared vbn with inpos risperidone nn only rb bodyweight jj gain nn occurred vbd significantly rb more rbr frequently rb with inpos olanzapine nn
false	54	24	in inpos comparison nn with inpos haloperidol nn the dt adverse jj events nns reported vbd significantly rb more rbr frequently rb with inpos olanzapine nn in inpos or cc float cd of inpos patients nns were vbd dry jj mouth nn bodyweight nn gain nn increased vbd appetite nn compared vbn with inpos risperidone nn only rb bodyweight jj gain nn occurred vbd significantly rb more rbr frequently rb with inpos olanzapine nn
false	8	44	pharmacoeconomic jj analyses nns indicate vbp that inpos olanzapine nn does vbz not rb significantly rb increase vb and cc may md even rb decrease vb the dt overall jj direct jj treatment nn costs nns of inpos schizophrenia nn compared vbn with inpos haloperidol nn
false	4	6	compared vbn with inpos risperidone nn olanzapine nn has vbz also rb been vbn reported vbn to topos decrease vb overall jj treatment nn costs nns despite inpos the dt several_fold jj higher jjr daily jj acquisition nn cost nn of inpos the dt drug nn
false	0	36	olanzapine nn treatment nn improves vbz quality nn of inpos life nn in inpos patients nns with inpos schizophrenia nn and cc related vbn psychoses nns to topos a dt greater jjr extent nn than inpos haloperidol nn and cc to topos broadly rb the dt same jj extent nn as inpos risperidone nn
false	0	52	olanzapine nn treatment nn improves vbz quality nn of inpos life nn in inpos patients nns with inpos schizophrenia nn and cc related vbn psychoses nns to topos a dt greater jjr extent nn than inpos haloperidol nn and cc to topos broadly rb the dt same jj extent nn as inpos risperidone nn
false	36	52	olanzapine nn treatment nn improves vbz quality nn of inpos life nn in inpos patients nns with inpos schizophrenia nn and cc related vbn psychoses nns to topos a dt greater jjr extent nn than inpos haloperidol nn and cc to topos broadly rb the dt same jj extent nn as inpos risperidone nn
false	0	14	olanzapine nn demonstrated vbd superior jj antipsychotic jj efficacy nn compared vbn with inpos haloperidol nn in inpos the dt treatment nn of inpos acute jj phase nn schizophrenia nn and cc in inpos the dt treatment nn of inpos some dt patients nns with inpos first_episode jj or cc treatment_resistant jj schizophrenia nn
false	22	26	the dt reduced vbn risk nn of inpos adverse jj events nns and cc therapeutic jj superiority nn compared vbn with inpos haloperidol nn and cc risperidone nn in inpos the dt treatment nn of inpos negative jj and cc depressive jj symptoms nns support vbp the dt choice nn of inpos olanzapine nn as inpos a dt first_line jj option nn in inpos the dt management nn of inpos schizophrenia nn in inpos the dt acute jj phase nn and cc for inpos the dt maintenance nn of inpos treatment nn response nn
false	22	52	the dt reduced vbn risk nn of inpos adverse jj events nns and cc therapeutic jj superiority nn compared vbn with inpos haloperidol nn and cc risperidone nn in inpos the dt treatment nn of inpos negative jj and cc depressive jj symptoms nns support vbp the dt choice nn of inpos olanzapine nn as inpos a dt first_line jj option nn in inpos the dt management nn of inpos schizophrenia nn in inpos the dt acute jj phase nn and cc for inpos the dt maintenance nn of inpos treatment nn response nn
false	26	52	the dt reduced vbn risk nn of inpos adverse jj events nns and cc therapeutic jj superiority nn compared vbn with inpos haloperidol nn and cc risperidone nn in inpos the dt treatment nn of inpos negative jj and cc depressive jj symptoms nns support vbp the dt choice nn of inpos olanzapine nn as inpos a dt first_line jj option nn in inpos the dt management nn of inpos schizophrenia nn in inpos the dt acute jj phase nn and cc for inpos the dt maintenance nn of inpos treatment nn response nn
false	8	12	the dt emerging vbg roles nns of inpos non_nucleoside_reverse_transcriptase_inhibitors nn in inpos antiretroviral nn therapy nn
false	8	16	the dt availability nn of inpos potent jj non_nucleoside_reverse_transcriptase_inhibitor nn based jj regimens nns for inpos antiretroviral nn therapy nn and cc concerns nns regarding vbg protease_inhibitor nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	8	26	the dt availability nn of inpos potent jj non_nucleoside_reverse_transcriptase_inhibitor nn based jj regimens nns for inpos antiretroviral jj therapy nn and cc concerns nns regarding vbg protease_inhibitor nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	8	5	the dt availability nn of inpos potent jj non_nucleoside_reverse_transcriptase_inhibitor nn based jj regimens nns for inpos antiretroviral jj therapy nn and cc concerns nns regarding vbg p nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	8	16	the dt availability nn of inpos potent jj nnrti nn based jj regimens nns for inpos antiretroviral nn therapy nn and cc concerns nns regarding vbg protease_inhibitor nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	8	26	the dt availability nn of inpos potent jj nnrti nn based jj regimens nns for inpos antiretroviral jj therapy nn and cc concerns nns regarding vbg protease_inhibitor nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	8	5	the dt availability nn of inpos potent jj nnrti nn based jj regimens nns for inpos antiretroviral jj therapy nn and cc concerns nns regarding vbg p nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	16	26	the dt availability nn of inpos potent jj non_nucleoside_reverse_transcriptase_inhibitor jj based jj regimens nns for inpos antiretroviral nn therapy nn and cc concerns nns regarding vbg protease_inhibitor nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	16	5	the dt availability nn of inpos potent jj non_nucleoside_reverse_transcriptase_inhibitor jj based jj regimens nns for inpos antiretroviral nn therapy nn and cc concerns nns regarding vbg p nn related jj metabolic jj disturbances nns have vbp led vbn to topos significant jj shifts nns in inpos treatment nn practices nns in inpos hiv nn infection nn
false	0	15	nnrti nn based jj regimens nns may md have vb several jj advantages nns over inpos p nn based jj therapy nn for inpos initial jj or cc prolonged jj therapy nn including vbg more rbr convenient jj administration nn regimens nns lower jjr tablet nn volume nn fewer jjr drug nn interactions nns central jj nervous jj system nn penetration nn
false	2	6	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	2	6	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	2	26	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	2	6	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	6	26	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	6	2	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	6	26	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	6	2	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	26	6	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	26	2	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	6	2	both cc efavirenz nn and cc nevirapine nn have vbp been vbn compared vbn to topos triple jj therapy nn with inpos the dt p nn indinavir nn over inpos num cd weeks nns as inpos initial jj therapy nn with inpos similar jj responses nns being vbg observed vbn with inpos nevirapine nn regimens nns and cc superiority nn observed vbn with inpos efavirenz nn
false	12	26	a dt smaller jjr num_week jj study nn has vbz suggested vbn nevirapine nn may md be vb superior jj to topos the dt p nn nelfinavir nn
false	12	26	a dt smaller jjr num_week jj study nn has vbz suggested vbn nevirapine nn may md be vb superior jj to topos the dt p nn nelfinavir nn
false	22	26	limited jj comparative jj data nns in inpos patients nns with inpos high jj viral jj loads nns treated vbn with inpos nevirapine nn hyph_or cc delavirdine nn based jj regimens nns currently rb exist vbp
false	6	10	the dt superiority nn of inpos efavirenz nn over inpos indinavir nn based jj regimens nns has vbz been vbn observed vbn in inpos comparative jj data nns in inpos a dt subset nn of inpos patients nns with inpos high jj viral jj loads nns
false	0	10	efavirenz nn has vbz demonstrated vbn superiority nn over inpos nelfinavir nn in inpos nucleoside_experienced jj patients nns although inpos combining vbg these dt num cd agents nns may md represent vb the dt best jjs approach nn in inpos these dt circumstances nns
false	16	70	methods nns clinical jj studies nns case nn reports nns commentaries nns editorials nns concerning vbg sildenafil nn published vbn in inpos the dt international jj literature nn between inpos january nnp num cd and cc august nnp num cd were vbd identified vbn through inpos searches nns of inpos medline nnp premedline nnp and cc international nnp pharmaceutical nnp abstracts nnps using vbg the dt terms nns sildenafil nn viagra nn erectile jj dysfunction nn
false	16	70	methods nns clinical jj studies nns case nn reports nns commentaries nns editorials nns concerning vbg sildenafil nn published vbn in inpos the dt international jj literature nn between inpos january nnp num cd and cc august nnp num cd were vbd identified vbn through inpos searches nns of inpos medline nnp premedline nnp and cc international nnp pharmaceutical nnp abstracts nnps using vbg the dt terms nns sildenafil nn viagra nn erectile jj dysfunction nn
false	0	40	sildenafil nn has vbz demonstrated vbn effectiveness nn in inpos men nns with inpos erectile jj dysfunction nn associated vbn with inpos prostatectomy nn radiation nn therapy nn diabetes nn mellitus nn certain jj neurologic jj disorders nns drug nn selective_serotonin_reuptake_inhibitors nn
false	0	40	sildenafil nn has vbz demonstrated vbn effectiveness nn in inpos men nns with inpos erectile jj dysfunction nn associated vbn with inpos prostatectomy nn radiation nn therapy nn diabetes nn mellitus nn certain jj neurologic jj disorders nns drug nn ssris nn
effect	22	48	however rb patients nns with inpos moderate jj to topos severe jj cardiovascular jj disease nn or cc those dt taking vbg nitrate nn therapy nn are vbp at inpos increased vbn risk nn for inpos potentially rb serious jj cardiovascular jj adverse jj effects nns with inpos sildenafil nn therapy nn
false	2	18	acute jj hydrocortisone nn administration nn does vbz not rb affect vb subjective jj responses nns to topos d_amphetamine nn in inpos humans nns
false	12	28	however rb the dt effects nns of inpos stress nn and cc glucocorticoids nn on inpos the dt subjective jj and cc behavioral jj effects nns of inpos psychostimulants nn have vbp not rb been vbn well rb studied vbn in inpos humans nns
false	12	30	to topos examine vb the dt effects nns of inpos acute jj hydrocortisone nn pretreatment nn on inpos the dt subjective jj and cc behavioral jj effects nns of inpos d_amphetamine nn
false	0	4	hydrocortisone nn and cc d_amphetamine nn were vbd administered vbn orally rb to topos num cd healthy jj male jj and cc female jj volunteers nns in inpos a dt four_session nn placebo_controlled jj within_subject jj crossover nn design nn
false	2	28	however rb hydrocortisone nn pretreatment nn did vbd not rb affect vb any dt of inpos the dt physiological jj behavioral jj subjective jj effects nns of inpos d_amphetamine nn
false	12	52	in inpos contrast nn to topos the dt effects nns of inpos glucocorticoids nn in inpos rodent nn studies nns these dt results nns indicate vbp that inpos an dt acute jj increase nn in inpos cortisol nn does vbz not rb enhance vb the dt psychostimulant jj effects nns of inpos d_amphetamine nn in inpos humans nns
false	6	12	the dt effects nns of inpos ketamine nn and cc of inpos innovar nn anesthesia nn on inpos digitalis nn tolerance nn in inpos dogs nns
false	6	18	the dt effects nns of inpos ketamine nn and cc of inpos innovar nnp anesthesia nn on inpos digitalis nn tolerance nn in inpos dogs nns
false	12	18	the dt effects nns of inpos ketamine nn and cc of inpos innovar nn anesthesia nn on inpos digitalis nn tolerance nn in inpos dogs nns
false	8	20	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	8	20	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos innovar_vet nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	8	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	8	34	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	8	34	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	8	20	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	8	22	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	8	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
effect	20	34	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	34	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	22	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
effect	20	28	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos innovar_vet nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	28	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos innovar_vet nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	60	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos innovar_vet nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	70	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos innovar_vet nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
effect	26	34	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	26	34	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	26	20	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	26	22	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	34	20	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	34	22	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	34	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	34	20	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	34	22	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	34	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	22	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	20	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
false	22	26	in inpos a dt comparison nn of inpos digitalis nn tolerance nn in inpos dogs nns anesthetized vbn with inpos ketamine nn innovar_vet nnp or cc pentobarbital nn the dt dosage nn of inpos ouabain nn needed vbn to topos cause vb ventricular jj tachycardia nn was vbd significantly rb higher jjr as inpos was vbd the dt ld50 nn of inpos ouabain nn with inpos ketamine nn or cc innovar nn than inpos with inpos pentobarbital nn
effect	8	28	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos innovar nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
effect	8	28	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos ketamine nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
effect	8	28	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos droperidol nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	8	44	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos innovar nnp ketamine nn droperidol nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	8	52	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos innovar nnp ketamine nn droperidol nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	28	40	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos innovar nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	28	48	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos innovar nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	28	40	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos ketamine nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	28	48	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos ketamine nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	28	40	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos droperidol nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	28	48	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos droperidol nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
false	44	52	ventricular jj tachycardia nn induced vbn by inpos ouabain nn was vbd generally rb converted vbn to topos sinus nn rhythm nn following vbg administration nn of inpos innovar nnp ketamine nn droperidol nn but cc not rb after inpos administration nn of inpos fentayl nn alone rb or cc after inpos pentobarbital nn
int	4	8	interaction nn of inpos clindamycin nn and cc gentamicin nn in fw vitro fw
false	10	14	the dt minimal jj inhibitory jj concentrations nns of inpos clindamycin nn and cc gentamicin nn alone rb and cc in inpos combinations nns were vbd determined vbn by inpos a dt microdilution nn method nn for inpos num cd aerobic jj facultative jj anaerobic jj clinical jj isolates nns
false	0	16	gentamicin nn did vbd not rb interfere vb with inpos the dt activity nn of inpos clindamycin nn within inpos the dt range nn of inpos concentrations nns tested vbn
effect	4	8	combinations nns of inpos clindamycin nn and cc gentamicin nn were vbd indifferent jj for inpos num cd strains nns and cc synergistic jj for inpos num cd strains nns
false	46	50	all dt num cd strains nns of inpos enterococcus nn num cd strains nns of inpos clostridium nnp num cd strains nns of inpos escherichia nnp coli nnp num cd strain nn of inpos proteus nnp rettgeri nns were vbd resistant jj to topos both cc clindamycin nn and cc gentamicin nn
effect	4	8	combinations nns of inpos clindamycin nn and cc gentamicin nn were vbd indifferent jj for inpos num cd and cc synergistic jj for inpos num cd of inpos the dt resistant jj strains nns
false	14	22	molecular jj basis nn for inpos the dt selective jj toxicity nn of inpos amphotericin_b nn for inpos yeast nn and cc filipin nn for inpos animal nn cells nns
false	4	10	among inpos the dt polyene_antibiotics nn many jj like inpos filipin nn can md not rb be vb used vbn clinically rb because inpos they prp are vbp toxic jj
false	8	20	both cc the dt toxicity nn of inpos filipin nn and cc the dt therapeutic jj value nn of inpos amphotericin_b nn can md be vb rationalized vbn at inpos the dt cellular jj and cc molecular jj level nn by inpos the dt following vbg observations nns these dt polyene_antibiotics nns showed vbd differential jj effects nns on inpos cells nns
false	8	50	both cc the dt toxicity nn of inpos filipin nn and cc the dt therapeutic jj value nn of inpos amphotericin_b nn can md be vb rationalized vbn at inpos the dt cellular jj and cc molecular jj level nn by inpos the dt following vbg observations nns these dt polyene_antibiotics nn showed vbd differential jj effects nns on inpos cells nns
false	20	50	both cc the dt toxicity nn of inpos filipin nn and cc the dt therapeutic jj value nn of inpos amphotericin_b nn can md be vb rationalized vbn at inpos the dt cellular jj and cc molecular jj level nn by inpos the dt following vbg observations nns these dt polyene_antibiotics nn showed vbd differential jj effects nns on inpos cells nns
false	0	22	filipin nn was vbd more rbr potent jj in inpos lysing vbg human jj red jj blood nn cells nns whereas inpos amphotericin_b nn was vbd more rbr potent jj in inpos inhibiting vbg yeast nn cell nn growth nn
false	8	46	and cc the dt effects nns of inpos filipin nn were vbd more rbr efficiently rb inhibited vbn by inpos added vbn cholesterol nn the dt major jj membrane nn sterol nn in inpos human jj cells nns whereas inpos the dt effects nns of inpos amphotericin_b nn were vbd more rbr efficiently rb inhibited vbn by inpos ergosterol nn the dt major jj membrane nn sterol nn in inpos yeast nn
false	2	4	the dt antifungal_drug nn miconazole_nitrate nn inhibits vbz the dt growth nn of inpos several jj species nns of inpos candida nnp
false	4	24	effect nn of inpos probenecid nn on inpos the dt apparent jj volume nn of inpos distribution nn and cc elimination nn of inpos cloxacillin nn
false	10	14	the dt higher jjr serum nn concentrations nns of inpos penicillins nn and cc cephaloridine nn reached vbn after inpos administration nn of inpos probenecid nn are vbp due jj not rb only rb to topos slower vb renal jj elimination nn but cc also rb to topos an dt altered jj distribution nn in inpos the dt body nn
mechanism	10	24	the dt higher jjr serum nn concentrations nns of inpos penicillins nn and cc cephaloridine nn reached vbn after inpos administration nn of inpos probenecid nn are vbp due jj not rb only rb to topos slower vb renal jj elimination nn but cc also rb to topos an dt altered jj distribution nn in inpos the dt body nn
mechanism	14	24	the dt higher jjr serum nn concentrations nns of inpos penicillins nns and cc cephaloridine nn reached vbn after inpos administration nn of inpos probenecid nn are vbp due jj not rb only rb to topos slower vb renal jj elimination nn but cc also rb to topos an dt altered jj distribution nn in inpos the dt body nn
false	6	24	to topos determine vb whether inpos probenecid nn has vbz a dt direct jj effect nn on inpos the dt distribution nn of inpos cloxacillin nn the dt elimination nn and cc distribution nn of inpos cloxacillin nn was vbd studied vbn in inpos num cd patients nns num cd lacking vbg kidney nn function nn and cc num cd with inpos a dt partially rb impaired jj renal jj function nn in inpos the dt presence nn or cc absence nn of inpos probenecid nn
false	6	24	to topos determine vb whether inpos probenecid nn has vbz a dt direct jj effect nn on inpos the dt distribution nn of inpos cloxacillin nn the dt elimination nn and cc distribution nn of inpos cloxacillin nn was vbd studied vbn in inpos num cd patients nns num cd lacking vbg kidney nn function nn and cc num cd with inpos a dt partially rb impaired jj renal jj function nn in inpos the dt presence nn or cc absence nn of inpos probenecid nn
false	24	6	to topos determine vb whether inpos probenecid nn has vbz a dt direct jj effect nn on inpos the dt distribution nn of inpos cloxacillin nn the dt elimination nn and cc distribution nn of inpos cloxacillin nn was vbd studied vbn in inpos num cd patients nns num cd lacking vbg kidney nn function nn and cc num cd with inpos a dt partially rb impaired jj renal jj function nn in inpos the dt presence nn or cc absence nn of inpos probenecid nn
false	24	6	to topos determine vb whether inpos probenecid nn has vbz a dt direct jj effect nn on inpos the dt distribution nn of inpos cloxacillin nn the dt elimination nn and cc distribution nn of inpos cloxacillin nn was vbd studied vbn in inpos num cd patients nns num cd lacking vbg kidney nn function nn and cc num cd with inpos a dt partially rb impaired jj renal jj function nn in inpos the dt presence nn or cc absence nn of inpos probenecid nn
false	30	38	no dt significant jj difference nn was vbd found vbn between inpos the dt mean jj values nns of inpos the dt volume nn of inpos distribution nn of inpos cloxacillin nn with inpos and cc without inpos probenecid nn
mechanism	16	26	this dt might md be vb explained vbn by inpos a dt blockade nn by inpos probenecid nn of inpos the dt elimination nn of inpos cloxacillin nn by inpos the dt liver nn
false	8	12	many jj people nns use vbp both cc alcohol nn and cc nicotine nn
false	6	10	the dt initiation nn of inpos alcohol nn or cc nicotine nn use nn may md be vb precipitated vbn by inpos similar jj personality nn characteristics nns in inpos the dt user nn such jj as inpos impulsivity nn and cc sensation nn seeking vbg
false	24	28	moreover rb the dt mechanisms nns underlying vbg the dt development nn of inpos dependence nn may md be vb similar jj for inpos alcohol nn and cc nicotine nn
false	12	16	lrb_dose_time jj effects nns of inpos competitive jj displacement nn of inpos radiopertechnetate nn by inpos sodium_perchlorate nn following vbg oral jj and cc intravenous jj administration nn
false	12	42	the dt effect nn of inpos various jj doses nns of inpos sodium_perchlorate nn in inpos several jj dose nn fractions nns on inpos the dt extent nn and cc the dt time nn scale nn of inpos displacement nn of inpos radiopertechnetate nn in inpos dependence nn on inpos application nn mode nn was vbd studied vbn
false	12	34	an dt intravenous jj dose nn of inpos num cd mg nn perchlorate nn was vbd in inpos respect nn of inpos competitive jj suppression nn of inpos organs nns actively rb concentrating vbg pertechnetate nn as inpos effective jj as inpos intravenous jj num cd mg nn clo_num nn simultaneously rb or cc num cd mg nn orally rb num cd min nn before inpos the dt injection nn of inpos radiopertechnetate nn
false	12	72	an dt intravenous jj dose nn of inpos num cd mg nn perchlorate nn was vbd in inpos respect nn of inpos competitive jj suppression nn of inpos organs nns actively rb concentrating vbg pertechnetate nn as inpos effective jj as inpos intravenous jj num cd mg nn clo_num nn simultaneously rb or cc num cd mg nn orally rb num cd min nn before inpos the dt injection nn of inpos radiopertechnetate nn
mechanism	8	32	an dt intravenous jj injection nn of inpos perchlorate nn given vbn later rb also rb produces vbz a dt complete jj and cc immediately rb beginning vbg depletion nn of inpos pertechnetate nn already rb accumulated vbn in inpos the dt thyroid nn within inpos a dt period nn of inpos num cd min nn after inpos 99m_tco_num_injection nn with inpos a dt corresponding jj increase nn in inpos blood nn levels nns
false	0	8	sirolimus nn mammalian jj target nn of inpos rapamycin nn inhibitor nn to topos prevent vb kidney nn rejection nn
false	0	10	sirolimus nn works vbz differently rb from inpos the dt immunosuppressants nn currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	0	66	sirolimus nn works vbz differently rb from inpos the dt immunosuppressants nns currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	0	70	sirolimus nn works vbz differently rb from inpos the dt immunosuppressants nns currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	10	0	sirolimus nnp works vbz differently rb from inpos the dt immunosuppressants nn currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	10	66	sirolimus nnp works vbz differently rb from inpos the dt immunosuppressants nn currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	10	70	sirolimus nnp works vbz differently rb from inpos the dt immunosuppressants nn currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	0	66	sirolimus nnp works vbz differently rb from inpos the dt immunosuppressants nns currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	0	70	sirolimus nnp works vbz differently rb from inpos the dt immunosuppressants nns currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	66	70	sirolimus nnp works vbz differently rb from inpos the dt immunosuppressants nns currently rb available jj and cc except inpos for inpos increased vbn lipid nn levels nns the dt adverse jj reaction nn profile nn of inpos sirolimus nn does vbz not rb appear vb to topos overlap vb to topos any dt great jj extent nn with inpos that dt associated vbn with inpos cyclosporine nn or cc tacrolimus nn
false	28	36	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	28	40	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	28	36	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	28	40	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	36	40	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	36	40	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	40	36	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	36	40	while inpos additional jj research nn is vbz needed vbn the dt initial jj clinical jj data nns in inpos kidney nn recipients nns suggest vbp that inpos sirolimus nn in inpos combination nn with inpos cyclosporine nn or cc tacrolimus nn might md have vb the dt potential nn to topos reduce vb the dt frequency nn of inpos rejection nn episodes nns permit nn reductions nns in inpos cyclosporine nn or cc tacrolimus nn dosage nn and cc permit nn steroid nn withdrawal nn
false	10	14	the dt concomitant jj administration nn of inpos either cc cocaine nn or cc amphetamine nn compounds nns which wdt inhibit vbp neuronal jj reuptake nn of inpos norepinephrine nn disrupts vbz the dt behavioral jj response nn of inpos the dt genetically rb nervous jj e_strain nn subjects nns to topos a dt far rb greater jjr extent nn than inpos the dt stable jj a_strain jj subjects nns
false	0	8	fluvastatin nn is vbz the dt first jj synthetic_num_hydroxy_num_methylglutaryl_coenzyme_a_hmgcoa_reductase_inhibitor nn to topos be vb approved vbn for inpos clinical jj use nn and cc has vbz been vbn studied vbn extensively rb in inpos humans nns since inpos num cd
mechanism	0	30	cholestyramine nn an dt anionic_binding jj resin nn has vbz a dt considerable jj effect nn in inpos lowering vbg the dt rate nn and cc extent nn of inpos fluvastatin nn bioavailability nn
effect	14	28	although inpos this dt effect nn was vbd noted vbn even rb when wrb cholestyramine nn was vbd given vbn num cd hours nns prior rb to topos fluvastatin nn this dt regimen nn did vbd not rb result vb in inpos diminished vbn efficacy nn
false	10	42	further rb no dt effects nns on inpos either dt warfarin nn levels nns or cc prothrombin nn times nns were vbd observed vbn in inpos a dt study nn involving vbg concomitant jj administration nn of inpos warfarin nn and cc fluvastatin nn
false	10	42	further rb no dt effects nns on inpos either dt warfarin nn levels nns or cc prothrombin nn times nns were vbd observed vbn in inpos a dt study nn involving vbg concomitant jj administration nn of inpos warfarin nn and cc fluvastatin nn
false	10	14	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	10	28	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	10	50	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	10	50	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	14	28	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	14	50	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	14	50	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	28	50	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	28	50	moreover rb additional jj interaction nn studies nns with inpos niacin nn and cc propranolol nn have vbp not rb demonstrated vbn any dt effect nn on inpos fluvastatin nn plasma nn levels nns and cc administration nn to topos a dt patient nn population nn chronically rb receiving vbg digoxin nn resulted vbd in inpos no dt difference nn in inpos the dt extent nn of inpos bioavailability nn of inpos digoxin nn relative jj to topos control vb data nns
false	22	28	the dt literature nn provides vbz considerable jj evidence nn indicating vbg that inpos several jj but cc not rb all dt antihistaminics nn are vbp indeed rb analgesic_agents nn and cc some dt are vbp analgesic_adjuvants nns as rb well rb
false	22	36	the dt literature nn provides vbz considerable jj evidence nn indicating vbg that inpos several jj but cc not rb all dt antihistaminics nn are vbp indeed rb analgesic_agents nns and cc some dt are vbp analgesic_adjuvants nn as rb well rb
false	28	36	the dt literature nn provides vbz considerable jj evidence nn indicating vbg that inpos several jj but cc not rb all dt antihistaminics nns are vbp indeed rb analgesic_agents nn and cc some dt are vbp analgesic_adjuvants nn as rb well rb
effect	26	38	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos diazepam nn and cc reduces vbz the dt action nn of inpos phentolamine nn
effect	26	38	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos phenazepam nn and cc reduces vbz the dt action nn of inpos phentolamine nn
effect	26	38	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos phenibut nn and cc reduces vbz the dt action nn of inpos phentolamine nn
effect	26	38	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos amizyl nn and cc reduces vbz the dt action nn of inpos phentolamine nn
effect	26	56	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos diazepam nn phenazepam nn phenibut nn amizyl nn and cc reduces vbz the dt action nn of inpos phentolamine nn
false	38	50	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos diazepam nn and cc reduces vbz the dt action nn of inpos phentolamine nn
false	38	50	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos phenazepam nn and cc reduces vbz the dt action nn of inpos phentolamine nn
false	38	50	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos phenibut nn and cc reduces vbz the dt action nn of inpos phentolamine nn
false	38	50	it prp has vbz been vbn shown vbn in inpos rats nns with inpos experimental jj toxic jj and cc traumatic jj edemas nns that inpos picrotoxin nn removes vbz the dt antiedematous jj action nn of inpos amizyl nn and cc reduces vbz the dt action nn of inpos phentolamine nn
false	4	20	lrb_stimulation nn by inpos cerulein nn an dt analog nn of inpos the dt octapeptide nn cholecystokinin nn of inpos 3h_spiroperidol nn binding nn after inpos the dt long_term jj administration nn of inpos neuroleptics nns
false	4	34	lrb_stimulation nn by inpos cerulein nn an dt analog nn of inpos the dt octapeptide nn cholecystokinin nn of inpos 3h_spiroperidol nn binding nn after inpos the dt long_term jj administration nn of inpos neuroleptics nn
false	20	34	lrb_stimulation nn by inpos cerulein nn an dt analog nn of inpos the dt octapeptide nn cholecystokinin nn of inpos 3h_spiroperidol nn binding nn after inpos the dt long_term jj administration nn of inpos neuroleptics nn
false	28	32	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	28	46	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	28	60	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	28	46	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	28	60	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	32	46	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	32	60	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	32	46	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	32	60	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	46	60	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	46	60	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	60	46	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	46	60	it prp has vbz been vbn established vbn in inpos experiments nns on inpos white jj male jj rats nns that wdt prolonged vbd administration nn of inpos haloperidol nn and cc pyreneperone nn resulted vbd in inpos the dt reduced vbn interaction nn between inpos 3h_spiroperidol nn and cc low jj affinity nn binding nn sites nns for inpos apomorphine nn in inpos subcortical jj structures nns whereas inpos 3h_spiroperidol nn binding nn with inpos high jj affinity nn binding nn sites nns for inpos apomorphine nn increased vbd both cc in inpos the dt frontal jj cortex nn and cc subcortical jj structures nns of inpos the dt forebrain nn
false	8	18	after inpos prolonged vbn administration nn of inpos neuroleptics nn the dt displacing vbg effect nn of inpos cerulein nn an dt analog nn of inpos cholecystokinin nn octapeptide nn was vbd replaced vbn by inpos the dt stimulant jj action nn on inpos 3h_spiroperidol nn binding nn
false	8	44	after inpos prolonged vbn administration nn of inpos neuroleptics nn the dt displacing vbg effect nn of inpos cerulein nn an dt analog nn of inpos cholecystokinin nn octapeptide nn was vbd replaced vbn by inpos the dt stimulant jj action nn on inpos 3h_spiroperidol nn binding nn
false	18	44	after inpos prolonged vbn administration nn of inpos neuroleptics nns the dt displacing vbg effect nn of inpos cerulein nn an dt analog nn of inpos cholecystokinin nn octapeptide nn was vbd replaced vbn by inpos the dt stimulant jj action nn on inpos 3h_spiroperidol nn binding nn
false	14	28	it prp is vbz assumed vbn that inpos increased vbd interaction nn between inpos 3h_spiroperidol nn and cc high jj affinity nn binding nn sites nns for inpos apomorphine nn on inpos dopamine2 nn and cc serotonin2_receptors nns underlies vbz the dt antipsychotic jj action nn of inpos neuroleptics nns after inpos their prp prolonged vbn administration nn
false	14	48	it prp is vbz assumed vbn that inpos increased vbd interaction nn between inpos 3h_spiroperidol nn and cc high jj affinity nn binding nn sites nns for inpos apomorphine nn on inpos dopamine2 nn and cc serotonin2_receptors nns underlies vbz the dt antipsychotic jj action nn of inpos neuroleptics nn after inpos their prp prolonged vbn administration nn
false	28	48	it prp is vbz assumed vbn that inpos increased vbd interaction nn between inpos 3h_spiroperidol nn and cc high jj affinity nn binding nn sites nns for inpos apomorphine nn on inpos dopamine2 nn and cc serotonin2_receptors nns underlies vbz the dt antipsychotic jj action nn of inpos neuroleptics nn after inpos their prp prolonged vbn administration nn
false	6	12	dual jj effect nn of inpos ouabain nn on inpos the dt palytoxin nn induced jj contraction nn and cc norepinephrine nn release nn in inpos the dt guinea_pig nn vas nn deferens nns
effect	8	12	in inpos the dt presence nn of inpos ouabain nn m nn rrb_ptx nn m nn rrb_failed vbd to topos cause vb the dt first jj contraction nn
effect	2	22	when wrb ouabain nn was vbd applied vbn to topos the dt muscle nn in inpos the dt presence nn of inpos phentolamine nn both cc first jj and cc second jj contractile jj responses nns to topos ptx nn were vbd abolished vbn
false	2	38	when wrb ouabain nn was vbd applied vbn to topos the dt muscle nn in inpos the dt presence nn of inpos phentolamine nn both cc first jj and cc second jj contractile jj responses nns to topos ptx nn were vbd abolished vbn
false	22	38	when wrb ouabain nn was vbd applied vbn to topos the dt muscle nn in inpos the dt presence nn of inpos phentolamine nn both cc first jj and cc second jj contractile jj responses nns to topos ptx nn were vbd abolished vbn
effect	10	20	exposure nn of inpos the dt muscle nn to topos ouabain nn m nn rrb_markedly rb increased vbd the dt ptx nn induced jj release nn
false	14	36	by inpos this dt procedure nn it prp was vbd observed vbn that inpos arsenate nn is vbz rapidly rb and cc essentially rb completely rb absorbed vbn from inpos the dt lumen nn at inpos as_v nn concentrations nns up rb to topos num cd mm nn declining vbg to topos about inpos num cd absorption nn at inpos num cd mm nn
false	2	6	furthermore rb arsenate nn and cc phosphate nn do vbp not rb appear vb to topos share vb a dt common jj transport nn pathway nn in inpos the dt duodenum nn and cc no dt evidence nn was vbd obtained vbn for inpos any dt interaction nn between inpos the dt num cd at inpos this dt level nn
mechanism	0	22	vitamin_d3 nn administration nn to topos rachitic jj chicks nns was vbd effective jj in inpos significantly rb elevating vbg duodenal jj arsenate nn absorption nn acting vbg primarily rb to topos enhance vb serosal jj transport nn
false	4	8	by inpos contrast nn spermidine nn and cc putrescine nn had vbd no dt significant jj effect nn on inpos the dt translocation nn when wrb added vbn alone rb
false	0	12	spermine nn and cc to topos a dt lesser jjr extent nn spermidine nn enhanced vbd the dt translocating vbg action nn of inpos oleate nn and cc increased vbd its prp effectiveness nn in inpos transferring vbg the dt phosphohydrolase nn from inpos the dt soluble jj to topos the dt microsomal jj fraction nn
false	0	6	slow_channel_calcium_blockers nn such jj as inpos verapamil nn inhibit vbp platelet nn activation nn in fw vitro fw and cc decrease vb platelet nn adhesion nn intravascularly rb
false	0	6	slow_channel_calcium_blockers nn such jj as inpos diltiazem nn inhibit vbp platelet nn activation nn in fw vitro fw and cc decrease vb platelet nn adhesion nn intravascularly rb
false	0	6	slow_channel_calcium_blockers nn such jj as inpos nifedipine nn inhibit vbp platelet nn activation nn in fw vitro fw and cc decrease vb platelet nn adhesion nn intravascularly rb
false	8	26	differential jj actions nns of inpos intrathecal jj naloxone nn on inpos blocking vbg the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn in inpos rats nns
false	8	30	differential jj actions nns of inpos intrathecal jj naloxone nn on inpos blocking vbg the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn in inpos rats nns
false	26	30	differential jj actions nns of inpos intrathecal jj naloxone nn on inpos blocking vbg the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn in inpos rats nns
false	18	38	the dt blockade nn of inpos the dt spinal jj endorphinergic jj system nn by inpos intrathecal jj naloxone nn on inpos the dt production nn of inpos tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn was vbd then rb studied vbn
false	18	42	the dt blockade nn of inpos the dt spinal jj endorphinergic jj system nn by inpos intrathecal jj naloxone nn on inpos the dt production nn of inpos tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn was vbd then rb studied vbn
false	38	42	the dt blockade nn of inpos the dt spinal jj endorphinergic jj system nn by inpos intrathecal jj naloxone nn on inpos the dt production nn of inpos tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn was vbd then rb studied vbn
false	6	10	intraventricular jj injection nn of inpos b_endorphin nn and cc morphine nn produced vbd an dt inhibition nn of inpos the dt tail_flick jj response nn to topos the dt heat nn stimulus nn in inpos rats nns
effect	6	54	intrathecal jj injection nn of inpos naloxone nn at inpos doses nns of inpos float cd to topos num cd micrograms nns caused vbd a dt dose_related jj blockade nn of inpos the dt inhibition nn of inpos the dt tail_flick jj response nn induced vbn by inpos intraventricular jj injection nn of inpos b_endorphin nn and cc a dt high jj dose nn of inpos naloxone nn completely rb blocked vbd the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn
false	6	54	intrathecal jj injection nn of inpos naloxone nn at inpos doses nns of inpos float cd to topos num cd micrograms nns caused vbd a dt dose_related jj blockade nn of inpos the dt inhibition nn of inpos the dt tail_flick jj response nn induced vbn by inpos intraventricular jj injection nn of inpos b_endorphin nn and cc a dt high jj dose nn of inpos naloxone nn completely rb blocked vbd the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn
false	54	6	intrathecal jj injection nn of inpos naloxone nn at inpos doses nns of inpos float cd to topos num cd micrograms nns caused vbd a dt dose_related jj blockade nn of inpos the dt inhibition nn of inpos the dt tail_flick jj response nn induced vbn by inpos intraventricular jj injection nn of inpos b_endorphin nn and cc a dt high jj dose nn of inpos naloxone nn completely rb blocked vbd the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn
effect	6	54	intrathecal jj injection nn of inpos naloxone nn at inpos doses nns of inpos float cd to topos num cd micrograms nns caused vbd a dt dose_related jj blockade nn of inpos the dt inhibition nn of inpos the dt tail_flick jj response nn induced vbn by inpos intraventricular jj injection nn of inpos b_endorphin nn and cc a dt high jj dose nn of inpos naloxone nn completely rb blocked vbd the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn
effect	10	38	on inpos the dt other jj hand nn intrathecal jj naloxone nn had vbd only rb a dt very rb weak jj effect nn on inpos the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj morphine nn
effect	6	46	intraventricular jj injection nn of inpos naloxone nn at inpos doses nns of inpos float cd to topos num cd micrograms nns equally rb antagonized vbn in inpos a dt dose_dependent jj manner nn the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn
effect	6	50	intraventricular jj injection nn of inpos naloxone nn at inpos doses nns of inpos float cd to topos num cd micrograms nns equally rb antagonized vbn in inpos a dt dose_dependent jj manner nn the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn
false	46	50	intraventricular jj injection nn of inpos naloxone nn at inpos doses nns of inpos float cd to topos num cd micrograms nns equally rb antagonized vbn in inpos a dt dose_dependent jj manner nn the dt tail_flick jj inhibition nn induced vbn by inpos intraventricular jj b_endorphin nn and cc morphine nn
false	12	32	the dt results nns indicate vbp that inpos a dt spinal jj naloxone nn sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine_induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	12	38	the dt results nns indicate vbp that inpos a dt spinal jj naloxone nn sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine nn induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	12	32	the dt results nns indicate vbp that inpos a dt spinal jj naloxone nn sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine_induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	12	38	the dt results nns indicate vbp that inpos a dt spinal jj naloxone nn sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine_induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	30	36	the dt results nns indicate vbp that inpos a dt spinal jj naloxone_sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine nn induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	30	36	the dt results nns indicate vbp that inpos a dt spinal jj naloxone_sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine_induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	36	30	the dt results nns indicate vbp that inpos a dt spinal jj naloxone_sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine nn induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	30	36	the dt results nns indicate vbp that inpos a dt spinal jj naloxone_sensitive jj endorphinergic jj system nn is vbz involved vbn in inpos the dt production nn of inpos b_endorphin nn but cc not rb morphine_induced jj tail_flick jj inhibition nn and cc suggest vbp that inpos intraventricular jj b_endorphin nn and cc morphine nn elicit vbp their prp pharmacological jj actions nns via inpos the dt activation nn of inpos different jj descending vbg pain nn inhibitory jj systems nns
false	12	16	descending vbg e nn and cc m nn systems nns for inpos b_endorphin nn and cc morphine nn respectively rb are vbp proposed vbn
false	10	14	neurochemical jj and cc functional jj consequences nns following vbg num_methyl_num_phenyl_nums_tetrahydropyridine nn and cc methamphetamine nn
false	10	14	neurochemical jj and cc functional jj consequences nns following vbg mptp nn and cc methamphetamine nn
false	12	38	the dt neurochemical jj and cc functional jj consequences nns following vbg mptp nn administration nn to topos the dt rat nn were vbd evaluated vbn and cc compared vbn to topos similar jj effects nns following vbg methamphetamine nn administration nn
effect	8	42	it prp was vbd observed vbn that inpos mptp nn induced vbd long rb lasting jj depletions nns of inpos striatal jj dopamine nn concentrations nns and cc this dt neurotoxic jj effect nn could md be vb prevented vbn by inpos pargyline nn pretreatment nn
effect	2	26	the dt mptp nn induced jj neuronal jj damage nn produced vbd a dt tolerance nn to topos the dt disruptive jj effects nns of inpos amphetamine nn and cc a dt supersensitivity nn to topos the dt disruptive jj effects nns of inpos apomorphine nn in inpos rats nns responding vbg in inpos a dt schedule nn controlled vbn paradigm nn
effect	2	44	the dt mptp nn induced jj neuronal jj damage nn produced vbd a dt tolerance nn to topos the dt disruptive jj effects nns of inpos amphetamine nn and cc a dt supersensitivity nn to topos the dt disruptive jj effects nns of inpos apomorphine nn in inpos rats nns responding vbg in inpos a dt schedule nn controlled vbn paradigm nn
false	24	42	the dt mptp_induced jj neuronal jj damage nn produced vbd a dt tolerance nn to topos the dt disruptive jj effects nns of inpos amphetamine nn and cc a dt supersensitivity nn to topos the dt disruptive jj effects nns of inpos apomorphine nn in inpos rats nns responding vbg in inpos a dt schedule nn controlled vbn paradigm nn
false	0	4	methamphetamine nn like inpos mptp nn produced vbd depletions nns of inpos striatal jj dopamine nn but cc these dt actions nns were vbd potentiated vbn by inpos pargyline nn pretreatment nn
effect	0	28	methamphetamine nn like inpos mptp nn produced vbd depletions nns of inpos striatal jj dopamine nn but cc these dt actions nns were vbd potentiated vbn by inpos pargyline nn pretreatment nn
false	4	28	methamphetamine nn like inpos mptp nn produced vbd depletions nns of inpos striatal jj dopamine nn but cc these dt actions nns were vbd potentiated vbn by inpos pargyline nn pretreatment nn
false	0	4	dexamethasone nn and cc retinyl_acetate nn similarly rb inhibit vbp and cc stimulate vbp egf nn or cc insulin_induced jj proliferation nn of inpos prostatic jj epithelium nn
effect	0	14	dexamethasone nn and cc retinyl_acetate nn similarly rb inhibit vbp and cc stimulate vbp egf nn hyph_or cc insulin_induced jj proliferation nn of inpos prostatic jj epithelium nn
effect	0	18	dexamethasone nn and cc retinyl_acetate nn similarly rb inhibit vbp and cc stimulate vbp egf nn or cc insulin nn induced jj proliferation nn of inpos prostatic jj epithelium nn
effect	4	14	dexamethasone nn and cc retinyl_acetate nn similarly rb inhibit vbp and cc stimulate vbp egf nn hyph_or cc insulin_induced jj proliferation nn of inpos prostatic jj epithelium nn
effect	4	18	dexamethasone nn and cc retinyl_acetate nn similarly rb inhibit vbp and cc stimulate vbp egf nn or cc insulin nn induced jj proliferation nn of inpos prostatic jj epithelium nn
false	14	18	dexamethasone nn and cc retinyl_acetate nn similarly rb inhibit vbp and cc stimulate vbp egf nn hyph_or cc insulin nn induced jj proliferation nn of inpos prostatic jj epithelium nn
false	4	8	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
false	4	28	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
effect	4	44	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
effect	4	48	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
false	8	28	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
effect	8	44	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
effect	8	48	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
false	28	44	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
false	28	48	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
false	44	48	although inpos neither cc dexamethasone nn nor cc retinyl_acetate nn affected vbd the dt proliferation nn of inpos prostatic jj epithelium nn in inpos rpmi1640 nn containing vbg transferrin nn alone rb they prp modify vbp the dt mitogenic jj effect nn of inpos egf nn and cc insulin nn
false	0	10	dexamethasone nn at inpos num cd m nn or cc retinyl_acetate nn at inpos about inpos num cd x_num cd m nn inhibits vbz proliferation nn stimulated vbn by inpos egf nn
effect	0	30	dexamethasone nn at inpos num cd m nn or cc retinyl_acetate nn at inpos about inpos num cd x_num cd m nn inhibits vbz proliferation nn stimulated vbn by inpos egf nn
effect	10	30	dexamethasone nn at inpos num cd m nn or cc retinyl_acetate nn at inpos about inpos num cd x_num cd m nn inhibits vbz proliferation nn stimulated vbn by inpos egf nn
false	6	14	higher jjr concentrations nns of inpos dexamethasone nn hyph_num cd m nn rrb_or cc retinyl_acetate nn hyph_num cd m nn rrb_enhance vbp the dt mitogenic jj activity nn of inpos egf nn
effect	6	30	higher jjr concentrations nns of inpos dexamethasone nn hyph_num cd m nn rrb_or cc retinyl_acetate nn hyph_num cd m nn rrb_enhance vbp the dt mitogenic jj activity nn of inpos egf nn
effect	14	30	higher jjr concentrations nns of inpos dexamethasone nn hyph_num cd m nn rrb_or cc retinyl_acetate nn hyph_num cd m nn rrb_enhance vbp the dt mitogenic jj activity nn of inpos egf nn
false	0	18	dexamethasone nn had vbd a dt similar jj effect nn in inpos the dt presence nn of inpos insulin nn
effect	2	26	however rb retinyl_acetate nn stimulated vbd but cc did vbd not rb significantly rb inhibit vb proliferation nn in inpos the dt presence nn of inpos insulin nn
false	10	12	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
false	10	18	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nn retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
false	10	20	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nn may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	10	52	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	10	56	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
false	12	18	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nn retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
false	12	20	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nn may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	12	52	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	12	56	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
false	18	20	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nn retinoids nn may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	18	52	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nn retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	18	56	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nn retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	20	52	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nn may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
effect	20	56	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nn may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
false	52	56	these dt results nns suggest vbp that inpos both cc dexamethasone nn retinyl_acetate nn possibly rb other jj glucocorticoids nns retinoids nns may md regulate vb the dt proliferation nn of inpos prostate nn epithelium nn by inpos a dt dose_dependent jj modification nn of inpos the dt activity nn of inpos insulin nn and cc egf nn
false	4	16	for inpos the dt calcium_entry_blocking_agents nn now rb available jj in inpos the dt united nnp verapamil nn these dt data nns appeared vbd well rb after inpos clinical jj patterns nns of inpos use nn evolved vbd
false	4	16	for inpos the dt calcium_entry_blocking_agents nn now rb available jj in inpos the dt united nnp nifedipine nn these dt data nns appeared vbd well rb after inpos clinical jj patterns nns of inpos use nn evolved vbd
false	4	16	for inpos the dt calcium_entry_blocking_agents nn now rb available jj in inpos the dt united nnp diltiazem nn these dt data nns appeared vbd well rb after inpos clinical jj patterns nns of inpos use nn evolved vbd
false	12	14	by inpos the dt nonlinear jj kinetic jj characteristics nns for inpos verapamil nn diltiazem nn the dt derivative jj implications nns for inpos decreased vbn dosing nn frequency nn requirements nns
false	12	14	by inpos the dt nonlinear jj kinetic jj characteristics nns for inpos verapamil nn nifedipine nn the dt derivative jj implications nns for inpos decreased vbn dosing nn frequency nn requirements nns
false	6	10	selective jj survival nn in inpos pentazocine nn and cc tripelennamine nn of inpos pseudomonas nnp aeruginosa nn serotype nn o11 nn from inpos drug nn addicts nns
false	18	22	the dt growth nn of inpos pseudomonas nnp aeruginosa nn particularly rb serotype nn o11 nn in inpos pentazocine nn and cc tripelennamine nn
false	14	22	twelve vb a dt frequent jj cause nn of inpos infection nn in inpos heroin nn but cc not rb in inpos pentazocine nn and cc tripelennamine nn addicts nns
false	14	26	twelve vb a dt frequent jj cause nn of inpos infection nn in inpos heroin nn but cc not rb in inpos pentazocine nn and cc tripelennamine nn addicts nns
effect	22	26	twelve vb a dt frequent jj cause nn of inpos infection nn in inpos heroin nn but cc not rb in inpos pentazocine nn and cc tripelennamine nn addicts nns
effect	8	32	dose_response jj curves nns showed vbd that inpos tripelennamine nn was vbd responsible jj for inpos the dt inhibitory jj activity nn which wdt was vbd partially rb antagonized vbn by inpos pentazocine nn
false	8	12	aureus rb to topos survive vb in inpos pentazocine nn and cc tripelennamine nn may md explain vb in inpos part nn a dt shift nn from inpos s nn
false	8	10	pharmacokinetic jj evaluation nn of inpos the dt digoxin nn hyph_amiodarone nn interaction nn
mechanism	0	12	amiodarone nn is vbz known vbn to topos raise vb serum nn digoxin nn levels nns
false	8	44	the dt pharmacokinetic jj variables nns for inpos digoxin nn were vbd determined vbn after inpos a dt float cd mg nn intravenous jj dose nn of inpos digoxin nn in inpos each dt subject nn before inpos and cc after inpos oral jj amiodarone nn num cd mg nn daily rb for inpos num cd weeks nns
false	8	44	the dt pharmacokinetic jj variables nns for inpos digoxin nn were vbd determined vbn after inpos a dt float cd mg nn intravenous jj dose nn of inpos digoxin nn in inpos each dt subject nn before inpos and cc after inpos oral jj amiodarone nn num cd mg nn daily rb for inpos num cd weeks nns
mechanism	2	12	during inpos amiodarone nn administration nn systemic jj clearance nn of inpos digoxin nn was vbd reduced vbn from inpos num cd +_num cd ml_min nn to topos num cd +_num cd ml_min nn
false	0	50	amiodarone nn caused vbd a dt three nn to topos fivefold jj increase nn in inpos serum nn reverse jj triiodothyronine nn levels nns but cc changes nns in inpos thyroid jj function nn were vbd not rb quantitatively rb related vbn to topos the dt changes nns in inpos digoxin nn pharmacokinetics nns
mechanism	6	14	these dt alterations nns in inpos digoxin nn pharmacokinetics nns produced vbn by inpos amiodarone nn explain vb the dt increase nn in inpos serum nn digoxin nn level nn that wdt has vbz been vbn observed vbn when wrb this dt drug nn combination nn has vbz been vbn used vbn clinically rb
false	14	6	these dt alterations nns in inpos digoxin nn pharmacokinetics nns produced vbn by inpos amiodarone nn explain vb the dt increase nn in inpos serum nn digoxin nn level nn that wdt has vbz been vbn observed vbn when wrb this dt drug nn combination nn has vbz been vbn used vbn clinically rb
effect	0	24	misonidazole nn protects vbz mouse nn tumour nn and cc normal jj tissues nns from inpos the dt toxicity nn of inpos oral jj ccnu nn
false	4	6	because inpos the dt nitrosourea nn ccnu nn is vbz given vbn exclusively rb by inpos the dt oral jj route nn in inpos man nn we prp have vbp carried vbn out rp studies nns in inpos mice nns on inpos the dt antitumour jj activity nn acute jj toxicity nn pharmacokinetics nns of inpos oral jj ccnu nn either cc alone rb or cc in inpos combination nn with inpos the dt chemosensitizer nn misonidazole nn
false	4	6	because inpos the dt nitrosourea nn ccnu nn is vbz given vbn exclusively rb by inpos the dt oral jj route nn in inpos man nn we prp have vbp carried vbn out rp studies nns in inpos mice nns on inpos the dt antitumour jj activity nn acute jj toxicity nn pharmacokinetics nns of inpos oral jj ccnu nn either cc alone rb or cc in inpos combination nn with inpos the dt chemosensitizer nn misonidazole nn
false	4	76	because inpos the dt nitrosourea nn ccnu nn is vbz given vbn exclusively rb by inpos the dt oral jj route nn in inpos man nn we prp have vbp carried vbn out rp studies nns in inpos mice nns on inpos the dt antitumour jj activity nn acute jj toxicity nn pharmacokinetics nns of inpos oral jj ccnu nn either cc alone rb or cc in inpos combination nn with inpos the dt chemosensitizer nn misonidazole nn
false	6	76	because inpos the dt nitrosourea nn ccnu nn is vbz given vbn exclusively rb by inpos the dt oral jj route nn in inpos man nn we prp have vbp carried vbn out rp studies nns in inpos mice nns on inpos the dt antitumour jj activity nn acute jj toxicity nn pharmacokinetics nns of inpos oral jj ccnu nn either cc alone rb or cc in inpos combination nn with inpos the dt chemosensitizer nn misonidazole nn
false	6	76	because inpos the dt nitrosourea nn ccnu nn is vbz given vbn exclusively rb by inpos the dt oral jj route nn in inpos man nn we prp have vbp carried vbn out rp studies nns in inpos mice nns on inpos the dt antitumour jj activity nn acute jj toxicity nn pharmacokinetics nns of inpos oral jj ccnu nn either cc alone rb or cc in inpos combination nn with inpos the dt chemosensitizer nn misonidazole nn
effect	0	14	misonidazole nn reduced vbd the dt antitumour jj activity nn of inpos oral jj ccnu nn by inpos dose nn modifying vbg factors nns of inpos float cd
mechanism	0	14	misonidazole nn has vbz a dt complex jj effect nn on inpos oral jj ccnu nn pharmacokinetics nns
mechanism	30	36	we prp propose vbp these dt pharmacokinetic jj changes nns to topos be vb the dt underlying vbg mechanism nn for inpos the dt reduction nn of inpos oral jj ccnu nn cytotoxicity nn by inpos misonidazole nn
mechanism	2	10	enhanced vbn theophylline nn clearance nn secondary jj to topos phenytoin nn therapy nn
mechanism	14	26	this dt report nn describes vbz num cd cases nns in inpos which wdt theophylline nn clearance nn accelerated vbd markedly rb with inpos concomitant jj phenytoin nn administration nn
effect	16	46	with inpos combined vbn use nn clinicians nns should md be vb aware jj when wrb phenytoin nn is vbz added vbn of inpos the dt potential nn for inpos reexacerbation nn of inpos pulmonary jj symptomatology nn due jj to topos lowered vbn serum nn theophylline nn concentrations nns
false	14	26	the dt behavioral jj effects nns of inpos the dt stereoisomers nns of inpos n_allylnormetazocine nn were vbd compared vbn with inpos those dt of inpos phencyclidine nn in inpos pigeons nns and cc squirrel nn monkeys nns responding vbg under inpos a dt multiple jj fixed_interval jj fixed_ratio jj schedule nn of inpos food nn presentation nn
false	14	26	the dt behavioral jj effects nns of inpos the dt stereoisomers nns of inpos n_allylnormetazocine nn were vbd compared vbn with inpos those dt of inpos pcp nn in inpos pigeons nns and cc squirrel nn monkeys nns responding vbg under inpos a dt multiple jj fixed_interval jj fixed_ratio jj schedule nn of inpos food nn presentation nn
false	14	26	the dt behavioral jj effects nns of inpos the dt stereoisomers nns of inpos nanm nn were vbd compared vbn with inpos those dt of inpos phencyclidine nn in inpos pigeons nns and cc squirrel nn monkeys nns responding vbg under inpos a dt multiple jj fixed_interval jj fixed_ratio jj schedule nn of inpos food nn presentation nn
false	14	26	the dt behavioral jj effects nns of inpos the dt stereoisomers nns of inpos nanm nn were vbd compared vbn with inpos those dt of inpos pcp nn in inpos pigeons nns and cc squirrel nn monkeys nns responding vbg under inpos a dt multiple jj fixed_interval jj fixed_ratio jj schedule nn of inpos food nn presentation nn
false	6	10	intermediate jj doses nns of inpos +_nanm nn or cc pcp nn produced vbd transient jj increases nns in inpos fi nn responding vbg in inpos monkeys nns and cc sustained jj increases nns in inpos fi nn responding vbg in inpos pigeons nns
false	4	20	in inpos monkeys nns nanm nn was vbd about rb num cd times nns more rbr potent jj than inpos +_nanm nn in inpos decreasing vbg responding vbg whereas inpos in inpos pigeons nns nanm nn was vbd about rb equipotent jj with inpos +_nanm nn
false	4	20	in inpos monkeys nns nanm nn was vbd about rb num cd times nns more rbr potent jj than inpos +_nanm nn in inpos decreasing vbg responding vbg whereas inpos in inpos pigeons nns nanm nn was vbd about rb equipotent jj with inpos +_nanm nn
false	20	4	in inpos monkeys nns nanm nn was vbd about rb num cd times nns more rbr potent jj than inpos +_nanm nn in inpos decreasing vbg responding vbg whereas inpos in inpos pigeons nns nanm nn was vbd about rb equipotent jj with inpos +_nanm nn
false	4	20	in inpos monkeys nns nanm nn was vbd about rb num cd times nns more rbr potent jj than inpos +_nanm nn in inpos decreasing vbg responding vbg whereas inpos in inpos pigeons nns nanm nn was vbd about rb equipotent jj with inpos +_nanm nn
false	6	12	in inpos both dt species nns nanm nn but cc not rb +_nanm nn antagonized vbd the dt rate_decreasing jj effects nns of inpos morphine nn on inpos fi nn and cc fr nn responding vbg
effect	6	24	in inpos both dt species nns nanm nn but cc not rb +_nanm nn antagonized vbd the dt rate_decreasing jj effects nns of inpos morphine nn on inpos fi nn and cc fr nn responding vbg
false	12	24	in inpos both dt species nns nanm nn but cc not rb +_nanm nn antagonized vbd the dt rate_decreasing jj effects nns of inpos morphine nn on inpos fi nn and cc fr nn responding vbg
false	10	16	in inpos monkeys nns the dt effects nns of inpos nanm nn but cc not rb +_nanm nn or cc pcp nn were vbd antagonized vbn by inpos naloxone nn
false	10	20	in inpos monkeys nns the dt effects nns of inpos nanm nn but cc not rb +_nanm nn or cc pcp nn were vbd antagonized vbn by inpos naloxone nn
effect	10	28	in inpos monkeys nns the dt effects nns of inpos nanm nn but cc not rb +_nanm nn or cc pcp nn were vbd antagonized vbn by inpos naloxone nn
false	16	20	in inpos monkeys nns the dt effects nns of inpos nanm nn but cc not rb +_nanm nn or cc pcp nn were vbd antagonized vbn by inpos naloxone nn
false	16	28	in inpos monkeys nns the dt effects nns of inpos nanm nn but cc not rb +_nanm nn or cc pcp nn were vbd antagonized vbn by inpos naloxone nn
false	20	28	in inpos monkeys nns the dt effects nns of inpos nanm nn but cc not rb +_nanm nn or cc pcp nn were vbd antagonized vbn by inpos naloxone nn
effect	6	20	the dt doses nns of inpos naloxone nn required vbn to topos antagonize vb the dt effects nns of inpos nanm nn were vbd more jjr than inpos num cd times nns higher jjr than inpos those dt required vbn to topos antagonize vb the dt effects nns of inpos morphine nn
effect	6	50	the dt doses nns of inpos naloxone nn required vbn to topos antagonize vb the dt effects nns of inpos nanm nn were vbd more jjr than inpos num cd times nns higher jjr than inpos those dt required vbn to topos antagonize vb the dt effects nns of inpos morphine nn
false	20	50	the dt doses nns of inpos naloxone nn required vbn to topos antagonize vb the dt effects nns of inpos nanm nn were vbd more jjr than inpos num cd times nns higher jjr than inpos those dt required vbn to topos antagonize vb the dt effects nns of inpos morphine nn
false	4	20	in inpos pigeons nns naloxone nn did vbd not rb systematically rb alter vb the dt effects nns of inpos nanm nn
false	4	20	in inpos pigeons nns naloxone nn did vbd not rb systematically rb alter vb the dt effects nns of inpos +_nanm nn
false	4	20	in inpos pigeons nns naloxone nn did vbd not rb systematically rb alter vb the dt effects nns of inpos pcp nn
effect	0	30	haloperidol nn reduced vbd or cc eliminated vbd the dt increases nns in inpos fi nn responding vbg produced vbn by inpos intermediate jj doses nns of inpos either cc +_nanm nn or cc pcp nn in inpos pigeons nns but cc did vbd not rb antagonize vb the dt decreases nns in inpos fi nn or cc fr nn responding vbg produced vbn by inpos high jj doses nns of inpos pcp nn or cc either cc stereoisomer nn of inpos nanm nn
effect	0	34	haloperidol nn reduced vbd or cc eliminated vbd the dt increases nns in inpos fi nn responding vbg produced vbn by inpos intermediate jj doses nns of inpos either cc +_nanm nn or cc pcp nn in inpos pigeons nns but cc did vbd not rb antagonize vb the dt decreases nns in inpos fi nn or cc fr nn responding vbg produced vbn by inpos high jj doses nns of inpos pcp nn or cc either cc stereoisomer nn of inpos nanm nn
false	0	30	haloperidol nn reduced vbd or cc eliminated vbd the dt increases nns in inpos fi nn responding vbg produced vbn by inpos intermediate jj doses nns of inpos either cc +_nanm nn or cc pcp nn in inpos pigeons nns but cc did vbd not rb antagonize vb the dt decreases nns in inpos fi nn or cc fr nn responding vbg produced vbn by inpos high jj doses nns of inpos pcp nn or cc either cc stereoisomer nn of inpos nanm nn
false	30	34	haloperidol nn reduced vbd or cc eliminated vbd the dt increases nns in inpos fi nn responding vbg produced vbn by inpos intermediate jj doses nns of inpos either cc +_nanm nn or cc pcp nn in inpos pigeons nns but cc did vbd not rb antagonize vb the dt decreases nns in inpos fi nn or cc fr nn responding vbg produced vbn by inpos high jj doses nns of inpos pcp nn or cc either cc stereoisomer nn of inpos nanm nn
false	34	30	haloperidol nn reduced vbd or cc eliminated vbd the dt increases nns in inpos fi nn responding vbg produced vbn by inpos intermediate jj doses nns of inpos either cc +_nanm nn or cc pcp nn in inpos pigeons nns but cc did vbd not rb antagonize vb the dt decreases nns in inpos fi nn or cc fr nn responding vbg produced vbn by inpos high jj doses nns of inpos pcp nn or cc either cc stereoisomer nn of inpos nanm nn
effect	6	16	increased vbn hepatotoxicity nn of inpos acetaminophen nn by inpos concomitant jj administration nn of inpos caffeine nn in inpos the dt rat nn
false	2	12	since inpos caffeine nn is vbz frequently rb co_administered vbn with inpos acetaminophen nn it prp is vbz of inpos clinical jj interest nn to topos study vb the dt effect nn of inpos caffeine nn on inpos the dt hepatotoxicity nn of inpos acetaminophen nn
false	2	12	since inpos caffeine nn is vbz frequently rb co_administered vbn with inpos acetaminophen nn it prp is vbz of inpos clinical jj interest nn to topos study vb the dt effect nn of inpos caffeine nn on inpos the dt hepatotoxicity nn of inpos acetaminophen nn
false	12	2	since inpos caffeine nn is vbz frequently rb co_administered vbn with inpos acetaminophen nn it prp is vbz of inpos clinical jj interest nn to topos study vb the dt effect nn of inpos caffeine nn on inpos the dt hepatotoxicity nn of inpos acetaminophen nn
false	2	12	since inpos caffeine nn is vbz frequently rb co_administered vbn with inpos acetaminophen nn it prp is vbz of inpos clinical jj interest nn to topos study vb the dt effect nn of inpos caffeine nn on inpos the dt hepatotoxicity nn of inpos acetaminophen nn
effect	14	22	careful jj observations nns on inpos hepatotoxicity nn are vbp suggested vbn when wrb acetaminophen nn is vbz prescribed vbn with inpos caffeine nn
effect	2	6	high_dose jj cisplatin nn with inpos sodium_thiosulfate nn protection nn
effect	0	12	sodium_thiosulfate nn is vbz a dt neutralizing vbg agent nn for inpos cisplatin nn that wdt protects vbz against inpos renal jj damage nn
false	10	22	to topos determine vb whether inpos injection nn of inpos thiosulfate nn would md permit vb larger jjr doses nns of inpos cisplatin nn to topos be vb administered vbn a dt fixed jj float cd dose nn of inpos thiosulfate nn was vbd given vbn intravenously rb over inpos num cd hours nns concurrently rb with inpos escalating vbg doses nns of inpos cisplatin nn
false	10	22	to topos determine vb whether inpos injection nn of inpos thiosulfate nn would md permit vb larger jjr doses nns of inpos cisplatin nn to topos be vb administered vbn a dt fixed jj float cd dose nn of inpos thiosulfate nn was vbd given vbn intravenously rb over inpos num cd hours nns concurrently rb with inpos escalating vbg doses nns of inpos cisplatin nn
false	22	10	to topos determine vb whether inpos injection nn of inpos thiosulfate nn would md permit vb larger jjr doses nns of inpos cisplatin nn to topos be vb administered vbn a dt fixed jj float cd dose nn of inpos thiosulfate nn was vbd given vbn intravenously rb over inpos num cd hours nns concurrently rb with inpos escalating vbg doses nns of inpos cisplatin nn
false	10	22	to topos determine vb whether inpos injection nn of inpos thiosulfate nn would md permit vb larger jjr doses nns of inpos cisplatin nn to topos be vb administered vbn a dt fixed jj float cd dose nn of inpos thiosulfate nn was vbd given vbn intravenously rb over inpos num cd hours nns concurrently rb with inpos escalating vbg doses nns of inpos cisplatin nn
false	0	20	cisplatin nn was vbd administered vbn over inpos the dt last jj num cd hours nns of inpos the dt thiosulfate nn infusion nn
false	4	22	comparison nn of inpos cisplatin nn pharmacokinetics nns in inpos patients nns treated vbn with inpos float cd mg_m2 nn plus cc thiosulfate nn to topos those dt in inpos patients nns treated vbn with inpos num cd mg_m2 nn without inpos thiosulfate nn indicated vbd that inpos there ex were vbd no dt changes nns in inpos the dt elimination nn rate nn constant nn volume nn of inpos distribution nn or cc total jj body nn clearance nn of inpos cisplatin nn
false	4	22	comparison nn of inpos cisplatin nn pharmacokinetics nns in inpos patients nns treated vbn with inpos float cd mg_m2 nn plus cc thiosulfate nn to topos those dt in inpos patients nns treated vbn with inpos num cd mg_m2 nn without inpos thiosulfate nn indicated vbd that inpos there ex were vbd no dt changes nns in inpos the dt elimination nn rate nn constant nn volume nn of inpos distribution nn or cc total jj body nn clearance nn of inpos cisplatin nn
false	22	4	comparison nn of inpos cisplatin nn pharmacokinetics nns in inpos patients nns treated vbn with inpos float cd mg_m2 nn plus cc thiosulfate nn to topos those dt in inpos patients nns treated vbn with inpos num cd mg_m2 nn without inpos thiosulfate nn indicated vbd that inpos there ex were vbd no dt changes nns in inpos the dt elimination nn rate nn constant nn volume nn of inpos distribution nn or cc total jj body nn clearance nn of inpos cisplatin nn
false	22	4	comparison nn of inpos cisplatin nn pharmacokinetics nns in inpos patients nns treated vbn with inpos float cd mg_m2 nn plus cc thiosulfate nn to topos those dt in inpos patients nns treated vbn with inpos num cd mg_m2 nn without inpos thiosulfate nn indicated vbd that inpos there ex were vbd no dt changes nns in inpos the dt elimination nn rate nn constant nn volume nn of inpos distribution nn or cc total jj body nn clearance nn of inpos cisplatin nn
mechanism	14	40	this dt study nn demonstrates vbz that inpos concurrent jj administration nn of inpos thiosulfate nn permits nns at inpos least jjs a dt twofold jj increase nn in inpos dose nn and cc total jj exposure nn to topos cisplatin nn
false	8	22	repeated vbn oral jj administration nn of inpos coumaphos nn in inpos sheep nns interactions nns of inpos coumaphos nns with inpos bishydroxycoumarin nn
false	8	22	repeated vbn oral jj administration nn of inpos coumaphos nn in inpos sheep nns interactions nns of inpos coumaphos nns with inpos trichlorfon nn
false	8	22	repeated vbn oral jj administration nn of inpos coumaphos nn in inpos sheep nns interactions nns of inpos coumaphos nns with inpos phenobarbital_sodium nn
false	8	22	repeated vbn oral jj administration nn of inpos coumaphos nns in inpos sheep nns interactions nns of inpos coumaphos nn with inpos bishydroxycoumarin nn
false	8	22	repeated vbn oral jj administration nn of inpos coumaphos nns in inpos sheep nns interactions nns of inpos coumaphos nn with inpos trichlorfon nn
false	8	22	repeated vbn oral jj administration nn of inpos coumaphos nns in inpos sheep nns interactions nns of inpos coumaphos nn with inpos phenobarbital_sodium nn
false	14	52	a dt daily jj dose nn of inpos num cd mg nn of inpos coumaphos nn kg nn of inpos body nn weight nn for inpos num cd days nns did vbd not rb affect vb the dt plasma nn enzymes nns or cc the dt antiprothrombinemic jj effect nn of inpos bishydroxy_coumarin nn in inpos wethers nns
effect	18	68	the dt treatment nn of inpos ewes nns with inpos an dt intravenous jj injection nn of inpos trichlorfon nn insufficient jj to topos produce vb significant jj inhibition nn of inpos erythrocyte nn acetylcholinesterase nn activity nn appeared vbd to topos produce vb additive jj effects nns with inpos those dt produced vbn by inpos subsequent jj treatment nn with inpos num cd mg nn of inpos coumaphos nn kg_day nn
effect	12	38	in inpos ewes nns given vbn num cd mg nn of inpos phenobarbital_sodium nn kg nn for inpos num cd days nns intraperitoneally rb the dt anticholinesterase nn effect nn of inpos num cd mg nn of inpos coumaphos nn kg nn was vbd significantly rb reduced vbn and cc signs nns of inpos toxicity nn were vbd not rb present jj
false	4	10	failure nn of inpos neomycin nn to topos modify vb acth nn induced vbd hypertension nn in inpos sheep nn
false	12	24	studies nns in inpos rats nns have vbp shown vbn that inpos neomycin nn administration nn attenuates vbz certain jj types nns of inpos adrenocortical_steroid nn dependent jj hypertension nn including vbg acth nn hypertension nn
effect	12	32	studies nns in inpos rats nns have vbp shown vbn that inpos neomycin nn administration nn attenuates vbz certain jj types nns of inpos adrenocortical_steroid nn dependent jj hypertension nn including vbg acth nn hypertension nn
false	24	32	studies nns in inpos rats nns have vbp shown vbn that inpos neomycin nn administration nn attenuates vbz certain jj types nns of inpos adrenocortical_steroid nn dependent jj hypertension nn including vbg acth nn hypertension nn
false	8	12	the dt effects nns of inpos oral jj neomycin nn on inpos acth nn induced vbn hypertension nn were vbd examined vbn in inpos conscious jj sheep nns
false	0	24	neomycin nn has vbz no dt effect nn on inpos the dt blood nn pressure nn or cc metabolic jj responses nns to topos acth nn in inpos sheep nn
false	16	20	the dt present jj work nn involved vbd the dt administration nn of inpos both cc ethynyl_estradiol nn and cc levonorgestrel nn to topos groups nns of inpos rats nns followed vbn by inpos determination nn of inpos the dt homocysteine nn excretion nn rate nn in inpos urine nn
false	44	66	the dt results nns indicate vbp that inpos a dt statistically rb significant jj difference nn exists vbz between inpos the dt excreted vbn levels nns of inpos homocysteine nn in inpos the dt urine nn of inpos both cc control nn and cc levonorgestrel nn treated jj rats nns and cc the dt levels nns shown vbn by inpos rats nns treated vbn with inpos ethynyl_estradiol nn
false	10	32	the dt num cd v_v nn solution nn of inpos alcohol nn was vbd prepared vbn in inpos water nn from inpos a dt stock nn solution nn of inpos num cd ethanol nn
effect	14	38	these dt results nns suggest vbp that inpos exposure nn to topos environmental jj lead nn may md alter vb the dt biological jj and cc behavioral jj responsiveness nn of inpos an dt animal nn to topos alcohol nn
effect	0	14	physostigmine nn pretreatment nn augmented vbd the dt depressant jj effect nn of inpos alcohol nn on inpos the dt early jj components nns p1 nn and cc n1 nn while inpos attenuating vbg alcohol nn s pos influence nn on inpos components nns p2 nn and cc p3 nn
effect	0	14	physostigmine nn pretreatment nn augmented vbd the dt depressant jj effect nn of inpos alcohol nn on inpos the dt early jj components nns p1 nn and cc n1 nn while inpos attenuating vbg alcohol nn s pos influence nn on inpos components nns p2 nn and cc p3 nn
false	0	14	atropine nn either cc alone rb or cc in inpos combination nn with inpos alcohol nn produced vbd approximately rb the dt same jj degree nn of inpos enhancement nn of inpos component nn p2 nn
false	12	14	hypothermia nn as inpos an dt index nn of inpos the dt disulfiram nn hyph_ethanol nn reaction nn in inpos the dt rat nn
false	28	30	decreased vbn core nn temperature nn in inpos female jj rats nns was vbd investigated vbn as inpos num cd possible jj index nn of inpos the dt disulfiram nn hyph_ethanol nn reaction nn
effect	22	36	core nn temperature nn was vbd decreased vbn in inpos rats nns in inpos a dt dose_dependent jj manner nn when wrb ethanol nn was vbd administered vbn to topos rats nns treated vbn with inpos disulfiram nn num cd hours nns before inpos the dt ethanol nn challenge nn
false	36	22	core nn temperature nn was vbd decreased vbn in inpos rats nns in inpos a dt dose_dependent jj manner nn when wrb ethanol nn was vbd administered vbn to topos rats nns treated vbn with inpos disulfiram nn num cd hours nns before inpos the dt ethanol nn challenge nn
false	22	26	the dt aim nn of inpos this dt paper nn was vbd to topos study vb the dt interaction nn between inpos neurotensin nn both cc enkephalins nn its prp synthetic jj analogue nn d_ala2_metenkephalinamide nn or cc tuftsin nn on inpos the dt antinonciceptive jj effect nn of inpos these dt peptides nns in inpos mice nns after inpos intracisternal jj injection nn
false	22	34	the dt aim nn of inpos this dt paper nn was vbd to topos study vb the dt interaction nn between inpos neurotensin nn both dt enkephalins nns its prp synthetic jj analogue nn d_ala2_metenkephalinamide nn or cc tuftsin nn on inpos the dt antinonciceptive jj effect nn of inpos these dt peptides nns in inpos mice nns after inpos intracisternal jj injection nn
false	22	38	the dt aim nn of inpos this dt paper nn was vbd to topos study vb the dt interaction nn between inpos neurotensin nn both dt enkephalins nns its prp synthetic jj analogue nn d_ala2_metenkephalinamide nn or cc tuftsin nn on inpos the dt antinonciceptive jj effect nn of inpos these dt peptides nns in inpos mice nns after inpos intracisternal jj injection nn
false	26	34	the dt aim nn of inpos this dt paper nn was vbd to topos study vb the dt interaction nn between inpos neurotensin nn both cc enkephalins nn its prp synthetic jj analogue nn d_ala2_metenkephalinamide nn or cc tuftsin nn on inpos the dt antinonciceptive jj effect nn of inpos these dt peptides nns in inpos mice nns after inpos intracisternal jj injection nn
false	26	38	the dt aim nn of inpos this dt paper nn was vbd to topos study vb the dt interaction nn between inpos neurotensin nn both cc enkephalins nn its prp synthetic jj analogue nn d_ala2_metenkephalinamide nn or cc tuftsin nn on inpos the dt antinonciceptive jj effect nn of inpos these dt peptides nns in inpos mice nns after inpos intracisternal jj injection nn
false	34	38	the dt aim nn of inpos this dt paper nn was vbd to topos study vb the dt interaction nn between inpos neurotensin nn both dt enkephalins nns its prp synthetic jj analogue nn d_ala2_metenkephalinamide nn or cc tuftsin nn on inpos the dt antinonciceptive jj effect nn of inpos these dt peptides nns in inpos mice nns after inpos intracisternal jj injection nn
effect	8	22	it prp was vbd shown vbn that inpos neurotensin nn antagonized vbd evidently rb the dt antinociceptive jj effect nn of inpos enkephalins nn and cc their prp analogue nn
effect	6	10	on inpos the dt contrary nn neurotensin nn and cc tuftsin nn were vbd agonists nns in inpos induction nn of inpos analgesia nn
effect	8	42	it prp is vbz concluded vbn that inpos neurotensin nn modulates vbz in inpos an dt opposite jj way nn the dt function nn of inpos the dt enkephalinergic jj neurons nns and cc the dt central jj action nn of inpos tuftsin nn
effect	32	44	among inpos the dt risk nn factors nns studied vbn num cd appear vbp to topos increase vb the dt risk nn of inpos are nn the dt prescription nn of inpos thiabendazole nn to topos treat vb strongyloidiasis nn during inpos the dt melarsoprol nn cure nn and cc the dt bad jj general jj clinical jj conditions nns of inpos patients nns
false	14	48	recommendations nns were vbd to topos avoid vb administration nn of inpos diffusible jj anti_helminthic nn treatment nn during inpos the dt cure nn and cc to topos improve vb the dt general jj conditions nns of inpos patients nns before inpos the dt cure nn of inpos melarsoprol nn
mechanism	4	8	interactions nns of inpos cobalt nn and cc iron nn in inpos absorption nn and cc retention nn
false	10	14	the dt effects nns of inpos supplementary jj oral jj cobalt nn and cc iron nn as rb well rb as inpos the dt interaction nn between inpos both dt at inpos the dt absorption nn site nn fecal jj and cc urinary jj excretion nn as rb well rb as inpos the dt retention nn of inpos these dt trace nn elements nns were vbd determined vbn by inpos using vbg num cd diets nns containing vbg either cc num cd or cc num cd micrograms_kg nn of inpos co nn and cc num cd or cc num cd mg_kg nn of inpos fe nnp over inpos a dt period nn of inpos num cd days nns in inpos a dt total nn of inpos num cd rats nns
false	10	2	the dt effects nns of inpos supplementary jj oral jj cobalt nn and cc iron nn as rb well rb as inpos the dt interaction nn between inpos both dt at inpos the dt absorption nn site nn fecal jj and cc urinary jj excretion nn as rb well rb as inpos the dt retention nn of inpos these dt trace nn elements nns were vbd determined vbn by inpos using vbg num cd diets nns containing vbg either cc num cd or cc num cd micrograms_kg nn of inpos co nn and cc num cd or cc num cd mg_kg nn of inpos fe nn over inpos a dt period nn of inpos num cd days nns in inpos a dt total nn of inpos num cd rats nns
false	14	10	the dt effects nns of inpos supplementary jj oral jj cobalt nn and cc iron nn as rb well rb as inpos the dt interaction nn between inpos both dt at inpos the dt absorption nn site nn fecal jj and cc urinary jj excretion nn as rb well rb as inpos the dt retention nn of inpos these dt trace nn elements nns were vbd determined vbn by inpos using vbg num cd diets nns containing vbg either cc num cd or cc num cd micrograms_kg nn of inpos co nn and cc num cd or cc num cd mg_kg nn of inpos fe nnp over inpos a dt period nn of inpos num cd days nns in inpos a dt total nn of inpos num cd rats nns
false	14	2	the dt effects nns of inpos supplementary jj oral jj cobalt nn and cc iron nn as rb well rb as inpos the dt interaction nn between inpos both dt at inpos the dt absorption nn site nn fecal jj and cc urinary jj excretion nn as rb well rb as inpos the dt retention nn of inpos these dt trace nn elements nns were vbd determined vbn by inpos using vbg num cd diets nns containing vbg either cc num cd or cc num cd micrograms_kg nn of inpos co nn and cc num cd or cc num cd mg_kg nn of inpos fe nn over inpos a dt period nn of inpos num cd days nns in inpos a dt total nn of inpos num cd rats nns
false	10	2	the dt effects nns of inpos supplementary jj oral jj cobalt nn and cc iron nn as rb well rb as inpos the dt interaction nn between inpos both dt at inpos the dt absorption nn site nn fecal jj and cc urinary jj excretion nn as rb well rb as inpos the dt retention nn of inpos these dt trace nn elements nns were vbd determined vbn by inpos using vbg num cd diets nns containing vbg either cc num cd or cc num cd micrograms_kg nn of inpos co nn and cc num cd or cc num cd mg_kg nn of inpos fe nn over inpos a dt period nn of inpos num cd days nns in inpos a dt total nn of inpos num cd rats nns
mechanism	2	14	additional jj iron nn significantly rb inhibited vbd the dt absorption nn of inpos cobalt nn in inpos both cc dietary jj cobalt nn treatments nns
mechanism	2	14	additional jj iron nn significantly rb inhibited vbd the dt absorption nn of inpos cobalt nn in inpos both cc dietary jj cobalt nn treatments nns
mechanism	22	56	the dt lower jjr rate nn of inpos absorption nn in inpos the dt groups nns receiving vbg num cd mg nn fe nn instead rb of inpos num cd mg nn of inpos fe nn per inpos kg nn diet nn resulted vbd in inpos a dt decreased vbn renal jj excretion nn of inpos cobalt nn
false	22	56	the dt lower jjr rate nn of inpos absorption nn in inpos the dt groups nns receiving vbg num cd mg nn fe nnp instead rb of inpos num cd mg nn of inpos fe nn per inpos kg nn diet nn resulted vbd in inpos a dt decreased vbn renal jj excretion nn of inpos cobalt nn
mechanism	8	18	consequently rb the dt effect nn of inpos iron nn on inpos the dt retention nn of inpos cobalt nn was vbd lower jjr than inpos on inpos absorption nn
false	10	22	because inpos of inpos the dt low jj dietary jj cobalt nn concentration nn as inpos compared vbn to topos the dt iron nn contents nns of inpos the dt diets nns no dt effect nn of inpos cobalt nn on inpos iron nn absorption nn and cc excretion nn occurred vbd
false	10	22	because inpos of inpos the dt low jj dietary jj cobalt nn concentration nn as inpos compared vbn to topos the dt iron nn contents nns of inpos the dt diets nns no dt effect nn of inpos cobalt nn on inpos iron nn absorption nn and cc excretion nn occurred vbd
false	22	10	because inpos of inpos the dt low jj dietary jj cobalt nn concentration nn as inpos compared vbn to topos the dt iron nn contents nns of inpos the dt diets nns no dt effect nn of inpos cobalt nn on inpos iron nn absorption nn and cc excretion nn occurred vbd
false	10	22	because inpos of inpos the dt low jj dietary jj cobalt nn concentration nn as inpos compared vbn to topos the dt iron nn contents nns of inpos the dt diets nns no dt effect nn of inpos cobalt nn on inpos iron nn absorption nn and cc excretion nn occurred vbd
false	4	0	differences nns in inpos iron nn balance nn were vbd only rb observed vbn between inpos both cc dietary jj concentrations nns showing vbg a dt higher jjr absolute jj but cc a dt lower jjr relative jj absorption nn as rb well rb as inpos retention nn in inpos the dt groups nns fed vbn further jj fe nn
false	4	8	effect nn of inpos estradiol nn on inpos endotoxin nn induced jj changes nns in inpos steroid nn hormone nn levels nns and cc lethality nn in inpos male jj rats nns
false	12	46	we prp examined vbd the dt effect nn of inpos exogenous jj estradiol nn on inpos the dt changes nns in inpos serum nn steroid nn hormone nn levels nns induced vbn by inpos a dt nonlethal jj dose nn of inpos escherichia fw coli fw endotoxin nn in inpos male jj rats nns and cc the dt deaths nns due jj to topos nonlethal jj and cc lethal jj doses nns of inpos endotoxin nn
false	12	46	we prp examined vbd the dt effect nn of inpos exogenous jj estradiol nn on inpos the dt changes nns in inpos serum nn steroid nn hormone nn levels nns induced vbn by inpos a dt nonlethal jj dose nn of inpos escherichia fw coli fw endotoxin nn in inpos male jj rats nns and cc the dt deaths nns due jj to topos nonlethal jj and cc lethal jj doses nns of inpos endotoxin nn
effect	4	20	injection nn of inpos estradiol nn num cd min nn before inpos a dt nonlethal jj dose nn of inpos endotoxin nn changed vbd the dt serum nn sex nn steroid nn hormone nn response nn of inpos male jj rats nns to topos endotoxin nn
false	4	20	injection nn of inpos estradiol nn num cd min nn before inpos a dt nonlethal jj dose nn of inpos endotoxin nn changed vbd the dt serum nn sex nn steroid nn hormone nn response nn of inpos male jj rats nns to topos endotoxin nn
mechanism	10	12	the dt serum nn estrogen nn concentrations nns of inpos estradiol nn +_endotoxin nn treated jj rats nns decreased vbd by inpos num cd while inpos those dt of inpos the dt endotoxin_treated jj rats nns increased vbd
false	10	14	the dt serum nn estrogen nn concentrations nns of inpos estradiol nn + cc endotoxin_treated jj rats nns decreased vbd by inpos num cd while inpos those dt of inpos the dt endotoxin nn treated jj rats nns increased vbd
false	10	12	the dt serum nn androgen nn concentrations nns of inpos estradiol nn +_endotoxin nn treated jj rats nns did vbd not rb change vb significantly rb while inpos those dt of inpos endotoxin_treated jj rats nns dropped vbd to topos num cd
false	10	14	the dt serum nn androgen nn concentrations nns of inpos estradiol nn + cc endotoxin_treated jj rats nns did vbd not rb change vb significantly rb while inpos those dt of inpos endotoxin nn treated jj rats nns dropped vbd to topos num cd
effect	2	18	exogenous jj estradiol nn also rb appeared vbd to topos influence vb the dt percentage nn of inpos endotoxin nn induced jj deaths nns in inpos a dt dose_dependent jj manner nn
false	0	4	loperamide nn and cc morphine nn
false	0	4	loperamide nn and cc morphine nn inhibited vbd the dt dmpge2 nn induced jj diarrhea nn in inpos cecectomized vbn rats nns
effect	0	10	loperamide nn and cc morphine nn inhibited vbd the dt dmpge2 nn induced jj diarrhea nn in inpos cecectomized vbn rats nns
effect	4	10	loperamide nn and cc morphine nn inhibited vbd the dt dmpge2 nn induced jj diarrhea nn in inpos cecectomized vbn rats nns
effect	0	14	n_methyllevallorphan nn completely rb antagonized vbd the dt inhibitory jj effect nn of inpos loperamide nn and cc partly rb antagonized vbd the dt effect nn of inpos morphine nn
effect	0	28	n_methyllevallorphan nn completely rb antagonized vbd the dt inhibitory jj effect nn of inpos loperamide nn and cc partly rb antagonized vbd the dt effect nn of inpos morphine nn
false	14	28	methyllevallorphan nn completely rb antagonized vbd the dt inhibitory jj effect nn of inpos loperamide nn and cc partly rb antagonized vbd the dt effect nn of inpos morphine nn
effect	18	20	therapeutic jj drug nn monitoring nn can md avoid vb iatrogenic jj alterations nns caused vbn by inpos 99mtc_methylene_diphosphonate nn hyph_gentamicin nn interaction nn
false	0	6	gentamicin nn is vbz an dt aminoglycoside_antibiotic nn used vbn to topos treat vb a dt wide jj variety nn of inpos infections nns caused vbn by inpos gram_negative jj organisms nns but cc it prp is vbz potentially rb toxic jj to topos the dt kidneys nns
mechanism	8	28	due jj to topos its prp nephrotoxicity nn gentamicin nn may md cause vb abnormal jj renal jj uptake nn to topos be vb seen vbn on inpos 99mtc_mdp nn bone nn scintigraphy nn
false	8	20	therapeutic jj drug nn monitoring nn of inpos gentamicin nn therapy nn and cc bone nn scintigraphy nn employing vbg 99mtc_mdp nn as inpos the dt radiopharmaceutical nn was vbd carried vbn out rp in inpos num cd patients nns
false	8	26	therapeutic jj drug nn monitoring nn of inpos gentamicin nn therapy nn and cc bone nn scintigraphy nn employing vbg 99mtc_mdp nn as inpos the dt radiopharmaceutical nn was vbd carried vbn out rp in inpos num cd patients nns
false	20	26	therapeutic jj drug nn monitoring nn of inpos gentamicin nn therapy nn and cc bone nn scintigraphy nn employing vbg 99mtc_mdp nn as inpos the dt radiopharmaceutical nn was vbd carried vbn out rp in inpos num cd patients nns
false	14	18	this dt article nn looks vbz at inpos num cd commonly rb used vbn immunosuppressive_drugs nn in inpos corticosteroids nn discussing vbg the dt main jj non_infection jj unwanted jj effects nns ways nns to topos avoid vb them prp what wp to topos do vb if inpos problems nns arise vbp
false	14	18	this dt article nn looks vbz at inpos num cd commonly rb used vbn immunosuppressive_drugs nn in inpos cyclosporin nn discussing vbg the dt main jj non_infection jj unwanted jj effects nns ways nns to topos avoid vb them prp what wp to topos do vb if inpos problems nns arise vbp
false	14	18	this dt article nn looks vbz at inpos num cd commonly rb used vbn immunosuppressive_drugs nn in inpos azathioprine nn discussing vbg the dt main jj non_infection jj unwanted jj effects nns ways nns to topos avoid vb them prp what wp to topos do vb if inpos problems nns arise vbp
false	14	18	this dt article nn looks vbz at inpos num cd commonly rb used vbn immunosuppressive_drugs nn in inpos methotrexate nn discussing vbg the dt main jj non_infection jj unwanted jj effects nns ways nns to topos avoid vb them prp what wp to topos do vb if inpos problems nns arise vbp
false	14	18	this dt article nn looks vbz at inpos num cd commonly rb used vbn immunosuppressive_drugs nn in inpos cyclophosphamide nn discussing vbg the dt main jj non_infection jj unwanted jj effects nns ways nns to topos avoid vb them prp what wp to topos do vb if inpos problems nns arise vbp
false	36	46	little jj has vbz been vbn studied vbn of inpos the dt adverse jj effects nns of inpos the dt exposure nn of inpos the dt liver nn to topos the dt interaction nn of inpos ethanol nn with inpos its prp congeners nns and cc acetaldehyde nn coexisting vbg in inpos the dt contents nns of inpos alcoholic jj beverages nns
effect	14	38	these dt results nns suggest vbp that inpos the dt hepatoxicity nn of inpos ethanol nn in inpos alcoholic jj beverages nns is vbz enhanced vbn by inpos interaction nn with inpos its prp congeners nns and cc acetaldehyde nn
false	20	24	induction nn of inpos apoptosis nn in inpos breast nn cancer nn cells nns in inpos response nn to topos vitamin_d nn and cc antiestrogens nn
false	2	12	num cd num_dihydroxycholecalciferol_d3 nn the dt active jj metabolite nn of inpos vitamin_d nn is vbz a dt potent jj inhibitor nn of inpos breast nn cancer nn cell nn growth nn both cc in fw vivo fw and cc in fw vitro fw
false	0	10	num_oh_2d3 nn the dt active jj metabolite nn of inpos vitamin_d nn is vbz a dt potent jj inhibitor nn of inpos breast nn cancer nn cell nn growth nn both cc in fw vivo fw and cc in fw vitro fw
false	20	26	in inpos the dt experiments nns reported vbn here rb we prp examined vbd the dt interactions nns between inpos num_oh_2d3 nn and cc the dt antiestrogen nn num_hydroxytamoxifen nn which wdt also rb induces vbz apoptosis nn in inpos mcf_num nn cells nns
false	20	28	in inpos the dt experiments nns reported vbn here rb we prp examined vbd the dt interactions nns between inpos num_oh_2d3 nn and cc the dt antiestrogen nn num_hydroxytamoxifen nn which wdt also rb induces vbz apoptosis nn in inpos mcf_num nn cells nns
false	20	28	in inpos the dt experiments nns reported vbn here rb we prp examined vbd the dt interactions nns between inpos num_oh_2d3 nn and cc the dt antiestrogen nn tam nn which wdt also rb induces vbz apoptosis nn in inpos mcf_num nn cells nns
false	26	28	in inpos the dt experiments nns reported vbn here rb we prp examined vbd the dt interactions nns between inpos num_oh_2d3 nn and cc the dt antiestrogen nn num_hydroxytamoxifen nn which wdt also rb induces vbz apoptosis nn in inpos mcf_num nn cells nns
false	26	28	in inpos the dt experiments nns reported vbn here rb we prp examined vbd the dt interactions nns between inpos num_oh_2d3 nn and cc the dt antiestrogen nn tam nn which wdt also rb induces vbz apoptosis nn in inpos mcf_num nn cells nns
effect	8	28	our prp data nns suggest vbp that inpos tam nn significantly rb potentiates vbz the dt reduction nn in inpos cell nn number nn induced vbn by inpos num_oh_2d3 nn alone rb
effect	6	10	combined vbn treatment nn with inpos num_oh_2d3 nn and cc tam nn enhances vbz the dt degree nn of inpos apoptosis nn assessed vbn using vbg morphological jj markers nns that wdt identify vbp chromatin nn and cc nuclear jj matrix nn protein nn condensation nn
false	30	42	these dt data nns emphasize vbp that inpos apoptosis nn can md be vb induced vbn in inpos mcf_num nn cells nns either cc by inpos activation nn of inpos vitamin_d nn mediated jj signalling nn or cc disruption nn of inpos estrogen nn dependent jj signalling nn
effect	8	20	the dt anxiogenic jj effects nns of inpos theophylline nn were vbd reduced vbn by inpos pretreatment nn with inpos cgs_num nn an dt a2_selective jj agonist nn but cc not rb by inpos n6_cyclopentyladenosine nn an dt a1_selective jj agonist nn
false	8	34	the dt anxiogenic jj effects nns of inpos theophylline nn were vbd reduced vbn by inpos pretreatment nn with inpos cgs_num nn an dt a2_selective jj agonist nn but cc not rb by inpos n6_cyclopentyladenosine nn an dt a1_selective jj agonist nn
false	8	34	the dt anxiogenic jj effects nns of inpos theophylline nn were vbd reduced vbn by inpos pretreatment nn with inpos cgs_num nn an dt a2_selective jj agonist nn but cc not rb by inpos cpa nn an dt a1_selective jj agonist nn
false	20	34	the dt anxiogenic jj effects nns of inpos theophylline nn were vbd reduced vbn by inpos pretreatment nn with inpos cgs_num nn an dt a2_selective jj agonist nn but cc not rb by inpos n6_cyclopentyladenosine nn an dt a1_selective jj agonist nn
false	20	34	the dt anxiogenic jj effects nns of inpos theophylline nn were vbd reduced vbn by inpos pretreatment nn with inpos cgs_num nn an dt a2_selective jj agonist nn but cc not rb by inpos cpa nn an dt a1_selective jj agonist nn
effect	10	20	however rb the dt antagonism nn of inpos the dt theophylline nn induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx_induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	10	46	however rb the dt antagonism nn of inpos the dt theophylline nn induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx nn induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	10	60	however rb the dt antagonism nn of inpos the dt theophylline nn induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx_induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	10	66	however rb the dt antagonism nn of inpos the dt theophylline nn induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx_induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	18	44	however rb the dt antagonism nn of inpos the dt theophylline_induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx nn induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	18	58	however rb the dt antagonism nn of inpos the dt theophylline_induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx_induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	18	64	however rb the dt antagonism nn of inpos the dt theophylline_induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx_induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	44	60	however rb the dt antagonism nn of inpos the dt theophylline_induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx nn induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	44	66	however rb the dt antagonism nn of inpos the dt theophylline_induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx nn induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	58	64	however rb the dt antagonism nn of inpos the dt theophylline_induced jj anxiogenic jj effects nns by inpos cgs21680 nn was vbd only rb observed vbn in inpos the dt time nn spent vbn in inpos the dt light jj zone nn and cc dpcpx_induced jj anxiogenic jj effects nns were vbd neither dt reversed vbn by inpos cgs_num nn nor cc by inpos cpa nn
false	8	14	the dt effects nns of inpos the dt immunodepressant nn the dt drug nn sandimmune nn on inpos hepatic jj microsomal jj monooxygenase nn activities nns were vbd studied vbn
false	6	18	lrb_the dt effect nn of inpos cimetidine nn on inpos the dt renal jj excretion nn of inpos verografin nn and cc iodamide nn in inpos dogs nns
false	6	22	lrb_the dt effect nn of inpos cimetidine nn on inpos the dt renal jj excretion nn of inpos verografin nn and cc iodamide nn in inpos dogs nns
false	18	22	lrb_the dt effect nn of inpos cimetidine nn on inpos the dt renal jj excretion nn of inpos verografin nn and cc iodamide nn in inpos dogs nns
mechanism	8	24	the dt intravenous jj injection nn of inpos cimetidine nn in inpos a dt dose nn of inpos num cd mg_kg nn enhanced vbd verografine nn and cc iodamide nn excretion nn in inpos chronic jj canine jj experiments nns
mechanism	8	28	the dt intravenous jj injection nn of inpos cimetidine nn in inpos a dt dose nn of inpos num cd mg_kg nn enhanced vbd verografine nn and cc iodamide nn excretion nn in inpos chronic jj canine jj experiments nns
false	24	28	the dt intravenous jj injection nn of inpos cimetidine nn in inpos a dt dose nn of inpos num cd mg_kg nn enhanced vbd verografine nn and cc iodamide nn excretion nn in inpos chronic jj canine jj experiments nns
false	4	8	the dt higher jjr verografine nn and cc iodamide nn excretion nn was vbd due jj to topos their prp increased vbn renal jj tubular jj secretion nn
false	4	14	in inpos dogs nns cimetidine nn unchanged vbd the dt secretion nn of inpos cardiotrast nn a dt test nn agent nn for inpos anionic jj transport nn
false	12	16	possible jj extrarenal jj mechanisms nns of inpos action nn of inpos cimetidine nn on inpos verografine nn and cc iodamide nn transport nn were vbd also rb examined vbn
false	12	20	possible jj extrarenal jj mechanisms nns of inpos action nn of inpos cimetidine nn on inpos verografine nn and cc iodamide nn transport nn were vbd also rb examined vbn
false	16	20	possible jj extrarenal jj mechanisms nns of inpos action nn of inpos cimetidine nn on inpos verografine nn and cc iodamide nn transport nn were vbd also rb examined vbn
false	10	32	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nns pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	10	40	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nns pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	10	46	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nns pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	24	32	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nn pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	24	40	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nn pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	24	46	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nn pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	32	40	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nns pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	32	46	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nns pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	40	46	specific jj and cc aspecific jj treatments nns of inpos magnesium nn depletion nn are vbp tricky jj using vbg for inpos example nn magnesium_sparing_diuretics nns pharmacological jj doses nns of inpos vitamin_b6 nn physiological jj doses nns of inpos vitamin_d nn and cc of inpos selenium nn
false	20	30	lastly rb local jj use nn of inpos the dt mucocutaneous jj and cc cytoprotective jj properties nns of inpos magnesium nn is vbz still rb valid jj in inpos cardioplegic_solutions nn and cc for inpos preservation nn of inpos transplants nns particularly rb
effect	4	8	interaction nn between inpos glycine nn and cc glutamate nn in inpos the dt development nn of inpos spontaneous jj motility nn in inpos chick nn embryos nns
effect	8	12	the dt successive jj application nn of inpos glycine nn and cc glutamate nn in inpos a dt num cd min nn interval nn significantly rb increased vbd the dt activation nn of inpos spontaneous jj motility nn of inpos num_day_old jj chick nn embryos nns in inpos comparison nn with inpos the dt effect nn of inpos glutamate nn alone rb
false	8	12	the dt successive jj application nn of inpos glycine nn and cc glutamate nn in inpos a dt num cd min nn interval nn significantly rb increased vbd the dt activation nn of inpos spontaneous jj motility nn of inpos num_day_old jj chick nn embryos nns in inpos comparison nn with inpos the dt effect nn of inpos glutamate nn alone rb
false	8	22	the dt ec50 nn values nns for inpos isoproterenol nn which wdt is vbz not rb a dt substrate nn for inpos norepinephrine nn uptake_num nn were vbd reduced vbn in inpos myocardium nn in inpos functional jj classes nns num cd to topos num cd and cc num cd compared vbn with inpos those dt in inpos nonfailing jj myocardium nn
false	6	10	the dt uptake nn inhibitors nns cocaine nn and cc desipramine nn potentiated vbd the dt positive jj inotropic jj effects nns of inpos norepinephrine nn in inpos nonfailing jj myocardium nn but cc not rb in inpos functional jj class nn num cd myocardium nn
effect	6	24	the dt uptake nn inhibitors nns cocaine nn and cc desipramine nn potentiated vbd the dt positive jj inotropic jj effects nns of inpos norepinephrine nn in inpos nonfailing jj myocardium nn but cc not rb in inpos functional jj class nn num cd myocardium nn
effect	10	24	the dt uptake nn inhibitors nns cocaine nn and cc desipramine nn potentiated vbd the dt positive jj inotropic jj effects nns of inpos norepinephrine nn in inpos nonfailing jj myocardium nn but cc not rb in inpos functional jj class nn num cd myocardium nn
false	16	34	radioligand nn binding nn experiments nns using vbg the dt uptake nn inhibitor nn hydrogen_num nn mazindol nn revealed vbd a dt significant jj decrease nn by inpos approximately rb num cd in inpos norepinephrine nn uptake_num nn carrier nn density nn in inpos functional jj classes nns num cd to topos num cd and cc num cd myocardium nn versus inpos nonfailing jj myocardium nn
false	36	40	this dt defect nn in inpos the dt failing vbg heart nn can md be vb mimicked vbn by inpos the dt effects nns of inpos uptake nn blocking vbg agents nns such jj as inpos cocaine nn and cc desipramine nn in inpos the dt nonfailing jj heart nn only rb
false	2	26	compromised vbn norepinephrine nn uptake_num nn in inpos functional jj class nn num cd can md not rb be vb further rbr increased vbn by inpos cocaine nn and cc desipramine nn
false	2	30	compromised vbn norepinephrine nn uptake_num nn in inpos functional jj class nn num cd can md not rb be vb further rbr increased vbn by inpos cocaine nn and cc desipramine nn
false	26	30	compromised vbn norepinephrine nn uptake_num nn in inpos functional jj class nn num cd can md not rb be vb further rbr increased vbn by inpos cocaine nn and cc desipramine nn
false	30	30	chronic jj experiments nns on inpos dogs nns with inpos gastric jj fistulas nns were vbd carried vbn out rp to topos study vb the dt influence nn of inpos angiotensin_num nn angiotensin_num nn on inpos pentagastrin nn histamine_induced jj gastric jj acid nn secretion nn
false	30	36	chronic jj experiments nns on inpos dogs nns with inpos gastric jj fistulas nns were vbd carried vbn out rp to topos study vb the dt influence nn of inpos angiotensin_num nn angiotensin_num nn on inpos pentagastrin nn hyph_histamine_induced jj gastric jj acid nn secretion nn
false	30	38	chronic jj experiments nns on inpos dogs nns with inpos gastric jj fistulas nns were vbd carried vbn out rp to topos study vb the dt influence nn of inpos angiotensin_num nn angiotensin_num nn on inpos pentagastrin nn histamine nn induced jj gastric jj acid nn secretion nn
false	30	36	chronic jj experiments nns on inpos dogs nns with inpos gastric jj fistulas nns were vbd carried vbn out rp to topos study vb the dt influence nn of inpos angiotensin_num nn angiotensin_num nn on inpos pentagastrin nn hyph_histamine_induced jj gastric jj acid nn secretion nn
false	30	38	chronic jj experiments nns on inpos dogs nns with inpos gastric jj fistulas nns were vbd carried vbn out rp to topos study vb the dt influence nn of inpos angiotensin_num nn angiotensin_num nn on inpos pentagastrin nn histamine nn induced jj gastric jj acid nn secretion nn
false	36	38	chronic jj experiments nns on inpos dogs nns with inpos gastric jj fistulas nns were vbd carried vbn out rp to topos study vb the dt influence nn of inpos angiotensin_num nn angiotensin_num nn on inpos pentagastrin nn hyph_histamine nn induced jj gastric jj acid nn secretion nn
false	24	32	it prp was vbd established vbn that inpos both dt angiotensins nns inhibited vbd gastric jj acid nn secretion nn stimulated vbn by inpos pentagastrin nn but cc not rb by inpos histamine nn
int	4	8	interaction nn of inpos gentamycin nn and cc atracurium nn in inpos anaesthetised vbn horses nns
false	32	46	evoked vbn hind nn limb nn digital jj extensor nn tension nn was vbd maintained vbn at inpos num cd of inpos baseline nn for inpos num cd h nn by inpos atracurium nn infusion nn in inpos num cd horses nns anaesthetised vbn with inpos halothane nn
false	0	34	atracurium nn was vbd again rb given vbn by inpos infusion nn to topos maintain vb num cd twitch nn for inpos a dt second jj hour nn then rb num cd mg nn gentamycin nn kg nn bwt nn were vbd given vbn i.v jj
false	26	44	recovery nn of inpos hoof nn twitch nn from inpos num cd to topos num cd took vbd float cd +_float cd min nn for inpos atracurium nn alone rb and cc float cd +_float cd min nn for inpos atracurium nn plus cc gentamycin nn
effect	26	44	recovery nn of inpos hoof nn twitch nn from inpos num cd to topos num cd took vbd float cd +_float cd min nn for inpos atracurium nn alone rb and cc float cd +_float cd min nn for inpos atracurium nn plus cc gentamycin nn
false	26	44	recovery nn from inpos num cd twitch nn to topos num cd fade nn recovery nn took vbd float cd +_float cd min nn for inpos atracurium nn alone rb and cc float cd +_float cd min nn for inpos atracurium nn plus cc gentamycin nn
effect	26	44	recovery nn from inpos num cd twitch nn to topos num cd fade nn recovery nn took vbd float cd +_float cd min nn for inpos atracurium nn alone rb and cc float cd +_float cd min nn for inpos atracurium nn plus cc gentamycin nn
false	22	38	at inpos num cd recovery nn of inpos fade nn hoof nn twitch nn was vbd num cd +_num cd for inpos atracurium nn alone rb and cc num cd +_num cd for inpos atracurium nn plus cc gentamycin nn
effect	22	38	at inpos num cd recovery nn of inpos fade nn hoof nn twitch nn was vbd num cd +_num cd for inpos atracurium nn alone rb and cc num cd +_num cd for inpos atracurium nn plus cc gentamycin nn
effect	10	24	it prp was vbd concluded vbn that inpos although inpos gentamycin nn did vbd augment vb the dt neuromuscular jj blockade nn of inpos atracurium nn the dt effect nn was vbd minimal jj
mechanism	6	2	acid_catalyzed jj ethanolysis nn of inpos temazepam nn in inpos anhydrous jj and cc aqueous jj ethanol nn solutions nns
false	2	12	the dt benzodiazepines nn are vbp a dt family nn of inpos anxiolytic nn and cc hypnotic_drugs nns
false	2	16	the dt benzodiazepines nn are vbp a dt family nn of inpos anxiolytic jj and cc hypnotic_drugs nn
false	12	16	the dt benzodiazepines nns are vbp a dt family nn of inpos anxiolytic nn and cc hypnotic_drugs nn
mechanism	28	32	in inpos addition nn to topos this dt pharmacological jj interaction nn this dt report nn describes vbz a dt novel jj chemical jj reaction nn between inpos temazepam nn and cc ethanol nn under inpos acidic jj conditions nns similar jj to topos those dt found vbn in fw vivo fw resulting vbg in inpos a dt num_ethoxylated jj product nn
false	28	32	in inpos addition nn to topos this dt pharmacological jj interaction nn this dt report nn describes vbz a dt novel jj chemical jj reaction nn between inpos benzodiazepine nn and cc ethanol nn under inpos acidic jj conditions nns similar jj to topos those dt found vbn in fw vivo fw resulting vbg in inpos a dt num_ethoxylated jj product nn
mechanism	36	40	the dt results nns raise vbp the dt possibility nn that inpos the dt ethanolysis nn reaction nn may md occur vb in inpos the dt stomach nn of inpos people nns who wp consume vbp alcohol nn and cc num_hydroxy_nums_benzodiazepine nn on inpos a dt regular jj basis nn
false	8	24	laboratory nnp tests nnps response nn to topos plenaxis nn should md be vb monitored vbn by inpos measuring vbg serum nn total jj testosterone nn concentrations nns just rb prior jj to topos administration nn on inpos day nn num cd and cc every dt num cd weeks nns thereafter rb
false	10	18	population nn pharmacokinetic jj analyses nns revealed vbd that inpos mtx nns did vbd not rb influence vb abatacept nn clearance nn
false	10	18	population nn pharmacokinetic jj analyses nns revealed vbd that inpos nsaids nns did vbd not rb influence vb abatacept nn clearance nn
false	10	18	population nn pharmacokinetic jj analyses nns revealed vbd that inpos corticosteroids nns did vbd not rb influence vb abatacept nn clearance nn
false	10	18	population nn pharmacokinetic jj analyses nns revealed vbd that inpos tnf_blocking_agents nn did vbd not rb influence vb abatacept nn clearance nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn mtx nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn nsaids nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn corticosteroids nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn tnf_blocking_agents nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn azathioprine nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn chloroquine nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn gold nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn hydroxychloroquine nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn leflunomide nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn sulfasalazine nn
false	36	38	the dt majority nn of inpos patients nns in inpos ra nn clinical jj studies nns received vbd num cd or cc more jjr of inpos the dt following vbg concomitant jj medications nns with inpos orencia nn anakinra nn
effect	8	12	concurrent jj administration nn of inpos a dt tnf_antagonist nn with inpos orencia nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns and cc no dt significant jj additional jj efficacy nn over inpos use nn of inpos the dt tnf_antagonists nns alone rb
false	12	52	concurrent jj administration nn of inpos a dt tnf_antagonist nn with inpos orencia nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns and cc no dt significant jj additional jj efficacy nn over inpos use nn of inpos the dt tnf_antagonists nn alone rb
advise	6	10	concurrent jj therapy nn with inpos orencia nn and cc tnf_antagonists nn is vbz not rb recommended vbn
advise	22	30	there ex is vbz insufficient jj experience nn to topos assess vb the dt safety nn and cc efficacy nn of inpos orencia nn administered vbn concurrently rb with inpos anakinra nn and cc therefore rb such jj use nn is vbz not rb recommended vbn
false	8	16	these dt medications nns have vbp included vbn heparin nns intravenous jj and cc oral jj nitrates nn
false	8	16	these dt medications nns have vbp included vbn heparin nns intravenous jj and cc oral jj ticlopidine nn
false	8	16	these dt medications nns have vbp included vbn heparin nns intravenous jj and cc oral jj aspirin nn
false	8	16	these dt medications nns have vbp included vbn warfarin nns intravenous jj and cc oral jj nitrates nn
false	8	16	these dt medications nns have vbp included vbn warfarin nns intravenous jj and cc oral jj ticlopidine nn
false	8	16	these dt medications nns have vbp included vbn warfarin nns intravenous jj and cc oral jj aspirin nn
false	8	16	these dt medications nns have vbp included vbn b_adrenergic_receptor_blockers nns intravenous jj and cc oral jj nitrates nn
false	8	16	these dt medications nns have vbp included vbn b_adrenergic_receptor_blockers nns intravenous jj and cc oral jj ticlopidine nn
false	8	16	these dt medications nns have vbp included vbn b_adrenergic_receptor_blockers nns intravenous jj and cc oral jj aspirin nn
false	8	16	these dt medications nns have vbp included vbn calcium_channel_antagonists nns intravenous jj and cc oral jj nitrates nn
false	8	16	these dt medications nns have vbp included vbn calcium_channel_antagonists nns intravenous jj and cc oral jj ticlopidine nn
false	8	16	these dt medications nns have vbp included vbn calcium_channel_antagonists nns intravenous jj and cc oral jj aspirin nn
false	8	16	these dt medications nns have vbp included vbn angiotensin_converting_enzyme_inhibitors nn intravenous jj and cc oral jj nitrates nn
false	8	16	these dt medications nns have vbp included vbn angiotensin_converting_enzyme_inhibitors nn intravenous jj and cc oral jj ticlopidine nn
false	8	16	these dt medications nns have vbp included vbn angiotensin_converting_enzyme_inhibitors nn intravenous jj and cc oral jj aspirin nn
false	28	32	patients nns with inpos haca nn titers nns may md have vb allergic jj or cc hypersensitivity nn reactions nns when wrb treated vbn with inpos other jj diagnostic nn or cc therapeutic nn bbbbbcom_monoclonal_antibodies_eeeeecom nn
false	8	12	the dt concomitant jj intake nn of inpos alcohol nn and cc acamprosate nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos either cc alcohol nn or cc acamprosate nn
false	8	12	the dt concomitant jj intake nn of inpos alcohol nn and cc acamprosate nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos either cc alcohol nn or cc acamprosate nn
false	12	8	the dt concomitant jj intake nn of inpos alcohol nn and cc acamprosate nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos either cc alcohol nn or cc acamprosate nn
false	8	12	the dt concomitant jj intake nn of inpos alcohol nn and cc acamprosate nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos either cc alcohol nn or cc acamprosate nn
false	12	16	pharmacokinetic jj studies nns indicate vbp that inpos administration nn of inpos disulfiram nn or cc diazepam nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos acamprosate nn
false	12	30	pharmacokinetic jj studies nns indicate vbp that inpos administration nn of inpos disulfiram nn or cc diazepam nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos acamprosate nn
false	16	30	pharmacokinetic jj studies nns indicate vbp that inpos administration nn of inpos disulfiram nn or cc diazepam nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos acamprosate nn
mechanism	4	8	co_administration nn of inpos naltrexone nn with inpos acamprosate nn produced vbd a dt num cd increase nn in inpos auc nn and cc a dt num cd increase nn in inpos the dt cmax nn of inpos acamprosate nn
false	4	8	co_administration nn of inpos naltrexone nn with inpos acamprosate nn produced vbd a dt num cd increase nn in inpos auc nn and cc a dt num cd increase nn in inpos the dt cmax nn of inpos acamprosate nn
false	6	16	the dt pharmacokinetics nns of inpos naltrexone nn and cc its prp major jj metabolite nn num_b_naltrexol nn were vbd unaffected jj following vbg co_administration nn with inpos acamprosate nn
false	6	28	the dt pharmacokinetics nns of inpos naltrexone nn and cc its prp major jj metabolite nn num_b_naltrexol nn were vbd unaffected jj following vbg co_administration nn with inpos acamprosate nn
false	16	28	the dt pharmacokinetics nns of inpos naltrexone nn and cc its prp major jj metabolite nn num_b_naltrexol nn were vbd unaffected jj following vbg co_administration nn with inpos acamprosate nn
false	26	32	other jj concomitant jj therapies nns in inpos clinical jj trials nns the dt safety nn profile nn in inpos subjects nns treated vbn with inpos acamprosate nn concomitantly rb with inpos anxiolytics nns was vbd similar jj to topos that dt of inpos subjects nns taking vbg placebo nn with inpos these dt concomitant jj medications nns
false	26	32	other jj concomitant jj therapies nns in inpos clinical jj trials nns the dt safety nn profile nn in inpos subjects nns treated vbn with inpos acamprosate nn concomitantly rb with inpos hypnotics nns was vbd similar jj to topos that dt of inpos subjects nns taking vbg placebo nn with inpos these dt concomitant jj medications nns
false	26	32	other jj concomitant jj therapies nns in inpos clinical jj trials nns the dt safety nn profile nn in inpos subjects nns treated vbn with inpos acamprosate nn concomitantly rb with inpos sedatives nns was vbd similar jj to topos that dt of inpos subjects nns taking vbg placebo nn with inpos these dt concomitant jj medications nns
false	26	32	other jj concomitant jj therapies nns in inpos clinical jj trials nns the dt safety nn profile nn in inpos subjects nns treated vbn with inpos acamprosate nn concomitantly rb with inpos benzodiazepines nns was vbd similar jj to topos that dt of inpos subjects nns taking vbg placebo nn with inpos these dt concomitant jj medications nns
false	26	32	other jj concomitant jj therapies nns in inpos clinical jj trials nns the dt safety nn profile nn in inpos subjects nns treated vbn with inpos acamprosate nn concomitantly rb with inpos non_opioid_analgesics nn was vbd similar jj to topos that dt of inpos subjects nns taking vbg placebo nn with inpos these dt concomitant jj medications nns
effect	4	10	patients nns taking vbg acamprosate nn concomitantly rb with inpos antidepressants nn more rbr commonly rb reported vbn both cc weight nn gain nn and cc weight nn loss nn compared vbn with inpos patients nns taking vbg either cc medication nn alone rb
false	8	12	these dt drugs nns include vbp the dt thiazides nn other jj diuretics nn corticosteroids nns phenothiazines nns thyroid_products nns estrogens nns oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	8	16	these dt drugs nns include vbp the dt thiazides nn and cc other jj diuretics nns corticosteroids nn
false	12	14	these dt drugs nns include vbp the dt thiazides nns other jj diuretics nn corticosteroids nn phenothiazines nns thyroid_products nns estrogens nns oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	14	18	these dt drugs nns include vbp the dt thiazides nns and cc other jj diuretics nn corticosteroids nns phenothiazines nn
false	8	10	these dt drugs nns include vbp the dt corticosteroids nns estrogens nn oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	18	20	these dt drugs nns include vbp the dt thiazides nns other jj diuretics nns corticosteroids nns phenothiazines nns thyroid_products nn estrogens nn oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	16	24	when wrb such jj drugs nns are vbp withdrawn vbn from inpos patients nns receiving vbg acarbose nn in inpos combination nn with inpos sulfonylureas nn or cc insulin nn patients nns should md be vb observed vbn closely rb for inpos any dt evidence nn of inpos hypoglycemia nn
false	16	28	when wrb such jj drugs nns are vbp withdrawn vbn from inpos patients nns receiving vbg acarbose nn in inpos combination nn with inpos sulfonylureas nn or cc insulin nn patients nns should md be vb observed vbn closely rb for inpos any dt evidence nn of inpos hypoglycemia nn
false	24	28	when wrb such jj drugs nns are vbp withdrawn vbn from inpos patients nns receiving vbg acarbose nn in inpos combination nn with inpos sulfonylureas nn or cc insulin nn patients nns should md be vb observed vbn closely rb for inpos any dt evidence nn of inpos hypoglycemia nn
false	0	4	intestinal_adsorbents nn and cc digestive_enzyme_preparations nn containing vbg carbohydrate_splitting jj enzymes nns may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	0	10	intestinal_adsorbents nn and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj amylase nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	0	10	intestinal_adsorbents nn and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj pancreatin nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
mechanism	0	22	intestinal_adsorbents nn and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj enzymes nns may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	0	4	charcoal nn and cc digestive_enzyme_preparations nn containing vbg carbohydrate_splitting jj enzymes nns may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	0	10	charcoal nn and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj amylase nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	0	10	charcoal nn and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj pancreatin nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
mechanism	0	22	charcoal nn and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj enzymes nns may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	4	10	intestinal_adsorbents nns and cc digestive_enzyme_preparations nn containing vbg carbohydrate_splitting jj amylase nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	4	10	intestinal_adsorbents nns and cc digestive_enzyme_preparations nn containing vbg carbohydrate_splitting jj pancreatin nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
false	4	22	intestinal_adsorbents nns and cc digestive_enzyme_preparations nn containing vbg carbohydrate_splitting jj enzymes nns may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
mechanism	10	22	intestinal_adsorbents nns and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj amylase nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
mechanism	10	22	intestinal_adsorbents nns and cc digestive_enzyme_preparations nns containing vbg carbohydrate_splitting jj pancreatin nn may md reduce vb the dt effect nn of inpos acarbose nn and cc should md not rb be vb taken vbn concomitantly rb
mechanism	0	16	acarbose nn has vbz been vbn shown vbn to topos change vb the dt bioavailabillty nn digoxin nn when wrb they prp are vbp co_administered vbn which wdt may md require vb digoxin nn dose nn adjustment nn
false	0	16	acarbose nn has vbz been vbn shown vbn to topos change vb the dt bioavailabillty nn digoxin nn when wrb they prp are vbp co_administered vbn which wdt may md require vb digoxin nn dose nn adjustment nn
false	14	36	studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos acarbose nn has vbz no dt effect nn on inpos either cc the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos digoxin nn
false	14	36	studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos acarbose nn has vbz no dt effect nn on inpos either cc the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos nifedipine nn
false	14	36	studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos acarbose nn has vbz no dt effect nn on inpos either cc the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos propranolol nn
false	14	36	studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos acarbose nn has vbz no dt effect nn on inpos either cc the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos ranitidine nn
false	0	22	acarbose nn did vbd not rb interfere vb with inpos the dt absorption nn or cc disposition nn of inpos the dt sulfonylurea nn glyburide nn in inpos diabetic jj patients nns
false	0	24	acarbose nn did vbd not rb interfere vb with inpos the dt absorption nn or cc disposition nn of inpos the dt sulfonylurea nn glyburide nn in inpos diabetic jj patients nns
false	22	24	acarbose nn did vbd not rb interfere vb with inpos the dt absorption nn or cc disposition nn of inpos the dt sulfonylurea nn glyburide nn in inpos diabetic jj patients nns
false	0	6	acarbose nn may md affect vb digoxin nn bioavailabillty nn may md require vb dose nn adjustment nn of inpos digoxin nn by inpos num cd decrease vb mean jj c nn max nn digoxin nn by inpos num cd decrease vb mean jj trough nn concentrations nns of inpos digoxin nn by inpos num cd
false	0	6	acarbose nn may md affect vb digoxin nn bioavailabillty nn may md require vb dose nn adjustment nn of inpos digoxin nn by inpos num cd decrease vb mean jj c nn max nn digoxin nn by inpos num cd decrease vb mean jj trough nn concentrations nns of inpos digoxin nn by inpos num cd
false	0	6	acarbose nn may md affect vb digoxin nn bioavailabillty nn may md require vb dose nn adjustment nn of inpos digoxin nn by inpos num cd decrease vb mean jj c nn max nn digoxin nn by inpos num cd decrease vb mean jj trough nn concentrations nns of inpos digoxin nn by inpos num cd
false	0	6	acarbose nn may md affect vb digoxin nn bioavailabillty nn may md require vb dose nn adjustment nn of inpos digoxin nn by inpos num cd decrease vb mean jj c nn max nn digoxin nn by inpos num cd decrease vb mean jj trough nn concentrations nns of inpos digoxin nn by inpos num cd
false	6	14	the dt amount nn of inpos metformin nn absorbed vbn while inpos taking vbg acarbose nn was vbd bioequivalent jj to topos the dt amount nn absorbed vbn when wrb taking vbg placebo nn as inpos indicated vbn by inpos the dt plasma nn auc nn values nns
mechanism	12	28	however rb the dt peak jj plasma nn level nn of inpos metformin nn was vbd reduced vbn by inpos approximately rb num cd when wrb taking vbg acarbose nn due jj to topos a dt slight jj delay nn in inpos the dt absorption nn of inpos metformin nn
mechanism	28	12	however rb the dt peak jj plasma nn level nn of inpos metformin nn was vbd reduced vbn by inpos approximately rb num cd when wrb taking vbg acarbose nn due jj to topos a dt slight jj delay nn in inpos the dt absorption nn of inpos metformin nn
false	18	22	there ex is vbz little jj if inpos any dt clinically rb significant jj interaction nn between inpos acarbose nn and cc metformin nn
false	0	6	catecholamine_depleting_drugs nn such jj as inpos reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking_agents nns
effect	0	24	catecholamine_depleting_drugs nn such jj as inpos reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking_agents nn
effect	6	24	catecholamine_depleting_drugs nns such jj as inpos reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking_agents nn
advise	6	10	patients nns treated vbn with inpos acebutolol nn plus cc catecholamine_depletors nn should md therefore rb be vb observed vbn closely rb for inpos evidence nn of inpos marked jj bradycardia nn or cc hypotension nn which wdt may md present vb as inpos vertigo nn syncope nn orthostatic jj changes nns in inpos blood nn pressure nn without inpos compensatory jj tachycardia nns
effect	22	26	exaggerated jj hypertensive jj responses nns have vbp been vbn reported vbn from inpos the dt combined jj use nn of inpos b_adrenergic_antagonists nn and cc ap_adrenergic_stimulants nn including vbg those dt contained vbn in inpos proprietary jj cold jj remedies nns and cc vasoconstrictive jj nasal jj drops nns
effect	12	16	blunting nn of inpos the dt antihypertensive jj effect nn of inpos b_adrenoceptor_blocking_agents nn by inpos nonsteroidal_anti_inflammatory_drugs nn has vbz been vbn reported vbn
mechanism	0	4	diamox nn modifies vbz phenytoin nn metabolism nn with inpos increased vbn serum nn levels nns of inpos phenytoin nn
mechanism	0	4	diamox nn modifies vbz phenytoin nn metabolism nn with inpos increased vbn serum nn levels nns of inpos phenytoin nn
false	12	14	by inpos decreasing vbg the dt gastrointestinal jj absorption nn of inpos primidone nn diamox nn may md decrease vb serum nn concentrations nns of inpos primidone nn and cc its prp metabolites nns with inpos a dt consequent jj possible jj decrease nn in inpos anticonvulsant jj effect nn
mechanism	14	12	by inpos decreasing vbg the dt gastrointestinal jj absorption nn of inpos primidone nn diamox nn may md decrease vb serum nn concentrations nns of inpos primidone nn and cc its prp metabolites nns with inpos a dt consequent jj possible jj decrease nn in inpos anticonvulsant jj effect nn
advise	20	28	caution nn is vbz advised vbn when wrb beginning vbg discontinuing vbg changing vbg the dt dose nn of inpos diamox nn in inpos patients nns receiving vbg primidone nn
effect	0	14	acetazolamide nn may md increase vb the dt effects nns of inpos other jj folic_acid_antagonists nn
mechanism	0	10	acetazolamide nn decreases vbz urinary jj excretion nn of inpos amphetamine nn and cc may md enhance vb the dt magnitude nn and cc duration nn of inpos their prp effect nn
mechanism	0	10	acetazolamide nn reduces vbz urinary jj excretion nn of inpos quinidine nn and cc may md enhance vb its prp effect nn
effect	0	16	acetazolamide nn may md prevent vb the dt urinary jj antiseptic jj effect nn of inpos methenamine nn
mechanism	0	4	acetazolamide nn increases vbz lithium nn excretion nn and cc the dt lithium nn may md be vb decreased vbn
false	0	4	acetazolamide nn increases vbz lithium nn excretion nn and cc the dt lithium nn may md be vb decreased vbn
effect	0	4	acetazolamide nn and cc sodium_bicarbonate nn used vbn concurrently rb increases vbz the dt risk nn of inpos renal jj calculus nn formation nn
mechanism	0	6	acetazolamide nn may md elevate vb cyclosporine nn levels nns
mechanism	4	8	co_administration nn of inpos probenecid nn with inpos acyclovir nn has vbz been vbn shown vbn to topos increase vb the dt mean jj half_life nn and cc the dt area nn under inpos the dt concentration_time jj curve nn
false	0	12	ethanol nn clinical jj evidence nn has vbz shown vbn that inpos etretinate nn can md be vb formed vbn with inpos concurrent jj ingestion nn of inpos acitretin nn and cc ethanol nn
false	0	28	ethanol nn clinical jj evidence nn has vbz shown vbn that inpos etretinate nn can md be vb formed vbn with inpos concurrent jj ingestion nn of inpos acitretin nn and cc ethanol nn
false	12	28	ethanol nn clinical jj evidence nn has vbz shown vbn that inpos etretinate nn can md be vb formed vbn with inpos concurrent jj ingestion nn of inpos acitretin nn and cc ethanol nn
false	12	0	ethanol nn clinical jj evidence nn has vbz shown vbn that inpos etretinate nn can md be vb formed vbn with inpos concurrent jj ingestion nn of inpos acitretin nn and cc ethanol nn
mechanism	28	0	ethanol nn clinical jj evidence nn has vbz shown vbn that inpos etretinate nn can md be vb formed vbn with inpos concurrent jj ingestion nn of inpos acitretin nn and cc ethanol nn
effect	16	34	in inpos a dt study nn of inpos num cd healthy jj male jj volunteers nns acitretin nn treatment nn potentiated vbd the dt blood nn glucose nn lowering vbg effect nn of inpos glibenclamide nn in inpos num cd of inpos the dt num cd subjects nns
false	16	38	in inpos a dt study nn of inpos num cd healthy jj male jj volunteers nns acitretin nn treatment nn potentiated vbd the dt blood nn glucose nn lowering vbg effect nn of inpos glibenclamide nn lrb_a dt sulfonylurea nn similar jj to topos chlorpropamide nn rrb_in inpos num cd of inpos the dt num cd subjects nns
false	16	44	in inpos a dt study nn of inpos num cd healthy jj male jj volunteers nns acitretin nn treatment nn potentiated vbd the dt blood nn glucose nn lowering vbg effect nn of inpos glibenclamide nn lrb_a dt sulfonylurea nn similar jj to topos chlorpropamide nn rrb_in inpos num cd of inpos the dt num cd subjects nns
false	34	38	in inpos a dt study nn of inpos num cd healthy jj male jj volunteers nns acitretin nn treatment nn potentiated vbd the dt blood nn glucose nn lowering vbg effect nn of inpos glibenclamide nn lrb_a dt sulfonylurea nn similar jj to topos chlorpropamide nn rrb_in inpos num cd of inpos the dt num cd subjects nns
false	34	44	in inpos a dt study nn of inpos num cd healthy jj male jj volunteers nns acitretin nn treatment nn potentiated vbd the dt blood nn glucose nn lowering vbg effect nn of inpos glibenclamide nn lrb_a dt sulfonylurea nn similar jj to topos chlorpropamide nn rrb_in inpos num cd of inpos the dt num cd subjects nns
false	4	10	glibenclamide nn a dt sulfonylurea nn similar jj to topos chlorpropamide nn
false	24	38	repeating vbg the dt study nn with inpos num cd healthy jj male jj volunteers nns in inpos the dt absence nn of inpos glibenclamide nn did vbd not rb detect vb an dt effect nn of inpos acitretin nn on inpos glucose nn tolerance nn
false	24	28	it prp has vbz not rb been vbn established vbn if inpos there ex is vbz a dt pharmacokinetic jj interaction nn between inpos acitretin nn and cc combined_oral_contraceptives nn
effect	12	28	however rb it prp has vbz been vbn established vbn that inpos acitretin nn interferes vbz with inpos the dt contraceptive jj effect nn of inpos microdosed vbn progestin nn minipill nn preparations nns
advise	4	20	microdosed vbn minipill nn progestin nn preparations nns are vbp not rb recommended vbn for inpos use nn with inpos soriatane nn
false	12	36	it prp is vbz not rb known vbn whether inpos other jj progestational_contraceptives nn such jj as inpos implants nns and cc injectables nns are vbp adequate jj methods nns of inpos contraception nn during inpos acitretin nn therapy nn
effect	28	32	an dt increased vbn risk nn of inpos hepatitis nn has vbz been vbn reported vbn to topos result vb from inpos combined vbn use nn of inpos methotrexate nn and cc etretinate nn
advise	8	12	consequently rb the dt combination nn of inpos methotrexate nn with inpos acitretin nn is vbz also rb contraindicated vbn
mechanism	2	12	if inpos acitretin nn is vbz given vbn concurrently rb with inpos phenytoin nn the dt protein nn binding nn of inpos phenytoin nn may md be vb reduced vbn
false	2	12	if inpos acitretin nn is vbz given vbn concurrently rb with inpos phenytoin nn the dt protein nn binding nn of inpos phenytoin nn may md be vb reduced vbn
effect	4	8	since inpos both cc acitretin nn and cc tetracyclines nn can md cause vb increased vbn intracranial jj pressure nn their prp combined vbn use nn is vbz contraindicated vbn
false	0	6	vitamin_a nn and cc oral jj retinoids nn
false	0	6	vitamin_a nn and cc oral jj retinoids nns concomitant jj administration nn of inpos vitamin_a nn and_or cc other jj oral jj retinoids nn with inpos acitretin nn must md be vb avoided vbn because inpos of inpos the dt risk nn of inpos hypervitaminosis nn a nn
false	0	26	vitamin_a nn and cc oral jj retinoids nns concomitant jj administration nn of inpos vitamin_a nn and_or cc other jj oral jj retinoids nns with inpos acitretin nn must md be vb avoided vbn because inpos of inpos the dt risk nn of inpos hypervitaminosis nn a nn
false	6	0	vitamin_a nn and cc oral jj retinoids nn concomitant jj administration nn of inpos vitamin_a nn and_or cc other jj oral jj retinoids nns with inpos acitretin nn must md be vb avoided vbn because inpos of inpos the dt risk nn of inpos hypervitaminosis nn a nn
false	6	26	vitamin_a nn and cc oral jj retinoids nn concomitant jj administration nn of inpos vitamin_a nn and_or cc other jj oral jj retinoids nns with inpos acitretin nn must md be vb avoided vbn because inpos of inpos the dt risk nn of inpos hypervitaminosis nn a nn
false	6	14	concomitant jj administration nn of inpos vitamin_a nn and_or cc other jj oral jj retinoids nn with inpos acitretin nn must md be vb avoided vbn because inpos of inpos the dt risk nn of inpos hypervitaminosis nn a nn
advise	6	18	concomitant jj administration nn of inpos vitamin_a nn and_or cc other jj oral jj retinoids nns with inpos acitretin nn must md be vb avoided vbn because inpos of inpos the dt risk nn of inpos hypervitaminosis nn a nn
advise	14	18	concomitant jj administration nn of inpos vitamin_a nn and_or cc other jj oral jj retinoids nn with inpos acitretin nn must md be vb avoided vbn because inpos of inpos the dt risk nn of inpos hypervitaminosis nn a nn
false	10	22	investigations nns into inpos the dt effect nn of inpos acitretin nn on inpos the dt protein nn binding nn of inpos anticoagulants_of_the_coumarin_type nn revealed vbd no dt interaction nn
false	10	22	investigations nns into inpos the dt effect nn of inpos acitretin nn on inpos the dt protein nn binding nn of inpos warfarin nn revealed vbd no dt interaction nn
false	0	20	humira nn has vbz been vbn studied vbn in inpos rheumatoid jj arthritis nn patients nns taking vbg concomitant jj mtx nn
false	24	28	the dt data nns do vbp not rb suggest vb the dt need nn for inpos dose nn adjustment nn of inpos either cc humira nn or cc mtx nn
false	0	8	anakinra nn concurrent jj administration nn of inpos interleukin_num_antagonist nn and cc another dt tnf_blocking_agent nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns an dt increased vbn risk nn of inpos neutropenia nn no dt additional jj benefit nn compared vbn to topos these dt medicinal jj products nns alone rb
false	0	14	anakinra nn concurrent jj administration nn of inpos anakinra nn and cc another dt tnf_blocking_agent nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns an dt increased vbn risk nn of inpos neutropenia nn no dt additional jj benefit nn compared vbn to topos these dt medicinal jj products nns alone rb
effect	6	12	concurrent jj administration nn of inpos anakinra nn and cc another dt tnf_blocking_agent nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns an dt increased vbn risk nn of inpos neutropenia nn no dt additional jj benefit nn compared vbn to topos these dt medicinal jj products nns alone rb
effect	6	12	concurrent jj administration nn of inpos interleukin_num_antagonist nn and cc another dt tnf_blocking_agent nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns an dt increased vbn risk nn of inpos neutropenia nn no dt additional jj benefit nn compared vbn to topos these dt medicinal jj products nns alone rb
false	10	20	the dt safety nn and cc efficacy nn of inpos anakinra nn used vbn in inpos combination nn with inpos humira nn has vbz not rb been vbn studied vbn
effect	8	14	therefore rb the dt combination nn of inpos anakinra nn with inpos other jj tnf_blocking_agents nn including vbg humira nn may md also rb result vb i nn n nn similar jj toxicities nns
effect	8	18	therefore rb the dt combination nn of inpos anakinra nn with inpos other jj tnf_blocking_agents nns including vbg humira nn may md also rb result vb i nn n nn similar jj toxicities nns
false	14	18	therefore rb the dt combination nn of inpos anakinra nn with inpos other jj tnf_blocking_agents nn including vbg humira nn may md also rb result vb i nn n nn similar jj toxicities nns
false	18	26	particular jj caution nn should md be vb exercised vbn in inpos using vbg preparations nns containing vbg sulfur nn in inpos combination nn with inpos differin nn gel nn
false	18	26	particular jj caution nn should md be vb exercised vbn in inpos using vbg preparations nns containing vbg resorcinol nn in inpos combination nn with inpos differin nn gel nn
false	18	26	particular jj caution nn should md be vb exercised vbn in inpos using vbg preparations nns containing vbg salicylic_acid nn in inpos combination nn with inpos differin nn gel nn
false	42	44	before inpos using vbg this dt medication nn tell vb your prp doctor nn or cc pharmacist nn of inpos all dt prescription nn and cc nonprescription nn products nns you prp may md use vb especially rb of inpos aminoglycosides nns amphotericin_b nn cyclosporine nn non_steroidal_anti_inflammatory jj drugs nns tacrolimus nn vancomycin nn
false	42	50	before inpos using vbg this dt medication nn tell vb your prp doctor nn or cc pharmacist nn of inpos all dt prescription nn and cc nonprescription nn products nns you prp may md use vb especially rb of inpos aminoglycosides nns amphotericin_b nn cyclosporine nn non_steroidal_anti_inflammatory jj drugs nns tacrolimus nn vancomycin nn
false	42	52	before inpos using vbg this dt medication nn tell vb your prp doctor nn or cc pharmacist nn of inpos all dt prescription nn and cc nonprescription nn products nns you prp may md use vb especially rb of inpos aminoglycosides nns amphotericin_b nn cyclosporine nn non_steroidal_anti_inflammatory jj drugs nns tacrolimus nn vancomycin nn
false	44	50	before inpos using vbg this dt medication nn tell vb your prp doctor nn or cc pharmacist nn of inpos all dt prescription nn and cc nonprescription nn products nns you prp may md use vb especially rb of inpos aminoglycosides nns amphotericin_b nn cyclosporine nn non_steroidal_anti_inflammatory jj drugs nns tacrolimus nn vancomycin nn
false	44	52	before inpos using vbg this dt medication nn tell vb your prp doctor nn or cc pharmacist nn of inpos all dt prescription nn and cc nonprescription nn products nns you prp may md use vb especially rb of inpos aminoglycosides nns amphotericin_b nn cyclosporine nn non_steroidal_anti_inflammatory jj drugs nns tacrolimus nn vancomycin nn
false	50	52	before inpos using vbg this dt medication nn tell vb your prp doctor nn or cc pharmacist nn of inpos all dt prescription nn and cc nonprescription nn products nns you prp may md use vb especially rb of inpos aminoglycosides nns amphotericin_b nn cyclosporine nn non_steroidal_anti_inflammatory jj drugs nns tacrolimus nn vancomycin nn
false	2	30	intravenous jj adenocard nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos quinidine nns without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	2	30	intravenous jj adenocard nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos b_adrenergic_blocking_agents nns without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	2	30	intravenous jj adenocard nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos calcium_channel_blocking_agents nns without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	2	30	intravenous jj adenocard nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos angiotensin_converting_enzyme_inhibitors nn without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	2	30	intravenous jj adenosine nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos quinidine nns without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	2	30	intravenous jj adenosine nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos b_adrenergic_blocking_agents nns without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	2	30	intravenous jj adenosine nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos calcium_channel_blocking_agents nns without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	2	30	intravenous jj adenosine nn has vbz been vbn effectively rb administered vbn in inpos the dt presence nn of inpos other jj cardioactive jj drugs nns such jj as inpos angiotensin_converting_enzyme_inhibitors nn without inpos any dt change nn in inpos the dt adverse jj reaction nn profile nn
false	0	4	digoxin nn and cc verapamil nn use nn may md be vb rarely rb associated vbn with inpos ventricular jj fibrillation nn when wrb combined vbn with inpos adenocard nn
effect	0	28	digoxin nn and cc verapamil nn use nn may md be vb rarely rb associated vbn with inpos ventricular jj fibrillation nn when wrb combined vbn with inpos adenocard nn
effect	4	28	digoxin nn and cc verapamil nn use nn may md be vb rarely rb associated vbn with inpos ventricular jj fibrillation nn when wrb combined vbn with inpos adenocard nn
effect	6	14	the dt use nn of inpos adenocard nn in inpos patients nns receiving vbg digitalis nn may md be vb rarely rb associated vbn with inpos ventricular jj fibrillation nn
effect	6	14	the dt effects nns of inpos adenosine nn are vbp antagonized vbn by inpos methylxanthines nn such jj as inpos caffeine nn and cc theophylline nn
effect	6	20	the dt effects nns of inpos adenosine nn are vbp antagonized vbn by inpos methylxanthines nns such jj as inpos caffeine nn and cc theophylline nn
effect	6	24	the dt effects nns of inpos adenosine nn are vbp antagonized vbn by inpos methylxanthines nns such jj as inpos caffeine nn and cc theophylline nn
false	14	20	the dt effects nns of inpos adenosine nn are vbp antagonized vbn by inpos methylxanthines nn such jj as inpos caffeine nn and cc theophylline nn
false	14	24	the dt effects nns of inpos adenosine nn are vbp antagonized vbn by inpos methylxanthines nn such jj as inpos caffeine nn and cc theophylline nn
false	20	24	the dt effects nns of inpos adenosine nn are vbp antagonized vbn by inpos methylxanthines nns such jj as inpos caffeine nn and cc theophylline nn
advise	10	18	in inpos the dt presence nn of inpos these dt methylxanthines nn larger jjr doses nns of inpos adenosine nn may md be vb required vbn or cc adenosine nn may md not rb be vb effective jj
advise	10	18	in inpos the dt presence nn of inpos these dt methylxanthines nn larger jjr doses nns of inpos adenosine nn may md be vb required vbn or cc adenosine nn may md not rb be vb effective jj
effect	0	10	adenosine nn effects nns are vbp potentiated vbn by inpos dipyridamole nn
effect	8	24	thus rb smaller jjr doses nns of inpos adenosine nn may md be vb effective jj in inpos the dt presence nn of inpos dipyridamole nn
effect	10	52	as inpos the dt primary jj effect nn of inpos adenosine nn is vbz to topos decrease vb conduction nn through inpos the dt a_v nn node nn higher jjr degrees nns of inpos heart nn block nn may md be vb produced vbn in inpos the dt presence nn of inpos carbamazepine nn
false	4	10	co_administration nn with inpos antifungal_agents nn such jj as inpos ketoconazole nn or cc itraconazole nn is vbz not rb recommended vbn
false	4	14	co_administration nn with inpos antifungal_agents nn such jj as inpos ketoconazole nn or cc itraconazole nn is vbz not rb recommended vbn
false	10	14	co_administration nn with inpos antifungal_agents nns such jj as inpos ketoconazole nn or cc itraconazole nn is vbz not rb recommended vbn
false	0	2	nafazodone nn fluvoxamine nn cimetidine nn
false	0	4	nafazodone nn fluvoxamine nn cimetidine nn
advise	0	4	nafazodone nn lrb_consider vb xanax nn dose nn reduction nn
false	2	4	nafazodone nn fluvoxamine nn cimetidine nn
advise	0	4	fluvoxamine nn lrb_consider vb xanax nn dose nn reduction nn
advise	0	4	cimetidine nn lrb_consider vb xanax nn dose nn reduction nn
false	8	24	steady_state jj trough nn concentrations nns of inpos albendazole_sulfoxide nn were vbd about rb num cd higher jjr when wrb num cd mg nn dexamethasone nn was vbd coadministered vbn with inpos each dt dose nn of inpos albendazole nn in inpos num cd neurocysticercosis nn patients nns
mechanism	24	8	steady_state jj trough nn concentrations nns of inpos albendazole_sulfoxide nn were vbd about rb num cd higher jjr when wrb num cd mg nn dexamethasone nn was vbd coadministered vbn with inpos each dt dose nn of inpos albendazole nn in inpos num cd neurocysticercosis nn patients nns
false	0	34	praziquantel nn in inpos the dt fed vbn state nn praziquantel nn increased vbd mean jj maximum jj plasma nn concentration nn and cc area nn under inpos the dt curve nn of inpos albendazole_sulfoxide nn by inpos about rb num cd in inpos healthy jj subjects nns compared vbn with inpos a dt separate jj group nn of inpos subjects nns given vbn albendazole nn alone rb
false	0	34	praziquantel nn in inpos the dt fed vbn state nn praziquantel nn increased vbd mean jj maximum jj plasma nn concentration nn and cc area nn under inpos the dt curve nn of inpos albendazole_sulfoxide nn by inpos about rb num cd in inpos healthy jj subjects nns compared vbn with inpos a dt separate jj group nn of inpos subjects nns given vbn albendazole nn alone rb
mechanism	0	34	praziquantel nnp in inpos the dt fed vbn state nn praziquantel nn increased vbd mean jj maximum jj plasma nn concentration nn and cc area nn under inpos the dt curve nn of inpos albendazole_sulfoxide nn by inpos about rb num cd in inpos healthy jj subjects nns compared vbn with inpos a dt separate jj group nn of inpos subjects nns given vbn albendazole nn alone rb
false	0	34	praziquantel nnp in inpos the dt fed vbn state nn praziquantel nn increased vbd mean jj maximum jj plasma nn concentration nn and cc area nn under inpos the dt curve nn of inpos albendazole_sulfoxide nn by inpos about rb num cd in inpos healthy jj subjects nns compared vbn with inpos a dt separate jj group nn of inpos subjects nns given vbn albendazole nn alone rb
false	6	18	the dt pharmacokinetics nns of inpos praziquantel nn were vbd unchanged jj following vbg coadministration nn with inpos albendazole nn
mechanism	0	30	albendazole_sulfoxide nn concentrations nns in inpos bile nn and cc cystic jj fluid nn were vbd increased vbn in inpos hydatid jj cyst nn patients nns treated vbn with inpos cimetidine nn compared vbn with inpos albendazole nn alone rb
false	30	0	albendazole_sulfoxide nn concentrations nns in inpos bile nn and cc cystic jj fluid nn were vbd increased vbn in inpos hydatid jj cyst nn patients nns treated vbn with inpos cimetidine nn compared vbn with inpos albendazole nn alone rb
false	0	10	theophylline nn the dt pharmacokinetics nns of inpos theophylline nn lrb_aminophylline nn float cd mg_kg nn infused vbn over inpos num cd minutes nns rrb_were vbd unchanged jj following vbg a dt single jj oral jj dose nn of inpos albendazole nn in inpos num cd healthy jj subjects nns
false	0	10	theophylline nn the dt pharmacokinetics nns of inpos theophylline nn lrb_aminophylline nn float cd mg_kg nn infused vbn over inpos num cd minutes nns rrb_were vbd unchanged jj following vbg a dt single jj oral jj dose nn of inpos albendazole nn in inpos num cd healthy jj subjects nns
false	6	24	the dt pharmacokinetics nns of inpos theophylline nn were vbd unchanged jj following vbg a dt single jj oral jj dose nn of inpos albendazole nn in inpos num cd healthy jj subjects nns
false	10	40	theophylline nn the dt pharmacokinetics nns of inpos theophylline nn lrb_aminophylline nn float cd mg_kg nn infused vbn over inpos num cd minutes nns rrb_were vbd unchanged jj following vbg a dt single jj oral jj dose nn of inpos albendazole nn in inpos num cd healthy jj subjects nns
effect	10	16	concurrent jj administration nn of inpos drugs nns possessing vbg aminoglycosides jj effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
effect	10	16	concurrent jj administration nn of inpos drugs nns possessing vbg indomethacin jj effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
effect	10	16	concurrent jj administration nn of inpos drugs nns possessing vbg cytotoxic jj effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
false	14	16	concurrent jj administration nn of inpos drugs nns possessing vbg nephrotoxic jj myelotoxic jj doxorubicin nn methotrexate nn effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
false	14	16	concurrent jj administration nn of inpos drugs nns possessing vbg nephrotoxic jj myelotoxic jj doxorubicin nn asparaginase nn effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
effect	10	16	concurrent jj administration nn of inpos drugs nns possessing vbg doxorubicin jj effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
effect	10	16	concurrent jj administration nn of inpos drugs nns possessing vbg methotrexate nn effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
effect	10	16	concurrent jj administration nn of inpos drugs nns possessing vbg asparaginase nn effects nns with inpos proleukin nn may md increase vb toxicity nn in inpos these dt organ nn systems nns
false	10	20	the dt safety nn and cc efficacy nn of inpos proleukin nn in inpos combination nn with inpos any dt antineoplastic_agents nn have vbp not rb been vbn established vbn
effect	28	32	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nn specifically rb dacarbazine nn cis_platinum nn tamoxifen nn interferon_alfa nn
effect	28	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nns specifically rb dacarbazine nn
effect	28	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nns specifically rb cis_platinum nn
effect	28	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nns specifically rb tamoxifen nn
effect	28	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nns specifically rb interferon_alfa nn
false	32	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nn specifically rb dacarbazine nn
false	32	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nn specifically rb cis_platinum nn
false	32	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nn specifically rb tamoxifen nn
false	32	36	hypersensitivity nn reactions nns have vbp been vbn reported vbn in inpos patients nns receiving vbg combination nn regimens nns containing vbg sequential jj high jj dose nn proleukin nn and cc antineoplastic_agents nn specifically rb interferon_alfa nn
effect	34	38	myocardial jj injury nn including vbg myocardial jj infarction nn myocarditis nn ventricular jj hypokinesia nn severe jj rhabdomyolysis nn appear vbp to topos be vb increased vbn in inpos patients nns receiving vbg proleukin nn and cc interferon_alfa nn concurrently rb
effect	40	44	exacerbation nn or cc the dt initial jj presentation nn of inpos a dt number nn of inpos autoimmune jj and cc inflammatory jj disorders nns has vbz been vbn observed vbn following vbg concurrent jj use nn of inpos interferon_alfa nn and cc proleukin nn including vbg crescentic jj iga nn glomerulonephritis nn oculo_bulbar jj myasthenia nn gravis nn inflammatory jj arthritis nn thyroiditis nn bullous jj pemphigoid jj stevens_johnson nnp syndrome nn
effect	2	14	although inpos glucocorticoids nn have vbp been vbn shown vbn to topos reduce vb proleukin nn induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	2	14	although inpos glucocorticoids nn have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	2	14	although inpos glucocorticoids nn have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	2	72	although inpos glucocorticoids nn have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nn other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	2	76	although inpos glucocorticoids nn have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nn may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	2	14	although inpos glucocorticoids nn have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	14	74	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin nn induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nn other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	14	78	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin nn induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nn may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	14	72	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nn other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	14	76	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nn may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	14	72	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nn other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	14	76	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nn may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
false	72	76	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nn other jj antihypertensives nn may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
effect	72	14	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nn other jj antihypertensives nns may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
effect	76	14	although inpos glucocorticoids nns have vbp been vbn shown vbn to topos reduce vb proleukin_induced jj side nn effects nns including vbg fever nn renal jj insufficiency nn hyperbilirubinemia nn confusion nn dyspnea nn concomitant jj administration nn of inpos these dt agents nns with inpos proleukin nn may md reduce vb the dt antitumor jj effectiveness nn of inpos proleukin nn thus rb should md be vb avoided. vbn num cd b_blockers nns other jj antihypertensives nn may md potentiate vb the dt hypotension nn seen vbn with inpos proleukin nn
effect	28	42	a dt review nn of inpos the dt literature nn revealed vbd that inpos float cd of inpos num cd patients nns treated vbn with inpos various jj interleukin_num nn containing vbg regimens nns who wp were vbd subsequently rb administered vbn radiographic_iodinated_contrast_media nn experienced vbd acute jj atypical jj adverse jj reactions nns
false	16	30	the dt duration nn of inpos the dt period nn following vbg treatment nn with inpos amevive nn before inpos one prp should md consider vb starting vbg other jj immunosuppressive nn therapy nn has vbz not rb been vbn evaluated vbn
false	8	28	an dt immune jj response nn to topos campath nn may md interfere vb with inpos subsequent jj diagnostic jj serum nn tests nns that wdt utilize vbp antibodies nn
mechanism	2	20	intravenous jj ranitidine nn was vbd shown vbn to topos double vb the dt bioavailability nn of inpos oral jj alendronate nn
false	4	10	products nns containing vbg calcium nn and cc other jj multivalent_cations nn likely rb will md interfere vb with inpos absorption nn of inpos alendronate nn
mechanism	4	24	products nns containing vbg calcium nn and cc other jj multivalent_cations nns likely rb will md interfere vb with inpos absorption nn of inpos alendronate nn
mechanism	10	24	products nns containing vbg calcium nn and cc other jj multivalent_cations nn likely rb will md interfere vb with inpos absorption nn of inpos alendronate nn
effect	32	46	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nn such jj as inpos barbiturates nns tranquilizers nns opioids nns inhalation nn general jj anesthetics nns
effect	32	52	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nns such jj as inpos barbiturates nns inhalation nn general jj anesthetics nns
effect	32	52	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nns such jj as inpos tranquilizers nns inhalation nn general jj anesthetics nns
effect	32	52	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nns such jj as inpos opioids nn inhalation nn general jj anesthetics nns
effect	32	62	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nns such jj as inpos barbiturates nns tranquilizers nns opioids nns inhalation nn general jj anesthetics nn
false	46	52	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nn such jj as inpos barbiturates nns inhalation nn general jj anesthetics nns
false	46	52	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nn such jj as inpos tranquilizers nns inhalation nn general jj anesthetics nns
false	46	52	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nn such jj as inpos opioids nn inhalation nn general jj anesthetics nns
false	46	62	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nn such jj as inpos barbiturates nns tranquilizers nns opioids nns inhalation nn general jj anesthetics nn
false	52	58	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nns such jj as inpos barbiturates nns inhalation nn general jj anesthetics nn
false	52	58	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nns such jj as inpos tranquilizers nns inhalation nn general jj anesthetics nn
false	52	58	both cc the dt magnitude nn and cc duration nn of inpos central jj nervous jj system nn and cc cardiovascular jj effects nns may md be vb enhanced vbn when wrb alfenta nn is vbz administered vbn in inpos combination nn with inpos other jj cns_depressants nns such jj as inpos opioids nn inhalation nn general jj anesthetics nn
mechanism	14	40	limited jj clinical jj experience nn indicates vbz that inpos requirements nns for inpos volatile_inhalation_anesthetics nn are vbp reduced vbn by inpos num cd to topos num cd for inpos the dt first jj sixty jj minutes nns following vbg alfenta nn induction nn the dt concomitant jj use nn of inpos erythromycin nn with inpos alfenta nn can md significantly rb inhibit vb alfenta nn clearance nn and cc may md increase vb the dt risk nn of inpos prolonged jj or cc delayed vbn respiratory jj depression nn
false	14	52	limited jj clinical jj experience nn indicates vbz that inpos requirements nns for inpos volatile_inhalation_anesthetics nn are vbp reduced vbn by inpos num cd to topos num cd for inpos the dt first jj sixty jj minutes nns following vbg alfenta nn induction nn the dt concomitant jj use nn of inpos erythromycin nn with inpos alfenta nn can md significantly rb inhibit vb alfenta nn clearance nn and cc may md increase vb the dt risk nn of inpos prolonged jj or cc delayed vbn respiratory jj depression nn
false	14	40	limited jj clinical jj experience nn indicates vbz that inpos requirements nns for inpos volatile_inhalation_anesthetics nn are vbp reduced vbn by inpos num cd to topos num cd for inpos the dt first jj sixty jj minutes nns following vbg alfenta nn induction nn the dt concomitant jj use nn of inpos erythromycin nn with inpos alfenta nn can md significantly rb inhibit vb alfenta nn clearance nn and cc may md increase vb the dt risk nn of inpos prolonged jj or cc delayed vbn respiratory jj depression nn
false	14	40	limited jj clinical jj experience nn indicates vbz that inpos requirements nns for inpos volatile_inhalation_anesthetics nn are vbp reduced vbn by inpos num cd to topos num cd for inpos the dt first jj sixty jj minutes nns following vbg alfenta nn induction nn the dt concomitant jj use nn of inpos erythromycin nn with inpos alfenta nn can md significantly rb inhibit vb alfenta nn clearance nn and cc may md increase vb the dt risk nn of inpos prolonged jj or cc delayed vbn respiratory jj depression nn
false	40	52	limited jj clinical jj experience nn indicates vbz that inpos requirements nns for inpos volatile_inhalation_anesthetics nns are vbp reduced vbn by inpos num cd to topos num cd for inpos the dt first jj sixty jj minutes nns following vbg alfenta nn induction nn the dt concomitant jj use nn of inpos erythromycin nn with inpos alfenta nn can md significantly rb inhibit vb alfenta nn clearance nn and cc may md increase vb the dt risk nn of inpos prolonged jj or cc delayed vbn respiratory jj depression nn
mechanism	52	40	limited jj clinical jj experience nn indicates vbz that inpos requirements nns for inpos volatile_inhalation_anesthetics nns are vbp reduced vbn by inpos num cd to topos num cd for inpos the dt first jj sixty jj minutes nns following vbg alfenta nn induction nn the dt concomitant jj use nn of inpos erythromycin nn with inpos alfenta nn can md significantly rb inhibit vb alfenta nn clearance nn and cc may md increase vb the dt risk nn of inpos prolonged jj or cc delayed vbn respiratory jj depression nn
false	52	40	limited jj clinical jj experience nn indicates vbz that inpos requirements nns for inpos volatile_inhalation_anesthetics nns are vbp reduced vbn by inpos num cd to topos num cd for inpos the dt first jj sixty jj minutes nns following vbg alfenta nn induction nn the dt concomitant jj use nn of inpos erythromycin nn with inpos alfenta nn can md significantly rb inhibit vb alfenta nn clearance nn and cc may md increase vb the dt risk nn of inpos prolonged jj or cc delayed vbn respiratory jj depression nn
mechanism	0	10	cimetidine nn reduces vbz the dt clearance nn of inpos alfenta nn
false	12	18	the dt pharmacokinetic jj and cc pharmacodynamic jj interactions nns between inpos uroxatral nn and cc other jj ap_blockers nn have vbp not rb been vbn determined vbn
advise	12	30	however rb interactions nns may md be vb expected vbn and cc uroxatral nn should md not rb be vb used vbn in inpos combination nn with inpos other jj ap_blockers nn
false	4	22	co_administration nn of inpos lovastatin nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos atenolol nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos warfarin nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos furosemide nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos digoxin nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos celecoxib nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos hydrochlorothiazide nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos ramipril nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos valsartan nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos metformin nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
false	4	22	co_administration nn of inpos amlodipine nn did vbd not rb result vb in inpos clinically rb significant jj increases nns in inpos aliskiren nn exposure nn
mechanism	4	8	co_administration nn of inpos irbesartan nn reduced vbd aliskiren nn cmax nn up inpos to topos num cd after inpos multiple jj dosing nn
mechanism	4	20	co_administration nn of inpos atorvastatin nn resulted vbd in inpos about rb a dt num cd increase nn in inpos aliskiren nn cmax nn and cc auc nn after inpos multiple jj dosing nn
false	0	16	ketoconazole nn co_administration nn of inpos num cd mg nn twice_daily jj ketoconazole nn with inpos aliskiren nn resulted vbd in inpos an dt approximate jj num cd increase nn in inpos plasma nn levels nns of inpos aliskiren nns
false	0	16	ketoconazole nn co_administration nn of inpos num cd mg nn twice_daily jj ketoconazole nn with inpos aliskiren nn resulted vbd in inpos an dt approximate jj num cd increase nn in inpos plasma nn levels nns of inpos aliskiren nn
mechanism	10	14	co_administration nn of inpos num cd mg nn twice_daily jj ketoconazole nn with inpos aliskiren nn resulted vbd in inpos an dt approximate jj num cd increase nn in inpos plasma nn levels nns of inpos aliskiren nns
false	10	14	co_administration nn of inpos num cd mg nn twice_daily jj ketoconazole nn with inpos aliskiren nn resulted vbd in inpos an dt approximate jj num cd increase nn in inpos plasma nn levels nns of inpos aliskiren nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos lovastatin nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos digoxin nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos valsartan nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos amlodipine nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos metformin nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos celecoxib nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos atenolol nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos atorvastatin nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos ramipril nn
false	4	20	co_administration nn of inpos aliskiren nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos hydrochlorothiazide nn
false	6	10	the dt effects nns of inpos aliskiren nn on inpos warfarin nn pharmacokinetics nns have vbp not rb been vbn evaluated vbn in inpos a dt well_controlled jj clinical jj trial nn
mechanism	2	10	when wrb aliskiren nn was vbd co_administered vbn with inpos furosemide nn the dt auc nn and cc cmax nn of inpos furosemide nn were vbd reduced vbn by inpos about rb num cd and cc num cd respectively rb
false	2	10	when wrb aliskiren nn was vbd co_administered vbn with inpos furosemide nn the dt auc nn and cc cmax nn of inpos furosemide nn were vbd reduced vbn by inpos about rb num cd and cc num cd respectively rb
advise	8	26	patients nns who wp are vbp applying vbg panretin nn gel nn should md not rb concurrently rb use vb products nns that wdt contain vbp deet nn a dt common jj component nn of inpos insect nn repellent nn products nns
advise	8	26	patients nns who wp are vbp applying vbg panretin nn gel nn should md not rb concurrently rb use vb products nns that wdt contain vbp n_diethyl_m_toluamide nn a dt common jj component nn of inpos insect nn repellent nn products nns
false	30	34	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nn including vbg protease_inhibitors nns the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	30	34	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nn including vbg macrolide_antibiotics nns the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	30	34	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nn including vbg azole_antifungals nn the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	30	46	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nn including vbg protease_inhibitors nns macrolide_antibiotics nns azole_antifungals nns the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	34	42	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nns including vbg protease_inhibitors nns the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	36	38	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nns including vbg protease_inhibitors nns macrolide_antibiotics nn azole_antifungals nn the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	34	42	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nns including vbg macrolide_antibiotics nns the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	34	42	although inpos there ex was vbd no dt clinical jj evidence nn in inpos the dt vehicle_controlled jj studies nns of inpos drug nn interactions nns with inpos systemic jj antiretroviral_agents nns including vbg azole_antifungals nn the dt effect nn of inpos panretin nn gel nn on inpos the dt steady_state jj concentrations nns of inpos these dt drugs nns is vbz not rb known vbn
false	0	2	mercaptopurine nn azathioprine nn
mechanism	0	12	allopurinol nn inhibits vbz the dt enzymatic jj oxidation nn of inpos mercaptopurine nn and cc azathioprine nn to topos num_thiouric_acid jj
mechanism	0	16	allopurinol nn inhibits vbz the dt enzymatic jj oxidation nn of inpos mercaptopurine nn and cc azathioprine nn to topos num_thiouric_acid jj
false	0	20	allopurinol nn inhibits vbz the dt enzymatic jj oxidation nn of inpos mercaptopurine nn and cc azathioprine nn to topos num_thiouric_acid nn
false	12	16	allopurinol nn inhibits vbz the dt enzymatic jj oxidation nn of inpos mercaptopurine nn and cc azathioprine nn to topos num_thiouric_acid jj
false	12	20	allopurinol nn inhibits vbz the dt enzymatic jj oxidation nn of inpos mercaptopurine nn and cc azathioprine nn to topos num_thiouric_acid nn
false	16	20	allopurinol nn inhibits vbz the dt enzymatic jj oxidation nn of inpos mercaptopurine nn and cc azathioprine nn to topos num_thiouric_acid nn
false	6	10	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	10	in inpos patients nns receiving vbg mercaptopurine nn or cc imuran nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	26	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	10	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	10	in inpos patients nns receiving vbg purinethol nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	10	in inpos patients nns receiving vbg purinethol nn or cc imuran nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	26	in inpos patients nns receiving vbg purinethol nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	64	in inpos patients nns receiving vbg purinethol nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	10	in inpos patients nns receiving vbg purinethol nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	10	26	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	10	6	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	10	26	in inpos patients nns receiving vbg mercaptopurine nn or cc imuran nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	10	6	in inpos patients nns receiving vbg mercaptopurine nn or cc imuran nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	10	68	in inpos patients nns receiving vbg mercaptopurine nn or cc imuran nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
advise	26	6	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
advise	26	10	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	6	10	in inpos patients nns receiving vbg mercaptopurine nn or cc azathioprine nn the dt concomitant jj administration nn of inpos num cd mg nn of inpos allopurinol nn per inpos day nn will md require vb a dt reduction nn in inpos dose nn to topos approximately rb one_third jj to topos one_fourth nn of inpos the dt usual jj dose nn of inpos mercaptopurine nn or cc azathioprine nn
false	10	14	subsequent jj adjustment nn of inpos doses nns of inpos mercaptopurine nn or cc azathioprine nn should md be vb made vbn on inpos the dt basis nn of inpos therapeutic jj response nn and cc the dt appearance nn of inpos toxic jj effects nns
false	10	22	it prp has vbz been vbn reported vbn that inpos allopurinol nn prolongs vbz the dt half_life nn of inpos the dt anticoagulant nn dicumarol nn
mechanism	10	24	it prp has vbz been vbn reported vbn that inpos allopurinol nn prolongs vbz the dt half_life nn of inpos the dt anticoagulant nn dicumarol nn
false	22	24	it prp has vbz been vbn reported vbn that inpos allopurinol nn prolongs vbz the dt half_life nn of inpos the dt anticoagulant nn dicumarol nn
false	32	46	the dt clinical jj basis nn of inpos this dt drug nn interaction nn has vbz not rb been vbn established vbn but cc should md be vb noted vbn when wrb allopurinol nn is vbz given vbn to topos patients nns already rb on inpos dicumarol nn therapy nn
false	8	22	since inpos the dt excretion nn of inpos oxipurinol nn is vbz similar jj to topos that dt of inpos urate nn uricosuric_agents nn which wdt increase vbp the dt excretion nn of inpos urate nn are vbp also rb likely jj to topos increase vb the dt excretion nn of inpos oxipurinol nn and cc thus rb lower jjr the dt degree nn of inpos inhibition nn of inpos xanthine nn oxidase nn
mechanism	22	8	since inpos the dt excretion nn of inpos oxipurinol nn is vbz similar jj to topos that dt of inpos urate nn uricosuric_agents nn which wdt increase vbp the dt excretion nn of inpos urate nn are vbp also rb likely jj to topos increase vb the dt excretion nn of inpos oxipurinol nn and cc thus rb lower jjr the dt degree nn of inpos inhibition nn of inpos xanthine nn oxidase nn
mechanism	8	12	the dt concomitant jj administration nn of inpos uricosuric_agents nn and cc allopurinol nn has vbz been vbn associated vbn with inpos a dt decrease nn in inpos the dt excretion nn of inpos oxypurines nns and cc an dt increase nn in inpos urinary jj uric jj acid nn excretion nn compared vbn with inpos that dt observed vbn with inpos allopurinol nn alone rb
false	8	12	the dt concomitant jj administration nn of inpos uricosuric_agents nn and cc allopurinol nn has vbz been vbn associated vbn with inpos a dt decrease nn in inpos the dt excretion nn of inpos oxypurines nns and cc an dt increase nn in inpos urinary jj uric jj acid nn excretion nn compared vbn with inpos that dt observed vbn with inpos allopurinol nn alone rb
false	32	44	although inpos clinical jj evidence nn to topos date nn has vbz not rb demonstrated vbn renal jj precipitation nn of inpos oxypurines nns in inpos patients nns either cc on inpos allopurinol nn alone rb or cc in inpos combination nn with inpos uricosuric_agents nn the dt possibility nn should md be vb kept vbn in inpos mind nn
effect	14	18	the dt reports nns that inpos the dt concomitant jj use nn of inpos allopurinol nn and cc thiazide_diuretics nn may md contribute vb to topos the dt enhancement nn of inpos allopurinol nn toxicity nn in inpos some dt patients nns have vbp been vbn reviewed vbn in inpos an dt attempt nn to topos establish vb a dt cause_and_effect jj relationship nn and cc a dt mechanism nn of inpos causation nn
false	18	14	the dt reports nns that inpos the dt concomitant jj use nn of inpos allopurinol nn and cc thiazide_diuretics nn may md contribute vb to topos the dt enhancement nn of inpos allopurinol nn toxicity nn in inpos some dt patients nns have vbp been vbn reviewed vbn in inpos an dt attempt nn to topos establish vb a dt cause_and_effect jj relationship nn and cc a dt mechanism nn of inpos causation nn
advise	48	52	although inpos a dt causal jj mechanism nn and cc a dt cause_and_effect jj relationship nn have vbp not rb been vbn established vbn current jj evidence nn suggests vbz that inpos renal jj function nn should md be vb monitored vbn in inpos patients nns on inpos thiazide_diuretics nn and cc allopurinol nn even rb in inpos the dt absence nn of inpos renal jj failure nn and cc dosage nn levels nns should md be vb even rb more rbr conservatively rb adjusted vbn in inpos those dt patients nns on inpos such jj combined jj therapy nn if inpos diminished vbn renal jj function nn is vbz detected vbn
false	0	2	ampicillin nn amoxicillin nn
false	28	32	an dt increase nn in inpos the dt frequency nn of inpos skin nn rash nn has vbz been vbn reported vbn among inpos patients nns receiving vbg ampicillin nn or cc amoxicillin nn concurrently rb with inpos allopurinol nn compared vbn to topos patients nns who wp are vbp not rb receiving vbg both dt drugs nns
effect	28	38	an dt increase nn in inpos the dt frequency nn of inpos skin nn rash nn has vbz been vbn reported vbn among inpos patients nns receiving vbg ampicillin nn or cc amoxicillin nn concurrently rb with inpos allopurinol nn compared vbn to topos patients nns who wp are vbp not rb receiving vbg both dt drugs nns
effect	32	38	an dt increase nn in inpos the dt frequency nn of inpos skin nn rash nn has vbz been vbn reported vbn among inpos patients nns receiving vbg ampicillin nn or cc amoxicillin nn concurrently rb with inpos allopurinol nn compared vbn to topos patients nns who wp are vbp not rb receiving vbg both dt drugs nns
false	0	12	cytotoxic_agents nn enhanced vbd bone nn marrow nn suppression nn by inpos cyclophosphamide nn and cc other jj cytotoxic_agents nns has vbz been vbn reported vbn among inpos patients nns with inpos neoplastic jj disease nn except inpos leukemia nn in inpos the dt presence nn of inpos allopurinol nn
false	0	48	cytotoxic_agents nn enhanced vbd bone nn marrow nn suppression nn by inpos cyclophosphamide nn and cc other jj cytotoxic_agents nns has vbz been vbn reported vbn among inpos patients nns with inpos neoplastic jj disease nn except inpos leukemia nn in inpos the dt presence nn of inpos allopurinol nn
false	10	16	enhanced vbn bone nn marrow nn suppression nn by inpos cyclophosphamide nn and cc other jj cytotoxic_agents nn has vbz been vbn reported vbn among inpos patients nns with inpos neoplastic jj disease nn except inpos leukemia nn in inpos the dt presence nn of inpos allopurinol nn
effect	10	46	enhanced vbn bone nn marrow nn suppression nn by inpos cyclophosphamide nn and cc other jj cytotoxic_agents nns has vbz been vbn reported vbn among inpos patients nns with inpos neoplastic jj disease nn except inpos leukemia nn in inpos the dt presence nn of inpos allopurinol nn
effect	16	46	enhanced vbn bone nn marrow nn suppression nn by inpos cyclophosphamide nn and cc other jj cytotoxic_agents nn has vbz been vbn reported vbn among inpos patients nns with inpos neoplastic jj disease nn except inpos leukemia nn in inpos the dt presence nn of inpos allopurinol nn
false	24	46	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos cyclophosphamide cc mechlorethamine nn
false	24	46	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos doxorubicin cc mechlorethamine nn
false	24	46	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos bleomycin cc mechlorethamine nn
false	24	46	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos procarbazine cc mechlorethamine nn
false	24	56	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos cyclophosphamide nn doxorubicin nn bleomycin nn procarbazine nn and_or cc mechlorethamine nn
false	46	48	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos cyclophosphamide cc mechlorethamine nn
false	46	48	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos doxorubicin cc mechlorethamine nn
false	46	48	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos bleomycin cc mechlorethamine nn
false	46	48	however rb in inpos a dt well_controlled jj study nn of inpos patients nns with inpos lymphoma nn on inpos combination nn therapy nn allopurinol nn did vbd not rb increase vb the dt marrow nn toxicity nn of inpos patients nns treated vbn with inpos procarbazine cc mechlorethamine nn
mechanism	0	16	chlorpropamide nn s vbz plasma nn half_life nn may md be vb prolonged vbn by inpos allopurinol nn since inpos allopurinol nn and cc chlorpropamide nn may md compete vb for inpos excretion nn in inpos the dt renal jj tubule nn
false	0	16	chlorpropamide nn s vbz plasma nn half_life nn may md be vb prolonged vbn by inpos allopurinol nn since inpos allopurinol nn and cc chlorpropamide nn may md compete vb for inpos excretion nn in inpos the dt renal jj tubule nn
false	14	0	chlorpropamides nns plasma nn half_life nn may md be vb prolonged vbn by inpos allopurinol nn since inpos allopurinol nn and cc chlorpropamide nn may md compete vb for inpos excretion nn in inpos the dt renal jj tubule nn
mechanism	14	0	chlorpropamides nns plasma nn half_life nn may md be vb prolonged vbn by inpos allopurinol nn since inpos allopurinol nn and cc chlorpropamide nn may md compete vb for inpos excretion nn in inpos the dt renal jj tubule nn
effect	24	28	the dt risk nn of inpos hypoglycemia nn secondary jj to topos this dt mechanism nn may md be vb increased vbn if inpos allopurinol nn and cc chlorpropamide nn are vbp given vbn concomitantly rb in inpos the dt presence nn of inpos renal jj insufficiency nn
mechanism	6	24	reports nns indicate vbp that inpos cyclosporine nn levels nns may md be vb increased vbn during inpos concomitant jj treatment nn with inpos allopurinol_sodium nn for inpos injection nn
false	28	32	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj ergot_type_medications nn axert nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
false	28	32	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj methysergide nn axert nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	28	34	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj ergot_type_medications nns axert nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc ergot_type_medications nn and cc axert nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc dihydroergotamine nn and cc axert nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc methysergide nn and cc axert nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
false	0	6	monoamine_oxidase_inhibitors nn coadministration nn of inpos moclobemide nn resulted vbd in inpos a dt num cd decrease nn in inpos almotriptan jj clearance nn and cc an dt increase nn in inpos cmax nn of inpos approximately rb num cd
false	0	20	monoamine_oxidase_inhibitors nn coadministration nn of inpos moclobemide nn resulted vbd in inpos a dt num cd decrease nn in inpos almotriptan nn clearance nn and cc an dt increase nn in inpos cmax nn of inpos approximately rb num cd
mechanism	4	18	coadministration nn of inpos moclobemide nn resulted vbd in inpos a dt num cd decrease nn in inpos almotriptan nn clearance nn and cc an dt increase nn in inpos cmax nn of inpos approximately rb num cd
false	2	26	other jj num_ht1b_1d_agonists nn concomitant jj use nn of inpos other jj num_ht1b_1d_agonists nns within inpos num cd hours nns of inpos treatment nn with inpos axert nn is vbz contraindicated vbn
advise	2	26	other jj num_ht1b_1d_agonists nns concomitant jj use nn of inpos other jj num_ht1b_1d_agonists nn within inpos num cd hours nns of inpos treatment nn with inpos axert nn is vbz contraindicated vbn
false	6	20	the dt pharmacokinetics nns of inpos almotriptan nn were vbd not rb affected vbn by inpos coadministration nn of inpos propranolol nn
false	0	2	selective_serotonin_reuptake_inhibitors nn fluoxetine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
false	0	2	selective_serotonin_reuptake_inhibitors nn fluvoxamine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
false	0	2	selective_serotonin_reuptake_inhibitors nn paroxetine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
false	0	2	selective_serotonin_reuptake_inhibitors nn sertraline nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
false	0	2	ssris nn fluoxetine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
false	0	2	ssris nn fluvoxamine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
false	0	2	ssris nn paroxetine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
false	0	2	ssris nn sertraline nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nns
effect	0	26	ssris nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	2	28	selective_serotonin_reuptake_inhibitors nns fluoxetine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	2	28	selective_serotonin_reuptake_inhibitors nns fluvoxamine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	2	28	selective_serotonin_reuptake_inhibitors nns paroxetine nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	2	28	selective_serotonin_reuptake_inhibitors nns sertraline nn have vbp been vbn rarely rb reported vbn to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
advise	8	14	if inpos concomitant jj treatment nn with inpos axert nn and cc an dt ssri nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
false	0	6	verapamil nn coadministration nn of inpos almotriptan nn and cc verapamil nn resulted vbd in inpos a dt num cd increase nn in inpos plasma nn concentrations nns of inpos almotriptan nn
false	0	6	verapamil nn coadministration nn of inpos almotriptan nn and cc verapamil nn resulted vbd in inpos a dt num cd increase nn in inpos plasma nn concentrations nns of inpos almotriptan nn
mechanism	4	8	coadministration nn of inpos almotriptan nn and cc verapamil nn resulted vbd in inpos a dt num cd increase nn in inpos plasma nn concentrations nns of inpos almotriptan nn
false	8	4	coadministration nn of inpos almotriptan nn and cc verapamil nn resulted vbd in inpos a dt num cd increase nn in inpos plasma nn concentrations nns of inpos almotriptan nn
mechanism	4	16	coadministration nn of inpos almotriptan nn and cc the dt potent jj cyp3a4 nn inhibitor nn ketoconazole nn resulted vbd in inpos an dt approximately rb num cd increase nn in inpos the dt area nn under inpos the dt plasma nn concentration_time jj curve nn and cc maximal jj plasma nn concentrations nns of inpos almotriptan nn
false	16	4	coadministration nn of inpos almotriptan nn and cc the dt potent jj cyp3a4 nn inhibitor nn ketoconazole nn resulted vbd in inpos an dt approximately rb num cd increase nn in inpos the dt area nn under inpos the dt plasma nn concentration_time jj curve nn and cc maximal jj plasma nn concentrations nns of inpos almotriptan nn
false	8	18	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn itraconazole nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan vb may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
false	8	18	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn ritonavir nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan vb may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
false	8	18	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn erythromycin nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan vb may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
false	18	8	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn itraconazole nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan nn may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
advise	18	8	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn itraconazole nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan vb may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
false	18	8	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn ritonavir nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan nn may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
advise	18	8	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn ritonavir nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan vb may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
false	18	8	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn erythromycin nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan nn may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
advise	18	8	although inpos the dt interaction nn between inpos almotriptan nn and cc other jj potent jj cyp3a4 nn erythromycin nn has vbz not rb been vbn studied vbn increased vbn exposures nns to topos almotriptan vb may md be vb expected vbn when wrb almotriptan nn is vbz used vbn concomitantly rb with inpos these dt medications nns
false	18	52	in inpos a dt pharmacokinetic jj study nn num cd healthy jj female jj subjects nns received vbd fluvoxamine nn in inpos escalating vbg doses nns from inpos num cd to topos num cd mg nn per inpos day nn for inpos num cd days nns with inpos coadministration nn of inpos alosetron nn num cd mg nn on inpos the dt last jj day nn
mechanism	0	6	fluvoxamine nn increased vbd mean jj alosetron nn plasma nn concentrations nns approximately rb num_fold rb and cc prolonged vbd the dt half_life nn by inpos approximately rb num_fold rb
advise	6	10	concomitant jj administration nn of inpos alosetron nn and cc fluvoxamine nn is vbz contraindicated vbn
advise	6	18	concomitant jj administration nn of inpos alosetron nn and cc moderate jj cyp1a2 nn inhibitors nns including vbg quinolone_antibiotics nn and cc cimetidine nn has vbz not rb been vbn evaluated vbn but cc should md be vb avoided vbn unless inpos clinically rb necessary jj because inpos of inpos similar jj potential jj drug nn interactions nns
advise	6	22	concomitant jj administration nn of inpos alosetron nn and cc moderate jj cyp1a2 nn inhibitors nns including vbg quinolone_antibiotics nns and cc cimetidine nn has vbz not rb been vbn evaluated vbn but cc should md be vb avoided vbn unless inpos clinically rb necessary jj because inpos of inpos similar jj potential jj drug nn interactions nns
false	18	22	concomitant jj administration nn of inpos alosetron nn and cc moderate jj cyp1a2 nn inhibitors nns including vbg quinolone_antibiotics nn and cc cimetidine nn has vbz not rb been vbn evaluated vbn but cc should md be vb avoided vbn unless inpos clinically rb necessary jj because inpos of inpos similar jj potential jj drug nn interactions nns
false	18	40	in inpos a dt pharmacokinetic jj study nn num cd healthy jj female jj subjects nns received vbd ketoconazole nn num cd mg nn twice rb daily rb for inpos num cd days nns with inpos coadministration nn of inpos alosetron nn num cd mg nn on inpos the dt last jj day nn
mechanism	0	6	ketoconazole nn increased vbd mean jj alosetron nn plasma nn concentrations nns by inpos num cd
advise	10	14	caution nn should md be vb used vbn when wrb alosetron nn and cc ketoconazole nn are vbp administered vbn concomitantly rb
advise	4	18	coadministration nn of inpos alosetron nn and cc strong jj cyp3a4 nn inhibitors nns such jj as inpos clarithromycin nn has vbz not rb been vbn evaluated vbn but cc should md be vb undertaken vbn with inpos caution nn because inpos of inpos similar jj potential jj drug nn interactions nns
advise	4	18	coadministration nn of inpos alosetron nn and cc strong jj cyp3a4 nn inhibitors nns such jj as inpos telithromycin nn has vbz not rb been vbn evaluated vbn but cc should md be vb undertaken vbn with inpos caution nn because inpos of inpos similar jj potential jj drug nn interactions nns
advise	4	18	coadministration nn of inpos alosetron nn and cc strong jj cyp3a4 nn inhibitors nns such jj as inpos protease_inhibitors nn has vbz not rb been vbn evaluated vbn but cc should md be vb undertaken vbn with inpos caution nn because inpos of inpos similar jj potential jj drug nn interactions nns
advise	4	18	coadministration nn of inpos alosetron nn and cc strong jj cyp3a4 nn inhibitors nns such jj as inpos voriconazole nn has vbz not rb been vbn evaluated vbn but cc should md be vb undertaken vbn with inpos caution nn because inpos of inpos similar jj potential jj drug nn interactions nns
advise	4	18	coadministration nn of inpos alosetron nn and cc strong jj cyp3a4 nn inhibitors nns such jj as inpos itraconazole nn has vbz not rb been vbn evaluated vbn but cc should md be vb undertaken vbn with inpos caution nn because inpos of inpos similar jj potential jj drug nn interactions nns
effect	8	34	although inpos not rb studied vbn with inpos alosetron nn inhibition nn of inpos n_acetyltransferase nn may md have vb clinically rb relevant jj consequences nns for inpos drugs nns such jj as inpos isoniazid nn
effect	8	34	although inpos not rb studied vbn with inpos alosetron nn inhibition nn of inpos n_acetyltransferase nn may md have vb clinically rb relevant jj consequences nns for inpos drugs nns such jj as inpos procainamide nn
effect	8	34	although inpos not rb studied vbn with inpos alosetron nn inhibition nn of inpos n_acetyltransferase nn may md have vb clinically rb relevant jj consequences nns for inpos drugs nns such jj as inpos hydralazine nn
false	8	32	another dt study nn showed vbd that inpos alosetron nn had vbd no dt clinically rb significant jj effect nn on inpos plasma nn concentrations nns of inpos the dt oral jj contraceptive_agents nn ethinyl_estradiol nn and cc levonorgestrel nn
false	8	34	another dt study nn showed vbd that inpos alosetron nn had vbd no dt clinically rb significant jj effect nn on inpos plasma nn concentrations nns of inpos the dt oral jj contraceptive_agents nns ethinyl_estradiol nn and cc levonorgestrel nn
false	8	38	another dt study nn showed vbd that inpos alosetron nn had vbd no dt clinically rb significant jj effect nn on inpos plasma nn concentrations nns of inpos the dt oral jj contraceptive_agents nns ethinyl_estradiol nn and cc levonorgestrel nn
false	32	34	another dt study nn showed vbd that inpos alosetron nn had vbd no dt clinically rb significant jj effect nn on inpos plasma nn concentrations nns of inpos the dt oral jj contraceptive_agents nn ethinyl_estradiol nn and cc levonorgestrel nn
false	32	38	another dt study nn showed vbd that inpos alosetron nn had vbd no dt clinically rb significant jj effect nn on inpos plasma nn concentrations nns of inpos the dt oral jj contraceptive_agents nn ethinyl_estradiol nn and cc levonorgestrel nn
false	34	38	another dt study nn showed vbd that inpos alosetron nn had vbd no dt clinically rb significant jj effect nn on inpos plasma nn concentrations nns of inpos the dt oral jj contraceptive_agents nns ethinyl_estradiol nn and cc levonorgestrel nn
false	16	26	a dt clinical jj interaction nn study nn was vbd also rb conducted vbn with inpos alosetron nn and cc the dt cyp3a4 nn substrate nn cisapride nn
false	2	6	the dt benzodiazepines nn including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj psychotropic_medications nns anticonvulsants nns antihistaminics nns ethanol nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	2	26	the dt benzodiazepines nn including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj psychotropic_medications nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	2	28	the dt benzodiazepines nn including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj psychotropic_medications nns anticonvulsants nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	2	26	the dt benzodiazepines nn including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj antihistaminics nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	2	26	the dt benzodiazepines nn including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj ethanol nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	6	26	the dt benzodiazepines nns including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj psychotropic_medications nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	6	28	the dt benzodiazepines nns including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj psychotropic_medications nns anticonvulsants nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	6	26	the dt benzodiazepines nns including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj antihistaminics nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
effect	6	26	the dt benzodiazepines nns including vbg alprazolam nn produce vbp additive jj cns nn depressant jj effects nns when wrb co_administered vbn with inpos other jj ethanol nn other jj drugs nns which wdt themselves prp produce vbp cns nn depression nn
false	12	16	the dt steady jj state nn plasma nn concentrations nns of inpos imipramine nn and cc desipramine nn have vbp been vbn reported vbn to topos be vb increased vbn an dt average nn of inpos num cd and cc num cd respectively rb by inpos the dt concomitant jj administration nn of inpos alprazolam nn tablets nns in inpos doses nns up rb to topos num cd mg_day nn
mechanism	12	54	the dt steady jj state nn plasma nn concentrations nns of inpos imipramine nn and cc desipramine nn have vbp been vbn reported vbn to topos be vb increased vbn an dt average nn of inpos num cd and cc num cd respectively rb by inpos the dt concomitant jj administration nn of inpos alprazolam nn tablets nns in inpos doses nns up rb to topos num cd mg_day nn
mechanism	16	54	the dt steady jj state nn plasma nn concentrations nns of inpos imipramine nn and cc desipramine nn have vbp been vbn reported vbn to topos be vb increased vbn an dt average nn of inpos num cd and cc num cd respectively rb by inpos the dt concomitant jj administration nn of inpos alprazolam nn tablets nns in inpos doses nns up rb to topos num cd mg_day nn
false	36	42	drugs nns demonstrated vbn to topos be vb cyp nn 3a nn inhibitors nns of inpos possible jj clinical jj significance nn on inpos the dt basis nnp of inpos clinical nnp studies nnp involving nnp alprazolam nn coadministration nn of inpos fluoxetine nn with inpos alprazolam nn increased vbd the dt maximum jj plasma nn concentration nn of inpos alprazolam nn by inpos num cd decreased vbd clearance nn by inpos num cd increased vbn half_life nn by inpos num cd decreased vbd measured vbn psychomotor nn performance nn
false	36	56	drugs nns demonstrated vbn to topos be vb cyp nn 3a nn inhibitors nns of inpos possible jj clinical jj significance nn on inpos the dt basis nnp of inpos clinical nnp studies nnp involving nnp alprazolam nnp lrb_caution nn is vbz recommended vbn during inpos coadministration nn with inpos alprazolam nn rrb_coadministration nn of inpos fluoxetine nn with inpos alprazolam nn increased vbd the dt maximum jj plasma nn concentration nn of inpos alprazolam nn by inpos num cd decreased vbd clearance nn by inpos num cd increased vbn half_life nn by inpos num cd decreased vbd measured vbn psychomotor nn performance nn
mechanism	4	8	coadministration nn of inpos fluoxetine nn with inpos alprazolam nn increased vbd the dt maximum jj plasma nn concentration nn of inpos alprazolam nn by inpos num cd decreased vbd clearance nn by inpos num cd increased vbn half_life nn by inpos num cd decreased vbd measured vbn psychomotor nn performance nn
false	4	8	coadministration nn of inpos fluoxetine nn with inpos alprazolam nn increased vbd the dt maximum jj plasma nn concentration nn of inpos alprazolam nn by inpos num cd decreased vbd clearance nn by inpos num cd increased vbn half_life nn by inpos num cd decreased vbd measured vbn psychomotor nn performance nn
mechanism	4	18	coadministration nn of inpos propoxyphene nn decreased vbd the dt maximum jj plasma nn concentration nn of inpos alprazolam nn by inpos num cd decreased vbd clearance nn by inpos num cd increased vbn half_life nn by inpos num cd
mechanism	6	20	coadministration nn of inpos oral jj contraceptives nn increased vbd the dt maximum jj plasma nn concentration nn of inpos alprazolam nn by inpos num cd decreased vbd clearance nn by inpos num cd increased vbn half_life nn by inpos num cd
false	34	42	drugs nns and cc other jj substances nns demonstrated vbd to topos be vb cyp nn 3a nn inhibitors nns on inpos the dt basis nn of inpos clinical jj studies nns involving vbg benzodiazepines nn metabolized vbd similarly rb to topos alprazolam nn or cc on inpos the dt basis nn of inpos in fw vitro fw studies nns with inpos alprazolam nn or cc other jj benzodiazepines nns
false	34	42	drugs nns and cc other jj substances nns demonstrated vbd to topos be vb cyp nn 3a nn inhibitors nns on inpos the dt basis nn of inpos clinical jj studies nns involving vbg benzodiazepines nn metabolized vbd similarly rb to topos alprazolam nn or cc on inpos the dt basis nn of inpos in fw vitro fw studies nns with inpos alprazolam nn or cc other jj benzodiazepines nns
false	34	42	drugs nns and cc other jj substances nns demonstrated vbd to topos be vb cyp nn 3a nn inhibitors nns on inpos the dt basis nn of inpos clinical jj studies nns involving vbg benzodiazepines nn metabolized vbd similarly rb to topos alprazolam nn or cc on inpos the dt basis nn of inpos in fw vitro fw studies nns with inpos alprazolam nn or cc other jj benzodiazepines nns lrb_caution nn is vbz recommended vbn during inpos coadministration nn with inpos alprazolam nn
false	42	34	drugs nns and cc other jj substances nns demonstrated vbd to topos be vb cyp nn 3a nn inhibitors nns on inpos the dt basis nn of inpos clinical jj studies nns involving vbg benzodiazepines nns metabolized vbd similarly rb to topos alprazolam nn or cc on inpos the dt basis nn of inpos in fw vitro fw studies nns with inpos alprazolam nn or cc other jj benzodiazepines nn
false	42	34	drugs nns and cc other jj substances nns demonstrated vbd to topos be vb cyp nn 3a nn inhibitors nns on inpos the dt basis nn of inpos clinical jj studies nns involving vbg benzodiazepines nns metabolized vbd similarly rb to topos alprazolam nn or cc on inpos the dt basis nn of inpos in fw vitro fw studies nns with inpos alprazolam nn or cc other jj benzodiazepines nn
false	34	42	drugs nns and cc other jj substances nns demonstrated vbd to topos be vb cyp nn 3a nn inhibitors nns on inpos the dt basis nn of inpos clinical jj studies nns involving vbg benzodiazepines nns metabolized vbd similarly rb to topos alprazolam nn or cc on inpos the dt basis nn of inpos in fw vitro fw studies nns with inpos alprazolam nn or cc other jj benzodiazepines nn lrb_caution nn is vbz recommended vbn during inpos coadministration nn with inpos alprazolam nn
false	12	18	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	12	18	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	12	40	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	12	42	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	12	40	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn macrolide_antibiotics nn grapefruit nn juice nn
false	12	50	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	12	52	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	18	40	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	18	42	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	18	40	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn macrolide_antibiotics nn grapefruit nn juice nn
false	18	50	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	18	52	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
int	18	40	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
int	18	42	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
int	18	40	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn macrolide_antibiotics nn grapefruit nn juice nn
int	18	50	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
int	18	52	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	40	42	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	40	50	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	40	52	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	42	50	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	42	52	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	50	52	available jj data nns from inpos clinical jj studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn diltiazem nn isoniazid nn macrolide_antibiotics nns such jj as inpos erythromycin nn clarithromycin nn grapefruit nn juice nn
false	12	34	data nns from inpos in fw vitro fw studies nns of inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn sertraline nn and cc paroxetine nn
false	12	38	data nns from inpos in fw vitro fw studies nns of inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn sertraline nn and cc paroxetine nn
int	12	34	data nns from inpos in fw vitro fw studies nns of inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn sertraline nn and cc paroxetine nn
int	12	38	data nns from inpos in fw vitro fw studies nns of inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn sertraline nn and cc paroxetine nn
false	34	38	data nns from inpos in fw vitro fw studies nns of inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn with inpos alprazolam nn for inpos the dt following nn sertraline nn and cc paroxetine nn
false	12	18	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn ergotamine nn cyclosporine nn amiodarone nn nicardipine nn nifedipine nn
int	12	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn ergotamine nn
int	12	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn cyclosporine nn
int	12	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn amiodarone nn
int	12	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn nicardipine nn
int	12	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nn other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn nifedipine nn
int	18	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn ergotamine nn
int	18	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn cyclosporine nn
int	18	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn amiodarone nn
int	18	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn nicardipine nn
int	18	36	data nns from inpos in fw vitro fw studies nns of inpos benzodiazepines nns other jj than inpos alprazolam nn suggest vbp a dt possible jj drug nn interaction nn for inpos the dt following nn nifedipine nn
false	6	12	standard jj therapy nn includes vbz antibiotics nn such jj as inpos penicillin nn and cc gentamicin nn
false	6	16	standard jj therapy nn includes vbz antibiotics nn such jj as inpos penicillin nn and cc gentamicin nn
false	12	16	standard jj therapy nn includes vbz antibiotics nns such jj as inpos penicillin nn and cc gentamicin nn
false	0	6	vasopressors nn such jj as inpos dopamine nn and cc isoproterenol nn
false	0	10	vasopressors nn such jj as inpos dopamine nn and cc isoproterenol nn
false	6	10	vasopressors nns such jj as inpos dopamine nn and cc isoproterenol nn
false	2	8	and cc diuretics nn such jj as inpos furosemide nn
false	12	16	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
false	12	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn acetylsalicylic_acid nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
false	12	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
false	12	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn abciximab nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
effect	12	54	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
false	16	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn acetylsalicylic_acid nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
false	16	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
false	16	26	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn abciximab nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
effect	16	54	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nn drugs nns that wdt alter vbp platelet nn function nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
int	26	54	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn acetylsalicylic_acid nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
effect	26	54	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn dipyridamole nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
effect	26	54	in inpos addition nn to topos bleeding vbg associated vbn with inpos heparin nn and cc vitamin_k_antagonists nns drugs nns that wdt alter vbp platelet nn abciximab nn may md increase vb the dt risk nn of inpos bleeding vbg if inpos administered vbn prior jj to topos during inpos or cc after inpos activase nn therapy nn
false	4	6	use nn of inpos antithrombotics nn aspirin nn and cc heparin nn have vbp been vbn administered vbn concomitantly rb with inpos and cc following vbg infusions nns of inpos activase nn in inpos the dt management nn of inpos acute jj myocardial jj infarction nn or cc pulmonary jj embolism nn
false	4	10	use nn of inpos antithrombotics nn aspirin nn and cc heparin nn have vbp been vbn administered vbn concomitantly rb with inpos and cc following vbg infusions nns of inpos activase nn in inpos the dt management nn of inpos acute jj myocardial jj infarction nn or cc pulmonary jj embolism nn
false	4	30	use nn of inpos antithrombotics nn aspirin nn and cc heparin nn have vbp been vbn administered vbn concomitantly rb with inpos and cc following vbg infusions nns of inpos activase nn in inpos the dt management nn of inpos acute jj myocardial jj infarction nn or cc pulmonary jj embolism nn
false	6	10	use nn of inpos antithrombotics nns aspirin nn and cc heparin nn have vbp been vbn administered vbn concomitantly rb with inpos and cc following vbg infusions nns of inpos activase nn in inpos the dt management nn of inpos acute jj myocardial jj infarction nn or cc pulmonary jj embolism nn
false	6	30	use nn of inpos antithrombotics nns aspirin nn and cc heparin nn have vbp been vbn administered vbn concomitantly rb with inpos and cc following vbg infusions nns of inpos activase nn in inpos the dt management nn of inpos acute jj myocardial jj infarction nn or cc pulmonary jj embolism nn
false	10	30	use nn of inpos antithrombotics nnp aspirin nnp and cc heparin nn have vbp been vbn administered vbn concomitantly rb with inpos and cc following vbg infusions nns of inpos activase nn in inpos the dt management nn of inpos acute jj myocardial jj infarction nn or cc pulmonary jj embolism nn
false	8	12	the dt concomitant jj use nn of inpos heparin nn or cc aspirin nn during inpos the dt first jj num cd hours nns following vbg symptom nn onset nn were vbd prohibited vbn in inpos the dt ninds nn t_pa nn stroke nnp trial nnp
effect	6	10	concurrent jj administration nn of inpos hexalen nn and cc antidepressants_of_the_mao_inhibitor_class nn may md cause vb severe jj orthostatic jj hypotension.cimetidine nn an dt inhibitor nn of inpos microsomal jj drug nn metabolism nn increased vbn altretamines nns half_life nn toxicity nn in inpos a dt rat nn model nn
false	6	22	concurrent jj administration nn of inpos hexalen nn and cc antidepressants_of_the_mao_inhibitor_class nn may md cause vb severe jj orthostatic jj hypotension. nn cimetidine nn an dt inhibitor nn of inpos microsomal jj drug nn metabolism nn increased vbn altretamines nns half_life nn toxicity nn in inpos a dt rat nn model nn
false	6	36	concurrent jj administration nn of inpos hexalen nn and cc antidepressants_of_the_mao_inhibitor_class nn may md cause vb severe jj orthostatic jj hypotension.cimetidine nn an dt inhibitor nn of inpos microsomal jj drug nn metabolism nn increased vbn altretamine nn s vbz half_life nn and cc toxicity nn in inpos a dt rat nn model nn
false	10	22	concurrent jj administration nn of inpos hexalen nn and cc antidepressants_of_the_mao_inhibitor_class nn may md cause vb severe jj orthostatic jj hypotension. nn cimetidine nn an dt inhibitor nn of inpos microsomal jj drug nn metabolism nn increased vbn altretamines nns half_life nn toxicity nn in inpos a dt rat nn model nn
false	10	36	concurrent jj administration nn of inpos hexalen nn and cc antidepressants_of_the_mao_inhibitor_class nn may md cause vb severe jj orthostatic jj hypotension.cimetidine nn an dt inhibitor nn of inpos microsomal jj drug nn metabolism nn increased vbn altretamine nn s vbz half_life nn and cc toxicity nn in inpos a dt rat nn model nn
mechanism	22	38	concurrent jj administration nn of inpos hexalen nn and cc antidepressants_of_the_mao_inhibitor_class nn may md cause vb severe jj orthostatic jj hypotension. nn cimetidine nn an dt inhibitor nn of inpos microsomal jj drug nn metabolism nn increased vbn altretamine nn s vbz half_life nn and cc toxicity nn in inpos a dt rat nn model nn
effect	12	16	data nns from inpos a dt randomized vbn trial nn of inpos hexalen nn and cc cisplatin nn plus cc or cc minus cc pyridoxine nn in inpos ovarian jj cancer nn indicated vbd that inpos pyridoxine nn significantly rb reduced vbd neurotoxicity nn
false	12	24	data nns from inpos a dt randomized vbn trial nn of inpos hexalen nn and cc cisplatin nn plus cc or cc minus cc pyridoxine nn in inpos ovarian jj cancer nn indicated vbd that inpos pyridoxine nn significantly rb reduced vbd neurotoxicity nn
false	12	24	data nns from inpos a dt randomized vbn trial nn of inpos hexalen nn and cc cisplatin nn plus cc or cc minus cc pyridoxine nn in inpos ovarian jj cancer nn indicated vbd that inpos pyridoxine nn significantly rb reduced vbd neurotoxicity nn
false	16	24	data nns from inpos a dt randomized vbn trial nn of inpos hexalen nn and cc cisplatin nn plus cc or cc minus cc pyridoxine nn in inpos ovarian jj cancer nn indicated vbd that inpos pyridoxine nn significantly rb reduced vbd neurotoxicity nn
false	16	24	data nns from inpos a dt randomized vbn trial nn of inpos hexalen nn and cc cisplatin nn plus cc or cc minus cc pyridoxine nn in inpos ovarian jj cancer nn indicated vbd that inpos pyridoxine nn significantly rb reduced vbd neurotoxicity nn
advise	16	28	however rb it prp adversely rb affected vbd response nn duration nn suggesting vbg that inpos pyridoxine nn should md not rb be vb administered vbn with inpos hexalen nn and_or cc cisplatin.1 nn
advise	16	32	however rb it prp adversely rb affected vbd response nn duration nn suggesting vbg that inpos pyridoxine nn should md not rb be vb administered vbn with inpos hexalen nn and_or cc cisplatin nn
false	28	32	however rb it prp adversely rb affected vbd response nn duration nn suggesting vbg that inpos pyridoxine nn should md not rb be vb administered vbn with inpos hexalen nn and_or cc cisplatin nn
advise	10	20	careful jj observation nn is vbz required vbn when wrb amantadine nn is vbz administered vbn concurrently rb with inpos central_nervous_system_stimulants nn
advise	18	26	special jj consideration nn should md be vb given vbn to topos the dt administration nn of inpos ethyol nn in inpos patients nns receiving vbg antihypertensive_medications nn or cc other jj drugs nns that wdt could md cause vb or cc potentiate vb hypotension nn
effect	2	16	when wrb amiloride nn hcl nn is vbz administered vbn concomitantly rb with inpos an dt angiotensin_converting_enzyme_inhibitor nn the dt risk nn of inpos hyperkalemia nn may md be vb increased vbn
advise	0	14	lithium nn generally rb should md not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp its prp renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
effect	14	22	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt loop nn
effect	14	22	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt potassium_sparing nn
effect	14	22	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt thiazide_diuretics nn
false	32	38	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
false	34	38	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
advise	4	8	therefore rb when wrb midamor nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic jj is vbz obtained vbn
false	4	44	therefore rb when wrb midamor nn and cc non_steroidal_anti_inflammatory_agents nns are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
false	8	44	therefore rb when wrb midamor nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
effect	2	6	since inpos indomethacin nn and cc potassium_sparing_diuretics nn including vbg midamor nn may md each dt be vb associated vbn with inpos increased vbn serum nn potassium nn levels nns the dt potential jj effects nns on inpos potassium nn kinetics nns and cc renal jj function nn should md be vb considered vbn when wrb these dt agents nns are vbp administered vbn concurrently rb
effect	2	10	since inpos indomethacin nn and cc potassium_sparing_diuretics nns including vbg midamor nn may md each dt be vb associated vbn with inpos increased vbn serum nn potassium nn levels nns the dt potential jj effects nns on inpos potassium nn kinetics nns and cc renal jj function nn should md be vb considered vbn when wrb these dt agents nns are vbp administered vbn concurrently rb
false	6	10	since inpos indomethacin nn and cc potassium_sparing_diuretics nn including vbg midamor nn may md each dt be vb associated vbn with inpos increased vbn serum nn potassium nn levels nns the dt potential jj effects nns on inpos potassium nn kinetics nns and cc renal jj function nn should md be vb considered vbn when wrb these dt agents nns are vbp administered vbn concurrently rb
mechanism	0	10	cytadren nn accelerates vbz the dt metabolism nn of inpos dexamethasone nn
false	4	12	therefore rb if inpos glucocorticoid nn replacement nn is vbz needed vbn hydrocortisone nn should md be vb prescribed vbn
effect	0	10	aminoglutethimide nn diminishes vbz the dt effect nn of inpos coumarin nn and cc warfarin nn
effect	0	14	aminoglutethimide nn diminishes vbz the dt effect nn of inpos coumarin nn and cc warfarin nn
false	10	14	aminoglutethimide nn diminishes vbz the dt effect nn of inpos coumarin nn and cc warfarin nn
effect	8	32	renal jj clearance nn measurements nns of inpos pah nn can md not rb be vb made vbn with inpos any dt significant jj accuracy nn in inpos patients nns receiving vbg sulfonamides nn
effect	8	32	renal jj clearance nn measurements nns of inpos pah nn can md not rb be vb made vbn with inpos any dt significant jj accuracy nn in inpos patients nns receiving vbg procaine nn
effect	8	32	renal jj clearance nn measurements nns of inpos pah nn can md not rb be vb made vbn with inpos any dt significant jj accuracy nn in inpos patients nns receiving vbg thiazolesulfone nn
mechanism	0	20	probenecid nn depresses vbz tubular jj secretion nn of inpos certain jj weak jj acids nns such jj as inpos pah nn
effect	6	22	therefore rb patients nns receiving vbg probenecid nn will md have vb erroneously rb low jj erpf nn and cc tm nn pah nn values nns
false	20	26	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known vbn photosensitizing_agents nn such jj as inpos griseofulvin nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
false	20	26	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known vbn photosensitizing_agents nn such jj as inpos thiazide_diuretics nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
false	20	26	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known vbn photosensitizing_agents nn such jj as inpos sulfonylureas nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
false	20	26	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known vbn photosensitizing_agents nn such jj as inpos phenothiazines nns and cc tetracyclines nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
false	20	26	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known vbn photosensitizing_agents nn such jj as inpos sulfonamides nn and cc tetracyclines nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
false	20	38	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known vbn photosensitizing_agents nn such jj as inpos griseofulvin nn thiazide_diuretics nns sulfonylureas nns phenothiazines nns sulfonamides nns and cc tetracyclines nn might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
effect	20	60	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known vbn photosensitizing_agents nn such jj as inpos griseofulvin nn thiazide_diuretics nns sulfonylureas nns phenothiazines nns sulfonamides nns tetracyclines nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
effect	20	44	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known jj griseofulvin nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
effect	20	44	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known jj thiazide_diuretics nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
effect	20	44	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known jj sulfonylureas nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
effect	20	44	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known jj phenothiazines nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
false	34	38	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known jj photosensitizing_agents nns such jj as inpos griseofulvin nn thiazide_diuretics nns sulfonylureas nns phenothiazines nns sulfonamides nn and cc tetracyclines nn might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
effect	26	50	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known jj photosensitizing_agents nns such jj as inpos sulfonamides nns might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
effect	20	44	it prp is vbz however rb possible jj that inpos concomitant jj use nn of inpos other jj known jj tetracyclines nn might md increase vb the dt photosensitivity nn reaction nn of inpos actinic jj keratoses nns treated vbn with inpos the dt levulan_kerastick nn for inpos topical nnp solution nnp
mechanism	0	12	aminosalicylic_acid nn may md decrease vb the dt amount nn of inpos digoxin nn that wdt gets vbz absorbed vbn into inpos your prp body nn
mechanism	0	12	aminosalicylic_acid nn may md decrease vb the dt amount nn of inpos lanoxin nn that wdt gets vbz absorbed vbn into inpos your prp body nn
false	0	12	aminosalicylic_acid nn may md decrease vb the dt amount nn of inpos lanoxicaps nn that wdt gets vbz absorbed vbn into inpos your prp body nn
advise	14	20	in inpos the dt case nn that inpos you prp are vbp taking vbg digoxin nn while inpos taking vbg aminosalicylic_acid nn higher jjr doses nns of inpos digoxin nn may md be vb needed vbn
false	20	14	in inpos the dt case nn that inpos you prp are vbp taking vbg digoxin nn while inpos taking vbg aminosalicylic_acid nn higher jjr doses nns of inpos digoxin nn may md be vb needed vbn
mechanism	0	14	aminosalicylic_acid nn may md also rb decrease vb the dt absorption nn of inpos vitamin_b12 nn which wdt can md lead vb to topos a dt deficiency nn
advise	14	22	therefore rb you prp may md need vb to topos take vb a dt vitamin_b12 nn supplement nn while inpos taking vbg aminosalicylic_acid nn
mechanism	14	22	a dt case nn report nn of inpos num cd patient nn taking vbg amiodarone nn num cd mg nn and cc indinavir nn num cd mg nn num cd times nns a dt day nn resulted vbd in inpos increases nns in inpos amiodarone nn concentrations nns from inpos float cd mg_l nn to topos float cd mg_l nn
false	22	14	a dt case nn report nn of inpos num cd patient nn taking vbg amiodarone nn num cd mg nn and cc indinavir nn num cd mg nn num cd times nns a dt day nn resulted vbd in inpos increases nns in inpos amiodarone nn concentrations nns from inpos float cd mg_l nn to topos float cd mg_l nn
false	4	26	monitoring vbg for inpos amiodarone nn toxicity nn and cc serial jj measurement nn of inpos amiodarone nn serum nn concentration nn during inpos concomitant jj protease_inhibitor nn therapy nn should md be vb considered vbn
advise	4	26	monitoring vbg for inpos amiodarone nn toxicity nn and cc serial jj measurement nn of inpos amiodarone nn serum nn concentration nn during inpos concomitant jj protease_inhibitor nn therapy nn should md be vb considered vbn
false	0	14	cimetidine nn inhibits vbz cyp3a4 nn and cc can md increase vb serum nn amiodarone nn levels nns
false	0	14	amiodarone nn may md suppress vb certain jj cyp450 nn enzymes nns including vbg cyp1a2 nn
false	0	14	amiodarone nn may md suppress vb certain jj cyp450 nn enzymes nns including vbg cyp2c9 nn
false	0	14	amiodarone nn may md suppress vb certain jj cyp450 nn enzymes nns including vbg cyp2d6 nn
false	0	14	amiodarone nn may md suppress vb certain jj cyp450 nn enzymes nns including vbg cyp3a4 nn
false	0	12	cyclosporine nn administered vbn in inpos combination nn with inpos oral jj amiodarone nn has vbz been vbn reported vbn to topos produce vb persistently rb elevated vbn plasma nn concentrations nns of inpos cyclosporine nn resulting vbg in inpos elevated jj creatinine nn despite inpos reduction nn in inpos dose nn of inpos cyclosporine nn
false	0	12	cyp3a4 nn administered vbn in inpos combination nn with inpos oral jj amiodarone nn has vbz been vbn reported vbn to topos produce vb persistently rb elevated vbn plasma nn concentrations nns of inpos cyclosporine nn resulting vbg in inpos elevated jj creatinine nn despite inpos reduction nn in inpos dose nn of inpos cyclosporine nn
false	0	34	cyp3a4 nn administered vbn in inpos combination nn with inpos oral jj amiodarone nn has vbz been vbn reported vbn to topos produce vb persistently rb elevated vbn plasma nn concentrations nns of inpos cyclosporine nn resulting vbg in inpos elevated jj creatinine nn despite inpos reduction nn in inpos dose nn of inpos cyclosporine nn
false	0	34	cyp3a4 nn administered vbn in inpos combination nn with inpos oral jj amiodarone nn has vbz been vbn reported vbn to topos produce vb persistently rb elevated vbn plasma nn concentrations nns of inpos cyclosporine nn resulting vbg in inpos elevated jj creatinine nn despite inpos reduction nn in inpos dose nn of inpos cyclosporine nn
false	12	0	cyclosporine nn administered vbn in inpos combination nn with inpos oral jj amiodarone nn has vbz been vbn reported vbn to topos produce vb persistently rb elevated vbn plasma nn concentrations nns of inpos cyclosporine nn resulting vbg in inpos elevated jj creatinine nn despite inpos reduction nn in inpos dose nn of inpos cyclosporine nn
false	12	0	cyclosporine nn administered vbn in inpos combination nn with inpos oral jj amiodarone nn has vbz been vbn reported vbn to topos produce vb persistently rb elevated vbn plasma nn concentrations nns of inpos cyclosporine nn resulting vbg in inpos elevated jj creatinine nn despite inpos reduction nn in inpos dose nn of inpos cyclosporine nn
false	0	8	simvastatin nn in inpos combination nn with inpos amiodarone nn has vbz been vbn associated vbn with inpos reports nns of inpos myopathy nn
false	0	8	cyp3a4 nn in inpos combination nn with inpos amiodarone nn has vbz been vbn associated vbn with inpos reports nns of inpos myopathy nn
false	6	16	in inpos patients nns receiving vbg digoxin nn therapy nn administration nn of inpos oral jj amiodarone nn regularly rb results vbz in inpos an dt increase nn in inpos serum nn digoxin nn concentration nn that wdt may md reach vb toxic jj levels nns with inpos resultant jj clinical jj toxicity nn
false	16	6	in inpos patients nns receiving vbg digoxin nn therapy nn administration nn of inpos oral jj amiodarone nn regularly rb results vbz in inpos an dt increase nn in inpos serum nn digoxin nn concentration nn that wdt may md reach vb toxic jj levels nns with inpos resultant jj clinical jj toxicity nn
false	0	8	amiodarone nn taken vbn concomitantly rb with inpos digoxin nn increases vbz the dt serum nn digoxin nn concentration nn by inpos num cd after inpos num cd day nn
false	0	8	amiodarone nn taken vbn concomitantly rb with inpos digoxin nn increases vbz the dt serum nn digoxin nn concentration nn by inpos num cd after inpos num cd day nn
advise	8	16	on inpos administration nn of inpos oral jj amiodarone nn the dt need nn for inpos digitalis nn therapy nn should md be vb reviewed vbn the dt dose nn reduced vbn by inpos approximately rb num cd discontinued vbn
false	0	12	antiarrhythmics nn other jj antiarrhythmic jj drugs nns such jj as inpos quinidine nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	12	antiarrhythmics nn other jj antiarrhythmic jj drugs nns such jj as inpos procainamide nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	12	antiarrhythmics nn other jj antiarrhythmic jj drugs nns such jj as inpos disopyramide nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	12	antiarrhythmics nn other jj antiarrhythmic jj drugs nns such jj as inpos phenytoin nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	30	antiarrhythmics nn other jj antiarrhythmic jj drugs nns such jj as inpos quinidine nn procainamide nn disopyramide nn phenytoin nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	12	antiarrhythmics nns other jj antiarrhythmic nn drugs nns such jj as inpos quinidine nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	12	antiarrhythmics nns other jj antiarrhythmic nn drugs nns such jj as inpos procainamide nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	12	antiarrhythmics nns other jj antiarrhythmic nn drugs nns such jj as inpos disopyramide nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	12	antiarrhythmics nns other jj antiarrhythmic nn drugs nns such jj as inpos phenytoin nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	0	30	antiarrhythmics nns other jj antiarrhythmic nn drugs nns such jj as inpos quinidine nn procainamide nn disopyramide nn phenytoin nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	12	24	antiarrhythmics nns other jj antiarrhythmic jj drugs nns such jj as inpos quinidine nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	12	24	antiarrhythmics nns other jj antiarrhythmic jj drugs nns such jj as inpos procainamide nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	12	24	antiarrhythmics nns other jj antiarrhythmic jj drugs nns such jj as inpos disopyramide nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	12	24	antiarrhythmics nns other jj antiarrhythmic jj drugs nns such jj as inpos phenytoin nn have vbp been vbn used vbn concurrently rb with inpos amiodarone nn
false	20	30	there ex have vbp been vbn case nn reports nns of inpos increased vbn steady_state jj levels nns of inpos quinidine nn during inpos concomitant jj therapy nn with inpos amiodarone nn
false	20	30	there ex have vbp been vbn case nn reports nns of inpos increased vbn steady_state jj levels nns of inpos procainamide nn during inpos concomitant jj therapy nn with inpos amiodarone nn
false	20	30	there ex have vbp been vbn case nn reports nns of inpos increased vbn steady_state jj levels nns of inpos phenytoin nn during inpos concomitant jj therapy nn with inpos amiodarone nn
false	0	8	amiodarone nn taken vbn concomitantly rb with inpos quinidine nn increases vbz quinidine nn serum nn concentration nn by inpos num cd after inpos num cd days nns
false	0	8	amiodarone nn taken vbn concomitantly rb with inpos quinidine nn increases vbz quinidine nn serum nn concentration nn by inpos num cd after inpos num cd days nns
false	0	8	amiodarone nn taken vbn concomitantly rb with inpos procainamide nn for inpos less jjr than inpos num cd days nns increases vbz plasma nn concentrations nns of inpos procainamide nn and cc n_acetyl nn procainamide nn by inpos num cd and cc num cd respectively rb
false	0	8	amiodarone nn taken vbn concomitantly rb with inpos procainamide nn for inpos less jjr than inpos num cd days nns increases vbz plasma nn concentrations nns of inpos procainamide nn and cc n_acetyl nn procainamide nn by inpos num cd and cc num cd respectively rb
false	0	8	amiodarone nn taken vbn concomitantly rb with inpos procainamide nn for inpos less jjr than inpos num cd days nns increases vbz plasma nn concentrations nns of inpos procainamide nn and cc n_acetyl nn procainamide nn by inpos num cd and cc num cd respectively rb
false	0	28	quinidine nn and cc procainamide nn doses nns should md be vb reduced vbn by inpos one_third nn when wrb either cc is vbz administered vbn with inpos amiodarone nn
false	6	28	plasma nn levels nns of inpos flecainide nn have vbp been vbn reported vbn to topos increase vb in inpos the dt presence nn of inpos oral jj amiodarone nn
false	12	24	because inpos of inpos this dt the dt dosage nn of inpos flecainide nn should md be vb adjusted vbn when wrb these dt drugs nn are vbp administered vbn concomitantly rb
false	4	10	combination nn of inpos amiodarone nn with inpos other jj antiarrhythmic nn therapy nn should md be vb reserved vbn for inpos patients nns with inpos life_threatening jj ventricular jj arrhythmias nns who wp are vbp incompletely rb responsive jj to topos a dt single jj agent nn or cc incompletely rb responsive jj to topos amiodarone nn
false	10	4	combination nn of inpos amiodarone nn with inpos other jj antiarrhythmic nn therapy nn should md be vb reserved vbn for inpos patients nns with inpos life_threatening jj ventricular jj arrhythmias nns who wp are vbp incompletely rb responsive jj to topos a dt single jj agent nn or cc incompletely rb responsive jj to topos amiodarone nn
false	12	30	the dt continued vbn need nn for inpos the dt other jj antiarrhythmic nn agent nn should md be vb reviewed vbn after inpos the dt effects nns of inpos amiodarone nn have vbp been vbn established vbn and cc discontinuation nn ordinarily rb should md be vb attempted vbn
false	2	14	in inpos amiodarone nn treated jj patients nns who wp require vbp additional jj antiarrhythmic nn therapy nn the dt initial jj dose nn of inpos such jj agents nns should md be vb approximately rb half dt of inpos the dt usual jj recommended vbn dose nn
false	0	18	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg agents nns or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	0	22	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg propranolol nn or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	0	22	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg cyp3a4 nn or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	0	26	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	0	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn verapamil nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	0	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	0	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn diltiazem nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	0	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	18	22	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg propranolol nn or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	18	22	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg cyp3a4 nn or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	18	26	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg agents nns or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	18	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg agents nns or cc calcium_channel nn verapamil nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	18	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg agents nns or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	18	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg agents nns or cc calcium_channel nn diltiazem nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	18	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hyph_receptor nn blocking vbg agents nns or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	26	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg propranolol nn or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg propranolol nn or cc calcium_channel nn verapamil nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg propranolol nn or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg propranolol nn or cc calcium_channel nn diltiazem nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg propranolol nn or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	26	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg cyp3a4 nn or cc calcium_channel nn antagonists nns because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg cyp3a4 nn or cc calcium_channel nn verapamil nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	22	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg cyp3a4 nn or cc calcium_channel nn diltiazem nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	26	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn verapamil nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	26	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	26	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn diltiazem nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	26	28	amiodarone nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg receptor nn blocking vbg agents nns or cc calcium_channel nn cyp3a4 nn because inpos of inpos the dt possible jj potentiation nn of inpos bradycardia nn sinus nn arrest nn av nn block nn
false	4	6	potentiation nn of inpos warfarin nn cyp2c9 nn anticoagulant jj response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	4	6	potentiation nn of inpos warfarin nn cyp3a4 nn anticoagulant jj response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	4	8	potentiation nn of inpos warfarin nn type jj anticoagulant nn response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	4	26	potentiation nn of inpos warfarin nn type jj anticoagulant jj response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	4	6	potentiation nn of inpos cyp2c9 nn anticoagulant nn response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	4	24	potentiation nn of inpos cyp2c9 nn anticoagulant jj response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	4	6	potentiation nn of inpos cyp3a4 nn anticoagulant nn response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	4	24	potentiation nn of inpos cyp3a4 nn anticoagulant jj response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	6	24	potentiation nn of inpos warfarin_type jj anticoagulant nn response nn is vbz almost rb always rb seen vbn in inpos patients nns receiving vbg amiodarone nn and cc can md result vb in inpos serious jj or cc fatal jj bleeding nn
false	10	14	since inpos the dt concomitant jj administration nn of inpos warfarin nn with inpos amiodarone nn increases vbz the dt prothrombin nn time nn by inpos num cd after inpos num cd to topos num cd days nns the dt dose nn of inpos the dt anticoagulant nn should md be vb reduced vbn by inpos one_third nn to topos one_half nn and cc prothrombin nn times nns should md be vb monitored vbn closely rb
false	10	46	since inpos the dt concomitant jj administration nn of inpos warfarin nn with inpos amiodarone nn increases vbz the dt prothrombin nn time nn by inpos num cd after inpos num cd to topos num cd days nns the dt dose nn of inpos the dt anticoagulant nn should md be vb reduced vbn by inpos one_third nn to topos one_half nn and cc prothrombin nn times nns should md be vb monitored vbn closely rb
false	14	46	since inpos the dt concomitant jj administration nn of inpos warfarin nn with inpos amiodarone nn increases vbz the dt prothrombin nn time nn by inpos num cd after inpos num cd to topos num cd days nns the dt dose nn of inpos the dt anticoagulant nn should md be vb reduced vbn by inpos one_third nn to topos one_half nn and cc prothrombin nn times nns should md be vb monitored vbn closely rb
false	2	18	some dt drugs nn are vbp known vbn to topos accelerate vb the dt metabolism nn of inpos amiodarone nn by inpos stimulating vbg the dt synthesis nn of inpos cyp3a4 nn
false	2	30	some dt drugs nn are vbp known vbn to topos accelerate vb the dt metabolism nn of inpos amiodarone nn by inpos stimulating vbg the dt synthesis nn of inpos cyp3a4 nn
false	18	30	some dt substances nns are vbp known vbn to topos accelerate vb the dt metabolism nn of inpos amiodarone nn by inpos stimulating vbg the dt synthesis nn of inpos cyp3a4 nn
false	0	12	rifampin nn is vbz a dt potent jj inducer nn of inpos cyp3a4 nn
false	4	12	administration nn of inpos rifampin nn concomitantly rb with inpos oral jj amiodarone nn has vbz been vbn shown vbn to topos result vb in inpos decreases nns in inpos serum nn concentrations nns of inpos amiodarone nn and cc desethylamiodarone nn
false	4	12	administration nn of inpos rifampin nn concomitantly rb with inpos oral jj amiodarone nn has vbz been vbn shown vbn to topos result vb in inpos decreases nns in inpos serum nn concentrations nns of inpos amiodarone nn and cc desethylamiodarone nn
false	4	40	administration nn of inpos rifampin nn concomitantly rb with inpos oral jj amiodarone nn has vbz been vbn shown vbn to topos result vb in inpos decreases nns in inpos serum nn concentrations nns of inpos amiodarone nn and cc desethylamiodarone nn
false	2	12	since inpos amiodarone nn is vbz a dt substrate nn for inpos cyp3a4 nn there ex is vbz the dt potential nn that inpos the dt use nn of inpos st nnp
false	0	8	fentanyl nn in inpos combination nn with inpos amiodarone nn may md cause vb hypotension nn bradycardia nn and cc decreased vbd cardiac jj output nn
false	0	8	cyp3a4 nn in inpos combination nn with inpos amiodarone nn may md cause vb hypotension nn bradycardia nn and cc decreased vbd cardiac jj output nn
false	14	22	sinus nnp bradycardia nn has vbz been vbn reported vbn with inpos oral jj amiodarone nn in inpos combination nn with inpos lidocaine nn given vbn for inpos local jj anesthesia nn
false	14	22	sinus nnp bradycardia nn has vbz been vbn reported vbn with inpos oral jj amiodarone nn in inpos combination nn with inpos cyp3a4 nn given vbn for inpos local jj anesthesia nn
false	14	30	sinus nnp bradycardia nn has vbz been vbn reported vbn with inpos oral jj amiodarone nn in inpos combination nn with inpos lidocaine nn given vbn for inpos local jj anesthesia nn
false	22	30	sinus nnp bradycardia nn has vbz been vbn reported vbn with inpos oral jj amiodarone nn in inpos combination nn with inpos lidocaine nn given vbn for inpos local jj anesthesia nn
false	22	30	sinus nnp bradycardia nn has vbz been vbn reported vbn with inpos oral jj amiodarone nn in inpos combination nn with inpos cyp3a4 nn given vbn for inpos local jj anesthesia nn
false	8	28	seizure nn associated vbn with inpos increased vbn lidocaine nn concentrations nns has vbz been vbn reported vbn with inpos concomitant jj administration nn of inpos intravenous jj amiodarone nn
false	0	12	dextromethorphan nn is vbz a dt substrate nn for inpos both cc cyp2d6 nn and cc cyp3a4 nn
false	0	16	dextromethorphan nn is vbz a dt substrate nn for inpos both cc cyp2d6 nn and cc cyp3a4 nn
false	12	16	dextromethorphan nn is vbz a dt substrate nn for inpos both cc cyp2d6 nn and cc cyp3a4 nn
false	0	4	amiodarone nn inhibits vbz cyp2d6 nn
false	0	10	cholestyramine nn increases vbz enterohepatic jj elimination nn of inpos amiodarone nn and cc may md reduce vb its prp serum nn levels nns and cc t1_num nn
false	0	26	cholestyramine nn increases vbz enterohepatic jj elimination nn of inpos amiodarone nn and cc may md reduce vb its prp serum nn levels nns and cc t1 nn
false	10	26	cholestyramine nn increases vbz enterohepatic jj elimination nn of inpos amiodarone nn and cc may md reduce vb its prp serum nn levels nns and cc t1 nn
false	28	32	there ex have vbp been vbn reports nns of inpos qtc nn prolongation nn with inpos or cc without inpos tdp nn in inpos patients nns taking vbg amiodarone nn when wrb fluoroquinolones nns were vbd administered vbn concomitantly rb
false	28	32	there ex have vbp been vbn reports nns of inpos qtc nn prolongation nn with inpos or cc without inpos tdp nn in inpos patients nns taking vbg amiodarone nn when wrb macrolide_antibiotics nns were vbd administered vbn concomitantly rb
false	18	28	in inpos addition nn to topos the dt interactions nns noted vbn above inpos chronic jj oral jj cordarone nn administration nn impairs vbz metabolism nn of inpos phenytoin nn
false	18	28	in inpos addition nn to topos the dt interactions nns noted vbn above inpos chronic jj oral jj cordarone nn administration nn impairs vbz metabolism nn of inpos dextromethorphan nn
false	18	28	in inpos addition nn to topos the dt interactions nns noted vbn above inpos chronic jj oral jj cordarone nn administration nn impairs vbz metabolism nn of inpos methotrexate nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn antidepressants nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn phenothiazines nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn type_1c_antiarrhythmics nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn propafenone nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn flecainide nn
false	8	12	while inpos all pdt the dt selective jj serotonin_reuptake_inhibitors nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	8	12	while inpos all pdt the dt selective jj serotonin_reuptake_inhibitors nn e.g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	8	12	while inpos all pdt the dt selective jj serotonin_reuptake_inhibitors nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	8	12	while inpos all pdt the dt selective jj ssris nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	8	12	while inpos all pdt the dt selective jj ssris nn e.g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	8	12	while inpos all pdt the dt selective jj ssris nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
effect	8	10	the dt extent nn to topos which wdt ssri nn hyph_tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbd
false	10	8	the dt extent nn to topos which wdt ssri nn tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbn
advise	16	26	nevertheless rb caution nn is vbz indicated vbn in inpos the dt coadministration nn of inpos tcas nn with inpos any dt of inpos the dt ssris nn and cc also rb in inpos switching vbg from inpos num cd class nn to topos the dt other jj
false	2	6	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	2	14	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic nn agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	2	20	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic nn drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	2	26	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	2	34	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nn of inpos dosages nns are vbp required vbn
false	6	14	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic nn agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	6	20	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic nn drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	6	26	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	6	34	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nn of inpos dosages nns are vbp required vbn
false	14	20	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic nn agents nns or cc sympathomimetic nn drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	14	26	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic nn agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	14	34	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic nn agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nn of inpos dosages nns are vbp required vbn
false	20	26	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic nn drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nns close jj supervision nn and cc careful jj adjustment nn of inpos dosages nns are vbp required vbn
false	20	34	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic nn drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nn of inpos dosages nns are vbp required vbn
false	26	34	and cc disulfiram nn when wrb amitriptyline_hcl nn is vbz given vbn with inpos anticholinergic jj agents nns or cc sympathomimetic jj drugs nns including vbg epinephrine nn combined vbn with inpos local jj anesthetics nn of inpos dosages nns are vbp required vbn
effect	10	18	hyperpyrexia nn has vbz been vbn reported vbn when wrb amitriptyline_hcl nn is vbz administered vbn with inpos anticholinergic nn agents nns with inpos neuroleptic jj drugs nns particularly rb during inpos hot jj weather nn
false	10	24	hyperpyrexia nn has vbz been vbn reported vbn when wrb amitriptyline_hcl nn is vbz administered vbn with inpos anticholinergic jj agents nns with inpos neuroleptic nn drugs nns particularly rb during inpos hot jj weather nn
false	18	24	hyperpyrexia nn has vbz been vbn reported vbn when wrb amitriptyline_hcl nn is vbz administered vbn with inpos anticholinergic nn agents nns with inpos neuroleptic nn drugs nns particularly rb during inpos hot jj weather nn
effect	14	22	paralytic jj ileus nn may md occur vb in inpos patients nns taking vbg tricyclic_antidepressants nn in inpos combination nn with inpos anticholinergic nn type jj drugs nns
mechanism	0	18	cimetidine nn is vbz reported vbn to topos reduce vb hepatic jj metabolism nn of inpos certain jj tricyclic_antidepressants nn thereby rb delaying vbg elimination nn and cc increasing vbg steady_state jj concentrations nns of inpos these dt drugs nns
false	0	38	cimetidine nn is vbz reported vbn to topos reduce vb hepatic jj metabolism nn of inpos certain jj tricyclic_antidepressants nns thereby rb delaying vbg elimination nn and cc increasing vbg steady_state jj concentrations nns of inpos these dt drugs nn
false	18	38	cimetidine nn is vbz reported vbn to topos reduce vb hepatic jj metabolism nn of inpos certain jj tricyclic_antidepressants nn thereby rb delaying vbg elimination nn and cc increasing vbg steady_state jj concentrations nns of inpos these dt drugs nn
effect	16	26	clinically rb significant jj effects nns have vbp been vbn reported vbn with inpos the dt tricyclic_antidepressants nn when wrb used vbn concomitantly rb with inpos cimetidine nn
false	10	32	increases nns in inpos plasma nn levels nns of inpos tricyclic_antidepressants nn and cc in inpos the dt frequency nn and cc severity nn of inpos side nn effects nns particularly rb anticholinergic nn have vbp been vbn reported vbn when wrb cimetidine nn was vbd added vbn to topos the dt drug nn regimen nn
mechanism	10	42	increases nns in inpos plasma nn levels nns of inpos tricyclic_antidepressants nn and cc in inpos the dt frequency nn and cc severity nn of inpos side nn effects nns particularly rb anticholinergic jj have vbp been vbn reported vbn when wrb cimetidine nn was vbd added vbn to topos the dt drug nn regimen nn
false	10	52	increases nns in inpos plasma nn levels nns of inpos tricyclic_antidepressants nn and cc in inpos the dt frequency nn and cc severity nn of inpos side nn effects nns particularly rb anticholinergic jj have vbp been vbn reported vbn when wrb cimetidine nn was vbd added vbn to topos the dt drug nn regimen nn
false	32	42	increases nns in inpos plasma nn levels nns of inpos tricyclic_antidepressants nns and cc in inpos the dt frequency nn and cc severity nn of inpos side nn effects nns particularly rb anticholinergic nn have vbp been vbn reported vbn when wrb cimetidine nn was vbd added vbn to topos the dt drug nn regimen nn
false	32	52	increases nns in inpos plasma nn levels nns of inpos tricyclic_antidepressants nns and cc in inpos the dt frequency nn and cc severity nn of inpos side nn effects nns particularly rb anticholinergic nn have vbp been vbn reported vbn when wrb cimetidine nn was vbd added vbn to topos the dt drug nn regimen nn
false	42	52	increases nns in inpos plasma nn levels nns of inpos tricyclic_antidepressants nns and cc in inpos the dt frequency nn and cc severity nn of inpos side nn effects nns particularly rb anticholinergic jj have vbp been vbn reported vbn when wrb cimetidine nn was vbd added vbn to topos the dt drug nn regimen nn
false	4	14	discontinuation nn of inpos cimetidine nn in inpos well_controlled jj patients nns receiving vbg tricyclic_antidepressants nn and cc cimetidine nn may md decrease vb the dt plasma nn levels nns and cc efficacy nn of inpos the dt antidepressants nns
false	4	14	discontinuation nn of inpos cimetidine nn in inpos well_controlled jj patients nns receiving vbg tricyclic_antidepressants nns and cc cimetidine nn may md decrease vb the dt plasma nn levels nns and cc efficacy nn of inpos the dt antidepressants nn
mechanism	14	4	discontinuation nn of inpos cimetidine nn in inpos well_controlled jj patients nns receiving vbg tricyclic_antidepressants nn and cc cimetidine nn may md decrease vb the dt plasma nn levels nns and cc efficacy nn of inpos the dt antidepressants nns
false	4	14	discontinuation nn of inpos cimetidine nn in inpos well_controlled jj patients nns receiving vbg tricyclic_antidepressants nns and cc cimetidine nn may md decrease vb the dt plasma nn levels nns and cc efficacy nn of inpos the dt antidepressants nn
effect	28	40	transient jj delirium nn has vbz been vbn reported vbn in inpos patients nns who wp were vbd treated vbn with inpos num cd gram nn of inpos ethchlorvynol nn and cc num cd hyph_num cd mg nn of inpos amitriptyline_hcl nn
effect	18	20	when wrb administered vbn concurrently rb the dt following vbg drugs nns may md interact vb with inpos amphotericin_b nn antineoplastic_agents nn may md enhance vb the dt potential nn for inpos renal jj toxicity nn bronchospasm nn hypotension nn
false	0	4	corticosteroids nn and cc corticotropin nn may md potentiate vb amphotericin_b nn induced jj hypokalemia nn which wdt may md predispose vb the dt patient nn to topos cardiac jj dysfunction nn
false	0	4	corticosteroids nn and cc acth nn may md potentiate vb amphotericin_b nn induced jj hypokalemia nn which wdt may md predispose vb the dt patient nn to topos cardiac jj dysfunction nn
effect	0	10	corticosteroids nn and cc corticotropin nn may md potentiate vb amphotericin_b nn hyph_induced vbn hypokalemia nn which wdt may md predispose vb the dt patient nn to topos cardiac jj dysfunction nn
effect	4	10	corticosteroids nns and cc corticotropin nn may md potentiate vb amphotericin_b nn hyph_induced vbn hypokalemia nn which wdt may md predispose vb the dt patient nn to topos cardiac jj dysfunction nn
effect	4	10	corticosteroids nns and cc acth nn may md potentiate vb amphotericin_b nn hyph_induced vbn hypokalemia nn which wdt may md predispose vb the dt patient nn to topos cardiac jj dysfunction nn
false	0	2	digitalis_glycosides nn amphotericin_b nn induced jj hypokalemia nn may md potentiate vb digitalis nn toxicity nn
effect	2	0	digitalis_glycosides nnp amphotericin_b nn induced jj hypokalemia nn may md potentiate vb digitalis nn toxicity nn
false	0	12	flucytosine nn while inpos a dt synergistic jj relationship nn with inpos amphotericin_b nn has vbz been vbn reported vbn concomitant jj use nn may md increase vb the dt toxicity nn of inpos flucytosine nn by inpos possibly rb increasing vbg its prp cellular jj uptake nn and_or cc impairing vbg its prp renal jj excretion nn
effect	12	0	flucytosine nn while inpos a dt synergistic jj relationship nn with inpos amphotericin_b nn has vbz been vbn reported vbn concomitant jj use nn may md increase vb the dt toxicity nn of inpos flucytosine nn by inpos possibly rb increasing vbg its prp cellular jj uptake nn and_or cc impairing vbg its prp renal jj excretion nn
false	0	20	imidazoles nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	imidazoles nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	ketoconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	ketoconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nn suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	ketoconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nn may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	ketoconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	miconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	miconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nn suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	miconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nn may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	miconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	clotrimazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	clotrimazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nn suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	clotrimazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nn may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	clotrimazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	fluconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	fluconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nn suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	24	fluconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nn may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	fluconazole nn in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	20	0	imidazoles nns in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nn suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	20	0	imidazoles nns in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nn may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	20	imidazoles nns in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nn suggest vbp that inpos imidazoles nns may md induce vb fungal jj resistance nn to topos amphotericin_b nn
effect	0	20	imidazoles nns in fw vitro fw and cc animal nn studies nns with inpos the dt combination nn of inpos amphotericin_b nn and cc imidazoles nns suggest vbp that inpos imidazoles nn may md induce vb fungal jj resistance nn to topos amphotericin_b nn
false	0	2	skeletal_muscle_relaxants nn amphotericin_b nn induced jj hypokalemia nn may md enhance vb the dt curariform jj effect nn of inpos skeletal_muscle_relaxants nns
false	0	18	skeletal_muscle_relaxants nn amphotericin_b_induced jj hypokalemia nn may md enhance vb the dt curariform jj effect nn of inpos tubocurarine nn
effect	2	0	skeletal_muscle_relaxants nns amphotericin_b nn induced jj hypokalemia nn may md enhance vb the dt curariform jj effect nn of inpos skeletal_muscle_relaxants nn
effect	2	20	skeletal_muscle_relaxants nns amphotericin_b nn induced jj hypokalemia nn may md enhance vb the dt curariform jj effect nn of inpos tubocurarine nn
false	0	22	leukocyte_transfusions nn acute jj pulmonary jj toxicity nn has vbz been vbn reported vbn in inpos patients nns receiving vbg intravenous jj amphotericin_b nn and cc leukocyte_transfusions nns
effect	22	0	leukocyte_transfusions nns acute jj pulmonary jj toxicity nn has vbz been vbn reported vbn in inpos patients nns receiving vbg intravenous jj amphotericin_b nn and cc leukocyte_transfusions nn
false	0	2	bacteriostatic_antibiotics nn chloramphenicol nns may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nns
false	0	2	bacteriostatic_antibiotics nn erythromycins nns may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nns
false	0	2	bacteriostatic_antibiotics nn sulfonamides nns may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nns
false	0	2	bacteriostatic_antibiotics nn tetracyclines nn may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nns
false	0	24	bacteriostatic_antibiotics nn chloramphenicol nn erythromycins nns sulfonamides nns tetracyclines nns may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nn
effect	2	18	bacteriostatic_antibiotics nns chloramphenicol nns may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nn
effect	2	18	bacteriostatic_antibiotics nns erythromycins nns may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nn
effect	2	18	bacteriostatic_antibiotics nns sulfonamides nns may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nn
effect	2	18	bacteriostatic_antibiotics nns tetracyclines nn may md interfere vb with inpos the dt bactericidal jj effect nn of inpos penicillins nn
mechanism	0	14	probenecid nn may md decrease vb renal jj tubular jj secretion nn of inpos ampicillin nn resulting vbg in inpos increased vbn blood nn levels nns and_or cc ampicillin nn toxicity nn
false	0	14	probenecid nn may md decrease vb renal jj tubular jj secretion nn of inpos ampicillin nn resulting vbg in inpos increased vbn blood nn levels nns and_or cc ampicillin nn toxicity nn
false	12	36	drug_laboratory nnp test nnp interaction nnp after inpos treatment nn with inpos ampicillin nn a dt false_positive jj reaction nn for inpos glucose nn in inpos the dt urine nn may md occur vb with inpos copper_sulfate nn tests nns but cc not rb with inpos enzyme nn based vbn tests nns such jj as inpos clinistix nnp and cc glucose nnp enzymatic nnp test nnp strip nnp usp nnp
false	6	20	the dt effect nn of inpos amprenavir nn on inpos total jj drug nn concentrations nns of inpos other jj hiv_protease_inhibitors nn in inpos subjects nns receiving vbg both dt agents nns was vbd evaluated vbn using vbg comparisons nns to topos historical jj data nns
mechanism	0	28	indinavir nn steady_state jj cmax nn a.c. nnp cmin nn were vbd decreased vbn by inpos num cd num cd num cd respectively rb by inpos concomitant jj amprenavir nn
mechanism	0	30	saquinavir nn steady_state jj cmax nn a.c. nnp cmin nn were vbd increased vbn num cd decreased vbd num cd decreased vbd num cd respectively rb by inpos concomitant jj amprenavir nn
mechanism	0	28	nelfinavir nn steady_state jj cmax nn a.c. nnp cmin nn were vbd increased vbn by inpos num cd num cd num cd respectively rb by inpos concomitant jj amprenavir nn
false	0	6	methadone nn coadministration nn of inpos amprenavir nn and cc methadone nn can md decrease vb plasma nn levels nns of inpos methadone nn
effect	4	8	coadministration nn of inpos amprenavir nn and cc methadone nn can md decrease vb plasma nn levels nns of inpos methadone nn
false	4	8	coadministration nn of inpos amprenavir nn and cc methadone nn can md decrease vb plasma nn levels nns of inpos methadone nn
mechanism	4	8	coadministration nn of inpos amprenavir nn and cc methadone nn as inpos compared vbn to topos a dt non_matched jj historicalcontrol nn group nn resulted vbd in inpos a dt num cd num cd num cd decrease nn in inpos serum nn amprenavir nn auc nn cmax nn andcmin nn respectively rb
false	8	4	coadministration nn of inpos amprenavir nn and cc methadone nn as inpos compared vbn to topos a dt non_matched jj historicalcontrol nn group nn resulted vbd in inpos a dt num cd num cd num cd decrease nn in inpos serum nn amprenavir nn auc nn cmax nn andcmin nn respectively rb
effect	6	12	the dt combination nn of inpos amprenavir nn and cc low_dose jj ritonavir nn has vbz been vbn associated vbn with inpos elevations nns of inpos cholesterol nn triglycerides nns sgot nn sgpt nn in inpos some dt patients nns
advise	24	28	appropriate jj laboratory nn testing nn should md be vb considered vbn prior jj to topos initiating vbg combination nn therapy nn with inpos amprenavir nn and cc ritonavir nn at inpos periodic jj intervals nns if inpos any dt clinical jj signs nns or cc symptoms nns of inpos hyperlipidemia nn or cc elevated jj liver nn function nn tests nns occur vbp during inpos therapy nn
false	18	38	for inpos comprehensive jj information nn concerning vbg laboratory nn test nn alterations nns associated vbn with inpos ritonavir nn physicians nns should md refer vb to topos the dt complete jj prescribing vbg information nn for inpos norvir nn
effect	2	8	taking vbg amyl_nitrite nn after inpos drinking vbg alcohol nn may md worsen vb side jj effects nns and cc may md cause vb severe jj hypotension nn and cc cardiovascular jj collapse nn
false	18	22	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	18	38	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	18	38	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	18	22	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	22	38	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	22	38	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	22	18	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	38	18	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	38	22	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	38	18	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	38	22	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	18	22	in fw vivo fw interaction nn studies nns in inpos humans nns have vbp demonstrated vbn that inpos digoxin nn and cc warfarin nn do vbp not rb affect vb the dt pk nn properties nns of inpos anagrelide nn nor cc does vbz anagrelide nn affect vb the dt pk nn properties nns of inpos digoxin nn or cc warfarin nn
false	32	42	although inpos additional jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn the dt most rbs common jj medications nns used vbn concomitantly rb with inpos anagrelide nn in inpos clinical jj trials nns were vbd aspirin nn
false	32	42	although inpos additional jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn the dt most rbs common jj medications nns used vbn concomitantly rb with inpos anagrelide nn in inpos clinical jj trials nns were vbd acetaminophen nn
false	32	42	although inpos additional jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn the dt most rbs common jj medications nns used vbn concomitantly rb with inpos anagrelide nn in inpos clinical jj trials nns were vbd furosemide nn
false	32	42	although inpos additional jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn the dt most rbs common jj medications nns used vbn concomitantly rb with inpos anagrelide nn in inpos clinical jj trials nns were vbd iron nn
false	32	42	although inpos additional jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn the dt most rbs common jj medications nns used vbn concomitantly rb with inpos anagrelide nn in inpos clinical jj trials nns were vbd ranitidine nn
false	32	42	although inpos additional jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn the dt most rbs common jj medications nns used vbn concomitantly rb with inpos anagrelide nn in inpos clinical jj trials nns were vbd hydroxyurea nn
false	32	42	although inpos additional jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn the dt most rbs common jj medications nns used vbn concomitantly rb with inpos anagrelide nn in inpos clinical jj trials nns were vbd allopurinol nn
false	28	48	an dt in fw vivo fw interaction nn study nn in inpos humans nns demonstrated vbd that inpos a dt single jj 1mg nn dose nn of inpos anagrelide nn administered vbn concomitantly rb with inpos a dt single jj num cd mg nn dose nn of inpos aspirin nn was vbd generally rb well rb tolerated vbn
false	12	16	no dt clinically rb relevant jj pharmacokinetic jj interactions nns between inpos anagrelide nn and cc acetylsalicylic_acid nn were vbd observed vbn
effect	0	36	anagrelide nn alone rb had vbd no dt effect nn on inpos platelet nn aggregation nn but cc did vbd slightly rb enhance vb the dt inhibition nn of inpos platelet nn aggregation nn by inpos aspirin nn
mechanism	24	48	it prp is vbz known vbn that inpos cyp1a2 nn is vbz inhibited vbn by inpos several jj medicinal jj products nns including vbg fluvoxamine nn and cc such jj medicinal jj products nns could md theoretically rb adversely rb influence vb the dt clearance nn of inpos anagrelide nn
mechanism	0	52	anagrelide nn demonstrates vbz some dt limited jj inhibitory jj activity nn towards inpos cyp1a2 nn which wdt may md present vb a dt theoretical jj potential nn for inpos interaction nn with inpos other jj coadministered vbn medicinal jj products nns sharing vbg that inpos clearance nn mechanism nn e.g. fw theophylline nn
effect	22	32	the dt effects nns of inpos medicinal jj products nns with inpos similar jj properties nns such jj as inpos inotropes nns milrinone nn may md be vb exacerbated vbn by inpos anagrelide nn
effect	22	32	the dt effects nns of inpos medicinal jj products nns with inpos similar jj properties nns such jj as inpos inotropes nns enoximone nn may md be vb exacerbated vbn by inpos anagrelide nn
effect	22	32	the dt effects nns of inpos medicinal jj products nns with inpos similar jj properties nns such jj as inpos inotropes nns amrinone nn may md be vb exacerbated vbn by inpos anagrelide nn
effect	22	32	the dt effects nns of inpos medicinal jj products nns with inpos similar jj properties nns such jj as inpos inotropes nns olprinone nn may md be vb exacerbated vbn by inpos anagrelide nn
effect	22	32	the dt effects nns of inpos medicinal jj products nns with inpos similar jj properties nns such jj as inpos inotropes nns cilostazol nn may md be vb exacerbated vbn by inpos anagrelide nn
mechanism	18	26	there ex is vbz a dt single jj case nn report nn which wdt suggests vbz that inpos sucralfate nn may md interfere vb with inpos anagrelide nn absorption nn
false	38	42	toxicologic jj and cc toxicokinetic jj studies nns in inpos rats nns did vbd not rb demonstrate vb any dt alterations nns in inpos the dt clearance nn or cc toxicologic jj profile nn of inpos either cc methotrexate nn or cc kineret nn when wrb the dt num cd agents nns were vbd administered vbn together rb
effect	36	40	in inpos a dt study nn in inpos which wdt patients nns with inpos active jj ra nn were vbd treated vbn for inpos up rb to topos num cd weeks nns with inpos concurrent jj kineret nn and cc etanercept nn therapy nn a dt num cd rate nn of inpos serious jj infections nns was vbd observed vbn which wdt was vbd higher jjr than inpos that dt observed vbn with inpos etanercept nn alone rb
false	36	40	in inpos a dt study nn in inpos which wdt patients nns with inpos active jj ra nn were vbd treated vbn for inpos up rb to topos num cd weeks nns with inpos concurrent jj kineret nn and cc etanercept vb therapy nn a dt num cd rate nn of inpos serious jj infections nns was vbd observed vbn which wdt was vbd higher jjr than inpos that dt observed vbn with inpos etanercept nn alone rb
effect	14	18	num cd percent nn of inpos patients nns treated vbn concurrently rb with inpos kineret nn and cc etanercept nn developed vbd neutropenia nn
false	0	14	anastrozole nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos antipyrine nn
false	22	64	although inpos there ex have vbp been vbn no dt formal jj interaction nn studies nns other jj than inpos with inpos antipyrine nn based vbn on inpos these dt in fw vivo fw and cc in fw vitro fw studies nns it prp is vbz unlikely jj that inpos co_administration nn of inpos a dt num cd mg nn dose nn of inpos arimidex nn with inpos other jj drugs nns will md result vb in inpos clinically rb significant jj drug nn inhibition nn of inpos cytochrome nn p450_mediated jj metabolism nn of inpos the dt other jj drugs nns
false	8	22	an dt interaction nn study nn with inpos warfarin nn showed vbd no dt clinically rb significant jj effect nn of inpos anastrozole nn on inpos warfarin nn pharmacokinetics nns or cc anticoagulant jj activity nn
false	22	8	an dt interaction nn study nn with inpos warfarin nn showed vbd no dt clinically rb significant jj effect nn of inpos anastrozole nn on inpos warfarin nn pharmacokinetics nns or cc anticoagulant jj activity nn
false	20	24	at inpos a dt median jj follow_up nn of inpos num cd months nns the dt combination nn of inpos arimidex nn and cc tamoxifen nn did vbd not rb demonstrate vb any dt efficacy nn benefit nn when wrb compared vbn with inpos tamoxifen nn in inpos all dt patients nns as rb well rb as inpos in inpos the dt hormone nn receptor_positive jj subpopulation nn
false	20	24	at inpos a dt median jj follow_up nn of inpos num cd months nns the dt combination nn of inpos arimidex nn and cc tamoxifen nn did vbd not rb demonstrate vb any dt efficacy nn benefit nn when wrb compared vbn with inpos tamoxifen nn in inpos all dt patients nns as rb well rb as inpos in inpos the dt hormone nn receptor_positive jj subpopulation nn
advise	20	32	based vbn on inpos clinical jj and cc pharmacokinetic jj results nns from inpos the dt atac nn trial nn tamoxifen nn should md not rb be vb administered vbn with inpos anastrozole nn
mechanism	4	8	co_administration nn of inpos anastrozole nn and cc tamoxifen nn resulted vbd in inpos a dt reduction nn of inpos anastrozole nn plasma nn levels nns by inpos num cd compared vbn with inpos those dt achieved vbn with inpos anastrozole nn alone rb
false	8	4	co_administration nn of inpos anastrozole nn and cc tamoxifen nn resulted vbd in inpos a dt reduction nn of inpos anastrozole nn plasma nn levels nns by inpos num cd compared vbn with inpos those dt achieved vbn with inpos anastrozole nn alone rb
false	8	4	co_administration nn of inpos anastrozole nn and cc tamoxifen nn resulted vbd in inpos a dt reduction nn of inpos anastrozole nn plasma nn levels nns by inpos num cd compared vbn with inpos those dt achieved vbn with inpos anastrozole nn alone rb
advise	0	16	estrogen nn containing jj therapies nns should md not rb be vb used vbn with inpos arimidex nn as inpos they prp may md diminish vb its prp pharmacologic jj action nn
advise	10	20	caution nn should md be vb observed vbn when wrb anileridine nn is vbz coadministered vbn with inpos other jj opioids nns as inpos these dt agents nns may md increase vb respiratory jj and cc circulatory jj depression nn
advise	10	20	caution nn should md be vb observed vbn when wrb anileridine nn is vbz coadministered vbn with inpos other jj sedatives nns as inpos these dt agents nns may md increase vb respiratory jj and cc circulatory jj depression nn
advise	10	20	caution nn should md be vb observed vbn when wrb anileridine nn is vbz coadministered vbn with inpos other jj phenothiazines nns as inpos these dt agents nns may md increase vb respiratory jj and cc circulatory jj depression nn
advise	10	20	caution nn should md be vb observed vbn when wrb anileridine nn is vbz coadministered vbn with inpos other jj anesthetics nn as inpos these dt agents nns may md increase vb respiratory jj and cc circulatory jj depression nn
mechanism	6	26	for inpos example nn since inpos cholestyramine nn may md reduce vb the dt gastrointestinal jj absorption nn of inpos both cc the dt oral jj anticoagulants nn and cc vitamin_k nn the dt net jj effects nns are vbp unpredictable jj
mechanism	6	30	for inpos example nn since inpos cholestyramine nn may md reduce vb the dt gastrointestinal jj absorption nn of inpos both cc the dt oral jj anticoagulants nns and cc vitamin_k nn the dt net jj effects nns are vbp unpredictable jj
false	26	30	for inpos example nn since inpos cholestyramine nn may md reduce vb the dt gastrointestinal jj absorption nn of inpos both cc the dt oral jj anticoagulants nn and cc vitamin_k nn the dt net jj effects nns are vbp unpredictable jj
mechanism	0	20	chloral_hydrate nn may md cause vb an dt increased vbn prothrombin nn response nn by inpos displacing vbg the dt anticoagulant nn from inpos protein nn binding nn sites nns or cc a dt diminished jj prothrombin nn response nn through inpos increased vbn metabolism nn of inpos the dt unbound jj drug nn by inpos hepatic jj enzyme nn induction nn thus rb leading vbg to topos inter_patient jj variation nn in inpos ultimate jj prothrombin nn effect nn
effect	16	38	drugs nns that wdt have vbp been vbn reported vbn to topos diminish vb oral jj anticoagulant nn response nn ie fw decreased vbd prothrom_bin nn time nn response nn in inpos man nn significantly rb include vbp adrenocortical_steroids nn
effect	12	30	drugs nns that wdt reportedly rb may md increase vb oral jj anticoagulant nn response nn ie fw increased vbn prothrombin nn response nn in inpos man nn include vbp alcohol nn
false	0	2	salicylates nn sulfinpyrazone nn
false	0	2	trimethoprim nn sulfamethoxazole nn
mechanism	2	16	oral jj anticoagulants nn may md potentiate vb the dt hypoglycemic jj action nn of inpos hypoglycemic_agents nn eg fw tolbutamide nn and cc chlorpropamide nn by inpos inhibiting vbg their prp metabolism nn in inpos the dt liver nn
mechanism	2	20	oral jj anticoagulants nn may md potentiate vb the dt hypoglycemic jj action nn of inpos hypoglycemic_agents nns eg fw tolbutamide nn and cc chlorpropamide nn by inpos inhibiting vbg their prp metabolism nn in inpos the dt liver nn
mechanism	2	24	oral jj anticoagulants nn may md potentiate vb the dt hypoglycemic jj action nn of inpos hypoglycemic_agents nns eg fw tolbutamide nn and cc chlorpropamide nn by inpos inhibiting vbg their prp metabolism nn in inpos the dt liver nn
false	16	20	oral jj anticoagulants nns may md potentiate vb the dt hypoglycemic jj action nn of inpos hypoglycemic_agents nn eg fw tolbutamide nn and cc chlorpropamide nn by inpos inhibiting vbg their prp metabolism nn in inpos the dt liver nn
false	16	24	oral jj anticoagulants nns may md potentiate vb the dt hypoglycemic jj action nn of inpos hypoglycemic_agents nn eg fw tolbutamide nn and cc chlorpropamide nn by inpos inhibiting vbg their prp metabolism nn in inpos the dt liver nn
false	20	24	oral jj anticoagulants nns may md potentiate vb the dt hypoglycemic jj action nn of inpos hypoglycemic_agents nns eg fw tolbutamide nn and cc chlorpropamide nn by inpos inhibiting vbg their prp metabolism nn in inpos the dt liver nn
mechanism	4	20	because inpos oral jj anticoagulants nn may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
false	4	30	because inpos oral jj anticoagulants nn may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
false	4	20	because inpos oral jj anticoagulants nn may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
false	20	30	because inpos oral jj anticoagulants nns may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
false	20	4	because inpos oral jj anticoagulants nns may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
false	30	4	because inpos oral jj anticoagulants nns may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
false	30	20	because inpos oral jj anticoagulants nns may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
mechanism	4	20	because inpos oral jj anticoagulants nns may md interfere vb with inpos the dt hepatic jj metabolism nn of inpos phenytoin nn toxic jj levels nns of inpos the dt anticonvulsant nn may md occur vb when wrb an dt oral jj anticoagulant nn and cc phenytoin nn are vbp administered vbn concurrently rb
false	24	36	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn antineoplastic_agents nn or cc drugs nns which wdt inhibit vbp platelet nn aspirin nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nns without inpos altering vbg prothrombin nn time nn determinations nns
false	24	36	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn antineoplastic_agents nn or cc drugs nns which wdt inhibit vbp platelet nn non_steroidal_anti_inflammatory_drugs nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nns without inpos altering vbg prothrombin nn time nn determinations nns
false	24	36	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn antineoplastic_agents nn or cc drugs nns which wdt inhibit vbp platelet nn dipyridamole nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nns without inpos altering vbg prothrombin nn time nn determinations nns
false	24	36	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn antineoplastic_agents nn or cc drugs nns which wdt inhibit vbp platelet nn hydrochloroquine nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nns without inpos altering vbg prothrombin nn time nn determinations nns
false	24	36	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn antineoplastic_agents nn or cc drugs nns which wdt inhibit vbp platelet nn clofibrate nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nns without inpos altering vbg prothrombin nn time nn determinations nns
false	24	36	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn antineoplastic_agents nn or cc drugs nns which wdt inhibit vbp platelet nn dextran nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nns without inpos altering vbg prothrombin nn time nn determinations nns
effect	24	52	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn antineoplastic_agents nn or cc drugs nns which wdt inhibit vbp platelet nn function nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nn without inpos altering vbg prothrombin nn time nn determinations nns
effect	36	52	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn depression nn or cc drugs nns which wdt inhibit vbp platelet nn aspirin nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nn without inpos altering vbg prothrombin nn time nn determinations nns
effect	36	52	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn depression nn or cc drugs nns which wdt inhibit vbp platelet nn non_steroidal_anti_inflammatory_drugs nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nn without inpos altering vbg prothrombin nn time nn determinations nns
effect	36	52	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn depression nn or cc drugs nns which wdt inhibit vbp platelet nn dipyridamole nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nn without inpos altering vbg prothrombin nn time nn determinations nns
effect	36	52	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn depression nn or cc drugs nns which wdt inhibit vbp platelet nn hydrochloroquine nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nn without inpos altering vbg prothrombin nn time nn determinations nns
effect	36	52	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn depression nn or cc drugs nns which wdt inhibit vbp platelet nn clofibrate nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nn without inpos altering vbg prothrombin nn time nn determinations nns
effect	36	52	drugs nns that wdt reduce vbp the dt number nn of inpos blood nn platelets nns by inpos causing vbg bone nn marrow nn depression nn or cc drugs nns which wdt inhibit vbp platelet nn dextran nn may md increase vb the dt bleeding vbg tendency nn produced vbn by inpos anticoagulants nn without inpos altering vbg prothrombin nn time nn determinations nns
advise	22	26	the dt beneficial jj effects nns on inpos arterial jj thrombus nn formation nn from inpos combined vbn therapy nn with inpos antiplatelet nn and cc anticoagulant nn bbbbbcom_medication_eeeeecom nn must md be vb weighed vbn against inpos an dt increased vbn risk nn of inpos inducing vbg hemorrhage nn
false	6	10	drug_laboratory nnp test nnp interferences nnps dicumarol nn and cc indanedione_anticoagulants nn including vbg anisindione nn or cc their prp metabolites nns may md color vb alkaline nn urine nn red_orange nn which wdt may md interfere vb with inpos spectrophotometrically rb determined vbn urinary jj laboratory nn tests nns
false	6	14	drug_laboratory nnp test nnp interferences nnps dicumarol nn and cc indanedione_anticoagulants nns including vbg anisindione nn or cc their prp metabolites nns may md color vb alkaline nn urine nn red_orange nn which wdt may md interfere vb with inpos spectrophotometrically rb determined vbn urinary jj laboratory nn tests nns
false	10	14	drug_laboratory nnp test nnp interferences nnps dicumarol nn and cc indanedione_anticoagulants nn including vbg anisindione nn or cc their prp metabolites nns may md color vb alkaline nn urine nn red_orange nn which wdt may md interfere vb with inpos spectrophotometrically rb determined vbn urinary jj laboratory nn tests nns
effect	22	30	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt 5ht3_antagonist_class nn is vbz contraindicated vbn
false	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt 5ht3_antagonist_class nn is vbz contraindicated vbn
false	22	30	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt ondansetron nn is vbz contraindicated vbn
false	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt granisetron nn is vbz contraindicated vbn
false	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt dolasetron nn is vbz contraindicated vbn
false	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt palonosetron nn is vbz contraindicated vbn
false	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt alosetron nn is vbz contraindicated vbn
false	30	22	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt 5ht3_antagonist_class nn is vbz contraindicated vbn
false	30	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt 5ht3_antagonist_class nn is vbz contraindicated vbn
false	30	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt granisetron nn is vbz contraindicated vbn
false	30	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt dolasetron nn is vbz contraindicated vbn
false	30	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt palonosetron nn is vbz contraindicated vbn
false	30	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt alosetron nn is vbz contraindicated vbn
advise	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt 5ht3_antagonist_class nn is vbz contraindicated vbn
advise	22	30	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt ondansetron nn is vbz contraindicated vbn
advise	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt granisetron nn is vbz contraindicated vbn
advise	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt dolasetron nn is vbz contraindicated vbn
advise	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt palonosetron nn is vbz contraindicated vbn
advise	22	50	based vbn on inpos reports nns of inpos profound jj hypotension nn and cc loss nn of inpos consciousness nn when wrb apomorphine nn was vbd administered vbn with inpos ondansetron nn the dt concomitant jj use nn of inpos apomorphine nn with inpos drugs nns of inpos the dt alosetron nn is vbz contraindicated vbn
false	0	6	antihypertensive_medication nn s nns and cc vasodilators nn
effect	24	28	the dt following vbg adverse jj events nns were vbd experienced vbn more rbr commonly rb in inpos patients nns receiving vbg concomitant jj antihypertensive_medications nn or cc vasodilators nn compared vbn to topos patients nns not rb receiving vbg these dt concomitant jj drugs nns hypotension nn num cd vs inpos num cd myocardial jj infarction nn num cd vs inpos num cd serious jj pneumonia nn num cd vs inpos num cd serious jj falls vbz num cd vs inpos num cd bone nn joint jj injuries nns num cd vs inpos num cd
false	2	8	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	2	18	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	2	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	2	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	2	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	2	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	2	30	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	2	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	8	18	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	8	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	8	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	8	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	8	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	8	30	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	8	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	18	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	18	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	18	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	18	26	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
effect	18	30	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	18	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nn such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	26	30	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	26	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	26	30	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
effect	26	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt phenothiazines nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	26	30	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
effect	26	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt butyrophenones nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
false	26	30	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
effect	26	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt thioxanthenes nn or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
effect	30	42	since inpos apomorphine nn is vbz a dt dopamine_agonist nn it prp is vbz possible jj that inpos dopamine_antagonists nns such jj as inpos the dt neuroleptics nns or cc metoclopramide nn may md diminish vb the dt effectiveness nn of inpos apokyn nn
advise	14	24	patients nns with inpos major jj psychotic jj disorders nns treated vbn with inpos neuroleptics nn should md be vb treated vbn with inpos dopamine_agonists nn only rb if inpos the dt potential jj benefits nns outweigh vbp the dt risks nns
advise	0	16	apraclonidine nn should md not rb be vb used vbn in inpos patients nns receiving vbg mao_inhibitors nn
advise	36	62	although inpos no dt specific jj drug nn interactions nns with inpos topical jj glaucoma nn drugs nns or cc systemic jj medications nns were vbd identified vbn in inpos clinical jj studies nns of inpos iopidine nn float cd ophthalmic nnp solution nnp the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos cns_depressants nn should md be vb considered vbn
advise	36	62	although inpos no dt specific jj drug nn interactions nns with inpos topical jj glaucoma nn drugs nns or cc systemic jj medications nns were vbd identified vbn in inpos clinical jj studies nns of inpos iopidine nn float cd ophthalmic nnp solution nnp the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos alcohol nn should md be vb considered vbn
advise	36	62	although inpos no dt specific jj drug nn interactions nns with inpos topical jj glaucoma nn drugs nns or cc systemic jj medications nns were vbd identified vbn in inpos clinical jj studies nns of inpos iopidine nn float cd ophthalmic nnp solution nnp the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos barbiturates nn should md be vb considered vbn
advise	36	62	although inpos no dt specific jj drug nn interactions nns with inpos topical jj glaucoma nn drugs nns or cc systemic jj medications nns were vbd identified vbn in inpos clinical jj studies nns of inpos iopidine nn float cd ophthalmic nnp solution nnp the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos opiates nn should md be vb considered vbn
advise	36	62	although inpos no dt specific jj drug nn interactions nns with inpos topical jj glaucoma nn drugs nns or cc systemic jj medications nns were vbd identified vbn in inpos clinical jj studies nns of inpos iopidine nn float cd ophthalmic nnp solution nnp the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos sedatives nn should md be vb considered vbn
advise	36	62	although inpos no dt specific jj drug nn interactions nns with inpos topical jj glaucoma nn drugs nns or cc systemic jj medications nns were vbd identified vbn in inpos clinical jj studies nns of inpos iopidine nn float cd ophthalmic nnp solution nnp the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos anesthetics nn should md be vb considered vbn
effect	0	22	tricyclic_antidepressants nn have vbp been vbn reported vbn to topos blunt vb the dt hypotensive jj effect nn of inpos systemic jj clonidine nn
effect	24	28	an dt additive jj hypotensive jj effect nn has vbz been vbn reported vbn with inpos the dt combination nn of inpos systemic jj clonidine nn and cc neuroleptic nn therapy nn
advise	2	28	since inpos apraclonidine nn may md reduce vb pulse nn and cc blood nn pressure nn caution nn in inpos using vbg drugs nns such jj as inpos b_blockers nns is vbz advised vbn
advise	2	28	since inpos apraclonidine nn may md reduce vb pulse nn and cc blood nn pressure nn caution nn in inpos using vbg drugs nns such jj as inpos antihypertensives nns is vbz advised vbn
advise	2	28	since inpos apraclonidine nn may md reduce vb pulse nn and cc blood nn pressure nn caution nn in inpos using vbg drugs nns such jj as inpos cardiac_glycosides nn is vbz advised vbn
mechanism	0	18	aprepitant nn has vbz been vbn shown vbn to topos induce vb the dt metabolism nn of inpos s_warfarin nn and cc tolbutamide nn which wdt are vbp metabolized vbn through inpos cyp2c9 nn
mechanism	0	22	aprepitant nn has vbz been vbn shown vbn to topos induce vb the dt metabolism nn of inpos s_warfarin nn and cc tolbutamide nn which wdt are vbp metabolized vbn through inpos cyp2c9 nn
false	18	22	aprepitant jj has vbz been vbn shown vbn to topos induce vb the dt metabolism nn of inpos s_warfarin nn and cc tolbutamide nn which wdt are vbp metabolized vbn through inpos cyp2c9 nn
mechanism	4	38	coadministration nn of inpos aprepitant nn with inpos these dt drugs nns or cc other jj drugs nns that wdt are vbp known vbn to topos be vb metabolized vbn by inpos cyp2c9 nn such jj as inpos phenytoin nn may md result vb in inpos lower jjr plasma nn concentrations nns of inpos these dt drugs nns
false	0	48	aprepitant nn is vbz unlikely jj to topos interact vb with inpos drugs nns that wdt are vbp substrates nns for inpos the dt p_glycoprotein nn transporter nn as inpos demonstrated vbn by inpos the dt lack nn of inpos interaction nn of inpos aprepitant jj with inpos digoxin nn in inpos a dt clinical jj drug nn interaction nn study nn
false	0	48	aprepitant jj is vbz unlikely jj to topos interact vb with inpos drugs nns that wdt are vbp substrates nns for inpos the dt p_glycoprotein nn transporter nn as inpos demonstrated vbn by inpos the dt lack nn of inpos interaction nn of inpos aprepitant nn with inpos digoxin nn in inpos a dt clinical jj drug nn interaction nn study nn
false	10	32	in inpos clinical jj drug nn interaction nn studies nns aprepitant nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos ondansetron nn or cc granisetron nn
false	10	36	in inpos clinical jj drug nn interaction nn studies nns aprepitant nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos ondansetron nn or cc granisetron nn
false	32	36	in inpos clinical jj drug nn interaction nn studies nns aprepitant nn did vbd not rb have vb clinically rb important jj effects nns on inpos the dt pharmacokinetics nns of inpos ondansetron nn or cc granisetron nn
false	0	2	corticosteroids nn dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	0	4	corticosteroids nn dexamethasone nn aprepitant nn when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	0	2	corticosteroids nn dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	0	4	corticosteroids nn dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant nn when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	0	2	corticosteroids nn dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	0	2	corticosteroids nn dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	2	4	corticosteroids nns dexamethasone nn aprepitant nn when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	2	4	corticosteroids nns dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant nn when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
mechanism	4	2	corticosteroids nns dexamethasone nn aprepitant nn when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	4	2	corticosteroids nns dexamethasone nn aprepitant nn when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	4	2	corticosteroids nns dexamethasone nn aprepitant nn when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant jj when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	2	4	corticosteroids nns dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant nn when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
mechanism	4	2	corticosteroids nns dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant nn when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
false	4	2	corticosteroids nns dexamethasone nn aprepitant jj when wrb given vbn as inpos a dt regimen nn of inpos 125mg nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos day nn num cd and cc aprepitant nn when wrb given vbn as inpos num cd mg_day nn with inpos dexamethasone nn coadministered vbn orally rb as inpos num cd mg nn on inpos days nns num cd through inpos num cd increased vbd the dt auc nn of inpos dexamethasone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos days nns num cd and cc num cd
advise	4	26	the dt oral jj dexamethasone nn doses nns should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant nn to topos achieve vb exposures nns of inpos dexamethasone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant jj
false	4	26	the dt oral jj dexamethasone nn doses nns should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant jj to topos achieve vb exposures nns of inpos dexamethasone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant nn
false	26	4	the dt oral jj dexamethasone nn doses nns should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant nn to topos achieve vb exposures nns of inpos dexamethasone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant jj
false	4	26	the dt oral jj dexamethasone nn doses nns should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant jj to topos achieve vb exposures nns of inpos dexamethasone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant nn
mechanism	8	20	the dt daily jj dose nn of inpos dexamethasone nn administered vbn in inpos clinical jj studies nns with inpos aprepitant nn reflects vbz an dt approximate jj num cd reduction nn of inpos the dt dose nn of inpos dexamethasone nn
false	20	8	the dt daily jj dose nn of inpos dexamethasone nn administered vbn in inpos clinical jj studies nns with inpos aprepitant nn reflects vbz an dt approximate jj num cd reduction nn of inpos the dt dose nn of inpos dexamethasone nn
mechanism	0	48	aprepitant nn when wrb given vbn as inpos a dt regimen nn of inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd increased vbd the dt auc nn of inpos methylprednisolone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos day nn num cd and cc by inpos float_fold jj on inpos day nn num cd when wrb methylprednisolone nn was vbd coadministered vbn intravenously rb as inpos num cd mg nn on inpos day nn num cd and cc orally rb as inpos num cd mg nn on inpos days nns num cd and cc num cd
false	0	48	aprepitant nn when wrb given vbn as inpos a dt regimen nn of inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd increased vbd the dt auc nn of inpos methylprednisolone nn a dt cyp3a4 nn substrate nn by inpos float_fold jj on inpos day nn num cd and cc by inpos float_fold jj on inpos day nn num cd when wrb methylprednisolone nn was vbd coadministered vbn intravenously rb as inpos num cd mg nn on inpos day nn num cd and cc orally rb as inpos num cd mg nn on inpos days nns num cd and cc num cd
advise	4	48	the dt num cd methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd and cc the dt oral jj methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant nn to topos achieve vb exposures nns of inpos methylprednisolone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant jj
false	4	48	the dt num cd methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd and cc the dt oral jj methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant jj to topos achieve vb exposures nns of inpos methylprednisolone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant nn
advise	4	48	the dt num cd methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd and cc the dt oral jj methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant nn to topos achieve vb exposures nns of inpos methylprednisolone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant jj
false	4	48	the dt num cd methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd and cc the dt oral jj methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant jj to topos achieve vb exposures nns of inpos methylprednisolone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant nn
false	48	4	the dt num cd methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd and cc the dt oral jj methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant nn to topos achieve vb exposures nns of inpos methylprednisolone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant jj
false	4	48	the dt num cd methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd and cc the dt oral jj methylprednisolone nn dose nn should md be vb reduced vbn by inpos approximately rb num cd when wrb coadministered vbn with inpos aprepitant jj to topos achieve vb exposures nns of inpos methylprednisolone nn similar jj to topos those dt obtained vbn when wrb it prp is vbz given vbn without inpos aprepitant nn
false	10	54	a dt single jj num_mg nn dose nn of inpos aprepitant nn was vbd administered vbn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd to topos healthy jj subjects nns who wp were vbd stabilized vbn on inpos chronic jj warfarin nn therapy nn
false	12	24	although inpos there ex was vbd no dt effect nn of inpos aprepitant nn on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s jj bbbbb22_warfarin_eeeee22 nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant jj
false	12	28	although inpos there ex was vbd no dt effect nn of inpos aprepitant nn on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s_warfarin nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant jj
false	12	28	although inpos there ex was vbd no dt effect nn of inpos aprepitant nn on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s_warfarin nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant jj
false	24	1	although inpos there ex was vbd no dt effect nn of inpos aprepitant jj on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s nn bbbbbcom_warfarin_eeeeecom nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant jj
false	24	52	although inpos there ex was vbd no dt effect nn of inpos aprepitant jj on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s jj bbbbb12_warfarin_eeeee12 nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant jj
false	24	12	although inpos there ex was vbd no dt effect nn of inpos aprepitant jj on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s jj bbbbb12_warfarin_eeeee12 nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant nn
false	28	28	although inpos there ex was vbd no dt effect nn of inpos aprepitant jj on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s_warfarin nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant jj
false	28	12	although inpos there ex was vbd no dt effect nn of inpos aprepitant jj on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s_warfarin nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant nn
mechanism	28	12	although inpos there ex was vbd no dt effect nn of inpos aprepitant jj on inpos the dt plasma nn auc nn of inpos r_+ nn or cc s_warfarin nn determined vbn on inpos day nn num cd there ex was vbd a dt num cd decrease nn in inpos s_warfarin nn trough nn concentration nn accompanied vbn by inpos a dt num cd decrease nn in inpos the dt prothrombin nn time nn num cd days nns after inpos completion nn of inpos dosing nn with inpos aprepitant nn
advise	8	60	in inpos patients nns on inpos chronic jj warfarin nn therapy nn the dt prothrombin nn time nn should md be vb closely rb monitored vbn in inpos the dt num_week jj period nn particularly rb at inpos num cd to topos num cd days nns following vbg initiation nn of inpos the dt num_day jj regimen nn of inpos aprepitant nn with inpos each dt chemotherapy nn cycle nn
false	0	2	tolbutamide nn aprepitant nn when wrb given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd decreased vbd the dt auc nn of inpos tolbutamide nn by inpos num cd on inpos day nn num cd num cd on inpos day nn num cd num cd on inpos day nnp num cd when wrb a dt single jj dose nn of inpos tolbutamide nn num cd mg nn was vbd admini nns stered vbd orally rb prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant jj and cc on inpos days nns num cd and cc num cd
false	0	2	tolbutamide nn aprepitant jj when wrb given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd decreased vbd the dt auc nn of inpos tolbutamide nn by inpos num cd on inpos day nn num cd num cd on inpos day nn num cd and cc num cd on inpos day nnp num cd when wrb a dt single jj dose nn of inpos tolbutamide nn num cd mg nn was vbd admini nns stered vbd orally rb prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant nn and cc on inpos days nns num cd and cc num cd
false	2	0	tolbutamide nn aprepitant nn when wrb given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd decreased vbd the dt auc nn of inpos tolbutamide nn by inpos num cd on inpos day nn num cd num cd on inpos day nn num cd num cd on inpos day nnp num cd when wrb a dt single jj dose nn of inpos tolbutamide nn num cd mg nn was vbd admini nns stered vbd orally rb prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant jj and cc on inpos days nns num cd and cc num cd
false	2	0	tolbutamide nn aprepitant nn when wrb given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd decreased vbd the dt auc nn of inpos tolbutamide nn by inpos num cd on inpos day nn num cd num cd on inpos day nn num cd num cd on inpos day nnp num cd when wrb a dt single jj dose nn of inpos tolbutamide nn num cd mg nn was vbd admini nns stered vbd orally rb prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant jj and cc on inpos days nns num cd and cc num cd
false	0	2	tolbutamide nn aprepitant jj when wrb given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd decreased vbd the dt auc nn of inpos tolbutamide nn by inpos num cd on inpos day nn num cd num cd on inpos day nn num cd and cc num cd on inpos day nnp num cd when wrb a dt single jj dose nn of inpos tolbutamide nn num cd mg nn was vbd admini nns stered vbd orally rb prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant nn and cc on inpos days nns num cd and cc num cd
mechanism	0	2	tolbutamide nn aprepitant jj when wrb given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd decreased vbd the dt auc nn of inpos tolbutamide nn by inpos num cd on inpos day nn num cd num cd on inpos day nn num cd and cc num cd on inpos day nnp num cd when wrb a dt single jj dose nn of inpos tolbutamide nn num cd mg nn was vbd admini nns stered vbd orally rb prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant nn and cc on inpos days nns num cd and cc num cd
false	2	4	oral jj contraceptives nn aprepitant nn when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	44	oral jj contraceptives nn aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	54	oral jj contraceptives nn aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	44	oral jj contraceptives nn aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	54	oral jj contraceptives nn aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	4	2	oral jj contraceptives nns aprepitant nn when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
mechanism	4	44	oral jj contraceptives nns aprepitant nn when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
mechanism	4	54	oral jj contraceptives nns aprepitant nn when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	4	44	oral jj contraceptives nns aprepitant nn when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	4	54	oral jj contraceptives nns aprepitant nn when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	44	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	54	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	44	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	2	54	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	44	54	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	44	54	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	54	44	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
false	44	54	oral jj contraceptives nns aprepitant jj when wrb given vbn once rb daily rb for inpos num cd days nns as inpos a dt num_mg jj capsule nn with inpos an dt oral jj contraceptive nn containing vbg num cd mcg nn of inpos ethinyl_estradiol nn and cc num cd mg nn of inpos norethindrone nn decreased vbd the dt auc nn of inpos ethinyl_estradiol nn by inpos num cd and cc decreased vbd the dt auc nn of inpos norethindrone nn by inpos num cd
effect	10	18	therefore rb the dt efficacy nn of inpos oral jj contraceptives nn during inpos administration nn of inpos aprepitant nn may md be vb reduced vbn
advise	10	20	although inpos a dt num_day jj regimen nn of inpos aprepitant nn given vbn concomitantly rb with inpos oral jj contraceptives nn has vbz not rb been vbn studied vbn alternative jj or cc back_up jj methods nns of inpos contraception nn should md be vb used vbn
mechanism	0	10	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn a dt sensitive jj cyp3a4 nn substrate nn by inpos float_fold jj on inpos day nn num cd and cc float_fold jj on inpos day nn num cd when wrb a dt single jj oral jj dose nn of inpos midazolam nn num cd mg nn was vbd coadministered vbn on inpos day nn num cd and cc day nn num cd of inpos a dt regimen nn of inpos aprepitant jj num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd through inpos num cd
false	0	10	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn a dt sensitive jj cyp3a4 nn substrate nn by inpos float_fold jj on inpos day nn num cd and cc float_fold jj on inpos day nn num cd when wrb a dt single jj oral jj dose nn of inpos midazolam nn num cd mg nn was vbd coadministered vbn on inpos day nn num cd and cc day nn num cd of inpos a dt regimen nn of inpos aprepitant jj num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd through inpos num cd
false	10	0	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn a dt sensitive jj cyp3a4 nn substrate nn by inpos float_fold jj on inpos day nn num cd and cc float_fold jj on inpos day nn num cd when wrb a dt single jj oral jj dose nn of inpos midazolam nn num cd mg nn was vbd coadministered vbn on inpos day nn num cd and cc day nn num cd of inpos a dt regimen nn of inpos aprepitant nn num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd through inpos num cd
false	10	0	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn a dt sensitive jj cyp3a4 nn substrate nn by inpos float_fold jj on inpos day nn num cd and cc float_fold jj on inpos day nn num cd when wrb a dt single jj oral jj dose nn of inpos midazolam nn num cd mg nn was vbd coadministered vbn on inpos day nn num cd and cc day nn num cd of inpos a dt regimen nn of inpos aprepitant nn num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd through inpos num cd
false	16	22	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nn metabolized vbn via inpos cyp3a4 nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant jj
false	16	28	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nns metabolized vbn via inpos alprazolam nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant jj
false	16	28	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nns metabolized vbn via inpos triazolam nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant jj
advise	16	46	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nns metabolized vbn via inpos cyp3a4 nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant nn
false	22	28	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nn metabolized vbn via inpos alprazolam nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant jj
false	22	28	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nn metabolized vbn via inpos triazolam nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant jj
advise	22	46	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nn metabolized vbn via inpos cyp3a4 nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant nn
advise	28	46	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nns metabolized vbn via inpos alprazolam nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant nn
advise	28	46	the dt potential jj effects nns of inpos increased vbn plasma nn concentrations nns of inpos midazolam nn or cc other jj benzodiazepines nns metabolized vbn via inpos triazolam nn should md be vb considered vbn when wrb coadministering vbg these dt agents nns with inpos aprepitant nn
false	14	16	in inpos another dt study nn with inpos intravenous jj administration nn of inpos midazolam nn aprepitant nn was vbd given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd and cc midazolam nn num cd mg nn num cd was vbd given vbn prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant jj and cc on inpos days nns num cd num cd num cd
false	14	16	in inpos another dt study nn with inpos intravenous jj administration nn of inpos midazolam nn aprepitant jj was vbd given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd and cc midazolam nn num cd mg nn num cd was vbd given vbn prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant nn and cc on inpos days nns num cd num cd num cd
false	16	14	in inpos another dt study nn with inpos intravenous jj administration nn of inpos midazolam nn aprepitant nn was vbd given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd and cc midazolam nn num cd mg nn num cd was vbd given vbn prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant jj and cc on inpos days nns num cd num cd num cd
false	14	16	in inpos another dt study nn with inpos intravenous jj administration nn of inpos midazolam nn aprepitant jj was vbd given vbn as inpos num cd mg nn on inpos day nn num cd and cc num cd mg_day nn on inpos days nns num cd and cc num cd and cc midazolam nn num cd mg nn num cd was vbd given vbn prior jj to topos the dt administration nn of inpos the dt num_day jj regimen nn of inpos aprepitant nn and cc on inpos days nns num cd num cd num cd
mechanism	0	10	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd and cc decreased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd relative jj to topos the dt dosing nn of inpos aprepitant jj on inpos days nns num cd through inpos num cd
mechanism	0	10	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd and cc decreased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd relative jj to topos the dt dosing nn of inpos aprepitant jj on inpos days nns num cd through inpos num cd
false	10	0	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd and cc decreased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd relative jj to topos the dt dosing nn of inpos aprepitant nn on inpos days nns num cd through inpos num cd
false	10	0	aprepitant nn increased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd and cc decreased vbd the dt auc nn of inpos midazolam nn by inpos num cd on inpos day nn num cd relative jj to topos the dt dosing nn of inpos aprepitant nn on inpos days nns num cd through inpos num cd
advise	8	16	consequently rb concomitant jj administration nn of inpos aprepitant nn with inpos strong jj cyp3a4 nn ketoconazole nn should md be vb approached vbn with inpos caution nn
advise	8	16	consequently rb concomitant jj administration nn of inpos aprepitant nn with inpos strong jj cyp3a4 nn itraconazole nn should md be vb approached vbn with inpos caution nn
advise	8	16	consequently rb concomitant jj administration nn of inpos aprepitant nn with inpos strong jj cyp3a4 nn nefazodone nn should md be vb approached vbn with inpos caution nn
advise	8	16	consequently rb concomitant jj administration nn of inpos aprepitant nn with inpos strong jj cyp3a4 nn troleandomycin nn should md be vb approached vbn with inpos caution nn
advise	8	16	consequently rb concomitant jj administration nn of inpos aprepitant nn with inpos strong jj cyp3a4 nn clarithromycin nn should md be vb approached vbn with inpos caution nn
advise	8	16	consequently rb concomitant jj administration nn of inpos aprepitant nn with inpos strong jj cyp3a4 nn ritonavir nn should md be vb approached vbn with inpos caution nn
advise	8	16	consequently rb concomitant jj administration nn of inpos aprepitant nn with inpos strong jj cyp3a4 nn nelfinavir nn should md be vb approached vbn with inpos caution nn
advise	6	24	because inpos moderate jj cyp3a4 nn diltiazem nn result vbp in inpos num_fold jj increase nn in inpos plasma nn concentrations nns of inpos aprepitant nn concomitant jj administration nn should md also rb be vb approached vbn with inpos caution nn
mechanism	6	20	therefore rb coadministration nn of inpos aprepitant nn with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn rifampin nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant jj
false	6	20	therefore rb coadministration nn of inpos aprepitant nn with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn carbamazepine nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant jj
mechanism	6	20	therefore rb coadministration nn of inpos aprepitant nn with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn phenytoin nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant jj
false	20	6	therefore rb coadministration nn of inpos aprepitant jj with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn rifampin nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant jj
false	20	6	therefore rb coadministration nn of inpos aprepitant jj with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn rifampin nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant nn
false	20	6	therefore rb coadministration nn of inpos aprepitant jj with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn carbamazepine nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant jj
false	20	6	therefore rb coadministration nn of inpos aprepitant jj with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn carbamazepine nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant nn
false	20	6	therefore rb coadministration nn of inpos aprepitant jj with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn phenytoin nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant jj
false	20	6	therefore rb coadministration nn of inpos aprepitant jj with inpos drugs nns that wdt strongly rb induce vbp cyp3a4 nn phenytoin nn may md result vb in inpos reduced vbn plasma nn concentrations nns of inpos aprepitant nn that wdt may md result vb in inpos decreased vbn efficacy nn of inpos aprepitant nn
mechanism	12	38	when wrb a dt single jj num_mg nn dose nn of inpos aprepitant nn was vbd administered vbn on inpos day5 nn of inpos a dt num_day jj regimen nn of inpos num cd mg_day nn of inpos ketoconazole nn a dt strong jj cyp3a4 nn inhibitor nn the dt auc nn of inpos aprepitant nn increased vbd approximately rb num_fold rb and cc the dt mean jj terminal jj half_life nn of inpos aprepitant nn increased vbd approximately rb num_fold rb
false	38	12	when wrb a dt single jj num_mg nn dose nn of inpos aprepitant jj was vbd administered vbn on inpos day5 nn of inpos a dt num_day jj regimen nn of inpos num cd mg_day nn of inpos ketoconazole nn a dt strong jj cyp3a4 nn inhibitor nn the dt auc nn of inpos aprepitant nn increased vbd approximately rb num_fold rb and cc the dt mean jj terminal jj half_life nn of inpos aprepitant nn increased vbd approximately rb num_fold rb
false	38	12	when wrb a dt single jj num_mg nn dose nn of inpos aprepitant jj was vbd administered vbn on inpos day5 nn of inpos a dt num_day jj regimen nn of inpos num cd mg_day nn of inpos ketoconazole nn a dt strong jj cyp3a4 nn inhibitor nn the dt auc nn of inpos aprepitant nn increased vbd approximately rb num_fold rb and cc the dt mean jj terminal jj half_life nn of inpos aprepitant nn increased vbd approximately rb num_fold rb
mechanism	12	38	when wrb a dt single jj num_mg nn dose nn of inpos aprepitant nn was vbd administered vbn on inpos day9 nn of inpos a dt num_day jj regimen nn of inpos num cd mg_day nn of inpos rifampin nn a dt strong jj cyp3a4 nn inducer nn the dt auc nn of inpos aprepitant jj decreased vbd approximately rb num_fold rb and cc the dt mean jj terminal jj half_life nn decreased vbd approximately rb num_fold rb
false	38	12	when wrb a dt single jj num_mg nn dose nn of inpos aprepitant jj was vbd administered vbn on inpos day9 nn of inpos a dt num_day jj regimen nn of inpos num cd mg_day nn of inpos rifampin nn a dt strong jj cyp3a4 nn inducer nn the dt auc nn of inpos aprepitant nn decreased vbd approximately rb num_fold rb and cc the dt mean jj terminal jj half_life nn decreased vbd approximately rb num_fold rb
mechanism	18	50	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos aprepitant nn once rb daily rb as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn of inpos the dt capsule nn formulation nn with inpos diltiazem nn num cd mg nn num cd times nns daily rb for inpos num cd days nns resulted vbd in inpos a dt num_fold jj increase nn of inpos aprepitant jj auc nn and cc a dt simultaneous jj float_fold jj increase nn of inpos diltiazem nn auc nn
false	18	50	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos aprepitant nn once rb daily rb as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn of inpos the dt capsule nn formulation nn with inpos diltiazem nn num cd mg nn num cd times nns daily rb for inpos num cd days nns resulted vbd in inpos a dt num_fold jj increase nn of inpos aprepitant jj auc nn and cc a dt simultaneous jj float_fold jj increase nn of inpos diltiazem nn auc nn
false	50	18	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos aprepitant jj once rb daily rb as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn of inpos the dt capsule nn formulation nn with inpos diltiazem nn num cd mg nn num cd times nns daily rb for inpos num cd days nns resulted vbd in inpos a dt num_fold jj increase nn of inpos aprepitant nn auc nn and cc a dt simultaneous jj float_fold jj increase nn of inpos diltiazem nn auc nn
false	18	50	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos aprepitant jj once rb daily rb as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn of inpos the dt capsule nn formulation nn with inpos diltiazem nn num cd mg nn num cd times nns daily rb for inpos num cd days nns resulted vbd in inpos a dt num_fold jj increase nn of inpos aprepitant nn auc nn and cc a dt simultaneous jj float_fold jj increase nn of inpos diltiazem nn auc nn
false	0	14	paroxetine nn coadministration nn of inpos once rb daily jj doses nns of inpos aprepitant nn as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn or cc num cd mg nn of inpos the dt capsule nn formulation nn with inpos paroxetine nn num cd mg nn once rb daily rb resulted vbd in inpos a dt decrease nn in inpos auc nn by inpos approximately rb num cd and cc cmax nn by inpos approximately rb num cd of inpos both cc aprepitant jj and cc paroxetine nn
false	0	14	paroxetine nn coadministration nn of inpos once rb daily jj doses nns of inpos aprepitant jj as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn or cc num cd mg nn of inpos the dt capsule nn formulation nn with inpos paroxetine nn num cd mg nn once rb daily rb resulted vbd in inpos a dt decrease nn in inpos auc nn by inpos approximately rb num cd and cc cmax nn by inpos approximately rb num cd of inpos both cc aprepitant nn and cc paroxetine nn
mechanism	12	46	coadministration nn of inpos once rb daily jj doses nns of inpos aprepitant nn as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn or cc num cd mg nn of inpos the dt capsule nn formulation nn with inpos paroxetine nn num cd mg nn once rb daily rb resulted vbd in inpos a dt decrease nn in inpos auc nn by inpos approximately rb num cd and cc cmax nn by inpos approximately rb num cd of inpos both cc aprepitant jj and cc paroxetine nn
false	12	46	coadministration nn of inpos once rb daily jj doses nns of inpos aprepitant nn as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn or cc num cd mg nn of inpos the dt capsule nn formulation nn with inpos paroxetine nn num cd mg nn once rb daily rb resulted vbd in inpos a dt decrease nn in inpos auc nn by inpos approximately rb num cd and cc cmax nn by inpos approximately rb num cd of inpos both cc aprepitant jj and cc paroxetine nn
false	46	12	coadministration nn of inpos once rb daily jj doses nns of inpos aprepitant jj as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn or cc num cd mg nn of inpos the dt capsule nn formulation nn with inpos paroxetine nn num cd mg nn once rb daily rb resulted vbd in inpos a dt decrease nn in inpos auc nn by inpos approximately rb num cd and cc cmax nn by inpos approximately rb num cd of inpos both cc aprepitant nn and cc paroxetine nn
false	12	46	coadministration nn of inpos once rb daily jj doses nns of inpos aprepitant jj as inpos a dt tablet nn formulation nn comparable jj to topos num cd mg nn or cc num cd mg nn of inpos the dt capsule nn formulation nn with inpos paroxetine nn num cd mg nn once rb daily rb resulted vbd in inpos a dt decrease nn in inpos auc nn by inpos approximately rb num cd and cc cmax nn by inpos approximately rb num cd of inpos both cc aprepitant nn and cc paroxetine nn
false	0	16	b_adrenergic_blocking_agents nn concurrent jj use nn may md blunt vb the dt response nn to topos arbutamine nn
advise	0	22	b_adrenergic_blocking_agents nn should md be vb withdrawn vbn at inpos least jjs num cd hours nns before inpos conducting vbg an dt arbutamine nn mediated jj stress nn test nn
false	0	8	antiarrhythmic_agents_nns_class_i nn concurrent jj use nn with inpos arbutamine nn may md have vb a dt proarrhythmic jj effect nn
false	0	8	flecainide nn concurrent jj use nn with inpos arbutamine nn may md have vb a dt proarrhythmic jj effect nn
false	0	8	lidocaine nn concurrent jj use nn with inpos arbutamine nn may md have vb a dt proarrhythmic jj effect nn
false	0	8	quinidine nn concurrent jj use nn with inpos arbutamine nn may md have vb a dt proarrhythmic jj effect nn
false	0	10	antidepressants nns digitalis_glycosides nns concurrent jj use nn with inpos arbutamine nn may md produce vb additive jj inotropic jj and_or cc chronotropic jj effects nns
false	0	10	tricyclic nns digitalis_glycosides nns concurrent jj use nn with inpos arbutamine nn may md produce vb additive jj inotropic jj and_or cc chronotropic jj effects nns
false	0	8	atropine nns concurrent jj use nn with inpos arbutamine nn may md produce vb additive jj inotropic jj and_or cc chronotropic jj effects nns
false	0	8	anticholinergic_agents nns concurrent jj use nn with inpos arbutamine nn may md produce vb additive jj inotropic jj and_or cc chronotropic jj effects nns
false	0	8	digitalis_glycosides nn concurrent jj use nn with inpos arbutamine nn may md produce vb additive jj inotropic jj and_or cc chronotropic jj effects nns
false	0	6	anticoagulants nn including vbg coumarin nn platelet_aggregation_inhibitors nn such jj as inpos nonsteroidal_anti_inflammatory_drugs nns and cc aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	0	18	anticoagulants nn including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nonsteroidal_anti_inflammatory_drugs nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	0	18	anticoagulants nn including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nsaids nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	0	20	anticoagulants nn including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nonsteroidal_anti_inflammatory_drugs nns aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
effect	0	42	anticoagulants nn including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nonsteroidal_anti_inflammatory_drugs nns aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	6	12	anticoagulants nns including vbg coumarin nn platelet_aggregation_inhibitors nn such jj as inpos nonsteroidal_anti_inflammatory_drugs nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	6	12	anticoagulants nns including vbg coumarin nn platelet_aggregation_inhibitors nn such jj as inpos nsaids nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	6	16	anticoagulants nns including vbg coumarin nn platelet_aggregation_inhibitors nn such jj as inpos nonsteroidal_anti_inflammatory_drugs nns and cc aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
effect	6	38	anticoagulants nns including vbg coumarin nn platelet_aggregation_inhibitors nn such jj as inpos nonsteroidal_anti_inflammatory_drugs nns and cc aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	18	20	anticoagulants nns including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nonsteroidal_anti_inflammatory_drugs nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
effect	18	42	anticoagulants nns including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nonsteroidal_anti_inflammatory_drugs nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
false	18	20	anticoagulants nns including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nsaids nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
effect	18	42	anticoagulants nns including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nsaids nn aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
effect	20	42	anticoagulants nns including vbg coumarin nn derivatives nns indandione nn derivatives nns platelet_aggregation_inhibitors nns such jj as inpos nonsteroidal_anti_inflammatory_drugs nns aspirin nn may md increase vb the dt risk nn of inpos bleeding vbg when wrb administered vbn concomitantly rb with inpos ardeparin nn
advise	4	46	if inpos additional jj adrenergic_drugs nn are vbp to topos be vb administered vbn by inpos any dt route nn they prp should md be vb used vbn with inpos caution nn because inpos the dt pharmacologically rb predictable jj sympathetic jj effects nns of inpos brovana nn may md be vb potentiated vbn
false	2	20	when wrb paroxetine nn a dt potent jj inhibitor nn of inpos cyp2d6 nn was vbd co_administered vbn with inpos brovana nn at inpos steady_state jj exposure nn to topos either cc drug nn was vbd not rb altered vbn
effect	6	20	concomitant jj treatment nn with inpos methylxanthines nns may md potentiate vb any dt hypokalemic jj effect nn of inpos adrenergic_agonists nn
effect	6	20	concomitant jj treatment nn with inpos aminophylline nns may md potentiate vb any dt hypokalemic jj effect nn of inpos adrenergic_agonists nn
effect	6	20	concomitant jj treatment nn with inpos theophylline nns may md potentiate vb any dt hypokalemic jj effect nn of inpos adrenergic_agonists nn
effect	6	20	concomitant jj treatment nn with inpos steroids nns may md potentiate vb any dt hypokalemic jj effect nn of inpos adrenergic_agonists nn
effect	6	20	concomitant jj treatment nn with inpos diuretics nn may md potentiate vb any dt hypokalemic jj effect nn of inpos adrenergic_agonists nn
effect	24	36	the dt ecg nn changes nns and_or cc hypokalemia nn that wdt may md result vb from inpos the dt administration nn of inpos non_potassium_sparing_diuretics nn can md be vb acutely rb worsened vbn by inpos b_agonists nn especially rb when wrb the dt recommended vbn dose nn of inpos the dt b_agonist nn is vbz exceeded vbn
false	24	36	the dt ecg nn changes nns and_or cc hypokalemia nn that wdt may md result vb from inpos the dt administration nn of inpos non_potassium_sparing_diuretics nn can md be vb acutely rb worsened vbn by inpos b_agonists nns especially rb when wrb the dt recommended vbn dose nn of inpos the dt b_agonist nn is vbz exceeded vbn
effect	24	36	the dt ecg nn changes nns and_or cc hypokalemia nn that wdt may md result vb from inpos the dt administration nn of inpos loop nn can md be vb acutely rb worsened vbn by inpos b_agonists nn especially rb when wrb the dt recommended vbn dose nn of inpos the dt b_agonist nn is vbz exceeded vbn
false	24	36	the dt ecg nn changes nns and_or cc hypokalemia nn that wdt may md result vb from inpos the dt administration nn of inpos loop nn can md be vb acutely rb worsened vbn by inpos b_agonists nns especially rb when wrb the dt recommended vbn dose nn of inpos the dt b_agonist nn is vbz exceeded vbn
effect	24	36	the dt ecg nn changes nns and_or cc hypokalemia nn that wdt may md result vb from inpos the dt administration nn of inpos thiazide_diuretics nn can md be vb acutely rb worsened vbn by inpos b_agonists nn especially rb when wrb the dt recommended vbn dose nn of inpos the dt b_agonist nn is vbz exceeded vbn
false	24	36	the dt ecg nn changes nns and_or cc hypokalemia nn that wdt may md result vb from inpos the dt administration nn of inpos thiazide_diuretics nn can md be vb acutely rb worsened vbn by inpos b_agonists nns especially rb when wrb the dt recommended vbn dose nn of inpos the dt b_agonist nn is vbz exceeded vbn
advise	34	38	although inpos the dt clinical jj significance nn of inpos these dt effects nns is vbz not rb known vbn caution nn is vbz advised vbn in inpos the dt co_administration nn of inpos b_agonists nn with inpos non_potassium_sparing_diuretics nn
false	0	8	brovana nn as inpos with inpos other jj b2_agonists nn should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns tricyclic_antidepressants nns drugs nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nns on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
advise	0	32	brovana nn as inpos with inpos other jj b2_agonists nns should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nns on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
advise	0	32	brovana nn as inpos with inpos other jj b2_agonists nns should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos tricyclic_antidepressants nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nns on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	0	58	brovana nn as inpos with inpos other jj b2_agonists nns should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns tricyclic_antidepressants nns drugs nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
advise	8	32	brovana nn as inpos with inpos other jj b2_agonists nn should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nns on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
advise	8	32	brovana nn as inpos with inpos other jj b2_agonists nn should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos tricyclic_antidepressants nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nns on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	8	58	brovana nn as inpos with inpos other jj b2_agonists nn should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns tricyclic_antidepressants nns drugs nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
effect	32	54	brovana nn as inpos with inpos other jj b2_agonists nns should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
effect	32	54	brovana nn as inpos with inpos other jj b2_agonists nns should md be vb administered vbn with inpos extreme jj caution nn to topos patients nns being vbg treated vbn with inpos tricyclic_antidepressants nns known vbn to topos prolong vb the dt qtc nn interval nn because inpos the dt action nn of inpos adrenergic_agonists nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	16	24	the dt concurrent jj use nn of inpos intravenously rb or cc orally rb administered vbn methylxanthines nn by inpos patients nns receiving vbg brovana nn has vbz not rb been vbn completely rb evaluated vbn
false	16	24	the dt concurrent jj use nn of inpos intravenously rb or cc orally rb administered vbn aminophylline nn by inpos patients nns receiving vbg brovana nn has vbz not rb been vbn completely rb evaluated vbn
false	16	24	the dt concurrent jj use nn of inpos intravenously rb or cc orally rb administered vbn theophylline nn by inpos patients nns receiving vbg brovana nn has vbz not rb been vbn completely rb evaluated vbn
false	18	66	in inpos num cd combined jj num_week jj placebo nn controlled jj trials nns that wdt included vbd brovana nn doses nns of inpos num cd mcg nn twice rb daily rb num cd mcg nn twice rb daily rb and cc num cd mcg nn once rb daily rb num cd of inpos num cd brovana nn treated jj subjects nns received vbd concomitant jj theophylline nn at inpos study nn entry nn
false	18	66	in inpos num cd combined jj num_week jj placebo nn controlled jj trials nns that wdt included vbd brovana nn doses nns of inpos num cd mcg nn twice rb daily rb num cd mcg nn twice rb daily rb and cc num cd mcg nn once rb daily rb num cd of inpos num cd brovana nn treated jj subjects nns received vbd concomitant jj theophylline nn at inpos study nn entry nn
false	24	46	in inpos a dt num_month jj controlled jj trial nn that wdt included vbd a dt num cd mcg nn once rb daily jj brovana nn dose nn num cd of inpos the dt num cd brovana nn treated jj subjects nns received vbd concomitant jj theophylline nn at inpos study nn entry nn
false	24	46	in inpos a dt num_month jj controlled jj trial nn that wdt included vbd a dt num cd mcg nn once rb daily jj brovana nn dose nn num cd of inpos the dt num cd brovana nn treated jj subjects nns received vbd concomitant jj theophylline nn at inpos study nn entry nn
effect	0	4	b_adrenergic_receptor_antagonists nn and cc brovana nn may md interfere vb with inpos the dt effect nn of inpos each dt other jj when wrb administered vbn concurrently rb
effect	0	4	b_blockers nn and cc brovana nn may md interfere vb with inpos the dt effect nn of inpos each dt other jj when wrb administered vbn concurrently rb
effect	0	16	b_blockers nn not rb only rb block vb the dt therapeutic jj effects nns of inpos b_agonists nn but cc may md produce vb severe jj bronchospasm nn in inpos copd nn patients nns
false	2	24	since inpos heparin nn is vbz contraindicated vbn in inpos patients nns with inpos heparin_induced jj thrombocytopenia nn the dt co_administration nn of inpos argatroban nn and cc heparin nn is vbz unlikely jj for inpos this dt indication nn
false	2	26	since inpos heparin nn is vbz contraindicated vbn in inpos patients nns with inpos heparin nn induced jj thrombocytopenia nn the dt co_administration nn of inpos argatroban nn and cc heparin nn is vbz unlikely jj for inpos this dt indication nn
false	24	2	since inpos heparin nn is vbz contraindicated vbn in inpos patients nns with inpos heparin_induced jj thrombocytopenia nn the dt co_administration nn of inpos argatroban nn and cc heparin nn is vbz unlikely jj for inpos this dt indication nn
false	4	20	however rb if inpos argatroban nn is vbz to topos be vb initiated vbn after inpos cessation nn of inpos heparin nn therapy nn allow vbp sufficient jj time nn for inpos heparins nns effect nn on inpos the dt aptt nn to topos decrease vb prior jj to topos initiation nn of inpos argatroban nnp therapy nn
false	20	4	however rb if inpos argatroban nnp is vbz to topos be vb initiated vbn after inpos cessation nn of inpos heparin nn therapy nn allow vbp sufficient jj time nn for inpos heparins nns effect nn on inpos the dt aptt nn to topos decrease vb prior jj to topos initiation nn of inpos argatroban nn therapy nn
false	0	2	aspirin nn acetaminophen nn
false	20	26	pharmacokinetic jj or cc pharmacodynamic jj drug_drug nn interactions nns have vbp not rb been vbn demonstrated vbn between inpos argatroban nn concomitantly rb administered vbn aspirin nn acetaminophen nn
false	20	28	pharmacokinetic jj or cc pharmacodynamic jj drug_drug nn interactions nns have vbp not rb been vbn demonstrated vbn between inpos argatroban nn concomitantly rb administered vbn aspirin nn acetaminophen nn
false	26	20	pharmacokinetic jj or cc pharmacodynamic jj drug_drug nn interactions nns have vbp not rb been vbn demonstrated vbn between inpos argatroban nnp concomitantly rb administered vbn aspirin nn lrb_float cd mg nn orally rb given vbn num cd and cc num cd hours nns prior rb to topos initiation nn of inpos argatroban nn num cd g_kg_min. nn over inpos num cd hours nns rrb_acetaminophen nn
false	26	28	pharmacokinetic jj or cc pharmacodynamic jj drug_drug nn interactions nns have vbp not rb been vbn demonstrated vbn between inpos argatroban nnp concomitantly rb administered vbn aspirin nn acetaminophen nn
false	26	20	pharmacokinetic jj or cc pharmacodynamic jj drug_drug nn interactions nns have vbp not rb been vbn demonstrated vbn between inpos argatroban nnp concomitantly rb administered vbn aspirin nn orally rb given vbn num cd num cd num cd hours nns prior rb to topos num cd and cc num cd hours nns subsequent jj to topos initiation nn of inpos argatroban nn float cd g_kg_min. nn over inpos num cd hours nns
false	20	64	pharmacokinetic jj or cc pharmacodynamic jj drug_drug nn interactions nns have vbp not rb been vbn demonstrated vbn between inpos argatroban nnp concomitantly rb administered vbn aspirin nn lrb_float cd mg nn orally rb given vbn num cd and cc num cd hours nns prior rb to topos initiation nn of inpos argatroban nn num cd g_kg_min. nn over inpos num cd hours nns rrb_acetaminophen nn
false	26	20	pharmacokinetic jj or cc pharmacodynamic jj drug_drug nn interactions nns have vbp not rb been vbn demonstrated vbn between inpos argatroban nnp concomitantly rb administered vbn acetaminophen nn orally rb given vbn num cd num cd num cd hours nns prior rb to topos num cd and cc num cd hours nns subsequent jj to topos initiation nn of inpos argatroban nn float cd g_kg_min. nn over inpos num cd hours nns
false	8	12	pharmacokinetic jj drug_drug nn interactions nns between inpos argatroban nn and cc warfarin nn have vbp not rb been vbn demonstrated vbn
effect	10	14	however rb the dt concomitant jj use nn of inpos argatroban nn and cc warfarin nn results vbz in inpos prolongation nn of inpos the dt prothrombin nn time nn and cc international nnp normalized nnp ratio nnp
false	10	14	the dt safety nn and cc effectiveness nn of inpos argatroban nn with inpos thrombolytic_agents nn have vbp not rb been vbn established vbn
effect	6	10	concomitant jj use nn of inpos argatroban nn with inpos antiplatelet_agents nn thrombolytics nns other jj anticoagulants nns may md increase vb the dt risk nn of inpos bleeding vbg
effect	6	12	concomitant jj use nn of inpos argatroban nn with inpos antiplatelet_agents nns thrombolytics nn other jj anticoagulants nns may md increase vb the dt risk nn of inpos bleeding vbg
effect	6	16	concomitant jj use nn of inpos argatroban nn with inpos antiplatelet_agents nns thrombolytics nns other jj anticoagulants nn may md increase vb the dt risk nn of inpos bleeding vbg
false	10	12	concomitant jj use nn of inpos argatroban nn with inpos antiplatelet_agents nn thrombolytics nn other jj anticoagulants nns may md increase vb the dt risk nn of inpos bleeding vbg
false	10	16	concomitant jj use nn of inpos argatroban nn with inpos antiplatelet_agents nn thrombolytics nns other jj anticoagulants nn may md increase vb the dt risk nn of inpos bleeding vbg
false	12	16	concomitant jj use nn of inpos argatroban nnp with inpos antiplatelet_agents nns thrombolytics nn other jj anticoagulants nn may md increase vb the dt risk nn of inpos bleeding vbg
false	16	28	drug_drug jj interactions nns given vbn the dt primary jj cns nn effects nns of inpos aripiprazole nn caution nn should md be vb used vbn when wrb abilify nn is vbz taken vbn in inpos combination nn with inpos other jj centrally_acting_drugs nns and cc alcohol nn
false	16	42	drug_drug jj interactions nns given vbn the dt primary jj cns nn effects nns of inpos aripiprazole nn caution nn should md be vb used vbn when wrb abilify nn is vbz taken vbn in inpos combination nn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
false	16	46	drug_drug jj interactions nns given vbn the dt primary jj cns nn effects nns of inpos aripiprazole nn caution nn should md be vb used vbn when wrb abilify nn is vbz taken vbn in inpos combination nn with inpos other jj centrally_acting_drugs nns and cc alcohol nn
advise	28	42	drug_drug jj interactions nns given vbn the dt primary jj cns nn effects nns of inpos aripiprazole nn caution nn should md be vb used vbn when wrb abilify nn is vbz taken vbn in inpos combination nn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
advise	28	46	drug_drug jj interactions nns given vbn the dt primary jj cns nn effects nns of inpos aripiprazole nn caution nn should md be vb used vbn when wrb abilify nn is vbz taken vbn in inpos combination nn with inpos other jj centrally_acting_drugs nns and cc alcohol nn
false	42	46	drug_drug jj interactions nns given vbn the dt primary jj cns nn effects nns of inpos aripiprazole nn caution nn should md be vb used vbn when wrb abilify nn is vbz taken vbn in inpos combination nn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
effect	8	28	num cd adrenergic jj receptor nn antagonism nn aripiprazole nn has vbz the dt potential nn to topos enhance vb the dt effect nn of inpos certain jj antihypertensive_agents nn
false	12	14	potential jj for inpos other jj drugs nns to topos affect vb abilify nn aripiprazole nn is vbz not rb a dt substrate nn of inpos cyp1a1 nn cyp1a2 nn cyp2a6 nn cyp2b6 nn cyp2c8 nn cyp2c9 nn cyp2c19 nn cyp2e1 nn enzymes nns
mechanism	6	18	agents nns that wdt induce vbp carbamazepine nn could md cause vb an dt increase nn in inpos aripiprazole nn clearance nn and cc lower jjr blood nn levels nns
false	4	8	inhibitors nns of inpos ketoconazole nn or cc quinidine nn can md inhibit vb aripiprazole nn elimination nn and cc cause vbp increased vbn blood nn levels nns
false	4	8	inhibitors nns of inpos ketoconazole nn or cc fluoxetine nn can md inhibit vb aripiprazole nn elimination nn and cc cause vbp increased vbn blood nn levels nns
false	4	8	inhibitors nns of inpos ketoconazole nn or cc paroxetine nn can md inhibit vb aripiprazole nn elimination nn and cc cause vbp increased vbn blood nn levels nns
mechanism	4	14	inhibitors nns of inpos ketoconazole nn or cc cyp2d6 nn can md inhibit vb aripiprazole nn elimination nn and cc cause vbp increased vbn blood nn levels nns
mechanism	8	14	inhibitors nns of inpos cyp3a4 nn or cc quinidine nn can md inhibit vb aripiprazole nn elimination nn and cc cause vbp increased vbn blood nn levels nns
mechanism	8	14	inhibitors nns of inpos cyp3a4 nn or cc fluoxetine nn can md inhibit vb aripiprazole nn elimination nn and cc cause vbp increased vbn blood nn levels nns
mechanism	8	14	inhibitors nns of inpos cyp3a4 nn or cc paroxetine nn can md inhibit vb aripiprazole nn elimination nn and cc cause vbp increased vbn blood nn levels nns
false	0	20	ketoconazole nn coadministration nn of inpos ketoconazole nn with inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn increased vbd the dt auc nn of inpos aripiprazole nn and cc its prp active jj metabolite nn by inpos num cd and cc num cd respectively rb
false	0	20	ketoconazole nn coadministration nn of inpos ketoconazole nn with inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn increased vbd the dt auc nn of inpos aripiprazole nn and cc its prp active jj metabolite nn by inpos num cd and cc num cd respectively rb
mechanism	4	18	coadministration nn of inpos ketoconazole nn with inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn increased vbd the dt auc nn of inpos aripiprazole nn and cc its prp active jj metabolite nn by inpos num cd and cc num cd respectively rb
false	4	18	coadministration nn of inpos ketoconazole nn with inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn increased vbd the dt auc nn of inpos aripiprazole nn and cc its prp active jj metabolite nn by inpos num cd and cc num cd respectively rb
advise	8	12	when wrb concomitant jj administration nn of inpos ketoconazole nn with inpos aripiprazole nn occurs vbz aripiprazole nn dose nn should md be vb reduced vbn to topos one_half nn of inpos its prp normal jj dose nn
false	8	12	when wrb concomitant jj administration nn of inpos ketoconazole nn with inpos aripiprazole nn occurs vbz aripiprazole nn dose nn should md be vb reduced vbn to topos one_half nn of inpos its prp normal jj dose nn
false	0	16	quinidine nn coadministration nn of inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn with inpos quinidine nn a dt potent jj inhibitor nn of inpos cyp2d6 nn increased vbd the dt auc nn of inpos aripiprazole nn by inpos num cd but cc decreased vbd the dt auc nn of inpos its prp active jj metabolite nn dehydroaripiprazole nn by inpos num cd
false	0	16	quinidine nn coadministration nn of inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn with inpos quinidine nn a dt potent jj inhibitor nn of inpos cyp2d6 nn increased vbd the dt auc nn of inpos aripiprazole nn by inpos num cd but cc decreased vbd the dt auc nn of inpos its prp active jj metabolite nn dehydroaripiprazole nn by inpos num cd
false	0	62	quinidine nn coadministration nn of inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn with inpos quinidine nn a dt potent jj inhibitor nn of inpos cyp2d6 nn increased vbd the dt auc nn of inpos aripiprazole nn by inpos num cd but cc decreased vbd the dt auc nn of inpos its prp active jj metabolite nn dehydroaripiprazole nn by inpos num cd
mechanism	14	18	coadministration nn of inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn with inpos quinidine nn a dt potent jj inhibitor nn of inpos cyp2d6 nn increased vbd the dt auc nn of inpos aripiprazole nn by inpos num cd but cc decreased vbd the dt auc nn of inpos its prp active jj metabolite nn dehydroaripiprazole nn by inpos num cd
false	18	14	coadministration nn of inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn with inpos quinidine nn a dt potent jj inhibitor nn of inpos cyp2d6 nn increased vbd the dt auc nn of inpos aripiprazole nn by inpos num cd but cc decreased vbd the dt auc nn of inpos its prp active jj metabolite nn dehydroaripiprazole nn by inpos num cd
false	18	60	coadministration nn of inpos a dt num_mg jj single jj dose nn of inpos aripiprazole nn with inpos quinidine nn a dt potent jj inhibitor nn of inpos cyp2d6 nn increased vbd the dt auc nn of inpos aripiprazole nn by inpos num cd but cc decreased vbd the dt auc nn of inpos its prp active jj metabolite nn dehydroaripiprazole nn by inpos num cd
false	0	30	aripiprazole nn dose nn should md be vb reduced vbn to topos one_half nn of inpos its prp normal jj dose nn when wrb concomitant jj administration nn of inpos quinidine nn with inpos aripiprazole nn occurs vbz
advise	30	0	aripiprazole nn dose nn should md be vb reduced vbn to topos one_half nn of inpos its prp normal jj dose nn when wrb concomitant jj administration nn of inpos quinidine nn with inpos aripiprazole nn occurs vbz
false	14	18	other jj significant jj inhibitors nns of inpos cyp2d6 nn such jj as inpos fluoxetine nn or cc paroxetine nn would md be vb expected vbn to topos have vb similar jj effects nns and cc therefore rb should md be vb accompanied vbn by inpos similar jj dose nn reductions nns
false	0	18	carbamazepine nn coadministration nn of inpos carbamazepine nn a dt potent jj cyp3a4 nn inducer nn with inpos aripiprazole nn resulted vbd in inpos an dt approximate jj num cd decrease nn in inpos cmax nn and cc auc nn values nns of inpos both cc aripiprazole nn and cc its prp active jj metabolite nn dehydro_aripiprazole nn
false	0	18	carbamazepine nn coadministration nn of inpos carbamazepine nn a dt potent jj cyp3a4 nn inducer nn with inpos aripiprazole nn resulted vbd in inpos an dt approximate jj num cd decrease nn in inpos cmax nn and cc auc nn values nns of inpos both cc aripiprazole nn and cc its prp active jj metabolite nn dehydro_aripiprazole nn
false	0	56	carbamazepine nn coadministration nn of inpos carbamazepine nn a dt potent jj cyp3a4 nn inducer nn with inpos aripiprazole nn resulted vbd in inpos an dt approximate jj num cd decrease nn in inpos cmax nn and cc auc nn values nns of inpos both cc aripiprazole nn and cc its prp active jj metabolite nn dehydro_aripiprazole nn
mechanism	0	18	carbamazepine nnp coadministration nn of inpos carbamazepine nn a dt potent jj cyp3a4 nn inducer nn with inpos aripiprazole nn resulted vbd in inpos an dt approximate jj num cd decrease nn in inpos cmax nn and cc auc nn values nns of inpos both cc aripiprazole nn and cc its prp active jj metabolite nn dehydro_aripiprazole nn
false	0	18	carbamazepine nnp coadministration nn of inpos carbamazepine nn a dt potent jj cyp3a4 nn inducer nn with inpos aripiprazole nn resulted vbd in inpos an dt approximate jj num cd decrease nn in inpos cmax nn and cc auc nn values nns of inpos both cc aripiprazole nn and cc its prp active jj metabolite nn dehydro_aripiprazole nn
false	0	56	carbamazepine nnp coadministration nn of inpos carbamazepine nn a dt potent jj cyp3a4 nn inducer nn with inpos aripiprazole nn resulted vbd in inpos an dt approximate jj num cd decrease nn in inpos cmax nn and cc auc nn values nns of inpos both cc aripiprazole nn and cc its prp active jj metabolite nn dehydro_aripiprazole nn
advise	2	10	when wrb carbamazepine nn is vbz added vbn to topos aripiprazole nn therapy nn aripiprazole nn dose nn should md be vb doubled vbn
false	2	10	when wrb carbamazepine nn is vbz added vbn to topos aripiprazole nn therapy nn aripiprazole nn dose nn should md be vb doubled vbn
advise	2	16	when wrb carbamazepine nn is vbz withdrawn vbn from inpos the dt combination nn therapy nn aripiprazole nn dose nn should md then rb be vb reduced vbn
false	10	24	no dt clinically rb significant jj effect nn of inpos famotidine nn was vbd seen vbn on inpos the dt pharmacokinetics nns of inpos aripiprazole nn
false	10	24	no dt clinically rb significant jj effect nn of inpos valproate nn was vbd seen vbn on inpos the dt pharmacokinetics nns of inpos aripiprazole nn
false	10	24	no dt clinically rb significant jj effect nn of inpos lithium nn was vbd seen vbn on inpos the dt pharmacokinetics nns of inpos aripiprazole nn
false	4	14	potential jj for inpos abilify nn to topos affect vb other jj drugs nnp aripiprazole nn is vbz unlikely jj to topos cause vb clinically rb important jj pharmacokinetic jj interactions nns with inpos drugs nns metabolized vbn by inpos cytochrome nn p450 nn enzymes nns
false	18	34	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos dextromethorphan nn cyp3a4 nn substrates nns
false	18	34	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos warfarin nn cyp3a4 nn substrates nns
false	18	34	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos omeprazole nn cyp3a4 nn substrates nns
false	18	34	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos warfarin nn cyp3a4 nn substrates nns
false	18	40	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos cyp2d6 nn cyp2c9 nn cyp2c19 nn dextromethorphan nn substrates nns
false	34	36	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos warfarin nn dextromethorphan nn substrates nns
false	34	36	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos omeprazole nn dextromethorphan nn substrates nns
false	34	36	in inpos in fw vivo fw studies nns num cd to topos num_mg_day jj doses nns of inpos aripiprazole nn had vbd no dt significant jj effect nn on inpos metabolism nn by inpos warfarin nn dextromethorphan nn substrates nns
false	12	18	there ex was vbd no dt significant jj difference nn between inpos aripiprazole nn coadministered vbn with inpos ethanol nn and cc placebo nn coadministered vbn with inpos ethanol nn on inpos performance nn of inpos gross jj motor nn skills nns or cc stimulus nn response nn in inpos healthy jj subjects nns
false	12	18	there ex was vbd no dt significant jj difference nn between inpos aripiprazole nn coadministered vbn with inpos ethanol nn and cc placebo nn coadministered vbn with inpos ethanol nn on inpos performance nn of inpos gross jj motor nn skills nns or cc stimulus nn response nn in inpos healthy jj subjects nns
advise	22	28	as inpos with inpos most jjs psychoactive jj medications nns patients nns should md be vb advised vbn to topos avoid vb alcohol nn while inpos taking vbg abilify nn
advise	8	30	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn antiarrhythmics nn or cc lead vb to topos electrolyte vb abnormalities nns
advise	8	30	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn thioridazine nn or cc lead vb to topos electrolyte vb abnormalities nns
advise	8	40	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn interval nn or cc lead vb to topos electrolyte vb diuretics nn
advise	8	40	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn interval nn or cc lead vb to topos electrolyte vb amphotericin_b nn
false	30	40	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn antiarrhythmics nn or cc lead vb to topos electrolyte vb diuretics nn
false	30	40	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn antiarrhythmics nn or cc lead vb to topos electrolyte vb amphotericin_b nn
false	30	40	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn thioridazine nn or cc lead vb to topos electrolyte vb diuretics nn
false	30	40	caution nn is vbz advised vbn when wrb trisenox nn is vbz coadministered vbn with inpos other jj medications nns that wdt can md prolong vb the dt qt nn thioridazine nn or cc lead vb to topos electrolyte vb amphotericin_b nn
effect	14	30	tissue nn culture nn and cc animal nn studies nns indicate vbp that inpos elspar nn can md diminish vb or cc abolish vb the dt effect nn of inpos methotrexate nn on inpos malignant jj cells.14 nns this dt effect nn on inpos methotrexate nn activity nn persists vbz as rb long rb as inpos plasma nn asparagine nn levels nns are vbp suppressed vbn
false	14	30	tissue nn culture nn and cc animal nn studies nns indicate vbp that inpos elspar nn can md diminish vb or cc abolish vb the dt effect nn of inpos methotrexate nn on inpos malignant jj cells.14 nns this dt effect nn on inpos methotrexate nn activity nn persists vbz as rb long rb as inpos plasma nn asparagine nn levels nns are vbp suppressed vbn
advise	22	26	these dt results nns would md seem vb to topos dictate vb against inpos the dt clinical jj use nn of inpos methotrexate nn with inpos elspar nn or cc during inpos the dt period nn following vbg elspar nn therapy nn when wrb plasma nn asparagine nn levels nns are vbp below inpos normal jj
false	22	26	these dt results nns would md seem vb to topos dictate vb against inpos the dt clinical jj use nn of inpos methotrexate nn with inpos elspar nn or cc during inpos the dt period nn following vbg elspar nn therapy nn when wrb plasma nn asparagine nn levels nns are vbp below inpos normal jj
effect	0	12	aspirin nn may md decrease vb the dt effects nns of inpos probenecid nn
effect	0	12	aspirin nn may md decrease vb the dt effects nns of inpos sulfinpyrazone nn
effect	0	12	aspirin nn may md decrease vb the dt effects nns of inpos phenylbutazone nn
effect	0	8	corticosteroids nn concomitant jj administration nn with inpos aspirin nn may md increase vb the dt risk nn of inpos gastrointestinal jj ulceration nn and cc may md reduce vb serum nn salicylate nn levels nns
effect	0	8	pyrazolone_derivatives nn concomitant jj administration nn with inpos aspirin nn may md increase vb the dt risk nn of inpos gastrointestinal jj ulceration nn
effect	0	8	phenylbutazone nn concomitant jj administration nn with inpos aspirin nn may md increase vb the dt risk nn of inpos gastrointestinal jj ulceration nn
effect	0	8	oxyphenbutazone nn concomitant jj administration nn with inpos aspirin nn may md increase vb the dt risk nn of inpos gastrointestinal jj ulceration nn
effect	0	8	dipyrone nn concomitant jj administration nn with inpos aspirin nn may md increase vb the dt risk nn of inpos gastrointestinal jj ulceration nn
advise	0	18	aspirin nn is vbz contraindicated vbn in inpos patients nns who wp are vbp hypersensitive jj to topos nonsteroidal_anti_inflammatory nn agents nns
false	2	16	decrease nn aspirin nn effectiveness nn by inpos increasing vbg the dt rate nn of inpos salicylate nn renal jj excretion nn
mechanism	0	4	phenobarbital nn decreases vbz aspirin nn effectiveness nn by inpos enzyme nn induction nn
effect	2	14	serum nn phenytoin nn levels nns may md be vb increased vbn by inpos aspirin nn
effect	0	6	propranolol nn may md decrease vb aspirins nn anti_inflammatory jj action nn by inpos competing vbg for inpos the dt same jj receptors nns
advise	4	18	enteric nnp coated nnp aspirin nn should md not rb be vb given vbn concurrently rb with inpos antacids nn since inpos an dt increase nn in inpos the dt ph nn of inpos the dt stomach nn may md effect vb the dt enteric jj coating nn of inpos the dt tablets nns
false	0	2	ketoconazole nn itraconazole nn macrolides nnp including vbg erythromycin nn
false	0	4	ketoconazole nn itraconazole nn macrolides nn including vbg erythromycin nn
false	0	8	ketoconazole nn itraconazole nn macrolides nnp including vbg erythromycin nn
false	2	4	ketoconazole nnp itraconazole nn macrolides nn including vbg erythromycin nn
false	2	8	ketoconazole nnp itraconazole nn macrolides nnp including vbg erythromycin nn
false	2	6	ketoconazole_itraconazole nn macrolides nn including vbg erythromycin nn
effect	2	20	catecholamine_depleting jj reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking_agent nn s nns
effect	0	20	calcium_channel_blockers nn may md also rb have vb an dt additive jj effect nn when wrb given vbn with inpos tenormin nn
effect	0	24	b_blockers nn may md exacerbate vb the dt rebound nn hypertension nn which wdt can md follow vb the dt withdrawal nn of inpos clonidine nn
advise	14	36	if inpos the dt num cd drugs nns are vbp coadministered vbn the dt b_blocker nn should md be vb withdrawn vbn several jj days nns before inpos the dt gradual jj withdrawal nn of inpos clonidine nn
false	4	8	if inpos replacing vbg clonidine nn by inpos b_blocker nn therapy nn the dt introduction nn of inpos b_blockers nns should md be vb delayed vbn for inpos several jj days nns after inpos clonidine nn administration nn has vbz stopped vbn
false	4	18	if inpos replacing vbg clonidine nn by inpos b_blocker nn therapy nn the dt introduction nn of inpos b_blockers nn should md be vb delayed vbn for inpos several jj days nns after inpos clonidine nn administration nn has vbz stopped vbn
false	8	18	if inpos replacing vbg clonidine nn by inpos b_blocker nn therapy nn the dt introduction nn of inpos b_blockers nn should md be vb delayed vbn for inpos several jj days nns after inpos clonidine nn administration nn has vbz stopped vbn
false	8	4	if inpos replacing vbg clonidine nn by inpos b_blocker nn therapy nn the dt introduction nn of inpos b_blockers nns should md be vb delayed vbn for inpos several jj days nns after inpos clonidine nn administration nn has vbz stopped vbn
advise	18	4	if inpos replacing vbg clonidine nn by inpos b_blocker nn therapy nn the dt introduction nn of inpos b_blockers nn should md be vb delayed vbn for inpos several jj days nns after inpos clonidine nn administration nn has vbz stopped vbn
effect	16	30	concomitant jj use nn of inpos prostaglandin nn synthase nn inhibiting vbg drugs nns eg fw indomethacin nn may md decrease vb the dt hypotensive jj effects nns of inpos b_blockers nn
false	10	14	information nn on inpos concurrent jj usage nn of inpos atenolol nn and cc aspirin nn is vbz limited vbn
false	30	34	data nns from inpos several jj studies nns ie fw timi_ii nn isis_num nn currently rb do vbp not rb suggest vb any dt clinical jj interaction nn between inpos aspirin nn and cc b_blockers nn in inpos the dt acute jj myocardial jj infarction nn setting vbg
false	4	6	drug_drug nnp interactions nns albuterol nn hyph_strattera nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos systemically_administered jj albuterol nn because inpos the dt action nn of inpos albuterol nn on inpos the dt cardiovascular jj system nn can md be vb potentiated vbn resulting vbg in inpos increases nns in inpos heart nn rate nn and cc blood nn pressure nn
false	4	30	drug_drug nnp interactions nns albuterol nn hyph_strattera nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos systemically_administered jj b2_agonists nn because inpos the dt action nn of inpos albuterol nn on inpos the dt cardiovascular jj system nn can md be vb potentiated vbn resulting vbg in inpos increases nns in inpos heart nn rate nn and cc blood nn pressure nn
advise	6	4	drug_drug nnp interactions nnp albuterol nnp hyph_strattera nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos systemically_administered jj albuterol nn because inpos the dt action nn of inpos albuterol nn on inpos the dt cardiovascular jj system nn can md be vb potentiated vbn resulting vbg in inpos increases nns in inpos heart nn rate nn and cc blood nn pressure nn
false	6	30	drug_drug nnp interactions nnp albuterol nnp hyph_strattera nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos systemically_administered jj b2_agonists nn because inpos the dt action nn of inpos albuterol nn on inpos the dt cardiovascular jj system nn can md be vb potentiated vbn resulting vbg in inpos increases nns in inpos heart nn rate nn and cc blood nn pressure nn
false	6	4	drug_drug nnp interactions nnp albuterol nnp hyph_strattera nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos systemically_administered jj albuterol nn because inpos the dt action nn of inpos albuterol nn on inpos the dt cardiovascular jj system nn can md be vb potentiated vbn resulting vbg in inpos increases nns in inpos heart nn rate nn and cc blood nn pressure nn
false	30	4	drug_drug nnp interactions nnp albuterol nnp hyph_strattera nn should md be vb administered vbn with inpos caution nn to topos patients nns being vbg treated vbn with inpos systemically_administered jj b2_agonists nn because inpos the dt action nn of inpos albuterol nn on inpos the dt cardiovascular jj system nn can md be vb potentiated vbn resulting vbg in inpos increases nns in inpos heart nn rate nn and cc blood nn pressure nn
advise	6	26	dosage nn adjustment nn of inpos strattera nn may md be vb necessary jj when wrb coadministered vbn with inpos cyp2d6 nn inhibitors nns e.g. fw paroxetine nn
advise	6	26	dosage nn adjustment nn of inpos strattera nn may md be vb necessary jj when wrb coadministered vbn with inpos cyp2d6 nn inhibitors nns e.g. fw fluoxetine nn
advise	6	26	dosage nn adjustment nn of inpos strattera nn may md be vb necessary jj when wrb coadministered vbn with inpos cyp2d6 nn inhibitors nns e.g. fw quinidine nn
false	10	14	in inpos em nn individuals nns treated vbn with inpos paroxetine nn or cc fluoxetine nn the dt auc nn of inpos atomoxetine nn is vbz approximately rb num cd to topos num_fold jj and cc css nnp max nn is vbz about rb num cd to topos num_fold rb greater jjr than inpos atomoxetine nn alone rb
mechanism	10	22	in inpos em nn individuals nns treated vbn with inpos paroxetine nn or cc fluoxetine nn the dt auc nn of inpos atomoxetine nn is vbz approximately rb num cd to topos num_fold jj and cc css nnp max nn is vbz about rb num cd to topos num_fold rb greater jjr than inpos atomoxetine nn alone rb
false	10	22	in inpos em nn individuals nns treated vbn with inpos paroxetine nn or cc fluoxetine nn the dt auc nn of inpos atomoxetine nn is vbz approximately rb num cd to topos num_fold jj and cc css nnp max nn is vbz about rb num cd to topos num_fold rb greater jjr than inpos atomoxetine nn alone rb
mechanism	14	22	in inpos em nn individuals nns treated vbn with inpos paroxetine nn or cc fluoxetine nn the dt auc nn of inpos atomoxetine nn is vbz approximately rb num cd to topos num_fold jj and cc css nnp max nn is vbz about rb num cd to topos num_fold rb greater jjr than inpos atomoxetine nn alone rb
false	14	22	in inpos em nn individuals nns treated vbn with inpos paroxetine nn or cc fluoxetine nn the dt auc nn of inpos atomoxetine nn is vbz approximately rb num cd to topos num_fold jj and cc css nnp max nn is vbz about rb num cd to topos num_fold rb greater jjr than inpos atomoxetine nn alone rb
mechanism	2	6	when wrb atorvastatin nn and cc maalox_tc nn suspension nn were vbd coadministered vbn plasma nn concentrations nns of inpos atorvastatin nn decreased vbd approximately rb num cd
false	6	2	when wrb atorvastatin nn and cc maalox_tc nn suspension nn were vbd coadministered vbn plasma nn concentrations nns of inpos atorvastatin nn decreased vbd approximately rb num cd
false	2	16	because inpos atorvastatin nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos antipyrine nn interactions nns with inpos other jj drugs nns metabolized vbn via inpos the dt same jj cytochrome nn isozymes nns are vbp not rb expected vbn
false	2	24	because inpos atorvastatin nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos antipyrine nn interactions nns with inpos other jj drugs nn metabolized vbn via inpos the dt same jj cytochrome nn isozymes nns are vbp not rb expected vbn
false	16	24	because inpos atorvastatin nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos antipyrine nn interactions nns with inpos other jj drugs nn metabolized vbn via inpos the dt same jj cytochrome nn isozymes nns are vbp not rb expected vbn
false	6	16	plasma nn concentrations nns of inpos atorvastatin nn decreased vbd approximately rb num cd when wrb colestipol nn and cc atorvastatin nn were vbd coadministered vbn
mechanism	16	6	plasma nn concentrations nns of inpos atorvastatin nn decreased vbd approximately rb num cd when wrb colestipol nn and cc atorvastatin nn were vbd coadministered vbn
effect	12	16	however rb ldl_c nn reduction nn was vbd greater jjr when wrb atorvastatin nn and cc colestipol nn were vbd coadministered vbn than inpos when wrb either cc drug nn was vbd given vbn alone rb
false	0	24	atorvastatin nn plasma nn concentrations nns and cc ldl_c nn reduction nn were vbd not rb altered vbn by inpos coadministration nn of inpos cimetidine nn
mechanism	8	12	when wrb multiple jj doses nns of inpos atorvastatin nn and cc digoxin nn were vbd coadministered vbn steady_state jj plasma nn digoxin nn concentrations nns increased vbd by inpos approximately rb num cd
false	8	12	when wrb multiple jj doses nns of inpos atorvastatin nn and cc digoxin nn were vbd coadministered vbn steady_state jj plasma nn digoxin nn concentrations nns increased vbd by inpos approximately rb num cd
false	0	14	erythromycin nn in inpos healthy jj individuals nns plasma nn concentrations nns of inpos atorvastatin nn increased vbd approximately rb num cd with inpos coadministration nn of inpos atorvastatin nn and cc erythromycin nn a dt known jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn
false	0	14	erythromycin nn in inpos healthy jj individuals nns plasma nn concentrations nns of inpos atorvastatin nn increased vbd approximately rb num cd with inpos coadministration nn of inpos atorvastatin nn and cc erythromycin nn a dt known jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn
false	14	0	erythromycin nn in inpos healthy jj individuals nns plasma nn concentrations nns of inpos atorvastatin nn increased vbd approximately rb num cd with inpos coadministration nn of inpos atorvastatin nn and cc erythromycin nn a dt known jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn
mechanism	14	0	erythromycin nn in inpos healthy jj individuals nns plasma nn concentrations nns of inpos atorvastatin nn increased vbd approximately rb num cd with inpos coadministration nn of inpos atorvastatin nn and cc erythromycin nn a dt known jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn
false	2	8	oral jj contraceptives nn coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
false	2	26	oral jj contraceptives nn coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
false	2	30	oral jj contraceptives nn coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
mechanism	4	12	coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
mechanism	4	22	coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
mechanism	4	26	coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
false	12	22	coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
false	12	26	coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
false	22	26	coadministration nn of inpos atorvastatin nn and cc an dt oral jj contraceptive nn increased vbd auc nn values nns for inpos norethindrone nn and cc ethinyl_estradiol nn by inpos approximately rb num cd and cc num cd
advise	18	28	these dt increases nns should md be vb considered vbn when wrb selecting vbg an dt oral jj contraceptive nn for inpos a dt woman nn taking vbg atorvastatin nn
false	0	30	atorvastatin nn had vbd no dt clinically rb significant jj effect nn on inpos prothrombin nn time nn when wrb administered vbn to topos patients nns receiving vbg chronic jj warfarin nn treatment nn
advise	12	50	caution nn should md be vb exercised vbn if inpos an dt hmg_coa_reductase_inhibitor nn is vbz administered vbn concomitantly rb with inpos drugs nns that wdt may md decrease vb the dt levels nns or cc activity nn of inpos endogenous jj steroid nn hormones nns such jj as inpos ketoconazole nn
advise	12	50	caution nn should md be vb exercised vbn if inpos an dt hmg_coa_reductase_inhibitor nn is vbz administered vbn concomitantly rb with inpos drugs nns that wdt may md decrease vb the dt levels nns or cc activity nn of inpos endogenous jj steroid nn hormones nns such jj as inpos spironolactone nn
advise	12	50	caution nn should md be vb exercised vbn if inpos an dt hmg_coa_reductase_inhibitor nn is vbz administered vbn concomitantly rb with inpos drugs nns that wdt may md decrease vb the dt levels nns or cc activity nn of inpos endogenous jj steroid nn hormones nns such jj as inpos cimetidine nn
false	14	42	the dt extent nn of inpos plasma nn protein nn binding nn of inpos atovaquone nn in inpos human jj plasma nn is vbz not rb affected vbn by inpos the dt presence nn of inpos therapeutic jj concentrations nns of inpos phenytoin nn nor cc is vbz the dt binding nn of inpos phenytoin nn affected vbn by inpos the dt presence nn of inpos atovaquone nn
false	14	42	the dt extent nn of inpos plasma nn protein nn binding nn of inpos atovaquone nn in inpos human jj plasma nn is vbz not rb affected vbn by inpos the dt presence nn of inpos therapeutic jj concentrations nns of inpos phenytoin nn nor cc is vbz the dt binding nn of inpos phenytoin nn affected vbn by inpos the dt presence nn of inpos atovaquone nn
false	42	14	the dt extent nn of inpos plasma nn protein nn binding nn of inpos atovaquone nn in inpos human jj plasma nn is vbz not rb affected vbn by inpos the dt presence nn of inpos therapeutic jj concentrations nns of inpos phenytoin nn nor cc is vbz the dt binding nn of inpos phenytoin nn affected vbn by inpos the dt presence nn of inpos atovaquone nn
false	42	14	the dt extent nn of inpos plasma nn protein nn binding nn of inpos atovaquone nn in inpos human jj plasma nn is vbz not rb affected vbn by inpos the dt presence nn of inpos therapeutic jj concentrations nns of inpos phenytoin nn nor cc is vbz the dt binding nn of inpos phenytoin nn affected vbn by inpos the dt presence nn of inpos atovaquone nn
false	0	10	rifampin nn coadministration nn of inpos rifampin nn and cc mepron nn suspension nn results vbz in inpos a dt significant jj decrease nn in inpos average jj steady jj state nn plasma nn atovaquone nn concentrations nns
false	0	34	rifampin nn coadministration nn of inpos rifampin nn and cc mepron nn suspension nn results vbz in inpos a dt significant jj decrease nn in inpos average jj steady jj state nn plasma nn atovaquone nn concentrations nns
mechanism	4	8	coadministration nn of inpos rifampin nn and cc mepron nn suspension nn results vbz in inpos a dt significant jj decrease nn in inpos average jj steady jj state nn plasma nn atovaquone nn concentrations nns
false	4	32	coadministration nn of inpos rifampin nn and cc mepron nn suspension nn results vbz in inpos a dt significant jj decrease nn in inpos average jj steady jj state nn plasma nn atovaquone nn concentrations nns
false	8	32	coadministration nn of inpos rifampin nn and cc mepron nn suspension nn results vbz in inpos a dt significant jj decrease nn in inpos average jj steady jj state nn plasma nn atovaquone nn concentrations nns
advise	4	26	alternatives nns to topos rifampin nn should md be vb considered vbn during inpos the dt course nn of inpos pcp nn treatment nn with inpos mepron nn
false	0	4	rifabutin nn another dt rifamycin nn is vbz structurally rb similar jj to topos rifampin nn and cc may md possibly rb have vb some dt of inpos the dt same jj drug nn interactions nns as inpos rifampin nn
false	0	14	rifabutin nn another dt rifamycin nn is vbz structurally rb similar jj to topos rifampin nn and cc may md possibly rb have vb some dt of inpos the dt same jj drug nn interactions nns as inpos rifampin nn
false	0	14	rifabutin nn another dt rifamycin nn is vbz structurally rb similar jj to topos rifampin nn and cc may md possibly rb have vb some dt of inpos the dt same jj drug nn interactions nns as inpos rifampin nn
false	4	14	rifabutin nn another dt rifamycin nn is vbz structurally rb similar jj to topos rifampin nn and cc may md possibly rb have vb some dt of inpos the dt same jj drug nn interactions nns as inpos rifampin nn
false	4	14	rifabutin nn another dt rifamycin nn is vbz structurally rb similar jj to topos rifampin nn and cc may md possibly rb have vb some dt of inpos the dt same jj drug nn interactions nns as inpos rifampin nn
false	14	18	no dt interaction nn trials nns have vbp been vbn conducted vbn with inpos mepron nn and cc rifabutin nn
effect	18	22	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn
false	2	8	certain jj antibiotics nn especially rb the dt aminoglycosides nn and cc polymyxins nns
false	2	12	certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nn
false	8	12	certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nn
effect	18	22	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	24	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	26	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	30	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	36	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	40	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	42	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	18	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	24	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	26	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	30	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	36	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	40	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	42	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	22	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	26	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	30	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	36	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	40	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	42	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	24	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	26	30	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	26	36	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	26	40	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	26	42	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	26	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	26	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	26	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	30	36	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	30	40	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	30	42	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	30	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	30	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	30	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nn especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	36	40	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	36	42	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	36	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	36	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	36	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nn and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	40	42	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	40	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	40	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	40	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nn lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	42	44	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	42	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	42	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	44	48	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	44	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
false	48	52	drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos tracrium nn include vbp enflurane nn isoflurane nn halothane nn certain jj antibiotics nns especially rb the dt aminoglycosides nns and cc polymyxins nns lithium nn magnesium nn salts nns procainamide nn and cc quinidine nn
effect	8	48	the dt prior jj administration nn of inpos succinylcholine nn does vbz not rb enhance vb the dt duration nn but cc quickens vbz the dt onset nn and cc may md increase vb the dt depth nn of inpos neuromuscular jj block nn induced vbn by inpos tracrium nn
advise	0	22	tracrium nn should md not rb be vb administered vbn until inpos a dt patient nn has vbz recovered vbn from inpos succinylcholine nn induced jj neuromuscular jj block nn
effect	2	6	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn than inpos when wrb atropine nn is vbz used vbn alone rb because inpos pralidoxime nn may md potentiate vb the dt effect nn of inpos atropine nn
false	2	6	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn than inpos when wrb atropine nn is vbz used vbn alone rb because inpos pralidoxime nn may md potentiate vb the dt effect nn of inpos atropine nn
false	6	2	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn than inpos when wrb atropine nn is vbz used vbn alone rb because inpos pralidoxime nn may md potentiate vb the dt effect nn of inpos atropine nn
false	6	2	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn than inpos when wrb atropine nn is vbz used vbn alone rb because inpos pralidoxime nn may md potentiate vb the dt effect nn of inpos atropine nn
false	2	6	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn than inpos when wrb atropine nn is vbz used vbn alone rb because inpos pralidoxime nn may md potentiate vb the dt effect nn of inpos atropine nn
effect	6	2	when wrb atropine nn and cc pralidoxime nn are vbp used vbn together rb the dt signs nns of inpos atropinization nn may md occur vb earlier rbr than inpos might md be vb expected vbn than inpos when wrb atropine nn is vbz used vbn alone rb because inpos pralidoxime nn may md potentiate vb the dt effect nn of inpos atropine nn
advise	48	52	the dt following vbg precautions nns should md be vb kept vbn in inpos mind nn in inpos the dt treatment nn of inpos anticholinesterase nn poisoning vbg although inpos they prp do vbp not rb bear vb directly rb on inpos the dt use nn of inpos atropine nn and cc pralidoxime nn
advise	2	12	since inpos barbiturates nn are vbp potentiated vbn by inpos the dt anticholinesterases nn they prp should md be vb used vbn cautiously rb in inpos the dt treatment nn of inpos convulsions nns
advise	0	28	auranofin nn should md be vb avoided vbn by inpos patients nns with inpos a dt history nn of inpos serious jj reaction nn to topos any dt gold_medication nn including vbg solganal jj and cc myochrysine nn
advise	0	32	auranofin nn should md be vb avoided vbn by inpos patients nns with inpos a dt history nn of inpos serious jj reaction nn to topos any dt gold_medication nn including vbg solganal nn and cc myochrysine nn
advise	0	36	auranofin nn should md be vb avoided vbn by inpos patients nns with inpos a dt history nn of inpos serious jj reaction nn to topos any dt gold_medication nn including vbg solganal jj and cc myochrysine nn
false	28	32	auranofin nn should md be vb avoided vbn by inpos patients nns with inpos a dt history nn of inpos serious jj reaction nn to topos any dt gold_medication nn including vbg solganal nn and cc myochrysine nn
false	28	36	auranofin nn should md be vb avoided vbn by inpos patients nns with inpos a dt history nn of inpos serious jj reaction nn to topos any dt gold_medication nn including vbg solganal jj and cc myochrysine nn
false	32	36	auranofin nn should md be vb avoided vbn by inpos patients nns with inpos a dt history nn of inpos serious jj reaction nn to topos any dt gold_medication nn including vbg solganal nn and cc myochrysine nn
advise	0	14	auranofin nn should md not rb be vb used vbn together rb with inpos penicillamine nn another dt arthritis nn medication nn
advise	0	14	auranofin nn should md not rb be vb used vbn together rb with inpos depen nn another dt arthritis nn medication nn
advise	0	14	auranofin nn should md not rb be vb used vbn together rb with inpos cuprimine nn another dt arthritis nn medication nn
effect	0	14	mao_inhibitors nn prolong vb and cc intensify vb the dt effects nns of inpos antihistamines nn
effect	6	10	concomitant jj use nn of inpos antihistamines nn with inpos alcohol nns other jj central_nervous_system_depressants nns may md have vb an dt additive jj effect nn
effect	6	10	concomitant jj use nn of inpos antihistamines nn with inpos tricyclic_antidepressants nns other jj central_nervous_system_depressants nns may md have vb an dt additive jj effect nn
effect	6	10	concomitant jj use nn of inpos antihistamines nn with inpos barbiturates nn other jj central_nervous_system_depressants nns may md have vb an dt additive jj effect nn
effect	6	18	concomitant jj use nn of inpos antihistamines nn with inpos alcohol nn tricyclic_antidepressants nns barbiturates nns other jj central_nervous_system_depressants nn may md have vb an dt additive jj effect nn
false	10	14	concomitant jj use nn of inpos antihistamines nns with inpos alcohol nns other jj central_nervous_system_depressants nn may md have vb an dt additive jj effect nn
false	10	14	concomitant jj use nn of inpos antihistamines nns with inpos tricyclic_antidepressants nns other jj central_nervous_system_depressants nn may md have vb an dt additive jj effect nn
false	10	14	concomitant jj use nn of inpos antihistamines nns with inpos barbiturates nn other jj central_nervous_system_depressants nn may md have vb an dt additive jj effect nn
effect	2	14	when wrb sympathomimetic_drugs nn are vbp given vbn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn hypertensive jj reactions nns including vbg hypertensive jj crises nns may md occur vb
effect	8	18	the dt antihypertensive jj effects nns of inpos methyldopa nns may md be vb reduced vbn by inpos sympathomimetics nn
effect	8	18	the dt antihypertensive jj effects nns of inpos mecamylamine nns may md be vb reduced vbn by inpos sympathomimetics nn
effect	8	18	the dt antihypertensive jj effects nns of inpos reserpine nns may md be vb reduced vbn by inpos sympathomimetics nn
effect	8	18	the dt antihypertensive jj effects nns of inpos veratrum_alkaloids nn may md be vb reduced vbn by inpos sympathomimetics nn
int	0	10	b_adrenergic_blocking_agents nn may md also rb interact vb with inpos sympathomimetics nn
effect	14	24	increased vbn ectopic jj pacemaker nn activity nn can md occur vb when wrb pseudoephedrine nn is vbz used vbn concomitantly rb with inpos digitalis nn
mechanism	0	14	antacids nn increase vbp the dt rate nn of inpos absorption nn of inpos pseudoephedrine nn while inpos kaolin nn decreases vbz it prp
false	0	18	antacids nn increase vbp the dt rate nn of inpos absorption nn of inpos pseudoephedrine nn while inpos kaolin nn decreases vbz it prp
mechanism	14	18	antacids nns increase vbp the dt rate nn of inpos absorption nn of inpos pseudoephedrine nn while inpos kaolin nn decreases vbz it prp
mechanism	12	20	the dt principal jj pathway nn for inpos detoxification nn of inpos azathioprine nn is vbz inhibited vbn by inpos allopurinol nn
advise	4	8	patients nns receiving vbg azathioprine nn and cc allopurinol nn concomitantly rb should md have vb a dt dose nn reduction nn of inpos azathioprine nn to topos approximately rb num cd to topos num cd the dt usual jj dose nn
false	8	4	patients nns receiving vbg azathioprine nn and cc allopurinol nn concomitantly rb should md have vb a dt dose nn reduction nn of inpos azathioprine nn to topos approximately rb num cd to topos num cd the dt usual jj dose nn
effect	6	20	the dt use nn of inpos angiotensin_converting_enzyme_inhibitors nn to topos control vb hypertension nn in inpos patients nns on inpos azathioprine nn has vbz been vbn reported vbn to topos induce vb severe jj leukopenia nn
false	4	20	co_administration nn of inpos nelfinavir nn at inpos steady_state jj with inpos a dt single jj dose nn of inpos azithromycin nn
effect	4	20	co_administration nn of inpos nelfinavir nn at inpos steady_state jj with inpos a dt single jj dose nn of inpos azithromycin nn results vbz in inpos increased vbn azithromycin nn serum nn concentrations nns
false	4	20	co_administration nn of inpos nelfinavir nn at inpos steady_state jj with inpos a dt single jj dose nn of inpos azithromycin nn results vbz in inpos increased vbn azithromycin nn serum nn concentrations nns
advise	10	28	although inpos a dt dose nn adjustment nn of inpos azithromycin nn is vbz not rb recommended vbn when wrb administered vbn in inpos combination nn with inpos nelfinavir nn close jj monitoring nn for inpos known jj side nn effects nns of inpos azithromycin nn such jj as inpos liver nn enzyme nn abnormalities nns and cc hearing vbg impairment nn is vbz warranted vbn
false	28	10	although inpos a dt dose nn adjustment nn of inpos azithromycin nn is vbz not rb recommended vbn when wrb administered vbn in inpos combination nn with inpos nelfinavir nn close jj monitoring nn for inpos known jj side nn effects nns of inpos azithromycin nn such jj as inpos liver nn enzyme nn abnormalities nns and cc hearing vbg impairment nn is vbz warranted vbn
false	0	26	azithromycin nn did vbd not rb affect vb the dt prothrombin nn time nn response nn to topos a dt single jj dose nn of inpos warfarin nn
advise	30	34	however rb prudent jj medical jj practice nn dictates vbz careful jj monitoring nn of inpos prothrombin nn time nn in inpos all dt patients nns treated vbn with inpos azithromycin nn and cc warfarin nn concomitantly rb
effect	6	10	concurrent jj use nn of inpos macrolides nn and cc warfarin nn in inpos clinical jj practice nn has vbz been vbn associated vbn with inpos increased vbn anticoagulant jj effects nns
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos atorvastatin nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos carbamazepine nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos cetirizine nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos didanosine nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos efavirenz nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos fluconazole nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos indinavir nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos midazolam nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos rifabutin nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos sildenafil nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos theophylline nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos triazolam nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos trimethoprim nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos sulfamethoxazole nn
mechanism	10	28	when wrb used vbn in inpos therapeutic jj doses nns azithromycin nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos zidovudine nn
false	4	8	co_administration nn with inpos efavirenz nn or cc fluconazole nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos azithromycin nn
mechanism	4	26	co_administration nn with inpos efavirenz nn or cc fluconazole nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos azithromycin nn
mechanism	8	26	co_administration nn with inpos efavirenz nn or cc fluconazole nn had vbd a dt modest jj effect nn on inpos the dt pharmacokinetics nns of inpos azithromycin nn
false	18	44	until inpos further jj data nns are vbp developed vbn regarding vbg drug nn interactions nns when wrb azithromycin nn and cc these dt drugs nns are vbp used vbn concomitantly rb careful jj monitoring nn of inpos patients nns is vbz advised vbn digoxin nn elevated vbd digoxin nn concentrations nns
false	18	44	until inpos further jj data nns are vbp developed vbn regarding vbg drug nn interactions nns when wrb azithromycin nn and cc these dt drugs nns are vbp used vbn concomitantly rb careful jj monitoring nn of inpos patients nns is vbz advised vbn digoxin nn elevated vbd digoxin nn concentrations nns
advise	0	14	azlocillin nn should md not rb be vb administered vbn concomitantly rb with inpos amikacin nn
advise	0	14	azlocillin nn should md not rb be vb administered vbn concomitantly rb with inpos ciprofloxacin nn
advise	0	14	azlocillin nn should md not rb be vb administered vbn concomitantly rb with inpos gentamicin nn
advise	0	14	azlocillin nn should md not rb be vb administered vbn concomitantly rb with inpos netilmicin nn
advise	0	14	azlocillin nn should md not rb be vb administered vbn concomitantly rb with inpos tobramycin nn
effect	14	22	interactions nns attributed vbn to topos the dt combined vbn use nn of inpos baclofen nn injection nn and cc epidural jj morphine nn include vbp hypotension nn and cc dyspnea nn
false	2	20	side nn kemstro nn the dt most rbs common jj adverse jj reaction nn during inpos treatment nn with inpos baclofen nn is vbz transient jj drowsiness nn
false	12	26	the dt adverse jj experience nn profile nn seen vbn with inpos kemstrotm nn was vbd similar jj to topos that dt seen vbn with inpos baclofen nn tablets nns
false	16	30	no dt drug nn interaction nn studies nns have vbp been vbn conducted vbn for inpos colazal nn however rb the dt use nn of inpos orally rb administered vbn antibiotics nn could md theoretically rb interfere vbp with inpos the dt release nn of inpos mesalamine nn in inpos the dt colon nn
false	16	46	no dt drug nn interaction nn studies nns have vbp been vbn conducted vbn for inpos colazal nn however rb the dt use nn of inpos orally rb administered vbn antibiotics nns could md theoretically rb interfere vbp with inpos the dt release nn of inpos mesalamine nn in inpos the dt colon nn
false	30	46	no dt drug nn interaction nn studies nns have vbp been vbn conducted vbn for inpos colazal nn however rb the dt use nn of inpos orally rb administered vbn antibiotics nn could md theoretically rb interfere vbp with inpos the dt release nn of inpos mesalamine nn in inpos the dt colon nn
false	12	26	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nn is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nns either cc azathioprine nn mycophenolate_mofetil nn
false	12	28	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nn is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nn either cc azathioprine nn mycophenolate_mofetil nn
false	12	32	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nn is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nns either cc azathioprine nn mycophenolate_mofetil nn
false	12	34	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nn is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nns either cc azathioprine nn mycophenolate_mofetil nn
false	26	28	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nnp is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nn either cc azathioprine nn mycophenolate_mofetil nn
false	26	32	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nnp is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nns either cc azathioprine nn mycophenolate_mofetil nn
false	26	34	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nnp is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nns either cc azathioprine nn mycophenolate_mofetil nn
false	28	32	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nnp is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nn either cc azathioprine nn mycophenolate_mofetil nn
false	28	34	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nnp is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nn either cc azathioprine nn mycophenolate_mofetil nn
false	32	34	no dt dose nn adjustment nn is vbz necessary jj when wrb simulect nnp is vbz added vbn to topos triple_immunosuppression jj regimens nns including vbg cyclosporine nn corticosteroids nns either cc azathioprine nn mycophenolate_mofetil nn
mechanism	8	28	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos cyclosporine nn usp nnp corticosteroids nns
mechanism	8	32	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos cyclosporine nn usp nnp corticosteroids nns
false	8	50	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos cyclosporine nns
false	8	50	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos corticosteroids nn
false	28	32	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos cyclosporine nn usp nnp corticosteroids nns
false	28	50	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos cyclosporine nns
false	28	50	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos corticosteroids nn
false	32	50	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos cyclosporine nns
false	32	50	total jj body nn clearance nn of inpos simulect nn was vbd reduced vbn by inpos an dt average jj num cd and cc num cd when wrb azathioprine nn and cc mycophenolate_mofetil nn respectively rb were vbd added vbn to topos a dt regimen nn consisting vbg of inpos corticosteroids nn
false	10	24	nonetheless rb the dt range nn of inpos individual jj simulect nn clearance nn values nns in inpos the dt presence nn of inpos azathioprine nn or cc mycophenolate_mofetil nn did vbd not rb extend vb outside inpos the dt range nn observed vbn with inpos dual jj therapy nn
false	10	28	nonetheless rb the dt range nn of inpos individual jj simulect nn clearance nn values nns in inpos the dt presence nn of inpos azathioprine nn or cc mycophenolate_mofetil nn did vbd not rb extend vb outside inpos the dt range nn observed vbn with inpos dual jj therapy nn
false	24	28	nonetheless rb the dt range nn of inpos individual jj simulect nnp clearance nn values nns in inpos the dt presence nn of inpos azathioprine nn or cc mycophenolate_mofetil nn did vbd not rb extend vb outside inpos the dt range nn observed vbn with inpos dual jj therapy nn
false	20	34	the dt following vbg medications nns have vbp been vbn administered vbn in inpos clinical jj trials nns with inpos simulect nn with inpos no dt increase nn in inpos adverse jj reactions nns azathioprine nn
false	20	34	the dt following vbg medications nns have vbp been vbn administered vbn in inpos clinical jj trials nns with inpos simulect nn with inpos no dt increase nn in inpos adverse jj reactions nns corticosteroids nn
false	20	34	the dt following vbg medications nns have vbp been vbn administered vbn in inpos clinical jj trials nns with inpos simulect nn with inpos no dt increase nn in inpos adverse jj reactions nns cyclosporine nn
false	20	34	the dt following vbg medications nns have vbp been vbn administered vbn in inpos clinical jj trials nns with inpos simulect nn with inpos no dt increase nn in inpos adverse jj reactions nns mycophenolate_mofetil nn
false	20	34	the dt following vbg medications nns have vbp been vbn administered vbn in inpos clinical jj trials nns with inpos simulect nn with inpos no dt increase nn in inpos adverse jj reactions nns muromonab_cd3 nn
false	0	4	albuterol nn antihistamines nnp antidiabetic_drugs nn diuretics nns digitalis nn
false	0	2	albuterol nns digitalis nn
false	0	2	antihistamines nns digitalis nn
false	0	2	antidiabetic_drugs nns digitalis nn
false	0	54	diuretics nn patients nns on inpos diuretics nns especially rb those dt in inpos whom wp diuretic jj therapy nn was vbd recently rb instituted vbn may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos therapy nn with inpos lotensin nn
effect	0	54	diuretics nns patients nns on inpos diuretics nn especially rb those dt in inpos whom wp diuretic jj therapy nn was vbd recently rb instituted vbn may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos therapy nn with inpos lotensin nn
false	12	28	the dt possibility nn of inpos hypotensive jj effects nns with inpos lotensin nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos lotensin nn
advise	28	12	the dt possibility nn of inpos hypotensive jj effects nns with inpos lotensin nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos lotensin nn
false	0	22	potassium nn supplements nns and cc potassium_sparing_diuretics nnp lotensin nnp can md attenuate vb potassium nn loss nn caused vbn by inpos thiazide_diuretics nn
effect	6	22	potassium nnp supplements nnps and cc potassium_sparing_diuretics nn lotensin nn can md attenuate vb potassium nn loss nn caused vbn by inpos thiazide_diuretics nn
false	0	4	spironolactone nn or cc potassium nn supplements nns can md increase vb the dt risk nn of inpos hyperkalemia nn
false	0	4	amiloride nn or cc potassium nn supplements nns can md increase vb the dt risk nn of inpos hyperkalemia nn
false	0	4	triamterene nn or cc potassium nn supplements nns can md increase vb the dt risk nn of inpos hyperkalemia nn
false	2	10	oral jj anticoagulants nn interaction nn studies nns with inpos warfarin nn and cc acenocoumarol nn failed vbd to topos identify vb any dt clinically rb important jj effects nns on inpos the dt serum nn concentrations nns or cc clinical jj effects nns of inpos these dt anticoagulants nns
false	2	14	oral jj anticoagulants nn interaction nn studies nns with inpos warfarin nn and cc acenocoumarol nn failed vbd to topos identify vb any dt clinically rb important jj effects nns on inpos the dt serum nn concentrations nns or cc clinical jj effects nns of inpos these dt anticoagulants nns
false	10	14	oral jj anticoagulants nnps interaction nn studies nns with inpos warfarin nn and cc acenocoumarol nn failed vbd to topos identify vb any dt clinically rb important jj effects nns on inpos the dt serum nn concentrations nns or cc clinical jj effects nns of inpos these dt anticoagulants nns
false	10	2	oral jj anticoagulants nnps interaction nn studies nns with inpos warfarin nn and cc acenocoumarol nn failed vbd to topos identify vb any dt clinically rb important jj effects nns on inpos the dt serum nn concentrations nns or cc clinical jj effects nns of inpos these dt anticoagulants nn
false	14	2	oral jj anticoagulants nnps interaction nn studies nns with inpos warfarin nn and cc acenocoumarol nn failed vbd to topos identify vb any dt clinically rb important jj effects nns on inpos the dt serum nn concentrations nns or cc clinical jj effects nns of inpos these dt anticoagulants nn
false	0	32	lithium nn increased vbd serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
false	4	30	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
false	4	30	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
mechanism	30	4	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
effect	4	18	if inpos a dt diuretic nn is vbz also rb used vbn the dt risk nn of inpos lithium nn toxicity nn may md be vb increased vbn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos hydrochlorothiazide nn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos chlorthalidone nn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos furosemide nn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos digoxin nn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos propranolol nn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos atenolol nn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos naproxen nn
false	16	26	other jj no nnp clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb lotensin nn was vbd administered vbn concomitantly rb with inpos cimetidine nn
false	0	12	lotensin nn has vbz been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nn without inpos evidence nn of inpos clinically rb important jj adverse jj interactions nns
false	0	14	lotensin nn has vbz been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns calcium_channel_blocking_agents nn without inpos evidence nn of inpos clinically rb important jj adverse jj interactions nns
false	0	16	lotensin nn has vbz been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns calcium_channel_blocking_agents nns diuretics nn without inpos evidence nn of inpos clinically rb important jj adverse jj interactions nns
false	0	12	lotensin nn has vbz been vbn used vbn concomitantly rb with inpos digoxin nn without inpos evidence nn of inpos clinically rb important jj adverse jj interactions nns
false	0	12	lotensin nn has vbz been vbn used vbn concomitantly rb with inpos hydralazine nn without inpos evidence nn of inpos clinically rb important jj adverse jj interactions nns
false	0	6	benazepril nn like inpos other jj ace_inhibitors nn has vbz had vbn less jjr than inpos additive jj effects nns with inpos b_adrenergic_blockers nns presumably rb because inpos both dt drugs nns lower jjr blood nn pressure nn by inpos inhibiting vbg parts nns of inpos the dt renin_angiotensin nn system nn
effect	0	22	benazepril nn like inpos other jj ace_inhibitors nns has vbz had vbn less jjr than inpos additive jj effects nns with inpos b_adrenergic_blockers nn presumably rb because inpos both dt drugs nns lower jjr blood nn pressure nn by inpos inhibiting vbg parts nns of inpos the dt renin_angiotensin nn system nn
effect	6	22	benazepril nnp like inpos other jj ace_inhibitors nn has vbz had vbn less jjr than inpos additive jj effects nns with inpos b_adrenergic_blockers nn presumably rb because inpos both dt drugs nns lower jjr blood nn pressure nn by inpos inhibiting vbg parts nns of inpos the dt renin_angiotensin nn system nn
false	10	12	may md interact vb with inpos the dt following nn cholestyramine nn colestipol nn lrb_use nn with inpos thiazide_diuretics nns may md prevent vb the dt diuretic jj from inpos working vbg properly rb
effect	10	18	may md interact vb with inpos the dt following nn cholestyramine nn colestipol nn lrb_use nn with inpos thiazide_diuretics nn may md prevent vb the dt diuretic jj from inpos working vbg properly rb
false	10	18	may md interact vb with inpos the dt following nn cholestyramine nn colestipol nn lrb_use nn with inpos thiazide_diuretics nns may md prevent vb the dt diuretic nn from inpos working vbg properly rb
effect	12	18	may md interact vb with inpos the dt following nn cholestyramine nn colestipol nn lrb_use nn with inpos thiazide_diuretics nn may md prevent vb the dt diuretic jj from inpos working vbg properly rb
false	12	18	may md interact vb with inpos the dt following nn cholestyramine nn colestipol nn lrb_use nn with inpos thiazide_diuretics nns may md prevent vb the dt diuretic nn from inpos working vbg properly rb
int	0	8	bentiromide nn may md interact vb with inpos acetaminophen nns para_aminobenzoic_acid jj containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	8	bentiromide nn may md interact vb with inpos tylenol nns para_aminobenzoic_acid jj containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	8	bentiromide nn may md interact vb with inpos chloramphenicol nns para_aminobenzoic_acid jj containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	8	bentiromide nn may md interact vb with inpos chloromycetin nns para_aminobenzoic_acid jj containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	8	bentiromide nn may md interact vb with inpos anesthetics nn para_aminobenzoic_acid jj containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	8	bentiromide nn may md interact vb with inpos benzocaine nn para_aminobenzoic_acid jj containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	8	bentiromide nn may md interact vb with inpos lidocaine nn para_aminobenzoic_acid jj containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
int	0	20	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
int	0	20	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
int	0	20	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
int	0	20	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
int	0	20	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	8	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos acetaminophen nns para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos acetaminophen nns para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos acetaminophen nns para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos acetaminophen nns para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos acetaminophen nns para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	8	16	bentiromide nn may md interact vb with inpos tylenol nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	16	bentiromide nn may md interact vb with inpos tylenol nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos tylenol nns para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos tylenol nns para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos tylenol nns para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos tylenol nns para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos tylenol nns para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	10	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	10	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloramphenicol nns para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloramphenicol nns para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloramphenicol nns para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloramphenicol nns para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloramphenicol nns para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	10	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloromycetin nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	10	16	bentiromide nn may md interact vb with inpos acetaminophen nn chloromycetin nn local jj anesthetics nns paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloromycetin nns para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloromycetin nns para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloromycetin nns para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloromycetin nns para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos chloromycetin nns para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	8	10	bentiromide nn may md interact vb with inpos anesthetics nn para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	10	bentiromide nn may md interact vb with inpos anesthetics nn paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos anesthetics nn para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos anesthetics nn para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos anesthetics nn para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos anesthetics nn para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos anesthetics nn para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	8	10	bentiromide nn may md interact vb with inpos benzocaine nn para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	10	bentiromide nn may md interact vb with inpos benzocaine nn paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos benzocaine nn para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos benzocaine nn para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos benzocaine nn para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos benzocaine nn para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos benzocaine nn para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	8	10	bentiromide nn may md interact vb with inpos lidocaine nn para_aminobenzoic_acid nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	10	bentiromide nn may md interact vb with inpos lidocaine nn paba nn containing jj preparations nns procainamide nn sulfonamides nns thiazide_diuretics nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos lidocaine nn para_aminobenzoic_acid jj containing jj multivitamins nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos lidocaine nn para_aminobenzoic_acid jj containing jj procainamide nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos lidocaine nn para_aminobenzoic_acid jj containing jj pronestyl nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos lidocaine nn para_aminobenzoic_acid jj containing jj sulfonamides nns pancreatic jj supplements nns
false	8	14	bentiromide nn may md interact vb with inpos lidocaine nn para_aminobenzoic_acid jj containing jj thiazide_diuretics nn pancreatic jj supplements nns
false	16	20	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj multivitamins nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns procainamide nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns pronestyl nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns sulfonamides nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns para_aminobenzoic_acid nn containing jj preparations nns thiazide_diuretics nn pancreatic jj supplements nns
false	16	20	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj multivitamins nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns procainamide nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns pronestyl nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns sulfonamides nns pancreatic jj supplements nns
false	16	22	bentiromide nn may md interact vb with inpos acetaminophen nn chloramphenicol nn local jj anesthetics nns paba nn containing jj preparations nns thiazide_diuretics nn pancreatic jj supplements nns
effect	10	30	hypertensive jj crises nns have vbp resulted vbn when wrb sympathomimetic_amines nn have vbp been vbn used vbn concomitantly rb num cd days nns following vbg use nn of inpos monoamine_oxidase_inhibitors nn
advise	0	16	didrex nn should md not rb be vb used vbn concomitantly rb with inpos other jj cns_stimulants nn
effect	0	14	amphetamines nn may md decrease vb the dt hypotensive jj effect nn of inpos antihypertensives nn
effect	0	12	amphetamines nn may md enhance vb the dt effects nns of inpos tricyclic_antidepressants nn
mechanism	0	18	urinary_acidifying nn agents nns decrease vbp blood nn levels nns and cc increase vb excretion nn of inpos amphetamines nn
int	0	8	benzthiazide nn may md interact vb with inpos alcohol nns like inpos aleve nnp or cc ibuprofen nnp high jj blood nn pressure nn medications nns
int	0	8	benzthiazide nn may md interact vb with inpos blood_thinner nns like inpos aleve nnp or cc ibuprofen nnp high jj blood nn pressure nn medications nns
int	0	8	benzthiazide nn may md interact vb with inpos decongestant_drugs nns like inpos aleve nnp or cc ibuprofen nnp high jj blood nn pressure nn medications nns
int	0	8	benzthiazide nn may md interact vb with inpos lithium nns like inpos aleve nnp or cc ibuprofen nnp high jj blood nn pressure nn medications nns
int	0	8	benzthiazide nn may md interact vb with inpos norepinephrine nns like inpos aleve nnp or cc ibuprofen nnp high jj blood nn pressure nn medications nns
int	0	8	benzthiazide nn may md interact vb with inpos nsaids nn like inpos aleve nnp or cc ibuprofen nnp high jj blood nn pressure nn medications nns
int	0	26	benzthiazide nn may md interact vb with inpos alcohol nn blood_thinners nns decongestant_drugs nns diabetic jj drugs nns lithium nn norepinephrine nn nsaids nns like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
int	0	30	benzthiazide nn may md interact vb with inpos alcohol nn blood_thinners nns decongestant_drugs nns diabetic jj drugs nns lithium nn norepinephrine nn nsaids nns like inpos aleve nnp or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	12	benzthiazide nn may md interact vb with inpos alcohol nns like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	16	benzthiazide nn may md interact vb with inpos alcohol nns like inpos aleve nnp or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	12	benzthiazide nn may md interact vb with inpos blood_thinner nns like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	16	benzthiazide nn may md interact vb with inpos blood_thinner nns like inpos aleve nnp or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	12	benzthiazide nn may md interact vb with inpos decongestant_drugs nns like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	16	benzthiazide nn may md interact vb with inpos decongestant_drugs nns like inpos aleve nnp or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	12	benzthiazide nn may md interact vb with inpos lithium nns like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	16	benzthiazide nn may md interact vb with inpos lithium nns like inpos aleve nnp or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	12	benzthiazide nn may md interact vb with inpos norepinephrine nns like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	16	benzthiazide nn may md interact vb with inpos norepinephrine nns like inpos aleve nnp or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	12	benzthiazide nn may md interact vb with inpos nsaids nn like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	8	14	benzthiazide nn may md interact vb with inpos nsaids nn like inpos aleve nnp ibuprofen nn and cc high jj blood nn pressure nn medications nns
false	26	30	benzthiazide nn may md interact vb with inpos alcohol nn blood_thinners nns decongestant_drugs nns diabetic jj drugs nns lithium nn norepinephrine nn nsaids nns like inpos aleve nn or cc ibuprofen nn high jj blood nn pressure nn medications nns
false	0	6	antipsychotic_drugs nn such jj as inpos phenothiazines nn or cc haloperidol nn
false	0	10	antipsychotic_drugs nn such jj as inpos phenothiazines nns or cc haloperidol nn
false	6	10	antipsychotic_drugs nns such jj as inpos phenothiazines nn or cc haloperidol nn
false	8	18	the dt concomitant jj use nn of inpos bepridil nn with inpos long jj and cc short_acting jj nitrates nn has vbz been vbn safely rb tolerated vbn in inpos patients nns with inpos stable jj angina nn pectoris nn
false	2	30	sublingual jj nitroglycerin nn may md be vb taken vbn if inpos necessary jj for inpos the dt control nn of inpos acute jj angina nn attacks nns during inpos bepridil nn therapy nn
false	8	12	the dt concomitant jj use nn of inpos bepridil nn and cc b_blocking_agents nn has vbz been vbn well rb tolerated vbn in inpos patients nns with inpos stable jj angina nn
mechanism	12	44	in inpos controlled vbn studies nns in inpos healthy jj volunteers nns bepridil_hydrochloride nn either cc had vbd no dt effect nn or cc was vbd associated vbn with inpos modest jj increases nns about rb num cd in inpos steady_state jj serum nn digoxin nn concentrations nns
false	16	20	limited jj clinical jj data nns in inpos angina nn patients nns receiving vbg concomitant jj bepridil_hydrochloride nn and cc digoxin nn therapy nn indicate vbp no dt discernible jj changes nns in inpos serum nn digoxin nn levels nns
false	0	40	bepridil nn has vbz been vbn safely rb used vbn in inpos diabetic jj patients nns without inpos significantly rb lowering vbg their prp blood nn glucose nn levels nns or cc altering vbg their prp need nn for inpos insulin nn or cc oral jj hypoglycemic_agents nns
false	0	46	bepridil nn has vbz been vbn safely rb used vbn in inpos diabetic jj patients nns without inpos significantly rb lowering vbg their prp blood nn glucose nn levels nns or cc altering vbg their prp need nn for inpos insulin nn or cc oral jj hypoglycemic_agents nn
false	40	46	bepridil nn has vbz been vbn safely rb used vbn in inpos diabetic jj patients nns without inpos significantly rb lowering vbg their prp blood nn glucose nn levels nns or cc altering vbg their prp need nn for inpos insulin nn or cc oral jj hypoglycemic_agents nn
false	28	32	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride nn including vbg anti_arrhythmic_agents nn such jj as inpos quinidine nn procainamide nn cardiac_glycosides nns tricyclic_anti_depressants nns
false	28	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride nn including vbg anti_arrhythmic_agents nns such jj as inpos quinidine nns
false	28	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride nn including vbg anti_arrhythmic_agents nns such jj as inpos procainamide nns
false	28	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride nn including vbg anti_arrhythmic_agents nns such jj as inpos cardiac_glycosides nns
false	28	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride nn including vbg anti_arrhythmic_agents nns such jj as inpos tricyclic_anti_depressants nn
false	32	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride vb including vbg anti_arrhythmic_agents nn such jj as inpos quinidine nns
false	32	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride vb including vbg anti_arrhythmic_agents nn such jj as inpos procainamide nns
false	32	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride vb including vbg anti_arrhythmic_agents nn such jj as inpos cardiac_glycosides nns
false	32	38	in inpos general jj these dt are vbp drugs nns that wdt have vbp num cd or cc more jjr pharmacologic jj activities nns similar jj to topos bepridil_hydrochloride vb including vbg anti_arrhythmic_agents nn such jj as inpos tricyclic_anti_depressants nn
false	0	4	anti_arrhythmics nn and cc tricyclic_anti_depressants nn could md exaggerate vb the dt prolongation nn of inpos the dt qt nn interval nn observed vbn with inpos bepridil_hydrochloride nn
effect	0	26	anti_arrhythmics nn and cc tricyclic_anti_depressants nns could md exaggerate vb the dt prolongation nn of inpos the dt qt nn interval nn observed vbn with inpos bepridil_hydrochloride nn
effect	4	26	anti_arrhythmics nns and cc tricyclic_anti_depressants nn could md exaggerate vb the dt prolongation nn of inpos the dt qt nn interval nn observed vbn with inpos bepridil_hydrochloride nn
effect	0	22	cardiac_glycosides nn could md exaggerate vb the dt depression nn of inpos av nn nodal jj conduction nn observed vbn with inpos bepridil_hydrochloride nn
false	14	28	the dt following vbg drugs nns have vbp been vbn coadministered vbn with inpos kerlone nn and cc have vbp not rb altered vbn its prp pharmacokinetics nns cimetidine nn
false	14	28	the dt following vbg drugs nns have vbp been vbn coadministered vbn with inpos kerlone nn and cc have vbp not rb altered vbn its prp pharmacokinetics nns nifedipine nn
false	14	28	the dt following vbg drugs nns have vbp been vbn coadministered vbn with inpos kerlone nn and cc have vbp not rb altered vbn its prp pharmacokinetics nns chlorthalidone nn
false	14	28	the dt following vbg drugs nns have vbp been vbn coadministered vbn with inpos kerlone nn and cc have vbp not rb altered vbn its prp pharmacokinetics nns hydrochlorothiazide nn
false	6	14	concomitant jj administration nn of inpos kerlone nn with inpos the dt oral jj anticoagulant nn warfarin nn has vbz been vbn shown vbn not rb to topos potentiate vb the dt anticoagulant jj effect nn of inpos warfarin nn
false	6	16	concomitant jj administration nn of inpos kerlone nn with inpos the dt oral jj anticoagulant jj warfarin nn has vbz been vbn shown vbn not rb to topos potentiate vb the dt anticoagulant jj effect nn of inpos warfarin nn
false	6	16	concomitant jj administration nn of inpos kerlone nn with inpos the dt oral jj anticoagulant jj warfarin nn has vbz been vbn shown vbn not rb to topos potentiate vb the dt anticoagulant jj effect nn of inpos warfarin nn
false	14	16	concomitant jj administration nn of inpos kerlone nnp with inpos the dt oral jj anticoagulant nn warfarin nn has vbz been vbn shown vbn not rb to topos potentiate vb the dt anticoagulant jj effect nn of inpos warfarin nn
false	14	16	concomitant jj administration nn of inpos kerlone nnp with inpos the dt oral jj anticoagulant nn warfarin nn has vbz been vbn shown vbn not rb to topos potentiate vb the dt anticoagulant jj effect nn of inpos warfarin nn
effect	2	20	catecholamine_depleting jj reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking nn agents nns
advise	20	24	should md it prp be vb decided vbn to topos discontinue vb therapy nn in inpos patients nns receiving vbg b_blockers nn and cc clonidine nn concurrently rb the dt b_blocker nn should md be vb discontinued vbn slowly rb over inpos several jj days nns before inpos the dt gradual jj withdrawal nn of inpos clonidine nn
false	20	24	should md it prp be vb decided vbn to topos discontinue vb therapy nn in inpos patients nns receiving vbg b_blockers nn and cc clonidine nn concurrently rb the dt b_blocker nn should md be vb discontinued vbn slowly rb over inpos several jj days nns before inpos the dt gradual jj withdrawal nn of inpos clonidine nn
false	24	20	should md it prp be vb decided vbn to topos discontinue vb therapy nn in inpos patients nns receiving vbg b_blockers nns and cc clonidine nn concurrently rb the dt b_blocker nn should md be vb discontinued vbn slowly rb over inpos several jj days nns before inpos the dt gradual jj withdrawal nn of inpos clonidine nn
advise	20	24	should md it prp be vb decided vbn to topos discontinue vb therapy nn in inpos patients nns receiving vbg b_blockers nns and cc clonidine nn concurrently rb the dt b_blocker nn should md be vb discontinued vbn slowly rb over inpos several jj days nns before inpos the dt gradual jj withdrawal nn of inpos clonidine nn
advise	10	24	literature nn reports nns suggest vbp that inpos oral jj calcium_antagonists nn may md be vb used vbn in inpos combination nn with inpos b_adrenergic_blocking_agents nn when wrb heart nn function nn is vbz normal jj but cc should md be vb avoided vbn in inpos patients nns with inpos impaired jj cardiac jj function nn
effect	30	38	hypotension nn av nn conduction nn disturbances nns and cc left vbd ventricular jj failure nn have vbp been vbn reported vbn in inpos some dt patients nns receiving vbg b_adrenergic_blocking_agents nn when wrb an dt oral jj calcium_antagonist nn was vbd added vbn to topos the dt treatment nn regimen nn
false	16	22	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative nn e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	16	26	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative jj e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	16	66	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative jj e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	16	70	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative jj e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	22	26	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative nn e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	22	66	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative nn e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	22	70	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative nn e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	26	66	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative jj e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	26	70	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative jj e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
false	66	70	hypotension nn was vbd more rbr likely jj to topos occur vb if inpos the dt calcium_antagonist nn were vbd a dt dihydropyridine_derivative jj e.g. fw nifedipine nn while inpos left jj ventricular jj failure nn and cc av nn conduction nn disturbances nns including vbg complete jj heart nn block nn were vbd more rbr likely jj to topos occur vb with inpos either cc verapamil nn or cc diltiazem nn
effect	14	24	although inpos it prp is vbz known vbn that inpos patients nns on inpos b_blockers nn may md be vb refractory jj to topos epinephrine nn in inpos the dt treatment nn of inpos anaphylactic jj shock nn b_blockers nns can md in inpos addition nn interfere vbp with inpos the dt modulation nn of inpos allergic jj reaction nn and cc lead vbp to topos an dt increased vbn severity nn and_or cc frequency nn of inpos attacks nns
false	24	14	although inpos it prp is vbz known vbn that inpos patients nns on inpos b_blockers nns may md be vb refractory jj to topos epinephrine nn in inpos the dt treatment nn of inpos anaphylactic jj shock nn b_blockers nn can md in inpos addition nn interfere vbp with inpos the dt modulation nn of inpos allergic jj reaction nn and cc lead vbp to topos an dt increased vbn severity nn and_or cc frequency nn of inpos attacks nns
false	18	26	in inpos study nn num cd patients nns with inpos colorectal jj cancer nn were vbd given vbn irinotecan nn with inpos or cc without inpos avastin nn
false	18	26	in inpos study nn num cd patients nns with inpos colorectal jj cancer nn were vbd given vbn num_fu nn with inpos or cc without inpos avastin nn
false	18	26	in inpos study nn num cd patients nns with inpos colorectal jj cancer nn were vbd given vbn leucovorin nn with inpos or cc without inpos avastin nn
false	0	26	irinotecan nn concentrations nns were vbd similar jj in inpos patients nns receiving vbg bolus_ifl nn alone rb and cc in inpos combination nn with inpos avastin nn
false	6	16	the dt concentrations nns of inpos sn38 nn the dt active jj metabolite nn of inpos irinotecan nn were vbd on inpos average jj num cd higher jjr in inpos patients nns receiving vbg bolus_ifl nn in inpos combination nn with inpos avastin nn when wrb compared vbn with inpos bolus_ifl nn alone rb
false	6	42	the dt concentrations nns of inpos sn38 nn the dt active jj metabolite nn of inpos irinotecan nn were vbd on inpos average jj num cd higher jjr in inpos patients nns receiving vbg bolus_ifl nn in inpos combination nn with inpos avastin nn when wrb compared vbn with inpos bolus_ifl nn alone rb
false	16	42	the dt concentrations nns of inpos sn38 nn the dt active jj metabolite nn of inpos irinotecan nn were vbd on inpos average jj num cd higher jjr in inpos patients nns receiving vbg bolus_ifl nn in inpos combination nn with inpos avastin nn when wrb compared vbn with inpos bolus_ifl nn alone rb
false	28	40	due jj to topos high jj inter_patient jj variability nn and cc limited jj sampling nn the dt extent nn of inpos the dt increase nn in inpos sn38 nn levels nns in inpos patients nns receiving vbg concurrent jj irinotecan nn and cc avastin nn is vbz uncertain jj
false	28	44	due jj to topos high jj inter_patient jj variability nn and cc limited jj sampling nn the dt extent nn of inpos the dt increase nn in inpos sn38 nn levels nns in inpos patients nns receiving vbg concurrent jj irinotecan nn and cc avastin nn is vbz uncertain jj
false	40	44	due jj to topos high jj inter_patient jj variability nn and cc limited jj sampling nn the dt extent nn of inpos the dt increase nn in inpos sn38 nn levels nns in inpos patients nns receiving vbg concurrent jj irinotecan nn and cc avastin nn is vbz uncertain jj
false	14	24	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn ketoconazole nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
false	14	24	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn itraconazole nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
false	14	24	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn erythromycin nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
false	14	24	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn gemfibrozil nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	24	14	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn ketoconazole nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	24	14	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn itraconazole nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	24	14	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn erythromycin nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	24	14	on inpos the dt basis nn of inpos the dt metabolism nn of inpos bexarotene nn by inpos cytochrome nn p450 nn 3a4 nn gemfibrozil nn other jj inhibitors nns of inpos cytochrome nn p450 nn 3a4 nn would md be vb expected vbn to topos lead vb to topos an dt increase nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	2	28	furthermore rb rifampin nn other jj inducers nns of inpos cytochrome nn p450 nn 3a4 nn may md cause vb a dt reduction nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	2	28	furthermore rb phenytoin nn other jj inducers nns of inpos cytochrome nn p450 nn 3a4 nn may md cause vb a dt reduction nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	2	28	furthermore rb phenobarbital nn other jj inducers nns of inpos cytochrome nn p450 nn 3a4 nn may md cause vb a dt reduction nn in inpos plasma nn bexarotene nn concentrations nns
mechanism	6	12	concomitant jj administration nn of inpos targretin nn capsules nns and cc gemfibrozil nn resulted vbd in inpos substantial jj increases nns in inpos plasma nn concentrations nns of inpos bexarotene nn probably rb at inpos least jjs partially rb related vbn to topos cytochrome nn p450 nn 3a4 nn inhibition nn by inpos gemfibrozil nn
false	6	30	concomitant jj administration nn of inpos targretin nn capsules nns and cc gemfibrozil nn resulted vbd in inpos substantial jj increases nns in inpos plasma nn concentrations nns of inpos bexarotene nn probably rb at inpos least jjs partially rb related vbn to topos cytochrome nn p450 nn 3a4 nn inhibition nn by inpos gemfibrozil nn
false	6	12	concomitant jj administration nn of inpos targretin nn capsules nns and cc gemfibrozil nn resulted vbd in inpos substantial jj increases nns in inpos plasma nn concentrations nns of inpos bexarotene nn probably rb at inpos least jjs partially rb related vbn to topos cytochrome nn p450 nn 3a4 nn inhibition nn by inpos gemfibrozil nn
false	12	30	concomitant jj administration nn of inpos targretin nn capsules nns and cc gemfibrozil nn resulted vbd in inpos substantial jj increases nns in inpos plasma nn concentrations nns of inpos bexarotene nn probably rb at inpos least jjs partially rb related vbn to topos cytochrome nn p450 nn 3a4 nn inhibition nn by inpos gemfibrozil nn
false	30	12	concomitant jj administration nn of inpos targretin nn capsules nns and cc gemfibrozil nn resulted vbd in inpos substantial jj increases nns in inpos plasma nn concentrations nns of inpos bexarotene nn probably rb at inpos least jjs partially rb related vbn to topos cytochrome nn p450 nn 3a4 nn inhibition nn by inpos gemfibrozil nn
false	6	20	under inpos similar jj conditions nns bexarotene nn concentrations nns were vbd not rb affected vbn by inpos concomitant jj atorvastatin nn administration nn
advise	6	10	concomitant jj administration nn of inpos gemfibrozil nn with inpos targretin nn capsules nns is vbz not rb recommended vbn
false	2	62	when wrb bezalip nn or cc bezalip_retard nnp is vbz used vbn at inpos the dt same jj time nn as inpos other jj medicines nns or cc substances nns the dt following vbg interactions nns must md be vb taken vbn into inpos account nn hyph_bezalip nnp and cc bezalip_retard nnp may md enhance vb the dt action nn of inpos anticoagulants_of_the_coumarin_type nn
false	6	62	when wrb bezalip nnp or cc bezalip_retard nn is vbz used vbn at inpos the dt same jj time nn as inpos other jj medicines nns or cc substances nns the dt following vbg interactions nns must md be vb taken vbn into inpos account nn hyph_bezalip nnp and cc bezalip_retard nnp may md enhance vb the dt action nn of inpos anticoagulants_of_the_coumarin_type nn
effect	2	62	when wrb bezalip nnp or cc bezalip_retard nnp is vbz used vbn at inpos the dt same jj time nn as inpos other jj medicines nns or cc substances nns the dt following vbg interactions nns must md be vb taken vbn into inpos account nn :_hyph_bezalip nn and cc bezalip_retard nnp may md enhance vb the dt action nn of inpos anticoagulants_of_the_coumarin_type nn
effect	6	62	when wrb bezalip nnp or cc bezalip_retard nnp is vbz used vbn at inpos the dt same jj time nn as inpos other jj medicines nns or cc substances nns the dt following vbg interactions nns must md be vb taken vbn into inpos account nn hyph_bezalip nnp and cc bezalip_retard nn may md enhance vb the dt action nn of inpos anticoagulants_of_the_coumarin_type nn
advise	14	40	for inpos this dt reason nn the dt dose nn of inpos the dt anticoagulant nn should md be vb reduced vbn by inpos num cd hyph_num cd at inpos the dt start nn of inpos treatment nn with inpos bezalip nn or cc bezalip nn retard nn and cc then rb titrated vbn according vbg to topos the dt blood nn clotting nn parameters nns
advise	14	40	for inpos this dt reason nn the dt dose nn of inpos the dt anticoagulant nn should md be vb reduced vbn by inpos num cd hyph_num cd at inpos the dt start nn of inpos treatment nn with inpos bezalip nn or cc bezalip nn retard nn and cc then rb titrated vbn according vbg to topos the dt blood nn clotting nn parameters nns
false	6	10	the dt action nn of inpos sulphonylureas nn and cc insulin nn may md be vb enhanced vbn by inpos bezalip nnp or cc bezalip_retard nnp
effect	6	20	the dt action nn of inpos sulphonylureas nn and cc insulin nn may md be vb enhanced vbn by inpos bezalip nn or cc bezalip_retard nnp
effect	6	24	the dt action nn of inpos sulphonylureas nn and cc insulin nn may md be vb enhanced vbn by inpos bezalip nn or cc bezalip_retard nn
effect	10	20	the dt action nn of inpos sulphonylureas nn and cc insulin nn may md be vb enhanced vbn by inpos bezalip nn or cc bezalip_retard nnp
effect	10	24	the dt action nn of inpos sulphonylureas nn and cc insulin nn may md be vb enhanced vbn by inpos bezalip nn or cc bezalip_retard nn
effect	38	46	in inpos isolated vbn cases nns a dt pronounced jj though inpos reversible jj impairment nn of inpos renal jj function nn has vbz been vbn reported vbn in inpos organ nn transplant nn patients nns receiving vbg immuno_suppressant nn therapy nn and cc concomitant jj bezafibrate nn
advise	2	16	hyph_when wrb bezalip nn or cc bezalip_retard nnp is vbz used vbn concurrently rb with inpos anion_exchange_resins nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nnp or cc bezalip_retard nnp is vbz impaired vbn
advise	2	16	hyph_when wrb bezalip nn or cc bezalip_retard nnp is vbz used vbn concurrently rb with inpos cholestryramine nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nnp or cc bezalip_retard nnp is vbz impaired vbn
advise	6	16	hyph_when wrb bezalip nn or cc bezalip_retard nn is vbz used vbn concurrently rb with inpos anion_exchange_resins nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nnp or cc bezalip_retard nnp is vbz impaired vbn
advise	6	16	hyph_when wrb bezalip nn or cc bezalip_retard nn is vbz used vbn concurrently rb with inpos cholestryramine nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nnp or cc bezalip_retard nnp is vbz impaired vbn
false	16	2	hyph_when wrb bezalip nnp or cc bezalip_retard nnp is vbz used vbn concurrently rb with inpos anion_exchange_resins nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nn or cc bezalip_retard nnp is vbz impaired vbn
false	16	6	hyph_when wrb bezalip nnp or cc bezalip_retard nnp is vbz used vbn concurrently rb with inpos anion_exchange_resins nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nn or cc bezalip_retard nn is vbz impaired vbn
false	16	2	hyph_when wrb bezalip nnp or cc bezalip_retard nnp is vbz used vbn concurrently rb with inpos cholestryramine nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nn or cc bezalip_retard nnp is vbz impaired vbn
false	16	6	hyph_when wrb bezalip nnp or cc bezalip_retard nnp is vbz used vbn concurrently rb with inpos cholestryramine nn an dt interval nn of inpos at inpos least jjs num cd hours nns should md be vb maintained vbn between inpos the dt num cd medicines nns since inpos the dt absorption nn of inpos bezalip nn or cc bezalip_retard nn is vbz impaired vbn
false	0	4	hyph_perhexiline_hydrogen_maleate nn or cc mao_inhibitors nn must md not rb be vb administered vbn together rb with inpos bezalip nnp or cc bezalip_retard nnp
advise	0	18	hyph_perhexiline_hydrogen_maleate nn or cc mao_inhibitors nns must md not rb be vb administered vbn together rb with inpos bezalip nn or cc bezalip_retard nnp
advise	0	22	hyph_perhexiline_hydrogen_maleate nn or cc mao_inhibitors nns must md not rb be vb administered vbn together rb with inpos bezalip nn or cc bezalip_retard nn
advise	4	18	hyph_perhexiline_hydrogen_maleate nn or cc mao_inhibitors nn must md not rb be vb administered vbn together rb with inpos bezalip nn or cc bezalip_retard nnp
advise	4	22	hyph_perhexiline_hydrogen_maleate nn or cc mao_inhibitors nn must md not rb be vb administered vbn together rb with inpos bezalip nn or cc bezalip_retard nn
mechanism	10	16	in fw vitro fw studies nns have vbp shown vbn casodex nn can md displace vb coumarin_anticoagulant nn s nns such jj as inpos warfarin nn from inpos their prp protein_binding jj sites nns
mechanism	10	22	in fw vitro fw studies nns have vbp shown vbn casodex nn can md displace vb coumarin_anticoagulants nns such jj as inpos warfarin nn from inpos their prp protein_binding jj sites nns
false	16	24	in fw vitro fw studies nns have vbp shown vbn casodex nn can md displace vb coumarin_anticoagulant nn s nns such jj as inpos warfarin nn from inpos their prp protein_binding jj sites nns
advise	10	24	it prp is vbz recommended vbn that inpos if inpos casodex nn is vbz started vbn in inpos patients nns already rb receiving vbg coumarin_anticoagulants nn prothrombin nn times nns should md be vb closely rb monitored vbn and cc adjustment nn of inpos the dt anticoagulant jj dose nn may md be vb necessary jj
advise	10	24	it prp is vbz recommended vbn that inpos if inpos casodex nn is vbz started vbn in inpos patients nns already rb receiving vbg coumarin_anticoagulants nns prothrombin nn times nns should md be vb closely rb monitored vbn and cc adjustment nn of inpos the dt anticoagulant nn dose nn may md be vb necessary jj
false	4	22	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	48	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	54	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	58	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	64	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	66	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	70	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	78	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	4	82	the dt central jj anticholinergic nn syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
effect	22	48	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	22	54	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	22	58	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	22	64	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	22	66	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	22	70	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	22	78	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
effect	22	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
false	48	54	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	48	58	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nn other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	48	54	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns and cc antihistamines nns
false	48	66	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns and cc antihistamines nns
false	48	70	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	48	78	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	48	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nn such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
false	54	58	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	54	64	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	54	66	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	54	70	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	54	78	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	54	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
false	58	64	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	58	66	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	58	70	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	58	78	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	58	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nn and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
false	48	50	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj antipsychotics nn tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	64	70	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	64	78	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	64	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nn tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
false	66	70	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	66	78	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	66	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nn certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
false	70	78	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nns
false	70	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nn such jj as inpos the dt quinidine nn salts nns antihistamines nn
false	78	82	the dt central jj anticholinergic jj syndrome nn can md occur vb when wrb anticholinergic jj agents nns such jj as inpos akineton nn are vbp administered vbn concomitantly rb with inpos drugs nns that wdt have vbp secondary jj anticholinergic jj actions nns e.g. fw certain jj narcotic_analgesics nns such jj as inpos meperidine nn the dt phenothiazines nns and cc other jj antipsychotics nns tricyclic_antidepressants nns certain jj antiarrhythmics nns such jj as inpos the dt quinidine nn salts nns antihistamines nn
advise	0	14	zebeta nn should md not rb be vb combined vbn with inpos other jj b_blocking_agents nn
false	12	16	patients nns receiving vbg catecholamine_depleting jj drugs nns such jj as inpos reserpine nn or cc guanethidine nn should md be vb closely rb monitored vbn because inpos the dt added vbn b_adrenergic jj blocking vbg action nn of inpos zebeta nn may md produce vb excessive jj reduction nn of inpos sympathetic jj activity nn
effect	12	40	patients nns receiving vbg catecholamine_depleting jj drugs nns such jj as inpos reserpine nn or cc guanethidine nn should md be vb closely rb monitored vbn because inpos the dt added vbn b_adrenergic jj blocking vbg action nn of inpos zebeta nn may md produce vb excessive jj reduction nn of inpos sympathetic jj activity nn
effect	16	40	patients nns receiving vbg catecholamine_depleting jj drugs nns such jj as inpos reserpine nn or cc guanethidine nn should md be vb closely rb monitored vbn because inpos the dt added vbn b_adrenergic jj blocking vbg action nn of inpos zebeta nn may md produce vb excessive jj reduction nn of inpos sympathetic jj activity nn
false	12	34	in inpos patients nns receiving vbg concurrent jj therapy nn with inpos clonidine nn if inpos therapy nn is vbz to topos be vb discontinued vbn it prp is vbz suggested vbn that inpos zebeta nn be vb discontinued vbn for inpos several jj days nns before inpos the dt withdrawal nn of inpos clonidine nn
advise	34	12	in inpos patients nns receiving vbg concurrent jj therapy nn with inpos clonidine nn if inpos therapy nn is vbz to topos be vb discontinued vbn it prp is vbz suggested vbn that inpos zebeta nn be vb discontinued vbn for inpos several jj days nns before inpos the dt withdrawal nn of inpos clonidine nn
advise	0	14	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
advise	0	30	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
advise	0	40	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
advise	0	42	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
advise	0	46	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
advise	0	48	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
advise	0	36	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns or cc antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
advise	0	42	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	30	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	40	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	42	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	46	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	48	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	36	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns or cc antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	42	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nn or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	32	40	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	32	42	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	32	46	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	32	48	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	32	36	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn or cc antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	30	38	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nn antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	8	10	zebeta nn particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns
false	8	14	zebeta nn particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns
false	8	16	zebeta nn particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns
false	38	50	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	40	60	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	10	14	zebeta nn particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns
false	10	16	zebeta nn particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns
false	40	50	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	42	60	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	14	16	zebeta nn particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns
false	44	50	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	46	60	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	46	50	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	48	60	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns lrb_particularly rb of inpos the dt phenylalkylamine nn lrb_verapamil nn rrb_and cc benzothiazepine nn lrb_diltiazem nn rrb_classes nns rrb_or cc antiarrhythmic_agents nns such jj as inpos disopyramide nn are vbp used vbn concurrently rb
false	36	42	zebeta nn should md be vb used vbn with inpos care nn when wrb myocardial_depressants nns or cc inhibitors nns of inpos av nn conduction nn such jj as inpos certain jj calcium_antagonists nns or cc antiarrhythmic_agents nn such jj as inpos disopyramide nn are vbp used vbn concurrently rb
mechanism	6	18	concurrent jj use nn of inpos rifampin nn increases vbz the dt metabolic jj clearance nn of inpos zebeta nn resulting vbg in inpos a dt shortened vbn elimination nn half_life nn of inpos zebeta nn
false	6	18	concurrent jj use nn of inpos rifampin nn increases vbz the dt metabolic jj clearance nn of inpos zebeta nn resulting vbg in inpos a dt shortened vbn elimination nn half_life nn of inpos zebeta nn
false	10	30	there ex was vbd no dt effect nn of inpos zebeta nn on inpos prothrombin nn time nn in inpos patients nns on inpos stable jj doses nns of inpos warfarin nn
advise	12	18	if inpos you prp are vbp also rb using vbg a dt steroid nn inhaler nn take vb bitolterol nn first rb then rb wait vb about inpos num cd minutes nns before inpos using vbg the dt steroid nn inhaler nn
advise	18	12	if inpos you prp are vbp also rb using vbg a dt steroid nn inhaler nn take vb bitolterol nn first rb then rb wait vb about inpos num cd minutes nns before inpos using vbg the dt steroid nn inhaler nn
effect	4	24	this dt allows vbz bitolterol nn to topos open vb air nn passages nns increasing vbg the dt effectiveness nn of inpos the dt steroid nn
effect	18	22	in inpos clinical jj trials nns in inpos patients nns undergoing vbg pci nn co_administration nn of inpos angiomax nn with inpos heparin nns glycoprotein nn iiia nn inhibitors nns was vbd associated vbn with inpos increased vbn risks nns of inpos major jj bleeding vbg events nns compared vbn to topos patients nns not rb receiving vbg these dt concomitant jj medications nns
effect	18	22	in inpos clinical jj trials nns in inpos patients nns undergoing vbg pci nn co_administration nn of inpos angiomax nn with inpos warfarin nns glycoprotein nn iiia nn inhibitors nns was vbd associated vbn with inpos increased vbn risks nns of inpos major jj bleeding vbg events nns compared vbn to topos patients nns not rb receiving vbg these dt concomitant jj medications nns
effect	18	22	in inpos clinical jj trials nns in inpos patients nns undergoing vbg pci nn co_administration nn of inpos angiomax nn with inpos thrombolytics nn glycoprotein nn iib nn inhibitors nns was vbd associated vbn with inpos increased vbn risks nns of inpos major jj bleeding vbg events nns compared vbn to topos patients nns not rb receiving vbg these dt concomitant jj medications nns
false	14	26	there ex is vbz no dt experience nn with inpos co_administration nn of inpos angiomax nn and cc plasma nn expanders nns such jj as inpos dextran nn
false	10	38	among inpos num cd subjects nns who wp received vbd angiomax nn in inpos clinical jj trials nns and cc were vbd tested vbn for inpos antibodies nns num cd subjects nns had vbd treatment_emergent jj positive jj bivalirudin nn antibody nn tests nns
advise	6	10	patients nns on inpos oral jj antidiabetic_agents nn receiving vbg velcade nn treatment nn may md require vb close jj monitoring nn of inpos their prp blood nn glucose nn levels nns and cc adjustment nn of inpos the dt dose nn of inpos their prp antidiabetic_medication nn
false	6	46	patients nns on inpos oral jj antidiabetic_agents nn receiving vbg velcade nn treatment nn may md require vb close jj monitoring nn of inpos their prp blood nn glucose nn levels nns and cc adjustment nn of inpos the dt dose nn of inpos their prp antidiabetic_medication nn
false	10	46	patients nns on inpos oral jj antidiabetic_agents nns receiving vbg velcade nn treatment nn may md require vb close jj monitoring nn of inpos their prp blood nn glucose nn levels nns and cc adjustment nn of inpos the dt dose nn of inpos their prp antidiabetic_medication nn
false	14	22	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive nn ortho_novum nnp produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
mechanism	14	24	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive jj ortho_novum nn produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	14	34	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive jj ortho_novum nnp produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	14	38	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive jj ortho_novum nnp produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	22	24	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive nn ortho_novum nn produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	22	34	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive nn ortho_novum nnp produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	22	38	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive nn ortho_novum nnp produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	24	34	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive jj ortho_novum nn produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	24	38	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive jj ortho_novum nn produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
false	34	38	an dt interaction nn study nn demonstrated vbd that inpos co_administration nn of inpos bosentan nn and cc the dt oral jj hormonal_contraceptive jj ortho_novum nnp produced vbd average jj decreases nns of inpos norethindrone nn and cc ethinyl_estradiol nn levels nns of inpos num cd and cc num cd respectively rb
effect	2	26	therefore rb hormonal_contraceptives nn including vbg oral jj injectable jj transdermal jj implantable jj forms nns may md not rb be vb reliable jj when wrb tracleer nn is vbz co_administered vbn
mechanism	2	28	steady_state jj bosentan nn plasma nn concentrations nns were vbd num cd to topos num_fold rb higher jjr than inpos in inpos the dt absence nn of inpos cyclosporine_a nn
advise	8	12	the dt concomitant jj administration nn of inpos bosentan nn and cc cyclosporine_a nn is vbz contraindicated vbn
mechanism	4	16	co_administration nn of inpos bosentan nn decreased vbd the dt plasma nn concentrations nns of inpos cyclosporine_a nn by inpos approximately rb num cd
false	0	10	tacrolimus nn co_administration nn of inpos tacrolimus nn and cc bosentan nn has vbz not rb been vbn studied vbn in inpos man nn
false	4	8	co_administration nn of inpos tacrolimus nn and cc bosentan nn has vbz not rb been vbn studied vbn in inpos man nn
mechanism	4	8	co_administration nn of inpos tacrolimus nn and cc bosentan nn resulted vbd in inpos markedly rb increased vbn plasma nn concentrations nns of inpos bosentan nn in inpos animals nns
false	4	8	co_administration nn of inpos tacrolimus nn and cc bosentan nn resulted vbd in inpos markedly rb increased vbn plasma nn concentrations nns of inpos bosentan nn in inpos animals nns
advise	10	14	caution nn should md be vb exercised vbn if inpos tacrolimus nn and cc bosentan nn are vbp used vbn together rb
advise	10	14	therefore rb the dt concomitant jj administration nn of inpos tracleer nn and cc glyburide nn is vbz contraindicated vbn and cc alternative jj hypoglycemic_agents nns should md be vb considered vbn
false	10	24	therefore rb the dt concomitant jj administration nn of inpos tracleer nn and cc glyburide nn is vbz contraindicated vbn and cc alternative jj hypoglycemic_agents nn should md be vb considered vbn
false	14	24	therefore rb the dt concomitant jj administration nn of inpos tracleer nn and cc glyburide nn is vbz contraindicated vbn and cc alternative jj hypoglycemic_agents nn should md be vb considered vbn
mechanism	4	16	co_administration nn of inpos bosentan nn decreased vbd the dt plasma nn concentrations nns of inpos glyburide nn by inpos approximately rb num cd
mechanism	0	22	bosentan nn is vbz also rb expected vbn to topos reduce vb plasma nn concentrations nns of inpos other jj oral jj hypoglycemic_agents nn that wdt are vbp predominantly rb metabolized vbn by inpos cyp2c9 nn or cc cyp3a4 nn
false	0	6	ketoconazole nn co_administration nn of inpos bosentan nn num cd mg nn b.i.d. nn and cc ketoconazole nn a dt potent jj cyp3a4 nn inhibitor nn increased vbd the dt plasma nn concentrations nns of inpos bosentan nn by inpos approximately rb num_fold rb
false	0	6	ketoconazole nn co_administration nn of inpos bosentan nn num cd mg nn b.i.d. nn and cc ketoconazole nn a dt potent jj cyp3a4 nn inhibitor nn increased vbd the dt plasma nn concentrations nns of inpos bosentan nn by inpos approximately rb num_fold rb
mechanism	4	14	co_administration nn of inpos bosentan nn num cd mg nn b.i.d. nn and cc ketoconazole nn a dt potent jj cyp3a4 nn inhibitor nn increased vbd the dt plasma nn concentrations nns of inpos bosentan nn by inpos approximately rb num_fold rb
false	14	4	co_administration nn of inpos bosentan nn num cd mg nn b.i.d. nn and cc ketoconazole nn a dt potent jj cyp3a4 nn inhibitor nn increased vbd the dt plasma nn concentrations nns of inpos bosentan nn by inpos approximately rb num_fold rb
false	0	6	simvastatin nn and cc other jj statins nn
false	0	12	simvastatin nn and cc other jj statins nnps co_administration nn of inpos bosentan nn decreased vbd the dt plasma nn concentrations nns of inpos simvastatin nn and cc its prp active jj hydroxy jj acid nn metabolite nn by inpos approximately rb num cd
false	6	12	simvastatin nn and cc other jj statins nn co_administration nn of inpos bosentan nn decreased vbd the dt plasma nn concentrations nns of inpos simvastatin nn and cc its prp active jj hydroxy jj acid nn metabolite nn by inpos approximately rb num cd
false	6	0	simvastatin nn and cc other jj statins nn co_administration nn of inpos bosentan nn decreased vbd the dt plasma nn concentrations nns of inpos simvastatin nn and cc its prp active jj hydroxy jj acid nn metabolite nn by inpos approximately rb num cd
mechanism	4	16	co_administration nn of inpos bosentan nn decreased vbd the dt plasma nn concentrations nns of inpos simvastatin nn and cc its prp active jj hydroxy jj acid nn metabolite nn by inpos approximately rb num cd
mechanism	0	20	bosentan nn is vbz also rb expected vbn to topos reduce vb plasma nn concentrations nns of inpos other jj statins nn that wdt have vbp significant jj metabolism nn by inpos cyp3a4 nn such jj as inpos lovastatin nn and cc atorvastatin nn
mechanism	0	38	bosentan nn is vbz also rb expected vbn to topos reduce vb plasma nn concentrations nns of inpos other jj statins nns that wdt have vbp significant jj metabolism nn by inpos cyp3a4 nn such jj as inpos lovastatin nn and cc atorvastatin nn
mechanism	0	42	bosentan nn is vbz also rb expected vbn to topos reduce vb plasma nn concentrations nns of inpos other jj statins nns that wdt have vbp significant jj metabolism nn by inpos cyp3a4 nn such jj as inpos lovastatin nn and cc atorvastatin nn
false	20	38	bosentan nnp is vbz also rb expected vbn to topos reduce vb plasma nn concentrations nns of inpos other jj statins nn that wdt have vbp significant jj metabolism nn by inpos cyp3a4 nn such jj as inpos lovastatin nn and cc atorvastatin nn
false	20	42	bosentan nnp is vbz also rb expected vbn to topos reduce vb plasma nn concentrations nns of inpos other jj statins nn that wdt have vbp significant jj metabolism nn by inpos cyp3a4 nn such jj as inpos lovastatin nn and cc atorvastatin nn
false	38	42	bosentan nnp is vbz also rb expected vbn to topos reduce vb plasma nn concentrations nns of inpos other jj statins nns that wdt have vbp significant jj metabolism nn by inpos cyp3a4 nn such jj as inpos lovastatin nn and cc atorvastatin nn
advise	8	22	patients nns using vbg cyp3a4 nn metabolized vbd statins nn should md have vb cholesterol nn levels nns monitored vbn after inpos tracleer nn is vbz initiated vbn to topos see vb whether inpos the dt statin nn dose nn needs vbz adjustment nn
false	22	8	patients nns using vbg cyp3a4 nn metabolized vbd statins nns should md have vb cholesterol nn levels nns monitored vbn after inpos tracleer nn is vbz initiated vbn to topos see vb whether inpos the dt statin nn dose nn needs vbz adjustment nn
false	0	6	warfarin nn co_administration nn of inpos bosentan nn num cd mg nn b.i.d. rb for inpos num cd days nns decreased vbd the dt plasma nn concentrations nns of inpos both cc s_warfarin nn and cc r_warfarin nn by inpos num cd and cc num cd respectively rb
mechanism	4	30	co_administration nn of inpos bosentan nn num cd mg nn b.i.d. rb for inpos num cd days nns decreased vbd the dt plasma nn concentrations nns of inpos both cc s_warfarin nn and cc r_warfarin nn by inpos num cd and cc num cd respectively rb
mechanism	4	34	co_administration nn of inpos bosentan nn num cd mg nn b.i.d. rb for inpos num cd days nns decreased vbd the dt plasma nn concentrations nns of inpos both cc s_warfarin nn and cc r_warfarin nn by inpos num cd and cc num cd respectively rb
false	30	34	co_administration nn of inpos bosentan nn num cd mg nn b.i.d. rb for inpos num cd days nns decreased vbd the dt plasma nn concentrations nns of inpos both cc s_warfarin nn and cc r_warfarin nn by inpos num cd and cc num cd respectively rb
false	12	16	clinical jj experience nn with inpos concomitant jj administration nn of inpos bosentan nn and cc warfarin nn in inpos patients nns with inpos pulmonary jj arterial jj hypertension nn did vbd not rb show vb clinically rb relevant jj changes nns in inpos inr nn or cc warfarin nn dose nn and cc the dt need nn to topos change vb the dt warfarin nn dose nn during inpos the dt trials nns due jj to topos changes nns in inpos inr nn or cc due jj to topos adverse jj events nns was vbd similar jj among inpos bosentan nn and cc placebo_treated jj patients nns
false	12	16	clinical jj experience nn with inpos concomitant jj administration nn of inpos bosentan nn and cc warfarin nn in inpos patients nns with inpos pulmonary jj arterial jj hypertension nn did vbd not rb show vb clinically rb relevant jj changes nns in inpos inr nn or cc warfarin nn dose nn and cc the dt need nn to topos change vb the dt warfarin nn dose nn during inpos the dt trials nns due jj to topos changes nns in inpos inr nn or cc due jj to topos adverse jj events nns was vbd similar jj among inpos bosentan nn and cc placebo_treated jj patients nns
false	12	16	clinical jj experience nn with inpos concomitant jj administration nn of inpos bosentan nn and cc warfarin nn in inpos patients nns with inpos pulmonary jj arterial jj hypertension nn did vbd not rb show vb clinically rb relevant jj changes nns in inpos inr nn or cc warfarin nn dose nn and cc the dt need nn to topos change vb the dt warfarin nn dose nn during inpos the dt trials nns due jj to topos changes nns in inpos inr nn or cc due jj to topos adverse jj events nns was vbd similar jj among inpos bosentan nn and cc placebo_treated jj patients nns
false	16	12	clinical jj experience nn with inpos concomitant jj administration nn of inpos bosentan nn and cc warfarin nn in inpos patients nns with inpos pulmonary jj arterial jj hypertension nn did vbd not rb show vb clinically rb relevant jj changes nns in inpos inr nn or cc warfarin nn dose nn and cc the dt need nn to topos change vb the dt warfarin nn dose nn during inpos the dt trials nns due jj to topos changes nns in inpos inr nn or cc due jj to topos adverse jj events nns was vbd similar jj among inpos bosentan nn hyph_and cc placebo_treated jj patients nns
false	16	12	clinical jj experience nn with inpos concomitant jj administration nn of inpos bosentan nn and cc warfarin nn in inpos patients nns with inpos pulmonary jj arterial jj hypertension nn did vbd not rb show vb clinically rb relevant jj changes nns in inpos inr nn or cc warfarin nn dose nn and cc the dt need nn to topos change vb the dt warfarin nn dose nn during inpos the dt trials nns due jj to topos changes nns in inpos inr nn or cc due jj to topos adverse jj events nns was vbd similar jj among inpos bosentan nn hyph_and cc placebo_treated jj patients nns
false	16	12	clinical jj experience nn with inpos concomitant jj administration nn of inpos bosentan nn and cc warfarin nn in inpos patients nns with inpos pulmonary jj arterial jj hypertension nn did vbd not rb show vb clinically rb relevant jj changes nns in inpos inr nn or cc warfarin nn dose nn and cc the dt need nn to topos change vb the dt warfarin nn dose nn during inpos the dt trials nns due jj to topos changes nns in inpos inr nn or cc due jj to topos adverse jj events nns was vbd similar jj among inpos bosentan nn hyph_and cc placebo_treated jj patients nns
false	0	14	bosentan nn has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	0	18	bosentan nn has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	0	22	bosentan nn has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	14	18	bosentan nnp has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	14	22	bosentan nnp has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	14	0	bosentan nnp has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	18	22	bosentan nnp has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	18	0	bosentan nnp has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
false	22	0	bosentan nnp has vbz no dt significant jj pharmacokinetic jj interactions nns with inpos digoxin nn and cc nimodipine nn and cc losartan nn has vbz no dt significant jj effect nn on inpos plasma nn levels nns of inpos bosentan nn
advise	4	12	co_administration nn of inpos botox nns interfering vbg with inpos neuromuscular jj curare_like_compounds nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	4	36	co_administration nn of inpos botox nns interfering vbg with inpos neuromuscular jj transmission nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	4	12	co_administration nn of inpos aminoglycosides nns interfering vbg with inpos neuromuscular jj curare_like_compounds nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	4	36	co_administration nn of inpos aminoglycosides nns interfering vbg with inpos neuromuscular jj transmission nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	18	42	co_administration nn of inpos botox nn aminoglycosides nns other jj agents nns interfering vbg with inpos neuromuscular jj curare_like_compounds nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
advise	4	12	co_administration nn of inpos myobloc nns interfering vbg with inpos neuromuscular jj curare_like_compounds nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	4	36	co_administration nn of inpos myobloc nns interfering vbg with inpos neuromuscular jj transmission nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	4	12	co_administration nn of inpos aminoglycosides nns interfering vbg with inpos neuromuscular jj curare_like_compounds nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	4	36	co_administration nn of inpos aminoglycosides nns interfering vbg with inpos neuromuscular jj transmission nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
false	18	42	co_administration nn of inpos myobloc nn aminoglycosides nns other jj agents nns interfering vbg with inpos neuromuscular jj curare_like_compounds nn should md only rb be vb performed vbn with inpos caution nn as inpos the dt effect nn of inpos the dt toxin nn may md be vb potentiated vbn
effect	0	26	digitalis nn toxicity nn may md be vb aggravated vbn by inpos the dt initial jj release nn of inpos norepinephrine nn caused vbn by inpos bretylium_tosylate nn injection nn
false	8	14	the dt pressor nn effects nns of inpos catecholamines nn such jj as inpos dopamine nn or cc norepinephrine nn are vbp enhanced vbn by inpos bretylium_tosylate nnp
false	8	18	the dt pressor nn effects nns of inpos catecholamines nn such jj as inpos dopamine nn or cc norepinephrine nn are vbp enhanced vbn by inpos bretylium_tosylate nnp
effect	8	26	the dt pressor nn effects nns of inpos catecholamines nn such jj as inpos dopamine nn or cc norepinephrine nn are vbp enhanced vbn by inpos bretylium_tosylate nn
false	14	18	the dt pressor nn effects nns of inpos catecholamines nns such jj as inpos dopamine nn or cc norepinephrine nn are vbp enhanced vbn by inpos bretylium_tosylate nnp
effect	14	26	the dt pressor nn effects nns of inpos catecholamines nns such jj as inpos dopamine nn or cc norepinephrine nn are vbp enhanced vbn by inpos bretylium_tosylate nn
effect	18	26	the dt pressor nn effects nns of inpos catecholamines nns such jj as inpos dopamine nn or cc norepinephrine nn are vbp enhanced vbn by inpos bretylium_tosylate nn
false	20	24	although inpos there ex is vbz little jj published vbn information nn on inpos concomitant jj administration nn of inpos lidocaine nn and cc bretylium_tosylate nn these dt drugs nns are vbp often rb administered vbn concurrently rb without inpos any dt evidence nn of inpos interactions nns resulting vbg in inpos adverse jj effects nns or cc diminished vbn efficacy nn
advise	20	40	although inpos specific jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn with inpos alphagan_p nn the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos cns_depressants nn should md be vb considered vbn
advise	20	40	although inpos specific jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn with inpos alphagan_p nn the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos alcohol nn should md be vb considered vbn
advise	20	40	although inpos specific jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn with inpos alphagan_p nn the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos barbiturates nn should md be vb considered vbn
advise	20	40	although inpos specific jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn with inpos alphagan_p nn the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos opiates nn should md be vb considered vbn
advise	20	40	although inpos specific jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn with inpos alphagan_p nn the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos sedatives nn should md be vb considered vbn
advise	20	40	although inpos specific jj drug nn interaction nn studies nns have vbp not rb been vbn conducted vbn with inpos alphagan_p nn the dt possibility nn of inpos an dt additive jj or cc potentiating vbg effect nn with inpos anesthetics nn should md be vb considered vbn
false	14	16	caution nn in inpos using vbg concomitant jj drugs nns such jj as inpos b_blockers nn anti_hypertensives nn and_or cc cardiac_glycosides nns is vbz advised vbn
false	14	20	caution nn in inpos using vbg concomitant jj drugs nns such jj as inpos b_blockers nn anti_hypertensives nns and_or cc cardiac_glycosides nn is vbz advised vbn
false	16	20	caution nn in inpos using vbg concomitant jj drugs nns such jj as inpos b_blockers nns anti_hypertensives nn and_or cc cardiac_glycosides nn is vbz advised vbn
effect	0	22	tricyclic_antidepressants nn have vbp been vbn reported vbn to topos blunt vb the dt hypotensive jj effect nn of inpos systemic jj clonidine nn .it nn is vbz not rb known vbn whether inpos the dt concurrent jj use nn of inpos these dt agents nns with inpos alphagan_p nn in inpos humans nns can md lead vb to topos resulting vbg interference nn with inpos the dt iop nn lowering nn effect nn
false	0	46	tricyclic_antidepressants nn have vbp been vbn reported vbn to topos blunt vb the dt hypotensive jj effect nn of inpos systemic jj clonidine.it nn is vbz not rb known vbn whether inpos the dt concurrent jj use nn of inpos these dt agents nns with inpos alphagan_p nn in inpos humans nns can md lead vb to topos resulting vbg interference nn with inpos the dt iop nn lowering nn effect nn
false	22	48	tricyclic_antidepressants nns have vbp been vbn reported vbn to topos blunt vb the dt hypotensive jj effect nn of inpos systemic jj clonidine nn .it nn is vbz not rb known vbn whether inpos the dt concurrent jj use nn of inpos these dt agents nns with inpos alphagan_p nn in inpos humans nns can md lead vb to topos resulting vbg interference nn with inpos the dt iop nn lowering nn effect nn
false	0	8	azopt nn num cd contains vbz a dt carbonic_anhydrase_inhibitor nn
false	0	8	brinzolamide nn num cd contains vbz a dt carbonic_anhydrase_inhibitor nn
int	12	32	however rb in inpos patients nns treated vbn with inpos oral jj carbonic_anhydrase_inhibitors nn rare jj instances nns of inpos drug nn interactions nns have vbp occurred vbn with inpos high_dose jj salicylate nn therapy nn
false	8	32	the dt risk nn of inpos using vbg bromocriptine_mesylate nn in inpos combination nn with inpos other jj drugs nns has vbz not rb been vbn systematically rb evaluated vbn but cc alcohol nn may md potentiate vb the dt side nn effects nns of inpos bromocriptine_mesylate nn
effect	32	8	the dt risk nn of inpos using vbg bromocriptine_mesylate nn in inpos combination nn with inpos other jj drugs nns has vbz not rb been vbn systematically rb evaluated vbn but cc alcohol nn may md potentiate vb the dt side nn effects nns of inpos bromocriptine_mesylate nn
int	0	8	bromocriptine_mesylate nn may md interact vb with inpos dopamine_antagonists nn butyrophenones nns certain jj other jj agents nns
int	0	10	bromocriptine_mesylate nn may md interact vb with inpos dopamine_antagonists nns butyrophenones nn certain jj other jj agents nns
false	8	10	bromocriptine_mesylate nnp may md interact vb with inpos dopamine_antagonists nn butyrophenones nn certain jj other jj agents nns
effect	20	22	compounds nns in inpos these dt categories nns result vbp in inpos a dt decreased vbn efficacy nn of inpos bromocriptine_mesylate nn phenothiazines nn
effect	20	24	compounds nns in inpos these dt categories nns result vbp in inpos a dt decreased vbn efficacy nn of inpos bromocriptine_mesylate nn phenothiazines nns haloperidol nn metoclopramide nn pimozide nn
effect	20	26	compounds nns in inpos these dt categories nns result vbp in inpos a dt decreased vbn efficacy nn of inpos bromocriptine_mesylate nn phenothiazines nns haloperidol nn metoclopramide nn pimozide nn
effect	20	28	compounds nns in inpos these dt categories nns result vbp in inpos a dt decreased vbn efficacy nn of inpos bromocriptine_mesylate nn phenothiazines nns haloperidol nn metoclopramide nn pimozide nn
false	24	26	compounds nns in inpos these dt categories nns result vbp in inpos a dt decreased vbn efficacy nn of inpos bromocriptine_mesylate nn phenothiazines nns haloperidol nn metoclopramide nn pimozide nn
false	24	28	compounds nns in inpos these dt categories nns result vbp in inpos a dt decreased vbn efficacy nn of inpos bromocriptine_mesylate nn phenothiazines nns haloperidol nn metoclopramide nn pimozide nn
false	26	28	compounds nns in inpos these dt categories nns result vbp in inpos a dt decreased vbn efficacy nn of inpos bromocriptine_mesylate nn phenothiazines nns haloperidol nn metoclopramide nn pimozide nn
advise	6	12	concomitant jj use nn of inpos bromocriptine_mesylate nn with inpos other jj ergot_alkaloids nn is vbz not rb recommended vbn
effect	0	8	dexbrompheniramine nn can md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
effect	0	8	dexbrompheniramine nn can md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	0	38	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
effect	0	8	dexbrompheniramine nn can md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	0	50	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
effect	0	26	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	0	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	0	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	8	38	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	8	40	dexbrompheniramine nn can md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	8	16	dexbrompheniramine nn can md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	4	20	dexbrompheniramine nn can md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	4	20	dexbrompheniramine nn can md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	14	38	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nn lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	8	40	dexbrompheniramine nn can md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	8	16	dexbrompheniramine nn can md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	4	20	dexbrompheniramine nn can md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	4	20	dexbrompheniramine nn can md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	38	40	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nn other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	38	52	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	8	40	dexbrompheniramine nn can md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	8	16	dexbrompheniramine nn can md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	4	20	dexbrompheniramine nn can md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	4	20	dexbrompheniramine nn can md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	50	52	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nn
false	26	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	26	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	10	40	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	10	42	this dt drug nn may md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	10	18	this dt drug nn may md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	6	22	this dt drug nn may md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	6	22	this dt drug nn may md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	16	40	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nn lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	10	42	this dt drug nn may md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	10	18	this dt drug nn may md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	6	22	this dt drug nn may md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	6	22	this dt drug nn may md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	40	42	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nn other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	40	54	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	10	42	this dt drug nn may md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	10	18	this dt drug nn may md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	6	22	this dt drug nn may md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	6	22	this dt drug nn may md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	52	54	this dt drug nn may md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nn
false	28	36	this dt drug nn may md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	28	36	this dt drug nn may md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
mechanism	8	30	concomitant jj oral jj administration nn of inpos ketoconazole nn caused vbd an dt eight_fold jj increase nn of inpos the dt systemic jj exposure nn to topos oral jj budesonide nn
advise	12	24	if inpos treatment nn with inpos inhibitors nns of inpos cyp3a4 nn ketoconazole nn is vbz indicated vbn reduction nn of inpos the dt budesonide nn dose nn should md be vb considered vbn
advise	12	24	if inpos treatment nn with inpos inhibitors nns of inpos cyp3a4 nn intraconazole nn is vbz indicated vbn reduction nn of inpos the dt budesonide nn dose nn should md be vb considered vbn
advise	12	24	if inpos treatment nn with inpos inhibitors nns of inpos cyp3a4 nn ritonavir nn is vbz indicated vbn reduction nn of inpos the dt budesonide nn dose nn should md be vb considered vbn
advise	12	24	if inpos treatment nn with inpos inhibitors nns of inpos cyp3a4 nn indinavir nn is vbz indicated vbn reduction nn of inpos the dt budesonide nn dose nn should md be vb considered vbn
advise	12	24	if inpos treatment nn with inpos inhibitors nns of inpos cyp3a4 nn saquinavir nn is vbz indicated vbn reduction nn of inpos the dt budesonide nn dose nn should md be vb considered vbn
advise	12	24	if inpos treatment nn with inpos inhibitors nns of inpos cyp3a4 nn erythromycin nn is vbz indicated vbn reduction nn of inpos the dt budesonide nn dose nn should md be vb considered vbn
advise	26	36	especially rb in inpos the dt presence nn of inpos impaired jj renal jj function nn the dt use nn of inpos parenterally rb administered vbn bumetanide nn in inpos patients nns to topos whom wp aminoglycoside_antibiotics nn are vbp also rb being vbg given vbn should md be vb avoided vbn except inpos in inpos life_threatening jj conditions nns
advise	0	14	lithium nn should md generally rb not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp its prp renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
advise	0	14	lithium nn should md generally rb not rb be vb given vbn with inpos bumetanide nn because inpos they prp reduce vbp its prp renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
false	14	0	lithium nn should md generally rb not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp its prp renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
false	14	0	lithium nn should md generally rb not rb be vb given vbn with inpos bumetanide nn because inpos they prp reduce vbp its prp renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
effect	4	22	pretreatment nn with inpos probenecid nn reduces vbz both cc the dt natriuresis nn and cc hyperreninemia nn produced vbn by inpos bumetanide nn
mechanism	8	12	this dt antagonistic jj effect nn of inpos probenecid nn on inpos bumetanide nn natriuresis nn is vbz not rb due jj to topos a dt direct jj action nn on inpos sodium nn excretion nn but cc is vbz probably rb secondary jj to topos its prp inhibitory jj effect nn on inpos renal jj tubular jj secretion nn of inpos bumetanide nn
false	8	12	this dt antagonistic jj effect nn of inpos probenecid nn on inpos bumetanide nn natriuresis nn is vbz not rb due jj to topos a dt direct jj action nn on inpos sodium nn excretion nn but cc is vbz probably rb secondary jj to topos its prp inhibitory jj effect nn on inpos renal jj tubular jj secretion nn of inpos bumetanide nn
advise	2	16	thus rb probenecid nn should md not rb be vb administered vbn concurrently rb with inpos bumetanide nn
mechanism	0	24	indomethacin nn blunts vbz the dt increases nns in inpos urine nn volume nn and cc sodium nn excretion nn seen vbn during inpos bumetanide nn treatment nn and cc inhibits vbz the dt bumetanide_induced jj increase nn in inpos plasma nn renin nn activity nn
effect	0	24	indomethacin nn blunts vbz the dt increases nns in inpos urine nn volume nn and cc sodium nn excretion nn seen vbn during inpos bumetanide nn treatment nn and cc inhibits vbz the dt bumetanide nn induced jj increase nn in inpos plasma nn renin nn activity nn
effect	0	14	bumetanide nn may md potentiate vb the dt effect nn of inpos various jj antihypertensive_drugs nn necessitating vbg a dt reduction nn in inpos the dt dosage nn of inpos these dt drugs nns
false	0	14	hyph_anticoagulants nn interaction nn studies nns in inpos humans nns have vbp shown vbn bumetanide nn to topos have vb no dt effect nn on inpos warfarin nn metabolism nn or cc on inpos plasma nn prothrombin nn activity nn
false	0	26	hyph_anticoagulants nn interaction nn studies nns in inpos humans nns have vbp shown vbn bumetanide nn to topos have vb no dt effect nn on inpos warfarin nn metabolism nn or cc on inpos plasma nn prothrombin nn activity nn
false	12	24	interaction nn studies nns in inpos humans nns have vbp shown vbn bumetanide nn to topos have vb no dt effect nn on inpos warfarin nn metabolism nn or cc on inpos plasma nn prothrombin nn activity nn
false	8	12	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
false	8	16	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
false	8	24	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
false	8	28	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
effect	12	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
effect	12	28	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
effect	16	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
effect	16	28	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
false	24	28	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
false	6	12	concurrent jj administration nn of inpos vasopressor_drugs nn and cc of inpos ergot_type_oxytocic_drugs nn may md cause vb severe jj persistent jj hypertension nn cerebrovascular jj accidents nns
false	0	4	phenothiazines nn and cc butyrophenones nn may md reduce vb or cc reverse vb the dt pressor nn effect nn of inpos epinephrine nn
effect	0	22	phenothiazines nn and cc butyrophenones nns may md reduce vb or cc reverse vb the dt pressor nn effect nn of inpos epinephrine nn
effect	4	22	phenothiazines nns and cc butyrophenones nn may md reduce vb or cc reverse vb the dt pressor nn effect nn of inpos epinephrine nn
false	18	36	because inpos cyp nn 3a4 nn inhibitors nns may md increase vb plasma nn concentrations nns of inpos buprenorphine nn patients nns already rb on inpos cyp nn 3a4 nn inhibitors nns such jj as inpos azole_antifungals nn lrb_e.g nn
false	0	12	ketoconazole nns should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	16	ketoconazole nns should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	12	macrolide_antibiotics nns should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	16	macrolide_antibiotics nns should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	12	erythromycin nns should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	16	erythromycin nns should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	12	hiv_protease_inhibitors nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	16	hiv_protease_inhibitors nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	12	ritonavir nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	16	ritonavir nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	12	indinavir nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	16	indinavir nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	12	saquinavir nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	0	16	saquinavir nn should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
false	16	20	ketoconazole nn rrb_macrolide_antibiotics nns hiv_protease_inhibitors nns should md have vb their prp dose nn of inpos subutex nn or cc suboxone nn adjusted vbn
int	20	24	based vbn on inpos anecdotal jj reports nns there ex may md be vb an dt interaction nn between inpos buprenorphine nn and cc benzodiazepines nn
effect	44	48	there ex have vbp been vbn a dt number nn of inpos reports nns in inpos the dt post_marketing jj experience nn of inpos coma nn and cc death nn associated vbn with inpos the dt concomitant jj intravenous jj misuse nn of inpos buprenorphine nn and cc benzodiazepines nn by inpos addicts nns
false	10	24	in inpos many jj of inpos these dt cases nns buprenorphine nn was vbd misused vbn by inpos self_injection nn of inpos crushed jj subutex nn tablets nns
false	0	4	subutex nn and cc suboxone nn should md be vb prescribed vbn with inpos caution nn to topos patients nns on inpos benzodiazepines nns or cc other jj drugs nns that wdt act vbp on inpos the dt central jj nervous jj system nn regardless rb of inpos whether inpos these dt drugs nns are vbp taken vbn on inpos the dt advice nn of inpos a dt physician nn or cc are vbp taken vbn as inpos drugs nns of inpos abuse nn
advise	0	22	subutex nn and cc suboxone nn should md be vb prescribed vbn with inpos caution nn to topos patients nns on inpos benzodiazepines nn or cc other jj drugs nns that wdt act vbp on inpos the dt central jj nervous jj system nn regardless rb of inpos whether inpos these dt drugs nns are vbp taken vbn on inpos the dt advice nn of inpos a dt physician nn or cc are vbp taken vbn as inpos drugs nns of inpos abuse nn
advise	4	22	subutex nn and cc suboxone nn should md be vb prescribed vbn with inpos caution nn to topos patients nns on inpos benzodiazepines nn or cc other jj drugs nns that wdt act vbp on inpos the dt central jj nervous jj system nn regardless rb of inpos whether inpos these dt drugs nns are vbp taken vbn on inpos the dt advice nn of inpos a dt physician nn or cc are vbp taken vbn as inpos drugs nns of inpos abuse nn
advise	26	36	patients nns should md be vb warned vbn of inpos the dt potential jj danger nn of inpos the dt intravenous jj self_administration nn of inpos benzodiazepines nn while inpos under inpos treatment nn with inpos suboxone nn or cc subutex nn
advise	26	40	patients nns should md be vb warned vbn of inpos the dt potential jj danger nn of inpos the dt intravenous jj self_administration nn of inpos benzodiazepines nn while inpos under inpos treatment nn with inpos suboxone nn or cc subutex nn
false	36	40	patients nns should md be vb warned vbn of inpos the dt potential jj danger nn of inpos the dt intravenous jj self_administration nn of inpos benzodiazepines nns while inpos under inpos treatment nn with inpos suboxone nn or cc subutex nn
int	18	32	therefore rb the dt potential jj exists vbz for inpos a dt drug nn interaction nn between inpos wellbutrin nn and cc drugs nns that wdt affect vbp the dt cyp2b6 nn orphenadrine nn
int	18	32	therefore rb the dt potential jj exists vbz for inpos a dt drug nn interaction nn between inpos wellbutrin nn and cc drugs nns that wdt affect vbp the dt cyp2b6 nn cyclophosphamide nn
false	12	22	the dt effects nns of inpos concomitant jj administration nn of inpos cimetidine nn on inpos the dt pharmacokinetics nns of inpos bupropion nn and cc its prp active jj metabolites nns were vbd studied vbn in inpos num cd healthy jj young jj male jj volunteers nns
false	28	36	following vbg oral jj administration nn of inpos num cd num_mg jj sustained_release nn tablets nns with inpos and cc without inpos num cd mg nn of inpos cimetidine nn the dt pharmacokinetics nns of inpos bupropion nn and cc hydroxybupropion nn were vbd unaffected jj
false	28	40	following vbg oral jj administration nn of inpos num cd num_mg jj sustained_release nn tablets nns with inpos and cc without inpos num cd mg nn of inpos cimetidine nn the dt pharmacokinetics nns of inpos bupropion nn and cc hydroxybupropion nn were vbd unaffected jj
false	36	40	however rb there ex were vbd num cd and cc num cd increases nns in inpos the dt auc nn and cc cmax nn respectively rb of inpos the dt combined vbn moieties nns of inpos threohydrobupropion nn and cc erythrohydrobupropion nn
false	20	22	drugs nns metabolized vbn by inpos cytochrome nn p450iid6 nn many jj drugs nns including vbg most jjs antidepressants nns b_blockers nn antiarrhythmics nn and cc antipsychotics nns are vbp metabolized vbn by inpos the dt cyp2d6 nn isoenzyme nn
mechanism	36	66	in inpos a dt study nn of inpos num cd male jj subjects nns who wp were vbd extensive jj metabolizers nns of inpos the dt cyp2d6 nn isoenzyme nn daily jj doses nns of inpos bupropion nn given vbn as inpos num cd mg nn twice rb daily rb followed vbn by inpos a dt single jj dose nn of inpos num cd mg nn desipramine nn increased vbd the dt cmax nn auc nn t1_num nn of inpos desipramine nn by inpos an dt average nn of inpos approximately rb num cd num cd and cc num_fold rb respectively rb
false	36	66	in inpos a dt study nn of inpos num cd male jj subjects nns who wp were vbd extensive jj metabolizers nns of inpos the dt cyp2d6 nn isoenzyme nn daily jj doses nns of inpos bupropion nn given vbn as inpos num cd mg nn twice rb daily rb followed vbn by inpos a dt single jj dose nn of inpos num cd mg nn desipramine nn increased vbd the dt cmax nn auc nn t1_num nn of inpos desipramine nn by inpos an dt average nn of inpos approximately rb num cd num cd and cc num_fold rb respectively rb
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj nortriptyline nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj imipramine nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj desipramine nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj paroxetine nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj fluoxetine nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj sertraline nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	30	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns antipsychotics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	30	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns haloperidol nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	30	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns risperidone nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	30	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns thioridazine nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj b_blockers nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj metoprolol nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj type_1c_antiarrhythmics nn should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj propafenone nn should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
advise	6	28	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj flecainide nn should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns antipsychotics nn b_blockers nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns antipsychotics nn metoprolol nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns haloperidol nn b_blockers nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns haloperidol nn metoprolol nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns risperidone nn b_blockers nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns risperidone nn metoprolol nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns thioridazine nn b_blockers nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	30	32	therefore rb co_administration nn of inpos bupropion nn with inpos drugs nns that wdt are vbp metabolized vbn by inpos cyp2d6 nn isoenzyme nn including vbg certain jj antidepressants nns thioridazine nn metoprolol nn and cc type_1c_antiarrhythmics nns should md be vb approached vbn with inpos caution nn and cc should md be vb initiated vbn at inpos the dt lower jjr end nn of inpos the dt dose nn range nn of inpos the dt concomitant jj medication nn
false	18	28	studies nns in inpos animals nns demonstrate vbp that inpos the dt acute jj toxicity nn of inpos bupropion nn is vbz enhanced vbn by inpos the dt mao_inhibitor nn phenelzine nn
effect	18	30	studies nns in inpos animals nns demonstrate vbp that inpos the dt acute jj toxicity nn of inpos bupropion nn is vbz enhanced vbn by inpos the dt mao_inhibitor nn phenelzine nn
false	28	30	studies nns in inpos animals nns demonstrate vbp that inpos the dt acute jj toxicity nn of inpos bupropion nn is vbz enhanced vbn by inpos the dt mao_inhibitor nn phenelzine nn
false	0	4	levodopa nn and cc amantadine nn
effect	26	34	limited jj clinical jj data nns suggest vbp a dt higher jjr incidence nn of inpos adverse jj experiences nns in inpos patients nns receiving vbg bupropion nn concurrently rb with inpos either cc levodopa nn or cc amantadine nn
effect	26	38	limited jj clinical jj data nns suggest vbp a dt higher jjr incidence nn of inpos adverse jj experiences nns in inpos patients nns receiving vbg bupropion nn concurrently rb with inpos either cc levodopa nn or cc amantadine nn
false	34	38	limited jj clinical jj data nns suggest vbp a dt higher jjr incidence nn of inpos adverse jj experiences nns in inpos patients nns receiving vbg bupropion nn concurrently rb with inpos either cc levodopa nn or cc amantadine nn
advise	4	16	administration nn of inpos wellbutrin nn tablets nns to topos patients nns receiving vbg either cc levodopa nn or cc amantadine nn concurrently rb should md be vb undertaken vbn with inpos caution nn using vbg small jj initial jj doses nns and cc small jj gradual jj dose nn increases nns
advise	4	20	administration nn of inpos wellbutrin nn tablets nns to topos patients nns receiving vbg either cc levodopa nn or cc amantadine nn concurrently rb should md be vb undertaken vbn with inpos caution nn using vbg small jj initial jj doses nns and cc small jj gradual jj dose nn increases nns
false	16	20	administration nn of inpos wellbutrin nnp tablets nnps to topos patients nns receiving vbg either cc levodopa nn or cc amantadine nn concurrently rb should md be vb undertaken vbn with inpos caution nn using vbg small jj initial jj doses nns and cc small jj gradual jj dose nn increases nns
advise	6	10	concurrent jj administration nn of inpos wellbutrin nn and cc antipsychotics nn that inpos lower jjr seizure nn threshold nn should md be vb undertaken vbn only rb with inpos extreme jj caution nn
advise	6	10	concurrent jj administration nn of inpos wellbutrin nn and cc antidepressants nn that inpos lower jjr seizure nn threshold nn should md be vb undertaken vbn only rb with inpos extreme jj caution nn
advise	6	10	concurrent jj administration nn of inpos wellbutrin nn and cc theophylline nn that inpos lower jjr seizure nn threshold nn should md be vb undertaken vbn only rb with inpos extreme jj caution nn
advise	6	10	concurrent jj administration nn of inpos wellbutrin nn and cc steroids nn that inpos lower jjr seizure nn threshold nn should md be vb undertaken vbn only rb with inpos extreme jj caution nn
false	0	52	alcohol nn in inpos post_marketing jj experience nn there ex have vbp been vbn rare jj reports nns of inpos adverse jj neuropsychiatric jj events nns or cc reduced vbn alcohol nn tolerance nn in inpos patients nns who wp were vbd drinking vbg alcohol nn during inpos treatment nn with inpos wellbutrin nn
false	0	52	alcohol nn in inpos post_marketing jj experience nn there ex have vbp been vbn rare jj reports nns of inpos adverse jj neuropsychiatric jj events nns or cc reduced vbn alcohol nn tolerance nn in inpos patients nns who wp were vbd drinking vbg alcohol nn during inpos treatment nn with inpos wellbutrin nn
effect	0	52	alcohol nn in inpos post_marketing jj experience nn there ex have vbp been vbn rare jj reports nns of inpos adverse jj neuropsychiatric jj events nns or cc reduced vbn alcohol nn tolerance nn in inpos patients nns who wp were vbd drinking vbg alcohol nn during inpos treatment nn with inpos wellbutrin nn
advise	6	14	the dt consumption nn of inpos alcohol nn during inpos treatment nn with inpos wellbutrin nn should md be vb minimized vbn or cc avoided vbn
advise	8	20	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nn because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nns have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	8	36	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nns because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nns have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	8	44	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nns because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nn have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	8	36	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nns because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nns have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	20	36	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nn because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nns have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	20	44	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nn because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nn have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	20	36	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nn because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nns have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	36	44	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nns because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nn have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
false	44	36	it prp is vbz recommended vbn that inpos buspirone_hydrochloride nn not rb be vb used vbn concomitantly rb with inpos mao_inhibitors nns because inpos the dt effects nns of inpos concomitant jj administration nn of inpos buspirone_hcl nn with inpos most jjs other jj psychotropic_drugs nn have vbp not rb been vbn studied vbn the dt concomitant jj use nn of inpos buspirone_hcl nn with inpos other jj cns_active jj drugs nns should md be vb approached vbn with inpos caution nn
effect	20	24	there ex is vbz num cd report nn suggesting vbg that inpos the dt concomitant jj use nn of inpos trazodone_hydrochloride nn and cc buspirone_hcl nn may md have vb caused vbn num cd to topos num_fold jj elevations nns on inpos sgpt nn in inpos a dt few jj patients nns
effect	20	24	there ex is vbz num cd report nn suggesting vbg that inpos the dt concomitant jj use nn of inpos desyrel nn and cc buspirone_hcl nn may md have vb caused vbn num cd to topos num_fold jj elevations nns on inpos sgpt nn in inpos a dt few jj patients nns
mechanism	18	22	in inpos a dt study nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos buspirone_hcl nn and cc haloperidol nn resulted vbd in inpos increased vbn serum nn haloperidol nn concentrations nns
false	18	22	in inpos a dt study nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos buspirone_hcl nn and cc haloperidol nn resulted vbd in inpos increased vbn serum nn haloperidol nn concentrations nns
false	4	20	in fw vitro fw buspirone nn does vbz not rb displace vb tightly rb bound vbn drugs nns like inpos phenytoin nn from inpos serum nn proteins nns
false	4	20	in fw vitro fw buspirone nn does vbz not rb displace vb tightly rb bound vbn drugs nns like inpos propranolol nn from inpos serum nn proteins nns
false	4	20	in fw vitro fw buspirone nn does vbz not rb displace vb tightly rb bound vbn drugs nns like inpos warfarin nn from inpos serum nn proteins nns
effect	22	44	however rb there ex has vbz been vbn num cd report nn of inpos prolonged jj prothrombin nn time nn when wrb buspirone nn was vbd added vbn to topos the dt regimen nn of inpos a dt patient nn treated vbn with inpos warfarin nn
mechanism	4	20	in fw vitro fw buspirone nn may md displace vb less rbr firmly rb bound vbn drugs nns like inpos digoxin nn
mechanism	0	4	itraconazole nn decreases vbz busulfan nn clearance nn by inpos up rb to topos num cd and cc may md produce vb aucs nns num cd m nn min nn in inpos some dt patients nns
false	0	4	fluconazole nn the dt num_ht3_antiemetics nn ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	0	6	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	0	6	fluconazole nn the dt num_ht3_antiemetics nns zofran nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	0	8	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	0	8	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn kytril nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	0	20	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	4	6	fluconazole nn the dt num_ht3_antiemetics nn ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	4	6	fluconazole nn the dt num_ht3_antiemetics nn zofran nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	4	8	fluconazole nn the dt num_ht3_antiemetics nn ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	4	8	fluconazole nn the dt num_ht3_antiemetics nn ondansetron nn kytril nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	4	20	fluconazole nn the dt num_ht3_antiemetics nn ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	6	8	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	6	8	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn kytril nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	6	20	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	6	8	fluconazole nn the dt num_ht3_antiemetics nns zofran nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	6	8	fluconazole nn the dt num_ht3_antiemetics nns zofran nn kytril nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	6	20	fluconazole nn the dt num_ht3_antiemetics nns zofran nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	8	20	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn granisetron nn have vbp all dt been vbn used vbn with inpos busulfex nn
false	8	20	fluconazole nn the dt num_ht3_antiemetics nns ondansetron nn kytril nn have vbp all dt been vbn used vbn with inpos busulfex nn
mechanism	0	10	phenytoin nn increases vbz the dt clearance nn of inpos busulfan nn by inpos num cd or cc more jjr possibly rb due jj to topos the dt induction nn of inpos glutathione_s_transferase nn
mechanism	8	22	since inpos the dt pharmacokinetics nns of inpos busulfex nn were vbd studied vbn in inpos patients nns treated vbn with inpos phenytoin nn the dt clearance nn of inpos busulfex nn at inpos the dt recommended vbn dose nn may md be vb lower jjr and cc exposure nn higher jjr in inpos patients nns not rb treated vbn with inpos phenytoin nn
false	8	22	since inpos the dt pharmacokinetics nns of inpos busulfex nn were vbd studied vbn in inpos patients nns treated vbn with inpos phenytoin nn the dt clearance nn of inpos busulfex nn at inpos the dt recommended vbn dose nn may md be vb lower jjr and cc exposure nn higher jjr in inpos patients nns not rb treated vbn with inpos phenytoin nn
false	22	8	since inpos the dt pharmacokinetics nns of inpos busulfex nn were vbd studied vbn in inpos patients nns treated vbn with inpos phenytoin nn the dt clearance nn of inpos busulfex nn at inpos the dt recommended vbn dose nn may md be vb lower jjr and cc exposure nn higher jjr in inpos patients nns not rb treated vbn with inpos phenytoin nn
false	8	22	since inpos the dt pharmacokinetics nns of inpos busulfex nn were vbd studied vbn in inpos patients nns treated vbn with inpos phenytoin nn the dt clearance nn of inpos busulfex nn at inpos the dt recommended vbn dose nn may md be vb lower jjr and cc exposure nn higher jjr in inpos patients nns not rb treated vbn with inpos phenytoin nn
false	2	26	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
false	2	38	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
false	2	26	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
mechanism	26	38	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
false	26	2	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
false	38	2	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
false	38	26	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
false	2	26	because inpos busulfan nn is vbz eliminated vbn from inpos the dt body nn via inpos conjugation nn with inpos glutathione nn use nn of inpos acetaminophen nn prior jj to topos or cc concurrent jj with inpos busulfex nn may md result vb in inpos reduced vbn busulfan nn clearance nn based vbn upon inpos the dt known jj property nn of inpos acetaminophen nn to topos decrease vb glutathione nn levels nns in inpos the dt blood nn and cc tissues nns
false	14	20	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nn carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	14	24	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	14	24	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns
false	14	18	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nn oral jj contraceptives nn containing vbg estrogens nns
false	14	22	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nn oral jj contraceptives nns containing vbg estrogens nn
false	14	24	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	14	18	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	14	20	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns blood_thinner nn carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	14	24	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns blood_thinner nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	14	24	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns blood_thinner nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns
false	14	18	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns blood_thinner nn oral jj contraceptives nn containing vbg estrogens nns
false	14	22	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns blood_thinner nn oral jj contraceptives nns containing vbg estrogens nn
false	14	24	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns blood_thinner nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	14	18	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns blood_thinner nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	12	16	interactions nns may md occur vb with inpos the dt following nn carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	12	22	interactions nns may md occur vb with inpos the dt following nn carbamazepine nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	12	22	interactions nns may md occur vb with inpos the dt following nn carbamazepine nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns
false	12	16	interactions nns may md occur vb with inpos the dt following nn carbamazepine nn oral jj contraceptives nn containing vbg estrogens nns
false	12	20	interactions nns may md occur vb with inpos the dt following nn carbamazepine nn oral jj contraceptives nns containing vbg estrogens nn
false	4	14	interactions nns may md carbamazepine nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	4	8	interactions nns may md carbamazepine nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	18	20	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	12	22	interactions nns may md occur vb with inpos the dt following nn corticotropin nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	12	22	interactions nns may md occur vb with inpos the dt following nn corticotropin nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns
false	12	16	interactions nns may md occur vb with inpos the dt following nn corticotropin nn oral jj contraceptives nn containing vbg estrogens nns
false	12	20	interactions nns may md occur vb with inpos the dt following nn corticotropin nn oral jj contraceptives nns containing vbg estrogens nn
false	4	14	interactions nns may md corticotropin nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	4	8	interactions nns may md corticotropin nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	20	36	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nn oral jj contraceptives nns containing vbg estrogens nns
false	20	36	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_divalproex_sodium nn oral jj contraceptives nns containing vbg estrogens nns
false	20	36	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	20	44	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nn containing vbg estrogens nns
false	20	48	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nn
false	20	44	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn lrb_barbiturates nn may md decrease vb the dt effects nns of inpos these dt medicines nns rrb_central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	12	22	interactions nns may md occur vb with inpos the dt following nn central_nervous_system_cns_depressants nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	12	22	interactions nns may md occur vb with inpos the dt following nn central_nervous_system_cns_depressants nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns
false	12	16	interactions nns may md occur vb with inpos the dt following nn central_nervous_system_cns_depressants nn oral jj contraceptives nn containing vbg estrogens nns
false	12	20	interactions nns may md occur vb with inpos the dt following nn central_nervous_system_cns_depressants nn oral jj contraceptives nns containing vbg estrogens nn
false	4	14	interactions nns may md central_nervous_system_cns_depressants nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	4	8	interactions nns may md central_nervous_system_cns_depressants nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	30	44	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj divalproex_sodium nn oral jj contraceptives nns containing vbg estrogens nns
false	30	44	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns
false	30	52	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nn containing vbg estrogens nns
false	30	56	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nn
false	30	52	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns lrb_using vbg these dt medicines nns with inpos barbiturates nn may md result vb in inpos increased vbn cns nn depressant jj effects nns rrb_divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	12	22	interactions nns may md occur vb with inpos the dt following nn divalproex_sodium nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns
false	12	16	interactions nns may md occur vb with inpos the dt following nn divalproex_sodium nn oral jj contraceptives nn containing vbg estrogens nns
false	12	20	interactions nns may md occur vb with inpos the dt following nn divalproex_sodium nn oral jj contraceptives nns containing vbg estrogens nn
false	4	14	interactions nns may md divalproex_sodium nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	4	8	interactions nns may md divalproex_sodium nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	12	22	interactions nns may md occur vb with inpos the dt following nn valproic_acid nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns
false	12	16	interactions nns may md occur vb with inpos the dt following nn valproic_acid nn oral jj contraceptives nn containing vbg estrogens nns
false	12	20	interactions nns may md occur vb with inpos the dt following nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nn
false	4	14	interactions nns may md valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	4	8	interactions nns may md valproic_acid nn oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	34	62	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nn containing vbg estrogens nns
false	34	66	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nn
false	34	62	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn lrb_using vbg these dt medicines nns with inpos barbiturates nn may md change vb the dt amount nn of inpos either cc medicine nn that inpos you prp need vbp to topos take vb rrb_oral jj contraceptives nns containing vbg estrogens nns lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	28	32	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nn containing vbg estrogens nn
false	28	34	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nn containing vbg estrogens nns lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	32	34	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nn lrb_barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nns and cc you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
false	32	28	interactions nns may md occur vb with inpos the dt following nn adrenocorticoids nns anticoagulants nns carbamazepine nn corticotropin nn central_nervous_system_cns_depressants nns divalproex_sodium nn valproic_acid nn oral jj contraceptives nns containing vbg estrogens nn lrb_barbiturates nns may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn and cc you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
effect	2	18	interactions nns barbiturates nn may md decrease vb the dt effectiveness nn of inpos these dt oral jj contraceptives nn and cc you prp may md need vb to topos change vb to topos a dt different jj type nn of inpos birth nn control nn
effect	8	18	the dt cns nn effects nns of inpos butalbital nn may md be vb enhanced vbn by inpos monoamine_oxidase_mao_inhibitors nn
effect	0	14	butalbital nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	0	16	butalbital nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	0	20	butalbital nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	0	22	butalbital nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	0	28	butalbital nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	0	30	butalbital nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	0	34	butalbital nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
false	2	6	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	2	20	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	2	22	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	2	26	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	2	28	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	2	34	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	2	36	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	2	40	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
effect	6	20	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	6	22	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	6	26	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	6	28	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	6	34	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	6	36	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
effect	6	40	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
false	20	24	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	20	28	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	20	30	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	20	36	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	20	38	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	20	42	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesic nn s nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
false	22	26	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	22	28	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	22	34	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	22	36	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	22	40	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
false	26	28	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	26	34	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	26	36	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	26	40	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nn tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
false	28	34	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	28	36	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	28	40	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nn such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
false	34	36	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nns causing vbg increased vbn cns nn depression nn
false	34	40	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nns other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
false	36	40	butalbital nnp acetaminophen nn and cc caffeine nn may md enhance vb the dt effects nns of inpos other jj narcotic_analgesics nns alcohol nn general jj anesthetics nns tranquilizers nns such jj as inpos chlordiazepoxide nn sedative_hypnotics nn other jj cns_depressants nn causing vbg increased vbn cns nn depression nn
effect	6	10	concurrent jj use nn of inpos butorphanol nn with inpos central_nervous_system_depressants nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
effect	6	10	concurrent jj use nn of inpos butorphanol nn with inpos alcohol nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
effect	6	10	concurrent jj use nn of inpos butorphanol nn with inpos barbiturates nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
effect	6	10	concurrent jj use nn of inpos butorphanol nn with inpos tranquilizers nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
effect	6	10	concurrent jj use nn of inpos butorphanol nn with inpos antihistamines nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
false	6	10	concurrent jj use nn of inpos butorphanol nn with inpos central_nervous_system_depressants nns may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
false	10	20	concurrent jj use nn of inpos butorphanol nn with inpos alcohol nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
false	10	20	concurrent jj use nn of inpos butorphanol nn with inpos barbiturates nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
false	10	20	concurrent jj use nn of inpos butorphanol nn with inpos tranquilizers nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
false	10	20	concurrent jj use nn of inpos butorphanol nn with inpos antihistamines nn may md result vb in inpos increased vbn central_nervous_system_depressant nn effects nns
false	18	72	when wrb used vbn concurrently rb with inpos such jj drugs nns the dt dose nn of inpos butorphanol nn should md be vb the dt smallest jjs effective jj dose nn and cc the dt frequency nn of inpos dosing nn reduced vbd as rb much rb as inpos possible jj when wrb administered vbn concomitantly rb with inpos drugs nns that wdt potentiate vbp the dt action nn of inpos opioids nn
false	20	26	in inpos healthy jj volunteers nns the dt pharmacokinetics nns of inpos a dt num_mg nn dose nn of inpos butorphanol nn administered vbn as inpos stadol_ns nn were vbd not rb affected vbn by inpos the dt coadministration nn of inpos a dt single jj num_mg nn subcutaneous jj dose nn of inpos sumatriptan nn
false	20	54	in inpos healthy jj volunteers nns the dt pharmacokinetics nns of inpos a dt num_mg nn dose nn of inpos butorphanol nn administered vbn as inpos stadol_ns nn were vbd not rb affected vbn by inpos the dt coadministration nn of inpos a dt single jj num_mg nn subcutaneous jj dose nn of inpos sumatriptan nn
false	26	54	in inpos healthy jj volunteers nns the dt pharmacokinetics nns of inpos a dt num_mg nn dose nn of inpos butorphanol nn administered vbn as inpos stadol_ns nn were vbd not rb affected vbn by inpos the dt coadministration nn of inpos a dt single jj num_mg nn subcutaneous jj dose nn of inpos sumatriptan nn
false	20	38	however rb in inpos another dt study nn in inpos healthy jj volunteers nns the dt pharmacokinetics nns of inpos butorphanol nn were vbd significantly rb altered vbn when wrb a dt num_mg nn dose nn of inpos stadol_ns nn was vbd administered vbn num cd minute nn after inpos a dt num_mg jj dose nn of inpos sumatriptan nn nasal jj spray nn
false	20	58	however rb in inpos another dt study nn in inpos healthy jj volunteers nns the dt pharmacokinetics nns of inpos butorphanol nn were vbd significantly rb altered vbn when wrb a dt num_mg nn dose nn of inpos stadol_ns nn was vbd administered vbn num cd minute nn after inpos a dt num_mg jj dose nn of inpos sumatriptan nn nasal jj spray nn
mechanism	38	58	however rb in inpos another dt study nn in inpos healthy jj volunteers nns the dt pharmacokinetics nns of inpos butorphanol nn were vbd significantly rb altered vbn when wrb a dt num_mg nn dose nn of inpos stadol_ns nn was vbd administered vbn num cd minute nn after inpos a dt num_mg jj dose nn of inpos sumatriptan nn nasal jj spray nn
mechanism	4	18	when wrb the dt stadol_ns nn was vbd administered vbn num cd minutes nns after inpos the dt sumatriptan nn nasal jj spray nn the dt auc nn of inpos butorphanol nn increased vbd num cd and cc cmax nn decreased vbd num cd
false	4	30	when wrb the dt stadol_ns nn was vbd administered vbn num cd minutes nns after inpos the dt sumatriptan nn nasal jj spray nn the dt auc nn of inpos butorphanol nn increased vbd num cd and cc cmax nn decreased vbd num cd
false	18	30	when wrb the dt stadol_ns nn was vbd administered vbn num cd minutes nns after inpos the dt sumatriptan nn nasal jj spray nn the dt auc nn of inpos butorphanol nn increased vbd num cd and cc cmax nn decreased vbd num cd
false	14	24	in inpos neither dt case nn were vbd the dt pharmacokinetics nns of inpos sumatriptan nn affected vbn by inpos coadministration nn with inpos stadol_ns nn
effect	16	36	these dt results nns suggest vbp that inpos the dt analgesic jj effect nn of inpos stadol_ns nn may md be vb diminished vbn when wrb it prp is vbz administered vbn shortly rb after inpos sumatriptan nn nasal jj spray nn but cc by inpos num cd minutes nns any dt such jj reduction nn in inpos effect nn should md be vb minimal jj
false	8	12	the dt safety nn of inpos using vbg stadol_ns nn and cc imitrex nn nasal nnp spray nnp during inpos the dt same jj episode nn of inpos migraine nn has vbz not rb been vbn established vbn
false	8	12	the dt safety nn of inpos using vbg stadol_ns nn and cc sumatriptan nn nasal nnp spray nnp during inpos the dt same jj episode nn of inpos migraine nn has vbz not rb been vbn established vbn
false	14	20	the dt pharmacokinetics nns of inpos a dt num_mg nn dose nn of inpos butorphanol nn administered vbn as inpos stadol_ns nn were vbd not rb affected vbn by inpos the dt coadministration nn of inpos cimetidine nn
false	14	36	the dt pharmacokinetics nns of inpos a dt num_mg nn dose nn of inpos butorphanol nn administered vbn as inpos stadol_ns nn were vbd not rb affected vbn by inpos the dt coadministration nn of inpos cimetidine nn
false	20	36	the dt pharmacokinetics nns of inpos a dt num_mg nn dose nn of inpos butorphanol nn administered vbn as inpos stadol_ns nn were vbd not rb affected vbn by inpos the dt coadministration nn of inpos cimetidine nn
false	8	30	conversely rb the dt administration nn of inpos stadol_ns nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos a dt num_mg jj dose nn of inpos cimetidine nn
false	8	30	conversely rb the dt administration nn of inpos butorphanol nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos a dt num_mg jj dose nn of inpos cimetidine nn
advise	16	38	it prp is vbz not rb known vbn if inpos the dt effects nns of inpos butorphanol nn are vbp altered vbn by inpos concomitant jj medications nns that wdt affect vbp hepatic jj metabolism nn of inpos erythromycin nn but cc physicians nns should md be vb alert jj to topos the dt possibility nn that inpos a dt smaller jjr initial jj dose nn and cc longer jjr intervals nns between inpos doses nns may md be vb needed vbn
false	6	26	the dt fraction nn of inpos stadol_ns nn absorbed vbn is vbz unaffected jj by inpos the dt concomitant jj administration nn of inpos a dt nasal_vasoconstrictor nn but cc the dt rate nn of inpos absorption nn is vbz decreased vbn
false	6	26	the dt fraction nn of inpos stadol_ns nn absorbed vbn is vbz unaffected jj by inpos the dt concomitant jj administration nn of inpos a dt oxymetazoline nn but cc the dt rate nn of inpos absorption nn is vbz decreased vbn
effect	16	34	therefore rb a dt slower jjr onset nn can md be vb anticipated vbn if inpos stadol_ns nn is vbz administered vbn concomitantly rb with inpos or cc immediately rb following vbg a dt nasal_vasoconstrictor nn
false	16	22	no dt information nn is vbz available jj about inpos the dt use nn of inpos butorphanol nn concurrently rb with inpos mao_inhibitors nn
advise	0	20	dostinex nn should md not rb be vb administered vbn concurrently rb with inpos d2_antagonists nns such jj as inpos phenothiazines nn
advise	0	20	dostinex nn should md not rb be vb administered vbn concurrently rb with inpos d2_antagonists nns such jj as inpos butyrophenones nn
advise	0	20	dostinex nn should md not rb be vb administered vbn concurrently rb with inpos d2_antagonists nns such jj as inpos thioxanthines nn
advise	0	20	dostinex nn should md not rb be vb administered vbn concurrently rb with inpos d2_antagonists nns such jj as inpos metoclopramide nn
advise	14	42	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn cimetidine nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
advise	14	42	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn ketoconazole nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
false	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenobarbital nn
false	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenytoin nn
false	14	42	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn cimetidine nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
false	14	42	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn ketoconazole nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
false	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenobarbital nn
false	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenytoin nn
false	42	14	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn cimetidine nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
false	42	14	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn cimetidine nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
false	42	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn cimetidine nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenobarbital nn
false	42	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn cimetidine nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenytoin nn
false	42	14	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn ketoconazole nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
false	42	14	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn ketoconazole nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn elimination nn
false	42	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn ketoconazole nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenobarbital nn
false	42	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn ketoconazole nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenytoin nn
advise	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenobarbital nn
advise	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenytoin nn
false	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenobarbital nn
false	14	72	based vbn on inpos adult jj data nns lower jjr doses nns of inpos caffeine nn may md be vb needed vbn following vbg coadministration nn of inpos drugs nns which wdt are vbp reported vbn to topos decrease vb caffeine nn elimination nn and cc higher jjr caffeine nn doses nns may md be vb needed vbn following vbg coadministration nn of inpos drugs nns that wdt increase vbp caffeine nn phenytoin nn
effect	0	8	caffeine nn administered vbn concurrently rb with inpos ketoprofen nn reduced vbd the dt urine nn volume nn in inpos num cd healthy jj volunteers nns
false	4	8	interconversion nn between inpos caffeine nn and cc theophylline nn has vbz been vbn reported vbn in inpos preterm jj neonates nns
false	4	6	interactions nns for inpos vitamin_d_analogues nn cholestyramine nn
false	4	6	interactions nns for inpos vitamin_d2 nn cholestyramine nn
false	4	6	interactions nns for inpos vitamin_d3 nn cholestyramine nn
false	4	6	interactions nns for inpos calcitriol nn cholestyramine nn
false	4	6	interactions nns for inpos calcidiol nn cholestyramine nn
mechanism	0	18	cholestyramine nn has vbz been vbn reported vbn to topos reduce vb intestinal jj absorption nn of inpos fat_soluble_vitamins nn
false	0	2	phenytoin nn phenobarbital nn
false	6	10	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	6	24	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos ergocalcitriol nn by inpos accelerating vbg metabolism nn
mechanism	6	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	10	24	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
mechanism	10	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	24	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	8	22	since inpos blood nn level nn of inpos calcitriol nn will md be vb reduced vbn higher jjr doses nns of inpos rocaltrol nn may md be vb necessary jj if inpos these dt drugs nns are vbp administered vbn simultaneously rb
effect	18	22	some dt reports nns have vbp shown vbn that inpos the dt concomitant jj administration nn of inpos thiazides nn with inpos vitamin_d nn causes vbz hypercalcemia nn
advise	0	24	vitamin_d nn dosage nn must md be vb determined vbn with inpos care nn in inpos patients nns undergoing vbg treatment nn with inpos digitalis nn as inpos hypercalcemia nn in inpos such jj patients nns may md precipitate vb cardiac jj arrhythmias nns
mechanism	0	18	ketoconazole nn may md inhibit vb both cc synthetic jj and cc catabolic jj enzymes nns of inpos vitamin_d nn
false	14	18	however rb in fw vivo fw drug nn interaction nn studies nns of inpos ketoconazole nn with inpos vitamin_d nn have vbp not rb been vbn investigated vbn
mechanism	14	26	a dt relationship nn of inpos functional jj antagonism nn exists vbz between inpos vitamin_d_analogues nn which wdt promote vbp calcium nn absorption nn and cc corticosteroids nn which wdt inhibit vbp calcium nn absorption nn
false	0	4	magnesium nn containing jj antacids nn may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
advise	0	30	magnesium nn containing jj preparations nns may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
advise	2	28	magnesium_containing jj antacids nn may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
false	4	6	interactions nns for inpos vitamin_d_analogues nn cholestyramine nn
false	4	6	interactions nns for inpos vitamin_d2 nn cholestyramine nn
false	4	6	interactions nns for inpos vitamin_d3 nn cholestyramine nn
false	4	6	interactions nns for inpos calcitriol nn cholestyramine nn
false	4	6	interactions nns for inpos calcidiol nn cholestyramine nn
mechanism	0	18	cholestyramine nn has vbz been vbn reported vbn to topos reduce vb intestinal jj absorption nn of inpos fat_soluble_vitamins nn
false	0	2	phenytoin nn phenobarbital nn
false	6	10	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	6	24	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos ergocalcitriol nn by inpos accelerating vbg metabolism nn
mechanism	6	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	10	24	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos ergocalcitriol nn by inpos accelerating vbg metabolism nn
mechanism	10	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	24	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	8	22	since inpos blood nn level nn of inpos calcitriol nn will md be vb reduced vbn higher jjr doses nns of inpos rocaltrol nn may md be vb necessary jj if inpos these dt drugs nns are vbp administered vbn simultaneously rb
false	0	20	thiazides nn are vbp known vbn to topos induce vb hypercalcemia nn by inpos the dt reduction nn of inpos calcium nn excretion nn in inpos urine nn
effect	18	22	some dt reports nns have vbp shown vbn that inpos the dt concomitant jj administration nn of inpos thiazides nn with inpos vitamin_d nn causes vbz hypercalcemia nn
advise	0	24	vitamin_d nn dosage nn must md be vb determined vbn with inpos care nn in inpos patients nns undergoing vbg treatment nn with inpos digitalis nn as inpos hypercalcemia nn in inpos such jj patients nns may md precipitate vb cardiac jj arrhythmias nns
mechanism	0	18	ketoconazole nn may md inhibit vb both cc synthetic jj and cc catabolic jj enzymes nns of inpos vitamin_d nn
false	14	18	however rb in fw vivo fw drug nn interaction nn studies nns of inpos ketoconazole nn with inpos vitamin_d nn have vbp not rb been vbn investigated vbn
mechanism	14	26	a dt relationship nn of inpos functional jj antagonism nn exists vbz between inpos vitamin_d_analogues nn which wdt promote vbp calcium nn absorption nn and cc corticosteroids nn which wdt inhibit vbp calcium nn absorption nn
false	0	4	magnesium nn containing jj antacids nn may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
advise	0	30	magnesium nn containing jj preparations nns may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
advise	2	28	magnesium_containing jj antacids nn may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
false	8	12	concomitant jj use nn with inpos other jj calcium nn containing jj antacids nn may md cause vb too rb much jj calcium nn in inpos the dt blood nn or cc urine nn which wdt may md increase vb the dt chance nn of inpos side nn effects nns
false	10	8	concomitant jj use nn with inpos other jj calcium_containing jj antacids nn may md cause vb too rb much jj calcium nn in inpos the dt blood nn or cc urine nn which wdt may md increase vb the dt chance nn of inpos side nn effects nns
effect	2	6	using vbg calcium_acetate nn with inpos digitalis_glycosides nn may md cause vb hypercalcemia nn which wdt could md increase vb the dt chance nn of inpos developing vbg an dt irregular jj heartbeat nn
false	6	2	using vbg calcium_acetate nn with inpos digitalis_glycosides nn may md cause vb hypercalcemia nn lrb_too rb much jj calcium nn in inpos the dt blood nn rrb_which wdt could md increase vb the dt chance nn of inpos developing vbg an dt irregular jj heartbeat nn
false	20	34	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos glyburide nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	20	34	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos nifedipine nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	20	34	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos digoxin nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	20	34	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos warfarin nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	20	34	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos hydrochlorothiazide nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	20	46	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos glyburide nn nifedipine nn digoxin nn warfarin nn hydrochlorothiazide nn oral jj contraceptives nn in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	20	62	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos glyburide nn nifedipine nn digoxin nn warfarin nn hydrochlorothiazide nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	38	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos glyburide nn oral jj contraceptives nn in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	54	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos glyburide nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	38	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos nifedipine nn oral jj contraceptives nn in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	54	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos nifedipine nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	38	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos digoxin nn oral jj contraceptives nn in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	54	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos digoxin nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	38	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos warfarin nn oral jj contraceptives nn in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	54	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos warfarin nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	38	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos hydrochlorothiazide nn oral jj contraceptives nn in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	34	54	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos hydrochlorothiazide nn and cc oral jj contraceptives nns in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	46	60	no dt significant jj drug nn interactions nns have vbp been vbn reported vbn in inpos studies nns of inpos candesartan_cilexetil nn given vbn with inpos other jj drugs nns such jj as inpos glyburide nn nifedipine nn digoxin nn warfarin nn hydrochlorothiazide nn oral jj contraceptives nn in inpos healthy jj volunteers nns or cc given vbn with inpos enalapril nn to topos patients nns with inpos heart nn failure nn
false	0	36	lithium nn reversible jj increases nns in inpos serum nn lithium nn concentrations nns and cc toxicity nn have vbp been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos ace_inhibitors nn and cc with inpos some dt angiotensin_ii_receptor_antagonists nns
false	0	44	lithium nn reversible jj increases nns in inpos serum nn lithium nn concentrations nns and cc toxicity nn have vbp been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos ace_inhibitors nns and cc with inpos some dt angiotensin_ii_receptor_antagonists nn
false	0	36	lithium nn reversible jj increases nns in inpos serum nn lithium nn concentrations nns and cc toxicity nn have vbp been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos ace_inhibitors nn and cc with inpos some dt angiotensin_ii_receptor_antagonists nns
false	0	44	lithium nn reversible jj increases nns in inpos serum nn lithium nn concentrations nns and cc toxicity nn have vbp been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos ace_inhibitors nns and cc with inpos some dt angiotensin_ii_receptor_antagonists nn
mechanism	0	36	lithium nn reversible jj increases nns in inpos serum nn lithium nn concentrations nns and cc toxicity nn have vbp been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos ace_inhibitors nn and cc with inpos some dt angiotensin_ii_receptor_antagonists nns
mechanism	0	44	lithium nn reversible jj increases nns in inpos serum nn lithium nn concentrations nns and cc toxicity nn have vbp been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos ace_inhibitors nns and cc with inpos some dt angiotensin_ii_receptor_antagonists nn
false	36	44	lithium nn reversible jj increases nns in inpos serum nn lithium nn concentrations nns and cc toxicity nn have vbp been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos ace_inhibitors nn and cc with inpos some dt angiotensin_ii_receptor_antagonists nn
false	8	30	an dt increase nn in inpos serum nn lithium nn concentration nn has vbz been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos atacand nn so rb careful jj monitoring nn of inpos serum nn lithium nn levels nns is vbz recommended vbn during inpos concomitant jj use nn
mechanism	8	30	an dt increase nn in inpos serum nn lithium nn concentration nn has vbz been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos atacand nn so rb careful jj monitoring nn of inpos serum nn lithium nn levels nns is vbz recommended vbn during inpos concomitant jj use nn
false	30	8	an dt increase nn in inpos serum nn lithium nn concentration nn has vbz been vbn reported vbn during inpos concomitant jj administration nn of inpos lithium nn with inpos atacand nn so rb careful jj monitoring nn of inpos serum nn lithium nn levels nns is vbz recommended vbn during inpos concomitant jj use nn
false	8	12	the dt effect nn of inpos an dt aluminum_hydroxide nn hyph_and cc magnesium_hydroxide nn containing jj antacid nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	8	14	the dt effect nn of inpos an dt aluminum_hydroxide nn hyph_and cc magnesium_hydroxide_containing jj antacid nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	8	14	the dt effect nn of inpos an dt aluminum_hydroxide nn hyph_and cc magnesium_hydroxide_containing jj maalox nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	8	24	the dt effect nn of inpos an dt aluminum_hydroxide nn hyph_and cc magnesium_hydroxide_containing jj antacid nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	12	16	the dt effect nn of inpos an dt aluminum_hydroxide nn and cc magnesium_hydroxide nn containing jj antacid nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	12	16	the dt effect nn of inpos an dt aluminum_hydroxide nn and cc magnesium_hydroxide nn containing jj maalox nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	12	26	the dt effect nn of inpos an dt aluminum_hydroxide nn and cc magnesium_hydroxide nn containing jj antacid nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	14	24	the dt effect nn of inpos an dt aluminum_hydroxide nn and cc magnesium_hydroxide_containing jj antacid nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	14	24	the dt effect nn of inpos an dt aluminum_hydroxide nn and cc magnesium_hydroxide_containing jj maalox nn on inpos the dt pharmacokinetics nns of inpos capecitabine nn was vbd investigated vbn in inpos num cd cancer nn patients nns
false	18	24	there ex was vbd a dt small jj increase nn in inpos plasma nn concentrations nns of inpos capecitabine nn and cc num cd num_dfcr nn
false	0	24	coumarin_anticoagulants nn altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nns such jj as inpos warfarin nn and cc phenprocoumon nn
false	0	30	coumarin_anticoagulants nn altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nn such jj as inpos warfarin nn and cc phenprocoumon nn
false	0	36	coumarin_anticoagulants nn altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nns such jj as inpos warfarin nn and cc phenprocoumon nn
false	0	40	coumarin_anticoagulants nn altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nns such jj as inpos warfarin nn and cc phenprocoumon nn
effect	24	30	coumarin_anticoagulants nns altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nn such jj as inpos warfarin nn and cc phenprocoumon nn
false	24	36	coumarin_anticoagulants nns altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nns such jj as inpos warfarin nn and cc phenprocoumon nn
effect	24	40	coumarin_anticoagulants nns altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nns such jj as inpos warfarin nn and cc phenprocoumon nn
false	30	36	coumarin_anticoagulants nns altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nn such jj as inpos warfarin nn and cc phenprocoumon nn
false	30	40	coumarin_anticoagulants nns altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nn such jj as inpos warfarin nn and cc phenprocoumon nn
false	36	40	coumarin_anticoagulants nns altered vbd coagulation nn parameters nns and_or cc bleeding vbg have vbp been vbn reported vbn in inpos patients nns taking vbg capecitabine nn concomitantly rb with inpos coumarin_derivative_anticoagulants nns such jj as inpos warfarin nn and cc phenprocoumon nn
advise	4	10	patients nns taking vbg coumarin_derivative_anticoagulants nn concomitantly rb with inpos capecitabine nn should md be vb monitored vbn regularly rb for inpos alterations nns in inpos their prp coagulation nn parameters nns
mechanism	6	26	the dt concentration nn of inpos num_fluorouracil nn is vbz increased vbn and cc its prp toxicity nn may md be vb enhanced vbn by inpos leucovorin nn
effect	28	32	deaths nns from inpos severe jj enterocolitis nn diarrhea nn dehydration nn have vbp been vbn reported vbn in inpos elderly jj patients nns receiving vbg weekly jj leucovorin nn and cc fluorouracil nn
effect	4	88	patients nns on inpos diuretics nn and cc especially rb those dt in inpos whom wp diuretic jj therapy nn was vbd recently rb instituted vbn as rb well rb as inpos those dt on inpos severe jj dietary jj salt nn restriction nn or cc dialysis nn may md occasionally rb experience vb a dt precipitous jj reduction nn of inpos blood nn pressure nn usually rb within inpos the dt first jj hour nn after inpos receiving vbg the dt initial jj dose nn of inpos captopril nn
false	4	88	patients nns on inpos diuretics nns and cc especially rb those dt in inpos whom wp diuretic nn therapy nn was vbd recently rb instituted vbn as rb well rb as inpos those dt on inpos severe jj dietary jj salt nn restriction nn or cc dialysis nn may md occasionally rb experience vb a dt precipitous jj reduction nn of inpos blood nn pressure nn usually rb within inpos the dt first jj hour nn after inpos receiving vbg the dt initial jj dose nn of inpos captopril nn
effect	12	28	the dt possibility nn of inpos hypotensive jj effects nns with inpos captopril nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn approximately rb num cd week nn prior jj to topos initiation nn of inpos treatment nn with inpos captopril nn or cc initiating vbg therapy nn with inpos small jj doses nns
false	28	12	the dt possibility nn of inpos hypotensive jj effects nns with inpos captopril nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn approximately rb num cd week nn prior jj to topos initiation nn of inpos treatment nn with inpos captopril nn or cc initiating vbg therapy nn with inpos small jj doses nns
false	28	12	the dt possibility nn of inpos hypotensive jj effects nns with inpos captopril nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn approximately rb num cd week nn prior jj to topos initiation nn of inpos treatment nn with inpos captopril nn or cc initiating vbg therapy nn with inpos small jj doses nns
false	18	26	data nns on inpos the dt effect nn of inpos concomitant jj use nn of inpos other jj vasodilators nn in inpos patients nns receiving vbg captopril nn for inpos heart nn failure nn are vbp not rb available jj
advise	2	24	therefore rb nitroglycerin nns having vbg vasodilator nn activity nn should md if inpos possible jj be vb discontinued vbn before inpos starting vbg captopril nn
advise	2	24	therefore rb nitrates nns having vbg vasodilator nn activity nn should md if inpos possible jj be vb discontinued vbn before inpos starting vbg captopril nn
effect	8	22	agents nns causing nnp renin nnp release nnp captopril nn s pos effect nn will md be vb augmented vbn by inpos antihypertensive_agents nn that wdt cause vbp renin nn release nn
false	38	46	agents nns affecting vbg sympathetic jj activity nn the dt sympathetic jj nervous jj system nn may md be vb especially rb important jj in inpos supporting vbg blood nn pressure nn in inpos patients nns receiving vbg captopril nn alone rb or cc with inpos diuretics nn
effect	0	14	b_adrenergic_blocking_drugs nn add vb some dt further jj antihypertensive jj effect nn to topos captopril nn but cc the dt overall jj response nn is vbz less jjr than inpos additive jj
false	0	6	potassium_sparing_diuretics nn such jj as inpos spironolactone nn potassium nn supplements nns should md be vb given vbn only rb for inpos documented vbn hypokalemia nn and cc then rb with inpos caution nn since inpos they prp may md lead vb to topos a dt significant jj increase nn of inpos serum nn potassium nn
false	0	6	potassium_sparing_diuretics nn such jj as inpos triamterene nn potassium nn supplements nns should md be vb given vbn only rb for inpos documented vbn hypokalemia nn and cc then rb with inpos caution nn since inpos they prp may md lead vb to topos a dt significant jj increase nn of inpos serum nn potassium nn
false	0	6	potassium_sparing_diuretics nn such jj as inpos amiloride nn potassium nn supplements nns should md be vb given vbn only rb for inpos documented vbn hypokalemia nn and cc then rb with inpos caution nn since inpos they prp may md lead vb to topos a dt significant jj increase nn of inpos serum nn potassium nn
false	6	0	potassium_sparing_diuretics nns such jj as inpos spironolactone nn or cc potassium nn supplements nns should md be vb given vbn only rb for inpos documented vbn hypokalemia nn and cc then rb with inpos caution nn since inpos they prp may md lead vb to topos a dt significant jj increase nn of inpos serum nn potassium nn
false	6	0	potassium_sparing_diuretics nns such jj as inpos triamterene nn or cc potassium nn supplements nns should md be vb given vbn only rb for inpos documented vbn hypokalemia nn and cc then rb with inpos caution nn since inpos they prp may md lead vb to topos a dt significant jj increase nn of inpos serum nn potassium nn
false	6	0	potassium_sparing_diuretics nns such jj as inpos amiloride nn or cc potassium nn supplements nns should md be vb given vbn only rb for inpos documented vbn hypokalemia nn and cc then rb with inpos caution nn since inpos they prp may md lead vb to topos a dt significant jj increase nn of inpos serum nn potassium nn
effect	20	34	inhibitors nns of inpos endogenous jj prostaglandin nn synthesis nn it prp has vbz been vbn reported vbn that inpos indomethacin nn may md reduce vb the dt antihypertensive jj effect nn of inpos captopril nn especially rb in inpos cases nns of inpos low jj renin nn hypertension nn
false	0	38	lithium nn increased vbd serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg concomitant jj lithium nn and cc ace_inhibitor nn therapy nn
false	4	36	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg concomitant jj lithium nn and cc ace_inhibitor nn therapy nn
false	4	36	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg concomitant jj lithium nn and cc ace_inhibitor nn therapy nn
effect	4	36	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg concomitant jj lithium nn and cc ace_inhibitor nn therapy nn
effect	4	24	if inpos a dt diuretic nn is vbz also rb used vbn it prp may md increase vb the dt risk nn of inpos lithium nn toxicity nn
false	28	30	in inpos a dt study nn of inpos young jj healthy jj male jj subjects nns no dt evidence nn of inpos a dt direct jj pharmacokinetic jj captopril nn hyph_digoxin nn interaction nn could md be vb found vbn
false	0	8	furosemide nn administered vbn concurrently rb with inpos captopril nn does vbz not rb alter vb the dt pharmacokinetics nns of inpos captopril nn in inpos renally rb impaired jj hypertensive jj patients nns
false	0	8	furosemide nn administered vbn concurrently rb with inpos captopril nn does vbz not rb alter vb the dt pharmacokinetics nns of inpos captopril nn in inpos renally rb impaired jj hypertensive jj patients nns
false	26	30	in inpos a dt study nn of inpos healthy jj male jj volunteers nns no dt significant jj pharmacokinetic jj interaction nn occurred vbd when wrb captopril nn and cc allopurinol nn were vbd administered vbn concomitantly rb for inpos num cd days nns
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn acetazolamide nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn azole_antifungals nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn cimetidine nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn clarithromycin nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn dalfopristin nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn danazol nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn delavirdine nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn diltiazem nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn erythromycin nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn fluoxetine nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn fluvoxamine nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn isoniazid nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn itraconazole nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn ketoconazole nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn loratadine nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn nefazodone nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn niacinamide nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn nicotinamide nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn protease_inhibitors nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn propoxyphene nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn quinine nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn quinupristin nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn troleandomycin nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn valproate nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn verapamil nn
mechanism	34	42	agents nns that wdt are vbp cyp3a4 nn inhibitors nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos increase vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn zileuton nn
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn cisplatin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn doxorubicin_hcl nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn felbamate nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn rifampin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nnp may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn phenobarbital nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nnp may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn phenytoin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn primidone nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn methsuximide nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nnp may md be vb necessary jj
mechanism	34	42	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn theophylline nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nnp may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn cisplatin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn cisplatin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn doxorubicin_hcl nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn doxorubicin_hcl nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn felbamate nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn felbamate nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn rifampin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn rifampin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn phenobarbital nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nnp may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn phenobarbital nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn phenytoin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn phenytoin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn primidone nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn primidone nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn methsuximide nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn methsuximide nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn theophylline nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nn and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nnp may md be vb necessary jj
false	42	34	agents nns that wdt are vbp cyp nn inducers nns that wdt have vbp been vbn found vbn or cc are vbp expected vbn to topos decrease vb plasma nn levels nns of inpos equetrotm nn are vbp the dt following nn theophylline nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos equetrotm nnp and cc then rb begins vbz a dt course nn of inpos treatment nn with inpos num cd of inpos these dt cyp3a4 nn inducers nns it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn increase nn for inpos equetrotm nn may md be vb necessary jj
mechanism	0	18	equetrotm nn increases vbz the dt plasma nn levels nns of inpos the dt following vbg agents nns clomipramine_hcl nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos num cd of inpos the dt agents nns in inpos this dt category nn and cc then rb begins vbz a dt course nn of inpos the dt treatment nn with inpos equetrotm nn it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn decrease nn for inpos the dt concomitant jj agent nn may md be vb necessary jj
mechanism	0	18	equetrotm nn increases vbz the dt plasma nn levels nns of inpos the dt following vbg agents nns phenytoin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos num cd of inpos the dt agents nns in inpos this dt category nn and cc then rb begins vbz a dt course nn of inpos the dt treatment nn with inpos equetrotm nn it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn decrease nn for inpos the dt concomitant jj agent nn may md be vb necessary jj
mechanism	0	18	equetrotm nn increases vbz the dt plasma nn levels nns of inpos the dt following vbg agents nns primidone nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos num cd of inpos the dt agents nns in inpos this dt category nn and cc then rb begins vbz a dt course nn of inpos the dt treatment nn with inpos equetrotm nn it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn decrease nn for inpos the dt concomitant jj agent nn may md be vb necessary jj
false	18	0	equetrotm nn increases vbz the dt plasma nn levels nns of inpos the dt following vbg agents nns clomipramine_hcl nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos num cd of inpos the dt agents nns in inpos this dt category nn and cc then rb begins vbz a dt course nn of inpos the dt treatment nn with inpos equetrotm nn it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn decrease nn for inpos the dt concomitant jj agent nn may md be vb necessary jj
false	18	0	equetrotm nn increases vbz the dt plasma nn levels nns of inpos the dt following vbg agents nns phenytoin nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos num cd of inpos the dt agents nns in inpos this dt category nn and cc then rb begins vbz a dt course nn of inpos the dt treatment nn with inpos equetrotm nn it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn decrease nn for inpos the dt concomitant jj agent nn may md be vb necessary jj
false	18	0	equetrotm nn increases vbz the dt plasma nn levels nns of inpos the dt following vbg agents nns primidone nn thus rb if inpos a dt patient nn has vbz been vbn titrated vbn to topos a dt stable jj dosage nn on inpos num cd of inpos the dt agents nns in inpos this dt category nn and cc then rb begins vbz a dt course nn of inpos the dt treatment nn with inpos equetrotm nn it prp is vbz reasonable jj to topos expect vb that inpos a dt dose nn decrease nn for inpos the dt concomitant jj agent nn may md be vb necessary jj
false	6	18	pharmacological_pharmacodynamic jj interactions nns with inpos carbamazepine nn concomitant jj administration nn of inpos carbamazepine nn and cc lithium nn may md increase vb the dt risk nn of inpos neurotoxic jj side nn effects nns
effect	6	18	pharmacological_pharmacodynamic jj interactions nns with inpos carbamazepine nn concomitant jj administration nn of inpos carbamazepine nn and cc lithium nn may md increase vb the dt risk nn of inpos neurotoxic jj side nn effects nns
false	10	12	given vbn the dt anticonvulsant jj properties nns of inpos carbamazepine nn equetrotm nn may md reduce vb the dt thyroid nn function nn as inpos has vbz been vbn reported vbn with inpos other jj anticonvulsants nns
false	10	36	given vbn the dt anticonvulsant jj properties nns of inpos carbamazepine nn equetrotm nnp may md reduce vb the dt thyroid nn function nn as inpos has vbz been vbn reported vbn with inpos other jj anticonvulsants nn
false	12	36	given vbn the dt anticonvulsant jj properties nns of inpos carbamazepine nn equetrotm nn may md reduce vb the dt thyroid nn function nn as inpos has vbz been vbn reported vbn with inpos other jj anticonvulsants nn
false	2	8	additionally rb anti_malarial_drugs nn such jj as inpos chloroquine nn and cc mefloquine nn may md antagonize vb the dt activity nn of inpos carbamazepine nn
false	2	12	additionally rb anti_malarial_drugs nn such jj as inpos chloroquine nn and cc mefloquine nn may md antagonize vb the dt activity nn of inpos carbamazepine nn
effect	2	24	additionally rb anti_malarial_drugs nn such jj as inpos chloroquine nn and cc mefloquine nn may md antagonize vb the dt activity nn of inpos carbamazepine nn
false	8	12	additionally rb anti_malarial_drugs nns such jj as inpos chloroquine nn and cc mefloquine nn may md antagonize vb the dt activity nn of inpos carbamazepine nn
effect	8	24	additionally rb anti_malarial_drugs nns such jj as inpos chloroquine nn and cc mefloquine nn may md antagonize vb the dt activity nn of inpos carbamazepine nn
effect	12	24	additionally rb anti_malarial_drugs nns such jj as inpos chloroquine nn and cc mefloquine nn may md antagonize vb the dt activity nn of inpos carbamazepine nn
advise	22	32	because inpos of inpos its prp primary jj cns nn effect nn caution nn should md be vb used vbn when wrb equetrotm nn is vbz taken vbn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
advise	22	36	because inpos of inpos its prp primary jj cns nn effect nn caution nn should md be vb used vbn when wrb equetrotm nn is vbz taken vbn with inpos other jj centrally_acting_drugs nns and cc alcohol nn
false	32	36	because inpos of inpos its prp primary jj cns nn effect nn caution nn should md be vb used vbn when wrb equetrotm nnp is vbz taken vbn with inpos other jj centrally_acting_drugs nn and cc alcohol nn
mechanism	0	24	geocillin nn blood nn levels nns may md be vb increased vbn and cc prolonged vbn by inpos concurrent jj administration nn of inpos probenecid nn
mechanism	0	24	carbenicillin_indanyl_sodium nn blood nn levels nns may md be vb increased vbn and cc prolonged vbn by inpos concurrent jj administration nn of inpos probenecid nn
false	24	30	caution nn should md be vb exercised vbn when wrb the dt following vbg drugs nns are vbp administered vbn concomitantly rb with inpos lodosyn nn given vbn with inpos levodopa nn or cc carbidopa_levodopa nn combination nn products nns
false	24	34	caution nn should md be vb exercised vbn when wrb the dt following vbg drugs nns are vbp administered vbn concomitantly rb with inpos lodosyn nn given vbn with inpos levodopa nn or cc carbidopa nn levodopa_combination nn products nns
false	24	30	caution nn should md be vb exercised vbn when wrb the dt following vbg drugs nns are vbp administered vbn concomitantly rb with inpos lodosyn nn given vbn with inpos levodopa nn or cc carbidopa nn levodopa nn combination nn products nns
false	24	30	caution nn should md be vb exercised vbn when wrb the dt following vbg drugs nns are vbp administered vbn concomitantly rb with inpos carbidopa nn given vbn with inpos levodopa nn or cc carbidopa_levodopa nn combination nn products nns
false	24	30	caution nn should md be vb exercised vbn when wrb the dt following vbg drugs nns are vbp administered vbn concomitantly rb with inpos carbidopa nn given vbn with inpos levodopa nn or cc carbidopa nn levodopa nn combination nn products nns
false	30	34	caution nn should md be vb exercised vbn when wrb the dt following vbg drugs nns are vbp administered vbn concomitantly rb with inpos lodosyn nn given vbn with inpos levodopa nn or cc carbidopa nn levodopa_combination nn products nns
false	34	30	caution nn should md be vb exercised vbn when wrb the dt following vbg drugs nns are vbp administered vbn concomitantly rb with inpos lodosyn nn given vbn with inpos levodopa nn or cc carbidopa nn hyph_levodopa nn combination nn products nns
false	0	4	dopamine_d2_receptor_antagonists nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
effect	0	18	dopamine_d2_receptor_antagonists nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
false	0	4	phenothiazines nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
effect	0	18	phenothiazines nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
false	0	4	butyrophenones nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
effect	0	18	butyrophenones nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
false	0	4	risperidone nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
effect	0	18	risperidone nn and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
effect	4	18	dopamine_d2_receptor_antagonists nns and cc isoniazid nn may md reduce vb the dt therapeutic jj effects nns of inpos levodopa nn
effect	12	34	in inpos addition nn the dt beneficial jj effects nns of inpos levodopa nn in inpos parkinsons nns disease nn have vbp been vbn reported vbn to topos be vb reversed vbn by inpos phenytoin nn and cc papaverine nn
effect	12	38	in inpos addition nn the dt beneficial jj effects nns of inpos levodopa nn in inpos parkinsons nns disease nn have vbp been vbn reported vbn to topos be vb reversed vbn by inpos phenytoin nn and cc papaverine nn
false	34	38	in inpos addition nn the dt beneficial jj effects nns of inpos levodopa nn in inpos parkinsons nns disease nn have vbp been vbn reported vbn to topos be vb reversed vbn by inpos phenytoin nn and cc papaverine nn
false	10	12	patients nns taking vbg these dt drugs nns with inpos lodosyn nn levodopa nn carbidopa_levodopa nn combination nn products nns should md be vb carefully rb observed vbn for inpos loss nn of inpos therapeutic jj response nn
false	10	14	patients nns taking vbg these dt drugs nns with inpos lodosyn nn levodopa nn carbidopa nn levodopa_combination nn products nns should md be vb carefully rb observed vbn for inpos loss nn of inpos therapeutic jj response nn
false	10	14	patients nns taking vbg these dt drugs nns with inpos lodosyn nn and cc levodopa nn or cc carbidopa nn levodopa nn combination nn products nns should md be vb carefully rb observed vbn for inpos loss nn of inpos therapeutic jj response nn
false	12	14	patients nns taking vbg these dt drugs nns with inpos lodosyn nn levodopa nn carbidopa nn levodopa_combination nn products nns should md be vb carefully rb observed vbn for inpos loss nn of inpos therapeutic jj response nn
false	10	10	patients nns taking vbg these dt drugs nns with inpos carbidopa_hyph_levodopa nn combination nn products nns should md be vb carefully rb observed vbn for inpos loss nn of inpos therapeutic jj response nn
mechanism	0	14	iron nn salts nns may md reduce vb the dt bioavailability nn of inpos carbidopa nn and cc levodopa nn
mechanism	0	18	iron nn salts nns may md reduce vb the dt bioavailability nn of inpos carbidopa nn and cc levodopa nn
false	14	18	iron nn salts nns may md reduce vb the dt bioavailability nn of inpos carbidopa nn and cc levodopa nn
mechanism	2	14	although inpos metoclopramide nn may md increase vb the dt bioavailability nn of inpos levodopa nn by inpos increasing vbg gastric jj emptying nn metoclopramide nn may md also rb adversely rb affect vb disease nn control nn by inpos its prp dopamine nn receptor nn antagonistic jj properties nns
false	14	2	although inpos metoclopramide nn may md increase vb the dt bioavailability nn of inpos levodopa nn by inpos increasing vbg gastric jj emptying nn metoclopramide nn may md also rb adversely rb affect vb disease nn control nn by inpos its prp dopamine nn receptor nn antagonistic jj properties nns
effect	0	18	iodine nn or cc iodine nn excess nn may md decrease vb the dt effect nn of inpos carbimazole nn and cc an dt iodine nn deficiency nn can md increase vb the dt effect nn of inpos carbimazole nn
false	0	18	iodine nn or cc iodine nn excess nn may md decrease vb the dt effect nn of inpos carbimazole nn and cc an dt iodine nn deficiency nn can md increase vb the dt effect nn of inpos carbimazole nn
false	0	18	iodine nn or cc iodine nn excess nn may md decrease vb the dt effect nn of inpos carbimazole nn and cc an dt iodine nn deficiency nn can md increase vb the dt effect nn of inpos carbimazole nn
false	0	18	iodine nn or cc iodine nn excess nn may md decrease vb the dt effect nn of inpos carbimazole nn and cc an dt iodine nn deficiency nn can md increase vb the dt effect nn of inpos carbimazole nn
false	18	0	iodine nn or cc iodine nn excess nn may md decrease vb the dt effect nn of inpos carbimazole nn and cc an dt iodine nn deficiency nn can md increase vb the dt effect nn of inpos carbimazole nn
effect	0	18	iodine nn or cc iodine nn excess nn may md decrease vb the dt effect nn of inpos carbimazole nn and cc an dt iodine nn deficiency nn can md increase vb the dt effect nn of inpos carbimazole nn
false	6	10	serum nn concentration nn of inpos digoxin nn and cc digitoxin nn may md increase vb when wrb patients nns take vbp antithyroid_agents nns
mechanism	6	22	serum nn concentration nn of inpos digoxin nn and cc digitoxin nn may md increase vb when wrb patients nns take vbp antithyroid_agents nn
mechanism	10	22	serum nn concentration nn of inpos digoxin nn and cc digitoxin nn may md increase vb when wrb patients nns take vbp antithyroid_agents nn
effect	0	12	antithyroid_agents nn may md decrease vb thyroidal jj uptake nn of inpos sodium_iodide_i131 nn a dt rebound nn in inpos uptake nn may md occur vb up inpos to topos num cd days nns after inpos sudden jj withdrawal nn of inpos carbimazole nn
false	0	42	antithyroid_agents nn may md decrease vb thyroidal jj uptake nn of inpos sodium_iodide_i131 nn a dt rebound nn in inpos uptake nn may md occur vb up inpos to topos num cd days nns after inpos sudden jj withdrawal nn of inpos carbimazole nn
false	12	42	antithyroid_agents nns may md decrease vb thyroidal jj uptake nn of inpos sodium_iodide_i131 nn a dt rebound nn in inpos uptake nn may md occur vb up inpos to topos num cd days nns after inpos sudden jj withdrawal nn of inpos carbimazole nn
effect	0	12	antihistamines nn may md enhance vb the dt effects nns of inpos tricyclic_antidepressants nn other jj cns_depressants nns
effect	0	12	antihistamines nn may md enhance vb the dt effects nns of inpos barbiturates nn other jj cns_depressants nns
effect	0	12	antihistamines nn may md enhance vb the dt effects nns of inpos alcohol nn other jj cns_depressants nns
effect	0	20	antihistamines nn may md enhance vb the dt effects nns of inpos tricyclic_antidepressants nns barbiturates nns alcohol nn other jj cns_depressants nn
false	12	16	antihistamines nns may md enhance vb the dt effects nns of inpos tricyclic_antidepressants nn other jj cns_depressants nn
false	12	16	antihistamines nns may md enhance vb the dt effects nns of inpos barbiturates nn other jj cns_depressants nn
false	12	16	antihistamines nns may md enhance vb the dt effects nns of inpos alcohol nn other jj cns_depressants nn
effect	0	16	mao_inhibitors nn prolong vb and cc intensify vb the dt anticholinergic jj effects nns of inpos antihistamines nn
effect	0	14	sympathomimetic_amines nn may md reduce vb the dt antihypertensive jj effects nns of inpos reserpine nn
effect	0	14	sympathomimetic_amines nn may md reduce vb the dt antihypertensive jj effects nns of inpos veratrum_alkaloids nn
effect	0	14	sympathomimetic_amines nn may md reduce vb the dt antihypertensive jj effects nns of inpos methyldopa nn
effect	0	14	sympathomimetic_amines nn may md reduce vb the dt antihypertensive jj effects nns of inpos mecamylamine nn
effect	4	12	effects nns of inpos sympathomimetics nn are vbp increased vbn with inpos mao_inhibitors nn and cc b_adrenergic_blockers nns
effect	4	16	effects nns of inpos sympathomimetics nn are vbp increased vbn with inpos mao_inhibitors nns and cc b_adrenergic_blockers nn
false	12	16	effects nns of inpos sympathomimetics nns are vbp increased vbn with inpos mao_inhibitors nn and cc b_adrenergic_blockers nn
effect	0	14	hemabate nn may md augment vb the dt activity nn of inpos other jj oxytocic_agents nn
advise	0	24	ocupress nn should md be vb used vbn with inpos caution nn in inpos patients nns who wp are vbp receiving vbg a dt b_adrenergic_blocking_agent nn orally rb because inpos of inpos the dt potential nn for inpos additive jj effects nns on inpos systemic jj b_blockade nn
advise	18	38	close jj observation nn of inpos the dt patient nn is vbz recommended vbn when wrb a dt b_blocker nn is vbz administered vbn to topos patients nns receiving vbg catecholamine_depleting jj drugs nns such jj as inpos reserpine nn because inpos of inpos possible jj additive jj effects nns and cc the dt production nn of inpos hypotension nn and_or cc marked jj bradycardia nn which wdt may md produce vb vertigo nn syncope nn postural jj hypotension nn
false	6	12	poor jj metabolizers nns of inpos debrisoquin nn interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos cyp2d6 nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	6	22	poor jj metabolizers nns of inpos debrisoquin nn interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos quinidine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	6	22	poor jj metabolizers nns of inpos debrisoquin nn interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos fluoxetine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	6	22	poor jj metabolizers nns of inpos debrisoquin nn interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos paroxetine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	6	22	poor jj metabolizers nns of inpos debrisoquin nn interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos propafenone nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	6	12	poor jj metabolizers nns of inpos debrisoquin nn interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos cyp2d6 nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	4	14	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos quinidine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	4	14	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos fluoxetine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	4	14	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos paroxetine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
false	4	14	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos propafenone nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
effect	14	4	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos quinidine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
effect	14	4	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos fluoxetine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
effect	14	4	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos paroxetine nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
effect	14	4	interactions nns of inpos carvedilol nn with inpos strong jj inhibitors nns of inpos propafenone nn have vbp not rb been vbn studied vbn but cc these dt drugs nns would md be vb expected vbn to topos increase vb blood nn levels nns of inpos the dt r nn enantiomer nn of inpos carvedilol nn
effect	6	20	patients nns taking vbg both cc agents_with_b_blocking_properties nn and cc a dt drug nn that wdt can md deplete vb reserpine nn should md be vb observed vbn closely rb for inpos signs nns of inpos hypotension nn and_or cc severe jj bradycardia nn
effect	6	20	patients nns taking vbg both cc agents_with_b_blocking_properties nn and cc a dt drug nn that wdt can md deplete vb monoamine_oxidase_inhibitors nn should md be vb observed vbn closely rb for inpos signs nns of inpos hypotension nn and_or cc severe jj bradycardia nn
false	0	12	clonidine nn concomitant jj administration nn of inpos clonidine nn with inpos agents_with_b_blocking_properties nn may md potentiate vb blood_pressure nn and cc heart_rate_lowering jj effects nns
effect	6	10	concomitant jj administration nn of inpos clonidine nn with inpos agents_with_b_blocking_properties nn may md potentiate vb blood_pressure nn and cc heart_rate_lowering jj effects nns
advise	8	12	when wrb concomitant jj treatment nn with inpos agents_with_b_blocking_properties nn and cc clonidine nn is vbz to topos be vb terminated vbn the dt b_blocking_agent nn should md be vb discontinued vbn first rb
false	8	24	when wrb concomitant jj treatment nn with inpos agents_with_b_blocking_properties nn and cc clonidine nn is vbz to topos be vb terminated vbn the dt b_blocking_agent nn should md be vb discontinued vbn first rb
false	12	24	when wrb concomitant jj treatment nn with inpos agents_with_b_blocking_properties nns and cc clonidine nn is vbz to topos be vb terminated vbn the dt b_blocking_agent nn should md be vb discontinued vbn first rb
mechanism	10	24	modest jj increases nns in inpos mean jj trough nn cyclosporine nn concentrations nns were vbd observed vbn following vbg initiation nn of inpos carvedilol nn treatment nn in inpos num cd renal jj transplant nn patients nns suffering vbg from inpos chronic jj vascular jj rejection nn
advise	28	44	due jj to topos wide jj interindividual jj variability nn in inpos the dt dose nn adjustment nn required vbd it prp is vbz recommended vbn that inpos cyclosporine nn concentrations nns be vb monitored vbn closely rb after inpos initiation nn of inpos carvedilol nn therapy nn and cc that inpos the dt dose nn of inpos cyclosporine nn be vb adjusted vbn as inpos appropriate jj
advise	44	28	due jj to topos wide jj interindividual jj variability nn in inpos the dt dose nn adjustment nn required vbd it prp is vbz recommended vbn that inpos cyclosporine nn concentrations nns be vb monitored vbn closely rb after inpos initiation nn of inpos carvedilol nn therapy nn and cc that inpos the dt dose nn of inpos cyclosporine nn be vb adjusted vbn as inpos appropriate jj
false	0	20	digoxin nn concentrations nns are vbp increased vbn by inpos about rb num cd when wrb digoxin nn and cc carvedilol nn are vbp administered vbn concomitantly rb
mechanism	0	20	digoxin nn concentrations nns are vbp increased vbn by inpos about rb num cd when wrb digoxin nn and cc carvedilol nn are vbp administered vbn concomitantly rb
effect	2	6	both cc digoxin nn and cc coreg nn slow jj av nn conduction nn
advise	8	24	therefore rb increased vbn monitoring nn of inpos digoxin nn is vbz recommended vbn when wrb initiating vbg adjusting nn or cc discontinuing vbg coreg nn
mechanism	0	10	rifampin nn reduced vbd plasma nn concentrations nns of inpos carvedilol nn by inpos about rb num cd
effect	18	26	isolated vbn cases nns of inpos conduction nn disturbance nn have vbp been vbn observed vbn when wrb coreg nn is vbz co_administered vbn with inpos diltiazem nn
false	6	10	as inpos with inpos other jj agents_with_b_blocking_properties nn if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nns of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	6	24	as inpos with inpos other jj agents_with_b_blocking_properties nn if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nn of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	6	30	as inpos with inpos other jj agents_with_b_blocking_properties nn if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nns of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	6	34	as inpos with inpos other jj agents_with_b_blocking_properties nn if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nns of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	10	24	as inpos with inpos other jj agents_with_b_blocking_properties nns if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nn of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
advise	10	30	as inpos with inpos other jj agents_with_b_blocking_properties nns if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nns of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
advise	10	34	as inpos with inpos other jj agents_with_b_blocking_properties nns if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nns of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	24	30	as inpos with inpos other jj agents_with_b_blocking_properties nns if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nn of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	24	34	as inpos with inpos other jj agents_with_b_blocking_properties nns if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nn of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	30	34	as inpos with inpos other jj agents_with_b_blocking_properties nns if inpos coreg nn is vbz to topos be vb administered vbn orally rb with inpos calcium_channel_blockers nns of inpos the dt verapamil nn or cc diltiazem nn type nn it prp is vbz recommended vbn that inpos ecg nn and cc blood nn pressure nn be vb monitored vbn
false	0	6	insulin nn or cc oral jj hypoglycemics nn
effect	0	14	agents_with_b_blocking_properties nn may md enhance vb the dt blood_sugar_reducing jj effect nn of inpos insulin nn and cc oral jj hypoglycemics nns
effect	0	20	agents_with_b_blocking_properties nn may md enhance vb the dt blood_sugar_reducing jj effect nn of inpos insulin nn and cc oral jj hypoglycemics nn
false	14	20	agents_with_b_blocking_properties nns may md enhance vb the dt blood_sugar_reducing jj effect nn of inpos insulin nn and cc oral jj hypoglycemics nn
false	8	14	therefore rb in inpos patients nns taking vbg insulin nn or cc oral jj hypoglycemics nn regular jj monitoring nn of inpos blood nn glucose nn is vbz recommended vbn
false	20	30	clinical jj studies nns in inpos healthy jj volunteers nns show vbp that inpos the dt pharmacokinetics nns of inpos cancidas nn are vbp not rb altered vbn by inpos itraconazole nn
false	20	30	clinical jj studies nns in inpos healthy jj volunteers nns show vbp that inpos the dt pharmacokinetics nns of inpos cancidas nn are vbp not rb altered vbn by inpos amphotericin_b nn
false	20	30	clinical jj studies nns in inpos healthy jj volunteers nns show vbp that inpos the dt pharmacokinetics nns of inpos cancidas nn are vbp not rb altered vbn by inpos mycophenolate nn
false	20	30	clinical jj studies nns in inpos healthy jj volunteers nns show vbp that inpos the dt pharmacokinetics nns of inpos cancidas nn are vbp not rb altered vbn by inpos nelfinavir nn
false	20	30	clinical jj studies nns in inpos healthy jj volunteers nns show vbp that inpos the dt pharmacokinetics nns of inpos cancidas nn are vbp not rb altered vbn by inpos tacrolimus nn
false	0	16	cancidas nn has vbz no dt effect nn on inpos the dt pharmacokinetics nns of inpos itraconazole nn amphotericin_b nn the dt active jj metabolite nn of inpos mycophenolate nn
false	0	18	cancidas nn has vbz no dt effect nn on inpos the dt pharmacokinetics nns of inpos itraconazole nn amphotericin_b nn the dt active jj metabolite nn of inpos mycophenolate nn
false	16	18	cancidas nn has vbz no dt effect nn on inpos the dt pharmacokinetics nns of inpos itraconazole nn amphotericin_b nn the dt active jj metabolite nn of inpos mycophenolate nn
mechanism	0	12	cancidas nn reduced vbd the dt blood nn auc0_num nn of inpos tacrolimus nn by inpos approximately rb num cd peak jj blood nn concentration nn by inpos num cd num_hour jj blood nn concentration nn by inpos num cd in inpos healthy jj subjects nns when wrb tacrolimus nn was vbd administered vbn on inpos the dt 10th jj day nn of inpos cancidas nn num cd mg nn daily rb as inpos compared vbn to topos results nns from inpos a dt control nn period nn in inpos which wdt tacrolimus nn was vbd administered vbn alone rb
false	0	12	cancidas nn reduced vbd the dt blood nn auc0_num nn of inpos tacrolimus nn by inpos approximately rb num cd peak jj blood nn concentration nn by inpos num cd num_hour jj blood nn concentration nn by inpos num cd in inpos healthy jj subjects nns when wrb tacrolimus nn was vbd administered vbn on inpos the dt 10th jj day nn of inpos cancidas nn num cd mg nn daily rb as inpos compared vbn to topos results nns from inpos a dt control nn period nn in inpos which wdt tacrolimus nn was vbd administered vbn alone rb
false	0	12	cancidas nn reduced vbd the dt blood nn auc0_num nn of inpos tacrolimus nn by inpos approximately rb num cd peak jj blood nn concentration nn by inpos num cd num_hour jj blood nn concentration nn by inpos num cd in inpos healthy jj subjects nns when wrb tacrolimus nn was vbd administered vbn on inpos the dt 10th jj day nn of inpos cancidas nn num cd mg nn daily rb as inpos compared vbn to topos results nns from inpos a dt control nn period nn in inpos which wdt tacrolimus nn was vbd administered vbn alone rb
false	12	0	cancidas nn reduced vbd the dt blood nn auc0_num nn of inpos tacrolimus nn by inpos approximately rb num cd peak jj blood nn concentration nn by inpos num cd num_hour jj blood nn concentration nn by inpos num cd in inpos healthy jj subjects nns when wrb tacrolimus nn was vbd administered vbn on inpos the dt 10th jj day nn of inpos cancidas nn num cd mg nn daily rb as inpos compared vbn to topos results nns from inpos a dt control nn period nn in inpos which wdt tacrolimus nn was vbd administered vbn alone rb
false	12	0	cancidas nn reduced vbd the dt blood nn auc0_num nn of inpos tacrolimus nn by inpos approximately rb num cd peak jj blood nn concentration nn by inpos num cd num_hour jj blood nn concentration nn by inpos num cd in inpos healthy jj subjects nns when wrb tacrolimus nn was vbd administered vbn on inpos the dt 10th jj day nn of inpos cancidas nn num cd mg nn daily rb as inpos compared vbn to topos results nns from inpos a dt control nn period nn in inpos which wdt tacrolimus nn was vbd administered vbn alone rb
false	0	12	cancidas nn reduced vbd the dt blood nn auc0_num nn of inpos tacrolimus nn by inpos approximately rb num cd peak jj blood nn concentration nn by inpos num cd num_hour jj blood nn concentration nn by inpos num cd in inpos healthy jj subjects nns when wrb tacrolimus nn was vbd administered vbn on inpos the dt 10th jj day nn of inpos cancidas nn num cd mg nn daily rb as inpos compared vbn to topos results nns from inpos a dt control nn period nn in inpos which wdt tacrolimus nn was vbd administered vbn alone rb
mechanism	8	18	in inpos num cd clinical jj studies nns cyclosporine nn increased vbd the dt auc nn of inpos caspofungin nn by inpos approximately rb num cd
false	0	16	cancidas nn did vbd not rb increase vb the dt plasma nn levels nns of inpos cyclosporine nn
effect	20	24	there ex were vbd transient jj increases nns in inpos liver nn alt nn and cc ast nn when wrb cancidas nn and cc cyclosporine nn were vbd co_administered vbn
mechanism	10	30	a dt drug_drug jj interaction nn study nn with inpos rifampin nn in inpos healthy jj volunteers nns has vbz shown vbn a dt num cd decrease nn in inpos caspofungin nn trough nn concentrations nns
advise	4	16	patients nns on inpos rifampin nn should md receive vb num cd mg nn of inpos cancidas nn daily jj
mechanism	36	40	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn efavirenz nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
false	36	56	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn efavirenz nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
mechanism	36	40	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn nevirapine nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
false	36	56	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn nevirapine nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
mechanism	36	40	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn phenytoin nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
false	36	56	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn phenytoin nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
mechanism	36	40	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn dexamethasone nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
false	36	56	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn dexamethasone nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
mechanism	36	40	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn carbamazepine nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
false	36	56	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn carbamazepine nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
false	40	56	in inpos addition nn results vbz from inpos regression nn analyses nns of inpos patient nn pharmacokinetic jj data nns suggest vbp that inpos co_administration nn of inpos other jj inducers nns of inpos drug nn clearance nn with inpos cancidas nn may md result vb in inpos clinically rb meaningful jj reductions nns in inpos caspofungin nn concentrations nns
advise	2	22	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos efavirenz nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
advise	2	22	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos nevirapine nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
advise	2	22	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos phenytoin nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
advise	2	22	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos dexamethasone nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
advise	2	22	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos carbamazepine nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
false	22	2	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos efavirenz nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
false	22	2	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos nevirapine nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
false	22	2	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos phenytoin nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
false	22	2	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos dexamethasone nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
false	22	2	when wrb cancidas nn is vbz co_administered vbn with inpos inducers nns of inpos drug nn clearance nn such jj as inpos carbamazepine nn use nn of inpos a dt daily jj dose nn of inpos num cd mg nn of inpos cancidas nn should md be vb considered vbn
mechanism	0	14	probenecid nn may md decrease vb renal jj tubular jj secretion nn of inpos cephalosporins nn when wrb used vbn concurrently rb resulting vbg in inpos increased vbn and cc more rbr prolonged jj cephalosporin nn blood nn levels nns
false	0	14	probenecid nn may md decrease vb renal jj tubular jj secretion nn of inpos cephalosporins nns when wrb used vbn concurrently rb resulting vbg in inpos increased vbn and cc more rbr prolonged jj cephalosporin nn blood nn levels nns
false	0	10	antacids nn concomitant jj administration nn of inpos num_mg jj cefdinir nn capsules nns with inpos num cd ml nn maalox_tc nn suspension nn reduces vbz the dt rate nn and cc extent nn of inpos absorption nn by inpos approximately rb num cd
false	0	20	antacids nn concomitant jj administration nn of inpos num_mg jj cefdinir nn capsules nns with inpos num cd ml nn maalox_tc nn suspension nn reduces vbz the dt rate nn and cc extent nn of inpos absorption nn by inpos approximately rb num cd
false	0	10	aluminum nn concomitant jj administration nn of inpos num_mg jj cefdinir nn capsules nns with inpos num cd ml nn maalox_tc nn suspension nn reduces vbz the dt rate nn and cc extent nn of inpos absorption nn by inpos approximately rb num cd
false	0	20	aluminum nn concomitant jj administration nn of inpos num_mg jj cefdinir nn capsules nns with inpos num cd ml nn maalox_tc nn suspension nn reduces vbz the dt rate nn and cc extent nn of inpos absorption nn by inpos approximately rb num cd
false	0	10	magnesium nn concomitant jj administration nn of inpos num_mg jj cefdinir nn capsules nns with inpos num cd ml nn maalox_tc nn suspension nn reduces vbz the dt rate nn and cc extent nn of inpos absorption nn by inpos approximately rb num cd
false	0	20	magnesium nn concomitant jj administration nn of inpos num_mg jj cefdinir nn capsules nns with inpos num cd ml nn maalox_tc nn suspension nn reduces vbz the dt rate nn and cc extent nn of inpos absorption nn by inpos approximately rb num cd
mechanism	8	18	concomitant jj administration nn of inpos num_mg jj cefdinir nn capsules nns with inpos num cd ml nn maalox_tc nn suspension nn reduces vbz the dt rate nn and cc extent nn of inpos absorption nn by inpos approximately rb num cd
false	12	20	there ex are vbp no dt significant jj effects nns on inpos cefdinir nn pharmacokinetics nns if inpos the dt antacid nn is vbz administered vbn num cd hours nns before inpos or cc num cd hours nns after inpos cefdinir nn
false	20	12	there ex are vbp no dt significant jj effects nns on inpos cefdinir nn pharmacokinetics nns if inpos the dt antacid nn is vbz administered vbn num cd hours nns before inpos or cc num cd hours nns after inpos cefdinir nn
false	2	10	if inpos antacids nn are vbp required vbn during inpos omnicef nn therapy nn omnicef nn should md be vb taken vbn at inpos least jjs num cd hours nns before inpos or cc after inpos the dt antacid nn
false	2	10	if inpos antacids nn are vbp required vbn during inpos omnicef nn therapy nn omnicef nn should md be vb taken vbn at inpos least jjs num cd hours nns before inpos or cc after inpos the dt antacid nn
false	10	2	if inpos antacids nns are vbp required vbn during inpos omnicef nn therapy nn omnicef nn should md be vb taken vbn at inpos least jjs num cd hours nns before inpos or cc after inpos the dt antacid nn
advise	10	2	if inpos antacids nns are vbp required vbn during inpos omnicef nn therapy nn omnicef nn should md be vb taken vbn at inpos least jjs num cd hours nns before inpos or cc after inpos the dt antacid nn
false	0	8	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nn probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
false	0	22	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nns probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
false	0	22	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nns probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
false	8	0	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
mechanism	8	22	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
false	8	22	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
mechanism	0	22	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nns probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
false	0	22	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nns probenecid nn inhibits vbz the dt renal jj excretion nn of inpos cefdinir nn resulting vbg in inpos an dt approximate jj doubling nn in inpos a.c. nnp a dt num cd increase nn in inpos peak jj cefdinir nn plasma nn levels nns and cc a dt num cd prolongation nn in inpos the dt apparent jj elimination nn half_life nn
false	0	18	iron_supplements nn and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nns supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	0	42	iron_supplements nn and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nn supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	0	18	iron_supplements nns and cc foods nns fortified vbn with inpos iron nn concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nns supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	0	42	iron_supplements nns and cc foods nns fortified vbn with inpos iron nn concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nn supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	18	0	iron_supplements nns and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nns supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
mechanism	18	0	iron_supplements nns and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nns supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	18	42	iron_supplements nns and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nn supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
mechanism	18	0	iron_supplements nns and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nns supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	0	42	iron_supplements nns and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nn supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	0	42	iron_supplements nns and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nn supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	42	0	iron_supplements nns and cc foods nnp fortified nnp with inpos iron nnp concomitant jj administration nn of inpos cefdinir nn with inpos a dt therapeutic jj iron_supplement nn containing vbg num cd mg nn of inpos elemental jj iron nn or cc vitamins nn supplemented vbn with inpos num cd mg nn of inpos elemental jj iron nn reduced vbd extent nn of inpos absorption nn by inpos num cd and cc num cd respectively rb
false	2	10	if inpos iron_supplements nn are vbp required vbn during inpos omnicef nn therapy nn omnicef nn should md be vb taken vbn at inpos least jjs num cd hours nns before inpos or cc after inpos the dt supplement nn
advise	2	10	if inpos iron_supplements nn are vbp required vbn during inpos omnicef nn therapy nn omnicef nn should md be vb taken vbn at inpos least jjs num cd hours nns before inpos or cc after inpos the dt supplement nn
false	16	20	the dt effect nn of inpos foods nns highly rb fortified vbn with inpos elemental jj iron nn on inpos cefdinir nn absorption nn has vbz not rb been vbn studied vbn
false	16	30	the dt effect nn of inpos foods nns highly rb fortified vbn with inpos elemental jj iron nn lrb_primarily rb iron nn fortified jj breakfast nn cereals nns rrb_on inpos cefdinir nn absorption nn has vbz not rb been vbn studied vbn
false	4	22	concomitantly rb administered vbn iron nn fortified jj infant nn formula nn has vbz no dt significant jj effect nn on inpos cefdinir nn pharmacokinetics nns
false	4	32	concomitantly rb administered vbn iron_fortified jj infant nn formula nn lrb_float cd mg nn elemental jj iron nn num nn oz nn rrb_has vbz no dt significant jj effect nn on inpos cefdinir nn pharmacokinetics nns
false	2	18	therefore rb omnicef nn for inpos oral nnp suspension nnp can md be vb administered vbn with inpos iron nn fortified jj infant nn formula nn
mechanism	26	34	the dt reddish jj color nn is vbz due inpos to topos the dt formation nn of inpos a dt nonabsorbable jj complex nn between inpos cefdinir nn its prp breakdown nn products nns iron nn in inpos the dt gastrointestinal jj tract nn
false	32	44	drug_laboratory nnp test nnp interactions nnps a dt false_positive jj reaction nn for inpos ketones nns in inpos the dt urine nn may md occur vb with inpos tests nns using vbg nitroprusside nn but cc not rb with inpos those dt using vbg nitroferricyanide nn
false	2	10	oral jj contraceptives nn multiple jj doses nns of inpos cefditoren_pivoxil nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn the dt estrogenic jj component nn in inpos most jjs oral jj contraceptives nns
false	2	26	oral jj contraceptives nn multiple jj doses nns of inpos cefditoren_pivoxil nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn the dt estrogenic jj component nn in inpos most jjs oral jj contraceptives nns
false	10	26	oral jj contraceptives nns multiple jj doses nns of inpos cefditoren_pivoxil nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn the dt estrogenic jj component nn in inpos most jjs oral jj contraceptives nns
false	10	2	oral jj contraceptives nns multiple jj doses nns of inpos cefditoren_pivoxil nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn the dt estrogenic jj component nn in inpos most jjs oral jj contraceptives nn
false	26	2	oral jj contraceptives nns multiple jj doses nns of inpos cefditoren_pivoxil nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn the dt estrogenic jj component nn in inpos most jjs oral jj contraceptives nn
advise	24	34	although inpos the dt clinical jj significance nn is vbz not rb known vbn it prp is vbz not rb recommended vbn that inpos cefditoren_pivoxil nn be vb taken vbn concomitantly rb with inpos antacids nn
false	0	18	h2_receptor_antagonists nn co_administration nn of inpos a dt single jj dose nn of inpos intravenously rb administered vbn famotidine nn reduced vbd the dt oral jj absorption nn of inpos a dt single jj num cd mg nn dose nn of inpos cefditoren_pivoxil nn administered vbn following vbg a dt meal nn as inpos evidenced vbn by inpos a dt num cd decrease nn in inpos mean jj cmax nn and cc a dt num cd decrease nn in inpos mean jj auc nn
false	0	42	h2_receptor_antagonists nn co_administration nn of inpos a dt single jj dose nn of inpos intravenously rb administered vbn famotidine nn reduced vbd the dt oral jj absorption nn of inpos a dt single jj num cd mg nn dose nn of inpos cefditoren_pivoxil nn administered vbn following vbg a dt meal nn as inpos evidenced vbn by inpos a dt num cd decrease nn in inpos mean jj cmax nn and cc a dt num cd decrease nn in inpos mean jj auc nn
mechanism	16	40	co_administration nn of inpos a dt single jj dose nn of inpos intravenously rb administered vbn famotidine nn reduced vbd the dt oral jj absorption nn of inpos a dt single jj num cd mg nn dose nn of inpos cefditoren_pivoxil nn administered vbn following vbg a dt meal nn as inpos evidenced vbn by inpos a dt num cd decrease nn in inpos mean jj cmax nn and cc a dt num cd decrease nn in inpos mean jj auc nn
false	24	34	although inpos the dt clinical jj significance nn is vbz not rb known vbn it prp is vbz not rb recommended vbn that inpos cefditoren_pivoxil nn be vb taken vbn concomitantly rb with inpos h2_receptor_antagonists nn
false	0	8	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nn co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nns with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
false	0	18	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nns co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nns with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
false	0	18	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nns co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nn with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
false	8	0	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nns with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
mechanism	8	18	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nns with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
false	8	18	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nn with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
mechanism	0	18	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nns co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nns with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
false	0	18	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nns co_administration nn of inpos probenecid nn with inpos cefditoren_pivoxil nn resulted vbd in inpos an dt increase nn in inpos the dt plasma nn exposure nn of inpos cefditoren nn with inpos a dt num cd increase nn in inpos mean jj cmax nn a dt num cd increase nn in inpos mean jj auc nn and cc a dt num cd increase nn in inpos half_life nn
advise	20	32	renal jj function nn should md be vb monitored vbn carefully rb if inpos high jj doses nns of inpos aminoglycosides nn are vbp to topos be vb administered vbn with inpos maxipime nn because inpos of inpos the dt increased vbn potential nn of inpos nephrotoxicity nn and cc ototoxicity nn of inpos aminoglycoside_antibiotics nns
false	20	54	renal jj function nn should md be vb monitored vbn carefully rb if inpos high jj doses nns of inpos aminoglycosides nn are vbp to topos be vb administered vbn with inpos maxipime nn because inpos of inpos the dt increased vbn potential nn of inpos nephrotoxicity nn and cc ototoxicity nn of inpos aminoglycoside_antibiotics nn
false	32	54	renal jj function nn should md be vb monitored vbn carefully rb if inpos high jj doses nns of inpos aminoglycosides nns are vbp to topos be vb administered vbn with inpos maxipime nn because inpos of inpos the dt increased vbn potential nn of inpos nephrotoxicity nn and cc ototoxicity nn of inpos aminoglycoside_antibiotics nn
effect	18	24	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos other jj cephalosporins nn with inpos potent jj diuretics nn such jj as inpos furosemide nn
effect	18	30	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos other jj cephalosporins nn with inpos potent jj diuretics nns such jj as inpos furosemide nn
false	24	30	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos other jj cephalosporins nns with inpos potent jj diuretics nn such jj as inpos furosemide nn
false	0	22	carbamazepine nn elevated vbd carbamazepine nn levels nns have vbp been vbn reported vbn in inpos postmarketing vbg experience nn when wrb suprax nn is vbz administered vbn concomitantly rb
mechanism	2	20	elevated jj carbamazepine nn levels nns have vbp been vbn reported vbn in inpos postmarketing vbg experience nn when wrb suprax nn is vbz administered vbn concomitantly rb
false	0	4	warfarin nn and cc anticoagulants nn increased vbn prothrombin nn time nn with inpos or cc without inpos clinical jj bleeding nn has vbz been vbn reported vbn when wrb cefixime nn is vbz administered vbn concomitantly rb
effect	0	30	warfarin nn and cc anticoagulants nnps increased vbn prothrombin nn time nn with inpos or cc without inpos clinical jj bleeding nn has vbz been vbn reported vbn when wrb cefixime nn is vbz administered vbn concomitantly rb
effect	4	30	warfarin nn and cc anticoagulants nn increased vbn prothrombin nn time nn with inpos or cc without inpos clinical jj bleeding nn has vbz been vbn reported vbn when wrb cefixime nn is vbz administered vbn concomitantly rb
false	32	44	drug_laboratory nnp test nnp interactions nnps a dt false_positive jj reaction nn for inpos ketones nns in inpos the dt urine nn may md occur vb with inpos tests nns using vbg nitroprusside nn but cc not rb with inpos those dt using vbg nitroferricyanide nn
effect	18	22	increased vbn nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nn and cc aminoglycoside_antibiotics nn
false	6	10	drug_laboratory nnp test nnp interactions nnp cephalosporins nn including vbg cefotaxime_sodium nn are vbp known vbn to topos occasionally rb induce vb a dt positive jj direct jj coombs nnp test nn
effect	2	8	if inpos cefotan nn and cc an dt aminoglycoside nn are vbp used vbn concomitantly rb renal jj function nn should md be vb carefully rb monitored vbn because inpos nephrotoxicity nn may md be vb potentiated vbn
false	6	14	as inpos with inpos other jj cephalosporins nn high jj concentrations nns of inpos cefotetan nn may md interfere vb with inpos measurement nn of inpos serum nn and cc urine nn creatinine nn levels nns by inpos jaffe nn reaction nn and cc produce vb false jj increases nns in inpos the dt levels nns of inpos creatinine nn reported vbd
effect	18	22	increased vbn nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nn and cc aminoglycoside_antibiotics nn
false	10	18	drug_laboratory nnp test nnp interactions nns as inpos with inpos cephalothin nn high jj concentrations nns of inpos cefoxitin nn may md interfere vb with inpos measurement nn of inpos serum nn and cc urine nn creatinine nn levels nns by inpos the dt jaff nnp reaction nn and cc produce vb false jj increases nns of inpos modest jj degree nn in inpos the dt levels nns of inpos creatinine nn reported vbd
effect	16	20	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos aminoglycoside_antibiotics nn and cc cephalosporin_antibiotics nn
mechanism	6	16	concomitant jj administration nn of inpos probenecid nn doubled vbd the dt auc nn for inpos cefprozil nn
false	14	34	the dt bioavailability nn of inpos the dt capsule nn formulation nn of inpos cefprozil nn was vbd not rb affected vbn when wrb administered vbn num cd minutes nns following vbg an dt antacid nn
effect	16	20	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nn with inpos aminoglycoside_antibiotics nn or cc potent jj diuretics nns such jj as inpos furosemide nn
effect	16	26	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nn with inpos aminoglycoside_antibiotics nns or cc potent jj diuretics nn such jj as inpos furosemide nn
effect	16	32	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nn with inpos aminoglycoside_antibiotics nns or cc potent jj diuretics nns such jj as inpos furosemide nn
false	20	26	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nns with inpos aminoglycoside_antibiotics nn or cc potent jj diuretics nn such jj as inpos furosemide nn
false	20	32	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nns with inpos aminoglycoside_antibiotics nn or cc potent jj diuretics nns such jj as inpos furosemide nn
false	26	32	nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos cephalosporins nns with inpos aminoglycoside_antibiotics nns or cc potent jj diuretics nn such jj as inpos furosemide nn
false	24	60	renal jj function nn should md be vb carefully rb monitored vbn especially rb if inpos higher jjr dosages nns of inpos the dt aminoglycosides nn are vbp to topos be vb administered vbn or cc if inpos therapy nn is vbz prolonged vbn because inpos of inpos the dt potential jj nephrotoxicity nn and cc ototoxicity nn of inpos aminoglycosidic_antibiotics nn
effect	0	16	chloramphenicol nn has vbz been vbn shown vbn to topos be vb antagonistic jj to topos b_lactam_antibiotics nn including vbg ceftazidime nn based vbn on inpos in fw vitro fw studies nns and cc time nn kill nn curves nns with inpos enteric jj gram_negative jj bacilli nns
effect	0	20	chloramphenicol nn has vbz been vbn shown vbn to topos be vb antagonistic jj to topos b_lactam_antibiotics nns including vbg ceftazidime nn based vbn on inpos in fw vitro fw studies nns and cc time nn kill nn curves nns with inpos enteric jj gram_negative jj bacilli nns
false	16	20	chloramphenicol nn has vbz been vbn shown vbn to topos be vb antagonistic jj to topos b_lactam_antibiotics nn including vbg ceftazidime nn based vbn on inpos in fw vitro fw studies nns and cc time nn kill nn curves nns with inpos enteric jj gram_negative jj bacilli nns
false	10	34	with inpos the dt morning nn dose nn of inpos ceftibuten nn on inpos day nn num cd each dt volunteer nn received vbd a dt single jj intravenous jj infusion nn of inpos theophylline nn
false	6	16	the dt effect nn of inpos ceftibuten nn on inpos the dt pharmacokinetics nns of inpos theophylline nn administered vbn orally rb has vbz not rb been vbn investigated vbn
false	0	4	antacids nn or cc h_num_receptor_antagonists nn
false	10	30	a dt single jj dose nn of inpos liquid jj antacid nn did vbd not rb affect vb the dt c nn max nn or cc auc nn of inpos ceftibuten nn
mechanism	8	22	however rb num cd mg nn of inpos ranitidine nn q12h nn for inpos num cd days nns increased vbd the dt ceftibuten nn c nn max nn by inpos num cd and cc ceftibuten jj auc nn by inpos num cd
mechanism	8	22	however rb num cd mg nn of inpos ranitidine nn q12h nn for inpos num cd days nns increased vbd the dt ceftibuten jj c nn max nn by inpos num cd and cc ceftibuten nn auc nn by inpos num cd
false	16	36	although inpos the dt occurrence nn has vbz not rb been vbn reported vbn with inpos cefizox nn nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos other jj cephalosporins nn and cc aminoglycosides nns
false	16	40	although inpos the dt occurrence nn has vbz not rb been vbn reported vbn with inpos cefizox nn nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos other jj cephalosporins nns and cc aminoglycosides nn
effect	36	40	although inpos the dt occurrence nn has vbz not rb been vbn reported vbn with inpos cefizox nn nephrotoxicity nn has vbz been vbn reported vbn following vbg concomitant jj administration nn of inpos other jj cephalosporins nn and cc aminoglycosides nn
int	6	20	clinical jj studies nns with inpos celecoxib nn have vbp identified vbn potentially rb significant jj interactions nns with inpos fluconazole nn and cc lithium nn
int	6	24	clinical jj studies nns with inpos celecoxib nn have vbp identified vbn potentially rb significant jj interactions nns with inpos fluconazole nn and cc lithium nn
false	20	24	clinical jj studies nns with inpos celecoxib nn have vbp identified vbn potentially rb significant jj interactions nns with inpos fluconazole nn and cc lithium nn
int	4	18	experience nn with inpos nonsteroidal_anti_inflammatory_drugs nn suggests vbz the dt potential nn for inpos interactions nns with inpos furosemide nn and cc ace_inhibitors nns
int	4	22	experience nn with inpos nonsteroidal_anti_inflammatory_drugs nn suggests vbz the dt potential nn for inpos interactions nns with inpos furosemide nn and cc ace_inhibitors nn
int	4	18	experience nn with inpos nsaids nn suggests vbz the dt potential nn for inpos interactions nns with inpos furosemide nn and cc ace_inhibitors nns
int	4	22	experience nn with inpos nsaids nn suggests vbz the dt potential nn for inpos interactions nns with inpos furosemide nn and cc ace_inhibitors nn
false	18	22	experience nn with inpos nonsteroidal_anti_inflammatory_drugs nns suggests vbz the dt potential nn for inpos interactions nns with inpos furosemide nn and cc ace_inhibitors nn
false	4	18	the dt effects nns celecoxib nn on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos glyburide nn have vbp been vbn studied vbn in fw vivo fw and cc clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	4	18	the dt effects nns celecoxib nn on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos ketoconazole nn have vbp been vbn studied vbn in fw vivo fw and cc clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	4	18	the dt effects nns celecoxib nn on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos methotrexate nn have vbp been vbn studied vbn in fw vivo fw and cc clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	4	18	the dt effects nns celecoxib nn on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos phenytoin nn have vbp been vbn studied vbn in fw vivo fw and cc clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	4	18	the dt effects nns celecoxib nn on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos tolbutamide nn have vbp been vbn studied vbn in fw vivo fw and cc clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	4	18	the dt effects nns celecoxib nn on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos warfarin nn have vbp been vbn studied vbn in fw vivo fw and cc clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	18	20	the dt effects nns celecoxib vbp on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos glyburide nn warfarin nn have vbp been vbn studied vbn in fw vivo fw clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	18	20	the dt effects nns celecoxib vbp on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos ketoconazole nn warfarin nn have vbp been vbn studied vbn in fw vivo fw clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	18	20	the dt effects nns celecoxib vbp on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos methotrexate nn warfarin nn have vbp been vbn studied vbn in fw vivo fw clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	18	20	the dt effects nns celecoxib vbp on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos phenytoin nn warfarin nn have vbp been vbn studied vbn in fw vivo fw clinically rb important jj interactions nns have vbp not rb been vbn found vbn
false	18	20	the dt effects nns celecoxib vbp on inpos the dt pharmacokinetics nns and_or cc pharmacodynamics nns of inpos tolbutamide nn warfarin nn have vbp been vbn studied vbn in fw vivo fw clinically rb important jj interactions nns have vbp not rb been vbn found vbn
effect	6	20	reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos angiotensin_converting_enzyme_ace_inhibitors nn
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg celebrex nn concomitantly rb with inpos ace_inhibitors nn
false	0	24	furosemide nn clinical jj studies nns as rb well rb as inpos post nn marketing nn observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
false	0	42	furosemide nn clinical jj studies nns as rb well rb as inpos post nn marketing nn observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
effect	24	0	furosemide nn clinical jj studies nns as rb well rb as inpos post nn marketing nn observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
effect	24	42	furosemide nn clinical jj studies nns as rb well rb as inpos post nn marketing nn observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	0	42	furosemide nn clinical jj studies nns as rb well rb as inpos post nn marketing nn observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
advise	0	14	celebrex nn can md be vb used vbn with inpos low jj dose nn aspirin nn
effect	8	12	however rb concomitant jj administration nn of inpos aspirin nn with inpos celebrex nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos celebrex nn alone rb
false	8	12	however rb concomitant jj administration nn of inpos aspirin nn with inpos celebrex nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos celebrex nn alone rb
false	14	26	because inpos of inpos its prp lack nn of inpos platelet nn effects nns celebrex nn is vbz not rb a dt substitute nn for inpos aspirin nn for inpos cardiovascular jj prophylaxis nn
false	0	30	fluconazole nn concomitant jj administration nn of inpos fluconazole nn at inpos num cd mg nn qd nn resulted vbd in inpos a dt two_fold jj increase nn in inpos celecoxib nn plasma nn concentration nn
mechanism	6	28	concomitant jj administration nn of inpos fluconazole nn at inpos num cd mg nn qd nn resulted vbd in inpos a dt two_fold jj increase nn in inpos celecoxib nn plasma nn concentration nn
mechanism	16	28	this dt increase nn is vbz due inpos to topos the dt inhibition nn of inpos celecoxib nn metabolism nn via inpos p450 nn 2c9 nn by inpos fluconazole nn
advise	0	24	celebrex nn should md be vb introduced vbn at inpos the dt lowest jjs recommended vbn dose nn in inpos patients nns receiving vbg fluconazole nn
false	18	46	in inpos a dt study nn conducted vbn in inpos healthy jj subjects nns mean jj steady_state jj lithium nn plasma nn levels nns increased vbd approximately rb num cd in inpos subjects nns receiving vbg lithium nn num cd mg nn bid nn with inpos celebrex nn num cd mg nn bid nn as inpos compared vbn to topos subjects nns receiving vbg lithium nn alone rb
mechanism	18	46	in inpos a dt study nn conducted vbn in inpos healthy jj subjects nns mean jj steady_state jj lithium nn plasma nn levels nns increased vbd approximately rb num cd in inpos subjects nns receiving vbg lithium nn num cd mg nn bid nn with inpos celebrex nn num cd mg nn bid nn as inpos compared vbn to topos subjects nns receiving vbg lithium nn alone rb
false	46	18	in inpos a dt study nn conducted vbn in inpos healthy jj subjects nns mean jj steady_state jj lithium nn plasma nn levels nns increased vbd approximately rb num cd in inpos subjects nns receiving vbg lithium nn num cd mg nn bid nn with inpos celebrex nn num cd mg nn bid nn as inpos compared vbn to topos subjects nns receiving vbg lithium nn alone rb
advise	4	18	patients nns on inpos lithium nn treatment nn should md be vb closely rb monitored vbn when wrb celebrex nn is vbz introduced vbn or cc withdrawn vbn
false	18	20	in inpos an dt interaction nn study nn of inpos rheumatoid jj arthritis nn patients nns taking vbg methotrexate nn celebrex nn did vbd not rb have vb a dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos methotrexate nn
false	20	18	in inpos an dt interaction nn study nn of inpos rheumatoid jj arthritis nn patients nns taking vbg methotrexate nn celebrex nn did vbd not rb have vb a dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos methotrexate nn
false	6	18	the dt effect nn of inpos celecoxib nn on inpos the dt anti_coagulant jj effect nn of inpos warfarin nn was vbd studied vbn in inpos a dt group nn of inpos healthy jj subjects nns receiving vbg daily jj doses nns of inpos num cd mg nn of inpos warfarin nn
false	6	18	the dt effect nn of inpos celecoxib nn on inpos the dt anti_coagulant jj effect nn of inpos warfarin nn was vbd studied vbn in inpos a dt group nn of inpos healthy jj subjects nns receiving vbg daily jj doses nns of inpos num cd mg nn of inpos warfarin nn
false	6	22	in inpos these dt subjects nns celecoxib nn did vbd not rb alter vb the dt anticoagulant jj effect nn of inpos warfarin nn as inpos determined vbn by inpos prothrombin nn time nn
advise	14	18	however rb caution nn should md be vb used vbn when wrb administering vbg celebrex nn with inpos warfarin nn since inpos these dt patients nns are vbp at inpos increased vbn risk nn of inpos bleeding vbg complications nns
mechanism	18	22	in inpos healthy jj subjects nns given vbn single jj num cd mg nn doses nns of inpos cephalexin nn and cc metformin nn plasma nn metformin nn mean jj cmax nn and cc auc nn increased vbd by inpos an dt average nn of inpos num cd and cc num cd respectively rb and cc metformin nn mean jj renal jj clearance nn decreased vbd by inpos num cd
false	18	22	in inpos healthy jj subjects nns given vbn single jj num cd mg nn doses nns of inpos cephalexin nn and cc metformin nn plasma nn metformin nn mean jj cmax nn and cc auc nn increased vbd by inpos an dt average nn of inpos num cd and cc num cd respectively rb and cc metformin nn mean jj renal jj clearance nn decreased vbd by inpos num cd
false	18	22	in inpos healthy jj subjects nns given vbn single jj num cd mg nn doses nns of inpos cephalexin nn and cc metformin nn plasma nn metformin nn mean jj cmax nn and cc auc nn increased vbd by inpos an dt average nn of inpos num cd and cc num cd respectively rb and cc metformin nn mean jj renal jj clearance nn decreased vbd by inpos num cd
false	16	20	no dt information nn is vbz available jj about inpos the dt interaction nn of inpos cephalexin nn and cc metformin nn following vbg multiple jj doses nns of inpos either dt drug nn
mechanism	28	32	although inpos not rb observed vbn in inpos this dt study nn adverse jj effects nns could md potentially rb arise vb from inpos co_administration nn of inpos cephalexin nn and cc metformin nn by inpos inhibition nn of inpos tubular jj secretion nn via inpos organic jj cationic jj transporter nn systems nns
false	16	30	accordingly rb careful jj patient nn monitoring nn and cc dose nn adjustment nn of inpos metformin nn is vbz recommended vbn in inpos patients nns concomitantly rb taking vbg cephalexin nn and cc metformin nn
advise	30	16	accordingly rb careful jj patient nn monitoring nn and cc dose nn adjustment nn of inpos metformin nn is vbz recommended vbn in inpos patients nns concomitantly rb taking vbg cephalexin nn and cc metformin nn
false	0	8	probenecid nn as inpos with inpos other jj b_lactams nn the dt renal jj excretion nn of inpos cephalexin nn is vbz inhibited vbn by inpos probenecid nn
false	0	18	probenecid nn as inpos with inpos other jj b_lactams nns the dt renal jj excretion nn of inpos cephalexin nn is vbz inhibited vbn by inpos probenecid nn
false	8	18	probenecid nnp as inpos with inpos other jj b_lactams nn the dt renal jj excretion nn of inpos cephalexin nn is vbz inhibited vbn by inpos probenecid nn
false	8	0	probenecid nnp as inpos with inpos other jj b_lactams nn the dt renal jj excretion nn of inpos cephalexin nn is vbz inhibited vbn by inpos probenecid nn
mechanism	18	0	probenecid nnp as inpos with inpos other jj b_lactams nns the dt renal jj excretion nn of inpos cephalexin nn is vbz inhibited vbn by inpos probenecid nn
false	0	4	immunosuppressive_drugs nn fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	0	6	immunosuppressive_drugs nn fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	0	8	immunosuppressive_drugs nn fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	0	10	immunosuppressive_drugs nn fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nn skeletal jj muscle nn
false	2	4	immunosuppressive_drugs nns fibric_acid_derivatives nn niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	2	6	immunosuppressive_drugs nns fibric_acid_derivatives nn niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	2	8	immunosuppressive_drugs nns fibric_acid_derivatives nn niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	2	10	immunosuppressive_drugs nns fibric_acid_derivatives nn niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nn skeletal jj muscle nn
false	4	6	immunosuppressive_drugs nns fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	4	8	immunosuppressive_drugs nns fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	4	10	immunosuppressive_drugs nns fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nn skeletal jj muscle nn
false	6	8	immunosuppressive_drugs nns fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nns skeletal jj muscle nn
false	6	10	immunosuppressive_drugs nns fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nn skeletal jj muscle nn
false	8	10	immunosuppressive_drugs nns fibric_acid_derivatives nns niacin nn lrb_nicotinic_acid nn erythromycin nn azole_antifungals nn skeletal jj muscle nn
false	0	18	cerivastatin nn plasma nn concentrations nns were vbd not rb affected vbn by inpos co_administration nn of inpos antacid nn
false	0	18	cerivastatin nn plasma nn concentrations nns were vbd not rb affected vbn by inpos co_administration nn of inpos cimetidine nn
false	12	22	the dt influence nn of inpos the dt bile_acidsequestering jj agent nn cholestyramine nn on inpos the dt pharmacokinetits nns of inpos cerivastatin_sodium nn was vbd evaluated vbn in inpos num cd healthy jj males nns in inpos num cd separate jj randomized vbn crossover nn studies nns
mechanism	18	26	in inpos the dt first jj study nn concomitant jj administration nn of inpos float cd mg nn cerivastatin_sodium nn and cc num cd g nn cholestyramine nn resulted vbd in inpos decreases nns of inpos more jjr than inpos num cd for inpos auc nn and cc num cd for inpos cmax nn when wrb compared vbn to topos dosing nn cerivastatin_sodium nn alone rb
false	26	18	in inpos the dt first jj study nn concomitant jj administration nn of inpos float cd mg nn cerivastatin_sodium nn and cc num cd g nn cholestyramine nn resulted vbd in inpos decreases nns of inpos more jjr than inpos num cd for inpos auc nn and cc num cd for inpos cmax nn when wrb compared vbn to topos dosing nn cerivastatin_sodium nn alone rb
mechanism	18	38	however rb in inpos the dt second jj study nn administration nn of inpos num cd g nn cholestyramine nn num cd hour nn before inpos the dt evening nn meal nn and cc float cd mg nn cerivastatin_sodium nn approximately rb num cd hours nns after inpos the dt same jj evening nn meal nn resulted vbd in inpos a dt decrease nn in inpos the dt cerivastatin nn auc nn of inpos less jjr than inpos num cd and cc a dt decrease nn in inpos cmax nn of inpos about inpos num cd when wrb compared vbn to topos dosing nn cerivastatin_sodium nn alone rb
false	18	38	however rb in inpos the dt second jj study nn administration nn of inpos num cd g nn cholestyramine nn num cd hour nn before inpos the dt evening nn meal nn and cc float cd mg nn cerivastatin_sodium nn approximately rb num cd hours nns after inpos the dt same jj evening nn meal nn resulted vbd in inpos a dt decrease nn in inpos the dt cerivastatin nn auc nn of inpos less jjr than inpos num cd and cc a dt decrease nn in inpos cmax nn of inpos about inpos num cd when wrb compared vbn to topos dosing nn cerivastatin_sodium nn alone rb
false	18	38	however rb in inpos the dt second jj study nn administration nn of inpos num cd g nn cholestyramine nn num cd hour nn before inpos the dt evening nn meal nn and cc float cd mg nn cerivastatin_sodium nn approximately rb num cd hours nns after inpos the dt same jj evening nn meal nn resulted vbd in inpos a dt decrease nn in inpos the dt cerivastatin nn auc nn of inpos less jjr than inpos num cd and cc a dt decrease nn in inpos cmax nn of inpos about inpos num cd when wrb compared vbn to topos dosing nn cerivastatin_sodium nn alone rb
false	20	30	therefore rb it prp would md be vb expected vbn that inpos a dt dosing nn schedule nn of inpos cerivastatin_sodium nn given vbn at inpos bedtime nn and cc cholestyramine nn given vbn before inpos the dt evening nn meal nn would md not rb result vb in inpos a dt significant jj decrease nn in inpos the dt clinical jj effect nn of inpos cerivastatin_sodium nn
false	30	20	therefore rb it prp would md be vb expected vbn that inpos a dt dosing nn schedule nn of inpos cerivastatin_sodium nn given vbn at inpos bedtime nn and cc cholestyramine nn given vbn before inpos the dt evening nn meal nn would md not rb result vb in inpos a dt significant jj decrease nn in inpos the dt clinical jj effect nn of inpos cerivastatin_sodium nn
false	2	32	plasma nn digoxin nn levels nns and cc digoxin nn clearance nn at inpos steady_state nn were vbd not rb affected vbn by inpos co_administration nn of inpos float cd mg nn cerivastatin_sodium nn
false	2	32	plasma nn digoxin nn levels nns and cc digoxin nn clearance nn at inpos steady_state nn were vbd not rb affected vbn by inpos co_administration nn of inpos float cd mg nn cerivastatin_sodium nn
false	0	20	cerivastatin nn plasma nn concentrations nns were vbd also rb not rb affected vbn by inpos co_administration nn of inpos digoxin nn
false	6	10	co jj administration nn of inpos warfarin nn and cc cerivastatin nn to topos healthy jj volunteers nns did vbd not rb result vb in inpos any dt changes nns in inpos prothrombin nn time nn or cc clotting vbg factor nn num cd when wrb compared vbn to topos co_administration nn of inpos warfarin nn and cc placebo nn
false	10	6	co jj administration nn of inpos warfarin nn and cc cerivastatin nn to topos healthy jj volunteers nns did vbd not rb result vb in inpos any dt changes nns in inpos prothrombin nn time nn or cc clotting vbg factor nn num cd when wrb compared vbn to topos co_administration nn of inpos warfarin nn and cc placebo nn
false	20	38	the dt auc nn and cc cmax nn of inpos both cc the dt and cc isomers nns of inpos warfarin nn were vbd unaffected jj by inpos concurrent jj dosing nn of inpos float cd mg nn cerivastatin_sodium nn
false	4	8	co_administration nn of inpos warfarin nn and cc cerivastatin nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos cerivastatin_sodium nn
false	4	22	co_administration nn of inpos warfarin nn and cc cerivastatin nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos cerivastatin_sodium nn
false	0	10	erythromycin nn in inpos hypercholesterolemic jj patients nns steady_state jj cerivastatin nn auc nn and cc cmax nn increased vbd approximately rb num cd and cc num cd respectively rb after inpos num cd days nns with inpos co_administration nn of inpos erythromycin nn a dt known jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn
mechanism	10	0	erythromycin nn in inpos hypercholesterolemic jj patients nns steady_state jj cerivastatin nn auc nn and cc cmax nn increased vbd approximately rb num cd and cc num cd respectively rb after inpos num cd days nns with inpos co_administration nn of inpos erythromycin nn a dt known jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn
false	20	30	although inpos specific jj interaction nn studies nns were vbd not rb performed vbn in inpos clinical jj studies nns cerivastatin_sodium nn was vbd used vbn concomitantly rb with inpos angiotensin_converting_enzyme_ace_inhibitors nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	30	although inpos specific jj interaction nn studies nns were vbd not rb performed vbn in inpos clinical jj studies nns cerivastatin_sodium nn was vbd used vbn concomitantly rb with inpos betablockers nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	30	although inpos specific jj interaction nn studies nns were vbd not rb performed vbn in inpos clinical jj studies nns cerivastatin_sodium nn was vbd used vbn concomitantly rb with inpos calcium_channel_blockers nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	30	although inpos specific jj interaction nn studies nns were vbd not rb performed vbn in inpos clinical jj studies nns cerivastatin_sodium nn was vbd used vbn concomitantly rb with inpos diuretics nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	30	although inpos specific jj interaction nn studies nns were vbd not rb performed vbn in inpos clinical jj studies nns cerivastatin_sodium nn was vbd used vbn concomitantly rb with inpos nonsteroidal_anti_inflammatory_drugs nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	30	although inpos specific jj interaction nn studies nns were vbd not rb performed vbn in inpos clinical jj studies nns cerivastatin_sodium nn was vbd used vbn concomitantly rb with inpos nsaids nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	8	20	pharmacokinetic jj interaction nn studies nns with inpos cetirizine nn in inpos adults nns were vbd conducted vbn with inpos pseudoephedrine nn
false	8	20	pharmacokinetic jj interaction nn studies nns with inpos cetirizine nn in inpos adults nns were vbd conducted vbn with inpos antipyrine nn
false	8	20	pharmacokinetic jj interaction nn studies nns with inpos cetirizine nn in inpos adults nns were vbd conducted vbn with inpos ketoconazole nn
false	8	20	pharmacokinetic jj interaction nn studies nns with inpos cetirizine nn in inpos adults nns were vbd conducted vbn with inpos erythromycin nn
false	8	20	pharmacokinetic jj interaction nn studies nns with inpos cetirizine nn in inpos adults nns were vbd conducted vbn with inpos azithromycin nn
mechanism	12	16	in inpos a dt multiple jj dose nn study nn of inpos theophylline nn and cc cetirizine nn a dt num cd decrease nn in inpos the dt clearance nn of inpos cetirizine nn was vbd observed vbn
false	12	16	in inpos a dt multiple jj dose nn study nn of inpos theophylline nn and cc cetirizine nn a dt num cd decrease nn in inpos the dt clearance nn of inpos cetirizine nn was vbd observed vbn
false	6	18	the dt disposition nn of inpos theophylline nn was vbd not rb altered vbn by inpos concomitant jj cetirizine nn administration nn
false	18	26	no dt clinically rb significant jj drug nn interactions nns have vbp been vbn found vbn with inpos theophylline nn at inpos a dt low jj azithromycin nn
false	18	26	no dt clinically rb significant jj drug nn interactions nns have vbp been vbn found vbn with inpos theophylline nn at inpos a dt low jj pseudoephedrine nn
false	18	26	no dt clinically rb significant jj drug nn interactions nns have vbp been vbn found vbn with inpos theophylline nn at inpos a dt low jj ketoconazole nn
false	18	26	no dt clinically rb significant jj drug nn interactions nns have vbp been vbn found vbn with inpos theophylline nn at inpos a dt low jj erythromycin nn
mechanism	18	32	there ex was vbd a dt small jj decrease nn in inpos the dt clearance nn of inpos cetirizine nn caused vbn by inpos a dt num_mg jj dose nn of inpos theophylline nn
false	16	28	a dt drug nn interaction nn study nn was vbd performed vbn in inpos which wdt erbitux nn was vbd administered vbn in inpos combination nn with inpos irinotecan nn
false	18	22	there ex was vbd no dt evidence nn of inpos any dt pharmacokinetic jj interactions nns between inpos erbitux nn and cc irinotecan nn
advise	0	18	cevimeline nn should md be vb administered vbn with inpos caution nn to topos patients nns taking vbg b_adrenergic_antagonists nn because inpos of inpos the dt possibility nn of inpos conduction nn disturbances nns
effect	60	64	although inpos clinical jj studies nns have vbp not rb established vbn a dt cause nn and cc effect nn relationship nn physicians nns should md be vb aware jj that inpos variable jj effects nns an dt blood nn coagulation nn have vbp been vbn reported vbn very rb rarely rb in inpos patients nns receiving vbg oral jj anticoagulants nn and cc chlordiazepoxide nn
false	8	14	the dt concomitant jj use nn of inpos alcohol nn or cc other jj central_nervous_system_depressants nn may md have vb an dt additive jj effect nn
false	8	12	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns tricyclic_antidepressants nns phenothiazines nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
false	8	16	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns tricyclic_antidepressants nns phenothiazines nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
false	8	24	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	8	24	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg tricyclic_antidepressants nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	8	24	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg phenothiazines nn may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	12	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	12	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg tricyclic_antidepressants nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	12	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg phenothiazines nn may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	16	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	16	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg tricyclic_antidepressants nns may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	16	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg phenothiazines nn may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
false	26	30	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns tricyclic_antidepressants nn or cc phenothiazines nn may md produce vb severe jj prolonged jj hypotension nn or cc hypertension nn
effect	6	10	concurrent jj administration nn of inpos vasopressor_drugs nn and cc ergot_type_oxytocic_drugs nn may md cause vb severe jj persistent jj hypertension nn cerebrovascular jj accidents nns
advise	2	24	therefore rb chloroprocaine nn should md not rb be vb used vbn in inpos any dt condition nn in inpos which wdt a dt sulfonamide_drug nn is vbz being vbg employed vbn
false	0	4	antacids nn and cc kaolin nn
false	0	4	antacids nn and cc kaolin nn can md reduce vb absorption nn of inpos chloroquine nn
mechanism	0	14	antacids nn and cc kaolin nn can md reduce vb absorption nn of inpos chloroquine nn
mechanism	4	14	antacids nns and cc kaolin nn can md reduce vb absorption nn of inpos chloroquine nn
mechanism	0	12	cimetidine nn can md inhibit vb the dt metabolism nn of inpos chloroquine nn increasing vbg its prp plasma nn level nn
mechanism	12	24	in inpos a dt study nn of inpos healthy jj volunteers nns chloroquine nn significantly rb reduced vbd the dt bioavailability nn of inpos ampicillin nn
false	0	8	cyclosporin nn after inpos introduction nn of inpos chloroquine nn a dt sudden jj increase nn in inpos serum nn cyclosporin nn level nn has vbz been vbn reported vbn
mechanism	8	0	cyclosporin nn after inpos introduction nn of inpos chloroquine nn a dt sudden jj increase nn in inpos serum nn cyclosporin nn level nn has vbz been vbn reported vbn
false	10	24	therefore rb close jj monitoring nn of inpos serum nn cyclosporin nn level nn is vbz recommended vbn and cc if inpos necessary jj chloroquine nn should md be vb discontinued vbn
false	0	2	hyph_antidiabetic_drugs nn insulin nn dosage nn adjustment nn of inpos the dt antidiabetic_drug nn may md be vb required vbn
false	0	10	hyph_insulin nn dosage nn adjustment nn of inpos the dt antidiabetic_drug nn may md be vb required vbn
false	0	4	hyph_cholestyramine nn and cc colestipol nn resins nns
false	0	6	hyph_cholestyramine nn and cc colestipol nn resins nn
false	4	6	hyph_cholestyramine nn and cc colestipol nn resins nn
false	0	4	cholestytamine nn and cc colestipol nn resins nns have vbp the dt potential nn of inpos binding nn thiazide_diuretics nns and cc reducing vbg diuretic jj absorption nn from inpos the dt gastrointestinal jj tract nn
false	0	6	cholestytamine nn and cc colestipol nn resins nn have vbp the dt potential nn of inpos binding nn thiazide_diuretics nns and cc reducing vbg diuretic jj absorption nn from inpos the dt gastrointestinal jj tract nn
mechanism	0	18	cholestytamine nn and cc colestipol nn resins nns have vbp the dt potential nn of inpos binding nn thiazide_diuretics nn and cc reducing vbg diuretic jj absorption nn from inpos the dt gastrointestinal jj tract nn
false	0	18	cholestytamine nn and cc colestipol nn resins nns have vbp the dt potential nn of inpos binding nn thiazide_diuretics nns and cc reducing vbg diuretic nn absorption nn from inpos the dt gastrointestinal jj tract nn
false	4	6	hyph_cholestyramine nn and cc colestipol nn resins nns cholestytamine nn and cc colestipol nn resins nn have vbp the dt potential nn of inpos binding nn thiazide_diuretics nns and cc reducing vbg diuretic jj absorption nn from inpos the dt gastrointestinal jj tract nn
mechanism	4	18	cholestytamine nn and cc colestipol nn resins nns have vbp the dt potential nn of inpos binding nn thiazide_diuretics nn and cc reducing vbg diuretic jj absorption nn from inpos the dt gastrointestinal jj tract nn
false	4	18	cholestytamine nn and cc colestipol nn resins nns have vbp the dt potential nn of inpos binding nn thiazide_diuretics nns and cc reducing vbg diuretic nn absorption nn from inpos the dt gastrointestinal jj tract nn
false	6	18	cholestytamine nn and cc colestipol nn resins nn have vbp the dt potential nn of inpos binding nn thiazide_diuretics nn and cc reducing vbg diuretic jj absorption nn from inpos the dt gastrointestinal jj tract nn
false	6	18	cholestytamine nn and cc colestipol nn resins nn have vbp the dt potential nn of inpos binding nn thiazide_diuretics nns and cc reducing vbg diuretic nn absorption nn from inpos the dt gastrointestinal jj tract nn
false	0	2	hyph_corticosteroids nn acth nn intensified vbn electrolyte nn depletion nn particularly rb hypokalemia nn
false	0	2	hyph_skeletal_muscle_relaxants nn tubocurarine nn
mechanism	0	12	diuretic_agents nn reduce vbp the dt renal jj clearance nn of inpos lithium nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
mechanism	0	12	diuretic_agents nn reduce vbp the dt renal jj clearance nn of inpos lithium nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
advise	12	28	refer vb to topos the dt package nn insert nn for inpos lithium nn preparations nns before inpos use nn of inpos such jj preparations nns with inpos chlorothiazide nn
false	0	16	hyph_non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing jj thiazide_diuretics nns
false	0	24	hyph_non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt loop nn
false	0	24	hyph_non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt potassium_sparing nn
false	0	24	hyph_non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt thiazide_diuretics nn
effect	16	24	hyph_non_steroidal_anti_inflammatory_drugs nns in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt loop nn
effect	16	24	hyph_non_steroidal_anti_inflammatory_drugs nns in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt potassium_sparing nn
effect	16	24	hyph_non_steroidal_anti_inflammatory_drugs nns in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt thiazide_diuretics nn
advise	4	8	therefore rb when wrb chlorothiazide nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic jj is vbz obtained vbn
false	4	44	therefore rb when wrb chlorothiazide nn and cc non_steroidal_anti_inflammatory_agents nns are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
false	8	44	therefore rb when wrb chlorothiazide nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
int	0	8	chlorotrianisene nn may md interact vb with inpos antidepressants nn
int	0	8	chlorotrianisene nn may md interact vb with inpos aspirin nn
int	0	10	chlorotrianisene nn may md interact vb with inpos antidepressants nns barbiturates nn
int	0	8	chlorotrianisene nn may md interact vb with inpos bromocriptine nn
int	0	8	chlorotrianisene nn may md interact vb with inpos calcium nn
int	0	10	chlorotrianisene nn may md interact vb with inpos antidepressants nns corticosteroids nn
int	0	8	chlorotrianisene nn may md interact vb with inpos corticotropin nn
int	0	8	chlorotrianisene nn may md interact vb with inpos cyclosporine nn
int	0	8	chlorotrianisene nn may md interact vb with inpos dantrolene nn
int	0	8	chlorotrianisene nn may md interact vb with inpos nicotine nn
int	0	8	chlorotrianisene nn may md interact vb with inpos somatropin nn
int	0	8	chlorotrianisene nn may md interact vb with inpos tamoxifen nn
int	0	8	chlorotrianisene nn may md interact vb with inpos warfarin nn
false	4	6	increased vbn toxicity nn cns_depressants nn mao_inhibitors nn tricyclic_antidepressants nns phenothiazines nns
false	4	6	increased vbn toxicity nn cns_depressants nns phenothiazines nn
false	6	10	increased vbn toxicity nn cns_depressants nns mao_inhibitors nn tricyclic_antidepressants nns phenothiazines nn
false	4	6	increased vbn toxicity nn tricyclic_antidepressants nn phenothiazines nn
effect	28	32	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt antiparkinsonian_drug nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	28	32	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt trihexyphenidyl nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	28	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt antiparkinsonian_drug nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	28	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt antiparkinsonian_drug nn and_or cc a dt amitriptyline nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	28	32	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt chlorpromazine nn an dt antiparkinsonian_drug nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	28	32	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt chlorpromazine nn an dt trihexyphenidyl nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	28	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt chlorpromazine nn an dt antiparkinsonian_drug nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	28	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt chlorpromazine nn an dt antiparkinsonian_drug nn and_or cc a dt amitriptyline nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	32	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt antiparkinsonian_drug nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	32	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt antiparkinsonian_drug nn and_or cc a dt amitriptyline nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	32	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt trihexyphenidyl nn and_or cc a dt tricyclic_antidepressant nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
effect	32	38	the dt concurrent jj use nn of inpos num cd or cc more jjr drugs nns with inpos anticholinergic jj activity nn such jj as inpos an dt antipsychotic_drug nn an dt trihexyphenidyl nn and_or cc a dt amitriptyline nn commonly rb results vbz in inpos excessive jj anticholinergic jj effects nns including vbg dry jj mouth nn and cc associated vbn dental jj complications nns blurred vbd vision nn and cc in inpos patients nns exposed vbn to topos high jj temperature nn and cc humidity nn hyperpyrexia nn
false	14	30	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	30	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn propranolol nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj sparfloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj grepafloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj guanethidine nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj guanadrel nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj metrizamide nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj cabergoline nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	46	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	50	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	30	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	30	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn propranolol nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj sparfloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj grepafloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj guanethidine nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj guanadrel nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj metrizamide nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj cabergoline nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	28	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	46	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	50	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	14	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nn drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	32	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	36	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	50	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	50	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	32	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn propranolol nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	36	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn propranolol nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	50	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn propranolol nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	30	50	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn propranolol nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	34	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	38	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	34	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns grepafloxacin nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	38	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns grepafloxacin nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns grepafloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns grepafloxacin nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	34	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanethidine nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	38	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanethidine nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanethidine nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanethidine nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	34	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanadrel nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	38	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanadrel nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanadrel nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns guanadrel nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	34	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns metrizamide nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	38	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns metrizamide nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns metrizamide nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns metrizamide nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	34	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns cabergoline nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	38	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns cabergoline nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns cabergoline nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns cabergoline nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	34	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns lithium nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	38	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns lithium nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	32	52	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns lithium nn narcotic jj pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	46	50	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic nn pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nns any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	46	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_anxiety_drugs nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	46	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic nn pain nn medication nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	50	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj antihistamines nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
false	50	64	interactions nns may md also rb occur vb with inpos the dt following nn anti_depressants nns drugs nns used vbn to topos treat vb an dt overactive jj thyroid nn b_blockers nns sparfloxacin nn grepafloxacin nn guanethidine nn guanadrel nn metrizamide nn cabergoline nn lithium nn narcotic jj pain nn codeine nn drugs nns used vbn to topos aid vb sleep nn drowsiness_causing jj diphenhydramine nn any dt other jj drugs nns that wdt may md make vb you prp drowsy vb
effect	8	24	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns chloramphenicol nn probenecid nn coumarins nns monoamine_oxidase_inhibitors nns b_adrenergic_blocking_agents nns
effect	8	40	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns other jj drugs nns that wdt are vbp highly rb protein nn bound vbn salicylates nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd sulfonamides nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd chloramphenicol nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd probenecid nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd coumarins nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd monoamine_oxidase_inhibitors nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd b_adrenergic_blocking_agents nn
false	24	40	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn other jj drugs nns that wdt are vbp highly rb protein nn bound vbn salicylates nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd sulfonamides nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd chloramphenicol nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd probenecid nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd coumarins nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd monoamine_oxidase_inhibitors nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylurea nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd b_adrenergic_blocking_agents nn
false	8	12	these dt drugs nns include vbp the dt thiazides nn other jj diuretics nn corticosteroids nns phenothiazines nns thyroid jj products nns estrogens nns oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	14	18	these dt drugs nns include vbp the dt thiazides nns and cc other jj diuretics nn corticosteroids nns phenothiazines nn
false	16	18	these dt drugs nns include vbp the dt thiazides nns and cc other jj diuretics nns corticosteroids nn phenothiazines nn
effect	16	30	since inpos animal nn studies nns suggest vbp that inpos the dt action nn of inpos barbiturates nn may md be vb prolonged vbn by inpos therapy nn with inpos chlorpropamide nn barbiturates nns should md be vb employed vbn with inpos caution nn
false	30	16	since inpos animal nn studies nns suggest vbp that inpos the dt action nn of inpos barbiturates nns may md be vb prolonged vbn by inpos therapy nn with inpos chlorpropamide nn barbiturates nn should md be vb employed vbn with inpos caution nn
false	8	28	in inpos some dt patients nns a dt disulfiram nn like jj reaction nn may md be vb produced vbn by inpos the dt ingestion nn of inpos alcohol nn
effect	10	16	a dt potential jj interaction nn between inpos oral jj miconazole nn and cc oral jj hypoglycemic_agents nn leading vbg to topos severe jj hypoglycemia nn has vbz been vbn reported vbn
mechanism	0	16	chlorprothixene nn may md increase vb the dt plasma_level nn of inpos concomitantly rb given vbn lithium nn
advise	2	12	if inpos chlorprothixene nn is vbz given vbn concomitantly rb with inpos opioids nn the dt opioid jj dose nn should md be vb reduced vbn because inpos chlorprothixene nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nns massively rb
false	2	12	if inpos chlorprothixene nn is vbz given vbn concomitantly rb with inpos opioids nns the dt opioid nn dose nn should md be vb reduced vbn because inpos chlorprothixene nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nns massively rb
false	2	12	if inpos chlorprothixene nn is vbz given vbn concomitantly rb with inpos opioids nns the dt opioid jj dose nn should md be vb reduced vbn because inpos chlorprothixene nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nn massively rb
false	12	2	if inpos chlorprothixene nn is vbz given vbn concomitantly rb with inpos opioids nn the dt opioid jj dose nn should md be vb reduced vbn because inpos chlorprothixene nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nns massively rb
false	12	2	if inpos chlorprothixene nn is vbz given vbn concomitantly rb with inpos opioids nns the dt opioid nn dose nn should md be vb reduced vbn because inpos chlorprothixene nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nns massively rb
effect	2	12	if inpos chlorprothixene nn is vbz given vbn concomitantly rb with inpos opioids nns the dt opioid jj dose nn should md be vb reduced vbn because inpos chlorprothixene nn amplifies vbz the dt therapeutic jj actions nns and cc side_effects nns of inpos opioids nn massively rb
advise	10	14	avoid vb the dt concomitant jj use nn of inpos chlorprothixene nn and cc tramadol nn
advise	10	14	avoid vb the dt concomitant jj use nn of inpos chlorprothixene nn and cc ultram nn
effect	20	28	consider vb additive jj sedative jj effects nns and cc confusional jj states nns to topos emerge vb if inpos chlorprothixene nn is vbz given vbn with inpos benzodiazepines nn or cc barbituates nns
effect	20	32	consider vb additive jj sedative jj effects nns and cc confusional jj states nns to topos emerge vb if inpos chlorprothixene nn is vbz given vbn with inpos benzodiazepines nns or cc barbituates nn
false	28	32	consider vb additive jj sedative jj effects nns and cc confusional jj states nns to topos emerge vb if inpos chlorprothixene nn is vbz given vbn with inpos benzodiazepines nn or cc barbituates nn
advise	10	16	exert nnp particular jj caution nn in inpos combining vbg chlorprothixene nn with inpos other jj anticholinergic_drugs nn
advise	10	16	exert nnp particular jj caution nn in inpos combining vbg chlorprothixene nn with inpos other jj tricyclic_antidepressants nn
advise	10	16	exert nnp particular jj caution nn in inpos combining vbg chlorprothixene nn with inpos other jj antiparkinsonian_agents nn
effect	0	20	chlorthalidone nn may md add vb to topos or cc potentiate vb the dt action nn of inpos other jj antihypertensive_drugs nn
effect	0	18	chlorthalidone nn and cc related vbn drugs nns may md increase vb the dt responsiveness nn to topos tubocurarine nn
effect	0	18	chlorthalidone nn and cc related vbn drugs nns may md decrease vb arterial jj responsiveness nn to topos norepinephrine nn
false	8	14	the dt concomitant jj use nn of inpos alcohol nn or cc other jj central_nervous_system_depressants nn may md have vb an dt additive jj effect nn
false	4	6	interactions nns for inpos vitamin_d nn calcitriol nn cholestyramine nn
false	4	6	interactions nns for inpos vitamin_d nn calcidiol nn cholestyramine nn
false	4	8	interactions nns for inpos vitamin_d nn analogues nns cholestyramine nn
false	6	8	interactions nns for inpos vitamin_d nn vitamin_d2 nn cholestyramine nn
false	6	8	interactions nns for inpos vitamin_d nn vitamin_d3 nn cholestyramine nn
false	6	8	interactions nns for inpos vitamin_d nn calcitriol nn cholestyramine nn
false	6	8	interactions nns for inpos vitamin_d nn calcidiol nn cholestyramine nn
mechanism	0	18	cholestyramine nn has vbz been vbn reported vbn to topos reduce vb intestinal jj absorption nn of inpos fat_soluble_vitamins nn
false	0	2	phenytoin nn phenobarbital nn
false	6	10	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos ergocalcitriol nn by inpos accelerating vbg metabolism nn
false	6	24	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos ergocalcitriol nn by inpos accelerating vbg metabolism nn
false	6	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	10	24	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos ergocalcitriol nn by inpos accelerating vbg metabolism nn
false	10	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	24	40	the dt coadministration nn of inpos phenytoin nn or cc phenobarbital nn will md not rb affect vb plasma nn concentrations nns of inpos vitamin_d nn but cc may md reduce vb endogenous jj plasma nn levels nns of inpos calcitriol nn by inpos accelerating vbg metabolism nn
false	8	22	since inpos blood nn level nn of inpos calcitriol nn will md be vb reduced vbn higher jjr doses nns of inpos rocaltrol nn may md be vb necessary jj if inpos these dt drugs nns are vbp administered vbn simultaneously rb
effect	18	22	some dt reports nns have vbp shown vbn that inpos the dt concomitant jj administration nn of inpos thiazides nn with inpos vitamin_d nn causes vbz hypercalcemia nn
advise	0	24	vitamin_d nn dosage nn must md be vb determined vbn with inpos care nn in inpos patients nns undergoing vbg treatment nn with inpos digitalis nn as inpos hypercalcemia nn in inpos such jj patients nns may md precipitate vb cardiac jj arrhythmias nns
mechanism	0	18	ketoconazole nn may md inhibit vb both cc synthetic jj and cc catabolic jj enzymes nns of inpos vitamin_d nn
false	14	18	however rb in fw vivo fw drug nn interaction nn studies nns of inpos ketoconazole nn with inpos vitamin_d nn have vbp not rb been vbn investigated vbn
effect	14	28	a dt relationship nn of inpos functional jj antagonism nn exists vbz between inpos vitamin_d nn analogues nns which wdt promote vbp calcium nn absorption nn and cc corticosteroids nn which wdt inhibit vbp calcium nn absorption nn
false	0	4	magnesium nn containing jj antacids nn may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
effect	0	30	magnesium nn containing jj preparations nns may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
effect	2	28	magnesium_containing jj antacids nn may md cause vb hypermagnesemia nn and cc should md therefore rb not rb be vb taken vbn during inpos therapy nn with inpos vitamin_d nn by inpos patients nns on inpos chronic jj renal jj dialysis nn
false	0	2	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj as inpos phenylbutazone nn warfarin nn thiazide_diuretics nns propranolol nn as rb well rb as inpos tetracycline nn penicillin_g nn phenobarbital nn thyroid nn thyroxine nn preparations nns estrogens nns progestins nns digitalis nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj phenylbutazone nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj warfarin nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj thiazide_diuretics nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj propranolol nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj tetracycline nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj penicillin_g nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj phenobarbital nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj thyroxine nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj estrogens nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj progestins nn
mechanism	0	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj digitalis nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj phenylbutazone nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj warfarin nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj thiazide_diuretics nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj propranolol nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj tetracycline nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj penicillin_g nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj phenobarbital nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj thyroxine nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj estrogens nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj progestins nn
false	2	26	cholestyramine nn resin nn may md delay vb or cc reduce vb the dt absorption nn of inpos concomitant jj oral jj medication nn such jj digitalis nn
false	0	2	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	0	2	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	0	62	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	0	2	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	2	0	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	2	62	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	2	0	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	0	2	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
mechanism	0	62	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	0	2	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	2	62	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	2	0	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	62	0	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	62	2	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	0	2	cholestyramine nn resin nn may md interfere vb with inpos the dt pharmacokinetics nns of inpos drugs nns that wdt undergo vbp enterohepatic jj circulation nn the dt discontinuance nn of inpos cholestyramine nn resin nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn such jj as inpos digitalis nn has vbz been vbn filtrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg cholestyramine nn resin nn
false	2	12	because inpos cholestyramine nn binds vbz bile nn acids nns cholestyramine nn resin nn may md interfere vb with inpos normal jj fat jj digestion nn and cc absorption nn and cc thus rb may md prevent vb absorption nn of inpos fat_soluble_vitamins nns such jj as inpos a nn d nnp e nnp k nn
false	2	42	because inpos cholestyramine nn binds vbz bile nn acids nns cholestyramine nn resin nn may md interfere vb with inpos normal jj fat jj digestion nn and cc absorption nn and cc thus rb may md prevent vb absorption nn of inpos fat_soluble_vitamins nn such jj as inpos a nn d nnp e nnp k nn
false	2	12	because inpos cholestyramine nn binds vbz bile nn acids nns cholestyramine nn resin nn may md interfere vb with inpos normal jj fat jj digestion nn and cc absorption nn and cc thus rb may md prevent vb absorption nn of inpos fat_soluble_vitamins nns such jj as inpos a nn d nnp e nnp k nn
false	2	42	because inpos cholestyramine nn binds vbz bile nn acids nns cholestyramine nn resin nn may md interfere vb with inpos normal jj fat jj digestion nn and cc absorption nn and cc thus rb may md prevent vb absorption nn of inpos fat_soluble_vitamins nn such jj as inpos a nn d nnp e nnp k nn
false	12	42	because inpos cholestyramine nn binds vbz bile nn acids nns cholestyramine nn resin nn may md interfere vb with inpos normal jj fat jj digestion nn and cc absorption nn and cc thus rb may md prevent vb absorption nn of inpos fat_soluble_vitamins nn such jj as inpos a nn d nnp e nnp k nn
false	2	4	when wrb cholestyramine nn resin nn is vbz given vbn for inpos long jj periods nns of inpos time nn concomitant jj supplementation nn with inpos water_miscible jj forms nns of inpos fat_soluble_vitamins nns should md be vb considered vbn
false	2	32	when wrb cholestyramine nn resin nn is vbz given vbn for inpos long jj periods nns of inpos time nn concomitant jj supplementation nn with inpos water_miscible jj forms nns of inpos fat_soluble_vitamins nn should md be vb considered vbn
false	4	32	when wrb cholestyramine nn resin nn is vbz given vbn for inpos long jj periods nns of inpos time nn concomitant jj supplementation nn with inpos water_miscible jj forms nns of inpos fat_soluble_vitamins nn should md be vb considered vbn
false	2	4	since nn cholestyramine nn resin nn may nnp bind nnp other nnp drugs nnp given nnp concurrently nnp it prp is vbz recommended jj that nn patients nns take vb other jj drugs nn at inpos least nn num cd hour nn before nn or cc num cd to topos num cd hours nns after inpos cholestyramine nnp resin nnp to topos avoid nnp impeding nnp their nnp absorption nnp
false	2	4	since nn cholestyramine nn resin nnp may nnp bind nnp other nnp drugs nnp given nnp concurrently nnp it prp is vbz recommended jj that nn patients nns take vb other jj drugs nn at inpos least nn num cd hour nn before nn or cc num cd to topos num cd hours nns after inpos cholestyramine nn resin nn to topos avoid nnp impeding nnp their nnp absorption nnp
false	4	2	since nn cholestyramine nn resin nn may nnp bind nnp other nnp drugs nnp given nnp concurrently nnp it prp is vbz recommended jj that nn patients nns take vb other jj drugs nn at inpos least nn num cd hour nn before nn or cc num cd to topos num cd hours nns after inpos cholestyramine nn resin nn to topos avoid nnp impeding nnp their nnp absorption nnp
false	2	4	since inpos cholestyramine nnp resin nnp may nnp bind nnp other nnp drugs nnp given nnp concurrently nnp it prp is vbz recommended jj that nn patients nns take vb other jj drugs nn at inpos least nn num cd hour nn before nn or cc num cd to topos num cd hours nns after inpos cholestyramine nn resin nn to topos avoid nnp impeding nnp their nnp absorption nnp
false	20	30	in fw vitro fw studies nns demonstrated vbd that inpos the dt plasma nn protein nn binding nn of inpos des_ciclesonide nn was vbd not rb affected vbn by inpos warfarin nn or cc salicylic_acid nn indicating vbg no dt potential nn for inpos protein nn binding_based jj drug nn interactions nns
false	20	34	in fw vitro fw studies nns demonstrated vbd that inpos the dt plasma nn protein nn binding nn of inpos des_ciclesonide nn was vbd not rb affected vbn by inpos warfarin nn or cc salicylic_acid nn indicating vbg no dt potential nn for inpos protein nn binding_based jj drug nn interactions nns
false	30	34	in fw vitro fw studies nns demonstrated vbd that inpos the dt plasma nn protein nn binding nn of inpos des_ciclesonide nn was vbd not rb affected vbn by inpos warfarin nn or cc salicylic_acid nn indicating vbg no dt potential nn for inpos protein nn binding_based jj drug nn interactions nns
false	18	24	in inpos a dt drug nn interaction nn study nn co_administration nn of inpos orally rb inhaled vbn ciclesonide nn and cc oral jj erythromycin nn an dt inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos either cc des_ciclesonide nn or cc erythromycin nn
false	18	24	in inpos a dt drug nn interaction nn study nn co_administration nn of inpos orally rb inhaled vbn ciclesonide nn and cc oral jj erythromycin nn an dt inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos either cc des_ciclesonide nn or cc erythromycin nn
false	24	54	in inpos a dt drug nn interaction nn study nn co_administration nn of inpos orally rb inhaled vbn ciclesonide nn and cc oral jj erythromycin nn an dt inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos either cc des_ciclesonide nn or cc erythromycin nn
false	54	24	in inpos a dt drug nn interaction nn study nn co_administration nn of inpos orally rb inhaled vbn ciclesonide nn and cc oral jj erythromycin nn an dt inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos either cc des_ciclesonide nn or cc erythromycin nn
mechanism	18	24	in inpos another dt drug nn interaction nn study nn co_administration nn of inpos orally rb inhaled vbn ciclesonide nn and cc oral jj ketoconazole nn a dt potent jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn increased vbd the dt exposure nn of inpos des_ciclesonide nn by inpos approximately rb float_fold rb at inpos steady jj state nn while inpos levels nns of inpos ciclesonide nn remained vbd unchanged jj
false	24	48	in inpos another dt drug nn interaction nn study nn co_administration nn of inpos orally rb inhaled vbn ciclesonide nn and cc oral jj ketoconazole nn a dt potent jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn increased vbd the dt exposure nn of inpos des_ciclesonide nn by inpos approximately rb float_fold rb at inpos steady jj state nn while inpos levels nns of inpos ciclesonide nn remained vbd unchanged jj
false	24	18	in inpos another dt drug nn interaction nn study nn co_administration nn of inpos orally rb inhaled vbn ciclesonide nn and cc oral jj ketoconazole nn a dt potent jj inhibitor nn of inpos cytochrome nn p450 nn 3a4 nn increased vbd the dt exposure nn of inpos des_ciclesonide nn by inpos approximately rb float_fold rb at inpos steady jj state nn while inpos levels nns of inpos ciclesonide nn remained vbd unchanged jj
advise	2	18	therefore rb ketoconazole nn should md be vb administered vbn with inpos caution nn with inpos intranasal jj ciclesonide nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj acetaminophen nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj acyclovir nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj angiotensin_converting_enzyme_inhibitors nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj aminosalicylic_acid nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj barbiturates nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj benzodiazepines nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj bumetanide nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj clofibrate nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj methotrexate nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj famotidine nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj furosemide nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj nonsteroidal_anti_inflammatory nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj theophylline nn
mechanism	0	28	probenecid nn is vbz known vbn to topos interact vb with inpos the dt metabolism nn or cc renal jj tubular jj excretion nn of inpos many jj zidovudine nn
advise	0	26	zidovudine nn should md either rb be vb temporarily rb discontinued vbn or cc decreased vbn by inpos num cd when wrb coadministered vbn with inpos probenecid nn on inpos the dt day nn of inpos vistide nn infusion nn
false	0	36	zidovudine nn should md either rb be vb temporarily rb discontinued vbn or cc decreased vbn by inpos num cd when wrb coadministered vbn with inpos probenecid nn on inpos the dt day nn of inpos vistide nn infusion nn
false	26	36	zidovudine nn should md either rb be vb temporarily rb discontinued vbn or cc decreased vbn by inpos num cd when wrb coadministered vbn with inpos probenecid nn on inpos the dt day nn of inpos vistide nn infusion nn
advise	6	22	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj aminoglycosides nns rrb_is vbz contraindicated vbn
advise	6	22	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj tobramycin nns rrb_is vbz contraindicated vbn
advise	6	22	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj gentamicin nns rrb_is vbz contraindicated vbn
advise	6	22	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj amikacin nns rrb_is vbz contraindicated vbn
advise	6	24	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj aminoglycosides nns amphotericin_b nns rrb_is vbz contraindicated vbn
advise	6	24	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj aminoglycosides nns foscarnet nns rrb_is vbz contraindicated vbn
advise	6	24	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj aminoglycosides nns pentamidine nns rrb_is vbz contraindicated vbn
advise	6	24	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj aminoglycosides nns vancomycin nns rrb_is vbz contraindicated vbn
advise	6	24	concomitant jj administration nn of inpos vistide nn and cc agents nns with inpos nephrotoxic jj potential nn lrb_e.g. fw intravenous jj aminoglycosides nns non_steroidal_anti_inflammatory_agents nn rrb_is vbz contraindicated vbn
false	2	46	since inpos pletal nn is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
false	2	50	since inpos pletal nn is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
false	2	64	since inpos pletal nn is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
advise	2	46	since inpos pletal nnp is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
advise	2	50	since inpos pletal nnp is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
advise	2	64	since inpos pletal nnp is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
false	46	50	since inpos pletal nnp is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
false	46	64	since inpos pletal nnp is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
false	50	64	since inpos pletal nnp is vbz extensively rb metabolized vbn by inpos cytochrome nn p_num nn isoenzymes nns caution nn should md be vb exercised vbn when wrb pletal nn is vbz coadministered vbn with inpos inhibitors nns of inpos c.p.a. nn such jj as inpos ketoconazole nn and cc erythromycin nn or cc inhibitors nns of inpos cyp2c19 nn such jj as inpos omeprazole nn
false	10	14	pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos omeprazole nn and cc erythromycin nn significantly rb increased vbd the dt systemic jj exposure nn of inpos cilostazol nn and_or cc its prp major jj metabolites nns
mechanism	10	28	pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos omeprazole nn and cc erythromycin nn significantly rb increased vbd the dt systemic jj exposure nn of inpos cilostazol nn and_or cc its prp major jj metabolites nns
mechanism	14	28	pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos omeprazole nn and cc erythromycin nn significantly rb increased vbd the dt systemic jj exposure nn of inpos cilostazol nn and_or cc its prp major jj metabolites nns
mechanism	14	26	population nn pharmacokinetic jj studies nns showed vbd higher jjr concentrations nns of inpos cilostazol nn among inpos patients nns concurrently rb treated vbn with inpos diltiazem nn an dt inhibitor nn of inpos c.p.a nn
false	0	42	pletal nn does vbz not rb however rb appear vbp to topos cause vb increased vbn blood nn levels nns of inpos drugs nns metabolized vbn by inpos cyp3a4 nn as inpos it prp had vbd no dt effect nn on inpos lovastatin nn a dt drug nn with inpos metabolism nn very rb sensitive jj to topos c.p.a. nnp inhibition nn
mechanism	0	38	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	40	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns phenytoin nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	40	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns propranolol nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	40	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns nifedipine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	40	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns chlordiazepoxide nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	40	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns diazepam nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	40	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns tricyclic_antidepressants nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	40	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns lidocaine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	56	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns phenytoin nn propranolol nn nifedipine nn chlordiazepoxide nn diazepam nn certain jj tricyclic_antidepressants nns lidocaine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
mechanism	0	58	tagamet nn apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns phenytoin nn propranolol nn nifedipine nn chlordiazepoxide nn diazepam nn certain jj tricyclic_antidepressants nns lidocaine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	38	40	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	38	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns phenytoin nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	44	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns phenytoin nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns propranolol nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	44	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns propranolol nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns nifedipine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	44	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns nifedipine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns chlordiazepoxide nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	44	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns chlordiazepoxide nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns diazepam nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	44	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns diazepam nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns tricyclic_antidepressants nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	44	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns tricyclic_antidepressants nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	42	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns lidocaine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	40	44	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns lidocaine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
false	56	58	tagamet nnp apparently rb through inpos an dt effect nn on inpos certain jj microsomal jj enzyme nn systems nns has vbz been vbn reported vbn to topos reduce vb the dt hepatic jj metabolism nn of inpos warfarin_type_anticoagulants nns phenytoin nn propranolol nn nifedipine nn chlordiazepoxide nn diazepam nn certain jj tricyclic_antidepressants nns lidocaine nn theophylline nn metronidazole nn thereby rb delaying vbg elimination nn and cc increasing vbg blood nn levels nns of inpos these dt drugs nns
advise	24	36	therefore rb close jj monitoring nn of inpos prothrombin nn time nn is vbz recommended vbn and cc adjustment nn of inpos the dt anticoagulant nn dose nn may md be vb necessary jj when wrb tagamet nn is vbz administered vbn concomitantly rb
mechanism	18	50	however rb a dt crossover nn study nn in inpos healthy jj subjects nns receiving vbg either cc tagamet nn num cd mg nn q.i.d. nn or cc num cd mg nn h.s. nn concomitantly rb with inpos a dt num cd mg nn b.i.d. nn dosage nn of inpos theophylline nn demonstrated vbd less jjr alteration nn in inpos steady_state jj theophylline nn peak jj serum nn levels nns with inpos the dt num cd mg nn h.s. nn regimen nn particularly rb in inpos subjects nns aged vbn num cd years nns and cc older jjr
mechanism	18	50	however rb a dt crossover nn study nn in inpos healthy jj subjects nns receiving vbg either cc tagamet nn num cd mg nn q.i.d. nn or cc num cd mg nn h.s. nn concomitantly rb with inpos a dt num cd mg nn b.i.d. nn dosage nn of inpos theo_dur nn demonstrated vbd less jjr alteration nn in inpos steady_state jj theophylline nn peak jj serum nn levels nns with inpos the dt num cd mg nn h.s. nn regimen nn particularly rb in inpos subjects nns aged vbn num cd years nns and cc older jjr
false	18	50	however rb a dt crossover nn study nn in inpos healthy jj subjects nns receiving vbg either cc tagamet nn num cd mg nn q.i.d. nn or cc num cd mg nn h.s. nn concomitantly rb with inpos a dt num cd mg nn b.i.d. nn dosage nn of inpos theophylline nn demonstrated vbd less jjr alteration nn in inpos steady_state jj theophylline nn peak jj serum nn levels nns with inpos the dt num cd mg nn h.s. nn regimen nn particularly rb in inpos subjects nns aged vbn num cd years nns and cc older jjr
false	50	62	however rb a dt crossover nn study nn in inpos healthy jj subjects nns receiving vbg either cc tagamet nn num cd mg nn q.i.d. nn or cc num cd mg nn h.s. nn concomitantly rb with inpos a dt num cd mg nn b.i.d. nn dosage nn of inpos theo_dur nn demonstrated vbd less jjr alteration nn in inpos steady_state jj theophylline nn peak jj serum nn levels nns with inpos the dt num cd mg nn h.s. nn regimen nn particularly rb in inpos subjects nns aged vbn num cd years nns and cc older jjr
false	0	18	amitriptyline nn concurrent jj administration nn of inpos num cd mg nn or cc num cd mg nn cinacalcet nn with inpos num cd mg nn amitriptyline nn increased vbd amitriptyline nn exposure nn and cc nortriptyline nn exposure nn by inpos approximately rb num cd in inpos cyp2d6 nn extensive jj metabolizers nns
false	0	36	amitriptyline nn concurrent jj administration nn of inpos num cd mg nn or cc num cd mg nn cinacalcet nn with inpos num cd mg nn amitriptyline nn increased vbd amitriptyline nn exposure nn and cc nortriptyline nn exposure nn by inpos approximately rb num cd in inpos cyp2d6 nn extensive jj metabolizers nns
mechanism	16	24	concurrent jj administration nn of inpos num cd mg nn or cc num cd mg nn cinacalcet nn with inpos num cd mg nn amitriptyline nn increased vbd amitriptyline nn exposure nn and cc nortriptyline nn exposure nn by inpos approximately rb num cd in inpos cyp2d6 nn extensive jj metabolizers nns
false	16	24	concurrent jj administration nn of inpos num cd mg nn or cc num cd mg nn cinacalcet nn with inpos num cd mg nn amitriptyline nn increased vbd amitriptyline nn exposure nn and cc nortriptyline nn exposure nn by inpos approximately rb num cd in inpos cyp2d6 nn extensive jj metabolizers nns
false	16	34	concurrent jj administration nn of inpos num cd mg nn or cc num cd mg nn cinacalcet nn with inpos num cd mg nn amitriptyline nn increased vbd amitriptyline nn exposure nn and cc nortriptyline nn exposure nn by inpos approximately rb num cd in inpos cyp2d6 nn extensive jj metabolizers nns
false	24	34	concurrent jj administration nn of inpos num cd mg nn or cc num cd mg nn cinacalcet nn with inpos num cd mg nn amitriptyline nn increased vbd amitriptyline nn exposure nn and cc nortriptyline nn exposure nn by inpos approximately rb num cd in inpos cyp2d6 nn extensive jj metabolizers nns
false	24	34	concurrent jj administration nn of inpos num cd mg nn or cc num cd mg nn cinacalcet nn with inpos num cd mg nn amitriptyline nn increased vbd amitriptyline nn exposure nn and cc nortriptyline nn exposure nn by inpos approximately rb num cd in inpos cyp2d6 nn extensive jj metabolizers nns
mechanism	4	18	co_administration nn of inpos ketoconazole nn a dt strong jj inhibitor nn of inpos cyp3a4 nn increased vbd cinacalcet nn exposure nn following vbg a dt single jj num cd mg nn dose nn of inpos sensipar nnp by inpos float cd fold jj
false	4	36	co_administration nn of inpos ketoconazole nn a dt strong jj inhibitor nn of inpos cyp3a4 nn increased vbd cinacalcet nn exposure nn following vbg a dt single jj num cd mg nn dose nn of inpos sensipar nn by inpos float cd fold jj
false	18	36	co_administration nn of inpos ketoconazole nn a dt strong jj inhibitor nn of inpos cyp3a4 nn increased vbd cinacalcet nn exposure nn following vbg a dt single jj num cd mg nn dose nn of inpos sensipar nn by inpos float cd fold jj
advise	6	60	dose nn adjustment nn of inpos sensipar nn may md be vb required vbn and cc pth nn and cc serum nn calcium nn concentrations nns should md be vb closely rb monitored vbn if inpos a dt patient nn initiates vbz or cc discontinues vbz therapy nn with inpos a dt strong jj cyp3a4 nn inhibitor nn lrb_e.g. fw ketoconazole nn erythromycin nn itraconazole nn
advise	6	62	dose nn adjustment nn of inpos sensipar nn may md be vb required vbn and cc pth nn and cc serum nn calcium nn concentrations nns should md be vb closely rb monitored vbn if inpos a dt patient nn initiates vbz or cc discontinues vbz therapy nn with inpos a dt strong jj cyp3a4 nn inhibitor nn lrb_e.g. fw ketoconazole nn erythromycin nn itraconazole nn
advise	6	64	dose nn adjustment nn of inpos sensipar nn may md be vb required vbn and cc pth nn and cc serum nn calcium nn concentrations nns should md be vb closely rb monitored vbn if inpos a dt patient nn initiates vbz or cc discontinues vbz therapy nn with inpos a dt strong jj cyp3a4 nn inhibitor nn lrb_e.g. fw ketoconazole nn erythromycin nn itraconazole nn
false	60	62	dose nn adjustment nn of inpos sensipar nnp may md be vb required vbn and cc pth nn and cc serum nn calcium nn concentrations nns should md be vb closely rb monitored vbn if inpos a dt patient nn initiates vbz or cc discontinues vbz therapy nn with inpos a dt strong jj cyp3a4 nn inhibitor nn lrb_e.g. fw ketoconazole nn erythromycin nn itraconazole nn
false	60	64	dose nn adjustment nn of inpos sensipar nnp may md be vb required vbn and cc pth nn and cc serum nn calcium nn concentrations nns should md be vb closely rb monitored vbn if inpos a dt patient nn initiates vbz or cc discontinues vbz therapy nn with inpos a dt strong jj cyp3a4 nn inhibitor nn lrb_e.g. fw ketoconazole nn erythromycin nn itraconazole nn
false	62	64	dose nn adjustment nn of inpos sensipar nnp may md be vb required vbn and cc pth nn and cc serum nn calcium nn concentrations nns should md be vb closely rb monitored vbn if inpos a dt patient nn initiates vbz or cc discontinues vbz therapy nn with inpos a dt strong jj cyp3a4 nn inhibitor nn lrb_e.g. fw ketoconazole nn erythromycin nn itraconazole nn
mechanism	8	26	elevated vbn plasma nn levels nns of inpos theophylline nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos some dt quinolones nn
false	10	26	there ex have vbp been vbn reports nns of inpos theophylline nn related jj side_effects nns in inpos patients nns on inpos concomitant jj theophylline nn quinolone nn therapy nn
effect	10	24	there ex have vbp been vbn reports nns of inpos theophylline_related jj side_effects nns in inpos patients nns on inpos concomitant jj theophylline nn hyph_quinolone nn therapy nn
mechanism	0	22	quinolones nn have vbp also rb been vbn shown vbn to topos interfere vb with inpos the dt metabolism nn of inpos caffeine nn
false	16	38	although inpos this dt interaction nn has vbz not rb been vbn reported vbn with inpos cinoxacin nn caution nn should md be vb exercised vbn when wrb cinoxacin nn is vbz given vbn concomitantly rb with inpos caffeine nn containing jj products nns
advise	16	38	although inpos this dt interaction nn has vbz not rb been vbn reported vbn with inpos cinoxacin nn caution nn should md be vb exercised vbn when wrb cinoxacin nn is vbz given vbn concomitantly rb with inpos caffeine nn containing jj products nns
false	0	4	antacids nn or cc sucralfate nn substantially rb interfere vbp with inpos the dt absorption nn of inpos some dt quinolones nns resulting vbg in inpos low jj urine nn levels nns
mechanism	0	20	antacids nn or cc sucralfate nn substantially rb interfere vb with inpos the dt absorption nn of inpos some dt quinolones nn resulting vbg in inpos low jj urine nn levels nns
mechanism	4	20	antacids nns or cc sucralfate nn substantially rb interfere vbp with inpos the dt absorption nn of inpos some dt quinolones nn resulting vbg in inpos low jj urine nn levels nns
mechanism	8	16	also rb concomitant jj administration nn of inpos quinolones nn with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn videx nnp chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	8	18	also rb concomitant jj administration nn of inpos quinolones nn with inpos products nns containing vbg iron nn multivitamins nn containing vbg zinc nn or cc videx nnp chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
mechanism	8	22	also rb concomitant jj administration nn of inpos quinolones nn with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn or cc videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
mechanism	8	24	also rb concomitant jj administration nn of inpos quinolones nn with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
mechanism	8	24	also rb concomitant jj administration nn of inpos quinolones nn with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	16	18	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nn containing vbg zinc nn or cc videx nnp chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	16	22	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	16	24	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	16	24	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	18	22	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nn containing vbg zinc nn or cc videx nnp chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	18	24	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nn containing vbg zinc nn videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	18	26	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nn containing vbg zinc nn or cc didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	22	24	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	22	24	also rb concomitant jj administration nn of inpos quinolones nns with inpos products nns containing vbg iron nn multivitamins nns containing vbg zinc nn didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md result vb in inpos low jj urine nn levels nns
false	0	4	quinolones nn including vbg cinoxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nns such jj as inpos warfarin nn or cc its prp derivatives nns
effect	0	18	quinolones nn including vbg cinoxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nn such jj as inpos warfarin nn or cc its prp derivatives nns
effect	0	24	quinolones nn including vbg cinoxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nns such jj as inpos warfarin nn or cc its prp derivatives nns
effect	4	18	quinolones nns including vbg cinoxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nn such jj as inpos warfarin nn or cc its prp derivatives nns
effect	4	24	quinolones nns including vbg cinoxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nns such jj as inpos warfarin nn or cc its prp derivatives nns
false	18	24	quinolones nns including vbg cinoxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nn such jj as inpos warfarin nn or cc its prp derivatives nns
effect	16	22	seizures nns have vbp been vbn reported vbn in inpos patients nns taking vbg another dt quinolone_class_antimicrobial nn and cc the dt nonsteroidal_anti_inflammatory_drug nn fenbufen nn concurrently rb
effect	16	24	seizures nns have vbp been vbn reported vbn in inpos patients nns taking vbg another dt quinolone_class_antimicrobial nn and cc the dt nonsteroidal_anti_inflammatory_drug jj fenbufen nn concurrently rb
false	22	24	seizures nns have vbp been vbn reported vbn in inpos patients nns taking vbg another dt quinolone_class_antimicrobial jj and cc the dt nonsteroidal_anti_inflammatory_drug nn fenbufen nn concurrently rb
advise	30	36	physicians nns are vbp provided vbn this dt information nn to topos increase vb awareness nn of inpos the dt potential nn for inpos serious jj interactions nns when wrb cinoxacin nn and cc certain jj nonsteroidal_anti_inflammatory_agents nn are vbp administered vbn concomitantly rb
false	2	24	elevated jj cyclosporine nn serum nn levels nns have vbp been vbn reported vbn with inpos the dt concomitant jj use nn of inpos quinolones nn and cc cyclosporine nn
mechanism	24	2	elevated jj cyclosporine nn serum nn levels nns have vbp been vbn reported vbn with inpos the dt concomitant jj use nn of inpos quinolones nn and cc cyclosporine nn
false	2	6	some dt quinolones nn including vbg ciprofloxacin nn have vbp also rb been vbn shown vbn to topos interfere vb with inpos the dt metabolism nn of inpos caffeine nn
mechanism	2	28	some dt quinolones nn including vbg ciprofloxacin nn have vbp also rb been vbn shown vbn to topos interfere vb with inpos the dt metabolism nn of inpos caffeine nn
mechanism	6	28	some dt quinolones nns including vbg ciprofloxacin nn have vbp also rb been vbn shown vbn to topos interfere vb with inpos the dt metabolism nn of inpos caffeine nn
false	2	6	some dt quinolones nn including vbg ciprofloxacin nn have vbp been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg cyclosporine nn concomitantly rb
effect	2	32	some dt quinolones nn including vbg ciprofloxacin nn have vbp been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg cyclosporine nn concomitantly rb
effect	6	32	some dt quinolones nns including vbg ciprofloxacin nn have vbp been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg cyclosporine nn concomitantly rb
effect	8	14	the dt concomitant jj administration nn of inpos ciprofloxacin nn with inpos the dt sulfonylurea nn glyburide nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
effect	8	16	the dt concomitant jj administration nn of inpos ciprofloxacin nn with inpos the dt sulfonylurea nn glyburide nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
false	14	16	the dt concomitant jj administration nn of inpos ciprofloxacin nn with inpos the dt sulfonylurea nn glyburide nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
false	0	22	histamine_h2_receptor_antagonists nn appear vbp to topos have vb no dt significant jj effect nn on inpos the dt bioavailability nn of inpos ciprofloxacin nn
false	0	26	methotrexate nn renal jj tubular jj transport nn of inpos methotrexate nn may md be vb inhibited vbn by inpos concomitant jj administration nn of inpos ciprofloxacin nn potentially rb leading vbg to topos increased vbn plasma nn levels nns of inpos methotrexate nn
mechanism	0	26	methotrexate nn renal jj tubular jj transport nn of inpos methotrexate nn may md be vb inhibited vbn by inpos concomitant jj administration nn of inpos ciprofloxacin nn potentially rb leading vbg to topos increased vbn plasma nn levels nns of inpos methotrexate nn
false	26	0	methotrexate nn renal jj tubular jj transport nn of inpos methotrexate nn may md be vb inhibited vbn by inpos concomitant jj administration nn of inpos ciprofloxacin nn potentially rb leading vbg to topos increased vbn plasma nn levels nns of inpos methotrexate nn
advise	6	22	therefore rb patients nns under inpos methotrexate nn therapy nn should md be vb carefully rb monitored vbn when wrb concomitant jj ciprofloxacin nn therapy nn is vbz indicated vbn
false	8	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos aluminum nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos antacids nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos sucralfate nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	52	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	52	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	8	52	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	8	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos aluminum nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos antacids nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos sucralfate nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	26	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	50	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	52	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
mechanism	12	52	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	28	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	28	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos aluminum nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos aluminum nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos aluminum nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos aluminum nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos aluminum nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos antacids nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos antacids nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos antacids nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos antacids nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos sucralfate nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos sucralfate nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos sucralfate nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos sucralfate nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	44	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	34	50	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	34	50	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	26	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn iron nn zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	52	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg calcium nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	50	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn chewable jj tablets nns pediatric jj powder nn or cc products nns containing vbg iron nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
false	52	12	concurrent jj administration nn of inpos a dt quinolone nn including vbg ciprofloxacin nn with inpos multivalent jj cation_containing jj products nns such jj as inpos magnesium nn aluminum nn antacids nns sucralfate nn videx nn buffered vbd tablets nns or cc pediatric jj powder nn or cc products nns containing vbg zinc nn may md substantially rb decrease vb the dt absorption nn of inpos ciprofloxacin nn resulting vbg in inpos serum nn and cc urine nn levels nns considerably rb lower jjr than inpos desired vbn
advise	22	46	this dt time nn window nn is vbz different jj than inpos for inpos other jj oral jj formulations nns of inpos ciprofloxacin nn which wdt are vbp usually rb administered vbn num cd hours nns before inpos or cc num cd hours nns after inpos antacids nn
false	14	22	the dt rate nn and cc extent nn of inpos absorption nn of inpos ciprofloxacin nn was vbd bioequivalent jj when wrb proquin_xr nn was vbd given vbn alone rb or cc when wrb proquin_xr nn was vbd given vbn num cd hours nns after inpos omeprazole nn at inpos the dt dose nn that wdt maximally rb suppresses vbz gastric jj acid nn secretion nn
false	14	22	the dt rate nn and cc extent nn of inpos absorption nn of inpos ciprofloxacin nn was vbd bioequivalent jj when wrb proquin_xr nn was vbd given vbn alone rb or cc when wrb proquin_xr nn was vbd given vbn num cd hours nns after inpos omeprazole nn at inpos the dt dose nn that wdt maximally rb suppresses vbz gastric jj acid nn secretion nn
false	14	46	the dt rate nn and cc extent nn of inpos absorption nn of inpos ciprofloxacin nn was vbd bioequivalent jj when wrb proquin_xr nn was vbd given vbn alone rb or cc when wrb proquin_xr nn was vbd given vbn num cd hours nns after inpos omeprazole nn at inpos the dt dose nn that wdt maximally rb suppresses vbz gastric jj acid nn secretion nn
false	22	46	the dt rate nn and cc extent nn of inpos absorption nn of inpos ciprofloxacin nn was vbd bioequivalent jj when wrb proquin_xr nn was vbd given vbn alone rb or cc when wrb proquin_xr nn was vbd given vbn num cd hours nns after inpos omeprazole nn at inpos the dt dose nn that wdt maximally rb suppresses vbz gastric jj acid nn secretion nn
false	22	46	the dt rate nn and cc extent nn of inpos absorption nn of inpos ciprofloxacin nn was vbd bioequivalent jj when wrb proquin_xr nn was vbd given vbn alone rb or cc when wrb proquin_xr nn was vbd given vbn num cd hours nns after inpos omeprazole nn at inpos the dt dose nn that wdt maximally rb suppresses vbz gastric jj acid nn secretion nn
false	0	14	omeprazole nn should md be vb taken vbn as inpos directed vbn and cc proquin_xr nn should md be vb taken vbn with inpos a dt main jj meal nn of inpos the dt day nn preferably rb the dt evening nn meal nn
false	0	26	phenytoin nn altered vbd serum nn levels nns of inpos phenytoin nn have vbp been vbn reported vbn in inpos patients nns receiving vbg concomitant jj ciprofloxacin nn
mechanism	8	24	altered vbn serum nn levels nns of inpos phenytoin nn have vbp been vbn reported vbn in inpos patients nns receiving vbg concomitant jj ciprofloxacin nn
mechanism	0	14	probenecid nn interferes vbz with inpos renal jj tubular jj secretion nn of inpos ciprofloxacin nn and cc produces vbz an dt increase nn in inpos the dt level nn of inpos ciprofloxacin nn in inpos serum nn
mechanism	0	14	probenecid nn interferes vbz with inpos renal jj tubular jj secretion nn of inpos ciprofloxacin nn and cc produces vbz an dt increase nn in inpos the dt level nn of inpos ciprofloxacin nn in inpos serum nn
false	8	16	as inpos with inpos some dt other jj quinolones nn concurrent jj administration nn of inpos ciprofloxacin nn with inpos theophylline nn may md lead vb to topos elevated jj serum nn concentrations nns of inpos theophylline nn and cc prolongation nn of inpos its prp elimination nn half_life nn
mechanism	8	20	as inpos with inpos some dt other jj quinolones nn concurrent jj administration nn of inpos ciprofloxacin nn with inpos theophylline nn may md lead vb to topos elevated jj serum nn concentrations nns of inpos theophylline nn and cc prolongation nn of inpos its prp elimination nn half_life nn
false	8	20	as inpos with inpos some dt other jj quinolones nn concurrent jj administration nn of inpos ciprofloxacin nn with inpos theophylline nn may md lead vb to topos elevated jj serum nn concentrations nns of inpos theophylline nn and cc prolongation nn of inpos its prp elimination nn half_life nn
mechanism	16	20	as inpos with inpos some dt other jj quinolones nns concurrent jj administration nn of inpos ciprofloxacin nn with inpos theophylline nn may md lead vb to topos elevated jj serum nn concentrations nns of inpos theophylline nn and cc prolongation nn of inpos its prp elimination nn half_life nn
false	16	20	as inpos with inpos some dt other jj quinolones nns concurrent jj administration nn of inpos ciprofloxacin nn with inpos theophylline nn may md lead vb to topos elevated jj serum nn concentrations nns of inpos theophylline nn and cc prolongation nn of inpos its prp elimination nn half_life nn
false	0	22	quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
effect	0	24	quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn or cc its prp derivatives nns
false	22	24	quinolones nns have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
mechanism	16	28	in fw vitro fw and_or cc in fw vivo fw data nns show vbp that inpos clarithromycin nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	16	28	in fw vitro fw and_or cc in fw vivo fw data nns show vbp that inpos clarithromycin nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	16	28	in fw vitro fw and_or cc in fw vivo fw data nns show vbp that inpos erythromycin nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	16	28	in fw vitro fw and_or cc in fw vivo fw data nns show vbp that inpos erythromycin nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	16	28	in fw vitro fw and_or cc in fw vivo fw data nns show vbp that inpos troleandomycin nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	16	28	in fw vitro fw and_or cc in fw vivo fw data nns show vbp that inpos troleandomycin nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	0	10	anticholinergics nn concurrent jj administration nn of inpos certain jj anticholinergic_compounds nn such jj as inpos belladonna_alkaloids nns and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
false	0	16	anticholinergics nn concurrent jj administration nn of inpos certain jj anticholinergic_compounds nns such jj as inpos belladonna_alkaloids nn and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
false	0	20	anticholinergics nn concurrent jj administration nn of inpos certain jj anticholinergic_compounds nns such jj as inpos belladonna_alkaloids nns and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
false	0	40	anticholinergics nn concurrent jj administration nn of inpos certain jj anticholinergic_compounds nns such jj as inpos belladonna_alkaloids nns and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
false	8	14	concurrent jj administration nn of inpos certain jj anticholinergic_compounds nn such jj as inpos belladonna_alkaloids nn and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
false	8	18	concurrent jj administration nn of inpos certain jj anticholinergic_compounds nn such jj as inpos belladonna_alkaloids nns and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
effect	8	38	concurrent jj administration nn of inpos certain jj anticholinergic_compounds nn such jj as inpos belladonna_alkaloids nns and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
false	14	18	concurrent jj administration nn of inpos certain jj anticholinergic_compounds nns such jj as inpos belladonna_alkaloids nn and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
effect	14	38	concurrent jj administration nn of inpos certain jj anticholinergic_compounds nns such jj as inpos belladonna_alkaloids nn and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
effect	18	38	concurrent jj administration nn of inpos certain jj anticholinergic_compounds nns such jj as inpos belladonna_alkaloids nns and cc dicyclomine nn would md be vb expected vbn to topos compromise vb the dt beneficial jj effects nns of inpos cisapride nn
advise	36	52	it prp is vbz advisable jj to topos check vb coagulation nn time nn within inpos the dt first jj few jj days nns after inpos the dt start nn and cc discontinuation nn of inpos cisapride nn therapy nn with inpos an dt appropriate jj adjustment nn of inpos the dt anticoagulant nn dose nn if inpos necessary jj
mechanism	10	20	in fw vitro fw data nns indicate vbp that inpos nefazodone nn inhibits vbz the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	10	20	in fw vitro fw data nns indicate vbp that inpos nefazodone nn inhibits vbz the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	16	18	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	16	22	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	16	34	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	16	34	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	18	22	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	18	34	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	18	34	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	22	34	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	22	34	in fw vitro fw and_or cc in fw vivo fw data nns indicate vbp that inpos fluconazole nn itraconazole nn oral jj ketoconazole nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	12	24	human jj pharmacokinetic jj data nns indicate vbp that inpos oral jj ketoconazole nn markedly rb inhibits vbz the dt metabolism nn of inpos cisapride nn resulting vbg in inpos a dt mean jj eight_fold jj increase nn in inpos auc nn of inpos cisapride nn
false	12	24	human jj pharmacokinetic jj data nns indicate vbp that inpos oral jj ketoconazole nn markedly rb inhibits vbz the dt metabolism nn of inpos cisapride nn resulting vbg in inpos a dt mean jj eight_fold jj increase nn in inpos auc nn of inpos cisapride nn
effect	26	30	a dt study nn in inpos num cd normal jj male jj and cc female jj volunteers nns suggests vbz that inpos coadministration nn of inpos cisapride nn and cc ketoconazole nn can md result vb in inpos prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	0	24	cimetidine nn coadministration nn leads vbz to topos an dt increased vbn peak jj plasma nn concentration nn and cc auc nn of inpos cisapride nn there ex is vbz no dt effect nn on inpos cisapride nn absorption nn when wrb it prp is vbz coadministered vbn with inpos ranitidine nn
false	0	24	cimetidine nn coadministration nn leads vbz to topos an dt increased vbn peak jj plasma nn concentration nn and cc auc nn of inpos cisapride nn there ex is vbz no dt effect nn on inpos cisapride nn absorption nn when wrb it prp is vbz coadministered vbn with inpos ranitidine nn
false	0	50	cimetidine nn coadministration nn leads vbz to topos an dt increased vbn peak jj plasma nn concentration nn and cc auc nn of inpos cisapride nn there ex is vbz no dt effect nn on inpos cisapride nn absorption nn when wrb it prp is vbz coadministered vbn with inpos ranitidine nn
false	24	50	cimetidine nn coadministration nn leads vbz to topos an dt increased vbn peak jj plasma nn concentration nn and cc auc nn of inpos cisapride nn there ex is vbz no dt effect nn on inpos cisapride nn absorption nn when wrb it prp is vbz coadministered vbn with inpos ranitidine nn
false	24	50	cimetidine nn coadministration nn leads vbz to topos an dt increased vbn peak jj plasma nn concentration nn and cc auc nn of inpos cisapride nn there ex is vbz no dt effect nn on inpos cisapride nn absorption nn when wrb it prp is vbz coadministered vbn with inpos ranitidine nn
false	8	12	the dt gastrointestinal jj absorption nn of inpos cimetidine nn and cc ranitidine nn is vbz accelerated vbn when wrb they prp are vbp coadministered vbn with inpos cisapride nn
mechanism	8	28	the dt gastrointestinal jj absorption nn of inpos cimetidine nn and cc ranitidine nn is vbz accelerated vbn when wrb they prp are vbp coadministered vbn with inpos cisapride nn
mechanism	12	28	the dt gastrointestinal jj absorption nn of inpos cimetidine nn and cc ranitidine nn is vbz accelerated vbn when wrb they prp are vbp coadministered vbn with inpos cisapride nn
false	10	14	in fw vitro fw data nns indicate vbp that inpos indinavir nn and cc ritonavir nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	10	26	in fw vitro fw data nns indicate vbp that inpos indinavir nn and cc ritonavir nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	10	26	in fw vitro fw data nns indicate vbp that inpos indinavir nn and cc ritonavir nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	14	26	in fw vitro fw data nns indicate vbp that inpos indinavir nn and cc ritonavir nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
false	14	26	in fw vitro fw data nns indicate vbp that inpos indinavir nn and cc ritonavir nn markedly rb inhibit vbp the dt metabolism nn of inpos cisapride nn which wdt can md result vb in inpos an dt increase nn in inpos plasma nn cisapride nn levels nns and cc prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
advise	0	32	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nn including vbg those dt of inpos class nnp ia nnp and cc class nn num cd
advise	0	42	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nns including vbg those dt of inpos class nn quinidine nn and cc class nn num cd
advise	0	42	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nns including vbg those dt of inpos class nn procainamide nn and cc class nn num cd
advise	0	48	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nns including vbg those dt of inpos class nnp ia nnp and cc class nn sotalol nn
false	32	42	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nn including vbg those dt of inpos class nn quinidine nn and cc class nn num cd
false	32	42	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nn including vbg those dt of inpos class nn procainamide nn and cc class nn num cd
false	32	48	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nn including vbg those dt of inpos class nnp ia nnp and cc class nn sotalol nn
false	42	48	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nns including vbg those dt of inpos class nn quinidine nn and cc class nn sotalol nn
false	42	48	cisapride nn should md not rb be vb used vbn concomitantly rb with inpos other jj drugs nns known vbn to topos prolong vb the dt qt nn interval nn certain jj antiarrhythmics nns including vbg those dt of inpos class nn procainamide nn and cc class nn sotalol nn
effect	6	28	administration nn of inpos float_mg_kg jj nimbex nn at inpos num cd or cc num cd recovery nn following vbg an dt intubating vbg dose nn of inpos succinylcholine nn produced vbd num cd neuromuscular jj block nn
effect	16	36	the dt time nn to topos onset nn of inpos maximum nn block nn following vbg nimbex nn is vbz approximately rb num cd minutes nns faster rbr with inpos prior jj administration nn of inpos succinylcholine nn
false	6	40	prior jj administration nn of inpos succinylcholine nn had vbd no dt effect nn on inpos the dt duration nn of inpos neuromuscular jj block nn following vbg initial jj or cc maintenance nn bolus nn doses nns of inpos nimbex nn
false	6	14	infusion nn requirements nns of inpos nimbex nn in inpos patients nns administered vbn succinylcholine nn prior rb to topos infusions nns of inpos nimbex nn were vbd comparable jj to topos or cc slightly rb greater jjr than inpos when wrb succinylcholine nn was vbd not rb administered vbn
false	6	14	infusion nn requirements nns of inpos nimbex nn in inpos patients nns administered vbn succinylcholine nn prior rb to topos infusions nns of inpos nimbex nn were vbd comparable jj to topos or cc slightly rb greater jjr than inpos when wrb succinylcholine nn was vbd not rb administered vbn
effect	14	6	infusion nn requirements nns of inpos nimbex nn in inpos patients nns administered vbn succinylcholine nn prior rb to topos infusions nns of inpos nimbex nn were vbd comparable jj to topos or cc slightly rb greater jjr than inpos when wrb succinylcholine nn was vbd not rb administered vbn
false	6	14	infusion nn requirements nns of inpos nimbex nn in inpos patients nns administered vbn succinylcholine nn prior rb to topos infusions nns of inpos nimbex nn were vbd comparable jj to topos or cc slightly rb greater jjr than inpos when wrb succinylcholine nn was vbd not rb administered vbn
false	6	10	the dt use nn of inpos nimbex nn before inpos succinylcholine nn to topos attenuate vb some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	6	10	the dt use nn of inpos nimbex nn before inpos succinylcholine nn to topos attenuate vb some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	26	54	although inpos not rb studied vbn systematically rb in inpos clinical jj trials nns no dt drug nn interactions nns were vbd observed vbn when wrb vecuronium nn were vbd administered vbn following vbg varying vbg degrees nns of inpos recovery nn from inpos single jj doses nns or cc infusions nns of inpos nimbex nn
false	26	54	although inpos not rb studied vbn systematically rb in inpos clinical jj trials nns no dt drug nn interactions nns were vbd observed vbn when wrb pancuronium nn were vbd administered vbn following vbg varying vbg degrees nns of inpos recovery nn from inpos single jj doses nns or cc infusions nns of inpos nimbex nn
false	26	54	although inpos not rb studied vbn systematically rb in inpos clinical jj trials nns no dt drug nn interactions nns were vbd observed vbn when wrb atracurium nn were vbd administered vbn following vbg varying vbg degrees nns of inpos recovery nn from inpos single jj doses nns or cc infusions nns of inpos nimbex nn
false	0	4	isoflurane nn or cc enflurane nn administered vbn with inpos oxygen nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
false	0	10	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
false	0	10	isoflurane nn or cc enflurane nn administered vbn with inpos oxygen nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
effect	0	54	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
effect	0	54	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
false	4	10	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
false	4	10	isoflurane nn or cc enflurane nn administered vbn with inpos oxygen nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
effect	4	54	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
effect	4	54	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
effect	10	54	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
effect	10	54	isoflurane nn or cc enflurane nn administered vbn with inpos nitrous_oxide nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
false	10	54	isoflurane nn or cc enflurane nn administered vbn with inpos oxygen nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
false	10	54	isoflurane nn or cc enflurane nn administered vbn with inpos oxygen nn to topos achieve vb float cd mac nnp lrb_minimum nnp alveolar nnp concentration nnp rrb_may md prolong vb the dt clinically rb effective jj duration nn of inpos action nn of inpos initial jj and cc maintenance nn doses nns of inpos nimbex nn and cc decrease vb the dt required jj infusion nn rate nn of inpos nimbex nn
false	18	22	num cd to topos num cd minutes nns of inpos exposure nn to topos float cd mac nn isoflurane nn or cc enflurane nn had vbd minimal jj effects nns on inpos the dt duration nn of inpos action nn of inpos initial jj doses nns of inpos nimbex nn and cc therefore rb no dt adjustment nn to topos the dt initial jj dose nn should md be vb necessary jj when wrb nimbex nn is vbz administered vbn shortly rb after inpos initiation nn of inpos volatile jj agents nns
false	18	48	num cd to topos num cd minutes nns of inpos exposure nn to topos float cd mac nn isoflurane nn or cc enflurane nn had vbd minimal jj effects nns on inpos the dt duration nn of inpos action nn of inpos initial jj doses nns of inpos nimbex nn and cc therefore rb no dt adjustment nn to topos the dt initial jj dose nn should md be vb necessary jj when wrb nimbex nn is vbz administered vbn shortly rb after inpos initiation nn of inpos volatile jj agents nns
false	18	48	num cd to topos num cd minutes nns of inpos exposure nn to topos float cd mac nn isoflurane nn or cc enflurane nn had vbd minimal jj effects nns on inpos the dt duration nn of inpos action nn of inpos initial jj doses nns of inpos nimbex nn and cc therefore rb no dt adjustment nn to topos the dt initial jj dose nn should md be vb necessary jj when wrb nimbex nn is vbz administered vbn shortly rb after inpos initiation nn of inpos volatile jj agents nns
false	22	48	num cd to topos num cd minutes nns of inpos exposure nn to topos float cd mac nn isoflurane nn or cc enflurane nn had vbd minimal jj effects nns on inpos the dt duration nn of inpos action nn of inpos initial jj doses nns of inpos nimbex nn and cc therefore rb no dt adjustment nn to topos the dt initial jj dose nn should md be vb necessary jj when wrb nimbex nn is vbz administered vbn shortly rb after inpos initiation nn of inpos volatile jj agents nns
false	22	48	num cd to topos num cd minutes nns of inpos exposure nn to topos float cd mac nn isoflurane nn or cc enflurane nn had vbd minimal jj effects nns on inpos the dt duration nn of inpos action nn of inpos initial jj doses nns of inpos nimbex nn and cc therefore rb no dt adjustment nn to topos the dt initial jj dose nn should md be vb necessary jj when wrb nimbex nn is vbz administered vbn shortly rb after inpos initiation nn of inpos volatile jj agents nns
false	10	14	in inpos long jj surgical jj procedures nns during inpos enflurane nn or cc isoflurane nn anesthesia nn less rbr frequent jj maintenance nn dosing nn lower jjr maintenance nn doses nns reduced vbn infusion nn rates nns of inpos nimbex nn may md be vb necessary jj
advise	10	40	in inpos long jj surgical jj procedures nns during inpos enflurane nn or cc isoflurane nn anesthesia nn less rbr frequent jj maintenance nn dosing nn lower jjr maintenance nn doses nns reduced vbn infusion nn rates nns of inpos nimbex nn may md be vb necessary jj
advise	14	40	in inpos long jj surgical jj procedures nns during inpos enflurane nn or cc isoflurane nn anesthesia nn less rbr frequent jj maintenance nn dosing nn lower jjr maintenance nn doses nns reduced vbn infusion nn rates nns of inpos nimbex nn may md be vb necessary jj
false	6	32	in inpos clinical jj studies nns propofol nn had vbd no dt effect nn on inpos the dt duration nn of inpos action nn or cc dosing nn requirements nns for inpos nimbex nn
effect	20	26	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn local jj anesthetics nns procainamide nn quinidine nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj antibiotics nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj aminoglycosides nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj tetracyclines nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj bacitracin nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj polymyxins nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj lincomycin nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj clindamycin nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj colistin nn
effect	20	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj sodium_colistemethate nn
effect	20	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn local jj anesthetics nns procainamide nn quinidine nn
effect	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
effect	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
effect	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
effect	20	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nn such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj aminoglycosides nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj tetracyclines nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj bacitracin nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj polymyxins nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj lincomycin nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj clindamycin nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj colistin nn
effect	26	32	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj sodium_colistemethate nn
effect	26	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn local jj anesthetics nns procainamide nn quinidine nn
effect	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
effect	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
effect	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
effect	26	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
false	34	38	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_agents nns such jj as inpos nimbex nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
effect	14	30	resistance nn to topos the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_neuromuscular_blocking_agents nn has vbz been vbn demonstrated vbn in inpos patients nns chronically rb administered vbn phenytoin nn or cc carbamazepine nn
effect	14	34	resistance nn to topos the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_neuromuscular_blocking_agents nn has vbz been vbn demonstrated vbn in inpos patients nns chronically rb administered vbn phenytoin nn or cc carbamazepine nn
false	30	34	resistance nn to topos the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing_neuromuscular_blocking_agents nns has vbz been vbn demonstrated vbn in inpos patients nns chronically rb administered vbn phenytoin nn or cc carbamazepine nn
false	10	14	while inpos the dt effects nns of inpos chronic jj phenytoin nn or cc carbamazepine nn therapy nn on inpos the dt action nn of inpos nimbex nn are vbp unknown jj slightly rb shorter jjr durations nns of inpos neuromuscular jj block nn may md be vb anticipated vbn and cc infusion nn rate nn requirements nns may md be vb higher jjr
effect	10	26	while inpos the dt effects nns of inpos chronic jj phenytoin nn or cc carbamazepine nn therapy nn on inpos the dt action nn of inpos nimbex nn are vbp unknown jj slightly rb shorter jjr durations nns of inpos neuromuscular jj block nn may md be vb anticipated vbn and cc infusion nn rate nn requirements nns may md be vb higher jjr
effect	14	26	while inpos the dt effects nns of inpos chronic jj phenytoin nn or cc carbamazepine nn therapy nn on inpos the dt action nn of inpos nimbex nn are vbp unknown jj slightly rb shorter jjr durations nns of inpos neuromuscular jj block nn may md be vb anticipated vbn and cc infusion nn rate nn requirements nns may md be vb higher jjr
mechanism	6	16	plasma nn levels nns of inpos anticonvulsant_agents nn may md become vb subtherapeutic jj during inpos cisplatin nn therapy nn
false	0	6	central_nervous_system_depressant nn drugs nns including vbg alcohol nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	0	6	central_nervous_system_depressant nn drugs nns including vbg antidepressants nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	0	6	central_nervous_system_depressant nn drugs nns including vbg antihistamines nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	0	6	central_nervous_system_depressant nn drugs nns including vbg antipsychotics nn blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	0	18	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn reserpine nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	0	18	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn methyldopa nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	0	18	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn b_blockers nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	0	26	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns
false	0	26	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn medications nns motion nn sickness nn medications nns narcotics nns
false	0	26	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn medications nns motion nn sickness nn medications nns sedatives nns
false	0	18	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn tranquilizers nn
false	6	12	central_nervous_system_depressant nn drugs nns including vbg alcohol nns blood nn pressure nn reserpine nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg alcohol nns blood nn pressure nn methyldopa nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg alcohol nns blood nn pressure nn b_blockers nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	20	central_nervous_system_depressant nn drugs nns including vbg alcohol nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns
false	2	16	central_nervous_system_depressant nn alcohol nns blood nn pressure nn medications nns motion nn sickness nn medications nns narcotics nns
false	2	16	central_nervous_system_depressant nn alcohol nns blood nn pressure nn medications nns motion nn sickness nn medications nns sedatives nns
false	2	8	central_nervous_system_depressant nn alcohol nns blood nn pressure nn tranquilizers nn
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antidepressants nns blood nn pressure nn reserpine nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antidepressants nns blood nn pressure nn methyldopa nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antidepressants nns blood nn pressure nn b_blockers nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	20	central_nervous_system_depressant nn drugs nns including vbg antidepressants nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns
false	2	16	central_nervous_system_depressant nn antidepressants nns blood nn pressure nn medications nns motion nn sickness nn medications nns narcotics nns
false	2	16	central_nervous_system_depressant nn antidepressants nns blood nn pressure nn medications nns motion nn sickness nn medications nns sedatives nns
false	2	8	central_nervous_system_depressant nn antidepressants nns blood nn pressure nn tranquilizers nn
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antihistamines nns blood nn pressure nn reserpine nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antihistamines nns blood nn pressure nn methyldopa nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antihistamines nns blood nn pressure nn b_blockers nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	20	central_nervous_system_depressant nn drugs nns including vbg antihistamines nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns
false	2	16	central_nervous_system_depressant nn antihistamines nns blood nn pressure nn medications nns motion nn sickness nn medications nns narcotics nns
false	2	16	central_nervous_system_depressant nn antihistamines nns blood nn pressure nn medications nns motion nn sickness nn medications nns sedatives nns
false	2	8	central_nervous_system_depressant nn antihistamines nns blood nn pressure nn tranquilizers nn
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antipsychotics nn blood nn pressure nn reserpine nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antipsychotics nn blood nn pressure nn methyldopa nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	12	central_nervous_system_depressant nn drugs nns including vbg antipsychotics nn blood nn pressure nn b_blockers nn motion nn sickness nn medications nns muscle_relaxants nns narcotics nns sedatives nns sleeping vbg pills nns tranquilizers nns
false	6	20	central_nervous_system_depressant nn drugs nns including vbg antipsychotics nn blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns
false	2	16	central_nervous_system_depressant nn antipsychotics nn blood nn pressure nn medications nns motion nn sickness nn medications nns narcotics nns
false	2	16	central_nervous_system_depressant nn antipsychotics nn blood nn pressure nn medications nns motion nn sickness nn medications nns sedatives nns
false	2	8	central_nervous_system_depressant nn antipsychotics nn blood nn pressure nn tranquilizers nn
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn reserpine nn motion nn sickness nn muscle_relaxants nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn reserpine nn motion nn sickness nn narcotics nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn reserpine nn motion nn sickness nn sedatives nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn reserpine nn motion nn sickness nn tranquilizers nn
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn methyldopa nn motion nn sickness nn muscle_relaxants nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn methyldopa nn motion nn sickness nn narcotics nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn methyldopa nn motion nn sickness nn sedatives nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn methyldopa nn motion nn sickness nn tranquilizers nn
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn b_blockers nn motion nn sickness nn muscle_relaxants nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn b_blockers nn motion nn sickness nn narcotics nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn b_blockers nn motion nn sickness nn sedatives nns
false	18	24	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn b_blockers nn motion nn sickness nn tranquilizers nn
false	26	30	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nn narcotics nns sedatives nn sleeping vbg pills nns tranquilizers nns
false	28	30	central_nervous_system_depressant nn drugs nns including vbg alcohol nn antidepressants nns antihistamines nns antipsychotics nns blood nn pressure nn medications nns motion nn sickness nn medications nns muscle_relaxants nns narcotics nn sedatives nn sleeping vbg pills nns tranquilizers nns
effect	8	12	the dt concurrent jj administration nn of inpos allopurinol nn and cc ampicillin nn increases vbz substantially rb the dt incidence nn of inpos rashes nns in inpos patients nns receiving vbg both dt drugs nns as inpos compared vbn to topos patients nns receiving vbg ampicillin nn alone rb
false	8	12	the dt concurrent jj administration nn of inpos allopurinol nn and cc ampicillin nn increases vbz substantially rb the dt incidence nn of inpos rashes nns in inpos patients nns receiving vbg both dt drugs nns as inpos compared vbn to topos patients nns receiving vbg ampicillin nn alone rb
effect	16	26	it prp is vbz not rb known vbn whether inpos this dt potentiation nn of inpos ampicillin nn rashes nns is vbz due jj to topos allopurinol nn or cc the dt hyperuricemia nn present jj in inpos these dt patients nns
false	10	20	in inpos controlled vbn clinical jj trials nns of inpos augmentin_xr nn num cd patients nns received vbd concomitant jj allopurinol nn and cc augmentin_xr nn
false	20	10	in inpos controlled vbn clinical jj trials nns of inpos augmentin_xr nn num cd patients nns received vbd concomitant jj allopurinol nn and cc augmentin_xr nn
false	44	48	however rb this dt sample nn size nn is vbz too rb small jj to topos allow vb for inpos any dt conclusions nns to topos be vb drawn vbn regarding vbg the dt risk nn of inpos rashes nns with inpos concomitant jj augmentin_xr nn and cc allopurinol nn use nn
false	8	10	in inpos common jj with inpos other jj broad_spectrum_antibiotics nn augmentin_xr nn may md reduce vb the dt efficacy nn of inpos oral jj contraceptives nns
effect	8	24	in inpos common jj with inpos other jj broad_spectrum_antibiotics nn augmentin_xr nn may md reduce vb the dt efficacy nn of inpos oral jj contraceptives nn
effect	10	24	in inpos common jj with inpos other jj broad_spectrum_antibiotics nns augmentin_xr nn may md reduce vb the dt efficacy nn of inpos oral jj contraceptives nn
effect	12	24	additive jj cns nn depression nn may md occur vb when wrb antihistamines nn are vbp administered vbn concomitantly rb with inpos other jj cns_depressants nn including vbg barbiturates nns tranquilizers nns alcohol nn
effect	12	28	additive jj cns nn depression nn may md occur vb when wrb antihistamines nn are vbp administered vbn concomitantly rb with inpos other jj cns_depressants nns including vbg barbiturates nn
effect	12	28	additive jj cns nn depression nn may md occur vb when wrb antihistamines nn are vbp administered vbn concomitantly rb with inpos other jj cns_depressants nns including vbg tranquilizers nn
effect	12	28	additive jj cns nn depression nn may md occur vb when wrb antihistamines nn are vbp administered vbn concomitantly rb with inpos other jj cns_depressants nns including vbg alcohol nn
false	24	28	additive jj cns nn depression nn may md occur vb when wrb antihistamines nns are vbp administered vbn concomitantly rb with inpos other jj cns_depressants nn including vbg barbiturates nn
false	24	28	additive jj cns nn depression nn may md occur vb when wrb antihistamines nns are vbp administered vbn concomitantly rb with inpos other jj cns_depressants nn including vbg tranquilizers nn
false	24	28	additive jj cns nn depression nn may md occur vb when wrb antihistamines nns are vbp administered vbn concomitantly rb with inpos other jj cns_depressants nn including vbg alcohol nn
advise	4	24	patients nns receiving vbg antihistamines nn should md be vb advised vbn against inpos the dt concurrent jj use nn of inpos other jj cns_depressant_drugs nn
effect	0	16	monoamine_oxidase_mao_inhibitors nn prolong vb and cc intensify vb the dt anticholinergic jj effects nns of inpos antihistamines nn
effect	0	12	amantadine nns may md increase vb anticholinergic jj effect nn of inpos clidinium nn
effect	0	12	tricyclic_antidepressants nns may md increase vb anticholinergic jj effect nn of inpos clidinium nn
effect	0	12	maois nn may md increase vb anticholinergic jj effect nn of inpos clidinium nn
effect	0	12	clidinium nn may md decrease vb the dt effect nn of inpos phenothiazines nn
effect	0	12	clidinium nn may md decrease vb the dt effect nn of inpos levodopa nn
effect	0	12	clidinium nn may md decrease vb the dt effect nn of inpos ketoconazole nn
effect	0	32	clindamycin nn has vbz been vbn shown vbn to topos have vb neuromuscular jj blocking vbg properties nns that wdt may md enhance vb the dt action nn of inpos other jj neuromuscular_blocking_agents nn
effect	10	14	antagonism nn has vbz been vbn demonstrated vbn between inpos clindamycin nn and cc erythromycin nn in fw vitro fw
effect	10	24	preliminary jj data nns which wdt suggest vbp that inpos dapsone nn may md inhibit vb the dt anti_inflammatory jj activity nn of inpos lamprene nn have vbp not rb been vbn confirmed vbn
advise	20	24	if inpos leprosy_associated jj inflammatory jj reactions nns develop vbp in inpos patients nns being vbg treated vbn with inpos dapsone nn and cc clofazimine nn it prp is vbz still rb advisable jj to topos continue vb treatment nn with inpos both dt drugs nns
advise	10	22	caution nn should md be vb exercised vbn when wrb anticoagulants nn are vbp given vbn in inpos conjunction nn with inpos atromid_s nn
mechanism	0	14	atromid_s nn may md displace vb acidic jj drugs nns such jj as inpos phenytoin nn or cc tolbutamide nn from inpos their prp binding vbg sites nns
mechanism	0	18	atromid_s nn may md displace vb acidic jj drugs nns such jj as inpos phenytoin nn or cc tolbutamide nn from inpos their prp binding vbg sites nns
false	14	18	atromid_s nn may md displace vb acidic jj drugs nns such jj as inpos phenytoin nn or cc tolbutamide nn from inpos their prp binding vbg sites nns
effect	8	22	the dt hypoglycemic jj effect nn of inpos tolbutamide nn has vbz been vbn reported vbn to topos increase vb when wrb atromid_s nn is vbz given vbn concurrently rb
effect	34	38	fulminant jj rhabdomyolysis nn has vbz been vbn seen vbn as rb early rb as inpos num cd weeks nns after inpos initiation nn of inpos combined vbn therapy nn with inpos another dt fibrate nn and cc lovastatin nn but cc may md be vb seen vbn after inpos several jj months nns
effect	56	62	for inpos these dt reasons nns it prp is vbz felt vbn that inpos in inpos most jjs subjects nns who wp have vbp had vbd an dt unsatisfactory jj lipid nn response nn to topos either cc drug nn alone rb the dt possible jj benefits nns of inpos combined jj therapy nn with inpos lovastatin nn and cc a dt fibrate nn do vbp not rb outweigh vb the dt risks nns of inpos severe jj myopathy nn rhabdomyolysis nn acute jj renal jj failure nn
false	20	26	while inpos it prp is vbz not rb known vbn whether inpos this dt interaction nn occurs vbz with inpos fibrates nn other jj than inpos gemfibrozil nn myopathy nn and cc rhabdomyolysis nn have vbp occasionally rb been vbn associated vbn with inpos the dt use nn of inpos fibrates nns alone rb including vbg clofibrate nn
false	20	56	while inpos it prp is vbz not rb known vbn whether inpos this dt interaction nn occurs vbz with inpos fibrates nn other jj than inpos gemfibrozil nn myopathy nn and cc rhabdomyolysis nn have vbp occasionally rb been vbn associated vbn with inpos the dt use nn of inpos fibrates nns alone rb including vbg clofibrate nn
false	26	20	while inpos it prp is vbz not rb known vbn whether inpos this dt interaction nn occurs vbz with inpos fibrates nns other jj than inpos gemfibrozil nn myopathy nn and cc rhabdomyolysis nn have vbp occasionally rb been vbn associated vbn with inpos the dt use nn of inpos fibrates nn alone rb including vbg clofibrate nn
false	26	56	while inpos it prp is vbz not rb known vbn whether inpos this dt interaction nn occurs vbz with inpos fibrates nns other jj than inpos gemfibrozil nn myopathy nn and cc rhabdomyolysis nn have vbp occasionally rb been vbn associated vbn with inpos the dt use nn of inpos fibrates nns alone rb including vbg clofibrate nn
false	20	56	while inpos it prp is vbz not rb known vbn whether inpos this dt interaction nn occurs vbz with inpos fibrates nns other jj than inpos gemfibrozil nn myopathy nn and cc rhabdomyolysis nn have vbp occasionally rb been vbn associated vbn with inpos the dt use nn of inpos fibrates nn alone rb including vbg clofibrate nn
advise	10	14	therefore rb the dt combined jj use nn of inpos lovastatin nn with inpos fibrates nn should md generally rb be vb avoided vbn
advise	0	12	anafranil nn should md not rb be vb used vbn with inpos mao_inhibitors nn
advise	20	28	close jj supervision nn and cc careful jj adjustment nn of inpos dosage nn are vbp required vbn when wrb anafranil nn is vbz administered vbn with inpos anticholinergic nn or cc sympathomimetic_drugs nns
advise	20	32	close jj supervision nn and cc careful jj adjustment nn of inpos dosage nn are vbp required vbn when wrb anafranil nn is vbz administered vbn with inpos anticholinergic jj or cc sympathomimetic_drugs nn
false	28	32	close jj supervision nn and cc careful jj adjustment nn of inpos dosage nn are vbp required vbn when wrb anafranil nnp is vbz administered vbn with inpos anticholinergic nn or cc sympathomimetic_drugs nn
effect	2	22	several jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nns
effect	2	24	several jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nns
effect	2	46	several jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nns
false	22	24	several jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nns
false	22	46	several jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nns
false	22	2	several jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nn
false	24	46	several jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nns
false	24	2	several jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nn
false	46	2	several jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos block vb the dt pharmacologic jj effects nns of inpos guanethidine nn clonidine nn similar jj agents nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn because inpos of inpos its prp structural jj similarity nn to topos other jj tricyclic_antidepressants nn
mechanism	8	32	the dt plasma nn concentration nn of inpos cmi nn has vbz been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos haloperidol nn
mechanism	12	36	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	12	44	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn cimetidine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	12	44	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn fluoxetine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	12	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	12	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	12	82	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nn have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	36	44	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn cimetidine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	36	44	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn fluoxetine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	36	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	36	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	36	82	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	44	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn cimetidine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	44	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn cimetidine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	44	82	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn cimetidine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	44	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn fluoxetine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
false	44	64	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn fluoxetine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	44	82	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn fluoxetine nn and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	64	82	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	64	82	plasma nn levels nns of inpos several jj closely rb related jj tricyclic_antidepressants nns have vbp been vbn reported vbn to topos be vb increased vbn by inpos the dt concomitant jj administration nn of inpos methylphenidate nn or cc hepatic jj enzyme nn inhibitors nns and cc decreased vbn by inpos the dt concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc such pdt an dt effect nn may md be vb anticipated vbn with inpos cmi nn as rb well rb
mechanism	4	24	administration nn of inpos cmi nn has vbz been vbn reported vbn to topos increase vb the dt plasma nn levels nns of inpos phenobarbital nn if inpos given vbn concomitantly rb
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn antidepressants nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn phenothiazines nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn type_1c_antiarrhythmics nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn propafenone nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn flecainide nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw fluvoxamine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw fluvoxamine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
mechanism	0	28	fluvoxamine nn has vbz also rb been vbn shown vbn to topos inhibit vb p450 nn 1a2 nn an dt isoform nn also rb involved vbn in inpos tca nn metabolism nn
int	8	10	the dt extent nn to topos which wdt ssri nn hyph_tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbd
false	10	8	the dt extent nn to topos which wdt ssri nn tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbn
advise	16	26	nevertheless rb caution nn is vbz indicated vbn in inpos the dt co_administration nn of inpos tcas nn with inpos any dt of inpos the dt ssris nn and cc also rb in inpos switching vbg from inpos num cd class nn to topos the dt other jj
advise	18	34	of inpos particular jj importance nn sufficient jj time nn must md elapse vb before inpos initiating vbg tca nn treatment nn in inpos a dt patient nn being vbg withdrawn vbn from inpos fluoxetine nn given vbn the dt long jj half_life nn of inpos the dt parent nn and cc active jj metabolite nn
false	12	50	concomitant jj use nn of inpos agents nns in inpos the dt tricyclic_antidepressant_class nn with inpos drugs nns that wdt can md inhibit vb cytochrome nn p450 nn 2d6 nn may md require vb lower jjr doses nns than inpos usually rb prescribed vbn for inpos either cc the dt tricyclic_antidepressant_agent nn or cc the dt other jj drug nn
false	12	50	concomitant jj use nn of inpos agents nns in inpos the dt anafranil nn with inpos drugs nns that wdt can md inhibit vb cytochrome nn p450 nn 2d6 nn may md require vb lower jjr doses nns than inpos usually rb prescribed vbn for inpos either cc the dt tricyclic_antidepressant_agent nn or cc the dt other jj drug nn
false	10	26	it prp is vbz desirable jj to topos monitor vb tca nn plasma nn levels nns whenever wrb an dt agent nn of inpos the dt tricyclic_antidepressant_class nn including vbg anafranil nnp is vbz going vbg to topos be vb co_administered vbn with inpos another dt drug nn known vbn to topos be vb an dt inhibitor nn of inpos p450 nn 2d6 nn
false	10	30	it prp is vbz desirable jj to topos monitor vb tca nn plasma nn levels nns whenever wrb an dt agent nn of inpos the dt tricyclic_antidepressant_class nn including vbg anafranil nn is vbz going vbg to topos be vb co_administered vbn with inpos another dt drug nn known vbn to topos be vb an dt inhibitor nn of inpos p450 nn 2d6 nn
false	24	28	it prp is vbz desirable jj to topos monitor vb tcaplasma nn levels nns whenever wrb an dt agent nn of inpos the dt tricyclic_antidepressant_class nn including vbg anafranil nn is vbz going vbg to topos be vb co_administered vbn with inpos another dt drug nn known vbn to topos be vb an dt inhibitor nn of inpos p450 nn 2d6 nn
false	2	44	because inpos anafranil nn is vbz highly rb bound vbn to topos serum nn protein nn the dt administration nn of inpos anafranil nn to topos patients nns taking vbg other jj drugs nns that wdt are vbp highly rb bound vbn to topos warfarin nn may md cause vb an dt increase nn in inpos plasma nn concentrations nns of inpos these dt drugs nns potentially rb resulting vbg in inpos adverse jj effects nns
false	2	44	because inpos anafranil nn is vbz highly rb bound vbn to topos serum nn protein nn the dt administration nn of inpos anafranil nn to topos patients nns taking vbg other jj drugs nns that wdt are vbp highly rb bound vbn to topos digoxin nn may md cause vb an dt increase nn in inpos plasma nn concentrations nns of inpos these dt drugs nns potentially rb resulting vbg in inpos adverse jj effects nns
mechanism	2	44	because inpos anafranil nnp is vbz highly rb bound vbn to topos serum nn protein nn the dt administration nn of inpos anafranil nn to topos patients nns taking vbg other jj drugs nns that wdt are vbp highly rb bound vbn to topos warfarin nn may md cause vb an dt increase nn in inpos plasma nn concentrations nns of inpos these dt drugs nns potentially rb resulting vbg in inpos adverse jj effects nns
mechanism	2	44	because inpos anafranil nnp is vbz highly rb bound vbn to topos serum nn protein nn the dt administration nn of inpos anafranil nn to topos patients nns taking vbg other jj drugs nns that wdt are vbp highly rb bound vbn to topos digoxin nn may md cause vb an dt increase nn in inpos plasma nn concentrations nns of inpos these dt drugs nns potentially rb resulting vbg in inpos adverse jj effects nns
false	0	18	clonazepam nn does vbz not rb appear vb to topos alter vb the dt pharmacokinetics nns of inpos phenytoin nn
false	0	18	clonazepam nn does vbz not rb appear vb to topos alter vb the dt pharmacokinetics nns of inpos carbamazepine nn
false	0	18	clonazepam nn does vbz not rb appear vb to topos alter vb the dt pharmacokinetics nns of inpos phenobarbital nn
false	8	30	literature nn reports nns suggest vbp that inpos ranitidine nn an dt agent nn that wdt decreases vbz stomach nn acidity nn does vbz not rb greatly rb alter vb clonazepam nn pharmacokinetics nns
mechanism	16	34	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	16	38	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn lrb_an dt anticholinergic_agent nn with inpos multiple jj effects nns on inpos the dt gi nn tract nn rrb_to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	16	34	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	34	38	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn lrb_an dt anticholinergic_agent nn with inpos multiple jj effects nns on inpos the dt gi nn tract nn rrb_to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	34	16	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	34	16	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	38	16	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn lrb_an dt anticholinergic_agent nn with inpos multiple jj effects nns on inpos the dt gi nn tract nn rrb_to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	38	16	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn lrb_an dt anticholinergic_agent nn with inpos multiple jj effects nns on inpos the dt gi nn tract nn rrb_to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	38	34	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn lrb_an dt anticholinergic_agent nn with inpos multiple jj effects nns on inpos the dt gi nn tract nn rrb_to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	16	34	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
mechanism	16	34	in inpos a dt study nn in inpos which wdt the dt num cd mg nn clonazepam nn orally rb disintegrating vbg tablet nn was vbd administered vbn with inpos and cc without inpos propantheline nn to topos healthy jj volunteers nns the dt auc nn of inpos clonazepam nn was vbd num cd lower jjr and cc the dt cmax nn of inpos clonazepam nn was vbd num cd lower jjr when wrb the dt orally rb disintegrating vbg tablet nn was vbd given vbn with inpos propantheline nn compared vbn to topos when wrb it prp was vbd given vbn alone rb
false	0	14	fluoxetine nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos clonazepam nn
mechanism	10	14	cytochrome nn p_num nn inducers nns such jj as inpos phenytoin nn induce vbp clonazepam nn metabolism nn causing vbg an dt approximately rb num cd decrease nn in inpos plasma nn clonazepam nn levels nns
false	10	14	cytochrome nn p_num nn inducers nns such jj as inpos phenytoin nn induce vbp clonazepam nn metabolism nn causing vbg an dt approximately rb num cd decrease nn in inpos plasma nn clonazepam nn levels nns
mechanism	10	14	cytochrome nn p_num nn inducers nns such jj as inpos carbamazepine nn induce vbp clonazepam nn metabolism nn causing vbg an dt approximately rb num cd decrease nn in inpos plasma nn clonazepam nn levels nns
false	10	14	cytochrome nn p_num nn inducers nns such jj as inpos carbamazepine nn induce vbp clonazepam nn metabolism nn causing vbg an dt approximately rb num cd decrease nn in inpos plasma nn clonazepam nn levels nns
mechanism	10	14	cytochrome nn p_num nn inducers nns such jj as inpos phenobarbital nn induce vbp clonazepam nn metabolism nn causing vbg an dt approximately rb num cd decrease nn in inpos plasma nn clonazepam nn levels nns
false	10	14	cytochrome nn p_num nn inducers nns such jj as inpos phenobarbital nn induce vbp clonazepam nn metabolism nn causing vbg an dt approximately rb num cd decrease nn in inpos plasma nn clonazepam nn levels nns
false	36	54	although inpos clinical jj studies nns have vbp not rb been vbn performed vbn based vbn on inpos the dt involvement nn of inpos the dt cytochrome nn p_num nn 3a nn family nn in inpos clonazepam nn metabolism nn inhibitors nns of inpos this dt enzyme nn system nn notably rb oral jj antifungal_agents nn should md be vb used vbn cautiously rb in inpos patients nns receiving vbg clonazepam nn
advise	54	36	although inpos clinical jj studies nns have vbp not rb been vbn performed vbn based vbn on inpos the dt involvement nn of inpos the dt cytochrome nn p_num nn 3a nn family nn in inpos clonazepam nn metabolism nn inhibitors nns of inpos this dt enzyme nn system nn notably rb oral jj antifungal_agents nn should md be vb used vbn cautiously rb in inpos patients nns receiving vbg clonazepam nn
effect	10	24	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	24	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos narcotics nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	24	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos barbiturates nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	24	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos nonbarbiturate_hypnotics nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	24	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos antianxiety_agents nn the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	24	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos phenothiazines nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	38	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone nn bbbbb22_classes_of_antipsychotic_agents_eeeee22 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	42	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	44	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
effect	10	24	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos tricyclic_antidepressants nn and cc by inpos other jj anticonvulsant_drugs nns
effect	10	54	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nn
false	24	26	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nns thioxanthene nn and cc butyrophenone nn bbbbb22_classes_of_antipsychotic_agents_eeeee22 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	30	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nns and cc by inpos other jj anticonvulsant_drugs nn
false	24	26	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos narcotics nns thioxanthene nn and cc butyrophenone nn bbbbb22_classes_of_antipsychotic_agents_eeeee22 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	30	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos narcotics nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos narcotics nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos narcotics nns and cc by inpos other jj anticonvulsant_drugs nn
false	24	26	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos barbiturates nns thioxanthene nn and cc butyrophenone nn bbbbb22_classes_of_antipsychotic_agents_eeeee22 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	30	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos barbiturates nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos barbiturates nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos barbiturates nns and cc by inpos other jj anticonvulsant_drugs nn
false	24	26	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos nonbarbiturate_hypnotics nns thioxanthene nn and cc butyrophenone nn bbbbb22_classes_of_antipsychotic_agents_eeeee22 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	30	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos nonbarbiturate_hypnotics nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos nonbarbiturate_hypnotics nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos nonbarbiturate_hypnotics nns and cc by inpos other jj anticonvulsant_drugs nn
false	24	30	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos antianxiety_agents nn the dt phenothiazines nns thioxanthene nn and cc butyrophenone nn bbbbb22_classes_of_antipsychotic_agents_eeeee22 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	34	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos antianxiety_agents nn the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	32	44	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nn the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	24	48	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos antianxiety_agents nn the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nn
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos phenothiazines nns and cc by inpos other jj anticonvulsant_drugs nn
false	38	42	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone nn bbbbbcom_classes_of_antipsychotic_agents_eeeeecom nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	38	46	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone nn bbbbb12_classes_of_antipsychotic_agents_eeeee12 nn monoamine_oxidase_inhibitors nn the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	38	50	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone nn bbbbb12_classes_of_antipsychotic_agents_eeeee12 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nn and cc by inpos other jj anticonvulsant_drugs nns
false	38	58	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone nn bbbbb12_classes_of_antipsychotic_agents_eeeee12 nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nn
false	42	44	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nn the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nns
false	42	48	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nn and cc by inpos other jj anticonvulsant_drugs nns
false	42	56	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nn monoamine_oxidase_inhibitors nns the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nn
false	44	50	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nn and cc by inpos other jj anticonvulsant_drugs nns
false	44	58	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos alcohol nn narcotics nns barbiturates nns nonbarbiturate_hypnotics nns antianxiety_agents nns the dt phenothiazines nns thioxanthene nn and cc butyrophenone_classes_of_antipsychotic_agents nns monoamine_oxidase_inhibitors nn and cc the dt tricyclic_antidepressants nns and cc by inpos other jj anticonvulsant_drugs nn
false	24	32	the dt cns_depressant jj action nn of inpos the dt benzodiazepine_class nn of inpos drugs nns may md be vb potentiated vbn by inpos tricyclic_antidepressants nn and cc by inpos other jj anticonvulsant_drugs nn
effect	10	18	tablet nn if inpos a dt patient nn receiving vbg clonidine_hydrochloride nn is vbz also rb taking vbg tricyclic_antidepressants nn the dt effect nn of inpos clonidine nn may md be vb reduced vbn thus rb necessitating vbg an dt increase nn in inpos dosage nn
false	18	10	tablet nn if inpos a dt patient nn receiving vbg clonidine_hydrochloride nn is vbz also rb taking vbg tricyclic_antidepressants nn the dt effect nn of inpos clonidine nn may md be vb reduced vbn thus rb necessitating vbg an dt increase nn in inpos dosage nn
effect	0	14	clonidine_hydrochloride nn may md enhance vb the dt cns_depressive jj effects nns of inpos alcohol nns
effect	0	14	clonidine_hydrochloride nn may md enhance vb the dt cns_depressive jj effects nns of inpos barbiturates nns
effect	0	14	clonidine_hydrochloride nn may md enhance vb the dt cns_depressive jj effects nns of inpos sedatives nn
effect	0	8	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos alcohol nn barbiturates nns other jj sedating_drugs nns
false	0	8	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos alcohol nn barbiturates nns other jj sedating_drugs nns
false	0	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos alcohol nns
false	0	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos barbiturates nns
false	0	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos sedating_drugs nn
false	8	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos alcohol nns
false	8	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos barbiturates nns
false	8	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos sedating_drugs nn
effect	8	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos alcohol nns
effect	8	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos barbiturates nns
effect	8	44	amitriptyline nn in inpos combination nn with inpos clonidine nn enhances vbz the dt manifestation nn of inpos corneal jj lesions nns in inpos rats nns epidural jj injection nn clonidine nn may md potentiate vb the dt cns_depressive jj effect nn of inpos sedating_drugs nn
effect	0	14	narcotic_analgesics nn may md potentiate vb the dt hypotensive jj effects nns of inpos clonidine nn
effect	0	14	tricyclic_antidepressants nn may md antagonize vb the dt hypotensive jj effects nns of inpos clonidine nn
false	6	10	the dt effects nns of inpos tricyclic_antidepressants nn on inpos clonidine nn s vbz analgesic jj actions nns are vbp not rb known vbn
effect	0	16	b_blockers nn may md exacerbate vb the dt hypertensive jj response nn seen vbn with inpos clonidine nn withdrawl nn
advise	40	64	also rb due jj to topos the dt potential nn for inpos additive jj effects nns such jj as inpos bradycardia nn and cc av nn block nn caution nn is vbz warranted vbn in inpos patients nns receiving vbg clonidine nn with inpos agents nns known vbn to topos affect vb sinus nn node nn function nn or cc av nn nodal jj digitalis nn
advise	40	64	also rb due jj to topos the dt potential nn for inpos additive jj effects nns such jj as inpos bradycardia nn and cc av nn block nn caution nn is vbz warranted vbn in inpos patients nns receiving vbg clonidine nn with inpos agents nns known vbn to topos affect vb sinus nn node nn function nn or cc av nn nodal jj calcium_channel_blockers nn
advise	40	64	also rb due jj to topos the dt potential nn for inpos additive jj effects nns such jj as inpos bradycardia nn and cc av nn block nn caution nn is vbz warranted vbn in inpos patients nns receiving vbg clonidine nn with inpos agents nns known vbn to topos affect vb sinus nn node nn function nn or cc av nn nodal jj b_blockers nn
effect	34	40	there ex is vbz num cd reported vbn case nn of inpos a dt patient nn with inpos acute jj delirium nn associated vbn with inpos the dt simultaneous jj use nn of inpos fluphenazine nn and cc oral jj clonidine nn
effect	2	24	epidural jj clonidine nn may md prolong vb the dt duration nn of inpos pharmacologic jj effects nns of inpos epidural jj local jj anesthetics nn including vbg both cc sensory jj and cc motor nn blockade nn
effect	8	20	animal nn experience nn indicates vbz that inpos clorazepate_dipotassium nn prolongs vbz the dt sleeping nn time nn after inpos hexobarbital nn or cc after inpos ethyl_alcohol nn increases vbz the dt inhibitory jj effects nns of inpos chlorpromazine nn but cc does vbz not rb exhibit vb monoamine nn oxidase nn inhibition nn
effect	8	26	animal nn experience nn indicates vbz that inpos clorazepate_dipotassium nn prolongs vbz the dt sleeping nn time nn after inpos hexobarbital nn or cc after inpos ethyl_alcohol nn increases vbz the dt inhibitory jj effects nns of inpos chlorpromazine nn but cc does vbz not rb exhibit vb monoamine nn oxidase nn inhibition nn
effect	8	38	animal nn experience nn indicates vbz that inpos clorazepate_dipotassium nn prolongs vbz the dt sleeping nn time nn after inpos hexobarbital nn or cc after inpos ethyl_alcohol nn increases vbz the dt inhibitory jj effects nns of inpos chlorpromazine nn but cc does vbz not rb exhibit vb monoamine nn oxidase nn inhibition nn
false	20	26	animal nn experience nn indicates vbz that inpos clorazepate_dipotassium nn prolongs vbz the dt sleeping nn time nn after inpos hexobarbital nn or cc after inpos ethyl_alcohol nn increases vbz the dt inhibitory jj effects nns of inpos chlorpromazine nn but cc does vbz not rb exhibit vb monoamine nn oxidase nn inhibition nn
false	20	38	animal nn experience nn indicates vbz that inpos clorazepate_dipotassium nn prolongs vbz the dt sleeping nn time nn after inpos hexobarbital nn or cc after inpos ethyl_alcohol nn increases vbz the dt inhibitory jj effects nns of inpos chlorpromazine nn but cc does vbz not rb exhibit vb monoamine nn oxidase nn inhibition nn
false	26	38	animal nn experience nn indicates vbz that inpos clorazepate_dipotassium nn prolongs vbz the dt sleeping nn time nn after inpos hexobarbital nn or cc after inpos ethyl_alcohol nn increases vbz the dt inhibitory jj effects nns of inpos chlorpromazine nn but cc does vbz not rb exhibit vb monoamine nn oxidase nn inhibition nn
effect	8	18	the dt actions nns of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos barbiturates nns
effect	8	18	the dt actions nns of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos narcotics nns
effect	8	18	the dt actions nns of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos phenothiazines nns
effect	8	18	the dt actions nns of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos monoamine_oxidase_inhibitors nns
effect	8	18	the dt actions nns of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos antidepressants nn
false	20	42	in inpos bioavailability nn studies nns with inpos normal jj subjects nns the dt concurrent jj administration nn of inpos antacids nn at inpos therapeutic jj levels nns did vbd not rb significantly rb influence vb the dt bioavailability nn of inpos tranxene nn tablets nns
effect	12	38	given vbn the dt primary jj cns nn effects nns of inpos clozapine nn caution nn is vbz advised vbn in inpos using vbg it prp concomitantly rb with inpos other jj cns_active jj drugs nns or cc alcohol nn
false	18	24	similar jj events nns have vbp been vbn reported vbn in inpos patients nns taking vbg other jj psychotropic_drugs nn or cc even rb clozapine nn by inpos itself prp
false	24	48	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos clozapine nns caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
false	24	56	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos clozapine nns caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
false	24	34	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos benzodiazepines nns caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
false	24	56	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos benzodiazepines nns caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
false	24	34	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos psychotropics nn caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
false	24	48	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos psychotropics nn caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
false	24	56	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos psychotropics nn caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
advise	24	26	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos clozapine nn benzodiazepines nns other jj psychotropics nns caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
advise	24	62	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos clozapine nn benzodiazepines nns other jj psychotropics nns caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
false	26	62	although inpos it prp has vbz not rb been vbn established vbn that inpos there ex is vbz an dt interaction nn between inpos clozapine nn benzodiazepines nns other jj psychotropics nns caution nn is vbz advised vbn when wrb clozapine nn is vbz initiated vbn in inpos patients nns taking vbg a dt benzodiazepine nn or cc any dt other jj psychotropic_drug nn
effect	0	14	clozapine nn may md potentiate vb the dt hypotensive jj effects nns of inpos antihypertensive_drugs nn and cc the dt anticholinergic jj effects nns of inpos atropine_type jj drugs nns
effect	0	26	clozapine nn may md potentiate vb the dt hypotensive jj effects nns of inpos antihypertensive_drugs nns and cc the dt anticholinergic jj effects nns of inpos atropine nn type jj drugs nns
false	14	26	clozapine nn may md potentiate vb the dt hypotensive jj effects nns of inpos antihypertensive_drugs nn and cc the dt anticholinergic jj effects nns of inpos atropine nn type jj drugs nns
mechanism	0	6	phenytoin nn may md decrease vb clozapine nn plasma nn levels nns resulting vbg in inpos a dt decrease nn in inpos effectiveness nn of inpos a dt previously rb effective jj clozapine nn dose nn
false	0	6	phenytoin nn may md decrease vb clozapine nn plasma nn levels nns resulting vbg in inpos a dt decrease nn in inpos effectiveness nn of inpos a dt previously rb effective jj clozapine nn dose nn
mechanism	0	6	nicotine nn may md decrease vb clozapine nn plasma nn levels nns resulting vbg in inpos a dt decrease nn in inpos effectiveness nn of inpos a dt previously rb effective jj clozapine nn dose nn
false	0	6	nicotine nn may md decrease vb clozapine nn plasma nn levels nns resulting vbg in inpos a dt decrease nn in inpos effectiveness nn of inpos a dt previously rb effective jj clozapine nn dose nn
mechanism	0	6	rifampin nn may md decrease vb clozapine nn plasma nn levels nns resulting vbg in inpos a dt decrease nn in inpos effectiveness nn of inpos a dt previously rb effective jj clozapine nn dose nn
false	0	6	rifampin nn may md decrease vb clozapine nn plasma nn levels nns resulting vbg in inpos a dt decrease nn in inpos effectiveness nn of inpos a dt previously rb effective jj clozapine nn dose nn
mechanism	0	12	cimetidine nn may md increase vb plasma nn levels nns of inpos clozapine nn potentially rb resulting vbg in inpos adverse jj effects nns
mechanism	0	12	caffeine nn may md increase vb plasma nn levels nns of inpos clozapine nn potentially rb resulting vbg in inpos adverse jj effects nns
mechanism	0	12	erythromycin nn may md increase vb plasma nn levels nns of inpos clozapine nn potentially rb resulting vbg in inpos adverse jj effects nns
advise	8	12	although inpos concomitant jj use nn of inpos clozapine nn and cc carbamazepine nn is vbz not rb recommended vbn it prp should md be vb noted vbn that inpos discontinuation nn of inpos concomitant jj carbamazepine nn administration nn may md result vb in inpos an dt increase nn in inpos clozapine nn plasma nn levels nns
false	8	12	although inpos concomitant jj use nn of inpos clozapine nn and cc carbamazepine nn is vbz not rb recommended vbn it prp should md be vb noted vbn that inpos discontinuation nn of inpos concomitant jj carbamazepine nn administration nn may md result vb in inpos an dt increase nn in inpos clozapine nn plasma nn levels nns
false	12	8	although inpos concomitant jj use nn of inpos clozapine nn and cc carbamazepine nn is vbz not rb recommended vbn it prp should md be vb noted vbn that inpos discontinuation nn of inpos concomitant jj carbamazepine nn administration nn may md result vb in inpos an dt increase nn in inpos clozapine nn plasma nn levels nns
mechanism	12	8	although inpos concomitant jj use nn of inpos clozapine nn and cc carbamazepine nn is vbz not rb recommended vbn it prp should md be vb noted vbn that inpos discontinuation nn of inpos concomitant jj carbamazepine nn administration nn may md result vb in inpos an dt increase nn in inpos clozapine nn plasma nn levels nns
false	16	26	in inpos a dt study nn of inpos schizophrenic jj patients nns who wp received vbd clozapine nn under inpos steady jj state nn conditions nns fluvoxamine nn or cc paroxetine nn was vbd added vbn in inpos num cd and cc num cd patients nns respectively rb
false	16	30	in inpos a dt study nn of inpos schizophrenic jj patients nns who wp received vbd clozapine nn under inpos steady jj state nn conditions nns fluvoxamine nn or cc paroxetine nn was vbd added vbn in inpos num cd and cc num cd patients nns respectively rb
false	26	30	in inpos a dt study nn of inpos schizophrenic jj patients nns who wp received vbd clozapine nn under inpos steady jj state nn conditions nns fluvoxamine nn or cc paroxetine nn was vbd added vbn in inpos num cd and cc num cd patients nns respectively rb
false	18	38	after inpos num cd days nns of inpos co_administration nn mean jj trough nn concentrations nns of inpos clozapine nn and cc its prp metabolites nns n_desmethylclozapine nn and cc clozapine_n_oxide nn were vbd elevated vbn with inpos fluvoxamine nn by inpos about rb three_fold jj compared vbn to topos baseline nn concentrations nns
false	26	30	after inpos num cd days nns of inpos co_administration nn mean jj trough nn concentrations nns of inpos clozapine nn and cc its prp metabolites nns n_desmethylclozapine nn and cc clozapine_n_oxide nn were vbd elevated vbn with inpos fluvoxamine nn by inpos about rb three_fold jj compared vbn to topos baseline nn concentrations nns
false	26	38	after inpos num cd days nns of inpos co_administration nn mean jj trough nn concentrations nns of inpos clozapine nn and cc its prp metabolites nns n_desmethylclozapine nn and cc clozapine_n_oxide nn were vbd elevated vbn with inpos fluvoxamine nn by inpos about rb three_fold jj compared vbn to topos baseline nn concentrations nns
false	30	38	after inpos num cd days nns of inpos co_administration nn mean jj trough nn concentrations nns of inpos clozapine nn and cc its prp metabolites nns n_desmethylclozapine nn and cc clozapine_n_oxide nn were vbd elevated vbn with inpos fluvoxamine nn by inpos about rb three_fold jj compared vbn to topos baseline nn concentrations nns
mechanism	0	18	paroxetine nn produced vbd only rb minor jj changes nns in inpos the dt levels nns of inpos clozapine nn and cc its prp metabolites nns
false	16	34	however rb other jj published vbn reports nns describe vbp modest jj elevations nns of inpos clozapine nn and cc metabolite nn concentrations nns when wrb clozapine nn was vbd taken vbn with inpos paroxetine nn
false	16	34	however rb other jj published vbn reports nns describe vbp modest jj elevations nns of inpos clozapine nn and cc metabolite nn concentrations nns when wrb clozapine nn was vbd taken vbn with inpos fluoxetine nn
false	16	34	however rb other jj published vbn reports nns describe vbp modest jj elevations nns of inpos clozapine nn and cc metabolite nn concentrations nns when wrb clozapine nn was vbd taken vbn with inpos sertraline nn
mechanism	16	34	however rb other jj published vbn reports nns describe vbp modest jj elevations nns of inpos clozapine nn and cc metabolite nn concentrations nns when wrb clozapine nn was vbd taken vbn with inpos paroxetine nn
mechanism	16	34	however rb other jj published vbn reports nns describe vbp modest jj elevations nns of inpos clozapine nn and cc metabolite nn concentrations nns when wrb clozapine nn was vbd taken vbn with inpos fluoxetine nn
mechanism	16	34	however rb other jj published vbn reports nns describe vbp modest jj elevations nns of inpos clozapine nn and cc metabolite nn concentrations nns when wrb clozapine nn was vbd taken vbn with inpos sertraline nn
advise	32	48	therefore rb such jj combined jj treatment nn should md be vb approached vbn with inpos caution nn and cc patients nns should md be vb monitored vbn closely rb when wrb clozapine nn is vbz combined vbn with inpos these dt drugs nns particularly rb with inpos fluvoxamine nn
false	24	26	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nns and cc clozapine nn
false	24	30	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nn and cc clozapine nn
false	24	34	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nns and cc clozapine nn
false	26	30	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nn and cc clozapine nn
false	26	34	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nns and cc clozapine nn
false	30	34	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nn and cc clozapine nn
advise	6	28	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	30	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns phenothiazines nns or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	28	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg carbamazepine nns or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	30	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns type_1c_antiarrhythmics nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	30	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns propafenone nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	30	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns flecainide nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	30	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns encainide nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	44	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns phenothiazines nns carbamazepine nn type_1c_antiarrhythmics nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	28	38	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	30	40	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns phenothiazines nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	28	38	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg carbamazepine nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	30	40	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns type_1c_antiarrhythmics nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	30	40	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns propafenone nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	30	40	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns flecainide nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	30	40	therefore rb co_administration nn of inpos clozapine nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isozyme nn including vbg antidepressants nns encainide nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	14	18	the dt risk nn of inpos a dt potential jj interaction nn between inpos novoseven nn and cc coagulation_factor nn concentrates nns has vbz not rb been vbn adequately rb evaluated vbn in inpos preclinical jj or cc clinical jj studies nns
false	48	52	although inpos the dt specific jj drug nn interaction nn was vbd not rb studied vbn in inpos a dt clinical jj trial nn there ex have vbp been vbn more jjr than inpos num cd episodes nns of inpos concomitant jj use nn of inpos antifibrinolytic jj tranexamic_acid nn and cc novoseven nn
false	48	52	although inpos the dt specific jj drug nn interaction nn was vbd not rb studied vbn in inpos a dt clinical jj trial nn there ex have vbp been vbn more jjr than inpos num cd episodes nns of inpos concomitant jj use nn of inpos antifibrinolytic jj aminocaproic_acid nn and cc novoseven nn
effect	0	10	codeine nn in inpos combination nn with inpos other jj narcotic_analgesics nns other jj cns_depressants nnps has vbz additive jj depressant jj effects nns
effect	0	10	codeine nn in inpos combination nn with inpos other jj anesthetics nns other jj cns_depressants nnps has vbz additive jj depressant jj effects nns
effect	0	10	codeine nn in inpos combination nn with inpos other jj phenothiazines nns other jj cns_depressants nnps has vbz additive jj depressant jj effects nns
effect	0	10	codeine nn in inpos combination nn with inpos other jj tranquilizers nns other jj cns_depressants nnps has vbz additive jj depressant jj effects nns
effect	0	10	codeine nn in inpos combination nn with inpos other jj sedative_hypnotics nn other jj cns_depressants nnps has vbz additive jj depressant jj effects nns
effect	0	24	codeine nn in inpos combination nn with inpos other jj narcotic_analgesics nns general jj anesthetics nns phenothiazines nns tranquilizers nns sedative_hypnotics nns other jj cns_depressants nn has vbz additive jj depressant jj effects nns
effect	0	24	codeine nn in inpos combination nn with inpos other jj narcotic_analgesics nns general jj anesthetics nns phenothiazines nns tranquilizers nns sedative_hypnotics nns other jj alcohol nn has vbz additive jj depressant jj effects nns
false	10	14	codeine nn in inpos combination nn with inpos other jj narcotic_analgesics nns other jj cns_depressants nn has vbz additive jj depressant jj effects nns
false	10	14	codeine nn in inpos combination nn with inpos other jj narcotic_analgesics nns other jj alcohol nn has vbz additive jj depressant jj effects nns
false	10	14	codeine nn in inpos combination nn with inpos other jj anesthetics nns other jj cns_depressants nn has vbz additive jj depressant jj effects nns
false	10	14	codeine nn in inpos combination nn with inpos other jj anesthetics nns other jj alcohol nn has vbz additive jj depressant jj effects nns
false	16	20	codeine nn in inpos combination nn with inpos other jj narcotic_analgesics nns general jj anesthetics nns phenothiazines nns other jj cns_depressants nn has vbz additive jj depressant jj effects nns
false	16	20	codeine nn in inpos combination nn with inpos other jj narcotic_analgesics nns general jj anesthetics nns phenothiazines nns other jj alcohol nn has vbz additive jj depressant jj effects nns
false	10	14	codeine nn in inpos combination nn with inpos other jj tranquilizers nns other jj cns_depressants nn has vbz additive jj depressant jj effects nns
false	10	14	codeine nn in inpos combination nn with inpos other jj tranquilizers nns other jj alcohol nn has vbz additive jj depressant jj effects nns
false	4	8	codeine nn in inpos sedative_hypnotics nn other jj cns_depressants nn has vbz additive jj depressant jj effects nns
false	4	8	codeine nn in inpos sedative_hypnotics nn other jj alcohol nn has vbz additive jj depressant jj effects nns
mechanism	0	8	colchicine nn is vbz inhibited vbn by inpos acidifying_agents nn
mechanism	6	14	the dt action nn of inpos colchicine nn is vbz potentiated vbn by inpos alkalinizing_agents nn
effect	0	12	colchicine nn may md increase vb sensitivity nn to topos the dt cns_depressants nn
effect	4	14	response nn to topos sympathomimetic_agents nn may md be vb enhanced vbn by inpos colchicine nn
false	0	24	welchol nn was vbd found vbn to topos have vb no dt significant jj effect nn on inpos the dt bioavailability nn of inpos digoxin nn
false	0	24	welchol nn was vbd found vbn to topos have vb no dt significant jj effect nn on inpos the dt bioavailability nn of inpos lovastatin nn
false	0	24	welchol nn was vbd found vbn to topos have vb no dt significant jj effect nn on inpos the dt bioavailability nn of inpos metoprolol nn
false	0	24	welchol nn was vbd found vbn to topos have vb no dt significant jj effect nn on inpos the dt bioavailability nn of inpos quinidine nn
false	0	24	welchol nn was vbd found vbn to topos have vb no dt significant jj effect nn on inpos the dt bioavailability nn of inpos valproic_acid nn
false	0	24	welchol nn was vbd found vbn to topos have vb no dt significant jj effect nn on inpos the dt bioavailability nn of inpos warfarin nn
mechanism	0	16	welchol nn decreased vbd the dt cmax nn and cc auc nn of inpos sustained_release nn verapamil nn by inpos approximately rb num cd and cc num cd respectively rb
mechanism	0	16	welchol nn decreased vbd the dt cmax nn and cc auc nn of inpos sustained_release nn calan_sr nn by inpos approximately rb num cd and cc num cd respectively rb
false	10	14	in inpos clinical jj studies nns coadministration nn of inpos welchol nn with inpos atorvastatin nn did vbd not rb interfere vb with inpos the dt lipid_lowering nn activity nn of inpos the dt hmg_coa_reductase_inhibitor nn
false	10	14	in inpos clinical jj studies nns coadministration nn of inpos welchol nn with inpos lovastatin nn did vbd not rb interfere vb with inpos the dt lipid_lowering nn activity nn of inpos the dt hmg_coa_reductase_inhibitor nn
false	10	14	in inpos clinical jj studies nns coadministration nn of inpos welchol nn with inpos simvastatin nn did vbd not rb interfere vb with inpos the dt lipid_lowering nn activity nn of inpos the dt hmg_coa_reductase_inhibitor nn
false	10	38	in inpos clinical jj studies nns coadministration nn of inpos welchol nn with inpos atorvastatin nn lovastatin nn simvastatin nn did vbd not rb interfere vb with inpos the dt lipid_lowering nn activity nn of inpos the dt hmg_coa_reductase_inhibitor nn
false	14	34	in inpos clinical jj studies nns coadministration nn of inpos welchol nn with inpos atorvastatin nn did vbd not rb interfere vb with inpos the dt lipid_lowering nn activity nn of inpos the dt hmg_coa_reductase_inhibitor nn
false	14	34	in inpos clinical jj studies nns coadministration nn of inpos welchol nn with inpos lovastatin nn did vbd not rb interfere vb with inpos the dt lipid_lowering nn activity nn of inpos the dt hmg_coa_reductase_inhibitor nn
false	14	34	in inpos clinical jj studies nns coadministration nn of inpos welchol nn with inpos simvastatin nn did vbd not rb interfere vb with inpos the dt lipid_lowering nn activity nn of inpos the dt hmg_coa_reductase_inhibitor nn
false	2	8	since inpos colestipol_hydrochloride nn is vbz an dt anion_exchange_resin nn it prp may md have vb a dt strong jj affinity nn for inpos anions nns other jj than inpos the dt bile nn acids nns
mechanism	6	22	repeated vbn doses nns of inpos colestipol_hydrochloride nn given vbn prior jj to topos a dt single jj dose nn of inpos propranolol nn in inpos human jj trials nns have vbp been vbn reported vbn to topos decrease vb propranolol nn absorption nn
false	6	22	repeated vbn doses nns of inpos colestipol_hydrochloride nn given vbn prior jj to topos a dt single jj dose nn of inpos propranolol nn in inpos human jj trials nns have vbp been vbn reported vbn to topos decrease vb propranolol nn absorption nn
false	22	48	however rb in inpos a dt follow_up jj study nn in inpos normal jj subjects nns single_dose jj administration nn of inpos colestipol_hydrochloride nn for inpos num cd days nns of inpos both dt agents nns did vbd not rb affect vb the dt extent nn of inpos propranolol nn absorption nn but cc had vbd a dt small jj yet rb statistically rb significant jj effect nn on inpos its prp rate nn of inpos absorption nn
advise	6	16	therefore rb patients nns on inpos propranolol nn should md be vb observed vbn when wrb colestid nn tablets nns are vbp either rb added vbn or cc deleted vbn from inpos a dt therapeutic jj regimen nn
mechanism	16	46	studies nns in inpos humans nns show vbp that inpos the dt absorption nn of inpos chlorothiazide nn as inpos reflected vbn in inpos urinary jj excretion nn is vbz markedly rb decreased vbn even rb when wrb administered vbn num cd hour nn before inpos colestipol_hydrochloride nn
mechanism	6	22	the dt absorption nn of inpos tetracycline nn was vbd significantly rb decreased vbn when wrb given vbn simultaneously rb with inpos colestipol_hydrochloride nn
mechanism	6	22	the dt absorption nn of inpos furosemide nn was vbd significantly rb decreased vbn when wrb given vbn simultaneously rb with inpos colestipol_hydrochloride nn
mechanism	6	22	the dt absorption nn of inpos penicillin_g nn was vbd significantly rb decreased vbn when wrb given vbn simultaneously rb with inpos colestipol_hydrochloride nn
mechanism	6	22	the dt absorption nn of inpos hydrochlorothiazide nn was vbd significantly rb decreased vbn when wrb given vbn simultaneously rb with inpos colestipol_hydrochloride nn
mechanism	6	22	the dt absorption nn of inpos gemfibrozil nn was vbd significantly rb decreased vbn when wrb given vbn simultaneously rb with inpos colestipol_hydrochloride nn
false	22	40	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clindamycin nn clofibrate nn methyldopa nn nicotinic_acid nn tolbutamide nn phenytoin nn or cc warfarin nn
false	22	40	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns clindamycin nn phenytoin nn or cc warfarin nn
false	22	40	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns clofibrate nn phenytoin nn or cc warfarin nn
false	22	40	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns methyldopa nn phenytoin nn or cc warfarin nn
false	22	40	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns nicotinic_acid nn phenytoin nn or cc warfarin nn
false	22	40	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns niacin nn phenytoin nn or cc warfarin nn
false	22	40	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns tolbutamide nn phenytoin nn or cc warfarin nn
false	22	52	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clindamycin nn clofibrate nn methyldopa nn nicotinic_acid nn tolbutamide nn phenytoin nn or cc warfarin nn
false	22	56	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clindamycin nn clofibrate nn methyldopa nn nicotinic_acid nn tolbutamide nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clindamycin nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clofibrate nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn methyldopa nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn nicotinic_acid nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn niacin nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn tolbutamide nn phenytoin nn or cc warfarin nn
false	40	52	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clindamycin nn clofibrate nn methyldopa nn nicotinic_acid nn tolbutamide nn phenytoin nn or cc warfarin nn
false	40	56	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clindamycin nn clofibrate nn methyldopa nn nicotinic_acid nn tolbutamide nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns clindamycin nn phenytoin nn or cc warfarin nn
false	40	46	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns clindamycin nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns clofibrate nn phenytoin nn or cc warfarin nn
false	40	46	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns clofibrate nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns methyldopa nn phenytoin nn or cc warfarin nn
false	40	46	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns methyldopa nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns nicotinic_acid nn phenytoin nn or cc warfarin nn
false	40	46	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns nicotinic_acid nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns niacin nn phenytoin nn or cc warfarin nn
false	40	46	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns niacin nn phenytoin nn or cc warfarin nn
false	40	42	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns tolbutamide nn phenytoin nn or cc warfarin nn
false	40	46	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns tolbutamide nn phenytoin nn or cc warfarin nn
false	52	56	no dt depressant jj effect nn on inpos blood nn levels nns in inpos humans nns was vbd noted vbn when wrb colestipol_hydrochloride nn was vbd administered vbn with inpos any dt of inpos the dt following vbg drugs nns aspirin nn clindamycin nn clofibrate nn methyldopa nn nicotinic_acid nn tolbutamide nn phenytoin nn or cc warfarin nn
effect	12	32	particular jj caution nn should md be vb observed vbn with inpos digitalis_preparations nn since inpos there ex are vbp conflicting vbg results nns for inpos the dt effect nn of inpos colestipol_hydrochloride nn on inpos the dt availability nn of inpos digoxin nn and cc digitoxin nn
false	12	42	particular jj caution nn should md be vb observed vbn with inpos digitalis_preparations nn since inpos there ex are vbp conflicting vbg results nns for inpos the dt effect nn of inpos colestipol_hydrochloride nn on inpos the dt availability nn of inpos digoxin nn and cc digitoxin nn
false	12	46	particular jj caution nn should md be vb observed vbn with inpos digitalis_preparations nn since inpos there ex are vbp conflicting vbg results nns for inpos the dt effect nn of inpos colestipol_hydrochloride nn on inpos the dt availability nn of inpos digoxin nn and cc digitoxin nn
mechanism	32	42	particular jj caution nn should md be vb observed vbn with inpos digitalis_preparations nns since inpos there ex are vbp conflicting vbg results nns for inpos the dt effect nn of inpos colestipol_hydrochloride nn on inpos the dt availability nn of inpos digoxin nn and cc digitoxin nn
mechanism	32	46	particular jj caution nn should md be vb observed vbn with inpos digitalis_preparations nns since inpos there ex are vbp conflicting vbg results nns for inpos the dt effect nn of inpos colestipol_hydrochloride nn on inpos the dt availability nn of inpos digoxin nn and cc digitoxin nn
false	42	46	particular jj caution nn should md be vb observed vbn with inpos digitalis_preparations nns since inpos there ex are vbp conflicting vbg results nns for inpos the dt effect nn of inpos colestipol_hydrochloride nn on inpos the dt availability nn of inpos digoxin nn and cc digitoxin nn
false	2	38	discontinuing vbg colestipol_hydrochloride nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn that wdt is vbz significantly rb bound vbn to topos the dt resin nn has vbz been vbn titrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg colestipol_hydrochloride nn
false	38	2	discontinuing vbg colestipol_hydrochloride nn could md pose vb a dt hazard nn to topos health nn if inpos a dt potentially rb toxic jj drug nn that wdt is vbz significantly rb bound vbn to topos the dt resin nn has vbz been vbn titrated vbn to topos a dt maintenance nn level nn while inpos the dt patient nn was vbd taking vbg colestipol_hydrochloride nn
mechanism	0	18	bile_acid_binding_resins nn may md also rb interfere vb with inpos the dt absorption nn of inpos oral jj phosphate nn supplements nns and cc hydrocortisone nn
mechanism	0	24	bile_acid_binding_resins nn may md also rb interfere vb with inpos the dt absorption nn of inpos oral jj phosphate nn supplements nns and cc hydrocortisone nn
false	18	24	bile_acid_binding_resins nns may md also rb interfere vb with inpos the dt absorption nn of inpos oral jj phosphate nn supplements nns and cc hydrocortisone nn
false	0	10	curariform_muscle_relaxants nn and cc other jj drugs nns including vbg succinylcholine nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
false	0	10	curariform_muscle_relaxants nn and cc other jj drugs nns including vbg gallamine nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
false	0	10	curariform_muscle_relaxants nn and cc other jj drugs nns including vbg decamethonium nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
false	0	10	curariform_muscle_relaxants nn and cc other jj drugs nns including vbg sodium_citrate nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
effect	0	54	curariform_muscle_relaxants nn and cc other jj drugs nns including vbg ether nn succinylcholine nn gallamine nn decamethonium nn sodium_citrate nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nn parenteral jj
false	0	10	tubocurarine nn and cc other jj drugs nns including vbg succinylcholine nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
false	0	10	tubocurarine nn and cc other jj drugs nns including vbg gallamine nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
false	0	10	tubocurarine nn and cc other jj drugs nns including vbg decamethonium nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
false	0	10	tubocurarine nn and cc other jj drugs nns including vbg sodium_citrate nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nnp parenteral nnp
effect	0	54	tubocurarine nn and cc other jj drugs nns including vbg ether nn succinylcholine nn gallamine nn decamethonium nn sodium_citrate nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nn parenteral jj
effect	10	46	curariform_muscle_relaxants nns and cc other jj drugs nns including vbg succinylcholine nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nn parenteral jj
effect	10	46	curariform_muscle_relaxants nns and cc other jj drugs nns including vbg gallamine nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nn parenteral jj
effect	10	46	curariform_muscle_relaxants nns and cc other jj drugs nns including vbg decamethonium nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nn parenteral jj
effect	10	46	curariform_muscle_relaxants nns and cc other jj drugs nns including vbg sodium_citrate nn potentiate vbp the dt neuromuscular jj blocking nn effect nn and cc should md be vb used vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos coly_mycin_m nn parenteral jj
effect	0	12	sodium_cephalothin nn may md enhance vb the dt nephrotoxicity nn of inpos coly_mycin_m nn parenteral jj
advise	8	12	the dt concomitant jj use nn of inpos sodium_cephalothin nn and cc coly_mycin_m nn parenteral nnp should md be vb avoided vbn
false	0	18	digoxin nn coadministration nn of inpos digoxin nn a dt p_glycoprotein nn substrate nn with inpos oral jj conivaptan nn resulted vbd in inpos a dt reduction nn in inpos clearance nn and cc an dt increase nn in inpos digoxin nn cmax nn and cc auc nn values nns
mechanism	0	18	digoxin nn coadministration nn of inpos digoxin nn a dt p_glycoprotein nn substrate nn with inpos oral jj conivaptan nn resulted vbd in inpos a dt reduction nn in inpos clearance nn and cc an dt increase nn in inpos digoxin nn cmax nn and cc auc nn values nns
false	18	0	digoxin nn coadministration nn of inpos digoxin nn a dt p_glycoprotein nn substrate nn with inpos oral jj conivaptan nn resulted vbd in inpos a dt reduction nn in inpos clearance nn and cc an dt increase nn in inpos digoxin nn cmax nn and cc auc nn values nns
mechanism	4	12	therefore rb if inpos digoxin nn is vbz administered vbn with inpos vaprisol nn the dt clinician nn should md be vb alert jj to topos the dt possibility nn of inpos increases nns in inpos digoxin nn levels nns
false	12	4	therefore rb if inpos digoxin nn is vbz administered vbn with inpos vaprisol nn the dt clinician nn should md be vb alert jj to topos the dt possibility nn of inpos increases nns in inpos digoxin nn levels nns
false	34	38	other jj binding nn proteins nns may md be vb elevated vbn in inpos serum nn sex nn hormone nn binding nn globulin nn rrb_leading vbg to topos increased vbn total jj circulating vbg corticosteroids nn and cc sex_steroids nn respectively rb
effect	0	16	corticotropin nn may md accentuate vb the dt electrolyte nn loss nn associated vbn with inpos diuretic nn therapy nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenobarbital nn may md increase vb the dt clearance nn of inpos corticosteroids nn and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
advise	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenobarbital nn may md increase vb the dt clearance nn of inpos corticosteroids nns and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenytoin nn may md increase vb the dt clearance nn of inpos corticosteroids nn and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
advise	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos phenytoin nn may md increase vb the dt clearance nn of inpos corticosteroids nns and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
mechanism	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos rifampin nn may md increase vb the dt clearance nn of inpos corticosteroids nn and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
advise	14	26	drugs nns that wdt induce vbp hepatic jj enzymes nns such jj as inpos rifampin nn may md increase vb the dt clearance nn of inpos corticosteroids nns and cc may md require vb increases nns in inpos corticosteroid nn dose nn to topos achieve vb the dt desired vbn response nn
false	6	10	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos corticosteroids nns and cc thus rb decrease vb their prp clearance nn
mechanism	6	22	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos corticosteroids nn and cc thus rb decrease vb their prp clearance nn
mechanism	10	22	drugs nns such jj as inpos troleandomycin nn and cc ketoconazole nn may md inhibit vb the dt metabolism nn of inpos corticosteroids nn and cc thus rb decrease vb their prp clearance nn
effect	0	18	corticosteroids nn may md increase vb the dt clearance nn of inpos chronic jj high jj dose nn aspirin nn
false	10	32	this dt could md lead vb to topos decreased vbn salicylate nn serum nn levels nns or cc increase vb the dt risk nn of inpos salicylate nn toxicity nn when wrb corticosteroid nn is vbz withdrawn vbn
effect	10	32	this dt could md lead vb to topos decreased vbn salicylate nn serum nn levels nns or cc increase vb the dt risk nn of inpos salicylate nn toxicity nn when wrb corticosteroid nn is vbz withdrawn vbn
advise	0	16	aspirin nn should md be vb used vbn cautiously rb in inpos conjunction nn with inpos cortico_steroids nn in inpos patients nns suffering vbg from inpos hypopro_thrombinemia nn
effect	6	12	the dt effect nn of inpos corticosteroids nn on inpos oral jj anticoagulants nn is vbz variable jj
effect	22	32	there ex are vbp reports nns of inpos enhanced vbn as rb well rb as inpos diminished vbn effects nns of inpos anticoagulants nn when wrb given vbn concurrently rb with inpos corticosteroids nn
effect	0	16	corticotropin nn may md accentuate vb the dt electrolyte nn loss nn associated vbn with inpos diuretic nn therapy nn
false	0	4	cromolyn_sodium nn and cc isoproterenol nn were vbd studied vbn following vbg subcutaneous jj injections nns in inpos pregnant jj mice nns
effect	12	22	the dt addition nn of inpos num cd mg_kg_day nn of inpos cromolyn_sodium nn to topos float cd mg_kg_day nn of inpos isoproterenol nn appears vbz to topos have vb increased vbn the dt incidence nn of inpos both dt resorptions nns and cc malformations nns
false	6	10	persons nns taking vbg most jjs antibiotics nn invalidate nn folic_acid nn and cc vitamin_b12 nn diagnostic jj blood nn assays nns
false	6	14	persons nns taking vbg most jjs antibiotics nn invalidate nn folic_acid nn and cc vitamin_b12 nn diagnostic jj blood nn assays nns
false	8	10	persons nns taking vbg most jjs antibiotics nns methotrexate nn pyrimethamine nn invalidate nn folic_acid nn vitamin_b12 nn diagnostic jj blood nn assays nns
false	8	14	persons nns taking vbg most jjs antibiotics nns methotrexate nn pyrimethamine nn invalidate nn folic_acid nn vitamin_b12 nn diagnostic jj blood nn assays nns
false	8	16	persons nns taking vbg most jjs antibiotics nns methotrexate nn pyrimethamine nn invalidate nn folic_acid nn vitamin_b12 nn diagnostic jj blood nn assays nns
false	10	14	persons nns taking vbg most jjs antibiotics nns methotrexate nn pyrimethamine nn invalidate nn folic_acid nn vitamin_b12 nn diagnostic jj blood nn assays nns
false	10	16	persons nns taking vbg most jjs antibiotics nns methotrexate nn pyrimethamine nn invalidate nn folic_acid nn vitamin_b12 nn diagnostic jj blood nn assays nns
false	14	16	persons nns taking vbg most jjs antibiotics nns methotrexate nn pyrimethamine nn invalidate nn folic_acid nn vitamin_b12 nn diagnostic jj blood nn assays nns
false	0	2	colchicine nn para_aminosalicylic_acid nn and cc heavy jj alcohol nn intake nn for inpos longer jjr than inpos num cd weeks nns may md produce vb malabsorption nn of inpos vitamin_b12 nn
false	0	8	colchicine nn para_aminosalicylic_acid jj and cc heavy jj alcohol nn intake nn for inpos longer jjr than inpos num cd weeks nns may md produce vb malabsorption nn of inpos vitamin_b12 nn
mechanism	0	30	colchicine nn para_aminosalicylic_acid jj and cc heavy jj alcohol nn intake nn for inpos longer jjr than inpos num cd weeks nns may md produce vb malabsorption nn of inpos vitamin_b12 nn
false	2	8	colchicine nn para_aminosalicylic_acid nn and cc heavy jj alcohol nn intake nn for inpos longer jjr than inpos num cd weeks nns may md produce vb malabsorption nn of inpos vitamin_b12 nn
mechanism	2	30	colchicine nn para_aminosalicylic_acid nn and cc heavy jj alcohol nn intake nn for inpos longer jjr than inpos num cd weeks nns may md produce vb malabsorption nn of inpos vitamin_b12 nn
mechanism	8	30	colchicine nn para_aminosalicylic_acid jj and cc heavy jj alcohol nn intake nn for inpos longer jjr than inpos num cd weeks nns may md produce vb malabsorption nn of inpos vitamin_b12 nn
int	0	12	flexeril nn may md have vb life_threatening jj interactions nns with inpos mao_inhibitors nn
effect	0	12	flexeril nn may md enhance vb the dt effects nns of inpos alcohol nn barbiturates nns other jj cns_depressants nns
effect	0	14	flexeril nn may md enhance vb the dt effects nns of inpos alcohol nn barbiturates nn other jj cns_depressants nns
effect	0	18	flexeril nn may md enhance vb the dt effects nns of inpos alcohol nn barbiturates nns other jj cns_depressants nn
false	12	14	flexeril nn may md enhance vb the dt effects nns of inpos alcohol nn barbiturates nn other jj cns_depressants nns
false	12	18	flexeril nn may md enhance vb the dt effects nns of inpos alcohol nn barbiturates nns other jj cns_depressants nn
false	14	18	flexeril nn may md enhance vb the dt effects nns of inpos alcohol nn barbiturates nn other jj cns_depressants nn
effect	0	14	tricyclic_antidepressants nn may md block vb the dt antihypertensive jj action nn of inpos guanethidine nn and cc similarly rb acting vbg compounds nns
effect	0	18	tricyclic_antidepressants nn may md enhance vb the dt seizure nn risk nn in inpos patients nns taking vbg tramadol nn
effect	0	16	cyclopentolate nn may md interfere vb with inpos the dt anti_glaucoma jj action nn of inpos carbachol nn or cc pilocarpine nn
effect	0	20	cyclopentolate nn may md interfere vb with inpos the dt anti_glaucoma jj action nn of inpos carbachol nn or cc pilocarpine nn
false	16	20	cyclopentolate nn may md interfere vb with inpos the dt anti_glaucoma jj action nn of inpos carbachol nn or cc pilocarpine nn
mechanism	18	40	the dt rate nn of inpos metabolism nn and cc the dt leukopenic jj activity nn of inpos cyclophosphamide nn reportedly rb are vbp increased vbn by inpos chronic jj administration nn of inpos high jj doses nns of inpos phenobarbital nn
effect	0	32	cyclophosphamide nn treatment nn which wdt causes vbz a dt marked jj and cc persistent jj inhibition nn of inpos cholinesterase nn activity nn potentiates vbz the dt effect nn of inpos succinylcholine_chloride nn
false	6	10	may md interact vb with inpos trecator_sc nn and cc isoniazid nn
false	6	10	may md interact vb with inpos trecator_sc nn and cc nydrazid nn
effect	0	16	mao_inhibitors nn prolong vb and cc intensify vb the dt anticholinergic jj effects nns of inpos antihistamines nn
effect	0	12	antihistamines nn may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw hypnotics nns sedatives nns tranquilizers nns antianxiety_agents nns
effect	0	18	antihistamines nn may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn e.g. fw hypnotics nns sedatives nns tranquilizers nns antianxiety_agents nns
effect	0	22	antihistamines nn may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nns e.g. fw hypnotics nns antianxiety_agents nns
effect	0	20	antihistamines nn may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw sedatives nns
effect	0	20	antihistamines nn may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw tranquilizers nns
effect	0	26	antihistamines nn may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw hypnotics nns sedatives nns tranquilizers nns antianxiety_agents nn
false	12	18	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn e.g. fw hypnotics nns sedatives nns tranquilizers nns antianxiety_agents nns
false	12	22	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nns e.g. fw hypnotics nns antianxiety_agents nns
false	12	20	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw sedatives nns
false	12	20	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw tranquilizers nns
false	12	26	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw hypnotics nns sedatives nns tranquilizers nns antianxiety_agents nn
false	18	22	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn e.g. fw hypnotics nns antianxiety_agents nns
false	18	22	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn e.g. fw sedatives nns
false	18	22	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn e.g. fw tranquilizers nns
false	18	28	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn e.g. fw hypnotics nns sedatives nns tranquilizers nns antianxiety_agents nn
false	22	24	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nns e.g. fw hypnotics nns antianxiety_agents nn
false	22	26	antihistamines nns may md have vb additive jj effects nns with inpos alcohol nn other jj cns_depressants nns e.g. fw hypnotics nns sedatives nn tranquilizers nns antianxiety_agents nn
false	4	24	drug_laboratorytest nnp interactions nns dactinomycin nn may md interfere vb with inpos bioassay nn procedures nns for inpos the dt determination nn of inpos antibacterial_drug nn levels nns
false	4	8	however rb neither cc phenobarbital nn nor cc diazepam nn appears vbz to topos affect vb dantrium nn metabolism nn
false	4	16	however rb neither cc phenobarbital nn nor cc diazepam nn appears vbz to topos affect vb dantrium nn metabolism nn
false	8	16	however rb neither cc phenobarbital nn nor cc diazepam nn appears vbz to topos affect vb dantrium nn metabolism nn
false	14	26	binding nn to topos plasma nn proteins nns is vbz reduced vbn by inpos warfarin nn and cc clotibrate nn and cc increased vbn by inpos tolbutamide nn
false	14	18	the dt combination nn of inpos therapeutic jj doses nns of inpos intravenous jj dantrolene_sodium nn and cc verapamil nn in inpos halothane nn a_chloralose jj anesthetized vbn swine nn has vbz resulted vbn in inpos ventricular jj fibrillation nn and cc cardiovascular jj collapse nn in inpos association nn with inpos marked jj hyperkalemia nn
false	14	22	the dt combination nn of inpos therapeutic jj doses nns of inpos intravenous jj dantrolene_sodium nn and cc verapamil nn in inpos halothane nn a_chloralose jj anesthetized vbn swine nn has vbz resulted vbn in inpos ventricular jj fibrillation nn and cc cardiovascular jj collapse nn in inpos association nn with inpos marked jj hyperkalemia nn
false	18	22	the dt combination nn of inpos therapeutic jj doses nns of inpos intravenous jj dantrolene_sodium nn and cc verapamil nn in inpos halothane nn a_chloralose jj anesthetized vbn swine nn has vbz resulted vbn in inpos ventricular jj fibrillation nn and cc cardiovascular jj collapse nn in inpos association nn with inpos marked jj hyperkalemia nn
advise	16	20	it prp is vbz recommended vbn that inpos the dt combination nn of inpos intravenous jj dantrolene_sodium nn and cc calcium_channel_blockers nn such jj as inpos verapamil nn not rb be vb used vbn together rb during inpos the dt management nn of inpos malignant jj hyperthermia nn crisis nn until inpos the dt relevance nn of inpos these dt findings nns to topos humans nns is vbz established vbn
advise	16	26	it prp is vbz recommended vbn that inpos the dt combination nn of inpos intravenous jj dantrolene_sodium nn and cc calcium_channel_blockers nns such jj as inpos verapamil nn not rb be vb used vbn together rb during inpos the dt management nn of inpos malignant jj hyperthermia nn crisis nn until inpos the dt relevance nn of inpos these dt findings nns to topos humans nns is vbz established vbn
false	20	26	it prp is vbz recommended vbn that inpos the dt combination nn of inpos intravenous jj dantrolene_sodium nn and cc calcium_channel_blockers nn such jj as inpos verapamil nn not rb be vb used vbn together rb during inpos the dt management nn of inpos malignant jj hyperthermia nn crisis nn until inpos the dt relevance nn of inpos these dt findings nns to topos humans nns is vbz established vbn
effect	4	10	administration nn of inpos dantrolene nn may md potentiate vb vecuronium nn induced jj neuromuscular jj block nn
false	22	38	a dt drug_drug jj interaction nn study nn evaluated vbd the dt effect nn of inpos the dt use nn of inpos aczone nn gel nn num cd in inpos combination nn with inpos double jj strength nn trimethoprim nn
false	22	38	a dt drug_drug jj interaction nn study nn evaluated vbd the dt effect nn of inpos the dt use nn of inpos aczone nn gel nn num cd in inpos combination nn with inpos double jj strength nn sulfamethoxazole nn
false	22	38	a dt drug_drug jj interaction nn study nn evaluated vbd the dt effect nn of inpos the dt use nn of inpos aczone nn gel nn num cd in inpos combination nn with inpos double jj strength nn tmp nn
false	22	38	a dt drug_drug jj interaction nn study nn evaluated vbd the dt effect nn of inpos the dt use nn of inpos aczone nn gel nn num cd in inpos combination nn with inpos double jj strength nn smx nn
false	38	40	a dt drug_drug jj interaction nn study nn evaluated vbd the dt effect nn of inpos the dt use nn of inpos aczone nn gel nn num cd in inpos combination nn with inpos double jj strength nn trimethoprim nn tmp nn
false	38	40	a dt drug_drug jj interaction nn study nn evaluated vbd the dt effect nn of inpos the dt use nn of inpos aczone nn gel nn num cd in inpos combination nn with inpos double jj strength nn trimethoprim nn smx nn
false	10	14	during inpos co_administration nn systemic jj levels nns of inpos tmp nn and cc smx nn were vbd essentially rb unchanged jj
false	8	26	notably rb systemic jj exposure nn of inpos dapsone_hydroxylamine nn was vbd more rbr than inpos doubled vbn in inpos the dt presence nn of inpos tmp nn
false	8	26	notably rb systemic jj exposure nn of inpos dapsone_hydroxylamine nn was vbd more rbr than inpos doubled vbn in inpos the dt presence nn of inpos smx nn
false	8	26	notably rb systemic jj exposure nn of inpos dha nn was vbd more rbr than inpos doubled vbn in inpos the dt presence nn of inpos tmp nn
false	8	26	notably rb systemic jj exposure nn of inpos dha nn was vbd more rbr than inpos doubled vbn in inpos the dt presence nn of inpos smx nn
false	10	12	certain jj concomitant jj medications nns lrb_such jj as inpos rifampin nn anticonvulsants nn st nnp
effect	4	8	with inpos oral jj dapsone nn treatment nn folic_acid_antagonists nn such jj as inpos pyrimethamine nn have vbp been vbn noted vbn to topos possibly rb increase vb the dt likelihood nn of inpos hematologic jj reactions nns
effect	4	14	with inpos oral jj dapsone nn treatment nn folic_acid_antagonists nns such jj as inpos pyrimethamine nn have vbp been vbn noted vbn to topos possibly rb increase vb the dt likelihood nn of inpos hematologic jj reactions nns
false	8	14	with inpos oral jj dapsone nn treatment nn folic_acid_antagonists nn such jj as inpos pyrimethamine nn have vbp been vbn noted vbn to topos possibly rb increase vb the dt likelihood nn of inpos hematologic jj reactions nns
false	0	8	warfarin nn concomitant jj administration nn of inpos daptomycin nn and cc warfarin nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos either dt drug nn and cc the dt inr nn was vbd not rb significantly rb altered vbn
false	6	10	concomitant jj administration nn of inpos daptomycin nn and cc warfarin nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos either dt drug nn and cc the dt inr nn was vbd not rb significantly rb altered vbn
false	0	2	hmg_coa_reductase_inhibitors nn inhibitors_of_hmg_coa_reductase nn may md cause vb myopathy nn which wdt is vbz manifested vbn as inpos muscle nn pain nn or cc weakness nn associated vbn with inpos elevated vbn levels nns of inpos cpk nn
false	40	52	there ex were vbd no dt reports nns of inpos skeletal jj myopathy nn in inpos a dt placebo_controlled jj phase nn num cd trial nn in inpos which wdt num cd healthy jj subjects nns on inpos stable jj simvastatin nn therapy nn were vbd treated vbn concurrently rb with inpos daptomycin nn for inpos num cd days nns
false	8	12	experience nn with inpos co_administration nn of inpos hmg_coa_reductase_inhibitors nn and cc fentanyl nn in inpos patients nns is vbz limited jj therefore rb consideration nn should md be vb given vbn to topos temporarily rb suspending vbg use nn of inpos hmg_coa_reductase_inhibitors nns in inpos patients nns receiving vbg fentanyl nn
false	8	12	experience nn with inpos co_administration nn of inpos hmg_coa_reductase_inhibitors nn and cc fentanyl nn in inpos patients nns is vbz limited jj therefore rb consideration nn should md be vb given vbn to topos temporarily rb suspending vbg use nn of inpos hmg_coa_reductase_inhibitors nns in inpos patients nns receiving vbg fentanyl nn
false	12	8	experience nn with inpos co_administration nn of inpos hmg_coa_reductase_inhibitors nns and cc fentanyl nn in inpos patients nns is vbz limited jj therefore rb consideration nn should md be vb given vbn to topos temporarily rb suspending vbg use nn of inpos hmg_coa_reductase_inhibitors nn in inpos patients nns receiving vbg fentanyl nn
advise	8	12	experience nn with inpos co_administration nn of inpos hmg_coa_reductase_inhibitors nns and cc fentanyl nn in inpos patients nns is vbz limited jj therefore rb consideration nn should md be vb given vbn to topos temporarily rb suspending vbg use nn of inpos hmg_coa_reductase_inhibitors nn in inpos patients nns receiving vbg fentanyl nn
advise	8	30	the dt daily jj dose nn of inpos enablex nn should md not rb exceed vb float cd mg nn when wrb coadministered vbn with inpos potent jj cyp3a4 nn ketoconazole nn
advise	8	30	the dt daily jj dose nn of inpos enablex nn should md not rb exceed vb float cd mg nn when wrb coadministered vbn with inpos potent jj cyp3a4 nn itraconazole nn
advise	8	30	the dt daily jj dose nn of inpos enablex nn should md not rb exceed vb float cd mg nn when wrb coadministered vbn with inpos potent jj cyp3a4 nn ritonavir nn
advise	8	30	the dt daily jj dose nn of inpos enablex nn should md not rb exceed vb float cd mg nn when wrb coadministered vbn with inpos potent jj cyp3a4 nn nelfinavir nn
advise	8	30	the dt daily jj dose nn of inpos enablex nn should md not rb exceed vb float cd mg nn when wrb coadministered vbn with inpos potent jj cyp3a4 nn clarithromycin nn
advise	10	52	caution nn should md be vb taken vbn when wrb enablex nn is vbz used vbn concomitantly rb with inpos medications nns that wdt are vbp predominantly rb metabolized vbn by inpos cyp2d6 nn and cc which wdt have vbp a dt narrow jj therapeutic jj window nn such jj as inpos flecainide nns
advise	10	52	caution nn should md be vb taken vbn when wrb enablex nn is vbz used vbn concomitantly rb with inpos medications nns that wdt are vbp predominantly rb metabolized vbn by inpos cyp2d6 nn and cc which wdt have vbp a dt narrow jj therapeutic jj window nn such jj as inpos thioridazine nns
advise	10	52	caution nn should md be vb taken vbn when wrb enablex nn is vbz used vbn concomitantly rb with inpos medications nns that wdt are vbp predominantly rb metabolized vbn by inpos cyp2d6 nn and cc which wdt have vbp a dt narrow jj therapeutic jj window nn such jj as inpos tricyclic_antidepressants nn
effect	8	14	the dt concomitant jj use nn of inpos enablex nn with inpos other jj anticholinergic_agents nn may md increase vb the dt frequency nn and_or cc severity nn of inpos dry jj mouth nn constipation nn blurred vbd vision nn and cc other jj anticholinergic jj pharmacological jj effects nns
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp ketoconazole nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp itraconazole nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp erythromycin nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp clarithromycin nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp ritonavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp atazanavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp indinavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp nefazodone nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp nelfinavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp saquinavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
mechanism	6	16	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp telithromycin nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	6	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp cyp3a4 nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp ketoconazole nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp itraconazole nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp erythromycin nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp clarithromycin nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp ritonavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp atazanavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp indinavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp nefazodone nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp nelfinavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp saquinavir nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
false	16	26	concomitant jj use nn of inpos sprycel nn and cc drugs nns that wdt inhibit vbp telithromycin nn may md increase vb exposure nn to topos dasatinib nn and cc should md be vb avoided vbn
advise	6	10	simultaneous jj administration nn of inpos sprycel nn with inpos antacids nn should md be vb avoided vbn
advise	2	48	if inpos antacid nn therapy nn is vbz needed vbn the dt antacid nn dose nn should md be vb administered vbn at inpos least jjs num cd hours nns prior jj to topos or cc num cd hours nns after inpos the dt dose nn of inpos sprycel nn
false	0	2	h2_blockers nn proton_pump_inhibitors nn
false	14	18	long_term jj suppression nn of inpos gastric jj acid nn secretion nn by inpos h2_blockers nn or cc proton_pump_inhibitors nn is vbz likely jj to topos reduce vb dasatinib nn exposure nn
false	14	18	long_term jj suppression nn of inpos gastric jj acid nn secretion nn by inpos h2_blockers nn or cc famotidine nn is vbz likely jj to topos reduce vb dasatinib nn exposure nn
false	14	18	long_term jj suppression nn of inpos gastric jj acid nn secretion nn by inpos h2_blockers nn or cc omeprazole nn is vbz likely jj to topos reduce vb dasatinib nn exposure nn
effect	14	28	long_term jj suppression nn of inpos gastric jj acid nn secretion nn by inpos h2_blockers nn or cc proton_pump_inhibitors nns is vbz likely jj to topos reduce vb dasatinib nn exposure nn
effect	18	28	long_term jj suppression nn of inpos gastric jj acid nn secretion nn by inpos h2_blockers nns or cc proton_pump_inhibitors nn is vbz likely jj to topos reduce vb dasatinib nn exposure nn
effect	18	28	long_term jj suppression nn of inpos gastric jj acid nn secretion nn by inpos h2_blockers nns or cc famotidine nn is vbz likely jj to topos reduce vb dasatinib nn exposure nn
effect	18	28	long_term jj suppression nn of inpos gastric jj acid nn secretion nn by inpos h2_blockers nns or cc omeprazole nn is vbz likely jj to topos reduce vb dasatinib nn exposure nn
false	8	12	the dt concomitant jj use nn of inpos h2_blockers nn or cc proton_pump_inhibitors nn with inpos sprycel nn is vbz not rb recommended vbn
advise	8	16	the dt concomitant jj use nn of inpos h2_blockers nn or cc proton_pump_inhibitors nns with inpos sprycel nn is vbz not rb recommended vbn
advise	12	16	the dt concomitant jj use nn of inpos h2_blockers nns or cc proton_pump_inhibitors nn with inpos sprycel nn is vbz not rb recommended vbn
false	6	20	the dt use nn of inpos antacids nn should md be vb considered vbn in inpos place nn of inpos h2_blockers nn or cc proton_pump_inhibitors nns in inpos patients nns receiving vbg sprycel nn therapy nn
false	6	24	the dt use nn of inpos antacids nn should md be vb considered vbn in inpos place nn of inpos h2_blockers nns or cc proton_pump_inhibitors nn in inpos patients nns receiving vbg sprycel nn therapy nn
false	6	32	the dt use nn of inpos antacids nn should md be vb considered vbn in inpos place nn of inpos h2_blockers nns or cc proton_pump_inhibitors nns in inpos patients nns receiving vbg sprycel nn therapy nn
false	20	24	the dt use nn of inpos antacids nns should md be vb considered vbn in inpos place nn of inpos h2_blockers nn or cc proton_pump_inhibitors nn in inpos patients nns receiving vbg sprycel nn therapy nn
advise	20	32	the dt use nn of inpos antacids nns should md be vb considered vbn in inpos place nn of inpos h2_blockers nn or cc proton_pump_inhibitors nns in inpos patients nns receiving vbg sprycel nn therapy nn
advise	24	32	the dt use nn of inpos antacids nns should md be vb considered vbn in inpos place nn of inpos h2_blockers nns or cc proton_pump_inhibitors nn in inpos patients nns receiving vbg sprycel nn therapy nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos alfentanil nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos astemizole nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos terfenadine nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos cisapride nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos cyclosporine nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos fentanyl nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos pimozide nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos quinidine nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos sirolimus nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos tacrolimus nns should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos ergot_alkaloids nn should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos ergotamine nn should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
advise	24	42	therefore rb cyp3a4 nn substrates nns known vbn to topos have vb a dt narrow jj therapeutic jj index nn such jj as inpos dihydroergotamine nn should md be vb administered vbn with inpos caution nn in inpos patients nns receiving vbg sprycel nn
effect	4	20	use nn of inpos cerubidine nn in inpos a dt patient nn who wp has vbz previously rb received vbn doxorubicin nn increases vbz the dt risk nn of inpos cardiotoxicity nn
advise	0	34	cerubidine nn should md not rb be vb used vbn in inpos patients nns who wp have vbp previously rb received vbn the dt recommended vbn maximum nn cumulative jj doses nns of inpos doxorubicin nn or cc cerubidine nn
false	34	0	cerubidine nn should md not rb be vb used vbn in inpos patients nns who wp have vbp previously rb received vbn the dt recommended vbn maximum nn cumulative jj doses nns of inpos doxorubicin nn or cc cerubidine nn
effect	0	8	cyclophosphamide nn used vbn concurrently rb with inpos cerubidine nn may md also rb result vb in inpos increased vbn cardiotoxicity nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nn local jj anesthetics nns like inpos lidocaine nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nn local jj anesthetics nns like inpos procaine nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nn local jj anesthetics nns like inpos b_blockers nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nn local jj anesthetics nns like inpos metaclopramide nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nn local jj anesthetics nns like inpos lithium_carbonate nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nn local jj anesthetics nns like inpos terbutaline nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nns local jj anesthetics nn like inpos lidocaine nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nns local jj anesthetics nn like inpos procaine nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nns local jj anesthetics nn like inpos b_blockers nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nns local jj anesthetics nn like inpos metaclopramide nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nns local jj anesthetics nn like inpos lithium_carbonate nn
false	18	26	in inpos addition nn neuromuscular jj blocking nn action nn is vbz enhanced vbn by inpos general jj anesthetics nns local jj anesthetics nn like inpos terbutaline nn
false	8	12	the dt concomitant jj administration nn of inpos exjade nn and cc aluminum nn containing jj antacid_preparations nns has vbz not rb been vbn formally rb studied vbn
false	8	14	the dt concomitant jj administration nn of inpos exjade nn and cc aluminum_containing jj antacid_preparations nn has vbz not rb been vbn formally rb studied vbn
false	12	16	the dt concomitant jj administration nn of inpos exjade nn and cc aluminum nn containing jj antacid_preparations nn has vbz not rb been vbn formally rb studied vbn
false	2	14	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nns
false	2	20	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nns
false	2	22	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nn should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nns
false	2	14	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum nn containing jj antacid_preparations nns
false	2	36	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nn
false	14	20	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nns
false	14	22	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nn should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nns
false	14	36	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nn
false	20	22	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nn should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nns
false	20	14	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum nn containing jj antacid_preparations nns
false	20	36	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nn
advise	22	14	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nn should md not rb be vb taken vbn with inpos aluminum nn containing jj antacid_preparations nns
false	22	36	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nn should md not rb be vb taken vbn with inpos aluminum_containing jj antacid_preparations nn
false	14	38	although inpos deferasirox nn has vbz a dt lower jjr affinity nn for inpos aluminum nn than inpos for inpos iron nn exjade nnp should md not rb be vb taken vbn with inpos aluminum nn containing jj antacid_preparations nn
false	6	22	in inpos healthy jj volunteers nns exjade nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn
false	6	10	the dt effect nn of inpos digoxin nn on inpos exjade nn pharmacokinetics nns has vbz not rb been vbn studied vbn
false	8	12	the dt concomitant jj administration nn of inpos exjade nn and cc vitamin_c nn has vbz not rb been vbn formally rb studied vbn
false	6	10	the dt interaction nn of inpos exjade nn with inpos hydroxyurea nn has vbz not rb been vbn formally rb studied vbn
false	6	12	no dt inhibition nn of inpos deferasirox nn metabolism nn by inpos hydroxyurea nn is vbz expected vbn based vbn on inpos the dt results nns of inpos an dt in fw vitro fw study nn
false	0	2	clarithromycin nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nnp
false	0	2	clarithromycin nn rifampin nn ritanovir nnp saquinavir nnp
false	0	2	clarithromycin nnp saquinavir nn
false	0	2	didanosine nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nnp
false	0	2	didanosine nn rifampin nn ritanovir nnp saquinavir nnp
false	0	2	didanosine nnp saquinavir nn
false	0	2	fluconazole nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nnp
false	0	2	fluconazole nn rifampin nn ritanovir nnp saquinavir nnp
false	0	2	fluconazole nnp saquinavir nn
false	0	2	fluoxetine nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nnp
false	0	2	fluoxetine nn rifampin nn ritanovir nnp saquinavir nnp
false	0	2	fluoxetine nnp saquinavir nn
false	0	2	ketoconazole nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nnp
false	0	2	ketoconazole nn rifampin nn ritanovir nnp saquinavir nnp
false	0	2	ketoconazole nnp saquinavir nn
false	0	2	phenytoin nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nnp
false	0	2	phenytoin nn rifampin nn ritanovir nnp saquinavir nnp
false	0	2	phenytoin nnp saquinavir nn
false	0	2	carbamazepine nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nnp
false	0	2	carbamazepine nn rifampin nn ritanovir nnp saquinavir nnp
false	0	2	carbamazepine nnp saquinavir nn
false	0	2	rifabutin nn rifampin nn ritanovir nnp saquinavir nnp
false	20	26	antiacid nn clarithromycin nn didanosine nn fluconazole nn fluoxetine nn indanavir nn ketoconazole nn phenytoin nn phenobarbitol nn carbamazepine nn rifabutin nn rifampin nnp ritanovir nnp saquinavir nn
int	8	12	possible jj drug nn interactions nns of inpos humorsol nn with inpos succinylcholine nn or cc with inpos other jj anticholinesterase_agents nns
int	8	20	possible jj drug nn interactions nns of inpos humorsol nn with inpos succinylcholine nn or cc with inpos other jj anticholinesterase_agents nn
false	12	20	possible jj drug nn interactions nns of inpos humorsol nn with inpos succinylcholine nn or cc with inpos other jj anticholinesterase_agents nn
advise	4	30	because inpos the dt tetracyclines nn have vbp been vbn shown vbn to topos depress vb plasma nn prothrombin nn activity nn patients nns who wp are vbp on inpos anticoagulant nn therapy nn may md require vb downward jj adjustment nn of inpos their prp anticoagulant jj dosage nn
false	4	30	because inpos the dt tetracyclines nn have vbp been vbn shown vbn to topos depress vb plasma nn prothrombin nn activity nn patients nns who wp are vbp on inpos anticoagulant jj therapy nn may md require vb downward jj adjustment nn of inpos their prp anticoagulant nn dosage nn
false	12	16	since inpos bacteriostatic jj drugs nns such jj as inpos the dt tetracycline_class nn of inpos antibiotics nn may md interfere vb with inpos the dt bactericidal jj action nn of inpos penicillins nns it prp is vbz not rb advisable jj to topos administer vb these dt drugs nns concomitantly rb
effect	12	32	since inpos bacteriostatic jj drugs nns such jj as inpos the dt tetracycline_class nn of inpos antibiotics nns may md interfere vb with inpos the dt bactericidal jj action nn of inpos penicillins nn it prp is vbz not rb advisable jj to topos administer vb these dt drugs nns concomitantly rb
false	16	32	since inpos bacteriostatic jj drugs nns such jj as inpos the dt tetracycline_class nn of inpos antibiotics nn may md interfere vb with inpos the dt bactericidal jj action nn of inpos penicillins nn it prp is vbz not rb advisable jj to topos administer vb these dt drugs nns concomitantly rb
effect	6	12	concurrent jj use nn of inpos tetracyclines nn with inpos oral jj contraceptives nn may md render vb oral jj contraceptives nns less rbr effective jj
false	6	12	concurrent jj use nn of inpos tetracyclines nn with inpos oral jj contraceptives nns may md render vb oral jj contraceptives nn less rbr effective jj
effect	4	26	taking vbg a dt rauwolfia_alkaloid nn while inpos you prp are vbp taking vbg or cc within inpos num cd weeks nns of inpos taking vbg mao_inhibitors nn may md increase vb the dt risk nn of inpos central jj nervous jj system nn depression nn or cc may md cause vb a dt severe jj high jj blood nn pressure nn reaction nn
false	2	4	like inpos isoflurane nn desflurane nn does vbz not rb predispose vb to topos premature vb ventricular jj arrhythmias nns in inpos the dt presence nn of inpos exogenously rb infused vbn epinephrine nn in inpos swine nn
false	2	32	like inpos isoflurane nn desflurane nn does vbz not rb predispose vb to topos premature vb ventricular jj arrhythmias nns in inpos the dt presence nn of inpos exogenously rb infused vbn epinephrine nn in inpos swine nn
false	4	32	like inpos isoflurane nn desflurane nn does vbz not rb predispose vb to topos premature vb ventricular jj arrhythmias nns in inpos the dt presence nn of inpos exogenously rb infused vbn epinephrine nn in inpos swine nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn antidepressants nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn phenothiazines nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn flecainide nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
int	8	10	the dt extent nn to topos which wdt ssri nn hyph_tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbd
false	10	8	the dt extent nn to topos which wdt ssri nn tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbn
advise	16	26	nevertheless rb caution nn is vbz indicated vbn in inpos the dt co_administration nn of inpos t.a. nn with inpos any dt of inpos the dt ssris nn and cc also rb in inpos switching vbg from inpos num cd class nn to topos the dt other jj
false	32	36	close jj supervision nn and cc careful jj adjustment nn of inpos dosage nn are vbp required vbn when wrb this dt drug nn is vbz given vbn concomitantly rb with inpos anticholinergic nn or cc sympathomimetic_drugs nn
effect	2	16	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nns or cc sedative jj careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
effect	2	22	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nn or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
effect	2	26	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
effect	2	26	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc hypnotics nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	2	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative jj careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nn are vbp additive jj
false	2	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative jj careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc chlordiazepoxide nn are vbp additive jj
false	2	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative jj careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc diazepam nn are vbp additive jj
false	16	22	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nn or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	16	26	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nns or cc sedative nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	16	26	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nns or cc hypnotics nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	16	2	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nns or cc sedative jj careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	16	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nns or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nn are vbp additive jj
false	16	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nns or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc chlordiazepoxide nn are vbp additive jj
false	16	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nn such jj as inpos tranquilizers nns or cc sedative jj careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc diazepam nn are vbp additive jj
false	22	26	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nn or cc sedative nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	22	26	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nn or cc hypnotics nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	22	2	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nn or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	22	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nn or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nn are vbp additive jj
false	22	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nn or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc chlordiazepoxide nn are vbp additive jj
false	22	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nn or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc diazepam nn are vbp additive jj
false	26	2	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	26	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nn are vbp additive jj
false	26	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc chlordiazepoxide nn are vbp additive jj
false	26	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc diazepam nn are vbp additive jj
false	26	2	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc hypnotics nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nns are vbp additive jj
false	26	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc hypnotics nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nn are vbp additive jj
false	26	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc hypnotics nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc chlordiazepoxide nn are vbp additive jj
false	26	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc hypnotics nn careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc diazepam nn are vbp additive jj
effect	2	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc benzodiazepines nn are vbp additive jj
effect	2	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc hypnotics nns careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc chlordiazepoxide nn are vbp additive jj
effect	2	66	if inpos desipramine_hydrochloride nn is vbz to topos be vb combined vbn with inpos other jj psychotropic_agents nns such jj as inpos tranquilizers nns or cc sedative jj careful jj consideration nn should md be vb given vbn to topos the dt pharmacology nn of inpos the dt agents nns employed vbn since inpos the dt sedative jj effects nns of inpos desipramine nn and cc diazepam nn are vbp additive jj
effect	16	30	both cc the dt sedative jj and cc anticholinergic jj effects nns of inpos the dt major_tranquilizers nn are vbp also rb additive jj to topos those dt of inpos desipramine nn
mechanism	6	10	concurrent jj administration nn of inpos cimetidine nn and cc tricyclic_antidepressants nn can md produce vb clinically rb significant jj increases nns in inpos the dt plasma nn levels nns of inpos the dt tricyclic_antidepressants nns
false	6	10	concurrent jj administration nn of inpos cimetidine nn and cc tricyclic_antidepressants nns can md produce vb clinically rb significant jj increases nns in inpos the dt plasma nn levels nns of inpos the dt tricyclic_antidepressants nn
mechanism	14	28	conversely rb decreases vbz in inpos plasma nn levels nns of inpos the dt tricyclic_antidepressants nn have vbp been vbn reported vbn upon inpos discontinuation nn of inpos cimetidine nn which wdt may md result vb in inpos the dt loss nn of inpos the dt therapeutic jj efficacy nn of inpos the dt tricyclic_antidepressant nn num cd
false	28	14	conversely rb decreases vbz in inpos plasma nn levels nns of inpos the dt tricyclic_antidepressants nns have vbp been vbn reported vbn upon inpos discontinuation nn of inpos cimetidine nn which wdt may md result vb in inpos the dt loss nn of inpos the dt therapeutic jj efficacy nn of inpos the dt tricyclic_antidepressant nn num cd
mechanism	26	30	there ex have vbp been vbn greater jjr than inpos two_fold jj increases nns of inpos previously rb stable jj plasma nn levels nns of inpos tricyclic_antidepressants nn when wrb fluoxetine nn has vbz been vbn administered vbn in inpos combination nn with inpos these dt agents nns
false	28	44	in inpos num cd controlled vbn crossover nn clinical jj pharmacology nn studies nns in inpos healthy jj male jj a dt nd nn female jj volunteers nns desloratadine nn float cd mg nn once rb daily jj was vbd coadministered vbn with inpos erythromycin nn num cd mg nn every dt num cd hours nns or cc ketoconazole nn num cd mg nn every dt num cd hours nns for inpos num cd days nns
false	28	58	in inpos num cd controlled vbn crossover nn clinical jj pharmacology nn studies nns in inpos healthy jj male jj a dt nd nn female jj volunteers nns desloratadine nn float cd mg nn once rb daily jj was vbd coadministered vbn with inpos erythromycin nn num cd mg nn every dt num cd hours nns or cc ketoconazole nn num cd mg nn every dt num cd hours nns for inpos num cd days nns
false	44	58	in inpos num cd controlled vbn crossover nn clinical jj pharmacology nn studies nns in inpos healthy jj male jj a dt nd nn female jj volunteers nns desloratadine nn float cd mg nn once rb daily jj was vbd coadministered vbn with inpos erythromycin nn num cd mg nn every dt num cd hours nns or cc ketoconazole nn num cd mg nn every dt num cd hours nns for inpos num cd days nns
false	18	42	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	18	70	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	18	70	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	18	106	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	42	70	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	42	70	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	42	106	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	70	106	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	70	106	in inpos num cd separate jj controlled jj parallel jj group nn clinical jj pharmacology nn studies nns desloratadine nn at inpos the dt clinical jj dose nn of inpos num cd mg nn has vbz been vbn coadministered vbn with inpos azithromycin nn num cd mg nn followed vbn by inpos num cd mg nn once rb daily rb for inpos num cd days nns or cc with inpos fluoxetine nn num cd mg nn once rb daily rb for inpos num cd days nns after inpos a dt num cd day nn pretreatment nn period nn with inpos fluoxetine nn or cc with inpos cimetidine nn num cd mg nn every dt num cd hours nns for inpos num cd days nns under inpos steady jj state nn conditions nns to topos normal jj healthy jj male jj and cc female jj volunteers nns
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nn and cc possibly rb with inpos griseofulvin nns
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nn and cc possibly rb with inpos ampicillin nns
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nn and cc possibly rb with inpos tetracyclines nn
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos phenytoin_sodium nn and cc possibly rb with inpos griseofulvin nns
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos phenytoin_sodium nn and cc possibly rb with inpos ampicillin nns
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos phenytoin_sodium nn and cc possibly rb with inpos tetracyclines nn
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos carbamazepine nn and cc possibly rb with inpos griseofulvin nns
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos carbamazepine nn and cc possibly rb with inpos ampicillin nns
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos carbamazepine nn and cc possibly rb with inpos tetracyclines nn
effect	0	12	aminoglutethimide nn may md diminish vb adrenal jj suppression nn by inpos corticosteroids nn
advise	2	14	when wrb corticosteroids nn are vbp administered vbn concomitantly rb with inpos potassium_depleting jj amphotericin_b nn patients nns should md be vb observed vbn closely rb for inpos development nn of inpos hypokalemia nn
advise	2	14	when wrb corticosteroids nn are vbp administered vbn concomitantly rb with inpos potassium_depleting jj diuretics nn patients nns should md be vb observed vbn closely rb for inpos development nn of inpos hypokalemia nn
effect	24	28	in inpos addition nn there ex have vbp been vbn cases nns reported vbn in inpos which wdt concomitant jj use nn of inpos amphotericin_b nn and cc hydrocortisone nn was vbd followed vbn by inpos cardiac jj enlargement nn and cc congestive jj heart nn failure nn
mechanism	0	20	macrolide_antibiotics nn have vbp been vbn reported vbn to topos cause vb a dt significant jj decrease nn in inpos corticosteroid nn clearance nn
false	0	8	anticholinesterases nn concomitant jj use nn of inpos anticholinesterase_agents nn and cc corticosteroids nns may md produce vb severe jj weakness nn in inpos patients nns with inpos myasthenia nn gravis nn
false	0	12	anticholinesterases nn concomitant jj use nn of inpos anticholinesterase_agents nns and cc corticosteroids nn may md produce vb severe jj weakness nn in inpos patients nns with inpos myasthenia nn gravis nn
effect	6	10	concomitant jj use nn of inpos anticholinesterase_agents nn and cc corticosteroids nn may md produce vb severe jj weakness nn in inpos patients nns with inpos myasthenia nn gravis nn
advise	4	24	if inpos possible jj anticholinesterase_agents nn should md be vb withdrawn vbn at inpos least jjs num cd hours nns before inpos initiating vbg corticosteroid nn therapy nn
false	0	8	anticoagulants nn oral jj co_administration nn of inpos corticosteroids nn and cc warfarin nn usually rb results vbz in inpos inhibition nn of inpos response nn to topos warfarin nn although inpos there ex have vbp been vbn some dt conflicting vbg reports nns
false	0	10	anticoagulants nn oral jj co_administration nn of inpos corticosteroids nns warfarin nn usually rb results vbz in inpos inhibition nn of inpos response nn to topos warfarin nn although inpos there ex have vbp been vbn some dt conflicting vbg reports nns
false	0	10	anticoagulants nn oral jj co_administration nn of inpos corticosteroids nns warfarin nn usually rb results vbz in inpos inhibition nn of inpos response nn to topos warfarin nn although inpos there ex have vbp been vbn some dt conflicting vbg reports nns
effect	4	8	co_administration nn of inpos corticosteroids nn and cc warfarin nn usually rb results vbz in inpos inhibition nn of inpos response nn to topos warfarin nn although inpos there ex have vbp been vbn some dt conflicting vbg reports nns
false	4	8	co_administration nn of inpos corticosteroids nn and cc warfarin nn usually rb results vbz in inpos inhibition nn of inpos response nn to topos warfarin nn although inpos there ex have vbp been vbn some dt conflicting vbg reports nns
effect	2	20	because inpos corticosteroids nn may md increase vb blood nn glucose nn concentrations nns dosage nn adjustments nns of inpos antidiabetic_agents nn may md be vb required vbn
mechanism	0	12	cholestyramine nn may md increase vb the dt clearance nn of inpos corticosteroids nn
false	0	14	cyclosporine nn increased vbd activity nn of inpos both cc cyclosporine nn and cc corticosteroids nn may md occur vb when wrb the dt num cd are vbp used vbn concurrently rb
effect	8	12	increased vbn activity nn of inpos both cc cyclosporine nn and cc corticosteroids nn may md occur vb when wrb the dt num cd are vbp used vbn concurrently rb
mechanism	0	14	ephedrine nn may md enhance vb the dt metabolic jj clearance nn of inpos corticosteroids nn resulting vbg in inpos decreased vbn blood nn levels nns and cc lessened vbd physiologic jj activity nn thus rb requiring vbg an dt increase nn in inpos corticosteroid nn dosage nn
false	0	14	ephedrine nn may md enhance vb the dt metabolic jj clearance nn of inpos corticosteroids nns resulting vbg in inpos decreased vbn blood nn levels nns and cc lessened vbd physiologic jj activity nn thus rb requiring vbg an dt increase nn in inpos corticosteroid nn dosage nn
false	0	6	estrogens nn including vbg oral jj contraceptives nn
mechanism	0	16	estrogens nn may md decrease vb the dt hepatic jj metabolism nn of inpos certain jj corticosteroids nn thereby rb increasing vbg their prp effect nn
mechanism	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn barbiturates nn may md enhance vb the dt metabolism nn of inpos corticosteroids nn and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
false	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn barbiturates nn may md enhance vb the dt metabolism nn of inpos corticosteroids nns and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
mechanism	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn phenytoin nn may md enhance vb the dt metabolism nn of inpos corticosteroids nn and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
false	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn phenytoin nn may md enhance vb the dt metabolism nn of inpos corticosteroids nns and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
mechanism	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn carbamazepine nn may md enhance vb the dt metabolism nn of inpos corticosteroids nn and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
false	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn carbamazepine nn may md enhance vb the dt metabolism nn of inpos corticosteroids nns and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
mechanism	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn rifampin nn may md enhance vb the dt metabolism nn of inpos corticosteroids nn and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
false	14	26	drugs nns which wdt induce vbp cytochrome nn p450 nn 3a4 nn enzyme nn rifampin nn may md enhance vb the dt metabolism nn of inpos corticosteroids nns and cc require vbp that inpos the dt dosage nn of inpos the dt corticosteroid nn be vb increased vbn
false	4	6	drugs nns e.g. fw ketoconazole nn macrolide_antibiotics nn such jj as inpos erythromycin nn
false	4	12	drugs nns e.g. fw ketoconazole nn macrolide_antibiotics nns such jj as inpos erythromycin nn
mechanism	12	42	drugs nns which wdt inhibit vbp cyp nn 3a4 nn lrb_e.g. fw ketoconazole nn macrolide_antibiotics nns such jj as inpos erythromycin nn rrb_have vbp the dt potential nn to topos result vb in inpos increased vbn plasma nn concentrations nns of inpos corticosteroids nn
false	6	12	drugs nns e.g. fw ketoconazole nn macrolide_antibiotics nn such jj as inpos erythromycin nn
mechanism	14	42	drugs nns which wdt inhibit vbp cyp nn 3a4 nn lrb_e.g. fw ketoconazole nn macrolide_antibiotics nn such jj as inpos erythromycin nn rrb_have vbp the dt potential nn to topos result vb in inpos increased vbn plasma nn concentrations nns of inpos corticosteroids nn
mechanism	20	42	drugs nns which wdt inhibit vbp cyp nn 3a4 nn lrb_e.g. fw ketoconazole nn macrolide_antibiotics nns such jj as inpos erythromycin nn rrb_have vbp the dt potential nn to topos result vb in inpos increased vbn plasma nn concentrations nns of inpos corticosteroids nn
mechanism	0	20	ketoconazole nn has vbz been vbn reported vbn to topos decrease vb the dt metabolism nn of inpos certain jj corticosteroids nn by inpos up rb to topos num cd leading vbg to topos increased vbn risk nn of inpos corticosteroid nn side nn effects nns
false	0	20	ketoconazole nn has vbz been vbn reported vbn to topos decrease vb the dt metabolism nn of inpos certain jj corticosteroids nns by inpos up rb to topos num cd leading vbg to topos increased vbn risk nn of inpos corticosteroid nn side nn effects nns
effect	4	14	in inpos addition nn ketoconazole nn alone rb can md inhibit vb adrenal jj corticosteroid nn synthesis nn and cc may md cause vb adrenal jj insufficiency nn during inpos corticosteroid nn withdrawal nn
false	0	8	nonsteroidal_anti_inflammatory_agents nn concomitant jj use nn of inpos aspirin nn and cc corticosteroids nns increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
false	0	8	nonsteroidal_anti_inflammatory_agents nn concomitant jj use nn of inpos nonsteroidal_antiinflammatory_agents nn and cc corticosteroids nns increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
false	0	12	nonsteroidal_anti_inflammatory_agents nn concomitant jj use nn of inpos aspirin nn and cc corticosteroids nn increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
false	0	8	nsaids nn concomitant jj use nn of inpos aspirin nn and cc corticosteroids nns increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
false	0	8	nsaids nn concomitant jj use nn of inpos nonsteroidal_antiinflammatory_agents nn and cc corticosteroids nns increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
false	0	12	nsaids nn concomitant jj use nn of inpos aspirin nn and cc corticosteroids nn increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
effect	6	10	concomitant jj use nn of inpos aspirin nn and cc corticosteroids nn increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
effect	6	10	concomitant jj use nn of inpos nonsteroidal_antiinflammatory_agents nn and cc corticosteroids nn increases vbz the dt risk nn of inpos gastrointestinal jj side nn effects nns
advise	0	16	aspirin nn should md be vb used vbn cautiously rb in inpos conjunction nn with inpos corticosteroids nn in inpos hypoprothrombinemia nn
mechanism	6	22	the dt clearance nn of inpos salicylates nn may md be vb increased vbn with inpos concurrent jj use nn of inpos corticosteroids nn
false	0	34	phenytoin nn in inpos post_marketing jj experience nn there ex have vbp been vbn reports nns of inpos both cc increases nns and cc decreases vbz in inpos phenytoin nn levels nns with inpos dexamethasone nn co_administration nn leading vbg to topos alterations nns in inpos seizure nn control nn
mechanism	0	34	phenytoin nn in inpos post_marketing jj experience nn there ex have vbp been vbn reports nns of inpos both cc increases nns and cc decreases vbz in inpos phenytoin nn levels nns with inpos dexamethasone nn co_administration nn leading vbg to topos alterations nns in inpos seizure nn control nn
effect	4	22	patients nns on inpos corticosteroid nn therapy nn may md exhibit vb a dt diminished jj response nn to topos toxoids nns live nn inactivated nn bbbbb22_vaccines_eeeee22 nn due inpos to topos inhibition nn of inpos antibody nn response nn
effect	4	28	patients nns on inpos corticosteroid nn therapy nn may md exhibit vb a dt diminished jj response nn to topos toxoids nns and cc live jj or cc inactivated_vaccines nn due jj to topos inhibition nn of inpos antibody nn response nn
false	24	28	patients nns on inpos corticosteroid nn therapy nn may md exhibit vb a dt diminished jj response nn to topos toxoids nns and cc live nn or cc inactivated nn bbbbbcom_vaccines_eeeeecom nn due inpos to topos inhibition nn of inpos antibody nn response nn
effect	0	22	corticosteroids nn may md also rb potentiate vb the dt replication nn of inpos some dt organisms nns contained vbn in inpos live_attenuated_vaccines nn
advise	6	20	routine nn administration nn of inpos vaccines nn or cc toxoids nns should md be vb deferred vbn until inpos corticosteroid nn therapy nn is vbz discontinued vbn if inpos possible jj
int	0	8	dexbrompheniramine nn can md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
int	0	8	dexbrompheniramine nn can md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	0	38	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
int	0	8	dexbrompheniramine nn can md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	0	50	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
int	0	26	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	0	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	0	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	8	38	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	8	40	dexbrompheniramine nn can md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	8	16	dexbrompheniramine nn can md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	4	20	dexbrompheniramine nn can md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	4	20	dexbrompheniramine nn can md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	14	38	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nn lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	8	40	dexbrompheniramine nn can md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	8	16	dexbrompheniramine nn can md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	4	20	dexbrompheniramine nn can md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	4	20	dexbrompheniramine nn can md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	38	40	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nn other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	38	52	dexbrompheniramine nn can md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	8	40	dexbrompheniramine nn can md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	8	16	dexbrompheniramine nn can md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	4	20	dexbrompheniramine nn can md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	4	20	dexbrompheniramine nn can md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	50	52	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nn
false	26	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	26	34	dexbrompheniramine nn can md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
effect	8	16	in inpos patients nns receiving vbg nonselective jj monoamine_oxidase_inhibitors nn in inpos combination nn with inpos serotoninergic_agents nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj monoamine_oxidase_inhibitors nn in inpos combination nn with inpos fluoxetine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj monoamine_oxidase_inhibitors nn in inpos combination nn with inpos fluvoxamine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj monoamine_oxidase_inhibitors nn in inpos combination nn with inpos paroxetine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj monoamine_oxidase_inhibitors nn in inpos combination nn with inpos sertraline nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj monoamine_oxidase_inhibitors nn in inpos combination nn with inpos venlafaxine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj maois nn in inpos combination nn with inpos serotoninergic_agents nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj maois nn in inpos combination nn with inpos fluoxetine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj maois nn in inpos combination nn with inpos fluvoxamine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj maois nn in inpos combination nn with inpos paroxetine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj maois nn in inpos combination nn with inpos sertraline nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj maois nn in inpos combination nn with inpos venlafaxine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj selegiline_hydrochloride nn in inpos combination nn with inpos serotoninergic_agents nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj selegiline_hydrochloride nn in inpos combination nn with inpos fluoxetine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj selegiline_hydrochloride nn in inpos combination nn with inpos fluvoxamine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj selegiline_hydrochloride nn in inpos combination nn with inpos paroxetine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj selegiline_hydrochloride nn in inpos combination nn with inpos sertraline nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
effect	8	16	in inpos patients nns receiving vbg nonselective jj selegiline_hydrochloride nn in inpos combination nn with inpos venlafaxine nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns
false	2	34	because inpos dexfenfluramine nn is vbz a dt serotonin nn releaser nn and cc reuptake nn inhibitor nn dexfenfluramine nn should md not rb be vb used vbn concomitantly rb with inpos a dt mao_inhibitor nn
advise	2	34	because inpos dexfenfluramine nn is vbz a dt serotonin nn releaser nn and cc reuptake nn inhibitor nn dexfenfluramine nn should md not rb be vb used vbn concomitantly rb with inpos a dt mao_inhibitor nn
advise	20	32	at inpos least jjs num cd days nns should md elapse vb between inpos discontinuation nn of inpos a dt mao_inhibitor nn and cc initiation nn of inpos treatment nn with inpos dexfenfluramine nn
advise	18	32	at inpos least jjs num cd weeks nns should md elapse vb between inpos discontinuation nn of inpos dexfenfluramine nn and cc initiation nn of inpos treatment nn with inpos a dt mao_inhibitor nn
effect	36	52	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos selective_serotonin_reuptake_inhibitors nn and cc agents nns for inpos migraine nn therapy nn such jj as inpos imitrex nn and cc dihydroergotamine nn
effect	36	52	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos selective_serotonin_reuptake_inhibitors nn and cc agents nns for inpos migraine nn therapy nn such jj as inpos sumatriptan_succinate nn and cc dihydroergotamine nn
effect	36	56	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos selective_serotonin_reuptake_inhibitors nn and cc agents nns for inpos migraine nn therapy nn such jj as inpos imitrex nn and cc dihydroergotamine nn
effect	36	52	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos ssris nn and cc agents nns for inpos migraine nn therapy nn such jj as inpos imitrex nn and cc dihydroergotamine nn
effect	36	52	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos ssris nn and cc agents nns for inpos migraine nn therapy nn such jj as inpos sumatriptan_succinate nn and cc dihydroergotamine nn
effect	36	56	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos ssris nn and cc agents nns for inpos migraine nn therapy nn such jj as inpos imitrex nn and cc dihydroergotamine nn
false	52	56	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos selective_serotonin_reuptake_inhibitors nns and cc agents nns for inpos migraine nn therapy nn such jj as inpos imitrex nn and cc dihydroergotamine nn
false	52	56	a dt rare jj but cc serious jj constellation nn of inpos symptoms nns termed vbn serotonin nn syndrome nn has vbz been vbn reported vbn with inpos the dt concomitant jj use nn of inpos selective_serotonin_reuptake_inhibitors nns and cc agents nns for inpos migraine nn therapy nn such jj as inpos sumatriptan_succinate nn and cc dihydroergotamine nn
advise	0	14	dexfenfluramine nn should md not rb be vb administered vbn with inpos other jj serotoninergic_agents nn
false	0	2	anesthetics nn sedatives nn
false	0	4	anesthetics nn sedatives nn hypnotics nn
false	0	4	anesthetics nn sedatives_hypnotics nn opioids nn
false	0	8	anesthetics nn sedatives_hypnotics_opioids nns co_administration nn of inpos precedex nn with inpos anesthetics nns sedatives nns hypnotics nns opioids nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	0	2	anesthetics nn sedatives_hypnotics_opioids nns co_administration nn of inpos precedex nn with inpos sedatives nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	0	2	anesthetics nn sedatives_hypnotics_opioids nns co_administration nn of inpos precedex nn with inpos hypnotics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	0	2	anesthetics nn sedatives_hypnotics_opioids nns co_administration nn of inpos precedex nn with inpos opioids nn is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	8	anesthetics nn sedatives nn co_administration nn of inpos precedex nn with inpos anesthetics nns sedatives nns hypnotics nns opioids nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	0	anesthetics nn sedatives nn co_administration nn of inpos precedex nn with inpos anesthetics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	12	anesthetics nn sedatives nn co_administration nn of inpos precedex nn with inpos hypnotics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	12	anesthetics nn sedatives nn co_administration nn of inpos precedex nn with inpos opioids nn is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	8	anesthetics_sedatives nn hypnotics nn co_administration nn of inpos precedex nn with inpos anesthetics nns sedatives nns hypnotics nns opioids nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	0	anesthetics_sedatives nn hypnotics nn co_administration nn of inpos precedex nn with inpos anesthetics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	0	anesthetics_sedatives nn hypnotics nn co_administration nn of inpos precedex nn with inpos sedatives nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	12	anesthetics_sedatives nn hypnotics nn co_administration nn of inpos precedex nn with inpos opioids nn is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	8	anesthetics_sedatives_hypnotics nn opioids nn co_administration nn of inpos precedex nn with inpos anesthetics nns sedatives nns hypnotics nns opioids nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	0	anesthetics_sedatives_hypnotics nn opioids nn co_administration nn of inpos precedex nn with inpos anesthetics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	0	anesthetics_sedatives_hypnotics nn opioids nn co_administration nn of inpos precedex nn with inpos sedatives nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	2	0	anesthetics_sedatives_hypnotics nn opioids nn co_administration nn of inpos precedex nn with inpos hypnotics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
effect	4	8	co_administration nn of inpos precedex nn with inpos anesthetics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
effect	4	8	co_administration nn of inpos precedex nn with inpos sedatives nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
effect	4	8	co_administration nn of inpos precedex nn with inpos hypnotics nns is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
effect	4	8	co_administration nn of inpos precedex nn with inpos opioids nn is vbz likely jj to topos lead vb to topos an dt enhancement nn of inpos effects nns
false	18	38	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative jj hypnotic jj or cc opioid nn may md be vb required vbn
false	18	40	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative nn hypnotic jj or cc opioid nn may md be vb required vbn
false	18	42	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic jj sedative jj hypnotic nn or cc opioid nn may md be vb required vbn
false	18	46	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic jj sedative jj hypnotic jj or cc opioid nn may md be vb required vbn
advise	18	38	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative jj hypnotic jj or cc opioid nn may md be vb required vbn
advise	18	40	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative nn hypnotic jj or cc opioid nn may md be vb required vbn
advise	18	42	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic jj sedative jj hypnotic nn or cc opioid nn may md be vb required vbn
advise	18	46	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic jj sedative jj hypnotic jj or cc opioid nn may md be vb required vbn
false	38	40	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative nn hypnotic jj or cc opioid nn may md be vb required vbn
false	38	42	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative jj hypnotic nn or cc opioid nn may md be vb required vbn
false	38	46	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative jj hypnotic jj or cc opioid nn may md be vb required vbn
false	40	46	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic nn sedative nn hypnotic jj or cc opioid nn may md be vb required vbn
false	42	46	however rb due jj to topos possible jj pharmacodynamic jj interactions nns when wrb co_administered vbn with inpos precedex nn a dt reduction nn in inpos dosage nn of inpos precedex nn on inpos the dt concomitant jj anesthetic jj sedative jj hypnotic nn or cc opioid nn may md be vb required vbn
false	18	68	in inpos num cd study nn of inpos num cd healthy jj volunteers nns administration nn of inpos precedex nn for inpos num cd minutes nns at inpos a dt plasma nn concentration nn of inpos num cd ng_ml nn resulted vbd in inpos no dt clinically rb meaningful jj increases nns in inpos the dt magnitude nn or cc neuromuscular jj blockade nn associated vbn with inpos rocuronium nn administration nn
false	0	14	zinecard nn does vbz not rb influence vb the dt pharmacokinetics nns of inpos doxorubicin nn
false	0	2	acidifying_agents nn guanethidine nn lower jjr absorption nn of inpos amphetamines nns
false	0	2	acidifying_agents nn reserpine nn lower jjr absorption nn of inpos amphetamines nns
false	0	2	acidifying_agents nn glutamic_acid_hcl nn lower jjr absorption nn of inpos amphetamines nns
false	0	2	acidifying_agents nn ascorbic_acid nn lower jjr absorption nn of inpos amphetamines nns
mechanism	0	8	gastrointestinal_acidifying_agents nn lower jjr absorption nn of inpos amphetamines nn
mechanism	2	10	acidifying_agents nns guanethidine nn lower jjr absorption nn of inpos amphetamines nn
mechanism	2	10	acidifying_agents nns reserpine nn lower jjr absorption nn of inpos amphetamines nn
mechanism	2	10	acidifying_agents nns glutamic_acid_hcl nn lower jjr absorption nn of inpos amphetamines nn
mechanism	2	10	acidifying_agents nns ascorbic_acid nn lower jjr absorption nn of inpos amphetamines nn
mechanism	0	20	urinary_acidifying_agents nn increase vbp the dt concentration nn of inpos the dt ionized vbn species nns of inpos the dt amphetamine nn molecule nn thereby rb increasing vbg urinary jj excretion nn
mechanism	0	20	ammonium_chloride nn increase vbp the dt concentration nn of inpos the dt ionized vbn species nns of inpos the dt amphetamine nn molecule nn thereby rb increasing vbg urinary jj excretion nn
mechanism	0	20	sodium_acid_phosphate nn increase vbp the dt concentration nn of inpos the dt ionized vbn species nns of inpos the dt amphetamine nn molecule nn thereby rb increasing vbg urinary jj excretion nn
effect	0	8	adrenergic_blockers nn are vbp inhibited vbn by inpos amphetamines nn
mechanism	4	12	gastrointestinal jj alkalinizing vbg sodium_bicarbonate nn increase nn absorption nn of inpos amphetamines nn
mechanism	4	24	urinary jj alkalinizing vbg acetazolamide nn increase vbp the dt concentration nn of inpos the dt non_ionized jj species nns of inpos the dt amphetamine nn molecule nn thereby rb decreasing vbg urinary jj excretion nn
mechanism	4	24	urinary jj alkalinizing vbg thiazides nn increase vbp the dt concentration nn of inpos the dt non_ionized jj species nns of inpos the dt amphetamine nn molecule nn thereby rb decreasing vbg urinary jj excretion nn
false	0	2	antidepressants nn tricyclic nn
effect	0	12	amphetamines nn may md enhance vb the dt activity nn of inpos tricyclic nn or cc sympathomimetic_agents nns
effect	0	16	amphetamines nn may md enhance vb the dt activity nn of inpos tricyclic jj or cc sympathomimetic_agents nn
false	12	16	amphetamines nns may md enhance vb the dt activity nn of inpos tricyclic nn or cc sympathomimetic_agents nn
mechanism	0	4	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
mechanism	0	6	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
mechanism	0	12	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	4	6	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	4	12	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	4	0	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	6	12	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	6	0	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	12	0	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	0	2	mao_inhibitors nn maoi_antidepressants nn as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
false	0	16	mao_inhibitors nn maoi_antidepressants nns as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
false	0	20	mao_inhibitors nn maoi_antidepressants nns as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
false	2	16	mao_inhibitors nns maoi_antidepressants nn as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
mechanism	2	20	mao_inhibitors nns maoi_antidepressants nn as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
mechanism	16	20	mao_inhibitors nns maoi_antidepressants nns as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
effect	0	14	amphetamines nn may md counteract vb the dt sedative jj effect nn of inpos antihistamines nn
effect	0	14	amphetamines nn may md antagonize vb the dt hypotensive jj effects nns of inpos antihypertensives nn
effect	0	26	chlorpromazine nn blocks vbz dopamine nn and cc norepinephrine nn reuptake nn thus rb inhibiting vbg the dt central jj stimulant jj effects nns of inpos amphetamines nn and cc can md be vb used vbn to topos treat vb amphetamine nn poisoning nn
false	0	26	chlorpromazine nn blocks vbz dopamine nn and cc norepinephrine nn reuptake nn thus rb inhibiting vbg the dt central jj stimulant jj effects nns of inpos amphetamines nns and cc can md be vb used vbn to topos treat vb amphetamine nn poisoning nn
mechanism	0	12	amphetamines nn may md delay vb intestinal jj absorption nn of inpos ethosuximide nn
effect	0	26	haloperidol nn blocks vbz dopamine nn and cc norepinephrine nn reuptake nn thus rb inhibiting vbg the dt central jj stimulant jj effects nns of inpos amphetamines nn
effect	8	18	the dt stimulatory jj effects nns of inpos amphetamines nn may md be vb inhibited vbn by inpos lithium_carbonate nn
effect	0	12	amphetamines nn potentiate vbp the dt analgesic jj effect nn of inpos meperidine nn
mechanism	6	22	urinary jj excretion nn of inpos amphetamines nn is vbz increased vbn and cc efficacy nn is vbz reduced vbn by inpos acidifying_agents nn used vbn in inpos methenamine nn therapy nn
false	6	28	urinary jj excretion nn of inpos amphetamines nn is vbz increased vbn and cc efficacy nn is vbz reduced vbn by inpos acidifying_agents nns used vbn in inpos methenamine nn therapy nn
false	22	28	urinary jj excretion nn of inpos amphetamines nns is vbz increased vbn and cc efficacy nn is vbz reduced vbn by inpos acidifying_agents nn used vbn in inpos methenamine nn therapy nn
effect	0	12	amphetamines nn enhance vbp the dt adrenergic jj effect nn of inpos norepinephrine nn
mechanism	0	12	amphetamines nn may md delay vb intestinal jj absorption nn of inpos phenobarbital nn
mechanism	0	12	amphetamines nn may md delay vb intestinal jj absorption nn of inpos phenytoin nn
effect	6	10	in inpos cases nns of inpos propoxyphene nn overdosage nn amphetamine nn cns nn stimulation nn is vbz potentiated jj and cc fatal jj convulsions nns can md occur vb
effect	0	12	amphetamines nn inhibit vbp the dt hypotensive jj effect nn of inpos veratrum_alkaloids nn
false	14	18	additive jj depressant jj effect nn when wrb used vbn with inpos general jj anesthetics nn other jj opiate_analgesics nn
false	16	20	additive jj depressant jj effect nn when wrb used vbn with inpos general jj anesthetics nns sedatives nn other jj opiate_analgesics nn
false	18	22	additive jj depressant jj effect nn when wrb used vbn with inpos general jj anesthetics nns sedatives nns antianxiety_drugs nn other jj opiate_analgesics nn
false	14	18	additive jj depressant jj effect nn when wrb used vbn with inpos general jj hypnotics nn other jj opiate_analgesics nn
false	14	18	additive jj depressant jj effect nn when wrb used vbn with inpos general jj alcohol nn other jj opiate_analgesics nn
false	8	10	may md interact vb with inpos thyroid jj levothyroxine nn iodine nn containing jj products nns antacids nns h2_antagonists nns and cc proton_pump_inhibitors nns
false	8	12	may md interact vb with inpos thyroid jj levothyroxine nns and cc proton_pump_inhibitors nn
false	8	12	may md interact vb with inpos thyroid jj levothyroxine nns and cc lansoprazole nn
false	8	12	may md interact vb with inpos thyroid jj levothyroxine nns and cc omeprazole nn
false	10	14	may md interact vb with inpos thyroid jj medication nn iodine nn containing jj antacids nns and cc proton_pump_inhibitors nns
false	10	14	may md interact vb with inpos thyroid jj medication nn iodine nn containing jj h2_antagonists nn and cc proton_pump_inhibitors nns
false	10	14	may md interact vb with inpos thyroid jj medication nn iodine nn containing jj famotidine nn and cc proton_pump_inhibitors nns
false	10	14	may md interact vb with inpos thyroid jj medication nn iodine nn containing jj ranitidine nn and cc proton_pump_inhibitors nns
false	10	22	may md interact vb with inpos thyroid jj medication nn iodine nn containing jj products nns antacids nns h2_antagonists nns and cc proton_pump_inhibitors nn
false	10	22	may md interact vb with inpos thyroid jj medication nn iodine nn containing jj products nns antacids nns h2_antagonists nns and cc lansoprazole nn
false	10	22	may md interact vb with inpos thyroid jj medication nn iodine nn containing jj products nns antacids nns h2_antagonists nns and cc omeprazole nn
false	8	12	may md interact vb with inpos thyroid jj antacids nns and cc proton_pump_inhibitors nn
false	8	12	may md interact vb with inpos thyroid jj antacids nns and cc lansoprazole nn
false	8	12	may md interact vb with inpos thyroid jj antacids nns and cc omeprazole nn
false	8	12	may md interact vb with inpos thyroid jj h2_antagonists nn and cc proton_pump_inhibitors nn
false	8	12	may md interact vb with inpos thyroid jj h2_antagonists nn and cc lansoprazole nn
false	8	12	may md interact vb with inpos thyroid jj h2_antagonists nn and cc omeprazole nn
false	8	12	may md interact vb with inpos thyroid jj famotidine nn and cc proton_pump_inhibitors nn
false	8	12	may md interact vb with inpos thyroid jj famotidine nn and cc lansoprazole nn
false	8	12	may md interact vb with inpos thyroid jj famotidine nn and cc omeprazole nn
false	8	12	may md interact vb with inpos thyroid jj ranitidine nn and cc proton_pump_inhibitors nn
false	8	12	may md interact vb with inpos thyroid jj ranitidine nn and cc lansoprazole nn
false	8	12	may md interact vb with inpos thyroid jj ranitidine nn and cc omeprazole nn
advise	16	20	caution nn is vbz advised vbn in inpos patients nns receiving vbg concomitant jj high_dose jj aspirin nn and cc carbonic_anhydrase_inhibitors nn as inpos anorexia nn tachypnea nn lethargy nn coma nn have vbp been vbn rarely rb reported vbn due jj to topos a dt possible jj drug nn interaction nn
false	0	8	aspirin nn concomitant jj administration nn of inpos diclofenac nn and cc aspirin nn is vbz not rb recommended vbn because inpos diclofenac nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns peak jj plasma nn levels nns auc nn values nns
false	0	8	aspirin nn concomitant jj administration nn of inpos diclofenac nn and cc aspirin nn is vbz not rb recommended vbn because inpos diclofenac nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns peak jj plasma nn levels nns auc nn values nns
advise	6	10	concomitant jj administration nn of inpos diclofenac nn and cc aspirin nn is vbz not rb recommended vbn because inpos diclofenac nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns peak jj plasma nn levels nns auc nn values nns
false	6	10	concomitant jj administration nn of inpos diclofenac nn and cc aspirin nn is vbz not rb recommended vbn because inpos diclofenac nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns peak jj plasma nn levels nns auc nn values nns
false	10	6	concomitant jj administration nn of inpos diclofenac nn and cc aspirin nn is vbz not rb recommended vbn because inpos diclofenac nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns peak jj plasma nn levels nns auc nn values nns
mechanism	6	10	concomitant jj administration nn of inpos diclofenac nn and cc aspirin nn is vbz not rb recommended vbn because inpos diclofenac nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns peak jj plasma nn levels nns auc nn values nns
false	10	18	while inpos studies nns have vbp not rb shown vbn diclofenac nn to topos interact vb with inpos anticoagulants_of_the_warfarin_type nn caution nn should md be vb exercised vbn nonetheless rb since inpos interactions nns have vbp been vbn seen vbn with inpos other jj nsaids nns
advise	10	44	while inpos studies nns have vbp not rb shown vbn diclofenac nn to topos interact vb with inpos anticoagulants_of_the_warfarin_type nn caution nn should md be vb exercised vbn nonetheless rb since inpos interactions nns have vbp been vbn seen vbn with inpos other jj nsaids nn
false	18	44	while inpos studies nns have vbp not rb shown vbn diclofenac nn to topos interact vb with inpos anticoagulants_of_the_warfarin_type nn caution nn should md be vb exercised vbn nonetheless rb since inpos interactions nns have vbp been vbn seen vbn with inpos other jj nsaids nn
false	18	42	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nn affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nns including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant jj dosage nn is vbz required vbn
false	18	46	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nn affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nns including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant jj dosage nn is vbz required vbn
false	18	74	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nn affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nns including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant nn dosage nn is vbz required vbn
false	18	42	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nns affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nn including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant jj dosage nn is vbz required vbn
advise	18	46	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nns affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nn including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant jj dosage nn is vbz required vbn
false	18	74	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nns affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nn including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant nn dosage nn is vbz required vbn
advise	42	46	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nns affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nns including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant jj dosage nn is vbz required vbn
false	42	74	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nns affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nns including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant nn dosage nn is vbz required vbn
false	46	74	because inpos prostaglandins nns play vbp an dt important jj role nn in inpos hemostasis nn and cc nsaids nns affect vbp platelet nn function nn as rb well rb concurrent jj therapy nn with inpos all dt nsaids nns including vbg diclofenac nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns to topos be vb certain jj that inpos no dt change nn in inpos their prp anticoagulant nn dosage nn is vbz required vbn
false	0	2	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nns may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	0	4	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nns may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	0	6	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nns may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	0	12	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nn may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	2	4	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nns may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	2	6	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nns may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	2	12	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nn may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	4	6	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nns may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	4	12	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nn may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
false	6	12	digoxin nn methotrexate nn cyclosporine nn diclofenac nn like inpos other jj nsaids nn may md affect vb renal jj prostaglandins nns and cc increase vb the dt toxicity nn of inpos certain jj drugs nns
mechanism	4	16	ingestion nn of inpos diclofenac nn may md increase vb serum nn concentrations nns of inpos digoxin nn and cc methotrexate nn and cc increase nn cyclosporine nn s vbz nephrotoxicity nn
mechanism	4	20	ingestion nn of inpos diclofenac nn may md increase vb serum nn concentrations nns of inpos digoxin nn and cc methotrexate nn and cc increase nn cyclosporine nn s vbz nephrotoxicity nn
effect	4	26	ingestion nn of inpos diclofenac nn may md increase vb serum nn concentrations nns of inpos digoxin nn and cc methotrexate nn and cc increase nn cyclosporine nn s vbz nephrotoxicity nn
false	16	20	ingestion nn of inpos diclofenac nn may md increase vb serum nn concentrations nns of inpos digoxin nn and cc methotrexate nn and cc increase nn cyclosporine nn s vbz nephrotoxicity nn
false	16	26	ingestion nn of inpos diclofenac nn may md increase vb serum nn concentrations nns of inpos digoxin nn and cc methotrexate nn and cc increase nn cyclosporine nn s vbz nephrotoxicity nn
false	20	26	ingestion nn of inpos diclofenac nn may md increase vb serum nn concentrations nns of inpos digoxin nn and cc methotrexate nn and cc increase nn cyclosporine nn s vbz nephrotoxicity nn
false	8	28	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg digoxin nn methotrexate nn cyclosporine nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
effect	8	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg digoxin nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
effect	8	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg methotrexate nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
effect	8	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg cyclosporine nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
false	8	28	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg digoxin nn methotrexate nn cyclosporine nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
false	8	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg digoxin nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
false	8	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg methotrexate nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
false	8	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg cyclosporine nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
effect	28	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg digoxin nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
effect	28	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg methotrexate nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
effect	28	34	patients nns who wp begin vbp taking vbg diclofenac nn or cc who wp increase vbp their prp diclofenac nn dose nn or cc any dt other jj nsaid nn while inpos taking vbg cyclosporine nn may md develop vb toxicity nn characteristics nns for inpos these dt drugs nns
mechanism	0	4	diclofenac nn decreases vbz lithium nn renal jj clearance nn and cc increases vbz lithium nn plasma nn levels nns
mechanism	0	4	diclofenac nn decreases vbz lithium nn renal jj clearance nn and cc increases vbz lithium nn plasma nn levels nns
effect	6	10	in inpos patients nns taking vbg diclofenac nn and cc lithium nn concomitantly rb lithium nn toxicity nn may md develop vb
false	6	10	in inpos patients nns taking vbg diclofenac nn and cc lithium nn concomitantly rb lithium nn toxicity nn may md develop vb
false	0	34	diclofenac nn does vbz not rb alter vb glucose nn metabolism nn in inpos normal jj subjects nns nor cc does vbz it prp alter vb the dt effects nns of inpos oral jj hypoglycemic_agents nn
false	26	32	there ex are vbp rare jj reports nns however rb from inpos marketing nn experiences nns of inpos changes nns in inpos effects nns of inpos insulin nn or cc oral jj hypoglycemic_agents nn in inpos the dt presence nn of inpos diclofenac nn that wdt necessitated vbd changes nns in inpos the dt doses nns of inpos such jj agents nns
effect	26	42	there ex are vbp rare jj reports nns however rb from inpos marketing nn experiences nns of inpos changes nns in inpos effects nns of inpos insulin nn or cc oral jj hypoglycemic_agents nns in inpos the dt presence nn of inpos diclofenac nn that wdt necessitated vbd changes nns in inpos the dt doses nns of inpos such jj agents nns
effect	32	42	there ex are vbp rare jj reports nns however rb from inpos marketing nn experiences nns of inpos changes nns in inpos effects nns of inpos insulin nn or cc oral jj hypoglycemic_agents nn in inpos the dt presence nn of inpos diclofenac nn that wdt necessitated vbd changes nns in inpos the dt doses nns of inpos such jj agents nns
effect	30	48	a dt direct jj causal jj relationship nn has vbz not rb been vbn established vbn but cc physicians nns should md consider vb the dt possibility nn that inpos diclofenac nn may md alter vb a dt diabetic jj patient nn s vbz response nn to topos insulin nn or cc oral jj hypoglycemic_agents nns
effect	30	54	a dt direct jj causal jj relationship nn has vbz not rb been vbn established vbn but cc physicians nns should md consider vb the dt possibility nn that inpos diclofenac nn may md alter vb a dt diabetic jj patient nn s vbz response nn to topos insulin nn or cc oral jj hypoglycemic_agents nn
false	48	54	a dt direct jj causal jj relationship nn has vbz not rb been vbn established vbn but cc physicians nns should md consider vb the dt possibility nn that inpos diclofenac nn may md alter vb a dt diabetic jj patient nn s vbz response nn to topos insulin nn or cc oral jj hypoglycemic_agents nn
false	0	6	diclofenac nn and cc other jj nsaids nn can md inhibit vb the dt activity nn of inpos diuretics nns
effect	0	18	diclofenac nn and cc other jj nsaids nns can md inhibit vb the dt activity nn of inpos diuretics nn
effect	6	18	diclofenac nn and cc other jj nsaids nn can md inhibit vb the dt activity nn of inpos diuretics nn
false	18	42	in inpos small jj groups nns of inpos patients nns the dt concomitant jj administration nn of inpos azathioprine nn did vbd not rb significantly rb affect vb the dt peak jj levels nns and cc auc nn values nns of inpos diclofenac nn
false	18	42	in inpos small jj groups nns of inpos patients nns the dt concomitant jj administration nn of inpos gold nn did vbd not rb significantly rb affect vb the dt peak jj levels nns and cc auc nn values nns of inpos diclofenac nn
false	18	42	in inpos small jj groups nns of inpos patients nns the dt concomitant jj administration nn of inpos chloroquine nn did vbd not rb significantly rb affect vb the dt peak jj levels nns and cc auc nn values nns of inpos diclofenac nn
false	18	42	in inpos small jj groups nns of inpos patients nns the dt concomitant jj administration nn of inpos d_penicillamine nn did vbd not rb significantly rb affect vb the dt peak jj levels nns and cc auc nn values nns of inpos diclofenac nn
false	18	42	in inpos small jj groups nns of inpos patients nns the dt concomitant jj administration nn of inpos prednisolone nn did vbd not rb significantly rb affect vb the dt peak jj levels nns and cc auc nn values nns of inpos diclofenac nn
false	18	42	in inpos small jj groups nns of inpos patients nns the dt concomitant jj administration nn of inpos doxycycline nn did vbd not rb significantly rb affect vb the dt peak jj levels nns and cc auc nn values nns of inpos diclofenac nn
false	18	42	in inpos small jj groups nns of inpos patients nns the dt concomitant jj administration nn of inpos digitoxin nn did vbd not rb significantly rb affect vb the dt peak jj levels nns and cc auc nn values nns of inpos diclofenac nn
false	0	38	phenobarbital nn toxicity nn has vbz been vbn reported vbn to topos have vb occurred vbn in inpos a dt patient nn on inpos chronic jj phenobarbital nn treatment nn following vbg the dt initiation nn of inpos diclofenac nn therapy nn
effect	0	38	phenobarbital nn toxicity nn has vbz been vbn reported vbn to topos have vb occurred vbn in inpos a dt patient nn on inpos chronic jj phenobarbital nn treatment nn following vbg the dt initiation nn of inpos diclofenac nn therapy nn
mechanism	8	32	protein nn binding nn in fw vitro fw diclofenac nn interferes vbz minimally rb or cc not rb at inpos all dt with inpos the dt protein nn binding nn of inpos salicylic_acid nn
mechanism	8	32	protein nn binding nn in fw vitro fw diclofenac nn interferes vbz minimally rb or cc not rb at inpos all dt with inpos the dt protein nn binding nn of inpos tolbutamide nn
mechanism	8	32	protein nn binding nn in fw vitro fw diclofenac nn interferes vbz minimally rb or cc not rb at inpos all dt with inpos the dt protein nn binding nn of inpos prednisolone nn
mechanism	8	32	protein nn binding nn in fw vitro fw diclofenac nn interferes vbz minimally rb or cc not rb at inpos all dt with inpos the dt protein nn binding nn of inpos warfarin nn
false	0	22	benzylpenicillin nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	22	ampicillin nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	22	oxacillin nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	22	chlortetracycline nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	22	doxycycline nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	22	cephalothin nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	22	erythromycin nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	22	sulfamethoxazole nn have vbp no dt influence nn in fw vitro fw on inpos the dt protein nn binding nn of inpos diclofenac nn in inpos human jj serum nn
false	0	4	tetracycline nn a dt bacteriostatic_antibiotic nn may md antagonize vb the dt bactercidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
effect	0	18	tetracycline nn a dt bacteriostatic_antibiotic jj may md antagonize vb the dt bactercidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
false	4	18	tetracycline nn a dt bacteriostatic_antibiotic nn may md antagonize vb the dt bactercidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
false	22	24	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents nns of inpos class nn antihistamines nns antipsychotic_agents nns benzodiazepines nns
false	22	26	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents nn of inpos class nn antihistamines nns antipsychotic_agents nns benzodiazepines nns
false	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents nns of inpos quinidine nn antihistamines nns antipsychotic_agents nns benzodiazepines nns
false	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents nns of inpos antihistamines nns
false	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents nns of inpos antipsychotic_agents nns
false	22	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents nns of inpos phenothiazines nns
false	22	36	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs nn amantadine nn antiarrhythmic_agents nns of inpos class nn antihistamines nns antipsychotic_agents nns benzodiazepines nn
false	24	26	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. nn amantadine nn antiarrhythmic_agents nn of inpos class nn antihistamines nns antipsychotic_agents nns benzodiazepines nns
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nns of inpos quinidine nn antihistamines nns antipsychotic_agents nns benzodiazepines nns
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nns of inpos antihistamines nns
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nns of inpos antipsychotic_agents nns
false	24	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nns of inpos phenothiazines nns
false	24	36	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nns of inpos class nn antihistamines nns antipsychotic_agents nns benzodiazepines nn
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. nn amantadine nn antiarrhythmic_agents nn of inpos quinidine nn antihistamines nns antipsychotic_agents nns benzodiazepines nns
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. nn amantadine nn antiarrhythmic_agents nn of inpos antihistamines nns
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nn of inpos antipsychotic_agents nns
false	26	30	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nn of inpos phenothiazines nns
false	26	36	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. nn amantadine nn antiarrhythmic_agents nn of inpos class nn antihistamines nns antipsychotic_agents nns benzodiazepines nn
false	30	36	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nns of inpos quinidine nn antihistamines nns antipsychotic_agents nns benzodiazepines nn
false	32	36	the dt following vbg agents nns may md increase vb certain jj actions nns or cc side jj effects nns of inpos anticholinergic_drugs. jj amantadine nn antiarrhythmic_agents nns of inpos class nn antihistamines nn antipsychotic_agents nns benzodiazepines nn
false	0	10	anticholinergics nn antagonize vbp the dt effects nns of inpos antiglaucoma_agents nn
mechanism	0	30	anticholinergic_agents nn may md affect vb gastrointestinal jj absorption nn of inpos various jj drugs nns such jj as inpos slowly rb dissolving vbg dosage nn forms nns of inpos digoxin nn
mechanism	0	28	anticholinergic_drugs nn may md antagonize vb the dt effects nns of inpos the dt drugs nns that wdt alter vbp gastrointestinal jj motility nn such jj as inpos metoclopramide nn
mechanism	2	16	because inpos antacids nn may md interfere vb with inpos the dt absorption nn of inpos anticholinergic_agents nn simultaneous jj use nn of inpos these dt drugs nns should md be vb avoided vbn
false	34	58	neuropathy nn has vbz occurred vbn more rbr frequently rb in inpos patients nns with inpos a dt history nn of inpos neuropathy nn or cc neurotoxic jj drug nn therapy nn including vbg stavudine nn and cc these dt patients nns may md be vb at inpos increased vbn risk nn of inpos neuropathy nn during inpos videx nn therapy nn
false	6	18	the dt auc nn of inpos didanosine nn was vbd increased vbn about rb num_fold rb when wrb allopurinol nn at inpos num cd mg_day nn was vbd coadministered vbn with inpos a dt single jj num_mg jj dose nn of inpos videx nn to topos num cd patients nns with inpos renal jj impairment nn
false	6	42	the dt auc nn of inpos didanosine nn was vbd increased vbn about rb num_fold rb when wrb allopurinol nn at inpos num cd mg_day nn was vbd coadministered vbn with inpos a dt single jj num_mg jj dose nn of inpos videx nn to topos num cd patients nns with inpos renal jj impairment nn
mechanism	18	42	the dt auc nn of inpos didanosine nn was vbd increased vbn about rb num_fold rb when wrb allopurinol nn at inpos num cd mg_day nn was vbd coadministered vbn with inpos a dt single jj num_mg jj dose nn of inpos videx nn to topos num cd patients nns with inpos renal jj impairment nn
false	6	10	the dt effects nns of inpos allopurinol nn on inpos didanosine nn pharmacokinetics nns in inpos subjects nns with inpos normal jj renal jj function nn are vbp not rb known vbn
false	0	12	antacids nn concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn chewable nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	0	16	antacids nn concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	0	20	antacids nn concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible jj buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	6	10	concomitant jj administration nn of inpos antacids nn containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	6	14	concomitant jj administration nn of inpos antacids nn containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
effect	6	18	concomitant jj administration nn of inpos antacids nn containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible jj buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	10	14	concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
effect	10	18	concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn chewable nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	10	6	concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
effect	14	18	concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn chewable nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	14	6	concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn dispersible nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	18	6	concomitant jj administration nn of inpos antacids nns containing vbg magnesium nn or cc aluminum nn with inpos videx nn chewable nnp buffered nnp tablets nnps or cc pediatric nnp powder nnp for inpos oral nnp solution nnp may md potentiate vb adverse jj events nns associated vbn with inpos the dt antacid nn components nns
false	6	10	drugs nns such jj as inpos ketoconazole nn and cc itraconazole nn should md be vb administered vbn at inpos least jjs num cd hours nns prior rb to topos dosing nn with inpos videx nn
advise	6	34	drugs nns such jj as inpos ketoconazole nn and cc itraconazole nn should md be vb administered vbn at inpos least jjs num cd hours nns prior rb to topos dosing nn with inpos videx nn
advise	10	34	drugs nns such jj as inpos ketoconazole nn and cc itraconazole nn should md be vb administered vbn at inpos least jjs num cd hours nns prior rb to topos dosing nn with inpos videx nn
false	0	6	ganciclovir nn administration nn of inpos videx nn num cd hours nns prior jj to topos or cc concurrent jj with inpos oral jj ganciclovir nn was vbd associated vbn with inpos a dt num cd increase nn in inpos the dt steady_state jj auc nn of inpos didanosine nn
false	0	48	ganciclovir nn administration nn of inpos videx nn num cd hours nns prior jj to topos or cc concurrent jj with inpos oral jj ganciclovir nn was vbd associated vbn with inpos a dt num cd increase nn in inpos the dt steady_state jj auc nn of inpos didanosine nn
mechanism	4	22	administration nn of inpos videx nn num cd hours nns prior jj to topos or cc concurrent jj with inpos oral jj ganciclovir nn was vbd associated vbn with inpos a dt num cd increase nn in inpos the dt steady_state jj auc nn of inpos didanosine nn
false	4	46	administration nn of inpos videx nn num cd hours nns prior jj to topos or cc concurrent jj with inpos oral jj ganciclovir nn was vbd associated vbn with inpos a dt num cd increase nn in inpos the dt steady_state jj auc nn of inpos didanosine nn
false	22	46	administration nn of inpos videx nn num cd hours nns prior jj to topos or cc concurrent jj with inpos oral jj ganciclovir nn was vbd associated vbn with inpos a dt num cd increase nn in inpos the dt steady_state jj auc nn of inpos didanosine nn
false	16	24	a dt num cd decrease nn in inpos the dt steady_state jj auc nn of inpos ganciclovir nn was vbd observed vbn when wrb videx nn was vbd administered vbn num cd hours nns prior rb to topos ganciclovir nn but cc not rb when wrb the dt num cd drugs nns were vbd administered vbn simultaneously rb
mechanism	24	16	a dt num cd decrease nn in inpos the dt steady_state jj auc nn of inpos ganciclovir nn was vbd observed vbn when wrb videx nn was vbd administered vbn num cd hours nns prior rb to topos ganciclovir nn but cc not rb when wrb the dt num cd drugs nns were vbd administered vbn simultaneously rb
advise	0	30	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg magnesium nn calcium nn aluminum nn
false	0	30	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg magnesium nn calcium nn aluminum nn
false	0	52	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg magnesium nn calcium nn aluminum nn
false	0	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg magnesium nn
false	0	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg calcium nn
false	0	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg aluminum nn
false	30	52	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg magnesium nn calcium nn aluminum nn
false	30	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg magnesium nn
false	30	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg calcium nn
false	30	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg aluminum nn
false	30	52	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg magnesium nn calcium nn aluminum nn
mechanism	30	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg magnesium nn
mechanism	30	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg calcium nn
mechanism	30	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg aluminum nn
false	52	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg magnesium nn
false	52	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg calcium nn
false	52	56	videx nn should md be vb administered vbn at inpos least jjs num cd hours nns after inpos or cc num cd hours nns before inpos dosing nn with inpos ciprofloxacin nn because inpos plasma nn concentrations nns of inpos ciprofloxacin nn are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg aluminum nn
false	16	58	in inpos num cd hiv_infected jj patients nns the dt steady_state jj auc nn of inpos ciprofloxacin nn was vbd decreased vbn an dt average nn of inpos num cd when wrb ciprofloxacin nn was vbd administered vbn num cd hours nns prior rb to topos a dt marketed vbn chewable jj tablet nn formulation nn of inpos videx nn
mechanism	16	58	in inpos num cd hiv_infected jj patients nns the dt steady_state jj auc nn of inpos ciprofloxacin nn was vbd decreased vbn an dt average nn of inpos num cd when wrb ciprofloxacin nn was vbd administered vbn num cd hours nns prior rb to topos a dt marketed vbn dispersible jj tablet nn formulation nn of inpos videx nn
false	6	34	the dt auc nn of inpos ciprofloxacin nn was vbd decreased vbn an dt average nn of inpos num_fold jj in inpos num cd healthy jj subjects nns given vbn ciprofloxacin nn and cc didanosine nn placebo jj tablets nns concurrently rb
mechanism	6	34	the dt auc nn of inpos ciprofloxacin nn was vbd decreased vbn an dt average nn of inpos num_fold jj in inpos num cd healthy jj subjects nns given vbn ciprofloxacin nn and cc didanosine nn placebo jj tablets nns concurrently rb
mechanism	16	30	in inpos a dt single jj subject nn given vbn num cd dose nn of inpos ciprofloxacin nn num cd hours nns after inpos a dt dose nn of inpos didanosine nn placebo jj tablets nns a dt greater jjr than inpos num cd reduction nn in inpos the dt auc nn of inpos ciprofloxacin nn was vbd observed vbn
false	30	16	in inpos a dt single jj subject nn given vbn num cd dose nn of inpos ciprofloxacin nn num cd hours nns after inpos a dt dose nn of inpos didanosine nn placebo jj tablets nns a dt greater jjr than inpos num cd reduction nn in inpos the dt auc nn of inpos ciprofloxacin nn was vbd observed vbn
false	6	18	plasma nn concentrations nns of inpos quinolone_antibiotics nn are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg magnesium nn calcium nn aluminum nn
mechanism	6	22	plasma nn concentrations nns of inpos quinolone_antibiotics nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg magnesium nn
mechanism	6	22	plasma nn concentrations nns of inpos quinolone_antibiotics nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg calcium nn
mechanism	6	22	plasma nn concentrations nns of inpos quinolone_antibiotics nn are vbp decreased vbn when wrb administered vbn with inpos antacids nns containing vbg aluminum nn
false	18	22	plasma nn concentrations nns of inpos quinolone_antibiotics nns are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg magnesium nn
false	18	22	plasma nn concentrations nns of inpos quinolone_antibiotics nns are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg calcium nn
false	18	22	plasma nn concentrations nns of inpos quinolone_antibiotics nns are vbp decreased vbn when wrb administered vbn with inpos antacids nn containing vbg aluminum nn
false	14	30	the dt optimal jj dosing nn interval nn for inpos coadministration nn with inpos videx nn should md be vb determined vbn by inpos consulting vbg the dt appropriate jj quinolone nn package nn insert nn
false	12	16	significant jj decreases nns in inpos the dt auc nn of inpos delavirdine nn and cc indinavir nn occurred vbd following vbg simultaneous jj administration nn of inpos these dt agents nns with inpos videx nn
mechanism	12	34	significant jj decreases nns in inpos the dt auc nn of inpos delavirdine nn and cc indinavir nn occurred vbd following vbg simultaneous jj administration nn of inpos these dt agents nns with inpos videx nn
mechanism	16	34	significant jj decreases nns in inpos the dt auc nn of inpos delavirdine nn and cc indinavir nn occurred vbd following vbg simultaneous jj administration nn of inpos these dt agents nns with inpos videx nn
false	8	12	to topos avoid vb this dt interaction nn delavirdine nn or cc indinavir nn should md be vb given vbn num cd hour nn prior jj to topos dosing nn with inpos videx nn
advise	8	32	to topos avoid vb this dt interaction nn delavirdine nn or cc indinavir nn should md be vb given vbn num cd hour nn prior jj to topos dosing nn with inpos videx nn
advise	12	32	to topos avoid vb this dt interaction nn delavirdine nn or cc indinavir nn should md be vb given vbn num cd hour nn prior jj to topos dosing nn with inpos videx nn
false	6	46	the dt pharmacokinetics nns of inpos nelfinavir nn are vbp not rb altered vbn to topos a dt clinically rb significant jj degree nn when wrb it prp is vbz administered vbn with inpos a dt light jj meal nn num cd hour nn after inpos videx nn
false	28	34	drug nnp laboratory nnp test nnp interactions nnp certain nnp endocrine nn and cc liver nn function nn tests nns may md be vb affected vbn by inpos estrogen nn containing jj oral jj contraceptives nn
false	0	2	antidiabetic_drug nn insulin nn may md be vb altered vbn
int	2	10	conversely rb diethylpropion nn may md interfere vb with inpos antihypertensive_drugs nn
int	2	10	conversely rb diethylpropion nn may md interfere vb with inpos guanethidine nn
int	2	10	conversely rb diethylpropion nn may md interfere vb with inpos a_methyldopa nn
effect	6	20	concurrent jj use nn of inpos phenothiazines nn may md antagonize vb the dt anorectic jj effect nn of inpos diethylpropion nn
false	4	28	may md interact vb anticoagulants nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn lrb_decreased vbn effect nn of inpos diethylstilbestrol nn rrb_corticosteroids nns
false	4	18	may md interact vb anticoagulants nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn corticosteroids nn
false	4	22	may md interact vb anticoagulants nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn corticosteroids nns lrb_increased vbn effect nn of inpos corticosteroids nn
false	4	28	may md interact vb barbiturates nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn lrb_decreased vbn effect nn of inpos diethylstilbestrol nn rrb_corticosteroids nns
false	4	18	may md interact vb barbiturates nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn corticosteroids nn
false	4	22	may md interact vb barbiturates nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn corticosteroids nns lrb_increased vbn effect nn of inpos corticosteroids nn
false	4	28	may md interact vb rifampin nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn lrb_decreased vbn effect nn of inpos diethylstilbestrol nn rrb_corticosteroids nns
false	4	18	may md interact vb rifampin nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn corticosteroids nn
false	4	22	may md interact vb rifampin nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn corticosteroids nns lrb_increased vbn effect nn of inpos corticosteroids nn
false	32	34	may md interact vb anticoagulants nns barbiturates nns rifampin nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn lrb_decreased vbn effect nn of inpos diethylstilbestrol nn rrb_corticosteroids nn
false	32	34	may md interact vb anticoagulants nns barbiturates nns rifampin nn other jj inducers nns of inpos hepatic jj microsomal jj enzyme nn oxidation nn system nn lrb_decreased vbn effect nn of inpos diethylstilbestrol nn rrb_corticosteroids nns lrb_increased vbn effect nn of inpos corticosteroids nn
false	2	20	oral jj anticoagulants nn in inpos some dt normal jj volunteers nns the dt concomitant jj administration nn of inpos diflunisal nn resulted vbd in inpos prolongation nn of inpos prothrombin nn time nn
false	2	20	oral jj anticoagulants nn in inpos some dt normal jj volunteers nns the dt concomitant jj administration nn of inpos warfarin nn resulted vbd in inpos prolongation nn of inpos prothrombin nn time nn
false	2	20	oral jj anticoagulants nn in inpos some dt normal jj volunteers nns the dt concomitant jj administration nn of inpos acenocoumarol nn resulted vbd in inpos prolongation nn of inpos prothrombin nn time nn
false	2	20	oral jj anticoagulants nn in inpos some dt normal jj volunteers nns the dt concomitant jj administration nn of inpos phenprocoumon nn resulted vbd in inpos prolongation nn of inpos prothrombin nn time nn
mechanism	8	14	this dt may md occur vb because inpos diflunisal nn competitively rb displaces vbz coumarins nn from inpos protein nn binding nn sites nns
advise	4	14	accordingly rb when wrb diflunisal nn is vbz administered vbn with inpos oral jj anticoagulants nn the dt prothrombin nn time nn should md be vb closely rb monitored vbn during inpos and cc for inpos several jj days nns after inpos concomitant jj drug nn administration nn
false	8	12	in inpos diabetic jj patients nns receiving vbg diflunisal nn and cc tolbutamide nn no dt significant jj effects nns were vbd seen vbn on inpos tolbutamide nn plasma nn levels nns or cc fasting vbg blood nn glucose nn
false	8	12	in inpos diabetic jj patients nns receiving vbg diflunisal nn and cc tolbutamide nn no dt significant jj effects nns were vbd seen vbn on inpos tolbutamide nn plasma nn levels nns or cc fasting vbg blood nn glucose nn
false	0	14	hydrochlorothiazide nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos diflunisal nn and cc hydrochlorothiazide nn resulted vbd in inpos significantly rb increased vbn plasma nn levels nns of inpos hydrochlorothiazide nn
mechanism	14	0	hydrochlorothiazide nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos diflunisal nn and cc hydrochlorothiazide nn resulted vbd in inpos significantly rb increased vbn plasma nn levels nns of inpos hydrochlorothiazide nn
false	14	0	hydrochlorothiazide nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos diflunisal nn and cc hydrochlorothiazide nn resulted vbd in inpos significantly rb increased vbn plasma nn levels nns of inpos hydrochlorothiazide nn
effect	0	12	diflunisal nn decreased vbd the dt hyperuricemic jj effect nn of inpos hydrochlorothiazide nn
false	0	16	furosemide nn in inpos normal jj volunteers nns the dt concomitant jj administration nn of inpos diflunisal nn and cc furosemide nn had vbd no dt effect nn on inpos the dt diuretic jj activity nn of inpos furosemide nn
false	16	0	furosemide nn in inpos normal jj volunteers nns the dt concomitant jj administration nn of inpos diflunisal nn and cc furosemide nn had vbd no dt effect nn on inpos the dt diuretic jj activity nn of inpos furosemide nn
false	16	0	furosemide nn in inpos normal jj volunteers nns the dt concomitant jj administration nn of inpos diflunisal nn and cc furosemide nn had vbd no dt effect nn on inpos the dt diuretic jj activity nn of inpos furosemide nn
effect	0	12	diflunisal nn decreased vbd the dt hyperuricemic jj effect nn of inpos furosemide nn
false	0	20	antacids nn concomitant jj administration nn of inpos antacids nns may md reduce vb plasma nn levels nns of inpos diflunisal nn
mechanism	6	18	concomitant jj administration nn of inpos antacids nn may md reduce vb plasma nn levels nns of inpos diflunisal nn
false	0	14	acetaminophen nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn resulted vbd in inpos an dt approximate jj num cd increase nn in inpos plasma nn levels nns of inpos acetaminophen nn
mechanism	14	0	acetaminophen nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn resulted vbd in inpos an dt approximate jj num cd increase nn in inpos plasma nn levels nns of inpos acetaminophen nn
false	14	0	acetaminophen nn in inpos normal jj volunteers nns concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn resulted vbd in inpos an dt approximate jj num cd increase nn in inpos plasma nn levels nns of inpos acetaminophen nn
false	0	16	acetaminophen nn had vbd no dt effect nn on inpos plasma nn levels nns of inpos diflunisal nn
false	2	26	since inpos acetaminophen nn in inpos high jj doses nns has vbz been vbn associated vbn with inpos hepatotoxicity nn concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn should md be vb used vbn cautiously rb with inpos careful jj monitoring nn of inpos patients nns
advise	26	2	since inpos acetaminophen nn in inpos high jj doses nns has vbz been vbn associated vbn with inpos hepatotoxicity nn concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn should md be vb used vbn cautiously rb with inpos careful jj monitoring nn of inpos patients nns
effect	6	10	concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn in inpos dogs nns but cc not rb in inpos rats nns at inpos approximately rb num cd times nns the dt recommended vbn maximum nn human jj therapeutic jj dose nn of inpos each dt resulted vbd in inpos greater jjr gastrointestinal jj toxicity nn than inpos when wrb either cc drug nn was vbd administered vbn alone rb
false	6	10	concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn in inpos dogs nns but cc not rb in inpos rats nns at inpos approximately rb num cd times nns the dt recommended vbn maximum nn human jj therapeutic jj dose nn of inpos each dt lrb_num cd to topos num cd mg_kg_day nn of inpos acetaminophen nn rrb_resulted vbd in inpos greater jjr gastrointestinal jj toxicity nn than inpos when wrb either cc drug nn was vbd administered vbn alone rb
false	10	6	concomitant jj administration nn of inpos diflunisal nn and cc acetaminophen nn in inpos dogs nns but cc not rb in inpos rats nns at inpos approximately rb num cd times nns the dt recommended vbn maximum nn human jj therapeutic jj dose nn of inpos each dt lrb_num cd to topos num cd mg_kg_day nn of inpos diflunisal nn rrb_resulted vbd in inpos greater jjr gastrointestinal jj toxicity nn than inpos when wrb either cc drug nn was vbd administered vbn alone rb
false	0	12	methotrexate nn caution nn should md be vb used vbn if inpos diflunisal nn is vbz administered vbn concomitantly rb with inpos methotrexate nn
advise	10	20	caution nn should md be vb used vbn if inpos diflunisal nn is vbz administered vbn concomitantly rb with inpos methotrexate nn
mechanism	0	20	nonsteroidal_anti_inflammatory_drugs nn have vbp been vbn reported vbn to topos decrease vb the dt tubular jj secretion nn of inpos methotrexate nn and cc to topos potentiate vb its prp toxicity nn
false	0	6	cyclosporine nn administration nn of inpos nonsteroial_anti_inflammatory_drugs nn concomitantly rb with inpos cyclosporine nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos cyclosporine_induced jj toxicity nn possibly rb due jj to topos decreased vbn synthesis nn of inpos renal jj prostacyclin nn
mechanism	4	10	administration nn of inpos nonsteroial_anti_inflammatory_drugs nn concomitantly rb with inpos cyclosporine nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos cyclosporine_induced jj toxicity nn possibly rb due jj to topos decreased vbn synthesis nn of inpos renal jj prostacyclin nn
false	4	10	administration nn of inpos nonsteroial_anti_inflammatory_drugs nn concomitantly rb with inpos cyclosporine nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos cyclosporine nn induced jj toxicity nn possibly rb due jj to topos decreased vbn synthesis nn of inpos renal jj prostacyclin nn
advise	0	18	nsaids nn should md be vb used vbn with inpos caution nn in inpos patients nns taking vbg cyclosporine nn and cc renal jj function nn should md be vb carefully rb monitored vbn
mechanism	6	16	the dt administration nn of inpos diflunisal nn to topos normal jj volunteers nns receiving vbg indomethacin nn decreased vbd the dt renal jj clearance nn and cc significantly rb increased vbd the dt plasma nn levels nns of inpos indomethacin nn
false	6	16	the dt administration nn of inpos diflunisal nn to topos normal jj volunteers nns receiving vbg indomethacin nn decreased vbd the dt renal jj clearance nn and cc significantly rb increased vbd the dt plasma nn levels nns of inpos indomethacin nn
effect	14	18	in inpos some dt patients nns the dt combined vbn use nn of inpos indomethacin nn and cc diflunisal nn has vbz been vbn associated vbn with inpos fatal jj gastrointestinal jj hemorrhage nn
advise	2	6	therefore rb indomethacin nn and cc diflunisal nn should md not rb be vb used vbn concomitantly rb
effect	8	16	the dt concomitant jj use nn of inpos diflunisal nn tablets nns and cc other jj nsaids nn is vbz not rb recommended vbn due inpos to topos the dt increased vbn possibility nn of inpos gastrointestinal jj toxicity nn with inpos little jj or cc no dt increase nn in inpos efficacy nn
false	0	16	aspirin nn in inpos normal jj volunteers nns a dt small jj decrease nn in inpos diflunisal nn levels nns was vbd observed vbn when wrb multiple jj doses nns of inpos diflunisal nn and cc aspirin nn were vbd administered vbn concomitantly rb
false	0	16	aspirin nn in inpos normal jj volunteers nns a dt small jj decrease nn in inpos diflunisal jj levels nns was vbd observed vbn when wrb multiple jj doses nns of inpos diflunisal nn and cc aspirin nn were vbd administered vbn concomitantly rb
false	16	0	aspirin nn in inpos normal jj volunteers nns a dt small jj decrease nn in inpos diflunisal nn levels nns was vbd observed vbn when wrb multiple jj doses nns of inpos diflunisal nn and cc aspirin nn were vbd administered vbn concomitantly rb
mechanism	16	0	aspirin nn in inpos normal jj volunteers nns a dt small jj decrease nn in inpos diflunisal jj levels nns was vbd observed vbn when wrb multiple jj doses nns of inpos diflunisal nn and cc aspirin nn were vbd administered vbn concomitantly rb
mechanism	8	12	the dt concomitant jj administration nn of inpos diflunisal nn and cc sulindac nn in inpos normal jj volunteers nns resulted vbd in inpos lowering nn of inpos the dt plasma nn levels nns of inpos the dt active jj sulindac nn sulfide nn metabolite nn by inpos approximately rb one_third jj
mechanism	8	12	the dt concomitant jj administration nn of inpos diflunisal nn and cc naproxen nn in inpos normal jj volunteers nns had vbd no dt effect nn on inpos the dt plasma nn levels nns of inpos naproxen nn but cc significantly rb decreased vbd the dt urinary jj excretion nn of inpos naproxen nn and cc its prp glucuronide nn metabolite nn
false	8	12	the dt concomitant jj administration nn of inpos diflunisal nn and cc naproxen nn in inpos normal jj volunteers nns had vbd no dt effect nn on inpos the dt plasma nn levels nns of inpos naproxen nn but cc significantly rb decreased vbd the dt urinary jj excretion nn of inpos naproxen nn and cc its prp glucuronide nn metabolite nn
false	8	12	the dt concomitant jj administration nn of inpos diflunisal nn and cc naproxen nn in inpos normal jj volunteers nns had vbd no dt effect nn on inpos the dt plasma nn levels nns of inpos naproxen nn but cc significantly rb decreased vbd the dt urinary jj excretion nn of inpos naproxen nn and cc its prp glucuronide nn metabolite nn
false	0	16	naproxen nn had vbd no dt effect nn on inpos plasma nn levels nns of inpos diflunisal nn
effect	0	14	potassium_depleting_diuretics nn are vbp a dt major jj contributing vbg factor nn to topos digitalis nn toxicity nn
mechanism	0	8	quinidine nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	quinidine nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	8	verapamil nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	verapamil nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	8	amiodarone nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	amiodarone nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	8	propafenone nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	propafenone nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	8	indomethacin nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	indomethacin nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	8	itraconazole nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	itraconazole nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	8	alprazolam nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	alprazolam nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	8	spironolactone nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	0	48	spironolactone nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
false	22	62	quinidine nn verapamil nn amiodarone nn propafenone nn indomethacin nn itraconazole nn alprazolam nn spironolactone nn raise vbp the dt serum nn digoxin nn concentration nn due jj to topos a dt reduction nn in inpos clearance nn and_or cc in inpos volume nn of inpos distribution nn of inpos the dt drug nn with inpos the dt implication nn that inpos digitalis nn intoxication nn may md result vb
mechanism	0	6	erythromycin nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	6	erythromycin nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	38	erythromycin nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
mechanism	0	6	clarithromycin nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	6	clarithromycin nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	38	clarithromycin nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
mechanism	0	6	macrolide_antibiotics nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	6	macrolide_antibiotics nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	38	macrolide_antibiotics nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
mechanism	0	6	tetracycline nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	6	tetracycline nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	38	tetracycline nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	10	42	erythromycin nn clarithromycin nn tetracycline nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	10	42	erythromycin nn clarithromycin nn tetracycline nn may md increase vb digoxin nn absorption nn in inpos patients nns who wp inactivate vbp digoxin nn by inpos bacterial jj metabolism nn in inpos the dt lower jjr intestine nn so inpos that inpos digitalis nn intoxication nn may md result vb
false	0	4	propantheline nn and cc diphenoxylate nn by inpos decreasing vbg gut nn motility nn may md increase vb digoxin nn absorption nn
mechanism	0	18	propantheline nn and cc diphenoxylate nn by inpos decreasing vbg gut nn motility nn may md increase vb digoxin nn absorption nn
mechanism	4	18	propantheline nn and cc diphenoxylate nn by inpos decreasing vbg gut nn motility nn may md increase vb digoxin nn absorption nn
false	0	2	antacids nn kaolin nn pectin nn sulfasalazine nn neomycin nn cholestyramine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	0	8	antacids nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
mechanism	0	18	antacids nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	2	6	antacids nns kaolin nn pectin nn sulfasalazine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	2	6	antacids nns kaolin nn pectin nn neomycin nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	2	6	antacids nns kaolin nn pectin nn cholestyramine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	2	18	antacids nns kaolin nn pectin nn sulfasalazine nn neomycin nn cholestyramine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
mechanism	2	28	antacids nns kaolin nn pectin nn sulfasalazine nn neomycin nn cholestyramine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	2	10	antacids nns sulfasalazine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
mechanism	2	20	antacids nns sulfasalazine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	2	10	antacids nns neomycin nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
mechanism	2	20	antacids nns neomycin nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
false	2	10	antacids nns cholestyramine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
mechanism	2	20	antacids nns cholestyramine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
mechanism	16	26	antacids nns kaolin_pectin nn sulfasalazine nn neomycin nn cholestyramine nn certain jj anticancer jj drugs nns metoclopramide nn may md interfere vb with inpos intestinal jj digoxin nn absorption nn resulting vbg in inpos unexpectedly rb low jj serum nn concentrations nns
mechanism	0	8	rifampin nn may md decrease vb serum nn digoxin nn concentration nn especially rb in inpos patients nns with inpos renal jj dysfunction nn by inpos increasing vbg the dt non_renal jj clearance nn of inpos digoxin nn
false	0	8	rifampin nn may md decrease vb serum nn digoxin nn concentration nn especially rb in inpos patients nns with inpos renal jj dysfunction nn by inpos increasing vbg the dt non_renal jj clearance nn of inpos digoxin nn
false	20	26	there ex have vbp been vbn inconsistent jj reports nns regarding vbg the dt effects nns of inpos other jj quinine nn on inpos serum nn digoxin nn concentration nn
false	20	26	there ex have vbp been vbn inconsistent jj reports nns regarding vbg the dt effects nns of inpos other jj penicillamine nn on inpos serum nn digoxin nn concentration nn
advise	0	26	thyroid nn administration nn to topos a dt digitalized vbn hypothyroid jj patient nn may md increase vb the dt dose nn requirement nn of inpos digoxin nn
effect	6	10	concomitant jj use nn of inpos digoxin nn and cc sympathomimetics nn increases vbz the dt risk nn of inpos cardiac jj arrhythmias nns
false	0	2	vasoconstrictors nn d.h.e._num nn injection nn usp nnp should md not rb be vb used vbn with inpos peripheral_vasoconstrictors nns because inpos the dt combination nn may md cause vb synergistic jj elevation nn of inpos blood nn pressure nn
false	0	2	vasoconstrictors nn dihydroergotamine_mesylate nn injection nn usp nnp should md not rb be vb used vbn with inpos peripheral_vasoconstrictors nns because inpos the dt combination nn may md cause vb synergistic jj elevation nn of inpos blood nn pressure nn
effect	2	18	vasoconstrictors nns d.h.e._num nn injection nn usp nnp should md not rb be vb used vbn with inpos peripheral_vasoconstrictors nn because inpos the dt combination nn may md cause vb synergistic jj elevation nn of inpos blood nn pressure nn
effect	2	18	vasoconstrictors nns dihydroergotamine_mesylate nn injection nn usp nnp should md not rb be vb used vbn with inpos peripheral_vasoconstrictors nn because inpos the dt combination nn may md cause vb synergistic jj elevation nn of inpos blood nn pressure nn
effect	0	32	sumatriptan nn has vbz been vbn reported vbn to topos cause vb coronary jj artery nn vasospasm nn and cc its prp effect nn could md be vb additive jj with inpos d.h.e._num nn injection nn usp nnp
effect	0	32	sumatriptan nn has vbz been vbn reported vbn to topos cause vb coronary jj artery nn vasospasm nn and cc its prp effect nn could md be vb additive jj with inpos dihydroergotamine_mesylate nn injection nn usp nnp
advise	0	4	sumatriptan nn and cc d.h.e._num nn injection nn usp nnp should md not rb be vb taken vbn within inpos num cd hours nns of inpos each dt other jj
advise	0	4	sumatriptan nn and cc dihydroergotamine_mesylate nn injection nn usp nnp should md not rb be vb taken vbn within inpos num cd hours nns of inpos each dt other jj
false	36	50	although inpos the dt results nns of inpos a dt clinical jj study nn did vbd not rb indicate vb a dt safe jj problem nn associated vbn with inpos the dt administration nn of inpos d.h.e._num nn injection nn usp nnp to topos subjects nns already rb receiving vbg propranolol nn there ex have vbp been vbn reports nns that inpos propranolol nn may md potentiate vb the dt vasoconstrictive jj action nn of inpos ergotamine nn by inpos blocking vbg the dt vasodilating vbg property nn of inpos epinephrine nn
false	36	50	although inpos the dt results nns of inpos a dt clinical jj study nn did vbd not rb indicate vb a dt safe jj problem nn associated vbn with inpos the dt administration nn of inpos d.h.e._num nn injection nn usp nnp to topos subjects nns already rb receiving vbg propranolol nn there ex have vbp been vbn reports nns that inpos propranolol nn may md potentiate vb the dt vasoconstrictive jj action nn of inpos ergotamine nn by inpos blocking vbg the dt vasodilating vbg property nn of inpos epinephrine nn
false	36	76	although inpos the dt results nns of inpos a dt clinical jj study nn did vbd not rb indicate vb a dt safe jj problem nn associated vbn with inpos the dt administration nn of inpos d.h.e._num nn injection nn usp nnp to topos subjects nns already rb receiving vbg propranolol nn there ex have vbp been vbn reports nns that inpos propranolol nn may md potentiate vb the dt vasoconstrictive jj action nn of inpos ergotamine nn by inpos blocking vbg the dt vasodilating vbg property nn of inpos epinephrine nn
false	36	50	although inpos the dt results nns of inpos a dt clinical jj study nn did vbd not rb indicate vb a dt safe jj problem nn associated vbn with inpos the dt administration nn of inpos dihydroergotamine_mesylate nn injection nn usp nnp to topos subjects nns already rb receiving vbg propranolol nn there ex have vbp been vbn reports nns that inpos propranolol nn may md potentiate vb the dt vasoconstrictive jj action nn of inpos ergotamine nn by inpos blocking vbg the dt vasodilating vbg property nn of inpos epinephrine nn
false	36	50	although inpos the dt results nns of inpos a dt clinical jj study nn did vbd not rb indicate vb a dt safe jj problem nn associated vbn with inpos the dt administration nn of inpos dihydroergotamine_mesylate nn injection nn usp nnp to topos subjects nns already rb receiving vbg propranolol nn there ex have vbp been vbn reports nns that inpos propranolol nn may md potentiate vb the dt vasoconstrictive jj action nn of inpos ergotamine nn by inpos blocking vbg the dt vasodilating vbg property nn of inpos epinephrine nn
false	50	76	although inpos the dt results nns of inpos a dt clinical jj study nn did vbd not rb indicate vb a dt safe jj problem nn associated vbn with inpos the dt administration nn of inpos d.h.e._num nnp injection nnp usp nnp to topos subjects nns already rb receiving vbg propranolol nn there ex have vbp been vbn reports nns that inpos propranolol nn may md potentiate vb the dt vasoconstrictive jj action nn of inpos ergotamine nn by inpos blocking vbg the dt vasodilating vbg property nn of inpos epinephrine nn
effect	50	76	although inpos the dt results nns of inpos a dt clinical jj study nn did vbd not rb indicate vb a dt safe jj problem nn associated vbn with inpos the dt administration nn of inpos d.h.e._num nnp injection nnp usp nnp to topos subjects nns already rb receiving vbg propranolol nn there ex have vbp been vbn reports nns that inpos propranolol nn may md potentiate vb the dt vasoconstrictive jj action nn of inpos ergotamine nn by inpos blocking vbg the dt vasodilating vbg property nn of inpos epinephrine nn
effect	0	28	nicotine nn may md provoke vb vasoconstriction nn in inpos some dt patients nns predisposing vbg to topos a dt greater jjr ischemic jj response nn to topos ergot nn therapy nn
false	0	6	macrolide_antibiotics nn lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	0	10	macrolide_antibiotics nn lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	0	8	macrolide_antibiotics nn agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	0	14	macrolide_antibiotics nn agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	0	14	macrolide_antibiotics nn agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt dihydroergotamine_mesylate nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	0	44	macrolide_antibiotics nn agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	6	10	macrolide_antibiotics nns e. fw g. fw erythromycin nn and cc troleandomycin nn
false	6	18	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	6	24	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	6	24	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt dihydroergotamine_mesylate nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	6	0	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nn of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	6	54	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	10	18	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	10	24	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	10	24	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt dihydroergotamine_mesylate nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	10	0	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nn of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	10	54	macrolide_antibiotics nns lrb_e. fw g. fw erythromycin nn and cc troleandomycin nn rrb_agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	8	14	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	8	14	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt dihydroergotamine_mesylate nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	8	0	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nn of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
mechanism	8	44	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	14	0	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nn of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
mechanism	14	44	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	14	0	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt dihydroergotamine_mesylate nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nn of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
mechanism	14	44	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt dihydroergotamine_mesylate nn injection nn usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nns of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
false	0	44	macrolide_antibiotics nns agents nns of inpos the dt ergot_alkaloid_class nn of inpos which wdt d.h.e._num nnp injection nnp usp nnp is vbz a dt member nn have vbp been vbn shown vbn to topos interact vb with inpos antibiotics nn of inpos the dt macrolide_class nn resulting vbg in inpos increased vbn plasma nn levels nns of inpos unchanged jj alkaloids nns and cc peripheral jj vasoconstriction nn
effect	18	32	vasospastic jj reactions nns have vbp been vbn reported vbn with inpos therapeutic jj doses nns of inpos ergotamine nn containing jj drugs nns when wrb co_administered vbn with inpos these dt antibiotics nn
false	0	20	ssris nn weakness nn hyperreflexia nn and cc incoordination nn have vbp been vbn reported vbn rarely rb when wrb num_ht1_agonists nn have vbp been vbn co_administered vbn with inpos ssris nns lrb_e. fw g nn
effect	20	0	ssris nns weakness nn hyperreflexia nn and cc incoordination nn have vbp been vbn reported vbn rarely rb when wrb num_ht1_agonists nn have vbp been vbn co_administered vbn with inpos ssris nn lrb_e. fw g nn
false	0	2	fluoxetine nn sertraline nn
false	0	2	fluvoxamine nn sertraline nn
false	0	2	paroxetine nn sertraline nn
false	26	30	there ex have vbp been vbn no dt reported vbn cases nns from inpos spontaneous jj reports nns of inpos drug nn interaction nn between inpos ssris nn and cc d.h.e._num nn injection nn usp nnp
false	26	30	there ex have vbp been vbn no dt reported vbn cases nns from inpos spontaneous jj reports nns of inpos drug nn interaction nn between inpos ssris nn and cc dihydroergotamine_mesylate nn injection nn usp nnp
false	8	18	the dt effect nn of inpos oral jj contraceptives nn on inpos the dt pharmacokinetics nns of inpos d.h.e._num nn injection nn usp nnp has vbz not rb been vbn studied vbn
false	8	18	the dt effect nn of inpos oral jj contraceptives nn on inpos the dt pharmacokinetics nns of inpos dihydroergotamine_mesylate nn injection nn usp nnp has vbz not rb been vbn studied vbn
effect	4	24	administration nn of inpos thiazide_diuretics nn to topos hypoparathyroid jj patients nns who wp are vbp concurrently rb being vbg treated vbn with inpos dihydrotachysterol nn may md cause vb hypercalcemia nn
false	30	34	pharmacologic jj studies nns indicate vbp that inpos there ex may md be vb additive jj effects nns in inpos prolonging vbg av nn conduction nn when wrb using vbg b_blockers nn or cc digitalis nn concomitantly rb with inpos tiazac nn
effect	30	40	pharmacologic jj studies nns indicate vbp that inpos there ex may md be vb additive jj effects nns in inpos prolonging vbg av nn conduction nn when wrb using vbg b_blockers nn or cc digitalis nn concomitantly rb with inpos tiazac nn
effect	34	40	pharmacologic jj studies nns indicate vbp that inpos there ex may md be vb additive jj effects nns in inpos prolonging vbg av nn conduction nn when wrb using vbg b_blockers nns or cc digitalis nn concomitantly rb with inpos tiazac nn
false	20	24	controlled vbn and cc uncontrolled jj domestic jj studies nns suggest vbp that inpos concomitant jj use nn of inpos diltiazem_hydrochloride nn and cc b_blockers nn is vbz usually rb well rb tolerated vbn but cc available jj data nns are vbp not rb sufficient jj to topos predict vb the dt effects nns of inpos concomitant jj treatment nn in inpos patients nns with inpos left jj ventricular jj dysfunction nn or cc cardiac jj conduction nn abnormalities nns
mechanism	4	10	administration nn of inpos diltiazem_hydrochloride nn concomitantly rb with inpos propranolol nn in inpos num cd normal jj volunteers nns resulted vbd in inpos increased vbn propranolol nn levels nns in inpos all dt subjects nns and cc bioavailability nn of inpos propranolol nn was vbd increased vbn approximately rb num cd
false	4	10	administration nn of inpos diltiazem_hydrochloride nn concomitantly rb with inpos propranolol nn in inpos num cd normal jj volunteers nns resulted vbd in inpos increased vbn propranolol nn levels nns in inpos all dt subjects nns and cc bioavailability nn of inpos propranolol nn was vbd increased vbn approximately rb num cd
false	4	10	administration nn of inpos diltiazem_hydrochloride nn concomitantly rb with inpos propranolol nn in inpos num cd normal jj volunteers nns resulted vbd in inpos increased vbn propranolol nn levels nns in inpos all dt subjects nns and cc bioavailability nn of inpos propranolol nn was vbd increased vbn approximately rb num cd
mechanism	4	24	in fw vitro fw propranolol nn appears vbz to topos be vb displaced vbn from inpos its prp binding nn sites nns by inpos diltiazem nn
false	26	46	a dt study nn in inpos num cd healthy jj volunteers nns has vbz shown vbn a dt significant jj increase nn in inpos peak jj diltiazem nn plasma nn levels nns and cc auc nn after inpos a dt num_week jj course nn of inpos cimetidine nn num cd mg_day nn and cc a dt single jj dose nn of inpos diltiazem nn 60mg nn
mechanism	46	26	a dt study nn in inpos num cd healthy jj volunteers nns has vbz shown vbn a dt significant jj increase nn in inpos peak jj diltiazem nn plasma nn levels nns and cc auc nn after inpos a dt num_week jj course nn of inpos cimetidine nn num cd mg_day nn and cc a dt single jj dose nn of inpos diltiazem nn 60mg nn
mechanism	12	46	the dt effect nn may md be vb mediated vbn by inpos cimetidine nn s vbz known vbn inhibition nn of inpos hepatic jj cytochrome nn p_num nn the dt enzyme nn system nn responsible jj for inpos the dt first_pass jj metabolism nn of inpos diltiazem nn
advise	6	42	patients nns currently rb receiving vbg diltiazem nn therapy nn should md be vb carefully rb monitored vbn for inpos a dt change nn in inpos pharmacological jj effect nn when wrb initiating vbg and cc discontinuing vbg therapy nn with inpos cimetidine nn
mechanism	4	8	administration nn of inpos diltiazem_hydrochloride nn with inpos digoxin nn in inpos num cd healthy jj male jj subjects nns increased vbd plasma nn digoxin nn concentrations nns approximately rb num cd
false	4	8	administration nn of inpos diltiazem_hydrochloride nn with inpos digoxin nn in inpos num cd healthy jj male jj subjects nns increased vbd plasma nn digoxin nn concentrations nns approximately rb num cd
false	20	50	since inpos there ex have vbp been vbn conflicting vbg results nns regarding vbg the dt effect nn of inpos digoxin nn levels nns it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg diltiazem_hydrochloride nn therapy nn to topos avoid vb possible jj over nn or cc under_digitalization nn
advise	20	50	since inpos there ex have vbp been vbn conflicting vbg results nns regarding vbg the dt effect nn of inpos digoxin nn levels nns it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg diltiazem_hydrochloride nn therapy nn to topos avoid vb possible jj over nn or cc under_digitalization nn
effect	30	40	the dt depression nn of inpos cardiac jj contractility nn conductivity nn automaticity nn as rb well rb as inpos the dt vascular jj dilation nn associated vbn with inpos anesthetics nn may md be vb potentiated vbn by inpos calcium_channel_blockers nn
advise	6	10	when wrb used vbn concomitantly rb anesthetics nn and cc calcium_channel_blockers nn should md be vb titrated vbn carefully rb
int	8	12	a dt pharmacokinetic jj interaction nn between inpos diltiazem nn and cc cyclosporine nn has vbz been vbn observed vbn during inpos studies nns involving vbg renal jj and cc cardiac jj transplant nn patients nns
mechanism	18	64	in inpos renal jj and cc cardiac jj transplant nn recipients nns a dt reduction nn of inpos cyclosporine nn dose nn ranging vbg from inpos num cd to topos num cd was vbd necessary jj to topos maintain vb cyclosporine nn trough nn concentrations nns similar jj to topos those dt seen vbn prior jj to topos the dt addition nn of inpos diltiazem nn
false	18	64	in inpos renal jj and cc cardiac jj transplant nn recipients nns a dt reduction nn of inpos cyclosporine nn dose nn ranging vbg from inpos num cd to topos num cd was vbd necessary jj to topos maintain vb cyclosporine nn trough nn concentrations nns similar jj to topos those dt seen vbn prior jj to topos the dt addition nn of inpos diltiazem nn
advise	16	30	if inpos these dt agents nns are vbp to topos be vb administered vbn concurrently rb cyclosporine nn concentrations nns should md be vb monitored vbn especially rb when wrb diltiazem nn therapy nn is vbz initiated vbn adjusted vbn discontinued vbn
false	6	10	the dt effect nn of inpos cyclosporine nn on inpos diltiazem nn plasma nn concentrations nns has vbz not rb been vbn evaluated vbn
mechanism	6	10	concomitant jj administration nn of inpos diltiazem nn with inpos carbamazepine nn has vbz been vbn reported vbn to topos result vb in inpos elevated jj serum nn levels nns of inpos carbamazepine nn resulting vbg in inpos toxicity nn in inpos some dt cases nns
false	6	10	concomitant jj administration nn of inpos diltiazem nn with inpos carbamazepine nn has vbz been vbn reported vbn to topos result vb in inpos elevated jj serum nn levels nns of inpos carbamazepine nn resulting vbg in inpos toxicity nn in inpos some dt cases nns
mechanism	6	16	studies nns showed vbd that inpos diltiazem nn increased vbd the dt auc nn of inpos midazolam nn and cc triazolam nn by inpos num cd fold rb and cc the dt cmax nn by inpos num_fold jj compared vbn to topos placebo nn
mechanism	6	20	studies nns showed vbd that inpos diltiazem nn increased vbd the dt auc nn of inpos midazolam nn and cc triazolam nn by inpos num cd fold rb and cc the dt cmax nn by inpos num_fold jj compared vbn to topos placebo nn
false	16	20	studies nns showed vbd that inpos diltiazem nn increased vbd the dt auc nn of inpos midazolam nn and cc triazolam nn by inpos num cd fold rb and cc the dt cmax nn by inpos num_fold jj compared vbn to topos placebo nn
false	10	14	the dt elimination nn half nn life nn of inpos midazolam nn and cc triazolam nn also rb increased vbd during inpos coadministration nn with inpos diltiazem nn
mechanism	10	26	the dt elimination nn half nn life nn of inpos midazolam nn and cc triazolam nn also rb increased vbd during inpos coadministration nn with inpos diltiazem nn
mechanism	14	26	the dt elimination nn half nn life nn of inpos midazolam nn and cc triazolam nn also rb increased vbd during inpos coadministration nn with inpos diltiazem nn
effect	10	30	these dt pharmacokinetic jj effects nns seen vbn during inpos diltiazem nn coadministration nn can md result vb in inpos increased vbn clinical jj effects nns of inpos both cc midazolam nn and cc triazolam nn
effect	10	34	these dt pharmacokinetic jj effects nns seen vbn during inpos diltiazem nn coadministration nn can md result vb in inpos increased vbn clinical jj effects nns of inpos both cc midazolam nn and cc triazolam nn
false	30	34	these dt pharmacokinetic jj effects nns seen vbn during inpos diltiazem nn coadministration nn can md result vb in inpos increased vbn clinical jj effects nns of inpos both cc midazolam nn and cc triazolam nn
mechanism	12	16	in inpos a dt ten_subject jj study nn coadministration nn of inpos diltiazem nn with inpos lovastatin nn resulted vbd in inpos a dt num cd times nns increase vbp in inpos mean jj lovastatin nn auc nn and cc cmax nn vs. inpos lovastatin nn alone rb
false	12	16	in inpos a dt ten_subject jj study nn coadministration nn of inpos diltiazem nn with inpos lovastatin nn resulted vbd in inpos a dt num cd times nns increase vbp in inpos mean jj lovastatin nn auc nn and cc cmax nn vs. inpos lovastatin nn alone rb
false	12	16	in inpos a dt ten_subject jj study nn coadministration nn of inpos diltiazem nn with inpos lovastatin nn resulted vbd in inpos a dt num cd times nns increase vbp in inpos mean jj lovastatin nn auc nn and cc cmax nn vs. inpos lovastatin nn alone rb
false	6	20	no dt change nn in inpos pravastatin nn auc nn and cc cmax nn was vbd observed vbn during inpos diltiazem nn coadministration nn
false	0	16	diltiazem nn plasma nn levels nns were vbd not rb significantly rb affected vbn by inpos lovastatin nn or cc pravastatin nn
false	0	20	diltiazem nn plasma nn levels nns were vbd not rb significantly rb affected vbn by inpos lovastatin nn or cc pravastatin nn
false	16	20	diltiazem nn plasma nn levels nns were vbd not rb significantly rb affected vbn by inpos lovastatin nn or cc pravastatin nn
mechanism	4	8	coadministration nn of inpos rifampin nn with inpos diltiazem nn lowered vbd the dt diltiazem nn plasma nn concentrations nns to topos undetectable jj levels nns
false	4	8	coadministration nn of inpos rifampin nn with inpos diltiazem nn lowered vbd the dt diltiazem nn plasma nn concentrations nns to topos undetectable jj levels nns
advise	4	8	coadministration nn of inpos diltiazem nn with inpos rifampin nn or cc any dt known vbn cyp3a4 nn inducer nn should md be vb avoided vbn when wrb possible jj and cc alternative jj therapy nn considered vbn
false	0	6	dimenhydrinate nn may md decrease vb emetic nn response nn to topos apomorphine nn
effect	0	12	dimenhydrinate nn may md decrease vb emetic jj response nn to topos apomorphine nn
false	6	12	dimenhydrinate nn may md decrease vb emetic nn response nn to topos apomorphine nn
false	0	6	oxytocin nn or cc other jj oxytocics nn lrb_concurrent jj use nn with inpos dinoprost nn may md result vb in inpos uterine jj hypertonus nn possibly rb causing vbg uterine jj rupture nn or cc cervical jj laceration nn especially rb in inpos the dt absence nn of inpos adequate jj cervical jj dilatation nn
effect	0	14	oxytocin nn or cc other jj oxytocics nns lrb_concurrent jj use nn with inpos dinoprost nn may md result vb in inpos uterine jj hypertonus nn possibly rb causing vbg uterine jj rupture nn or cc cervical jj laceration nn especially rb in inpos the dt absence nn of inpos adequate jj cervical jj dilatation nn
effect	6	14	oxytocin nn or cc other jj oxytocics nn lrb_concurrent jj use nn with inpos dinoprost nn may md result vb in inpos uterine jj hypertonus nn possibly rb causing vbg uterine jj rupture nn or cc cervical jj laceration nn especially rb in inpos the dt absence nn of inpos adequate jj cervical jj dilatation nn
effect	0	14	prostin_e2 nn may md augment vb the dt activity nn of inpos other jj oxytocic_drugs nn
effect	0	10	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nns
effect	0	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn
effect	0	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj hypnotics nn
effect	0	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj sedatives nn
effect	0	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj tranquilizers nn
false	10	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj cns_depressants nn
false	10	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj hypnotics nn
false	10	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj sedatives nn
false	10	16	diphenhydramine_hydrochloride nn has vbz additive jj effects nns with inpos alcohol nn and cc other jj tranquilizers nn
effect	0	16	mao_inhibitors nn prolong vb and cc intensify vb the dt anticholinergic jj effects nns of inpos antihistamines nn
false	0	38	anticholinergics nn or cc other jj medications nns with inpos anticholinergic jj activity nn hyph_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos diphenidol nn
false	0	8	apomorphine nn hyph_prior jj ingestion nn of inpos diphenidol nn may md decrease vb the dt emetic jj response nn to topos apomorphine nn in inpos the dt treatment nn of inpos poisoning vbg
false	0	16	apomorphine nn hyph_prior jj ingestion nn of inpos diphenidol nn may md decrease vb the dt emetic nn response nn to topos apomorphine nn in inpos the dt treatment nn of inpos poisoning vbg
false	8	16	apomorphine nn hyph_prior jj ingestion nn of inpos diphenidol nn may md decrease vb the dt emetic nn response nn to topos apomorphine nn in inpos the dt treatment nn of inpos poisoning vbg
effect	8	0	apomorphine nn hyph_prior jj ingestion nn of inpos diphenidol nn may md decrease vb the dt emetic jj response nn to topos apomorphine nn in inpos the dt treatment nn of inpos poisoning vbg
false	16	0	apomorphine nn hyph_prior jj ingestion nn of inpos diphenidol nn may md decrease vb the dt emetic nn response nn to topos apomorphine nn in inpos the dt treatment nn of inpos poisoning vbg
false	0	4	diphenoxylate_hcl nn and cc atropine_sulfate nn may md interact vb with inpos mao_inhibitors nns in inpos studies nns with inpos male jj rats nns diphenoxylate_hydrochloride nn was vbd found vbn to topos inhibit vb the dt hepatic jj microsomal jj enzyme nn system nn at inpos a dt dose nn of inpos num cd mg_kg_day nn
int	0	12	diphenoxylate_hcl nn and cc atropine_sulfate nn may md interact vb with inpos mao_inhibitors nn in inpos studies nns with inpos male jj rats nns diphenoxylate_hydrochloride nn was vbd found vbn to topos inhibit vb the dt hepatic jj microsomal jj enzyme nn system nn at inpos a dt dose nn of inpos num cd mg_kg_day nn
false	0	24	diphenoxylate_hcl nn and cc atropine_sulfate nn may md interact vb with inpos mao_inhibitors nns in inpos studies nns with inpos male jj rats nns diphenoxylate_hydrochloride nn was vbd found vbn to topos inhibit vb the dt hepatic jj microsomal jj enzyme nn system nn at inpos a dt dose nn of inpos num cd mg_kg_day nn
int	4	12	diphenoxylate_hcl nn and cc atropine_sulfate nn may md interact vb with inpos mao_inhibitors nn in inpos studies nns with inpos male jj rats nns diphenoxylate_hydrochloride nn was vbd found vbn to topos inhibit vb the dt hepatic jj microsomal jj enzyme nn system nn at inpos a dt dose nn of inpos num cd mg_kg_day nn
false	4	24	diphenoxylate_hcl nn and cc atropine_sulfate nn may md interact vb with inpos mao_inhibitors nns in inpos studies nns with inpos male jj rats nns diphenoxylate_hydrochloride nn was vbd found vbn to topos inhibit vb the dt hepatic jj microsomal jj enzyme nn system nn at inpos a dt dose nn of inpos num cd mg_kg_day nn
false	12	24	diphenoxylate_hcl nn and cc atropine_sulfate nn may md interact vb with inpos mao_inhibitors nn in inpos studies nns with inpos male jj rats nns diphenoxylate_hydrochloride nn was vbd found vbn to topos inhibit vb the dt hepatic jj microsomal jj enzyme nn system nn at inpos a dt dose nn of inpos num cd mg_kg_day nn
false	10	40	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	10	42	this dt drug nn may md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	10	18	this dt drug nn may md interact vb with inpos alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	6	22	this dt drug nn may md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	6	22	this dt drug nn may md alcohol nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	16	40	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nn lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	10	42	this dt drug nn may md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	10	18	this dt drug nn may md interact vb with inpos cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	6	22	this dt drug nn may md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	6	22	this dt drug nn may md cns_depressants nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	40	42	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nn other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns
false	40	54	this dt drug nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nns lrb_may md potentiate vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc antihistamines nn rrb_anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	10	42	this dt drug nn may md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nns
false	10	18	this dt drug nn may md interact vb with inpos anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn
false	6	22	this dt drug nn may md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	6	22	this dt drug nn may md anticholinergics nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nns lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
false	52	54	this dt drug nn may md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn lrb_anticholinergic jj effects nns may md be vb potentiated vbn when wrb these dt medications nns are vbp used vbn concurrently rb with inpos antihistamines nn rrb_monoamine_oxidase_mao_inhibitors nn
false	28	36	this dt drug nn may md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nn may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nns
false	28	36	this dt drug nn may md interact vb with inpos alcohol nn other jj cns_depressants nns anticholinergics nns other jj medications nns with inpos anticholinergic jj activity nn monoamine_oxidase_mao_inhibitors nn lrb_concurrent jj use nn with inpos antihistamines nns may md prolong vb and cc intensify vb the dt anticholinergic jj and cc cns nn depressant jj effects nns of inpos antihistamines nn
mechanism	0	26	dipyridamole nn has vbz been vbn reported vbn to topos increase vb the dt plasma nn levels nns and cc cardiovascular jj effects nns of inpos adenosine nn
effect	0	14	dipyridamole nn may md counteract vb the dt anticholinesterase nn effect nn of inpos cholinesterase_inhibitors nn thereby rb potentially rb aggravating vbg myasthenia nn gravis nn
false	14	28	in inpos a dt prospective jj study nn involving vbg six_healthy_male jj volunteers nns dirithromycin nn did vbd not rb affect vb the dt metabolism nn of inpos terfenadine nn
false	8	30	these dt num cd volunteers nns received vbd terfenadine nn alone rb for inpos num cd days nns followed vbn by inpos terfenadine nn in inpos combination nn with inpos dirithromycin nn for inpos num cd days nns
false	8	30	these dt num cd volunteers nns received vbd terfenadine nn alone rb for inpos num cd days nns followed vbn by inpos terfenadine nn in inpos combination nn with inpos dirithromycin nn for inpos num cd days nns
false	6	48	the dt pharmacokinetics nns of inpos terfenadine nn its prp acid nn metabolite nn the dt electrocardiographic jj qt nn c nn interval nn were vbd measured vbn during inpos both dt periods nns with inpos terfenadine nn alone rb and cc with inpos terfenadine nn plus cc dirithromycin nn
false	6	48	the dt pharmacokinetics nns of inpos terfenadine nn its prp acid nn metabolite nn the dt electrocardiographic jj qt nn c nn interval nn were vbd measured vbn during inpos both dt periods nns with inpos terfenadine nn alone rb and cc with inpos terfenadine nn plus cc dirithromycin nn
false	6	48	the dt pharmacokinetics nns of inpos terfenadine nn its prp acid nn metabolite nn the dt electrocardiographic jj qt nn c nn interval nn were vbd measured vbn during inpos both dt periods nns with inpos terfenadine nn alone rb and cc with inpos terfenadine nn plus cc dirithromycin nn
false	14	40	in inpos num cd man nn the dt c nn max nn of inpos terfenadine nn was vbd float cd ng_ml nn with inpos terfenadine nn alone rb and cc float cd ng_ml nn with inpos terfenadine nn plus cc dirithromycin nn
false	14	40	in inpos num cd man nn the dt c nn max nn of inpos terfenadine nn was vbd float cd ng_ml nn with inpos terfenadine nn alone rb and cc float cd ng_ml nn with inpos terfenadine nn plus cc dirithromycin nn
mechanism	14	40	in inpos num cd man nn the dt c nn max nn of inpos terfenadine nn was vbd float cd ng_ml nn with inpos terfenadine nn alone rb and cc float cd ng_ml nn with inpos terfenadine nn plus cc dirithromycin nn
false	16	30	the dt mean jj qt nn c nn interval nn was vbd num cd with inpos terfenadine nn alone rb and cc num cd with inpos terfenadine nn plus cc dirithromycin nn
effect	16	30	the dt mean jj qt nn c nn interval nn was vbd num cd with inpos terfenadine nn alone rb and cc num cd with inpos terfenadine nn plus cc dirithromycin nn
false	20	24	also rb in fw vitro fw experiments nns demonstrated vbd a dt lack nn of inpos interaction nn between inpos dirithromycin nn and cc terfenadine nn
int	10	14	thus rb the dt interaction nn observed vbn between inpos erythromycin nn and cc terfenadine nn is vbz not rb expected vbn for inpos dirithromycin nn
false	10	24	thus rb the dt interaction nn observed vbn between inpos erythromycin nn and cc terfenadine nn is vbz not rb expected vbn for inpos dirithromycin nn
false	14	24	thus rb the dt interaction nn observed vbn between inpos erythromycin nn and cc terfenadine nn is vbz not rb expected vbn for inpos dirithromycin nn
effect	24	32	serious jj cardiac jj dysrhythmias nns some dt resulting vbg in inpos death nn have vbp occurred vbn in inpos patients nns receiving vbg terfenadine nn concomitantly rb with inpos other jj macrolide_antibiotics nn
advise	6	18	in inpos addition nn most jjs macrolides nn are vbp contraindicated vbn in inpos patients nns receiving vbg terfenadine nn therapy nn who wp have vbp pre_existing jj cardiac jj abnormalities nns or cc electrolyte nn disturbances nns
false	10	24	following vbg co_administration nn of inpos num cd num_mg jj dirithromycin nn tablets nns administered vbn once rb daily rb with inpos num_mg jj theophylline nn tablets nns administered vbn twice rb daily rb for inpos num cd days nns to topos num cd healthy jj subjects nns the dt steady_state jj plasma nn concentration nn of inpos theophylline nn was vbd not rb significantly rb altered vbn
false	10	24	following vbg co_administration nn of inpos num cd num_mg jj dirithromycin nn tablets nns administered vbn once rb daily rb with inpos num_mg jj theophylline nn tablets nns administered vbn twice rb daily rb for inpos num cd days nns to topos num cd healthy jj subjects nns the dt steady_state jj plasma nn concentration nn of inpos theophylline nn was vbd not rb significantly rb altered vbn
false	12	22	in inpos general jj most jjs patients nns treated vbn with inpos dirithromycin nn who wp are vbp receiving vbg concomitant jj theophylline nn therapy nn may md not rb require vb empiric jj adjustment nn of inpos theophylline nn dosage nn or cc monitoring nn of inpos theophylline nn plasma nn concentrations nns
false	12	22	in inpos general jj most jjs patients nns treated vbn with inpos dirithromycin nn who wp are vbp receiving vbg concomitant jj theophylline nn therapy nn may md not rb require vb empiric jj adjustment nn of inpos theophylline nn dosage nn or cc monitoring nn of inpos theophylline nn plasma nn concentrations nns
false	12	22	in inpos general jj most jjs patients nns treated vbn with inpos dirithromycin nn who wp are vbp receiving vbg concomitant jj theophylline nn therapy nn may md not rb require vb empiric jj adjustment nn of inpos theophylline nn dosage nn or cc monitoring nn of inpos theophylline nn plasma nn concentrations nns
false	0	4	antacids nn or cc h_num_receptor_antagonists nn
mechanism	2	12	when wrb dirithromycin nn is vbz administered vbn immediately rb following vbg antacids nn or cc h_num_receptor_antagonists nns the dt absorption nn of inpos dirithromycin nn is vbz slightly rb enhanced vbn
mechanism	2	16	when wrb dirithromycin nn is vbz administered vbn immediately rb following vbg antacids nns or cc h_num_receptor_antagonists nn the dt absorption nn of inpos dirithromycin nn is vbz slightly rb enhanced vbn
false	12	16	when wrb dirithromycin nn is vbz administered vbn immediately rb following vbg antacids nn or cc h_num_receptor_antagonists nn the dt absorption nn of inpos dirithromycin nn is vbz slightly rb enhanced vbn
false	12	2	when wrb dirithromycin nn is vbz administered vbn immediately rb following vbg antacids nn or cc h_num_receptor_antagonists nns the dt absorption nn of inpos dirithromycin nn is vbz slightly rb enhanced vbn
false	16	2	when wrb dirithromycin nn is vbz administered vbn immediately rb following vbg antacids nns or cc h_num_receptor_antagonists nn the dt absorption nn of inpos dirithromycin nn is vbz slightly rb enhanced vbn
mechanism	0	18	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos triazolam nn
effect	0	18	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos triazolam nn
false	0	8	digoxin nn concomitant jj administration nn of inpos erythromycin nn and cc digoxin nn has vbz been vbn reported vbn to topos result vb in inpos elevated jj digoxin nn serum nn levels nns
mechanism	6	10	concomitant jj administration nn of inpos erythromycin nn and cc digoxin nn has vbz been vbn reported vbn to topos result vb in inpos elevated jj digoxin nn serum nn levels nns
false	6	10	concomitant jj administration nn of inpos erythromycin nn and cc digoxin nn has vbz been vbn reported vbn to topos result vb in inpos elevated jj digoxin nn serum nn levels nns
effect	18	24	there ex have vbp been vbn reports nns of inpos increased vbn anticoagulant jj effects nns when wrb erythromycin nn and cc oral jj anticoagulants nn were vbd used vbn concomitantly rb
false	0	8	ergotamine nn concurrent jj use nn of inpos erythromycin nn has vbz been vbn associated vbn in inpos some dt patients nns with inpos acute jj ergot nn toxicity nn characterized vbn by inpos severe jj peripheral jj vasospasm nn and cc dysesthesia nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg cyclosporine nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg hexobarbital nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg carbamazepine nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg alfentanil nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg disopyramide nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg phenytoin nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg bromocriptine nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg valproate nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg astemizole nn
int	22	32	other jj drugs nns drug nn interactions nns have vbp been vbn reported vbn with inpos concomitant jj administration nn of inpos erythromycin nn and cc other jj medications nns including vbg lovastatin nn
mechanism	2	22	if inpos phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns are vbp taken vbn concurrently rb with inpos norpace nn or cc norpace_cr nn lower jjr plasma nn levels nns of inpos disopyramide nn may md occur vb
mechanism	2	26	if inpos phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns are vbp taken vbn concurrently rb with inpos norpace nn or cc norpace_cr nn lower jjr plasma nn levels nns of inpos disopyramide nn may md occur vb
false	2	36	if inpos phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns are vbp taken vbn concurrently rb with inpos norpace nn or cc norpace_cr nn lower jjr plasma nn levels nns of inpos disopyramide nn may md occur vb
false	22	36	if inpos phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns are vbp taken vbn concurrently rb with inpos norpace nn or cc norpace_cr nn lower jjr plasma nn levels nns of inpos disopyramide nn may md occur vb
false	26	36	if inpos phenytoin nn or cc other jj hepatic jj enzyme nn inducers nns are vbp taken vbn concurrently rb with inpos norpace nn or cc norpace_cr nn lower jjr plasma nn levels nns of inpos disopyramide nn may md occur vb
false	2	16	other jj antiarrhythmic_drugs nn have vbp occasionally rb been vbn used vbn concurrently rb with inpos norpace nn
false	2	16	other jj quinidine nn have vbp occasionally rb been vbn used vbn concurrently rb with inpos norpace nn
false	2	16	other jj procainamide nn have vbp occasionally rb been vbn used vbn concurrently rb with inpos norpace nn
false	2	16	other jj lidocaine nn have vbp occasionally rb been vbn used vbn concurrently rb with inpos norpace nn
false	2	16	other jj propranolol nn have vbp occasionally rb been vbn used vbn concurrently rb with inpos norpace nn
false	20	30	in inpos healthy jj subjects nns no dt significant jj drug_drug jj interaction nn was vbd observed vbn when wrb norpace nn was vbd coadministered vbn with inpos either cc propranolol nn or cc diazepam nn
false	20	34	in inpos healthy jj subjects nns no dt significant jj drug_drug jj interaction nn was vbd observed vbn when wrb norpace nn was vbd coadministered vbn with inpos either cc propranolol nn or cc diazepam nn
false	30	34	in inpos healthy jj subjects nns no dt significant jj drug_drug jj interaction nn was vbd observed vbn when wrb norpace nnp was vbd coadministered vbn with inpos either cc propranolol nn or cc diazepam nn
mechanism	6	10	concomitant jj administration nn of inpos norpace nn and cc quinidine nn resulted vbd in inpos slight jj increases nns in inpos plasma nn disopyramide nn levels nns and cc slight jj decreases nns in inpos plasma nn quinidine nn levels nns
false	6	24	concomitant jj administration nn of inpos norpace nn and cc quinidine nn resulted vbd in inpos slight jj increases nns in inpos plasma nn disopyramide nn levels nns and cc slight jj decreases nns in inpos plasma nn quinidine nn levels nns
false	6	10	concomitant jj administration nn of inpos norpace nn and cc quinidine nn resulted vbd in inpos slight jj increases nns in inpos plasma nn disopyramide nn levels nns and cc slight jj decreases nns in inpos plasma nn quinidine nn levels nns
false	10	24	concomitant jj administration nn of inpos norpace nn and cc quinidine nn resulted vbd in inpos slight jj increases nns in inpos plasma nn disopyramide nn levels nns and cc slight jj decreases nns in inpos plasma nn quinidine nn levels nns
false	24	10	concomitant jj administration nn of inpos norpace nn and cc quinidine nn resulted vbd in inpos slight jj increases nns in inpos plasma nn disopyramide nn levels nns and cc slight jj decreases nns in inpos plasma nn quinidine nn levels nns
false	0	10	norpace nn does vbz not rb increase vb serum nn digoxin nn levels nns
mechanism	4	8	patients nns taking vbg disopyramide_phosphate nn and cc erythromycin nn concomitantly rb may md develop vb increased vbn serum nn concentrations nns of inpos disopyramide nn resulting vbg in inpos excessive jj widening nn of inpos the dt qrs nn complex nn and_or cc prolongation nn of inpos the dt q_t nn interval nn
false	8	4	patients nns taking vbg disopyramide_phosphate nn and cc erythromycin nn concomitantly rb may md develop vb increased vbn serum nn concentrations nns of inpos disopyramide nn resulting vbg in inpos excessive jj widening nn of inpos the dt qrs nn complex nn and_or cc prolongation nn of inpos the dt q_t nn interval nn
false	12	16	until inpos data nns on inpos possible jj interactions nns between inpos verapamil nn and cc disopyramide_phosphate nn are vbp obtained vbn disopyramide nn should md not rb be vb administered vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos verapamil nn administration nn
false	12	16	until inpos data nns on inpos possible jj interactions nns between inpos verapamil nn and cc disopyramide_phosphate nn are vbp obtained vbn disopyramide nn should md not rb be vb administered vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos verapamil nn administration nn
false	16	12	until inpos data nns on inpos possible jj interactions nns between inpos verapamil nn and cc disopyramide_phosphate nn are vbp obtained vbn disopyramide nn should md not rb be vb administered vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos verapamil nn administration nn
advise	16	12	until inpos data nns on inpos possible jj interactions nns between inpos verapamil nn and cc disopyramide_phosphate nn are vbp obtained vbn disopyramide nn should md not rb be vb administered vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos verapamil nn administration nn
advise	0	20	disulfiram nn should nnp be nnp used nnp with nnp caution nn in inpos those nnp patients nns reveiving vbg phenytoin nn and cc its prp congeners nns
false	22	32	since inpos the dt concomitant nn administration nn of inpos these nnp two nnp drugs nnp can nnp lead nnp to topos phenytoin nn intoxication nn prior nnp to topos administering vbg disulfiram nn to topos a nnp patient nnp on nnp phenytoin nnp therapy nnp a nnp baseline nnp phenytoin nnp serum nnp level nnp should nnp be nnp obtained vbd
effect	32	22	since inpos the dt concomitant nn administration nn of inpos these nnp two nnp drugs nnp can nnp lead nnp to topos phenytoin nnp intoxication nnp prior nnp to topos administering vbg disulfiram nn to topos a nn patient nnp on nnp phenytoin nn therapy nn a nnp baseline nnp phenytoin nnp serum nnp level nnp should nnp be nnp obtained vbd
false	32	22	since inpos the dt concomitant nn administration nn of inpos these nnp two nnp drugs nnp can nnp lead nnp to topos phenytoin nnp intoxication nnp prior nnp to topos administering vbg disulfiram nn to topos a nnp patient nnp on nnp phenytoin nn therapy nn a dt baseline nn phenytoin nn serum nn level nnp should nnp be nnp obtained vbd
advise	20	30	it prp may md be vb necessary jj to topos adjust vb the dt dosage nn of inpos oral jj anticoagulants nn upon inpos beginning vbg or cc stopping vbg disulfiram nn since inpos disulfiram nn may md prolong vb prothrombin nn time nn
false	20	30	it prp may md be vb necessary jj to topos adjust vb the dt dosage nn of inpos oral jj anticoagulants nn upon inpos beginning vbg or cc stopping vbg disulfiram. nn since inpos disulfiram nn may md prolong vb prothrombin nn time nn
advise	4	8	patients nns taking vbg isoniazid nn when wrb disulfiram nn is vbz given vbn should md be vb observed vbn for inpos the dt appearance nn of inpos unsteady jj gait nn or cc marked jj changes nns in inpos mental jj status nn
effect	10	14	in inpos rats nns simultaneous jj ingestion nn of inpos disulfiram nn and cc nitrite nn in inpos the dt diet nn for inpos num cd weeks nns has vbz been vbn reported vbn to topos cause vb tumors nns and cc it prp has vbz been vbn suggested vbn that inpos disulfiram nn may md react vb with inpos nitrites nns in inpos the dt rat nn stomach nn to topos form vb a dt nitrosamine nn which wdt is vbz tumorigenic jj
false	10	60	in inpos rats nns simultaneous jj ingestion nn of inpos disulfiram nn and cc nitrite nn in inpos the dt diet nn for inpos num cd weeks nns has vbz been vbn reported vbn to topos cause vb tumors nns and cc it prp has vbz been vbn suggested vbn that inpos disulfiram nn may md react vb with inpos nitrites nn in inpos the dt rat nn stomach nn to topos form vb a dt nitrosamine nn which wdt is vbz tumorigenic jj
false	14	10	in inpos rats nns simultaneous jj ingestion nn of inpos disulfiram nn and cc nitrite nn in inpos the dt diet nn for inpos num cd weeks nns has vbz been vbn reported vbn to topos cause vb tumors nns and cc it prp has vbz been vbn suggested vbn that inpos disulfiram nn may md react vb with inpos nitrites nns in inpos the dt rat nn stomach nn to topos form vb a dt nitrosamine nn which wdt is vbz tumorigenic jj
effect	10	60	in inpos rats nns simultaneous jj ingestion nn of inpos disulfiram nn and cc nitrite nn in inpos the dt diet nn for inpos num cd weeks nns has vbz been vbn reported vbn to topos cause vb tumors nns and cc it prp has vbz been vbn suggested vbn that inpos disulfiram nn may md react vb with inpos nitrites nn in inpos the dt rat nn stomach nn to topos form vb a dt nitrosamine nn which wdt is vbz tumorigenic jj
effect	8	30	animal jj studies nns indicate vbp that inpos dobutamine nn may md be vb ineffective jj if inpos the dt patient nn has vbz recently rb received vbn a dt b_blocking_drug nn
effect	16	20	preliminary jj studies nns indicate vbp that inpos the dt concomitant jj use nn of inpos dobutamine nn and cc nitroprusside nn results vbz in inpos a dt higher jjr cardiac jj output nn and cc usually rb a dt lower jjr pulmonary jj wedge nn pressure nn than inpos when wrb either cc drug nn is vbz used vbn alone rb
false	24	40	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns furosemide nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns spironolactone nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns lidocaine nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns glyceryl_trinitrate nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns isosorbide_dinitrate nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns morphine nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns atropine nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns heparin nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns protamine nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns potassium_chloride nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns folic_acid nn
false	24	42	there ex was vbd no dt evidence nn of inpos drug nn interactions nns in inpos clinical jj studies nns in inpos which wdt dobutamine nn was vbd administered vbn concurrently rb with inpos other jj drugs nns including vbg digitalis_preparations nns acetaminophen nn
mechanism	18	60	in fw vitro fw studies nns have vbp shown vbn that inpos the dt metabolism nn of inpos docetaxel nn may md be vb modified vbn by inpos the dt concomitant jj administration nn of inpos compounds nns that wdt induce vbp inhibit vbp are vbp metabolized vbn by inpos cytochrome nn p450 nn 3a4 nn such jj as inpos cyclosporine nn
mechanism	18	60	in fw vitro fw studies nns have vbp shown vbn that inpos the dt metabolism nn of inpos docetaxel nn may md be vb modified vbn by inpos the dt concomitant jj administration nn of inpos compounds nns that wdt induce vbp inhibit vbp are vbp metabolized vbn by inpos cytochrome nn p450 nn 3a4 nn such jj as inpos terfenadine nn
mechanism	18	60	in fw vitro fw studies nns have vbp shown vbn that inpos the dt metabolism nn of inpos docetaxel nn may md be vb modified vbn by inpos the dt concomitant jj administration nn of inpos compounds nns that wdt induce vbp inhibit vbp are vbp metabolized vbn by inpos cytochrome nn p450 nn 3a4 nn such jj as inpos ketoconazole nn
mechanism	18	60	in fw vitro fw studies nns have vbp shown vbn that inpos the dt metabolism nn of inpos docetaxel nn may md be vb modified vbn by inpos the dt concomitant jj administration nn of inpos compounds nns that wdt induce vbp inhibit vbp are vbp metabolized vbn by inpos cytochrome nn p450 nn 3a4 nn such jj as inpos erythromycin nn
mechanism	18	60	in fw vitro fw studies nns have vbp shown vbn that inpos the dt metabolism nn of inpos docetaxel nn may md be vb modified vbn by inpos the dt concomitant jj administration nn of inpos compounds nns that wdt induce vbp inhibit vbp are vbp metabolized vbn by inpos cytochrome nn p450 nn 3a4 nn such jj as inpos troleandomycin nn
mechanism	0	14	cimetidine nn at inpos num cd mg nn bid nn co_administered vbn with inpos tikosyn nn for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb dofetilide nn plasma nn levels nns by inpos num cd
false	0	32	cimetidine nn at inpos num cd mg nn bid nn co_administered vbn with inpos tikosyn nn for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb dofetilide nn plasma nn levels nns by inpos num cd
false	14	32	cimetidine nn at inpos num cd mg nn bid nn co_administered vbn with inpos tikosyn nn for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb dofetilide nn plasma nn levels nns by inpos num cd
mechanism	0	26	cimetidine nn at inpos doses nns of inpos num cd mg nn bid nn resulted vbd in inpos a dt num cd increase nn in inpos dofetilide nn plasma nn levels nns
false	8	12	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos omeprazole nn ranitidine nn antacids nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	8	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos omeprazole nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	8	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos ranitidine nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	8	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos antacids nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	8	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos aluminum nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	8	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos magnesium_hydroxide nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
advise	8	40	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos omeprazole nn ranitidine nn antacids nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	12	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos omeprazole nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	12	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos ranitidine nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	12	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos antacids nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	12	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos aluminum nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	12	24	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos magnesium_hydroxide nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	12	40	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos omeprazole nn ranitidine nn antacids nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	12	8	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer nn therapy nn it prp is vbz suggested vbn that inpos omeprazole nn ranitidine nn antacids nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	36	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos omeprazole nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	8	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos omeprazole nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	36	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos ranitidine nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	8	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos ranitidine nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	36	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos antacids nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	8	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos antacids nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	36	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos aluminum nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	8	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos aluminum nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	36	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos magnesium_hydroxide nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	24	8	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos magnesium_hydroxide nn be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
false	40	8	if inpos a dt patient nn requires vbz tikosyn nn and cc anti_ulcer jj therapy nn it prp is vbz suggested vbn that inpos omeprazole nn ranitidine nn antacids nns be vb used vbn as inpos alternatives nns to topos cimetidine nn as inpos these dt agents nns have vbp no dt effect nn on inpos the dt pharmacokinetic jj profile nn of inpos tikosyn nn
mechanism	4	8	co_administration nn of inpos tikosyn nn with inpos verapamil nn resulted vbd in inpos increases nns in inpos dofetilide nn peak nn plasma nn levels nns of inpos num cd although inpos overall jj exposure nn to topos dofetilide nn was vbd not rb significantly rb increased vbd
false	4	18	co_administration nn of inpos tikosyn nn with inpos verapamil nn resulted vbd in inpos increases nns in inpos dofetilide nn peak nn plasma nn levels nns of inpos num cd although inpos overall jj exposure nn to topos dofetilide nn was vbd not rb significantly rb increased vbd
false	4	18	co_administration nn of inpos tikosyn nn with inpos verapamil nn resulted vbd in inpos increases nns in inpos dofetilide nn peak nn plasma nn levels nns of inpos num cd although inpos overall jj exposure nn to topos dofetilide nn was vbd not rb significantly rb increased vbd
false	8	18	co_administration nn of inpos tikosyn nn with inpos verapamil nn resulted vbd in inpos increases nns in inpos dofetilide nn peak nn plasma nn levels nns of inpos num cd although inpos overall jj exposure nn to topos dofetilide nn was vbd not rb significantly rb increased vbd
false	8	18	co_administration nn of inpos tikosyn nn with inpos verapamil nn resulted vbd in inpos increases nns in inpos dofetilide nn peak nn plasma nn levels nns of inpos num cd although inpos overall jj exposure nn to topos dofetilide nn was vbd not rb significantly rb increased vbd
effect	30	34	in inpos an dt analysis nn of inpos the dt supraventricular jj arrhythmia nn and cc diamond nn patient nn populations nns the dt concomitant jj administration nn of inpos verapamil nn with inpos dofetilide nn was vbd associated vbn with inpos a dt higher jjr occurrence nn of inpos torsade fw de fw pointes fw
mechanism	0	14	ketoconazole nn at inpos num cd mg nn daily rb co_administered vbn with inpos tikosyn nn for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb dofetilide nn cmax nn by inpos num cd in inpos males nns num cd in inpos females nns auc nn by inpos num cd in inpos males nns and cc num cd in inpos females nns
false	0	32	ketoconazole nn at inpos num cd mg nn daily rb co_administered vbn with inpos tikosyn nn for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb dofetilide nn cmax nn by inpos num cd in inpos males nns num cd in inpos females nns auc nn by inpos num cd in inpos males nns and cc num cd in inpos females nns
false	14	32	ketoconazole nn at inpos num cd mg nn daily rb co_administered vbn with inpos tikosyn nn for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb dofetilide nn cmax nn by inpos num cd in inpos males nns num cd in inpos females nns auc nn by inpos num cd in inpos males nns and cc num cd in inpos females nns
false	0	12	trimethoprim nn alone nn or cc in inpos combination nn with inpos sulfamethoxazole nn
false	0	12	trimethoprim nn alone nn or cc in inpos combination nn with inpos sulfamethoxazole nn concomitant jj use nn of inpos trimethoprim nn alone rb or cc in inpos combination nn with inpos sulfamethoxazole nn is vbz contraindicated vbn
false	12	0	trimethoprim nnp alone nnp or cc in inpos combination nn with inpos sulfamethoxazole nn concomitant jj use nn of inpos trimethoprim nn alone rb or cc in inpos combination nn with inpos sulfamethoxazole nn is vbz contraindicated vbn
false	6	18	concomitant jj use nn of inpos trimethoprim nn alone rb or cc in inpos combination nn with inpos sulfamethoxazole nn is vbz contraindicated vbn
false	0	12	hydrochlorothiazide nn alone nn or cc in inpos combination nn with inpos triamterene nn
false	0	20	hydrochlorothiazide nn alone nn or cc in inpos combination nn with inpos triamterene nn concomitant jj use nn of inpos hctz nn alone rb or cc in inpos combination nn with inpos triamterene nn is vbz contraindicated vbn
false	0	12	hydrochlorothiazide nn alone nn or cc in inpos combination nn with inpos triamterene nn concomitant jj use nn of inpos hctz nn alone rb or cc in inpos combination nn with inpos triamterene nn is vbz contraindicated vbn
false	0	12	hctz nn alone nn or cc in inpos combination nn with inpos triamterene nn
false	0	12	hctz nn alone nn or cc in inpos combination nn with inpos triamterene nn concomitant jj use nn of inpos hctz nn alone rb or cc in inpos combination nn with inpos triamterene nn is vbz contraindicated vbn
false	12	20	hydrochlorothiazide nn alone nnp or cc in inpos combination nn with inpos triamterene nn concomitant jj use nn of inpos hctz nn alone rb or cc in inpos combination nn with inpos triamterene nn is vbz contraindicated vbn
false	6	18	concomitant jj use nn of inpos hctz nn alone rb or cc in inpos combination nn with inpos triamterene nn is vbz contraindicated vbn
false	0	10	hctz nn num cd mg nn qd nn or cc triamterene nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns
false	0	24	hctz nn num cd mg nn qd nn or cc hctz nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns
false	0	40	hctz nn num cd mg nn qd nn or cc triamterene nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns lrb_following vbg num cd days nns of inpos diuretic nn use nn at inpos half jj dose nn
false	0	24	hctz nn num cd mg nn qd nn or cc hctz nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns
false	0	40	hctz nn num cd mg nn qd nn or cc hctz nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns lrb_following vbg num cd days nns of inpos diuretic nn use nn at inpos half jj dose nn
false	10	24	hctz nn num cd mg nn qd nn or cc triamterene nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns
false	10	40	hctz nn num cd mg nn qd nn or cc triamterene nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns lrb_following vbg num cd days nns of inpos diuretic nn use nn at inpos half jj dose nn
false	24	40	hctz nn num cd mg nn qd nn or cc triamterene nn num cd mg nn qd nn was vbd co_administered vbn with inpos tikosyn nn for inpos num cd days nns lrb_following vbg num cd days nns of inpos diuretic nn use nn at inpos half jj dose nn
mechanism	6	10	in inpos patients nns receiving vbg hctz nn alone rb dofetilide nn auc nn increased vbd by inpos num cd and cc cmax nn by inpos num cd
false	18	22	in inpos the dt diamond nn trials nns num cd patients nns were vbd treated vbn with inpos tikosyn nn and cc diuretics nn concomitantly rb of inpos whom wp num cd died vbd compared vbn to topos num cd deaths nns among inpos the dt num cd patients nns receiving vbg placebo nn and cc diuretics nns
false	18	22	in inpos the dt diamond nn trials nns num cd patients nns were vbd treated vbn with inpos tikosyn nn and cc diuretics nns concomitantly rb of inpos whom wp num cd died vbd compared vbn to topos num cd deaths nns among inpos the dt num cd patients nns receiving vbg placebo nn and cc diuretics nn
false	12	38	of inpos the dt num cd patients nns who wp had vbd potassium_depleting_diuretics nn added vbn to topos their prp concomitant jj medications nns in inpos the dt diamond nn trials nns the dt patients nns on inpos tikosyn nn had vbd a dt non_significantly rb reduced vbn relative jj risk nn for inpos death nn of inpos float cd
advise	18	38	in inpos addition nn drugs nns that wdt are vbp actively rb secreted vbn via inpos this dt triamterene nn should md be vb co_administered vbn with inpos care nn as inpos they prp might md increase vb dofetilide nn levels nns
advise	18	38	in inpos addition nn drugs nns that wdt are vbp actively rb secreted vbn via inpos this dt metformin nn should md be vb co_administered vbn with inpos care nn as inpos they prp might md increase vb dofetilide nn levels nns
advise	18	38	in inpos addition nn drugs nns that wdt are vbp actively rb secreted vbn via inpos this dt amiloride nn should md be vb co_administered vbn with inpos care nn as inpos they prp might md increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt macrolide_antibiotics nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt macrolide_antibiotics nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt azole_antifungal_agents nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt azole_antifungal_agents nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt protease_inhibitors nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt protease_inhibitors nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt serotonin_reuptake_inhibitors nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt serotonin_reuptake_inhibitors nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt amiodarone nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt amiodarone nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt cannabinoids nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt cannabinoids nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt diltiazem nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt diltiazem nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt nefazadone nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt nefazadone nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt norfloxacin nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt norfloxacin nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt quinine nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt quinine nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
advise	6	18	inhibitors nns of inpos this dt zafirlukast nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	6	30	inhibitors nns of inpos this dt zafirlukast nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	18	30	inhibitors nns of inpos this dt isoenzyme nn should md be vb cautiously rb coadministered vbn with inpos tikosyn nn as inpos they prp can md potentially rb increase vb dofetilide nn levels nns
false	14	28	studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos digoxin nn
effect	12	16	in inpos patients nns the dt concomitant jj administration nn of inpos digoxin nn with inpos dofetilide nn was vbd associated vbn with inpos a dt higher jjr occurrence nn of inpos torsade fw de fw pointes fw
false	20	46	it prp is vbz not rb clear jj whether inpos this dt represents vbz an dt interaction nn with inpos tikosyn nn or cc the dt presence nn of inpos more rbr severe jj structural jj heart nn disease nn in inpos patients nns on inpos digoxin nn
false	10	26	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	30	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn hormone nn replacement nn antacid nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn hormone nn replacement nn aluminum nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn hormone nn replacement nn magnesium_hydroxide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn hormone nn replacement nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	34	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn hormone nn replacement nn therapy nn antacid nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	26	other jj drugs nns in inpos healthy jj volunteers nns phenytoin nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	30	other jj drugs nns in inpos healthy jj volunteers nns phenytoin nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns phenytoin nn hormone nn replacement nn antacid nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns phenytoin nn hormone nn replacement nn aluminum nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns phenytoin nn hormone nn replacement nn magnesium_hydroxide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns phenytoin nn hormone nn replacement nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	34	other jj drugs nns in inpos healthy jj volunteers nns phenytoin nn hormone nn replacement nn therapy nn antacid nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	26	other jj drugs nns in inpos healthy jj volunteers nns glyburide nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	30	other jj drugs nns in inpos healthy jj volunteers nns glyburide nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns glyburide nn hormone nn replacement nn antacid nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns glyburide nn hormone nn replacement nn aluminum nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns glyburide nn hormone nn replacement nn magnesium_hydroxide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns glyburide nn hormone nn replacement nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	34	other jj drugs nns in inpos healthy jj volunteers nns glyburide nn hormone nn replacement nn therapy nn antacid nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	26	other jj drugs nns in inpos healthy jj volunteers nns ranitidine nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	30	other jj drugs nns in inpos healthy jj volunteers nns ranitidine nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns ranitidine nn hormone nn replacement nn antacid nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns ranitidine nn hormone nn replacement nn aluminum nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns ranitidine nn hormone nn replacement nn magnesium_hydroxide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns ranitidine nn hormone nn replacement nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	34	other jj drugs nns in inpos healthy jj volunteers nns ranitidine nn hormone nn replacement nn therapy nn antacid nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	26	other jj drugs nns in inpos healthy jj volunteers nns omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	30	other jj drugs nns in inpos healthy jj volunteers nns omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns omeprazole nn hormone nn replacement nn antacid nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns omeprazole nn hormone nn replacement nn aluminum nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns omeprazole nn hormone nn replacement nn magnesium_hydroxide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	16	other jj drugs nns in inpos healthy jj volunteers nns omeprazole nn hormone nn replacement nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	34	other jj drugs nns in inpos healthy jj volunteers nns omeprazole nn hormone nn replacement nn therapy nn antacid nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	10	14	other jj a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn
false	34	40	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	34	40	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_aluminum nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	34	40	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_magnesium_hydroxide nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	34	44	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	34	58	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nn and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	38	40	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	38	40	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_aluminum nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	38	40	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_magnesium_hydroxide nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	38	44	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	38	58	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn therapy nn lrb_a dt combination nn of inpos conjugated vbn estrogens nns and cc medroxyprogesterone nn rrb_antacid nn and cc theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	24	38	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn antacid nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	24	38	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn aluminum nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	24	38	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn magnesium_hydroxide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	24	38	other jj drugs nns in inpos healthy jj volunteers nns amlodipine nn phenytoin nn glyburide nn ranitidine nn omeprazole nn hormone nn replacement nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos tikosyn nn
false	18	36	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos propranolol nn phenytoin nn theophylline nn oral jj contraceptives nns
false	18	46	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos propranolol nn oral jj contraceptives nns
false	18	46	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos phenytoin nn oral jj contraceptives nns
false	18	46	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos theophylline nn oral jj contraceptives nns
false	18	54	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos propranolol nn phenytoin nn theophylline nn oral jj contraceptives nn
false	36	46	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos propranolol nn oral jj contraceptives nns
false	36	46	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos phenytoin nn oral jj contraceptives nns
false	36	46	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos theophylline nn oral jj contraceptives nns
false	36	54	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos propranolol nn phenytoin nn theophylline nn oral jj contraceptives nn
false	46	50	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos propranolol nn oral jj contraceptives nn
false	46	50	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos phenytoin nn oral jj contraceptives nn
false	46	50	in inpos addition nn studies nns in inpos healthy jj volunteers nns have vbp shown vbn that inpos tikosyn nn does vbz not rb affect vb the dt pharmacokinetics nns or cc pharmacodynamics nns of inpos warfarin nn or cc the dt pharmacokinetics nns of inpos theophylline nn oral jj contraceptives nn
false	10	32	concomitant jj medications nns were vbd grouped vbn as inpos cardiac_glycosides nns of inpos cyp3a4 nn substrates nns inhibitors nns of inpos cyp3a4 nn substrates nns inhibitors nns of inpos p_glycoprotein nn nitrates nns of inpos tubular jj organic jj cation nn transport nn qtc_prolonging jj drugs nns
false	10	16	concomitant jj medications nns were vbd grouped vbn as inpos cardiac_glycosides nns of inpos cyp3a4 nn sulphonylureas nns of inpos tubular jj organic jj cation nn transport nn qtc_prolonging jj drugs nns
false	10	16	concomitant jj medications nns were vbd grouped vbn as inpos cardiac_glycosides nns of inpos cyp3a4 nn loop_diuretics nns of inpos tubular jj organic jj cation nn transport nn qtc_prolonging jj drugs nns
false	10	16	concomitant jj medications nns were vbd grouped vbn as inpos cardiac_glycosides nns of inpos cyp3a4 nn potassium_sparing_diuretics nns of inpos tubular jj organic jj cation nn transport nn qtc_prolonging jj drugs nns
mechanism	8	26	the dt mean jj clearances nns of inpos dofetilide nn were vbd num cd and cc num cd lower jjr in inpos patients nns on inpos thiazide_diuretics nn and cc inhibitors nns of inpos tubular jj organic jj cation nn transport nn respectively rb
false	6	22	blood nn levels nns of inpos hydrodolasetron nn increased vbd num cd when wrb dolasetron nn was vbd coadministered vbn with inpos cimetidine nn for inpos num cd days nns and cc decreased vbd num cd with inpos coadministration nn of inpos rifampin nn for inpos num cd days nns
false	6	42	blood nn levels nns of inpos hydrodolasetron nn increased vbd num cd when wrb dolasetron nn was vbd coadministered vbn with inpos cimetidine nn for inpos num cd days nns and cc decreased vbd num cd with inpos coadministration nn of inpos rifampin nn for inpos num cd days nns
mechanism	6	22	blood nn levels nns of inpos hydrodolasetron nn increased vbd num cd when wrb dolasetron nn was vbd coadministered vbn with inpos cimetidine nn for inpos num cd days nns and cc decreased vbd num cd with inpos coadministration nn of inpos rifampin nn for inpos num cd days nns
mechanism	6	42	blood nn levels nns of inpos hydrodolasetron nn increased vbd num cd when wrb dolasetron nn was vbd coadministered vbn with inpos cimetidine nn for inpos num cd days nns and cc decreased vbd num cd with inpos coadministration nn of inpos rifampin nn for inpos num cd days nns
false	22	42	blood nn levels nns of inpos hydrodolasetron nn increased vbd num cd when wrb dolasetron nn was vbd coadministered vbn with inpos cimetidine nn for inpos num cd days nns and cc decreased vbd num cd with inpos coadministration nn of inpos rifampin nn for inpos num cd days nns
false	6	32	in inpos patients nns taking vbg furosemide nn and cc various jj chemotherapy nn agents nns no dt effect nn was vbd shown vbn on inpos the dt clearance nn of inpos hydrodolasetron nn
false	6	32	in inpos patients nns taking vbg nifedipine nn and cc various jj chemotherapy nn agents nns no dt effect nn was vbd shown vbn on inpos the dt clearance nn of inpos hydrodolasetron nn
false	6	32	in inpos patients nns taking vbg diltiazem nn and cc various jj chemotherapy nn agents nns no dt effect nn was vbd shown vbn on inpos the dt clearance nn of inpos hydrodolasetron nn
false	6	32	in inpos patients nns taking vbg ace_inhibitors nn and cc various jj chemotherapy nn agents nns no dt effect nn was vbd shown vbn on inpos the dt clearance nn of inpos hydrodolasetron nn
false	6	32	in inpos patients nns taking vbg verapamil nn and cc various jj chemotherapy nn agents nns no dt effect nn was vbd shown vbn on inpos the dt clearance nn of inpos hydrodolasetron nn
false	6	32	in inpos patients nns taking vbg glyburide nn and cc various jj chemotherapy nn agents nns no dt effect nn was vbd shown vbn on inpos the dt clearance nn of inpos hydrodolasetron nn
false	6	32	in inpos patients nns taking vbg propranolol nn and cc various jj chemotherapy nn agents nns no dt effect nn was vbd shown vbn on inpos the dt clearance nn of inpos hydrodolasetron nn
false	4	16	clearance nn of inpos hydrodolasetron nn decreased vbd by inpos about rb num cd when wrb dolasetron_mesylate nn was vbd administered vbn intravenously rb concomitantly rb with inpos atenolol nn
false	4	28	clearance nn of inpos hydrodolasetron nn decreased vbd by inpos about rb num cd when wrb dolasetron_mesylate nn was vbd administered vbn intravenously rb concomitantly rb with inpos atenolol nn
mechanism	16	28	clearance nn of inpos hydrodolasetron nn decreased vbd by inpos about rb num cd when wrb dolasetron_mesylate nn was vbd administered vbn intravenously rb concomitantly rb with inpos atenolol nn
false	0	18	dolasetron_mesylate nn did vbd not rb inhibit vb the dt antitumor jj activity nn of inpos num cd chemotherapeutic_agents nn in inpos num cd murine jj models nns
false	0	18	dolasetron_mesylate nn did vbd not rb inhibit vb the dt antitumor jj activity nn of inpos num cd cisplatin nn in inpos num cd murine jj models nns
false	0	18	dolasetron_mesylate nn did vbd not rb inhibit vb the dt antitumor jj activity nn of inpos num cd num_fluorouracil nn in inpos num cd murine jj models nns
false	0	18	dolasetron_mesylate nn did vbd not rb inhibit vb the dt antitumor jj activity nn of inpos num cd doxorubicin nn in inpos num cd murine jj models nns
false	0	18	dolasetron_mesylate nn did vbd not rb inhibit vb the dt antitumor jj activity nn of inpos num cd cyclophosphamide nn in inpos num cd murine jj models nns
advise	12	34	patients nns who wp have vbp been vbn treated vbn with inpos mao_inhibitors nn within inpos num cd to topos num cd weeks nns prior rb to topos the dt administration nn of inpos dopamine_hcl nn should md receive vb initial jj doses nns of inpos dopamine_hcl nn no rb greater jjr than inpos one_tenth nn of inpos the dt usual jj dose nn
false	12	34	patients nns who wp have vbp been vbn treated vbn with inpos mao_inhibitors nn within inpos num cd to topos num cd weeks nns prior rb to topos the dt administration nn of inpos dopamine_hcl nn should md receive vb initial jj doses nns of inpos dopamine_hcl nn no rb greater jjr than inpos one_tenth nn of inpos the dt usual jj dose nn
effect	8	12	concurrent jj administration nn of inpos low_dose jj dopamine_hcl nn and cc diuretic_agents nn may md produce vb an dt additive jj or cc potentiating vbg effect nn on inpos urine nn flow nn
effect	6	14	cardiac jj effects nns of inpos dopamine nn are vbp antagonized vbn by inpos b_adrenergic_blocking_agents nn such jj as inpos propranolol nn and cc metoprolol nn
effect	6	20	cardiac jj effects nns of inpos dopamine nn are vbp antagonized vbn by inpos b_adrenergic_blocking_agents nns such jj as inpos propranolol nn and cc metoprolol nn
effect	6	24	cardiac jj effects nns of inpos dopamine nn are vbp antagonized vbn by inpos b_adrenergic_blocking_agents nns such jj as inpos propranolol nn and cc metoprolol nn
false	14	20	cardiac jj effects nns of inpos dopamine nn are vbp antagonized vbn by inpos b_adrenergic_blocking_agents nn such jj as inpos propranolol nn and cc metoprolol nn
false	14	24	cardiac jj effects nns of inpos dopamine nn are vbp antagonized vbn by inpos b_adrenergic_blocking_agents nn such jj as inpos propranolol nn and cc metoprolol nn
false	20	24	cardiac jj effects nns of inpos dopamine nn are vbp antagonized vbn by inpos b_adrenergic_blocking_agents nns such jj as inpos propranolol nn and cc metoprolol nn
effect	16	24	the dt peripheral jj vasoconstriction nn caused vbn by inpos high jj doses nns of inpos dopamine_hcl nn is vbz antagonized vbn by inpos ap_adrenergic_blocking_agents nn
false	0	22	dopamine nn induced jj renal jj and cc mesenteric jj vasodilation nn is vbz not rb antagonized vbn by inpos either cc ap nn or cc b nn bbbbb22_adrenergic_blocking_agents_eeeee22 nn
false	0	26	dopamine nn induced jj renal jj and cc mesenteric jj vasodilation nn is vbz not rb antagonized vbn by inpos either cc ap nn or cc b_adrenergic_blocking_agents nn
false	20	11	dopamine_induced jj renal jj and cc mesenteric jj vasodilation nn is vbz not rb antagonized vbn by inpos either cc ap nn or cc b nn hyph_bbbbbcom_adrenergic_blocking_agents_eeeeecom nn
false	0	4	butyrophenones nn and cc phenothiazines nn can md suppress vb the dt dopaminergic jj renal jj and cc mesenteric jj vasodilation nn induced vbn with inpos low jj dose nn dopamine nn infusion nn
effect	0	12	butyrophenones nn and cc phenothiazines nns can md suppress vb the dt dopamine nn rgic jj renal jj and cc mesenteric jj vasodilation nn induced vbn with inpos low jj dose nn dopamine nn infusion nn
false	0	4	haloperidol nn and cc phenothiazines nn can md suppress vb the dt dopaminergic jj renal jj and cc mesenteric jj vasodilation nn induced vbn with inpos low jj dose nn dopamine nn infusion nn
effect	0	12	haloperidol nn and cc phenothiazines nns can md suppress vb the dt dopamine nn rgic jj renal jj and cc mesenteric jj vasodilation nn induced vbn with inpos low jj dose nn dopamine nn infusion nn
effect	4	12	butyrophenones nns and cc phenothiazines nn can md suppress vb the dt dopamine nn rgic jj renal jj and cc mesenteric jj vasodilation nn induced vbn with inpos low jj dose nn dopamine nn infusion nn
false	0	4	cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nn increase vbp cardiac jj autonomic jj irritability nn and cc may md sensitize vb the dt myocardium nn to topos the dt action nn of inpos certain jj intravenously rb administered vbn catecholamines nns such jj as inpos dopamine nn
effect	0	38	cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nns increase vbp cardiac jj autonomic jj irritability nn and cc may md sensitize vb the dt myocardium nn to topos the dt action nn of inpos certain jj intravenously rb administered vbn catecholamines nn such jj as inpos dopamine nn
effect	0	44	cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nns increase vbp cardiac jj autonomic jj irritability nn and cc may md sensitize vb the dt myocardium nn to topos the dt action nn of inpos certain jj intravenously rb administered vbn catecholamines nns such jj as inpos dopamine nn
effect	4	38	cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nn increase vbp cardiac jj autonomic jj irritability nn and cc may md sensitize vb the dt myocardium nn to topos the dt action nn of inpos certain jj intravenously rb administered vbn catecholamines nn such jj as inpos dopamine nn
effect	4	44	cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nn increase vbp cardiac jj autonomic jj irritability nn and cc may md sensitize vb the dt myocardium nn to topos the dt action nn of inpos certain jj intravenously rb administered vbn catecholamines nns such jj as inpos dopamine nn
false	38	44	cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nns increase vbp cardiac jj autonomic jj irritability nn and cc may md sensitize vb the dt myocardium nn to topos the dt action nn of inpos certain jj intravenously rb administered vbn catecholamines nn such jj as inpos dopamine nn
advise	16	24	therefore rb extreme nn caution nn should md be vb exercised vbn when wrb administering vbg dopamine_hcl nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nns
advise	16	28	therefore rb extreme nn caution nn should md be vb exercised vbn when wrb administering vbg dopamine_hcl nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nn
false	24	28	therefore rb extreme nn caution nn should md be vb exercised vbn when wrb administering vbg dopamine_hcl nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_anesthetics nn
effect	24	44	it prp has vbz been vbn reported vbn that inpos results nns of inpos studies nns in inpos animals nns indicate vbp that inpos dopamine nn induced jj ventricular jj arrhythmias nns during inpos anesthesia nn can md be vb reversed vbn by inpos propranolol nn
false	8	14	the dt concomitant jj use nn of inpos vasopressor nn s nns vasoconstricting vbg ergonovine nn and cc some dt oxytocic_drugs nns may md result vb in inpos severe jj hypertension nn
effect	12	18	the dt concomitant jj use nn of inpos vasopressors nns vasoconstricting vbg ergonovine nn and cc some dt oxytocic_drugs nn may md result vb in inpos severe jj hypertension nn
effect	4	12	administration nn of inpos phenytoin nn to topos patients nns receiving vbg dopamine_hcl nn has vbz been vbn reported vbn to topos lead vb to topos hypotension nn and cc bradycardia nn
advise	14	20	it prp is vbz suggested vbn that inpos in inpos patients nns receiving vbg dopamine_hcl nn alternatives nns to topos phenytoin nn should md be vb used vbn if inpos anticonvulsant jj therapy nn is vbz needed vbn
false	14	30	it prp is vbz suggested vbn that inpos in inpos patients nns receiving vbg dopamine_hcl nn alternatives nns to topos phenytoin nn should md be vb used vbn if inpos anticonvulsant nn therapy nn is vbz needed vbn
false	20	30	it prp is vbz suggested vbn that inpos in inpos patients nns receiving vbg dopamine_hcl nn alternatives nns to topos phenytoin nn should md be vb used vbn if inpos anticonvulsant nn therapy nn is vbz needed vbn
false	10	48	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns
false	10	50	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns bronchodilators nns
false	10	56	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns bronchodilators nns enzyme nn supplements nns vitamins nn oral jj inhaled vbn corticosteroids nns analgesics nns
false	10	64	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns bronchodilators nns enzyme nn supplements nns vitamins nns oral jj or cc inhaled vbn corticosteroids nn analgesics nns
false	10	64	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns bronchodilators nns enzyme nn supplements nns vitamins nns oral jj inhaled vbn corticosteroids nns analgesics nn
false	48	56	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns oral jj or cc inhaled vbn corticosteroids nn analgesics nns
false	50	58	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns bronchodilators nns oral jj or cc inhaled vbn corticosteroids nn analgesics nns
false	56	64	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns bronchodilators nns enzyme nn supplements nns vitamins nn oral jj or cc inhaled vbn corticosteroids nn analgesics nns
false	64	66	clinical jj trials nns have vbp indicated vbn that inpos pulmozyme nn can md be vb effectively rb and cc safely rb used vbn in inpos conjunction nn with inpos standard jj cystic jj fibrosis nn therapies nns including vbg oral jj inhaled vbd and_or cc parenteral jj antibiotics nns bronchodilators nns enzyme nn supplements nns vitamins nns oral jj or cc inhaled vbn corticosteroids nn analgesics nn
effect	26	42	although inpos acid_base nn and cc electrolyte nn disturbances nns were vbd not rb reported vbn in inpos the dt clinical jj trials nns with inpos dorzolamide nn these dt disturbances nns have vbp been vbn reported vbn with inpos oral jj carbonic_anhydrase_inhibitors nn have vbp in inpos some dt instances nns resulted vbd in inpos drug nn interactions nns
false	26	70	although inpos acid_base nn and cc electrolyte nn disturbances nns were vbd not rb reported vbn in inpos the dt clinical jj trials nns with inpos dorzolamide nn these dt disturbances nns have vbp been vbn reported vbn with inpos oral jj carbonic_anhydrase_inhibitors nns have vbp in inpos some dt instances nns resulted vbd in inpos drug nn interactions nns lrb_e.g. fw toxicity nn associated vbn with inpos high_dose jj salicylate nn therapy nn
false	42	70	although inpos acid_base nn and cc electrolyte nn disturbances nns were vbd not rb reported vbn in inpos the dt clinical jj trials nns with inpos dorzolamide nn these dt disturbances nns have vbp been vbn reported vbn with inpos oral jj carbonic_anhydrase_inhibitors nn have vbp in inpos some dt instances nns resulted vbd in inpos drug nn interactions nns lrb_e.g. fw toxicity nn associated vbn with inpos high_dose jj salicylate nn therapy nn
false	6	30	prior jj administration nn of inpos succinylcholine nn has vbz no dt clinically rb important jj effect nn on inpos the dt neuromuscular jj blocking vbg action nn of inpos nuromax nn
false	6	10	the dt use nn of inpos nuromax nn before inpos succinylcholine nn to topos attenuate vb some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	6	10	the dt use nn of inpos nuromax nn before inpos succinylcholine nn to topos attenuate vb some dt of inpos the dt side nn effects nns of inpos succinylcholine nn has vbz not rb been vbn studied vbn
false	18	26	there ex are vbp no dt clinical jj data nns on inpos concomitant jj use nn of inpos nuromax nn and cc other jj nondepolarizing jj neuromuscular_blocking_agents nn
mechanism	0	10	isoflurane nn decrease vbp the dt ed50 nn of inpos nuromax nn by inpos num cd to topos num cd
mechanism	0	10	enflurane nn decrease vbp the dt ed50 nn of inpos nuromax nn by inpos num cd to topos num cd
mechanism	0	10	halothane nn decrease vbp the dt ed50 nn of inpos nuromax nn by inpos num cd to topos num cd
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj aminoglycosides nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj tetracyclines nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj bacitracin nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj polymyxins nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj lincomycin nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj clindamycin nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj colistin nn
effect	28	34	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj sodium_colistimethate nn
effect	28	36	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn local jj anesthetics nns procainamide nn quinidine nn
effect	28	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
effect	28	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
effect	28	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
effect	28	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
false	36	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns lithium nn
false	36	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns anesthetics nn
false	36	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns procainamide nn
false	36	40	other jj drugs nns which wdt may md enhance vb the dt neuromuscular jj blocking vbg action nn of inpos nondepolarizing vbg agents nns such jj as inpos nuromax nn include vbp certain jj antibiotics nns magnesium nn salts nns quinidine nn
false	8	28	as inpos with inpos some dt other jj nondepolarizing_neuromuscular_blocking_agents nn the dt time nn of inpos onset nn of inpos neuromuscular jj block nn induced vbn by inpos nuromax nn is vbz lengthened vbn and cc the dt duration nn of inpos block nn is vbz shortened vbn in inpos patients nns receiving vbg phenytoin nn or cc carbamazepine nn
effect	8	54	as inpos with inpos some dt other jj nondepolarizing_neuromuscular_blocking_agents nn the dt time nn of inpos onset nn of inpos neuromuscular jj block nn induced vbn by inpos nuromax nn is vbz lengthened vbn and cc the dt duration nn of inpos block nn is vbz shortened vbn in inpos patients nns receiving vbg phenytoin nn or cc carbamazepine nn
effect	8	58	as inpos with inpos some dt other jj nondepolarizing_neuromuscular_blocking_agents nn the dt time nn of inpos onset nn of inpos neuromuscular jj block nn induced vbn by inpos nuromax nn is vbz lengthened vbn and cc the dt duration nn of inpos block nn is vbz shortened vbn in inpos patients nns receiving vbg phenytoin nn or cc carbamazepine nn
effect	28	54	as inpos with inpos some dt other jj nondepolarizing_neuromuscular_blocking_agents nns the dt time nn of inpos onset nn of inpos neuromuscular jj block nn induced vbn by inpos nuromax nn is vbz lengthened vbn and cc the dt duration nn of inpos block nn is vbz shortened vbn in inpos patients nns receiving vbg phenytoin nn or cc carbamazepine nn
effect	28	58	as inpos with inpos some dt other jj nondepolarizing_neuromuscular_blocking_agents nns the dt time nn of inpos onset nn of inpos neuromuscular jj block nn induced vbn by inpos nuromax nn is vbz lengthened vbn and cc the dt duration nn of inpos block nn is vbz shortened vbn in inpos patients nns receiving vbg phenytoin nn or cc carbamazepine nn
false	54	58	as inpos with inpos some dt other jj nondepolarizing_neuromuscular_blocking_agents nns the dt time nn of inpos onset nn of inpos neuromuscular jj block nn induced vbn by inpos nuromax nn is vbz lengthened vbn and cc the dt duration nn of inpos block nn is vbz shortened vbn in inpos patients nns receiving vbg phenytoin nn or cc carbamazepine nn
effect	4	16	administration nn of inpos doxapram nn to topos patients nns who wp are vbp receiving vbg sympathomimetic nn or cc monoamine_oxidase_inhibiting_drugs nns may md result vb in inpos an dt additive jj pressor nn effect nn
effect	4	20	administration nn of inpos doxapram nn to topos patients nns who wp are vbp receiving vbg sympathomimetic jj or cc monoamine_oxidase_inhibiting_drugs nn may md result vb in inpos an dt additive jj pressor nn effect nn
false	16	20	administration nn of inpos doxapram nn to topos patients nns who wp are vbp receiving vbg sympathomimetic nn or cc monoamine_oxidase_inhibiting_drugs nn may md result vb in inpos an dt additive jj pressor nn effect nn
false	10	12	in inpos patients nns who wp have vbp received vbn muscle_relaxants nn doxapram nn may md temporarily rb mask vb the dt residual jj effects nns of inpos muscle_relaxant_drugs nns
false	10	28	in inpos patients nns who wp have vbp received vbn muscle_relaxants nn doxapram nn may md temporarily rb mask vb the dt residual jj effects nns of inpos muscle_relaxant_drugs nn
effect	12	28	in inpos patients nns who wp have vbp received vbn muscle_relaxants nns doxapram nn may md temporarily rb mask vb the dt residual jj effects nns of inpos muscle_relaxant_drugs nn
false	16	32	in fw vitro fw data nns in inpos human jj plasma nn indicate vbp that inpos doxazosin_mesylate nn has vbz no dt effect nn on inpos protein nn binding nn of inpos digoxin nn
false	16	32	in fw vitro fw data nns in inpos human jj plasma nn indicate vbp that inpos doxazosin_mesylate nn has vbz no dt effect nn on inpos protein nn binding nn of inpos warfarin nn
false	16	32	in fw vitro fw data nns in inpos human jj plasma nn indicate vbp that inpos doxazosin_mesylate nn has vbz no dt effect nn on inpos protein nn binding nn of inpos phenytoin nn
false	16	32	in fw vitro fw data nns in inpos human jj plasma nn indicate vbp that inpos doxazosin_mesylate nn has vbz no dt effect nn on inpos protein nn binding nn of inpos indomethacin nn
false	0	30	doxazosin_mesylate nn has vbz been vbn administered vbn without inpos any dt evidence nn of inpos an dt adverse jj drug nn interaction nn to topos patients nns receiving vbg thiazide_diuretics nns
false	0	30	doxazosin_mesylate nn has vbz been vbn administered vbn without inpos any dt evidence nn of inpos an dt adverse jj drug nn interaction nn to topos patients nns receiving vbg b_blocking_agent nns
false	0	30	doxazosin_mesylate nn has vbz been vbn administered vbn without inpos any dt evidence nn of inpos an dt adverse jj drug nn interaction nn to topos patients nns receiving vbg nonsteroidal_anti_inflammatory_drugs nn
mechanism	32	52	in inpos a dt placebo_controlled jj trial nn in inpos normal jj volunteers nns the dt administration nn of inpos a dt single jj num cd mg nn dose nn of inpos doxazosin nn on inpos day nn num cd of inpos a dt four_day jj regimen nn of inpos oral jj cimetidine nn resulted vbd in inpos a dt num cd increase nn in inpos mean jj auc nn of inpos doxazosin nn and cc a dt slight jj but cc not rb statistically rb significant jj increase nn in inpos mean jj cmax nn and cc mean jj half_life nn of inpos doxazosin nn
false	52	32	in inpos a dt placebo_controlled jj trial nn in inpos normal jj volunteers nns the dt administration nn of inpos a dt single jj num cd mg nn dose nn of inpos doxazosin nn on inpos day nn num cd of inpos a dt four_day jj regimen nn of inpos oral jj cimetidine nn resulted vbd in inpos a dt num cd increase nn in inpos mean jj auc nn of inpos doxazosin nn and cc a dt slight jj but cc not rb statistically rb significant jj increase nn in inpos mean jj cmax nn and cc mean jj half_life nn of inpos doxazosin nn
false	52	32	in inpos a dt placebo_controlled jj trial nn in inpos normal jj volunteers nns the dt administration nn of inpos a dt single jj num cd mg nn dose nn of inpos doxazosin nn on inpos day nn num cd of inpos a dt four_day jj regimen nn of inpos oral jj cimetidine nn resulted vbd in inpos a dt num cd increase nn in inpos mean jj auc nn of inpos doxazosin nn and cc a dt slight jj but cc not rb statistically rb significant jj increase nn in inpos mean jj cmax nn and cc mean jj half_life nn of inpos doxazosin nn
false	0	2	analgesic nn anti_inflammatory nn
false	0	2	analgesic nn acetaminophen nn
false	0	2	analgesic nn aspirin nn
false	0	2	analgesic nn codeine nn
false	0	2	analgesic nn codeine nn
false	0	2	analgesic nn ibuprofen nn
false	0	2	analgesic nn indomethacin nn
false	0	4	sedatives nn and cc tranquilizers nn
false	0	4	sedatives nn and cc diazepam nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn antidepressants nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn phenothiazines nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn type_1c_antiarrhythmics nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn propafenone nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn flecainide nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw citalopram nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw escitalopram nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw citalopram nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw escitalopram nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	10	while inpos all pdt the dt ssris nn e.g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
int	8	10	the dt extent nn to topos which wdt ssri nn hyph_tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbd
false	10	8	the dt extent nn to topos which wdt ssri nn tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbn
advise	16	26	nevertheless rb caution nn is vbz indicated vbn in inpos the dt co_administration nn of inpos tcas nn with inpos any dt of inpos the dt ssris nn and cc also rb in inpos switching vbg from inpos num cd class nn to topos the dt other jj
false	4	8	inhibitors nns i.e. fw quinidine nn selective_serotonin_reuptake_inhibitors nns lrb_ssris nn
mechanism	8	22	inhibitors nns or cc substrates nns of inpos quinidine nn may md increase vb the dt plasma nn concentration nn of inpos doxepin nn when wrb administered vbn concomitantly rb
false	6	8	inhibitors nns i.e. fw quinidine nn selective_serotonin_reuptake_inhibitors nn lrb_ssris nn
mechanism	8	22	inhibitors nns or cc substrates nns of inpos selective_serotonin_reuptake_inhibitors nn may md increase vb the dt plasma nn concentration nn of inpos doxepin nn when wrb administered vbn concomitantly rb
mechanism	16	30	inhibitors nns or cc substrates nns of inpos cyp2d6 nn lrb_i.e. fw quinidine nn selective_serotonin_reuptake_inhibitors nns lrb_ssris nn rrb_rrb_may md increase vb the dt plasma nn concentration nn of inpos doxepin nn when wrb administered vbn concomitantly rb
advise	2	34	therefore rb mao_inhibitors nn should md be vb discontinued vbn at inpos least jjs num cd weeks nns prior rb to topos the dt cautious jj initiation nn of inpos therapy nn with inpos sinequan nn
mechanism	0	30	cimetidine nn has vbz been vbn reported vbn to topos produce vb clinically rb significant jj fluctuations nns in inpos steady_state jj serum nn concentrations nns of inpos various jj tricyclic_antidepressants nn
effect	26	30	serious jj anticholinergic jj symptoms nns have vbp been vbn associated vbn with inpos elevations nns in inpos the dt serum nn levels nns of inpos tricyclic_antidepressant nn when wrb cimetidine nn therapy nn is vbz initiated vbn
mechanism	8	34	additionally rb higher jjr than inpos expected vbn tricyclic_antidepressant nn levels nns have vbp been vbn observed vbn when wrb they prp are vbp begun vbn in inpos patients nns already rb taking vbg cimetidine nn
false	22	28	in inpos patients nns who wp have vbp been vbn reported vbn to topos be vb well rb controlled vbn on inpos tricyclic_antidepressants nn receiving vbg concurrent jj cimetidine nn therapy nn discontinuation nn of inpos cimetidine nn has vbz been vbn reported vbn to topos decrease vb established jj steady_state jj serum nn tricyclic_antidepressant nn levels nns and cc compromise vbp their prp therapeutic jj effects nns
false	22	28	in inpos patients nns who wp have vbp been vbn reported vbn to topos be vb well rb controlled vbn on inpos tricyclic_antidepressants nn receiving vbg concurrent jj cimetidine nn therapy nn discontinuation nn of inpos cimetidine nn has vbz been vbn reported vbn to topos decrease vb established jj steady_state jj serum nn tricyclic_antidepressant nn levels nns and cc compromise vbp their prp therapeutic jj effects nns
false	28	22	in inpos patients nns who wp have vbp been vbn reported vbn to topos be vb well rb controlled vbn on inpos tricyclic_antidepressants nns receiving vbg concurrent jj cimetidine nn therapy nn discontinuation nn of inpos cimetidine nn has vbz been vbn reported vbn to topos decrease vb established jj steady_state jj serum nn tricyclic_antidepressant nn levels nns and cc compromise vbp their prp therapeutic jj effects nns
mechanism	28	22	in inpos patients nns who wp have vbp been vbn reported vbn to topos be vb well rb controlled vbn on inpos tricyclic_antidepressants nns receiving vbg concurrent jj cimetidine nn therapy nn discontinuation nn of inpos cimetidine nn has vbz been vbn reported vbn to topos decrease vb established jj steady_state jj serum nn tricyclic_antidepressant nn levels nns and cc compromise vbp their prp therapeutic jj effects nns
mechanism	14	38	it prp should md be vb borne vbn in inpos mind nn that inpos alcohol nn ingestion nn may md increase vb the dt danger nn inherent jj in inpos any dt intentional jj or cc unintentional jj sinequan nn overdosage nn
effect	32	46	a dt case nn of inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos a dt type nn num cd diabetic jj patient nn maintained vbn on inpos tolazamide nn num cd days nns after inpos the dt addition nn of inpos doxepin nn
false	0	26	doxil nn may md interact vb with inpos drugs nns known vbn to topos interact vb with inpos the dt conventional jj formulation nn of inpos doxorubicin_hcl nn
advise	2	28	because inpos tetracyclines nn have vbp been vbn shown vbn to topos depress vb plasma nn prothrombin nn activity nn patients nns who wp are vbp on inpos anticoagulant nn therapy nn may md require vb downward jj adjustment nn of inpos their prp anticoagulant jj dosage nn
false	2	28	because inpos tetracyclines nn have vbp been vbn shown vbn to topos depress vb plasma nn prothrombin nn activity nn patients nns who wp are vbp on inpos anticoagulant jj therapy nn may md require vb downward jj adjustment nn of inpos their prp anticoagulant nn dosage nn
false	20	34	since inpos bacteriostatic jj drugs nns may md interfere vb with inpos the dt bactericidal jj action nn of inpos penicillin nn it prp is vbz advisable jj to topos avoid vb giving vbg tetracyclines nn in inpos conjunction nn with inpos penicillin nn
advise	34	20	since inpos bacteriostatic jj drugs nns may md interfere vb with inpos the dt bactericidal jj action nn of inpos penicillin nn it prp is vbz advisable jj to topos avoid vb giving vbg tetracyclines nn in inpos conjunction nn with inpos penicillin nn
false	4	12	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nn containing vbg aluminum nn calcium nn magnesium nn iron_containing jj preparations nns
mechanism	4	16	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg aluminum nn iron_containing jj preparations nns
mechanism	4	16	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg calcium nn iron_containing jj preparations nns
mechanism	4	16	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg magnesium nn iron_containing jj preparations nns
mechanism	4	22	absorption nn of inpos tetracyclines nn is vbz impaired vbn by inpos antacids nns containing vbg aluminum nn calcium nn magnesium nn iron nn containing jj preparations nns
false	12	16	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg aluminum nn iron_containing jj preparations nns
false	12	16	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg calcium nn iron_containing jj preparations nns
false	12	16	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg magnesium nn iron_containing jj preparations nns
false	12	22	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nn containing vbg aluminum nn calcium nn magnesium nn iron nn containing jj preparations nns
false	16	18	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nns containing vbg aluminum nn iron nn containing jj preparations nns
false	16	18	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nns containing vbg calcium nn iron nn containing jj preparations nns
false	16	18	absorption nn of inpos tetracyclines nns is vbz impaired vbn by inpos antacids nns containing vbg magnesium nn iron nn containing jj preparations nns
mechanism	4	12	absorption nn of inpos tetracycline nn is vbz impaired vbn by inpos bismuth_subsalicylate nn
mechanism	0	10	barbiturates nn decrease vbp the dt half_life nn of inpos doxycycline nn
mechanism	0	10	carbamazepine nn decrease vbp the dt half_life nn of inpos doxycycline nn
mechanism	0	10	phenytoin nn decrease vbp the dt half_life nn of inpos doxycycline nn
effect	8	12	the dt concurrent jj use nn of inpos tetracycline nn and cc penthrane nn has vbz been vbn reported vbn to topos result vb in inpos fatal jj renal jj toxicity nn
effect	8	12	the dt concurrent jj use nn of inpos tetracycline nn and cc methoxyflurane nn has vbz been vbn reported vbn to topos result vb in inpos fatal jj renal jj toxicity nn
effect	6	14	concurrent jj use nn of inpos tetracycline nn may md render vb oral jj contraceptives nn less rbr effective jj
false	8	28	potential jj drug nn interactions nns for inpos doxylamine nn include vbp increased vbn sedation nn if inpos doxylamine nn is vbz combined vbn with inpos other jj cns_depressant_drugs nn
effect	8	28	potential jj drug nn interactions nns for inpos doxylamine nn include vbp increased vbn sedation nn if inpos doxylamine nn is vbz combined vbn with inpos other jj cns_depressant_drugs nn
effect	0	16	antihistamines nn may md partially rb counteract vb the dt anticoagulation nn effects nns of inpos heparin nn or cc warfarin nn
effect	0	20	antihistamines nn may md partially rb counteract vb the dt anticoagulation nn effects nns of inpos heparin nn or cc warfarin nn
false	16	20	antihistamines nns may md partially rb counteract vb the dt anticoagulation nn effects nns of inpos heparin nn or cc warfarin nn
effect	0	12	doxylamine nn may md enhance vb the dt effects nns of inpos epinephrine nn
mechanism	6	10	concurrent jj administration nn of inpos oxyphenbutazone nn and cc androgens nn may md result vb in inpos elevated jj serum nn levels nns of inpos oxyphenbutazone nn
false	10	6	concurrent jj administration nn of inpos oxyphenbutazone nn and cc androgens nn may md result vb in inpos elevated jj serum nn levels nns of inpos oxyphenbutazone nn
effect	14	28	in inpos diabetic jj patients nns the dt metabolic jj effects nns of inpos androgens nn may md decrease vb blood nn glucose nn and cc therefore rb insulin nn requirements nns
effect	2	16	other jj cns_depressant_drugs nn have vbp additive jj or cc potentiating vbg effects nns with inpos inapsine nn
effect	2	16	other jj barbiturates nn have vbp additive jj or cc potentiating vbg effects nns with inpos inapsine nn
effect	2	16	other jj tranquilizers nn have vbp additive jj or cc potentiating vbg effects nns with inpos inapsine nn
effect	2	16	other jj opioids nn have vbp additive jj or cc potentiating vbg effects nns with inpos inapsine nn
effect	2	16	other jj anesthetics nn have vbp additive jj or cc potentiating vbg effects nns with inpos inapsine nn
advise	8	18	following vbg the dt administration nn of inpos inapsine nn the dt dose nn of inpos other jj cns_depressant_drugs nn should md be vb reduced vbn
false	32	50	approximately rb num cd of inpos the dt patients nns in inpos the dt phase nn num cd study nn received vbd either cc prophylactic jj low jj dose nn heparin nn lrb_unfractionated_heparin nn up inpos to topos num cd units_day nn rrb_or cc prophylactic jj doses nns of inpos low_molecular_weight_heparins nn as inpos indicated vbn in inpos the dt prescribing vbg information nn for inpos the dt specific jj products nns
false	12	40	concomitant jj use nn of inpos prophylactic jj low jj dose nn heparin nn did vbd not rb appear vb to topos affect vb safety nn however rb its prp effects nns on inpos the dt efficacy nn of inpos xigris nn have vbp not rb been vbn evaluated vbn in inpos an dt adequate jj and cc well_controlled jj clinical jj trial nn
mechanism	6	10	concomitant jj use nn of inpos duloxetine nn with inpos fluvoxamine nn an dt inhibitor nn of inpos cyp1a2 nn results vbz in inpos approximately rb a dt num_fold jj increase nn in inpos auc nn and cc about inpos a dt float_fold jj increase nn in inpos cmax nn of inpos duloxetine nn
false	10	6	concomitant jj use nn of inpos duloxetine nn with inpos fluvoxamine nn an dt inhibitor nn of inpos cyp1a2 nn results vbz in inpos approximately rb a dt num_fold jj increase nn in inpos auc nn and cc about inpos a dt float_fold jj increase nn in inpos cmax nn of inpos duloxetine nn
mechanism	0	10	paroxetine nn increased vbd the dt concentration nn of inpos duloxetine nn by inpos about rb num cd and cc greater jjr degrees nns of inpos inhibition nn are vbp expected vbn with inpos higher jjr doses nns of inpos paroxetine nn
false	10	0	paroxetine nn increased vbd the dt concentration nn of inpos duloxetine nn by inpos about rb num cd and cc greater jjr degrees nns of inpos inhibition nn are vbp expected vbn with inpos higher jjr doses nns of inpos paroxetine nn
mechanism	2	24	when wrb duloxetine nn was vbd administered vbn in inpos conjunction nn with inpos a dt single jj num_mg jj dose nn of inpos desipramine nn a dt cyp2d6 nn substrate nn the dt auc nn of inpos desipramine nn increased vbd num_fold rb
false	2	24	when wrb duloxetine nn was vbd administered vbn in inpos conjunction nn with inpos a dt single jj num_mg jj dose nn of inpos desipramine nn a dt cyp2d6 nn substrate nn the dt auc nn of inpos desipramine nn increased vbd num_fold rb
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj antidepressants nns should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj tricyclic_antidepressants nns should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj tcas nns should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj nortriptyline nns should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj amitriptyline nns should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj imipramine nns should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj phenothiazines nns should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj type_1c_antiarrhythmics nn should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj propafenone nn should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj flecainide nn should md be vb approached vbn with inpos caution nn
false	48	52	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj antidepressants nns phenothiazines nn and cc type_1c_antiarrhythmics nn should md be vb approached vbn with inpos caution nn
false	48	52	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj antidepressants nns phenothiazines nn and cc propafenone nn should md be vb approached vbn with inpos caution nn
false	48	52	therefore rb co_administration nn of inpos duloxetine nn with inpos other jj drugs nns that wdt are vbp extensively rb metabolized vbn by inpos this dt isozyme nn and cc which wdt have vbp a dt narrow jj therapeutic jj index nn including vbg certain jj antidepressants nns phenothiazines nn and cc flecainide nn should md be vb approached vbn with inpos caution nn
false	2	50	plasma nn tca nn concentrations nns may md need vb to topos be vb monitored vbn and cc the dt dose nn of inpos the dt tca nn may md need vb to topos be vb reduced vbn if inpos a dt tca nn is vbz co_administered vbn with inpos duloxetine nn
false	2	50	plasma nn tca nn concentrations nns may md need vb to topos be vb monitored vbn and cc the dt dose nn of inpos the dt tca nn may md need vb to topos be vb reduced vbn if inpos a dt tca nn is vbz co_administered vbn with inpos duloxetine nn
advise	2	50	plasma nn tca nn concentrations nns may md need vb to topos be vb monitored vbn and cc the dt dose nn of inpos the dt tca nn may md need vb to topos be vb reduced vbn if inpos a dt tca nn is vbz co_administered vbn with inpos duloxetine nn
false	36	38	because inpos of inpos the dt risk nn of inpos serious jj ventricular jj arrhythmias nns and cc sudden jj death nn potentially rb associated vbn with inpos elevated vbn plasma nn levels nns of inpos thioridazine nn duloxetine nn and cc thioridazine nn should md not rb be vb co_administered vbn
advise	38	36	because inpos of inpos the dt risk nn of inpos serious jj ventricular jj arrhythmias nns and cc sudden jj death nn potentially rb associated vbn with inpos elevated vbn plasma nn levels nns of inpos thioridazine nn duloxetine nn and cc thioridazine nn should md not rb be vb co_administered vbn
false	0	24	duloxetine nn may md have vb a dt clinically rb important jj interaction nn with inpos the dt following vbg other nnp drugs nnp alcohol nn
false	2	6	when wrb duloxetine nn and cc ethanol nn were vbd administered vbn several jj hours nns apart rb so inpos that inpos peak nn concentrations nns of inpos each dt would md coincide vb duloxetine nn did vbd not rb increase vb the dt impairment nn of inpos mental jj and cc motor nn skills nns caused vbn by inpos alcohol nn
false	2	60	when wrb duloxetine nn and cc ethanol nn were vbd administered vbn several jj hours nns apart rb so inpos that inpos peak nn concentrations nns of inpos each dt would md coincide vb duloxetine nn did vbd not rb increase vb the dt impairment nn of inpos mental jj and cc motor nn skills nns caused vbn by inpos alcohol nn
false	6	2	when wrb duloxetine nn and cc ethanol nn were vbd administered vbn several jj hours nns apart rb so inpos that inpos peak nn concentrations nns of inpos each dt would md coincide vb duloxetine nn did vbd not rb increase vb the dt impairment nn of inpos mental jj and cc motor nn skills nns caused vbn by inpos alcohol nn
false	6	60	when wrb duloxetine nn and cc ethanol nn were vbd administered vbn several jj hours nns apart rb so inpos that inpos peak nn concentrations nns of inpos each dt would md coincide vb duloxetine nn did vbd not rb increase vb the dt impairment nn of inpos mental jj and cc motor nn skills nns caused vbn by inpos alcohol nn
false	2	60	when wrb duloxetine nn and cc ethanol nn were vbd administered vbn several jj hours nns apart rb so inpos that inpos peak nn concentrations nns of inpos each dt would md coincide vb duloxetine nn did vbd not rb increase vb the dt impairment nn of inpos mental jj and cc motor nn skills nns caused vbn by inpos alcohol nn
false	6	10	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn hyph_magnesium_containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	6	12	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn magnesium nn containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	6	10	however rb co_administration nn of inpos duloxetine nn with inpos antacids nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	6	24	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn and cc magnesium_containing jj antacids nns or cc duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	10	12	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn hyph_magnesium nn containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	10	14	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn hyph_magnesium_containing jj antacids nn duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	10	6	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn hyph_magnesium_containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	10	20	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn hyph_magnesium_containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	10	6	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn hyph_magnesium_containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	12	16	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn magnesium nn containing jj antacids nn duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	12	6	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn magnesium nn containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	12	22	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn magnesium nn containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	12	6	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn magnesium nn containing jj antacids nns duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	10	14	however rb co_administration nn of inpos duloxetine nn with inpos antacids nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	10	6	however rb co_administration nn of inpos duloxetine nn with inpos antacids nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	6	24	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn and cc magnesium_containing jj antacids nns or cc duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	24	6	however rb co_administration nn of inpos duloxetine nn with inpos aluminum nn and cc magnesium_containing jj antacids nns or cc duloxetine nn with inpos famotidine nn had vbd no dt significant jj effect nn on inpos the dt rate nn or cc extent nn of inpos duloxetine nn absorption nn after inpos administration nn of inpos a dt num_mg jj oral jj dose nn
false	16	20	it prp is vbz unknown jj whether inpos the dt concomitant jj administration nn of inpos proton_pump_inhibitors nn affects vbz duloxetine nn absorption nn
false	4	6	synergism nn between inpos xanthine_bronchodilators nn ephedrine nn other jj sympathomimetic_bronchodilators nns has vbz been vbn reported vbn
effect	4	10	synergism nn between inpos xanthine_bronchodilators nn ephedrine nn other jj sympathomimetic_bronchodilators nn has vbz been vbn reported vbn
false	4	6	synergism nn between inpos theophylline nn ephedrine nn other jj sympathomimetic_bronchodilators nns has vbz been vbn reported vbn
effect	4	10	synergism nn between inpos theophylline nn ephedrine nn other jj sympathomimetic_bronchodilators nn has vbz been vbn reported vbn
effect	6	10	synergism nn between inpos xanthine_bronchodilators nns ephedrine nn other jj sympathomimetic_bronchodilators nn has vbz been vbn reported vbn
mechanism	6	10	concurrent jj administration nn of inpos dyphylline nn and cc probenecid nn which wdt competes vbz for inpos tubular jj secretion nn has vbz been vbn shown vbn to topos increase vb the dt plasma nn half_life nn of inpos dyphylline nn
false	10	6	concurrent jj administration nn of inpos dyphylline nn and cc probenecid nn which wdt competes vbz for inpos tubular jj secretion nn has vbz been vbn shown vbn to topos increase vb the dt plasma nn half_life nn of inpos dyphylline nn
effect	0	6	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nn such jj as inpos succinylcholine nn organophosphate nn carbamate_insecticides nns
effect	0	12	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nns such jj as inpos succinylcholine nns
effect	0	16	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nns such jj as inpos succinylcholine nn or cc organophosphate nn and cc carbamate nn bbbbb22_insecticide_eeeee22 nn s nns
effect	0	12	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nns such jj as inpos carbamate_i_ecticide nn s nns
false	6	12	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nn such jj as inpos succinylcholine nns
false	6	16	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nn such jj as inpos succinylcholine nn or cc organophosphate nn and cc carbamate nn bbbbb22_insecticide_eeeee22 nn s nns
false	6	12	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nn such jj as inpos carbamate_i_ecticide nn s nns
false	12	16	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nns such jj as inpos succinylcholine nn or cc organophosphate nn and cc carbamate nn bbbbb22_insecticide_eeeee22 nn s nns
false	16	20	phospholine_iodide nn potentiates vbz other jj cholinesterase_inhibitors nns such jj as inpos succinylcholine nn or cc organophosphate nn and cc carbamate nn bbbbbcom_insecticide_eeeeecom nn s nns
effect	0	12	steroids nn enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nnp interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc. nn num cd
false	0	12	steroids nn enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nn interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc. nn num cd
false	0	32	steroids nn enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nnp interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc. nn num cd
false	0	32	steroids nn enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nnp interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc nn num cd
false	12	32	steroids nns enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nnp interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc. nn num cd
false	12	32	steroids nns enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nnp interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc nn num cd
mechanism	12	32	steroids nns enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nn interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc. nn num cd
false	12	32	steroids nns enhance vbp the dt renal jj toxicity nn of inpos edetate_calcium_disodium nn in inpos animals. nn num cd edetate_calcium_disodium nn interferes vbz with inpos the dt action nn of inpos zinc_insulin nn preparations nns by inpos chelating vbg the dt zinc nn num cd
advise	0	14	raptiva nn should md not rb be vb used vbn with inpos other jj immunosuppressive_drugs nn
false	0	6	acellular nn live jj and cc live_attenuated nn bbbbbcom_vaccines_eeeeecom nn should md not rb be vb administered vbn during inpos raptiva nn treatment nn
advise	0	20	acellular nn live jj and cc live_attenuated jj bbbbb12_vaccines_eeeee12 nn should md not rb be vb administered vbn during inpos raptiva nn treatment nn
advise	0	14	live jj bbbbb12_vaccines_eeeee12 nn should md not rb be vb administered vbn during inpos raptiva nn treatment nn
advise	6	18	acellular jj live jj and cc live_attenuated_vaccines nn should md not rb be vb administered vbn during inpos raptiva nn treatment nn
mechanism	8	26	drugs nns which wdt induce vbp cyp3a4 nn phenobarbital nn would md be vb expected vbn to topos increase vb the dt clearance nn of inpos efavirenz nn resulting vbg in inpos lowered vbn plasma nn concentrations nns
mechanism	8	26	drugs nns which wdt induce vbp cyp3a4 nn rifampin nn would md be vb expected vbn to topos increase vb the dt clearance nn of inpos efavirenz nn resulting vbg in inpos lowered vbn plasma nn concentrations nns
mechanism	8	26	drugs nns which wdt induce vbp cyp3a4 nn rifabutin nn would md be vb expected vbn to topos increase vb the dt clearance nn of inpos efavirenz nn resulting vbg in inpos lowered vbn plasma nn concentrations nns
false	0	8	benzodiazepines nn gi nnp motility nnp agents nnps anti_migraine nn antifungal jj
false	0	10	benzodiazepines nn gi nnp motility nnp agents nnps anti_migraine nnp antifungal nn
false	8	10	benzodiazepines nnp gi nnp motility nnp agents nnps anti_migraine nn antifungal nn
false	0	2	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	0	4	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	0	6	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	0	12	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	2	4	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	2	6	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	2	12	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	4	6	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	4	12	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	6	12	astemizole nn midazolam nn triazolam nn cisapride nn ergot nn derivatives nns voriconazole nn
false	6	22	when wrb coadministered vbn with inpos sustiva nn in inpos treatment_naive jj patients nns the dt recommended vbn dose nn of inpos atazanavir nn is vbz num cd mg nn with inpos ritonavir nn num cd mg nn and cc sustiva nn num cd mg nn
false	6	32	when wrb coadministered vbn with inpos sustiva nn in inpos treatment_naive jj patients nns the dt recommended vbn dose nn of inpos atazanavir nn is vbz num cd mg nn with inpos ritonavir nn num cd mg nn and cc sustiva nn num cd mg nn
false	22	32	when wrb coadministered vbn with inpos sustiva nn in inpos treatment_naive jj patients nns the dt recommended vbn dose nn of inpos atazanavir nn is vbz num cd mg nn with inpos ritonavir nn num cd mg nn and cc sustiva nn num cd mg nn
false	22	6	when wrb coadministered vbn with inpos sustiva nn in inpos treatment_naive jj patients nns the dt recommended vbn dose nn of inpos atazanavir nn is vbz num cd mg nn with inpos ritonavir nn num cd mg nn and cc sustiva nn num cd mg nn
false	32	6	when wrb coadministered vbn with inpos sustiva nn in inpos treatment_naive jj patients nns the dt recommended vbn dose nn of inpos atazanavir nn is vbz num cd mg nn with inpos ritonavir nn num cd mg nn and cc sustiva nn num cd mg nn
false	6	10	dosing vbg recommendations nns for inpos sustiva nn and cc atazanavir nn in inpos treatment_experienced jj patients nns have vbp not rb been vbn established vbn
effect	16	20	in inpos uninfected jj volunteers nns num cd developed vbd rash nn while inpos receiving vbg sustiva nn and cc clarithromycin nn
false	8	20	no dt dose nn adjustment nn of inpos sustiva nn is vbz recommended vbn when wrb given vbn with inpos clarithromycin nn
false	4	10	alternatives nns to topos clarithromycin nn such jj as inpos azithromycin nn should md be vb considered vbn
false	2	8	other jj macrolide_antibiotics nn such jj as inpos erythromycin nn have vbp not rb been vbn studied vbn in inpos combination nn with inpos sustiva nn
false	2	24	other jj macrolide_antibiotics nn such jj as inpos erythromycin nn have vbp not rb been vbn studied vbn in inpos combination nn with inpos sustiva nn
false	8	24	other jj macrolide_antibiotics nns such jj as inpos erythromycin nn have vbp not rb been vbn studied vbn in inpos combination nn with inpos sustiva nn
false	8	20	the dt optimal jj dose nn of inpos indinavir nn when wrb given vbn in inpos combination nn with inpos sustiva nn is vbz not rb known vbn
false	4	40	increasing vbg the dt indinavir nn dose nn to topos num cd mg nn every dt num cd hours nns does vbz not rb compensate vb for inpos the dt increased vbn indinavir nn metabolism nn due inpos to topos sustiva nn
mechanism	4	40	increasing vbg the dt indinavir nn dose nn to topos num cd mg nn every dt num cd hours nns does vbz not rb compensate vb for inpos the dt increased vbn indinavir nn metabolism nn due inpos to topos sustiva nn
mechanism	2	18	when wrb indinavir nn at inpos an dt increased vbn dose nn was vbd given vbn with inpos sustiva nn the dt indinavir nn auc nn and cc cmin nn were vbd decreased vbn on inpos average nn by inpos num cd and cc num cd respectively rb compared vbn to topos when wrb indinavir nn was vbd given vbn alone rb
false	18	2	when wrb indinavir nn at inpos an dt increased vbn dose nn was vbd given vbn with inpos sustiva nn the dt indinavir nn auc nn and cc cmin nn were vbd decreased vbn on inpos average nn by inpos num cd and cc num cd respectively rb compared vbn to topos when wrb indinavir nn was vbd given vbn alone rb
false	18	2	when wrb indinavir nn at inpos an dt increased vbn dose nn was vbd given vbn with inpos sustiva nn the dt indinavir nn auc nn and cc cmin nn were vbd decreased vbn on inpos average nn by inpos num cd and cc num cd respectively rb compared vbn to topos when wrb indinavir nn was vbd given vbn alone rb
false	0	2	lopinavir nn ritonavir nn
advise	8	40	a dt dose nn increase nn of inpos lopinavir nn to topos num cd mg nn twice rb daily rb taken vbn with inpos food nn is vbz recommended vbn when wrb used vbn in inpos combination nn with inpos sustiva nn
advise	8	40	a dt dose nn increase nn of inpos ritonavir nn to topos num cd mg nn twice rb daily rb taken vbn with inpos food nn is vbz recommended vbn when wrb used vbn in inpos combination nn with inpos sustiva nn
false	34	42	coadministration nn in inpos hiv_infected jj individuals nns with inpos a dt history nn of inpos injection nn drug nn use nn resulted vbd in inpos decreased vbn plasma nn levels nns of inpos methadone nn and cc signs nns of inpos opiate nn withdrawal nn
advise	10	16	because inpos the dt potential jj interaction nn of inpos efavirenz nn with inpos oral jj contraceptives nn has vbz not rb been vbn fully rb characterized vbn a dt reliable jj method nn of inpos barrier nn contraception nn should md be vb used vbn in inpos addition nn to topos oral jj contraceptives nns
false	10	16	because inpos the dt potential jj interaction nn of inpos efavirenz nn with inpos oral jj contraceptives nns has vbz not rb been vbn fully rb characterized vbn a dt reliable jj method nn of inpos barrier nn contraception nn should md be vb used vbn in inpos addition nn to topos oral jj contraceptives nn
advise	14	26	monitoring nn of inpos liver nn enzymes nns is vbz recommended vbn when wrb sustiva nn is vbz used vbn in inpos combination nn with inpos ritonavir nn
false	12	20	should md not rb be vb used vbn as inpos sole jj protease_inhibitor nn in inpos combination nn with inpos sustiva nn
false	0	2	anticoagulants nn warfarin nn
false	0	2	anticonvulsants nn phenytoin nn phenobarbital nn carbamazepine nn
false	0	4	anticonvulsants nn phenytoin nn phenobarbital nn carbamazepine nn
false	0	6	anticonvulsants nn phenytoin nn phenobarbital nn carbamazepine nn
false	2	4	anticonvulsants nns phenytoin nn phenobarbital nn carbamazepine nn
false	2	6	anticonvulsants nns phenytoin nn phenobarbital nn carbamazepine nn
false	4	6	anticonvulsants nns phenytoin nn phenobarbital nn carbamazepine nn
mechanism	8	12	potential jj for inpos reduction nn in inpos anticonvulsant nn and_or cc efavirenz nn plasma nn levels nns
false	0	2	antifungals nn itraconazole nn ketoconazole nn
false	0	4	antifungals nn itraconazole nn ketoconazole nn
false	2	4	antifungals nns itraconazole nn ketoconazole nn
false	8	14	drug nn interaction nn studies nns with inpos sustiva nn and cc these dt imidazole nn and cc triazole nn bbbbb22_antifungals_eeeee22 nn have vbp not rb been vbn conducted vbn
mechanism	0	18	sustiva nn has vbz the dt potential nn to topos decrease vb plasma nn concentrations nns of inpos itraconazole nn and cc ketoconazole nn
mechanism	0	22	sustiva nn has vbz the dt potential nn to topos decrease vb plasma nn concentrations nns of inpos itraconazole nn and cc ketoconazole nn
false	18	22	sustiva nn has vbz the dt potential nn to topos decrease vb plasma nn concentrations nns of inpos itraconazole nn and cc ketoconazole nn
false	0	2	anti_hiv_protease_inhibitors nn saquinavir nn combination nn
false	0	2	anti_hiv_protease_inhibitors nn ritonavir nn combination nn
false	14	30	expected vbn to topos substantially rb decrease vb plasma nn levels nns of inpos efavirenz nn has vbz not rb been vbn studied vbn in inpos combination nn with inpos sustiva nn
false	28	40	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns azithromycin nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns cetirizine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns famotidine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns fluconazole nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns lamivudine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns lorazepam nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns nelfinavir nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns paroxetine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb sustiva nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns zidovudine nn
false	28	40	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns azithromycin nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns cetirizine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns famotidine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns fluconazole nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns lamivudine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns lorazepam nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns nelfinavir nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns paroxetine nn
false	28	42	based vbn on inpos the dt results nns of inpos drug nn interaction nn studies nns no dt dosage nn adjustment nn is vbz recommended vbn when wrb efavirenz nn is vbz given vbn with inpos the dt following nn aluminum_magnesium_hydroxide_antacids nns zidovudine nn
false	18	22	specific jj drug nn interaction nn studies nns have vbp not rb been vbn performed vbn with inpos sustiva nn and cc nrtis nn other jj than inpos lamivudine nn and cc zidovudine nn
false	18	28	specific jj drug nn interaction nn studies nns have vbp not rb been vbn performed vbn with inpos sustiva nn and cc nrtis nns other jj than inpos lamivudine nn and cc zidovudine nn
false	18	32	specific jj drug nn interaction nn studies nns have vbp not rb been vbn performed vbn with inpos sustiva nn and cc nrtis nns other jj than inpos lamivudine nn and cc zidovudine nn
false	22	28	specific jj drug nn interaction nn studies nns have vbp not rb been vbn performed vbn with inpos sustiva nn and cc nrtis nn other jj than inpos lamivudine nn and cc zidovudine nn
false	22	32	specific jj drug nn interaction nn studies nns have vbp not rb been vbn performed vbn with inpos sustiva nn and cc nrtis nn other jj than inpos lamivudine nn and cc zidovudine nn
false	28	32	specific jj drug nn interaction nn studies nns have vbp not rb been vbn performed vbn with inpos sustiva nn and cc nrtis nns other jj than inpos lamivudine nn and cc zidovudine nn
false	18	34	clinically rb significant jj interactions nns would md not rb be vb expected vbn since inpos the dt nrtis nn are vbp metabolized vbn via inpos a dt different jj route nn than inpos efavirenz nn and cc would md be vb unlikely jj to topos compete vb for inpos the dt same jj metabolic jj enzymes nns and cc elimination nn pathways nns
false	12	26	the dt potential nn for inpos drug nn interactions nns with inpos emtriva nn has vbz been vbn studied vbn in inpos combination nn with inpos indinavir nn
false	12	26	the dt potential nn for inpos drug nn interactions nns with inpos emtriva nn has vbz been vbn studied vbn in inpos combination nn with inpos stavudine nn
false	12	26	the dt potential nn for inpos drug nn interactions nns with inpos emtriva nn has vbz been vbn studied vbn in inpos combination nn with inpos famciclovir nn
false	12	26	the dt potential nn for inpos drug nn interactions nns with inpos emtriva nn has vbz been vbn studied vbn in inpos combination nn with inpos tenofovir_disoproxil_fumarate nn
effect	4	54	patients nns on inpos diuretics nn and cc especially rb those dt in inpos whom wp diuretic jj therapy nn was vbd recently rb instituted vbn may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos therapy nn with inpos enalapril nn or cc enalaprilat nn
effect	4	58	patients nns on inpos diuretics nn and cc especially rb those dt in inpos whom wp diuretic jj therapy nn was vbd recently rb instituted vbn may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos therapy nn with inpos enalapril nn or cc enalaprilat nn
effect	12	32	the dt possibility nn of inpos hypotensive jj effects nns with inpos enalapril nn or cc enalaprilat nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos enalapril nn or cc enalaprilat nn
effect	16	32	the dt possibility nn of inpos hypotensive jj effects nns with inpos enalapril nn or cc enalaprilat nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos enalapril nn or cc enalaprilat nn
false	32	12	the dt possibility nn of inpos hypotensive jj effects nns with inpos enalapril nn or cc enalaprilat nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos enalapril nn or cc enalaprilat nn
false	32	16	the dt possibility nn of inpos hypotensive jj effects nns with inpos enalapril nn or cc enalaprilat nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos enalapril nn or cc enalaprilat nn
effect	8	22	the dt antihypertensive jj effect nn of inpos enalapril nn and cc enalapril nn num cd is vbz augmented vbn by inpos antihypertensive_agents nn that wdt cause vbp renin nn release nn
effect	8	30	the dt antihypertensive jj effect nn of inpos enalapril nn and cc enalapril nn num cd is vbz augmented vbn by inpos antihypertensive_agents nns that wdt cause vbp renin nn diuretics nn
effect	8	22	the dt antihypertensive jj effect nn of inpos enalapril nn and cc enalapril nn num cd is vbz augmented vbn by inpos antihypertensive_agents nn that wdt cause vbp renin nn release nn
effect	8	30	the dt antihypertensive jj effect nn of inpos enalapril nn and cc enalapril nn num cd is vbz augmented vbn by inpos antihypertensive_agents nns that wdt cause vbp renin nn diuretics nn
false	22	30	the dt antihypertensive jj effect nn of inpos enalapril nn and cc enalapril nn num cd is vbz augmented vbn by inpos antihypertensive_agents nn that wdt cause vbp renin nn diuretics nn
effect	24	32	in inpos some dt patients nns with inpos compromised vbn renal jj function nn who wp are vbp being vbg treated vbn with inpos nonsteroidal_anti_inflammatory_drugs nn the dt co_administration nn of inpos enalapril nn may md result vb in inpos a dt further jj deterioration nn of inpos renal jj function nn
false	10	14	in inpos a dt clinical jj pharmacology nn study nn indomethacin nn or cc sulindac nn was vbd administered vbn to topos hypertensive jj patients nns receiving vbg vasotec nns
false	10	28	in inpos a dt clinical jj pharmacology nn study nn indomethacin nn or cc sulindac nn was vbd administered vbn to topos hypertensive jj patients nns receiving vbg vasotec nn
false	14	28	in inpos a dt clinical jj pharmacology nn study nn indomethacin nn or cc sulindac nn was vbd administered vbn to topos hypertensive jj patients nns receiving vbg vasotec nn
effect	8	22	however rb reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nn
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg nsaids nn concomitantly rb with inpos ace_inhibitors nn
false	0	18	enalapril nn and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nn and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nn and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns nitrates nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nn and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns calcium_blocking_agents nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nn and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	28	enalapril nn and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn nitrates nns calcium_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	30	enalapril nn and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn nitrates nns calcium_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	18	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns nitrates nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns calcium_blocking_agents nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	20	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	28	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn nitrates nns calcium_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	30	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn nitrates nns calcium_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	22	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	24	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	22	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns nitrates nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	24	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns nitrates nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	22	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns calcium_blocking_agents nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	24	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns calcium_blocking_agents nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	22	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	24	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	28	30	enalapril nnp and cc enalapril nn num cd have vbp been vbn used vbn concomitantly rb with inpos b_adrenergic_blocking_agents nns methyldopa nn nitrates nns calcium_blocking_agents nns hydralazine nn prazosin nn digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	14	enalapril nn num cd has vbz been vbn used vbn concomitantly rb with inpos digitalis nn without inpos evidence nn of inpos clinically rb significant jj adverse jj reactions nns
effect	0	18	enalapril nn and cc enalapril nn num cd attenuate nn potassium nn loss nn caused vbn by inpos thiazide_type_diuretics nn
effect	0	18	enalapril nnp and cc enalapril nn num cd attenuate nn potassium nn loss nn caused vbn by inpos thiazide_type_diuretics nn
false	0	2	spironolactone nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	0	2	spironolactone nn potassium nn supplements nns potassium nn containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	0	2	triamterene nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	0	2	triamterene nn potassium nn supplements nns potassium nn containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	0	2	amiloride nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	0	2	amiloride nn potassium nn supplements nns potassium nn containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	0	36	lithium nn toxicity nn has vbz been vbn reported vbn in inpos patients nns receiving vbg lithium nn concomitantly rb with inpos drugs nns which wdt cause vbp elimination nn of inpos sodium nn including vbg ace_inhibitors nn
effect	0	36	lithium nn toxicity nn has vbz been vbn reported vbn in inpos patients nns receiving vbg lithium nn concomitantly rb with inpos drugs nns which wdt cause vbp elimination nn of inpos sodium nn including vbg ace_inhibitors nn
false	10	22	it prp is vbz recommended vbn that inpos serum nn lithium nn levels nns be vb monitored vbn frequently rb if inpos enalapril nn is vbz administered vbn concomitantly rb with inpos lithium nn
advise	22	10	it prp is vbz recommended vbn that inpos serum nn lithium nn levels nns be vb monitored vbn frequently rb if inpos enalapril nn is vbz administered vbn concomitantly rb with inpos lithium nn
false	46	52	if inpos the dt usual jj amounts nns of inpos nondepolarizing jj relaxants nns are vbp given vbn the dt time nn for inpos recovery nn from inpos neuromuscular jj blockade nn will md be vb longer rbr in inpos the dt presence nn of inpos enflurane nn than inpos when wrb halothane nn or cc nitrous_oxide nn with inpos a dt balanced jj technique nn are vbp used vbn
false	46	56	if inpos the dt usual jj amounts nns of inpos nondepolarizing jj relaxants nns are vbp given vbn the dt time nn for inpos recovery nn from inpos neuromuscular jj blockade nn will md be vb longer rbr in inpos the dt presence nn of inpos enflurane nn than inpos when wrb halothane nn or cc nitrous_oxide nn with inpos a dt balanced jj technique nn are vbp used vbn
false	52	56	if inpos the dt usual jj amounts nns of inpos nondepolarizing jj relaxants nns are vbp given vbn the dt time nn for inpos recovery nn from inpos neuromuscular jj blockade nn will md be vb longer rbr in inpos the dt presence nn of inpos enflurane nn than inpos when wrb halothane nn or cc nitrous_oxide nn with inpos a dt balanced jj technique nn are vbp used vbn
false	10	32	no dt drug nn interactions nns with inpos other jj antiretroviral_medications nn have vbp been vbn identified vbn that wdt would md warrant vb alteration nn of inpos either cc the dt enfuvirtide nn dose nn or cc the dt dose nn of inpos the dt other jj antiretroviral_medication nn
false	32	10	no dt drug nn interactions nns with inpos other jj antiretroviral_medications nns have vbp been vbn identified vbn that wdt would md warrant vb alteration nn of inpos either cc the dt enfuvirtide nn dose nn or cc the dt dose nn of inpos the dt other jj antiretroviral_medication nn
false	0	10	bismuth nn bismuth_subsalicylate nn given vbn concomitantly rb with inpos enoxacin nn or cc num cd minutes nns following vbg enoxacin nn administration nn decreased vbd enoxacin nn bioavailability nn by inpos approximately rb num cd
false	0	10	bismuth nn bismuth_subsalicylate nn given vbn concomitantly rb with inpos enoxacin nn or cc num cd minutes nns following vbg enoxacin nn administration nn decreased vbd enoxacin nn bioavailability nn by inpos approximately rb num cd
false	0	10	bismuth nn bismuth_subsalicylate nn given vbn concomitantly rb with inpos enoxacin nn or cc num cd minutes nns following vbg enoxacin nn administration nn decreased vbd enoxacin nn bioavailability nn by inpos approximately rb num cd
mechanism	2	10	bismuth nnp bismuth_subsalicylate nn given vbn concomitantly rb with inpos enoxacin nn or cc num cd minutes nns following vbg enoxacin nn administration nn decreased vbd enoxacin nn bioavailability nn by inpos approximately rb num cd
false	2	10	bismuth nnp bismuth_subsalicylate nn given vbn concomitantly rb with inpos enoxacin nn or cc num cd minutes nns following vbg enoxacin nn administration nn decreased vbd enoxacin nn bioavailability nn by inpos approximately rb num cd
false	2	10	bismuth nnp bismuth_subsalicylate nn given vbn concomitantly rb with inpos enoxacin nn or cc num cd minutes nns following vbg enoxacin nn administration nn decreased vbd enoxacin nn bioavailability nn by inpos approximately rb num cd
advise	8	12	thus rb concomitant jj administration nn of inpos enoxacin nn and cc bismuth_subsalicylate nn should md be vb avoided vbn
mechanism	0	30	enoxacin nn is vbz a dt potent jj inhibitor nn of inpos the dt cytochrome nn p_num nn isozymes nns responsible jj for inpos the dt metabolism nn of inpos methylxanthines nn
mechanism	8	30	in inpos a dt multiple_dose jj study nn enoxacin nn caused vbd a dt dose_related jj increase nn in inpos the dt mean jj elimination nn half_life nn of inpos caffeine nn thereby rb decreasing vbg the dt clearance nn of inpos caffeine nn by inpos up rb to topos num cd and cc leading vbg to topos a dt five_fold jj increase nn in inpos the dt auc nn and cc the dt half_life nn of inpos caffeine nn
false	8	30	in inpos a dt multiple_dose jj study nn enoxacin nn caused vbd a dt dose_related jj increase nn in inpos the dt mean jj elimination nn half_life nn of inpos caffeine nn thereby rb decreasing vbg the dt clearance nn of inpos caffeine nn by inpos up rb to topos num cd and cc leading vbg to topos a dt five_fold jj increase nn in inpos the dt auc nn and cc the dt half_life nn of inpos caffeine nn
false	8	30	in inpos a dt multiple_dose jj study nn enoxacin nn caused vbd a dt dose_related jj increase nn in inpos the dt mean jj elimination nn half_life nn of inpos caffeine nn thereby rb decreasing vbg the dt clearance nn of inpos caffeine nn by inpos up rb to topos num cd and cc leading vbg to topos a dt five_fold jj increase nn in inpos the dt auc nn and cc the dt half_life nn of inpos caffeine nn
false	4	18	trough inpos plasma nn enoxacin nn levels nns were vbd also rb num cd higher jjr when wrb caffeine nn and cc enoxacin nn were vbd administered vbn concomitantly rb
mechanism	18	4	trough inpos plasma nn enoxacin nn levels nns were vbd also rb num cd higher jjr when wrb caffeine nn and cc enoxacin nn were vbd administered vbn concomitantly rb
false	0	28	caffeine nn related jj adverse jj effects nns have vbp occurred vbn in inpos patients nns consuming vbg caffeine nn while inpos on inpos therapy nn with inpos enoxacin nn
effect	0	26	caffeine_related jj adverse jj effects nns have vbp occurred vbn in inpos patients nns consuming vbg caffeine nn while inpos on inpos therapy nn with inpos enoxacin nn
false	0	38	cyclosporine nn elevated vbd serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos other jj members nns of inpos the dt quinolone_class nn
false	8	36	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos other jj members nns of inpos the dt quinolone_class nn
mechanism	8	36	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos other jj members nns of inpos the dt quinolone_class nn
mechanism	0	8	enoxacin nn may md raise vb serum nn digoxin nn levels nns in inpos some dt individuals nns
false	12	20	if inpos signs nns and cc symptoms nns suggestive jj of inpos digoxin nn toxicity nn occur vbp when wrb enoxacin nn and cc digoxin nn are vbp given vbn concomitantly rb physicians nns are vbp advised vbn to topos obtain vb serum nn digoxin nn levels nns and cc adjust jj digoxin nn doses nns appropriately rb
effect	20	12	if inpos signs nns and cc symptoms nns suggestive jj of inpos digoxin nn toxicity nn occur vbp when wrb enoxacin nn and cc digoxin nn are vbp given vbn concomitantly rb physicians nns are vbp advised vbn to topos obtain vb serum nn digoxin nn levels nns and cc adjust jj digoxin nn doses nns appropriately rb
false	20	12	if inpos signs nns and cc symptoms nns suggestive jj of inpos digoxin nn toxicity nn occur vbp when wrb enoxacin nn and cc digoxin nn are vbp given vbn concomitantly rb physicians nns are vbp advised vbn to topos obtain vb serum nn digoxin nn levels nns and cc adjust jj digoxin nn doses nns appropriately rb
false	20	12	if inpos signs nns and cc symptoms nns suggestive jj of inpos digoxin nn toxicity nn occur vbp when wrb enoxacin nn and cc digoxin nn are vbp given vbn concomitantly rb physicians nns are vbp advised vbn to topos obtain vb serum nn digoxin nn levels nns and cc adjust jj digoxin nn doses nns appropriately rb
false	14	22	seizures nns have vbp been vbn reported vbn in inpos patients nns taking vbg enoxacin nn concomitantly rb with inpos the dt nonsteroidal_anti_inflammatory_drug nn fenbufen nn
effect	14	24	seizures nns have vbp been vbn reported vbn in inpos patients nns taking vbg enoxacin nn concomitantly rb with inpos the dt nonsteroidal_anti_inflammatory_drug jj fenbufen nn
false	22	24	seizures nns have vbp been vbn reported vbn in inpos patients nns taking vbg enoxacin nn concomitantly rb with inpos the dt nonsteroidal_anti_inflammatory_drug nn fenbufen nn
false	0	4	sucralfate nn and cc antacids nn
false	6	10	therefore rb administration nn of inpos quinolones nn with inpos antacids nn containing vbg calcium nn magnesium nn aluminum nn
false	6	14	therefore rb administration nn of inpos quinolones nn with inpos antacids nns containing vbg calcium nn
false	6	14	therefore rb administration nn of inpos quinolones nn with inpos antacids nns containing vbg magnesium nn
false	6	14	therefore rb administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn
false	10	14	therefore rb administration nn of inpos quinolones nns with inpos antacids nn containing vbg calcium nn
false	10	14	therefore rb administration nn of inpos quinolones nns with inpos antacids nn containing vbg magnesium nn
false	10	14	therefore rb administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn
false	4	8	or cc with inpos multivitamins nn containing vbg zinc nn may md substantially rb interfere vb with inpos drug nn absorption nn and cc result vbp in inpos insufficient jj plasma nn and cc tissue nn quinolone nn concentrations nns
false	4	36	or cc with inpos multivitamins nn containing vbg zinc nn may md substantially rb interfere vb with inpos drug nn absorption nn and cc result vbp in inpos insufficient jj plasma nn and cc tissue nn quinolone nn concentrations nns
mechanism	8	36	or cc with inpos multivitamins nns containing vbg zinc nn may md substantially rb interfere vb with inpos drug nn absorption nn and cc result vbp in inpos insufficient jj plasma nn and cc tissue nn quinolone nn concentrations nns
false	0	4	antacids nn containing vbg aluminum_hydroxide nn and cc magnesium_hydroxide nn reduce vbp the dt oral jj absorption nn of inpos enoxacin nn by inpos num cd
false	0	8	antacids nn containing vbg aluminum_hydroxide nn and cc magnesium_hydroxide nn reduce vbp the dt oral jj absorption nn of inpos enoxacin nn by inpos num cd
false	0	20	antacids nn containing vbg aluminum_hydroxide nn and cc magnesium_hydroxide nn reduce vbp the dt oral jj absorption nn of inpos enoxacin nn by inpos num cd
false	4	8	antacids nns containing vbg aluminum_hydroxide nn and cc magnesium_hydroxide nn reduce vbp the dt oral jj absorption nn of inpos enoxacin nn by inpos num cd
mechanism	4	20	antacids nns containing vbg aluminum_hydroxide nn and cc magnesium_hydroxide nn reduce vbp the dt oral jj absorption nn of inpos enoxacin nn by inpos num cd
mechanism	8	20	antacids nns containing vbg aluminum_hydroxide nn and cc magnesium_hydroxide nn reduce vbp the dt oral jj absorption nn of inpos enoxacin nn by inpos num cd
mechanism	8	24	the dt oral jj bioavailability nn of inpos enoxacin nn is vbz reduced vbn by inpos num cd with inpos coadministration nn of inpos ranitidine nn
mechanism	0	30	enoxacin nn is vbz a dt potent jj inhibitor nn of inpos the dt cytochrome nn p_num nn isozymes nns responsible jj for inpos the dt metabolism nn of inpos methylxanthines nn
mechanism	0	12	enoxacin nn interferes vbz with inpos the dt metabolism nn of inpos theophylline nn resulting vbg in inpos a dt num cd to topos num cd dose_related jj decrease nn in inpos theophylline nn clearance nn and cc a dt subsequent jj num cd to topos num cd increase nn in inpos serum nn theophylline nn levels nns
false	0	12	enoxacin nn interferes vbz with inpos the dt metabolism nn of inpos theophylline nn resulting vbg in inpos a dt num cd to topos num cd dose_related jj decrease nn in inpos theophylline nn clearance nn and cc a dt subsequent jj num cd to topos num cd increase nn in inpos serum nn theophylline nn levels nns
false	0	22	theophylline nn related jj adverse jj effects nns have vbp occurred vbn in inpos patients nns when wrb theophylline nn and cc enoxacin nn were vbd coadministered vbn
effect	0	20	theophylline_related jj adverse jj effects nns have vbp occurred vbn in inpos patients nns when wrb theophylline nn and cc enoxacin nn were vbd coadministered vbn
false	0	2	warfarin nn quinolones nn including vbg enoxacin nn decrease vb the dt clearance nn of inpos r_warfarin nn the dt less rbr active jj isomer nn of inpos racemic jj warfarin nn
false	0	6	warfarin nn quinolones nns including vbg enoxacin nn decrease vb the dt clearance nn of inpos r_warfarin nn the dt less rbr active jj isomer nn of inpos racemic jj warfarin nn
false	2	6	warfarin nnp quinolones nn including vbg enoxacin nn decrease vb the dt clearance nn of inpos r_warfarin nn the dt less rbr active jj isomer nn of inpos racemic jj warfarin nn
mechanism	2	16	warfarin nnp quinolones nn including vbg enoxacin nn decrease vb the dt clearance nn of inpos r_warfarin nn the dt less rbr active jj isomer nn of inpos racemic jj warfarin nn
false	2	0	warfarin nnp quinolones nn including vbg enoxacin nn decrease vb the dt clearance nn of inpos r_warfarin nn the dt less rbr active jj isomer nn of inpos racemic jj warfarin nn
mechanism	6	16	warfarin nnp quinolones nns including vbg enoxacin nn decrease vb the dt clearance nn of inpos r_warfarin nn the dt less rbr active jj isomer nn of inpos racemic jj warfarin nn
false	6	0	warfarin nnp quinolones nns including vbg enoxacin nn decrease vb the dt clearance nn of inpos r_warfarin nn the dt less rbr active jj isomer nn of inpos racemic jj warfarin nn
false	0	44	enoxacin nn does vbz not rb affect vb the dt clearance nn of inpos the dt active jj s_isomer nn and cc changes nns in inpos clotting nn time nn have vbp not rb been vbn observed vbn when wrb enoxacin nn and cc warfarin nn were vbd coadministered vbn
false	0	44	enoxacin nn does vbz not rb affect vb the dt clearance nn of inpos the dt active jj s_isomer nn and cc changes nns in inpos clotting nn time nn have vbp not rb been vbn observed vbn when wrb enoxacin nn and cc warfarin nn were vbd coadministered vbn
false	12	14	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nn platelet_inhibitors nn including vbg acetylsalicylic_acid nn sali_cylates nns nsaids nns dipyridamole nn sulfinpyrazone nn
false	12	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nn platelet_inhibitors nns including vbg acetylsalicylic_acid nn
false	12	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nn platelet_inhibitors nns including vbg nsaids nn
false	12	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nn platelet_inhibitors nns including vbg ketorolac_tromethamine nn
false	12	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nn platelet_inhibitors nns including vbg dipyridamole nn
false	12	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nn platelet_inhibitors nns including vbg sulfinpyrazone nn
false	14	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nns platelet_inhibitors nn including vbg acetylsalicylic_acid nn
false	14	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nns platelet_inhibitors nn including vbg nsaids nn
false	14	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nns platelet_inhibitors nn including vbg ketorolac_tromethamine nn
false	14	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nns platelet_inhibitors nn including vbg dipyridamole nn
false	14	18	these dt agents nns include vbp medications nns such jj as inpos anticoagulants nns platelet_inhibitors nn including vbg sulfinpyrazone nn
false	18	34	in fw vitro fw studies nns have vbp shown vbn no dt binding nn displacement nn between inpos entacapone nn and cc other jj highly rb bound vbn drugs nns such jj as inpos warfarin nn
false	18	34	in fw vitro fw studies nns have vbp shown vbn no dt binding nn displacement nn between inpos entacapone nn and cc other jj highly rb bound vbn drugs nns such jj as inpos salicylic_acid nn
false	18	34	in fw vitro fw studies nns have vbp shown vbn no dt binding nn displacement nn between inpos entacapone nn and cc other jj highly rb bound vbn drugs nns such jj as inpos phenylbutazone nn
false	18	34	in fw vitro fw studies nns have vbp shown vbn no dt binding nn displacement nn between inpos entacapone nn and cc other jj highly rb bound vbn drugs nns such jj as inpos diazepam nn
false	4	10	treatment nn with inpos entacapone nn coadministered vbn with inpos levodopa nn does vbz not rb change vb these dt effects nns
false	4	10	treatment nn with inpos entacapone nn coadministered vbn with inpos dopa_decarboxylase_inhibitor nn does vbz not rb change vb these dt effects nns
false	12	14	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt dopa_decarboxylase_inhibitor nn
false	12	28	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt dopa_decarboxylase_inhibitor nn
false	12	38	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt levodopa nn
false	12	38	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt dopa_decarboxylase_inhibitor nn
false	14	28	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt dopa_decarboxylase_inhibitor nn
false	14	38	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt levodopa nn
false	14	38	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt dopa_decarboxylase_inhibitor nn
false	28	38	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt levodopa nn
false	28	38	no dt interaction nn was vbd noted vbn with inpos the dt mao_b_inhibitor nn selegiline nn in inpos num cd multiple_dose jj interaction nn studies nns when wrb entacapone nn was vbd coadministered vbn with inpos a dt dopa_decarboxylase_inhibitor nn
false	22	30	more jjr than inpos num cd parkinsons nnps disease nn patients nns in inpos clinical jj trials nns have vbp used vbn selegiline nn in inpos combination nn with inpos entacapone nn and cc levodopa nn
false	22	34	more jjr than inpos num cd parkinsons nnps disease nn patients nns in inpos clinical jj trials nns have vbp used vbn selegiline nn in inpos combination nn with inpos entacapone nn and cc levodopa nn
false	22	34	more jjr than inpos num cd parkinsons nnps disease nn patients nns in inpos clinical jj trials nns have vbp used vbn selegiline nn in inpos combination nn with inpos entacapone nn and cc dopa_decarboxylase_inhibitor nn
false	30	34	more jjr than inpos num cd parkinsons nnps disease nn patients nns in inpos clinical jj trials nns have vbp used vbn selegiline nn in inpos combination nn with inpos entacapone nn and cc levodopa nn
false	30	34	more jjr than inpos num cd parkinsons nnps disease nn patients nns in inpos clinical jj trials nns have vbp used vbn selegiline nn in inpos combination nn with inpos entacapone nn and cc dopa_decarboxylase_inhibitor nn
false	4	6	these dt include vbp probenecid nn cholestyramine nn some dt antibiotics nns
false	4	10	these dt include vbp probenecid nn cholestyramine nn some dt antibiotics nn
false	4	10	these dt include vbp probenecid nn cholestyramine nn some dt erythromycin nn
false	4	10	these dt include vbp probenecid nn cholestyramine nn some dt ampicillin nn
false	4	10	these dt include vbp probenecid nn cholestyramine nn some dt chloramphenicol nn
false	6	10	these dt include vbp probenecid nn cholestyramine nn some dt antibiotics nn
false	6	10	these dt include vbp probenecid nn cholestyramine nn some dt erythromycin nn
false	6	10	these dt include vbp probenecid nn cholestyramine nn some dt ampicillin nn
false	6	10	these dt include vbp probenecid nn cholestyramine nn some dt chloramphenicol nn
false	8	10	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn levodopa nn
false	8	26	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn dopa_decarboxylase_inhibitor nn
false	8	32	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn levodopa nn
false	8	32	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn dopa_decarboxylase_inhibitor nn
false	10	26	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn dopa_decarboxylase_inhibitor nn
false	10	32	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn levodopa nn
false	10	32	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn dopa_decarboxylase_inhibitor nn
false	26	32	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn levodopa nn
false	26	32	no dt interaction nn with inpos the dt tricyclic_antidepressant nn imipramine nn was vbd shown vbn in inpos a dt single_dose jj study nn with inpos entacapone nn without inpos coadministered vbn dopa_decarboxylase_inhibitor nn
false	2	20	since inpos entecavir nn is vbz primarily rb eliminated vbn by inpos the dt kidneys nns coadministration nn of inpos baraclude nn with inpos drugs nns that wdt reduce vbp renal jj function nn or cc compete vb for inpos active jj tubular jj secretion nn may md increase vb serum nn concentrations nns of inpos either cc entecavir nn or cc the dt coadministered vbn drug nn
false	20	2	since inpos entecavir nn is vbz primarily rb eliminated vbn by inpos the dt kidneys nns coadministration nn of inpos baraclude nn with inpos drugs nns that wdt reduce vbp renal jj function nn or cc compete vb for inpos active jj tubular jj secretion nn may md increase vb serum nn concentrations nns of inpos either cc entecavir nn or cc the dt coadministered vbn drug nn
false	4	8	coadministration nn of inpos entecavir nn with inpos lamivudine nn did vbd not rb result vb in inpos significant jj drug nn interactions nns
false	4	8	coadministration nn of inpos entecavir nn with inpos adefovir_dipivoxil nn did vbd not rb result vb in inpos significant jj drug nn interactions nns
false	4	8	coadministration nn of inpos entecavir nn with inpos tenofovir_disoproxil_fumarate nn did vbd not rb result vb in inpos significant jj drug nn interactions nns
advise	2	18	all dt vasopressors nn should md be vb used vbn cautiously rb in inpos patients nns taking vbg monoamine_oxidase_mao_inhibitors nn
advise	0	16	epinephrine nn should md not rb be vb administered vbn concomitantly rb with inpos other jj sympathomimetic_drugs nn because inpos of inpos possible jj additive jj effects nns and cc increased vbn toxicity nn
advise	0	16	epinephrine nn should md not rb be vb administered vbn concomitantly rb with inpos other jj isoproterenol nn because inpos of inpos possible jj additive jj effects nns and cc increased vbn toxicity nn
effect	4	12	administration nn of inpos epinephrine nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_general_anesthetics nns such jj as inpos halothane nn which wdt sensitize vbp the dt myocardium nn may md induce vb cardiac jj arrhythmia nn
effect	4	16	administration nn of inpos epinephrine nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_general_anesthetics nn such jj as inpos halothane nn which wdt sensitize vbp the dt myocardium nn may md induce vb cardiac jj arrhythmia nn
effect	4	22	administration nn of inpos epinephrine nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_general_anesthetics nns such jj as inpos halothane nn which wdt sensitize vbp the dt myocardium nn may md induce vb cardiac jj arrhythmia nn
false	12	16	administration nn of inpos epinephrine nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_general_anesthetics nn such jj as inpos halothane nn which wdt sensitize vbp the dt myocardium nn may md induce vb cardiac jj arrhythmia nn
false	12	22	administration nn of inpos epinephrine nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_general_anesthetics nns such jj as inpos halothane nn which wdt sensitize vbp the dt myocardium nn may md induce vb cardiac jj arrhythmia nn
false	16	22	administration nn of inpos epinephrine nn to topos patients nns receiving vbg cyclopropane nn or cc halogenated_hydrocarbon_general_anesthetics nn such jj as inpos halothane nn which wdt sensitize vbp the dt myocardium nn may md induce vb cardiac jj arrhythmia nn
advise	0	16	epinephrine nn also rb should md be vb used vbn cautiously rb with inpos other jj digitalis nn that wdt sensitize vbp the dt myocardium nn to topos the dt actions nns of inpos sympathomimetic_drugs nns
advise	0	16	epinephrine nn also rb should md be vb used vbn cautiously rb with inpos other jj glycosides nn that wdt sensitize vbp the dt myocardium nn to topos the dt actions nns of inpos sympathomimetic_drugs nns
false	0	34	epinephrine nn also rb should md be vb used vbn cautiously rb with inpos other jj drugs nns that wdt sensitize vbp the dt myocardium nn to topos the dt actions nns of inpos sympathomimetic_drugs nn
false	16	34	epinephrine nn also rb should md be vb used vbn cautiously rb with inpos other jj digitalis nn that wdt sensitize vbp the dt myocardium nn to topos the dt actions nns of inpos sympathomimetic_drugs nn
false	16	34	epinephrine nn also rb should md be vb used vbn cautiously rb with inpos other jj glycosides nn that wdt sensitize vbp the dt myocardium nn to topos the dt actions nns of inpos sympathomimetic_drugs nn
effect	0	20	diuretic_agents nn may md decrease vb vascular jj response nn to topos pressor nn drugs nns such jj as inpos epinephrine nn
effect	0	16	epinephrine nn may md antagonize vb the dt neuron nn blockade nn produced vbn by inpos guanethidine nn resulting vbg in inpos decreased vbn antihypertensive jj effect nn and cc requiring vbg increased vbn dosage nn of inpos the dt latter jj
advise	6	24	concomitant jj use nn of inpos ellence nn with inpos other jj cardioactive jj compounds nns that wdt could md cause vb heart nn calcium_channel_blockers nn requires vbz close jj monitoring nn of inpos cardiac jj function nn throughout inpos treatment nn
mechanism	0	10	cimetidine nn increased vbd the dt auc nn of inpos epirubicin nn by inpos num cd
advise	0	16	cimetidine nn treatment nn should md be vb stopped vbn during inpos treatment nn with inpos ellence nn
mechanism	22	30	a dt pharmacokinetic jj study nn evaluating vbg the dt administration nn of inpos a dt single jj dose nn of inpos inspra nn num cd mg nn with inpos ketoconazole nn num cd mg nn bid nn a dt potent jj inhibitor nn of inpos the dt cyp3a4 nn pathway nn showed vbd a dt float_fold jj increase nn in inpos cmax nn of inpos eplerenone nn and cc a dt float_fold jj increase nn in inpos auc nn of inpos eplerenone nn
false	22	66	a dt pharmacokinetic jj study nn evaluating vbg the dt administration nn of inpos a dt single jj dose nn of inpos inspra nn num cd mg nn with inpos ketoconazole nn num cd mg nn bid nn a dt potent jj inhibitor nn of inpos the dt cyp3a4 nn pathway nn showed vbd a dt float_fold jj increase nn in inpos cmax nn of inpos eplerenone nn and cc a dt float_fold jj increase nn in inpos auc nn of inpos eplerenone nn
false	22	66	a dt pharmacokinetic jj study nn evaluating vbg the dt administration nn of inpos a dt single jj dose nn of inpos inspra nn num cd mg nn with inpos ketoconazole nn num cd mg nn bid nn a dt potent jj inhibitor nn of inpos the dt cyp3a4 nn pathway nn showed vbd a dt float_fold jj increase nn in inpos cmax nn of inpos eplerenone nn and cc a dt float_fold jj increase nn in inpos auc nn of inpos eplerenone nn
false	30	66	a dt pharmacokinetic jj study nn evaluating vbg the dt administration nn of inpos a dt single jj dose nn of inpos inspra nnp num cd mg nn with inpos ketoconazole nn num cd mg nn bid nn a dt potent jj inhibitor nn of inpos the dt cyp3a4 nn pathway nn showed vbd a dt float_fold jj increase nn in inpos cmax nn of inpos eplerenone nn and cc a dt float_fold jj increase nn in inpos auc nn of inpos eplerenone nn
false	30	66	a dt pharmacokinetic jj study nn evaluating vbg the dt administration nn of inpos a dt single jj dose nn of inpos inspra nnp num cd mg nn with inpos ketoconazole nn num cd mg nn bid nn a dt potent jj inhibitor nn of inpos the dt cyp3a4 nn pathway nn showed vbd a dt float_fold jj increase nn in inpos cmax nn of inpos eplerenone nn and cc a dt float_fold jj increase nn in inpos auc nn of inpos eplerenone nn
mechanism	4	16	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
mechanism	4	24	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
mechanism	4	32	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
mechanism	4	40	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
false	4	12	administration nn e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn
false	4	20	administration nn e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn
false	4	28	administration nn e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn
false	16	4	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
false	12	20	administration nn e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn
false	12	28	administration nn e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn
false	24	4	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
false	20	28	administration nn e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn
false	32	4	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
false	40	4	administration nn of inpos eplerenone nn with inpos other jj cyp3a4 nn inhibitors nns lrb_e.g. fw erythromycin nn num cd mg nn bid nn verapamil nn num cd mg nn qd nn saquinavir nn num cd mg nn tid nn fluconazole nn num cd mg nn qd nn rrb_resulted vbd in inpos increases nns in inpos cmax nn of inpos eplerenone nn ranging vbg from inpos float cd to topos float cd fold rb and cc auc nn from inpos float cd to topos float cd fold jj
false	0	4	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc angiotensin_ii_receptor_antagonists nns
false	0	16	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nn num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc angiotensin_ii_receptor_antagonists nns
false	0	4	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc angiotensin_ii_receptor_antagonists nn
false	0	34	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc acei nn
false	0	34	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc arb nn
false	4	16	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos ephesus nnp num cd patients nns receiving vbg inspra nn num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc angiotensin_ii_receptor_antagonists nns
false	4	0	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nn or cc angiotensin_ii_receptor_antagonists nns
false	4	34	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc acei nn
false	4	34	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc arb nn
false	16	0	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nn num cd to topos num cd mg nn also rb received vbd ace_inhibitors nn or cc angiotensin_ii_receptor_antagonists nns
false	16	4	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nn num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc angiotensin_ii_receptor_antagonists nn
false	16	34	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nn num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc acei nn
false	16	34	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nn num cd to topos num cd mg nn also rb received vbd ace_inhibitors nns or cc arb nn
false	0	4	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nn or cc angiotensin_ii_receptor_antagonists nn
false	0	34	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nn or cc acei nn
false	0	34	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos ephesus nnp num cd patients nns receiving vbg inspra nnp num cd to topos num cd mg nn also rb received vbd ace_inhibitors nn or cc arb nn
false	0	4	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns increased vbd mean jj serum nn potassium nn slightly rb
false	0	26	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns increased vbd mean jj serum nn potassium nn slightly rb
false	0	4	ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn increased vbd mean jj serum nn potassium nn slightly rb
false	4	26	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns increased vbd mean jj serum nn potassium nn slightly rb
false	4	0	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn hyph_in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns increased vbd mean jj serum nn potassium nn slightly rb
effect	26	0	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nns increased vbd mean jj serum nn potassium nn slightly rb
effect	26	4	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nn increased vbd mean jj serum nn potassium nn slightly rb
false	0	4	ace_inhibitors nns and cc angiotensin_ii_receptor_antagonists nns in inpos clinical jj studies nns of inpos patients nns with inpos hypertension nn the dt addition nn of inpos inspra nn num cd to topos num cd mg nn to topos ace_inhibitors nn and cc angiotensin_ii_receptor_antagonists nn increased vbd mean jj serum nn potassium nn slightly rb
false	14	26	in inpos a dt study nn in inpos diabetics nns with inpos microalbuminuria nn inspra nn num cd mg nn combined vbn with inpos the dt ace_inhibitor nn enalapril nn num cd mg nn increased vbd the dt frequency nn of inpos hyperkalemia nn from inpos num cd on inpos enalapril nn alone rb to topos num cd
effect	14	28	in inpos a dt study nn in inpos diabetics nns with inpos microalbuminuria nn inspra nn num cd mg nn combined vbn with inpos the dt ace_inhibitor nn enalapril nn num cd mg nn increased vbd the dt frequency nn of inpos hyperkalemia nn from inpos num cd on inpos enalapril nn alone rb to topos num cd
false	14	28	in inpos a dt study nn in inpos diabetics nns with inpos microalbuminuria nn inspra nn num cd mg nn combined vbn with inpos the dt ace_inhibitor nn enalapril nn num cd mg nn increased vbd the dt frequency nn of inpos hyperkalemia nn from inpos num cd on inpos enalapril nn alone rb to topos num cd
false	26	28	in inpos a dt study nn in inpos diabetics nns with inpos microalbuminuria nn inspra nnp num cd mg nn combined vbn with inpos the dt ace_inhibitor nn enalapril nn num cd mg nn increased vbd the dt frequency nn of inpos hyperkalemia nn from inpos num cd on inpos enalapril nn alone rb to topos num cd
false	26	28	in inpos a dt study nn in inpos diabetics nns with inpos microalbuminuria nn inspra nnp num cd mg nn combined vbn with inpos the dt ace_inhibitor nn enalapril nn num cd mg nn increased vbd the dt frequency nn of inpos hyperkalemia nn from inpos num cd on inpos enalapril nn alone rb to topos num cd
false	0	12	lithium nn a nn drug nn interaction nn study nn of inpos eplerenone nn with inpos lithium nn has vbz not rb been vbn conducted vbn
false	10	0	lithium_a nn drug nn interaction nn study nn of inpos eplerenone nn with inpos lithium nn has vbz not rb been vbn conducted vbn
false	2	16	serum nn lithium nn levels nns should md be vb monitored vbn frequently rb if inpos inspra nn is vbz administered vbn concomitantly rb with inpos lithium nn
advise	16	2	serum nn lithium nn levels nns should md be vb monitored vbn frequently rb if inpos inspra nn is vbz administered vbn concomitantly rb with inpos lithium nn
false	0	12	nonsteroidal_anti_inflammatory_drugs nn a nn drug nn interaction nn study nn of inpos eplerenone nn with inpos an dt nsaid nn has vbz not rb been vbn conducted vbn
false	0	18	nonsteroidal_anti_inflammatory_drugs nn a nn drug nn interaction nn study nn of inpos eplerenone nn with inpos an dt nsaid nn has vbz not rb been vbn conducted vbn
false	0	12	nsaids nn a nn drug nn interaction nn study nn of inpos eplerenone nn with inpos an dt nsaid nn has vbz not rb been vbn conducted vbn
false	12	18	nonsteroidal_anti_inflammatory_drugs jj a nn drug nn interaction nn study nn of inpos eplerenone nn with inpos an dt nsaid nn has vbz not rb been vbn conducted vbn
effect	8	12	the dt administration nn of inpos other jj potassium_sparing_antihypertensives nn with inpos nsaids nn has vbz been vbn shown vbn to topos reduce vb the dt antihypertensive jj effect nn in inpos some dt patients nns and cc result vbp in inpos severe jj hyperkalemia nn in inpos patients nns with inpos impaired jj renal jj function nn
advise	4	8	therefore rb when wrb inspra nn and cc nsaids nn are vbp used vbn concomitantly rb patients nns should md be vb observed vbn to topos determine vb whether inpos the dt desired vbn effect nn on inpos blood nn pressure nn is vbz obtained vbn
effect	16	24	additional jj reductions nns in inpos blood nn pressure nn may md occur vb when wrb flolan nn is vbz administered vbn with inpos diuretics nn antihypertensive_agents nns other jj vasodilators nns
effect	16	26	additional jj reductions nns in inpos blood nn pressure nn may md occur vb when wrb flolan nn is vbz administered vbn with inpos diuretics nns antihypertensive_agents nn other jj vasodilators nns
effect	16	30	additional jj reductions nns in inpos blood nn pressure nn may md occur vb when wrb flolan nn is vbz administered vbn with inpos diuretics nns antihypertensive_agents nns other jj vasodilators nn
false	24	26	additional jj reductions nns in inpos blood nn pressure nn may md occur vb when wrb flolan nn is vbz administered vbn with inpos diuretics nn antihypertensive_agents nn other jj vasodilators nns
false	24	30	additional jj reductions nns in inpos blood nn pressure nn may md occur vb when wrb flolan nn is vbz administered vbn with inpos diuretics nn antihypertensive_agents nns other jj vasodilators nn
false	26	30	additional jj reductions nns in inpos blood nn pressure nn may md occur vb when wrb flolan nn is vbz administered vbn with inpos diuretics nns antihypertensive_agents nn other jj vasodilators nn
false	4	8	when wrb other jj antiplatelet_agents nn or cc anticoagulants nn are vbp used vbn concomitantly rb there ex is vbz the dt potential nn for inpos flolan nn to topos increase vb the dt risk nn of inpos bleeding vbg
effect	4	26	when wrb other jj antiplatelet_agents nn or cc anticoagulants nns are vbp used vbn concomitantly rb there ex is vbz the dt potential nn for inpos flolan nn to topos increase vb the dt risk nn of inpos bleeding vbg
effect	8	26	when wrb other jj antiplatelet_agents nns or cc anticoagulants nn are vbp used vbn concomitantly rb there ex is vbz the dt potential nn for inpos flolan nn to topos increase vb the dt risk nn of inpos bleeding vbg
false	10	24	however rb patients nns receiving vbg infusions nns of inpos flolan nn in inpos clinical jj trials nns were vbd maintained vbn on inpos anticoagulants nn without inpos evidence nn of inpos increased vbn bleeding vbg
false	6	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos diuretics nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos anticoagulants nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos vasodilators nn supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	26	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	48	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	48	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	18	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	6	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	18	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos diuretics nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos diuretics nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	44	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos diuretics nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	6	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos diuretics nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos diuretics nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	44	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos diuretics nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	18	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos anticoagulants nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos anticoagulants nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	44	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos anticoagulants nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	6	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos anticoagulants nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos anticoagulants nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	44	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos anticoagulants nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	18	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos vasodilators nn supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos vasodilators nn supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	44	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos vasodilators nn supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	6	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos vasodilators nn supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	40	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos vasodilators nn supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	44	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos vasodilators nn supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	26	50	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	26	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	26	6	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	26	50	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	26	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen nn .in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	48	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
mechanism	48	6	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	48	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
mechanism	14	6	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	14	48	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	48	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	6	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
false	48	14	in inpos clinical jj trials nns flolan nn was vbd used vbn with inpos digoxin nn diuretics nns anticoagulants nns oral jj vasodilators nns supplemental jj oxygen.in nn a dt pharmacokinetic jj substudy nn in inpos patients nns with inpos congestive jj heart nn failure nn receiving vbg furosemide nn or cc digoxin nn in inpos whom wp therapy nn with inpos flolan nn was vbd initiated vbn apparent jj oral jj clearance nn values nns for inpos furosemide nn and cc digoxin nn were vbd decreased vbn by inpos num cd and cc num cd respectively rb on inpos the dt second jj day nn of inpos therapy nn and cc had vbd returned vbn to topos baseline nn values nns by inpos day nn num cd
mechanism	6	30	however rb patients nns on inpos digoxin nn may md show vb elevations nns of inpos digoxin nn concentrations nns after inpos initiation nn of inpos therapy nn with inpos flolan nn which wdt may md be vb clinically rb significant jj in inpos patients nns prone jj to topos digoxin nn toxicity nn
false	6	30	however rb patients nns on inpos digoxin nn may md show vb elevations nns of inpos digoxin nn concentrations nns after inpos initiation nn of inpos therapy nn with inpos flolan nn which wdt may md be vb clinically rb significant jj in inpos patients nns prone jj to topos digoxin nn toxicity nn
false	30	6	however rb patients nns on inpos digoxin nn may md show vb elevations nns of inpos digoxin nn concentrations nns after inpos initiation nn of inpos therapy nn with inpos flolan nn which wdt may md be vb clinically rb significant jj in inpos patients nns prone jj to topos digoxin nn toxicity nn
false	0	24	eprosartan nn has vbz been vbn shown vbn to topos have vb no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn and cc the dt pharmacodynamics nns of inpos warfarin nn and cc glyburide nn
false	0	34	eprosartan nn has vbz been vbn shown vbn to topos have vb no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn and cc the dt pharmacodynamics nns of inpos warfarin nn and cc glyburide nn
false	0	38	eprosartan nn has vbz been vbn shown vbn to topos have vb no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn and cc the dt pharmacodynamics nns of inpos warfarin nn and cc glyburide nn
false	24	34	eprosartan nnp has vbz been vbn shown vbn to topos have vb no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn and cc the dt pharmacodynamics nns of inpos warfarin nn and cc glyburide nn
false	24	38	eprosartan nnp has vbz been vbn shown vbn to topos have vb no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn and cc the dt pharmacodynamics nns of inpos warfarin nn and cc glyburide nn
false	34	38	eprosartan nnp has vbz been vbn shown vbn to topos have vb no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn and cc the dt pharmacodynamics nns of inpos warfarin nn and cc glyburide nn
false	2	46	because inpos eprosartan nn is vbz not rb metabolized vbn by inpos the dt cytochrome nn p450 nn system nn inhibitors nns of inpos cyp450 nn enzyme nn would md not rb be vb expected vbn to topos affect vb its prp metabolism nn and cc ketoconazole nn and cc fluconazole nn potent jj inhibitors nns of inpos cyp3a nn and cc 2c9 nn respectively rb have vbp been vbn shown vbn to topos have vb no dt effect nn on inpos eprosartan nn pharmacokinetics nns
false	2	50	because inpos eprosartan nn is vbz not rb metabolized vbn by inpos the dt cytochrome nn p450 nn system nn inhibitors nns of inpos cyp450 nn enzyme nn would md not rb be vb expected vbn to topos affect vb its prp metabolism nn and cc ketoconazole nn and cc fluconazole nn potent jj inhibitors nns of inpos cyp3a nn and cc 2c9 nn respectively rb have vbp been vbn shown vbn to topos have vb no dt effect nn on inpos eprosartan nn pharmacokinetics nns
false	46	50	because inpos eprosartan nn is vbz not rb metabolized vbn by inpos the dt cytochrome nn p450 nn system nn inhibitors nns of inpos cyp450 nn enzyme nn would md not rb be vb expected vbn to topos affect vb its prp metabolism nn and cc ketoconazole nn and cc fluconazole nn potent jj inhibitors nns of inpos cyp3a nn and cc 2c9 nn respectively rb have vbp been vbn shown vbn to topos have vb no dt effect nn on inpos eprosartan nn pharmacokinetics nns
false	46	2	because inpos eprosartan nn is vbz not rb metabolized vbn by inpos the dt cytochrome nn p450 nn system nn inhibitors nns of inpos cyp450 nn enzyme nn would md not rb be vb expected vbn to topos affect vb its prp metabolism nn and cc ketoconazole nn and cc fluconazole nn potent jj inhibitors nns of inpos cyp3a nn and cc 2c9 nn respectively rb have vbp been vbn shown vbn to topos have vb no dt effect nn on inpos eprosartan nn pharmacokinetics nns
false	50	2	because inpos eprosartan nn is vbz not rb metabolized vbn by inpos the dt cytochrome nn p450 nn system nn inhibitors nns of inpos cyp450 nn enzyme nn would md not rb be vb expected vbn to topos affect vb its prp metabolism nn and cc ketoconazole nn and cc fluconazole nn potent jj inhibitors nns of inpos cyp3a nn and cc 2c9 nn respectively rb have vbp been vbn shown vbn to topos have vb no dt effect nn on inpos eprosartan nn pharmacokinetics nns
false	0	12	ranitidine nn also rb has vbz no dt effect nn on inpos eprosartan nn pharmacokinetics nns
false	0	18	eprosartan nn doses nns have vbp been vbn safely rb used vbn concomitantly rb with inpos a dt thiazide_diuretic nn
false	0	18	eprosartan nn doses nns have vbp been vbn safely rb used vbn concomitantly rb with inpos a dt hydrochlorothiazide nn
false	0	30	eprosartan nn doses nns of inpos up inpos to topos num cd mg nn b.i.d. rb have vbp been vbn safely rb used vbn concomitantly rb with inpos sustained_release jj calcium_channel_blockers nn with inpos no dt clinically rb significant jj adverse jj interactions nns
false	0	30	eprosartan nn doses nns of inpos up inpos to topos num cd mg nn b.i.d. rb have vbp been vbn safely rb used vbn concomitantly rb with inpos sustained_release jj nifedipine nn with inpos no dt clinically rb significant jj adverse jj interactions nns
false	0	36	enoxaparin nn dosed vbd as inpos a dt float cd mg_kg nn subcutaneous jj injection nn q12h nn for inpos num cd doses nns did vbd not rb alter vb the dt pharmacokinetics nns of inpos eptifibatide nn or cc the dt level nn of inpos platelet nn aggregation nn in inpos healthy jj adults nns
mechanism	0	12	mineral_oil nn interferes vbz with inpos the dt absorption nn of inpos fat_soluble_vitamins nn including vbg vitamin_d_preparations nns
mechanism	0	16	mineral_oil nn interferes vbz with inpos the dt absorption nn of inpos fat_soluble_vitamins nns including vbg vitamin_d_preparations nn
false	12	16	mineral_oil nnp interferes vbz with inpos the dt absorption nn of inpos fat_soluble_vitamins nn including vbg vitamin_d_preparations nn
effect	4	24	administration nn of inpos thiazide_diuretics nn to topos hypoparathyroid jj patients nns who wp are vbp concurrently rb being vbg treated vbn with inpos ergocalciferol nn may md cause vb hypercalcemia nn
mechanism	6	16	the dt effects nns of inpos ergomar nn may md be vb potentiated vbn by inpos triacetyloleandomycin nn which wdt inhibits vbz the dt metabolism nn of inpos ergotamine nn
false	6	28	the dt effects nns of inpos ergomar nn may md be vb potentiated vbn by inpos triacetyloleandomycin nn which wdt inhibits vbz the dt metabolism nn of inpos ergotamine nn
mechanism	16	28	the dt effects nns of inpos ergomar nn may md be vb potentiated vbn by inpos triacetyloleandomycin nn which wdt inhibits vbz the dt metabolism nn of inpos ergotamine nn
effect	8	14	the dt pressor nn effects nns of inpos ergomar nn and cc other jj vasoconstrictor_drugs nn can md combine vb to topos cause vb dangerous jj hypertension nn
mechanism	12	16	co_treatment nn with inpos the dt potent jj cyp3a4 nn inhibitor nn ketoconazole nn increases vbz erlotinib nn auc nn by inpos num cd
advise	16	20	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos atazanavir nn clarithromycin nn indinavir nn itraconazole nn nefazodone nn nelfinavir nn ritonavir nn saquinavir nn telithromycin nn troleandomycin nn voriconazole nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos atazanavir nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos clarithromycin nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos indinavir nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos itraconazole nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos nefazodone nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos nelfinavir nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos ritonavir nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos saquinavir nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos telithromycin nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos troleandomycin nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos tao nn
advise	16	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos voriconazole nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos atazanavir nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos clarithromycin nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos indinavir nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos itraconazole nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos nefazodone nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos nelfinavir nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos ritonavir nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos saquinavir nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos telithromycin nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos troleandomycin nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos tao nn
false	20	44	caution nn should md be vb used vbn when wrb administering vbg or cc taking vbg tarceva nn with inpos ketoconazole nn and cc other jj strong jj cyp3a4 nn inhibitors nns such jj as inpos but cc not rb limited vbn to topos voriconazole nn
mechanism	10	14	pre_treatment nn with inpos the dt cyp3a4 nn inducer nn rifampicin nn decreased vbd erlotinib nn auc nn by inpos about rb num cd
advise	4	34	if inpos the dt tarceva nn dose nn is vbz adjusted vbn upward rb the dt dose nn will md need vb to topos be vb reduced vbn upon inpos discontinuation nn of inpos rifampicin nn or cc other jj inducers nns
false	4	10	patients nns taking vbg warfarin nn or cc other jj coumarin_derivative_anticoagulants nn should md be vb monitored vbn regularly rb for inpos changes nns in inpos prothrombin nn time nn or cc inr nn
false	2	10	when wrb ertapenem nn is vbz co_administered vbn with inpos probenecid nn probenecid nn competes nns for inpos active jj tubular jj secretion nn and cc reduces vbz the dt renal jj clearance nn of inpos ertapenem nn
false	2	10	when wrb ertapenem nn is vbz co_administered vbn with inpos probenecid nn probenecid nn competes nns for inpos active jj tubular jj secretion nn and cc reduces vbz the dt renal jj clearance nn of inpos ertapenem nn
false	10	2	when wrb ertapenem nn is vbz co_administered vbn with inpos probenecid nn probenecid nn competes nns for inpos active jj tubular jj secretion nn and cc reduces vbz the dt renal jj clearance nn of inpos ertapenem nn
mechanism	10	2	when wrb ertapenem nn is vbz co_administered vbn with inpos probenecid nn probenecid nn competes nns for inpos active jj tubular jj secretion nn and cc reduces vbz the dt renal jj clearance nn of inpos ertapenem nn
mechanism	6	10	based vbn on inpos total jj ertapenem nn concentrations nns probenecid nn increased vbd the dt auc nn by inpos num cd and cc reduced vbd the dt plasma nn and cc renal jj clearances nns by inpos num cd and cc num cd respectively rb
advise	20	32	because inpos of inpos the dt small jj effect nn on inpos half_life nn the dt coadministration nn with inpos probenecid nn to topos extend vb the dt half_life nn of inpos ertapenem nn is vbz not rb recommended vbn
false	10	24	in fw vitro fw studies nns indicate vbp that inpos ertapenem nn does vbz not rb inhibit vb p_glycoprotein_mediated jj transport nn of inpos digoxin nn or cc vinblastine nn and cc that inpos ertapenem nn is vbz not rb a dt substrate nn for inpos p_glycoprotein_mediated jj transport nn
false	10	28	in fw vitro fw studies nns indicate vbp that inpos ertapenem nn does vbz not rb inhibit vb p_glycoprotein_mediated jj transport nn of inpos digoxin nn or cc vinblastine nn and cc that inpos ertapenem nn is vbz not rb a dt substrate nn for inpos p_glycoprotein_mediated jj transport nn
false	24	28	in fw vitro fw studies nns indicate vbp that inpos ertapenem nn does vbz not rb inhibit vb p_glycoprotein_mediated jj transport nn of inpos digoxin nn or cc vinblastine nn and cc that inpos ertapenem nn is vbz not rb a dt substrate nn for inpos p_glycoprotein_mediated jj transport nn
false	24	10	in fw vitro fw studies nns indicate vbp that inpos ertapenem nn does vbz not rb inhibit vb p_glycoprotein_mediated jj transport nn of inpos digoxin nn or cc vinblastine nn and cc that inpos ertapenem nn is vbz not rb a dt substrate nn for inpos p_glycoprotein_mediated jj transport nn
false	28	10	in fw vitro fw studies nns indicate vbp that inpos ertapenem nn does vbz not rb inhibit vb p_glycoprotein_mediated jj transport nn of inpos digoxin nn or cc vinblastine nn and cc that inpos ertapenem nn is vbz not rb a dt substrate nn for inpos p_glycoprotein_mediated jj transport nn
effect	0	20	erythromycin nn use nn in inpos patients nns who wp are vbp receiving vbg high jj doses nns of inpos theophylline nn may md be vb associated vbn with inpos an dt increase nn in inpos serum nn theophylline nn levels nns and cc potential jj theophylline nn toxicity nn
false	0	20	erythromycin nn use nn in inpos patients nns who wp are vbp receiving vbg high jj doses nns of inpos theophylline nn may md be vb associated vbn with inpos an dt increase nn in inpos serum nn theophylline nn levels nns and cc potential jj theophylline nn toxicity nn
false	0	20	erythromycin nn use nn in inpos patients nns who wp are vbp receiving vbg high jj doses nns of inpos theophylline nn may md be vb associated vbn with inpos an dt increase nn in inpos serum nn theophylline nn levels nns and cc potential jj theophylline nn toxicity nn
false	6	46	in inpos case nn of inpos theophylline nn toxicity nn and_or cc elevated jj serum nn theophylline nn levels nns the dt dose nn of inpos theophylline nn should md be vb reduced vbn while inpos the dt patient nn is vbz receiving vbg concomitant jj erythromycin nn therapy nn
false	6	46	in inpos case nn of inpos theophylline nn toxicity nn and_or cc elevated jj serum nn theophylline nn levels nns the dt dose nn of inpos theophylline nn should md be vb reduced vbn while inpos the dt patient nn is vbz receiving vbg concomitant jj erythromycin nn therapy nn
advise	6	46	in inpos case nn of inpos theophylline nn toxicity nn and_or cc elevated jj serum nn theophylline nn levels nns the dt dose nn of inpos theophylline nn should md be vb reduced vbn while inpos the dt patient nn is vbz receiving vbg concomitant jj erythromycin nn therapy nn
mechanism	6	10	concomitant jj administration nn of inpos erythromycin nn and cc digoxin nn has vbz been vbn reported vbn to topos result vb in inpos elevated jj digoxin nn serum nn levels nns
false	6	10	concomitant jj administration nn of inpos erythromycin nn and cc digoxin nn has vbz been vbn reported vbn to topos result vb in inpos elevated jj digoxin nn serum nn levels nns
effect	18	24	there ex have vbp been vbn reports nns of inpos increased vbn anticoagulant jj effects nns when wrb erythromycin nn and cc oral jj anticoagulants nn were vbd used vbn concomitantly rb
mechanism	0	18	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc midazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos these dt benzodiazepines nns
mechanism	0	22	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc midazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos these dt benzodiazepines nns
effect	0	42	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc midazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos these dt benzodiazepines nn
false	18	22	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc midazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos these dt benzodiazepines nns
false	18	42	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc midazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos these dt benzodiazepines nn
false	22	42	erythromycin nn has vbz been vbn reported vbn to topos decrease vb the dt clearance nn of inpos triazolam nn and cc midazolam nn and cc thus rb may md increase vb the dt pharmacologic jj effect nn of inpos these dt benzodiazepines nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos carbamazepine nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos cyclosporine nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos tacrolimus nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos hexobarbital nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos phenytoin nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos alfentanil nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos cisapride nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos disopyramide nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos lovastatin nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos bromocriptine nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos valproate nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos terfenadine nn
int	14	18	there ex have vbp been vbn reports nns of inpos interactions nns of inpos erythromycin nn with inpos astemizole nn
false	0	22	erythromycin nn has vbz been vbn reported vbn to topos significantly rb alter vb the dt metabolism nn of inpos nonsedating jj antihistamines nn terfenadine nn and cc astemizole nn when wrb taken vbn concomitantly rb
mechanism	0	24	erythromycin nn has vbz been vbn reported vbn to topos significantly rb alter vb the dt metabolism nn of inpos nonsedating jj antihistamines nns terfenadine nn and cc astemizole nn when wrb taken vbn concomitantly rb
mechanism	0	28	erythromycin nn has vbz been vbn reported vbn to topos significantly rb alter vb the dt metabolism nn of inpos nonsedating jj antihistamines nns terfenadine nn and cc astemizole nn when wrb taken vbn concomitantly rb
false	22	24	erythromycin nn has vbz been vbn reported vbn to topos significantly rb alter vb the dt metabolism nn of inpos nonsedating jj antihistamines nn terfenadine nn and cc astemizole nn when wrb taken vbn concomitantly rb
false	22	28	erythromycin nn has vbz been vbn reported vbn to topos significantly rb alter vb the dt metabolism nn of inpos nonsedating jj antihistamines nn terfenadine nn and cc astemizole nn when wrb taken vbn concomitantly rb
false	24	28	erythromycin nn has vbz been vbn reported vbn to topos significantly rb alter vb the dt metabolism nn of inpos nonsedating jj antihistamines nns terfenadine nn and cc astemizole nn when wrb taken vbn concomitantly rb
effect	22	26	in inpos addition nn deaths nns have vbp been vbn reported vbn rarely rb with inpos concomitant jj administration nn of inpos terfenadine nn and cc erythromycin nn
effect	18	26	there ex have vbp been vbn postmarketing vbg reports nns of inpos drug nn interactions nns when wrb erythromycin nn is vbz coadministered vbn with inpos cisapride nn resulting vbg in inpos qt nn prolongation nn cardiac jj arrythmias nns ventricular jj tachycardia nn ventricular jj fibrulation nn torsades nns de fw pointes nns most jjs like inpos due jj to topos inhibition nn of inpos hepatic jj metabolism nn of inpos cisapride nn by inpos erythromycin nn
false	18	26	there ex have vbp been vbn postmarketing vbg reports nns of inpos drug nn interactions nns when wrb erythromycin nn is vbz coadministered vbn with inpos cisapride nn resulting vbg in inpos qt nn prolongation nn cardiac jj arrythmias nns ventricular jj tachycardia nn ventricular jj fibrulation nn torsades nns de fw pointes nns most jjs like inpos due jj to topos inhibition nn of inpos hepatic jj metabolism nn of inpos cisapride nn by inpos erythromycin nn
false	26	18	there ex have vbp been vbn postmarketing vbg reports nns of inpos drug nn interactions nns when wrb erythromycin nn is vbz coadministered vbn with inpos cisapride nn resulting vbg in inpos qt nn prolongation nn cardiac jj arrythmias nns ventricular jj tachycardia nn ventricular jj fibrulation nn torsades nns de fw pointes nns most jjs like inpos due jj to topos inhibition nn of inpos hepatic jj metabolism nn of inpos cisapride nn by inpos erythromycin nn
mechanism	26	18	there ex have vbp been vbn postmarketing vbg reports nns of inpos drug nn interactions nns when wrb erythromycin nn is vbz coadministered vbn with inpos cisapride nn resulting vbg in inpos qt nn prolongation nn cardiac jj arrythmias nns ventricular jj tachycardia nn ventricular jj fibrulation nn torsades nns de fw pointes nns most jjs like inpos due jj to topos inhibition nn of inpos hepatic jj metabolism nn of inpos cisapride nn by inpos erythromycin nn
advise	6	10	patients nns receiving vbg concomitant jj lovastatin nn and cc erythromycin nn should md be vb carefully rb monitored vbn
false	0	4	alcohol nn hyph_although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nns the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	0	40	alcohol nn hyph_although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nn the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	0	4	alcohol nn hyph_although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nns the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	4	0	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nns the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	4	40	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nn the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	4	0	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nns the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	0	40	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nn the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	0	4	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nns the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
false	40	0	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nn the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
advise	40	4	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nn the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
advise	0	4	alcohol nn although inpos lexapro nn did vbd not rb potentiate vb the dt cognitive jj and cc motor jj effects nns of inpos alcohol nn in inpos a dt clinical jj trial nn as inpos with inpos other jj psychotropic_medications nns the dt use nn of inpos alcohol nn by inpos patients nns taking vbg lexapro nn is vbz not rb recommended vbn
effect	32	74	epidemiological jj studies nns of inpos the dt case_control nn and cc cohort jj design nn that wdt have vbp demonstrated vbn an dt association nn between inpos use nn of inpos psychotropic_drugs nn that wdt interfere vbp with inpos serotonin nn reuptake nn and cc the dt occurrence nn of inpos upper jj gastrointestinal jj bleeding nn have vbp also rb shown vbn that inpos concurrent jj use nn of inpos an dt nsaid nn or cc aspirin nn potentiated vbd the dt risk nn of inpos bleeding vbg
effect	32	78	epidemiological jj studies nns of inpos the dt case_control nn and cc cohort jj design nn that wdt have vbp demonstrated vbn an dt association nn between inpos use nn of inpos psychotropic_drugs nn that wdt interfere vbp with inpos serotonin nn reuptake nn and cc the dt occurrence nn of inpos upper jj gastrointestinal jj bleeding nn have vbp also rb shown vbn that inpos concurrent jj use nn of inpos an dt nsaid nn or cc aspirin nn potentiated vbd the dt risk nn of inpos bleeding vbg
false	74	78	epidemiological jj studies nns of inpos the dt case_control nn and cc cohort jj design nn that wdt have vbp demonstrated vbn an dt association nn between inpos use nn of inpos psychotropic_drugs nns that wdt interfere vbp with inpos serotonin nn reuptake nn and cc the dt occurrence nn of inpos upper jj gastrointestinal jj bleeding nn have vbp also rb shown vbn that inpos concurrent jj use nn of inpos an dt nsaid nn or cc aspirin nn potentiated vbd the dt risk nn of inpos bleeding vbg
false	0	24	cimetidine nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos num cd mg_day nn cimetidine nn for inpos num cd days nns resulted vbd in inpos an dt increase nn in inpos citalopram nn auc nn and cc cmax nn of inpos num cd and cc num cd respectively rb
false	0	24	cimetidine nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos num cd mg_day nn cimetidine nn for inpos num cd days nns resulted vbd in inpos an dt increase nn in inpos citalopram nn auc nn and cc cmax nn of inpos num cd and cc num cd respectively rb
mechanism	24	0	cimetidine nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos num cd mg_day nn cimetidine nn for inpos num cd days nns resulted vbd in inpos an dt increase nn in inpos citalopram nn auc nn and cc cmax nn of inpos num cd and cc num cd respectively rb
false	0	24	cimetidine nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos num cd mg_day nn cimetidine nn for inpos num cd days nns resulted vbd in inpos an dt increase nn in inpos citalopram nn auc nn and cc cmax nn of inpos num cd and cc num cd respectively rb
false	0	24	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	0	24	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	0	24	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	24	0	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	24	0	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	24	0	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	24	0	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	0	24	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	24	0	digoxin nn in inpos subjects nns who wp had vbd received vbn num cd days nns of inpos num cd mg_day nn racemic jj citalopram nn combined jj administration nn of inpos citalopram nn and cc digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc digoxin nn
false	0	8	lithium nn hyph_coadministration nn of inpos racemic jj citalopram nn and cc lithium nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos citalopram nn or cc lithium nn
false	0	8	lithium nn hyph_coadministration nn of inpos racemic jj citalopram nn and cc lithium nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos citalopram nn or cc lithium nn
false	8	0	lithium nn hyph_coadministration nn of inpos racemic jj citalopram nn and cc lithium nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos citalopram nn or cc lithium nn
false	8	0	lithium nn hyph_coadministration nn of inpos racemic jj citalopram nn and cc lithium nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos citalopram nn or cc lithium nn
false	0	8	lithium nn hyph_coadministration nn of inpos racemic jj citalopram nn and cc lithium nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos citalopram nn or cc lithium nn
false	8	0	lithium nn hyph_coadministration nn of inpos racemic jj citalopram nn and cc lithium nn had vbd no dt significant jj effect nn on inpos the dt pharmacokinetics nns of inpos citalopram nn or cc lithium nn
effect	2	16	because inpos lithium nn may md enhance vb the dt serotonergic jj effects nns of inpos escitalopram nn caution nn should md be vb exercised vbn when wrb lexapro nn and cc lithium nn are vbp coadministered vbn
false	2	28	because inpos lithium nn may md enhance vb the dt serotonergic jj effects nns of inpos escitalopram nn caution nn should md be vb exercised vbn when wrb lexapro nn and cc lithium nn are vbp coadministered vbn
false	16	28	because inpos lithium nn may md enhance vb the dt serotonergic jj effects nns of inpos escitalopram nn caution nn should md be vb exercised vbn when wrb lexapro nn and cc lithium nn are vbp coadministered vbn
false	16	2	because inpos lithium nn may md enhance vb the dt serotonergic jj effects nns of inpos escitalopram nn caution nn should md be vb exercised vbn when wrb lexapro nn and cc lithium nn are vbp coadministered vbn
advise	28	2	because inpos lithium nn may md enhance vb the dt serotonergic jj effects nns of inpos escitalopram nn caution nn should md be vb exercised vbn when wrb lexapro nn and cc lithium nn are vbp coadministered vbn
false	0	4	pimozide nn and cc celexa nn in inpos a dt controlled jj study nn a dt single jj dose nn of inpos pimozide nn num cd mg nn co_administered vbn with inpos racemic jj citalopram nn num cd mg nn given vbn once rb daily rb for inpos num cd days nns was vbd associated vbn with inpos a dt mean jj increase nn in inpos qtc nn values nns of inpos approximately rb num cd msec nn compared vbn to topos pimozide nn given vbn alone rb
false	0	34	pimozide nn and cc celexa nnp in inpos a dt controlled jj study nn a dt single jj dose nn of inpos pimozide nn num cd mg nn co_administered vbn with inpos racemic jj citalopram nn num cd mg nn given vbn once rb daily rb for inpos num cd days nns was vbd associated vbn with inpos a dt mean jj increase nn in inpos qtc nn values nns of inpos approximately rb num cd msec nn compared vbn to topos pimozide nn given vbn alone rb
false	4	0	pimozide nn and cc celexa nn in inpos a dt controlled jj study nn a dt single jj dose nn of inpos pimozide nn num cd mg nn co_administered vbn with inpos racemic jj citalopram nn num cd mg nn given vbn once rb daily rb for inpos num cd days nns was vbd associated vbn with inpos a dt mean jj increase nn in inpos qtc nn values nns of inpos approximately rb num cd msec nn compared vbn to topos pimozide nn given vbn alone rb
false	4	34	pimozide nn and cc celexa nn in inpos a dt controlled jj study nn a dt single jj dose nn of inpos pimozide nn num cd mg nn co_administered vbn with inpos racemic jj citalopram nn num cd mg nn given vbn once rb daily rb for inpos num cd days nns was vbd associated vbn with inpos a dt mean jj increase nn in inpos qtc nn values nns of inpos approximately rb num cd msec nn compared vbn to topos pimozide nn given vbn alone rb
false	4	0	pimozide nn and cc celexa nn in inpos a dt controlled jj study nn a dt single jj dose nn of inpos pimozide nn num cd mg nn co_administered vbn with inpos racemic jj citalopram nn num cd mg nn given vbn once rb daily rb for inpos num cd days nns was vbd associated vbn with inpos a dt mean jj increase nn in inpos qtc nn values nns of inpos approximately rb num cd msec nn compared vbn to topos pimozide nn given vbn alone rb
effect	0	34	pimozide nn and cc celexa nnp in inpos a dt controlled jj study nn a dt single jj dose nn of inpos pimozide nn num cd mg nn co_administered vbn with inpos racemic jj citalopram nn num cd mg nn given vbn once rb daily rb for inpos num cd days nns was vbd associated vbn with inpos a dt mean jj increase nn in inpos qtc nn values nns of inpos approximately rb num cd msec nn compared vbn to topos pimozide nn given vbn alone rb
false	34	0	pimozide nn and cc celexa nnp in inpos a dt controlled jj study nn a dt single jj dose nn of inpos pimozide nn num cd mg nn co_administered vbn with inpos racemic jj citalopram nn num cd mg nn given vbn once rb daily rb for inpos num cd days nns was vbd associated vbn with inpos a dt mean jj increase nn in inpos qtc nn values nns of inpos approximately rb num cd msec nn compared vbn to topos pimozide nn given vbn alone rb
false	2	22	racemic jj citalopram nn did vbd not rb alter vb the dt mean jj auc nn or cc cmax nn of inpos pimozide nn
false	0	36	sumatriptan nn hyph_there ex have vbp been vbn rare jj postmarketing jj reports nns describing vbg patients nns with inpos weakness nn hyperreflexia nn incoordination nn following vbg the dt use nn of inpos a dt selective_serotonin_reuptake_inhibitor nn sumatriptan nn
false	0	36	sumatriptan nn hyph_there ex have vbp been vbn rare jj postmarketing jj reports nns describing vbg patients nns with inpos weakness nn hyperreflexia nn incoordination nn following vbg the dt use nn of inpos a dt ssri nn sumatriptan nn
effect	36	0	sumatriptan nnp hyph_there ex have vbp been vbn rare jj postmarketing jj reports nns describing vbg patients nns with inpos weakness nn hyperreflexia nn incoordination nn following vbg the dt use nn of inpos a dt selective_serotonin_reuptake_inhibitor nn sumatriptan nn
effect	36	0	sumatriptan nnp hyph_there ex have vbp been vbn rare jj postmarketing jj reports nns describing vbg patients nns with inpos weakness nn hyperreflexia nn incoordination nn following vbg the dt use nn of inpos a dt ssri nn sumatriptan nn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt ssri nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt fluoxetine nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt fluvoxamine nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt paroxetine nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt sertraline nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt citalopram nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
advise	8	14	if inpos concomitant jj treatment nn with inpos sumatriptan nn and cc an dt escitalopram nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
false	0	10	theophylline nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp1a2 nn substrate nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos theophylline nn
false	10	0	theophylline nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp1a2 nn substrate nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos theophylline nn
false	10	0	theophylline nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp1a2 nn substrate nn theophylline nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos theophylline nn
false	6	16	the dt effect nn of inpos theophylline nn on inpos the dt pharmacokinetics nns of inpos citalopram nn was vbd not rb evaluated vbn
false	0	12	warfarin nn hyph_administration nn of inpos num cd mg_day nn racemic jj citalopram nn for inpos num cd days nns did vbd not rb affect vb the dt pharmacokinetics nns of inpos warfarin nn a dt cyp3a4 nn substrate nn
false	12	0	warfarin nn hyph_administration nn of inpos num cd mg_day nn racemic jj citalopram nn for inpos num cd days nns did vbd not rb affect vb the dt pharmacokinetics nns of inpos warfarin nn a dt cyp3a4 nn substrate nn
false	0	10	carbamazepine nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc carbamazepine nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos carbamazepine nn a dt cyp3a4 nn substrate nn
false	10	0	carbamazepine nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc carbamazepine nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos carbamazepine nn a dt cyp3a4 nn substrate nn
false	10	0	carbamazepine nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc carbamazepine nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos carbamazepine nn a dt cyp3a4 nn substrate nn
false	4	24	although inpos trough jj citalopram nn plasma nn levels nns were vbd unaffected jj given vbn the dt enzyme_inducing jj properties nns of inpos carbamazepine nn the dt possibility nn that inpos carbamazepine nn might md increase vb the dt clearance nn of inpos escitalopram nn should md be vb considered vbn if inpos the dt num cd drugs nns are vbp coadministered vbn
false	4	24	although inpos trough jj citalopram nn plasma nn levels nns were vbd unaffected jj given vbn the dt enzyme_inducing jj properties nns of inpos carbamazepine nn the dt possibility nn that inpos carbamazepine nn might md increase vb the dt clearance nn of inpos escitalopram nn should md be vb considered vbn if inpos the dt num cd drugs nns are vbp coadministered vbn
false	24	44	although inpos trough jj citalopram nn plasma nn levels nns were vbd unaffected jj given vbn the dt enzyme_inducing jj properties nns of inpos carbamazepine nn the dt possibility nn that inpos carbamazepine nn might md increase vb the dt clearance nn of inpos escitalopram nn should md be vb considered vbn if inpos the dt num cd drugs nns are vbp coadministered vbn
mechanism	24	44	although inpos trough jj citalopram nn plasma nn levels nns were vbd unaffected jj given vbn the dt enzyme_inducing jj properties nns of inpos carbamazepine nn the dt possibility nn that inpos carbamazepine nn might md increase vb the dt clearance nn of inpos escitalopram nn should md be vb considered vbn if inpos the dt num cd drugs nns are vbp coadministered vbn
false	0	10	triazolam nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp3a4 nn substrate nn triazolam nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc triazolam nn
false	0	10	triazolam nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp3a4 nn substrate nn triazolam nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc triazolam nn
false	10	0	triazolam nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp3a4 nn substrate nn triazolam nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc triazolam nn
false	10	0	triazolam nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp3a4 nn substrate nn triazolam nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc triazolam nn
false	0	10	triazolam nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp3a4 nn substrate nn triazolam nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc triazolam nn
false	10	0	triazolam nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc the dt cyp3a4 nn substrate nn triazolam nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos either cc citalopram nn or cc triazolam nn
false	0	10	ketoconazole nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc ketoconazole nn decreased vbd the dt cmax nn and cc auc nn of inpos ketoconazole nn by inpos num cd and cc num cd respectively rb and cc did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos citalopram nn
false	0	10	ketoconazole nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc ketoconazole nn decreased vbd the dt cmax nn and cc auc nn of inpos ketoconazole nn by inpos num cd and cc num cd respectively rb and cc did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos citalopram nn
mechanism	10	0	ketoconazole nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc ketoconazole nn decreased vbd the dt cmax nn and cc auc nn of inpos ketoconazole nn by inpos num cd and cc num cd respectively rb and cc did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos citalopram nn
false	10	0	ketoconazole nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc ketoconazole nn decreased vbd the dt cmax nn and cc auc nn of inpos ketoconazole nn by inpos num cd and cc num cd respectively rb and cc did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos citalopram nn
false	0	10	ketoconazole nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc ketoconazole nn decreased vbd the dt cmax nn and cc auc nn of inpos ketoconazole nn by inpos num cd and cc num cd respectively rb and cc did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos citalopram nn
false	0	10	ketoconazole nn hyph_combined vbn administration nn of inpos racemic jj citalopram nn and cc ketoconazole nn decreased vbd the dt cmax nn and cc auc nn of inpos ketoconazole nn by inpos num cd and cc num cd respectively rb and cc did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos citalopram nn
false	0	40	ritonavir nn hyph_combined vbn administration nn of inpos a dt single jj dose nn of inpos ritonavir nn both cc a dt cyp3a4 nn substrate nn and cc a dt potent jj inhibitor nn of inpos cyp3a4 nn and cc escitalopram nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos either cc ritonavir nn or cc escitalopram nn
false	0	40	ritonavir nn hyph_combined vbn administration nn of inpos a dt single jj dose nn of inpos ritonavir nn both cc a dt cyp3a4 nn substrate nn and cc a dt potent jj inhibitor nn of inpos cyp3a4 nn and cc escitalopram nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos either cc ritonavir nn or cc escitalopram nn
false	0	40	ritonavir nn hyph_combined vbn administration nn of inpos a dt single jj dose nn of inpos ritonavir nn both cc a dt cyp3a4 nn substrate nn and cc a dt potent jj inhibitor nn of inpos cyp3a4 nn and cc escitalopram nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos either cc ritonavir nn or cc escitalopram nn
false	0	40	ritonavir nn hyph_combined vbn administration nn of inpos a dt single jj dose nn of inpos ritonavir nn both cc a dt cyp3a4 nn substrate nn and cc a dt potent jj inhibitor nn of inpos cyp3a4 nn and cc escitalopram nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos either cc ritonavir nn or cc escitalopram nn
false	40	0	ritonavir nn hyph_combined vbn administration nn of inpos a dt single jj dose nn of inpos ritonavir nn both cc a dt cyp3a4 nn substrate nn and cc a dt potent jj inhibitor nn of inpos cyp3a4 nn and cc escitalopram nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos either cc ritonavir nn or cc escitalopram nn
false	0	40	ritonavir nn hyph_combined vbn administration nn of inpos a dt single jj dose nn of inpos ritonavir nn both cc a dt cyp3a4 nn substrate nn and cc a dt potent jj inhibitor nn of inpos cyp3a4 nn and cc escitalopram nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos either cc ritonavir nn or cc escitalopram nn
false	6	10	however rb coadministration nn of inpos escitalopram nn and cc ritonavir nn a dt potent jj inhibitor nn of inpos cyp3a4 nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos escitalopram nn
false	10	6	however rb coadministration nn of inpos escitalopram nn and cc ritonavir nn a dt potent jj inhibitor nn of inpos cyp3a4 nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos escitalopram nn
false	28	42	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
false	28	44	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
false	28	44	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
false	28	42	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
mechanism	28	44	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
false	28	44	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
false	42	44	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
false	42	44	however rb there ex are vbp limited vbn in fw vivo fw data nns suggesting vbg a dt modest jj cyp2d6 nn inhibitory jj effect nn for inpos escitalopram nn i.e. fw coadministration nn of inpos escitalopram nn with inpos the dt tricyclic_antidepressant nn desipramine nn a dt substrate nn for inpos cyp2d6 nn resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc a dt num cd increase nn in inpos auc nn of inpos desipramine nn
false	0	10	metoprolol nn hyph_administration nn of inpos num cd mg_day nn lexapro nn for inpos num cd days nns in inpos healthy jj volunteers nns resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc num cd increase nn in inpos auc nn of inpos the dt b_adrenergic_blocker nn metoprolol nn
false	0	52	metoprolol nn hyph_administration nn of inpos num cd mg_day nn lexapro nn for inpos num cd days nns in inpos healthy jj volunteers nns resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc num cd increase nn in inpos auc nn of inpos the dt b_adrenergic_blocker nn metoprolol nn
false	10	52	metoprolol nn hyph_administration nn of inpos num cd mg_day nn lexapro nn for inpos num cd days nns in inpos healthy jj volunteers nns resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc num cd increase nn in inpos auc nn of inpos the dt b_adrenergic_blocker nn metoprolol nn
mechanism	10	0	metoprolol nn hyph_administration nn of inpos num cd mg_day nn lexapro nn for inpos num cd days nns in inpos healthy jj volunteers nns resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc num cd increase nn in inpos auc nn of inpos the dt b_adrenergic_blocker nn metoprolol nn
false	52	0	metoprolol nn hyph_administration nn of inpos num cd mg_day nn lexapro nn for inpos num cd days nns in inpos healthy jj volunteers nns resulted vbd in inpos a dt num cd increase nn in inpos cmax nn and cc num cd increase nn in inpos auc nn of inpos the dt b_adrenergic_blocker nn metoprolol nn
false	4	8	coadministration nn of inpos lexapro nn and cc metoprolol nn had vbd no dt clinically rb significant jj effects nns on inpos blood nn pressure nn or cc heart nn rate nn
false	8	28	concomitant jj administration nn with inpos racemic jj citalopram nn citalopram nn since inpos escitalopram nn is vbz the dt active jj isomer nn of inpos racemic jj celexa nn the dt num cd agents nns should md not rb be vb coadministered vbn
false	8	28	concomitant jj administration nn with inpos racemic nnp citalopram nnp citalopram nn hyph_since inpos escitalopram nn is vbz the dt active jj isomer nn of inpos racemic jj celexa nn the dt num cd agents nns should md not rb be vb coadministered vbn
advise	14	28	concomitant jj administration nn with inpos racemic nnp citalopram nnp citalopram nnp since inpos escitalopram nn is vbz the dt active jj isomer nn of inpos racemic jj celexa nn the dt num cd agents nns should md not rb be vb coadministered vbn
effect	6	24	catecholamine_depleting jj drugs nns e.g. fw reserpine nn may md have vb an dt additive jj effect nn when wrb given vbn with inpos b_blocking_agents nn
false	10	14	a dt study nn of inpos interaction nn between inpos brevibloc nn and cc warfarin nn showed vbd that inpos concomitant jj administration nn of inpos brevibloc nn and cc warfarin nn does vbz not rb alter vb warfarin nn plasma nn levels nns
false	10	14	a dt study nn of inpos interaction nn between inpos brevibloc nn and cc warfarin nn showed vbd that inpos concomitant jj administration nn of inpos brevibloc nn and cc warfarin nn does vbz not rb alter vb warfarin nn plasma nn levels nns
false	10	14	a dt study nn of inpos interaction nn between inpos brevibloc nn and cc warfarin nn showed vbd that inpos concomitant jj administration nn of inpos brevibloc nn and cc warfarin nn does vbz not rb alter vb warfarin nn plasma nn levels nns
false	14	10	a dt study nn of inpos interaction nn between inpos brevibloc nn and cc warfarin nn showed vbd that inpos concomitant jj administration nn of inpos brevibloc nn and cc warfarin nn does vbz not rb alter vb warfarin nn plasma nn levels nns
false	10	14	a dt study nn of inpos interaction nn between inpos brevibloc nn and cc warfarin nn showed vbd that inpos concomitant jj administration nn of inpos brevibloc nn and cc warfarin nn does vbz not rb alter vb warfarin nn plasma nn levels nns
false	10	14	a dt study nn of inpos interaction nn between inpos brevibloc nn and cc warfarin nn showed vbd that inpos concomitant jj administration nn of inpos brevibloc nn and cc warfarin nn does vbz not rb alter vb warfarin nn plasma nn levels nns
mechanism	0	16	brevibloc nn concentrations nns were vbd equivocally rb higher jjr when wrb given vbn with inpos warfarin nn but cc this dt is vbz not rb likely jj to topos be vb clinically rb important jj
mechanism	2	6	when wrb digoxin nn and cc brevibloc nn were vbd concomitantly rb administered vbn intravenously rb to topos normal jj volunteers nns there ex was vbd a dt num cd increase nn in inpos digoxin nn blood nn levels nns at inpos some dt time nn points nns
false	6	2	when wrb digoxin nn and cc brevibloc nn were vbd concomitantly rb administered vbn intravenously rb to topos normal jj volunteers nns there ex was vbd a dt num cd increase nn in inpos digoxin nn blood nn levels nns at inpos some dt time nn points nns
false	0	8	digoxin nn did vbd not rb affect vb brevibloc nn pharmacokinetics nns
false	4	8	when wrb intravenous jj morphine nn and cc brevibloc nn were vbd concomitantly rb administered vbn in inpos normal jj subjects nns no dt effect nn on inpos morphine nn blood nn levels nns was vbd seen vbn but cc brevibloc nn steady_state jj blood nn levels nns were vbd increased vbn by inpos num cd in inpos the dt presence nn of inpos morphine nn
false	4	8	when wrb intravenous jj morphine nn and cc brevibloc nn were vbd concomitantly rb administered vbn in inpos normal jj subjects nns no dt effect nn on inpos morphine nn blood nn levels nns was vbd seen vbn but cc brevibloc nn steady_state jj blood nn levels nns were vbd increased vbn by inpos num cd in inpos the dt presence nn of inpos morphine nn
false	8	4	when wrb intravenous jj morphine nn and cc brevibloc nn were vbd concomitantly rb administered vbn in inpos normal jj subjects nns no dt effect nn on inpos morphine nn blood nn levels nns was vbd seen vbn but cc brevibloc nn steady_state jj blood nn levels nns were vbd increased vbn by inpos num cd in inpos the dt presence nn of inpos morphine nn
false	8	4	when wrb intravenous jj morphine nn and cc brevibloc nn were vbd concomitantly rb administered vbn in inpos normal jj subjects nns no dt effect nn on inpos morphine nn blood nn levels nns was vbd seen vbn but cc brevibloc nn steady_state jj blood nn levels nns were vbd increased vbn by inpos num cd in inpos the dt presence nn of inpos morphine nn
false	4	8	when wrb intravenous jj morphine nn and cc brevibloc nn were vbd concomitantly rb administered vbn in inpos normal jj subjects nns no dt effect nn on inpos morphine nn blood nn levels nns was vbd seen vbn but cc brevibloc nn steady_state jj blood nn levels nns were vbd increased vbn by inpos num cd in inpos the dt presence nn of inpos morphine nn
mechanism	8	4	when wrb intravenous jj morphine nn and cc brevibloc nn were vbd concomitantly rb administered vbn in inpos normal jj subjects nns no dt effect nn on inpos morphine nn blood nn levels nns was vbd seen vbn but cc brevibloc nn steady_state jj blood nn levels nns were vbd increased vbn by inpos num cd in inpos the dt presence nn of inpos morphine nn
false	6	16	the dt effect nn of inpos brevibloc nn on inpos the dt duration nn of inpos succinylcholine nn induced jj neuromuscular jj blockade nn was vbd studied vbn in inpos patients nns undergoing vbg surgery nn
effect	12	20	the dt onset nn of inpos neuromuscular jj blockade nn by inpos succinylcholine nn was vbd unaffected jj by inpos brevibloc nn but cc the dt duration nn of inpos neuromuscular jj blockade nn was vbd prolonged vbn from inpos num cd minutes nns to topos num cd minutes nns
advise	32	56	although inpos the dt interactions nns observed vbn in inpos these dt studies nns do vbp not rb appear vb to topos be vb of inpos major jj clinical jj importance nn brevibloc nn should md be vb titrated vbn with inpos caution nn in inpos patients nns being vbg treated vbn concurrently rb with inpos digoxin nn
advise	32	56	although inpos the dt interactions nns observed vbn in inpos these dt studies nns do vbp not rb appear vb to topos be vb of inpos major jj clinical jj importance nn brevibloc nn should md be vb titrated vbn with inpos caution nn in inpos patients nns being vbg treated vbn concurrently rb with inpos morphine nn
advise	32	56	although inpos the dt interactions nns observed vbn in inpos these dt studies nns do vbp not rb appear vb to topos be vb of inpos major jj clinical jj importance nn brevibloc nn should md be vb titrated vbn with inpos caution nn in inpos patients nns being vbg treated vbn concurrently rb with inpos succinylcholine nn
advise	32	56	although inpos the dt interactions nns observed vbn in inpos these dt studies nns do vbp not rb appear vb to topos be vb of inpos major jj clinical jj importance nn brevibloc nn should md be vb titrated vbn with inpos caution nn in inpos patients nns being vbg treated vbn concurrently rb with inpos warfarin nn
advise	18	22	caution nn should md be vb exercised vbn when wrb considering vbg the dt use nn of inpos brevibloc nn and cc verapamil nn in inpos patients nns with inpos depressed jj myocardial jj function nn
advise	2	44	additionally rb brevibloc nn should md not rb be vb used vbn to topos control vb supraventricular jj tachycardia nn in inpos the dt presence nn of inpos agents nns which wdt are vbp vasoconstrictive jj and cc inotropic jj such jj as inpos dopamine nn because inpos of inpos the dt danger nn of inpos blocking vbg cardiac jj contractility nn when wrb systemic jj vascular jj resistance nn is vbz high jj
advise	2	44	additionally rb brevibloc nn should md not rb be vb used vbn to topos control vb supraventricular jj tachycardia nn in inpos the dt presence nn of inpos agents nns which wdt are vbp vasoconstrictive jj and cc inotropic jj such jj as inpos epinephrine nn because inpos of inpos the dt danger nn of inpos blocking vbg cardiac jj contractility nn when wrb systemic jj vascular jj resistance nn is vbz high jj
advise	2	44	additionally rb brevibloc nn should md not rb be vb used vbn to topos control vb supraventricular jj tachycardia nn in inpos the dt presence nn of inpos agents nns which wdt are vbp vasoconstrictive jj and cc inotropic jj such jj as inpos norepinephrine nn because inpos of inpos the dt danger nn of inpos blocking vbg cardiac jj contractility nn when wrb systemic jj vascular jj resistance nn is vbz high jj
false	12	30	drug nn interaction nn studies nns have vbp shown vbn that inpos esomeprazole nn does vbz not rb have vb any dt clinically rb significant jj interactions nns with inpos phenytoin nn
false	12	30	drug nn interaction nn studies nns have vbp shown vbn that inpos esomeprazole nn does vbz not rb have vb any dt clinically rb significant jj interactions nns with inpos warfarin nn
false	12	30	drug nn interaction nn studies nns have vbp shown vbn that inpos esomeprazole nn does vbz not rb have vb any dt clinically rb significant jj interactions nns with inpos quinidine nn
false	12	30	drug nn interaction nn studies nns have vbp shown vbn that inpos esomeprazole nn does vbz not rb have vb any dt clinically rb significant jj interactions nns with inpos clarithromycin nn
false	12	30	drug nn interaction nn studies nns have vbp shown vbn that inpos esomeprazole nn does vbz not rb have vb any dt clinically rb significant jj interactions nns with inpos amoxicillin nn
false	28	32	post_marketing jj reports nns of inpos changes nns in inpos prothrombin nn measures nns have vbp been vbn received vbn among inpos patients nns on inpos concomitant jj warfarin nn and cc esomeprazole nn therapy nn
effect	6	10	patients nns treated vbn with inpos proton_pump_inhibitors nn and cc warfarin nn concomitantly rb may md need vb to topos be vb monitored vbn for inpos increases nns in inpos inr nn and cc prothrombin nn time nn
mechanism	4	12	coadministration nn of inpos esomeprazole nn num cd mg nn and cc diazepam nn a dt cyp2c19 nn substrate nn resulted vbd in inpos a dt num cd decrease nn in inpos clearance nn of inpos diazepam nn
false	4	12	coadministration nn of inpos esomeprazole nn num cd mg nn and cc diazepam nn a dt cyp2c19 nn substrate nn resulted vbd in inpos a dt num cd decrease nn in inpos clearance nn of inpos diazepam nn
mechanism	2	34	therefore rb esomeprazole nn may md interfere vb with inpos the dt absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos ketoconazole nn
mechanism	2	34	therefore rb esomeprazole nn may md interfere vb with inpos the dt absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos iron nn
mechanism	2	34	therefore rb esomeprazole nn may md interfere vb with inpos the dt absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos digoxin nn
false	6	26	coadministration nn of inpos oral jj contraceptives nn did vbd not rb seem vb to topos change vb the dt pharmacokinetic jj profile nn of inpos esomeprazole nn
false	8	28	coadministration nn of inpos oral jj contraceptives nns diazepam nn did vbd not rb seem vb to topos change vb the dt pharmacokinetic jj profile nn of inpos esomeprazole nn
false	8	28	coadministration nn of inpos oral jj contraceptives nns phenytoin nn did vbd not rb seem vb to topos change vb the dt pharmacokinetic jj profile nn of inpos esomeprazole nn
false	8	28	coadministration nn of inpos oral jj contraceptives nns quinidine nn did vbd not rb seem vb to topos change vb the dt pharmacokinetic jj profile nn of inpos esomeprazole nn
advise	6	10	concomitant jj administration nn of inpos clarithromycin nn with inpos pimozide nn is vbz contraindicated vbn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos anticonvulsants nns other jj drugs nns that wdt produce vbp cns nn depression nn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos antihistamines nns other jj drugs nns that wdt produce vbp cns nn depression nn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos alcohol nns other jj drugs nns that wdt produce vbp cns nn depression nn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos barbiturates nns other jj drugs nns that wdt produce vbp cns nn depression nn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos monoamine_oxidase_inhibitors nns other jj drugs nns that wdt produce vbp cns nn depression nn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos narcotics nns other jj drugs nns that wdt produce vbp cns nn depression nn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos phenothiazines nns other jj drugs nns that wdt produce vbp cns nn depression nn
effect	8	18	the dt action nn of inpos the dt benzodiazepines nn may md be vb potentiated vbn by inpos psychotropic_medications nn other jj drugs nns that wdt produce vbp cns nn depression nn
mechanism	20	40	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn carbamazepine nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
mechanism	20	40	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn phenytoin nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
mechanism	20	40	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn rifampin nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
mechanism	20	40	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn barbiturates nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
false	40	20	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn carbamazepine nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
false	40	20	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn phenytoin nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
false	40	20	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn rifampin nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
false	40	20	while inpos no dt in fw vivo fw drug_drug jj interaction nn studies nns were vbd conducted vbn between inpos estazolam nn and cc inducers nns of inpos cyp3a nn compounds nns that wdt are vbp potent jj cyp3a nn barbiturates nn would md be vb expected vbn to topos decrease vb estazolam nn concentrations nns
false	6	30	the dt metabolism nn of inpos estazolam nn to topos the dt major jj circulating vbg metabolite nn num_hydroxy_estazolam nn and cc the dt metabolism nn of inpos other jj triazolobenzodiazepines nn is vbz catalyzed vbn by inpos cyp3a nn
false	18	30	the dt metabolism nn of inpos estazolam nn to topos the dt major jj circulating vbg metabolite nn num_hydroxy_estazolam nn and cc the dt metabolism nn of inpos other jj triazolobenzodiazepines nn is vbz catalyzed vbn by inpos cyp3a nn
advise	2	16	consequently rb estazolam nn should md be vb avoided vbn in inpos patients nns receiving vbg ketoconazole nn and cc itraconazole nn which wdt are vbp very rb potent jj inhibitors nns of inpos cyp3a nn
advise	2	20	consequently rb estazolam nn should md be vb avoided vbn in inpos patients nns receiving vbg ketoconazole nn and cc itraconazole nn which wdt are vbp very rb potent jj inhibitors nns of inpos cyp3a nn
false	16	20	consequently rb estazolam nn should md be vb avoided vbn in inpos patients nns receiving vbg ketoconazole nn and cc itraconazole nn which wdt are vbp very rb potent jj inhibitors nns of inpos cyp3a nn
mechanism	28	40	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nn presumably rb through inpos inhibition nn of inpos cyp3a nn nefazodone nn some dt macrolide_antibiotics nns
mechanism	28	40	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nn presumably rb through inpos inhibition nn of inpos cyp3a nn fluvoxamine nn some dt macrolide_antibiotics nns
mechanism	28	40	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nn presumably rb through inpos inhibition nn of inpos cyp3a nn cimetidine nn some dt macrolide_antibiotics nns
mechanism	28	40	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nn presumably rb through inpos inhibition nn of inpos cyp3a nn diltiazem nn some dt macrolide_antibiotics nns
mechanism	28	40	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nn presumably rb through inpos inhibition nn of inpos cyp3a nn isoniazide nn some dt macrolide_antibiotics nns
mechanism	28	52	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nn presumably rb through inpos inhibition nn of inpos cyp3a nn nefazodone nn fluvoxamine nn cimetidine nn diltiazem nn isoniazide nn some dt macrolide_antibiotics nn
false	40	44	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nns presumably rb through inpos inhibition nn of inpos cyp3a nn nefazodone nn some dt macrolide_antibiotics nn
false	40	44	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nns presumably rb through inpos inhibition nn of inpos cyp3a nn fluvoxamine nn some dt macrolide_antibiotics nn
false	40	44	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nns presumably rb through inpos inhibition nn of inpos cyp3a nn cimetidine nn some dt macrolide_antibiotics nn
false	40	44	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nns presumably rb through inpos inhibition nn of inpos cyp3a nn diltiazem nn some dt macrolide_antibiotics nn
false	40	44	the dt following vbg are vbp examples nns of inpos drugs nns known vbn to topos inhibit vb the dt metabolism nn of inpos other jj related jj benzodiazepines nns presumably rb through inpos inhibition nn of inpos cyp3a nn isoniazide nn some dt macrolide_antibiotics nn
false	20	36	a dt multiple_dose jj study nn was vbd conducted vbn to topos assess vb the dt effect nn of inpos fluoxetine nn num cd mg nn bid nn on inpos the dt pharmacokinetics nns of inpos estazolam nn num cd mg nn qhs nn after inpos num cd days nns
false	6	18	the dt pharmacokinetics nns of inpos estazolam nn were vbd not rb affected vbn during inpos multiple_dose jj fluoxetine nn suggesting vbg no dt clinically rb significant jj pharmacokinetic jj interaction nn
false	40	44	other jj binding nn proteins nns may md be vb elevated vbn in inpos serum nn i.e. fw corticosteroid nn binding nn globulin nn sex nn hormone_binding jj globulin nn leading vbg to topos increased vbn total jj circulating vbg corticosteroids nn and cc sex_steroids nn respectively rb
mechanism	6	24	milk nn milk nn products nns calcium nn rich jj foods nns drugs nns may md impair vb the dt absorption nn of inpos emcyt nn
false	4	28	cns_active jj drugs nns ethanol nn an dt additive jj effect nn on inpos psychomotor nn performance nn was vbd seen vbn with inpos coadministration nn of inpos eszopiclone nn and cc ethanol nn float cd g_kg nn for inpos up inpos to topos num cd hours nns after inpos ethanol nn administration nn
effect	28	4	cns_active jj drugs nns ethanol nn an dt additive jj effect nn on inpos psychomotor nn performance nn was vbd seen vbn with inpos coadministration nn of inpos eszopiclone nn and cc ethanol nn float cd g_kg nn for inpos up inpos to topos num cd hours nns after inpos ethanol nn administration nn
false	28	4	cns_active jj drugs nns ethanol nn an dt additive jj effect nn on inpos psychomotor nn performance nn was vbd seen vbn with inpos coadministration nn of inpos eszopiclone nn and cc ethanol nn float cd g_kg nn for inpos up inpos to topos num cd hours nns after inpos ethanol nn administration nn
false	0	12	paroxetine nn coadministration nn of inpos single jj doses nns of inpos eszopiclone nn num cd mg nn and cc paroxetine nn num cd mg nn daily rb for inpos num cd days nns produced vbd no dt pharmacokinetic jj or cc pharmacodynamic jj interaction nn
false	10	18	coadministration nn of inpos single jj doses nns of inpos eszopiclone nn num cd mg nn and cc paroxetine nn num cd mg nn daily rb for inpos num cd days nns produced vbd no dt pharmacokinetic jj or cc pharmacodynamic jj interaction nn
false	0	12	lorazepam nn coadministration nn of inpos single jj doses nns of inpos eszopiclone nn num cd mg nn and cc lorazepam nn num cd mg nn did vbd not rb have vb clinically rb relevant jj effects nns on inpos the dt pharmacodynamics nns or cc pharmacokinetics nns of inpos either dt drug nn
false	10	18	coadministration nn of inpos single jj doses nns of inpos eszopiclone nn num cd mg nn and cc lorazepam nn num cd mg nn did vbd not rb have vb clinically rb relevant jj effects nns on inpos the dt pharmacodynamics nns or cc pharmacokinetics nns of inpos either dt drug nn
false	0	6	olanzapine nn coadministration nn of inpos eszopiclone nn num cd mg nn and cc olanzapine nn num cd mg nn produced vbd a dt decrease nn in inpos dsst nn scores nns
effect	4	12	coadministration nn of inpos eszopiclone nn num cd mg nn and cc olanzapine nn num cd mg nn produced vbd a dt decrease nn in inpos dsst nn scores nns
false	6	26	drugs nns that wdt inhibit vbp ketoconazole nn cyp3a4 nn is vbz a dt major jj metabolic jj pathway nn for inpos elimination nn of inpos eszopiclone nn
mechanism	6	20	the dt auc nn of inpos eszopiclone nn was vbd increased vbn float_fold rb by inpos coadministration nn of inpos ketoconazole nn a dt potent jj inhibitor nn of inpos cyp3a4 nn num cd mg nn daily rb for inpos num cd days nns
false	6	10	drugs nns that dt induce nnp rifampicin nn racemic jj zopiclone nn exposure nn was vbd decreased vbn num cd by inpos concomitant jj useof nn rifampicin nn a dt potent jj inducer nn of inpos cyp3a4 nn
mechanism	10	26	drugs nns that dt induce nnp cyp3a4 nn racemic jj zopiclone nn exposure nn was vbd decreased vbn num cd by inpos concomitant jj useof nn rifampicin nn a dt potent jj inducer nn of inpos cyp3a4 nn
false	12	22	drugs nns with inpos a nnp narrow nnp therapeutic nnp index nnp digoxin nn a nn single jj dose nn of inpos eszopiclone nn num cd mg nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos digoxin nn measured vbn at inpos steady jj state nn following vbg dosing nn of inpos float cd mg nn twice rb daily rb for inpos num cd day nn and cc float cd mg nn daily rb for inpos the dt next jj num cd days nns
false	22	12	drugs nns with inpos a nnp narrow nnp therapeutic nnp index nnp digoxin nnp a dt single jj dose nn of inpos eszopiclone nn num cd mg nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos digoxin nn measured vbn at inpos steady jj state nn following vbg dosing nn of inpos float cd mg nn twice rb daily rb for inpos num cd day nn and cc float cd mg nn daily rb for inpos the dt next jj num cd days nns
false	0	6	eszopiclone nn num cd mg nn administered vbn daily rb for inpos num cd days nns did vbd not rb affect vb the dt pharmacokinetics nns of inpos r nn or cc following vbg a dt single jj num cd mg nn oral jj dose nn of inpos warfarin nn
false	0	26	eszopiclone nn num cd mg nn administered vbn daily rb for inpos num cd days nns did vbd not rb affect vb the dt pharmacokinetics nns s_warfarin_nn nn nor cc were vbd there rb any dt changes nns in inpos the dt pharmacodynamic jj profile nn lrb_prothrombin nn time nn rrb_following vbg a dt single jj num cd mg nn oral jj dose nn of inpos warfarin nn
false	0	48	eszopiclone nn num cd mg nn administered vbn daily rb for inpos num cd days nns did vbd not rb affect vb the dt pharmacokinetics nns of_r nn or cc following vbg a dt single jj num cd mg nn oral jj dose nn of inpos w nn arfarin nn
false	6	34	eszopiclone nn num cd mg nn administered vbn daily rb for inpos num cd days nns did vbd not rb affect vb the dt pharmacokinetics nns of inpos r nn lrb_s jj bbbbb12_warfarin_eeeee12 nn s_warfarin_nn nn nor cc were vbd there rb any dt changes nns in inpos the dt pharmacodynamic jj profile nn lrb_prothrombin nn time nn rrb_following vbg a dt single jj num cd mg nn oral jj dose nn of inpos warfarin nn
false	6	50	eszopiclone nn num cd mg nn administered vbn daily rb for inpos num cd days nns did vbd not rb affect vb the dt pharmacokinetics nns of inpos r nn or cc following vbg a dt single jj num cd mg nn oral jj dose nn of inpos w nn arfarin nn
false	16	26	however rb it prp was vbd observed vbn that inpos the dt pharmacokinetics nns of inpos enbrel nn was vbd unaltered jj by inpos concomitant jj methotrexate nn in inpos rheumatoid jj arthritis nn patients nns
effect	36	40	in inpos a dt study nn in inpos which wdt patients nns with inpos active jj ra nn were vbd treated vbn for inpos up rb to topos num cd weeks nns with inpos concurrent jj enbrel nn and cc anakinra nn therapy nn a dt num cd rate nn of inpos serious jj infections nns was vbd observed vbn which wdt was vbd higher jjr than inpos that dt observed vbn with inpos enbrel nn alone rb
false	40	36	in inpos a dt study nn in inpos which wdt patients nns with inpos active jj ra nn were vbd treated vbn for inpos up rb to topos num cd weeks nns with inpos concurrent jj enbrel nn and cc anakinra nn therapy nn a dt num cd rate nn of inpos serious jj infections nns was vbd observed vbn which wdt was vbd higher jjr than inpos that dt observed vbn with inpos enbrel nn alone rb
effect	14	18	num cd percent nn of inpos patients nns treated vbn concurrently rb with inpos enbrel nn and cc anakinra nn developed vbd neutropenia nn
effect	22	28	patients nns in inpos a dt clinical jj study nn who wp were vbd on inpos established vbn therapy nn with inpos sulfasalazine nn to topos which wdt enbrel nn was vbd added vbn were vbd noted vbn to topos develop vb a dt mild jj decrease nn in inpos mean jj neutrophil nn counts nns in inpos comparison nn to topos groups nns treated vbn with inpos either cc enbrel nn ci nn or cc sulfasalazine nn alone rb
false	22	28	patients nns in inpos a dt clinical jj study nn who wp were vbd on inpos established vbn therapy nn with inpos sulfasalazine nn to topos which wdt enbrel nn was vbd added vbn were vbd noted vbn to topos develop vb a dt mild jj decrease nn in inpos mean jj neutrophil nn counts nns in inpos comparison nn to topos groups nns treated vbn with inpos either cc enbrel nn ci nn or cc sulfasalazine nn alone rb
false	28	22	patients nns in inpos a dt clinical jj study nn who wp were vbd on inpos established vbn therapy nn with inpos sulfasalazine nn to topos which wdt enbrel nn was vbd added vbn were vbd noted vbn to topos develop vb a dt mild jj decrease nn in inpos mean jj neutrophil nn counts nns in inpos comparison nn to topos groups nns treated vbn with inpos either cc enbrel nn ci nn or cc sulfasalazine nn alone rb
false	28	22	patients nns in inpos a dt clinical jj study nn who wp were vbd on inpos established vbn therapy nn with inpos sulfasalazine nn to topos which wdt enbrel nn was vbd added vbn were vbd noted vbn to topos develop vb a dt mild jj decrease nn in inpos mean jj neutrophil nn counts nns in inpos comparison nn to topos groups nns treated vbn with inpos either cc enbrel nn ci nn or cc sulfasalazine nn alone rb
mechanism	0	14	lithium nn generally rb should md not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp its prp renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
false	14	0	lithium nn generally rb should md not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp its prp renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
effect	0	22	edecrin nn may md increase vb the dt ototoxic jj potential nn of inpos other jj drugs nns such jj as inpos aminoglycoside nn and cc some dt cephalosporin_antibiotics nns
effect	0	28	edecrin nn may md increase vb the dt ototoxic jj potential nn of inpos other jj drugs nns such jj as inpos aminoglycoside nn and cc some dt cephalosporin_antibiotics nn
false	22	28	edecrin nn may md increase vb the dt ototoxic jj potential nn of inpos other jj drugs nns such jj as inpos aminoglycoside nn and cc some dt cephalosporin_antibiotics nn
mechanism	10	22	a dt number nn of inpos drugs nns including vbg ethacrynic_acid nn have vbp been vbn shown vbn to topos displace vb warfarin nn from inpos plasma nn protein nn
effect	14	22	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_antiinflammatory_agent nn can md reduce vb the dt loop nn
effect	14	22	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_antiinflammatory_agent nn can md reduce vb the dt potassium_sparing nn
effect	14	22	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_antiinflammatory_agent nn can md reduce vb the dt thiazide_diuretics nn
false	32	38	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_antiinflammatory_agent jj can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
false	34	38	in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_antiinflammatory_agent jj can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
effect	4	8	therefore rb when wrb edecrin nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic jj is vbz obtained vbn
false	4	44	therefore rb when wrb edecrin nn and cc non_steroidal_anti_inflammatory_agents nns are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
false	8	44	therefore rb when wrb edecrin nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
mechanism	16	22	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nns
false	16	26	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nns
false	16	98	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nn
false	22	26	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nns
false	22	16	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nns
false	22	16	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nns
false	22	98	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nn
false	26	16	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nns
false	26	16	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nns
false	16	98	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nn
false	16	98	the dt results nns of inpos a dt study nn of inpos coadministration nn of inpos ethambutol nn with inpos an dt aluminum_hydroxide nn containing vbg antacid nn to topos num cd patients nns with inpos tuberculosis nn showed vbd a dt reduction nn of inpos mean jj serum nn concentrations nns and cc urinary jj excretion nn of inpos ethambutol nn of inpos approximately rb num cd and cc num cd respectively rb suggesting vbg that inpos the dt oral jj absorption nn of inpos ethambutol nn may md be vb reduced vbn by inpos these dt antacid_products nn
advise	16	20	it prp is vbz recommended vbn to topos avoid vb concurrent jj administration nn of inpos ethambutol nn with inpos aluminum_hydroxide nn containing vbg antacids nns for inpos at inpos least jjs num cd hours nns following vbg ethambutol nn administration nn
false	16	24	it prp is vbz recommended vbn to topos avoid vb concurrent jj administration nn of inpos ethambutol nn with inpos aluminum_hydroxide nn containing vbg antacids nn for inpos at inpos least jjs num cd hours nns following vbg ethambutol nn administration nn
false	20	24	it prp is vbz recommended vbn to topos avoid vb concurrent jj administration nn of inpos ethambutol nn with inpos aluminum_hydroxide nn containing vbg antacids nn for inpos at inpos least jjs num cd hours nns following vbg ethambutol nn administration nn
false	20	16	it prp is vbz recommended vbn to topos avoid vb concurrent jj administration nn of inpos ethambutol nn with inpos aluminum_hydroxide nn containing vbg antacids nns for inpos at inpos least jjs num cd hours nns following vbg ethambutol nn administration nn
false	24	16	it prp is vbz recommended vbn to topos avoid vb concurrent jj administration nn of inpos ethambutol nn with inpos aluminum_hydroxide nn containing vbg antacids nn for inpos at inpos least jjs num cd hours nns following vbg ethambutol nn administration nn
false	0	4	dicumarol nn and cc warfarin nn may md decrease vb hypoprothrombinemic jj effect nn
effect	8	24	other jj depressasnts nns such jj as inpos alcohol nns may md enhance vb cns nn depression nn when wrb administered vbn with inpos ethchlorvynol nn
effect	8	24	other jj depressasnts nns such jj as inpos barbiturates nns may md enhance vb cns nn depression nn when wrb administered vbn with inpos ethchlorvynol nn
effect	8	24	other jj depressasnts nns such jj as inpos maois nn may md enhance vb cns nn depression nn when wrb administered vbn with inpos ethchlorvynol nn
false	12	18	may md interact vb with inpos addictive jj medications nns especially rb central_nervous_system_cns_depressants nn with inpos habituating vbg alcohol nn depression nn producing vbg medications nns
false	12	56	may md interact vbp with inpos addictive jj medications nns especially rb central_nervous_system_cns_depressants nn with inpos habituating vbg potential nn alcohol nn cns nn depression nn producing vbg medications nns lrb_concurrent jj use nn may md increase vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc ethinamate nn
false	20	58	may md interact vbp with inpos addictive jj medications nns especially rb central_nervous_system_cns_depressants nns with inpos habituating vbg potential nn alcohol nn or cc cns nn depression nn producing vbg medications nns lrb_concurrent jj use nn may md increase vb the dt cns nn depressant jj effects nns of inpos either dt these dt medications nns or cc ethinamate nn
false	20	26	certain jj endocrine nn and cc liver nn function nn tests nns may md be vb affected vbn by inpos estrogen nn containing jj oral jj contraceptives nn
mechanism	0	20	trecator nn has vbz been vbn found vbn to topos temporarily rb raise vb serum nn concentrations nns of inpos isoniazid nn
effect	0	16	trecator nn may md potentiate vb the dt adverse jj effects nns of inpos other jj antituberculous_drugs nn administered vbn concomitantly rb
effect	14	22	in inpos particular jj convulsions nns have vbp been vbn reported vbn when wrb ethionamide nn is vbz administered vbn with inpos cycloserine nn and cc special jj care nn should md be vb taken vbn when wrb the dt treatment nn regimen nn includes vbz both dt of inpos these dt drugs nns
effect	0	8	ethopropazine nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nns causing vbg increased vbn sedative jj effects nns
effect	0	14	ethopropazine nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nn causing vbg increased vbn sedative jj effects nns
false	8	14	ethopropazine nn may md interact vb with inpos alcohol nn or cc other jj cns_depressants nn causing vbg increased vbn sedative jj effects nns
mechanism	0	8	ethopropazine nn can md interact vb with inpos chlorpromazine nn increasing vbg the dt metabolism nn of inpos chlorpromazine nn
false	0	8	ethopropazine nn can md interact vb with inpos chlorpromazine nn increasing vbg the dt metabolism nn of inpos chlorpromazine nn
int	2	14	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj
false	2	38	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	2	44	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	2	52	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	2	38	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
int	2	14	since inpos ethosuximide nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj
false	2	44	since inpos ethosuximide nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	2	52	since inpos ethosuximide nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nns periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	14	38	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	14	44	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	14	52	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	14	38	since inpos zarontin nn may md interact vb with inpos concurrently rb administered vbn antiepileptic_drugs nn periodic jj serum nn level nn determinations nns of inpos these dt drugs nns may md be vb necessary jj lrb_eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
mechanism	4	10	since inpos eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	4	18	since inpos eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	10	18	since inpos eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
false	10	4	since inpos eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
mechanism	18	4	since inpos eg fw ethosuximide nn may md elevate vb phenytoin nn serum nn levels nns and cc valproic_acid nn has vbz been vbn reported vbn to topos both cc increase vb and cc decrease vb ethosuximide nn levels nns
advise	12	22	considerable jj caution nn should md be vb exercised vbn if inpos peganone nn is vbz administered vbn concurrently rb with inpos phenurone nn since inpos paranoid jj symptoms nns have vbp been vbn reported vbn during inpos therapy nn with inpos this dt combination nn
advise	12	22	considerable jj caution nn should md be vb exercised vbn if inpos peganone nn is vbz administered vbn concurrently rb with inpos phenacemide nn since inpos paranoid jj symptoms nns have vbp been vbn reported vbn during inpos therapy nn with inpos this dt combination nn
int	10	12	a dt two_way jj interaction nn between inpos the dt hydantoin_antiepileptic nn phenytoin nn and cc the dt coumarin_anticoagulants nns has vbz been vbn suggested vbn
int	10	18	a dt two_way jj interaction nn between inpos the dt hydantoin_antiepileptic nn phenytoin nn and cc the dt coumarin_anticoagulant nn s nn has vbz been vbn suggested vbn
false	12	18	a dt two_way jj interaction nn between inpos the dt hydantoin_antiepileptic jj phenytoin nn and cc the dt coumarin_anticoagulant nn s nn has vbz been vbn suggested vbn
mechanism	2	14	presumably rb phenytoin nn acts vbz as inpos a dt stimulator nn of inpos coumarin nn metabolism nn and cc has vbz been vbn reported vbn to topos cause vb decreased vbn serum nn levels nns of inpos the dt coumarin_anticoagulants nns and cc increased vbn prothrombin_proconvertin nn concentrations nns
mechanism	2	40	presumably rb phenytoin nn acts vbz as inpos a dt stimulator nn of inpos coumarin nn metabolism nn and cc has vbz been vbn reported vbn to topos cause vb decreased vbn serum nn levels nns of inpos the dt coumarin_anticoagulants nn and cc increased vbn prothrombin_proconvertin nn concentrations nns
mechanism	4	34	conversely rb the dt coumarin_anticoagulants nn have vbp been vbn reported vbn to topos increase vb the dt serum nn levels nns and cc prolong vb the dt serum nn half_life nn of inpos phenytoin nn by inpos inhibiting vbg its prp metabolism nn
false	22	28	although inpos there ex is vbz no dt documentation nn of inpos such jj a dt similar jj interaction nn between inpos ethotoin nn and cc the dt coumarin_anticoagulants nn may md occur vb
advise	12	20	caution nn is vbz therefore rb advised vbn when wrb administering vbg peganone nn to topos patients nns receiving vbg coumarin_anticoagulants nn
effect	0	12	ethoxzolamide nn may md increase vb the dt action nn of inpos tricyclics nn
effect	0	12	ethoxzolamide nn may md increase vb the dt action nn of inpos amphetamines nn
effect	0	12	ethoxzolamide nn may md increase vb the dt action nn of inpos procainamide nn
effect	0	12	ethoxzolamide nn may md increase vb the dt action nn of inpos quinidine nn
false	10	26	it prp may md increase vb excretion nn of inpos barbiturates nn and cc may md also rb increase vb the dt toxicity nn of inpos salicylates nn
false	12	14	it prp may md increase vb excretion nn of inpos barbiturates nns lithium nn asa nn and cc may md also rb increase vb the dt toxicity nn of inpos salicylates nns
false	12	30	it prp may md increase vb excretion nn of inpos barbiturates nns lithium nn asa nn and cc may md also rb increase vb the dt toxicity nn of inpos salicylates nn
false	14	30	it prp may md increase vb excretion nn of inpos barbiturates nns lithium nn asa nn and cc may md also rb increase vb the dt toxicity nn of inpos salicylates nn
effect	4	10	coadministration nn of inpos ethoxzolamide nn with inpos other jj diuretics nns may md cause vb hypokalemia nn
effect	4	10	coadministration nn of inpos ethoxzolamide nn with inpos other jj amphotericin_b nns may md cause vb hypokalemia nn
effect	4	10	coadministration nn of inpos ethoxzolamide nn with inpos other jj corticosteroids nn may md cause vb hypokalemia nn
mechanism	0	12	acetaminophen nn may md increase vb plasma nn concentration nn of inpos synthetic_estrogens nn possibly rb by inpos inhibiting vbg conjugation nn
mechanism	2	18	combination nn hormonal_contraceptives nn may md also rb decrease vb the dt plasma nn concentration nn of inpos acetaminophen nn
effect	0	16	acitretin nn interferes vbz with inpos the dt contraceptive jj effect nn of inpos microdosed jj progestin nn containing jj minipill nn preparations nns
mechanism	0	12	aminoglutethimide nn may md increase vb cyp nn metabolism nn of inpos progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
false	34	44	pregnancy nn has vbz been vbn reported vbn following vbg concomitant jj use nn however rb pharmacokinetic jj studies nns have vbp not rb shown vbn consistent jj effects nns with inpos these dt antibiotics nn on inpos plasma nn concentrations nns of inpos synthetic_steroids nn
false	0	4	anticoagulants nn combination nn hormonal_contraceptives nn may md increase vb or cc decrease vb the dt effects nns of inpos coumarin_derivatives nns
false	0	20	anticoagulants nn combination nn hormonal_contraceptives nns may md increase vb or cc decrease vb the dt effects nns of inpos coumarin_derivatives nn
effect	2	18	combination nn hormonal_contraceptives nn may md increase vb or cc decrease vb the dt effects nns of inpos coumarin_derivatives nn
mechanism	0	10	anticonvulsants nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nns leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	16	anticonvulsants nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	10	carbamazepine nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nns leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	16	carbamazepine nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	10	felbamate nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nns leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	16	felbamate nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	10	phenobarbital nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nns leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	16	phenobarbital nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	10	phenytoin nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nns leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	16	phenytoin nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	10	topiramate nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nns leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	0	16	topiramate nn increase vbp the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
false	8	14	increase vb the dt metabolism nn of inpos ethinyl_estradiol nn and_or cc some dt progestins nn leading vbg to topos possible jj decrease nn in inpos contraceptive jj effectiveness nn
mechanism	4	26	doses nns of inpos ascorbic_acid nn num cd g_day nn have vbp been vbn reported vbn to topos increase vb plasma nn concentration nn of inpos synthetic_estrogens nn by inpos num cd possibly rb by inpos inhibiting vbg conjugation nn
mechanism	4	26	doses nns of inpos vitamin_c nn num cd g_day nn have vbp been vbn reported vbn to topos increase vb plasma nn concentration nn of inpos synthetic_estrogens nn by inpos num cd possibly rb by inpos inhibiting vbg conjugation nn
mechanism	0	10	atorvastatin nn increases vbz the dt auc nn for inpos norethindrone nn and cc ethinyl_estradiol nn
mechanism	0	14	atorvastatin nn increases vbz the dt auc nn for inpos norethindrone nn and cc ethinyl_estradiol nn
false	10	14	atorvastatin nn increases vbz the dt auc nn for inpos norethindrone nn and cc ethinyl_estradiol nn
false	0	4	benzodiazepines nn combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nns and cc increase vb the dt clearance nn of inpos others nns
false	0	18	benzodiazepines nn combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt alprazolam nn and cc increase vb the dt clearance nn of inpos others nns
false	0	18	benzodiazepines nn combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt chlordiazepoxide nn and cc increase vb the dt clearance nn of inpos others nns
false	0	18	benzodiazepines nn combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt diazepam nn and cc increase vb the dt clearance nn of inpos others nns
false	0	30	benzodiazepines nn combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nns and cc increase vb the dt clearance nn of inpos lorazepam nn
false	0	30	benzodiazepines nn combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nns and cc increase vb the dt clearance nn of inpos oxazepam nn
false	0	30	benzodiazepines nn combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nns and cc increase vb the dt clearance nn of inpos temazepam nn
mechanism	2	16	combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nn and cc increase vb the dt clearance nn of inpos others nns
mechanism	2	16	combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt alprazolam nn and cc increase vb the dt clearance nn of inpos others nns
mechanism	2	16	combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt chlordiazepoxide nn and cc increase vb the dt clearance nn of inpos others nns
mechanism	2	16	combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt diazepam nn and cc increase vb the dt clearance nn of inpos others nns
mechanism	2	28	combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nns and cc increase vb the dt clearance nn of inpos lorazepam nn
mechanism	2	28	combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nns and cc increase vb the dt clearance nn of inpos oxazepam nn
mechanism	2	28	combination nn hormonal_contraceptives nn may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nns and cc increase vb the dt clearance nn of inpos temazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nn and cc increase vb the dt clearance nn of inpos lorazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nn and cc increase vb the dt clearance nn of inpos oxazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt benzodiazepines nn and cc increase vb the dt clearance nn of inpos temazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt alprazolam nn and cc increase vb the dt clearance nn of inpos lorazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt alprazolam nn and cc increase vb the dt clearance nn of inpos oxazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt alprazolam nn and cc increase vb the dt clearance nn of inpos temazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt chlordiazepoxide nn and cc increase vb the dt clearance nn of inpos lorazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt chlordiazepoxide nn and cc increase vb the dt clearance nn of inpos oxazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt chlordiazepoxide nn and cc increase vb the dt clearance nn of inpos temazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt diazepam nn and cc increase vb the dt clearance nn of inpos lorazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt diazepam nn and cc increase vb the dt clearance nn of inpos oxazepam nn
false	16	28	combination nn hormonal_contraceptives nns may md decrease vb the dt clearance nn of inpos some dt diazepam nn and cc increase vb the dt clearance nn of inpos temazepam nn
false	0	4	clofibric_acid nn combination nn hormonal_contraceptives nn may md increase vb the dt clearance nn of inpos clofibric_acid nn
mechanism	2	14	combination nn hormonal_contraceptives nn may md increase vb the dt clearance nn of inpos clofibric_acid nn
false	0	4	cyclosporine nn combination nn hormonal_contraceptives nn may md inhibit vb the dt metabolism nn of inpos cyclosporine nn leading vbg to topos increased vbn plasma nn concentrations nns
mechanism	2	14	combination nn hormonal_contraceptives nn may md inhibit vb the dt metabolism nn of inpos cyclosporine nn leading vbg to topos increased vbn plasma nn concentrations nns
mechanism	0	12	griseofulvin nn may md induce vb the dt metabolism nn of inpos combination_hormonal_contraceptives nn causing vbg menstrual jj changes nns
false	0	4	morphine nn combination nn hormonal_contraceptives nn may md increase vb the dt clearance nn of inpos morphine nn
mechanism	2	14	combination nn hormonal_contraceptives nn may md increase vb the dt clearance nn of inpos morphine nn
mechanism	0	12	nevirapine nn may md decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nn
mechanism	0	12	ethinyl_estradiol nn may md inhibit vb the dt metabolism nn of inpos prednisolone nn leading vbg to topos increased vbn plasma nn concentrations nns
false	0	2	protease_inhibitors nn amprenavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nns
false	0	2	protease_inhibitors nn lopinavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nns
false	0	2	protease_inhibitors nn nelfinavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nns
false	0	2	protease_inhibitors nn ritonavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nns
false	0	26	protease_inhibitors nn amprenavir nn lopinavir nn nelfinavir nn ritonavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nn
mechanism	2	20	protease_inhibitors nns amprenavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nn
mechanism	2	20	protease_inhibitors nns lopinavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nn
mechanism	2	20	protease_inhibitors nns nelfinavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nn
mechanism	2	20	protease_inhibitors nns ritonavir nn have vbp been vbn shown vbn to topos decrease vb plasma nn levels nns of inpos combination_hormonal_contraceptives nn
mechanism	0	18	indinavir nn has vbz been vbn shown vbn to topos increase vb plasma nn levels nns of inpos combination_hormonal_contraceptives nn
mechanism	0	10	rifampin nn increases vbz the dt metabolism nn of inpos ethinyl_estradiol nn and cc some dt progestins nns resulting vbg in inpos decreased vbn contraceptive jj effectiveness nn and cc increased vbd menstrual jj irregularities nns
mechanism	0	16	rifampin nn increases vbz the dt metabolism nn of inpos ethinyl_estradiol nn and cc some dt progestins nn resulting vbg in inpos decreased vbn contraceptive jj effectiveness nn and cc increased vbd menstrual jj irregularities nns
mechanism	0	16	rifampin nn increases vbz the dt metabolism nn of inpos ethinyl_estradiol nn and cc some dt norethindrone nn resulting vbg in inpos decreased vbn contraceptive jj effectiveness nn and cc increased vbd menstrual jj irregularities nns
false	10	16	rifampin nn increases vbz the dt metabolism nn of inpos ethinyl_estradiol nn and cc some dt progestins nn resulting vbg in inpos decreased vbn contraceptive jj effectiveness nn and cc increased vbd menstrual jj irregularities nns
false	10	16	rifampin nn increases vbz the dt metabolism nn of inpos ethinyl_estradiol nn and cc some dt norethindrone nn resulting vbg in inpos decreased vbn contraceptive jj effectiveness nn and cc increased vbd menstrual jj irregularities nns
false	0	4	salicylic_acid nn combination nn hormonal_contraceptives nn may md increase vb the dt clearance nn of inpos salicylic_acid nn
mechanism	2	14	combination nn hormonal_contraceptives nn may md increase vb the dt clearance nn of inpos salicylic_acid nn
mechanism	0	14	combination_hormonal_contraceptives nn may md increase vb the dt serum nn concentration nn of inpos selegiline nn
mechanism	0	12	ethinyl_estradiol nn may md inhibit vb the dt metabolism nn of inpos theophylline nn leading vbg to topos increased vbn plasma nn concentrations nns
mechanism	0	12	tricyclic_antidepressants nn metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nn increasing vbg plasma nn levels nns of inpos antidepressant nn
mechanism	0	12	amitriptyline nn metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nn increasing vbg plasma nn levels nns of inpos antidepressant nn
false	0	22	amitriptyline nn metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nns increasing vbg plasma nn levels nns of inpos antidepressant nn
mechanism	0	12	imipramine nn metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nn increasing vbg plasma nn levels nns of inpos antidepressant nn
false	0	22	imipramine nn metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nns increasing vbg plasma nn levels nns of inpos antidepressant nn
mechanism	0	12	nortriptyline nn metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nn increasing vbg plasma nn levels nns of inpos antidepressant nn
false	0	22	nortriptyline nn metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nns increasing vbg plasma nn levels nns of inpos antidepressant nn
false	10	20	metabolism nn may md be vb inhibited vbn by inpos combination_hormonal_contraceptives nn increasing vbg plasma nn levels nns of inpos antidepressant nn
false	6	16	cns nn effects nns of inpos caffeine nn may md be vb enhanced vbn if inpos combination_hormonal_contraceptives nn are vbp used vbn concurrently rb with inpos caffeine nn
effect	16	6	cns nn effects nns of inpos caffeine nn may md be vb enhanced vbn if inpos combination_hormonal_contraceptives nn are vbp used vbn concurrently rb with inpos caffeine nn
false	6	22	grapefruit nn juice nn increases vbz ethinyl_estradiol nn concentrations nns and cc would md be vb expected vbn to topos increase vb progesterone nn serum nn levels nns as rb well rb
effect	28	36	there ex have vbp been vbn isolated vbn reports nns of inpos patients nns experiencing vbg increases nns in inpos their prp prothrombin nn times nns when wrb etidronate nn was vbd added vbn to topos warfarin nn therapy nn
false	0	8	ace_inhibitors nn reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nns
effect	8	0	ace_inhibitors nns reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nn
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg nsaids nn concomitantly rb with inpos ace_inhibitors nn
false	8	30	the dt concomitant jj administration nn of inpos antacids nn has vbz no dt apparent jj effect nn on inpos the dt extent nn of inpos absorption nn of inpos lodine nn
mechanism	2	10	when wrb lodine nn is vbz administered vbn with inpos aspirin nn its prp protein nn binding nn is vbz reduced vbn although inpos the dt clearance nn of inpos free jj etodolac nn is vbz not rb altered vbn
false	2	32	when wrb lodine nn is vbz administered vbn with inpos aspirin nn its prp protein nn binding nn is vbz reduced vbn although inpos the dt clearance nn of inpos free jj etodolac nn is vbz not rb altered vbn
false	10	32	when wrb lodine nn is vbz administered vbn with inpos aspirin nn its prp protein nn binding nn is vbz reduced vbn although inpos the dt clearance nn of inpos free jj etodolac nn is vbz not rb altered vbn
false	8	16	however rb as inpos with inpos other jj nsaids nn concomitant jj administration nn of inpos lodine nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
false	8	20	however rb as inpos with inpos other jj nsaids nn concomitant jj administration nn of inpos lodine nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
advise	16	20	however rb as inpos with inpos other jj nsaids nns concomitant jj administration nn of inpos lodine nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
false	6	12	cyclosporine nn digoxin nn methotrexate nn lodine nn like inpos other jj nsaids nn through inpos effects nns on inpos renal jj prostaglandins nns may md cause vb changes nns in inpos the dt elimination nn of inpos these dt drugs nns leading vbg to topos elevated jj serum nn levels nns of inpos cyclosporine nn digoxin nn methotrexate nn increased vbd toxicity nn
mechanism	6	0	cyclosporine nn digoxin nn methotrexate nn lodine nn like inpos other jj nsaids nns through inpos effects nns on inpos renal jj prostaglandins nns may md cause vb changes nns in inpos the dt elimination nn of inpos these dt drugs nns leading vbg to topos elevated jj serum nn levels nns of inpos cyclosporine nn increased vbd toxicity nn
mechanism	6	2	cyclosporine nn digoxin nn methotrexate nn lodine nn like inpos other jj nsaids nns through inpos effects nns on inpos renal jj prostaglandins nns may md cause vb changes nns in inpos the dt elimination nn of inpos these dt drugs nns leading vbg to topos elevated jj serum nn levels nns of inpos digoxin nn increased vbd toxicity nn
mechanism	6	4	cyclosporine nn digoxin nn methotrexate nn lodine nn like inpos other jj nsaids nns through inpos effects nns on inpos renal jj prostaglandins nns may md cause vb changes nns in inpos the dt elimination nn of inpos these dt drugs nns leading vbg to topos elevated jj serum nn levels nns of inpos methotrexate nn increased vbd toxicity nn
mechanism	12	0	cyclosporine nn digoxin nn methotrexate nnp lodine nnp like inpos other jj nsaids nn through inpos effects nns on inpos renal jj prostaglandins nns may md cause vb changes nns in inpos the dt elimination nn of inpos these dt drugs nns leading vbg to topos elevated jj serum nn levels nns of inpos cyclosporine nn increased vbd toxicity nn
mechanism	12	2	cyclosporine nn digoxin nn methotrexate nnp lodine nnp like inpos other jj nsaids nn through inpos effects nns on inpos renal jj prostaglandins nns may md cause vb changes nns in inpos the dt elimination nn of inpos these dt drugs nns leading vbg to topos elevated jj serum nn levels nns of inpos digoxin nn increased vbd toxicity nn
mechanism	12	4	cyclosporine nn digoxin nn methotrexate nnp lodine nnp like inpos other jj nsaids nn through inpos effects nns on inpos renal jj prostaglandins nns may md cause vb changes nns in inpos the dt elimination nn of inpos these dt drugs nns leading vbg to topos elevated jj serum nn levels nns of inpos methotrexate nn increased vbd toxicity nn
false	14	20	patients nns receiving vbg these dt drugs nns who wp are vbp given vbn lodine nn any dt other jj nsaid nn particularly rb those dt patients nns with inpos altered vbn renal jj function nn should md be vb observed vbn for inpos the dt development nn of inpos the dt specific jj toxicities nns of inpos these dt drugs nns
false	18	22	etodolac nn has vbz no dt apparent jj pharmacokinetic jj interaction nn when wrb administered vbn with inpos furosemide nn or cc hydrochlorothiazide nn
effect	22	36	nevertheless rb clinical jj studies nns as rb well rb as inpos postmarketing jj observations nns have vbp shown vbn that inpos lodine nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
effect	22	40	nevertheless rb clinical jj studies nns as rb well rb as inpos postmarketing jj observations nns have vbp shown vbn that inpos lodine nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	36	40	nevertheless rb clinical jj studies nns as rb well rb as inpos postmarketing jj observations nns have vbp shown vbn that inpos lodine nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	0	18	etodolac nn has vbz no dt apparent jj pharmacokinetic jj interaction nn when wrb administered vbn with inpos glyburide nn
mechanism	0	14	nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
false	0	14	nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
effect	4	8	thus rb when wrb nsaids nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
false	4	8	thus rb when wrb nsaids nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
mechanism	0	16	phenylbutazone nn causes vbz increase nn in inpos the dt free jj fraction nn of inpos etodolac nn
advise	22	36	although inpos in fw vivo fw studies nns have vbp not rb been vbn done vbn to topos see vb if inpos etodolac nn clearance nn is vbz changed vbn by inpos coadministration nn of inpos phenylbutazone nn it prp is vbz not rb recommended vbn that inpos they prp be vb coadministered vbn
false	0	18	etodolac nn has vbz no dt apparent jj pharmacokinetic jj interaction nn when wrb administered vbn with inpos phenytoin nn
effect	6	10	the dt effects nns of inpos warfarin nn and cc nsaids nn on inpos gi nn bleeding nn are vbp synergistic jj such jj that inpos users nns of inpos both dt drugs nns together rb have vbp a dt risk nn of inpos serious jj gi nn bleeding vbg higher jjr than inpos that dt of inpos users nns of inpos either dt drug nn alone rb
mechanism	18	22	short_term jj pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos concomitant jj administration nn of inpos warfarin nn and cc lodine nn results vbz in inpos reduced vbn protein nn binding nn of inpos warfarin nn but cc there ex was vbd no dt change nn in inpos the dt clearance nn of inpos free jj warfarin nn
mechanism	18	22	short_term jj pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos concomitant jj administration nn of inpos warfarin nn and cc etodolac nn results vbz in inpos reduced vbn protein nn binding nn of inpos warfarin nn but cc there ex was vbd no dt change nn in inpos the dt clearance nn of inpos free jj warfarin nn
false	22	18	short_term jj pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos concomitant jj administration nn of inpos warfarin nn and cc lodine nn results vbz in inpos reduced vbn protein nn binding nn of inpos warfarin nn but cc there ex was vbd no dt change nn in inpos the dt clearance nn of inpos free jj warfarin nn
false	22	18	short_term jj pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos concomitant jj administration nn of inpos warfarin nn and cc lodine nn results vbz in inpos reduced vbn protein nn binding nn of inpos warfarin nn but cc there ex was vbd no dt change nn in inpos the dt clearance nn of inpos free jj warfarin nn
false	22	18	short_term jj pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos concomitant jj administration nn of inpos warfarin nn and cc etodolac nn results vbz in inpos reduced vbn protein nn binding nn of inpos warfarin nn but cc there ex was vbd no dt change nn in inpos the dt clearance nn of inpos free jj warfarin nn
false	22	18	short_term jj pharmacokinetic jj studies nns have vbp demonstrated vbn that inpos concomitant jj administration nn of inpos warfarin nn and cc etodolac nn results vbz in inpos reduced vbn protein nn binding nn of inpos warfarin nn but cc there ex was vbd no dt change nn in inpos the dt clearance nn of inpos free jj warfarin nn
false	20	34	there ex was vbd no dt significant jj difference nn in inpos the dt pharmacodynamic jj effect nn of inpos warfarin nn administered vbn alone rb and cc warfarin nn administered vbn with inpos lodine nn as inpos measured vbn by inpos prothrombin nn time nn
false	20	34	there ex was vbd no dt significant jj difference nn in inpos the dt pharmacodynamic jj effect nn of inpos warfarin nn administered vbn alone rb and cc warfarin nn administered vbn with inpos lodine nn as inpos measured vbn by inpos prothrombin nn time nn
false	8	12	thus rb concomitant jj therapy nn with inpos warfarin nn and cc lodine nn should md not rb require vb dosage nn adjustment nn of inpos either dt drug nn
effect	44	54	however rb caution nn should md be vb exercised vbn because inpos there ex have vbp been vbn a dt few jj spontaneous jj reports nns of inpos prolonged vbn prothrombin nn times nns with inpos or cc without inpos bleeding nn in inpos etodolac nn treated jj patients nns receiving vbg concomitant jj warfarin nn therapy nn
false	18	52	drug_laboratory nnp test nnp interactions nnps the dt urine nn of inpos patients nns who wp take vbp lodine nn can md give vb a dt false_positive jj reaction nn for inpos urinary jj bilirubin nn due jj to topos the dt presence nn of inpos phenolic jj metabolites nns of inpos etodolac nn
false	0	8	probenecid nn prolonged vbd action nn of inpos etomidate nn
false	0	2	zimelidine nn etomidate nn antagonism nn
false	0	2	aminophylline nn etomidate nn antagonism nn
int	0	14	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	14	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	16	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
int	0	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
int	0	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
int	0	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
int	0	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	14	16	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	14	16	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	44	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	14	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns tylenol nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos tetracycline nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos antifungals nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos gris_peg nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos nizoral nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos sporanox nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos atorvastatin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos lipitor nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos clofibrate nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos atromid_s nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos cyclosporine nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos neoral nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos sandimmune nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	22	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	16	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	16	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	16	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	16	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nn such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	26	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	26	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	26	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	26	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	26	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	26	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	26	28	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos tetracycline nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn anticonvulsants nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn dilantin nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn phenobarbital nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn tegretol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn trileptal nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn topamax nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	36	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	42	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	28	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn and cc tetracycline nn felbatol nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos antifungals nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos gris_peg nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos nizoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sporanox nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atorvastatin nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos lipitor nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos clofibrate nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos atromid_s nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos neoral nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	32	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	34	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	40	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	22	46	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos sandimmune nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nn st. nnp johns nnp wort nn vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos agenerase nn st. nnp johns nnp wort nn vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos crixivan nn st. nnp johns nnp wort nn vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos fortovase nn st. nnp johns nnp wort nn vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos invirase nn st. nnp johns nnp wort nn vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos kaletra nn st. nnp johns nnp wort nn vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos norvir nn st. nnp johns nnp wort nn vitamin_c nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn temazepam nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn theophylline nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn theo_dur nn
false	44	52	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos viracept nn st. nnp johns nnp wort nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp temazepam nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp theophylline nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp theo_dur nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn rifadin nn st. nnp johns nnp vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp temazepam nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp theophylline nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp theo_dur nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns astramorph nn rifadin nn st. nnp johns nnp vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp temazepam nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp theophylline nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp theo_dur nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns kadian nn rifadin nn st. nnp johns nnp vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp temazepam nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp theophylline nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp theo_dur nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns ms_contin nn rifadin nn st. nnp johns nnp vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp temazepam nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp theophylline nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp theo_dur nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns phenylbutazone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	48	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifampin nn st. nnp johns nnp wort nn temazepam nn theophylline nn vitamin_c nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp temazepam nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp theophylline nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp theo_dur nn
false	46	54	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns prelone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp temazepam nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theophylline nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp theo_dur nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifadin nn st. nnp johns nnp vitamin_c nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp temazepam nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp theophylline nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp theo_dur nn
false	52	58	etonogestrel nn may md interact vb with inpos the dt following vbg medications nns acetaminophen nn antibiotics nns such jj as inpos ampicillin nn tetracycline nn anticonvulsants nns antifungals nns atorvastatin nn clofibrate nn cyclosporine nn hiv nn drugs nns classified vbn as inpos protease_inhibitors nns morphine nn phenylbutazone nn prednisolone nn rifampin nn st. nnp johns nnp vitamin_c nn
advise	12	30	caution nn should md be vb exercised vbn when wrb administering vbg etopophos nn with inpos drugs nns that wdt are vbp known vbn to topos inhibit vb phosphatase nn levamisole_hydrochloride nn
mechanism	2	22	high_dose jj cyclosporin_a nn resulting vbg in inpos concentrations nns above inpos num cd ng_ml nn administered vbn with inpos oral jj etoposide nn has vbz led vbn to topos an dt num cd increase nn in inpos etoposide nn exposure nn with inpos a dt num cd decrease nn in inpos total jj body nn clearance nn of inpos etoposide nn compared vbn to topos etoposide nn alone rb
false	2	22	high_dose jj cyclosporin_a nn resulting vbg in inpos concentrations nns above inpos num cd ng_ml nn administered vbn with inpos oral jj etoposide nn has vbz led vbn to topos an dt num cd increase nn in inpos etoposide nn exposure nn with inpos a dt num cd decrease nn in inpos total jj body nn clearance nn of inpos etoposide nn compared vbn to topos etoposide nn alone rb
false	2	22	high_dose jj cyclosporin_a nn resulting vbg in inpos concentrations nns above inpos num cd ng_ml nn administered vbn with inpos oral jj etoposide nn has vbz led vbn to topos an dt num cd increase nn in inpos etoposide nn exposure nn with inpos a dt num cd decrease nn in inpos total jj body nn clearance nn of inpos etoposide nn compared vbn to topos etoposide nn alone rb
false	2	22	high_dose jj cyclosporin_a nn resulting vbg in inpos concentrations nns above inpos num cd ng_ml nn administered vbn with inpos oral jj etoposide nn has vbz led vbn to topos an dt num cd increase nn in inpos etoposide nn exposure nn with inpos a dt num cd decrease nn in inpos total jj body nn clearance nn of inpos etoposide nn compared vbn to topos etoposide nn alone rb
false	0	20	exemestane nn is vbz extensively rb metabolized vbn by inpos cyp nn 3a4 nn but cc coadministration nn of inpos ketoconazole nn a dt potent jj inhibitor nn of inpos cyp nn 3a4 nn has vbz no dt significant jj effect nn on inpos exemestane nn pharmacokinetics nns
false	20	0	exemestane nn is vbz extensively rb metabolized vbn by inpos cyp nn 3a4 nn but cc coadministration nn of inpos ketoconazole nn a dt potent jj inhibitor nn of inpos cyp nn 3a4 nn has vbz no dt significant jj effect nn on inpos exemestane nn pharmacokinetics nns
mechanism	8	20	co_medications nns that wdt induce vbp cyp nn rifampicin nn may md significantly rb decrease vb exposure nn to topos exemestane nn
mechanism	8	20	co_medications nns that wdt induce vbp cyp nn phenytoin nn may md significantly rb decrease vb exposure nn to topos exemestane nn
mechanism	8	20	co_medications nns that wdt induce vbp cyp nn carbamazepine nn may md significantly rb decrease vb exposure nn to topos exemestane nn
mechanism	8	20	co_medications nns that wdt induce vbp cyp nn phenobarbital nn may md significantly rb decrease vb exposure nn to topos exemestane nn
mechanism	6	42	concurrent jj use nn with inpos probenecid nn or cc other jj drugs nns significantly rb eliminated vbn by inpos active jj renal jj tubular jj secretion nn may md result vb in inpos increased vbn plasma nn concentrations nns of inpos penciclovir nn
false	10	18	use nn in inpos conjunction nn with inpos other jj antiepileptic_drugs nn the dt addition nn of inpos felbatol nn to topos antiepileptic_drugs nns affects vbz the dt steady_state jj plasma nn concentrations nns of inpos aeds nns
mechanism	18	10	use nn in inpos conjunction nn with inpos other jj antiepileptic_drugs nns the dt addition nn of inpos felbatol nn to topos antiepileptic_drugs nn affects vbz the dt steady_state jj plasma nn concentrations nns of inpos aeds nns
mechanism	18	22	use nn in inpos conjunction nn with inpos other jj antiepileptic_drugs nns the dt addition nn of inpos felbatol nn to topos aeds nn affects vbz the dt steady_state jj plasma nn concentrations nns of inpos aeds nns
false	18	36	use nn in inpos conjunction nn with inpos other jj antiepileptic_drugs nns the dt addition nn of inpos felbatol nn to topos antiepileptic_drugs nns affects vbz the dt steady_state jj plasma nn concentrations nns of inpos aeds nn
false	10	24	the dt addition nn of inpos felbatol nn to topos antiepileptic_drugs nn affects vbz the dt steady_state jj plasma nn concentrations nns of inpos aeds nn
false	24	28	the dt net jj effect nn of inpos these dt interactions nns is vbz summarized vbn in inpos the dt following vbg table nn aed nn aed vbd felbatol nn
false	24	28	the dt net jj effect nn of inpos these dt interactions nns is vbz summarized vbn in inpos the dt following vbg table nn aed vbn aed nn felbatol nn
false	6	12	specific jj effects nns of inpos felbatol nn on inpos other jj antiepileptic_drugs nn phenytoin nn
false	6	14	specific jj effects nns of inpos felbatol nn on inpos other jj antiepileptic_drugs nns phenytoin nn
false	12	14	specific jj effects nns of inpos felbatol nn on inpos other jj antiepileptic_drugs nn phenytoin nn
false	12	6	specific jj effects nns of inpos felbatol nn on inpos other jj antiepileptic_drugs nn phenytoin nn felbatol nn causes vbz an dt increase nn in inpos steady_state jj phenytoin nn plasma nn concentrations nns
false	14	6	specific jj effects nns of inpos felbatol nn on inpos other jj antiepileptic_drugs nnp phenytoin nn felbatol nn causes vbz an dt increase nn in inpos steady_state jj phenytoin nn plasma nn concentrations nns
mechanism	6	14	specific jj effects nns of inpos felbatol nn on inpos other jj antiepileptic_drugs nnp phenytoin nn felbatol nn causes vbz an dt increase nn in inpos steady_state jj phenytoin nn plasma nn concentrations nns
mechanism	4	30	increasing vbg the dt felbamate nn dose nn to topos num cd mg_day nn in inpos num cd of inpos these dt subjects nns increased vbd the dt steady_state jj phenytoin nn cmin nn to topos num cd num cd micrograms_ml nns
false	8	22	in inpos order nn to topos maintain vb phenytoin nn levels nns limit vbp adverse jj experiences nns achieve vb the dt felbamate nn dose nn of inpos num cd mg_day nn a dt phenytoin nn dose nn reduction nn of inpos approximately rb num cd was vbd necessary jj for inpos num cd of inpos these dt num cd subjects nns
advise	22	8	in inpos order nn to topos maintain vb phenytoin nn levels nns limit vbp adverse jj experiences nns achieve vb the dt felbamate nn dose nn of inpos num cd mg_day nn a dt phenytoin nn dose nn reduction nn of inpos approximately rb num cd was vbd necessary jj for inpos num cd of inpos these dt num cd subjects nns
false	20	32	in inpos a dt controlled jj clinical jj trial nn a dt num cd reduction nn of inpos the dt phenytoin nn dose nn at inpos the dt initiation nn of inpos felbatol nn therapy nn resulted vbd in inpos phenytoin nn levels nns comparable jj to topos those dt prior jj to topos felbatol nn administration nn
false	20	32	in inpos a dt controlled jj clinical jj trial nn a dt num cd reduction nn of inpos the dt phenytoin nn dose nn at inpos the dt initiation nn of inpos felbatol nn therapy nn resulted vbd in inpos phenytoin nn levels nns comparable jj to topos those dt prior jj to topos felbatol nn administration nn
false	32	20	in inpos a dt controlled jj clinical jj trial nn a dt num cd reduction nn of inpos the dt phenytoin nn dose nn at inpos the dt initiation nn of inpos felbatol nn therapy nn resulted vbd in inpos phenytoin nn levels nns comparable jj to topos those dt prior jj to topos felbatol nn administration nn
false	20	32	in inpos a dt controlled jj clinical jj trial nn a dt num cd reduction nn of inpos the dt phenytoin nn dose nn at inpos the dt initiation nn of inpos felbatol nn therapy nn resulted vbd in inpos phenytoin nn levels nns comparable jj to topos those dt prior jj to topos felbatol nn administration nn
false	0	2	carbamazepine nn felbatol nn causes vbz a dt decrease nn in inpos the dt steady_state jj carbamazepine nn plasma nn concentrations nns and cc an dt increase nn in inpos the dt steady_state jj carbamazepine_epoxide nn plasma nn concentration nn
mechanism	2	0	carbamazepine nnp felbatol nn causes vbz a dt decrease nn in inpos the dt steady_state jj carbamazepine nn plasma nn concentrations nns and cc an dt increase nn in inpos the dt steady_state jj carbamazepine_epoxide nn plasma nn concentration nn
false	2	34	carbamazepine nnp felbatol nn causes vbz a dt decrease nn in inpos the dt steady_state jj carbamazepine nn plasma nn concentrations nns and cc an dt increase nn in inpos the dt steady_state jj carbamazepine_epoxide nn plasma nn concentration nn
mechanism	2	22	the dt carbamazepine nn steady_state jj cmin nn decreased vbd num cd to topos num cd num cd micrograms_ml nn when wrb felbamate nn was vbd coadministered vbn
false	0	34	carbamazepine_epoxide nn steady_state jj cmin nn concentrations nns increased vbd num cd from inpos float cd float cd to topos float cd float cd micrograms_ml nns with inpos the dt addition nn of inpos felbamate nn
false	0	2	valproate nn felbatol nn causes vbz an dt increase nn in inpos steady_state jj valproate nn concentrations nns
mechanism	2	0	valproate nn felbatol nn causes vbz an dt increase nn in inpos steady_state jj valproate nn concentrations nns
mechanism	4	20	increasing vbg the dt felbamate nn dose nn to topos num cd mg_day nn increased vbd the dt steadystate nn valproate nn cmin nn to topos num cd num cd micrograms_ml nns
false	8	40	corresponding vbg values nns for inpos free jj valproate nn cmin nn concentrations nns were vbd num cd num cd num cd num cd num cd num cd micrograms_ml nns for inpos num cd num cd num cd mg_day nn felbatol nn respectively rb
false	14	54	the dt ratios nns of inpos the dt aucs nns of inpos unbound jj valproate nn to topos the dt aucs nns of inpos the dt total jj valproate nn were vbd float cd float cd float cd with inpos coadministration nn of inpos num cd num cd num cd mg_day nn of inpos felbatol nn respectively rb
false	14	54	the dt ratios nns of inpos the dt aucs nns of inpos unbound jj valproate nn to topos the dt aucs nns of inpos the dt total jj valproate nn were vbd float cd float cd float cd with inpos coadministration nn of inpos num cd num cd num cd mg_day nn of inpos felbatol nn respectively rb
false	0	6	phenobarbital nn coadministration nn of inpos felbamate nn with inpos phenobarbital nn causes vbz an dt increase nn in inpos phenobarbital nn plasma nn concentrations nns in inpos num cd otherwise rb healthy jj male jj volunteers nns ingesting vbg phenobarbital nn the dt steady_state jj trough nn phenobarbital nn concentration nn was vbd float cd micrograms_ml nns
mechanism	4	8	coadministration nn of inpos felbamate nn with inpos phenobarbital nn causes vbz an dt increase nn in inpos phenobarbital nn plasma nn concentrations nns in inpos num cd otherwise rb healthy jj male jj volunteers nns ingesting vbg phenobarbital nn the dt steady_state jj trough nn phenobarbital nn concentration nn was vbd float cd micrograms_ml nns
false	4	8	coadministration nn of inpos felbamate nn with inpos phenobarbital nn causes vbz an dt increase nn in inpos phenobarbital nn plasma nn concentrations nns in inpos num cd otherwise rb healthy jj male jj volunteers nns ingesting vbg phenobarbital nn the dt steady_state jj trough nn phenobarbital nn concentration nn was vbd float cd micrograms_ml nns
false	4	8	coadministration nn of inpos felbamate nn with inpos phenobarbital nn causes vbz an dt increase nn in inpos phenobarbital nn plasma nn concentrations nns in inpos num cd otherwise rb healthy jj male jj volunteers nns ingesting vbg phenobarbital nn the dt steady_state jj trough nn phenobarbital nn concentration nn was vbd float cd micrograms_ml nns
false	4	8	coadministration nn of inpos felbamate nn with inpos phenobarbital nn causes vbz an dt increase nn in inpos phenobarbital nn plasma nn concentrations nns in inpos num cd otherwise rb healthy jj male jj volunteers nns ingesting vbg phenobarbital nn the dt steady_state jj trough nn phenobarbital nn concentration nn was vbd float cd micrograms_ml nns
false	6	10	effects nns of inpos other jj antiepileptic_drugs nn on inpos felbatol nn phenytoin nn
false	6	12	effects nns of inpos other jj antiepileptic_drugs nn on inpos felbatol nn phenytoin nn
false	10	12	effects nns of inpos other jj antiepileptic_drugs nns on inpos felbatol nn phenytoin nn
mechanism	0	18	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
mechanism	0	18	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbamate nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	0	18	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	0	18	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	18	0	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	18	0	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbamate nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	18	60	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbamate nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	18	60	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbamate nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
mechanism	0	18	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	0	18	phenytoin nn causes vbz an dt approximate jj doubling nn of inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos phenytoin nn causes vbz an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
mechanism	0	20	carbamazepine nn causes vbz an dt approximate jj num cd increase nn in inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos carbamazepine nn results vbz in inpos an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	0	20	carbamazepine nn causes vbz an dt approximate jj num cd increase nn in inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos carbamazepine nn results vbz in inpos an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	0	20	carbamazepine nn causes vbz an dt approximate jj num cd increase nn in inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos carbamazepine nn results vbz in inpos an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	20	0	carbamazepine nn causes vbz an dt approximate jj num cd increase nn in inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos carbamazepine nn results vbz in inpos an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
mechanism	0	20	carbamazepine nn causes vbz an dt approximate jj num cd increase nn in inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos carbamazepine nn results vbz in inpos an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	0	20	carbamazepine nn causes vbz an dt approximate jj num cd increase nn in inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn and cc therefore rb the dt addition nn of inpos carbamazepine nn results vbz in inpos an dt approximate jj num cd decrease nn in inpos the dt steady_state jj trough nn concentrations nns of inpos felbatol nn as inpos compared vbn to topos the dt same jj dose nn of inpos felbatol nn given vbn as inpos monotherapy nn
false	20	30	available jj data nns suggest vbp that inpos there ex is vbz no dt significant jj effect nn of inpos valproate nn on inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn therefore rb the dt addition nn of inpos valproate nn is vbz not rb expected vbn to topos cause vb a dt clinically rb important jj effect nn on inpos felbatol nn plasma nn concentrations nns
false	20	30	available jj data nns suggest vbp that inpos there ex is vbz no dt significant jj effect nn of inpos valproate nn on inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn therefore rb the dt addition nn of inpos valproate nn is vbz not rb expected vbn to topos cause vb a dt clinically rb important jj effect nn on inpos felbatol nn plasma nn concentrations nns
false	20	68	available jj data nns suggest vbp that inpos there ex is vbz no dt significant jj effect nn of inpos valproate nn on inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn therefore rb the dt addition nn of inpos valproate nn is vbz not rb expected vbn to topos cause vb a dt clinically rb important jj effect nn on inpos felbamate nn plasma nn concentrations nns
false	30	20	available jj data nns suggest vbp that inpos there ex is vbz no dt significant jj effect nn of inpos valproate nn on inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn therefore rb the dt addition nn of inpos valproate nn is vbz not rb expected vbn to topos cause vb a dt clinically rb important jj effect nn on inpos felbatol nn plasma nn concentrations nns
false	30	68	available jj data nns suggest vbp that inpos there ex is vbz no dt significant jj effect nn of inpos valproate nn on inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn therefore rb the dt addition nn of inpos valproate nn is vbz not rb expected vbn to topos cause vb a dt clinically rb important jj effect nn on inpos felbamate nn plasma nn concentrations nns
false	20	30	available jj data nns suggest vbp that inpos there ex is vbz no dt significant jj effect nn of inpos valproate nn on inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn therefore rb the dt addition nn of inpos valproate nn is vbz not rb expected vbn to topos cause vb a dt clinically rb important jj effect nn on inpos felbatol nn plasma nn concentrations nns
false	20	68	available jj data nns suggest vbp that inpos there ex is vbz no dt significant jj effect nn of inpos valproate nn on inpos the dt clearance nn of inpos felbatol nn at inpos steady jj state nn therefore rb the dt addition nn of inpos valproate nn is vbz not rb expected vbn to topos cause vb a dt clinically rb important jj effect nn on inpos felbamate nn plasma nn concentrations nns
mechanism	6	14	it prp appears vbz that inpos phenobarbital nn may md reduce vb plasma nn felbamate nn concentrations nns
false	4	8	effects nns of inpos antacids nn on inpos felbatol nn the dt rate nn and cc extent nn of inpos absorption nn of inpos a dt num cd mg nn dose nn of inpos felbatol nn as inpos monotherapy nn given vbn as inpos tablets nns was vbd not rb affected vbn when wrb coadministered vbn with inpos antacids nns
false	4	8	effects nns of inpos antacids nn on inpos felbatol nnp the dt rate nn and cc extent nn of inpos absorption nn of inpos a dt num cd mg nn dose nn of inpos felbatol nn as inpos monotherapy nn given vbn as inpos tablets nns was vbd not rb affected vbn when wrb coadministered vbn with inpos antacids nns
false	8	4	effects nns of inpos antacids nns on inpos felbatol nn the dt rate nn and cc extent nn of inpos absorption nn of inpos a dt num cd mg nn dose nn of inpos felbatol nn as inpos monotherapy nn given vbn as inpos tablets nns was vbd not rb affected vbn when wrb coadministered vbn with inpos antacids nn
false	8	4	effects nns of inpos antacids nns on inpos felbatol nnp the dt rate nn and cc extent nn of inpos absorption nn of inpos a dt num cd mg nn dose nn of inpos felbatol nn as inpos monotherapy nn given vbn as inpos tablets nns was vbd not rb affected vbn when wrb coadministered vbn with inpos antacids nn
false	4	8	effects nns of inpos erythromycin nn on inpos felbatol nn the dt coadministration nn of inpos erythromycin nn for inpos num cd days nns did vbd not rb alter vb the dt pharmacokinetic jj parameters nns of inpos cmax nn cmin nn auc nn ci_kg nn tmax nn at inpos felbamate nn daily jj doses nns of inpos num cd or cc num cd mg_day nn in inpos num cd otherwise rb healthy jj subjects nns with inpos epilepsy nn
false	4	50	effects nns of inpos erythromycin nn on inpos felbatol nnp the dt coadministration nn of inpos erythromycin nn for inpos num cd days nns did vbd not rb alter vb the dt pharmacokinetic jj parameters nns of inpos cmax nn cmin nn auc nn ci_kg nn tmax nn at inpos felbamate nn daily jj doses nns of inpos num cd or cc num cd mg_day nn in inpos num cd otherwise rb healthy jj subjects nns with inpos epilepsy nn
false	8	4	effects nns of inpos erythromycin nn on inpos felbatol nn the dt coadministration nn of inpos erythromycin nn for inpos num cd days nns did vbd not rb alter vb the dt pharmacokinetic jj parameters nns of inpos cmax nn cmin nn auc nn ci_kg nn tmax nn at inpos felbamate nn daily jj doses nns of inpos num cd or cc num cd mg_day nn in inpos num cd otherwise rb healthy jj subjects nns with inpos epilepsy nn
false	8	50	effects nns of inpos erythromycin nn on inpos felbatol nn the dt coadministration nn of inpos erythromycin nn for inpos num cd days nns did vbd not rb alter vb the dt pharmacokinetic jj parameters nns of inpos cmax nn cmin nn auc nn ci_kg nn tmax nn at inpos felbamate nn daily jj doses nns of inpos num cd or cc num cd mg_day nn in inpos num cd otherwise rb healthy jj subjects nns with inpos epilepsy nn
false	4	50	effects nns of inpos erythromycin nn on inpos felbatol nnp the dt coadministration nn of inpos erythromycin nn for inpos num cd days nns did vbd not rb alter vb the dt pharmacokinetic jj parameters nns of inpos cmax nn cmin nn auc nn ci_kg nn tmax nn at inpos felbamate nn daily jj doses nns of inpos num cd or cc num cd mg_day nn in inpos num cd otherwise rb healthy jj subjects nns with inpos epilepsy nn
false	4	10	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nn a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	4	10	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive nn regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	4	48	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	4	56	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	4	76	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	4	10	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive nn cycles nns
false	10	48	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nn a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	10	56	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nn a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	10	76	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nn a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	10	48	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive nn regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	10	56	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive nn regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	10	76	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive nn regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	48	56	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	48	76	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	48	10	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive nn cycles nns
false	56	76	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive jj cycles nns
false	56	10	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive nn cycles nns
false	76	10	effects nns of inpos felbatol nn on inpos low_dose jj combination_oral_contraceptives nns a nn group nn of inpos num cd nonsmoking jj healthy jj white jj female jj volunteers nns established vbn on inpos an dt oral jj contraceptive jj regimen nn containing vbg num cd mg nn ethinyl_estradiol nn and cc num cd mg nn gestodene nn for inpos at inpos least jjs num cd months nns received vbd num cd mg_day nn of inpos felbamate nn from inpos midcycle nn to topos midcycle nn of inpos num cd consecutive jj oral jj contraceptive nn cycles nns
mechanism	0	18	felbamate nn treatment nn resulted vbd in inpos a dt num cd decrease nn in inpos the dt gestodene nn auc nn num cd but cc no dt clinically rb relevant jj effect nn was vbd observed vbn on inpos the dt pharmacokinetic jj parameters nns of inpos ethinyl_estradiol nn
false	0	48	felbamate nn treatment nn resulted vbd in inpos a dt num cd decrease nn in inpos the dt gestodene nn auc nn num cd but cc no dt clinically rb relevant jj effect nn was vbd observed vbn on inpos the dt pharmacokinetic jj parameters nns of inpos ethinyl_estradiol nn
false	18	48	felbamate nn treatment nn resulted vbd in inpos a dt num cd decrease nn in inpos the dt gestodene nn auc nn num cd but cc no dt clinically rb relevant jj effect nn was vbd observed vbn on inpos the dt pharmacokinetic jj parameters nns of inpos ethinyl_estradiol nn
false	6	10	co_administration nn of inpos cyp3a4 nn ketoconazole nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	6	10	co_administration nn of inpos cyp3a4 nn ketoconazole nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	6	10	co_administration nn of inpos cyp3a4 nn itraconazole nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	6	10	co_administration nn of inpos cyp3a4 nn itraconazole nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	6	10	co_administration nn of inpos cyp3a4 nn erythromycin nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	6	10	co_administration nn of inpos cyp3a4 nn erythromycin nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	6	10	co_administration nn of inpos cyp3a4 nn cimetidine nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	6	10	co_administration nn of inpos cyp3a4 nn cimetidine nn with inpos felodipine nn may md lead vb to topos several jj fold jj increases nns in inpos the dt plasma nn levels nns of inpos felodipine nn either cc due jj to topos an dt increase nn in inpos bioavailability nn or cc due jj to topos a dt decrease nn in inpos metabolism nn
false	10	20	caution nn should md be vb used vbn when wrb cyp3a4 nn inhibitors nns are vbp co_administered vbn with inpos felodipine nn
false	16	0	itraconazole nn co_administration nn of inpos another dt extended vbn release nn formulation nn of inpos felodipine nn with inpos itraconazole nn resulted vbd in inpos approximately rb num_fold jj increase nn in inpos the dt auc nn more jjr than inpos num cd fold jj increase nn in inpos the dt cmax nn and cc num_fold jj prolongation nn in inpos the dt half nn life nn of inpos felodipine nn
false	0	16	itraconazole nn co_administration nn of inpos another dt extended vbn release nn formulation nn of inpos felodipine nn with inpos itraconazole nn resulted vbd in inpos approximately rb num_fold jj increase nn in inpos the dt auc nn more jjr than inpos num cd fold jj increase nn in inpos the dt cmax nn and cc num_fold jj prolongation nn in inpos the dt half nn life nn of inpos felodipine nn
false	6	0	erythromycin nn co_administration nn of inpos felodipine nn with inpos erythromycin nn resulted vbd in inpos approximately rb float cd fold jj increase nn in inpos the dt auc nn and cc cmax nn and cc about rb num cd fold jj prolongation nn in inpos the dt half nn life nn of inpos felodipine nn
false	6	0	erythromycin nn co_administration nn of inpos plendil nn with inpos erythromycin nn resulted vbd in inpos approximately rb float cd fold jj increase nn in inpos the dt auc nn and cc cmax nn and cc about rb num cd fold jj prolongation nn in inpos the dt half nn life nn of inpos felodipine nn
false	6	54	erythromycin nn co_administration nn of inpos plendil nn with inpos erythromycin nn resulted vbd in inpos approximately rb float cd fold jj increase nn in inpos the dt auc nn and cc cmax nn and cc about rb num cd fold jj prolongation nn in inpos the dt half nn life nn of inpos felodipine nn
false	0	6	erythromycin nn co_administration nn of inpos felodipine nn with inpos erythromycin nn resulted vbd in inpos approximately rb float cd fold jj increase nn in inpos the dt auc nn and cc cmax nn and cc about rb num cd fold jj prolongation nn in inpos the dt half nn life nn of inpos felodipine nn
false	6	0	cimetidine nn co_administration nn of inpos felodipine nn with inpos cimetidine nn resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt auc nn and cc the dt cmax nn of inpos felodipine nn
false	0	6	cimetidine nn co_administration nn of inpos felodipine nn with inpos cimetidine nn resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt auc nn and cc the dt cmax nn of inpos felodipine nn
false	12	20	b_blocking jj agents nnps a dt pharmacokinetic jj study nn of inpos felodipine nn in inpos conjunction nn with inpos metoprolol nn demonstrated vbd no dt significant jj effects nns on inpos the dt pharmacokinetics nns of inpos felodipine nn
false	20	12	b_blocking jj agents nnps a dt pharmacokinetic jj study nn of inpos felodipine nn in inpos conjunction nn with inpos metoprolol nn demonstrated vbd no dt significant jj effects nns on inpos the dt pharmacokinetics nns of inpos felodipine nn
false	10	14	in inpos controlled vbn clinical jj trials nns however rb b_blockers nn including vbg metoprolol nn were vbd concurrently rb administered vbn with inpos felodipine nn and cc were vbd well rb tolerated vbn
false	10	24	in inpos controlled vbn clinical jj trials nns however rb b_blockers nn including vbg metoprolol nn were vbd concurrently rb administered vbn with inpos felodipine nn and cc were vbd well rb tolerated vbn
false	14	24	in inpos controlled vbn clinical jj trials nns however rb b_blockers nns including vbg metoprolol nn were vbd concurrently rb administered vbn with inpos felodipine nn and cc were vbd well rb tolerated vbn
false	10	0	digoxin nn when wrb given vbn concomitantly rb with inpos plendil nn the dt pharmacokinetics nns of inpos digoxin nn in inpos patients nns with inpos heart nn failure nn were vbd not rb significantly rb altered vbn
false	0	18	anticonvulsants nn in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant jj therapy nn than inpos in inpos healthy jj volunteers nns
false	0	38	anticonvulsants nn in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant jj phenytoin nn than inpos in inpos healthy jj volunteers nns
false	0	38	anticonvulsants nn in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant jj carbamazepine nn than inpos in inpos healthy jj volunteers nns
false	0	38	anticonvulsants nn in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant jj phenobarbital nn than inpos in inpos healthy jj volunteers nns
mechanism	18	0	anticonvulsants nns in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant nn therapy nn than inpos in inpos healthy jj volunteers nns
mechanism	18	38	anticonvulsants nns in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant jj phenytoin nn than inpos in inpos healthy jj volunteers nns
mechanism	18	38	anticonvulsants nns in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant jj carbamazepine nn than inpos in inpos healthy jj volunteers nns
mechanism	18	38	anticonvulsants nns in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant jj phenobarbital nn than inpos in inpos healthy jj volunteers nns
false	0	38	anticonvulsants nns in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant nn phenytoin nn than inpos in inpos healthy jj volunteers nns
false	0	38	anticonvulsants nns in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant nn carbamazepine nn than inpos in inpos healthy jj volunteers nns
false	0	38	anticonvulsants nns in inpos a dt pharmacokinetic jj study nn maximum jj plasma nn concentrations nns of inpos felodipine nn were vbd considerably rb lower jjr in inpos epileptic jj patients nns on inpos long_term jj anticonvulsant nn phenobarbital nn than inpos in inpos healthy jj volunteers nns
false	2	0	tacrolimus nn felodipine nn may md increase vb the dt blood nn concentration nn of inpos tacrolimus nn
false	8	12	when wrb given vbn concomitantly rb with inpos felodipine nn the dt tacrolimus nn blood nn concentration nn should md be vb followed vbn and cc the dt tacrolimus nn dose nn may md need vb to topos be vb adjusted vbn
false	26	36	other jj concomitant jj therapy nn in inpos healthy jj subjects nns there ex were vbd no dt clinically rb significant jj interactions nns when wrb felodipine nn was vbd given vbn concomitantly rb with inpos indomethacin nn or cc spironolactone nn
false	26	40	other jj concomitant jj therapy nn in inpos healthy jj subjects nns there ex were vbd no dt clinically rb significant jj interactions nns when wrb felodipine nn was vbd given vbn concomitantly rb with inpos indomethacin nn or cc spironolactone nn
false	36	40	other jj concomitant jj therapy nn in inpos healthy jj subjects nns there ex were vbd no dt clinically rb significant jj interactions nns when wrb felodipine nn was vbd given vbn concomitantly rb with inpos indomethacin nn or cc spironolactone nn
effect	0	14	fenfluramine nn may md increase vb slightly rb the dt effect nn of inpos antihypertensive_drugs nn e.g. fw guanethidine nn methyldopa nn reserpine nn
effect	0	18	fenfluramine nn may md increase vb slightly rb the dt effect nn of inpos antihypertensive_drugs nns e.g. fw guanethidine nn
effect	0	18	fenfluramine nn may md increase vb slightly rb the dt effect nn of inpos antihypertensive_drugs nns e.g. fw methyldopa nn
effect	0	18	fenfluramine nn may md increase vb slightly rb the dt effect nn of inpos antihypertensive_drugs nns e.g. fw reserpine nn
false	14	18	fenfluramine nn may md increase vb slightly rb the dt effect nn of inpos antihypertensive_drugs nn e.g. fw guanethidine nn
false	14	18	fenfluramine nn may md increase vb slightly rb the dt effect nn of inpos antihypertensive_drugs nn e.g. fw methyldopa nn
false	14	18	fenfluramine nn may md increase vb slightly rb the dt effect nn of inpos antihypertensive_drugs nn e.g. fw reserpine nn
advise	2	20	other jj cns_depressant_drugs nn should md be vb used vbn with inpos caution nn in inpos patients nns taking vbg fenfluramine nn since inpos the dt effects nns may md be vb additive jj
false	2	26	oral jj anticoagulants nn caution nn should nn be nnp exercised vbd when wrb coumarin_anticoagulants nns are vbp given nn in inpos conjunction nn with inpos tricor nn
advise	14	26	oral jj anticoagulants nnps caution nnp should nnp be nnp exercised vbd when wrb coumarin_anticoagulants nn are vbp given nn in inpos conjunction nn with inpos tricor nn
advise	8	12	the dt combined jj use nn of inpos tricor nn and cc hmg_coa_reductase_inhibitors nn should md be vb avoided vbn unless inpos the dt benefit nn of inpos further jj alterations nns in inpos lipid nn levels nns is vbz likely jj to topos outweigh vb the dt increased vbn risk nn of inpos this dt drug nn combination nn
false	2	22	since inpos bile_acid_sequestrants nn may md bind vb other jj drugs nns given vbn concurrently rb patients nns should md take vb tricor nn at inpos least jjs num cd hour nn before inpos or cc num cd hours nns after inpos a dt bile_acid_binding_resin nn to topos avoid vb impeding vbg its prp absorption nn
false	2	44	since inpos bile_acid_sequestrants nn may md bind vb other jj drugs nns given vbn concurrently rb patients nns should md take vb tricor nn at inpos least jjs num cd hour nn before inpos or cc num cd hours nns after inpos a dt bile_acid_binding_resin nn to topos avoid vb impeding vbg its prp absorption nn
mechanism	22	44	since inpos bile_acid_sequestrants nns may md bind vb other jj drugs nns given vbn concurrently rb patients nns should md take vb tricor nn at inpos least jjs num cd hour nn before inpos or cc num cd hours nns after inpos a dt bile_acid_binding_resin nn to topos avoid vb impeding vbg its prp absorption nn
effect	2	50	because inpos cyclosporine nn can md produce vb nephrotoxicity nn with inpos decreases nns in inpos creatinine nn clearance nn and cc rises vbz in inpos serum nn creatinine nn and cc because inpos renal jj excretion nn is vbz the dt primary jj elimination nn route nn of inpos fibrate_drugs nn including vbg tricor nn there ex is vbz a dt risk nn that inpos an dt interaction nn will md lead vb to topos deterioration nn
effect	2	54	because inpos cyclosporine nn can md produce vb nephrotoxicity nn with inpos decreases nns in inpos creatinine nn clearance nn and cc rises vbz in inpos serum nn creatinine nn and cc because inpos renal jj excretion nn is vbz the dt primary jj elimination nn route nn of inpos fibrate_drugs nns including vbg tricor nn there ex is vbz a dt risk nn that inpos an dt interaction nn will md lead vb to topos deterioration nn
false	50	54	because inpos cyclosporine nn can md produce vb nephrotoxicity nn with inpos decreases nns in inpos creatinine nn clearance nn and cc rises vbz in inpos serum nn creatinine nn and cc because inpos renal jj excretion nn is vbz the dt primary jj elimination nn route nn of inpos fibrate_drugs nn including vbg tricor nn there ex is vbz a dt risk nn that inpos an dt interaction nn will md lead vb to topos deterioration nn
advise	10	14	the dt benefits nns risks nns of inpos using vbg tricor nn with inpos immunosuppressants nn other jj potentially rb nephrotoxic jj agents nns should md be vb carefully rb considered vbn and cc the dt lowest jjs effective jj dose nn employed vbd
false	22	26	drug_drug jj interactions nns in fw vitro fw studies nns using vbg human jj liver nn microsomes nns indicate vbp that inpos fenofibrate nn and cc fenofibric_acid nn are vbp not rb inhibitors nns of inpos cytochrome nn p450 nn isoforms nns cyp3a4 nn cyp2d6 nn cyp2e1 nn cyp1a2 nn
advise	2	30	therefore rb fenofibrate nn should md be vb taken vbn at inpos least jjs num cd hour nn before inpos or cc num cd hours nns after inpos a dt bile_acid_binding_resin nn to topos avoid vb impeding vbg its prp absorption nn
false	6	14	concomitant jj administration nn of inpos fenofibrate nn lrb_equivalent jj to topos 145mg nn tricor nn rrb_with inpos pravastatin nn once rb daily rb for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb the dt mean jj cmax nn and cc auc nn values nns for inpos pravastatin nn by inpos num cd and cc num cd respectively rb and cc for inpos num cd hydroxy_iso_pravastatin nn by inpos num cd and cc num cd respectively rb in inpos num cd healthy jj adults nns
mechanism	6	10	concomitant jj administration nn of inpos fenofibrate nn with inpos pravastatin nn once rb daily rb for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb the dt mean jj cmax nn and cc auc nn values nns for inpos pravastatin nn by inpos num cd and cc num cd respectively rb and cc for inpos num cd hydroxy_iso_pravastatin nn by inpos num cd and cc num cd respectively rb in inpos num cd healthy jj adults nns
false	6	10	concomitant jj administration nn of inpos fenofibrate nn with inpos pravastatin nn once rb daily rb for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb the dt mean jj cmax nn and cc auc nn values nns for inpos pravastatin nn by inpos num cd and cc num cd respectively rb and cc for inpos num cd hydroxy_iso_pravastatin nn by inpos num cd and cc num cd respectively rb in inpos num cd healthy jj adults nns
mechanism	14	18	concomitant jj administration nn of inpos fenofibrate nn lrb_equivalent jj to topos 145mg nn tricor nn rrb_with inpos pravastatin nn once rb daily rb for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb the dt mean jj cmax nn and cc auc nn values nns for inpos pravastatin nn by inpos num cd and cc num cd respectively rb and cc for inpos num cd hydroxy_iso_pravastatin nn by inpos num cd and cc num cd respectively rb in inpos num cd healthy jj adults nns
false	14	18	concomitant jj administration nn of inpos fenofibrate nn lrb_equivalent jj to topos 145mg nn tricor nn rrb_with inpos pravastatin nn once rb daily rb for inpos num cd days nns has vbz been vbn shown vbn to topos increase vb the dt mean jj cmax nn and cc auc nn values nns for inpos pravastatin nn by inpos num cd and cc num cd respectively rb and cc for inpos num cd hydroxy_iso_pravastatin nn by inpos num cd and cc num cd respectively rb in inpos num cd healthy jj adults nns
false	8	28	a dt single jj dose nn of inpos pravastatin nn had vbd no dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos fenofibric_acid nn
false	6	16	concomitant jj administration nn of inpos fenofibrate nn lrb_equivalent jj to topos num cd mg nn tricor nn rrb_with inpos atorvastatin nn once rb daily rb for inpos num cd days nns resulted vbd in inpos approximately rb num cd decrease nn in inpos atorvastatin nn auc nn values nns in inpos num cd healthy jj males nns
mechanism	6	10	concomitant jj administration nn of inpos fenofibrate nn with inpos atorvastatin nn once rb daily rb for inpos num cd days nns resulted vbd in inpos approximately rb num cd decrease nn in inpos atorvastatin nn auc nn values nns in inpos num cd healthy jj males nns
false	6	10	concomitant jj administration nn of inpos fenofibrate nn with inpos atorvastatin nn once rb daily rb for inpos num cd days nns resulted vbd in inpos approximately rb num cd decrease nn in inpos atorvastatin nn auc nn values nns in inpos num cd healthy jj males nns
mechanism	16	20	concomitant jj administration nn of inpos fenofibrate nn lrb_equivalent jj to topos num cd mg nn tricor nn rrb_with inpos atorvastatin nn once rb daily rb for inpos num cd days nns resulted vbd in inpos approximately rb num cd decrease nn in inpos atorvastatin nn auc nn values nns in inpos num cd healthy jj males nns
false	16	20	concomitant jj administration nn of inpos fenofibrate nn lrb_equivalent jj to topos num cd mg nn tricor nn rrb_with inpos atorvastatin nn once rb daily rb for inpos num cd days nns resulted vbd in inpos approximately rb num cd decrease nn in inpos atorvastatin nn auc nn values nns in inpos num cd healthy jj males nns
false	2	18	the dt atorvastatin nn cmax nn values nns were vbd not rb significantly rb affected vbn by inpos fenofibrate nn
false	6	18	the dt pharmacokinetics nns of inpos fenofibric_acid nn were vbd not rb significantly rb affected vbn by inpos atorvastatin nn
false	6	14	drug nn interactions nns with inpos b_blockers nn concomitant jj use nn of inpos fenoldopam nn with inpos b_blockers nns should md be vb avoided vbn
advise	6	10	concomitant jj use nn of inpos fenoldopam nn with inpos b_blockers nn should md be vb avoided vbn
false	18	36	although inpos there ex have vbp been vbn no dt formal jj interaction nn studies nns intravenous jj fenoldopam nn has vbz been vbn administered vbn safely rb with inpos drugs nns such jj as inpos digitalis nn and cc sublingual jj nitroglycerin nn
false	18	42	although inpos there ex have vbp been vbn no dt formal jj interaction nn studies nns intravenous jj fenoldopam nn has vbz been vbn administered vbn safely rb with inpos drugs nns such jj as inpos digitalis nn and cc sublingual jj nitroglycerin nn
false	36	42	although inpos there ex have vbp been vbn no dt formal jj interaction nn studies nns intravenous jj fenoldopam nn has vbz been vbn administered vbn safely rb with inpos drugs nns such jj as inpos digitalis nn and cc sublingual jj nitroglycerin nn
false	12	18	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nn such jj as inpos ap_blockers nns
false	12	18	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nn such jj as inpos calcium_channel_blockers nns
false	12	18	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nn such jj as inpos ace_inhibitors nns
false	12	18	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nn such jj as inpos diuretics nn
false	12	28	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nn such jj as inpos ap_blockers nns calcium_channel_blockers nns ace_inhibitors nns diuretics nns lrb_both dt thiazide nn like jj and cc loop nn
false	18	22	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nns such jj as inpos ap_blockers nns lrb_both dt thiazide nn like jj and cc loop nn
false	18	22	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nns such jj as inpos calcium_channel_blockers nns lrb_both dt thiazide nn like jj and cc loop nn
false	18	22	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nns such jj as inpos ace_inhibitors nns lrb_both dt thiazide nn like jj and cc loop nn
false	18	22	there ex is vbz limited jj experience nn with inpos concomitant jj antihypertensive_agents nns such jj as inpos diuretics nn lrb_both dt thiazide nn like jj and cc loop nn
mechanism	6	18	the dt coadministration nn of inpos aspirin nn decreases vbz the dt biologic jj half_life nn of inpos fenoprofen nn because inpos of inpos an dt increase nn in inpos metabolic jj clearance nn that wdt results vbz in inpos a dt greater jjr amount nn of inpos hydroxylated_fenoprofen nn in inpos the dt urine nn
false	6	48	the dt coadministration nn of inpos aspirin nn decreases vbz the dt biologic jj half_life nn of inpos fenoprofen nn because inpos of inpos an dt increase nn in inpos metabolic jj clearance nn that wdt results vbz in inpos a dt greater jjr amount nn of inpos hydroxylated_fenoprofen nn in inpos the dt urine nn
mechanism	12	16	although inpos the dt mechanism nn of inpos interaction nn between inpos fenoprofen nn and cc aspirin nn is vbz not rb totally rb known vbn enzyme nn induction nn and cc displacement nn of inpos fenoprofen nn from inpos plasma nn albumin nn binding nn sites nns are vbp possibilities nns
false	16	12	although inpos the dt mechanism nn of inpos interaction nn between inpos fenoprofen nn and cc aspirin nn is vbz not rb totally rb known vbn enzyme nn induction nn and cc displacement nn of inpos fenoprofen nn from inpos plasma nn albumin nn binding nn sites nns are vbp possibilities nns
false	2	30	because inpos nalfon nn has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nns is vbz not rb recommended vbn
false	2	30	because inpos nalfon nn has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nns is vbz not rb recommended vbn
false	2	66	because inpos nalfon nn has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nn is vbz not rb recommended vbn
false	30	2	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nn the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nns is vbz not rb recommended vbn
false	30	2	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nn and cc salicylates nns is vbz not rb recommended vbn
false	30	66	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nn is vbz not rb recommended vbn
mechanism	30	2	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nn the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nns is vbz not rb recommended vbn
false	30	2	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nn and cc salicylates nns is vbz not rb recommended vbn
false	30	66	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nn is vbz not rb recommended vbn
false	2	66	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nn the dt concomitant jj use nn of inpos nalfon nnp and cc salicylates nn is vbz not rb recommended vbn
advise	2	66	because inpos nalfon nnp has vbz not rb been vbn shown vbn to topos produce vb any dt additional jj effect nn beyond inpos that dt obtained vbn with inpos aspirin nn alone rb and cc because inpos aspirin nn increases vbz the dt rate nn of inpos excretion nn of inpos nalfon nnp the dt concomitant jj use nn of inpos nalfon nn and cc salicylates nn is vbz not rb recommended vbn
mechanism	6	38	chronic jj administration nn of inpos phenobarbital nn a dt known vbn enzyme nn inducer nn may md be vb associated vbn with inpos a dt decrease nn in inpos the dt plasma nn half_life nn of inpos fenoprofen nn
advise	2	24	when wrb phenobarbital nn is vbz added vbn to topos or cc withdrawn vbn from inpos treatment nn dosage nn adjustment nn of inpos nalfon nn may md be vb required vbn
effect	6	14	in inpos patients nns receiving vbg coumarin_type_anticoagulants nn the dt addition nn of inpos nalfon nn to topos therapy nn could md prolong vb the dt prothrombin nn time nn
effect	6	22	patients nns treated vbn with inpos nalfon nn may md be vb resistant jj to topos the dt effects nns of inpos loop_diuretics nn
advise	6	12	in inpos patients nns receiving vbg nalfon nn and cc a dt steroid nn concomitantly rb any dt reduction nn in inpos steroid nn dosage nn should md be vb gradual jj in inpos order nn to topos avoid vb the dt possible jj complications nns of inpos sudden jj steroid nn withdrawal nn
false	6	12	in inpos patients nns receiving vbg nalfon nn and cc a dt steroid nn concomitantly rb any dt reduction nn in inpos steroid nn dosage nn should md be vb gradual jj in inpos order nn to topos avoid vb the dt possible jj complications nns of inpos sudden jj steroid nn withdrawal nn
false	6	12	in inpos patients nns receiving vbg nalfon nn and cc a dt steroid nn concomitantly rb any dt reduction nn in inpos steroid nn dosage nn should md be vb gradual jj in inpos order nn to topos avoid vb the dt possible jj complications nns of inpos sudden jj steroid nn withdrawal nn
false	14	50	agents nns affecting vbg cytochrome nn p450 nn 3a4 nn isoenzyme nn system nn fentanyl nn is vbz metabolized vbn mainly rb via inpos the dt human jj cytochrome nn p450 nn 3a4 nn isoenzyme nn system nn therefore rb potential jj interactions nns may md occur vb when wrb duragesic nn is vbz given vbn concurrently rb with inpos agents nns that wdt affect vbp cyp3a4 nn activity nn
mechanism	10	14	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos ketoconazole nn itraconazole nn troleandomycin nn clarithromycin nn nelfinavir nn nefazadone nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
mechanism	10	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos ketoconazole nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
mechanism	10	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos itraconazole nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
mechanism	10	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos troleandomycin nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
mechanism	10	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos clarithromycin nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
mechanism	10	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos nelfinavir nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	14	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos ketoconazole nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	14	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos itraconazole nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	14	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos troleandomycin nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	14	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos clarithromycin nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	14	30	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos nelfinavir nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	14	10	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos ketoconazole nn itraconazole nn troleandomycin nn clarithromycin nn nelfinavir nn nefazadone nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	30	10	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos ketoconazole nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	30	10	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos itraconazole nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	30	10	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos troleandomycin nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	30	10	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos clarithromycin nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	30	10	the dt concomitant jj use nn of inpos transdermal jj fentanyl nn with inpos ritonavir nn or cc other jj potent jj 3a4 nn inhibitors nns such jj as inpos nelfinavir nn may md result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns
false	18	22	the dt concomitant jj use nn of inpos other jj cyp3a4 nn inhibitors nns such jj as inpos diltiazem nn and cc erythromycin nn with inpos transdermal jj fentanyl nn may md also rb result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns which wdt could md increase vb prolong vb adverse jj drug nn effects nns may md cause vb serious jj respiratory jj depression nn
mechanism	18	28	the dt concomitant jj use nn of inpos other jj cyp3a4 nn inhibitors nns such jj as inpos diltiazem nn and cc erythromycin nn with inpos transdermal jj fentanyl nn may md also rb result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns which wdt could md increase vb prolong vb adverse jj drug nn effects nns may md cause vb serious jj respiratory jj depression nn
false	18	28	the dt concomitant jj use nn of inpos other jj cyp3a4 nn inhibitors nns such jj as inpos diltiazem nn and cc erythromycin nn with inpos transdermal jj fentanyl nn may md also rb result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns which wdt could md increase vb prolong vb adverse jj drug nn effects nns may md cause vb serious jj respiratory jj depression nn
mechanism	22	28	the dt concomitant jj use nn of inpos other jj cyp3a4 nn inhibitors nns such jj as inpos diltiazem nn and cc erythromycin nn with inpos transdermal jj fentanyl nn may md also rb result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns which wdt could md increase vb prolong vb adverse jj drug nn effects nns may md cause vb serious jj respiratory jj depression nn
false	22	28	the dt concomitant jj use nn of inpos other jj cyp3a4 nn inhibitors nns such jj as inpos diltiazem nn and cc erythromycin nn with inpos transdermal jj fentanyl nn may md also rb result vb in inpos an dt increase nn in inpos fentanyl nn plasma nn concentrations nns which wdt could md increase vb prolong vb adverse jj drug nn effects nns may md cause vb serious jj respiratory jj depression nn
effect	8	14	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nns hypnotics nns tranquilizers nns general jj anesthetics nns phenothiazines nns skeletal_muscle_relaxants nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	30	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj hypnotics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj tranquilizers nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj benzodiazepines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj anesthetics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj phenothiazines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj skeletal_muscle_relaxants nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	46	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nns hypnotics nns tranquilizers nns general jj anesthetics nns phenothiazines nns skeletal_muscle_relaxants nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	14	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nns hypnotics nns tranquilizers nns general jj anesthetics nns phenothiazines nns skeletal_muscle_relaxants nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	30	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj hypnotics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj tranquilizers nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj benzodiazepines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj anesthetics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj phenothiazines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	28	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj skeletal_muscle_relaxants nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
effect	8	46	the dt concomitant jj use nn of inpos fentanyl nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nns hypnotics nns tranquilizers nns general jj anesthetics nns phenothiazines nns skeletal_muscle_relaxants nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj opioids nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	30	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nn hypnotics nns tranquilizers nns general jj anesthetics nns phenothiazines nns skeletal_muscle_relaxants nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj hypnotics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj tranquilizers nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj benzodiazepines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj anesthetics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj phenothiazines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	28	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj skeletal_muscle_relaxants nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	14	46	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nn including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nns hypnotics nns tranquilizers nns general jj anesthetics nns phenothiazines nns skeletal_muscle_relaxants nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	28	30	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nn sedatives nn hypnotics nns tranquilizers nns general jj anesthetics nns phenothiazines nns skeletal_muscle_relaxants nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	30	34	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nn hypnotics nns tranquilizers nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	30	34	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nn hypnotics nns benzodiazepines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	28	32	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj hypnotics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	34	38	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nns hypnotics nns tranquilizers nn general jj phenothiazines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	34	38	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj opioids nns sedatives nns hypnotics nns benzodiazepines nn general jj phenothiazines nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	28	32	the dt concomitant jj use nn of inpos duragesic nn with inpos other jj central_nervous_system_depressants nns including vbg but cc not rb limited vbn to topos other jj anesthetics nns and cc alcohol nn may md cause vb respiratory jj depression nn hypotension nn profound jj sedation nn or cc potentially rb result vbp in inpos coma nn or cc death nn
false	0	2	mao_inhibitors nn duragesic nn is vbz not rb recommended vbn for inpos use nn in inpos patients nns who wp have vbp received vbn maoi nn within inpos num cd days nns because inpos severe jj and cc unpredictable jj potentiation nn by inpos mao_inhibitors nns has vbz been vbn reported vbn with inpos opioid_analgesics nns
advise	2	24	mao_inhibitors nns duragesic nn is vbz not rb recommended vbn for inpos use nn in inpos patients nns who wp have vbp received vbn maoi nn within inpos num cd days nns because inpos severe jj and cc unpredictable jj potentiation nn by inpos mao_inhibitors nns has vbz been vbn reported vbn with inpos opioid_analgesics nns
false	2	0	mao_inhibitors nns duragesic nn is vbz not rb recommended vbn for inpos use nn in inpos patients nns who wp have vbp received vbn maoi nn within inpos num cd days nns because inpos severe jj and cc unpredictable jj potentiation nn by inpos mao_inhibitors nn has vbz been vbn reported vbn with inpos opioid_analgesics nns
false	2	54	mao_inhibitors nns duragesic nn is vbz not rb recommended vbn for inpos use nn in inpos patients nns who wp have vbp received vbn maoi nn within inpos num cd days nns because inpos severe jj and cc unpredictable jj potentiation nn by inpos mao_inhibitors nns has vbz been vbn reported vbn with inpos opioid_analgesics nn
false	22	42	duragesic nn is vbz not rb recommended vbn for inpos use nn in inpos patients nns who wp have vbp received vbn maoi nn within inpos num cd days nns because inpos severe jj and cc unpredictable jj potentiation nn by inpos mao_inhibitors nn has vbz been vbn reported vbn with inpos opioid_analgesics nns
false	22	52	duragesic nn is vbz not rb recommended vbn for inpos use nn in inpos patients nns who wp have vbp received vbn maoi nn within inpos num cd days nns because inpos severe jj and cc unpredictable jj potentiation nn by inpos mao_inhibitors nns has vbz been vbn reported vbn with inpos opioid_analgesics nn
advise	42	52	duragesic nn is vbz not rb recommended vbn for inpos use nn in inpos patients nns who wp have vbp received vbn maoi nn within inpos num cd days nns because inpos severe jj and cc unpredictable jj potentiation nn by inpos mao_inhibitors nn has vbz been vbn reported vbn with inpos opioid_analgesics nn
false	6	10	drug nnp interaction nnp with inpos erythromycin nn and cc ketoconazole nn fexofenadine nn has vbz been vbn shown vbn to topos exhibit vb minimal jj metabolism nn
false	6	12	drug nnp interaction nnp with inpos erythromycin nn and cc ketoconazole nn fexofenadine nn has vbz been vbn shown vbn to topos exhibit vb minimal jj metabolism nn
false	10	12	drug nnp interaction nnp with inpos erythromycin nn and cc ketoconazole nn fexofenadine nn has vbz been vbn shown vbn to topos exhibit vb minimal jj metabolism nn
mechanism	8	14	however rb co nn administration nn of inpos fexofenadine_hydrochloride nn with inpos either cc ketoconazole nn or cc erythromycin nn led vbd to topos increased vbn plasma nn concentrations nns of inpos fexofenadine nn
mechanism	8	18	however rb co nn administration nn of inpos fexofenadine_hydrochloride nn with inpos either cc ketoconazole nn or cc erythromycin nn led vbd to topos increased vbn plasma nn concentrations nns of inpos fexofenadine nn
false	14	18	however rb co nn administration nn of inpos fexofenadine_hydrochloride nn with inpos either cc ketoconazole nn or cc erythromycin nn led vbd to topos increased vbn plasma nn concentrations nns of inpos fexofenadine nn
false	14	8	however rb co nn administration nn of inpos fexofenadine_hydrochloride nn with inpos either cc ketoconazole nn or cc erythromycin nn led vbd to topos increased vbn plasma nn concentrations nns of inpos fexofenadine nn
false	18	8	however rb co nn administration nn of inpos fexofenadine_hydrochloride nn with inpos either cc ketoconazole nn or cc erythromycin nn led vbd to topos increased vbn plasma nn concentrations nns of inpos fexofenadine nn
false	0	18	fexofenadine nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos either cc erythromycin nn or cc ketoconazole nn
false	0	22	fexofenadine nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos either cc erythromycin nn or cc ketoconazole nn
false	18	22	fexofenadine nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos either cc erythromycin nn or cc ketoconazole nn
false	8	26	in inpos num cd separate jj studies nns fexofenadine_hydrochloride nn num cd mg nn twice rb daily rb was vbd co_administered vbn with inpos either cc erythromycin nn num cd mg nn every dt num cd hours nns or cc ketoconazole nn num cd mg nn once rb daily rb under inpos steady_state jj conditions nns to topos healthy jj volunteers nns
false	8	40	in inpos num cd separate jj studies nns fexofenadine_hydrochloride nn num cd mg nn twice rb daily rb was vbd co_administered vbn with inpos either cc erythromycin nn num cd mg nn every dt num cd hours nns or cc ketoconazole nn num cd mg nn once rb daily rb under inpos steady_state jj conditions nns to topos healthy jj volunteers nns
false	26	40	in inpos num cd separate jj studies nns fexofenadine_hydrochloride nn num cd mg nn twice rb daily rb was vbd co_administered vbn with inpos either cc erythromycin nn num cd mg nn every dt num cd hours nns or cc ketoconazole nn num cd mg nn once rb daily rb under inpos steady_state jj conditions nns to topos healthy jj volunteers nns
false	28	42	no dt differences nns in inpos adverse jj events nns or cc qtc nn interval nn were vbd observed vbn when wrb subjects nns were vbd administered vbn fexofenadine_hydrochloride nn alone rb or cc in inpos combination nn with inpos either cc erythromycin nn or cc ketoconazole nn
false	28	46	no dt differences nns in inpos adverse jj events nns or cc qtc nn interval nn were vbd observed vbn when wrb subjects nns were vbd administered vbn fexofenadine_hydrochloride nn alone rb or cc in inpos combination nn with inpos either cc erythromycin nn or cc ketoconazole nn
false	42	46	no dt differences nns in inpos adverse jj events nns or cc qtc nn interval nn were vbd observed vbn when wrb subjects nns were vbd administered vbn fexofenadine_hydrochloride nn alone rb or cc in inpos combination nn with inpos either cc erythromycin nn or cc ketoconazole nn
false	8	12	these dt studies nns indicate vbp that inpos ketoconazole nn or cc erythromycin nn co_administration nn enhances vbz fexofenadine nn gastrointestinal jj absorption nn
mechanism	8	18	these dt studies nns indicate vbp that inpos ketoconazole nn or cc erythromycin nn co_administration nn enhances vbz fexofenadine nn gastrointestinal jj absorption nn
mechanism	12	18	these dt studies nns indicate vbp that inpos ketoconazole nn or cc erythromycin nn co_administration nn enhances vbz fexofenadine nn gastrointestinal jj absorption nn
false	14	58	this dt observed vbn increase nn in inpos the dt bioavailability nn of inpos fexofenadine nn may md be vb due jj to topos transport_related jj effects nns such jj as inpos p_glycoprotein. fw in fw vivo fw animal nn studies nns also rb suggest vbp that inpos in inpos addition nn to topos enhancing vbg absorption nn ketoconazole nn decreases vbz fexofenadine nn gastrointestinal jj secretion nn while inpos erythromycin nn may md also rb decrease vb biliary jj excretion nn
false	14	70	this dt observed vbn increase nn in inpos the dt bioavailability nn of inpos fexofenadine nn may md be vb due jj to topos transport_related jj effects nns such jj as inpos p_glycoprotein. fw in fw vivo fw animal nn studies nns also rb suggest vbp that inpos in inpos addition nn to topos enhancing vbg absorption nn ketoconazole nn decreases vbz fexofenadine nn gastrointestinal jj secretion nn while inpos erythromycin nn may md also rb decrease vb biliary jj excretion nn
mechanism	58	14	this dt observed vbn increase nn in inpos the dt bioavailability nn of inpos fexofenadine nn may md be vb due jj to topos transport_related jj effects nns such jj as inpos p_glycoprotein. fw in fw vivo fw animal nn studies nns also rb suggest vbp that inpos in inpos addition nn to topos enhancing vbg absorption nn ketoconazole nn decreases vbz fexofenadine nn gastrointestinal jj secretion nn while inpos erythromycin nn may md also rb decrease vb biliary jj excretion nn
false	58	70	this dt observed vbn increase nn in inpos the dt bioavailability nn of inpos fexofenadine nn may md be vb due jj to topos transport_related jj effects nns such jj as inpos p_glycoprotein. fw in fw vivo fw animal nn studies nns also rb suggest vbp that inpos in inpos addition nn to topos enhancing vbg absorption nn ketoconazole nn decreases vbz fexofenadine nn gastrointestinal jj secretion nn while inpos erythromycin nn may md also rb decrease vb biliary jj excretion nn
false	14	70	this dt observed vbn increase nn in inpos the dt bioavailability nn of inpos fexofenadine nn may md be vb due jj to topos transport_related jj effects nns such jj as inpos p_glycoprotein. fw in fw vivo fw animal nn studies nns also rb suggest vbp that inpos in inpos addition nn to topos enhancing vbg absorption nn ketoconazole nn decreases vbz fexofenadine nn gastrointestinal jj secretion nn while inpos erythromycin nn may md also rb decrease vb biliary jj excretion nn
false	6	18	drug nn interactions nns with inpos antacids nn administration nn of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	6	30	drug nn interactions nns with inpos antacids nn administration nn of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	6	34	drug nn interactions nns with inpos antacids nn administration nn of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	6	38	drug nn interactions nns with inpos antacids nn administration nn of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg maalox nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	6	18	drug nn interactions nns with inpos antacids nn administration nn of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
mechanism	18	30	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
mechanism	18	34	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
mechanism	18	6	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
mechanism	18	38	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg maalox nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	30	34	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	30	6	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	30	38	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg maalox nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	30	18	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	34	6	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	34	38	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg maalox nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	34	18	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	6	18	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg antacid nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
false	38	18	drug nn interactions nns with inpos antacids nnp administration nnp of inpos num cd mg nn of inpos fexofenadine_hydrochloride nn within inpos num cd minutes nns of inpos an dt aluminum nn and cc magnesium nn containing vbg maalox nn decreased vbd fexofenadine nn auc nn by inpos num cd and cc cmax nn by inpos num cd
advise	0	18	allegra nn should md not rb be vb taken vbn closely rb in inpos time nn with inpos aluminum nn and cc magnesium nn containing vbg antacids nns
advise	0	22	allegra nn should md not rb be vb taken vbn closely rb in inpos time nn with inpos aluminum nn and cc magnesium nn containing vbg antacids nns
false	0	26	allegra nn should md not rb be vb taken vbn closely rb in inpos time nn with inpos aluminum nn and cc magnesium nn containing vbg antacids nn
false	18	22	allegra nn should md not rb be vb taken vbn closely rb in inpos time nn with inpos aluminum nn and cc magnesium nn containing vbg antacids nns
false	18	26	allegra nn should md not rb be vb taken vbn closely rb in inpos time nn with inpos aluminum nn and cc magnesium nn containing vbg antacids nn
false	22	26	allegra nn should md not rb be vb taken vbn closely rb in inpos time nn with inpos aluminum nn and cc magnesium nn containing vbg antacids nn
false	12	22	therefore rb to topos maximize vb the dt effects nns of inpos fexofenadine nn it prp is vbz recommended vbn that inpos allegra nn should md be vb taken vbn with inpos water nn
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetylsalicylic_acid nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos analgesics nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos benzodiazepines nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nn acetylsalicylic_acid nn a_blockers nns analgesics nns angiotensin_converting_enzyme_ace_inhibitors nns b_blockers nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos nitrates nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos diuretics nns and cc quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos h2_antagonists nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos hmg_coa_reductase_inhibitors nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos prostaglandin_synthetase_inhibitors nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	86	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nn acetylsalicylic_acid nn a_blockers nns analgesics nns angiotensin_converting_enzyme_ace_inhibitors nns anticonvulsants nns benzodiazepines nns b_blockers nns calcium_channel_blockers nns cardiac jj nitrates nns diuretics nns h2_antagonists nns hmg_coa_reductase_inhibitors nns prostaglandin_synthetase_inhibitors nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	20	48	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos quinolone_anti_infectives nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	52	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nns angiotensin_converting_enzyme_ace_inhibitors nns b_blockers nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	52	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetylsalicylic_acid nns angiotensin_converting_enzyme_ace_inhibitors nns b_blockers nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetylsalicylic_acid nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	52	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos analgesics nn angiotensin_converting_enzyme_ace_inhibitors nns b_blockers nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos analgesics nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	12	22	other jj concomitant jj therapy nn although inpos specific jj interaction nn angiotensin_converting_enzyme_ace_inhibitors nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	52	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos anticonvulsants nn benzodiazepines nns h2_antagonists nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	52	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos anticonvulsants nn benzodiazepines nns prostaglandin_synthetase_inhibitors nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	12	22	other jj concomitant jj therapy nn although inpos specific jj interaction nn anticonvulsants nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	52	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos anticonvulsants nn benzodiazepines nns quinolone_anti_infectives nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos benzodiazepines nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	58	68	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nn acetylsalicylic_acid nn a_blockers nns analgesics nns angiotensin_converting_enzyme_ace_inhibitors nns b_blockers nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	12	22	other jj concomitant jj therapy nn although inpos specific jj interaction nn calcium_channel_blockers nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos nitrates nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	12	22	other jj concomitant jj therapy nn although inpos specific jj interaction nn diuretics nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos h2_antagonists nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	48	58	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos hmg_coa_reductase_inhibitors nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	76	86	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nn acetylsalicylic_acid nn a_blockers nns analgesics nns angiotensin_converting_enzyme_ace_inhibitors nns anticonvulsants nns benzodiazepines nns b_blockers nns calcium_channel_blockers nns cardiac jj nitrates nns diuretics nns h2_antagonists nns hmg_coa_reductase_inhibitors nns prostaglandin_synthetase_inhibitors nn lrb_also rb referred vbn to topos as inpos nsaids nn rrb_and cc quinolone_anti_infectives nns without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	86	88	other jj concomitant jj therapy nn although inpos specific jj interaction nn studies nns were vbd not rb performed vbn finasteride nn doses nns of inpos num cd mg nn or cc more jjr were vbd concomitantly rb used vbn in inpos clinical jj studies nns with inpos acetaminophen nn acetylsalicylic_acid nn a_blockers nns analgesics nns angiotensin_converting_enzyme_ace_inhibitors nns anticonvulsants nns benzodiazepines nns b_blockers nns calcium_channel_blockers nns cardiac jj nitrates nns diuretics nns h2_antagonists nns hmg_coa_reductase_inhibitors nns prostaglandin_synthetase_inhibitors nns lrb_also rb referred vbn to topos as inpos nsaids nn rrb_quinolone_anti_infectives nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	14	tambocor nn has vbz been vbn administered vbn to topos patients nns receiving vbg digitalis_preparations nn or cc b_adrenergic_blocking_agents nns without inpos adverse jj effects nns
false	0	18	tambocor nn has vbz been vbn administered vbn to topos patients nns receiving vbg digitalis_preparations nns or cc b_adrenergic_blocking_agents nn without inpos adverse jj effects nns
false	14	18	tambocor nn has vbz been vbn administered vbn to topos patients nns receiving vbg digitalis_preparations nn or cc b_adrenergic_blocking_agents nn without inpos adverse jj effects nns
mechanism	14	34	during inpos administration nn of inpos multiple jj oral jj doses nns of inpos tambocor nn to topos healthy jj subjects nns stabilized vbn on inpos a dt maintenance nn dose nn of inpos digoxin nn a dt num cd num cd increase nn in inpos plasma nn digoxin nn levels nns occurred vbd at inpos num cd hours nns postdose vbp
false	14	34	during inpos administration nn of inpos multiple jj oral jj doses nns of inpos tambocor nn to topos healthy jj subjects nns stabilized vbn on inpos a dt maintenance nn dose nn of inpos digoxin nn a dt num cd num cd increase nn in inpos plasma nn digoxin nn levels nns occurred vbd at inpos num cd hours nns postdose vbp
mechanism	14	18	in inpos a dt study nn involving vbg healthy jj subjects nns receiving vbg tambocor nn and cc propranolol nn concurrently rb plasma nn flecainide nn levels nns were vbd increased vbn about rb num cd and cc propranolol nn levels nns were vbd increased vbn about rb num cd compared vbn to topos control nn values nns
false	14	24	in inpos a dt study nn involving vbg healthy jj subjects nns receiving vbg tambocor nn and cc propranolol nn concurrently rb plasma nn flecainide nn levels nns were vbd increased vbn about rb num cd and cc propranolol nn levels nns were vbd increased vbn about rb num cd compared vbn to topos control nn values nns
false	14	18	in inpos a dt study nn involving vbg healthy jj subjects nns receiving vbg tambocor nn and cc propranolol nn concurrently rb plasma nn flecainide nn levels nns were vbd increased vbn about rb num cd and cc propranolol nn levels nns were vbd increased vbn about rb num cd compared vbn to topos control nn values nns
false	18	24	in inpos a dt study nn involving vbg healthy jj subjects nns receiving vbg tambocor nn and cc propranolol nn concurrently rb plasma nn flecainide nn levels nns were vbd increased vbn about rb num cd and cc propranolol nn levels nns were vbd increased vbn about rb num cd compared vbn to topos control nn values nns
false	24	18	in inpos a dt study nn involving vbg healthy jj subjects nns receiving vbg tambocor nn and cc propranolol nn concurrently rb plasma nn flecainide nn levels nns were vbd increased vbn about rb num cd and cc propranolol nn levels nns were vbd increased vbn about rb num cd compared vbn to topos control nn values nns
false	10	14	in inpos this dt formal jj interaction nn study nn tambocor nn and cc propranolol nn were vbd each dt found vbn to topos have vb negative jj inotropic jj effects nns
effect	12	16	the dt effects nns of inpos concomitant jj administration nn of inpos tambocor nn and cc propranolol nn on inpos the dt pr nn interval nn were vbd less jjr than inpos additive jj
false	2	16	in inpos tambocor nn clinical jj trials nns patients nns who wp were vbd receiving vbg b_blockers nn concurrently rb did vbd not rb experience vb an dt increased vbn incidence nn of inpos side nn effects nns
effect	18	22	nevertheless rb the dt possibility nn of inpos additive jj negative jj inotropic jj effects nns of inpos b_blockers nn and cc flecainide nn should md be vb recognized vbn
false	0	22	tambocor nn has vbz been vbn used vbn in inpos a dt large jj number nn of inpos patients nns receiving vbg diuretics nn without inpos apparent jj interaction nn
mechanism	14	34	limited jj data nns in inpos patients nns receiving vbg known vbn enzyme nn phenytoin nn indicate vbp only rb a dt num cd increase nn in inpos the dt rate nn of inpos flecainide nn elimination nn
mechanism	14	34	limited jj data nns in inpos patients nns receiving vbg known vbn enzyme nn phenobarbital nn indicate vbp only rb a dt num cd increase nn in inpos the dt rate nn of inpos flecainide nn elimination nn
mechanism	14	34	limited jj data nns in inpos patients nns receiving vbg known vbn enzyme nn carbamazepine nn indicate vbp only rb a dt num cd increase nn in inpos the dt rate nn of inpos flecainide nn elimination nn
mechanism	8	18	in inpos healthy jj subjects nns receiving vbg cimetidine nn for inpos num cd week nn plasma nn flecainide nn levels nns increased vbd by inpos about rb num cd and cc half_life nn increased vbn by inpos about rb num cd
mechanism	2	10	when wrb amiodarone nn is vbz added vbn to topos flecainide nn therapy nn plasma nn flecainide nn levels nns may md increase vb two_fold jj or cc more jjr in inpos some dt patients nns if inpos flecainide nn dosage nn is vbz not rb reduced vbn
false	2	10	when wrb amiodarone nn is vbz added vbn to topos flecainide nn therapy nn plasma nn flecainide nn levels nns may md increase vb two_fold jj or cc more jjr in inpos some dt patients nns if inpos flecainide nn dosage nn is vbz not rb reduced vbn
false	2	10	when wrb amiodarone nn is vbz added vbn to topos flecainide nn therapy nn plasma nn flecainide nn levels nns may md increase vb two_fold jj or cc more jjr in inpos some dt patients nns if inpos flecainide nn dosage nn is vbz not rb reduced vbn
mechanism	14	28	drugs nns that wdt inhibit vbp cytochrome nn p450iid6 nn such jj as inpos quinidine nn might md increase vb the dt plasma nn concentrations nns of inpos flecainide nn in inpos patients nns that wdt are vbp on inpos chronic jj flecainide nn therapy nn
false	14	28	drugs nns that wdt inhibit vbp cytochrome nn p450iid6 nn such jj as inpos quinidine nn might md increase vb the dt plasma nn concentrations nns of inpos flecainide nn in inpos patients nns that wdt are vbp on inpos chronic jj flecainide nn therapy nn
false	18	22	there ex has vbz been vbn little jj experience nn with inpos the dt coadministration nn of inpos tambocor nn either cc disopyramide nn verapamil nn
false	18	24	there ex has vbz been vbn little jj experience nn with inpos the dt coadministration nn of inpos tambocor nn either cc disopyramide nn verapamil nn
false	22	24	there ex has vbz been vbn little jj experience nn with inpos the dt coadministration nn of inpos tambocor nn either cc disopyramide nn verapamil nn
false	30	38	because inpos both dt of inpos these dt drugs nns have vbp negative jj inotropic jj properties nns and cc the dt effects nns of inpos coadministration nn with inpos tambocor nn are vbp unknown jj neither cc disopyramide nn nor cc verapamil nn should md be vb administered vbn concurrently rb with inpos tambocor nn unless inpos in inpos the dt judgment nn of inpos the dt physician nn the dt benefits nns of inpos this dt combination nn outweigh vbp the dt risks nns
false	30	42	because inpos both dt of inpos these dt drugs nns have vbp negative jj inotropic jj properties nns and cc the dt effects nns of inpos coadministration nn with inpos tambocor nn are vbp unknown jj neither cc disopyramide nn nor cc verapamil nn should md be vb administered vbn concurrently rb with inpos tambocor nn unless inpos in inpos the dt judgment nn of inpos the dt physician nn the dt benefits nns of inpos this dt combination nn outweigh vbp the dt risks nns
false	38	42	because inpos both dt of inpos these dt drugs nns have vbp negative jj inotropic jj properties nns and cc the dt effects nns of inpos coadministration nn with inpos tambocor nn are vbp unknown jj neither cc disopyramide nn nor cc verapamil nn should md be vb administered vbn concurrently rb with inpos tambocor nn unless inpos in inpos the dt judgment nn of inpos the dt physician nn the dt benefits nns of inpos this dt combination nn outweigh vbp the dt risks nns
advise	38	30	because inpos both dt of inpos these dt drugs nns have vbp negative jj inotropic jj properties nns and cc the dt effects nns of inpos coadministration nn with inpos tambocor nn are vbp unknown jj neither cc disopyramide nn nor cc verapamil nn should md be vb administered vbn concurrently rb with inpos tambocor nn unless inpos in inpos the dt judgment nn of inpos the dt physician nn the dt benefits nns of inpos this dt combination nn outweigh vbp the dt risks nns
advise	42	30	because inpos both dt of inpos these dt drugs nns have vbp negative jj inotropic jj properties nns and cc the dt effects nns of inpos coadministration nn with inpos tambocor nn are vbp unknown jj neither cc disopyramide nn nor cc verapamil nn should md be vb administered vbn concurrently rb with inpos tambocor nn unless inpos in inpos the dt judgment nn of inpos the dt physician nn the dt benefits nns of inpos this dt combination nn outweigh vbp the dt risks nns
false	20	24	there ex has vbz been vbn too rb little jj experience nn with inpos the dt coadministration nn of inpos tambocor nn with inpos nifedipine nn or cc diltiazem nn to topos recommend vb concomitant jj use nn
false	20	28	there ex has vbz been vbn too rb little jj experience nn with inpos the dt coadministration nn of inpos tambocor nn with inpos nifedipine nn or cc diltiazem nn to topos recommend vb concomitant jj use nn
false	24	28	there ex has vbz been vbn too rb little jj experience nn with inpos the dt coadministration nn of inpos tambocor nn with inpos nifedipine nn or cc diltiazem nn to topos recommend vb concomitant jj use nn
false	0	4	cytosine_arabinoside nn a dt cytostatic_agent nn has vbz been vbn reported vbn to topos inactivate vb the dt antifungal jj activity nn of inpos flucytosine nn by inpos competitive jj inhibition nn
effect	0	24	cytosine_arabinoside nn a dt cytostatic_agent nn has vbz been vbn reported vbn to topos inactivate vb the dt antifungal jj activity nn of inpos flucytosine nn by inpos competitive jj inhibition nn
false	4	24	cytosine_arabinoside nn a dt cytostatic_agent nn has vbz been vbn reported vbn to topos inactivate vb the dt antifungal jj activity nn of inpos flucytosine nn by inpos competitive jj inhibition nn
advise	6	18	the dt use nn of inpos fludara nn for inpos injection nn in inpos combination nn with inpos pentostatin nn is vbz not rb recommended vbn due inpos to topos the dt risk nn of inpos severe jj pulmonary jj toxicity nn
false	0	4	amphotericin_b nn or cc potassium_depleting_diuretics nn enhanced vbd hypokalemia nn
false	0	4	amphotericin_b nn or cc benzothiadiazines nn enhanced vbd hypokalemia nn
false	0	4	amphotericin_b nn or cc ethacrynic_acid nn enhanced vbd hypokalemia nn
false	0	4	amphotericin_b nn or cc furosemide nn enhanced vbd hypokalemia nn
false	2	18	rarely rb salicylate nn toxicity nn may md occur vb in inpos patients nns who wp discontinue vbp steroids nn after inpos concurrent jj high_dose jj aspirin nn therapy nn
false	2	26	rarely rb salicylate nn toxicity nn may md occur vb in inpos patients nns who wp discontinue vbp steroids nns after inpos concurrent jj high_dose jj aspirin nn therapy nn
effect	18	26	rarely rb salicylate nn toxicity nn may md occur vb in inpos patients nns who wp discontinue vbp steroids nn after inpos concurrent jj high_dose jj aspirin nn therapy nn
false	2	18	monitor nn salicylate nn levels nns or cc the dt therapeutic jj effect nn for inpos which wdt aspirin nn is vbz given vbn
mechanism	0	10	barbiturates nn increased vbd metabolic jj clearance nn of inpos fludrocortisone_acetate nn because inpos of inpos the dt induction nn of inpos hepatic jj enzymes nns
mechanism	0	10	phenytoin nn increased vbd metabolic jj clearance nn of inpos fludrocortisone_acetate nn because inpos of inpos the dt induction nn of inpos hepatic jj enzymes nns
mechanism	0	10	rifampin nn increased vbd metabolic jj clearance nn of inpos fludrocortisone_acetate nn because inpos of inpos the dt induction nn of inpos hepatic jj enzymes nns
false	2	16	when wrb estrogen nn therapy nn is vbz initiated vbn a dt reduction nn in inpos corticosteroid nn dosage nn may md be vb required vbn and cc increased vbn amounts nns may md be vb required vbn when wrb estrogen nn is vbz terminated vbn
false	16	2	when wrb estrogen nn therapy nn is vbz initiated vbn a dt reduction nn in inpos corticosteroid nn dosage nn may md be vb required vbn and cc increased vbn amounts nns may md be vb required vbn when wrb estrogen nn is vbz terminated vbn
false	4	10	interaction nn with inpos central_nervous_system_depressants nn other jj than inpos benzodiazepines nn has vbz not rb been vbn specifically rb studied vbn
false	14	22	however rb no dt deleterious jj interactions nns were vbd seen vbn when wrb romazicon nn was vbd administered vbn after inpos narcotics nns muscle nn relaxant jj antagonists nns administered vbn in inpos conjunction nn with inpos sedation nn or cc anesthesia nn
false	14	22	however rb no dt deleterious jj interactions nns were vbd seen vbn when wrb romazicon nn was vbd administered vbn after inpos anesthetics nns muscle nn relaxant jj antagonists nns administered vbn in inpos conjunction nn with inpos sedation nn or cc anesthesia nn
false	14	22	however rb no dt deleterious jj interactions nns were vbd seen vbn when wrb romazicon nn was vbd administered vbn after inpos muscle_relaxants nn muscle nn relaxant jj antagonists nns administered vbn in inpos conjunction nn with inpos sedation nn or cc anesthesia nn
effect	12	44	particular jj caution nn is vbz necessary jj when wrb using vbg romazicon nn in inpos cases nns of inpos mixed vbn drug nn overdosage nn since inpos the dt toxic jj effects nns of inpos other jj drugs nns taken vbn in inpos cyclic_antidepressants nn may md emerge vb with inpos the dt reversal nn of inpos the dt benzodiazepine nn effect nn by inpos flumazenil nn
false	12	60	particular jj caution nn is vbz necessary jj when wrb using vbg romazicon nn in inpos cases nns of inpos mixed vbn drug nn overdosage nn since inpos the dt toxic jj effects nns of inpos other jj drugs nns taken vbn in inpos overdose nn may md emerge vb with inpos the dt reversal nn of inpos the dt benzodiazepine nn effect nn by inpos flumazenil nn
false	12	66	particular jj caution nn is vbz necessary jj when wrb using vbg romazicon nn in inpos cases nns of inpos mixed vbn drug nn overdosage nn since inpos the dt toxic jj effects nns of inpos other jj drugs nns taken vbn in inpos overdose nn may md emerge vb with inpos the dt reversal nn of inpos the dt benzodiazepine nn effect nn by inpos flumazenil nn
false	44	60	particular jj caution nn is vbz necessary jj when wrb using vbg romazicon nn in inpos cases nns of inpos mixed vbn drug nn overdosage nn since inpos the dt toxic jj effects nns of inpos other jj drugs nns taken vbn in inpos cyclic_antidepressants nn may md emerge vb with inpos the dt reversal nn of inpos the dt benzodiazepine nn effect nn by inpos flumazenil nn
false	44	66	particular jj caution nn is vbz necessary jj when wrb using vbg romazicon nn in inpos cases nns of inpos mixed vbn drug nn overdosage nn since inpos the dt toxic jj effects nns of inpos other jj drugs nns taken vbn in inpos cyclic_antidepressants nn may md emerge vb with inpos the dt reversal nn of inpos the dt benzodiazepine nn effect nn by inpos flumazenil nn
false	60	66	particular jj caution nn is vbz necessary jj when wrb using vbg romazicon nn in inpos cases nns of inpos mixed vbn drug nn overdosage nn since inpos the dt toxic jj effects nns of inpos other jj drugs nns taken vbn in inpos overdose nn may md emerge vb with inpos the dt reversal nn of inpos the dt benzodiazepine nn effect nn by inpos flumazenil nn
effect	20	34	the dt effects nns of inpos nonbenzodiazepine jj agonists nns at inpos benzodiazepine nn receptors nns such jj as inpos zopiclone nn triazolopyridazines nns others nns are vbp also rb blocked vbn by inpos romazicon nn
false	6	20	the dt pharmacokinetics nns of inpos benzodiazepines nn are vbp unaltered jj in inpos the dt presence nn of inpos flumazenil nn and cc vice nn versa nn
false	12	16	there ex is vbz no dt pharmacokinetic jj interaction nn between inpos ethanol nn and cc flumazenil nn
false	14	26	use nn in inpos ambulatory jj patients nns the dt effects nns of inpos romazicon nn may md wear vb off rp before inpos a dt long_acting_benzodiazepine nn is vbz completely rb cleared vbn from inpos the dt body nn
false	28	38	an dt adequate jj period nn of inpos observation nn must md be vb provided vbn for inpos any dt patient nn in inpos whom wp either cc long_acting_benzodiazepines nn or cc large jj doses nns of inpos short_acting_benzodiazepines nn have vbp been vbn used vbn
false	28	50	an dt adequate jj period nn of inpos observation nn must md be vb provided vbn for inpos any dt patient nn in inpos whom wp either cc long_acting_benzodiazepines nn or cc large jj doses nns of inpos short_acting_benzodiazepines nns lrb_such jj as inpos num cd mg nn of inpos midazolam nn rrb_have vbp been vbn used vbn
false	28	38	an dt adequate jj period nn of inpos observation nn must md be vb provided vbn for inpos any dt patient nn in inpos whom wp either cc diazepam nn or cc large jj doses nns of inpos short_acting_benzodiazepines nn have vbp been vbn used vbn
false	28	50	an dt adequate jj period nn of inpos observation nn must md be vb provided vbn for inpos any dt patient nn in inpos whom wp either cc diazepam nn or cc large jj doses nns of inpos short_acting_benzodiazepines nns lrb_such jj as inpos num cd mg nn of inpos midazolam nn rrb_have vbp been vbn used vbn
false	38	50	an dt adequate jj period nn of inpos observation nn must md be vb provided vbn for inpos any dt patient nn in inpos whom wp either cc long_acting_benzodiazepines nns or cc large jj doses nns of inpos short_acting_benzodiazepines nn lrb_such jj as inpos num cd mg nn of inpos midazolam nn rrb_have vbp been vbn used vbn
false	28	100	because inpos of inpos the dt increased vbn risk nn of inpos adverse jj reactions nns in inpos patients nns who wp have vbp been vbn taking vbg benzodiazepines nn on inpos a dt regular jj basis nn it prp is vbz particularly rb important jj that inpos physicians vbz query nn patients nns or cc their prp guardians nns carefully rb about inpos benzodiazepine nn alcohol nn sedative jj use nn as inpos part nn of inpos the dt history nn prior jj to topos any dt procedure nn in inpos which wdt the dt use nn of inpos romazicon nn is vbz planned vbn
false	28	94	because inpos of inpos the dt increased vbn risk nn of inpos adverse jj reactions nns in inpos patients nns who wp have vbp been vbn taking vbg benzodiazepines nns on inpos a dt regular jj basis nn it prp is vbz particularly rb important jj that inpos physicians vbz query nn patients nns or cc their prp guardians nns carefully rb about inpos benzodiazepine nn as inpos part nn of inpos the dt history nn prior jj to topos any dt procedure nn in inpos which wdt the dt use nn of inpos romazicon nn is vbz planned vbn
false	28	58	because inpos of inpos the dt increased vbn risk nn of inpos adverse jj reactions nns in inpos patients nns who wp have vbp been vbn taking vbg alcohol nn as inpos part nn of inpos the dt history nn prior jj to topos any dt procedure nn in inpos which wdt the dt use nn of inpos romazicon nn is vbz planned vbn
false	28	58	because inpos of inpos the dt increased vbn risk nn of inpos adverse jj reactions nns in inpos patients nns who wp have vbp been vbn taking vbg sedative nn as inpos part nn of inpos the dt history nn prior jj to topos any dt procedure nn in inpos which wdt the dt use nn of inpos romazicon nn is vbz planned vbn
false	18	24	talk nn to topos your prp doctor nn if inpos you prp are vbp taking vbg certain jj antibiotics nn such jj as inpos erythromycin nn
false	18	24	talk nn to topos your prp doctor nn if inpos you prp are vbp taking vbg certain jj antibiotics nn such jj as inpos clarithromycin nn
false	18	24	talk nn to topos your prp doctor nn if inpos you prp are vbp taking vbg certain jj antibiotics nn such jj as inpos azithromycin nn
false	18	24	caution nn should md be vb exercised vbn when wrb taking vbg this dt medicine nn certain jj antibiotics nn such jj as inpos erythromycin nn
false	18	24	caution nn should md be vb exercised vbn when wrb taking vbg this dt medicine nn certain jj antibiotics nn such jj as inpos clarithromycin nn
false	18	24	caution nn should md be vb exercised vbn when wrb taking vbg this dt medicine nn certain jj antibiotics nn such jj as inpos azithromycin nn
advise	10	18	wait vb num cd weeks nns after inpos stopping vbg escitalopram nn before inpos starting vbg a dt non_selective_mao_inhibitor nn
advise	12	18	wait vb num cd weeks nns after inpos stopping vbg an dt mao_inhibitor nn before inpos starting vbg escitalopram nn
false	24	26	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn coumadin nn other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	30	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	32	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	34	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	24	52	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinner nn s vbz other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	4	coumadin nn other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	6	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	8	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	10	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	10	coumadin nn other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	12	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	12	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	14	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	16	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	16	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	18	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	20	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	20	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	22	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	24	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	0	26	coumadin nn other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	30	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	32	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	34	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	34	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	28	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nn metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	32	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	34	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	34	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	30	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	34	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	34	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	32	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nn carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	36	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	34	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines vbz tegretol nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	38	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	36	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn tagamet nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	40	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	38	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nn fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	42	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	40	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns prozac nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	42	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	42	44	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	42	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	42	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	42	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn sporanox nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	44	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	44	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	44	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	44	46	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	44	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	44	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn nizoral nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	46	48	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nns birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	46	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
false	48	50	tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg drugs nns blood_thinners nns other jj antidepressants nns metoprolol nn antihistamines nns carbamazepine nn cimetidine nn estrogens nns fluoxetine nn intraconazole nn ketoconazole nn levodopa nn lithium nn muscle_relaxants nn birth nn control nn pills nns sleeping vbg pills nns thyroid jj medications nns
mechanism	6	10	concurrent jj administration nn of inpos oxyphenbutazone nn and cc androgens nn may md result vb in inpos elevated jj serum nn levels nns of inpos oxyphenbutazone nn
false	10	6	concurrent jj administration nn of inpos oxyphenbutazone nn and cc androgens nn may md result vb in inpos elevated jj serum nn levels nns of inpos oxyphenbutazone nn
effect	14	28	in inpos diabetic jj patients nns the dt metabolic jj effects nns of inpos androgens nn may md decrease vb blood nn glucose nn and cc therefore rb insulin nn requirements nns
int	0	14	flupenthixol nn may md interact vb with inpos some dt drugs nns like inpos monoamine_oxidase_inhibitors nn
int	0	14	flupenthixol nn may md interact vb with inpos some dt drugs nns like inpos maoi nn
effect	0	8	maoi nn could md theoretically rb affect vb flupenthixol nn pharmacodynamics nns arecoline nn hyph_eproxindine nn hyph_ethanol nn
false	0	12	maoi nn could md theoretically rb affect vb flupenthixol nn pharmacodynamics nns arecoline nn hyph_eproxindine nn hyph_ethanol nn
false	0	16	maoi nn could md theoretically rb affect vb flupenthixol nn pharmacodynamics nns arecoline nn hyph_eproxindine nn hyph_ethanol nn
false	8	12	maoi nn could md theoretically rb affect vb flupenthixol nn pharmacodynamics nns arecoline nn hyph_eproxindine nn hyph_ethanol nn
false	8	16	maoi nn could md theoretically rb affect vb flupenthixol nn pharmacodynamics nns arecoline nn hyph_eproxindine nn hyph_ethanol nn
false	12	16	maoi nn could md theoretically rb affect vb flupenthixol nn pharmacodynamics nns arecoline nn hyph_eproxindine nn hyph_ethanol nn
effect	0	4	flupenthixol nn and cc ethanol nn cause vbp additive jj cns nn depression nn hyph_tricyclic_antidepressants nns
false	0	14	flupenthixol nn and cc ethanol nn cause vbp additive jj cns nn depression nn hyph_tricyclic_antidepressants nn
false	4	14	flupenthixol nn and cc ethanol nn cause vbp additive jj cns nn depression nn hyph_tricyclic_antidepressants nn
effect	0	10	flupenthixol nn increases vbz the dt effect nn of inpos tricyclic_antidepressants nn
false	0	6	antacids nn administration nn of inpos flurbiprofen nn to topos volunteers nns under inpos fasting jj conditions nns or cc with inpos antacid nn suspension nn yielded vbd similar jj serum nn flurbiprofen nn time nn profiles nns in inpos young jj subjects nns
false	0	6	antacids nn administration nn of inpos flurbiprofen nn to topos volunteers nns under inpos fasting jj conditions nns or cc with inpos antacid nn suspension nn yielded vbd similar jj serum nn flurbiprofen nn time nn profiles nns in inpos young jj subjects nns
false	4	20	administration nn of inpos flurbiprofen nn to topos volunteers nns under inpos fasting jj conditions nns or cc with inpos antacid nn suspension nn yielded vbd similar jj serum nn flurbiprofen nn time nn profiles nns in inpos young jj subjects nns
false	20	4	administration nn of inpos flurbiprofen nn to topos volunteers nns under inpos fasting jj conditions nns or cc with inpos antacid nn suspension nn yielded vbd similar jj serum nn flurbiprofen nn time nn profiles nns in inpos young jj subjects nns
false	0	2	anticoagulants nn flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nns has vbz been vbn shown vbn to topos affect vb bleeding vbg parameters nns in inpos patients nns receiving vbg anti_coagulants nns and cc serious jj clinical jj bleeding nn has vbz been vbn reported vbn
false	0	8	anticoagulants nn flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nn has vbz been vbn shown vbn to topos affect vb bleeding vbg parameters nns in inpos patients nns receiving vbg anti_coagulants nns and cc serious jj clinical jj bleeding nn has vbz been vbn reported vbn
false	0	30	anticoagulants nn flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nns has vbz been vbn shown vbn to topos affect vb bleeding vbg parameters nns in inpos patients nns receiving vbg anti_coagulants nn and cc serious jj clinical jj bleeding nn has vbz been vbn reported vbn
false	2	8	anticoagulants nns flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nn has vbz been vbn shown vbn to topos affect vb bleeding vbg parameters nns in inpos patients nns receiving vbg anti_coagulants nns and cc serious jj clinical jj bleeding nn has vbz been vbn reported vbn
effect	2	30	anticoagulants nns flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nns has vbz been vbn shown vbn to topos affect vb bleeding vbg parameters nns in inpos patients nns receiving vbg anti_coagulants nn and cc serious jj clinical jj bleeding nn has vbz been vbn reported vbn
effect	8	30	anticoagulants nns flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nn has vbz been vbn shown vbn to topos affect vb bleeding vbg parameters nns in inpos patients nns receiving vbg anti_coagulants nn and cc serious jj clinical jj bleeding nn has vbz been vbn reported vbn
advise	14	22	the dt physician nn should md be vb cautious jj when wrb administering vbg flurbiprofen nn to topos patients nns taking vbg anticoagulants nn
false	0	12	aspirin nn concurrent jj administration nn of inpos aspirin nn and cc flurbiprofen nn resulted vbd in inpos num cd lower jjr serum nn flurbiprofen nn concentrations nns
false	0	12	aspirin nn concurrent jj administration nn of inpos aspirin nn and cc flurbiprofen nn resulted vbd in inpos num cd lower jjr serum nn flurbiprofen nn concentrations nns
mechanism	6	10	concurrent jj administration nn of inpos aspirin nn and cc flurbiprofen nn resulted vbd in inpos num cd lower jjr serum nn flurbiprofen nn concentrations nns
false	6	10	concurrent jj administration nn of inpos aspirin nn and cc flurbiprofen nn resulted vbd in inpos num cd lower jjr serum nn flurbiprofen nn concentrations nns
false	6	22	this dt effect nn of inpos aspirin nn lrb_which wdt also rb lowers vbz serum nn concentrations nns of inpos other jj nonsteroidal_anti_inflammatory_drugs nn given vbn with inpos it prp rrb_has vbz been vbn demonstrated vbn in inpos patients nns with inpos rheumatoid jj arthritis nn as rb well rb as inpos normal jj volunteers nns
advise	6	10	concurrent jj use nn of inpos flurbiprofen nn and cc aspirin nn is vbz therefore rb not rb recommended vbn
false	6	18	the dt effect nn of inpos flurbiprofen nn on inpos blood nn pressure nn response nn to topos propranolol nn and cc atenolol nn was vbd evaluated vbn in inpos men nns with inpos mild jj uncomplicated jj hypertension nn
false	6	22	the dt effect nn of inpos flurbiprofen nn on inpos blood nn pressure nn response nn to topos propranolol nn and cc atenolol nn was vbd evaluated vbn in inpos men nns with inpos mild jj uncomplicated jj hypertension nn
false	18	22	the dt effect nn of inpos flurbiprofen nn on inpos blood nn pressure nn response nn to topos propranolol nn and cc atenolol nn was vbd evaluated vbn in inpos men nns with inpos mild jj uncomplicated jj hypertension nn
effect	0	22	flurbiprofen nn pretreatment nn attenuated vbd the dt hypotensive jj effect nn of inpos a dt single jj dose nn of inpos propranolol nn but cc not rb atenolol nn
false	0	28	flurbiprofen nn pretreatment nn attenuated vbd the dt hypotensive jj effect nn of inpos a dt single jj dose nn of inpos propranolol nn but cc not rb atenolol nn
false	22	28	flurbiprofen nn pretreatment nn attenuated vbd the dt hypotensive jj effect nn of inpos a dt single jj dose nn of inpos propranolol nn but cc not rb atenolol nn
int	0	36	flurbiprofen nn did vbd not rb affect vb the dt pharmacokinetic jj profile nn of inpos either dt drug nn and cc the dt mechanism nn under inpos lying vbg the dt interference nn with inpos propranolol nn s vbz hypotensive jj effect nn is vbz unknown jj
advise	6	12	patients nns taking vbg both cc flurbiprofen nn and cc a dt b_blocker nn should md be vb monitored vbn to topos ensure vb that inpos a dt satisfactory jj hypotensive jj effect nn is vbz achieved vbn
false	0	2	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	0	2	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	0	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	0	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	2	0	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	2	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	2	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	2	0	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	0	2	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	0	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	0	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	2	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	2	26	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	2	0	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	26	0	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
mechanism	26	0	cimetidine nn ranitidine nn in inpos normal jj volunteers nns pretreatment nn with inpos cimetidine nn or cc ranitidine nn did vbd not rb affect vb flurbiprofen nn pharmacokinetics nns except inpos that inpos a dt small jj but cc statistically rb significant jj increase nn in inpos the dt area nn under inpos the dt serum nn concentration nn curve nn of inpos flurbiprofen nn resulted vbd with inpos cimetidine nn
false	10	14	studies nns of inpos concomitant jj administration nn of inpos flurbiprofen nn and cc digoxin nn to topos healthy jj men nns did vbd not rb show vb a dt change nn in inpos the dt steady jj state nn serum nn levels nns of inpos either dt drug nn
false	14	20	studies nns in inpos normal jj volunteers nns have vbp shown vbn that inpos flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nn can md interfere vb with inpos the dt effects nns of inpos furosemide nn
effect	14	34	studies nns in inpos normal jj volunteers nns have vbp shown vbn that inpos flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nns can md interfere vb with inpos the dt effects nns of inpos furosemide nn
effect	20	34	studies nns in inpos normal jj volunteers nns have vbp shown vbn that inpos flurbiprofen nn like inpos other jj nonsteroidal_anti_inflammatory_drugs nn can md interfere vb with inpos the dt effects nns of inpos furosemide nn
effect	2	24	other jj nonsteroidal_anti_inflammatory_drugs nn that wdt inhibit vbp prostaglandin nn synthesis nn have vbp been vbn shown vbn to topos interfere vb with inpos thiazide_diuretics nn in inpos some dt studies nns and cc with inpos potassium_sparing_diuretics nns
effect	2	36	other jj nonsteroidal_anti_inflammatory_drugs nn that wdt inhibit vbp prostaglandin nn synthesis nn have vbp been vbn shown vbn to topos interfere vb with inpos thiazide_diuretics nns in inpos some dt studies nns and cc with inpos potassium_sparing_diuretics nn
false	24	36	other jj nonsteroidal_anti_inflammatory_drugs nns that wdt inhibit vbp prostaglandin nn synthesis nn have vbp been vbn shown vbn to topos interfere vb with inpos thiazide_diuretics nn in inpos some dt studies nns and cc with inpos potassium_sparing_diuretics nn
false	2	10	oral jj hypoglycemic_agents nn in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	2	30	oral jj hypoglycemic_agents nn in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	2	32	oral jj hypoglycemic_agents nn in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	2	34	oral jj hypoglycemic_agents nn in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	2	38	oral jj hypoglycemic_agents nn in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	2	30	oral jj hypoglycemic_agents nn in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	2	38	oral jj hypoglycemic_agents nn in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	10	30	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	10	32	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	10	34	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	10	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	10	30	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	10	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	30	32	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	30	34	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	30	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	30	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	32	34	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	32	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	32	30	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	32	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	34	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	34	30	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	34	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	38	30	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
false	30	38	oral jj hypoglycemic_agents nns in inpos num cd study nn flurbiprofen nn was vbd given vbn to topos adult jj diabetics nns who wp were vbd already rb receiving vbg glyburide nn metformin nn chlorpropamide nn with inpos phenformin nn glyburide nn with inpos phenformin nn
effect	28	32	although inpos there ex was vbd a dt slight jj reduction nn in inpos blood nn sugar nn concentrations nns during inpos concomitant jj administration nn of inpos flurbiprofen nn and cc hypoglycemic_agents nn there ex were vbd no dt signs nns or cc symptoms nns of inpos hypoglycemia nn
effect	24	30	increases nns in inpos prothrombin nn time nn have vbp been vbn noted vbn in inpos patients nns receiving vbg long jj term nn warfarin nn therapy nn after inpos flutamide nn was vbd initiated vbn
false	24	36	therefore rb close jj monitoring nn of inpos prothrombin nn time nn is vbz recommended vbn and cc adjustment nn of inpos the dt anticoagulant nn dose nn may md be vb necessary jj when wrb eulexin nn capsules nns are vbp administered vbn concomitantly rb with inpos warfarin nn
false	24	48	therefore rb close jj monitoring nn of inpos prothrombin nn time nn is vbz recommended vbn and cc adjustment nn of inpos the dt anticoagulant nn dose nn may md be vb necessary jj when wrb eulexin nn capsules nns are vbp administered vbn concomitantly rb with inpos warfarin nn
advise	36	48	therefore rb close jj monitoring nn of inpos prothrombin nn time nn is vbz recommended vbn and cc adjustment nn of inpos the dt anticoagulant jj dose nn may md be vb necessary jj when wrb eulexin nn capsules nns are vbp administered vbn concomitantly rb with inpos warfarin nn
effect	8	16	in inpos patients nns receiving vbg another dt serotonin_reuptake_inhibitor_drug nn in inpos combination nn with inpos monoamine_oxidase_inhibitors nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns including vbg hyperthermia nn rigidity nn myoclonus nn autonomic jj instability nn with inpos possible jj rapid jj fluctuations nns of inpos vital jj signs nns and cc mental jj status nn changes nns that wdt include vbp extreme jj agitation nn progressing vbg to topos delirium nn and cc coma nn
effect	8	16	in inpos patients nns receiving vbg another dt serotonin_reuptake_inhibitor_drug nn in inpos combination nn with inpos maoi nn there ex have vbp been vbn reports nns of inpos serious jj sometimes rb fatal jj reactions nns including vbg hyperthermia nn rigidity nn myoclonus nn autonomic jj instability nn with inpos possible jj rapid jj fluctuations nns of inpos vital jj signs nns and cc mental jj status nn changes nns that wdt include vbp extreme jj agitation nn progressing vbg to topos delirium nn and cc coma nn
advise	10	26	therefore rb it prp is vbz recommended vbn that inpos fluvoxamine nn tablets vbz not rb be vb used vbn in inpos combination nn with inpos maois nn or cc within inpos num cd days nns of inpos discontinuing vbg treatment nn with inpos a dt maoi nn
advise	10	26	therefore rb it prp is vbz recommended vbn that inpos fluvoxamine nn tablets vbz not rb be vb used vbn in inpos combination nn with inpos maois nns or cc within inpos num cd days nns of inpos discontinuing vbg treatment nn with inpos a dt maoi nn
advise	4	28	after inpos stopping vbg fluvoxamine nn tablets nns at inpos least jjs num cd weeks nns should md be vb allowed vbn before inpos starting vbg a dt maoi nn
false	2	4	potential jj terfenadine nn astemizole nn cisapride nn interactions nns
false	2	6	potential jj terfenadine nn astemizole nn cisapride nn interactions nns
false	4	6	potential jj terfenadine nn astemizole nn cisapride nn interactions nns
mechanism	0	30	terfenadine nn are vbp all dt metabolized vbn by inpos the dt cytochrome nn p450iiia4 nn isozyme nn and cc it prp has vbz been vbn demonstrated vbn that inpos ketoconazole nn a dt potent jj inhibitor nn of inpos num cd blocks vbz the dt metabolism nn of inpos these dt drugs nns resulting vbg in inpos increased vbn plasma nn concentrations nns of inpos parent nn drug nn
mechanism	0	30	astemizole nn are vbp all dt metabolized vbn by inpos the dt cytochrome nn p450iiia4 nn isozyme nn and cc it prp has vbz been vbn demonstrated vbn that inpos ketoconazole nn a dt potent jj inhibitor nn of inpos num cd blocks vbz the dt metabolism nn of inpos these dt drugs nns resulting vbg in inpos increased vbn plasma nn concentrations nns of inpos parent nn drug nn
mechanism	0	30	cisapride nn are vbp all dt metabolized vbn by inpos the dt cytochrome nn p450iiia4 nn isozyme nn and cc it prp has vbz been vbn demonstrated vbn that inpos ketoconazole nn a dt potent jj inhibitor nn of inpos num cd blocks vbz the dt metabolism nn of inpos these dt drugs nns resulting vbg in inpos increased vbn plasma nn concentrations nns of inpos parent nn drug nn
false	12	20	as inpos noted vbn below inpos a dt sub nn for inpos fluvoxamine nn in inpos combination nn with inpos alprazolam nn a dt drug nn that wdt is vbz known vbn to topos be vb metabolized vbn by inpos the dt num cd isozyme nn
false	16	52	although inpos it prp has vbz not rb been vbn definitively rb demonstrated vbd that inpos fluvoxamine nn is vbz a dt potent jj num cd inhibitor nn it prp is vbz likely jj to topos be vb given vbn the dt substantial jj interaction nn of inpos fluvoxamine nn with inpos alprazolam nn
int	16	52	although inpos it prp has vbz not rb been vbn definitively rb demonstrated vbd that inpos fluvoxamine nn is vbz a dt potent jj num cd inhibitor nn it prp is vbz likely jj to topos be vb given vbn the dt substantial jj interaction nn of inpos fluvoxamine nn with inpos alprazolam nn
advise	10	26	consequently rb it prp is vbz recommended vbn that inpos fluvoxamine nn not rb be vb used vbn in inpos combination nn with inpos either cc terbinafine nn
advise	10	26	consequently rb it prp is vbz recommended vbn that inpos fluvoxamine nn not rb be vb used vbn in inpos combination nn with inpos either cc astemizole nn
advise	10	26	consequently rb it prp is vbz recommended vbn that inpos fluvoxamine nn not rb be vb used vbn in inpos combination nn with inpos either cc cisapride nn
false	0	8	benzodiazepines nn metabolized vbn by inpos hepatic jj alprazolam nn should md be vb used vbn with inpos caution nn because inpos the dt clearance nn of inpos these dt drugs nns is vbz likely jj to topos be vb reduced vbn by inpos fluvoxamine nn
false	0	8	benzodiazepines nn metabolized vbn by inpos hepatic jj midazolam nn should md be vb used vbn with inpos caution nn because inpos the dt clearance nn of inpos these dt drugs nns is vbz likely jj to topos be vb reduced vbn by inpos fluvoxamine nn
false	0	8	benzodiazepines nn metabolized vbn by inpos hepatic jj triazolam nn should md be vb used vbn with inpos caution nn because inpos the dt clearance nn of inpos these dt drugs nns is vbz likely jj to topos be vb reduced vbn by inpos fluvoxamine nn
mechanism	0	44	benzodiazepines nn metabolized vbn by inpos hepatic jj oxidation nn should md be vb used vbn with inpos caution nn because inpos the dt clearance nn of inpos these dt drugs nns is vbz likely jj to topos be vb reduced vbn by inpos fluvoxamine nn
mechanism	8	44	benzodiazepines nns metabolized vbn by inpos hepatic jj alprazolam nn should md be vb used vbn with inpos caution nn because inpos the dt clearance nn of inpos these dt drugs nns is vbz likely jj to topos be vb reduced vbn by inpos fluvoxamine nn
mechanism	8	44	benzodiazepines nns metabolized vbn by inpos hepatic jj midazolam nn should md be vb used vbn with inpos caution nn because inpos the dt clearance nn of inpos these dt drugs nns is vbz likely jj to topos be vb reduced vbn by inpos fluvoxamine nn
mechanism	8	44	benzodiazepines nns metabolized vbn by inpos hepatic jj triazolam nn should md be vb used vbn with inpos caution nn because inpos the dt clearance nn of inpos these dt drugs nns is vbz likely jj to topos be vb reduced vbn by inpos fluvoxamine nn
false	6	12	the dt clearance nn of inpos benzodiazepines nn metabolized vbn by inpos lorazepam nn is vbz unlikely jj to topos be vb affected vbn by inpos fluvoxamine nn
false	6	12	the dt clearance nn of inpos benzodiazepines nn metabolized vbn by inpos oxazepam nn is vbz unlikely jj to topos be vb affected vbn by inpos fluvoxamine nn
false	6	12	the dt clearance nn of inpos benzodiazepines nn metabolized vbn by inpos temazepam nn is vbz unlikely jj to topos be vb affected vbn by inpos fluvoxamine nn
false	6	26	the dt clearance nn of inpos benzodiazepines nn metabolized vbn by inpos glucuronidation nn is vbz unlikely jj to topos be vb affected vbn by inpos fluvoxamine nn
false	12	26	the dt clearance nn of inpos benzodiazepines nns metabolized vbn by inpos lorazepam nn is vbz unlikely jj to topos be vb affected vbn by inpos fluvoxamine nn
false	12	26	the dt clearance nn of inpos benzodiazepines nns metabolized vbn by inpos oxazepam nn is vbz unlikely jj to topos be vb affected vbn by inpos fluvoxamine nn
false	12	26	the dt clearance nn of inpos benzodiazepines nns metabolized vbn by inpos temazepam nn is vbz unlikely jj to topos be vb affected vbn by inpos fluvoxamine nn
mechanism	2	6	when wrb fluvoxamine_maleate nn and cc alprazolam nn of inpos alprazolam nn were vbd approximately rb twice rb those dt observed vbn when wrb alprazolam nn was vbd administered vbn alone rb
false	2	6	when wrb fluvoxamine_maleate nn and cc alprazolam nn of inpos alprazolam nn were vbd approximately rb twice rb those dt observed vbn when wrb alprazolam nn was vbd administered vbn alone rb
false	2	6	when wrb fluvoxamine_maleate nn and cc alprazolam nn of inpos alprazolam nn were vbd approximately rb twice rb those dt observed vbn when wrb alprazolam nn was vbd administered vbn alone rb
advise	2	10	if inpos alprazolam nn is vbz co_administered vbn with inpos fluvoxamine nn tablets nns the dt initial jj alprazolam nn dosage nn should md be vb at inpos least jjs halved vbn and cc titration nn to topos the dt lowest jjs effective jj dose nn is vbz recommended vbn
false	10	2	if inpos alprazolam nn is vbz co_administered vbn with inpos fluvoxamine nn tablets nns the dt initial jj alprazolam nn dosage nn should md be vb at inpos least jjs halved vbn and cc titration nn to topos the dt lowest jjs effective jj dose nn is vbz recommended vbn
advise	6	12	the dt co_administration nn of inpos fluvoxamine nn tablets nns and cc diazepam nn is vbz generally rb not rb advisable jj
mechanism	2	14	because inpos fluvoxamine nn reduces vbz the dt clearance nn of inpos both cc diazepam nn and cc its prp active jj metabolite nn n_desmethyldiazepam nn there ex is vbz a dt strong jj likelihood nn of inpos substantial jj accumulation nn of inpos both dt species nns during inpos chronic jj co_administration nn
mechanism	2	24	because inpos fluvoxamine nn reduces vbz the dt clearance nn of inpos both cc diazepam nn and cc its prp active jj metabolite nn n_desmethyldiazepam nn there ex is vbz a dt strong jj likelihood nn of inpos substantial jj accumulation nn of inpos both dt species nns during inpos chronic jj co_administration nn
advise	20	24	evidence nn supporting vbg the dt conclusion nn that inpos it prp is vbz inadvisable jj to topos co_administer vb fluvoxamine nn and cc diazepam nn is vbz derived vbn from inpos a dt study nn in inpos which wdt healthy jj volunteers nns taking vbg num cd mg_day nn of inpos fluvoxamine nn were vbd administered vbn a dt single jj oral jj dose nn of inpos num cd mg nn of inpos diazepam nn
false	20	24	evidence nn supporting vbg the dt conclusion nn that inpos it prp is vbz inadvisable jj to topos co_administer vb fluvoxamine nn and cc diazepam nn is vbz derived vbn from inpos a dt study nn in inpos which wdt healthy jj volunteers nns taking vbg num cd mg_day nn of inpos fluvoxamine nn were vbd administered vbn a dt single jj oral jj dose nn of inpos num cd mg nn of inpos diazepam nn
false	24	20	evidence nn supporting vbg the dt conclusion nn that inpos it prp is vbz inadvisable jj to topos co_administer vb fluvoxamine nn and cc diazepam nn is vbz derived vbn from inpos a dt study nn in inpos which wdt healthy jj volunteers nns taking vbg num cd mg_day nn of inpos fluvoxamine nn were vbd administered vbn a dt single jj oral jj dose nn of inpos num cd mg nn of inpos diazepam nn
false	20	24	evidence nn supporting vbg the dt conclusion nn that inpos it prp is vbz inadvisable jj to topos co_administer vb fluvoxamine nn and cc diazepam nn is vbz derived vbn from inpos a dt study nn in inpos which wdt healthy jj volunteers nns taking vbg num cd mg_day nn of inpos fluvoxamine nn were vbd administered vbn a dt single jj oral jj dose nn of inpos num cd mg nn of inpos diazepam nn
effect	8	16	moreover rb as inpos noted vbn with inpos alprazolam nn the dt effect nn of inpos fluvoxamine nn may md even rb be vb more rbr pronounced jj when wrb it prp is vbz administered vbn at inpos higher jjr doses nns
advise	2	6	accordingly rb diazepam nn and cc fluvoxamine nn should md not rb ordinarily rb be vb co_administered vbn
false	8	32	the dt effect nn of inpos steady_state jj fluvoxamine nn l50 nn mg nn bid rb on inpos the dt pharmacokinetics nns of inpos a dt single jj dose nn of inpos theophylline nn as inpos num cd mg nn aminophylline nn was vbd evaluated vbn in inpos num cd healthy jj non_smoking jj male jj volunteers nns
false	8	40	the dt effect nn of inpos steady_state jj fluvoxamine nn l50 nn mg nn bid rb on inpos the dt pharmacokinetics nns of inpos a dt single jj dose nn of inpos theophylline nn as inpos num cd mg nn aminophylline nn was vbd evaluated vbn in inpos num cd healthy jj non_smoking jj male jj volunteers nns
false	32	40	the dt effect nn of inpos steady_state jj fluvoxamine nn l50 nn mg nn bid rb on inpos the dt pharmacokinetics nns of inpos a dt single jj dose nn of inpos theophylline nn as inpos num cd mg nn aminophylline nn was vbd evaluated vbn in inpos num cd healthy jj non_smoking jj male jj volunteers nns
advise	4	12	therefore rb if inpos theophylline nn is vbz co_administered vbn with inpos fluvoxamine_maleate nn its prp dose nn should md be vb reduced vbn to topos num cd third nn of inpos the dt usual jj daily jj maintenance nn dose nn and cc plasma nn concentrations nns of inpos theophylline nn should md to topos monitored vb
false	12	4	therefore rb if inpos theophylline nn is vbz co_administered vbn with inpos fluvoxamine_maleate nn its prp dose nn should md be vb reduced vbn to topos num cd third nn of inpos the dt usual jj daily jj maintenance nn dose nn and cc plasma nn concentrations nns of inpos theophylline nn should md to topos monitored vb
mechanism	2	12	when wrb fluvoxamine_maleate nn was vbd administered vbn concomitantly rb with inpos warfarin nn for inpos num cd weeks nns warfarin nn plasma nn concentrations nns increased vbn by inpos num cd and cc prothrombin nn times nns were vbd prolonged vbn
false	2	12	when wrb fluvoxamine_maleate nn was vbd administered vbn concomitantly rb with inpos warfarin nn for inpos num cd weeks nns warfarin nn plasma nn concentrations nns increased vbn by inpos num cd and cc prothrombin nn times nns were vbd prolonged vbn
advise	8	12	thus rb patients nns receiving vbg oral jj anticoagulants nn and cc fluvoxamine nn tablets nns should md have vb their prp prothrombin nn time nn monitored vbd and cc their prp anticoagulant jj dose nn adjusted vbn accordingly rb
false	12	8	thus rb patients nns receiving vbg oral jj anticoagulants nns and cc fluvoxamine nn tablets nns should md have vb their prp prothrombin nn time nn monitored vbd and cc their prp anticoagulant nn dose nn adjusted vbd accordingly rb
false	14	16	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	18	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nn metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	22	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	16	medications nns can md interfere vb with inpos folate jj utilization nn including vbg phenytoin nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	18	medications nns can md interfere vb with inpos folate jj utilization nn including vbg phenytoin nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg phenytoin nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg phenytoin nn metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	22	medications nns can md interfere vb with inpos folate jj utilization nn including vbg phenytoin nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg phenytoin nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg phenytoin nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	16	medications nns can md interfere vb with inpos folate jj utilization nn including vbg primidone nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	18	medications nns can md interfere vb with inpos folate jj utilization nn including vbg primidone nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg primidone nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg primidone nn metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	22	medications nns can md interfere vb with inpos folate jj utilization nn including vbg primidone nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg primidone nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	14	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg primidone nn metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	16	18	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	16	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	16	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	16	22	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	16	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	16	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	18	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	18	20	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	18	22	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	18	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	18	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	20	22	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	20	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	20	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	20	22	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	20	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	20	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn diuretic nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	22	40	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	22	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
int	40	44	medications nns can md interfere vb with inpos folate jj utilization nn including vbg anticonvulsant_medications nns metformin nn sulfasalazine nn triamterene nn methotrexate nn there ex has vbz been vbn concern nn about inpos the dt interaction nn between inpos vitamin_b12 nn and cc folic_acid nn
false	26	30	it prp is vbz important jj for inpos older jjr adults nns to topos be vb aware jj of inpos the dt relationship nn between inpos folic_acid nn and cc vitamin_b12 nn because inpos they prp are vbp at inpos greater jjr risk nn of inpos having vbg a dt vitamin nn b12 nn deficiency nn
mechanism	6	30	oral jj doses nns of inpos antizol nn via inpos alcohol nn dehydrogenase nn inhibition nn significantly rb reduced vbd the dt rate nn of inpos elimination nn of inpos ethanol nn given vbn to topos healthy jj volunteers nns in inpos moderate jj doses nns
mechanism	2	16	similarly rb ethanol nn decreased vbd the dt rate nn of inpos elimination nn of inpos antizol nn by inpos the dt same jj mechanism nn
mechanism	16	36	reciprocal jj interactions nns may md occur vb with inpos concomitant jj use nn of inpos antizol nn and cc drugs nns that wdt increase vbp or cc inhibit vbp the dt cytochrome nn p450 nn phenytoin nn though inpos this dt has vbz not rb been vbn studied vbn
mechanism	16	36	reciprocal jj interactions nns may md occur vb with inpos concomitant jj use nn of inpos antizol nn and cc drugs nns that wdt increase vbp or cc inhibit vbp the dt cytochrome nn p450 nn carbamazepine nn though inpos this dt has vbz not rb been vbn studied vbn
mechanism	16	36	reciprocal jj interactions nns may md occur vb with inpos concomitant jj use nn of inpos antizol nn and cc drugs nns that wdt increase vbp or cc inhibit vbp the dt cytochrome nn p450 nn cimetidine nn though inpos this dt has vbz not rb been vbn studied vbn
mechanism	16	36	reciprocal jj interactions nns may md occur vb with inpos concomitant jj use nn of inpos antizol nn and cc drugs nns that wdt increase vbp or cc inhibit vbp the dt cytochrome nn p450 nn ketoconazole nn though inpos this dt has vbz not rb been vbn studied vbn
false	10	22	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nn the dt concomitant jj use nn of inpos oral jj anticoagulants nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	10	22	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nn the dt concomitant jj use nn of inpos oral jj warfarin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	10	24	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nn the dt concomitant jj use nn of inpos oral jj anticoagulants nns platelet_inhibitors nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	10	24	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nn the dt concomitant jj use nn of inpos oral jj anticoagulants nns acetylsalicylic_acid nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	10	22	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nn the dt concomitant jj use nn of inpos oral jj nsaids nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	10	22	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nn the dt concomitant jj use nn of inpos oral jj piroxicam nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	10	22	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nn the dt concomitant jj use nn of inpos oral jj digoxin nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	22	24	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj anticoagulants nn platelet_inhibitors nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	22	24	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj anticoagulants nn acetylsalicylic_acid nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	22	38	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj anticoagulants nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	22	24	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj warfarin nn platelet_inhibitors nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	22	24	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj warfarin nn acetylsalicylic_acid nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	22	38	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj warfarin nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	24	40	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj anticoagulants nns platelet_inhibitors nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	24	40	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj anticoagulants nns acetylsalicylic_acid nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	22	38	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj nsaids nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	22	38	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj piroxicam nn did vbd not rb significantly rb affect vb the dt pharmacodynamics nns of inpos fondaparinux_sodium nn
false	22	38	in inpos clinical jj studies nns performed vbn with inpos fondaparinux nnp the dt concomitant jj use nn of inpos oral jj digoxin nn did vbd not rb significantly rb affect vb the dt pharmacokinetics nns of inpos fondaparinux_sodium nn
false	4	16	in inpos addition nn fondaparinux nn neither cc influenced vbd the dt pharmacodynamics nns of inpos warfarin nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
false	4	16	in inpos addition nn fondaparinux nn neither cc influenced vbd the dt pharmacodynamics nns of inpos acetylsalicylic_acid nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
false	4	16	in inpos addition nn fondaparinux nn neither cc influenced vbd the dt pharmacodynamics nns of inpos piroxicam nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
false	4	16	in inpos addition nn fondaparinux nn neither cc influenced vbd the dt pharmacodynamics nns of inpos digoxin nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
false	4	22	in inpos addition nn fondaparinux nn neither cc influenced vbd the dt pharmacodynamics nns of inpos warfarin nn acetylsalicylic_acid nn piroxicam nn digoxin nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
false	16	26	in inpos addition nn fondaparinux nnp neither cc influenced vbd the dt pharmacodynamics nns of inpos warfarin nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
false	16	26	in inpos addition nn fondaparinux nnp neither cc influenced vbd the dt pharmacodynamics nns of inpos acetylsalicylic_acid nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
false	16	26	in inpos addition nn fondaparinux nnp neither cc influenced vbd the dt pharmacodynamics nns of inpos piroxicam nn nor cc the dt pharmacokinetics nns of inpos digoxin nn at inpos steady jj state nn
mechanism	28	32	in inpos an dt in fw vitro fw study nn in inpos human jj liver nn microsomes nns inhibition nn of inpos cyp2a6 nn hydroxylation nn of inpos coumarin nn by inpos fondaparinux nn was vbd num cd
false	2	36	aerosol nn bronchodilators nn of inpos the dt short_acting jj adrenergic jj stimulant nn type nn may md be vb used vbn for inpos relief nn of inpos breakthrough nn symptoms nns while inpos using vbg formoterol nn
effect	8	22	concomitant jj administration nn of inpos other jj sympathomimetic_agents nn may md potentiate vb the dt undesirable jj effects nns of inpos foradil nn
false	0	4	monoamine_oxidase_inhibitors nn and cc tricyclic_antidepressants nn
advise	0	24	foradil nn should md be vb administered vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns because inpos the dt action nn of inpos formoterol nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
advise	0	28	foradil nn should md be vb administered vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn because inpos the dt action nn of inpos formoterol nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	0	38	foradil nn should md be vb administered vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nns because inpos the dt action nn of inpos formoterol nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	24	28	foradil nn should md be vb administered vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nn because inpos the dt action nn of inpos formoterol nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	24	38	foradil nn should md be vb administered vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns because inpos the dt action nn of inpos formoterol nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	28	38	foradil nn should md be vb administered vbn with inpos extreme jj caution nn in inpos patients nns being vbg treated vbn with inpos monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn because inpos the dt action nn of inpos formoterol nn on inpos the dt cardiovascular jj system nn may md be vb potentiated vbn by inpos these dt agents nns
false	0	8	corticosteroids nnps concomitant jj treatment nn with inpos xanthine_derivatives nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	8	corticosteroids nnps concomitant jj treatment nn with inpos diuretics nn may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	28	corticosteroids nnps concomitant jj treatment nn with inpos xanthine_derivatives nns steroids nns diuretics nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists. nn
false	2	6	corticosteroids nns methylxanthines nn and cc diuretics nn concomitant jj treatment nn with inpos xanthine_derivatives nns steroids nns diuretics nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	8	methylxanthines nns concomitant jj treatment nn with inpos xanthine_derivatives nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	8	methylxanthines nns concomitant jj treatment nn with inpos steroids nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	8	methylxanthines nns concomitant jj treatment nn with inpos diuretics nn may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	28	methylxanthines nns concomitant jj treatment nn with inpos xanthine_derivatives nns steroids nns diuretics nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists. nn
false	0	8	diuretics nn concomitant jj treatment nn with inpos xanthine_derivatives nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	8	diuretics nn concomitant jj treatment nn with inpos steroids nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists nns
false	0	28	diuretics nn concomitant jj treatment nn with inpos xanthine_derivatives nns steroids nns diuretics nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists. nn
effect	12	28	corticosteroids nns methylxanthines nnps diuretics nnps concomitant jj treatment nn with inpos xanthine_derivatives nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists. nn
effect	0	28	corticosteroids nns methylxanthines nnps diuretics nnps concomitant jj treatment nn with inpos steroids nns may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists. nn
effect	4	28	corticosteroids nns methylxanthines nnps diuretics nnps concomitant jj treatment nn with inpos diuretics nn may md potentiate vb a dt possible jj hypokalemic jj effect nn of inpos b2_agonists. nn
false	18	24	acute jj symptoms nns should md be vb treated vbn with inpos a dt short_acting jj inhaled vbd b2_agonist nn such jj as inpos salbutamol nn
false	0	24	foradil nn should md not rb be vb used vbn as inpos a dt substitute nn for inpos oral jj or cc inhaled vbn corticosteroids nn
false	14	52	guardians nns of inpos children nns who wp have vbp been vbn prescribed vbn foradil nn should md be vb alerted vbn to topos the dt general jj concern nn regarding vbg asthma nn therapy nn compliance nn especially rb neglect nn of inpos anti_inflammatory jj therapy nn overuse nn of inpos short_acting_b2_agonists. nn
int	10	16	a dt possible jj drug nn interaction nn of inpos foscavir nn and cc intravenous jj pentamidine nn has vbz been vbn described vbn
effect	20	26	concomitant jj treatment nn of inpos num cd patients nns in inpos the dt united nnp kingdom nnp with inpos foscavir nn and cc intravenous jj pentamidine nn may md have vb caused vbn hypocalcemia nn
false	4	24	because inpos of inpos foscarnet nn s vbz tendency nn to topos cause vb renal jj impairment nn the dt use nn of inpos foscavir nn should md be vb avoided vbn in inpos combination nn with inpos potentially rb nephrotoxic jj drugs nns such jj as inpos aminoglycosides nns amphotericin_b nn intravenous jj pentamidine nn unless inpos the dt potential jj benefits nns outweigh vbp the dt risks nns to topos the dt patient nn
false	4	48	because inpos of inpos foscarnet nn s vbz tendency nn to topos cause vb renal jj impairment nn the dt use nn of inpos foscavir nn should md be vb avoided vbn in inpos combination nn with inpos potentially rb nephrotoxic jj drugs nns such jj as inpos aminoglycosides nn unless inpos the dt potential jj benefits nns outweigh vbp the dt risks nns to topos the dt patient nn
false	4	48	because inpos of inpos foscarnet nn s vbz tendency nn to topos cause vb renal jj impairment nn the dt use nn of inpos foscavir nn should md be vb avoided vbn in inpos combination nn with inpos potentially rb nephrotoxic jj drugs nns such jj as inpos amphotericin_b nn unless inpos the dt potential jj benefits nns outweigh vbp the dt risks nns to topos the dt patient nn
false	4	48	because inpos of inpos foscarnet nn s vbz tendency nn to topos cause vb renal jj impairment nn the dt use nn of inpos foscavir nn should md be vb avoided vbn in inpos combination nn with inpos potentially rb nephrotoxic jj drugs nns such jj as inpos pentamidine nn unless inpos the dt potential jj benefits nns outweigh vbp the dt risks nns to topos the dt patient nn
advise	22	46	because inpos of inpos foscarnets nns tendency nn to topos cause vb renal jj impairment nn the dt use nn of inpos foscavir nn should md be vb avoided vbn in inpos combination nn with inpos potentially rb nephrotoxic jj drugs nns such jj as inpos aminoglycosides nn unless inpos the dt potential jj benefits nns outweigh vbp the dt risks nns to topos the dt patient nn
advise	22	46	because inpos of inpos foscarnets nns tendency nn to topos cause vb renal jj impairment nn the dt use nn of inpos foscavir nn should md be vb avoided vbn in inpos combination nn with inpos potentially rb nephrotoxic jj drugs nns such jj as inpos amphotericin_b nn unless inpos the dt potential jj benefits nns outweigh vbp the dt risks nns to topos the dt patient nn
advise	22	46	because inpos of inpos foscarnets nns tendency nn to topos cause vb renal jj impairment nn the dt use nn of inpos foscavir nn should md be vb avoided vbn in inpos combination nn with inpos potentially rb nephrotoxic jj drugs nns such jj as inpos pentamidine nn unless inpos the dt potential jj benefits nns outweigh vbp the dt risks nns to topos the dt patient nn
false	6	10	the dt pharmacokinetics nns of inpos foscarnet nn and cc ganciclovir nn were vbd not rb altered vbn in inpos num cd patients nns receiving vbg either cc concomitant jj therapy nn or cc daily rb alternating vbg therapy nn for inpos maintenance nn of inpos cmv nn disease nn
false	0	8	metoclopramide nn when wrb coadministered vbn with inpos monurol nn metoclopramide nn a dt drug nn which wdt increases vbz gastrointestinal jj motility nn lowers vbz the dt serum nn concentration nn and cc urinary jj excretion nn of inpos fosfomycin nn
false	0	40	metoclopramide nn when wrb coadministered vbn with inpos monurol nn metoclopramide nn a dt drug nn which wdt increases vbz gastrointestinal jj motility nn lowers vbz the dt serum nn concentration nn and cc urinary jj excretion nn of inpos fosfomycin nn
mechanism	8	0	metoclopramide nn when wrb coadministered vbn with inpos monurol nn metoclopramide nn a dt drug nn which wdt increases vbz gastrointestinal jj motility nn lowers vbz the dt serum nn concentration nn and cc urinary jj excretion nn of inpos fosfomycin nn
false	8	40	metoclopramide nn when wrb coadministered vbn with inpos monurol nn metoclopramide nn a dt drug nn which wdt increases vbz gastrointestinal jj motility nn lowers vbz the dt serum nn concentration nn and cc urinary jj excretion nn of inpos fosfomycin nn
false	0	40	metoclopramide nn when wrb coadministered vbn with inpos monurol nn metoclopramide nn a dt drug nn which wdt increases vbz gastrointestinal jj motility nn lowers vbz the dt serum nn concentration nn and cc urinary jj excretion nn of inpos fosfomycin nn
false	0	14	cimetidine nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos fosfomycin nn when wrb coadministered vbn with inpos monurol nn
false	0	22	cimetidine nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos fosfomycin nn when wrb coadministered vbn with inpos monurol nn
false	14	22	cimetidine nn does vbz not rb affect vb the dt pharmacokinetics nns of inpos fosfomycin nn when wrb coadministered vbn with inpos monurol nn
false	0	48	diuretics nn patients nns on inpos diuretics nns especially rb those dt with inpos intravascular jj volume nn depletion nn may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos therapy nn with inpos fosinopril_sodium nn
effect	0	48	diuretics nns patients nns on inpos diuretics nn especially rb those dt with inpos intravascular jj volume nn depletion nn may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos therapy nn with inpos fosinopril_sodium nn
effect	24	46	the dt possibility nn of inpos hypotensive jj effects nns can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos fosinopril_sodium nn
effect	0	14	fosinopril_sodium nn can md attenuate vb potassium nn loss nn caused vbn by inpos thiazide_diuretics nn
false	0	4	spironolactone nn or cc potassium nn supplements nns can md increase vb the dt risk nn of inpos hyperkalemia nn
false	0	4	amiloride nn or cc potassium nn supplements nns can md increase vb the dt risk nn of inpos hyperkalemia nn
false	0	4	triamterene nn or cc potassium nn supplements nns can md increase vb the dt risk nn of inpos hyperkalemia nn
false	0	32	lithium nn increased vbd serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
false	4	30	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
false	4	30	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
effect	30	4	increased vbn serum nn lithium nn levels nns and cc symptoms nns of inpos lithium nn toxicity nn have vbp been vbn reported vbn in inpos patients nns receiving vbg ace_inhibitors nn during inpos therapy nn with inpos lithium nn
mechanism	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	36	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
mechanism	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt aluminum_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	36	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt aluminum_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt aluminum_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	54	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt aluminum_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nn may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt aluminum_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
mechanism	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt magnesium_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	36	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt magnesium_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt magnesium_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	54	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt magnesium_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nn may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt magnesium_hydroxide nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
mechanism	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt simethicone nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	36	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt simethicone nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt simethicone nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	16	54	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt simethicone nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nn may md impair vb absorption nn of inpos fosinopril nn
false	16	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt simethicone nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nns may md impair vb absorption nn of inpos fosinopril nn
false	20	54	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nn may md impair vb absorption nn of inpos fosinopril nn
false	36	54	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nn may md impair vb absorption nn of inpos fosinopril nn
false	20	54	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nn may md impair vb absorption nn of inpos fosinopril nn
mechanism	54	20	in inpos a dt clinical jj pharmacology nn study nn coadministration nn of inpos an dt antacid nn with inpos fosinopril nn reduced vbd serum nn levels nns and cc urinary jj excretion nn of inpos fosinoprilat nn as inpos compared vbn with inpos fosinopril nn administered vbn alone rb suggesting vbg that inpos antacids nn may md impair vb absorption nn of inpos fosinopril nn
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos chlorthalidone nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos chlorthalidone nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos nifedipine nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos nifedipine nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos propanolol nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos propanolol nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos hydrochlorothiazide nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos hydrochlorothiazide nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos cimetidine nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos cimetidine nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos metoclopramide nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos metoclopramide nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos propantheline nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos propantheline nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos digoxin nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos digoxin nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos warfarin nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	20	28	in inpos separate jj single jj or cc multiple jj dose nn pharmacokinetic jj interaction nn studies nns with inpos warfarin nn the dt bioavailability nn of inpos fosinoprilat nn was vbd not rb altered vbn by inpos coadministration nn of inpos fosinopril nn with inpos any dt num cd of inpos these dt drugs nns
false	14	18	in inpos a dt study nn with inpos concomitant jj administration nn of inpos aspirin nn and cc fosinopril_sodium nn the dt bioavailability nn of inpos unbound jj fosinoprilat nn was vbd not rb altered vbn
false	14	28	in inpos a dt study nn with inpos concomitant jj administration nn of inpos aspirin nn and cc fosinopril_sodium nn the dt bioavailability nn of inpos unbound jj fosinoprilat nn was vbd not rb altered vbn
false	18	28	in inpos a dt study nn with inpos concomitant jj administration nn of inpos aspirin nn and cc fosinopril_sodium nn the dt bioavailability nn of inpos unbound jj fosinoprilat nn was vbd not rb altered vbn
false	6	24	drug_laboratory nnp test nnp interaction nnp fosinopril nn may md cause vb a dt false jj low jj measurement nn of inpos serum nn digoxin nn levels nns with inpos the dt digi nnp tab nnp ria nnp kit nnp for inpos digoxin nn
false	6	24	drug_laboratory nnp test nnp interaction nnp fosinopril nn may md cause vb a dt false jj low jj measurement nn of inpos serum nn digoxin nn levels nns with inpos the dt digi nnp tab nnp ria nnp kit nn for inpos digoxin nn
false	12	22	the dt pharmacokinetics nns and cc protein nn binding nn of inpos fosphenytoin nn were vbd not rb altered vbn when wrb diazepam nn and cc cerebyx nn were vbd concurrently rb administered vbn in inpos single jj submaximal jj doses nns
false	12	26	the dt pharmacokinetics nns and cc protein nn binding nn of inpos fosphenytoin nn were vbd not rb altered vbn when wrb diazepam nn and cc cerebyx nn were vbd concurrently rb administered vbn in inpos single jj submaximal jj doses nns
false	12	22	the dt pharmacokinetics nns and cc protein nn binding nn of inpos phenytoin nn were vbd not rb altered vbn when wrb diazepam nn and cc cerebyx nn were vbd concurrently rb administered vbn in inpos single jj submaximal jj doses nns
false	12	26	the dt pharmacokinetics nns and cc protein nn binding nn of inpos phenytoin nn were vbd not rb altered vbn when wrb diazepam nn and cc cerebyx nn were vbd concurrently rb administered vbn in inpos single jj submaximal jj doses nns
false	12	26	the dt pharmacokinetics nns and cc protein nn binding nn of inpos diazepam nn were vbd not rb altered vbn when wrb diazepam nn and cc cerebyx nn were vbd concurrently rb administered vbn in inpos single jj submaximal jj doses nns
false	16	30	the dt pharmacokinetics nns and cc protein nn binding nn of inpos fosphenytoin nn phenytoin nn diazepam nn were vbd not rb altered vbn when wrb diazepam nn and cc cerebyx nn were vbd concurrently rb administered vbn in inpos single jj submaximal jj doses nns
false	16	36	the dt most rbs significant jj drug nn interactions nns following vbg administration nn of inpos cerebyx nn are vbp expected vbn to topos occur vb with inpos drugs nns that wdt interact vbp with inpos phenytoin nn
mechanism	28	36	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn intake nn amiodarone nn chboramphenicol nn chlordiazepoxide nn cimetidine nn diazepam nn dicumarol nn disulfiram nn estrogens nns ethosuximide nn fluoxetine nn h2_antagonists nns halothane nn isoniazid nn methylphenidate nn phenothiazines nns phenylbutazone nn salicylates nns succinimides nns sulfonamides nns tolbutamide nn trazodone nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn amiodarone nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn chlordiazepoxide nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn cimetidine nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn diazepam nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn dicumarol nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn disulfiram nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn estrogens nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn ethosuximide nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn fluoxetine nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn h2_antagonists nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn halothane nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn isoniazid nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn methylphenidate nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn phenothiazines nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn phenylbutazone nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn salicylates nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn succinimides nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn sulfonamides nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn tolbutamide nn
mechanism	28	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn trazodone nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn amiodarone nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn chlordiazepoxide nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn cimetidine nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn diazepam nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn dicumarol nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn disulfiram nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn estrogens nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn ethosuximide nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn fluoxetine nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn h2_antagonists nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn halothane nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn isoniazid nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn methylphenidate nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn phenothiazines nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn phenylbutazone nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn salicylates nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn succinimides nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn sulfonamides nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn tolbutamide nn
false	36	38	the dt most rbs commonly rb occurring vbg drug nn interactions nns are vbp listed vbn below inpos :_hyph_drugs nns that wdt may md increase vb plasma nn phenytoin nn concentrations nns include vbp acute jj alcohol nn trazodone nn
mechanism	10	16	hyph_drugs nns that wdt may md decrease vb plasma nn phenytoin nn concentrations nns include vbp carbamazepine nn chronic jj alcohol nn abuse nn reserpine nn
mechanism	10	20	hyph_drugs nns that wdt may md decrease vb plasma nn phenytoin nn concentrations nns include vbp carbamazepine nn chronic jj alcohol nn abuse nn reserpine nn
mechanism	10	24	hyph_drugs nns that wdt may md decrease vb plasma nn phenytoin nn concentrations nns include vbp carbamazepine nn chronic jj alcohol nn abuse nn reserpine nn
false	16	20	hyph_drugs nns that wdt may md decrease vb plasma nn phenytoin nn concentrations nns include vbp carbamazepine nn chronic jj alcohol nn abuse nn reserpine nn
false	16	24	hyph_drugs nns that wdt may md decrease vb plasma nn phenytoin nn concentrations nns include vbp carbamazepine nn chronic jj alcohol nn abuse nn reserpine nn
false	20	24	hyph_drugs nns that wdt may md decrease vb plasma nn phenytoin nn concentrations nns include vbp carbamazepine nn chronic jj alcohol nn abuse nn reserpine nn
mechanism	16	22	hyph_drugs nns that wdt may md either cc increase vb or cc decrease vb plasma nn phenytoin nn concentrations nns include vbp phenobarbital nn
mechanism	16	22	hyph_drugs nns that wdt may md either cc increase vb or cc decrease vb plasma nn phenytoin nn concentrations nns include vbp sodium_valproate nn
effect	8	12	similarly rb the dt effects nns of inpos phenytoin nn on inpos phenobarbital nn plasma nn valproate nn concentrations nns are vbp unpredictable jj
effect	8	12	similarly rb the dt effects nns of inpos phenytoin nn on inpos valproic_acid nn plasma nn valproate nn concentrations nns are vbp unpredictable jj
effect	8	20	similarly rb the dt effects nns of inpos phenytoin nn on inpos phenobarbital nn valproic_acid nn sodium nn plasma nn valproate nn concentrations nns are vbp unpredictable jj
false	12	16	similarly rb the dt effects nns of inpos phenytoin nn on inpos phenobarbital nn plasma nn valproate nn concentrations nns are vbp unpredictable jj
false	12	16	similarly rb the dt effects nns of inpos phenytoin nn on inpos valproic_acid nn plasma nn valproate nn concentrations nns are vbp unpredictable jj
effect	12	28	although inpos not rb a dt true jj drug nn interaction nn tricyclic_antidepressants nn may md precipitate vb seizures nns in inpos susceptible jj patients nns and cc cerebyx nn dosage nn may md need vb to topos be vb adjusted vbn
effect	12	16	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nn
effect	12	18	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nn estrogens nns furosemide nn oral jj contraceptives nns rifampin nn quinidine nn theophylline nn vitamin_d nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns coumarin nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns digitoxin nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns doxycycline nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns estrogens nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns furosemide nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns contraceptives nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns rifampin nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns quinidine nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns theophylline nn
effect	12	20	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nns vitamin_d nn
false	18	22	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nn estrogens nns furosemide nn
false	18	22	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nn estrogens nns contraceptives nn
false	18	22	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nn estrogens nns rifampin nn
false	18	22	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nn estrogens nns quinidine nn
false	18	22	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nn estrogens nns theophylline nn
false	18	22	hyph_drugs nns whose wp efficacy nn is vbz impaired vbn by inpos phenytoin nn include vbp anticoagulants nns corticosteroids nn estrogens nns vitamin_d nn
false	22	28	care nnp should md be vb taken vbn when wrb using vbg immunoanalytical jj methods nns to topos measure vb plasma nn phenytoin nn concentrations nns following vbg cerebyx nn administration nn
false	22	28	due jj to topos a dt theoretical jj risk nn of inpos a dt pharmacodynamic jj interaction nn use nn of inpos ergotamine nn containing jj or cc ergot_type_medications nn and cc frova nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
false	22	28	due jj to topos a dt theoretical jj risk nn of inpos a dt pharmacodynamic jj interaction nn use nn of inpos ergotamine nn containing jj or cc methysergide nn and cc frova nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
advise	22	24	due jj to topos a dt theoretical jj risk nn of inpos a dt pharmacodynamic jj interaction nn use nn of inpos ergotamine nn frova nn within inpos num cd hours nns of inpos each dt other jj should md be vb avoided vbn
effect	0	26	selective_serotonin_reuptake_inhibitors nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	0	26	ssris nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	0	26	fluoxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	0	26	fluvoxamine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	0	26	paroxetine nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
effect	0	26	sertraline nn have vbp been vbn reported vbn rarely rb to topos cause vb weakness nn hyperreflexia nn incoordination nn when wrb coadministered vbn with inpos num_ht1_agonists nn
advise	8	14	if inpos concomitant jj treatment nn with inpos frovatriptan nn and cc an dt ssri nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
effect	0	14	furosemide nn may md increase vb the dt ototoxic jj potential nn of inpos aminoglycoside_antibiotics nn especially rb in inpos the dt presence nn of inpos impaired jj renal jj function nn
advise	0	14	furosemide nn should md not rb be vb used vbn concomitantly rb with inpos ethacrynic_acid nn because inpos of inpos the dt possibility nn of inpos ototoxicity nn
effect	10	16	patients nns receiving vbg high jj doses nns of inpos salicylates nn concomitantly rb with inpos furosemide nn as inpos in inpos rheumatic jj disease nn may md experience vb salicylate nn toxicity nn at inpos lower jjr doses nns because inpos of inpos competitive jj renal jj excretory jj sites nns
false	16	10	patients nns receiving vbg high jj doses nns of inpos salicylates nns concomitantly rb with inpos furosemide nn as inpos in inpos rheumatic jj disease nn may md experience vb salicylate nn toxicity nn at inpos lower jjr doses nns because inpos of inpos competitive jj renal jj excretory jj sites nns
effect	0	24	furosemide nn has vbz a dt tendency nn to topos antagonize vb the dt skeletal jj muscle nn relaxing nn effect nn of inpos tubocurarine nn and cc may md potentiate vb the dt action nn of inpos succinylcholine nn
effect	0	38	furosemide nn has vbz a dt tendency nn to topos antagonize vb the dt skeletal jj muscle nn relaxing nn effect nn of inpos tubocurarine nn and cc may md potentiate vb the dt action nn of inpos succinylcholine nn
false	24	38	furosemide nn has vbz a dt tendency nn to topos antagonize vb the dt skeletal jj muscle nn relaxing nn effect nn of inpos tubocurarine nn and cc may md potentiate vb the dt action nn of inpos succinylcholine nn
advise	0	14	lithium nn generally rb should md not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp lithiums nns renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
false	14	0	lithium nn generally rb should md not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp lithium nn s vbz renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
false	14	0	lithium nn generally rb should md not rb be vb given vbn with inpos diuretics nn because inpos they prp reduce vbp lithiums nns renal jj clearance nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
effect	0	22	furosemide nn may md add vb to topos or cc potentiate vb the dt therapeutic jj effect nn of inpos other jj antihypertensive_drugs nn
false	6	10	potentiation nn occurs vbz with inpos ganglionic nn or cc peripheral nn bbbbbcom_adrenergic_blocking_drugs_eeeeecom nn
effect	0	12	furosemide nn may md decrease vb arterial jj responsiveness nn to topos norepinephrine nn
effect	8	12	tablets nns simultaneous jj administration nn of inpos sucralfate nn and cc furosemide nn tablets nns may md reduce vb the dt natriuretic jj and cc antihypertensive jj effects nns of inpos furosemide nn
false	8	12	tablets nns simultaneous jj administration nn of inpos sucralfate nn and cc furosemide nn tablets nns may md reduce vb the dt natriuretic jj and cc antihypertensive jj effects nns of inpos furosemide nn
advise	6	10	the dt intake nn of inpos furosemide nn and cc sucralfate nn should md be vb separated vbn by inpos at inpos least jjs num cd hours nns
effect	28	32	tablets nns injection nn oral nnp solution nnp num cd study nn in inpos num cd subjects nns demonstrated vbd that inpos the dt combination nn of inpos furosemide nn and cc acetylsalicylic_acid nn temporarily rb reduced vbd creatinine nn clearance nn in inpos patients nns with inpos chronic jj renal jj insufficiency nn
effect	36	48	there ex are vbp case nn reports nns of inpos patients nns who wp developed vbd increased vbn bun nn serum nn creatinine nn serum nn potassium nn levels nns weight nn gain nn when wrb furosemide nn was vbd used vbn in inpos conjunction nn with inpos nsaids nn
effect	12	30	literature nn reports nns indicate vbp that inpos coadministration nn of inpos indomethacin nn may md reduce vb the dt natriuretic jj and cc antihypertensive jj effects nns of inpos furosemide nn in inpos some dt patients nns by inpos inhibiting vbg prostaglandin nn synthesis nn
advise	6	10	patients nns receiving vbg both cc indomethacin nn and cc furosemide nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn diuretic jj and_or cc antihypertensive jj effect nn of inpos furosemide nn is vbz achieved vbn
false	6	10	patients nns receiving vbg both cc indomethacin nn and cc furosemide nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn diuretic jj and_or cc antihypertensive jj effect nn of inpos furosemide nn is vbz achieved vbn
false	0	30	gabapentin nn is vbz not rb appreciably rb metabolized vbn nor cc does vbz it prp interfere vb with inpos the dt metabolism nn of inpos commonly rb coadministered vbn antiepileptic_drugs nn
false	16	28	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	16	42	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	16	28	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	16	28	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	16	42	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	28	42	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	28	42	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	42	28	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	42	28	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	28	42	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	28	42	in inpos a dt single jj and cc multiple jj dose nn study nn of inpos neurontin nn in inpos epileptic jj patients nns maintained vbn on inpos phenytoin nn monotherapy nn for inpos at inpos least jjs num cd months nns gabapentin nn had vbd no dt effect nn on inpos the dt steady_state jj trough nn plasma nn concentrations nns of inpos phenytoin nn and cc phenytoin nn had vbd no dt effect nn on inpos gabapentin nn pharmacokinetics nns
false	6	26	steady_state jj trough nn plasma nn carbamazepine nn and cc carbamazepine_num nn num_epoxide nn concentrations nns were vbd not rb affected vbn by inpos concomitant jj gabapentin nn lrb_num cd mg nn tid nn
false	10	24	steady_state jj trough nn plasma nn carbamazepine nn and cc carbamazepine_num_nn_num_epoxide nn concentrations nns were vbd not rb affected vbn by inpos concomitant jj gabapentin nn lrb_num cd mg nn tid nn
false	2	12	likewise rb gabapentin nn pharmacokinetics nns were vbd unaltered jj by inpos carbamazepine nn administration nn
false	10	24	the dt mean jj steady_state jj trough nn serum nn valproic_acid nn concentrations nns prior rb to topos and cc during inpos concomitant jj gabapentin nn administration nn lrb_num cd mg nn tid nn
false	14	24	num nn rrb_were vbd not rb different jj and cc neither dt were vbd gabapentin nn pharmacokinetic jj parameters nns affected vbn by inpos valproic_acid nn
false	12	16	estimates nns of inpos steady_state jj pharmacokinetic jj parameters nns for inpos phenobarbital nn or cc gabapentin nn lrb_num cd mg nn tid nn
false	0	12	naproxen nn coadministration nn of inpos naproxen_sodium nn capsules nns with inpos neurontin nn appears vbz to topos increase vb the dt amount nn of inpos gabapentin nn absorbed vbn by inpos num cd to topos num cd
false	0	26	naproxen nn coadministration nn of inpos naproxen_sodium nn capsules nns with inpos neurontin nn appears vbz to topos increase vb the dt amount nn of inpos gabapentin nn absorbed vbn by inpos num cd to topos num cd
mechanism	4	10	coadministration nn of inpos naproxen_sodium nn capsules nns with inpos neurontin nn appears vbz to topos increase vb the dt amount nn of inpos gabapentin nn absorbed vbn by inpos num cd to topos num cd
false	4	24	coadministration nn of inpos naproxen_sodium nn capsules nns with inpos neurontin nn appears vbz to topos increase vb the dt amount nn of inpos gabapentin nn absorbed vbn by inpos num cd to topos num cd
false	10	24	coadministration nn of inpos naproxen_sodium nn capsules nns with inpos neurontin nn appears vbz to topos increase vb the dt amount nn of inpos gabapentin nn absorbed vbn by inpos num cd to topos num cd
false	0	10	gabapentin nn had vbd no dt effect nn on inpos naproxen nn pharmacokinetic jj parameters nns
false	0	6	hydrocodone nn coadministration nn of inpos neurontin nn lrb_num cd to topos num cd mg nn
mechanism	0	4	hydrocodone nn increases vbz gabapentin nn auc nn values nns by inpos num cd
mechanism	18	38	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	18	44	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	18	44	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	38	44	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	38	44	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	38	18	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	44	18	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	44	18	a dt literature nn article nn reported vbd that inpos when wrb a dt num_mg jj controlled_release nn morphine nn capsule nn was vbd administered vbn num cd hours nns prior rb to topos a dt num_mg jj neurontin nn capsule nn mean jj gabapentin nn auc nn increased vbd by inpos num cd compared vbn to topos gabapentin nn administered vbn without inpos morphine nn
false	0	20	morphine nn pharmacokinetic jj parameter nn values nns were vbd not rb affected vbn by inpos administration nn of inpos neurontin nn num cd hours nns after inpos morphine nn
false	20	0	morphine nn pharmacokinetic jj parameter nn values nns were vbd not rb affected vbn by inpos administration nn of inpos neurontin nn num cd hours nns after inpos morphine nn
mechanism	8	30	in inpos the dt presence nn of inpos cimetidine nn at inpos num cd mg nn qid vbd the dt mean jj apparent jj oral jj clearance nn of inpos gabapentin nn fell vbd by inpos num cd and cc creatinine nn clearance nn fell vbd by inpos num cd
mechanism	2	20	thus rb cimetidine nn appeared vbd to topos alter vb the dt renal jj excretion nn of inpos both cc gabapentin nn and cc creatinine nn an dt endogenous jj marker nn of inpos renal jj function nn
mechanism	12	16	this dt small jj decrease nn in inpos excretion nn of inpos gabapentin nn by inpos cimetidine nn is vbz not rb expected vbn to topos be vb of inpos clinical jj importance nn
false	6	10	the dt effect nn of inpos gabapentin nn on inpos cimetidine nn was vbd not rb evaluated vbn
false	18	22	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
false	18	22	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
false	18	66	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
false	22	40	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
false	22	66	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
false	40	22	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
false	40	66	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
false	22	66	based vbn on inpos auc nn and cc half_life nn multiple_dose jj pharmacokinetic jj profiles nns of inpos norethindrone nn and cc ethinyl_estradiol nn following vbg administration nn of inpos tablets nns containing vbg float cd mg nn of inpos norethindrone_acetate nn and cc num cd mcg nn of inpos ethinyl_estradiol nn were vbd similar jj with inpos and cc without inpos coadministration nn of inpos gabapentin nn lrb_num cd mg nn tid nn
mechanism	6	24	the dt cmax nn of inpos norethindrone nn was vbd num cd higher jjr when wrb it prp was vbd coadministered vbn with inpos gabapentin nn
mechanism	0	10	maalox nn reduced vbd the dt bioavailability nn of inpos gabapentin nn by inpos about rb num cd
mechanism	16	28	this dt decrease nn in inpos bioavailability nn was vbd about rb num cd when wrb gabapentin nn was vbd administered vbn num cd hours nns after inpos maalox nn
advise	8	24	it prp is vbz recommended vbn that inpos gabapentin nn be vb taken vbn at inpos least jjs num cd hours nns following vbg maalox nn administration nn
false	0	12	gabapentin nn pharmacokinetic jj parameters nns without inpos and cc with inpos probenecid nn were vbd comparable jj
false	6	34	this dt indicates vbz that inpos gabapentin nn does vbz not rb undergo vb renal jj tubular jj secretion nn by inpos the dt pathway nn that wdt is vbz blocked vbn by inpos probenecid nn
false	40	50	drug_laboratory nnp tests nnps interactions nnps because inpos false jj positive jj readings nns were vbd reported vbn with inpos the dt ames nnp n_multistix nnp sg nnp dipstick jj test nn for inpos urinary jj protein nn when wrb gabapentin nn was vbd added vbn to topos other jj antiepileptic_drugs nn the dt more rbr specific jj sulfosalicylic jj acid nn precipitation nn procedure nn is vbz recommended vbn to topos determine vb the dt presence nn of inpos urine nn protein nn
false	18	22	in inpos patients nns receiving vbg a dt potent jj cyp3a4 nn inducer nn such jj as inpos rifampicin nn or cc phenytoin nn a dt dose nn increase nn to topos num cd mg nn daily rb should md be vb considered vbn in inpos the dt absence nn of inpos severe jj adverse jj drug nn reaction nn and cc clinical jj response nn and cc adverse jj events nns should md be vb carefully rb monitored vbn
effect	28	34	international nnp normalized nnp ratio nnp elevations nns and_or cc bleeding vbg events nns have vbp been vbn reported vbn in inpos some dt patients nns taking vbg warfarin nn while inpos on inpos iressa nn therapy nn
mechanism	14	18	substances nns that wdt are vbp potent jj inhibitors nns of inpos cyp3a4 nn ketoconazole nn decrease nn gefitinib nn metabolism nn and cc increase vb gefitinib nn plasma nn concentrations nns
mechanism	14	18	substances nns that wdt are vbp potent jj inhibitors nns of inpos cyp3a4 nn ketoconazole nn decrease nn gefitinib nn metabolism nn and cc increase vb gefitinib nn plasma nn concentrations nns
mechanism	14	18	substances nns that wdt are vbp potent jj inhibitors nns of inpos cyp3a4 nn itraconazole nn decrease nn gefitinib nn metabolism nn and cc increase vb gefitinib nn plasma nn concentrations nns
mechanism	14	18	substances nns that wdt are vbp potent jj inhibitors nns of inpos cyp3a4 nn itraconazole nn decrease nn gefitinib nn metabolism nn and cc increase vb gefitinib nn plasma nn concentrations nns
mechanism	16	28	drugs nns that wdt cause vbp significant jj sustained jj elevation nn in inpos gastric jj histamine_h2_receptor_antagonists nn may md reduce vb plasma nn concentrations nns of inpos iressa nn and cc therefore rb potentially rb may md reduce vb efficacy nn
mechanism	16	28	drugs nns that wdt cause vbp significant jj sustained jj elevation nn in inpos gastric jj ranitidine nn may md reduce vb plasma nn concentrations nns of inpos iressa nn and cc therefore rb potentially rb may md reduce vb efficacy nn
mechanism	16	28	drugs nns that wdt cause vbp significant jj sustained jj elevation nn in inpos gastric jj cimetidine nn may md reduce vb plasma nn concentrations nns of inpos iressa nn and cc therefore rb potentially rb may md reduce vb efficacy nn
false	12	16	phase nn num cd clinical jj trial nn data nns where wrb iressa nn and cc vinorelbine nn have vbp been vbn used vbn concomitantly rb indicate vbp that inpos iressa nn may md exacerbate vb the dt neutropenic jj effect nn of inpos vinorelbine nn
false	12	16	phase nn num cd clinical jj trial nn data nns where wrb iressa nn and cc vinorelbine nn have vbp been vbn used vbn concomitantly rb indicate vbp that inpos iressa nn may md exacerbate vb the dt neutropenic jj effect nn of inpos vinorelbine nn
false	16	12	phase nn num cd clinical jj trial nn data nns where wrb iressa nn and cc vinorelbine nn have vbp been vbn used vbn concomitantly rb indicate vbp that inpos iressa nn may md exacerbate vb the dt neutropenic jj effect nn of inpos vinorelbine nn
effect	12	16	phase nn num cd clinical jj trial nn data nns where wrb iressa nn and cc vinorelbine nn have vbp been vbn used vbn concomitantly rb indicate vbp that inpos iressa nn may md exacerbate vb the dt neutropenic jj effect nn of inpos vinorelbine nn
false	12	16	for inpos information nn on inpos the dt pharmacokinetics nns of inpos gemzar nn and cc cisplatin nn in inpos combination nn see vb drug nnp interactions nnp under inpos clinical jj pharmacology nn section nn
false	10	30	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt ethinylestradiol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	10	32	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt levonorgestrol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	10	36	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt ethinylestradiol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	10	40	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt levonorgestrol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	30	32	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt ethinylestradiol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	30	36	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt ethinylestradiol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	30	40	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt ethinylestradiol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	32	36	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt ethinylestradiol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	32	40	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt levonorgestrol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
false	36	40	administration nn of inpos repeat nn doses nns of inpos factive nn had vbd no dt effect nn on inpos the dt repeat nn dose nn pharmacokinetics nns of inpos theophylline nn digoxin nn an dt ethinylestradiol nn oral jj contraceptive_product nn in inpos healthy jj subjects nns
mechanism	6	10	concomitant jj administration nn of inpos factive nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
mechanism	6	10	concomitant jj administration nn of inpos factive nn an dt progesterone nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
mechanism	6	14	concomitant jj administration nn of inpos factive nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	30	concomitant jj administration nn of inpos factive nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	10	concomitant jj administration nn of inpos calcium_carbonate nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	10	concomitant jj administration nn of inpos calcium_carbonate nn an dt progesterone nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	14	concomitant jj administration nn of inpos calcium_carbonate nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	30	concomitant jj administration nn of inpos calcium_carbonate nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	10	concomitant jj administration nn of inpos cimetidine nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	10	concomitant jj administration nn of inpos cimetidine nn an dt progesterone nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	14	concomitant jj administration nn of inpos cimetidine nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	30	concomitant jj administration nn of inpos cimetidine nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	10	concomitant jj administration nn of inpos omeprazole nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	10	concomitant jj administration nn of inpos omeprazole nn an dt progesterone nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	14	concomitant jj administration nn of inpos omeprazole nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	6	30	concomitant jj administration nn of inpos omeprazole nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	16	20	concomitant jj administration nn of inpos factive nn calcium_carbonate nn cimetidine nn omeprazole nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	16	36	concomitant jj administration nn of inpos factive nn calcium_carbonate nn cimetidine nn omeprazole nn an dt estrogen nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	16	20	concomitant jj administration nn of inpos factive nn calcium_carbonate nn cimetidine nn omeprazole nn an dt progesterone nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	16	36	concomitant jj administration nn of inpos factive nn calcium_carbonate nn cimetidine nn omeprazole nn an dt progesterone nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
false	20	36	concomitant jj administration nn of inpos factive nn calcium_carbonate nn cimetidine nn omeprazole nn an dt progesterone nn oral jj contraceptive nn produced vbd minor jj changes nns in inpos the dt pharmacokinetics nns of inpos gemifloxacin nn which wdt were vbd considered vbn to topos be vb without inpos clinical jj significance nn
mechanism	6	10	concomitant jj administration nn of inpos factive nn with inpos probenecid nn resulted vbd in inpos a dt num cd increase nn in inpos systemic jj exposure nn to topos gemifloxacin nn
false	6	30	concomitant jj administration nn of inpos factive nn with inpos probenecid nn resulted vbd in inpos a dt num cd increase nn in inpos systemic jj exposure nn to topos gemifloxacin nn
false	10	30	concomitant jj administration nn of inpos factive nn with inpos probenecid nn resulted vbd in inpos a dt num cd increase nn in inpos systemic jj exposure nn to topos gemifloxacin nn
false	0	20	factive nn had vbd no dt significant jj effect nn on inpos the dt anticoagulant jj effect nn of inpos warfarin nn in inpos healthy jj subjects nns on inpos stable jj warfarin nn therapy nn
false	0	20	factive nn had vbd no dt significant jj effect nn on inpos the dt anticoagulant jj effect nn of inpos warfarin nn in inpos healthy jj subjects nns on inpos stable jj warfarin nn therapy nn
effect	6	26	however rb because inpos some dt quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt anticoagulant jj effects nns of inpos warfarin nn or cc its prp derivatives nns in inpos patients nns the dt prothrombin nn time nn or cc other jj suitable jj coagulation nn test nn should md be vb closely rb monitored vbn if inpos a dt quinolone_antimicrobial nn is vbz administered vbn concomitantly rb with inpos warfarin nn or cc its prp derivatives nns
false	6	66	however rb because inpos some dt quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt anticoagulant jj effects nns of inpos warfarin nn or cc its prp derivatives nns in inpos patients nns the dt prothrombin nn time nn or cc other jj suitable jj coagulation nn test nn should md be vb closely rb monitored vbn if inpos a dt quinolone_antimicrobial nn is vbz administered vbn concomitantly rb with inpos warfarin nn or cc its prp derivatives nns
false	6	26	however rb because inpos some dt quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt anticoagulant jj effects nns of inpos warfarin nn or cc its prp derivatives nns in inpos patients nns the dt prothrombin nn time nn or cc other jj suitable jj coagulation nn test nn should md be vb closely rb monitored vbn if inpos a dt quinolone_antimicrobial nn is vbz administered vbn concomitantly rb with inpos warfarin nn or cc its prp derivatives nns
false	26	66	however rb because inpos some dt quinolones nns have vbp been vbn reported vbn to topos enhance vb the dt anticoagulant jj effects nns of inpos warfarin nn or cc its prp derivatives nns in inpos patients nns the dt prothrombin nn time nn or cc other jj suitable jj coagulation nn test nn should md be vb closely rb monitored vbn if inpos a dt quinolone_antimicrobial nn is vbz administered vbn concomitantly rb with inpos warfarin nn or cc its prp derivatives nns
advise	66	26	however rb because inpos some dt quinolones nns have vbp been vbn reported vbn to topos enhance vb the dt anticoagulant jj effects nns of inpos warfarin nn or cc its prp derivatives nns in inpos patients nns the dt prothrombin nn time nn or cc other jj suitable jj coagulation nn test nn should md be vb closely rb monitored vbn if inpos a dt quinolone_antimicrobial nn is vbz administered vbn concomitantly rb with inpos warfarin nn or cc its prp derivatives nns
false	8	28	the dt absorption nn of inpos oral jj gemifloxacin nn is vbz significantly rb reduced vbn by inpos the dt concomitant jj administration nn of inpos an dt antacid nn containing vbg aluminum nn and cc magnesium nn
mechanism	8	32	the dt absorption nn of inpos oral jj gemifloxacin nn is vbz significantly rb reduced vbn by inpos the dt concomitant jj administration nn of inpos an dt antacid nn containing vbg aluminum nn and cc magnesium nn
mechanism	8	36	the dt absorption nn of inpos oral jj gemifloxacin nn is vbz significantly rb reduced vbn by inpos the dt concomitant jj administration nn of inpos an dt antacid nn containing vbg aluminum nn and cc magnesium nn
false	28	32	the dt absorption nn of inpos oral jj gemifloxacin nn is vbz significantly rb reduced vbn by inpos the dt concomitant jj administration nn of inpos an dt antacid nn containing vbg aluminum nn and cc magnesium nn
false	28	36	the dt absorption nn of inpos oral jj gemifloxacin nn is vbz significantly rb reduced vbn by inpos the dt concomitant jj administration nn of inpos an dt antacid nn containing vbg aluminum nn and cc magnesium nn
false	32	36	the dt absorption nn of inpos oral jj gemifloxacin nn is vbz significantly rb reduced vbn by inpos the dt concomitant jj administration nn of inpos an dt antacid nn containing vbg aluminum nn and cc magnesium nn
false	0	4	magnesium nn hyph_and_or cc aluminum nn containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	0	2	magnesium nn hyph_antacids nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	0	2	magnesium nn hyph_ferrous_sulfate nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	0	12	magnesium nn hyph_and_or cc aluminum_containing jj antacids nns products nns containing vbg iron nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	0	14	magnesium nn hyph_and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	0	18	magnesium nn hyph_and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	0	28	magnesium nn hyph_and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	0	28	magnesium nn hyph_and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	0	72	magnesium nn hyph_and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	4	8	magnesium nn and_or cc aluminum nn containing jj antacids nn products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	4	14	magnesium nn and_or cc aluminum nn containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	4	14	magnesium nn and_or cc aluminum nn containing jj antacids nns products nns containing vbg iron nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	4	16	magnesium nn and_or cc aluminum nn containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	4	20	magnesium nn and_or cc aluminum nn containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	4	30	magnesium nn and_or cc aluminum nn containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	4	30	magnesium nn and_or cc aluminum nn containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	4	74	magnesium nn and_or cc aluminum nn containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	6	12	magnesium jj and_or cc aluminum_containing jj antacids nn products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	6	12	magnesium jj and_or cc aluminum_containing jj antacids nn products nns containing vbg iron nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	6	14	magnesium jj and_or cc aluminum_containing jj antacids nn products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	6	18	magnesium jj and_or cc aluminum_containing jj antacids nn products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	6	28	magnesium jj and_or cc aluminum_containing jj antacids nn products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	6	28	magnesium jj and_or cc aluminum_containing jj antacids nn products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	6	70	magnesium jj and_or cc aluminum_containing jj antacids nn products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	14	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	18	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	12	70	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	14	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg iron nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	18	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg iron nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg iron nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	12	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg iron nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	12	72	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg iron nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	14	18	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	14	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	14	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	14	72	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nn containing vbg zinc nn or cc other jj metal nn cations nns videx nnp buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	18	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
false	18	28	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	18	70	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	28	70	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	28	70	magnesium jj and_or cc aluminum_containing jj antacids nns products nns containing vbg ferrous_sulfate nn multivitamin_preparations nns containing vbg zinc nn or cc other jj metal nn cations nns didanosine nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb taken vbn within inpos num cd hours nns before inpos or cc num cd hours nns after inpos factive nn
advise	0	18	sucralfate nn should md not rb be vb taken vbn within inpos num cd hours nns of inpos factive nn
false	20	48	results nns from inpos existing vbg clinical jj trials nns suggest vbp no dt significant jj interactions nns between inpos copaxone nn and cc other jj therapies nns commonly rb used vbn in inpos ms nn patients nns including vbg the dt concurrent jj use nn of inpos corticosteroids nn for inpos up rb to topos num cd days nns
false	0	18	copaxone nn has vbz not rb been vbn formally rb evaluated vbn in inpos combination nn with inpos interferon_b nn
false	16	20	however rb num cd patients nns who wp switched vbd from inpos therapy nn with inpos interferon_b nn to topos copaxone nn did vbd not rb report vb any dt serious jj and cc unexpected jj adverse jj reactions nns thought vbn to topos be vb related vbn to topos treatment nn
effect	8	24	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns chloramphenicol nn probenecid nn coumarins nns monoamine_oxidase_inhibitors nns b_adrenergic_blocking_agents nns
effect	8	40	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns other jj drugs nns that wdt are vbp highly rb protein nn bound vbn salicylates nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd sulfonamides nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd chloramphenicol nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd probenecid nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd coumarins nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd monoamine_oxidase_inhibitors nns
effect	8	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd b_adrenergic_blocking_agents nn
false	24	40	the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn other jj drugs nns that wdt are vbp highly rb protein nn bound vbn salicylates nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd sulfonamides nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd chloramphenicol nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd probenecid nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd coumarins nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd monoamine_oxidase_inhibitors nns
false	24	42	the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd b_adrenergic_blocking_agents nn
false	8	12	these dt drugs nns include vbp the dt thiazides nn other jj diuretics nn corticosteroids nns phe_nothiazines nns thyroid_products nns estrogens nns oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimet_ics nns calcium_channel_blocking_drugs nns isoniazid nn
false	8	16	these dt drugs nns include vbp the dt thiazides nn and cc other jj diuretics nns corticosteroids nn
false	12	14	these dt drugs nns include vbp the dt thiazides nns other jj diuretics nn corticosteroids nn phe_nothiazines nns thyroid_products nns estrogens nns oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimet_ics nns calcium_channel_blocking_drugs nns isoniazid nn
false	8	10	these dt drugs nns include vbp the dt corticosteroids nns estrogens nn oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimet_ics nns calcium_channel_blocking_drugs nns isoniazid nn
false	18	20	these dt drugs nns include vbp the dt thiazides nns other jj diuretics nns corticosteroids nns phe_nothiazines nns thyroid_products nn estrogens nn oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimet_ics nns calcium_channel_blocking_drugs nns isoniazid nn
int	8	12	a dt possible jj interaction nn between inpos glyburide nn and cc ciprofloxacin nn a dt fluoroquinolone_antibiotic jj has vbz been vbn reported vbn resulting vbg in inpos a dt potentiation nn of inpos the dt hypoglycemic jj action nn of inpos glyburide nn
false	8	16	a dt possible jj interaction nn between inpos glyburide nn and cc ciprofloxacin nn a dt fluoroquinolone_antibiotic nn has vbz been vbn reported vbn resulting vbg in inpos a dt potentiation nn of inpos the dt hypoglycemic jj action nn of inpos glyburide nn
false	12	16	a dt possible jj interaction nn between inpos glyburide nn and cc ciprofloxacin nn a dt fluoroquinolone_antibiotic nn has vbz been vbn reported vbn resulting vbg in inpos a dt potentiation nn of inpos the dt hypoglycemic jj action nn of inpos glyburide nn
false	12	8	a dt possible jj interaction nn between inpos glyburide nn and cc ciprofloxacin nn a dt fluoroquinolone_antibiotic jj has vbz been vbn reported vbn resulting vbg in inpos a dt potentiation nn of inpos the dt hypoglycemic jj action nn of inpos glyburide nn
false	16	8	a dt possible jj interaction nn between inpos glyburide nn and cc ciprofloxacin nn a dt fluoroquinolone_antibiotic nn has vbz been vbn reported vbn resulting vbg in inpos a dt potentiation nn of inpos the dt hypoglycemic jj action nn of inpos glyburide nn
effect	10	16	a dt potential jj interaction nn between inpos oral jj miconazole nn and cc oral jj hypoglycemic_agents nn leading vbg to topos severe jj hypoglycemia nn has vbz been vbn reported vbn
advise	4	30	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magnesium_choline_salicylate nn salsalate nn choline_salicylate nn magnesium_salicylate nn bismuth_subsalicylate nn
advise	4	36	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magnesium_choline_salicylate nn salsalate nn choline_salicylate nn magnesium_salicylate nn bismuth_subsalicylate nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magnesium_choline_salicylate nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos trilisate nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos salsalate nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos disalcid nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos choline_salicylate nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos arthropan nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magnesium_salicylate nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magan nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos bismuth_subsalicylate nn
advise	4	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos pepto_bismol nn
false	30	36	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magnesium_choline_salicylate nn salsalate nn choline_salicylate nn magnesium_salicylate nn bismuth_subsalicylate nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magnesium_choline_salicylate nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos trilisate nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos salsalate nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos disalcid nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos choline_salicylate nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos arthropan nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magnesium_salicylate nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magan nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos bismuth_subsalicylate nn
false	30	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos pepto_bismol nn
false	36	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos trilisate nn
false	36	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos salsalate nn
false	36	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos disalcid nn
false	36	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos arthropan nn
false	36	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos magan nn
false	36	42	before inpos taking vbg glimepiride nn tell vb your prp doctor nn if inpos you prp are vbp taking vbg any dt of inpos the dt following vbg medicines nns hyph_aspirin nn or cc another dt salicylate nn such jj as inpos pepto_bismol nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos ibuprofen nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos motrin nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos advil nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos nuprin nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos ketoprofen nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos orudis nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos orudis_kt nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos oruvail nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos diclofenac nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos voltaren nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos cataflam nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos etodolac nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos lodine nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos indomethacin nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos indocin nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos nabumetone nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos relafen nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos oxaprozin nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos daypro nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos naproxen nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos anaprox nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos naprosyn nn
false	2	8	a dt nonsteroidal_anti_inflammatory_drug nn such jj as inpos aleve nn
false	2	8	a dt nsaid nn such jj as inpos ibuprofen nn
false	2	8	a dt nsaid nn such jj as inpos motrin nn
false	2	8	a dt nsaid nn such jj as inpos advil nn
false	2	8	a dt nsaid nn such jj as inpos nuprin nn
false	2	8	a dt nsaid nn such jj as inpos ketoprofen nn
false	2	8	a dt nsaid nn such jj as inpos orudis nn
false	2	8	a dt nsaid nn such jj as inpos orudis_kt nn
false	2	8	a dt nsaid nn such jj as inpos oruvail nn
false	2	8	a dt nsaid nn such jj as inpos diclofenac nn
false	2	8	a dt nsaid nn such jj as inpos voltaren nn
false	2	8	a dt nsaid nn such jj as inpos cataflam nn
false	2	8	a dt nsaid nn such jj as inpos etodolac nn
false	2	8	a dt nsaid nn such jj as inpos lodine nn
false	2	8	a dt nsaid nn such jj as inpos indomethacin nn
false	2	8	a dt nsaid nn such jj as inpos indocin nn
false	2	8	a dt nsaid nn such jj as inpos nabumetone nn
false	2	8	a dt nsaid nn such jj as inpos relafen nn
false	2	8	a dt nsaid nn such jj as inpos oxaprozin nn
false	2	8	a dt nsaid nn such jj as inpos daypro nn
false	2	8	a dt nsaid nn such jj as inpos naproxen nn
false	2	8	a dt nsaid nn such jj as inpos anaprox nn
false	2	8	a dt nsaid nn such jj as inpos naprosyn nn
false	2	8	a dt nsaid nn such jj as inpos aleve nn
false	10	12	a dt sulfa_based jj drug nn such jj as inpos sulfamethoxazole nn hyph_trimethoprim nn
false	10	12	a dt sulfa_based jj drug nn such jj as inpos sulfamethoxazole nn bactrim nn
false	10	12	a dt sulfa_based jj drug nn such jj as inpos sulfamethoxazole nn septra nn
false	10	14	a dt sulfa_based jj drug nn such jj as inpos sulfamethoxazole nn trimethoprim jj sulfisoxazole nn or cc sulfasalazine nn
false	10	14	a dt sulfa_based jj drug nn such jj as inpos sulfamethoxazole nn trimethoprim jj gantrisin nn or cc sulfasalazine nn
false	10	18	a dt sulfa_based jj drug nn such jj as inpos sulfamethoxazole nn trimethoprim jj sulfisoxazole nn or cc sulfasalazine nn
false	10	18	a dt sulfa_based jj drug nn such jj as inpos sulfamethoxazole nn trimethoprim jj sulfisoxazole nn or cc azulfidine nn
false	2	8	a dt monoamine_oxidase_inhibitor nn such jj as inpos isocarboxazid nn
false	2	8	a dt monoamine_oxidase_inhibitor nn such jj as inpos marplan nn
false	2	8	a dt monoamine_oxidase_inhibitor nn such jj as inpos tranylcypromine nn
false	2	8	a dt monoamine_oxidase_inhibitor nn such jj as inpos parnate nn
false	2	8	a dt monoamine_oxidase_inhibitor nn such jj as inpos phenelzine nn
false	2	8	a dt monoamine_oxidase_inhibitor nn such jj as inpos nardil nn
false	2	8	a dt maoi nn such jj as inpos isocarboxazid nn
false	2	8	a dt maoi nn such jj as inpos marplan nn
false	2	8	a dt maoi nn such jj as inpos tranylcypromine nn
false	2	8	a dt maoi nn such jj as inpos parnate nn
false	2	8	a dt maoi nn such jj as inpos phenelzine nn
false	2	8	a dt maoi nn such jj as inpos nardil nn
false	2	8	a dt b_blocker nn such jj as inpos propranolol nns
false	2	8	a dt b_blocker nn such jj as inpos inderal nns
false	2	8	a dt b_blocker nn such jj as inpos atenolol nns
false	2	8	a dt b_blocker nn such jj as inpos tenormin nns
false	2	8	a dt b_blocker nn such jj as inpos acebutolol nns
false	2	8	a dt b_blocker nn such jj as inpos sectral nns
false	2	8	a dt b_blocker nn such jj as inpos metoprolol nns
false	2	8	a dt b_blocker nn such jj as inpos lopressor nns
false	2	8	a dt diuretic nn such jj as inpos hydrochlorothiazide nns
false	2	8	a dt diuretic nn such jj as inpos hctz nns
false	2	8	a dt diuretic nn such jj as inpos hydrodiuril nns
false	2	8	a dt diuretic nn such jj as inpos chlorothiazide nns
false	2	8	a dt diuretic nn such jj as inpos diuril nns
false	2	8	a dt steroid_medicine nn such jj as inpos prednisone nns
false	2	8	a dt steroid_medicine nn such jj as inpos deltasone nns
false	2	8	a dt steroid_medicine nn such jj as inpos orasone nns
false	2	8	a dt steroid_medicine nn such jj as inpos methylprednisolone nns
false	2	8	a dt steroid_medicine nn such jj as inpos medrol nns
false	2	8	a dt steroid_medicine nn such jj as inpos prednisolone nns
false	2	8	a dt steroid_medicine nn such jj as inpos prelone nns
false	2	8	a dt steroid_medicine nn such jj as inpos pediapred nns
false	2	8	a dt phenothiazine nn such jj as inpos chlorpromazine nns
false	2	8	a dt phenothiazine nn such jj as inpos thorazine nns
false	2	8	a dt phenothiazine nn such jj as inpos fluphenazine nns
false	2	8	a dt phenothiazine nn such jj as inpos prolixin nns
false	2	8	a dt phenothiazine nn such jj as inpos permitil nns
false	2	8	a dt phenothiazine nn such jj as inpos prochlorperazine nns
false	2	8	a dt phenothiazine nn such jj as inpos compazine nns
false	2	8	a dt phenothiazine nn such jj as inpos promethazine nns
false	2	8	a dt phenothiazine nn such jj as inpos phenergan nns
effect	18	34	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns chloramphenicol nn probenecid nn coumarins nns monoamine_oxidase_inhibitors nns b_adrenergic_blocking_agents nns
effect	18	34	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg azoles nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns chloramphenicol nn probenecid nn coumarins nns monoamine_oxidase_inhibitors nns b_adrenergic_blocking_agents nns
effect	18	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbn salicylates nns
effect	18	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd sulfonamides nns
effect	18	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd chloramphenicol nns
effect	18	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd probenecid nns
effect	18	60	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns coumarins nns and cc b_adrenergic_blocking_agents nns
effect	18	60	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns monoamine_oxidase_inhibitors nn and cc b_adrenergic_blocking_agents nns
effect	18	60	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nn may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns b_adrenergic_blocking_agents nn
false	34	38	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nn and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns chloramphenicol nn probenecid nn coumarins nns monoamine_oxidase_inhibitors nns b_adrenergic_blocking_agents nns
false	34	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbn salicylates nns
false	34	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd sulfonamides nns
false	34	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd chloramphenicol nns
false	34	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd probenecid nns
false	34	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd coumarins nns
false	34	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd monoamine_oxidase_inhibitors nns
false	34	56	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nn some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd b_adrenergic_blocking_agents nn
false	38	54	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nn other jj drugs nns that wdt are vbp highly rb protein nn bound vbn salicylates nns
false	34	46	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg azoles nns that wdt are vbp highly rb protein nn bound vbd sulfonamides nns
false	34	46	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg azoles nns that wdt are vbp highly rb protein nn bound vbd chloramphenicol nns
false	34	46	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg azoles nns that wdt are vbp highly rb protein nn bound vbd probenecid nns
false	34	46	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg azoles nns that wdt are vbp highly rb protein nn bound vbd coumarins nns
false	34	46	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg azoles nns that wdt are vbp highly rb protein nn bound vbd monoamine_oxidase_inhibitors nns
false	34	50	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg azoles nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nns b_adrenergic_blocking_agents nn
false	58	60	immediate nnp and cc extended nnp release nnp tablets nnps the dt hypoglycemic jj action nn of inpos sulfonylureas nns may md be vb potentiated vbn by inpos certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns some dt azoles nns and cc other jj drugs nns that wdt are vbp highly rb protein nn bound vbd salicylates nns sulfonamides nn b_adrenergic_blocking_agents nn
false	20	28	in fw vitro fw binding nn studies nns with inpos human jj serum nn proteins nns indicate vbp that inpos glipizide nn binds vbz differently rb than inpos tolbutamide nn and cc does vbz not rb interact vb with inpos salicylate nn or cc dicumarol nn
false	20	40	in fw vitro fw binding nn studies nns with inpos human jj serum nn proteins nns indicate vbp that inpos glipizide nn binds vbz differently rb than inpos tolbutamide nn and cc does vbz not rb interact vb with inpos salicylate nn or cc dicumarol nn
false	20	44	in fw vitro fw binding nn studies nns with inpos human jj serum nn proteins nns indicate vbp that inpos glipizide nn binds vbz differently rb than inpos tolbutamide nn and cc does vbz not rb interact vb with inpos salicylate nn or cc dicumarol nn
false	28	40	in fw vitro fw binding nn studies nns with inpos human jj serum nn proteins nns indicate vbp that inpos glipizide nn binds vbz differently rb than inpos tolbutamide nn and cc does vbz not rb interact vb with inpos salicylate nn or cc dicumarol nn
false	28	44	in fw vitro fw binding nn studies nns with inpos human jj serum nn proteins nns indicate vbp that inpos glipizide nn binds vbz differently rb than inpos tolbutamide nn and cc does vbz not rb interact vb with inpos salicylate nn or cc dicumarol nn
false	40	44	in fw vitro fw binding nn studies nns with inpos human jj serum nn proteins nns indicate vbp that inpos glipizide nn binds vbz differently rb than inpos tolbutamide nn and cc does vbz not rb interact vb with inpos salicylate nn or cc dicumarol nn
false	8	12	these dt drugs nns include vbp the dt thiazides nn other jj diuretics nn corticosteroids nns phenothiazines nns thyroid_products nns estrogens nns oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	8	16	these dt drugs nns include vbp the dt thiazides nn and cc other jj diuretics nns corticosteroids nn
false	12	14	these dt drugs nns include vbp the dt thiazides nns other jj diuretics nn corticosteroids nn phenothiazines nns thyroid_products nns estrogens nns oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	14	18	these dt drugs nns include vbp the dt thiazides nns and cc other jj diuretics nn corticosteroids nns phenothiazines nn
false	8	10	these dt drugs nns include vbp the dt corticosteroids nns estrogens nn oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
false	18	20	these dt drugs nns include vbp the dt thiazides nns other jj diuretics nns corticosteroids nns phenothiazines nns thyroid_products nn estrogens nn oral jj contraceptives nns phenytoin nn nicotinic_acid nn sympathomimetics nns calcium_channel_blocking_drugs nns isoniazid nn
int	10	16	a dt potential jj interaction nn between inpos oral jj miconazole nn and cc oral jj hypoglycemic_agents nn leading vbg to topos severe jj hypoglycemia nn has vbz been vbn reported vbn
int	12	16	the dt effect nn of inpos concomitant jj administration nn of inpos fluconazole nn and cc glipizide nn has vbz been vbn demonstrated vbn in inpos a dt placebo_controlled jj crossover nn study nn in inpos normal jj volunteers nns
false	6	24	all dt subjects nns received vbd glipizide nn alone rb and cc following vbg treatment nn with inpos num cd mg nn of inpos fluconazole nn as inpos a dt single jj daily jj oral jj dose nn for inpos num cd days nns
mechanism	12	18	the dt mean jj percentage nn increase nn in inpos the dt glipizide nn auc nn after inpos fluconazole nn administration nn was vbd float cd
effect	8	16	the dt concurrent jj use nn of inpos robinul nn injection nn with inpos other jj anticholinergics nn or cc medications nns with inpos anticholinergic jj activity nn such jj as inpos phenothiazines nns antiparkinson_drugs nns tricyclic_antidepressants nns may md intensify vb the dt antimuscarinic jj effects nns and cc may md result vb in inpos an dt increase nn in inpos anticholinergic jj side nn effects nns
effect	8	32	the dt concurrent jj use nn of inpos robinul nn injection nn with inpos other jj anticholinergics nns or cc medications nns with inpos anticholinergic jj activity nn such jj as inpos phenothiazines nns may md intensify vb the dt antimuscarinic jj effects nns and cc may md result vb in inpos an dt increase nn in inpos anticholinergic jj side nn effects nns
effect	8	32	the dt concurrent jj use nn of inpos robinul nn injection nn with inpos other jj anticholinergics nns or cc medications nns with inpos anticholinergic jj activity nn such jj as inpos antiparkinson_drugs nns may md intensify vb the dt antimuscarinic jj effects nns and cc may md result vb in inpos an dt increase nn in inpos anticholinergic jj side nn effects nns
effect	8	32	the dt concurrent jj use nn of inpos robinul nn injection nn with inpos other jj anticholinergics nns or cc medications nns with inpos anticholinergic jj activity nn such jj as inpos tricyclic_antidepressants nn may md intensify vb the dt antimuscarinic jj effects nns and cc may md result vb in inpos an dt increase nn in inpos anticholinergic jj side nn effects nns
false	16	32	the dt concurrent jj use nn of inpos robinul nnp injection nnp with inpos other jj anticholinergics nn or cc medications nns with inpos anticholinergic jj activity nn such jj as inpos phenothiazines nns may md intensify vb the dt antimuscarinic jj effects nns and cc may md result vb in inpos an dt increase nn in inpos anticholinergic jj side nn effects nns
false	16	32	the dt concurrent jj use nn of inpos robinul nnp injection nnp with inpos other jj anticholinergics nn or cc medications nns with inpos anticholinergic jj activity nn such jj as inpos antiparkinson_drugs nns may md intensify vb the dt antimuscarinic jj effects nns and cc may md result vb in inpos an dt increase nn in inpos anticholinergic jj side nn effects nns
false	16	32	the dt concurrent jj use nn of inpos robinul nnp injection nnp with inpos other jj anticholinergics nn or cc medications nns with inpos anticholinergic jj activity nn such jj as inpos tricyclic_antidepressants nn may md intensify vb the dt antimuscarinic jj effects nns and cc may md result vb in inpos an dt increase nn in inpos anticholinergic jj side nn effects nns
mechanism	6	12	concomitant jj administration nn of inpos robinul nn injection nn and cc potassium_chloride nn in inpos a dt wax nn matrix nn may md increase vb the dt severity nn of inpos potassium nn chloride_induced jj gastrointestinal jj lesions nns as inpos a dt result nn of inpos a dt slower jjr gastrointestinal jj transit nn time nn
false	16	24	the dt gonadotropin nn levels nns may md be vb transiently rb elevated vbn by inpos spironolactone nn minimally rb elevated vbn by inpos levodopa nn and cc suppressed vbn by inpos oral jj contraceptives nns and cc digoxin nn
false	16	34	the dt gonadotropin nn levels nns may md be vb transiently rb elevated vbn by inpos spironolactone nn minimally rb elevated vbn by inpos levodopa nn and cc suppressed vbn by inpos oral jj contraceptives nn and cc digoxin nn
false	16	38	the dt gonadotropin nn levels nns may md be vb transiently rb elevated vbn by inpos spironolactone nn minimally rb elevated vbn by inpos levodopa nn and cc suppressed vbn by inpos oral jj contraceptives nns and cc digoxin nn
false	24	34	the dt gonadotropin nn levels nns may md be vb transiently rb elevated vbn by inpos spironolactone nn minimally rb elevated vbn by inpos levodopa nn and cc suppressed vbn by inpos oral jj contraceptives nn and cc digoxin nn
false	24	38	the dt gonadotropin nn levels nns may md be vb transiently rb elevated vbn by inpos spironolactone nn minimally rb elevated vbn by inpos levodopa nn and cc suppressed vbn by inpos oral jj contraceptives nns and cc digoxin nn
false	34	38	the dt gonadotropin nn levels nns may md be vb transiently rb elevated vbn by inpos spironolactone nn minimally rb elevated vbn by inpos levodopa nn and cc suppressed vbn by inpos oral jj contraceptives nn and cc digoxin nn
effect	6	16	the dt response nn to topos factrel nn may md be vb blunted vbn by inpos phenothiazines nn and cc dopamine_antagonists nns which wdt cause vbp a dt rise nn in inpos prolactin nn
effect	6	20	the dt response nn to topos factrel nn may md be vb blunted vbn by inpos phenothiazines nns and cc dopamine_antagonists nn which wdt cause vbp a dt rise nn in inpos prolactin nn
false	16	20	the dt response nn to topos factrel nn may md be vb blunted vbn by inpos phenothiazines nn and cc dopamine_antagonists nn which wdt cause vbp a dt rise nn in inpos prolactin nn
false	0	2	antacids nn sucralfate nn metal nnp cations nnp multivitamins nnp quinolones nnp form nn chelates nns with inpos alkaline nn earth nn and cc transition nn metal nn cations nns
false	0	8	antacids nn sucralfate nnp metal nnp cations nnp multivitamins nn quinolones nns form nn chelates nns with inpos alkaline nn earth nn and cc transition nn metal nn cations nns
false	0	10	antacids nn sucralfate nnp metal nnp cations nnp multivitamins nnp quinolones nn form nn chelates vbz with inpos alkaline nn earth nn and cc transition nn metal nn cations nns
false	2	8	antacids nns sucralfate nn metal nnp cations nnp multivitamins nn quinolones nns form nn chelates nns with inpos alkaline nn earth nn and cc transition nn metal nn cations nns
false	2	10	antacids nns sucralfate nn metal nnp cations nnp multivitamins nnp quinolones nn form nn chelates vbz with inpos alkaline nn earth nn and cc transition nn metal nn cations nns
false	8	10	antacids nns sucralfate nnp metal nnp cations nnp multivitamins nn quinolones nn form nn chelates vbz with inpos alkaline nn earth nn and cc transition nn metal nn cations nns
false	4	8	administration nn of inpos quinolones nn with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	12	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	12	administration nn of inpos quinolones nn with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	12	administration nn of inpos quinolones nn with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	20	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	32	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	36	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	32	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	44	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	64	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
mechanism	4	64	administration nn of inpos quinolones nn with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	12	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	12	administration nn of inpos quinolones nns with inpos antacids nn containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	12	administration nn of inpos quinolones nns with inpos antacids nn containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	20	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	32	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	36	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	32	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	44	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	64	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	64	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	8	4	administration nn of inpos quinolones nns with inpos antacids nn containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	16	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	28	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	32	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	28	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	40	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	60	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	60	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	16	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	28	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	32	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	28	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	40	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	60	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	60	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg magnesium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	16	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	28	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	32	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	28	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	40	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	60	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	60	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	12	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	20	32	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	20	36	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	20	32	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	20	44	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	20	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	20	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	20	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	36	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	44	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	36	32	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	36	44	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	36	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	36	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	36	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nn containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	44	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	32	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	44	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	44	64	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	44	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	64	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	64	4	administration nn of inpos quinolones nns with inpos antacids nns containing vbg aluminum nn magnesium nn calcium nn with inpos sucralfate nn with inpos metal nn cations nns such jj as inpos iron nn with inpos multivitamins nns containing vbg iron nn or cc zinc nn with inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj concentrations nns considerably rb lower jjr than inpos desired vbn
false	0	2	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	0	4	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	0	10	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nn may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	0	2	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	2	4	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	2	10	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nn may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	2	0	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	4	10	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nn may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
mechanism	4	0	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
mechanism	4	2	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
mechanism	10	0	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nn may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
mechanism	10	2	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nn may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	0	2	caffeine nn theobromine nn grepafloxacin nn like inpos other jj quinolones nns may md inhibit vb the dt metabolism nn of inpos caffeine nn and cc theobromine nn
false	32	36	in inpos some dt patients nns this dt may md lead vb to topos reduced vbn clearance nn prolongation nn of inpos plasma nn half_life nn enhanced vbn effects nns of inpos caffeine nn and cc theobromine nn
mechanism	0	18	grepafloxacin nn is vbz a dt competitive jj inhibitor nn of inpos the dt metabolism nn of inpos theophylline nn
false	2	10	serum nn theophylline nn concentrations nns increase vbp when wrb grepafloxacin nn is vbz initiated vbn in inpos a dt patient nn maintained vbn on inpos theophylline nn
mechanism	10	2	serum nn theophylline nn concentrations nns increase vbp when wrb grepafloxacin nn is vbz initiated vbn in inpos a dt patient nn maintained vbn on inpos theophylline nn
false	12	24	when wrb initiating vbg a dt multi_day jj course nn of inpos grepafloxacin nn in inpos a dt patient nn maintained vbn on inpos theophylline nn the dt theophylline nn maintenance nn dose nn should md be vb halved vbn for inpos the dt period nn of inpos concurrent jj use nn of inpos grepafloxacin nn and cc monitoring nn of inpos serum nn theophylline nn concentrations nns should md be vb initiated vbn as inpos a dt guide nn to topos further jj dosage nn adjustments nns
false	12	24	when wrb initiating vbg a dt multi_day jj course nn of inpos grepafloxacin nn in inpos a dt patient nn maintained vbn on inpos theophylline nn the dt theophylline nn maintenance nn dose nn should md be vb halved vbn for inpos the dt period nn of inpos concurrent jj use nn of inpos grepafloxacin nn and cc monitoring nn of inpos serum nn theophylline nn concentrations nns should md be vb initiated vbn as inpos a dt guide nn to topos further jj dosage nn adjustments nns
false	12	24	when wrb initiating vbg a dt multi_day jj course nn of inpos grepafloxacin nn in inpos a dt patient nn maintained vbn on inpos theophylline nn the dt theophylline nn maintenance nn dose nn should md be vb halved vbn for inpos the dt period nn of inpos concurrent jj use nn of inpos grepafloxacin nn and cc monitoring nn of inpos serum nn theophylline nn concentrations nns should md be vb initiated vbn as inpos a dt guide nn to topos further jj dosage nn adjustments nns
false	24	12	when wrb initiating vbg a dt multi_day jj course nn of inpos grepafloxacin nn in inpos a dt patient nn maintained vbn on inpos theophylline nn the dt theophylline nn maintenance nn dose nn should md be vb halved vbn for inpos the dt period nn of inpos concurrent jj use nn of inpos grepafloxacin nn and cc monitoring nn of inpos serum nn theophylline nn concentrations nns should md be vb initiated vbn as inpos a dt guide nn to topos further jj dosage nn adjustments nns
advise	24	12	when wrb initiating vbg a dt multi_day jj course nn of inpos grepafloxacin nn in inpos a dt patient nn maintained vbn on inpos theophylline nn the dt theophylline nn maintenance nn dose nn should md be vb halved vbn for inpos the dt period nn of inpos concurrent jj use nn of inpos grepafloxacin nn and cc monitoring nn of inpos serum nn theophylline nn concentrations nns should md be vb initiated vbn as inpos a dt guide nn to topos further jj dosage nn adjustments nns
false	12	24	when wrb initiating vbg a dt multi_day jj course nn of inpos grepafloxacin nn in inpos a dt patient nn maintained vbn on inpos theophylline nn the dt theophylline nn maintenance nn dose nn should md be vb halved vbn for inpos the dt period nn of inpos concurrent jj use nn of inpos grepafloxacin nn and cc monitoring nn of inpos serum nn theophylline nn concentrations nns should md be vb initiated vbn as inpos a dt guide nn to topos further jj dosage nn adjustments nns
false	0	28	warfarin nn in inpos subjects nns receiving vbg warfarin nn no dt significant jj change nn in inpos clotting nn time nn was vbd observed vbn when wrb grepafloxacin nn was vbd coadministered vbn
false	0	28	warfarin nn in inpos subjects nns receiving vbg warfarin nn no dt significant jj change nn in inpos clotting nn time nn was vbd observed vbn when wrb grepafloxacin nn was vbd coadministered vbn
effect	6	24	however rb because inpos some dt quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos warfarin nn or cc its prp derivatives nns prothrombin nn time nn or cc other jj suitable jj anticoagulation nn test nn should md be vb monitored vbn closely rb if inpos a dt quinolone_antimicrobial nn is vbz administered vbn with inpos warfarin nn or cc its prp derivatives nns
false	6	58	however rb because inpos some dt quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos warfarin nn or cc its prp derivatives nns prothrombin nn time nn or cc other jj suitable jj anticoagulation nn test nn should md be vb monitored vbn closely rb if inpos a dt quinolone_antimicrobial nn is vbz administered vbn with inpos warfarin nn or cc its prp derivatives nns
false	6	24	however rb because inpos some dt quinolones nn have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos warfarin nn or cc its prp derivatives nns prothrombin nn time nn or cc other jj suitable jj anticoagulation nn test nn should md be vb monitored vbn closely rb if inpos a dt quinolone_antimicrobial nn is vbz administered vbn with inpos warfarin nn or cc its prp derivatives nns
false	24	58	however rb because inpos some dt quinolones nns have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos warfarin nn or cc its prp derivatives nns prothrombin nn time nn or cc other jj suitable jj anticoagulation nn test nn should md be vb monitored vbn closely rb if inpos a dt quinolone_antimicrobial nn is vbz administered vbn with inpos warfarin nn or cc its prp derivatives nns
advise	58	24	however rb because inpos some dt quinolones nns have vbp been vbn reported vbn to topos enhance vb the dt effects nns of inpos warfarin nn or cc its prp derivatives nns prothrombin nn time nn or cc other jj suitable jj anticoagulation nn test nn should md be vb monitored vbn closely rb if inpos a dt quinolone_antimicrobial nn is vbz administered vbn with inpos warfarin nn or cc its prp derivatives nns
false	28	32	drugs nns metabolized vbn by inpos cytochrome nn p450 nn enzymes nns the dt drug nn interaction nn study nn evaluating vbg the dt effect nn of inpos grepafloxacin nn on inpos theophylline nn indicates vbz that inpos grepafloxacin nn inhibits vbz theophylline nn metabolism nn which wdt is vbz mediated vbn by inpos cyp1a2 nn
false	28	32	drugs nns metabolized vbn by inpos cytochrome nn p450 nn enzymes nns the dt drug nn interaction nn study nn evaluating vbg the dt effect nn of inpos grepafloxacin nn on inpos theophylline nn indicates vbz that inpos grepafloxacin nn inhibits vbz theophylline nn metabolism nn which wdt is vbz mediated vbn by inpos cyp1a2 nn
false	32	28	drugs nns metabolized vbn by inpos cytochrome nn p450 nn enzymes nns the dt drug nn interaction nn study nn evaluating vbg the dt effect nn of inpos grepafloxacin nn on inpos theophylline nn indicates vbz that inpos grepafloxacin nn inhibits vbz theophylline nn metabolism nn which wdt is vbz mediated vbn by inpos cyp1a2 nn
mechanism	28	32	drugs nns metabolized vbn by inpos cytochrome nn p450 nn enzymes nns the dt drug nn interaction nn study nn evaluating vbg the dt effect nn of inpos grepafloxacin nn on inpos theophylline nn indicates vbz that inpos grepafloxacin nn inhibits vbz theophylline nn metabolism nn which wdt is vbz mediated vbn by inpos cyp1a2 nn
false	16	28	substrates nns in fw vitro fw data nns suggest vbp similar jj effects nns of inpos grepafloxacin nn in inpos cyp3a4 nn mediated vbn metabolism nn and cc theophylline nn metabolism nn
mechanism	6	26	in inpos addition nn other jj quinolones nn have vbp been vbn reported vbn to topos decrease vb the dt cyp3a4_mediated jj metabolism nn of inpos cyclosporine nn
effect	10	16	the dt concomitant jj administration nn of inpos a dt nonsteroidal_anti_inflammatory_drug nn with inpos a dt quinolone nn may md increase vb the dt risks nns of inpos cns nn stimulation nn and cc convulsions nns
false	0	34	antidiabetic_agents nn disturbances nns of inpos blood nn glucose nn including vbg hyperglycemia nn and cc hypoglycemia nn have vbp been vbn reported vbn in inpos patients nns treated vbn concomitantly rb with inpos quinolones nn and cc an dt antidiabetic_agent nn
effect	34	0	antidiabetic_agents nns disturbances nns of inpos blood nn glucose nn including vbg hyperglycemia nn and cc hypoglycemia nn have vbp been vbn reported vbn in inpos patients nns treated vbn concomitantly rb with inpos quinolones nn and cc an dt antidiabetic_agent nn
advise	4	28	patients nns on inpos warfarin_type_anticoagulant nn therapy nn may md require vb dosage nn adjustment nn of inpos the dt anticoagulant nn during inpos and cc after inpos griseofulvin nn therapy nn
effect	6	12	concomitant jj use nn of inpos barbiturates nn usually rb depresses vbz griseofulvin nn activity nn and cc may md necessitate vb raising vbg the dt dosage nn
effect	8	28	the dt concomitant jj administration nn of inpos griseofulvin nn has vbz been vbn reported vbn to topos reduce vb the dt efficacy nn of inpos oral jj contraceptives nn and cc to topos increase vb the dt incidence nn of inpos breakthrough nn bleeding nn
effect	6	28	the dt use nn of inpos codeine nn may md result vb in inpos additive jj cns nn depressant jj effects nns when wrb coadministered vbn with inpos alcohol nns that wdt produce vbp cns nn depression nn
effect	6	28	the dt use nn of inpos codeine nn may md result vb in inpos additive jj cns nn depressant jj effects nns when wrb coadministered vbn with inpos antihistamines nns that wdt produce vbp cns nn depression nn
effect	6	28	the dt use nn of inpos codeine nn may md result vb in inpos additive jj cns nn depressant jj effects nns when wrb coadministered vbn with inpos psychotropics nns that wdt produce vbp cns nn depression nn
effect	10	18	serious jj toxicity nn may md result vb if inpos dextromethorphan nn is vbz coadministered vbn with inpos monoamine_oxidase_inhibitors nn
effect	10	18	serious jj toxicity nn may md result vb if inpos dextromethorphan nn is vbz coadministered vbn with inpos maois nn
effect	6	28	the dt use nn of inpos dextromethorphan_hydrobromide nn may md result vb in inpos additive jj cns nn depressant jj effects nns when wrb coadministered vbn with inpos alcohol nns that wdt produce vbp cns nn depression nn
effect	6	28	the dt use nn of inpos dextromethorphan_hydrobromide nn may md result vb in inpos additive jj cns nn depressant jj effects nns when wrb coadministered vbn with inpos antihistamines nns that wdt produce vbp cns nn depression nn
effect	6	28	the dt use nn of inpos dextromethorphan_hydrobromide nn may md result vb in inpos additive jj cns nn depressant jj effects nns when wrb coadministered vbn with inpos psychotropics nns that wdt produce vbp cns nn depression nn
effect	12	22	the dt potential nn for inpos increased vbn sedation nn when wrb guanfacine nn is vbz given vbn with inpos other jj cns_depressant_drug nn should md be vb appreciated vbn
mechanism	6	18	the dt administration nn of inpos guanfacine nn concomitantly rb with inpos known vbn microsomal jj enzyme nn phenobarbital nn to topos num cd patients nns with inpos renal jj impairment nn reportedly rb resulted vbd in inpos significant jj reductions nns in inpos elimination nn half_life nn and cc plasma nn concentration nn
mechanism	6	18	the dt administration nn of inpos guanfacine nn concomitantly rb with inpos known vbn microsomal jj enzyme nn phenytoin nn to topos num cd patients nns with inpos renal jj impairment nn reportedly rb resulted vbd in inpos significant jj reductions nns in inpos elimination nn half_life nn and cc plasma nn concentration nn
effect	0	12	tcas nn decrease vbp the dt hypotensive jj effect nn of inpos guanfacine nn
effect	0	12	noncardioselective_b_blockers nn may md exacerbate vb rebound vb hypertension nn when wrb guanfacine nn is vbz withdrawn vbn
effect	0	12	nadolol nn may md exacerbate vb rebound vb hypertension nn when wrb guanfacine nn is vbz withdrawn vbn
effect	0	12	timolol nn may md exacerbate vb rebound vb hypertension nn when wrb guanfacine nn is vbz withdrawn vbn
false	8	14	the dt gradual jj withdrawal nn of inpos guafacine nn or cc a dt cardioselective_b_blocker nn could md be vb substituted vbn
false	14	20	num cd patients nns who wp were vbd stabilized vbn on inpos oral jj anticoagulants nn were vbd given vbn guanfacine nn num cd mg_day nn for inpos num cd weeks nns
false	8	18	in inpos several jj well_controlled jj studies nns guanfacine nn was vbd administered vbn together rb with inpos diuretics nn with inpos no dt drug nn interactions nns reported vbd
false	12	18	the dt principal jj drugs nns given vbn were vbd cardiac_glycosides nns sedatives nn and cc hypnotics nns coronary_vasodilators nns
false	10	20	the dt principal jj drugs nns given vbn were vbd sedatives nns cough nn and cc cold jj preparations nns nsaids nns
false	10	20	the dt principal jj drugs nns given vbn were vbd hypnotics nns cough nn and cc cold jj preparations nns nsaids nns
false	16	20	the dt principal jj drugs nns given vbn were vbd cardiac_glycosides nns sedatives nns hypnotics nns coronary_vasodilators nn oral jj antigout_drugs nns
false	30	34	the dt principal jj drugs nns given vbn were vbd cardiac_glycosides nns sedatives nns hypnotics nns coronary_vasodilators nns oral jj hypoglycemics nns cough nn and cc cold jj preparations nns nsaids nn antihyperlipidemics nns antigout_drugs nn oral jj contraceptives nns bronchodilators nns insulin nn b_blockers nns
effect	32	36	an dt encephalopathic jj syndrome nn followed vbn by inpos irreversible jj brain nn damage nn has vbz occurred vbn in inpos a dt few jj patients nns treated vbn with inpos lithium nn plus cc haldol nn
false	22	26	a dt causal jj relationship nn between inpos these dt events nns and cc the dt concomitant jj administration nn of inpos lithium nn and cc haldol nn has vbz not rb been vbn established vbn
false	6	18	as inpos with inpos other jj antipsychotic_agents nn it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nns such jj as inpos anesthetics nns opiates nns alcohol nn
effect	6	30	as inpos with inpos other jj antipsychotic_agents nn it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nn such jj as inpos anesthetics nns opiates nns alcohol nn
effect	6	36	as inpos with inpos other jj antipsychotic_agents nn it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nns such jj as inpos anesthetics nn
effect	6	36	as inpos with inpos other jj antipsychotic_agents nn it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nns such jj as inpos opiates nn
effect	6	36	as inpos with inpos other jj antipsychotic_agents nn it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nns such jj as inpos alcohol nn
effect	18	30	as inpos with inpos other jj antipsychotic_agents nns it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nn such jj as inpos anesthetics nns opiates nns alcohol nn
effect	18	36	as inpos with inpos other jj antipsychotic_agents nns it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nns such jj as inpos anesthetics nn
effect	18	36	as inpos with inpos other jj antipsychotic_agents nns it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nns such jj as inpos opiates nn
effect	18	36	as inpos with inpos other jj antipsychotic_agents nns it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nns such jj as inpos alcohol nn
false	30	36	as inpos with inpos other jj antipsychotic_agents nns it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nn such jj as inpos anesthetics nn
false	30	36	as inpos with inpos other jj antipsychotic_agents nns it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nn such jj as inpos opiates nn
false	30	36	as inpos with inpos other jj antipsychotic_agents nns it prp should md be vb noted vbn that inpos haldol nn may md be vb capable jj of inpos potentiating vbg cns_depressants nn such jj as inpos alcohol nn
mechanism	18	22	in inpos a dt study nn of inpos num cd schizophrenic jj patients nns coadministered vbn oral jj haloperidol nn and cc rifampin nn plasma nn haloperidol nn levels nns were vbd decreased vbn by inpos a dt mean nn of inpos num cd and cc mean jj scores nns on inpos the dt brief nnp psychiatric nnp rating nnp scale nnp were vbd increased vbn from inpos baseline nn
false	22	18	in inpos a dt study nn of inpos num cd schizophrenic jj patients nns coadministered vbn oral jj haloperidol nn and cc rifampin nn plasma nn haloperidol nn levels nns were vbd decreased vbn by inpos a dt mean nn of inpos num cd and cc mean jj scores nns on inpos the dt brief nnp psychiatric nnp rating nnp scale nnp were vbd increased vbn from inpos baseline nn
false	16	20	in inpos num cd other jj schizophrenic jj patients nns treated vbn with inpos oral jj haloperidol nn and cc rifampin nn discontinuation nn of inpos rifampin nn produced vbd a dt mean jj float_fold jj increase nn in inpos haloperidol nn concentrations nns
false	16	20	in inpos num cd other jj schizophrenic jj patients nns treated vbn with inpos oral jj haloperidol nn and cc rifampin nn discontinuation nn of inpos rifampin nn produced vbd a dt mean jj float_fold jj increase nn in inpos haloperidol nn concentrations nns
false	20	16	in inpos num cd other jj schizophrenic jj patients nns treated vbn with inpos oral jj haloperidol nn and cc rifampin nn discontinuation nn of inpos rifampin nn produced vbd a dt mean jj float_fold jj increase nn in inpos haloperidol nn concentrations nns
mechanism	20	16	in inpos num cd other jj schizophrenic jj patients nns treated vbn with inpos oral jj haloperidol nn and cc rifampin nn discontinuation nn of inpos rifampin nn produced vbd a dt mean jj float_fold jj increase nn in inpos haloperidol nn concentrations nns
advise	18	30	thus rb careful jj monitoring nn of inpos clinical jj status nn is vbz warranted vbn when wrb rifampin nn is vbz administered vbn or cc discontinued vbn in inpos haloperidol nn treated jj patients nns
effect	0	10	fluothane nn augments vbz the dt action nn of inpos non_depolarising_muscle_relaxant nn s nns and cc the dt muscle nn relaxant jj effects nns of inpos aminoglycosides nns
effect	0	24	fluothane nn augments vbz the dt action nn of inpos non_depolarising_muscle_relaxants nns and cc the dt muscle nn relaxant jj effects nns of inpos aminoglycosides nn
false	10	26	fluothane nn augments vbz the dt action nn of inpos non_depolarising_muscle_relaxant nn s nns and cc the dt muscle nn relaxant jj effects nns of inpos aminoglycosides nn
effect	0	22	fluothane nn may md augment vb the dt hypotension nn caused vbn by inpos the dt ganglionic_blocking jj effect nn of inpos tubocurarine nn
advise	16	26	caution nn should md be vb exercised vbn during inpos the dt administration nn of inpos adrenaline nn to topos patients nns anaesthetised vbn with inpos fluothane nn as inpos arrhythmias nns may md be vb precipitated vbn
false	12	24	for inpos this dt reason nn the dt dose nn of inpos adrenaline nn should md be vb restricted vbn and cc an dt antiarrhythmic_agent nn administered vbn as inpos appropriate jj
false	14	20	caution nn should md also rb be vb applied vbn for inpos other jj sympathomimetics nn and cc for inpos aminophylline nns which wdt may md also rb precipitate vb arrhythmias nns
false	14	20	caution nn should md also rb be vb applied vbn for inpos other jj sympathomimetics nn and cc for inpos theophylline nns which wdt may md also rb precipitate vb arrhythmias nns
false	14	20	caution nn should md also rb be vb applied vbn for inpos other jj sympathomimetics nn and cc for inpos tricyclic_antidepressants nn which wdt may md also rb precipitate vb arrhythmias nns
false	10	16	drug nnp interactions nnps a. fw drugs nns enhancing vbg heparin nn effect nn oral jj anticoagulants nn
advise	4	12	therefore rb when wrb heparin_sodium nn is vbz given vbn with inpos dicumarol nn or cc warfarin_sodium nn a dt period nn of inpos at inpos least jjs num cd hours nns after inpos the dt last jj intravenous jj dose nn or cc num cd hours nns after inpos the dt last jj subcutaneous jj dose nn should md elapse vb before inpos blood nn is vbz drawn vbn if inpos a dt valid jj prothrombin nn time nn is vbz to topos be vb obtained vbn
advise	4	16	therefore rb when wrb heparin_sodium nn is vbz given vbn with inpos dicumarol nn or cc warfarin_sodium nn a dt period nn of inpos at inpos least jjs num cd hours nns after inpos the dt last jj intravenous jj dose nn or cc num cd hours nns after inpos the dt last jj subcutaneous jj dose nn should md elapse vb before inpos blood nn is vbz drawn vbn if inpos a dt valid jj prothrombin nn time nn is vbz to topos be vb obtained vbn
false	12	16	therefore rb when wrb heparin_sodium nn is vbz given vbn with inpos dicumarol nn or cc warfarin_sodium nn a dt period nn of inpos at inpos least jjs num cd hours nns after inpos the dt last jj intravenous jj dose nn or cc num cd hours nns after inpos the dt last jj subcutaneous jj dose nn should md elapse vb before inpos blood nn is vbz drawn vbn if inpos a dt valid jj prothrombin nn time nn is vbz to topos be vb obtained vbn
false	0	8	platelet_inhibitors nn drugs nns such jj as inpos acetylsalicylic_acid nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
false	0	8	platelet_inhibitors nn drugs nns such jj as inpos dextran nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
false	0	8	platelet_inhibitors nn drugs nns such jj as inpos phenylbutazone nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
false	0	8	platelet_inhibitors nn drugs nns such jj as inpos ibuprofen nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
false	0	8	platelet_inhibitors nn drugs nns such jj as inpos indomethacin nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
false	0	8	platelet_inhibitors nn drugs nns such jj as inpos dipyridamole nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
false	0	8	platelet_inhibitors nn drugs nns such jj as inpos hydroxychloroquine nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
false	0	58	platelet_inhibitors nn drugs nns such jj as inpos acetylsalicylic_acid nn dextran nn phenylbutazone nn ibuprofen nn indomethacin nn dipyridamole nn hydroxychloroquine nn others nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	44	platelet_inhibitors nns drugs nns such jj as inpos acetylsalicylic_acid nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	44	platelet_inhibitors nns drugs nns such jj as inpos dextran nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	44	platelet_inhibitors nns drugs nns such jj as inpos phenylbutazone nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	44	platelet_inhibitors nns drugs nns such jj as inpos ibuprofen nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	44	platelet_inhibitors nns drugs nns such jj as inpos indomethacin nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	44	platelet_inhibitors nns drugs nns such jj as inpos dipyridamole nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	44	platelet_inhibitors nns drugs nns such jj as inpos hydroxychloroquine nns that wdt interfere vbp with inpos platelet_aggregation nn reactions nns may md induce vb bleeding nn and cc should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg heparin_sodium nn
effect	8	22	the dt anticoagulant jj effect nn of inpos heparin nn is vbz enhanced vbn by inpos concurrent jj treatment nn with inpos antithrombin_iii nn in inpos patients nns with inpos hereditary jj antithrombin nn num cd deficiency nn
advise	18	30	thus rb in inpos order nn to topos avoid vb bleeding nn reduced vbd dosage nn of inpos heparin nn is vbz recommended vbn during inpos treatment nn with inpos antithrombin_iii nn
false	4	8	drugs nns decreasing vbg heparin nn effect nn digitalis nns may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
false	4	10	drugs nns decreasing vbg heparin nn effect nn digitalis nnp tetracyclines nn nicotine nn or cc antihistamines nns may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
false	4	8	drugs nns decreasing vbg heparin nn effect nn nicotine nns may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
false	4	8	drugs nns decreasing vbg heparin nn effect nn antihistamines nn may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
effect	8	24	drugs nns decreasing vbg heparin nn effect nn digitalis nns may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
false	10	12	drugs nns decreasing vbg heparin nn effect nn digitalis nnp tetracyclines nn nicotine nn or cc antihistamines nns may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
effect	10	32	drugs nns decreasing vbg heparin nn effect nn digitalis nnp tetracyclines nn nicotine nn or cc antihistamines nns may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
effect	8	24	drugs nns decreasing vbg heparin nn effect nn nicotine nns may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
effect	8	24	drugs nns decreasing vbg heparin nn effect nn antihistamines nn may md partially rb counteract vb the dt anticoagulant jj action nn of inpos heparin_sodium nn
false	0	14	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos doxorubicin nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	0	14	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos droperidol nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	0	14	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos ciprofloxacin nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	0	14	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos mitoxantrone nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	14	0	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos doxorubicin nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	14	0	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos droperidol nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	14	0	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos ciprofloxacin nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	14	0	heparin_sodium nn injection nn should md not rb be vb mixed vbn with inpos mitoxantrone nn since inpos it prp has vbz been vbn reported vbn that inpos these dt drugs nns are vbp incompatible jj with inpos heparin nn and cc a dt precipitate nn may md form vb
false	0	6	opioids nn are vbp strong jj central_nervous_system_depressants nn but cc regular jj users nns develop vbp physiological jj tolerance nn allowing vbg gradually rb increased vbn dosages nns
effect	8	10	in inpos combination nn with inpos other jj central_nervous_system_depressants nn heroin nn may md still rb kill vb even rb experienced jj users nns particularly rb if inpos their prp tolerance nn to topos the dt drug nn has vbz reduced vbn or cc the dt strength nn of inpos their prp usual jj dose nn has vbz increased vbn
effect	6	22	toxicology nnp studies nns of inpos heroin nn related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nn including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
effect	6	26	toxicology nnp studies nns of inpos heroin nn related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
effect	6	28	toxicology nnp studies nns of inpos heroin nn related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nn such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
effect	6	34	toxicology nnp studies nns of inpos heroin nn related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
effect	6	34	toxicology nnp studies nns of inpos heroin nn related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos valium nn and cc to topos a dt rising vbg degree nn methadone nn
effect	6	46	toxicology nnp studies nns of inpos heroin nn related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	20	24	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nn including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	20	26	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nn including vbg alcohol nn benzodiazepines nn such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	20	32	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nn including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	20	32	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nn including vbg alcohol nn benzodiazepines nns such jj as inpos valium nn and cc to topos a dt rising vbg degree nn methadone nn
false	20	44	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nn including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	24	26	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nn such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	24	32	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	24	32	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos valium nn and cc to topos a dt rising vbg degree nn methadone nn
false	24	44	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	26	32	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nn such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	26	32	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nn such jj as inpos valium nn and cc to topos a dt rising vbg degree nn methadone nn
false	26	44	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nn such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	32	44	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos diazepam nn and cc to topos a dt rising vbg degree nn methadone nn
false	32	44	toxicology nnp studies nns of inpos heroin_related jj deaths nns reveal vbp frequent jj involvement nn of inpos other jj central_nervous_system_depressants nns including vbg alcohol nn benzodiazepines nns such jj as inpos valium nn and cc to topos a dt rising vbg degree nn methadone nn
false	2	18	ironically rb benzodiazepines nn are vbp often rb used vbn in inpos the dt treatment nn of inpos heroin nn addiction nn while inpos they prp cause vbp much rb more rbr severe jj withdrawal nn symptoms nns
effect	0	22	cocaine nn sometimes rb proves vbz to topos be vb fatal jj when wrb used vbn in inpos combination nn with inpos heroin nn
effect	0	14	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns
effect	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj antibiotics nns
effect	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj quinidine nns
effect	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj theophylline nns
effect	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj corticosteroids nns
effect	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj anticoagulants nns
effect	0	18	barbiturates nn may md decrease vb the dt effectiveness nn of inpos oral jj contraceptives nns certain jj b_blockers nn
advise	0	18	mao_inhibitors nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg hydralazine nn
effect	8	14	when wrb other jj potent jj parental jj antihypertensive_drugs nn such jj as inpos diazoxide nn are vbp used vbn in inpos combination nn with inpos hydralazine nn patients nns should md be vb continuously rb observed vbn for inpos several jj hours nns for inpos any dt excessive jj fall nn in inpos blood nn pressure nn
effect	8	26	when wrb other jj potent jj parental jj antihypertensive_drugs nn such jj as inpos diazoxide nn are vbp used vbn in inpos combination nn with inpos hydralazine nn patients nns should md be vb continuously rb observed vbn for inpos several jj hours nns for inpos any dt excessive jj fall nn in inpos blood nn pressure nn
false	14	26	when wrb other jj potent jj parental jj antihypertensive_drugs nns such jj as inpos diazoxide nn are vbp used vbn in inpos combination nn with inpos hydralazine nn patients nns should md be vb continuously rb observed vbn for inpos several jj hours nns for inpos any dt excessive jj fall nn in inpos blood nn pressure nn
effect	12	18	profound jj hypotensive jj episodes nns may md occur vb when wrb diazoxide nn infection nn and cc hydralazine nn are vbp used vbn concomitantly rb
mechanism	0	4	propranolol nn increases vbz hydralazine nn s vbz serum nn concentrations nns
effect	0	14	nsaids nn may md decrease vb the dt hemodynamic jj effects nns of inpos hydralazine nn
false	0	2	alcohol nn barbiturates nn narcotics nns potentiation nn of inpos orthostatic jj hypotension nn may md occur vb
false	0	2	antidiabetic_drugs nn insulin nn hyph_dosage nn adjustment nn of inpos the dt antidiabetic_drug nn may md be vb required vbn
false	0	10	insulin nn hyph_dosage nn adjustment nn of inpos the dt antidiabetic_drug nn may md be vb required vbn
false	0	4	cholestyramine nn and cc colestipol nn resins nns
false	0	6	cholestyramine nn and cc colestipol nn resins nn
false	0	12	cholestyramine nn and cc colestipol nn resins vbz absorption nn of inpos hydrochlorothiazide nn is vbz impaired jj in inpos the dt presence nn of inpos anionic_exchange_resins nns
false	0	26	cholestyramine nn and cc colestipol nn resins vbz absorption nn of inpos hydrochlorothiazide nn is vbz impaired jj in inpos the dt presence nn of inpos anionic_exchange_resins nn
false	4	6	cholestyramine nn and cc colestipol nn resins nn
false	4	12	cholestyramine nn and cc colestipol nn resins vbz absorption nn of inpos hydrochlorothiazide nn is vbz impaired jj in inpos the dt presence nn of inpos anionic_exchange_resins nns
false	4	26	cholestyramine nn and cc colestipol nn resins vbz absorption nn of inpos hydrochlorothiazide nn is vbz impaired jj in inpos the dt presence nn of inpos anionic_exchange_resins nn
false	6	12	cholestyramine nn and cc colestipol nn resins nn absorption nn of inpos hydrochlorothiazide nn is vbz impaired jj in inpos the dt presence nn of inpos anionic_exchange_resins nns
mechanism	4	18	absorption nn of inpos hydrochlorothiazide nn is vbz impaired jj in inpos the dt presence nn of inpos anionic_exchange_resins nn
false	8	12	single jj doses nns of inpos either cc cholestyramine nn or cc colestipol nn resins nns bind vbp the dt hydrochlorothiazide nn and cc reduce vb its prp absorption nn from inpos the dt gastrointestinal jj tract nn by inpos up rb to topos num cd and cc num cd percent nn respectively rb
false	8	14	single jj doses nns of inpos either cc cholestyramine nn or cc colestipol nn resins nn bind vbp the dt hydrochlorothiazide nn and cc reduce vb its prp absorption nn from inpos the dt gastrointestinal jj tract nn by inpos up rb to topos num cd and cc num cd percent nn respectively rb
mechanism	8	20	single jj doses nns of inpos either cc cholestyramine nn or cc colestipol nn resins nns bind vbp the dt hydrochlorothiazide nn and cc reduce vb its prp absorption nn from inpos the dt gastrointestinal jj tract nn by inpos up rb to topos num cd and cc num cd percent nn respectively rb
false	12	14	single jj doses nns of inpos either cc cholestyramine nn or cc colestipol nn resins nn bind vbp the dt hydrochlorothiazide nn and cc reduce vb its prp absorption nn from inpos the dt gastrointestinal jj tract nn by inpos up rb to topos num cd and cc num cd percent nn respectively rb
mechanism	12	20	single jj doses nns of inpos either cc cholestyramine nn or cc colestipol nn resins nns bind vbp the dt hydrochlorothiazide nn and cc reduce vb its prp absorption nn from inpos the dt gastrointestinal jj tract nn by inpos up rb to topos num cd and cc num cd percent nn respectively rb
false	14	20	single jj doses nns of inpos either cc cholestyramine nn or cc colestipol nn resins nn bind vbp the dt hydrochlorothiazide nn and cc reduce vb its prp absorption nn from inpos the dt gastrointestinal jj tract nn by inpos up rb to topos num cd and cc num cd percent nn respectively rb
false	0	2	corticosteroids nn acth nn intensified vbn electrolyte nn depletion nn particularly rb hypokalemia nn
false	0	2	skeletal_muscle_relaxants nn tubocurarine nn possible jj increased vbn responsiveness nn to topos the dt muscle_relaxant nn
false	2	0	skeletal_muscle_relaxants nns tubocurarine nn possible jj increased vbn responsiveness nn to topos the dt muscle_relaxant nn
advise	0	14	lithium nn generally rb should md not rb be vb given vbn with inpos diuretics nn
mechanism	0	12	diuretic_agents nn reduce vbp the dt renal jj clearance nn of inpos lithium nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
effect	0	12	diuretic_agents nn reduce vbp the dt renal jj clearance nn of inpos lithium nn and cc add vb a dt high jj risk nn of inpos lithium nn toxicity nn
advise	12	28	refer vb to topos the dt package nn insert nn for inpos lithium nn preparations nns before inpos use nn of inpos such jj preparations nns with inpos hydrochlorothiazide nn
false	0	16	non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing jj thiazide_diuretics nns
false	0	24	non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt loop nn
false	0	24	non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt potassium_sparing nn
false	0	24	non_steroidal_anti_inflammatory_drugs nn in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent jj can md reduce vb the dt thiazide_diuretics nn
effect	16	24	non_steroidal_anti_inflammatory_drugs nns in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt loop nn
effect	16	24	non_steroidal_anti_inflammatory_drugs nns in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt potassium_sparing nn
effect	16	24	non_steroidal_anti_inflammatory_drugs nns in inpos some dt patients nns the dt administration nn of inpos a dt non_steroidal_anti_inflammatory_agent nn can md reduce vb the dt thiazide_diuretics nn
advise	4	8	therefore rb when wrb hydrochlorothiazide nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic jj is vbz obtained vbn
false	4	44	therefore rb when wrb hydrochlorothiazide nn and cc non_steroidal_anti_inflammatory_agents nns are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
false	8	44	therefore rb when wrb hydrochlorothiazide nn and cc non_steroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
false	6	10	patients nns receiving vbg other jj narcotic_analgesics nns other jj cns_depressants nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	6	10	patients nns receiving vbg other jj narcotic_analgesics nns other jj alcohol nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
effect	6	16	patients nns receiving vbg other jj narcotic_analgesics nns other jj cns_depressants nns concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	6	20	patients nns receiving vbg other jj narcotic_analgesics nns other jj cns_depressants nns concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	8	14	patients nns receiving vbg other jj narcotic_analgesics nns antipsychotics nn antianxiety_agents nns other jj cns_depressants nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	8	14	patients nns receiving vbg other jj narcotic_analgesics nns antipsychotics nn antianxiety_agents nns other jj alcohol nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
effect	6	16	patients nns receiving vbg other jj antipsychotics nns other jj cns_depressants nns concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	6	20	patients nns receiving vbg other jj antipsychotics nns other jj cns_depressants nns concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	6	10	patients nns receiving vbg other jj antianxiety_agents nn other jj cns_depressants nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	6	10	patients nns receiving vbg other jj antianxiety_agents nn other jj alcohol nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
effect	6	16	patients nns receiving vbg other jj antianxiety_agents nn other jj cns_depressants nns concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	6	20	patients nns receiving vbg other jj antianxiety_agents nn other jj cns_depressants nns concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
effect	14	20	patients nns receiving vbg other jj narcotic_analgesics nns antipsychotics nns antianxiety_agents nns other jj cns_depressants nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	14	24	patients nns receiving vbg other jj narcotic_analgesics nns antipsychotics nns antianxiety_agents nns other jj cns_depressants nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
effect	14	20	patients nns receiving vbg other jj narcotic_analgesics nns antipsychotics nns antianxiety_agents nns other jj alcohol nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	14	24	patients nns receiving vbg other jj narcotic_analgesics nns antipsychotics nns antianxiety_agents nns other jj alcohol nn concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	20	24	patients nns receiving vbg other jj narcotic_analgesics nns antipsychotics nns antianxiety_agents nns other jj cns_depressants nns concomitantly rb with inpos hydrocodone nn and cc acetaminophen nn tablets nns may md exhibit vb an dt additive jj cns nn depression nn
false	6	10	the dt use nn of inpos mao_inhibitors nn or cc tricyclic_antidepressants nn with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
effect	6	14	the dt use nn of inpos mao_inhibitors nn or cc tricyclic_antidepressants nns with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
false	6	10	the dt use nn of inpos mao_inhibitors nn or cc tricyclic_antidepressants nns with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
false	6	14	the dt use nn of inpos mao_inhibitors nn or cc tricyclic_antidepressants nns with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
effect	10	14	the dt use nn of inpos mao_inhibitors nns or cc tricyclic_antidepressants nn with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
false	10	14	the dt use nn of inpos mao_inhibitors nns or cc tricyclic_antidepressants nn with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
false	14	10	the dt use nn of inpos mao_inhibitors nns or cc tricyclic_antidepressants nns with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
false	10	14	the dt use nn of inpos mao_inhibitors nns or cc tricyclic_antidepressants nns with inpos hydrocodone nn preparations nns may md increase vb the dt effect nn of inpos either cc the dt antidepressant nn or cc hydrocodone nn
effect	8	12	the dt concurrent jj use nn of inpos anticholinergics nn with inpos hydrocodone nn may md produce vb paralytic jj ileus nn
false	0	6	antihypertensive_medications nn other jj especially rb diazoxide nn or cc preanesthetic jj and cc anesthetic jj agents nns used vbn in inpos surgery nn or cc skeletal_muscle_relaxants nns nondepolarizing vbg used vbn in inpos surgery nn
false	0	12	antihypertensive_medications nn other jj especially rb diazoxide nn or cc pre jj anesthetic nn and cc anesthetic jj agents nns used vbn in inpos surgery nn or cc skeletal_muscle_relaxants nns nondepolarizing vbg used vbn in inpos surgery nn
false	0	26	antihypertensive_medications nn other jj especially rb diazoxide nn or cc preanesthetic jj and cc anesthetic jj agents nns used vbn in inpos surgery nn or cc skeletal_muscle_relaxants nn nondepolarizing jj used vbn in inpos surgery nn
false	6	12	antihypertensive_medications nns other jj especially rb diazoxide nn or cc pre jj anesthetic nn and cc anesthetic jj agents nns used vbn in inpos surgery nn or cc skeletal_muscle_relaxants nns nondepolarizing vbg used vbn in inpos surgery nn
false	6	26	antihypertensive_medications nns other jj especially rb diazoxide nn or cc preanesthetic jj and cc anesthetic jj agents nns used vbn in inpos surgery nn or cc skeletal_muscle_relaxants nn nondepolarizing jj used vbn in inpos surgery nn
false	12	28	antihypertensive_medications nns other jj especially rb diazoxide nn or cc pre jj anesthetic nn and cc anesthetic jj agents nns used vbn in inpos surgery nn or cc skeletal_muscle_relaxants nn nondepolarizing jj used vbn in inpos surgery nn
effect	8	20	lrb_concurrent jj concurrent jj use nn with inpos thiazide_diuretics nn may md enhance vb the dt possibility nn of inpos digitalis nn toxicity nn associated vbn with inpos hypokalemia nn
advise	12	26	for inpos adult_onset jj diabetics nns dosage nn adjustment nn of inpos hypoglycemic_medications nn may md be vb necessary jj during inpos and cc after inpos thiazide_diuretic nn therapy nn
false	8	24	lrb_concurrent jj concurrent jj use nn with inpos thiazide_diuretics nn is vbz not rb recommended vbn as inpos they prp may md provoke vb lithium nn toxicity nn because inpos of inpos reduced vbn renal jj clearance nn
effect	8	16	lrb_in inpos some dt patients nns the dt steroidal_anti_inflammatory_agent nn can md reduce vb the dt loop nn thiazide nn bbbbb22_diuretics_eeeee22 nn
effect	8	16	lrb_in inpos some dt patients nns the dt steroidal_anti_inflammatory_agent nn can md reduce vb the dt potassium_sparing nn thiazide nn bbbbb22_diuretics_eeeee22 nn
effect	8	16	lrb_in inpos some dt patients nns the dt steroidal_anti_inflammatory_agent nn can md reduce vb the dt thiazide_diuretics nn
false	26	32	lrb_in inpos some dt patients nns the dt steroidal_anti_inflammatory_agent nn can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
false	28	32	lrb_in inpos some dt patients nns the dt steroidal_anti_inflammatory_agent nn can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
advise	4	8	therefore rb when wrb hydroflumethiazide nn and cc nonsteroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic jj is vbz obtained vbn
false	4	44	therefore rb when wrb hydroflumethiazide nn and cc nonsteroidal_anti_inflammatory_agents nns are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
false	8	44	therefore rb when wrb hydroflumethiazide nn and cc nonsteroidal_anti_inflammatory_agents nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
effect	0	12	lrb_thiazides nn may md decrease vb arterial jj responsiveness nn to topos norepinephrine nn
effect	0	12	lrb_thiazide_drugs nn may md increase vb the dt responsiveness nn to topos tubocurarine nn
false	6	14	patients nns receiving vbg other jj narcotic_analgesic nn s nns general jj anesthetics nns phenothiazines nn tranquilizers nns sedative_hypnotics nns tricyclic_antidepressants nns other jj cns_depressants nns concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
false	0	6	patient_narcotic_analgesic nns or cc other jj cns_depressants nn concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
false	0	6	patient_narcotic_analgesic nns or cc other jj alcohol nn concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	0	12	patient_narcotic_analgesic nns or cc other jj cns_depressants nns concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	6	18	patients nns receiving vbg other jj anesthetics nns or cc other jj cns_depressants nns concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	6	18	patients nns receiving vbg other jj phenothiazines nns or cc other jj cns_depressants nns concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	6	12	patients nns receiving vbg other jj tranquilizers nns concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	6	12	patients nns receiving vbg other jj sedative_hypnotics nns concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	0	6	tricyclic_antidepressants nns concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	6	12	patients nns receiving vbg other jj cns_depressants nn concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	6	12	patients nns receiving vbg other jj alcohol nn concomitantly rb with inpos dilaudid nn may md exhibit vb an dt additive jj cns nn depression nn
effect	2	24	since inpos hydroxyurea nn may md raise vb the dt serum nn uric jj acid nn level nn dosage nn adjustment nn of inpos uricosuric_medication nn may md be vb necessary jj
effect	8	32	the dt potentiating nn action nn of inpos hydroxyzine nn must nn be nn considered vbn when wrb the dt drug nn is vbz used nnp in inpos conjunction nn with inpos central_nervous_system_depressants nn such nnp as nnp narcotics nnp non_narcotic_analgesics nnp and cc barbiturates nns
effect	8	38	the dt potentiating nn action nn of inpos hydroxyzine nn must nn be nn considered vbn when wrb the dt drug nn is vbz used nnp in nnp conjunction nnp with nnp central_nervous_system_depressants nnps such jj as jj narcotics nn non_narcotic_analgesics nn and cc barbiturates nns
effect	8	40	the dt potentiating nn action nn of inpos hydroxyzine nn must nn be nn considered vbn when wrb the dt drug nn is vbz used nnp in nnp conjunction nnp with nnp central_nervous_system_depressants nnp such nnp as nnp narcotics nnp non_narcotic_analgesics nn and cc barbiturates nns
effect	8	44	the dt potentiating nn action nn of inpos hydroxyzine nn must nn be nn considered vbn when wrb the dt drug nn is vbz used nnp in nnp conjunction nnp with nnp central_nervous_system_depressants nnp such nnp as nnp narcotics nnp non_narcotic_analgesics nn and cc barbiturates nn
false	32	38	the dt potentiating nn action nn of inpos hydroxyzine nnp must nnp be nnp considered nnp when wrb the dt drug nn is vbz used nnp in inpos conjunction nn with inpos central_nervous_system_depressants nn such jj as jj narcotics nn non_narcotic_analgesics nn and cc barbiturates nns
false	32	40	the dt potentiating nn action nn of inpos hydroxyzine nnp must nnp be nnp considered nnp when wrb the dt drug nn is vbz used nnp in inpos conjunction nn with inpos central_nervous_system_depressants nn such jj as jj narcotics nn non_narcotic_analgesics nn and cc barbiturates nns
false	32	44	the dt potentiating nn action nn of inpos hydroxyzine nnp must nnp be nnp considered nnp when wrb the dt drug nn is vbz used nnp in inpos conjunction nn with inpos central_nervous_system_depressants nn such nnp as nnp narcotics nnp non_narcotic_analgesics nn and cc barbiturates nn
false	38	40	the dt potentiating nn action nn of inpos hydroxyzine nnp must nnp be nnp considered nnp when wrb the dt drug nn is vbz used nnp in nnp conjunction nnp with nnp central_nervous_system_depressants nnps such jj as jj narcotics nn non_narcotic_analgesics nn and cc barbiturates nns
false	38	44	the dt potentiating nn action nn of inpos hydroxyzine nnp must nnp be nnp considered nnp when wrb the dt drug nn is vbz used nnp in nnp conjunction nnp with nnp central_nervous_system_depressants nnps such jj as jj narcotics nn non_narcotic_analgesics nn and cc barbiturates nn
false	40	44	the dt potentiating nn action nn of inpos hydroxyzine nnp must nnp be nnp considered nnp when wrb the dt drug nn is vbz used nnp in nnp conjunction nnp with nnp central_nervous_system_depressants nnp such nnp as nnp narcotics nnp non_narcotic_analgesics nn and cc barbiturates nn
advise	4	14	therefore rb when wrb central_nervous_system_depressants nn are vbp administered vbn concomitantly rb with inpos hydroxyzine nn their prp dosage nn should md be vb reduced vbn
false	20	34	patients nns should md be vb advised vbn against inpos the dt simultaneous jj use nn of inpos other jj cns_depressant_drugs nn and cc cautioned vbd that inpos the dt effect nn of inpos alcohol nn may md be vb increased vbn
effect	20	32	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antimuscarinics nns
effect	20	34	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antimuscarinics nns amantadine nns
effect	20	34	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antimuscarinics nns haloperidol nns
effect	20	34	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antimuscarinics nns phenothiazines nns
effect	20	34	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antimuscarinics nns monoamine_oxidase_mao_inhibitors nns
effect	20	34	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antimuscarinics nns tricyclic_antidepressants nns
effect	20	32	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antihistamines nn
false	42	48	additive jj adverse jj effects nns resulting vbg from inpos cholinergic jj blockade nn may md occur vb when wrb levsin nn is vbz administered vbn concomitantly rb with inpos other jj antimuscarinics nns amantadine nn haloperidol nn phenothiazines nns monoamine_oxidase_mao_inhibitors nns tricyclic_antidepressants nn or cc some dt antihistamines nn
mechanism	0	14	antacids nn may md interfere vb with inpos the dt absorption nn of inpos levsin nn
false	0	2	calcium nn antacids nn
false	4	12	products nns containing vbg calcium nn and cc other jj multivalent jj aluminum nn are vbp likely jj to topos interfere vb with inpos absorption nn of inpos ibandronate nn
false	4	12	products nns containing vbg calcium nn and cc other jj multivalent jj magnesium nn are vbp likely jj to topos interfere vb with inpos absorption nn of inpos ibandronate nn
false	4	12	products nns containing vbg calcium nn and cc other jj multivalent jj iron nn are vbp likely jj to topos interfere vb with inpos absorption nn of inpos ibandronate nn
mechanism	4	28	products nns containing vbg calcium nn and cc other jj multivalent jj cations nns are vbp likely jj to topos interfere vb with inpos absorption nn of inpos ibandronate nn
mechanism	12	28	products nns containing vbg calcium nn and cc other jj multivalent jj aluminum nn are vbp likely jj to topos interfere vb with inpos absorption nn of inpos ibandronate nn
mechanism	12	28	products nns containing vbg calcium nn and cc other jj multivalent jj magnesium nn are vbp likely jj to topos interfere vb with inpos absorption nn of inpos ibandronate nn
mechanism	12	28	products nns containing vbg calcium nn and cc other jj multivalent jj iron nn are vbp likely jj to topos interfere vb with inpos absorption nn of inpos ibandronate nn
advise	0	28	ibandronate nn should md be vb taken vbn at inpos least jjs num cd minutes nns before inpos any dt oral jj medications nns containing vbg multivalent jj antacids nn
advise	0	28	ibandronate nn should md be vb taken vbn at inpos least jjs num cd minutes nns before inpos any dt oral jj medications nns containing vbg multivalent jj vitamins nn
false	0	4	h2_blockers nn and cc proton_pump_inhibitors nn
false	0	4	h2_blockers nn and cc ppis nn
false	14	32	of inpos over inpos num cd patients nns enrolled vbn in inpos the dt ibandronate nn osteoporosis nn treatment nn and cc prevention nn studies nns num cd used vbn anti_peptic jj h2_blockers nn
false	14	32	of inpos over inpos num cd patients nns enrolled vbn in inpos the dt ibandronate nn osteoporosis nn treatment nn and cc prevention nn studies nns num cd used vbn anti_peptic jj ppis nn
false	0	2	aspirin nn nonsteroidal_antiinflammatory_drug nn s nns
false	0	2	aspirin nn nsaids nn
false	2	4	aspirin nn nonsteroidal_antiinflammatory_drug nn nsaids nn
false	14	18	in inpos the dt large jj placebo_controlled jj osteoporosis nn treatment nnp study nnp aspirin nn and cc nonsteroidal_anti_inflammatory_drugs nn were vbd taken vbn by inpos num cd of inpos the dt num cd patients nns
false	2	6	among inpos aspirin nn or cc nsaid nn users nns the dt incidence nn of inpos upper jj gastrointestinal jj adverse jj events nns in inpos patients nns treated vbn with inpos ibandronate nn float cd mg nn daily jj was vbd similar jj to topos that dt in inpos placebo_treated jj patients nns
false	2	32	among inpos aspirin nn or cc nsaid nn users nns the dt incidence nn of inpos upper jj gastrointestinal jj adverse jj events nns in inpos patients nns treated vbn with inpos ibandronate nn float cd mg nn daily jj was vbd similar jj to topos that dt in inpos placebo_treated jj patients nns
false	6	32	among inpos aspirin nn or cc nsaid nn users nns the dt incidence nn of inpos upper jj gastrointestinal jj adverse jj events nns in inpos patients nns treated vbn with inpos ibandronate nn float cd mg nn daily jj was vbd similar jj to topos that dt in inpos placebo_treated jj patients nns
false	14	18	similarly rb in inpos the dt num_year jj monthly jj comparison nn study nn aspirin nn and cc nonsteroidal_anti_inflammatory_drugs nn were vbd taken vbn by inpos num cd of inpos the dt num cd patients nns
false	20	24	the dt incidence nn of inpos upper jj gastrointestinal jj events nns in inpos patients nns concomitantly rb taking vbg aspirin nn or cc nsaids nn was vbd similar jj in inpos patients nns taking vbg ibandronate jj float cd mg nn daily jj and cc num cd mg nn once rb monthly jj
false	20	36	the dt incidence nn of inpos upper jj gastrointestinal jj events nns in inpos patients nns concomitantly rb taking vbg aspirin nn or cc nsaids nns was vbd similar jj in inpos patients nns taking vbg ibandronate nn float cd mg nn daily jj and cc num cd mg nn once rb monthly jj
false	24	36	the dt incidence nn of inpos upper jj gastrointestinal jj events nns in inpos patients nns concomitantly rb taking vbg aspirin nn or cc nsaids nn was vbd similar jj in inpos patients nns taking vbg ibandronate nn float cd mg nn daily jj and cc num cd mg nn once rb monthly jj
false	4	40	however rb since inpos aspirin nns are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nn with inpos ibandronate nn
false	4	44	however rb since inpos aspirin nns are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nns with inpos ibandronate nn
false	4	36	however rb since inpos nsaids nns are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nns with inpos ibandronate nn
false	4	44	however rb since inpos nsaids nns are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nns with inpos ibandronate nn
false	4	36	however rb since inpos bisphosphonates nn are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nns with inpos ibandronate nn
false	4	40	however rb since inpos bisphosphonates nn are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nn with inpos ibandronate nn
false	4	44	however rb since inpos bisphosphonates nn are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nns with inpos ibandronate nn
false	4	6	however rb since inpos aspirin nn nsaids nns bisphosphonates nns are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nn with inpos ibandronate nn
advise	4	48	however rb since inpos aspirin nn nsaids nns bisphosphonates nns are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nns with inpos ibandronate nn
advise	6	48	however rb since inpos aspirin nn nsaids nns bisphosphonates nns are vbp all dt associated vbn with inpos gastrointestinal jj irritation nn caution nn should md be vb exercised vbn in inpos the dt concomitant jj use nn of inpos aspirin nn or cc nsaids nn with inpos ibandronate nn
false	16	50	several jj short_term jj controlled jj studies nns failed vbd to topos wshow vb that dt ibuprofen nn significantly rb affected vbd prothrombin nn times nns or cc a dt variety nn of inpos other jj clotting vbg factors nns when wrb administered vbn to topos individuals nns on inpos coumarin_type_anticoagulants nn
false	14	20	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nn have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nns the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nns
effect	14	34	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nns have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nn the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nns
false	14	34	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nns have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nns the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nn
effect	20	34	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nn have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nn the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nns
false	20	14	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nn have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nns the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nns
false	20	34	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nn have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nns the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nn
false	34	14	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nns have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nn the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nns
advise	14	34	however rb because inpos bleeding nn has vbz been vbn reported vbn when wrb ibuprofen nn and cc other jj nonsteroidal_anti_inflammatory_agents nns have vbp been vbn administered vbn to topos patients nns on inpos coumarin_type_anticoagulants nns the dt physician nn should md be vb cautious jj when wrb administering vbg ibuprofen nn to topos patients nns on inpos anticoagulants nn
effect	8	14	animal jj studies nns wshow vbp that inpos aspirin nn given vbn with inpos nonsteroidal_anti_inflammatory_agents nn including vbg ibuprofen nn yields vbz a dt net jj decrease nn in inpos anti_inflammatory jj activity nn with inpos lowered vbn blood nn levels nns of inpos the dt non_aspirin jj drug nn
effect	8	18	animal jj studies nns wshow vbp that inpos aspirin nn given vbn with inpos nonsteroidal_anti_inflammatory_agents nns including vbg ibuprofen nn yields vbz a dt net jj decrease nn in inpos anti_inflammatory jj activity nn with inpos lowered vbn blood nn levels nns of inpos the dt non_aspirin jj drug nn
false	14	18	animal jj studies nns wshow vbp that inpos aspirin nn given vbn with inpos nonsteroidal_anti_inflammatory_agents nn including vbg ibuprofen nn yields vbz a dt net jj decrease nn in inpos anti_inflammatory jj activity nn with inpos lowered vbn blood nn levels nns of inpos the dt non_aspirin jj drug nn
false	28	32	single jj dose nn bioavailability nn studies nns in inpos normal jj volunteers nns have vbp failed vbn to topos wshow vb an dt effect nn of inpos aspirin nn on inpos ibuprofen nn blood nn levels nns
false	0	2	methotrexate nn ibuprofen nn as rb well rb as inpos other jj nonsteroidal_anti_inflammatory_drugs nns probably rb reduces vbz the dt tubular jj secretion nn of inpos methotrexate nn based vbn on inpos in fw vitro fw studies nns in inpos rabbit nn kidney nn slices nns
false	0	12	methotrexate nn ibuprofen nn as rb well rb as inpos other jj nonsteroidal_anti_inflammatory_drugs nn probably rb reduces vbz the dt tubular jj secretion nn of inpos methotrexate nn based vbn on inpos in fw vitro fw studies nns in inpos rabbit nn kidney nn slices nns
false	2	12	methotrexate nn ibuprofen nn as rb well rb as inpos other jj nonsteroidal_anti_inflammatory_drugs nn probably rb reduces vbz the dt tubular jj secretion nn of inpos methotrexate nn based vbn on inpos in fw vitro fw studies nns in inpos rabbit nn kidney nn slices nns
mechanism	2	0	methotrexate nn ibuprofen nn as rb well rb as inpos other jj nonsteroidal_anti_inflammatory_drugs nns probably rb reduces vbz the dt tubular jj secretion nn of inpos methotrexate nn based vbn on inpos in fw vitro fw studies nns in inpos rabbit nn kidney nn slices nns
mechanism	12	0	methotrexate nn ibuprofen nn as rb well rb as inpos other jj nonsteroidal_anti_inflammatory_drugs nn probably rb reduces vbz the dt tubular jj secretion nn of inpos methotrexate nn based vbn on inpos in fw vitro fw studies nns in inpos rabbit nn kidney nn slices nns
effect	8	20	this dt may md indicate vb that inpos ibuprofen nn could md enhance vb the dt toxicity nn of inpos methotrexate nn
advise	10	20	caution nn should md be vb used vbn if inpos ibuprofen nn is vbz administered vbn concomitantly rb with inpos methotrexate nn
false	14	18	in inpos studies nns with inpos human jj volunteers nns co_administration nn of inpos cimetidine nn or cc ranitidine nn with inpos ibuprofen nn had vbd no dt substantive jj effect nn on inpos ibuprofen nn serum nn concentrations nns
false	14	22	in inpos studies nns with inpos human jj volunteers nns co_administration nn of inpos cimetidine nn or cc ranitidine nn with inpos ibuprofen nn had vbd no dt substantive jj effect nn on inpos ibuprofen nn serum nn concentrations nns
false	14	22	in inpos studies nns with inpos human jj volunteers nns co_administration nn of inpos cimetidine nn or cc ranitidine nn with inpos ibuprofen nn had vbd no dt substantive jj effect nn on inpos ibuprofen nn serum nn concentrations nns
false	18	22	in inpos studies nns with inpos human jj volunteers nns co_administration nn of inpos cimetidine nn or cc ranitidine nn with inpos ibuprofen nn had vbd no dt substantive jj effect nn on inpos ibuprofen nn serum nn concentrations nns
false	18	22	in inpos studies nns with inpos human jj volunteers nns co_administration nn of inpos cimetidine nn or cc ranitidine nn with inpos ibuprofen nn had vbd no dt substantive jj effect nn on inpos ibuprofen nn serum nn concentrations nns
false	0	22	furosemide nn clinical jj studies nns as rb well rb as inpos random jj observations nns have vbp shown vbn that inpos ibuprofen nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos random jj observations nns have vbp shown vbn that inpos ibuprofen nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
effect	22	0	furosemide nn clinical jj studies nns as rb well rb as inpos random jj observations nns have vbp shown vbn that inpos ibuprofen nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
effect	22	40	furosemide nn clinical jj studies nns as rb well rb as inpos random jj observations nns have vbp shown vbn that inpos ibuprofen nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos random jj observations nns have vbp shown vbn that inpos ibuprofen nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	8	42	during inpos concomitant jj therapy nn with inpos ibuprofen nn the dt patient nn should md be vb observed vbn closely rb for inpos signs nns of inpos renal jj failure nn as rb well rb as inpos to topos assure vb diuretic nn efficacy nn
mechanism	0	12	ibuprofen nn produced vbd an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn in inpos a dt study nn of inpos num cd normal jj volunteers nns
false	0	12	ibuprofen nn produced vbd an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn in inpos a dt study nn of inpos num cd normal jj volunteers nns
advise	4	8	thus rb when wrb ibuprofen nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
false	4	8	thus rb when wrb ibuprofen nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
false	4	28	coadministration nn of inpos digoxin nn did vbd not rb have vb effects nns on inpos either cc the dt safety nn or cc efficacy nn of inpos ibutilide nn in inpos the dt clinical jj trials nns
false	0	6	calcium_channel_blocking_agents nn coadministration nn of inpos calcium_channel_blockers nn did vbd not rb have vb any dt effect nn on inpos either cc the dt safety nn or cc efficacy nn of inpos ibutilide nn in inpos the dt clinical jj trials nns
false	0	32	calcium_channel_blocking_agents nn coadministration nn of inpos calcium_channel_blockers nns did vbd not rb have vb any dt effect nn on inpos either cc the dt safety nn or cc efficacy nn of inpos ibutilide nn in inpos the dt clinical jj trials nns
false	4	30	coadministration nn of inpos calcium_channel_blockers nn did vbd not rb have vb any dt effect nn on inpos either cc the dt safety nn or cc efficacy nn of inpos ibutilide nn in inpos the dt clinical jj trials nns
false	0	32	b_adrenergic_blocking_agents nn coadministration nn of inpos b_adrenergic_blocking_agents nns did vbd not rb have vb any dt effect nn on inpos either cc the dt safety nn or cc efficacy nn of inpos ibutilide nn in inpos the dt clinical jj trials nns
false	4	30	coadministration nn of inpos b_adrenergic_blocking_agents nn did vbd not rb have vb any dt effect nn on inpos either cc the dt safety nn or cc efficacy nn of inpos ibutilide nn in inpos the dt clinical jj trials nns
false	24	10	a dt clinical jj study nn in inpos num cd insulin_dependent jj diabetic jj patients nns demonstrated vbd no dt effect nn of inpos extraneal nn on inpos insulin nn absorption nn from inpos the dt peritoneal jj cavity nn or cc on inpos insulins nns ability nn to topos control vb blood nn glucose nn when wrb insulin nn was vbd administered vbn intraperitoneally rb with inpos extraneal nn
false	24	10	a dt clinical jj study nn in inpos num cd insulin_dependent jj diabetic jj patients nns demonstrated vbd no dt effect nn of inpos extraneal nn on inpos insulin nn absorption nn from inpos the dt peritoneal jj cavity nn or cc on inpos insulin nn s nn ability nn to topos control vb blood nn glucose nn when wrb insulin nn was vbd administered vbn intraperitoneally rb with inpos extraneal nn
false	24	10	a dt clinical jj study nn in inpos num cd insulin_dependent jj diabetic jj patients nns demonstrated vbd no dt effect nn of inpos extraneal nn on inpos insulin nn absorption nn from inpos the dt peritoneal jj cavity nn or cc on inpos insulins nns ability nn to topos control vb blood nn glucose nn when wrb insulin nn was vbd administered vbn intraperitoneally rb with inpos extraneal nn
false	10	24	a dt clinical jj study nn in inpos num cd insulin_dependent jj diabetic jj patients nns demonstrated vbd no dt effect nn of inpos extraneal nn on inpos insulin nn absorption nn from inpos the dt peritoneal jj cavity nn or cc on inpos insulins nns ability nn to topos control vb blood nn glucose nn when wrb insulin nn was vbd administered vbn intraperitoneally rb with inpos extraneal nn
false	10	24	a dt clinical jj study nn in inpos num cd insulin_dependent jj diabetic jj patients nns demonstrated vbd no dt effect nn of inpos extraneal nn on inpos insulin nn absorption nn from inpos the dt peritoneal jj cavity nn or cc on inpos insulin nn s nn ability nn to topos control vb blood nn glucose nn when wrb insulin nn was vbd administered vbn intraperitoneally rb with inpos extraneal nn
false	10	24	a dt clinical jj study nn in inpos num cd insulin_dependent jj diabetic jj patients nns demonstrated vbd no dt effect nn of inpos extraneal nn on inpos insulin nn absorption nn from inpos the dt peritoneal jj cavity nn or cc on inpos insulins nns ability nn to topos control vb blood nn glucose nn when wrb insulin nn was vbd administered vbn intraperitoneally rb with inpos extraneal nn
advise	22	32	however rb appropriate jj monitoring nn of inpos blood nn glucose nn should md be vb performed vbn when wrb initiating vbg extraneal nn in inpos diabetic jj patients nns and cc insulin nn dosage nn should md be vb adjusted vbn if inpos needed vbn
false	18	22	in fw vitro fw studies nns demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos heparin nn with inpos extraneal nn
false	18	34	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos vancomycin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
false	18	38	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos vancomycin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nns with inpos extraneal nn
false	18	34	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos cefazolin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
false	18	38	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos cefazolin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nns with inpos extraneal nn
false	18	34	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos ampicillin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
false	18	38	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos ampicillin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nns with inpos extraneal nn
false	18	34	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos ampicillin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
false	18	38	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos ampicillin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nns with inpos extraneal nn
false	18	34	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos ceftazidime nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
false	18	38	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos ceftazidime nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nns with inpos extraneal nn
false	18	34	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos gentamicin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
false	18	38	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos gentamicin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nns with inpos extraneal nn
false	18	34	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos amphotericin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
false	18	38	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos amphotericin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nns with inpos extraneal nn
false	46	50	in fw vitro fw studies nns evaluating vbg the dt minimum jj inhibitory jj concentration nn of inpos vancomycin nn cefazolin nn ampicillin nn flucoxacillin nn ceftazidime nn gentamicin nn amphotericin nn demonstrated vbd no dt evidence nn of inpos incompatibility nn of inpos these dt antibiotics nn with inpos extraneal nn
int	8	10	interactions nns may md occur vb between inpos epa nn aspirin nns such jj as inpos garlic nn and cc ginkgo nn
int	8	10	interactions nns may md occur vb between inpos epa nn non_steroidal_anti_inflammatory_drugs nns such jj as inpos garlic nn and cc ginkgo nn
int	8	28	interactions nns may md occur vb between inpos epa nn supplements nns aspirin nn other jj non_steroidal_anti_inflammatory_drugs nns herbs nns such jj as inpos garlic nn and cc ginkgo nn
int	8	28	interactions nns may md occur vb between inpos epa nn supplements nns aspirin nn other jj non_steroidal_anti_inflammatory_drugs nns herbs nns such jj as inpos garlic nn and cc ginkgo_biloba nn
false	10	20	interactions nns may md occur vb between inpos epa nnp aspirin nns such jj as inpos garlic nn and cc ginkgo nn
false	10	20	interactions nns may md occur vb between inpos epa nnp aspirin nns such jj as inpos garlic nn and cc ginkgo_biloba nn
false	10	20	interactions nns may md occur vb between inpos epa nnp non_steroidal_anti_inflammatory_drugs nns such jj as inpos garlic nn and cc ginkgo nn
false	10	20	interactions nns may md occur vb between inpos epa nnp non_steroidal_anti_inflammatory_drugs nns such jj as inpos garlic nn and cc ginkgo_biloba nn
advise	8	48	when wrb you prp are vbp using vbg idoxuridine nn it prp is vbz especially rb important jj that inpos your prp health nn care nn professional jj know nn if inpos you prp are vbp using vbg the dt following nn eye nn product nn containing vbg boric_acid nn
mechanism	0	10	boric_acid nn may md interact vb with inpos the dt idoxuridine nn preparation nn causing vbg a dt gritty jj substance nn to topos form vb or cc may md interact vb with inpos the dt preservative nn in inpos the dt idoxuridine nn preparation nn causing vbg a dt toxic jj effect nn in inpos the dt eye nn
false	0	10	boric_acid nn may md interact vb with inpos the dt idoxuridine nn preparation nn causing vbg a dt gritty jj substance nn to topos form vb or cc may md interact vb with inpos the dt preservative nn in inpos the dt idoxuridine nn preparation nn causing vbg a dt toxic jj effect nn in inpos the dt eye nn
effect	2	22	however rb iloprost nn has vbz the dt potential nn to topos increase vb the dt hypotensive jj effect nn of inpos vasodilators nn and cc antihypertensive_agents nns
effect	2	26	however rb iloprost nn has vbz the dt potential nn to topos increase vb the dt hypotensive jj effect nn of inpos vasodilators nns and cc antihypertensive_agents nn
false	22	26	however rb iloprost nn has vbz the dt potential nn to topos increase vb the dt hypotensive jj effect nn of inpos vasodilators nn and cc antihypertensive_agents nn
effect	2	38	since inpos iloprost nn inhibits vbz platelet nn function nn there ex is vbz a dt potential nn for inpos increased vbn risk nn of inpos bleeding vbg particularly rb in inpos patients nns maintained vbn on inpos anticoagulants nn
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos anticoagulants nns other jj medications nns
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos diuretics nns other jj medications nns
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos cardiac_glycosides nns other jj medications nns
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos calcium_channel_blockers nns other jj medications nns
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos analgesics nns other jj medications nns
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos antipyretics nns other jj medications nns
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos nonsteroidal_antiinflammatories nns other jj medications nns
false	6	16	during inpos clinical jj trials nns iloprost nn was vbd used vbn concurrently rb with inpos corticosteroids nn other jj medications nns
false	6	22	intravenous jj infusion nn of inpos iloprost nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos digoxin nn
false	0	14	acetylsalicylic_acid nn did vbd not rb alter vb the dt clearance nn of inpos iloprost nn
false	8	38	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn family nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn ketoconazole nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn itraconazole nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn erythromycin nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn clarithromycin nn
false	8	38	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn family nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn ketoconazole nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn itraconazole nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn erythromycin nn
false	8	50	drugs nns that wdt may md alter vb imatinib nn plasma nn concentrations nns drugs nns that wdt may md increase vb imatinib nn plasma nn concentrations nns caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn clarithromycin nn
advise	10	22	caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn ketoconazole nn
advise	10	22	caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn itraconazole nn
advise	10	22	caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn erythromycin nn
advise	10	22	caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos inhibitors nns of inpos the dt cyp3a4 nn clarithromycin nn
false	16	20	there ex is vbz a dt significant jj increase nn in inpos exposure nn to topos imatinib nn when wrb gleevec nn is vbz coadministered vbn with inpos ketoconazole nn
false	16	28	there ex is vbz a dt significant jj increase nn in inpos exposure nn to topos imatinib nn when wrb gleevec nn is vbz coadministered vbn with inpos ketoconazole nn
mechanism	20	28	there ex is vbz a dt significant jj increase nn in inpos exposure nn to topos imatinib vb when wrb gleevec nn is vbz coadministered vbn with inpos ketoconazole nn
mechanism	16	30	pretreatment nn of inpos healthy jj volunteers nns with inpos multiple jj doses nns of inpos rifampin nn followed vbn by inpos a dt single jj dose nn of inpos gleevec nn increased vbd gleevec nn oral_dose jj clearance nn by inpos float_fold rb which wdt significantly rb decreased vbd mean jj cmax nn and cc auc nn
false	16	30	pretreatment nn of inpos healthy jj volunteers nns with inpos multiple jj doses nns of inpos rifampin nn followed vbn by inpos a dt single jj dose nn of inpos gleevec nnp increased vbd gleevec nn oral_dose jj clearance nn by inpos float_fold rb which wdt significantly rb decreased vbd mean jj cmax nn and cc auc nn
false	18	36	drugs nns that wdt may md have vb their prp plasma nn concentration nn altered vbn by inpos gleevec nn gleevec nn increases vbz the dt mean jj cmax nn and cc auc nn of inpos simvastatin nn num cd and cc float_fold rb respectively rb suggesting vbg an dt inhibition nn of inpos the dt cyp3a4 nn by inpos gleevec nn
mechanism	18	36	drugs nns that wdt may md have vb their prp plasma nn concentration nn altered vbn by inpos gleevec nn gleevec nn increases vbz the dt mean jj cmax nn and cc auc nn of inpos simvastatin nn num cd and cc float_fold rb respectively rb suggesting vbg an dt inhibition nn of inpos the dt cyp3a4 nn by inpos gleevec nn
false	36	18	drugs nns that wdt may md have vb their prp plasma nn concentration nn altered vbn by inpos gleevec nnp gleevec nnp increases vbz the dt mean jj cmax nn and cc auc nn of inpos simvastatin nn num cd and cc float_fold rb respectively rb suggesting vbg an dt inhibition nn of inpos the dt cyp3a4 nn by inpos gleevec nn
advise	12	30	particular jj caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos cyp3a4 nn substrates nns that wdt have vbp a dt narrow jj therapeutic jj cyclosporine nn
advise	12	30	particular jj caution nn is vbz recommended vbn when wrb administering vbg gleevec nn with inpos cyp3a4 nn substrates nns that wdt have vbp a dt narrow jj therapeutic jj pimozide nn
mechanism	0	16	gleevec nn will md increase vb plasmaconcentration nn of inpos other jj cyp3a4 nn metabolized vbd benzodiazepines nn
mechanism	0	16	gleevec nn will md increase vb plasmaconcentration nn of inpos other jj cyp3a4 nn metabolized vbd dihydropyridine_calcium_channel_blockers nn
mechanism	0	16	gleevec nn will md increase vb plasmaconcentration nn of inpos other jj cyp3a4 nn metabolized vbd hmg_coa_reductase_inhibitors nn
false	2	36	because inpos warfarin nn is vbz metabolized vbn by inpos cyp2c9 nn and cc cyp3a4 nn patients nns who wp require vbp anticoagulation nn should md receive vb low_molecular jj weight nn or cc standard jj heparin nn
mechanism	6	24	systemic jj exposure nn to topos acetaminophen nn is vbz expected vbn to topos be vb increased vbn when wrb coadministered vbn with inpos gleevec nn
false	14	20	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nn and cc local jj anesthetics nn which wdt contain vbp any dt sympathomimetic_amine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nns can md potentiate vb the dt effects nns of inpos catecholamines nns
false	14	28	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nn and cc local jj anesthetics nns which wdt contain vbp any dt sympathomimetic_amine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nns can md potentiate vb the dt effects nns of inpos catecholamines nns
false	14	28	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nn and cc local jj anesthetics nns which wdt contain vbp any dt epinephrine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nns can md potentiate vb the dt effects nns of inpos catecholamines nns
false	14	28	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nn and cc local jj anesthetics nns which wdt contain vbp any dt norepinephrine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nns can md potentiate vb the dt effects nns of inpos catecholamines nns
advise	14	42	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nn and cc local jj anesthetics nns which wdt contain vbp any dt sympathomimetic_amine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nn can md potentiate vb the dt effects nns of inpos catecholamines nns
false	20	28	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nns and cc local jj anesthetics nn which wdt contain vbp any dt sympathomimetic_amine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nns can md potentiate vb the dt effects nns of inpos catecholamines nns
false	20	28	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nns and cc local jj anesthetics nn which wdt contain vbp any dt epinephrine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nns can md potentiate vb the dt effects nns of inpos catecholamines nns
false	20	28	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nns and cc local jj anesthetics nn which wdt contain vbp any dt norepinephrine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nns can md potentiate vb the dt effects nns of inpos catecholamines nns
advise	20	42	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nns and cc local jj anesthetics nn which wdt contain vbp any dt sympathomimetic_amine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nn can md potentiate vb the dt effects nns of inpos catecholamines nns
advise	28	42	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nns and cc local jj anesthetics nns which wdt contain vbp any dt sympathomimetic_amine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nn can md potentiate vb the dt effects nns of inpos catecholamines nns
advise	28	42	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nns and cc local jj anesthetics nns which wdt contain vbp any dt epinephrine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nn can md potentiate vb the dt effects nns of inpos catecholamines nns
advise	28	42	avoid vb the dt use nn of inpos preparations nns such jj as inpos decongestants nns and cc local jj anesthetics nns which wdt contain vbp any dt norepinephrine nn since inpos it prp has vbz been vbn reported vbn that inpos tricyclic_antidepressants nn can md potentiate vb the dt effects nns of inpos catecholamines nns
effect	0	12	imipramine_hydrochloride nn may md potentiate vb the dt effects nns of inpos cns_depressant_drugs nn
mechanism	8	32	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn cimetidine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
mechanism	8	32	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn fluoxetine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
mechanism	8	50	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn inhibitors nns and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
mechanism	8	50	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn inhibitors nns and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	32	50	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn cimetidine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	32	50	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn cimetidine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	32	8	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn cimetidine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	32	50	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn fluoxetine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	32	50	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn fluoxetine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	32	8	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn fluoxetine nn and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn inducers nns and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	50	8	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn inhibitors nns and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn barbiturates nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	50	8	the dt plasma nn concentration nn of inpos imipramine nn may md increase vb when wrb the dt drug nn is vbz given vbn concomitantly rb with inpos hepatic jj enzyme nn inhibitors nns and cc decrease nn by inpos concomitant jj administration nn of inpos hepatic jj enzyme nn phenytoin nn and cc adjustment nn of inpos the dt dosage nn of inpos imipramine nn may md therefore rb be vb necessary jj
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn antidepressants nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn phenothiazines nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn type_1c_antiarrhythmics nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn propafenone nn
false	0	16	cimetidine nn rrb_and cc many jj that wdt are vbp substrates nns for inpos p450 nn flecainide nn
false	6	12	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e. fw g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	12	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e. fw g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	12	while inpos all pdt the dt selective_serotonin_reuptake_inhibitors nn e. fw g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	12	while inpos all pdt the dt ssris nn e. fw g. fw fluoxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	12	while inpos all pdt the dt ssris nn e. fw g. fw sertraline nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
false	6	12	while inpos all pdt the dt ssris nn e. fw g. fw paroxetine nn inhibit vbp p450 nn 2d6 nn they prp may md vary vb in inpos the dt extent nn of inpos inhibition nn
int	8	10	the dt extent nn to topos which wdt ssri nn hyph_tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbd
false	10	8	the dt extent nn to topos which wdt ssri nn tca nn interactions nns may md pose vb clinical jj problems nns will md depend vb on inpos the dt degree nn of inpos inhibition nn and cc the dt pharmacokinetics nns of inpos the dt ssri nn involved vbn
false	4	28	coadministration nn of inpos crixivan nn and cc other jj drugs nns that wdt inhibit vbp cyp3a4 nn may md decrease vb the dt clearance nn of inpos indinavir nn and cc may md result vb in inpos increased vbn plasma nn concentrations nns of inpos indinavir nn
false	4	28	coadministration nn of inpos crixivan nn and cc other jj drugs nns that wdt inhibit vbp cyp3a4 nn may md decrease vb the dt clearance nn of inpos indinavir nn and cc may md result vb in inpos increased vbn plasma nn concentrations nns of inpos indinavir nn
false	0	2	antiarrhythmics nn amiodarone nn
false	4	10	ergot nn derivatives nns dihydroergotamine nn ergonovine jj ergotamine nn methylergonovine nn
false	4	10	ergot nn derivatives nns dihydroergotamine nn ergonovine jj ergotamine nn methylergonovine nn
false	0	2	sedative nn hypnotics nn midazolam nn triazolam nn
false	0	4	sedative nn hypnotics nns midazolam nn triazolam nn
false	0	6	sedative nn hypnotics nns midazolam nn triazolam nn
false	2	4	sedative nn hypnotics nn midazolam nn triazolam nn
false	2	6	sedative nn hypnotics nn midazolam nn triazolam nn
false	2	4	sedative_hypnotics nns midazolam nn triazolam nn
false	0	2	neuroleptic nn pimozide nn
false	22	34	may md lead vb to topos loss nn of inpos virologic jj response nn and cc possible jj resistance nn to topos crixivan nn or cc to topos the dt class nn of inpos protease_inhibitors nn
false	0	2	antimycobacterial nn rifampin nn
false	22	34	may md lead vb to topos loss nn of inpos virologic jj response nn and cc possible jj resistance nn to topos crixivan nn or cc to topos the dt class nn of inpos protease_inhibitors nn or cc other jj coadministered vbn antiretroviral_agents nns
false	22	42	may md lead vb to topos loss nn of inpos virologic jj response nn and cc possible jj resistance nn to topos crixivan nn or cc to topos the dt class nn of inpos protease_inhibitors nns or cc other jj coadministered vbn antiretroviral_agents nn
false	34	42	may md lead vb to topos loss nn of inpos virologic jj response nn and cc possible jj resistance nn to topos crixivan nn or cc to topos the dt class nn of inpos protease_inhibitors nn or cc other jj coadministered vbn antiretroviral_agents nn
false	0	2	hmg_coa_reductase_inhibitors nn lovastatin nn simvastatin nn
false	0	4	hmg_coa_reductase_inhibitors nn lovastatin nn simvastatin nn
false	2	4	hmg_coa_reductase_inhibitors nns lovastatin nn simvastatin nn
false	0	2	protease_inhibitor nn atazanavir nn
false	2	6	both cc crixivan nn and cc atazanavir nn are vbp associated vbn with inpos indirect jj hyperbilirubinemia nn
advise	22	26	combinations nns of inpos these dt drugs nns have vbp not rb been vbn studied vbn and cc coadministration nn of inpos crixivan nn and cc atazanavir nn is vbz not rb recommended vbn
advise	6	30	dose nn reduction nn of inpos crixivan nn to topos num cd mg nn every dt num cd hours nns should md be vb considered vbn when wrb taking vbg delavirdine nn num cd mg nn num cd times nns a dt day nn
advise	0	4	indinavir nn and cc didanosine nn formulations nns containing vbg buffer nn should md be vb administered vbn at inpos least jjs num cd hour nn apart rb on inpos an dt empty jj stomach nn
false	8	20	the dt optimal jj dose nn of inpos indinavir nn when wrb given vbn in inpos combination nn with inpos efavirenz nn is vbz not rb known vbn
false	4	40	increasing vbg the dt indinavir nn dose nn to topos num cd mg nn every dt num cd hours nns does vbz not rb compensate vb for inpos the dt increased vbn indinavir nn metabolism nn due inpos to topos efavirenz nn
mechanism	4	40	increasing vbg the dt indinavir nn dose nn to topos num cd mg nn every dt num cd hours nns does vbz not rb compensate vb for inpos the dt increased vbn indinavir nn metabolism nn due inpos to topos efavirenz nn
mechanism	0	18	indinavir nn concentrations nns may md be vb decreased vbn in inpos the dt presence nn of inpos nevirapine nn
false	0	4	indinavir nn concentration nn ritonavir nn concentration nn
effect	28	36	preliminary jj clinical jj data nns suggest vbp that inpos the dt incidence nn of inpos nephrolithiasis nn is vbz higher jjr in inpos patients nns receiving vbg indinavir nn in inpos combination nn with inpos ritonavir nn than inpos those dt receiving vbg crixivan nn num cd mg nn q8h nn
false	28	44	preliminary jj clinical jj data nns suggest vbp that inpos the dt incidence nn of inpos nephrolithiasis nn is vbz higher jjr in inpos patients nns receiving vbg indinavir nn in inpos combination nn with inpos ritonavir nn than inpos those dt receiving vbg crixivan nn num cd mg nn q8h nn
false	36	44	preliminary jj clinical jj data nns suggest vbp that inpos the dt incidence nn of inpos nephrolithiasis nn is vbz higher jjr in inpos patients nns receiving vbg indinavir nn in inpos combination nn with inpos ritonavir nn than inpos those dt receiving vbg crixivan nn num cd mg nn q8h nn
false	0	2	antiarrhythmics nn bepridil nn
false	0	2	antiarrhythmics nn lidocaine nn
false	0	2	antiarrhythmics nn quinidine nn
advise	20	28	caution nn is vbz warranted vbn and cc therapeutic jj concentration nn monitoring nn is vbz recommended vbn for inpos antiarrhythmics nn when wrb coadministered vbn with inpos crixivan nn
false	0	2	anticonvulsants nn carbamazepine nn phenobarbital nn phenytoin nn
false	0	4	anticonvulsants nn carbamazepine nn phenobarbital nn phenytoin nn
false	0	6	anticonvulsants nn carbamazepine nn phenobarbital nn phenytoin nn
false	2	4	anticonvulsants nns carbamazepine nn phenobarbital nn phenytoin nn
false	2	6	anticonvulsants nns carbamazepine nn phenobarbital nn phenytoin nn
false	4	6	anticonvulsants nns carbamazepine nn phenobarbital nn phenytoin nn
effect	0	16	crixivan nn may md not rb be vb effective jj due jj to topos decreased vbn indinavir nn concentrations nns in inpos patients nns taking vbg these dt agents nns concomitantly rb
false	0	2	calcium_channel_blockers nn dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	0	6	calcium_channel_blockers nn dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	0	8	calcium_channel_blockers nn dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	0	10	calcium_channel_blockers nn dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	2	6	calcium_channel_blockers nns dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	2	8	calcium_channel_blockers nns dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	2	10	calcium_channel_blockers nns dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	6	8	calcium_channel_blockers nns dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	6	10	calcium_channel_blockers nns dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	8	10	calcium_channel_blockers nns dihydropyridine nn e.g. fw felodipine nn nifedipine nn nicardipine nn
false	0	4	clarithromycin nn concentration nn indinavir nn concentration nn
false	0	2	hmg_coa_reductase_inhibitor nn atorvastatin nn
false	10	22	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nn that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos pravastatin nn fluvastatin nn rosuvastatin nn in inpos combination nn with inpos crixivan nn
false	10	42	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nns that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos pravastatin nn in inpos combination nn with inpos crixivan nn
false	10	42	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nns that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos fluvastatin nn in inpos combination nn with inpos crixivan nn
false	10	42	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nns that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos rosuvastatin nn in inpos combination nn with inpos crixivan nn
advise	10	54	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nns that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos pravastatin nn fluvastatin nn rosuvastatin nn in inpos combination nn with inpos crixivan nn
false	22	42	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nn that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos pravastatin nn in inpos combination nn with inpos crixivan nn
false	22	42	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nn that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos fluvastatin nn in inpos combination nn with inpos crixivan nn
false	22	42	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nn that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos rosuvastatin nn in inpos combination nn with inpos crixivan nn
advise	22	54	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nn that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos pravastatin nn fluvastatin nn rosuvastatin nn in inpos combination nn with inpos crixivan nn
false	42	50	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nns that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos pravastatin nn in inpos combination nn with inpos crixivan nn
false	42	50	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nns that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos fluvastatin nn in inpos combination nn with inpos crixivan nn
false	42	50	use nnp lowest jjs possible jj dose nn of inpos atorvastatin nn with inpos careful jj monitoring nn or cc consider vb hmg_coa_reductase_inhibitors nns that wdt are vbp not rb primarily rb metabolized vbn by inpos cyp3a4 nn such jj as inpos rosuvastatin nn in inpos combination nn with inpos crixivan nn
false	0	2	immunosuppressants nn cyclosporine nn tacrolimus nn sirolimus nn
false	0	4	immunosuppressants nn cyclosporine nn tacrolimus nn sirolimus nn
false	0	6	immunosuppressants nn cyclosporine nn tacrolimus nn sirolimus nn
false	2	4	immunosuppressants nns cyclosporine nn tacrolimus nn sirolimus nn
false	2	6	immunosuppressants nns cyclosporine nn tacrolimus nn sirolimus nn
false	4	6	immunosuppressants nns cyclosporine nn tacrolimus nn sirolimus nn
advise	6	28	dose nn reduction nn of inpos crixivan nn to topos num cd mg nn every dt num cd hours nns is vbz recommended vbn when wrb administering vbg itraconazole nn concurrently rb
false	0	4	indinavir nn concentration nn rifabutin nn concentration nn
false	6	28	dose nn reduction nn of inpos rifabutin nn to topos half pdt the dt standard jj dose nn and cc a dt dose nn increase nn of inpos crixivan nn to topos num cd mg nn every dt num cd hours nns are vbp recommended vbn when wrb rifabutin nn and cc crixivan nn are vbp coadministered vbn
false	6	28	dose nn reduction nn of inpos rifabutin nn to topos half pdt the dt standard jj dose nn and cc a dt dose nn increase nn of inpos crixivan nn to topos num cd mg nn every dt num cd hours nns are vbp recommended vbn when wrb rifabutin nn and cc crixivan nn are vbp coadministered vbn
false	28	6	dose nn reduction nn of inpos rifabutin nn to topos half pdt the dt standard jj dose nn and cc a dt dose nn increase nn of inpos crixivan nn to topos num cd mg nn every dt num cd hours nns are vbp recommended vbn when wrb rifabutin nn and cc crixivan nn are vbp coadministered vbn
advise	6	28	dose nn reduction nn of inpos rifabutin nn to topos half pdt the dt standard jj dose nn and cc a dt dose nn increase nn of inpos crixivan nn to topos num cd mg nn every dt num cd hours nns are vbp recommended vbn when wrb rifabutin nn and cc crixivan nn are vbp coadministered vbn
advise	0	38	sildenafil nn dose nn should md not rb exceed vb a dt maximum nn of inpos num cd mg nn in inpos a dt num cd hour nn period nn in inpos patients nns receiving vbg concomitant jj indinavir nn therapy nn
advise	0	38	tadalafil nn dose nn should md not rb exceed vb a dt maximum nn of inpos num cd mg nn in inpos a dt num cd hour nn period nn in inpos patients nns receiving vbg concomitant jj indinavir nn therapy nn
advise	0	36	vardenafil nn dose nn should md not rb exceed vb a dt maximum nn of inpos float cd mg nn in inpos a dt num_hour jj period nn in inpos patients nns receiving vbg concomitant jj indinavir nn therapy nn
false	8	16	in inpos normal jj volunteers nns receiving vbg indomethacin nn the dt administration nn of inpos diflunisal nn decreased vbd the dt renal jj clearance nn and cc significantly rb increased vbd the dt plasma nn levels nns of inpos indomethacin nn
mechanism	16	8	in inpos normal jj volunteers nns receiving vbg indomethacin nn the dt administration nn of inpos diflunisal nn decreased vbd the dt renal jj clearance nn and cc significantly rb increased vbd the dt plasma nn levels nns of inpos indomethacin nn
effect	12	16	in inpos some dt patients nns combined vbn use nn of inpos indocin nn and cc diflunisal nn has vbz been vbn associated vbn with inpos fatal jj gastrointestinal jj hemorrhage nn
advise	2	6	therefore rb diflunisal nn and cc indocin nn should md not rb be vb used vbn concomitantly rb
mechanism	34	42	in inpos a dt study nn in inpos normal jj volunteers nns it prp was vbd found vbn that inpos chronic jj concurrent jj administration nn of inpos float cd g nn of inpos aspirin nn per inpos day nn decreases vbz indomethacin nn blood nn levels nns approximately rb num cd
advise	8	14	the dt concomitant jj use nn of inpos indocin nn with inpos other jj nsaids nn is vbz not rb recommended vbn due inpos to topos the dt increased vbn possibility nn of inpos gastrointestinal jj toxicity nn with inpos little jj or cc no dt increase nn in inpos efficacy nn
false	10	26	clinical jj studies nns have vbp shown vbn that inpos indocin nn does vbz not rb influence vb the dt hypoprothrombinemia nn produced vbn by inpos anticoagulants nn
advise	12	30	however rb when wrb any dt additional jj drug nn including vbg indocin nn is vbz added vbn to topos the dt treatment nn of inpos patients nns on inpos anticoagulant nn therapy nn the dt patients nns should md be vb observed vbn for inpos alterations nns of inpos the dt prothrombin nn time nn
effect	26	30	in inpos post_marketing jj experience nn bleeding nn has vbz been vbn reported vbn in inpos patients nns on inpos concomitant jj treatment nn with inpos anticoagulants nn and cc indocin nn
advise	10	14	caution nn should md be vb exercised vbn when wrb indocin nn and cc anticoagulants nn are vbp administered vbn concomitantly rb
mechanism	2	14	when wrb indocin nn is vbz given vbn to topos patients nns receiving vbg probenecid nn the dt plasma nn levels nns of inpos indomethacin nn are vbp likely jj to topos be vb increased vbn
false	2	24	when wrb indocin nn is vbz given vbn to topos patients nns receiving vbg probenecid nn the dt plasma nn levels nns of inpos indomethacin nn are vbp likely jj to topos be vb increased vbn
false	14	24	when wrb indocin nn is vbz given vbn to topos patients nns receiving vbg probenecid nn the dt plasma nn levels nns of inpos indomethacin nn are vbp likely jj to topos be vb increased vbn
advise	10	20	caution nn should md be vb used vbn if inpos indocin nn is vbz administered vbn simultaneously rb with inpos methotrexate nn
mechanism	0	20	indocin nn has vbz been vbn reported vbn to topos decrease vb the dt tubular jj secretion nn of inpos methotrexate nn and cc to topos potentiate vb its prp toxicity nn
effect	4	10	administration nn of inpos non_steroidal_anti_inflammatory_drugs nn concomitantly rb with inpos cyclosporine nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos cyclosporine_induced jj toxicity nn possibly rb due jj to topos decreased vbn synthesis nn of inpos renal jj prostacyclin nn
false	4	10	administration nn of inpos non_steroidal_anti_inflammatory_drugs nn concomitantly rb with inpos cyclosporine nn has vbz been vbn associated vbn with inpos an dt increase nn in inpos cyclosporine nn induced jj toxicity nn possibly rb due jj to topos decreased vbn synthesis nn of inpos renal jj prostacyclin nn
advise	0	18	nsaids nn should md be vb used vbn with inpos caution nn in inpos patients nns taking vbg cyclosporine nn and cc renal jj function nn should md be vb carefully rb monitored vbn
mechanism	2	24	capsules nns indocin nn num cd mg nn t.i.d. nn produced vbd a dt clinically rb relevant jj elevation nn of inpos plasma nn lithium nn and cc reduction nn in inpos renal jj lithium nn clearance nn in inpos psychiatric jj patients nns and cc normal jj subjects nns with inpos steady jj state nn plasma nn lithium nn concentrations nns
false	2	24	capsules nns indocin nn num cd mg nn t.i.d. nn produced vbd a dt clinically rb relevant jj elevation nn of inpos plasma nn lithium nn and cc reduction nn in inpos renal jj lithium nn clearance nn in inpos psychiatric jj patients nns and cc normal jj subjects nns with inpos steady jj state nn plasma nn lithium nn concentrations nns
false	2	24	capsules nns indocin nn num cd mg nn t.i.d. nn produced vbd a dt clinically rb relevant jj elevation nn of inpos plasma nn lithium nn and cc reduction nn in inpos renal jj lithium nn clearance nn in inpos psychiatric jj patients nns and cc normal jj subjects nns with inpos steady jj state nn plasma nn lithium nn concentrations nns
advise	8	12	as inpos a dt consequence nn when wrb indocin nn and cc lithium nn are vbp given vbn concomitantly rb the dt patient nn should md be vb carefully rb observed vbn for inpos signs nns of inpos lithium nn toxicity nn
false	8	12	as inpos a dt consequence nn when wrb indocin nn and cc lithium nn are vbp given vbn concomitantly rb the dt patient nn should md be vb carefully rb observed vbn for inpos signs nns of inpos lithium nn toxicity nn
mechanism	0	8	indocin nn given vbn concomitantly rb with inpos digoxin nn has vbz been vbn reported vbn to topos increase vb the dt serum nn concentration nn and cc prolong vb the dt half_life nn of inpos digoxin nn
false	0	8	indocin nn given vbn concomitantly rb with inpos digoxin nn has vbz been vbn reported vbn to topos increase vb the dt serum nn concentration nn and cc prolong vb the dt half_life nn of inpos digoxin nn
advise	4	8	therefore rb when wrb indocin nn and cc digoxin nn are vbp used vbn concomitantly rb serum nn digoxin nn levels nns should md be vb closely rb monitored vbn
false	4	8	therefore rb when wrb indocin nn and cc digoxin nn are vbp used vbn concomitantly rb serum nn digoxin nn levels nns should md be vb closely rb monitored vbn
effect	12	20	in inpos some dt patients nns the dt administration nn of inpos indocin nn can md reduce vb the dt loop nn thiazide nn bbbbb22_diuretics_eeeee22 nn
effect	12	20	in inpos some dt patients nns the dt administration nn of inpos indocin nn can md reduce vb the dt potassium_sparing nn thiazide nn bbbbb22_diuretics_eeeee22 nn
effect	12	20	in inpos some dt patients nns the dt administration nn of inpos indocin nn can md reduce vb the dt thiazide_diuretics nn
false	30	36	in inpos some dt patients nns the dt administration nn of inpos indocin nn can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
false	32	36	in inpos some dt patients nns the dt administration nn of inpos indocin nn can md reduce vb the dt diuretic jj natriuretic jj antihypertensive jj effects nns of inpos loop nn potassium_sparing nn and cc thiazide nn bbbbbcom_diuretics_eeeeecom nn
false	0	2	indomethacin nn diuretics nn are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic jj is vbz obtained vbn
false	0	2	indomethacin nn diuretics nns are vbp used vbn concomitantly rb the dt patient nn should md be vb observed vbn closely rb to topos determine vb if inpos the dt desired vbn effect nn of inpos the dt diuretic nn is vbz obtained vbn
false	0	30	indocin nn reduces vbz basal jj plasma nn renin nn activity nn as rb well rb as inpos those dt elevations nns of inpos pra nn induced vbn by inpos furosemide nn administration nn salt nn volume nn depletion nn
effect	16	28	it prp has vbz been vbn reported vbn that inpos the dt addition nn of inpos triamterene nn to topos a dt maintenance nn schedule nn of inpos indocin nn resulted vbd in inpos reversible jj acute jj renal jj failure nn in inpos num cd of inpos num cd healthy jj volunteers nns
advise	0	4	indocin nn and cc triamterene nn should md not rb be vb administered vbn together rb
false	0	4	indocin nn and cc potassium_sparing_diuretics nn each dt may md be vb associated vbn with inpos increased vbn serum nn potassium nn levels nns
effect	8	12	the dt potential jj effects nns of inpos indocin nn and cc potassium_sparing_diuretics nn on inpos potassium nn kinetics nns and cc renal jj function nn should md be vb considered vbn when wrb these dt agents nns are vbp administered vbn concurrently rb
effect	12	44	most jjs of inpos the dt above jj effects nns concerning vbg diuretics nn have vbp been vbn attributed vbn at inpos least jjs in inpos part nn to topos mechanisms nns involving vbg inhibition nn of inpos prostaglandin nn synthesis nn by inpos indocin nn
effect	12	16	blunting nn of inpos the dt antihypertensive jj effect nn of inpos b_adrenoceptor_blocking_agents nn by inpos non_steroidal_antiinflammatory_drugs nn including vbg indocin nn has vbz been vbn reported vbn
effect	12	20	blunting nn of inpos the dt antihypertensive jj effect nn of inpos b_adrenoceptor_blocking_agents nn by inpos non_steroidal_antiinflammatory_drugs nns including vbg indocin nn has vbz been vbn reported vbn
false	16	20	blunting nn of inpos the dt antihypertensive jj effect nn of inpos b_adrenoceptor_blocking_agents nns by inpos non_steroidal_antiinflammatory_drugs nn including vbg indocin nn has vbz been vbn reported vbn
effect	0	14	indocin nn can md reduce vb the dt antihypertensive jj effects nns of inpos captopril nn and cc losartan nn
effect	0	18	indocin nn can md reduce vb the dt antihypertensive jj effects nns of inpos captopril nn and cc losartan nn
false	14	18	indocin nn can md reduce vb the dt antihypertensive jj effects nns of inpos captopril nn and cc losartan nn
effect	6	10	concurrent jj administration nn of inpos etanercept nn and cc anakinra nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns and cc increased vbn risk nn of inpos neutropenia nn and cc no dt additional jj benefit nn compared vbn to topos these dt medicinal jj products nns alone rb
false	6	10	concurrent jj administration nn of inpos etanercept nn and cc interleukin_num_antagonist nn has vbz been vbn associated vbn with inpos an dt increased vbn risk nn of inpos serious jj infections nns and cc increased vbn risk nn of inpos neutropenia nn and cc no dt additional jj benefit nn compared vbn to topos these dt medicinal jj products nns alone rb
effect	2	12	other jj tnfa_blocking_agents nn used vbn in inpos combination nn with inpos anakinra nn may md also rb result vb in inpos similar jj toxicities nns
effect	2	12	other jj remicade nn used vbn in inpos combination nn with inpos anakinra nn may md also rb result vb in inpos similar jj toxicities nns
false	12	16	in inpos rheumatoid jj arthritis nn concomitant jj medications nns besides inpos mtx nn were vbd nonsteroidal_anti_inflammatory_agents cc narcotics nns
false	12	18	in inpos rheumatoid jj arthritis nn concomitant jj medications nns besides inpos mtx nn were vbd nonsteroidal_anti_inflammatory_agents nns folic_acid nn corticosteroids nns and_or cc narcotics nns
false	12	16	in inpos rheumatoid jj arthritis nn concomitant jj medications nns besides inpos mtx nn were vbd corticosteroids cc narcotics nns
false	12	24	in inpos rheumatoid jj arthritis nn concomitant jj medications nns besides inpos mtx nn were vbd nonsteroidal_anti_inflammatory_agents nns folic_acid nn corticosteroids nns and_or cc narcotics nn
false	16	18	in inpos rheumatoid jj arthritis nn concomitant jj medications nns besides inpos mtx nn were vbd nonsteroidal_anti_inflammatory_agents cc narcotics nn
false	18	24	in inpos rheumatoid jj arthritis nn concomitant jj medications nns besides inpos mtx nn were vbd nonsteroidal_anti_inflammatory_agents nns folic_acid nn corticosteroids nns and_or cc narcotics nn
false	20	24	in inpos rheumatoid jj arthritis nn concomitant jj medications nns besides inpos mtx nn were vbd nonsteroidal_anti_inflammatory_agents nns folic_acid nn corticosteroids nn and_or cc narcotics nn
false	14	16	concomitant jj crohn nn s vbz disease nn medications nns were vbd antibiotics nns antivirals nn corticosteroids nn aza nnp and cc aminosalicylates vbz
false	16	30	in inpos psoriatic jj arthritis nn clinical jj trials nns concomitant jj medications nns included vbd mtx nn in inpos approximately rb half nn of inpos the dt patients nns nonsteroidal_anti_inflammatory_agents nns
false	16	30	in inpos psoriatic jj arthritis nn clinical jj trials nns concomitant jj medications nns included vbd mtx nn in inpos approximately rb half nn of inpos the dt patients nns folic_acid nns
false	16	30	in inpos psoriatic jj arthritis nn clinical jj trials nns concomitant jj medications nns included vbd mtx nn in inpos approximately rb half nn of inpos the dt patients nns corticosteroids nn
false	2	40	serum nn infliximab nn concentrations nns appeared vbd to topos be vb unaffected jj by inpos baseline nn use nn of inpos medications nns for inpos the dt treatment nn of inpos crohn nn s vbz disease nn including vbg corticosteroids vbz
false	2	42	serum nn infliximab nn concentrations nns appeared vbd to topos be vb unaffected jj by inpos baseline nn use nn of inpos medications nns for inpos the dt treatment nn of inpos crohn nn s nn disease nn including vbg corticosteroids nns antibiotics nn and cc aminosalicylates vbz
false	2	42	serum nn infliximab nn concentrations nns appeared vbd to topos be vb unaffected jj by inpos baseline nn use nn of inpos medications nns for inpos the dt treatment nn of inpos crohn nn s nn disease nn including vbg corticosteroids nns metronidazole nn and cc aminosalicylates vbz
false	2	42	serum nn infliximab nn concentrations nns appeared vbd to topos be vb unaffected jj by inpos baseline nn use nn of inpos medications nns for inpos the dt treatment nn of inpos crohn nn s nn disease nn including vbg corticosteroids nns ciprofloxacin nn and cc aminosalicylates vbz
false	40	42	serum nn infliximab nn concentrations nns appeared vbd to topos be vb unaffected jj by inpos baseline nn use nn of inpos medications nns for inpos the dt treatment nn of inpos crohn nn s nn disease nn including vbg corticosteroids nn antibiotics nn and cc aminosalicylates vbz
false	40	42	serum nn infliximab nn concentrations nns appeared vbd to topos be vb unaffected jj by inpos baseline nn use nn of inpos medications nns for inpos the dt treatment nn of inpos crohn nn s nn disease nn including vbg corticosteroids nn metronidazole nn and cc aminosalicylates vbz
false	40	42	serum nn infliximab nn concentrations nns appeared vbd to topos be vb unaffected jj by inpos baseline nn use nn of inpos medications nns for inpos the dt treatment nn of inpos crohn nn s nn disease nn including vbg corticosteroids nn ciprofloxacin nn and cc aminosalicylates vbz
false	38	42	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetes nns products nns ace_inhibitors nn mao_inhibitors nns propoxyphene nns
false	38	42	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetes nns products nns ace_inhibitors nn mao_inhibitors nns somatostatin_analog nns
false	38	42	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetes nns products nns ace_inhibitors nn mao_inhibitors nns octreotide nns
false	38	42	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetes nns products nns ace_inhibitors nn mao_inhibitors nns sulfonamide_antibiotics nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns diuretics nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns sympathomimetic_agents nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns epinephrine nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns albuterol nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns terbutaline nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns isoniazid nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns phenothiazine_derivatives nns
false	26	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns thyroid_hormones nn estrogens nns progestogens nns
false	26	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns estrogens nns
false	26	46	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	26	54	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	28	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn phenothiazine_derivatives nns estrogens nns
false	30	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn danazol nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns diuretics nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns diuretics nn phenothiazine_derivatives nns estrogens nns
false	30	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns diuretics nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn diuretics nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns sympathomimetic_agents nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns sympathomimetic_agents nn phenothiazine_derivatives nns thyroid_hormones nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns sympathomimetic_agents nn phenothiazine_derivatives nns estrogens nns
false	30	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns sympathomimetic_agents nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn sympathomimetic_agents nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns epinephrine nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns epinephrine nn phenothiazine_derivatives nns thyroid_hormones nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns epinephrine nn phenothiazine_derivatives nns estrogens nns
false	30	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns epinephrine nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn epinephrine nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns albuterol nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns albuterol nn phenothiazine_derivatives nns thyroid_hormones nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns albuterol nn phenothiazine_derivatives nns estrogens nns
false	30	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns albuterol nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn albuterol nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns terbutaline nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns terbutaline nn phenothiazine_derivatives nns thyroid_hormones nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns terbutaline nn phenothiazine_derivatives nns estrogens nns
false	30	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns terbutaline nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn terbutaline nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns isoniazid nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns isoniazid nn phenothiazine_derivatives nns estrogens nns
false	30	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns isoniazid nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn isoniazid nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	32	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns phenothiazine_derivatives nns progestogens nn
false	30	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns phenothiazine_derivatives nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	40	42	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns somatropin nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn somatropin nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	30	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns thyroid_hormones nn estrogens nns progestogens nn
false	28	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn thyroid_hormones nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	40	48	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns estrogens nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	46	54	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn corticosteroids nns danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn lrb_e.g. fw in inpos oral jj contraceptives nn
effect	0	20	b_blockers nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
effect	2	22	b_blockers nns clonidine nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
effect	2	22	b_blockers nns lithium nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
effect	2	22	b_blockers nns alcohol nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
false	34	36	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nn disopyramide nn fibrates nns fluoxetine nn monoamine_oxidase_mao_inhibitors nns propoxyphene nn salicylates nns somatostatin_analog nn sulfonamide_antibiotics nns
false	34	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nns disopyramide nns
false	34	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nns fluoxetine nns
false	34	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nns monoamine_oxidase_mao_inhibitors nns
false	34	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nns propoxyphene nns
false	34	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nns somatostatin_analog nns
false	34	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nns octreotide nns
false	34	38	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nn ace_inhibitors nns sulfonamide_antibiotics nn
false	36	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nns ace_inhibitors nn monoamine_oxidase_mao_inhibitors nns propoxyphene nns
false	36	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nns ace_inhibitors nn monoamine_oxidase_mao_inhibitors nns somatostatin_analog nns
false	36	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nns ace_inhibitors nn monoamine_oxidase_mao_inhibitors nns octreotide nns
false	36	40	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md increase vb the dt blood_glucose_lowering jj effect nn and cc susceptibility nn to topos hypoglycemia nn oral jj antidiabetic_products nns ace_inhibitors nn monoamine_oxidase_mao_inhibitors nns sulfonamide_antibiotics nn
false	24	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nn phenothiazine_derivatives nns somatropin nns progestogens nns
false	24	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn
false	24	32	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns niacin nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns niacin nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns danazol nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns danazol nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns diuretics nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns diuretics nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns sympathomimetic_agents nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns sympathomimetic_agents nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns epinephrine nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns epinephrine nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns salbutamol nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns salbutamol nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns terbutaline nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns terbutaline nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns isoniazid nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns isoniazid nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns phenothiazine_derivatives nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns phenothiazine_derivatives nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	28	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns somatropin nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns somatropin nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	30	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns thyroid_hormones nn estrogens nns progestogens nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns thyroid_hormones nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	26	34	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns estrogens nns lrb_e.g. fw in inpos oral jj contraceptives nn
false	44	52	the dt following vbg are vbp examples nns of inpos substances nns that wdt may md reduce vb the dt blood_glucose_lowering jj effect nn corticosteroids nns niacin nn danazol nn diuretics nns sympathomimetic_agents nns isoniazid nn phenothiazine_derivatives nns somatropin nn thyroid_hormones nns estrogens nns progestogens nn lrb_e.g. fw in inpos oral jj contraceptives nn
effect	0	20	b_blockers nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
effect	2	22	b_blockers nns clonidine nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
effect	2	22	b_blockers nns lithium nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
effect	2	22	b_blockers nns alcohol nn may md either cc potentiate vb or cc weaken vb the dt blood_glucose_lowering jj effect nn of inpos insulin nn
false	20	24	a dt clinical jj study nn in inpos healthy jj male jj volunteers nns demonstrated vbd that inpos mixing vbg novolog nn with inpos nph_human_insulin nn immediately rb before inpos injection nn produced vbd some dt attenuation nn in inpos the dt peak jj concentration nn of inpos novolog nnp but cc that inpos the dt time nn to topos peak vb and cc the dt total jj bioavailability nn of inpos novolog nn were vbd not rb significantly rb affected vbn
false	24	20	a dt clinical jj study nn in inpos healthy jj male jj volunteers nns demonstrated vbd that inpos mixing vbg novolog nnp with inpos nph_human_insulin nn immediately rb before inpos injection nn produced vbd some dt attenuation nn in inpos the dt peak jj concentration nn of inpos novolog nn but cc that inpos the dt time nn to topos peak vb and cc the dt total jj bioavailability nn of inpos novolog nn were vbd not rb significantly rb affected vbn
false	24	20	a dt clinical jj study nn in inpos healthy jj male jj volunteers nns demonstrated vbd that inpos mixing vbg novolog nnp with inpos nph_human_insulin nn immediately rb before inpos injection nn produced vbd some dt attenuation nn in inpos the dt peak jj concentration nn of inpos novolog nnp but cc that inpos the dt time nn to topos peak vb and cc the dt total jj bioavailability nn of inpos novolog nn were vbd not rb significantly rb affected vbn
false	2	10	if inpos novolog nn is vbz mixed vbn with inpos nph_human_insulin nn novolog nnp should md be vb drawn vbn into inpos the dt syringe nn first rb
false	10	2	if inpos novolog nnp is vbz mixed vbn with inpos nph_human_insulin nn novolog nn should md be vb drawn vbn into inpos the dt syringe nn first rb
false	18	24	because inpos there ex are vbp no dt data nns on inpos the dt compatibility nn of inpos novolog nn and cc crystalline nn zinc_insulin nn preparations nns novolog nnp should md not rb be vb mixed vbn with inpos these dt preparations nns
false	24	18	because inpos there ex are vbp no dt data nns on inpos the dt compatibility nn of inpos novolog nn and cc crystalline nn zinc_insulin nn preparations nns novolog nn should md not rb be vb mixed vbn with inpos these dt preparations nns
false	8	12	the dt effects nns of inpos mixing vbg novolog nn with inpos insulins nn of inpos animal nn source nn or cc insulin nn preparations nns produced vbn by inpos other jj manufacturers nns have vbp not rb been vbn studied vbn
false	8	12	the dt effects nns of inpos mixing vbg novolog nn with inpos insulins nns of inpos animal nn source nn or cc insulin nn preparations nns produced vbn by inpos other jj manufacturers nns have vbp not rb been vbn studied vbn
false	16	18	when wrb used vbn in inpos external jj subcutaneous jj infusion nn pumps nns for inpos insulin nn novolog nn should md not rb be vb mixed vbn with inpos any dt other jj insulins nns or cc diluent jj
false	18	34	when wrb used vbn in inpos external jj subcutaneous jj infusion nn pumps nns for inpos insulin nn novolog nn should md not rb be vb mixed vbn with inpos any dt other jj insulins nn or cc diluent jj
false	30	34	although inpos studies nns designed vbn to topos examine vb drug nn interactions nns have vbp not rb been vbn done vbn it prp was vbd noted vbn that inpos corticosteroid nn or cc acth nn treatment nn of inpos relapses nns for inpos periods nns of inpos up inpos to topos num cd days nns has vbz been vbn administered vbn to topos patients nns receiving vbg betaseron nn
false	30	68	although inpos studies nns designed vbn to topos examine vb drug nn interactions nns have vbp not rb been vbn done vbn it prp was vbd noted vbn that inpos corticosteroid nn or cc acth nn treatment nn of inpos relapses nns for inpos periods nns of inpos up inpos to topos num cd days nns has vbz been vbn administered vbn to topos patients nns receiving vbg betaseron nn
false	34	68	although inpos studies nns designed vbn to topos examine vb drug nn interactions nns have vbp not rb been vbn done vbn it prp was vbd noted vbn that inpos corticosteroid nn or cc acth nn treatment nn of inpos relapses nns for inpos periods nns of inpos up inpos to topos num cd days nns has vbz been vbn administered vbn to topos patients nns receiving vbg betaseron nn
mechanism	0	44	betaseron nn administration nn to topos num cd cancer nn patients nns over inpos a dt dose nn range nn of inpos float cd mg nn to topos float cd mg nn led vbd to topos a dt dose_dependent jj inhibition nn of inpos antipyrine nn elimination.14 nn the dt effect nn of inpos alternate_day jj administration nn of inpos float cd mg nn of inpos betaseron nn on inpos drug nn metabolism nn in inpos ms nn patients nns is vbz unknown jj
false	44	0	betaseron nn administration nn to topos num cd cancer nn patients nns over inpos a dt dose nn range nn of inpos float cd mg nn to topos float cd mg nn led vbd to topos a dt dose_dependent jj inhibition nn of inpos antipyrine nn elimination.14 nn the dt effect nn of inpos alternate_day jj administration nn of inpos float cd mg nn of inpos betaseron nn on inpos drug nn metabolism nn in inpos ms nn patients nns is vbz unknown jj
false	0	22	atrovent nn inhalation nnp aerosol nnp has vbz been vbn used vbn concomitantly rb with inpos other jj drugs nns including vbg sympathomimetic_bronchodilators nns commonly rb used vbn in inpos the dt treatment nn of inpos chronic jj obstructive jj pulmonary jj disease nn
false	0	22	atrovent nn inhalation nnp aerosol nnp has vbz been vbn used vbn concomitantly rb with inpos other jj drugs nns including vbg methylxanthines nns commonly rb used vbn in inpos the dt treatment nn of inpos chronic jj obstructive jj pulmonary jj disease nn
false	0	22	atrovent nn inhalation nnp aerosol nnp has vbz been vbn used vbn concomitantly rb with inpos other jj drugs nns including vbg steroids nn commonly rb used vbn in inpos the dt treatment nn of inpos chronic jj obstructive jj pulmonary jj disease nn
false	8	32	with inpos the dt exception nn of inpos albuterol nn there ex are vbp no dt formal jj studies nns fully rb evaluating vbg the dt interaction nn effects nns of inpos atrovent nn inhalation nn aerosol nn and cc these dt drugs nns with inpos respect nn to topos effectiveness nn
effect	2	40	although inpos ipratropium_bromide nn is vbz minimally rb absorbed vbn into inpos the dt systemic jj circulation nn there ex is vbz some dt potential nn for inpos an dt additive jj interaction nn with inpos concomitantly rb used vbn anticholinergic_medications nn
advise	16	26	caution nn is vbz therefore rb advised vbn in inpos the dt coadministration nn of inpos atrovent nn inhalation nn aerosol nn with inpos other jj anticholinergic nn containing jj drugs nns
false	16	26	however rb in inpos clinical jj studies nns the dt consequences nns of inpos concomitant jj irbesartan nn on inpos the dt pharmacodynamics nns of inpos warfarin nn were vbd negligible jj
false	18	20	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos warfarin nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	18	52	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos warfarin nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	18	20	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos hydrochlorothiazide nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	18	44	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos hydrochlorothiazide nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	18	52	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos hydrochlorothiazide nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	18	20	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos digoxin nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	18	44	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos digoxin nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	24	18	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos warfarin nn hydrochlorothiazide nn digoxin nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	24	22	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos warfarin nn hydrochlorothiazide nn digoxin nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	18	22	in inpos separate jj studies nns of inpos patients nns receiving vbg maintenance nn doses nns of inpos warfarin nn hydrochlorothiazide nn digoxin nn irbesartan nn administration nn for inpos num cd days nns had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos warfarin nn or cc pharmacokinetics nns of inpos digoxin nn
false	6	20	the dt pharmacokinetics nns of inpos irbesartan nn were vbd not rb affected vbn by inpos coadministration nn of inpos nifedipine nn or cc hydrochlorothiazide nn
false	6	24	the dt pharmacokinetics nns of inpos irbesartan nn were vbd not rb affected vbn by inpos coadministration nn of inpos nifedipine nn or cc hydrochlorothiazide nn
false	20	24	the dt pharmacokinetics nns of inpos irbesartan nn were vbd not rb affected vbn by inpos coadministration nn of inpos nifedipine nn or cc hydrochlorothiazide nn
effect	8	36	the dt adverse jj effects nns of inpos camptosar nn such jj as inpos myelosuppression nn and cc diarrhea nn would md be vb expected vbn to topos be vb exacerbated vbn by inpos other jj antineoplastic_agents nn having vbg similar jj adverse jj effects nns
effect	14	32	lymphocytopenia nnp has vbz been vbn reported vbn in inpos patients nns receiving vbg camptosar nn and cc it prp is vbz possible jj that inpos the dt administration nn of inpos dexamethasone nn as inpos antiemetic jj prophylaxis nn may md have vb enhanced vbn the dt likelihood nn of inpos this dt effect nn
effect	30	46	the dt incidence nn of inpos akathisia nn in inpos clinical jj trials nns of inpos the dt weekly jj dosage nn schedule nn was vbd greater jjr when wrb prochlorperazine nn was vbd administered vbn on inpos the dt same jj day nn as inpos camptosar nn than inpos when wrb these dt drugs nns were vbd given vbn on inpos separate jj days nns
effect	10	20	it prp would md be vb expected vbn that inpos laxative nn use nn during inpos therapy nn with inpos camptosar nn would md worsen vb the dt incidence nn or cc severity nn of inpos diarrhea nn but cc this dt has vbz not rb been vbn studied vbn
false	30	44	in inpos view nn of inpos the dt potential jj risk nn of inpos dehydration nn secondary jj to topos vomiting vbg and_or cc diarrhea nn induced vbn by inpos camptosar nn the dt physician nn may md wish vb to topos withhold vb diuretics nn during inpos dosing nn with inpos camptosar nn and cc certainly rb during inpos periods nns of inpos active jj vomiting nn or cc diarrhea nn
effect	44	30	in inpos view nn of inpos the dt potential jj risk nn of inpos dehydration nn secondary jj to topos vomiting vbg and_or cc diarrhea nn induced vbn by inpos camptosar nn the dt physician nn may md wish vb to topos withhold vb diuretics nn during inpos dosing nn with inpos camptosar nn and cc certainly rb during inpos periods nns of inpos active jj vomiting nn or cc diarrhea nn
advise	0	18	isocarboxazid nn should md be vb administered vbn with inpos caution nn to topos patients nns receiving vbg antabuse nn
advise	0	18	isocarboxazid nn should md be vb administered vbn with inpos caution nn to topos patients nns receiving vbg disulfiram nn
effect	22	26	in inpos a dt single jj study nn rats nns given vbn high jj intraperitoneal jj doses nns of inpos an dt mao_inhibitor nn plus cc disulfiram nn experienced vbd severe jj toxicity nn including vbg convulsions nns and cc death nn
advise	6	12	concomitant jj use nn of inpos isocarboxazid nn and cc other jj psychotropic_agents nn is vbz generally rb not rb recommended vbn because inpos of inpos possible jj potentiating vbg effects nns
false	10	32	may md interact vb with inpos the dt following nn b_adrenergic_blocking_agents nn lrb_these dt medicines nns may md make vb your prp condition nn worse jjr and cc prevent vb the dt adrenergic_bronchodilators nn from inpos working vbg properly rb rrb_disopyramide nn quinidine nn phenothiazines nns procainamide nn
false	32	40	may md interact vb with inpos the dt following nn b_adrenergic_blocking_agents nns lrb_these dt medicines nns may md make vb your prp condition nn worse jjr and cc prevent vb the dt adrenergic_bronchodilators nn from inpos working vbg properly rb rrb_disopyramide nn
false	32	40	may md interact vb with inpos the dt following nn b_adrenergic_blocking_agents nns lrb_these dt medicines nns may md make vb your prp condition nn worse jjr and cc prevent vb the dt adrenergic_bronchodilators nn from inpos working vbg properly rb rrb_quinidine nn
false	32	40	may md interact vb with inpos the dt following nn b_adrenergic_blocking_agents nns lrb_these dt medicines nns may md make vb your prp condition nn worse jjr and cc prevent vb the dt adrenergic_bronchodilators nn from inpos working vbg properly rb rrb_phenothiazines nn
false	32	40	may md interact vb with inpos the dt following nn b_adrenergic_blocking_agents nns lrb_these dt medicines nns may md make vb your prp condition nn worse jjr and cc prevent vb the dt adrenergic_bronchodilators nn from inpos working vbg properly rb rrb_procainamide nn
effect	0	16	isoflurane nn potentiates vbz the dt muscle nn relaxant jj effect nn of inpos all dt muscle_relaxants nn most rbs notably rb nondepolarizing_muscle_relaxants nns and cc mac nnp is vbz reduced vbn by inpos concomitant jj administration nn of inpos n nn 2o nn
effect	0	22	isoflurane nn potentiates vbz the dt muscle nn relaxant jj effect nn of inpos all dt muscle_relaxants nns most rbs notably rb nondepolarizing_muscle_relaxants nn and cc mac nnp is vbz reduced vbn by inpos concomitant jj administration nn of inpos n nn 2o nn
effect	8	24	a dt report nn of inpos severe jj acetaminophen nn toxicity nn was vbd reported vbn in inpos a dt patient nn receiving vbg isoniazid nn
effect	30	34	it prp is vbz believed vbn that inpos the dt toxicity nn may md have vb resulted vbn from inpos a dt previously rb unrecognized jj interaction nn between inpos isoniazid nn and cc acetaminophen nn and cc a dt molecular jj basis nn for inpos this dt interaction nn has vbz been vbn proposed vbn
mechanism	12	54	furthermore rb it prp has vbz been vbn proposed vbn that inpos isoniazid nn resulted vbd in inpos induction nn of inpos p_450iie1 nn in inpos the dt patients nns liver nn which wdt in inpos turn nn resulted vbd in inpos a dt greater jjr proportion nn of inpos the dt ingested vbn acetaminophen nn being vbg converted vbn to topos the dt toxic jj metabolites nns
mechanism	0	16	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nn signs nns symptoms nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	0	16	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine nn levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nn signs nns symptoms nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	0	16	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nn signs nns symptoms nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	0	80	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nn signs nns symptoms nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	16	0	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	16	80	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nn signs nns symptoms nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
advise	16	0	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine nn levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	16	80	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine nn levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nn signs nns symptoms nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	0	16	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	0	76	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	16	80	isoniazid nn is vbz known vbn to topos slow vb the dt metabolism nn of inpos carbamazepine nn and cc increase vb its prp serum nn levels nns carbamazepine vbp levels nns should md be vb determined vbn prior jj to topos concurrent jj administration nn with inpos isoniazid nn signs nns symptoms nns of inpos carbamazepine nn toxicity nn should md be vb monitored vbn closely rb and cc appropriate jj dosage nn adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
false	0	12	ketoconazole nn potential jj interaction nn of inpos ketoconazole nn and cc isoniazid nn may md exist vb
int	6	10	potential jj interaction nn of inpos ketoconazole nn and cc isoniazid nn may md exist vb
mechanism	0	12	isoniazid nn may md increase vb serum nn levels nns of inpos phenytoin nn
false	4	16	to topos avoid vb phenytoin nn intoxication nn appropriate jj adjustment nn of inpos the dt anticonvulsant nn should md be vb made vbn
mechanism	18	22	a dt recent jj study nn has vbz shown vbn that inpos concomitan jj administration nn of inpos isoniazid nn and cc theophylline nn may md cause vb elevated jj plasma nn levels nns of inpos theophylline nn and cc in inpos some dt instances nns a dt slight jj decrease nn in inpos the dt elimination nn of inpos isoniazid nn
false	18	22	a dt recent jj study nn has vbz shown vbn that inpos concomitan jj administration nn of inpos isoniazid nn and cc theophylline nn may md cause vb elevated jj plasma nn levels nns of inpos theophylline nn and cc in inpos some dt instances nns a dt slight jj decrease nn in inpos the dt elimination nn of inpos isoniazid nn
false	22	18	a dt recent jj study nn has vbz shown vbn that inpos concomitan jj administration nn of inpos isoniazid nn and cc theophylline nn may md cause vb elevated jj plasma nn levels nns of inpos theophylline nn and cc in inpos some dt instances nns a dt slight jj decrease nn in inpos the dt elimination nn of inpos isoniazid nn
false	22	18	a dt recent jj study nn has vbz shown vbn that inpos concomitan jj administration nn of inpos isoniazid nn and cc theophylline nn may md cause vb elevated jj plasma nn levels nns of inpos theophylline nn and cc in inpos some dt instances nns a dt slight jj decrease nn in inpos the dt elimination nn of inpos isoniazid nn
mechanism	28	38	a dt recent jj case nn study nn has vbz shown vbn a dt possible jj increase nn in inpos the dt plasma nn level nn of inpos valproate nn when wrb co nn administered vbn with inpos isoniazid nn
false	2	14	plasma nn valproate nn concentration nn should md be vb monitored vbn when wrb isoniazid nn and cc valproate nn are vbp co nn administered vbn and cc appropriate jj dosage nn adjustments nns of inpos valproate nn should md be vb made vbn
advise	14	2	plasma nn valproate nn concentration nn should md be vb monitored vbn when wrb isoniazid nn and cc valproate nn are vbp co nn administered vbn and cc appropriate jj dosage nn adjustments nns of inpos valproate nn should md be vb made vbn
false	14	2	plasma nn valproate nn concentration nn should md be vb monitored vbn when wrb isoniazid nn and cc valproate nn are vbp co nn administered vbn and cc appropriate jj dosage nn adjustments nns of inpos valproate nn should md be vb made vbn
advise	0	6	isoproterenol_hydrochloride nn injection nn and cc epinephrine nn should md not rb be vb administered vbn simultaneously rb because inpos both dt drugs nns are vbp direct jj cardiac jj stimulants nns and cc their prp combined vbn effects nns may md induce vb serious jj arrhythmias nns
advise	0	24	isuprel nn should md be vb used vbn with inpos caution nn if inpos at inpos all dt when wrb potent jj inhalational jj anesthetics nn such jj as inpos halothane nn are vbp employed vbn because inpos of inpos potential nn to topos sensitize vb the dt myocardium nn to topos effects nns of inpos sympathomimetic_amines nns
advise	0	30	isuprel nn should md be vb used vbn with inpos caution nn if inpos at inpos all dt when wrb potent jj inhalational jj anesthetics nns such jj as inpos halothane nn are vbp employed vbn because inpos of inpos potential nn to topos sensitize vb the dt myocardium nn to topos effects nns of inpos sympathomimetic_amines nns
false	0	56	isuprel nn should md be vb used vbn with inpos caution nn if inpos at inpos all dt when wrb potent jj inhalational jj anesthetics nns such jj as inpos halothane nn are vbp employed vbn because inpos of inpos potential nn to topos sensitize vb the dt myocardium nn to topos effects nns of inpos sympathomimetic_amines nn
false	24	30	isuprel nn should md be vb used vbn with inpos caution nn if inpos at inpos all dt when wrb potent jj inhalational jj anesthetics nn such jj as inpos halothane nn are vbp employed vbn because inpos of inpos potential nn to topos sensitize vb the dt myocardium nn to topos effects nns of inpos sympathomimetic_amines nns
false	24	56	isuprel nn should md be vb used vbn with inpos caution nn if inpos at inpos all dt when wrb potent jj inhalational jj anesthetics nn such jj as inpos halothane nn are vbp employed vbn because inpos of inpos potential nn to topos sensitize vb the dt myocardium nn to topos effects nns of inpos sympathomimetic_amines nn
false	30	56	isuprel nn should md be vb used vbn with inpos caution nn if inpos at inpos all dt when wrb potent jj inhalational jj anesthetics nns such jj as inpos halothane nn are vbp employed vbn because inpos of inpos potential nn to topos sensitize vb the dt myocardium nn to topos effects nns of inpos sympathomimetic_amines nn
effect	8	24	the dt vasodilating vbg effects nns of inpos isosorbide_dinitrate nn may md be vb additive jj with inpos those dt of inpos other jj vasodilators nn
effect	8	24	the dt vasodilating vbg effects nns of inpos isosorbide_mononitrate nn may md be vb additive jj with inpos those dt of inpos other jj vasodilators nn
effect	16	20	marked jj symptomatic jj orthostatic jj hypotension nn has vbz been vbn reported vbn when wrb calcium_channel_blockers nn and cc organic_nitrates nn were vbd used vbn in inpos combination nn
effect	10	14	because inpos of inpos the dt relationship nn of inpos accutane nn to topos vitamin_a nn patients nns should md be vb advised vbn against inpos taking vbg vitamin_supplements nns containing vbg vitamin_a nn to topos avoid vb additive jj toxic jj effects nns
false	10	28	because inpos of inpos the dt relationship nn of inpos accutane nn to topos vitamin_a nn patients nns should md be vb advised vbn against inpos taking vbg vitamin_supplements nn containing vbg vitamin_a nn to topos avoid vb additive jj toxic jj effects nns
false	10	14	because inpos of inpos the dt relationship nn of inpos accutane nn to topos vitamin_a nn patients nns should md be vb advised vbn against inpos taking vbg vitamin_supplements nns containing vbg vitamin_a nn to topos avoid vb additive jj toxic jj effects nns
false	14	28	because inpos of inpos the dt relationship nn of inpos accutane nn to topos vitamin_a nn patients nns should md be vb advised vbn against inpos taking vbg vitamin_supplements nn containing vbg vitamin_a nn to topos avoid vb additive jj toxic jj effects nns
false	28	14	because inpos of inpos the dt relationship nn of inpos accutane nn to topos vitamin_a nn patients nns should md be vb advised vbn against inpos taking vbg vitamin_supplements nn containing vbg vitamin_a nn to topos avoid vb additive jj toxic jj effects nns
false	0	8	tetracyclines nn concomitant jj treatment nn with inpos accutane nn and cc tetracyclines nns should md be vb avoided vbn because inpos accutane nnp use nn has vbz been vbn associated vbn with inpos a dt number nn of inpos cases nns of inpos pseudotumor nn cerebri nn some dt of inpos which wdt involved vbd concomitant jj use nn of inpos tetracyclines nns
false	0	8	tetracyclines nn concomitant jj treatment nn with inpos accutane nn and cc tetracyclines nns should md be vb avoided vbn because inpos accutane nn use nn has vbz been vbn associated vbn with inpos a dt number nn of inpos cases nns of inpos pseudotumor nn cerebri nn some dt of inpos which wdt involved vbd concomitant jj use nn of inpos tetracyclines nns
advise	6	10	concomitant jj treatment nn with inpos accutane nn and cc tetracyclines nn should md be vb avoided vbn because inpos accutane nnp use nn has vbz been vbn associated vbn with inpos a dt number nn of inpos cases nns of inpos pseudotumor nn cerebri nn some dt of inpos which wdt involved vbd concomitant jj use nn of inpos tetracyclines nns
false	6	10	concomitant jj treatment nn with inpos accutane nn and cc tetracyclines nns should md be vb avoided vbn because inpos accutane nnp use nn has vbz been vbn associated vbn with inpos a dt number nn of inpos cases nns of inpos pseudotumor nn cerebri nn some dt of inpos which wdt involved vbd concomitant jj use nn of inpos tetracyclines nn
false	10	6	concomitant jj treatment nn with inpos accutane nn and cc tetracyclines nn should md be vb avoided vbn because inpos accutane nn use nn has vbz been vbn associated vbn with inpos a dt number nn of inpos cases nns of inpos pseudotumor nn cerebri nn some dt of inpos which wdt involved vbd concomitant jj use nn of inpos tetracyclines nns
effect	6	10	concomitant jj treatment nn with inpos accutane nn and cc tetracyclines nns should md be vb avoided vbn because inpos accutane nn use nn has vbz been vbn associated vbn with inpos a dt number nn of inpos cases nns of inpos pseudotumor nn cerebri nn some dt of inpos which wdt involved vbd concomitant jj use nn of inpos tetracyclines nn
false	2	24	micro_dosed jj progesterone nn preparations nns micro_dosed jj progesterone nn preparations nns lrb_minipills nns that wdt do vbp not rb contain vb an dt estrogen nn rrb_may md be vb an dt inadequate jj method nn of inpos contraception nn during inpos accutane nn therapy nn
false	2	24	micro_dosed jj progesterone nn preparations nns micro_dosed jj progesterone nn preparations nns lrb_minipills nns that wdt do vbp not rb contain vb an dt estrogen nn rrb_may md be vb an dt inadequate jj method nn of inpos contraception nn during inpos accutane nn therapy nn
effect	2	22	micro_dosed jj progesterone nn preparations nns may md be vb an dt inadequate jj method nn of inpos contraception nn during inpos accutane nn therapy nn
false	24	42	micro_dosed jj progesterone nn preparations nns micro_dosed jj progesterone nn preparations nns lrb_minipills nns that wdt do vbp not rb contain vb an dt estrogen nn rrb_may md be vb an dt inadequate jj method nn of inpos contraception nn during inpos accutane nn therapy nn
false	4	34	although inpos other jj hormonal_contraceptives nn are vbp highly rb effective jj there ex have vbp been vbn reports nns of inpos pregnancy nn from inpos women nns who wp have vbp used vbn combined_oral_contraceptives nn as rb well rb as inpos insertable jj hormonal jj birth nn control nn products nns
false	10	26	it prp is vbz not rb known vbn if inpos hormonal_contraceptives nn differ vbp in inpos their prp effectiveness nn when wrb used vbn with inpos accutane nn
false	0	20	accutane nn has vbz not rb been vbn shown vbn to topos alter vb the dt pharmacokinetics nns of inpos phenytoin nn in inpos a dt study nn in inpos num cd healthy jj volunteers nns
false	38	42	no dt formal jj clinical jj studies nns have vbp been vbn conducted vbn to topos assess vb if inpos there ex is vbz an dt interactive jj effect nn on inpos bone nn loss nn between inpos phenytoin nn and cc accutane nn
false	38	42	no dt formal jj clinical jj studies nns have vbp been vbn conducted vbn to topos assess vb if inpos there ex is vbz an dt interactive jj effect nn on inpos bone nn loss nn between inpos systemic_corticosteroids nn and cc accutane nn
false	0	2	nitroglycerin nn isradipine nn has vbz been vbn safely rb coadministered vbn with inpos nitroglycerin nn
false	0	12	dynacirc nn has vbz been vbn safely rb coadministered vbn with inpos nitroglycerin nn
false	2	0	nitroglycerin nn isradipine nn has vbz been vbn safely rb coadministered vbn with inpos nitroglycerin nn
false	24	28	a dt study nn in inpos normal jj healthy jj volunteers nns has vbz shown vbn that inpos concomitant jj administration nn of inpos dynacirc nn and cc hydrochlorothiazide nn does vbz not rb result vb in inpos altered vbn pharmacoktnetics nns of inpos either dt drug nn
false	24	28	a dt study nn in inpos normal jj healthy jj volunteers nns has vbz shown vbn that inpos concomitant jj administration nn of inpos isradipine nn and cc hydrochlorothiazide nn does vbz not rb result vb in inpos altered vbn pharmacoktnetics nns of inpos either dt drug nn
false	16	22	in inpos a dt study nn in inpos hypertensive jj patients nns addition nn of inpos isradipine nn to topos existing vbg hydrochlorothiazide nn therapy nn did vbd not rb result vb in inpos any dt unexpected jj adverse jj effects nns and cc isradipine nn had vbd an dt additional jj antihypertensive jj effect nn
false	22	16	in inpos a dt study nn in inpos hypertensive jj patients nns addition nn of inpos isradipine nn to topos existing vbg hydrochlorothiazide nn therapy nn did vbd not rb result vb in inpos any dt unexpected jj adverse jj effects nns and cc isradipine nn had vbd an dt additional jj antihypertensive jj effect nn
false	20	50	in inpos a dt single jj dose nn study nn in inpos normal jj volunteers nns coadministration nn of inpos propranolol nn had vbd a dt small jj effect nn on inpos the dt rate nn but cc no dt effect nn on inpos the dt extent nn of inpos isradipine nn bioavailability nn
false	0	44	propranolol nn to topos healthy jj volunteers nns under inpos steady_state jj conditions nns had vbd no dt relevant jj effect nn on inpos either cc drug nn s vbz bioavailability nn auc nn cmax nn differences nns were vbd num cd between inpos isradipine nn given vbn singly rb and cc in inpos combination nn with inpos propranolol nn and cc between inpos propranolol nn given vbn singly rb and cc in inpos combination nn with inpos isradipine nn
false	0	44	propranolol nn to topos healthy jj volunteers nns under inpos steady_state jj conditions nns had vbd no dt relevant jj effect nn on inpos either cc drug nn s vbz bioavailability nn auc nn cmax nn differences nns were vbd num cd between inpos isradipine nn given vbn singly rb and cc in inpos combination nn with inpos propranolol nn and cc between inpos propranolol nn given vbn singly rb and cc in inpos combination nn with inpos isradipine nn
false	44	0	propranolol nn to topos healthy jj volunteers nns under inpos steady_state jj conditions nns had vbd no dt relevant jj effect nn on inpos either cc drug nn s vbz bioavailability nn auc nn cmax nn differences nns were vbd num cd between inpos isradipine nn given vbn singly rb and cc in inpos combination nn with inpos propranolol nn and cc between inpos propranolol nn given vbn singly rb and cc in inpos combination nn with inpos isradipine nn
false	44	0	propranolol nn to topos healthy jj volunteers nns under inpos steady_state jj conditions nns had vbd no dt relevant jj effect nn on inpos either cc drug nn s vbz bioavailability nn auc nn cmax nn differences nns were vbd num cd between inpos isradipine nn given vbn singly rb and cc in inpos combination nn with inpos propranolol nn and cc between inpos propranolol nn given vbn singly rb and cc in inpos combination nn with inpos isradipine nn
false	0	44	propranolol nn to topos healthy jj volunteers nns under inpos steady_state jj conditions nns had vbd no dt relevant jj effect nn on inpos either cc drug nn s vbz bioavailability nn auc nn cmax nn differences nns were vbd num cd between inpos isradipine nn given vbn singly rb and cc in inpos combination nn with inpos propranolol nn and cc between inpos propranolol nn given vbn singly rb and cc in inpos combination nn with inpos isradipine nn
false	0	44	propranolol nn to topos healthy jj volunteers nns under inpos steady_state jj conditions nns had vbd no dt relevant jj effect nn on inpos either cc drug nn s vbz bioavailability nn auc nn cmax nn differences nns were vbd num cd between inpos isradipine nn given vbn singly rb and cc in inpos combination nn with inpos propranolol nn and cc between inpos propranolol nn given vbn singly rb and cc in inpos combination nn with inpos isradipine nn
mechanism	20	44	in inpos a dt study nn in inpos healthy jj volunteers nns a dt one_week jj course nn of inpos cimetidine nn at inpos num cd mg nn b.i.d. rb with inpos a dt single jj num cd mg nn dose nn of inpos isradipine nn on inpos the dt sixth jj day nn showed vbd an dt increase nn in inpos isradipine nn mean jj peak jj plasma nn concentrations nns and cc significant jj increase nn in inpos area nn under inpos the dt curve nn
false	20	44	in inpos a dt study nn in inpos healthy jj volunteers nns a dt one_week jj course nn of inpos cimetidine nn at inpos num cd mg nn b.i.d. rb with inpos a dt single jj num cd mg nn dose nn of inpos isradipine nn on inpos the dt sixth jj day nn showed vbd an dt increase nn in inpos isradipine nn mean jj peak jj plasma nn concentrations nns and cc significant jj increase nn in inpos area nn under inpos the dt curve nn
advise	2	20	if inpos isradipine nn therapy nn is vbz initiated vbn in inpos a dt patient nn currently rb receiving vbg cimetidine nn careful jj monitoring nn for inpos adverse jj reactions nns is vbz advised vbn and cc downward jj dose nn adjustment nn may md be vb required vbn
mechanism	20	44	in inpos a dt study nn in inpos healthy jj volunteers nns a dt six_day jj course nn of inpos rifampicin nn at inpos num cd mg_day nn followed vbn by inpos a dt single jj num cd mg nn dose nn of inpos isradipine nn resulted vbd in inpos a dt reduction nn in inpos isradipine nn levels nns to topos below inpos detectable jj limits nns
false	20	44	in inpos a dt study nn in inpos healthy jj volunteers nns a dt six_day jj course nn of inpos rifampicin nn at inpos num cd mg_day nn followed vbn by inpos a dt single jj num cd mg nn dose nn of inpos isradipine nn resulted vbd in inpos a dt reduction nn in inpos isradipine nn levels nns to topos below inpos detectable jj limits nns
mechanism	2	10	if inpos rifampicin nn therapy nn is vbz required vbn isradipine nn concentrations nns and cc therapeutic jj effects nns are vbp likely jj to topos be vb markedly rb reduced vbn or cc abolished vbn as inpos a dt consequence nn of inpos increased vbn metabolism nn and cc higher jjr clearance nn of inpos isradipine nn
false	2	10	if inpos rifampicin nn therapy nn is vbz required vbn isradipine nn concentrations nns and cc therapeutic jj effects nns are vbp likely jj to topos be vb markedly rb reduced vbn or cc abolished vbn as inpos a dt consequence nn of inpos increased vbn metabolism nn and cc higher jjr clearance nn of inpos isradipine nn
false	28	34	in inpos a dt study nn in inpos healthy jj volunteers nns no dt clinically rb relevant jj pharmacokinetic jj or cc pharmacodynamic jj interaction nn between inpos isradipine nn and cc racemic jj warfarin nn was vbd seen vbn when wrb num cd single jj oral jj doses nns of inpos warfarin nn were vbd administered vbn during inpos num cd days nns of inpos multipledose jj treatment nn with inpos num cd mg nn b.i.d. nn isradipine nn
false	28	34	in inpos a dt study nn in inpos healthy jj volunteers nns no dt clinically rb relevant jj pharmacokinetic jj or cc pharmacodynamic jj interaction nn between inpos isradipine nn and cc racemic jj warfarin nn was vbd seen vbn when wrb num cd single jj oral jj doses nns of inpos warfarin nn were vbd administered vbn during inpos num cd days nns of inpos multipledose jj treatment nn with inpos num cd mg nn b.i.d. nn isradipine nn
false	34	28	in inpos a dt study nn in inpos healthy jj volunteers nns no dt clinically rb relevant jj pharmacokinetic jj or cc pharmacodynamic jj interaction nn between inpos isradipine nn and cc racemic jj warfarin nn was vbd seen vbn when wrb num cd single jj oral jj doses nns of inpos warfarin nn were vbd administered vbn during inpos num cd days nns of inpos multipledose jj treatment nn with inpos num cd mg nn b.i.d. nn isradipine nn
false	34	28	in inpos a dt study nn in inpos healthy jj volunteers nns no dt clinically rb relevant jj pharmacokinetic jj or cc pharmacodynamic jj interaction nn between inpos isradipine nn and cc racemic jj warfarin nn was vbd seen vbn when wrb num cd single jj oral jj doses nns of inpos warfarin nn were vbd administered vbn during inpos num cd days nns of inpos multipledose jj treatment nn with inpos num cd mg nn b.i.d. nn isradipine nn
false	4	8	neither cc racemic jj warfarin nn nor cc isradipine nn binding nn to topos plasma nn proteins nns in fw vitro fw was vbd altered vbn by inpos the dt addition nn of inpos the dt other jj drug nn
false	8	12	the dt concomitant jj administration nn of inpos dynacirc nn and cc digoxin nn in inpos a dt single_dose jj pharmacokinetic jj study nn did vbd not rb affect vb renal jj nonrenal jj total jj body nn clearance nn of inpos digoxin nn
false	8	12	the dt concomitant jj administration nn of inpos dynacirc nn and cc digoxin nn in inpos a dt single_dose jj pharmacokinetic jj study nn did vbd not rb affect vb renal jj nonrenal jj total jj body nn clearance nn of inpos digoxin nn
false	8	12	the dt concomitant jj administration nn of inpos isradipine nn and cc digoxin nn in inpos a dt single_dose jj pharmacokinetic jj study nn did vbd not rb affect vb renal jj nonrenal jj total jj body nn clearance nn of inpos digoxin nn
false	8	12	the dt concomitant jj administration nn of inpos isradipine nn and cc digoxin nn in inpos a dt single_dose jj pharmacokinetic jj study nn did vbd not rb affect vb renal jj nonrenal jj total jj body nn clearance nn of inpos digoxin nn
false	0	30	fentanyl nn anesthesia nnp severe nnp hypotension nn has vbz been vbn reported vbn during inpos fentanyl nn anesthesia nn with inpos concomitant jj use nn of inpos a dt b_blocker nn and cc a dt calcium_channel_blocker nn
false	0	36	fentanyl nn anesthesia nnp severe nnp hypotension nn has vbz been vbn reported vbn during inpos fentanyl nn anesthesia nn with inpos concomitant jj use nn of inpos a dt b_blocker nn and cc a dt calcium_channel_blocker nn
effect	12	26	severe jj hypotension nn has vbz been vbn reported vbn during inpos fentanyl nn anesthesia nn with inpos concomitant jj use nn of inpos a dt b_blocker nn and cc a dt calcium_channel_blocker nn
effect	12	32	severe jj hypotension nn has vbz been vbn reported vbn during inpos fentanyl nn anesthesia nn with inpos concomitant jj use nn of inpos a dt b_blocker nn and cc a dt calcium_channel_blocker nn
false	26	32	severe jj hypotension nn has vbz been vbn reported vbn during inpos fentanyl nn anesthesia nn with inpos concomitant jj use nn of inpos a dt b_blocker nn and cc a dt calcium_channel_blocker nn
mechanism	4	8	coadministration nn of inpos terfenadine nn with inpos itraconazole nn has vbz led vbn to topos elevated vbn plasma nn concentrations nns of inpos terfenadine nn resulting vbg in inpos rare jj instances nns of inpos life nn threatening jj cardiac jj dysrhythmias nns and cc num cd death nn
false	8	4	coadministration nn of inpos terfenadine nn with inpos itraconazole nn has vbz led vbn to topos elevated vbn plasma nn concentrations nns of inpos terfenadine nn resulting vbg in inpos rare jj instances nns of inpos life nn threatening jj cardiac jj dysrhythmias nns and cc num cd death nn
false	4	6	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	4	16	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	4	16	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	4	40	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
mechanism	6	16	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	6	16	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	6	40	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	16	40	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	16	40	another dt oral jj azole_antifungal nn ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastermizole nn which wdt may md prolong vb qt nn intervals nns
false	10	18	in fw vitro fw data nns suggest vbp that inpos itraconazole nn when wrb compared vbn to topos ketoconazole nn has vbz a dt less rbr pronounced jj effect nn on inpos the dt biotransformation nn system nn responsible jj for inpos the dt metabolism nn of inpos astemizole nn
mechanism	10	48	in fw vitro fw data nns suggest vbp that inpos itraconazole nn when wrb compared vbn to topos ketoconazole nn has vbz a dt less rbr pronounced jj effect nn on inpos the dt biotransformation nn system nn responsible jj for inpos the dt metabolism nn of inpos astemizole nn
false	18	48	in fw vitro fw data nns suggest vbp that inpos itraconazole nn when wrb compared vbn to topos ketoconazole nn has vbz a dt less rbr pronounced jj effect nn on inpos the dt biotransformation nn system nn responsible jj for inpos the dt metabolism nn of inpos astemizole nn
false	12	16	based vbn on inpos the dt chemical jj resemblance nn of inpos itraconazole nn and cc ketoconazole nn coadministration nn of inpos astemizole nn with inpos itraconazole nn is vbz contraindicated vbn
false	12	22	based vbn on inpos the dt chemical jj resemblance nn of inpos itraconazole nn and cc ketoconazole nn coadministration nn of inpos astemizole nn with inpos itraconazole nn is vbz contraindicated vbn
false	16	22	based vbn on inpos the dt chemical jj resemblance nn of inpos itraconazole nn and cc ketoconazole nn coadministration nn of inpos astemizole nn with inpos itraconazole nn is vbz contraindicated vbn
false	16	12	based vbn on inpos the dt chemical jj resemblance nn of inpos itraconazole nn and cc ketoconazole nn coadministration nn of inpos astemizole nn with inpos itraconazole nn is vbz contraindicated vbn
advise	22	12	based vbn on inpos the dt chemical jj resemblance nn of inpos itraconazole nn and cc ketoconazole nn coadministration nn of inpos astemizole nn with inpos itraconazole nn is vbz contraindicated vbn
mechanism	12	24	human jj pharmacokinetics nns data nns indicate vbp that inpos oral jj ketoconazole nn potently rb inhibits vbz the dt metabolism nn of inpos cisapride nn resulting vbg in inpos an dt eight_fold jj increase nn in inpos the dt mean jj auc nn of inpos cisapride nn
false	12	24	human jj pharmacokinetics nns data nns indicate vbp that inpos oral jj ketoconazole nn potently rb inhibits vbz the dt metabolism nn of inpos cisapride nn resulting vbg in inpos an dt eight_fold jj increase nn in inpos the dt mean jj auc nn of inpos cisapride nn
effect	12	16	data nns suggest vbp that inpos coadministration nn of inpos oral jj ketoconazole nn and cc cisapride nn can md result vb in inpos prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
mechanism	10	36	in fw vitro fw data nns suggest vbp that inpos itraconazole nn also rb markedly rb inhibits vbz the dt biotransformation nn system nn mainly rb responsible jj for inpos the dt metabolism nn of inpos cisapride nn
advise	8	12	therefore rb concomitant jj administration nn of inpos itraconazole nn with inpos cisapride nn is vbz contraindicated vbn
mechanism	4	10	coadministration nn of inpos itraconazole nn with inpos oral jj midazolam nn or cc triazolam nn has vbz resulted vbn in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj num cd drugs nns
mechanism	4	14	coadministration nn of inpos itraconazole nn with inpos oral jj midazolam nn or cc triazolam nn has vbz resulted vbn in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj num cd drugs nns
false	10	14	coadministration nn of inpos itraconazole nn with inpos oral jj midazolam nn or cc triazolam nn has vbz resulted vbn in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj num cd drugs nns
advise	0	18	cyclosporine nn concentrations nns should md be vb monitored vbn at inpos the dt initiation nn of inpos itraconazole nn therapy nn and cc frequently rb thereafter rb and cc the dt dose nn of inpos these dt num cd drug nn products nns adjusted vbn appropriately rb
advise	0	18	tacrolimus nn concentrations nns should md be vb monitored vbn at inpos the dt initiation nn of inpos itraconazole nn therapy nn and cc frequently rb thereafter rb and cc the dt dose nn of inpos these dt num cd drug nn products nns adjusted vbn appropriately rb
advise	0	18	digoxin nn concentrations nns should md be vb monitored vbn at inpos the dt initiation nn of inpos itraconazole nn therapy nn and cc frequently rb thereafter rb and cc the dt dose nn of inpos these dt num cd drug nn products nns adjusted vbn appropriately rb
effect	14	26	rhabdomyolysis nn has vbz been vbn observed vbn in inpos patients nns receiving vbg hmg_coa_reductase_inhibitors nn administered vbn alone rb or cc concomitantly rb with inpos immunosuppressive_drugs nn including vbg cyclosporine nn
effect	14	30	rhabdomyolysis nn has vbz been vbn observed vbn in inpos patients nns receiving vbg hmg_coa_reductase_inhibitors nn administered vbn alone rb or cc concomitantly rb with inpos immunosuppressive_drugs nns including vbg cyclosporine nn
false	26	30	rhabdomyolysis nn has vbz been vbn observed vbn in inpos patients nns receiving vbg hmg_coa_reductase_inhibitors nns administered vbn alone rb or cc concomitantly rb with inpos immunosuppressive_drugs nn including vbg cyclosporine nn
mechanism	2	10	when wrb itraconazole nn was vbd coadministered vbn with inpos phenytoin nns reduced vbn plasma nn concentrations nns of inpos itraconazole nn were vbd reported vbn
mechanism	2	10	when wrb itraconazole nn was vbd coadministered vbn with inpos rifampin nns reduced vbn plasma nn concentrations nns of inpos itraconazole nn were vbd reported vbn
false	10	2	when wrb itraconazole nn was vbd coadministered vbn with inpos phenytoin nns reduced vbn plasma nn concentrations nns of inpos itraconazole nn were vbd reported vbn
false	10	2	when wrb itraconazole nn was vbd coadministered vbn with inpos rifampin nns reduced vbn plasma nn concentrations nns of inpos itraconazole nn were vbd reported vbn
mechanism	18	22	although inpos no dt studies nns have vbp been vbn conducted vbn concomitant jj administration nn of inpos itraconazole nn and cc phenytoin nn may md alter vb the dt metabolism nn of inpos phenytoin nn
false	18	22	although inpos no dt studies nns have vbp been vbn conducted vbn concomitant jj administration nn of inpos itraconazole nn and cc phenytoin nn may md alter vb the dt metabolism nn of inpos phenytoin nn
advise	8	30	therefore rb plasma nn concentrations nns of inpos phenytoin nn should md also rb be vb monitored vbn when wrb it prp is vbz given vbn concurrently rb with inpos itraconazole nn
effect	10	22	it prp has vbz been vbn reported vbn that inpos itraconazole nn enhances vbz the dt anticoagulant jj effect nn of inpos coumarin nn like jj drugs nns
advise	20	24	therefore rb prothrombin nn time nn should md be vb carefully rb monitored vbn in inpos patients nns receiving vbg itraconazole nn and cc coumarin nn like jj drugs nns simultaneously rb
mechanism	6	20	plasma nn concentrations nns of inpos azole_antifungal_agents nn are vbp reduced vbn when wrb given vbn concurrently rb with inpos isoniazid nn
false	0	18	itraconazole nn plasma nn concentrations nns should md be vb monitored vbn when wrb itraconazole nn and cc isoniazid nn are vbp coadministered vbn
advise	0	18	itraconazole nn plasma nn concentrations nns should md be vb monitored vbn when wrb itraconazole nn and cc isoniazid nn are vbp coadministered vbn
effect	18	24	severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg azole_antifungal_agents nn and cc oral jj hypoglycemic_agents nn
advise	16	22	blood nn glucose nn concentrations nns should md be vb carefully rb monitored vbn when wrb itraconazole nn and cc oral jj hypoglycemic_agents nn are vbp coadministered vbn
effect	22	26	tinnitus nnp and cc decreased vbn hearing nn have vbp been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg itraconazole nn and cc quinidine nn
effect	16	20	edema nnp has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg itraconazole nn and cc dihydropyridine_calcium_channel_blockers nn
false	26	60	the dt results nns from inpos a dt study nn in inpos which wdt num cd hiv_infected jj individuals nns were vbd treated vbn with inpos zidovudine nn num cd +_float cd mg_kg_day nn showed vbd that inpos the dt pharmacokinetics nns of inpos zidovudine nn were vbd not rb affected vbn during inpos concomitant jj administration nn of inpos itraconazole nn num cd mg nn b.i.d nn
false	26	60	the dt results nns from inpos a dt study nn in inpos which wdt num cd hiv_infected jj individuals nns were vbd treated vbn with inpos zidovudine nn num cd +_float cd mg_kg_day nn showed vbd that inpos the dt pharmacokinetics nns of inpos zidovudine nn were vbd not rb affected vbn during inpos concomitant jj administration nn of inpos itraconazole nn num cd mg nn b.i.d nn
effect	10	16	in fw vitro fw mixing nn of inpos an dt aminoglycoside nn with inpos b_lactamtype nn antibiotics nn may md result vb in inpos a dt significant jj mutual jj inactivation nn
effect	10	16	in fw vitro fw mixing nn of inpos an dt aminoglycoside nn with inpos b_lactamtype nn penicillins nn may md result vb in inpos a dt significant jj mutual jj inactivation nn
effect	10	16	in fw vitro fw mixing nn of inpos an dt aminoglycoside nn with inpos b_lactamtype nn cephalosporins nn may md result vb in inpos a dt significant jj mutual jj inactivation nn
mechanism	6	12	even rb when wrb an dt aminoglycoside nn and cc a dt penicillin nn type jj drug nn are vbp administered vbn separately rb by inpos different jj routes nns a dt reduction nn in inpos aminoglycoside nn serum nn half_life nn or cc serum nn levels nns has vbz been vbn reported vbn in inpos patients nns with inpos impaired jj renal jj function nn and cc in inpos some dt patients nns with inpos normal jj renal jj function nn
false	12	6	even rb when wrb an dt aminoglycoside nn and cc a dt penicillin nn type jj drug nn are vbp administered vbn separately rb by inpos different jj routes nns a dt reduction nn in inpos aminoglycoside nn serum nn half_life nn or cc serum nn levels nns has vbz been vbn reported vbn in inpos patients nns with inpos impaired jj renal jj function nn and cc in inpos some dt patients nns with inpos normal jj renal jj function nn
false	12	16	prolonged vbn recovery nn time nn may md occur vb if inpos barbiturates nn and_or cc narcotics nn are vbp used vbn concurrently rb with inpos ketamine nn
effect	12	26	prolonged vbn recovery nn time nn may md occur vb if inpos barbiturates nn and_or cc narcotics nns are vbp used vbn concurrently rb with inpos ketamine nn
effect	16	26	prolonged vbn recovery nn time nn may md occur vb if inpos barbiturates nns and_or cc narcotics nn are vbp used vbn concurrently rb with inpos ketamine nn
false	0	22	ketamine nn is vbz clinically rb compatible jj with inpos the dt commonly rb used vbn general jj and cc local jj anesthetic_agents nn when wrb an dt adequate jj respiratory jj exchange nn is vbz maintained vbn
mechanism	0	12	ketoconazole nn tablets nns inhibit vbp the dt metabolism nn of inpos terfenadine nn resulting vbg in inpos an dt increased vbn plasma nn concentration nn of inpos terfenadine nn and cc a dt delay nn in inpos the dt elimination nn of inpos its prp acid nn metabolite nn
false	0	12	ketoconazole nn tablets nns inhibit vbp the dt metabolism nn of inpos terfenadine nn resulting vbg in inpos an dt increased vbn plasma nn concentration nn of inpos terfenadine nn and cc a dt delay nn in inpos the dt elimination nn of inpos its prp acid nn metabolite nn
effect	10	20	pharmacokinetic jj data nns indicate vbp that inpos oral jj ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn levels nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastemizole nn which wdt may md prolong vb qt nn intervals nns
false	10	20	pharmacokinetic jj data nns indicate vbp that inpos oral jj ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn levels nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastemizole nn which wdt may md prolong vb qt nn intervals nns
false	10	44	pharmacokinetic jj data nns indicate vbp that inpos oral jj ketoconazole nn inhibits vbz the dt metabolism nn of inpos astemizole nn resulting vbg in inpos elevated vbn plasma nn levels nns of inpos astemizole nn and cc its prp active jj metabolite nn desmethylastemizole nn which wdt may md prolong vb qt nn intervals nns
advise	4	8	coadministration nn of inpos astemizole nn with inpos ketoconazole nn tablets nns is vbz therefore rb contraindicated vbn
mechanism	12	24	human jj pharmacokinetics nns data nns indicate vbp that inpos oral jj ketoconazole nn potently rb inhibits vbz the dt metabolism nn of inpos cisapride nn resulting vbg in inpos a dt mean jj eight_fold jj increase nn in inpos auc nn of inpos cisapride nn
false	12	24	human jj pharmacokinetics nns data nns indicate vbp that inpos oral jj ketoconazole nn potently rb inhibits vbz the dt metabolism nn of inpos cisapride nn resulting vbg in inpos a dt mean jj eight_fold jj increase nn in inpos auc nn of inpos cisapride nn
effect	12	16	data nns suggest vbp that inpos coadministration nn of inpos oral jj ketoconazole nn and cc cisapride nn can md result vb in inpos prolongation nn of inpos the dt qt nn interval nn on inpos the dt ecg nn
advise	8	14	therefore rb concomitant jj administration nn of inpos ketoconazole nn tablets nns with inpos cisapride nn is vbz contraindicated vbn
mechanism	0	14	ketoconazole nn tablets nns may md alter vb the dt metabolism nn of inpos cyclosporine nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj drugs nns
mechanism	0	14	ketoconazole nn tablets nns may md alter vb the dt metabolism nn of inpos tacrolimus nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj drugs nns
mechanism	0	14	ketoconazole nn tablets nns may md alter vb the dt metabolism nn of inpos methylprednisolone nn resulting vbg in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj drugs nns
false	12	22	dosage nn adjustment nn may md be vb required vbn if inpos cyclosporine nn are vbp given vbn concomitantly rb with inpos nizoral nn tablets nns
false	12	22	dosage nn adjustment nn may md be vb required vbn if inpos tacrolimus nn are vbp given vbn concomitantly rb with inpos nizoral nn tablets nns
false	12	22	dosage nn adjustment nn may md be vb required vbn if inpos methylprednisolone nn are vbp given vbn concomitantly rb with inpos nizoral nn tablets nns
mechanism	4	10	coadministration nn of inpos nizoral nn tablets nns with inpos midazolam nn or cc triazolam nn has vbz resulted vbn in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj num cd drugs nns
mechanism	4	14	coadministration nn of inpos nizoral nn tablets nns with inpos midazolam nn or cc triazolam nn has vbz resulted vbn in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj num cd drugs nns
false	10	14	coadministration nn of inpos nizoral nnp tablets nnps with inpos midazolam nn or cc triazolam nn has vbz resulted vbn in inpos elevated vbn plasma nn concentrations nns of inpos the dt latter jj num cd drugs nns
advise	12	22	it prp is vbz therefore rb advisable jj to topos monitor vb digoxin nn concentrations nns in inpos patients nns receiving vbg ketoconazole nn
false	6	10	when wrb taken vbn orally rb imidazole_compounds nn like inpos ketoconazole nn may md enhance vb the dt anticoagulant jj effect nn of inpos coumarin_like jj drugs nns
effect	6	24	when wrb taken vbn orally rb imidazole_compounds nn like inpos ketoconazole nn may md enhance vb the dt anticoagulant jj effect nn of inpos coumarin nn like jj drugs nns
effect	10	24	when wrb taken vbn orally rb imidazole_compounds nns like inpos ketoconazole nn may md enhance vb the dt anticoagulant jj effect nn of inpos coumarin nn like jj drugs nns
advise	8	12	in inpos simultaneous jj treatment nn with inpos imidazole_drugs nn and cc coumarin_drugs nn the dt anticoagulant jj effect nn should md be vb carefully rb titrated vbn and cc monitored vbn
effect	22	28	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj miconazole nn and cc oral jj hypoglycemic_agents nn such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn tablets nns can md not rb be vb ruled vbn out rp
false	22	54	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj miconazole nn and cc oral jj hypoglycemic_agents nns such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn tablets nns can md not rb be vb ruled vbn out rp
false	22	56	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj miconazole nn and cc oral jj hypoglycemic_agents nns such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn imidazole nn can md not rb be vb ruled vbn out rp
false	22	28	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj imidazole nn and cc oral jj hypoglycemic_agents nn such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn tablets nns can md not rb be vb ruled vbn out rp
false	22	54	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj imidazole nn and cc oral jj hypoglycemic_agents nns such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn tablets nns can md not rb be vb ruled vbn out rp
false	28	54	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj miconazole nn and cc oral jj hypoglycemic_agents nn such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn tablets nns can md not rb be vb ruled vbn out rp
false	28	56	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj miconazole nn and cc oral jj hypoglycemic_agents nn such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn imidazole nn can md not rb be vb ruled vbn out rp
false	54	56	because inpos severe jj hypoglycemia nn has vbz been vbn reported vbn in inpos patients nns concomitantly rb receiving vbg oral jj miconazole nn and cc oral jj hypoglycemic_agents nns such pdt a dt potential jj interaction nn involving vbg the dt latter jj agents nns when wrb used vbn concomitantly rb with inpos ketoconazole nn imidazole nn can md not rb be vb ruled vbn out rp
mechanism	6	12	concomitant jj administration nn of inpos ketoconazole nn tablets nns with inpos phenytoin nn may md alter vb the dt metabolism nn of inpos num cd or cc both dt of inpos the dt drugs nns
advise	12	16	it prp is vbz suggested vbn to topos monitor vb both cc ketoconazole nn and cc phenytoin nn
mechanism	6	10	concomitant jj administration nn of inpos rifampin nn with inpos ketoconazole nn tablets nns reduces vbz the dt blood nn levels nns of inpos the dt latter jj
mechanism	0	12	inh nn is vbz also rb reported vbn to topos affect vb ketoconazole nn concentrations nns adversely rb
mechanism	0	12	isoniazid nn is vbz also rb reported vbn to topos affect vb ketoconazole nn concentrations nns adversely rb
mechanism	14	32	after inpos the dt coadministration nn of inpos num cd mg nn oral jj ketoconazole nn twice rb daily rb and cc num cd num cd mg nn dose nn of inpos loratadine nn to topos num cd subjects nns the dt auc nn and cc cmax nn of inpos loratadine nn averaged vbd num cd and cc num cd respectively rb of inpos those dt obtained vbn after inpos co_treatment nn with inpos placebo nn
false	14	32	after inpos the dt coadministration nn of inpos num cd mg nn oral jj ketoconazole nn twice rb daily rb and cc num cd num cd mg nn dose nn of inpos loratadine nn to topos num cd subjects nns the dt auc nn and cc cmax nn of inpos loratadine nn averaged vbd num cd and cc num cd respectively rb of inpos those dt obtained vbn after inpos co_treatment nn with inpos placebo nn
false	22	34	also rb there ex were vbd no dt clinically rb significant jj differences nns in inpos adverse jj events nns when wrb loratadine nn was vbd administered vbn with inpos or cc without inpos ketoconazole nn
false	22	50	the dt possibility nn of inpos increased vbn interaction nn should md be vb kept vbn in inpos mind nn when wrb orudis nn doses vbz greater jjr than inpos num cd mg nn as inpos a dt single jj dose nn or cc num cd mg nn of inpos ketoprofen nn per inpos day nn are vbp used vbn concomitantly rb with inpos highly rb bound vbn drugs nns
false	0	8	antacids nn concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nnp
false	0	12	antacids nn concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nnp
false	0	38	antacids nn concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nnp
false	0	44	antacids nn concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nn
false	6	10	concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nnp
false	6	36	concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nnp
false	6	42	concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nn
false	10	36	concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nnp
false	10	42	concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nn
false	36	42	concomitant jj administration nn of inpos magnesium_hydroxide nn and cc aluminum_hydroxide nn does vbz not rb interfere vb with inpos the dt rate nn or cc extent nn of inpos the dt absorption nn of inpos ketoprofen nn administered vbn as inpos orudis nn
false	0	8	ketoprofen nn does vbz not rb alter vb aspirin nn absorption nn
mechanism	22	26	however rb in inpos a dt study nn of inpos num cd normal jj subjects nns concurrent jj administration nn of inpos aspirin nn decreased vbd ketoprofen nn protein nn binding nn and cc increased vbn ketoprofen nn plasma nn clearance nn from inpos float cd l_kg_h nn without inpos aspirin nn to topos float cd l_kg_h nn with inpos aspirin nn
mechanism	22	26	however rb in inpos a dt study nn of inpos num cd normal jj subjects nns concurrent jj administration nn of inpos aspirin nn decreased vbd ketoprofen nn protein nn binding nn and cc increased vbn ketoprofen nn plasma nn clearance nn from inpos float cd l_kg_h nn without inpos aspirin nn to topos float cd l_kg_h nn with inpos aspirin nn
false	26	22	however rb in inpos a dt study nn of inpos num cd normal jj subjects nns concurrent jj administration nn of inpos aspirin nn decreased vbd ketoprofen nn protein nn binding nn and cc increased vbn ketoprofen nn plasma nn clearance nn from inpos float cd l_kg_h nn without inpos aspirin nn to topos float cd l_kg_h nn with inpos aspirin nn
false	26	22	however rb in inpos a dt study nn of inpos num cd normal jj subjects nns concurrent jj administration nn of inpos aspirin nn decreased vbd ketoprofen nn protein nn binding nn and cc increased vbn ketoprofen nn plasma nn clearance nn from inpos float cd l_kg_h nn without inpos aspirin nn to topos float cd l_kg_h nn with inpos aspirin nn
false	26	22	however rb in inpos a dt study nn of inpos num cd normal jj subjects nns concurrent jj administration nn of inpos aspirin nn decreased vbd ketoprofen nn protein nn binding nn and cc increased vbn ketoprofen nn plasma nn clearance nn from inpos float cd l_kg_h nn without inpos aspirin nn to topos float cd l_kg_h nn with inpos aspirin nn
false	26	22	however rb in inpos a dt study nn of inpos num cd normal jj subjects nns concurrent jj administration nn of inpos aspirin nn decreased vbd ketoprofen nn protein nn binding nn and cc increased vbn ketoprofen nn plasma nn clearance nn from inpos float cd l_kg_h nn without inpos aspirin nn to topos float cd l_kg_h nn with inpos aspirin nn
advise	8	12	therefore rb concurrent jj use nn of inpos aspirin nn and cc ketoprofen nn is vbz not rb recommended vbn
false	0	2	diuretic nn hydrochlorothiazide nn given vbn concomitantly rb with inpos ketoprofen nn produces vbz a dt reduction nn in inpos urinary jj potassium nn and cc chloride nn excretion nn compared vbn to topos hydrochlorothiazide vb alone rb
false	0	10	diuretic nn hydrochlorothiazide nn given vbn concomitantly rb with inpos ketoprofen nn produces vbz a dt reduction nn in inpos urinary jj potassium nn and cc chloride nn excretion nn compared vbn to topos hydrochlorothiazide vb alone rb
false	0	2	diuretic nn hydrochlorothiazide nn given vbn concomitantly rb with inpos ketoprofen nn produces vbz a dt reduction nn in inpos urinary jj potassium nn and cc chloride nn excretion nn compared vbn to topos hydrochlorothiazide nn alone rb
effect	2	10	diuretic jj hydrochlorothiazide nn given vbn concomitantly rb with inpos ketoprofen nn produces vbz a dt reduction nn in inpos urinary jj potassium nn and cc chloride nn excretion nn compared vbn to topos hydrochlorothiazide vb alone rb
false	10	2	diuretic jj hydrochlorothiazide nn given vbn concomitantly rb with inpos ketoprofen nn produces vbz a dt reduction nn in inpos urinary jj potassium nn and cc chloride nn excretion nn compared vbn to topos hydrochlorothiazide nn alone rb
false	22	26	in inpos a dt study nn in inpos num cd patients nns with inpos congestive jj heart nn failure nn where wrb ketoprofen nn and cc digoxin nn were vbd concomitantly rb administered vbn ketoprofen nn did vbd not rb alter vb the dt serum nn levels nns of inpos digoxin nn
false	22	26	in inpos a dt study nn in inpos num cd patients nns with inpos congestive jj heart nn failure nn where wrb ketoprofen nn and cc digoxin nn were vbd concomitantly rb administered vbn ketoprofen nn did vbd not rb alter vb the dt serum nn levels nns of inpos digoxin nn
false	26	22	in inpos a dt study nn in inpos num cd patients nns with inpos congestive jj heart nn failure nn where wrb ketoprofen nn and cc digoxin nn were vbd concomitantly rb administered vbn ketoprofen nn did vbd not rb alter vb the dt serum nn levels nns of inpos digoxin nn
false	22	26	in inpos a dt study nn in inpos num cd patients nns with inpos congestive jj heart nn failure nn where wrb ketoprofen nn and cc digoxin nn were vbd concomitantly rb administered vbn ketoprofen nn did vbd not rb alter vb the dt serum nn levels nns of inpos digoxin nn
false	18	36	in inpos a dt short_term jj controlled vbn study nn in inpos num cd normal jj volunteers nns ketoprofen nn did vbd not rb significantly rb interfere vb with inpos the dt effect nn of inpos warfarin nn on inpos prothrombin nn time nn
false	22	38	bleeding vbg from inpos a dt number nn of inpos sites nns may md be vb a dt complication nn of inpos warfarin nn treatment nn and cc gi nn bleeding vbg a dt complication nn of inpos ketoprofen nn treatment nn
false	18	46	because inpos prostaglandina nn play vbp an dt important jj role nn in inpos hemostasis nn and cc ketoprofen nn has vbz an dt effect nn on inpos platelet nn function nn as rb well rb concurent jj therapy nn with inpos ketoprofen nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns on inpos both dt drugs nns
advise	18	46	because inpos prostaglandina nn play vbp an dt important jj role nn in inpos hemostasis nn and cc ketoprofen nn has vbz an dt effect nn on inpos platelet nn function nn as rb well rb concurent jj therapy nn with inpos ketoprofen nn and cc warfarin nn requires vbz close jj monitoring nn of inpos patients nns on inpos both dt drugs nns
mechanism	0	12	probenecid nn increases vbz both cc free jj and cc bound vbn ketoprofen nn by inpos reducing vbg the dt plasma nn clearance nn of inpos ketoprofen nn to topos about inpos one_third nn as rb well rb as inpos decreasing vbg its prp protein nn binding nn
false	0	12	probenecid nn increases vbz both cc free jj and cc bound vbn ketoprofen nn by inpos reducing vbg the dt plasma nn clearance nn of inpos ketoprofen nn to topos about inpos one_third nn as rb well rb as inpos decreasing vbg its prp protein nn binding nn
advise	8	12	therefore rb the dt combination nn of inpos ketoprofen nn and cc probenecid nn is vbz not rb recommended vbn
false	0	2	methotrexate nn ketoprofen nn like inpos other jj nsaids nns may md cause vb changes nns in inpos the dt elimination nn of inpos methotrexate nn leading vbg to topos elevated jj serum nn levels nns of inpos the dt drug nn and cc increased vbn toxicity nn
false	0	8	methotrexate nn ketoprofen nnp like inpos other jj nsaids nn may md cause vb changes nns in inpos the dt elimination nn of inpos methotrexate nn leading vbg to topos elevated jj serum nn levels nns of inpos the dt drug nn and cc increased vbn toxicity nn
false	2	8	methotrexate nn ketoprofen nn like inpos other jj nsaids nn may md cause vb changes nns in inpos the dt elimination nn of inpos methotrexate nn leading vbg to topos elevated jj serum nn levels nns of inpos the dt drug nn and cc increased vbn toxicity nn
mechanism	2	0	methotrexate nn ketoprofen nn like inpos other jj nsaids nns may md cause vb changes nns in inpos the dt elimination nn of inpos methotrexate nn leading vbg to topos elevated jj serum nn levels nns of inpos the dt drug nn and cc increased vbn toxicity nn
mechanism	8	0	methotrexate nn ketoprofen nnp like inpos other jj nsaids nn may md cause vb changes nns in inpos the dt elimination nn of inpos methotrexate nn leading vbg to topos elevated jj serum nn levels nns of inpos the dt drug nn and cc increased vbn toxicity nn
mechanism	0	16	nonsteroidal_anti_inflammatory_agents nn have vbp been vbn reported vbn to topos increase vb steadystate nn plasma nn lithium nn levels nns
false	10	20	it prp is vbz recommended vbn that inpos plasma nn lithium nn levels nns be vb monitored vbn when wrb ketoprofen nn is vbz coadministered vbn with inpos lithium nn
advise	20	10	it prp is vbz recommended vbn that inpos plasma nn lithium nn levels nns be vb monitored vbn when wrb ketoprofen nn is vbz coadministered vbn with inpos lithium nn
false	0	2	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	0	8	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	0	38	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	0	38	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	2	8	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	2	0	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	2	38	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	2	38	warfarin nn digoxin nn salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	4	6	warfarin nnp digoxin nn salicylate nn heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	4	0	warfarin nnp digoxin nn salicylate nn heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	4	36	warfarin nnp digoxin nn salicylate nn heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	4	36	warfarin nnp digoxin nn salicylate nn heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	8	0	warfarin nnp digoxin nnp salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	8	38	warfarin nnp digoxin nnp salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	8	38	warfarin nnp digoxin nnp salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
mechanism	0	38	warfarin nnp digoxin nnp salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	0	38	warfarin nnp digoxin nnp salicylate nnp and cc heparin nn the dt in fw vitro fw binding nn of inpos warfarin nn to topos plasma nn proteins nns is vbz only rb slightly rb reduced vbn by inpos ketorolac_tromethamine nn when wrb ketorolac nn plasma nn concentrations nns reach vbp num cd to10 nn m nn g_ml nn
false	0	8	ketorolac nn does vbz not rb alter vb digoxin nn protein nn binding nn
mechanism	18	26	in fw vitro fw studies nns indicate vbp that inpos at inpos therapeutic jj concentrations nns of inpos salicylate nn the dt binding nn of inpos ketorolac nn was vbd reduced vbn from inpos approximately rb float cd to topos float cd representing vbg a dt potential jj twofold jj increase nn in inpos unbound jj ketorolac nn plasma nn levels nns
false	18	26	in fw vitro fw studies nns indicate vbp that inpos at inpos therapeutic jj concentrations nns of inpos salicylate nn the dt binding nn of inpos ketorolac nn was vbd reduced vbn from inpos approximately rb float cd to topos float cd representing vbg a dt potential jj twofold jj increase nn in inpos unbound jj ketorolac nn plasma nn levels nns
false	6	14	therapeutic jj concentrations nns of inpos digoxin nn did vbd not rb alter vb ketorolac_tromethamine nn protein nn binding nn
false	6	14	therapeutic jj concentrations nns of inpos warfarin nn did vbd not rb alter vb ketorolac_tromethamine nn protein nn binding nn
false	6	14	therapeutic jj concentrations nns of inpos ibuprofen nn did vbd not rb alter vb ketorolac_tromethamine nn protein nn binding nn
false	6	14	therapeutic jj concentrations nns of inpos naproxen nn did vbd not rb alter vb ketorolac_tromethamine nn protein nn binding nn
false	6	14	therapeutic jj concentrations nns of inpos piroxicam nn did vbd not rb alter vb ketorolac_tromethamine nn protein nn binding nn
false	6	14	therapeutic jj concentrations nns of inpos acetaminophen nn did vbd not rb alter vb ketorolac_tromethamine nn protein nn binding nn
false	6	14	therapeutic jj concentrations nns of inpos phenytoin nn did vbd not rb alter vb ketorolac_tromethamine nn protein nn binding nn
false	20	36	although inpos these dt results nns do vbp not rb indicate vb a dt significant jj interaction nn between inpos toradol nn the dt administration nn of inpos toradol nn to topos patients nns taking vbg anticoagulants nn should md be vb done vbn extremely rb cautiously rb and cc patients nns should md be vb closely rb monitored vbn
false	20	28	although inpos these dt results nns do vbp not rb indicate vb a dt significant jj interaction nn between inpos warfarin nn the dt administration nn of inpos toradol nn to topos patients nns taking vbg anticoagulants nns should md be vb done vbn extremely rb cautiously rb and cc patients nns should md be vb closely rb monitored vbn
false	20	36	although inpos these dt results nns do vbp not rb indicate vb a dt significant jj interaction nn between inpos warfarin nn the dt administration nn of inpos toradol nn to topos patients nns taking vbg anticoagulants nn should md be vb done vbn extremely rb cautiously rb and cc patients nns should md be vb closely rb monitored vbn
false	20	28	although inpos these dt results nns do vbp not rb indicate vb a dt significant jj interaction nn between inpos heparin nn the dt administration nn of inpos toradol nn to topos patients nns taking vbg anticoagulants nns should md be vb done vbn extremely rb cautiously rb and cc patients nns should md be vb closely rb monitored vbn
false	20	36	although inpos these dt results nns do vbp not rb indicate vb a dt significant jj interaction nn between inpos heparin nn the dt administration nn of inpos toradol nn to topos patients nns taking vbg anticoagulants nn should md be vb done vbn extremely rb cautiously rb and cc patients nns should md be vb closely rb monitored vbn
advise	20	40	although inpos these dt results nns do vbp not rb indicate vb a dt significant jj interaction nn between inpos toradol nn warfarin nn heparin nn the dt administration nn of inpos toradol nn to topos patients nns taking vbg anticoagulants nn should md be vb done vbn extremely rb cautiously rb and cc patients nns should md be vb closely rb monitored vbn
false	0	8	toradol nn num cd reduced vbd the dt diuretic nn response nn to topos furosemide nn in inpos normovolemic jj healthy jj subjects nns by inpos approximately rb num cd
effect	0	14	toradol nn im nn reduced vbd the dt diuretic jj response nn to topos furosemide nn in inpos normovolemic jj healthy jj subjects nns by inpos approximately rb num cd
false	8	14	toradol nn im nn reduced vbd the dt diuretic nn response nn to topos furosemide nn in inpos normovolemic jj healthy jj subjects nns by inpos approximately rb num cd
false	0	8	probenecid nn concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
false	0	26	probenecid nn concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
false	0	26	probenecid nn concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
mechanism	6	12	concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
false	6	24	concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
false	6	24	concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
false	12	24	concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
false	12	24	concomitant jj administration nn of inpos toradol nn oral nn and cc probenecid nn resulted vbd in inpos decreased vbn clearance nn of inpos ketorolac nn and cc significant jj increases nns in inpos ketorolac nn plasma nn levels nns and cc terminal jj half_life nn increased vbd approximately rb twofold rb from inpos float cd to topos float cd hours nns
advise	8	12	therefore rb concomitant jj use nn of inpos toradol nn and cc probenecid nn is vbz contraindicated vbn
false	6	12	the dt effect nn of inpos toradol nn on inpos plasma nn lithium nn has vbz not rb been vbn studied vbn but cc cases nns of inpos increased vbn lithium nn plasma nn levels nns during inpos toradol nn therapy nn have vbp been vbn reported vbn
false	6	12	the dt effect nn of inpos toradol nn on inpos plasma nn lithium nn has vbz not rb been vbn studied vbn but cc cases nns of inpos increased vbn lithium nn plasma nn levels nns during inpos toradol nn therapy nn have vbp been vbn reported vbn
false	12	6	the dt effect nn of inpos toradol nn on inpos plasma nn lithium nn has vbz not rb been vbn studied vbn but cc cases nns of inpos increased vbn lithium nn plasma nn levels nns during inpos toradol nn therapy nn have vbp been vbn reported vbn
mechanism	12	6	the dt effect nn of inpos toradol nn on inpos plasma nn lithium nn has vbz not rb been vbn studied vbn but cc cases nns of inpos increased vbn lithium nn plasma nn levels nns during inpos toradol nn therapy nn have vbp been vbn reported vbn
false	0	14	methotrexate nn concomitant jj administration nn of inpos methotrexate nn and cc some dt nsaids nn has vbz been vbn reported vbn to topos reduce vb the dt clearance nn of inpos methotrexate nn enhancing vbg the dt toxicity nn of inpos methotrexate nn
mechanism	6	12	concomitant jj administration nn of inpos methotrexate nn and cc some dt nsaids nn has vbz been vbn reported vbn to topos reduce vb the dt clearance nn of inpos methotrexate nn enhancing vbg the dt toxicity nn of inpos methotrexate nn
false	12	6	concomitant jj administration nn of inpos methotrexate nn and cc some dt nsaids nn has vbz been vbn reported vbn to topos reduce vb the dt clearance nn of inpos methotrexate nn enhancing vbg the dt toxicity nn of inpos methotrexate nn
false	12	6	concomitant jj administration nn of inpos methotrexate nn and cc some dt nsaids nn has vbz been vbn reported vbn to topos reduce vb the dt clearance nn of inpos methotrexate nn enhancing vbg the dt toxicity nn of inpos methotrexate nn
false	6	10	the dt effect nn of inpos toradol nn on inpos methotrexate nn clearance nn has vbz not rb been vbn studied vbn
false	8	12	the dt concurrent jj use nn of inpos toradol nn with inpos muscle_relaxants nn has vbz not rb been vbn formally rb studied vbn
effect	22	26	sporadic jj cases nns of inpos seizures nns have vbp been vbn reported vbn during inpos concomitant jj use nn of inpos toradol nn and cc antiepileptic_drugs nn
effect	22	26	sporadic jj cases nns of inpos seizures nns have vbp been vbn reported vbn during inpos concomitant jj use nn of inpos toradol nn and cc phenytoin nn
effect	22	26	sporadic jj cases nns of inpos seizures nns have vbp been vbn reported vbn during inpos concomitant jj use nn of inpos toradol nn and cc carbamazepine nn
effect	10	22	hallucinations nns have vbp been vbn reported vbn when wrb toradol nn was vbd used vbn in inpos patients nns taking vbg psychoactive_drugs nn
effect	10	22	hallucinations nns have vbp been vbn reported vbn when wrb toradol nn was vbd used vbn in inpos patients nns taking vbg fluoxetine nn
effect	10	22	hallucinations nns have vbp been vbn reported vbn when wrb toradol nn was vbd used vbn in inpos patients nns taking vbg thiothixene nn
effect	10	22	hallucinations nns have vbp been vbn reported vbn when wrb toradol nn was vbd used vbn in inpos patients nns taking vbg alprazolam nn
false	6	10	do vbp not rb mix vb toradol nn and cc morphine nn in inpos the dt same jj syringe nn
false	0	2	cyclosporine nn hyph_l_arginine nn may md counteract vb the dt antinaturetic jj effect nn of inpos cyclosporin nn
effect	2	0	cyclosporine nn hyph_l_arginine nn may md counteract vb the dt antinaturetic jj effect nn of inpos cyclosporin nn
false	0	2	ibuprofen nn hyph_l_arginine nn may md increase vb the dt absorption nn of inpos ibuprofen nn if inpos taken vbn concomitantly rb
mechanism	2	0	ibuprofen nn hyph_l_arginine nn may md increase vb the dt absorption nn of inpos ibuprofen nn if inpos taken vbn concomitantly rb
false	2	4	organic jj nitrates nn hyph_l_arginine nn supplements nns theoretically rb may md potentiate vb the dt effects nns of inpos organic jj nitrates nns if inpos taken vbn concomitantly rb
effect	4	2	organic jj nitrates nns hyph_l_arginine nn supplements nns theoretically rb may md potentiate vb the dt effects nns of inpos organic jj nitrates nn if inpos taken vbn concomitantly rb
false	0	4	sildenafil_citrate nn hyph_theoretically rb l_arginine nn supplements nns taken vbn concomitantly rb with inpos sildenafil_citrate nn may md potentiate vb the dt effects nns of inpos the dt drug nn
effect	4	0	sildenafil_citrate nn hyph_theoretically rb l_arginine nn supplements nns taken vbn concomitantly rb with inpos sildenafil_citrate nn may md potentiate vb the dt effects nns of inpos the dt drug nn
false	0	8	human_growth_hormone nn hyph_concomitant jj use nn of inpos l_glutamine nn and cc human_growth_hormone nn may md enhance vb nutrient jj absorption nn in inpos those dt with inpos severe jj short jj bowel nn syndrome nn
mechanism	8	0	human_growth_hormone nn hyph_concomitant jj use nn of inpos l_glutamine nn and cc human_growth_hormone nn may md enhance vb nutrient jj absorption nn in inpos those dt with inpos severe jj short jj bowel nn syndrome nn
false	0	8	indomethacin nn hyph_concomitant jj use nn of inpos l_glutamine nn and cc indomethacin nn may md ameliorate vb increased vbn intestinal jj permeability nn caused vbn by inpos indomethacin nn
effect	8	0	indomethacin nn hyph_concomitant jj use nn of inpos l_glutamine nn and cc indomethacin nn may md ameliorate vb increased vbn intestinal jj permeability nn caused vbn by inpos indomethacin nn
false	8	0	indomethacin nn hyph_concomitant jj use nn of inpos l_glutamine nn and cc indomethacin nn may md ameliorate vb increased vbn intestinal jj permeability nn caused vbn by inpos indomethacin nn
false	0	28	methotrexate nn hyph_there ex is vbz num cd report nn that inpos methotrexate nn may md decrease vb the dt possible jj effectiveness nn of inpos supplemental jj l_glutamine nn for inpos chemotherapy_induced jj mucositis nn
effect	0	28	methotrexate nn hyph_there ex is vbz num cd report nn that inpos methotrexate nn may md decrease vb the dt possible jj effectiveness nn of inpos supplemental jj l_glutamine nn for inpos chemotherapy_induced jj mucositis nn
effect	30	42	in inpos another dt report nn num cd patients nns with inpos breast nn cancer nn were vbd reported vbn to topos have vb decreased vbn symptoms nns of inpos methotrexate nn related jj toxicity nn when wrb given vbn supplemental jj l_glutamine nn at inpos a dt dose nn of inpos float cd gram_day nn
false	0	8	paclitaxel nn in inpos num cd report nn l_glutamine nn at inpos a dt dose nn of inpos num cd grams nns num cd times nns daily rb given vbn num cd hours nns after inpos receiving vbg paclitaxel nn appeared vbd to topos prevent vb the dt development nn of inpos myalgia nn and cc arthralgia nn adverse jj reactions nns of inpos paclitaxel nn
effect	8	0	paclitaxel nn in inpos num cd report nn l_glutamine nn at inpos a dt dose nn of inpos num cd grams nns num cd times nns daily rb given vbn num cd hours nns after inpos receiving vbg paclitaxel nn appeared vbd to topos prevent vb the dt development nn of inpos myalgia nn and cc arthralgia nn adverse jj reactions nns of inpos paclitaxel nn
false	8	0	paclitaxel nn in inpos num cd report nn l_glutamine nn at inpos a dt dose nn of inpos num cd grams nns num cd times nns daily rb given vbn num cd hours nns after inpos receiving vbg paclitaxel nn appeared vbd to topos prevent vb the dt development nn of inpos myalgia nn and cc arthralgia nn adverse jj reactions nns of inpos paclitaxel nn
false	0	2	medroxyprogesterone_acetate nn hyph_l_histidine nn was vbd observed vbn to topos enhance vb the dt effect nn of inpos medroxyprogesterone_acetate nn in inpos reducing vbg the dt number nn of inpos human jj breast nn cancer nn cells nns that wdt were vbd in inpos the dt s nn phase nn
effect	2	0	medroxyprogesterone_acetate nn hyph_l_histidine nn was vbd observed vbn to topos enhance vb the dt effect nn of inpos medroxyprogesterone_acetate nn in inpos reducing vbg the dt number nn of inpos human jj breast nn cancer nn cells nns that wdt were vbd in inpos the dt s nn phase nn
false	0	4	h1 nn and cc h2 nn bbbbbcom_blockers_eeeeecom nn hyph_although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2_blockers nns
false	0	14	h1 nn and cc h2 nn bbbbb12_blockers_eeeee12 nn hyph_although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2_blockers nns
false	0	40	h1 nn and cc h2 nn bbbbb12_blockers_eeeee12 nn hyph_although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2_blockers nn
false	4	12	h1 nn and cc h2_blockers nn hyph_although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2_blockers nns
false	4	0	h1 nn and cc h2_blockers nn hyph_although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2 nn bbbbb22_blockers_eeeee22 nn
effect	12	0	h1 nn and cc h2_blockers nns although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2 nn bbbbb22_blockers_eeeee22 nn
effect	12	4	h1 nn and cc h2_blockers nns although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2_blockers nn
false	0	4	h1 nn and cc h2_blockers nns although inpos not rb reported vbn l_histidine nn via inpos its prp metabolism nn to topos histamine nn might md decrease vb the dt efficacy nn of inpos h1 nn and cc h2 nn bbbbbcom_blockers_eeeeecom nn
mechanism	6	12	concomitant jj use nn of inpos calcium nn supplements nns and cc l_lysine nn may md increase vb calcium nn absorption nn
false	12	6	concomitant jj use nn of inpos calcium nn supplements nns and cc l_lysine nn may md increase vb calcium nn absorption nn
false	0	4	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
false	0	6	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
false	0	4	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
false	4	6	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
false	4	0	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
effect	6	0	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
effect	6	4	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
false	0	4	acetaminophen nn and cc methotrexate nn hyph_l_methionine nn may md decrease vb hepatic jj toxicity nn in inpos those dt with inpos acetaminophen nn overdosage nn or cc in inpos those dt taking vbg methotrexate nn
false	0	2	gentamicin nn hyph_methionine nn may md protect vb against inpos the dt ototoxic jj effects nns of inpos gentamicin nn
effect	2	0	gentamicin nn hyph_methionine nn may md protect vb against inpos the dt ototoxic jj effects nns of inpos gentamicin nn
false	0	4	non_selective_monoamine_oxidase_mao_inhibitors nn hyph_including vbg phenelzine_sulfate nn
false	0	4	non_selective_monoamine_oxidase_mao_inhibitors nn hyph_including vbg tranylcypromine_sulfate nn
false	0	4	non_selective_monoamine_oxidase_mao_inhibitors nn hyph_including vbg pargyline nn
effect	6	10	concomitant jj use nn of inpos l_phenylalanine nn and cc non_selective_mao_inhibitors nn may md cause vb hypertension nn
false	0	2	selegiline nn hyph_l_phenylalanine nn and cc the dt selective_mao_inhibitor nn selegiline nn may md have vb synergistic jj antidepressant nn activity nn if inpos used vbn concomitantly rb
false	0	8	selegiline nn hyph_l_phenylalanine nn and cc the dt selective_mao_inhibitor nn selegiline nn may md have vb synergistic jj antidepressant nn activity nn if inpos used vbn concomitantly rb
false	2	8	selegiline nn hyph_l_phenylalanine nn and cc the dt selective_mao_inhibitor nn selegiline nn may md have vb synergistic jj antidepressant nn activity nn if inpos used vbn concomitantly rb
effect	2	0	selegiline nn hyph_l_phenylalanine nn and cc the dt selective_mao_inhibitor nn selegiline nn may md have vb synergistic jj antidepressant nn activity nn if inpos used vbn concomitantly rb
false	8	0	selegiline nn hyph_l_phenylalanine nn and cc the dt selective_mao_inhibitor nn selegiline nn may md have vb synergistic jj antidepressant nn activity nn if inpos used vbn concomitantly rb
effect	0	2	neuroleptic_drugs nn hyph_l_phenylalanine nn may md potentiate vb the dt tardive jj dyskinesia nn side nn reactions nns of inpos neuroleptic_drugs nns if inpos used vbn concomitantly rb with inpos them prp
false	2	0	neuroleptic_drugs nns hyph_l_phenylalanine nn may md potentiate vb the dt tardive jj dyskinesia nn side nn reactions nns of inpos neuroleptic_drugs nn if inpos used vbn concomitantly rb with inpos them prp
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos isocarboxazid nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos marplan nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos phenelzine nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos nardil nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos procarbazine nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos matulane nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos selegiline nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos eldepryl nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos tranylcypromine nn
false	0	6	monoamine_oxidase_mao_inhibitors nn such jj as inpos parnate nn
false	0	24	monoamine_oxidase_mao_inhibitors nn such jj as inpos isocarboxazid nn phenelzine nn procarbazine nn selegiline nn tranylcypromine nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos isocarboxazid nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos marplan nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos phenelzine nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos nardil nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos procarbazine nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos matulane nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos selegiline nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos eldepryl nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos tranylcypromine nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	6	16	monoamine_oxidase_mao_inhibitors nns such jj as inpos parnate nn using vbg these dt medicines nns with inpos l_tryptophan nn may md increase vb the dt chance nn of inpos side nn effects nns
false	0	4	non_selective_mao_inhibitors nn including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn
false	0	6	non_selective_mao_inhibitors nn including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn
false	0	8	non_selective_mao_inhibitors nn including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn
false	0	18	non_selective_mao_inhibitors nn including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nns may md cause vb hypertension nn
false	4	6	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn
false	4	8	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn
false	4	18	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nns may md cause vb hypertension nn
false	4	0	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nn may md cause vb hypertension nn
false	6	8	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn
false	6	18	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nns may md cause vb hypertension nn
false	6	0	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nn may md cause vb hypertension nn
false	8	18	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nns may md cause vb hypertension nn
false	8	0	non_selective_mao_inhibitors nns including vbg tranylcypromine_sulfate nn phenelzine_sulfate nn pargyline nn hc1 nn concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nn may md cause vb hypertension nn
effect	6	12	concomitant jj use nn of inpos l_tyrosine nn and cc non_selective jj mao_inhibitors nn may md cause vb hypertension nn
effect	14	22	in inpos num cd survey nn float cd of inpos patients nns taking vbg labetalol_hcl nn in inpos combination nn with inpos tricyclic_antidepressants nn experienced vbd tremor nn as inpos compared vbn to topos float cd reported vbn to topos occur vb with inpos labetalol_hcl nn alone rb
false	22	14	in inpos num cd survey nn float cd of inpos patients nns taking vbg labetalol_hcl nn in inpos combination nn with inpos tricyclic_antidepressants nn experienced vbd tremor nn as inpos compared vbn to topos float cd reported vbn to topos occur vb with inpos labetalol_hcl nn alone rb
mechanism	0	18	cimetidine nn has vbz been vbn shown vbn to topos increase vb the dt bioavailability nn of inpos labetalol_hcl nn
effect	10	20	synergism nn has vbz been vbn shown vbn between inpos halothane nn anesthesia nn and cc intravenously rb administered vbn labetalol_hcl nn
effect	10	18	during inpos controlled vbn hypotensive jj anesthesia nn using vbg labetalol_hcl nn in inpos association nn with inpos halothane nn high jj concentrations nns of inpos halothane nn should md not rb be vb used vbn because inpos the dt degree nn of inpos hypotension nn will md be vb increased vbn and cc because inpos of inpos the dt possibility nn of inpos a dt large jj reduction nn in inpos cardiac jj output nn and cc an dt increase nn in inpos central jj venous jj pressure nn
false	10	18	during inpos controlled vbn hypotensive jj anesthesia nn using vbg labetalol_hcl nn in inpos association nn with inpos halothane nn high jj concentrations nns of inpos halothane nn should md not rb be vb used vbn because inpos the dt degree nn of inpos hypotension nn will md be vb increased vbn and cc because inpos of inpos the dt possibility nn of inpos a dt large jj reduction nn in inpos cardiac jj output nn and cc an dt increase nn in inpos central jj venous jj pressure nn
effect	0	14	labetalol_hcl nn blunts vbz the dt reflex nn tachycardia nn produced vbn by inpos nitroglycerin nn without inpos preventing vbg its prp hypotensive jj effect nn
effect	2	10	if inpos labetalol_hcl nn is vbz used vbn with inpos nitroglycerin nn in inpos patients nns with inpos angina nn pectoris nn additional jj antihypertensive jj effects nns may md occur vb
advise	10	20	care nnp should md be vb taken vbn if inpos labetalol nn is vbz used vbn concomitantly rb with inpos calcium_antagonist nn s nns of inpos the dt verapamil nn type nn
false	10	26	care nnp should md be vb taken vbn if inpos labetalol nn is vbz used vbn concomitantly rb with inpos calcium_antagonists nns of inpos the dt verapamil nn type nn
false	20	28	care nnp should md be vb taken vbn if inpos labetalol nn is vbz used vbn concomitantly rb with inpos calcium_antagonist nn s nns of inpos the dt verapamil nn type nn
false	0	24	labetalol_hcl nn has vbz also rb been vbn reported vbn to topos produce vb a dt false jj positive jj test nn for inpos amphetamine nn when wrb screening vbg urine nn for inpos the dt presence nn of inpos drugs nns using vbg the dt commercially rb available jj assay nn methods nns toxi_lab jj a nn and cc emit_d.a.u nn
false	10	24	when wrb patients nns being vbg treated vbn with inpos labetalol nn have vbp a dt positive jj urine nn test nn for inpos amphetamine nn using vbg these dt techniques nns confirmation nn should md be vb made vbn by inpos using vbg more rbr specific jj methods nns such jj as inpos a dt gas nn chromatographic_mass nn spectrometer nn technique nn
mechanism	22	30	results nns of inpos preliminary jj studies nns in inpos humans nns and cc rats nns suggest vbp that inpos nonabsorbable jj antacids nn given vbn concurrently rb with inpos lactulose nn may md inhibit vb the dt desired vbn lactulose_induced jj drop nn in inpos colonic jj ph nn
false	22	30	results nns of inpos preliminary jj studies nns in inpos humans nns and cc rats nns suggest vbp that inpos nonabsorbable jj antacids nn given vbn concurrently rb with inpos lactulose nn may md inhibit vb the dt desired vbn lactulose nn induced jj drop nn in inpos colonic jj ph nn
false	16	28	there ex is vbz no dt information nn regarding vbg the dt effect nn on inpos lamivudine nn pharmacokinetics nns of inpos higher jjr doses nns of inpos tmp nn such jj as inpos those dt used vbn to topos treat vb pneumocystis nnp carinii nn pneumonia nn
false	16	28	there ex is vbz no dt information nn regarding vbg the dt effect nn on inpos lamivudine nn pharmacokinetics nns of inpos higher jjr doses nns of inpos smx nn such jj as inpos those dt used vbn to topos treat vb pneumocystis nnp carinii nn pneumonia nn
effect	0	4	lamivudine nn and cc zalcitabine nn may md inhibit vb the dt intracellular jj phosphorylation nn of inpos num cd another dt
advise	6	14	therefore rb use nn of inpos lamivudine nn in inpos combination nn with inpos zalcitabine nn is vbz not rb recommended vbn
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos warfarin nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos antipyrine nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos indomethacin nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos ibuprofen nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos phenytoin nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos propranolol nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos prednisone nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos diazepam nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos clarithromycin nn in inpos healthy jj subjects nns
false	8	44	studies nns have vbp shown vbn that inpos lansoprazole nn does vbz not rb have vb clinically rb significant jj interactions nns with inpos other jj drugs nns metabolized vbn by inpos the dt cytochrome nn p450 nn system nn such jj as inpos terfenadine nn in inpos healthy jj subjects nns
mechanism	2	12	when wrb lansoprazole nn was vbd administered vbn concomitantly rb with inpos theophylline nn a dt minor jj increase nn in inpos the dt clearance nn of inpos theophylline nn was vbd seen vbn
false	2	12	when wrb lansoprazole nn was vbd administered vbn concomitantly rb with inpos theophylline nn a dt minor jj increase nn in inpos the dt clearance nn of inpos theophylline nn was vbd seen vbn
advise	18	24	nonetheless rb individual jj patients nns may md require vb additional jj titration nn of inpos their prp theophylline nn dosage nn when wrb lansoprazole nn is vbz started vbn or cc stopped vbn to topos ensure vb clinically rb effective jj blood nn levels nns
false	0	24	lansoprazole nn has vbz also rb been vbn shown vbn to topos have vb no dt clinically rb significant jj interaction nn with inpos amoxicillin nn
false	12	20	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nns was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
false	12	38	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nns was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
false	12	50	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nn was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
false	12	38	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nns was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
false	20	38	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nns was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
false	20	50	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nn was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
false	20	38	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nns was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
false	38	50	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nn was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
mechanism	50	38	in inpos a dt single_dose jj crossover nn study nn examining vbg lansoprazole nn num cd mg nn and cc omeprazole nn num cd mg nn each dt administered vbn alone rb and cc concomitantly rb with inpos sucralfate nn num cd gram nn absorption nn of inpos the dt proton_pump_inhibitors nn was vbd delayed vbn and cc their prp bioavailability nn was vbd reduced vbn by inpos num cd and cc num cd respectively rb when wrb administered vbn concomitantly rb with inpos sucralfate nn
advise	2	22	therefore rb proton_pump_inhibitors nn should md be vb taken vbn at inpos least jjs num cd minutes nns prior rb to topos sucralfate nn
false	6	16	in inpos clinical jj trials nns antacids nn were vbd administered vbn concomitantly rb with inpos lansoprazole nn delayed_release nn capsules nns
mechanism	12	44	therefore rb it prp is vbz theoretically rb possible jj that inpos lansoprazole nn may md interfere vb with inpos the dt absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos ketoconazole nn
mechanism	12	44	therefore rb it prp is vbz theoretically rb possible jj that inpos lansoprazole nn may md interfere vb with inpos the dt absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos ampicillin nn
mechanism	12	44	therefore rb it prp is vbz theoretically rb possible jj that inpos lansoprazole nn may md interfere vb with inpos the dt absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos iron nn
mechanism	12	44	therefore rb it prp is vbz theoretically rb possible jj that inpos lansoprazole nn may md interfere vb with inpos the dt absorption nn of inpos drugs nns where wrb gastric jj ph nn is vbz an dt important jj determinant nn of inpos digoxin nn
mechanism	8	38	in inpos healthy jj subjects nns receiving vbg ketoconazole nn a dt cyp3a4 nn inhibitor nn at inpos num cd mg nn twice rb daily rb for inpos num cd days nns systemic jj exposure nn to topos lapatinib nn was vbd increased vbn to topos approximately rb float_fold rb of inpos control nn and cc half_life nn increased vbd to topos float_fold rb of inpos control nn
mechanism	14	54	in inpos healthy jj subjects nns receiving vbg the dt cyp3a4 nn inducer nn carbamazepine nn at inpos num cd mg nn twice rb daily rb for inpos num cd days nns and cc num cd mg nn twice rb daily rb for inpos num cd days nns systemic jj exposure nn to topos lapatinib nn was vbd decreased vbn approximately rb num cd
false	2	24	if inpos tykerb nn is vbz administered vbn with inpos drugs nns that wdt inhibit vbp pgp nn increased vbn concentrations nns of inpos lapatinib nn are vbp likely jj and cc caution nn should md be vb exercised vbn
false	20	24	other jj chemotherapy nnp agents nnps in inpos a dt separate jj study nn concomitant jj administration nn of inpos lapatinib nn with inpos capecitabine nn did vbd not rb meaningfully rb alter vb the dt pharmacokinetics nns of inpos either dt agent nn
false	20	24	other jj chemotherapy nnp agents nnps in inpos a dt separate jj study nn concomitant jj administration nn of inpos lapatinib nn with inpos capecitabine nn did vbd not rb meaningfully rb alter vb the dt pharmacokinetics nns of inpos either cc agent nn lrb_or cc the dt metabolites nns of inpos capecitabine nn
false	24	32	in fw vitro fw studies nns have vbp shown vbn that inpos precipitation nn occurs vbz when wrb eye nn drops vbz containing vbg thimerosal nn are vbp mixed vbn with inpos latanoprost nn
false	0	4	cholestyramine nn and cc charcoal nn administration nn of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn concentration nn
false	0	14	cholestyramine nn and cc charcoal nnp administration nnp of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn concentration nn
false	0	52	cholestyramine nn and cc charcoal nnp administration nnp of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn lrb_the dt active jj metabolite nn of inpos leflunomide nn rrb_concentration nn
false	4	0	cholestyramine nn and cc charcoal nn administration nn of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn concentration nn
false	4	52	cholestyramine nn and cc charcoal nn administration nn of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn lrb_the dt active jj metabolite nn of inpos leflunomide nn rrb_concentration nn
false	0	14	cholestyramine nn and cc charcoal nnp administration nnp of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn concentration nn
mechanism	0	52	cholestyramine nn and cc charcoal nnp administration nnp of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn lrb_the dt active jj metabolite nn of inpos leflunomide nn rrb_concentration nn
mechanism	14	52	cholestyramine nn and cc charcoal nnp administration nnp of inpos cholestyramine nn or cc activated_charcoal nn in inpos patients nns and cc volunteers nns resulted vbd in inpos a dt rapid jj and cc significant jj decrease nn in inpos plasma nn m1 nn lrb_the dt active jj metabolite nn of inpos leflunomide nn rrb_concentration nn
effect	12	16	in inpos a dt small jj combination nn study nn of inpos arava nn with inpos methotrexate nn a dt num cd to topos num_fold jj elevation nn in inpos liver nn enzymes nns was vbd seen vbn in inpos num cd of inpos num cd patients nns
false	0	40	nsaids nn in fw in fw vitro fw studies nns m1 nn was vbd shown vbn to topos cause vb increases nns ranging vbg from inpos num cd hyph_num cd in inpos the dt free jj fraction nn of inpos diclofenac nn and cc ibuprofen nn at inpos concentrations nns in inpos the dt clinical jj range nn
false	0	44	nsaids nn in fw in fw vitro fw studies nns m1 nn was vbd shown vbn to topos cause vb increases nns ranging vbg from inpos num cd hyph_num cd in inpos the dt free jj fraction nn of inpos diclofenac nn and cc ibuprofen nn at inpos concentrations nns in inpos the dt clinical jj range nn
false	40	44	nsaids nns in fw in fw vitro fw studies nns m1 nn was vbd shown vbn to topos cause vb increases nns ranging vbg from inpos num cd hyph_num cd in inpos the dt free jj fraction nn of inpos diclofenac nn and cc ibuprofen nn at inpos concentrations nns in inpos the dt clinical jj range nn
mechanism	16	30	following vbg concomitant jj administration nn of inpos a dt single jj dose nn of inpos arava nn to topos subjects nns receiving vbg multiple jj doses nns of inpos rifampin nn m1 nn peak nn levels nns were vbd increased vbn over inpos those dt seen vbn when wrb arava nn was vbd given vbn alone rb
false	30	16	following vbg concomitant jj administration nn of inpos a dt single jj dose nn of inpos arava nn to topos subjects nns receiving vbg multiple jj doses nns of inpos rifampin nn m1 nn peak nn levels nns were vbd increased vbn over inpos those dt seen vbn when wrb arava nn was vbd given vbn alone rb
false	10	54	because inpos of inpos the dt potential nn for inpos arava nn levels nns to topos continue vb to topos increase vb with inpos multiple jj dosing nn caution nn should md be vb used vbn if inpos patients nns are vbp to topos be vb receiving vbg both cc arava nn and cc rifampin nn
advise	10	54	because inpos of inpos the dt potential nn for inpos arava nn levels nns to topos continue vb to topos increase vb with inpos multiple jj dosing nn caution nn should md be vb used vbn if inpos patients nns are vbp to topos be vb receiving vbg both cc arava nn and cc rifampin nn
false	0	8	warfarin nn increased vbd inr nn when wrb arava nn and cc warfarin nn were vbd co_administered vbn has vbz been vbn rarely rb reported vbn
effect	6	10	increased vbn inr nn when wrb arava nn and cc warfarin nn were vbd co_administered vbn has vbz been vbn rarely rb reported vbn
false	24	52	results nns from inpos human jj in fw vitro fw metabolism nn studies nns and cc nonclinical jj studies nns show vbp that inpos revlimid nn is vbz neither dt metabolized vbn by inpos nor cc inhibits vbz induces vbz the dt cytochrome nn p450 nn pathway nn suggesting vbg that inpos lenalidomide nn is vbz not rb likely jj to topos cause vb be vb subject jj to topos p450_based jj metabolic jj drug nn interactions nns in inpos man nn
false	16	0	co_administration nn of inpos multiple jj doses nns of inpos num cd mg nn of inpos lenalidomide nn had vbd no dt effect nn on inpos the dt single jj dose nn pharmacokinetics nns of inpos r nn and cc s nn bbbbb22_warfarin_eeeee22 nn
false	16	40	co_administration nn of inpos multiple jj doses nns of inpos num cd mg nn of inpos lenalidomide nn had vbd no dt effect nn on inpos the dt single jj dose nn pharmacokinetics nns of inpos r nn and cc s_warfarin nn
false	0	0	co_administration nn of inpos multiple jj doses nns of inpos num cd mg nn of inpos lenalidomide nn had vbd no dt effect nn on inpos the dt single jj dose nn pharmacokinetics nns of inpos r nn and cc s nn bbbbbcom_warfarin_eeeeecom nn
false	10	28	co_administration nn of inpos single jj num_mg nn dose nn warfarin nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos total jj lenalidomide nn
false	24	44	expected vbn changes nns in inpos laboratory nn assessments nns of inpos pt nn and cc inr nn were vbd observed vbn after inpos warfarin nn administration nn but cc these dt changes nns were vbd not rb affected vbn by inpos concomitant jj lenalidomide nn administration nn
false	6	32	concomitant jj treatment nn with inpos thrombolytics nn may md hyph_increase vb the dt risk nn of inpos bleeding vbg complications nns considerably rb enhance vbp the dt effect nn of inpos refludan nn on inpos aptt nn prolongation nn
false	6	32	concomitant jj treatment nn with inpos streptokinase nn may md hyph_increase vb the dt risk nn of inpos bleeding vbg complications nns considerably rb enhance vbp the dt effect nn of inpos refludan nn on inpos aptt nn prolongation nn
false	8	12	clinical jj interaction nn studies nns with inpos cimetidine nn and cc warfarin nn indicated vbd that inpos the dt coadministration nn of inpos femara nnp with inpos these dt drugs nns does vbz not rb result vb in inpos clinically jj significant jj drug nn interactions nns
false	8	24	clinical jj interaction nn studies nns with inpos cimetidine nn and cc warfarin nn indicated vbd that inpos the dt coadministration nn of inpos femara nn with inpos these dt drugs nns does vbz not rb result vb in inpos clinically jj significant jj drug nn interactions nns
false	12	24	clinical jj interaction nn studies nns with inpos cimetidine nn and cc warfarin nn indicated vbd that inpos the dt coadministration nn of inpos femara nn with inpos these dt drugs nns does vbz not rb result vb in inpos clinically jj significant jj drug nn interactions nns
mechanism	4	8	coadministration nn of inpos femara nn and cc tamoxifen nn num cd mg nn daily rb resulted vbd in inpos a dt reduction nn of inpos letrozole nn plasma nn levels nns by inpos num cd on inpos average nn
false	4	26	coadministration nn of inpos femara nn and cc tamoxifen nn num cd mg nn daily rb resulted vbd in inpos a dt reduction nn of inpos letrozole nn plasma nn levels nns by inpos num cd on inpos average nn
false	8	26	coadministration nn of inpos femara nnp and cc tamoxifen nn num cd mg nn daily rb resulted vbd in inpos a dt reduction nn of inpos letrozole nn plasma nn levels nns by inpos num cd on inpos average nn
effect	0	20	folic_acid nn in inpos large jj amounts nns may md counteract vb the dt antiepileptic jj effect nn of inpos phenobarbital nn and cc increase vb the dt frequency nn of inpos seizures nns in inpos susceptible jj pediatric jj patients nns
effect	0	20	folic_acid nn in inpos large jj amounts nns may md counteract vb the dt antiepileptic jj effect nn of inpos phenytoin nn and cc increase vb the dt frequency nn of inpos seizures nns in inpos susceptible jj pediatric jj patients nns
effect	0	20	folic_acid nn in inpos large jj amounts nns may md counteract vb the dt antiepileptic jj effect nn of inpos primidone nn and cc increase vb the dt frequency nn of inpos seizures nns in inpos susceptible jj pediatric jj patients nns
false	26	68	preliminary jj animal nn and cc human jj studies nns have vbp shown vbn that inpos small jj quantities nns of inpos systemically rb administered vbn leucovorin nn enter vbp the dt csf nn primarily rb as inpos num_methyltetrahydro_folate jj and cc in inpos humans nns remain vbp num cd to topos num cd orders nns of inpos magnitude nn lower jjr than inpos the dt usual jj methotrexate nn concentrations nns following vbg intrathecal jj administration nn
effect	8	24	however rb high jj doses nns of inpos leucovorin nn may md reduce vb the dt efficacy nn of inpos intrathecally rb administered vbn methotrexate nn
effect	0	12	leucovorin nn may md enhance vb the dt toxicity nn of inpos num_fluorouracil nn
effect	0	26	ergamisol nn has vbz been vbn reported vbn to topos produce vb antabuse_like jj side nn effects nns when wrb given vbn concomitantly rb with inpos alcohol nn
effect	0	26	levamisole_hydrochloride nn has vbz been vbn reported vbn to topos produce vb antabuse_like jj side nn effects nns when wrb given vbn concomitantly rb with inpos alcohol nn
advise	34	38	because inpos of inpos reports nns of inpos prolongation nn of inpos the dt prothrombin nn time nn beyond inpos the dt therapeutic jj range nn in inpos patients nns taking vbg concurrent jj levamisole nn and cc warfarin_sodium nn it prp is vbz suggested vbn that inpos the dt prothrombin nn time nn be vb monitored vbn carefully rb and cc the dt dose nn of inpos warfarin_sodium nn or cc other jj coumarin_like jj drugs nns should md be vb adjusted vbn accordingly rb in inpos patients nns taking vbg both dt drugs nns
false	34	38	because inpos of inpos reports nns of inpos prolongation nn of inpos the dt prothrombin nn time nn beyond inpos the dt therapeutic jj range nn in inpos patients nns taking vbg concurrent jj levamisole nn and cc warfarin_sodium nn it prp is vbz suggested vbn that inpos the dt prothrombin nn time nn be vb monitored vbn carefully rb and cc the dt dose nn of inpos warfarin_sodium nn or cc other jj coumarin_like jj drugs nns should md be vb adjusted vbn accordingly rb in inpos patients nns taking vbg both dt drugs nns
false	34	74	because inpos of inpos reports nns of inpos prolongation nn of inpos the dt prothrombin nn time nn beyond inpos the dt therapeutic jj range nn in inpos patients nns taking vbg concurrent jj levamisole nn and cc warfarin_sodium nn it prp is vbz suggested vbn that inpos the dt prothrombin nn time nn be vb monitored vbn carefully rb and cc the dt dose nn of inpos warfarin_sodium nn or cc other jj coumarin nn like jj drugs nns should md be vb adjusted vbn accordingly rb in inpos patients nns taking vbg both dt drugs nns
false	38	74	because inpos of inpos reports nns of inpos prolongation nn of inpos the dt prothrombin nn time nn beyond inpos the dt therapeutic jj range nn in inpos patients nns taking vbg concurrent jj levamisole nn and cc warfarin_sodium nn it prp is vbz suggested vbn that inpos the dt prothrombin nn time nn be vb monitored vbn carefully rb and cc the dt dose nn of inpos warfarin_sodium nn or cc other jj coumarin nn like jj drugs nns should md be vb adjusted vbn accordingly rb in inpos patients nns taking vbg both dt drugs nns
false	38	74	because inpos of inpos reports nns of inpos prolongation nn of inpos the dt prothrombin nn time nn beyond inpos the dt therapeutic jj range nn in inpos patients nns taking vbg concurrent jj levamisole nn and cc warfarin_sodium nn it prp is vbz suggested vbn that inpos the dt prothrombin nn time nn be vb monitored vbn carefully rb and cc the dt dose nn of inpos warfarin_sodium nn or cc other jj coumarin nn like jj drugs nns should md be vb adjusted vbn accordingly rb in inpos patients nns taking vbg both dt drugs nns
false	4	22	in inpos addition nn levetiracetam nn does vbz not rb affect vb the dt in fw vitro fw glucuronidation nn of inpos valproic_acid nn
false	6	12	drug_drug jj interactions nns between inpos keppra nn and cc other jj antiepileptic_drugs nn phenytoin nn keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	6	12	drug_drug jj interactions nns between inpos keppra nn and cc other jj aeds nn phenytoin nn keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	6	14	drug_drug jj interactions nns between inpos keppra nn and cc other jj antiepileptic_drugs nnp phenytoin nn keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	6	14	drug_drug jj interactions nns between inpos keppra nn and cc other jj antiepileptic_drugs nnp phenytoin nnp keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	12	14	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj antiepileptic_drugs nn phenytoin nn keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	12	6	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj antiepileptic_drugs nn phenytoin nn keppra nn had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	12	14	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj antiepileptic_drugs nn phenytoin nn keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	12	14	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj aeds nn phenytoin nn keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	12	6	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj aeds nn phenytoin nn keppra nn had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	12	14	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj aeds nn phenytoin nn keppra nnp had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	14	6	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj antiepileptic_drugs nnp phenytoin nn keppra nn had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	6	14	drug_drug nnp interactions nnp between nnp keppra nnp and cc other jj antiepileptic_drugs nnp phenytoin nn keppra nn had vbd no dt effect nn on inpos the dt pharmacokinetic jj disposition nn of inpos phenytoin nn in inpos patients nns with inpos refractory jj epilepsy nn
false	4	16	pharmacokinetics nns of inpos levetiracetam nn were vbd also rb not rb affected vbn by inpos phenytoin nn
false	0	2	valproate nn keppra nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos valproate nn in inpos healthy jj volunteers nns
false	2	0	valproate nn keppra nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos valproate nn in inpos healthy jj volunteers nns
false	0	24	valproate nn num cd mg nn twice rb daily rb did vbd not rb modify vb the dt rate nn extent nn of inpos levetiracetam nn absorption nn its prp plasma nn clearance nn urinary jj excretion nn
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj aeds nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj carbamazepine nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj gabapentin nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj lamotrigine nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj phenobarbital nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj phenytoin nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj primidone nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj valproate nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	34	potential jj drug nn interactions nns between inpos keppra nn and cc other jj aeds nns were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	8	14	potential jj drug nn interactions nns between inpos keppra nn and cc other jj aeds nns were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj aeds nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj carbamazepine nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	40	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj carbamazepine nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj gabapentin nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	40	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj gabapentin nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj lamotrigine nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	40	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj lamotrigine nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj phenobarbital nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	40	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj phenobarbital nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj phenytoin nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	40	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj phenytoin nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj primidone nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	40	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj primidone nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	14	34	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj valproate nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nns during inpos placebo_controlled jj clinical jj studies nns
false	14	40	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj valproate nn were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	34	14	potential jj drug nn interactions nns between inpos keppra nnp and cc other jj aeds nns were vbd also rb assessed vbn by inpos evaluating vbg the dt serum nn concentrations nns of inpos levetiracetam nn and cc these dt aeds nn during inpos placebo_controlled jj clinical jj studies nns
false	8	26	these dt data nns indicate vbp that inpos levetiracetam nn does vbz not rb influence vb the dt plasma nn concentration nn of inpos other jj aeds nn and cc that inpos these dt aeds nns do vbp not rb influence vb the dt pharmacokinetics nns of inpos levetiracetam nn
false	8	26	these dt data nns indicate vbp that inpos levetiracetam nn does vbz not rb influence vb the dt plasma nn concentration nn of inpos other jj aeds nns and cc that inpos these dt aeds nn do vbp not rb influence vb the dt pharmacokinetics nns of inpos levetiracetam nn
false	26	8	these dt data nns indicate vbp that inpos levetiracetam nn does vbz not rb influence vb the dt plasma nn concentration nn of inpos other jj aeds nn and cc that inpos these dt aeds nns do vbp not rb influence vb the dt pharmacokinetics nns of inpos levetiracetam nn
false	26	8	these dt data nns indicate vbp that inpos levetiracetam nn does vbz not rb influence vb the dt plasma nn concentration nn of inpos other jj aeds nns and cc that inpos these dt aeds nn do vbp not rb influence vb the dt pharmacokinetics nns of inpos levetiracetam nn
false	4	36	effect nn of inpos aeds nn in inpos pediatric nnp patients nnps there ex was vbd about inpos a dt num cd increase nn of inpos apparent jj total jj body nn clearance nn of inpos levetiracetam nn when wrb it prp was vbd co_administered vbn with inpos enzyme_inducing jj aeds nns
mechanism	36	4	effect nn of inpos aeds nns in inpos pediatric nnp patients nnps there ex was vbd about inpos a dt num cd increase nn of inpos apparent jj total jj body nn clearance nn of inpos levetiracetam nn when wrb it prp was vbd co_administered vbn with inpos enzyme_inducing jj aeds nn
false	0	16	levetiracetam nn had vbd no dt effect nn on inpos plasma nn concentrations nns of inpos carbamazepine nn
false	0	16	levetiracetam nn had vbd no dt effect nn on inpos plasma nn concentrations nns of inpos valproate nn
false	0	16	levetiracetam nn had vbd no dt effect nn on inpos plasma nn concentrations nns of inpos topiramate nn
false	0	16	levetiracetam nn had vbd no dt effect nn on inpos plasma nn concentrations nns of inpos lamotrigine nn
false	8	10	other nnp drug nnp interactions nnp oral nnp contraceptives nn keppra nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	8	36	other nnp drug nnp interactions nnp oral nnp contraceptives nn keppra nnp did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	8	44	other nnp drug nnp interactions nnp oral nnp contraceptives nn keppra nnp did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	10	8	other nnp drug nnp interactions nnp oral nnp contraceptives nnps keppra nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	10	36	other nnp drug nnp interactions nnp oral nnp contraceptives nnps keppra nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	10	44	other nnp drug nnp interactions nnp oral nnp contraceptives nnps keppra nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	8	36	other nnp drug nnp interactions nnp oral nnp contraceptives nnps keppra nnp did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	8	44	other nnp drug nnp interactions nnp oral nnp contraceptives nnps keppra nnp did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	36	44	other nnp drug nnp interactions nnp oral nnp contraceptives nnps keppra nnp did vbd not rb influence vb the dt pharmacokinetics nns of inpos an dt oral jj contraceptive nn containing vbg float cd mg nn ethinyl_estradiol nn and cc float cd mg nn levonorgestrel nn or cc of inpos the dt luteinizing nn hormone nn and cc progesterone nn levels nns indicating vbg that inpos impairment nn of inpos contraceptive jj efficacy nn is vbz unlikely jj
false	8	22	coadministration nn of inpos this dt oral jj contraceptive nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos levetiracetam nn
false	0	2	digoxin nn keppra nn did vbd not rb influence vb the dt pharmacokinetics nns and cc pharmacodynamics nns of inpos digoxin nn given vbn as inpos a dt float cd mg nn dose nn every dt day nn
false	2	0	digoxin nn keppra nn did vbd not rb influence vb the dt pharmacokinetics nns and cc pharmacodynamics nns of inpos digoxin nn given vbn as inpos a dt float cd mg nn dose nn every dt day nn
false	4	18	coadministration nn of inpos digoxin nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos levetiracetam nn
false	0	2	warfarin nn keppra nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos r nn and cc s_warfarin nn
false	2	20	warfarin nn keppra nn did vbd not rb influence vb the dt pharmacokinetics nns of inpos r nn and cc s_warfarin nn
false	0	12	warfarin nnp keppra nnp did vbd not rb influence vb the dt pharmacokinetics nns of inpos r nn and cc s nn bbbbbcom_warfarin_eeeeecom nn
false	4	18	coadministration nn of inpos warfarin nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos levetiracetam nn
false	0	50	probenecid nn probenecid nn a dt renal jj tubular jj secretion nn blocking vbg agent nn administered vbn at inpos a dt dose nn of inpos num cd mg nn num cd times nns a dt day nn did vbd not rb change vb the dt pharmacokinetics nns of inpos levetiracetam nn num cd mg nn twice rb daily rb
false	0	50	probenecid nnp probenecid nn a dt renal jj tubular jj secretion nn blocking vbg agent nn administered vbn at inpos a dt dose nn of inpos num cd mg nn num cd times nns a dt day nn did vbd not rb change vb the dt pharmacokinetics nns of inpos levetiracetam nn num cd mg nn twice rb daily rb
false	6	10	the dt effect nn of inpos keppra nn on inpos probenecid nn was vbd not rb studied vbn
false	2	40	although inpos betagan nn used vbn alone rb has vbz little jj or cc no dt effect nn on inpos pupil nn size nn mydriasis nn resulting vbg from inpos concomitant jj therapy nn with inpos betagan nn and cc epinephrine nn may md occur vb
effect	2	40	although inpos betagan nn used vbn alone rb has vbz little jj or cc no dt effect nn on inpos pupil nn size nn mydriasis nn resulting vbg from inpos concomitant jj therapy nn with inpos betagan nn and cc epinephrine nn may md occur vb
advise	18	38	close jj observation nn of inpos the dt patient nn is vbz recommended vbn when wrb a dt b_blocker nn is vbz administered vbn to topos patients nns receiving vbg catecholamine_depleting jj drugs nns such jj as inpos reserpine nn because inpos of inpos possible jj additive jj effects nns and cc the dt production nn of inpos hypotension nn and_or cc marked jj bradycardia nn which wdt may md produce vb vertigo nn syncope nn postural jj hypotension nn
advise	4	18	patients nns receiving vbg b_adrenergic_blocking_agents nn along inpos with inpos either cc oral jj or cc intravenous jj calcium_antagonists nn should md be vb monitored vbn for inpos possible jj atrioventricular jj conduction nn disturbances nns left vbd ventricular jj failure nn and cc hypotension nn
effect	8	12	the dt concomitant jj use nn of inpos b_adrenergic_blocking_agents nn with inpos digitalis nn and cc calcium_antagonists nns may md have vb additive jj effects nns on inpos prolonging vbg atrioventricular jj conduction nn time nn
effect	8	16	the dt concomitant jj use nn of inpos b_adrenergic_blocking_agents nn with inpos digitalis nn and cc calcium_antagonist nn s nns may md have vb additive jj effects nns on inpos prolonging vbg atrioventricular jj conduction nn time nn
false	12	16	the dt concomitant jj use nn of inpos b_adrenergic_blocking_agents nns with inpos digitalis nn and cc calcium_antagonist nn s nns may md have vb additive jj effects nns on inpos prolonging vbg atrioventricular jj conduction nn time nn
mechanism	0	4	phenothiazine_related_compounds nn and cc b_adrenergic_blocking_agents nn may md have vb additive jj hypotensite nn effects nns due jj to topos the dt inhibition nn of inpos each dt other jj s nn metabolism nn
advise	0	22	chirocaine nn should md be vb used vbn with inpos caution nn in inpos patients nns receiving vbg other jj local jj anesthetics nn or cc agents nns structurally rb related jj to topos amide_type jj local jj anesthetics nns since inpos the dt toxic jj effects nns of inpos these dt drugs nns could md be vb additive jj
false	30	34	in fw vitro fw studies nns indicate vbp cyp3a4 nn isoform nn and cc cyp1a2 nn isoform nn mediate vbp the dt metabolism nn of inpos levobupivacaine nn to topos desbutyl_levobupivacaine nn and cc num_hydroxy_levobupivacaine nn respectively rb
mechanism	28	44	although inpos no dt clinical jj studies nns have vbp been vbn conducted vbn it prp is vbz likely jj that inpos the dt metabolism nn of inpos levobupivacaine nn may md be vb affected vbn by inpos the dt known vbn cyp3a4 nn phenytoin nn cyp3a4 nn inhibitors nns lrb_azole nn antimycotics nns e.g. fw ketoconazole nn
mechanism	28	44	although inpos no dt clinical jj studies nns have vbp been vbn conducted vbn it prp is vbz likely jj that inpos the dt metabolism nn of inpos levobupivacaine nn may md be vb affected vbn by inpos the dt known vbn cyp3a4 nn phenobarbital nn cyp3a4 nn inhibitors nns lrb_azole nn antimycotics nns e.g. fw ketoconazole nn
mechanism	28	44	although inpos no dt clinical jj studies nns have vbp been vbn conducted vbn it prp is vbz likely jj that inpos the dt metabolism nn of inpos levobupivacaine nn may md be vb affected vbn by inpos the dt known vbn cyp3a4 nn rifampin nn cyp3a4 nn inhibitors nns lrb_azole nn antimycotics nns e.g. fw ketoconazole nn
mechanism	28	56	although inpos no dt clinical jj studies nns have vbp been vbn conducted vbn it prp is vbz likely jj that inpos the dt metabolism nn of inpos levobupivacaine nn may md be vb affected vbn by inpos the dt known vbn cyp3a4 nn inducers nns cyp3a4 nn inhibitors nns lrb_azole nn antimycotics nns e.g. fw ketoconazole nn
false	44	56	although inpos no dt clinical jj studies nns have vbp been vbn conducted vbn it prp is vbz likely jj that inpos the dt metabolism nn of inpos levobupivacaine nn may md be vb affected vbn by inpos the dt known vbn cyp3a4 nn phenytoin nn cyp3a4 nn inhibitors nns lrb_azole nn antimycotics nns e.g. fw ketoconazole nn
false	44	56	although inpos no dt clinical jj studies nns have vbp been vbn conducted vbn it prp is vbz likely jj that inpos the dt metabolism nn of inpos levobupivacaine nn may md be vb affected vbn by inpos the dt known vbn cyp3a4 nn phenobarbital nn cyp3a4 nn inhibitors nns lrb_azole nn antimycotics nns e.g. fw ketoconazole nn
false	44	56	although inpos no dt clinical jj studies nns have vbp been vbn conducted vbn it prp is vbz likely jj that inpos the dt metabolism nn of inpos levobupivacaine nn may md be vb affected vbn by inpos the dt known vbn cyp3a4 nn rifampin nn cyp3a4 nn inhibitors nns lrb_azole nn antimycotics nns e.g. fw ketoconazole nn
false	0	4	macrolide_antibiotics nn e.g. fw erythromycin nn
false	2	6	and cc calcium_channel_antagonists nn e.g. fw verapamil nn rrb_cyp1a2 nn inducers nns cyp1a2 nn inhibitors nns
false	2	10	and cc calcium_channel_antagonists nn e.g. fw verapamil nn rrb_cyp1a2 nn omeprazole nn cyp1a2 nn inhibitors nns
false	2	14	and cc calcium_channel_antagonists nn e.g. fw verapamil nn rrb_cyp1a2 nn inducers nns cyp1a2 nn furafylline nn
false	2	14	and cc calcium_channel_antagonists nn e.g. fw verapamil nn rrb_cyp1a2 nn inducers nns cyp1a2 nn clarithromycin nn
false	6	10	and cc calcium_channel_antagonists nns e.g. fw verapamil nn rrb_cyp1a2 nn omeprazole nn cyp1a2 nn inhibitors nns
false	6	14	and cc calcium_channel_antagonists nns e.g. fw verapamil nn rrb_cyp1a2 nn inducers nns cyp1a2 nn furafylline nn
false	6	14	and cc calcium_channel_antagonists nns e.g. fw verapamil nn rrb_cyp1a2 nn inducers nns cyp1a2 nn clarithromycin nn
false	10	14	and cc calcium_channel_antagonists nns e.g. fw verapamil nn rrb_cyp1a2 nn omeprazole nn cyp1a2 nn furafylline nn
false	10	14	and cc calcium_channel_antagonists nns e.g. fw verapamil nn rrb_cyp1a2 nn omeprazole nn cyp1a2 nn clarithromycin nn
mechanism	12	30	however rb the dt systemic jj administration nn of inpos some dt quinolones nn has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
mechanism	12	42	however rb the dt systemic jj administration nn of inpos some dt quinolones nn has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	12	56	however rb the dt systemic jj administration nn of inpos some dt quinolones nn has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
effect	12	58	however rb the dt systemic jj administration nn of inpos some dt quinolones nn has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
effect	12	92	however rb the dt systemic jj administration nn of inpos some dt quinolones nn has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	30	42	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	30	56	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	30	58	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	30	92	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	42	56	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	42	58	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	42	92	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	56	58	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	56	92	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
false	58	92	however rb the dt systemic jj administration nn of inpos some dt quinolones nns has vbz been vbn shown vbn to topos elevate vb plasma nn concentrations nns of inpos theophylline nn interfere vbp with inpos the dt metabolism nn of inpos caffeine nn enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn and cc its prp derivatives nns has vbz been vbn associated vbn with inpos transient jj elevations nns in inpos serum nn creatinine nn in inpos patients nns receiving vbg systemic jj cyclosporine nn concomitantly rb
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt central_nervous_system_depressants nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt alcohol nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt sedatives nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt hypnotics nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt opioids nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt anesthetics nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt barbiturates nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt tricyclic_antidepressants nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt phenothiazines nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt tranquilizers nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt skeletal_muscle_relaxants nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
effect	6	12	concurrent jj use nn of inpos levo_dromoran nn with inpos all dt antihistamines nn may md result vb in inpos additive jj central jj nervous jj system nn depressant jj effects nns
false	8	12	although inpos no dt interaction nn between inpos mao_inhibitors nn and cc levo_dromoran nn has vbz been vbn observed vbn it prp is vbz not rb recommended vbn for inpos use nn with inpos mao_inhibitors nns
advise	12	8	although inpos no dt interaction nn between inpos mao_inhibitors nns and cc levo_dromoran nn has vbz been vbn observed vbn it prp is vbz not rb recommended vbn for inpos use nn with inpos mao_inhibitors nn
false	18	84	most jjs cases nns of inpos serious jj or cc fatal jj adverse jj events nns involving vbg levo_dromoran nn reported vbn to topos the dt manufacturer nn or cc the dt fda nnp have vbp involved vbn either cc the dt administration nn of inpos large jj initial jj doses nns or cc too rb frequent jj doses nns of inpos the dt drug nn to topos nonopioid jj tolerant jj patients nns or cc the dt simultaneous jj administration nn of inpos levorphanol nn with inpos other jj drugs nns affecting vbg respiration nn
false	4	6	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nn pentazocine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran jj
false	4	6	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nn nalbuphine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran jj
false	4	6	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nn butorphanol nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran jj
false	4	6	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nn dezocine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran jj
false	4	6	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nn buprenorphine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran jj
false	0	40	agonist_antagonist_analgesics nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic nn such jj as inpos levo_dromoran jj
advise	0	46	agonist_antagonist_analgesics nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran nn
false	6	46	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps pentazocine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic nn such jj as inpos levo_dromoran jj
advise	6	52	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps pentazocine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran nn
false	6	46	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps nalbuphine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic nn such jj as inpos levo_dromoran jj
advise	6	52	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps nalbuphine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran nn
false	6	46	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps butorphanol nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic nn such jj as inpos levo_dromoran jj
advise	6	52	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps butorphanol nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran nn
false	6	46	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps dezocine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic nn such jj as inpos levo_dromoran jj
advise	6	52	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps dezocine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran nn
false	6	46	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps buprenorphine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic nn such jj as inpos levo_dromoran jj
advise	6	52	interactions nns with inpos mixed_agonist_antagonist_opioid_analgesics nnps buprenorphine nn should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic jj such jj as inpos levo_dromoran nn
advise	40	46	agonist_antagonist_analgesics nns should md not rb be vb administered vbn to topos a dt patient nn who wp has vbz received vbn or cc is vbz receiving vbg a dt course nn of inpos therapy nn with inpos a dt pure_agonist_opioid_analgesic nn such jj as inpos levo_dromoran nn
false	2	8	in inpos opioid nn dependent jj patients nns mixed_agonist_antagonist_analgesics nn may md precipitate vb withdrawal nn symptoms nns
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos captopril nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos b_blockers nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos felodipine nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos digoxin nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos warfarin nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos isosorbide_mononitrate nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos carvedilol nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos ethanol nn
false	10	28	no dt important jj interactions nns to topos date vb levosimendan nn does vbz not rb have vb clinically rb important jj pharmacokinetic jj interactions nns with inpos itraconazole nn
mechanism	18	28	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn aluminum_hydoxide nn sucralfate nn
mechanism	18	28	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn cholestyramine nn sucralfate nn
mechanism	18	28	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn colestipol_hydrochloride nn sucralfate nn
mechanism	18	28	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn ferrous_sulfate nn sucralfate nn
mechanism	18	28	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn sodium_polystyrene_sulfonate nn sucralfate nn
mechanism	18	44	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn aluminum_hydoxide nn cholestyramine nn resin nn colestipol_hydrochloride nn ferrous_sulfate nn sodium_polystyrene_sulfonate nn soybean nn flour nn sucralfate nn
false	28	30	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn aluminum_hydoxide nn sucralfate nn
false	28	30	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn cholestyramine nn sucralfate nn
false	28	30	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn colestipol_hydrochloride nn sucralfate nn
false	28	30	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn ferrous_sulfate nn sucralfate nn
false	28	30	the dt following vbg agents nns may md bind vb and cc decrease vb absorption nn of inpos levothyroxine_sodium nn from inpos the dt gastrointestinal jj tract nn sodium_polystyrene_sulfonate nn sucralfate nn
mechanism	12	38	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns num_fluorouracil nn furosemide nn glucocorticoids nns meclofenamic_acid nn mefenamic_acid nn methadone nn perphenazine nn phenylbutazone nn phenytoin nn salicylates nns tamoxifen nn
mechanism	12	38	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns anabolic_hormones nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns asparaginase nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns clofibrate nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns estrogens nns tamoxifen nn
mechanism	12	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns related jj anabolic_hormones nns estrogen_containing_compounds nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns num_fluorouracil nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns furosemide nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns glucocorticoids nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns meclofenamic_acid nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns mefenamic_acid nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns methadone nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns perphenazine nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns phenylbutazone nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns phenytoin nns tamoxifen nn
mechanism	12	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns salicylates nn
mechanism	12	74	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns asparaginase nn clofibrate nn estrogens nns estrogen_containing_compounds nns num_fluorouracil nn furosemide nn glucocorticoids nns meclofenamic_acid nn mefenamic_acid nn methadone nn perphenazine nn phenylbutazone nn phenytoin nn salicylates nns tamoxifen nn
false	38	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn and cc related jj anabolic_hormones nns estrogens nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns num_fluorouracil nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns furosemide nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns glucocorticoids nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns meclofenamic_acid nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns mefenamic_acid nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns methadone nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns perphenazine nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns phenylbutazone nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns phenytoin nns tamoxifen nn
false	38	44	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns salicylates nn
false	38	64	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nn estrogens nns estrogen_containing_compounds nns num_fluorouracil nn furosemide nn glucocorticoids nns meclofenamic_acid nn mefenamic_acid nn methadone nn perphenazine nn phenylbutazone nn phenytoin nn salicylates nns tamoxifen nn
false	38	40	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns anabolic_hormones nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns asparaginase nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns clofibrate nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns estrogens nns tamoxifen nn
false	44	46	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns related jj anabolic_hormones nns estrogen_containing_compounds nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns num_fluorouracil nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns furosemide nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns glucocorticoids nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns meclofenamic_acid nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns mefenamic_acid nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns methadone nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns perphenazine nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns phenylbutazone nns tamoxifen nn
false	46	48	the dt following vbg agents nns may md either cc inhibit vb levothyroxine_sodium nn binding nn to topos serum nn proteins nns or cc alter vb the dt concentrations nns of inpos serum nn binding nn proteins nns androgens nns and cc related jj anabolic_hormones nns phenytoin nns tamoxifen nn
false	4	10	requirements nns for inpos insulin nn or cc oral jj antidiabetic_agents nn may md be vb reduced vbn in inpos hypothyroid jj patients nns with inpos diabetes nn mellitus nn and cc may md subsequently rb increase vb with inpos the dt initiation nn of inpos thyroid nn hormone nn replacement nn therapy nn
effect	26	30	marked jj hypertension nn and cc tachycardia nn have vbp been vbn reported vbn in inpos association nn with inpos concomitant jj administration nn of inpos levothyroxine_sodium nn and cc ketamine nn
false	0	2	sodium_iodide nn sodium_pertechnetate_tc99m nn
false	0	2	somatrem nn somatropin nn
false	0	12	somatrem nn somatropin nn excessive jj concurrent jj use nn of inpos thyroid_hormone nn may md accelerate vb epiphyseal nn closure nn
false	2	12	somatrem jj somatropin nn excessive jj concurrent jj use nn of inpos thyroid_hormone nn may md accelerate vb epiphyseal nn closure nn
false	18	22	untreated jj hypothyroidism nn may md interfere vb with inpos the dt growth nn response nn to topos somatrem nn or cc somatropin nn
false	8	12	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
false	8	16	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
false	8	24	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
false	8	28	the dt administration nn of inpos local jj anesthetic_solutions nn containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
effect	12	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
effect	12	28	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
effect	16	24	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nns may md produce vb severe jj prolonged vbd hypertension nn
effect	16	28	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nns or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
false	24	28	the dt administration nn of inpos local jj anesthetic_solutions nns containing vbg epinephrine nn or cc norepinephrine nn to topos patients nns receiving vbg monoamine_oxidase_inhibitors nn or cc tricyclic_antidepressants nn may md produce vb severe jj prolonged vbd hypertension nn
false	0	4	phenothiazines nn and cc butyrophenones nn may md reduce vb or cc reverse vb the dt pressor nn effect nn of inpos epinephrine nn
effect	0	22	phenothiazines nn and cc butyrophenones nns may md reduce vb or cc reverse vb the dt pressor nn effect nn of inpos epinephrine nn
effect	4	22	phenothiazines nns and cc butyrophenones nn may md reduce vb or cc reverse vb the dt pressor nn effect nn of inpos epinephrine nn
false	6	10	concurrent jj administration nn of inpos vasopressor_drugs nn and cc ergot_type_oxytocic_drugs nn may md cause vb severe jj persistent jj hypertension nn cerebrovascular jj accidents nns
effect	0	32	lincomycin nn has vbz been vbn shown vbn to topos have vb neuromuscular jj blocking vbg properties nns that wdt may md enhance vb the dt action nn of inpos other jj neuromuscular_blocking_agents nn
effect	4	8	antagonism nn between inpos lincomycin nn and cc erythromycin nn in fw vitro fw has vbz been vbn demonstrated vbn
int	2	16	therefore rb linezolid nn has vbz the dt potential nn for inpos interaction nn with inpos adrenergic nn and cc serotonergic_agents nns
int	2	20	therefore rb linezolid nn has vbz the dt potential nn for inpos interaction nn with inpos adrenergic jj and cc serotonergic_agents nn
false	16	20	therefore rb linezolid nn has vbz the dt potential nn for inpos interaction nn with inpos adrenergic nn and cc serotonergic_agents nn
false	0	8	adrenergic_agents nn some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj sympathomimetic_agents nns vasopressor nn dopaminergic_agents nns
false	0	32	adrenergic_agents nn some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj sympathomimetic_agents nns
false	0	32	adrenergic_agents nn some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj vasopressor nns
false	0	38	adrenergic_agents nn some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj sympathomimetic_agents nns vasopressor nn or cc dopaminergic_agents nn
effect	8	32	adrenergic_agents nns some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj sympathomimetic_agents nns
effect	8	32	adrenergic_agents nns some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj vasopressor nns
effect	8	38	adrenergic_agents nns some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj sympathomimetic_agents nns vasopressor nn or cc dopaminergic_agents nn
false	32	38	adrenergic_agents nns some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj sympathomimetic_agents nn vasopressor nn or cc dopaminergic_agents nn
false	34	38	adrenergic_agents nns some dt individuals nns receiving vbg zyvox nn may md experience vb a dt reversible jj enhancement nn of inpos the dt pressor nn response nn to topos indirect_acting jj sympathomimetic_agents nns vasopressor nn or cc dopaminergic_agents nn
false	10	14	commonly rb used vbn drugs nns such jj as inpos phenylpropanolamine nn and cc pseudoephedrine nn have vbp been vbn specifically rb studied vbn
false	6	12	initial jj doses nns of inpos adrenergic_agents nn such jj as inpos dopamine nn or cc epinephrine nn should md be vb reduced vbn and cc titrated vbn to topos achieve vb the dt desired vbn response nn
false	6	16	initial jj doses nns of inpos adrenergic_agents nn such jj as inpos dopamine nn or cc epinephrine nn should md be vb reduced vbn and cc titrated vbn to topos achieve vb the dt desired vbn response nn
false	12	16	initial jj doses nns of inpos adrenergic_agents nns such jj as inpos dopamine nn or cc epinephrine nn should md be vb reduced vbn and cc titrated vbn to topos achieve vb the dt desired vbn response nn
false	0	6	serotonergic_agents nn co_administration nn of inpos linezolid nn and cc serotonergic_agents nns was vbd not rb associated vbn with inpos serotonin nn syndrome nn in inpos phase nn num cd num cd num cd studies nns
false	4	8	co_administration nn of inpos linezolid nn and cc serotonergic_agents nn was vbd not rb associated vbn with inpos serotonin nn syndrome nn in inpos phase nn num cd num cd num cd studies nns
effect	18	22	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nn including vbg antidepressants nns such jj as inpos selective_serotonin_reuptake_inhibitors nns have vbp been vbn reported vbn
effect	18	26	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nns including vbg antidepressants nn such jj as inpos selective_serotonin_reuptake_inhibitors nns have vbp been vbn reported vbn
effect	18	32	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nns including vbg antidepressants nns such jj as inpos selective_serotonin_reuptake_inhibitors nn have vbp been vbn reported vbn
effect	18	32	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nns including vbg antidepressants nns such jj as inpos ssris nn have vbp been vbn reported vbn
false	22	26	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nn including vbg antidepressants nn such jj as inpos selective_serotonin_reuptake_inhibitors nns have vbp been vbn reported vbn
false	22	32	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nn including vbg antidepressants nns such jj as inpos selective_serotonin_reuptake_inhibitors nn have vbp been vbn reported vbn
false	22	32	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nn including vbg antidepressants nns such jj as inpos ssris nn have vbp been vbn reported vbn
false	26	32	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nns including vbg antidepressants nn such jj as inpos selective_serotonin_reuptake_inhibitors nn have vbp been vbn reported vbn
false	26	32	spontaneous jj reports nns of inpos serotonin nn syndrome nn associated vbn with inpos co_administration nn of inpos zyvox nn and cc serotonergic_agents nns including vbg antidepressants nn such jj as inpos ssris nn have vbp been vbn reported vbn
effect	10	16	patients nns who wp are vbp treated vbn with inpos zyvox nn and cc concomitant jj serotonergic_agents nn should md be vb closely rb observed vbn for inpos signs nns and cc symptoms nns of inpos serotonin nn syndrome nn
advise	8	20	patients nns stabilized vbd on inpos oral jj anticoagulants nn who wp are vbp found vbn to topos require vb thyroid nn replacement nn therapy nn should md be vb watched vbn very rb closely rb when wrb thyroid nn is vbz started vbn
false	0	6	insulin nn or cc oral jj hypoglycemics nn
false	0	6	insulin nn or cc oral jj hypoglycemics nnp initiating vbg thyroid jj replacement nn therapy nn may md cause vb increases nns in inpos insulin nn or cc oral jj hypoglycemic nn requirements nns
false	6	0	insulin nn or cc oral jj hypoglycemics nn initiating vbg thyroid jj replacement nn therapy nn may md cause vb increases nns in inpos insulin nn or cc oral jj hypoglycemic jj requirements nns
false	16	22	initiating vbg thyroid jj replacement nn therapy nn may md cause vb increases nns in inpos insulin nn or cc oral jj hypoglycemic nn requirements nns
false	4	10	patients nns receiving vbg insulin nn or cc oral jj hypoglycemics nn should md be vb closely rb watched vbn during inpos initiation nn of inpos thyroid jj replacement nn therapy nn
mechanism	0	6	cholestyramine nn binds vbz both cc t4 nn and cc t3 nn in inpos the dt intestine nn thus rb impairing vbg absorption nn of inpos these dt thyroid_hormones nns
mechanism	0	10	cholestyramine nn binds vbz both cc t4 nn and cc t3 nn in inpos the dt intestine nn thus rb impairing vbg absorption nn of inpos these dt thyroid_hormones nns
false	0	28	cholestyramine nn binds vbz both cc t4 nn and cc t3 nn in inpos the dt intestine nn thus rb impairing vbg absorption nn of inpos these dt thyroid_hormones nn
false	6	10	cholestyramine nn binds vbz both cc t4 nn and cc t3 nn in inpos the dt intestine nn thus rb impairing vbg absorption nn of inpos these dt thyroid_hormones nns
false	6	28	cholestyramine nn binds vbz both cc t4 nn and cc t3 nn in inpos the dt intestine nn thus rb impairing vbg absorption nn of inpos these dt thyroid_hormones nn
false	10	28	cholestyramine nn binds vbz both cc t4 nn and cc t3 nn in inpos the dt intestine nn thus rb impairing vbg absorption nn of inpos these dt thyroid_hormones nn
advise	20	24	therefore rb num cd to topos num cd hours nns should md elapse vb between inpos administration nn of inpos cholestyramine nn and cc thyroid_hormones nn
false	0	4	estrogen nn oral jj contraceptives nn
mechanism	30	40	in inpos a dt patient nn with inpos a dt nonfunctioning jj thyroid nn gland nn who wp is vbz receiving vbg thyroid jj replacement nn therapy nn free jj levothyroxine nn may md be vb decreased vbn when wrb estrogens nn are vbp started vbn thus rb increasing vbg thyroid nn requirements nns
false	30	12	in inpos a dt patient nn with inpos a dt nonfunctioning jj thyroid nn gland nn who wp is vbz receiving vbg thyroid jj replacement nn therapy nn free jj levothyroxine nn may md be vb decreased vbn when wrb estrogens nns are vbp started vbn thus rb increasing vbg thyroid nn requirements nns
false	40	12	in inpos a dt patient nn with inpos a dt nonfunctioning jj thyroid nn gland nn who wp is vbz receiving vbg thyroid jj replacement nn therapy nn free jj levothyroxine nn may md be vb decreased vbn when wrb estrogens nn are vbp started vbn thus rb increasing vbg thyroid nn requirements nns
advise	10	42	therefore rb patients nns without inpos a dt functioning vbg thyroid nn gland nn who wp are vbp on inpos thyroid jj replacement nn therapy nn may md need vb to topos increase vb their prp thyroid jj dose nn if inpos estrogens nn or cc estrogen_containing jj oral jj contraceptives nns are vbp given vbn
false	10	42	therefore rb patients nns without inpos a dt functioning vbg thyroid nn gland nn who wp are vbp on inpos thyroid jj replacement nn therapy nn may md need vb to topos increase vb their prp thyroid jj dose nn if inpos estrogens nns or cc estrogen nn containing jj oral jj contraceptives nns are vbp given vbn
advise	10	50	therefore rb patients nns without inpos a dt functioning vbg thyroid nn gland nn who wp are vbp on inpos thyroid jj replacement nn therapy nn may md need vb to topos increase vb their prp thyroid jj dose nn if inpos estrogens nns or cc estrogen_containing jj oral jj contraceptives nn are vbp given vbn
false	42	50	therefore rb patients nns without inpos a dt functioning vbg thyroid nn gland nn who wp are vbp on inpos thyroid jj replacement nn therapy nn may md need vb to topos increase vb their prp thyroid jj dose nn if inpos estrogens nn or cc estrogen_containing jj oral jj contraceptives nn are vbp given vbn
false	42	52	therefore rb patients nns without inpos a dt functioning vbg thyroid nn gland nn who wp are vbp on inpos thyroid jj replacement nn therapy nn may md need vb to topos increase vb their prp thyroid jj dose nn if inpos estrogens nns or cc estrogen nn containing jj oral jj contraceptives nn are vbp given vbn
false	0	6	tricyclic_antidepressants nn use nn of inpos thyroid_products nn with inpos imipramine nn and cc other jj tricyclic_antidepressants nns may md increase vb receptor nn sensitivity nn and cc enhance vbp antidepressant nn activity nn transient jj cardiac jj arrhythmias nns have vbp been vbn observed vbn
false	0	10	tricyclic_antidepressants nn use nn of inpos thyroid_products nns with inpos imipramine nn and cc other jj tricyclic_antidepressants nns may md increase vb receptor nn sensitivity nn and cc enhance vbp antidepressant nn activity nn transient jj cardiac jj arrhythmias nns have vbp been vbn observed vbn
effect	4	8	use nn of inpos thyroid_products nn with inpos imipramine nn and cc other jj tricyclic_antidepressants nns may md increase vb receptor nn sensitivity nn and cc enhance vbp antidepressant nn activity nn transient jj cardiac jj arrhythmias nns have vbp been vbn observed vbn
effect	4	14	use nn of inpos thyroid_products nn with inpos imipramine nn and cc other jj tricyclic_antidepressants nn may md increase vb receptor nn sensitivity nn and cc enhance vbp antidepressant nn activity nn transient jj cardiac jj arrhythmias nns have vbp been vbn observed vbn
false	8	14	use nn of inpos thyroid_products nns with inpos imipramine nn and cc other jj tricyclic_antidepressants nn may md increase vb receptor nn sensitivity nn and cc enhance vbp antidepressant nn activity nn transient jj cardiac jj arrhythmias nns have vbp been vbn observed vbn
effect	0	14	thyroid_preparations nn may md potentiate vb the dt toxic jj effects nns of inpos digitalis nn
effect	12	18	when wrb administered vbn to topos patients nns on inpos a dt thyroid_preparation nn this dt parenteral jj anesthetic nn may md cause vb hypertension nn and cc tachycardia nn
effect	0	18	thyroxine nn increases vbz the dt adrenergic jj effect nn of inpos catecholamines nns such jj as inpos epinephrine nn and cc norepinephrine nn
effect	0	22	thyroxine nn increases vbz the dt adrenergic jj effect nn of inpos catecholamines nns such jj as inpos epinephrine nn and cc norepinephrine nn
false	38	42	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	38	44	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nn estrogens nns oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	38	46	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nn oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	38	50	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nns oral jj contraceptives nn containing vbg estrogens nns iodine_containing jj preparations nns and cc the dt numerous jj preparations nns containing vbg salicylates nns
false	38	42	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn estrogens nns the dt numerous jj preparations nns containing vbg salicylates nns
false	38	56	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nns oral jj contraceptives nns containing vbg estrogens nns iodine nn containing jj preparations nns and cc the dt numerous jj preparations nns containing vbg salicylates nns
false	38	68	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nns oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nn
false	42	44	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nn corticosteroids nn estrogens nns oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	42	46	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nn corticosteroids nns estrogens nn oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	42	46	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns oral jj contraceptives nn containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	42	50	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns oral jj contraceptives nns containing vbg estrogens nn iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	42	52	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns oral jj contraceptives nns containing vbg estrogens nns iodine nn containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	42	64	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nn
false	44	46	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nn estrogens nn oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	44	50	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nn estrogens nns oral jj contraceptives nn containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	44	46	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nn estrogens nns oral jj contraceptives nns containing vbg estrogens nn iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	44	56	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nn estrogens nns oral jj contraceptives nns containing vbg estrogens nns iodine nn containing jj preparations nns and cc the dt numerous jj preparations nns containing vbg salicylates nns
false	44	68	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nn estrogens nns oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nn
false	46	50	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nn oral jj contraceptives nn containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	46	56	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nn oral jj contraceptives nns containing vbg estrogens nns iodine nn containing jj preparations nns and cc the dt numerous jj preparations nns containing vbg salicylates nns
false	46	68	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nn oral jj contraceptives nns containing vbg estrogens nns iodine_containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nn
false	50	56	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nns oral jj contraceptives nn containing vbg estrogens nns iodine nn containing jj preparations nns and cc the dt numerous jj preparations nns containing vbg salicylates nns
false	50	70	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nns oral jj contraceptives nn containing vbg estrogens nns iodine_containing jj preparations nns and cc the dt numerous jj preparations nns containing vbg salicylates nn
false	46	56	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nns oral jj contraceptives nns containing vbg estrogens nn iodine nn containing jj preparations nns the dt numerous jj preparations nns containing vbg salicylates nns
false	42	52	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn estrogens nns the dt numerous jj preparations nns containing vbg salicylates nn
false	56	72	drug_laboratory nnp test nnp interactions nnps the dt following vbg drugs nns or cc moieties nns are vbp known vbn to topos interfere vb with inpos laboratory nn tests nns performed vbn in inpos patients nns on inpos thyroid_hormone nn therapy nn androgens nns corticosteroids nns estrogens nns oral jj contraceptives nns containing vbg estrogens nns iodine nn containing jj preparations nns and cc the dt numerous jj preparations nns containing vbg salicylates nn
false	2	10	pregnancy nn estrogens nn and cc estrogen_containing jj oral jj contraceptives nn increase nn tbg nn concentrations nns
false	2	12	pregnancy nn estrogens nns and cc estrogen nn containing jj oral jj contraceptives nn increase nn tbg nn concentrations nns
false	22	26	decreases nns in inpos tbg nn concentrations nns are vbp observed vbn in inpos nephrosis nn acromegaly rb and cc after inpos androgen nn or cc corticosteroid nn therapy nn
mechanism	8	28	urinary jj acidifying vbg agents nns these dt ammonium_chloride nn increase vbp the dt concentration nn of inpos the dt ionized vbn species nns of inpos the dt amphetamine nn molecule nn thereby rb increasing vbg urinary jj excretion nn
mechanism	8	28	urinary jj acidifying vbg agents nns these dt sodium_acid_phosphate nn increase vbp the dt concentration nn of inpos the dt ionized vbn species nns of inpos the dt amphetamine nn molecule nn thereby rb increasing vbg urinary jj excretion nn
false	0	10	adrenergic_blockers nn adrenergic_blockers nns are vbp inhibited vbn by inpos amphetamines nn
effect	0	10	adrenergic_blockers nns adrenergic_blockers nn are vbp inhibited vbn by inpos amphetamines nn
false	0	2	antidepressants nn tricyclic nn amphetamines nns may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nns or cc sympathomimetic_agents nns
false	0	4	antidepressants nn tricyclic jj amphetamines nn may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nns or cc sympathomimetic_agents nns
false	0	20	antidepressants nn tricyclic jj amphetamines nns may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nns or cc sympathomimetic_agents nn
false	2	4	antidepressants nns tricyclic nn amphetamines nn may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nns or cc sympathomimetic_agents nns
false	2	20	antidepressants nns tricyclic nn amphetamines nns may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nns or cc sympathomimetic_agents nn
effect	4	16	antidepressants nns tricyclic jj amphetamines nn may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nn or cc sympathomimetic_agents nns
effect	4	20	antidepressants nns tricyclic jj amphetamines nn may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nns or cc sympathomimetic_agents nn
false	16	20	antidepressants nns tricyclic jj amphetamines nns may md enhance vb the dt activity nn of inpos tricyclic_antidepressants nn or cc sympathomimetic_agents nn
mechanism	0	4	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
mechanism	0	6	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
mechanism	0	12	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	4	6	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	4	12	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	4	0	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	6	12	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	6	0	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nns cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	12	0	d_amphetamine nn with inpos desipramine nn protriptyline nn possibly rb other jj tricyclics nn cause vbp striking jj and cc sustained jj increases nns in inpos the dt concentration nn of inpos d_amphetamine nn in inpos the dt brain nn
false	0	2	mao_inhibitors nn maoi_antidepressants nn as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
false	0	16	mao_inhibitors nn maoi_antidepressants nns as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
false	0	20	mao_inhibitors nn maoi_antidepressants nns as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
false	2	16	mao_inhibitors nns maoi_antidepressants nn as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
mechanism	2	20	mao_inhibitors nns maoi_antidepressants nn as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
mechanism	16	20	mao_inhibitors nns maoi_antidepressants nns as rb well rb as inpos a dt metabolite nn of inpos furazolidone nn slow jj amphetamine nn metabolism nn
effect	0	14	amphetamines nn may md counteract vb the dt sedative jj effect nn of inpos antihistamines nn
effect	0	14	amphetamines nn may md antagonize vb the dt hypotensive jj effects nns of inpos antihypertensives nn
effect	0	26	chlorpromazine nn blocks vbz dopamine nn and cc norepinephrine nn receptors nns thus rb inhibiting vbg the dt central jj stimulant jj effects nns of inpos amphetamines nn and cc can md be vb used vbn to topos treat vb amphetamine nn poisoning nn
false	0	26	chlorpromazine nn blocks vbz dopamine nn and cc norepinephrine nn receptors nns thus rb inhibiting vbg the dt central jj stimulant jj effects nns of inpos amphetamines nns and cc can md be vb used vbn to topos treat vb amphetamine nn poisoning nn
mechanism	0	12	amphetamines nn may md delay vb intestinal jj absorption nn of inpos ethosuximide nn
false	0	24	haloperidol nn haloperidol nn blocks vbz dopamine nn receptors nns thus rb inhibiting vbg the dt central jj stimulant jj effects nns of inpos amphetamines nn
effect	0	24	haloperidol nn haloperidol nn blocks vbz dopamine nn receptors nns thus rb inhibiting vbg the dt central jj stimulant jj effects nns of inpos amphetamines nn
effect	12	22	the dt anorectic jj and cc stimulatory jj effects nns of inpos amphetamines nn may md be vb inhibited vbn by inpos lithium_carbonate nn
effect	0	12	amphetamines nn potentiate vbp the dt analgesic jj effect nn of inpos meperidine nn
false	0	10	methenamine nn therapy nn urinary jj excretion nn of inpos amphetamines nn is vbz increased vbn and cc efficacy nn is vbz reduced vbn by inpos acidifying vbg agents nns used vbn in inpos methenamine nn therapy nn
mechanism	10	0	methenamine nn therapy nn urinary jj excretion nn of inpos amphetamines nn is vbz increased vbn and cc efficacy nn is vbz reduced vbn by inpos acidifying vbg agents nns used vbn in inpos methenamine nn therapy nn
effect	0	12	amphetamines nn enhance vbp the dt adrenergic jj effect nn of inpos norepinephrine nn
mechanism	0	12	amphetamines nn may md delay vb intestinal jj absorption nn of inpos phenobarbital nn
mechanism	0	12	amphetamines nn may md delay vb intestinal jj absorption nn of inpos phenytoin nn
effect	6	10	in inpos cases nns of inpos propoxyphene nn overdosage nn amphetamine nn cns nn stimulation nn is vbz potentiated jj and cc fatal jj convulsions nns can md occur vb
effect	0	12	amphetamines nn inhibit vbp the dt hypotensive jj effect nn of inpos veratrum_alkaloids nn
effect	14	64	hypotension nn hyph_patients nns on inpos diuretic jj therapy nn patients nns on inpos diuretics nn and cc especially rb those dt in inpos whom wp diuretic jj therapy nn was vbd recently rb instituted vbn may md occasionally rb experience vb an dt excessive jj reduction nn of inpos blood nn pressure nn after inpos initiation nn of inpos therapy nn with inpos prinivil nn
false	12	28	the dt possibility nn of inpos hypotensive jj effects nns with inpos prinivil nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos prinivil nn
effect	28	12	the dt possibility nn of inpos hypotensive jj effects nns with inpos prinivil nn can md be vb minimized vbn by inpos either cc discontinuing vbg the dt diuretic nn or cc increasing vbg the dt salt nn intake nn prior jj to topos initiation nn of inpos treatment nn with inpos prinivil nn
advise	14	22	if inpos it prp is vbz necessary jj to topos continue vb the dt diuretic nn initiate vbp therapy nn with inpos prinivil nn at inpos a dt dose nn of inpos num cd mg nn daily rb and cc provide vbp close jj medical jj supervision nn after inpos the dt initial jj dose nn until inpos blood nn pressure nn has vbz stabilized vbn
effect	4	24	when wrb a dt diuretic nn is vbz added vbn to topos the dt therapy nn of inpos a dt patient nn receiving vbg prinivil nn an dt additional jj antihypertensive jj effect nn is vbz usually rb observed vbn
false	4	12	studies nns with inpos ace_inhibitors nn in inpos combination nn with inpos diuretics nn indicate vbp that inpos the dt dose nn of inpos the dt ace_inhibitor nn can md be vb reduced vbn when wrb it prp is vbz given vbn with inpos a dt diuretic jj
false	4	12	studies nns with inpos ace_inhibitors nn in inpos combination nn with inpos diuretics nns indicate vbp that inpos the dt dose nn of inpos the dt ace_inhibitor nn can md be vb reduced vbn when wrb it prp is vbz given vbn with inpos a dt diuretic nn
false	12	4	studies nns with inpos ace_inhibitors nns in inpos combination nn with inpos diuretics nn indicate vbp that inpos the dt dose nn of inpos the dt ace_inhibitor nn can md be vb reduced vbn when wrb it prp is vbz given vbn with inpos a dt diuretic jj
advise	4	12	studies nns with inpos ace_inhibitors nns in inpos combination nn with inpos diuretics nns indicate vbp that inpos the dt dose nn of inpos the dt ace_inhibitor nn can md be vb reduced vbn when wrb it prp is vbz given vbn with inpos a dt diuretic nn
effect	24	32	in inpos some dt patients nns with inpos compromised vbn renal jj function nn who wp are vbp being vbg treated vbn with inpos non_steroidal_anti_inflammatory_drugs nn the dt co_administration nn of inpos lisinopril nn may md result vb in inpos a dt further jj deterioration nn of inpos renal jj function nn
effect	6	20	reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nn including vbg lisinopril nn
effect	6	24	reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nns including vbg lisinopril nn
false	20	24	reports nns suggest vbp that inpos nsaids nns may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nn including vbg lisinopril nn
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg nsaids nn concomitantly rb with inpos ace_inhibitors nn
false	32	50	in inpos a dt study nn in inpos num cd patients nns with inpos mild jj to topos moderate jj hypertension nn where wrb the dt antihypertensive jj effects nns of inpos prinivil nn alone rb were vbd compared vbn to topos prinivil nn given vbn concomitantly rb with inpos indomethacin nn the dt use nn of inpos indomethacin nn was vbd associated vbn with inpos a dt reduced vbn antihypertensive jj effect nn although inpos the dt difference nn between inpos the dt num cd regimens nns was vbd not rb significant jj
false	32	50	in inpos a dt study nn in inpos num cd patients nns with inpos mild jj to topos moderate jj hypertension nn where wrb the dt antihypertensive jj effects nns of inpos prinivil nn alone rb were vbd compared vbn to topos prinivil nn given vbn concomitantly rb with inpos indomethacin nn the dt use nn of inpos indomethacin nn was vbd associated vbn with inpos a dt reduced vbn antihypertensive jj effect nn although inpos the dt difference nn between inpos the dt num cd regimens nns was vbd not rb significant jj
false	32	50	in inpos a dt study nn in inpos num cd patients nns with inpos mild jj to topos moderate jj hypertension nn where wrb the dt antihypertensive jj effects nns of inpos prinivil nn alone rb were vbd compared vbn to topos prinivil nn given vbn concomitantly rb with inpos indomethacin nn the dt use nn of inpos indomethacin nn was vbd associated vbn with inpos a dt reduced vbn antihypertensive jj effect nn although inpos the dt difference nn between inpos the dt num cd regimens nns was vbd not rb significant jj
false	32	50	in inpos a dt study nn in inpos num cd patients nns with inpos mild jj to topos moderate jj hypertension nn where wrb the dt antihypertensive jj effects nns of inpos prinivil nn alone rb were vbd compared vbn to topos prinivil nn given vbn concomitantly rb with inpos indomethacin nn the dt use nn of inpos indomethacin nn was vbd associated vbn with inpos a dt reduced vbn antihypertensive jj effect nn although inpos the dt difference nn between inpos the dt num cd regimens nns was vbd not rb significant jj
false	0	12	prinivil nn has vbz been vbn used vbn concomitantly rb with inpos nitrates nn and_or cc digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	0	16	prinivil nn has vbz been vbn used vbn concomitantly rb with inpos nitrates nns and_or cc digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	12	16	prinivil nn has vbz been vbn used vbn concomitantly rb with inpos nitrates nn and_or cc digoxin nn without inpos evidence nn of inpos clinically rb significant jj adverse jj interactions nns
false	14	24	no dt clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb prinivil nn was vbd used vbn concomitantly rb with inpos propranolol nn or cc hydrochlorothiazide nn
false	14	28	no dt clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb prinivil nn was vbd used vbn concomitantly rb with inpos propranolol nn or cc hydrochlorothiazide nn
false	24	28	no dt clinically rb important jj pharmacokinetic jj interactions nns occurred vbd when wrb prinivil nn was vbd used vbn concomitantly rb with inpos propranolol nn or cc hydrochlorothiazide nn
effect	0	12	prinivil nn attenuates vbz potassium nn loss nn caused vbn by inpos thiazide_type_diuretics nn
effect	4	8	use nn of inpos prinivil nn with inpos potassium_sparing_diuretics nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
effect	4	8	use nn of inpos prinivil nn with inpos spironolactone nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
effect	4	8	use nn of inpos prinivil nn with inpos triamterene nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
effect	4	8	use nn of inpos prinivil nn with inpos amiloride nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
effect	4	8	use nn of inpos prinivil nn with inpos potassium_sparing_diuretics nns potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	8	10	use nn of inpos prinivil nn with inpos spironolactone nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	8	10	use nn of inpos prinivil nn with inpos triamterene nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	8	10	use nn of inpos prinivil nn with inpos amiloride nn potassium nn supplements nns potassium_containing jj salt nn substitutes nns may md lead vb to topos significant jj increases nns in inpos serum nn potassium nn
false	0	36	lithium nn toxicity nn has vbz been vbn reported vbn in inpos patients nns receiving vbg lithium nn concomitantly rb with inpos drugs nns which wdt cause vbp elimination nn of inpos sodium nn including vbg ace_inhibitors nn
effect	0	36	lithium nn toxicity nn has vbz been vbn reported vbn in inpos patients nns receiving vbg lithium nn concomitantly rb with inpos drugs nns which wdt cause vbp elimination nn of inpos sodium nn including vbg ace_inhibitors nn
false	0	22	lithium nn toxicity nn was vbd usually rb reversible jj upon inpos discontinuation nn of inpos lithium nn and cc the dt ace_inhibitor nn
effect	0	22	lithium nn toxicity nn was vbd usually rb reversible jj upon inpos discontinuation nn of inpos lithium nn and cc the dt ace_inhibitor nn
false	10	22	it prp is vbz recommended vbn that inpos serum nn lithium nn levels nns be vb monitored vbn frequently rb if inpos prinivil nn is vbz administered vbn concomitantly rb with inpos lithium nn
advise	22	10	it prp is vbz recommended vbn that inpos serum nn lithium nn levels nns be vb monitored vbn frequently rb if inpos prinivil nn is vbz administered vbn concomitantly rb with inpos lithium nn
effect	0	16	hyph_lofexidine nn may md enhance vb the dt cns nn depressive jj effects nns of inpos alcohol nns
effect	0	16	hyph_lofexidine nn may md enhance vb the dt cns nn depressive jj effects nns of inpos barbiturates nns
effect	0	16	hyph_lofexidine nn may md enhance vb the dt cns nn depressive jj effects nns of inpos sedatives nn
effect	0	12	hyph_lofexidine nn may md enhance vb the dt effects nns of inpos anti_hypertensive_drug nn therapy nn
effect	6	18	hyph_concomitant jj use nn of inpos tricyclic_antidepressants nn may md reduce vb the dt efficacy nn of inpos lofexidine nn
false	18	42	in inpos num cd pharmacokinetic jj studies nns including vbg num cd normal jj healthy jj subjects nns theophylline nn clearance nn and cc concentration nn were vbd not rb significantly rb altered vbn by inpos the dt addition nn of inpos lomefloxacin nn
false	16	20	in inpos clinical jj studies nns where wrb patients nns were vbd on inpos chronic jj theophylline nn therapy nn lomefloxacin nn had vbd no dt measurable jj effect nn on inpos the dt mean jj distribution nn of inpos theophylline nn concentrations nns or cc the dt mean jj estimates nns of inpos theophylline nn clearance nn
false	20	16	in inpos clinical jj studies nns where wrb patients nns were vbd on inpos chronic jj theophylline nn therapy nn lomefloxacin nn had vbd no dt measurable jj effect nn on inpos the dt mean jj distribution nn of inpos theophylline nn concentrations nns or cc the dt mean jj estimates nns of inpos theophylline nn clearance nn
false	20	16	in inpos clinical jj studies nns where wrb patients nns were vbd on inpos chronic jj theophylline nn therapy nn lomefloxacin nn had vbd no dt measurable jj effect nn on inpos the dt mean jj distribution nn of inpos theophylline nn concentrations nns or cc the dt mean jj estimates nns of inpos theophylline nn clearance nn
false	0	4	antacids nn and cc sucralfate nn
false	0	4	sucralfate nn and cc antacids nn containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	0	8	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
false	0	12	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	0	36	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	0	36	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
mechanism	0	64	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	4	8	sucralfate nn and cc antacids nn containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	4	12	sucralfate nn and cc antacids nn containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	4	36	sucralfate nn and cc antacids nn containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	4	36	sucralfate nn and cc antacids nn containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
false	4	64	sucralfate nn and cc antacids nn containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
false	8	12	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
false	8	36	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
false	8	36	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
mechanism	8	64	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
false	12	36	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
false	12	36	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
mechanism	12	64	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nnp buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
mechanism	36	64	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos videx nn buffered vbd tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn interfere vb with inpos its prp bioavailability nn
mechanism	36	64	sucralfate nn and cc antacids nns containing vbg magnesium nn or cc aluminum nn as rb well rb as inpos formulations nns containing vbg divalent jj and cc trivalent jj cations nns such jj as inpos didanosine nn chewable jj tablets nns the dt pediatric jj powder nn for inpos oral jj solution nn can md form vb chelation nn complexes nns with inpos lomefloxacin nn and cc interfere vb with inpos its prp bioavailability nn
mechanism	0	10	sucralfate nn administered vbn num cd hours nns before inpos lomefloxacin nn resulted vbd in inpos a dt slower jjr absorption nn and cc a dt lesser jjr extent nn of inpos absorption nn
false	0	4	magnesium nn hyph_and cc aluminum nn containing jj antacids nns administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
false	0	6	magnesium nn hyph_and cc aluminum_containing jj antacids nn administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
mechanism	0	14	magnesium nn hyph_and cc aluminum_containing jj antacids nns administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
false	0	14	magnesium nn hyph_and cc aluminum_containing jj antacids nns administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
false	4	8	magnesium nn and cc aluminum nn containing jj antacids nn administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
mechanism	4	16	magnesium nn and cc aluminum nn containing jj antacids nns administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
false	4	16	magnesium nn and cc aluminum nn containing jj antacids nns administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
mechanism	6	14	magnesium jj and cc aluminum_containing jj antacids nn administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
false	6	14	magnesium jj and cc aluminum_containing jj antacids nn administered vbn concomitantly rb with inpos lomefloxacin nn significantly rb decreased vbd the dt bioavailability nn of inpos lomefloxacin nn
mechanism	8	12	separating vbg the dt doses nns of inpos antacid nn and cc lomefloxacin nn minimizes vbz this dt decrease nn in inpos bioavailability nn
false	8	38	num cd num cd mg nn of inpos caffeine nn was vbd administered vbn to topos num cd normal jj healthy jj volunteers nns who wp had vbd achieved vbn steady_state jj blood nn concentrations nns of inpos lomefloxacin nn after inpos being vbg dosed vbn at inpos num cd mg nn qd nn
false	34	44	this dt did vbd not rb result vb in inpos any dt statistically rb or cc clinically rb relevant jj changes nns in inpos the dt pharmacokinetic jj parameters nns of inpos either cc caffeine nn or cc its prp major jj metabolite nn paraxanthine nn
mechanism	2	24	other jj quinolones nn have vbp demonstrated vbn moderate jj to topos marked jj interference nn with inpos the dt metabolism nn of inpos caffeine nn resulting vbg in inpos a dt reduced vbn clearance nn a dt prolongation nn of inpos plasma nn half_life nn and cc an dt increase nn in inpos symptoms nns that wdt accompany vbp high jj levels nns of inpos caffeine nn
false	2	24	other jj quinolones nn have vbp demonstrated vbn moderate jj to topos marked jj interference nn with inpos the dt metabolism nn of inpos caffeine nn resulting vbg in inpos a dt reduced vbn clearance nn a dt prolongation nn of inpos plasma nn half_life nn and cc an dt increase nn in inpos symptoms nns that wdt accompany vbp high jj levels nns of inpos caffeine nn
mechanism	0	22	cimetidine nn has vbz been vbn demonstrated vbn to topos interfere vb with inpos the dt elimination nn of inpos other jj quinolones nn
false	6	10	the dt interaction nn between inpos lomefloxacin nn and cc cimetidine nn has vbz not rb been vbn studied vbn
false	0	38	cyclosporine nn elevated vbd serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos other jj members nns of inpos the dt quinolone_class nn
false	8	36	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos other jj members nns of inpos the dt quinolone_class nn
mechanism	8	36	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos other jj members nns of inpos the dt quinolone_class nn
false	4	8	interaction nn between inpos lomefloxacin nn and cc cyclosporine nn has vbz not rb been vbn studied vbn
false	10	46	no dt clinically rb significant jj changes nns in inpos lomefloxacin nn pharmacokinetics nns were vbd observed vbn when wrb a dt single jj dose nn of inpos lomefloxacin nn num cd mg nn was vbd given vbn after inpos multiple jj doses nns of inpos omeprazole nn in inpos num cd healthy jj volunteers nns
false	10	46	no dt clinically rb significant jj changes nns in inpos lomefloxacin nn pharmacokinetics nns were vbd observed vbn when wrb a dt single jj dose nn of inpos lomefloxacin nn num cd mg nn was vbd given vbn after inpos multiple jj doses nns of inpos omeprazole nn in inpos num cd healthy jj volunteers nns
false	14	44	no dt significant jj differences nns were vbd observed vbn in inpos mean jj phenytoin nn auc nn c nn max nn c nn min nn t nn max nn when wrb extended vbn phenytoin_sodium nn capsules nns were vbd coadministered vbn with inpos lomefloxacin nn for inpos num cd days nns in inpos num cd healthy jj males nns
false	34	44	no dt significant jj differences nns were vbd observed vbn in inpos mean jj phenytoin nn auc nn c nn max nn c nn min nn t nn max nn when wrb extended vbn phenytoin_sodium nn capsules nns were vbd coadministered vbn with inpos lomefloxacin nn for inpos num cd days nns in inpos num cd healthy jj males nns
false	0	18	lomefloxacin nn is vbz unlikely jj to topos have vb a dt significant jj effect nn on inpos phenytoin nn metabolism nn
false	28	34	no dt clinically rb significant jj changes nns occurred vbd in inpos heart nn rate nn or cc corrected vbn qt nn intervals nns or cc in inpos terfenadine nn metabolite nn or cc lomefloxacin nn pharmacokinetics nns during inpos concurrent jj administration nn of inpos lomefloxacin nn and cc terfenadine nn at inpos steady_state jj in inpos num cd healthy jj males nns
false	28	34	no dt clinically rb significant jj changes nns occurred vbd in inpos heart nn rate nn or cc corrected vbn qt nn intervals nns or cc in inpos terfenadine nn metabolite nn or cc lomefloxacin nn pharmacokinetics nns during inpos concurrent jj administration nn of inpos lomefloxacin nn and cc terfenadine nn at inpos steady_state jj in inpos num cd healthy jj males nns
false	34	28	no dt clinically rb significant jj changes nns occurred vbd in inpos heart nn rate nn or cc corrected vbn qt nn intervals nns or cc in inpos terfenadine nn metabolite nn or cc lomefloxacin nn pharmacokinetics nns during inpos concurrent jj administration nn of inpos lomefloxacin nn and cc terfenadine nn at inpos steady_state jj in inpos num cd healthy jj males nns
false	34	28	no dt clinically rb significant jj changes nns occurred vbd in inpos heart nn rate nn or cc corrected vbn qt nn intervals nns or cc in inpos terfenadine nn metabolite nn or cc lomefloxacin nn pharmacokinetics nns during inpos concurrent jj administration nn of inpos lomefloxacin nn and cc terfenadine nn at inpos steady_state jj in inpos num cd healthy jj males nns
effect	0	16	quinolones nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
effect	0	18	quinolones nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
false	16	18	quinolones nns may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
false	24	60	however rb no dt clinically rb or cc statistically rb significant jj differences nns in inpos prothrombin nn time nn ratio nn or cc warfarin nn enantiomer nn pharmacokinetics nns were vbd observed vbn in inpos a dt small jj study nn of inpos num cd healthy jj males nns who wp received vbd both cc warfarin nn and cc lomefloxacin nn under inpos steady_state jj conditions nns
false	24	60	however rb no dt clinically rb or cc statistically rb significant jj differences nns in inpos prothrombin nn time nn ratio nn or cc warfarin nn enantiomer nn pharmacokinetics nns were vbd observed vbn in inpos a dt small jj study nn of inpos num cd healthy jj males nns who wp received vbd both cc warfarin nn and cc lomefloxacin nn under inpos steady_state jj conditions nns
false	0	8	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nn renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
false	0	16	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nns renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
false	0	16	probenecid nn as inpos with inpos other jj b_lactam_antibiotics nns renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
false	8	16	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
mechanism	8	0	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
false	8	16	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nn renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
mechanism	16	0	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nns renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
false	0	16	probenecid nnp as inpos with inpos other jj b_lactam_antibiotics nns renal jj excretion nn of inpos loracarbef nn is vbz inhibited vbn by inpos probenecid nn and cc resulted vbd in inpos an dt approximate jj num cd increase nn in inpos the dt auc nn for inpos loracarbef nn
false	0	16	loratadine nn has vbz been vbn coadministered vbn with inpos therapeutic jj doses nns of inpos erythromycin nn in inpos controlled vbn clinical jj pharmacology nn studies nns in inpos adult jj volunteers nns
false	0	16	loratadine nn has vbz been vbn coadministered vbn with inpos therapeutic jj doses nns of inpos cimetidine nn in inpos controlled vbn clinical jj pharmacology nn studies nns in inpos adult jj volunteers nns
false	0	16	loratadine nn has vbz been vbn coadministered vbn with inpos therapeutic jj doses nns of inpos ketoconazole nn in inpos controlled vbn clinical jj pharmacology nn studies nns in inpos adult jj volunteers nns
false	12	16	no dt effects nns on inpos plasma nn concentrations nns of inpos cimetidine nn or cc ketoconazole nn were vbd observed vbn
mechanism	6	18	plasma nn concentrations nns of inpos erythromycin nn decreased vbd num cd with inpos coadministration nn of inpos loratadine nn relative jj to topos that dt observed vbn with inpos erythromycin nn alone rb
false	18	6	plasma nn concentrations nns of inpos erythromycin nn decreased vbd num cd with inpos coadministration nn of inpos loratadine nn relative jj to topos that dt observed vbn with inpos erythromycin nn alone rb
false	32	36	there ex does vbz not rb appear vb to topos be vb an dt increase nn in inpos adverse jj events nns in inpos subjects nns who wp received vbd oral jj contraceptives nn and cc loratadine nn
false	4	8	tablets nns the dt benzodiazepines nn including vbg lorazepam nn produce vbp cns_depressant jj effects nns when wrb administered vbn with inpos such jj medications nns as inpos barbiturates nns or cc alcohol nn
effect	4	28	tablets nns the dt benzodiazepines nn including vbg lorazepam nn produce vbp cns_depressant jj effects nns when wrb administered vbn with inpos such jj medications nns as inpos barbiturates nn or cc alcohol nn
effect	4	32	tablets nns the dt benzodiazepines nn including vbg lorazepam nn produce vbp cns_depressant jj effects nns when wrb administered vbn with inpos such jj medications nns as inpos barbiturates nns or cc alcohol nn
effect	8	28	tablets nns the dt benzodiazepines nns including vbg lorazepam nn produce vbp cns_depressant jj effects nns when wrb administered vbn with inpos such jj medications nns as inpos barbiturates nn or cc alcohol nn
effect	8	32	tablets nns the dt benzodiazepines nns including vbg lorazepam nn produce vbp cns_depressant jj effects nns when wrb administered vbn with inpos such jj medications nns as inpos barbiturates nns or cc alcohol nn
false	28	32	tablets nns the dt benzodiazepines nns including vbg lorazepam nn produce vbp cns_depressant jj effects nns when wrb administered vbn with inpos such jj medications nns as inpos barbiturates nn or cc alcohol nn
false	2	12	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	2	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	2	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos phenothiazines nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	2	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos barbiturates nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	2	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos mao_inhibitors nn other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	2	44	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	2	46	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	12	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	12	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos phenothiazines nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	12	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos barbiturates nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	12	34	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos mao_inhibitors nn other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	12	44	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	12	46	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	12	2	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nn produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	38	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nns other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	40	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	2	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	38	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos phenothiazines nns other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	40	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos phenothiazines nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	2	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos phenothiazines nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	38	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos barbiturates nns other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	40	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos barbiturates nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	2	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos barbiturates nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	38	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos mao_inhibitors nn other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	40	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos mao_inhibitors nn other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	34	2	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos mao_inhibitors nn other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	44	48	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
false	44	2	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants nn .when nn scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
effect	46	2	injection nn lorazepam nn injection nn like inpos other jj injectable jj benzodiazepines nns produces vbz depression nn of inpos the dt central jj nervous jj system nn when wrb administered vbn with inpos ethyl_alcohol nn phenothiazines nns barbiturates nns mao_inhibitors nns other jj antidepressants.when jj scopolamine nn is vbz used vbn concomitantly rb with inpos injectable jj lorazepam nn an dt increased vbn incidence nn of inpos sedation nn hallucinations nns and cc irrational jj behavior nn has vbz been vbn observed vbn
mechanism	0	20	rifampin nn an dt inducer nn of inpos drug nn metabolism nn decreased vbd the dt concentrations nns of inpos losartan nn and cc its prp active jj metabolite nn
false	0	14	ketoconazole nn did vbd not rb affect vb the dt conversion nn of inpos losartan nn to topos the dt active jj metabolite nn after inpos intravenous jj administration nn of inpos losartan nn and cc erythromycin nn had vbd no dt clinically rb significant jj effect nn after inpos oral jj administration nn
false	0	14	ketoconazole nn did vbd not rb affect vb the dt conversion nn of inpos losartan nn to topos the dt active jj metabolite nn after inpos intravenous jj administration nn of inpos losartan nn and cc erythromycin nn had vbd no dt clinically rb significant jj effect nn after inpos oral jj administration nn
false	0	36	ketoconazole nn did vbd not rb affect vb the dt conversion nn of inpos losartan nn to topos the dt active jj metabolite nn after inpos intravenous jj administration nn of inpos losartan nn and cc erythromycin nn had vbd no dt clinically rb significant jj effect nn after inpos oral jj administration nn
false	14	36	ketoconazole nn did vbd not rb affect vb the dt conversion nn of inpos losartan nn to topos the dt active jj metabolite nn after inpos intravenous jj administration nn of inpos losartan nn and cc erythromycin nn had vbd no dt clinically rb significant jj effect nn after inpos oral jj administration nn
false	14	36	ketoconazole nn did vbd not rb affect vb the dt conversion nn of inpos losartan nn to topos the dt active jj metabolite nn after inpos intravenous jj administration nn of inpos losartan nn and cc erythromycin nn had vbd no dt clinically rb significant jj effect nn after inpos oral jj administration nn
mechanism	0	24	fluconazole nn an dt inhibitor nn of inpos p450 nn 2c9 nn decreased vbd active jj metabolite nn concentration nn and cc increased vbn losartan nn concentration nn
false	28	30	as inpos with inpos other jj drugs nns that wdt block vbp angiotensin nn num cd or cc its prp effects nns concomitant jj use nn of inpos spironolactone nn potassium nn supplements nns salt nn substitutes nns containing vbg potassium nn may md lead vb to topos increases nns in inpos serum nn potassium nn
false	28	30	as inpos with inpos other jj drugs nns that wdt block vbp angiotensin nn num cd or cc its prp effects nns concomitant jj use nn of inpos triamterene nn potassium nn supplements nns salt nn substitutes nns containing vbg potassium nn may md lead vb to topos increases nns in inpos serum nn potassium nn
false	28	30	as inpos with inpos other jj drugs nns that wdt block vbp angiotensin nn num cd or cc its prp effects nns concomitant jj use nn of inpos amiloride nn potassium nn supplements nns salt nn substitutes nns containing vbg potassium nn may md lead vb to topos increases nns in inpos serum nn potassium nn
false	6	16	as inpos with inpos other jj antihypertensive_agents nn the dt antihypertensive jj effect nn of inpos losartan nn may md be vb blunted vbn by inpos the dt non_steroidal_anti_inflammatory_drug jj indomethacin nn
false	6	28	as inpos with inpos other jj antihypertensive_agents nn the dt antihypertensive jj effect nn of inpos losartan nn may md be vb blunted vbn by inpos the dt non_steroidal_anti_inflammatory_drug nn indomethacin nn
false	6	30	as inpos with inpos other jj antihypertensive_agents nn the dt antihypertensive jj effect nn of inpos losartan nn may md be vb blunted vbn by inpos the dt non_steroidal_anti_inflammatory_drug jj indomethacin nn
false	16	28	as inpos with inpos other jj antihypertensive_agents nns the dt antihypertensive jj effect nn of inpos losartan nn may md be vb blunted vbn by inpos the dt non_steroidal_anti_inflammatory_drug nn indomethacin nn
effect	16	30	as inpos with inpos other jj antihypertensive_agents nns the dt antihypertensive jj effect nn of inpos losartan nn may md be vb blunted vbn by inpos the dt non_steroidal_anti_inflammatory_drug jj indomethacin nn
false	28	30	as inpos with inpos other jj antihypertensive_agents nns the dt antihypertensive jj effect nn of inpos losartan nn may md be vb blunted vbn by inpos the dt non_steroidal_anti_inflammatory_drug nn indomethacin nn
false	0	2	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nnp hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	0	4	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	0	6	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	0	8	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	0	10	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nn nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	0	12	itraconazole nn ketoconazole nn erythromycin nnp clarithromycin nnp telithromycin nnp hiv_protease_inhibitors nnps nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	0	14	itraconazole nn ketoconazole nn erythromycin nnp clarithromycin nnp telithromycin nnp hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	2	4	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	2	6	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	2	8	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	2	10	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nn nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	2	12	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	2	14	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	4	6	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	4	8	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	4	10	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nn nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	4	12	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	4	14	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	6	8	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	6	10	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nn nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	6	12	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	6	14	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	8	10	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nn nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	8	12	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	8	14	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nns nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	10	12	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nn nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	10	14	itraconazole nn ketoconazole nn erythromycin nn clarithromycin nn telithromycin nn hiv_protease_inhibitors nn nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	12	14	itraconazole nn ketoconazole nn erythromycin nnp clarithromycin nnp telithromycin nnp hiv_protease_inhibitors nnps nefazodone nn cyclosporine nn large jj quantities nns of inpos grapefruit nn juice nn
false	0	4	gemfibrozil nn other jj fibrates nn niacin nn
false	0	6	gemfibrozil nn other jj fibrates nns niacin nn
false	0	6	gemfibrozil nn other jj fibrates nns nicotinic_acid nn
false	4	6	gemfibrozil nn other jj fibrates nn niacin nn
false	4	6	gemfibrozil nn other jj fibrates nn nicotinic_acid nn
effect	20	32	the dt risk nn of inpos myopathy nn is vbz increased vbn by inpos concomitant jj administration nn of inpos danazol nn particularly rb with inpos higher jjr doses nns of inpos lovastatin nn
false	0	4	amiodarone nn or cc verapamil nn
false	16	20	the dt risk nn of inpos myopathy nn is vbz increased vbn when wrb either cc amiodarone nn or cc verapamil nn is vbz used vbn concomitantly rb with inpos a dt closely rb related jj member nn of inpos the dt hmg_coa_reductase_inhibitor_class nn
effect	16	42	the dt risk nn of inpos rhabdomyolysis nn is vbz increased vbn when wrb either cc amiodarone nn or cc verapamil nn is vbz used vbn concomitantly rb with inpos a dt closely rb related jj member nn of inpos the dt hmg_coa_reductase_inhibitor_class nn
effect	20	42	the dt risk nn of inpos rhabdomyolysis nn is vbz increased vbn when wrb either cc amiodarone nn or cc verapamil nn is vbz used vbn concomitantly rb with inpos a dt closely rb related jj member nn of inpos the dt hmg_coa_reductase_inhibitor_class nn
false	14	22	in inpos a dt small jj clinical jj trial nn in inpos which wdt lovastatin nn was vbd administered vbn to topos warfarin nn treated vbn patients nns no dt effect nn on inpos prothrombin nn time nn was vbd detected vbn
effect	4	46	however rb another dt hmg_coa_reductase_inhibitor nn has vbz been vbn found vbn to topos produce vb a dt less jjr than inpos two_second jj increase nn in inpos prothrombin nn time nn in inpos healthy jj volunteers nns receiving vbg low jj doses nns of inpos warfarin nn
effect	28	36	also rb bleeding vbg and_or cc increased vbn prothrombin nn time nn have vbp been vbn reported vbn in inpos a dt few jj patients nns taking vbg coumarin_anticoagulant nn s vbz concomitantly rb with inpos lovastatin nn
advise	14	28	it prp is vbz recommended vbn that inpos in inpos patients nns taking vbg anticoagulants nn prothrombin nn time nn be vb determined vbn before inpos starting vbg lovastatin nn and cc frequently rb enough rb during inpos early jj therapy nn to topos insure vb that inpos no dt significant jj alteration nn of inpos prothrombin nn time nn occurs vbz
false	0	36	lovastatin nn therapy nn has vbz not rb been vbn associated vbn with inpos bleeding nn or cc with inpos changes nns in inpos prothrombin nn time nn in inpos patients nns not rb taking vbg anticoagulants nn
false	0	40	propranolol nn in inpos normal jj volunteers nns there ex was vbd no dt clinically rb significant jj pharmacokinetic jj or cc pharmacodynamic jj interaction nn with inpos concomitant jj administration nn of inpos single jj doses nns of inpos lovastatin nn and cc propranolol nn
false	40	0	propranolol nn in inpos normal jj volunteers nns there ex was vbd no dt clinically rb significant jj pharmacokinetic jj or cc pharmacodynamic jj interaction nn with inpos concomitant jj administration nn of inpos single jj doses nns of inpos lovastatin nn and cc propranolol nn
false	0	16	digoxin nn in inpos patients nns with inpos hypercholesterolemia nn concomitant jj administration nn of inpos lovastatin nn and cc digoxin nn resulted vbd in inpos no dt effect nn on inpos digoxin nn plasma nn concentrations nns
false	16	0	digoxin nn in inpos patients nns with inpos hypercholesterolemia nn concomitant jj administration nn of inpos lovastatin nn and cc digoxin nn resulted vbd in inpos no dt effect nn on inpos digoxin nn plasma nn concentrations nns
false	16	0	digoxin nn in inpos patients nns with inpos hypercholesterolemia nn concomitant jj administration nn of inpos lovastatin nn and cc digoxin nn resulted vbd in inpos no dt effect nn on inpos digoxin nn plasma nn concentrations nns
false	8	34	in inpos pharmacokinetic jj studies nns of inpos mevacor nn in inpos hypercholesterolemic jj noninsulin nn dependent jj diabetic jj patients nns there ex was vbd no dt drug nn interaction nn with inpos glipizide nn or cc with inpos chlorpropamide nn
false	8	40	in inpos pharmacokinetic jj studies nns of inpos mevacor nn in inpos hypercholesterolemic jj noninsulin nn dependent jj diabetic jj patients nns there ex was vbd no dt drug nn interaction nn with inpos glipizide nn or cc with inpos chlorpropamide nn
false	34	40	in inpos pharmacokinetic jj studies nns of inpos mevacor nn in inpos hypercholesterolemic jj noninsulin nn dependent jj diabetic jj patients nns there ex was vbd no dt drug nn interaction nn with inpos glipizide nn or cc with inpos chlorpropamide nn
effect	34	38	there ex have vbp been vbn rare jj reports nns of inpos significant jj respiratory jj depression nn stupor nn and_or cc hypotension nn with inpos the dt concomitant jj use nn of inpos loxapine nn and cc lorazepam nn
mechanism	6	28	the dt absorption nn of inpos lymecycline nn may md be vb affected vbn by inpos the dt simultaneous jj administration nn of inpos indigestion nn remedies nns iron nn or cc zinc nn supplements nns
mechanism	6	32	the dt absorption nn of inpos lymecycline nn may md be vb affected vbn by inpos the dt simultaneous jj administration nn of inpos indigestion nn remedies nns iron nn or cc zinc nn supplements nns
false	28	32	the dt absorption nn of inpos lymecycline nn may md be vb affected vbn by inpos the dt simultaneous jj administration nn of inpos indigestion nn remedies nns iron nn or cc zinc nn supplements nns
effect	2	20	oral jj contraceptives nn may md be vb less rbr effective jj while inpos you prp are vbp taking vbg lymecycline nn
false	0	10	meclofenamate_sodium nn enhances vbz the dt effect nn of inpos warfarin nn
advise	4	18	therefore rb when wrb meclofenamate_sodium nn is vbz given vbn to topos a dt patient nn receiving vbg warfarin nn the dt dosage nn of inpos warfarin nn should md be vb reduced vbn to topos prevent vb excessive jj prolongation nn of inpos the dt prothrombin nn time nn
false	4	18	therefore rb when wrb meclofenamate_sodium nn is vbz given vbn to topos a dt patient nn receiving vbg warfarin nn the dt dosage nn of inpos warfarin nn should md be vb reduced vbn to topos prevent vb excessive jj prolongation nn of inpos the dt prothrombin nn time nn
false	0	14	aspirin nn concurrent jj administration nn of inpos aspirin nn may md lower vb meclofenamate_sodium nn plasma nn levels nns possibly rb by inpos competing vbg for inpos protein_binding jj sites nns
mechanism	6	12	concurrent jj administration nn of inpos aspirin nn may md lower vb meclofenamate_sodium nn plasma nn levels nns possibly rb by inpos competing vbg for inpos protein_binding jj sites nns
false	8	16	the dt urinary jj excretion nn of inpos meclofenamate_sodium nn is vbz unaffected jj by inpos aspirin nn indicating vbg no dt change nn in inpos meclofenamate_sodium nn absorption nn
false	16	8	the dt urinary jj excretion nn of inpos meclofenamate_sodium nn is vbz unaffected jj by inpos aspirin nn indicating vbg no dt change nn in inpos meclofenamate_sodium nn absorption nn
false	0	10	meclofenamate_sodium nn does vbz not rb affect vb serum nn salicylate nn levels nns
false	8	22	the dt concurrent jj administration nn of inpos propoxyphene_hydrochloride nn does vbz not rb affect vb the dt bioavailability nn of inpos meclofenamate_sodium nn
false	0	8	antacids nn concomitant jj administration nn of inpos aluminum nn and cc magnesium nn bbbbb22_hydroxide_eeeee22 nn s nn does vbz not rb interfere vb with inpos absorption nn of inpos meclofenamate_sodium nn
false	0	12	antacids nn concomitant jj administration nn of inpos aluminum nn and cc magnesium_hydroxide nn s nn does vbz not rb interfere vb with inpos absorption nn of inpos meclofenamate_sodium nn
false	0	26	antacids nn concomitant jj administration nn of inpos aluminum nn and cc magnesium_hydroxides nns does vbz not rb interfere vb with inpos absorption nn of inpos meclofenamate_sodium nn
false	6	10	concomitant jj administration nn of inpos aluminum nn and cc magnesium nn bbbbbcom_hydroxide_eeeeecom nn s nn does vbz not rb interfere vb with inpos absorption nn of inpos meclofenamate_sodium nn
false	6	28	concomitant jj administration nn of inpos aluminum nn and cc magnesium nn bbbbb12_hydroxide_eeeee12 nn s nn does vbz not rb interfere vb with inpos absorption nn of inpos meclofenamate_sodium nn
false	10	26	concomitant jj administration nn of inpos aluminum nn and cc magnesium_hydroxide nn s nn does vbz not rb interfere vb with inpos absorption nn of inpos meclofenamate_sodium nn
false	0	8	aspirin nn as inpos with inpos other jj nsaids nn concomitant jj administration nn of inpos ponstel nnp and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
false	0	16	aspirin nn as inpos with inpos other jj nsaids nns concomitant jj administration nn of inpos ponstel nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
false	8	16	aspirin nn as inpos with inpos other jj nsaids nn concomitant jj administration nn of inpos ponstel nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
advise	8	0	aspirin nn as inpos with inpos other jj nsaids nn concomitant jj administration nn of inpos ponstel nnp and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
advise	16	0	aspirin nn as inpos with inpos other jj nsaids nns concomitant jj administration nn of inpos ponstel nn and cc aspirin nn is vbz not rb generally rb recommended vbn because inpos of inpos the dt potential nn of inpos increased vbn adverse jj effects nns
mechanism	0	14	nsaids nn have vbp been vbn reported vbn to topos competitively rb inhibit vb methotrexate nn accumulation nn in inpos rabbit nn kidney nn slices nns
advise	10	20	caution nn should md be vb used vbn when wrb nsaids nn are vbp administered vbn concomitantly rb with inpos methotrexate nn
effect	6	20	reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nn
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg nsaids nn concomitantly rb with inpos ace_inhibitors nn
false	0	22	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
effect	22	0	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
effect	22	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
advise	8	12	during inpos concomitant jj therapy nn of inpos ponstel nn with inpos furosemide nn the dt patient nn should md be vb observed vbn closely rb for inpos signs nns of inpos renal jj failure nn as rb well rb as inpos to topos assure vb diuretic jj efficacy nn
mechanism	0	14	nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
mechanism	0	14	nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
advise	4	8	thus rb when wrb nsaids nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
false	4	8	thus rb when wrb nsaids nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
effect	6	10	the dt effects nns of inpos warfarin nn and cc nsaids nn on inpos gi nn bleeding nn are vbp synergistic jj such jj that inpos users nns of inpos both dt drugs nns together rb have vbp a dt risk nn of inpos serious jj gi nn bleeding vbg higher jjr than inpos users nns of inpos either dt drug nn alone rb
false	16	24	in inpos a dt single jj dose nn study nn ingestion nn of inpos an dt antacid nn containing vbg float_gram nn of inpos magnesium_hydroxide nn with inpos num cd of inpos mefenamic_acid nn increased vbd the dt cmax nn and cc auc nn of inpos mefenamic_acid nn by inpos num cd and cc num cd respectively rb
false	16	32	in inpos a dt single jj dose nn study nn ingestion nn of inpos an dt antacid nn containing vbg float_gram nn of inpos magnesium_hydroxide nn with inpos num cd of inpos mefenamic_acid nn increased vbd the dt cmax nn and cc auc nn of inpos mefenamic_acid nn by inpos num cd and cc num cd respectively rb
false	16	32	in inpos a dt single jj dose nn study nn ingestion nn of inpos an dt antacid nn containing vbg float_gram nn of inpos magnesium_hydroxide nn with inpos num cd of inpos mefenamic_acid nn increased vbd the dt cmax nn and cc auc nn of inpos mefenamic_acid nn by inpos num cd and cc num cd respectively rb
mechanism	24	32	in inpos a dt single jj dose nn study nn ingestion nn of inpos an dt antacid nn containing vbg float_gram nn of inpos magnesium_hydroxide nn with inpos num cd of inpos mefenamic_acid nn increased vbd the dt cmax nn and cc auc nn of inpos mefenamic_acid nn by inpos num cd and cc num cd respectively rb
false	24	32	in inpos a dt single jj dose nn study nn ingestion nn of inpos an dt antacid nn containing vbg float_gram nn of inpos magnesium_hydroxide nn with inpos num cd of inpos mefenamic_acid nn increased vbd the dt cmax nn and cc auc nn of inpos mefenamic_acid nn by inpos num cd and cc num cd respectively rb
advise	26	46	because inpos of inpos the dt danger nn of inpos a dt potentially rb fatal jj prolongation nn of inpos the dt qtc nn interval nn halofantrine nn must md not rb be vb given vbn simultaneously rb with inpos or cc subsequent jj to topos mefloquine nn
effect	6	14	concomitant jj administration nn of inpos mefloquine nn and cc other jj related jj quinine nn may md produce vb electrocardiographic jj abnormalities nns and cc increase vb the dt risk nn of inpos convulsions nns
effect	6	14	concomitant jj administration nn of inpos mefloquine nn and cc other jj related jj quinidine nn may md produce vb electrocardiographic jj abnormalities nns and cc increase vb the dt risk nn of inpos convulsions nns
effect	6	14	concomitant jj administration nn of inpos mefloquine nn and cc other jj related jj chloroquine nn may md produce vb electrocardiographic jj abnormalities nns and cc increase vb the dt risk nn of inpos convulsions nns
effect	26	48	this dt appears vbz to topos be vb the dt only rb clinically rb relevant jj interaction nn of inpos this dt kind nn with inpos mefloquine nn although inpos theoretically rb coadministration nn of inpos other jj drugs nns known vbn to topos alter vb cardiac jj anti_arrhythmic nn might md also rb contribute vb to topos a dt prolongation nn of inpos the dt qtc nn interval nn
effect	26	48	this dt appears vbz to topos be vb the dt only rb clinically rb relevant jj interaction nn of inpos this dt kind nn with inpos mefloquine nn although inpos theoretically rb coadministration nn of inpos other jj drugs nns known vbn to topos alter vb cardiac jj b_adrenergic_blocking_agents nn might md also rb contribute vb to topos a dt prolongation nn of inpos the dt qtc nn interval nn
effect	26	48	this dt appears vbz to topos be vb the dt only rb clinically rb relevant jj interaction nn of inpos this dt kind nn with inpos mefloquine nn although inpos theoretically rb coadministration nn of inpos other jj drugs nns known vbn to topos alter vb cardiac jj calcium_channel_blockers nn might md also rb contribute vb to topos a dt prolongation nn of inpos the dt qtc nn interval nn
effect	26	48	this dt appears vbz to topos be vb the dt only rb clinically rb relevant jj interaction nn of inpos this dt kind nn with inpos mefloquine nn although inpos theoretically rb coadministration nn of inpos other jj drugs nns known vbn to topos alter vb cardiac jj antihistamines nn might md also rb contribute vb to topos a dt prolongation nn of inpos the dt qtc nn interval nn
effect	26	48	this dt appears vbz to topos be vb the dt only rb clinically rb relevant jj interaction nn of inpos this dt kind nn with inpos mefloquine nn although inpos theoretically rb coadministration nn of inpos other jj drugs nns known vbn to topos alter vb cardiac jj h1_blocking_agents nn might md also rb contribute vb to topos a dt prolongation nn of inpos the dt qtc nn interval nn
effect	26	48	this dt appears vbz to topos be vb the dt only rb clinically rb relevant jj interaction nn of inpos this dt kind nn with inpos mefloquine nn although inpos theoretically rb coadministration nn of inpos other jj drugs nns known vbn to topos alter vb cardiac jj tricyclic_antidepressants nn might md also rb contribute vb to topos a dt prolongation nn of inpos the dt qtc nn interval nn
effect	26	48	this dt appears vbz to topos be vb the dt only rb clinically rb relevant jj interaction nn of inpos this dt kind nn with inpos mefloquine nn although inpos theoretically rb coadministration nn of inpos other jj drugs nns known vbn to topos alter vb cardiac jj phenothiazines nn might md also rb contribute vb to topos a dt prolongation nn of inpos the dt qtc nn interval nn
effect	8	18	in inpos patients nns taking vbg an dt anticonvulsant nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
effect	8	18	in inpos patients nns taking vbg an dt valproic_acid nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
false	8	42	in inpos patients nns taking vbg an dt valproic_acid nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
effect	8	18	in inpos patients nns taking vbg an dt carbamazepine nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
false	8	42	in inpos patients nns taking vbg an dt carbamazepine nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
effect	8	18	in inpos patients nns taking vbg an dt phenobarbital nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
false	8	42	in inpos patients nns taking vbg an dt phenobarbital nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
effect	8	18	in inpos patients nns taking vbg an dt phenytoin nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
false	8	42	in inpos patients nns taking vbg an dt phenytoin nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
false	18	8	in inpos patients nns taking vbg an dt anticonvulsant nn the dt concomitant jj use nn of inpos mefloquine nn may md reduce vb seizure nn control nn by inpos lowering vbg the dt plasma nn levels nns of inpos the dt anticonvulsant nn
effect	2	14	when wrb mefloquine nn is vbz taken vbn concurrently rb with inpos oral jj live_typhoid_vaccines nn attenuation nn of inpos immunization nn can md not rb be vb excluded vbn
advise	8	28	nevertheless rb the dt effects nns of inpos mefloquine nn on inpos travelers nns receiving vbg comedication nn particularly rb diabetics nns or cc patients nns using vbg anticoagulants nn should md be vb checked vbn before inpos departure nn
false	14	18	in inpos clinical jj trials nns the dt concomitant jj administration nn of inpos sulfadoxine nn and cc pyrimethamine nn did vbd not rb alter vb the dt adverse jj reaction nn profile nn
false	0	18	broad_spectrum_antibiotics nn broad_spectrum_antibiotics nns may md sterilize vb the dt bowel nn and cc decrease vb the dt vitamin_k nn contribution nn to topos the dt body nn by inpos the dt intestinal jj microflora nns
false	0	18	broad_spectrum_antibiotics jj broad_spectrum_antibiotics nn may md sterilize vb the dt bowel nn and cc decrease vb the dt vitamin_k nn contribution nn to topos the dt body nn by inpos the dt intestinal jj microflora nns
false	0	12	cephalosporins nn cephalosporins nns containing vbg side nn chains nns of inpos cefmenoxime nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nns containing vbg side nn chains nns of inpos cefoperazone nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nns containing vbg side nn chains nns of inpos cefotetan nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nns containing vbg side nn chains nns of inpos cefamandole nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nns containing vbg side nn chains nns of inpos latamoxef nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	16	cephalosporins nn cephalosporins nns containing vbg side nn chains nns of inpos n_methylthiotetrazole nn or cc cefazolin nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nn containing vbg side nn chains nns of inpos cefmenoxime nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nn containing vbg side nn chains nns of inpos cefoperazone nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nn containing vbg side nn chains nns of inpos cefotetan nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nn containing vbg side nn chains nns of inpos cefamandole nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cephalosporins nn cephalosporins nn containing vbg side nn chains nns of inpos latamoxef nn or cc methylthiadiazole nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	16	cephalosporins nn cephalosporins nn containing vbg side nn chains nns of inpos n_methylthiotetrazole nn or cc cefazolin nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	10	14	cephalosporins_cephalosporins nns containing vbg side nn chains nns of inpos cefmenoxime nn or cc cefazolin nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	10	14	cephalosporins_cephalosporins nns containing vbg side nn chains nns of inpos cefoperazone nn or cc cefazolin nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	10	14	cephalosporins_cephalosporins nns containing vbg side nn chains nns of inpos cefotetan nn or cc cefazolin nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	10	14	cephalosporins_cephalosporins nns containing vbg side nn chains nns of inpos cefamandole nn or cc cefazolin nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	10	14	cephalosporins_cephalosporins nns containing vbg side nn chains nns of inpos latamoxef nn or cc cefazolin nn can md cause vb vitamin nn k nn deficiency nn and cc hypoprothrombinemia nn
false	0	12	cholestyramine nn concomitant jj intake nn of inpos cholestyramine nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	12	cholestyramine nn concomitant jj intake nn of inpos cholestyramine nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
mechanism	0	10	cholestyramine_concomitant jj intake nn of inpos cholestyramine nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	10	cholestyramine_concomitant jj intake nn of inpos cholestyramine nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	12	colestipol nn concomitant jj intake nn of inpos colestipol nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	12	colestipol nn concomitant jj intake nn of inpos colestipol nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
mechanism	0	10	colestipol_concomitant jj intake nn of inpos colestipol nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	10	colestipol_concomitant jj intake nn of inpos colestipol nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	12	mineral_oil nn concomitant jj intake nn of inpos mineral_oil nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	12	mineral_oil nn concomitant jj intake nn of inpos mineral_oil nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
mechanism	0	10	mineral_oil_concomitant jj intake nn of inpos mineral_oil nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	10	mineral_oil_concomitant jj intake nn of inpos mineral_oil nn and cc vitamin_k nn may md reduce vb the dt absorption nn of inpos vitamin_k nn
false	0	14	orlistat nn orlistat nn may md decrease vb the dt absorption nn of inpos vitamin_k nn
mechanism	0	14	orlistat jj orlistat nn may md decrease vb the dt absorption nn of inpos vitamin_k nn
false	0	2	warfarin nn hyph_vitamin_k nn can md antagonize vb the dt effect nn of inpos warfarin nn
effect	2	0	warfarin jj vitamin_k nn can md antagonize vb the dt effect nn of inpos warfarin nn
advise	0	24	nabilone nn should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nn or cc cns_depressants nns including vbg alcohol nn barbiturates nns narcotic_analgesics nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
advise	0	28	nabilone nn should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nns or cc cns_depressants nn including vbg alcohol nn barbiturates nns narcotic_analgesics nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
advise	0	32	nabilone nn should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nns or cc cns_depressants nns including vbg alcohol nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
advise	0	32	nabilone nn should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nns or cc cns_depressants nns including vbg barbiturates nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
advise	0	32	nabilone nn should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nns or cc cns_depressants nns including vbg narcotic_analgesics nn or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
false	24	28	nabilone nnp should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nn or cc cns_depressants nn including vbg alcohol nn barbiturates nns narcotic_analgesics nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
false	24	32	nabilone nnp should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nn or cc cns_depressants nns including vbg alcohol nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
false	24	32	nabilone nnp should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nn or cc cns_depressants nns including vbg barbiturates nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
false	24	32	nabilone nnp should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nn or cc cns_depressants nns including vbg narcotic_analgesics nn or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
false	28	32	nabilone nnp should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nns or cc cns_depressants nn including vbg alcohol nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
false	28	32	nabilone nnp should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nns or cc cns_depressants nn including vbg barbiturates nns or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
false	28	32	nabilone nnp should md be vb administered vbn with inpos caution nn to topos patients nns who wp are vbp taking vbg other jj psychoactive_drugs nns or cc cns_depressants nn including vbg narcotic_analgesics nn or cc to topos those dt with inpos a dt history nn of inpos psychiatric jj disorder nn
effect	0	30	nabilone nn has vbz been vbn shown vbn to topos have vb an dt additive jj cns nn depressant nn effect nn when wrb given vbn with inpos either cc diazepam nn
effect	0	30	nabilone nn has vbz been vbn shown vbn to topos have vb an dt additive jj cns nn depressant nn effect nn when wrb given vbn with inpos either cc secobarbitone_sodium nn
effect	0	30	nabilone nn has vbz been vbn shown vbn to topos have vb an dt additive jj cns nn depressant nn effect nn when wrb given vbn with inpos either cc alcohol nn
effect	0	30	nabilone nn has vbz been vbn shown vbn to topos have vb an dt additive jj cns nn depressant nn effect nn when wrb given vbn with inpos either cc codeine nn
advise	12	16	caution nn should md be vb exercised vbn when wrb administering vbg nabumetone nn with inpos warfarin nn since inpos interactions nns have vbp been vbn seen vbn with inpos other jj nsaids nns
false	12	32	caution nn should md be vb exercised vbn when wrb administering vbg nabumetone nn with inpos warfarin nn since inpos interactions nns have vbp been vbn seen vbn with inpos other jj nsaids nn
int	16	32	caution nn should md be vb exercised vbn when wrb administering vbg nabumetone nn with inpos warfarin nn since inpos interactions nns have vbp been vbn seen vbn with inpos other jj nsaids nn
false	8	12	concomitant jj administration nn of inpos an dt aluminum nn containing jj antacid nn had vbd no dt significant jj effect nn in inpos the dt bioavailability nn of inpos 6mna nn
false	8	30	concomitant jj administration nn of inpos an dt aluminum nn containing jj antacid nn had vbd no dt significant jj effect nn in inpos the dt bioavailability nn of inpos 6mna nn
false	10	28	concomitant jj administration nn of inpos an dt aluminum_containing jj antacid nn had vbd no dt significant jj effect nn in inpos the dt bioavailability nn of inpos 6mna nn
int	18	20	when wrb administered vbn concurrently rb the dt following vbg drugs nns may md interact vb with inpos b_adrenergic_receptor_blocking_agents nn anesthetics nn general jj exaggeration nn of inpos the dt hypotension nn induced vbn by inpos general jj anesthetics nns
false	18	20	when wrb administered vbn concurrently rb the dt following vbg drugs nns may md interact vb with inpos b_adrenergic_receptor_blocking_agents nn anesthetics nns general jj exaggeration nn of inpos the dt hypotension nn induced vbn by inpos general jj anesthetics nn
false	0	4	tetracycline nn a dt bacteriostatic_antibiotic nn may md antagonize vb the dt bactericidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
effect	0	18	tetracycline nn a dt bacteriostatic_antibiotic jj may md antagonize vb the dt bactericidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
false	4	18	tetracycline nn a dt bacteriostatic_antibiotic nn may md antagonize vb the dt bactericidal jj effect nn of inpos penicillin nn and cc concurrent jj use nn of inpos these dt drugs nns should md be vb avoided vbn
mechanism	8	20	elevated vbn plasma nn levels nns of inpos theophylline nn have vbp been vbn reported vbn with inpos concomitant jj quinolone nn use nn
false	10	30	there ex have vbp been vbn reports nns of inpos theophylline nn related jj side nn effects nns in inpos patients nns on inpos concomitant jj therapy nn with inpos quinolones nn and cc theophylline nn
effect	28	10	there ex have vbp been vbn reports nns of inpos theophylline_related jj side nn effects nns in inpos patients nns on inpos concomitant jj therapy nn with inpos quinolones nn and cc theophylline nn
mechanism	0	20	quinolones nn have vbp been vbn shown vbn to topos interfere vb with inpos the dt metabolism nn of inpos caffeine nn
false	0	4	quinolones nn including vbg nalidixic_acid nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn or cc its prp derivatives nns
false	0	20	quinolones nn including vbg nalidixic_acid nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
effect	0	22	quinolones nn including vbg nalidixic_acid nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn or cc its prp derivatives nns
false	4	20	quinolones nns including vbg nalidixic_acid nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
effect	4	22	quinolones nns including vbg nalidixic_acid nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant jj warfarin nn or cc its prp derivatives nns
false	20	22	quinolones nns including vbg nalidixic_acid nn may md enhance vb the dt effects nns of inpos the dt oral jj anticoagulant nn warfarin nn or cc its prp derivatives nns
effect	0	14	nitrofurantoin nn interferes vbz with inpos the dt therapeutic jj action nn of inpos nalidixic_acid nn
false	0	4	antacids nn containing vbg magnesium nn
false	0	4	antacids nn containing vbg aluminum nn
false	0	4	antacids nn containing vbg calcium nn
false	0	16	sucralfate nn or cc divalent jj or cc trivalent jj cations nns such jj as inpos iron nn
false	0	4	multivitamins nn containing vbg zinc nn
false	2	4	and cc videx nn didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nns resulting vbg in inpos systemic jj levels nns considerably rb lower jjr than inpos desired vbn
mechanism	2	36	and cc videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj levels nns considerably rb lower jjr than inpos desired vbn
mechanism	4	38	and cc videx nnp didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn may md substantially rb interfere vb with inpos the dt absorption nn of inpos quinolones nn resulting vbg in inpos systemic jj levels nns considerably rb lower jjr than inpos desired vbn
false	8	28	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos the dt concomitant jj use nn of inpos some dt quinolones nn and cc cyclosporine nn
mechanism	28	8	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos the dt concomitant jj use nn of inpos some dt quinolones nn and cc cyclosporine nn
false	12	22	studies nns to topos evaluate vb possible jj interactions nns between inpos revia nn and cc drugs nns other jj than inpos opiates nn have vbp not rb been vbn performed vbn
effect	16	20	the dt safety nn and cc efficacy nn of inpos concomitant jj use nn of inpos revia nn and cc disulfiram nn is vbz unknown jj and cc the dt concomitant jj use nn of inpos num cd potentially rb hepatotoxic jj medications nns is vbz not rb ordinarily rb recommended vbn unless inpos the dt probable jj benefits nns outweigh vbp the dt known jj risks nns
effect	18	22	lethargy nn and cc somnolence nn have vbp been vbn reported vbn following vbg doses nns of inpos revia nn and cc thioridazine nn
effect	4	14	patients nns taking vbg revia nn may md not rb benefit vb from inpos opioid nn containing vbg medicines nns such jj as inpos cough nn cold jj preparations nns antidiarrheal jj preparations nns opioid_analgesics nns
effect	4	24	patients nns taking vbg revia nn may md not rb benefit vb from inpos opioid jj containing vbg medicines nns such jj as inpos opioid_analgesics nn
effect	28	10	in inpos an dt emergency nn situation nn when wrb opioid jj analgesia nn must md be vb administered vbn to topos a dt patient nn receiving vbg revia nn the dt amount nn of inpos opioid nn required vbn may md be vb greater jjr than inpos usual jj and cc the dt resulting vbg respiratory jj depression nn may md be vb deeper jjr and cc more rbr prolonged jj
effect	6	18	the dt use nn of inpos nsaids nn in inpos patients nns who wp are vbp receiving vbg ace_inhibitors nn may md potentiate vb renal jj disease nn states nns
advise	6	10	concomitant jj administration nn of inpos naproxen nn and cc aspirin nn is vbz not rb recommended vbn because inpos naproxen nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns and cc peak jj plasma nn levels nns
false	6	10	concomitant jj administration nn of inpos naproxen nn and cc aspirin nn is vbz not rb recommended vbn because inpos naproxen nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns and cc peak jj plasma nn levels nns
false	10	6	concomitant jj administration nn of inpos naproxen nn and cc aspirin nn is vbz not rb recommended vbn because inpos naproxen nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns and cc peak jj plasma nn levels nns
advise	6	10	concomitant jj administration nn of inpos naproxen nn and cc aspirin nn is vbz not rb recommended vbn because inpos naproxen nn is vbz displaced vbn from inpos its prp binding vbg sites nns during inpos the dt concomitant jj administration nn of inpos aspirin nn resulting vbg in inpos lower jjr plasma nn concentrations nns and cc peak jj plasma nn levels nns
false	0	6	naproxen nn and cc other jj nsaids nn can md reduce vb the dt antihypertensive jj effect nn of inpos propranolol nn and cc other jj b_blockers nns
effect	0	20	naproxen nn and cc other jj nsaids nns can md reduce vb the dt antihypertensive jj effect nn of inpos propranolol nn and cc other jj b_blockers nns
effect	0	26	naproxen nn and cc other jj nsaids nns can md reduce vb the dt antihypertensive jj effect nn of inpos propranolol nn and cc other jj b_blockers nn
effect	6	20	naproxen nnp and cc other jj nsaids nn can md reduce vb the dt antihypertensive jj effect nn of inpos propranolol nn and cc other jj b_blockers nns
effect	6	26	naproxen nnp and cc other jj nsaids nn can md reduce vb the dt antihypertensive jj effect nn of inpos propranolol nn and cc other jj b_blockers nn
false	20	26	naproxen nnp and cc other jj nsaids nns can md reduce vb the dt antihypertensive jj effect nn of inpos propranolol nn and cc other jj b_blockers nn
mechanism	0	8	probenecid nn given vbn concurrently rb increases vbz naproxen nn anion nn plasma nn levels nns and cc extends vbz its prp plasma nn half_life nn significantly rb
advise	10	20	caution nn should md be vb used vbn if inpos naproxen nn is vbz administered vbn concomitantly rb with inpos methotrexate nn
mechanism	0	28	naproxen nn naproxen_sodium nn and cc other jj nsaids nns have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb increasing vbg the dt toxicity nn of inpos methotrexate nn
false	0	28	naproxen nn naproxen_sodium nn and cc other jj nsaids nns have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb increasing vbg the dt toxicity nn of inpos methotrexate nn
mechanism	0	20	naproxen_sodium nns have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb increasing vbg the dt toxicity nn of inpos methotrexate nn
false	0	20	naproxen_sodium nns have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb increasing vbg the dt toxicity nn of inpos methotrexate nn
mechanism	0	20	nsaids nn have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb increasing vbg the dt toxicity nn of inpos methotrexate nn
false	0	20	nsaids nn have vbp been vbn reported vbn to topos reduce vb the dt tubular jj secretion nn of inpos methotrexate nn in inpos an dt animal nn model nn possibly rb increasing vbg the dt toxicity nn of inpos methotrexate nn
false	28	32	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj ergot_type_medications nn naratriptan nn within inpos num cd hours nns is vbz contraindicated vbn
false	28	32	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj methysergide nn naratriptan nn within inpos num cd hours nns is vbz contraindicated vbn
advise	28	34	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine nn containing jj ergot_type_medications nns naratriptan nn within inpos num cd hours nns is vbz contraindicated vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc ergot_type_medications nn and cc naratriptan nn within inpos num cd hours nns is vbz contraindicated vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc dihydroergotamine nn and cc naratriptan nn within inpos num cd hours nns is vbz contraindicated vbn
advise	32	36	because inpos there ex is vbz a dt theoretical jj basis nn that inpos these dt effects nns may md be vb additive jj use nn of inpos ergotamine_containing jj or cc methysergide nn and cc naratriptan nn within inpos num cd hours nns is vbz contraindicated vbn
false	6	12	the dt administration nn of inpos naratriptan nn with inpos other jj num_ht1_agonists nn has vbz not rb been vbn evaluated vbn in inpos migraine nn patients nns
advise	18	24	because inpos their prp vasospastic jj effects nns may md be vb additive jj coadministration nn of inpos naratriptan nn and cc other jj num_ht1_agonists nn within inpos num cd hours nns of inpos each dt other jj is vbz not rb recommended vbn
advise	8	14	if inpos concomitant jj treatment nn with inpos naratriptan nn and cc an dt ssri nn is vbz clinically rb warranted vbn appropriate jj observation nn of inpos the dt patient nn is vbz advised vbn
false	6	8	after inpos multiple jj dosing nn interferon_b_1a nn lrb_avonex nn num cd mcg nn im nn once rb weekly rb rrb_reduced vbd tysabri nn clearance nn by inpos approximately rb num cd
mechanism	6	10	after inpos multiple jj dosing nn interferon_b_1a nn reduced vbd tysabri nn clearance nn by inpos approximately rb num cd
mechanism	8	22	after inpos multiple jj dosing nn interferon_b_1a nn lrb_avonex nn num cd mcg nn im nn once rb weekly rb rrb_reduced vbd tysabri nn clearance nn by inpos approximately rb num cd
false	8	22	the dt similarity nn of inpos the dt tysabri nn associated jj adverse jj event nn profile nn between inpos study nn avonex nn and cc study nn num cd indicates vbz that inpos this dt alteration nn in inpos clearance nn does vbz not rb necessitate vb reduction nn of inpos the dt tysabri nn dose nn to topos maintain vb safety nn general nnp
false	8	28	the dt similarity nn of inpos the dt tysabri nn associated jj adverse jj event nn profile nn between inpos study nn num cd and cc study nn avonex nn indicates vbz that inpos this dt alteration nn in inpos clearance nn does vbz not rb necessitate vb reduction nn of inpos the dt tysabri nn dose nn to topos maintain vb safety nn general nnp
false	22	8	the dt similarity nn of inpos the dt tysabri nn associated jj adverse jj event nn profile nn between inpos study nn avonex nn and cc study nn num cd indicates vbz that inpos this dt alteration nn in inpos clearance nn does vbz not rb necessitate vb reduction nn of inpos the dt tysabri nn dose nn to topos maintain vb safety nn general nnp
false	28	8	the dt similarity nn of inpos the dt tysabri nn associated jj adverse jj event nn profile nn between inpos study nn num cd and cc study nn avonex nn indicates vbz that inpos this dt alteration nn in inpos clearance nn does vbz not rb necessitate vb reduction nn of inpos the dt tysabri nn dose nn to topos maintain vb safety nn general nnp
false	16	24	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn and cc concomitant jj interferon_b_1a nn lrb_avonex nn num cd mcg nn im nn once rb weekly jj rrb_or cc glatiramer_acetate nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	16	42	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	16	46	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	22	24	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn and cc concomitant jj interferon_b_1a nn lrb_avonex nn num cd mcg nn im nn once rb weekly jj rrb_or cc glatiramer_acetate nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	16	42	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg interferon_b_1a nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	16	46	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg interferon_b_1a nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	24	38	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn and cc concomitant jj interferon_b_1a nn lrb_avonex nn num cd mcg nn im nn once rb weekly jj rrb_or cc glatiramer_acetate nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	22	60	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn concomitant jj interferon_b_1a nn lrb_avonex nn num cd mcg nn im nn once rb weekly rb rrb_glatiramer_acetate nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	24	38	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn and cc concomitant jj interferon_b_1a nn lrb_avonex nn num cd mcg nn im nn once rb weekly jj rrb_or cc glatiramer_acetate nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	16	42	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg glatiramer_acetate nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
false	48	22	results nns of inpos studies nns in inpos multiple jj sclerosis nn patients nns taking vbg tysabri nn concomitant jj interferon_b_1a nn glatiramer_acetate nn were vbd inconclusive jj with inpos regard nn to topos the dt need nn for inpos dose nn adjustment nn of inpos the dt b_interferon nn or cc glatiramer_acetate nn
mechanism	0	46	starlix nn is vbz a dt potential jj inhibitor nn of inpos the dt cyp2c9 nn isoenzyme nn in fw vivo fw as inpos indicated vbn by inpos its prp ability nn to topos inhibit vb the dt in fw vitro fw metabolism nn of inpos tolbutamide nn
false	0	32	glyburide nn in inpos a dt randomized vbn multiple_dose jj crossover nn study nn patients nns with inpos type nn num cd diabetes nns were vbd administered vbn num cd mg nn starlix nn num cd times nns a dt day nn before inpos meals nns for inpos num cd day nn in inpos combination nn with inpos glyburide nn num cd mg nn daily jj
false	32	0	glyburide nn in inpos a dt randomized vbn multiple_dose jj crossover nn study nn patients nns with inpos type nn num cd diabetes nns were vbd administered vbn num cd mg nn starlix nn num cd times nns a dt day nn before inpos meals nns for inpos num cd day nn in inpos combination nn with inpos glyburide nn num cd mg nn daily jj
false	2	28	when wrb starlix nn num cd mg nn num cd times nns daily rb before inpos meals nns was vbd administered vbn in inpos combination nn with inpos metformin nn num cd mg nn num cd times nns daily rb to topos patients nns with inpos type nn num cd diabetes nns there ex were vbd no dt clinically rb relevant jj changes nns in inpos the dt pharmacokinetics nns of inpos either dt agent nn
false	2	32	when wrb starlix nn num cd mg nn before inpos meals nns was vbd administered vbn in inpos combination nn with inpos a dt single jj num_mg nn dose nn of inpos digoxin nn to topos healthy jj volunteers nns there ex were vbd no dt clinically rb relevant jj changes nns in inpos the dt pharmacokinetics nns of inpos either dt agent nn
false	10	46	when wrb healthy jj subjects nns were vbd administered vbn starlix nn num cd mg nn num cd times nns daily rb before inpos meals nns for inpos num cd days nns in inpos combination nn with inpos a dt single jj dose nn of inpos warfarin nn num cd mg nn on inpos day nn num cd there ex were vbd no dt alterations nns in inpos the dt pharmacokinetics nns of inpos either dt agent nn
false	0	16	diclofenac nn administration nn of inpos morning nn and cc lunch nn doses nns of inpos starlix nn num cd mg nn in inpos combination nn with inpos a dt single jj num_mg nn dose nn of inpos diclofenac nn in inpos healthy jj volunteers nns resulted vbd in inpos no dt significant jj changes nns to topos the dt pharmacokinetics nns of inpos either dt agent nn
false	14	36	administration nn of inpos morning nn and cc lunch nn doses nns of inpos starlix nn num cd mg nn in inpos combination nn with inpos a dt single jj num_mg nn dose nn of inpos diclofenac nn in inpos healthy jj volunteers nns resulted vbd in inpos no dt significant jj changes nns to topos the dt pharmacokinetics nns of inpos either dt agent nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos furosemide nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos propranolol nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos captopril nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos nicardipine nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos pravastatin nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos glyburide nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos warfarin nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos phenytoin nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos acetylsalicylic_acid nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos tolbutamide nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	20	36	in fw vitro fw displacement nn studies nns with inpos highly rb protein_bound jj drugs nns such jj as inpos metformin nn showed vbd no dt influence nn on inpos the dt extent nn of inpos nateglinide nn protein nn binding nn
false	2	22	similarly rb nateglinide nn had vbd no dt influence nn on inpos the dt serum nn protein nn binding nn of inpos propranolol nn in fw vitro fw
false	2	22	similarly rb nateglinide nn had vbd no dt influence nn on inpos the dt serum nn protein nn binding nn of inpos glyburide nn in fw vitro fw
false	2	22	similarly rb nateglinide nn had vbd no dt influence nn on inpos the dt serum nn protein nn binding nn of inpos nicardipine nn in fw vitro fw
false	2	22	similarly rb nateglinide nn had vbd no dt influence nn on inpos the dt serum nn protein nn binding nn of inpos warfarin nn in fw vitro fw
false	2	22	similarly rb nateglinide nn had vbd no dt influence nn on inpos the dt serum nn protein nn binding nn of inpos phenytoin nn in fw vitro fw
false	2	22	similarly rb nateglinide nn had vbd no dt influence nn on inpos the dt serum nn protein nn binding nn of inpos acetylsalicylic_acid nn in fw vitro fw
false	2	22	similarly rb nateglinide nn had vbd no dt influence nn on inpos the dt serum nn protein nn binding nn of inpos tolbutamide nn in fw vitro fw
effect	6	20	certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg nsaids nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg nsaids nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg salicylates nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg salicylates nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg monoamine_oxidase_inhibitors nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg monoamine_oxidase_inhibitors nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg non_selective_b_adrenergic_blocking_agents nn may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg non_selective_b_adrenergic_blocking_agents nn may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
false	26	34	certain jj drugs nns including vbg nonsteroidal_anti_inflammatory_agents nns salicylates nns monoamine_oxidase_inhibitors nns non_selective_b_adrenergic_blocking_agents nns may md potentiate vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg thiazides nns may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg thiazides nns may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg corticosteroids nns may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg corticosteroids nns may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg thyroid_products nns may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg thyroid_products nns may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
effect	6	20	certain jj drugs nns including vbg sympathomimetics nn may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nns
effect	6	28	certain jj drugs nns including vbg sympathomimetics nn may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nnp and cc other jj oral jj antidiabetic_drugs nn
false	26	34	certain jj drugs nns including vbg thiazides nns corticosteroids nns thyroid_products nns sympathomimetics nns may md reduce vb the dt hypoglycemic jj action nn of inpos starlix nn and cc other jj oral jj antidiabetic_drugs nn
false	6	30	in inpos clinical jj studies nns tilade nn has vbz been vbn co_administered vbn with inpos other jj anti_asthma jj medications nns including vbg inhaled vbn and cc oral jj bronchodilators nn and cc inhaled vbd corticosteroids nns with inpos no dt evidence nn of inpos increased vbn frequency nn of inpos adverse jj events nns or cc laboratory nn abnormalities nns
false	6	36	in inpos clinical jj studies nns tilade nn has vbz been vbn co_administered vbn with inpos other jj anti_asthma jj medications nns including vbg inhaled vbn and cc oral jj bronchodilators nns and cc inhaled vbd corticosteroids nn with inpos no dt evidence nn of inpos increased vbn frequency nn of inpos adverse jj events nns or cc laboratory nn abnormalities nns
false	30	36	in inpos clinical jj studies nns tilade nnp has vbz been vbn co_administered vbn with inpos other jj anti_asthma jj medications nns including vbg inhaled vbn and cc oral jj bronchodilators nn and cc inhaled vbd corticosteroids nn with inpos no dt evidence nn of inpos increased vbn frequency nn of inpos adverse jj events nns or cc laboratory nn abnormalities nns
false	4	16	coadministration nn of inpos viracept nn and cc drugs nns primarily rb metabolized vbn by inpos dihydropyridine_calcium_channel_blockers nn may md result vb in inpos increased vbn plasma nn concentrations nns of inpos the dt other jj drug nn that wdt could md increase vb or cc prolong vb both cc its prp therapeutic jj and cc adverse jj effects nns
false	4	20	coadministration nn of inpos viracept nn and cc drugs nns that wdt induce vbp cyp3a nn may md decrease vb nelfinavir nn plasma nn concentrations nns and cc reduce vb its prp therapeutic jj effect nn
false	4	20	coadministration nn of inpos viracept nn and cc drugs nns that wdt inhibit vbp cyp3a nn may md increase vb nelfinavir nn plasma nn concentrations nns
advise	14	16	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	18	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	20	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	22	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	24	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	26	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	30	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	14	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	18	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	20	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	22	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	24	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	26	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	30	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	16	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nn amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	20	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	22	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	24	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	26	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	30	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	18	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	22	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	24	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	26	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	30	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	20	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	24	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	26	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	30	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nnp antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	22	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nn astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	26	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	30	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	24	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	26	30	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	26	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	26	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	26	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	26	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	26	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	26	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	30	32	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	30	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	30	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	30	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	30	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	30	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nn antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	32	34	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	32	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	32	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	32	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	32	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nn rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	34	36	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	34	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	34	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	34	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	36	38	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	36	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	36	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nn midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	38	40	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	38	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
false	40	48	drugs nns that wdt should md not rb be vb coadministered vbn with inpos viracept nn antiarrhythmics nns amiodarone nn quinidine nn antihistamines nns astemizole nn terfenadine nn antimigraine nn ergot_derivatives nns antimycobacterial_agents nns rifampin nn benzodiazepines nns midazolam nn triazolam nn gi nn motility nn agents nns cisapride nn
advise	18	20	drugs nns which wdt require vbp a dt dose nnp reduction nnp when wrb coadminstered vbn with inpos viracept nn antimycobacterial_agents nn rifabutin nn
advise	18	22	drugs nns which wdt require vbp a dt dose nnp reduction nnp when wrb coadminstered vbn with inpos viracept nn antimycobacterial_agents nns rifabutin nn
false	20	22	drugs nns which wdt require vbp a dt dose nnp reduction nnp when wrb coadminstered vbn with inpos viracept nn antimycobacterial_agents nn rifabutin nn
false	12	28	sym_this dt table nn is vbz not rb all dt inclusive jj viracept nn may md not rb be vb effective jj due jj to topos decreased vbn nelfinavir nn plasma nn concentrations nns in inpos patients nns taking vbg these dt agents nns concomitantly rb
false	0	10	terfenadine nn administration nn of inpos terfenadine nn with inpos viracept nn resulted vbd in inpos the dt appearance nn of inpos unchanged jj terfenadine nn in inpos plasma nn
false	4	8	administration nn of inpos terfenadine nn with inpos viracept nn resulted vbd in inpos the dt appearance nn of inpos unchanged jj terfenadine nn in inpos plasma nn
false	8	4	administration nn of inpos terfenadine nn with inpos viracept nn resulted vbd in inpos the dt appearance nn of inpos unchanged jj terfenadine nn in inpos plasma nn
advise	2	16	therefore rb viracept nn should md not rb be vb administered vbn concurrently rb with inpos terfenadine nn because inpos of inpos the dt potential nn for inpos serious jj and_or cc life_threatening jj cardiac jj arrhythmias nns
advise	12	28	because inpos a dt similar jj interaction nn is vbz likely jj viracept nn should md also rb not rb be vb administered vbn concurrently rb with inpos astemizole nn
false	0	10	indinavir nn coadministration nn of inpos indinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos indinavir nn plasma nn a.c nn
false	0	24	indinavir nn coadministration nn of inpos indinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos indinavir nn plasma nn a.c nn
mechanism	4	8	coadministration nn of inpos indinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos indinavir nn plasma nn a.c nn
false	4	22	coadministration nn of inpos indinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos indinavir nn plasma nn a.c nn
false	8	22	coadministration nn of inpos indinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos indinavir nn plasma nn a.c nn
false	8	4	coadministration nn of inpos indinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos indinavir nn plasma nn a.c nn
false	22	4	coadministration nn of inpos indinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos indinavir nn plasma nn a.c nn
false	0	10	ritonavir nn coadministration nn of inpos ritonavir nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc very rb little jj change nn in inpos ritonavir nn plasma nn a.c nn
false	0	24	ritonavir nn coadministration nn of inpos ritonavir nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc very rb little jj change nn in inpos ritonavir nn plasma nn a.c nn
mechanism	4	8	coadministration nn of inpos ritonavir nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc very rb little jj change nn in inpos ritonavir nn plasma nn a.c nn
false	4	22	coadministration nn of inpos ritonavir nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc very rb little jj change nn in inpos ritonavir nn plasma nn a.c nn
false	8	22	coadministration nn of inpos ritonavir nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc very rb little jj change nn in inpos ritonavir nn plasma nn a.c nn
false	8	4	coadministration nn of inpos ritonavir nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc very rb little jj change nn in inpos ritonavir nn plasma nn a.c nn
false	22	4	coadministration nn of inpos ritonavir nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc very rb little jj change nn in inpos ritonavir nn plasma nn a.c nn
false	0	10	saquinavir nn coadministration nn of inpos saquinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	0	24	saquinavir nn coadministration nn of inpos saquinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
mechanism	4	8	coadministration nn of inpos saquinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	4	22	coadministration nn of inpos saquinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	0	28	saquinavir nn coadministration nn of inpos saquinavir nn lrb_using vbg an dt experimental jj soft_gelatin nn capsule nn formulation nn of inpos saquinavir nn 1200mg nn rrb_with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	0	42	saquinavir nn coadministration nn of inpos saquinavir nn lrb_using vbg an dt experimental jj soft_gelatin nn capsule nn formulation nn of inpos saquinavir nn 1200mg nn rrb_with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	8	22	coadministration nn of inpos saquinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	8	4	coadministration nn of inpos saquinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	22	4	coadministration nn of inpos saquinavir nn with inpos viracept nn resulted vbd in inpos an dt num cd increase nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num_fold jj increase nn in inpos saquinavir nn plasma nn a.c nn
false	0	10	ketoconazole nn coadministration nn of inpos ketoconazole nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn a.c nn
false	0	24	ketoconazole nn coadministration nn of inpos ketoconazole nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn a.c nn
mechanism	4	8	coadministration nn of inpos ketoconazole nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn a.c nn
false	4	22	coadministration nn of inpos ketoconazole nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn a.c nn
false	8	22	coadministration nn of inpos ketoconazole nn with inpos viracept nn resulted vbd in inpos a dt num cd increase nn in inpos nelfinavir nn plasma nn a.c nn
false	28	32	this dt change nn was vbd not rb considered vbn clinically rb significant jj and cc no dt dose nn adjustment nn is vbz needed vbn when wrb ketoconazole nn and cc viracept nn are vbp coadministered vbn
advise	2	28	therefore rb nelfinavir nn should md be vb administered vbn num cd hour nn after inpos or cc more jjr than inpos num cd hours nns before inpos didanosine nn
advise	14	22	a dt dose nn adjustment nn is vbz not rb needed vbn when wrb zidovudine nn is vbz administered vbn with inpos viracept nn
false	26	34	little jj or cc no dt change nn in inpos the dt pharmacokinetics nns of inpos either dt drug nn was vbd observed vbn when wrb viracept nn was vbd coadministered vbn with inpos lamivudine nn or cc stavudine nn
false	26	38	little jj or cc no dt change nn in inpos the dt pharmacokinetics nns of inpos either dt drug nn was vbd observed vbn when wrb viracept nn was vbd coadministered vbn with inpos lamivudine nn or cc stavudine nn
false	34	38	little jj or cc no dt change nn in inpos the dt pharmacokinetics nns of inpos either dt drug nn was vbd observed vbn when wrb viracept nn was vbd coadministered vbn with inpos lamivudine nn or cc stavudine nn
false	0	10	rifabutin nn coadministration nn of inpos rifabutin nn and cc viracept nn resulted vbd in inpos a dt num cd decrease nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos rifabutin nn plasma nn a.c nn
false	0	24	rifabutin nn coadministration nn of inpos rifabutin nn and cc viracept nn resulted vbd in inpos a dt num cd decrease nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos rifabutin nn plasma nn a.c nn
mechanism	4	8	coadministration nn of inpos rifabutin nn and cc viracept nn resulted vbd in inpos a dt num cd decrease nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos rifabutin nn plasma nn a.c nn
false	4	22	coadministration nn of inpos rifabutin nn and cc viracept nn resulted vbd in inpos a dt num cd decrease nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos rifabutin nn plasma nn a.c nn
false	8	22	coadministration nn of inpos rifabutin nn and cc viracept nn resulted vbd in inpos a dt num cd decrease nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos rifabutin nn plasma nn a.c nn
false	8	4	coadministration nn of inpos rifabutin nn and cc viracept nn resulted vbd in inpos a dt num cd decrease nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos rifabutin nn plasma nn a.c nn
false	22	4	coadministration nn of inpos rifabutin nn and cc viracept nn resulted vbd in inpos a dt num cd decrease nn in inpos nelfinavir nn plasma nn auc nn and cc a dt num cd increase nn in inpos rifabutin nn plasma nn a.c nn
advise	14	36	it prp is vbz recommended vbn that inpos the dt dose nn of inpos rifabutin nn be vb reduced vbn to topos one_half rb the dt usual jj dose nn when wrb administered vbn with inpos viracept nn
false	0	10	rifampin nn coadministration nn of inpos rifampin nn and cc viracept nn resulted vbd in inpos an dt num cd decrease nn in inpos nelfinavir nn plasma nn a.c nn
false	0	24	rifampin nn coadministration nn of inpos rifampin nn and cc viracept nn resulted vbd in inpos an dt num cd decrease nn in inpos nelfinavir nn plasma nn a.c nn
mechanism	4	8	coadministration nn of inpos rifampin nn and cc viracept nn resulted vbd in inpos an dt num cd decrease nn in inpos nelfinavir nn plasma nn a.c nn
false	4	22	coadministration nn of inpos rifampin nn and cc viracept nn resulted vbd in inpos an dt num cd decrease nn in inpos nelfinavir nn plasma nn a.c nn
false	8	22	coadministration nn of inpos rifampin nn and cc viracept nn resulted vbd in inpos an dt num cd decrease nn in inpos nelfinavir nn plasma nn a.c nn
advise	0	4	viracept nn and cc rifampin nn should md not rb be vb coadministered vbn
false	0	4	ethinyl_estradiol nn and cc norethindrone nn
false	0	10	ethinyl_estradiol nn and cc norethindrone nnp coadministration nnp of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	0	14	ethinyl_estradiol nn and cc norethindrone nnp coadministration nnp of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	0	4	ethinyl_estradiol nn and cc norethindrone nnp coadministration nnp of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	4	10	ethinyl_estradiol nn and cc norethindrone nn coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	4	14	ethinyl_estradiol nn and cc norethindrone nn coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	4	0	ethinyl_estradiol nn and cc norethindrone nn coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
mechanism	4	8	coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	4	22	coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	4	34	coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	8	22	coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	8	34	coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	22	34	coadministration nn of inpos viracept nn with inpos ovcon_num nn resulted vbd in inpos a dt num cd decrease nn in inpos ethinyl_estradiol nn and cc an dt num cd decrease nn in inpos norethindrone nn plasma nn concentrations nns
false	24	26	caution nn should md also rb be vb taken vbn in inpos concurrent jj or cc serial jj use nn of inpos other jj aminoglycosides nn polymyxins nn because inpos they prp may md enhance vb neomycin nn s vbz nephrotoxicity nn and_or cc ototoxicity nn potentiate vb neomycin_sulfate jj neuromuscular jj blocking nn effects nns
false	24	48	caution nn should md also rb be vb taken vbn in inpos concurrent jj or cc serial jj use nn of inpos other jj aminoglycosides nn polymyxins nns because inpos they prp may md enhance vb neomycin nn s vbz nephrotoxicity nn and_or cc ototoxicity nn potentiate vb neomycin_sulfate nn neuromuscular jj blocking nn effects nns
false	26	48	caution nn should md also rb be vb taken vbn in inpos concurrent jj or cc serial jj use nn of inpos other jj aminoglycosides nns polymyxins nn because inpos they prp may md enhance vb neomycin nn s vbz nephrotoxicity nn and_or cc ototoxicity nn potentiate vb neomycin_sulfate nn neuromuscular jj blocking nn effects nns
mechanism	2	14	oral jj neomycin nn inhibits vbz the dt gastrointestinal jj absorption nn of inpos penicillin_v nn
mechanism	2	14	oral jj neomycin nn inhibits vbz the dt gastrointestinal jj absorption nn of inpos vitamin_b_num nn
mechanism	2	14	oral jj neomycin nn inhibits vbz the dt gastrointestinal jj absorption nn of inpos methotrexate nn
mechanism	2	14	oral jj neomycin nn inhibits vbz the dt gastrointestinal jj absorption nn of inpos num_fluorouracil nn
effect	2	14	oral jj neomycin_sulfate nn may md enhance vb the dt effect nn of inpos coumarin nn in inpos anticoagulants nns by inpos decreasing vbg vitamin nn k nn availability nn
effect	2	18	oral jj neomycin_sulfate nn may md enhance vb the dt effect nn of inpos coumarin nn in inpos anticoagulants nn by inpos decreasing vbg vitamin nn k nn availability nn
false	14	18	oral jj neomycin_sulfate nn may md enhance vb the dt effect nn of inpos coumarin nn in inpos anticoagulants nn by inpos decreasing vbg vitamin nn k nn availability nn
advise	2	44	these dt antibiotics nn should md be vb used vbn in inpos the dt myasthenic jj patient nn only rb where wrb definitely rb indicated vbn and cc then rb careful jj adjustment nn should md be vb made vbn of inpos adjunctive jj anticholinesterase nn dosage nn
false	6	12	the dt co_administration nn of inpos natrecor nn with inpos num cd vasodilators nn such jj as inpos nitroglycerin nn nitroprusside nn milrinone nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn
false	6	18	the dt co_administration nn of inpos natrecor nn with inpos num cd vasodilators nns such jj as inpos nitroglycerin nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn
false	6	18	the dt co_administration nn of inpos natrecor nn with inpos num cd vasodilators nns such jj as inpos nitroprusside nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn
false	6	18	the dt co_administration nn of inpos natrecor nn with inpos num cd vasodilators nns such jj as inpos milrinone nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn
false	6	26	the dt co_administration nn of inpos natrecor nn with inpos num cd vasodilators nns such jj as inpos nitroglycerin nn nitroprusside nn milrinone nn num cd ace_inhibitors nn has vbz not rb been vbn evaluated vbn
false	12	18	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nn such jj as inpos nitroglycerin nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn
false	12	18	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nn such jj as inpos nitroprusside nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn
false	12	18	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nn such jj as inpos milrinone nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn
false	12	26	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nn such jj as inpos nitroglycerin nn nitroprusside nn milrinone nn num cd ace_inhibitors nn has vbz not rb been vbn evaluated vbn
false	12	6	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nn such jj as inpos nitroglycerin nn nitroprusside nn milrinone nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn lrb_these dt drugs nns were vbd not rb co_administered vbn with inpos natrecor nn in inpos clinical jj trials nns
false	18	22	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nns such jj as inpos nitroglycerin nn num cd ace_inhibitors nn has vbz not rb been vbn evaluated vbn
false	18	6	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nns such jj as inpos nitroglycerin nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn lrb_these dt drugs nns were vbd not rb co_administered vbn with inpos natrecor nn in inpos clinical jj trials nns
false	18	22	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nns such jj as inpos nitroprusside nn num cd ace_inhibitors nn has vbz not rb been vbn evaluated vbn
false	18	6	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nns such jj as inpos nitroprusside nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn lrb_these dt drugs nns were vbd not rb co_administered vbn with inpos natrecor nn in inpos clinical jj trials nns
false	18	22	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nns such jj as inpos milrinone nn num cd ace_inhibitors nn has vbz not rb been vbn evaluated vbn
false	18	6	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nns such jj as inpos milrinone nn num cd ace_inhibitors nns has vbz not rb been vbn evaluated vbn lrb_these dt drugs nns were vbd not rb co_administered vbn with inpos natrecor nn in inpos clinical jj trials nns
false	26	6	the dt co_administration nn of inpos natrecor nnp with inpos num cd vasodilators nns such jj as inpos nitroglycerin nn nitroprusside nn milrinone nn num cd ace_inhibitors nn has vbz not rb been vbn evaluated vbn lrb_these dt drugs nns were vbd not rb co_administered vbn with inpos natrecor nn in inpos clinical jj trials nns
advise	0	16	netilmicin nn should md not rb be vb administered vbn concomitantly rb with inpos potent jj loop_diuretics nn such jj as inpos furosemide nn and cc ethacrynic_acid nn as inpos the dt potential nn for inpos ototoxicity nn is vbz enhanced vbn by inpos the dt combination nn
advise	0	22	netilmicin nn should md not rb be vb administered vbn concomitantly rb with inpos potent jj loop_diuretics nns such jj as inpos furosemide nn and cc ethacrynic_acid nn as inpos the dt potential nn for inpos ototoxicity nn is vbz enhanced vbn by inpos the dt combination nn
advise	0	26	netilmicin nn should md not rb be vb administered vbn concomitantly rb with inpos potent jj loop_diuretics nns such jj as inpos furosemide nn and cc ethacrynic_acid nn as inpos the dt potential nn for inpos ototoxicity nn is vbz enhanced vbn by inpos the dt combination nn
false	16	22	netilmicin nn should md not rb be vb administered vbn concomitantly rb with inpos potent jj loop_diuretics nn such jj as inpos furosemide nn and cc ethacrynic_acid nn as inpos the dt potential nn for inpos ototoxicity nn is vbz enhanced vbn by inpos the dt combination nn
false	16	26	netilmicin nn should md not rb be vb administered vbn concomitantly rb with inpos potent jj loop_diuretics nn such jj as inpos furosemide nn and cc ethacrynic_acid nn as inpos the dt potential nn for inpos ototoxicity nn is vbz enhanced vbn by inpos the dt combination nn
false	22	26	netilmicin nn should md not rb be vb administered vbn concomitantly rb with inpos potent jj loop_diuretics nns such jj as inpos furosemide nn and cc ethacrynic_acid nn as inpos the dt potential nn for inpos ototoxicity nn is vbz enhanced vbn by inpos the dt combination nn
false	10	16	the dt in fw vitro fw interaction nn between inpos nevirapine nn and cc the dt antithrombotic_agent nn warfarin nn is vbz complex jj
int	10	18	the dt in fw vitro fw interaction nn between inpos nevirapine nn and cc the dt antithrombotic_agent jj warfarin nn is vbz complex jj
false	16	18	the dt in fw vitro fw interaction nn between inpos nevirapine nn and cc the dt antithrombotic_agent nn warfarin nn is vbz complex jj
advise	2	10	when wrb warfarin nn is vbz co_administered vbn with inpos nevirapine nn anticoagulation nn levels nns should md be vb monitored vbn frequently rb
mechanism	0	12	clarithromycin nn exposure nn was vbd significantly rb decreased vbn by inpos nevirapine nn
false	4	10	alternatives nns to topos clarithromycin nn such jj as inpos azithromycin nn should md be vb considered vbn
false	0	4	ethinyl_estradiol nn and cc norethindrone nn
false	0	2	ethinyl_estradiol nn norethindrone nn
advise	2	38	oral jj contraceptives nn and cc other jj hormonalmethods nns of inpos birth nn control nn should md not rb be vb usedas inpos the dt sole jj method nn of inpos contraception nn inwomen nns taking vbg nevirapine nn since inpos nevirapinemay nn lower jjr the dt plasma nn levels nns of inpos thesemedications nns
advise	0	4	nevirapine nn and cc ketoconazole nn should md not rb beadministered vbn concomitantly rb becausedecreases vbz in inpos ketoconazole nn plasmaconcentrations nns may md reduce vb the dt efficacy nn of inpos the dt drug nn
false	0	4	nevirapine nn and cc ketoconazole nn should md not rb beadministered vbn concomitantly rb becausedecreases vbz in inpos ketoconazole nn plasmaconcentrations nns may md reduce vb the dt efficacy nn of inpos the dt drug nn
false	0	2	lopinavir nn ritonavir nn
advise	8	32	a dt dose nn increase nn of inpos lopinavir nn to topos num cd mg nn twice rb daily rb with inpos food nn isrecommended vbn in inpos combination nn with inpos nevirapine nn
advise	8	32	a dt dose nn increase nn of inpos ritonavir nn to topos num cd mg nn twice rb daily rb with inpos food nn isrecommended vbn in inpos combination nn with inpos nevirapine nn
false	0	28	methadone nn levels nns may md be vb decreased vbn increased vbn dosages nns may md be vb required vbn to topos prevent vb symptoms nns of inpos opiate nn withdrawal nn
advise	0	8	methadone nn maintained vbd patients nns beginning vbg nevirapine nn therapy nn should md be vb monitored vbn forevidence nn of inpos withdrawal nn and cc methadone nn dose nn should md be vb adjusted vbn accordingly rb
false	8	0	methadone nn maintained vbd patients nns beginning vbg nevirapine nn therapy nn should md be vb monitored vbn forevidence nn of inpos withdrawal nn and cc methadone nn dose nn should md be vb adjusted vbn accordingly rb
false	8	14	the dt appropriate jj dose nn for inpos nelfinavir nn incombination nn with inpos nevirapine nn with inpos respectto nn safety nn and cc efficacy nn has vbz not rb been vbn established vbn
advise	0	4	nevirapine nn and cc rifampin nn should md not rb beadministered vbn concomitantly rb becausedecreases vbz in inpos nevirapine nn plasmaconcentrations nns may md reduce vb the dt efficacy nn ofthe nn drug nn
false	4	0	nevirapine nn and cc rifampin nn should md not rb beadministered vbn concomitantly rb becausedecreases vbz in inpos nevirapine nn plasmaconcentrations nns may md reduce vb the dt efficacy nn ofthe nn drug nn
false	18	26	physicians nns needing vbg to topos treatpatients nns co_infected vbn with inpos tuberculosis nn andusing vbg a dt nevirapine nn containing vbg regimen nn mayuse nn rifabutin nn instead rb
effect	22	26	abased vbn on inpos reports nns of inpos narcotic jj withdrawal nn syndrome nn in inpos patients nns treated vbn with inpos nevirapine nn and cc methadone nn concurrently rb and cc evidence nn of inpos decreased vbn plasma nn concentrations nns of inpos methadone nn
false	22	26	abased vbn on inpos reports nns of inpos narcotic jj withdrawal nn syndrome nn in inpos patients nns treated vbn with inpos nevirapine nn and cc methadone nn concurrently rb and cc evidence nn of inpos decreased vbn plasma nn concentrations nns of inpos methadone nn
false	0	2	amiodarone nn disopyramide nn lidocaine nn
false	0	4	amiodarone nn disopyramide nn lidocaine nn
false	2	4	amiodarone nn disopyramide nn lidocaine nn
false	0	2	carbamazepine nn clonazepam nn ethosuximide nn
false	0	4	carbamazepine nn clonazepam nn ethosuximide nn
false	2	4	carbamazepine nn clonazepam nn ethosuximide nn
false	0	2	diltiazem nn nifedipine nn verapamil nn
false	0	4	diltiazem nn nifedipine nn verapamil nn
false	2	4	diltiazem nn nifedipine nn verapamil nn
false	0	2	cyclosporin nn tacrolimus nn sirolimus nn
false	0	4	cyclosporin nn tacrolimus nn sirolimus nn
false	2	4	cyclosporin nn tacrolimus nn sirolimus nn
false	4	6	interactions nns for inpos vitamin_b3 nn antihypertensive nn therapy nn
false	4	6	interactions nns for inpos niacin nn antihypertensive nn therapy nn
effect	0	12	nicotinic_acid nn may md potentiate vb the dt effects nns of inpos ganglionic_blocking_agents nn and cc vasoactive jj drugs nns resulting vbg in inpos postural jj hypotension nn
false	0	18	aspirin nn concomitant jj aspirin nn may md decrease vb the dt metabolic jj clearance nn of inpos nicotinic_acid nn
mechanism	2	16	concomitant jj aspirin nn may md decrease vb the dt metabolic jj clearance nn of inpos nicotinic_acid nn
false	0	10	b_blockers nn in inpos controlled jj clinical jj studies nns adrenergic_b_receptor_blockers nn have vbp been vbn frequently rb administered vbn concomitantly rb with inpos nicardipine_hcl nn
false	0	24	b_blockers nn in inpos controlled jj clinical jj studies nns adrenergic_b_receptor_blockers nns have vbp been vbn frequently rb administered vbn concomitantly rb with inpos nicardipine_hcl nn
false	10	24	b_blockers nns in inpos controlled jj clinical jj studies nns adrenergic_b_receptor_blockers nn have vbp been vbn frequently rb administered vbn concomitantly rb with inpos nicardipine_hcl nn
mechanism	0	4	cimetidine nn increases vbz nicardipine_hcl nn plasma nn levels nns
mechanism	2	14	some dt calcium_blockers nn may md increase vb the dt concentration nn of inpos digitalis_preparations nn in inpos the dt blood nn
false	0	18	nicardipine_hcl nn usually rb does vbz not rb alter vb the dt plasma nn levels nns of inpos digoxin nn however rb serum nn digoxin nn levels nns should md be vb evaluated vbn after inpos concomitant jj therapy nn with inpos nicardipine_hcl nn is vbz initiated vbn
false	0	18	nicardipine_hcl nn usually rb does vbz not rb alter vb the dt plasma nn levels nns of inpos digoxin nn however rb serum nn digoxin nn levels nns should md be vb evaluated vbn after inpos concomitant jj therapy nn with inpos nicardipine_hcl nn is vbz initiated vbn
false	18	0	nicardipine_hcl nn usually rb does vbz not rb alter vb the dt plasma nn levels nns of inpos digoxin nn however rb serum nn digoxin nn levels nns should md be vb evaluated vbn after inpos concomitant jj therapy nn with inpos nicardipine_hcl nn is vbz initiated vbn
advise	18	0	nicardipine_hcl nn usually rb does vbz not rb alter vb the dt plasma nn levels nns of inpos digoxin nn however rb serum nn digoxin nn levels nns should md be vb evaluated vbn after inpos concomitant jj therapy nn with inpos nicardipine_hcl nn is vbz initiated vbn
false	0	16	maalox nn coadministration nn of inpos maalox_tc nn had vbd no dt effect nn on inpos nicardipine_hcl nn absorption nn
false	6	16	maalox nn coadministration nn of inpos maalox_tc nn had vbd no dt effect nn on inpos nicardipine_hcl nn absorption nn
false	0	8	cyclosporine nn concomitant jj administration nn of inpos nicardipine nn and cc cyclosporine nn levels nns
false	6	10	concomitant jj administration nn of inpos nicardipine nn and cc cyclosporine nn levels nns
advise	6	36	plasma nn concentrations nns of inpos cyclosporine nn should md therefore rb be vb closely rb monitored vbn and cc its prp dosage nn reduced vbd accordingly rb in inpos patients nns treated vbn with inpos nicardipine nn
false	8	30	when wrb therapeutic jj concentrations nns of inpos furosemide nn were vbd added vbn to topos human jj plasma nn the dt plasma nn protein nn binding nn of inpos nicardipine_hcl nn was vbd not rb altered vbn
false	8	30	when wrb therapeutic jj concentrations nns of inpos propranolol nn were vbd added vbn to topos human jj plasma nn the dt plasma nn protein nn binding nn of inpos nicardipine_hcl nn was vbd not rb altered vbn
false	8	30	when wrb therapeutic jj concentrations nns of inpos dipyridamole nn were vbd added vbn to topos human jj plasma nn the dt plasma nn protein nn binding nn of inpos nicardipine_hcl nn was vbd not rb altered vbn
false	8	30	when wrb therapeutic jj concentrations nns of inpos warfarin nn were vbd added vbn to topos human jj plasma nn the dt plasma nn protein nn binding nn of inpos nicardipine_hcl nn was vbd not rb altered vbn
false	8	30	when wrb therapeutic jj concentrations nns of inpos quinidine nn were vbd added vbn to topos human jj plasma nn the dt plasma nn protein nn binding nn of inpos nicardipine_hcl nn was vbd not rb altered vbn
false	8	30	when wrb therapeutic jj concentrations nns of inpos naproxen nn were vbd added vbn to topos human jj plasma nn the dt plasma nn protein nn binding nn of inpos nicardipine_hcl nn was vbd not rb altered vbn
false	18	42	physiological jj changes nns resulting vbg from inpos smoking nn cessation nn with inpos or cc without inpos nicotine nn replacement nn may md alter vb the dt pharmacokinetics nns of inpos certain jj concomitant jj medications nns such jj as inpos tricyclic_antidepressants nn and cc theophylline nn
false	18	46	physiological jj changes nns resulting vbg from inpos smoking nn cessation nn with inpos or cc without inpos nicotine nn replacement nn may md alter vb the dt pharmacokinetics nns of inpos certain jj concomitant jj medications nns such jj as inpos tricyclic_antidepressants nns and cc theophylline nn
false	42	46	physiological jj changes nns resulting vbg from inpos smoking nn cessation nn with inpos or cc without inpos nicotine nn replacement nn may md alter vb the dt pharmacokinetics nns of inpos certain jj concomitant jj medications nns such jj as inpos tricyclic_antidepressants nn and cc theophylline nn
false	0	34	b_adrenergic_blocking_agents nn experience nn in inpos over inpos num cd patients nns in inpos a dt non_comparative jj clinical jj trial nn has vbz shown vbn that inpos concomitant jj administration nn of inpos nifedipine nn and cc b_blocking_agents nns is vbz usually rb well rb tolerated vbn but cc there ex have vbp been vbn occasional jj literature nn reports nns suggesting vbg that inpos the dt combination nn may md increase vb the dt likelihood nn of inpos congestive jj heart nn failure nn severe jj hypotension nn exacerbation nn of inpos angina nn
false	0	38	b_adrenergic_blocking_agents nn experience nn in inpos over inpos num cd patients nns in inpos a dt non_comparative jj clinical jj trial nn has vbz shown vbn that inpos concomitant jj administration nn of inpos nifedipine nn and cc b_blocking_agents nn is vbz usually rb well rb tolerated vbn but cc there ex have vbp been vbn occasional jj literature nn reports nns suggesting vbg that inpos the dt combination nn may md increase vb the dt likelihood nn of inpos congestive jj heart nn failure nn severe jj hypotension nn exacerbation nn of inpos angina nn
effect	32	36	experience nn in inpos over inpos num cd patients nns in inpos a dt non_comparative jj clinical jj trial nn has vbz shown vbn that inpos concomitant jj administration nn of inpos nifedipine nn and cc b_blocking_agents nn is vbz usually rb well rb tolerated vbn but cc there ex have vbp been vbn occasional jj literature nn reports nns suggesting vbg that inpos the dt combination nn may md increase vb the dt likelihood nn of inpos congestive jj heart nn failure nn severe jj hypotension nn exacerbation nn of inpos angina nn
false	0	12	nifedipine nn may md be vb safely rb co_administered vbn with inpos nitrates nn but cc there ex have vbp been vbn no dt controlled jj studies nns to topos evaluate vb the dt antianginal jj effectiveness nn of inpos this dt combination nn
false	20	42	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns and cc there ex is vbz a dt possible jj interaction nn between inpos digoxin nn and cc nifedipine nn it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
false	20	42	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns and cc there ex is vbz a dt possible jj interaction nn between inpos digoxin nn and cc nifedipine nn it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
int	20	42	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns and cc there ex is vbz a dt possible jj interaction nn between inpos digoxin nn and cc nifedipine nn it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
false	20	42	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns and cc there ex is vbz a dt possible jj interaction nn between inpos digoxin nn and cc nifedipine nn it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
false	42	20	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns and cc there ex is vbz a dt possible jj interaction nn between inpos digoxin nn and cc nifedipine nn it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
advise	20	42	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns and cc there ex is vbz a dt possible jj interaction nn between inpos digoxin nn and cc nifedipine nn it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
false	4	8	administration nn of inpos nifedipine nn with inpos digoxin nn increased vbd digoxin nn levels nns in inpos num cd of inpos num cd normal jj volunteers nns
false	4	8	administration nn of inpos nifedipine nn with inpos digoxin nn increased vbd digoxin nn levels nns in inpos num cd of inpos num cd normal jj volunteers nns
false	20	50	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
advise	20	50	since inpos there ex have vbp been vbn isolated vbn reports nns of inpos patients nns with inpos elevated jj digoxin nn levels nns it prp is vbz recommended vbn that inpos digoxin nn levels nns be vb monitored vbn when wrb initiating vbg adjusting nn and cc discontinuing vbg nifedipine nn to topos avoid vb possible jj over nn or cc under_digitalization nn
mechanism	18	22	there ex have vbp been vbn rare jj reports nns of inpos an dt interaction nn between inpos quinidine nn and cc nifedipine nn
false	22	18	there ex have vbp been vbn rare jj reports nns of inpos an dt interaction nn between inpos quinidine nn and cc nifedipine nn lrb_with inpos a dt decreased vbn plasma nn level nn of inpos quinidine nn
effect	24	30	there ex have vbp been vbn rare jj reports nns of inpos increased vbn prothrombin nn time nn in inpos patients nns taking vbg coumarin_anticoagulants nn to topos whom wp nifedipine nn was vbd administered vbn
false	26	48	a dt study nn in inpos num cd healthy jj volunteers nns has vbz shown vbn a dt significant jj increase nn in inpos peak jj nifedipine nn plasma nn levels nns and cc area_under_the_curve nn after inpos a dt num cd week nn course nn of inpos cimetidine nn at inpos num cd mg nn per inpos day nn and cc nifedipine nn at inpos num cd mg nn per inpos day nn
mechanism	48	26	a dt study nn in inpos num cd healthy jj volunteers nns has vbz shown vbn a dt significant jj increase nn in inpos peak jj nifedipine nn plasma nn levels nns and cc area_under_the_curve nn after inpos a dt num cd week nn course nn of inpos cimetidine nn at inpos num cd mg nn per inpos day nn and cc nifedipine nn at inpos num cd mg nn per inpos day nn
false	20	50	the dt effect nn may md be vb mediated vbn by inpos the dt known jj inhibition nn of inpos cimetidine nn on inpos hepatic jj cytochrome nn p_num nn the dt enzyme nn system nn probably rb responsible jj for inpos the dt first_pass jj metabolism nn of inpos nifedipine nn
advise	2	20	if inpos nifedipine nn therapy nn is vbz initiated vbn in inpos a dt patient nn currently rb receiving vbg cimetidine nn cautious jj titration nn is vbz advised vbn
advise	6	16	for inpos example nn when wrb vitamin_k_antagonists nn are vbp administered vbn concomitantly rb with inpos nilutamide nn prothrombin nn time nn should md be vb carefully rb monitored vbn and cc if inpos necessary jj the dt dosage nn of inpos vitamin_k_antagonists nns should md be vb reduced vbn
false	16	6	for inpos example nn when wrb vitamin_k_antagonists nns are vbp administered vbn concomitantly rb with inpos nilutamide nn prothrombin nn time nn should md be vb carefully rb monitored vbn and cc if inpos necessary jj the dt dosage nn of inpos vitamin_k_antagonists nn should md be vb reduced vbn
effect	18	34	it prp is vbz possible jj that inpos the dt cardiovascular jj action nn of inpos other jj calcium_channel_blockers nn could md be vb enhanced vbn by inpos the dt addition nn of inpos nimotop nn
effect	4	22	in inpos europe nnp nimotop nn was vbd observed vbn to topos occasionally rb intensify vb the dt effect nn of inpos antihypertensive_compounds nn taken vbn concomitantly rb by inpos patients nns suffering vbg from inpos hypertension nn
false	28	66	a dt study nn in inpos num cd healthy jj volunteers nns has vbz shown vbn a dt num cd increase nn in inpos mean jj peak jj nimodipine nn plasma nn concentrations nns and cc a dt num cd increase nn in inpos mean jj area nn under inpos the dt curve nn after inpos a dt num cd week nn course nn of inpos cimetidine nn at inpos num cd mg_day nn and cc nimodipine nn at inpos num cd mg_day nn
mechanism	66	28	a dt study nn in inpos num cd healthy jj volunteers nns has vbz shown vbn a dt num cd increase nn in inpos mean jj peak jj nimodipine nn plasma nn concentrations nns and cc a dt num cd increase nn in inpos mean jj area nn under inpos the dt curve nn after inpos a dt num cd week nn course nn of inpos cimetidine nn at inpos num cd mg_day nn and cc nimodipine nn at inpos num cd mg_day nn
false	30	46	this dt effect nn may md be vb mediated vbn by inpos the dt known jj inhibition nn of inpos hepatic jj cytochrome nn p nn num cd by inpos cimetidine nn which wdt could md decrease vb first jj pass nn metabolism nn of inpos nimodipine nn
mechanism	20	34	a dt num cd to topos num cd increase nn in inpos auc nn and cc cmax nn of inpos nisoldipine nn was vbd observed vbn with inpos concomitant jj administration nn of inpos cimetidine_num_mg nn twice rb daily rb
false	0	20	ranitidine nn num cd mg nn twice rb daily rb did vbd not rb interact vb significantly rb with inpos nisoldipine nn
mechanism	4	12	coadministration nn of inpos phenytoin nn with inpos num cd mg nn sular nn tablets nns in inpos epileptic jj patients nns lowered vbd the dt nisoldipine nn plasma nn concentrations nns to topos undetectable jj levels nns
false	4	26	coadministration nn of inpos phenytoin nn with inpos num cd mg nn sular nn tablets nns in inpos epileptic jj patients nns lowered vbd the dt nisoldipine nn plasma nn concentrations nns to topos undetectable jj levels nns
false	12	26	coadministration nn of inpos phenytoin nn with inpos num cd mg nn sular nn tablets nns in inpos epileptic jj patients nns lowered vbd the dt nisoldipine nn plasma nn concentrations nns to topos undetectable jj levels nns
advise	4	8	coadministration nn of inpos sular nn with inpos phenytoin nn or cc any dt known vbn cyp3a4 nn inducer nn should md be vb avoided vbn and cc alternative jj antihypertensive jj therapy nn should md be vb considered vbn
false	4	30	coadministration nn of inpos sular nn with inpos phenytoin nn or cc any dt known vbn cyp3a4 nn inducer nn should md be vb avoided vbn and cc alternative jj antihypertensive nn therapy nn should md be vb considered vbn
false	8	30	coadministration nn of inpos sular nn with inpos phenytoin nn or cc any dt known vbn cyp3a4 nn inducer nn should md be vb avoided vbn and cc alternative jj antihypertensive nn therapy nn should md be vb considered vbn
false	6	10	pharmacokinetic jj interactions nns between inpos nisoldipine nn and cc b_blockers nn were vbd variable jj and cc not rb significant jj
false	6	10	pharmacokinetic jj interactions nns between inpos nisoldipine nn and cc atenolol nn were vbd variable jj and cc not rb significant jj
false	6	10	pharmacokinetic jj interactions nns between inpos nisoldipine nn and cc propranolol nn were vbd variable jj and cc not rb significant jj
effect	0	22	propranolol nn attenuated vbd the dt heart nn rate nn increase nn following vbg administration nn of inpos immediate jj release nn nisoldipine nn
effect	10	26	the dt blood nn pressure nn effect nn of inpos sular nn tended vbd to topos be vb greater jjr in inpos patients nns on inpos atenolol nn than inpos in inpos patients nns on inpos no dt other jj antihypertensive jj therapy nn
false	10	40	the dt blood nn pressure nn effect nn of inpos sular nn tended vbd to topos be vb greater jjr in inpos patients nns on inpos atenolol nn than inpos in inpos patients nns on inpos no dt other jj antihypertensive nn therapy nn
false	26	40	the dt blood nn pressure nn effect nn of inpos sular nn tended vbd to topos be vb greater jjr in inpos patients nns on inpos atenolol nn than inpos in inpos patients nns on inpos no dt other jj antihypertensive nn therapy nn
mechanism	0	18	quinidine nn at inpos num cd mg nn bid rb decreased vbd the dt bioavailability nn of inpos nisoldipine nn by inpos num cd but cc not rb the dt peak jj concentration nn
mechanism	18	24	the dt immediate jj release nn but cc not rb the dt coat_core nn formulation nn of inpos nisoldipine nn increased vbd plasma nn quinidine nn concentrations nns by inpos about rb num cd
mechanism	14	50	therefore rb caution nn should md be vb used vbn when wrb administering vbg nitazoxanide nn concurrently rb with inpos other jj highly rb plasma nn protein_bound jj drugs nns with inpos narrow jj therapeutic jj indices nns as inpos competition nn for inpos binding vbg sites nns may md warfarin vb
false	0	10	inomax nn has vbz been vbn administered vbn with inpos tolazoline nn high_frequency nn ventilation nn
false	0	10	inomax nn has vbz been vbn administered vbn with inpos dopamine nn high_frequency nn ventilation nn
false	0	10	inomax nn has vbz been vbn administered vbn with inpos dobutamine nn high_frequency nn ventilation nn
false	0	10	inomax nn has vbz been vbn administered vbn with inpos steroids nn high_frequency nn ventilation nn
false	0	10	inomax nn has vbz been vbn administered vbn with inpos surfactant nn high_frequency nn ventilation nn
false	20	24	although inpos there ex are vbp no dt study nn data nns to topos evaluate vb the dt possibility nn nitric_oxide_donor_compounds nn including vbg sodium_nitroprusside nn and cc nitroglycerin nn may md have vb an dt additive jj effect nn with inpos inomax nn on inpos the dt risk nn of inpos developing vbg methemoglobinemia nn
false	20	28	although inpos there ex are vbp no dt study nn data nns to topos evaluate vb the dt possibility nn nitric_oxide_donor_compounds nn including vbg sodium_nitroprusside nn and cc nitroglycerin nn may md have vb an dt additive jj effect nn with inpos inomax nn on inpos the dt risk nn of inpos developing vbg methemoglobinemia nn
effect	20	42	although inpos there ex are vbp no dt study nn data nns to topos evaluate vb the dt possibility nn nitric_oxide_donor_compounds nn including vbg sodium_nitroprusside nn and cc nitroglycerin nn may md have vb an dt additive jj effect nn with inpos inomax nn on inpos the dt risk nn of inpos developing vbg methemoglobinemia nn
false	24	28	although inpos there ex are vbp no dt study nn data nns to topos evaluate vb the dt possibility nn nitric_oxide_donor_compounds nns including vbg sodium_nitroprusside nn and cc nitroglycerin nn may md have vb an dt additive jj effect nn with inpos inomax nn on inpos the dt risk nn of inpos developing vbg methemoglobinemia nn
effect	24	42	although inpos there ex are vbp no dt study nn data nns to topos evaluate vb the dt possibility nn nitric_oxide_donor_compounds nns including vbg sodium_nitroprusside nn and cc nitroglycerin nn may md have vb an dt additive jj effect nn with inpos inomax nn on inpos the dt risk nn of inpos developing vbg methemoglobinemia nn
effect	28	42	although inpos there ex are vbp no dt study nn data nns to topos evaluate vb the dt possibility nn nitric_oxide_donor_compounds nns including vbg sodium_nitroprusside nn and cc nitroglycerin nn may md have vb an dt additive jj effect nn with inpos inomax nn on inpos the dt risk nn of inpos developing vbg methemoglobinemia nn
false	0	4	antacids nn containing vbg magnesium_trisilicate nn when wrb administered vbn concomitantly rb with inpos nitrofurantoin nn reduce vbp both cc the dt rate nn and cc extent nn of inpos absorption nn
false	0	14	antacids nn containing vbg magnesium_trisilicate nn when wrb administered vbn concomitantly rb with inpos nitrofurantoin nn reduce vbp both cc the dt rate nn and cc extent nn of inpos absorption nn
mechanism	4	14	antacids nns containing vbg magnesium_trisilicate nn when wrb administered vbn concomitantly rb with inpos nitrofurantoin nn reduce vbp both cc the dt rate nn and cc extent nn of inpos absorption nn
mechanism	18	28	the dt mechanism nn for inpos this dt interaction nn probably rb is vbz adsorption nn of inpos nitrofurantoin nn onto inpos the dt surface nn of inpos magnesium_trisilicate nn
false	0	6	uricosuric_drugs nn such jj as inpos probenecid nn and cc sulfinpyrazone nn can md inhibit vb renal jj tubular jj secretion nn of inpos nitrofurantoin nn
false	0	10	uricosuric_drugs nn such jj as inpos probenecid nn and cc sulfinpyrazone nn can md inhibit vb renal jj tubular jj secretion nn of inpos nitrofurantoin nn
mechanism	0	24	uricosuric_drugs nn such jj as inpos probenecid nn and cc sulfinpyrazone nn can md inhibit vb renal jj tubular jj secretion nn of inpos nitrofurantoin nn
false	6	10	uricosuric_drugs nns such jj as inpos probenecid nn and cc sulfinpyrazone nn can md inhibit vb renal jj tubular jj secretion nn of inpos nitrofurantoin nn
mechanism	6	24	uricosuric_drugs nns such jj as inpos probenecid nn and cc sulfinpyrazone nn can md inhibit vb renal jj tubular jj secretion nn of inpos nitrofurantoin nn
mechanism	10	24	uricosuric_drugs nns such jj as inpos probenecid nn and cc sulfinpyrazone nn can md inhibit vb renal jj tubular jj secretion nn of inpos nitrofurantoin nn
false	8	46	the dt resulting vbg increase nn in inpos nitrofurantoin nn serum nn levels nns may md increase vb toxicity nn and cc the dt decreased vbn urinary jj levels nns could md lessen vb its prp efficacy nn as inpos a dt urinary jj tract nn antibacterial nn
effect	8	24	the dt vasodilating vbg effects nns of inpos nitroglycerin nn may md be vb additive jj with inpos those dt of inpos other jj vasodilators nn
effect	16	22	marked jj symptomatic jj orthostatic jj hypotension nn has vbz been vbn reported vbn when wrb calcium_channel_blockers nn and cc organic jj nitrates nn were vbd used vbn in inpos combination nn
effect	8	24	the dt hypotensive jj effect nn of inpos sodium_nitroprusside nn is vbz augmented vbn by inpos that dt of inpos most jjs other jj hypotensive_drugs nn including vbg ganglionic_blocking_agents nns negative jj inotropic jj agents nns and cc inhaled vbd anesthetics nns
effect	8	28	the dt hypotensive jj effect nn of inpos sodium_nitroprusside nn is vbz augmented vbn by inpos that dt of inpos most jjs other jj hypotensive_drugs nns including vbg ganglionic_blocking_agents nn negative jj inotropic jj agents nns inhaled vbd anesthetics nns
effect	8	38	the dt hypotensive jj effect nn of inpos sodium_nitroprusside nn is vbz augmented vbn by inpos that dt of inpos most jjs other jj hypotensive_drugs nns including vbg ganglionic_blocking_agents nns negative jj inotropic jj agents nns inhaled vbd anesthetics nn
false	24	28	the dt hypotensive jj effect nn of inpos sodium_nitroprusside nn is vbz augmented vbn by inpos that dt of inpos most jjs other jj hypotensive_drugs nn including vbg ganglionic_blocking_agents nn negative jj inotropic jj agents nns and cc inhaled vbd anesthetics nns
false	24	40	the dt hypotensive jj effect nn of inpos sodium_nitroprusside nn is vbz augmented vbn by inpos that dt of inpos most jjs other jj hypotensive_drugs nn including vbg ganglionic_blocking_agents nns negative jj inotropic jj agents nns and cc inhaled vbd anesthetics nn
false	28	38	the dt hypotensive jj effect nn of inpos sodium_nitroprusside nn is vbz augmented vbn by inpos that dt of inpos most jjs other jj hypotensive_drugs nns including vbg ganglionic_blocking_agents nn negative jj inotropic jj agents nns inhaled vbd anesthetics nn
false	14	24	in inpos patients nns given vbn very rb high jj doses nns of inpos aspirin nn daily rb increases nns in inpos serum nn salicylate nn levels nns were vbd seen vbn when wrb nizatidine nn num cd mg nn b.i.d. rb was vbd administered vbn concurrently rb
mechanism	14	34	in inpos patients nns given vbn very rb high jj doses nns of inpos aspirin nn daily rb increases nns in inpos serum nn salicylate nn levels nns were vbd seen vbn when wrb nizatidine nn num cd mg nn b.i.d. rb was vbd administered vbn concurrently rb
false	24	34	in inpos patients nns given vbn very rb high jj doses nns of inpos aspirin nn daily rb increases nns in inpos serum nn salicylate nn levels nns were vbd seen vbn when wrb nizatidine nn num cd mg nn b.i.d. rb was vbd administered vbn concurrently rb
false	6	30	the dt effectiveness nn of inpos progestin nn only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nn phenytoin nn carbamazepine nn barbiturates nns the dt antituberculosis_drug jj rifampin nn
effect	6	32	the dt effectiveness nn of inpos progestin nn only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns phenytoin nns the dt antituberculosis_drug jj rifampin nn
effect	6	32	the dt effectiveness nn of inpos progestin nn only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns carbamazepine nns the dt antituberculosis_drug jj rifampin nn
effect	6	32	the dt effectiveness nn of inpos progestin nn only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns barbiturates nn the dt antituberculosis_drug jj rifampin nn
false	6	40	the dt effectiveness nn of inpos progestin nn only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns phenytoin nn carbamazepine nn barbiturates nns the dt antituberculosis_drug nn rifampin nn
effect	6	42	the dt effectiveness nn of inpos progestin nn only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns phenytoin nn carbamazepine nn barbiturates nns the dt antituberculosis_drug jj rifampin nn
false	28	30	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nn phenytoin nns the dt antituberculosis_drug jj rifampin nn
false	28	30	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nn carbamazepine nns the dt antituberculosis_drug jj rifampin nn
false	28	30	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nn barbiturates nn the dt antituberculosis_drug jj rifampin nn
false	28	38	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nn phenytoin nn carbamazepine nn barbiturates nns the dt antituberculosis_drug nn rifampin nn
false	28	40	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nn phenytoin nn carbamazepine nn barbiturates nns the dt antituberculosis_drug jj rifampin nn
false	30	34	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns phenytoin nns the dt antituberculosis_drug nn rifampin nn
false	30	36	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns phenytoin nns the dt antituberculosis_drug jj rifampin nn
false	30	34	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns carbamazepine nns the dt antituberculosis_drug nn rifampin nn
false	30	36	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns carbamazepine nns the dt antituberculosis_drug jj rifampin nn
false	30	34	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns barbiturates nn the dt antituberculosis_drug nn rifampin nn
false	30	36	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns barbiturates nn the dt antituberculosis_drug jj rifampin nn
false	38	40	the dt effectiveness nn of inpos progestin_only jj pills nns is vbz reduced vbn by inpos hepatic jj enzyme_inducing jj drugs nns such jj as inpos the dt anticonvulsants nns phenytoin nn carbamazepine nn barbiturates nns the dt antituberculosis_drug nn rifampin nn
mechanism	8	20	elevated vbn plasma nn levels nns of inpos theophylline nn have vbp been vbn reported vbn with inpos concomitant jj quinolone nn use nn
false	10	30	there ex have vbp been vbn reports nns of inpos theophylline nn related jj side nn effects nns in inpos patients nns on inpos concomitant jj therapy nn with inpos norfloxacin nn and cc theophylline nn
effect	28	10	there ex have vbp been vbn reports nns of inpos theophylline_related jj side nn effects nns in inpos patients nns on inpos concomitant jj therapy nn with inpos norfloxacin nn and cc theophylline nn
false	8	28	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos norfloxacin nn
mechanism	8	28	elevated jj serum nn levels nns of inpos cyclosporine nn have vbp been vbn reported vbn with inpos concomitant jj use nn of inpos cyclosporine nn with inpos norfloxacin nn
false	0	4	quinolones nn including vbg norfloxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nns including vbg warfarin nn its prp derivatives nns similar jj agents nns
effect	0	18	quinolones nn including vbg norfloxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nn including vbg warfarin nn its prp derivatives nns similar jj agents nns
effect	0	22	quinolones nn including vbg norfloxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nns including vbg warfarin nns
effect	4	18	quinolones nns including vbg norfloxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nn including vbg warfarin nn its prp derivatives nns similar jj agents nns
effect	4	22	quinolones nns including vbg norfloxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nns including vbg warfarin nns
false	18	22	quinolones nns including vbg norfloxacin nn may md enhance vb the dt effects nns of inpos oral jj anticoagulants nn including vbg warfarin nns
false	8	12	the dt concomitant jj administration nn of inpos quinolones nn including vbg norfloxacin nn with inpos glyburide nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
effect	8	16	the dt concomitant jj administration nn of inpos quinolones nn including vbg norfloxacin nn with inpos glyburide nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
false	8	16	the dt concomitant jj administration nn of inpos quinolones nn including vbg norfloxacin nn with inpos sulfonylurea_agent nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
effect	12	16	the dt concomitant jj administration nn of inpos quinolones nns including vbg norfloxacin nn with inpos glyburide nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
false	12	16	the dt concomitant jj administration nn of inpos quinolones nns including vbg norfloxacin nn with inpos sulfonylurea_agent nn has vbz on inpos rare jj occasions nns resulted vbd in inpos severe jj hypoglycemia nn
false	8	26	diminished vbn urinary jj excretion nn of inpos norfloxacin nn has vbz been vbn reported vbn during inpos the dt concomitant jj administration nn of inpos probenecid nn and cc norfloxacin nn
mechanism	26	8	diminished vbn urinary jj excretion nn of inpos norfloxacin nn has vbz been vbn reported vbn during inpos the dt concomitant jj administration nn of inpos probenecid nn and cc norfloxacin nn
false	8	32	the dt concomitant jj use nn of inpos nitrofurantoin nn is vbz not rb recommended vbn since inpos nitrofurantoin nn may md antagonize vb the dt antibacterial jj effect nn of inpos norfloxacin nn in inpos the dt urinary jj tract nn
effect	8	32	the dt concomitant jj use nn of inpos nitrofurantoin nn is vbz not rb recommended vbn since inpos nitrofurantoin nn may md antagonize vb the dt antibacterial jj effect nn of inpos norfloxacin nn in inpos the dt urinary jj tract nn
false	0	10	multivitamins nn or cc other jj products nns containing vbg iron nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	0	10	multivitamins nn or cc other jj products nns containing vbg zinc nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	0	10	multivitamins nn or cc other jj products nns containing vbg antacids nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	0	10	multivitamins nn or cc other jj products nns containing vbg sucralfate nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
advise	0	46	multivitamins nn or cc other jj products nns containing vbg iron nn zinc nn antacids nns sucralfate nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	0	46	multivitamins nn or cc other jj products nns containing vbg iron nn zinc nn antacids nns sucralfate nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
advise	10	40	multivitamins nns or cc other jj products nns containing vbg iron nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	10	40	multivitamins nns or cc other jj products nns containing vbg iron nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
advise	10	40	multivitamins nns or cc other jj products nns containing vbg zinc nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	10	40	multivitamins nns or cc other jj products nns containing vbg zinc nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
advise	10	40	multivitamins nns or cc other jj products nns containing vbg antacids nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	10	40	multivitamins nns or cc other jj products nns containing vbg antacids nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
advise	10	40	multivitamins nns or cc other jj products nns containing vbg sucralfate nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	10	40	multivitamins nns or cc other jj products nns containing vbg sucralfate nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos they prp may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
advise	0	48	videx nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos these dt products nns may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	0	48	videx nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos these dt products nns may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
advise	0	48	didanosine nn chewable jj tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos these dt products nns may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
false	0	48	didanosine nn buffered vbd tablets nns or cc the dt pediatric jj powder nn for inpos oral jj solution nn should md not rb be vb administered vbn concomitantly rb with inpos or cc within inpos num cd hours nns of inpos the dt administration nn of inpos norfloxacin nn because inpos these dt products nns may md interfere vb with inpos absorption nn resulting vbg in inpos lower jjr serum nn and cc urine nn levels nns of inpos norfloxacin nn
mechanism	2	24	some dt quinolones nn have vbp also rb been vbn shown vbn to topos interfere vb with inpos the dt metabolism nn of inpos caffeine nn
false	20	28	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nns num cd
false	20	32	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nn num cd
false	22	30	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns phenylbutazone nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nns num cd
false	22	34	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns phenylbutazone nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nn num cd
false	22	30	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns phenytoin_sodium nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nns num cd
false	22	34	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns phenytoin_sodium nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nn num cd
false	22	30	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns carbamazepine nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nns num cd
false	22	34	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns carbamazepine nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nn num cd
false	22	30	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns griseofulvin nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nns num cd
false	22	34	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns griseofulvin nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nn num cd
false	22	30	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns topiramate nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nns num cd
false	22	34	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns topiramate nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nn num cd
false	38	42	a dt similar jj association nn though inpos less rbr marked jj has vbz been vbn suggested vbn with inpos barbiturates nns phenylbutazone nn phenytoin_sodium nn carbamazepine nn griseofulvin nn topiramate nn and cc possibly rb with inpos ampicillin nn and cc tetracyclines nn num cd
mechanism	8	22	steady_state jj serum nn concentrations nns of inpos tricyclic_antidepressants nn are vbp reported vbn to topos fluctuate vb significantly rb when wrb cimetidine nn is vbz either cc added vbn or cc deleted vbn from inpos the dt drug nn regimen nn
effect	26	30	serious jj anticholinergic jj symptoms nns have vbp been vbn associated vbn with inpos elevations nns in inpos the dt serum nn levels nns of inpos tricyclic_antidepressants nn when wrb cimetidine nn is vbz added vbn to topos the dt drug nn regimen nn
mechanism	16	40	in inpos addition nn higher_than jj expected vbn steady_state jj serum nn concentrations nns of inpos tricyclic_antidepressants nn have vbp been vbn observed vbn when wrb therapy nn is vbz initiated vbn in inpos patients nns already rb taking vbg cimetidine nn
mechanism	14	32	in inpos well_controlled jj patients nns undergoing vbg concurrent jj therapy nn with inpos cimetidine nn a dt decrease nn in inpos the dt steady_state jj serum nn concentrations nns of inpos tricyclic_antidepressants nn may md occur vb when wrb cime_tidine nn therapy nn is vbz discontinued vbn
effect	8	24	the dt therapeutic jj efficacy nn of inpos tricyclic_antidepressants nn may md be vb compromised vbn in inpos these dt patients nns when wrb cimetidine nn is vbz discontinued vbn
false	28	32	there ex have vbp been vbn greater jjr than inpos num_fold jj increases nns in inpos previously rb stable jj plasma nn levels nns of inpos other jj antidepressants nn including vbg nortriptyline nn when wrb fluoxetine_hydrochloride nn has vbz been vbn administered vbn in inpos combination nn with inpos these dt agents nns
mechanism	28	36	there ex have vbp been vbn greater jjr than inpos num_fold jj increases nns in inpos previously rb stable jj plasma nn levels nns of inpos other jj antidepressants nn including vbg nortriptyline nn when wrb fluoxetine_hydrochloride nn has vbz been vbn administered vbn in inpos combination nn with inpos these dt agents nns
mechanism	32	36	there ex have vbp been vbn greater jjr than inpos num_fold jj increases nns in inpos previously rb stable jj plasma nn levels nns of inpos other jj antidepressants nns including vbg nortriptyline nn when wrb fluoxetine_hydrochloride nn has vbz been vbn administered vbn in inpos combination nn with inpos these dt agents nns
effect	4	14	administration nn of inpos reserpine nn during inpos therapy nn with inpos a dt tricyclic_antidepressant nn has vbz been vbn shown vbn to topos produce vb a dt stimulating jj effect nn in inpos some dt depressed jj patients nns
advise	22	32	close jj supervision nn and cc careful jj adjustment nn of inpos the dt dosage nn are vbp required vbn when wrb nortriptyline_hydrochloride nn is vbz used vbn with inpos other jj anticholinergic_drugs nn or cc sympathomimetic_drugs nns
advise	22	36	close jj supervision nn and cc careful jj adjustment nn of inpos the dt dosage nn are vbp required vbn when wrb nortriptyline_hydrochloride nn is vbz used vbn with inpos other jj anticholinergic_drugs nns or cc sympathomimetic_drugs nn
false	32	36	close jj supervision nn and cc careful jj adjustment nn of inpos the dt dosage nn are vbp required vbn when wrb nortriptyline_hydrochloride nn is vbz used vbn with inpos other jj anticholinergic_drugs nn or cc sympathomimetic_drugs nn
false	24	26	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nns
false	24	30	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nn
false	26	30	such jj individuals nns are vbp referred vbn to topos as inpos poor jj metabolizers nns of inpos drugs nns such jj as inpos debrisoquin nn dextromethorphan nn the dt tricyclic_antidepressants nn
advise	6	32	therefore rb co_administration nn of inpos tricyclic_antidepressants nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns phenothiazines nns or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	32	therefore rb co_administration nn of inpos tricyclic_antidepressants nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns type_1c_antiarrhythmics nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	32	therefore rb co_administration nn of inpos tricyclic_antidepressants nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns propafenone nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	32	therefore rb co_administration nn of inpos tricyclic_antidepressants nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns flecainide nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	32	therefore rb co_administration nn of inpos tricyclic_antidepressants nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns encainide nn or cc that wdt inhibit vbp this dt enzyme nn should md be vb approached vbn with inpos caution nn
advise	6	46	therefore rb co_administration nn of inpos tricyclic_antidepressants nn with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns phenothiazines nns carbamazepine nn type_1c_antiarrhythmics nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	6	40	therefore rb co_administration nn of inpos tricyclic_antidepressants nns with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	32	42	therefore rb co_administration nn of inpos tricyclic_antidepressants nns with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns phenothiazines nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	6	16	therefore rb co_administration nn of inpos tricyclic_carbamazepine nns or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	32	42	therefore rb co_administration nn of inpos tricyclic_antidepressants nns with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns type_1c_antiarrhythmics nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	32	42	therefore rb co_administration nn of inpos tricyclic_antidepressants nns with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns propafenone nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	32	42	therefore rb co_administration nn of inpos tricyclic_antidepressants nns with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns flecainide nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
false	32	42	therefore rb co_administration nn of inpos tricyclic_antidepressants nns with inpos other jj drugs nns that wdt are vbp metabolized vbn by inpos this dt isoenzyme nn including vbg other jj antidepressants nns encainide nn or cc that wdt inhibit vbp this dt quinidine nn should md be vb approached vbn with inpos caution nn
mechanism	6	30	in inpos addition nn several jj aed nn s nns that wdt are vbp cytochrome nn p450 nn inducers nns can md decrease vb plasma nn concentrations nns of inpos oxcarbazepine nn and cc mhd nn
false	6	34	in inpos addition nn several jj aed nn s nns that wdt are vbp cytochrome nn p450 nn inducers nns can md decrease vb plasma nn concentrations nns of inpos oxcarbazepine nn and cc mhd nn
false	30	34	in inpos addition nn several jj aed jj s nns that wdt are vbp cytochrome nn p450 nn inducers nns can md decrease vb plasma nn concentrations nns of inpos oxcarbazepine nn and cc mhd nn
false	6	18	results nns demonstrate vbp that inpos oxcarbazepine nn and cc its prp pharmacologically rb active jj num_monohydroxy jj mhd nn have vbp little jj or cc no dt capacity nn to topos function vb as inpos inhibitors nns for inpos most jjs of inpos the dt human jj cytochrome nn p450 nn enzymes nns evaluated vbn with inpos the dt exception nn of inpos cyp2c19 nn and cc cyp3a4_num nn
false	12	16	although inpos inhibition nn of inpos cyp nn 3a4_num nn by inpos oxc nn and cc mhd nn did vbd occur vb at inpos high jj concentrations nns it prp is vbz not rb likely jj to topos be vb of inpos clinical jj significance nn
false	10	14	the dt inhibition nn of inpos cyp_2c19 nn by inpos oxc nn and cc mhd nn however rb is vbz clinically rb relevant jj
false	8	16	increases nns of inpos num cd with inpos mhd nn and cc num cd with inpos oxcarbazepine nn were vbd observed vbn
false	2	62	as inpos mhd nn the dt predominant jj plasma nn substrate nn is vbz only rb a dt weak jj inducer nn of inpos udp_glucuronyl nn transferase nn it prp is vbz unlikely jj to topos have vb an dt effect nn on inpos drugs nns that wdt are vbp mainly rb eliminated vbn by inpos conjugation nn through inpos udp_glucuronyl nn valproic_acid nn
false	2	62	as inpos mhd nn the dt predominant jj plasma nn substrate nn is vbz only rb a dt weak jj inducer nn of inpos udp_glucuronyl nn transferase nn it prp is vbz unlikely jj to topos have vb an dt effect nn on inpos drugs nns that wdt are vbp mainly rb eliminated vbn by inpos conjugation nn through inpos udp_glucuronyl nn lamotrigine nn
false	4	8	in inpos addition nn oxcarbazepine nn and cc mhd nn induce vbp a dt subgroup nn of inpos the dt cytochrome nn p450 nn 3a nn family nn responsible jj for inpos the dt metabolism nn of inpos dihydropyridine_calcium_antagonists nns and cc oral jj contraceptives nns resulting vbg in inpos a dt lower jjr plasma nn concentration nn of inpos these dt drugs nns
false	4	38	in inpos addition nn oxcarbazepine nn and cc mhd nn induce vbp a dt subgroup nn of inpos the dt cytochrome nn p450 nn 3a nn family nn responsible jj for inpos the dt metabolism nn of inpos dihydropyridine_calcium_antagonists nn and cc oral jj contraceptives nns resulting vbg in inpos a dt lower jjr plasma nn concentration nn of inpos these dt drugs nns
false	4	44	in inpos addition nn oxcarbazepine nn and cc mhd nn induce vbp a dt subgroup nn of inpos the dt cytochrome nn p450 nn 3a nn family nn responsible jj for inpos the dt metabolism nn of inpos dihydropyridine_calcium_antagonists nns and cc oral jj contraceptives nn resulting vbg in inpos a dt lower jjr plasma nn concentration nn of inpos these dt drugs nns
false	8	38	in inpos addition nn oxcarbazepine nn and cc mhd nn induce vbp a dt subgroup nn of inpos the dt cytochrome nn p450 nn 3a nn family nn responsible jj for inpos the dt metabolism nn of inpos dihydropyridine_calcium_antagonists nn and cc oral jj contraceptives nns resulting vbg in inpos a dt lower jjr plasma nn concentration nn of inpos these dt drugs nns
false	8	44	in inpos addition nn oxcarbazepine nn and cc mhd nn induce vbp a dt subgroup nn of inpos the dt cytochrome nn p450 nn 3a nn family nn responsible jj for inpos the dt metabolism nn of inpos dihydropyridine_calcium_antagonists nns and cc oral jj contraceptives nn resulting vbg in inpos a dt lower jjr plasma nn concentration nn of inpos these dt drugs nns
false	38	44	in inpos addition nn oxcarbazepine nn and cc mhd nn induce vbp a dt subgroup nn of inpos the dt cytochrome nn p450 nn 3a nn family nn responsible jj for inpos the dt metabolism nn of inpos dihydropyridine_calcium_antagonists nn and cc oral jj contraceptives nn resulting vbg in inpos a dt lower jjr plasma nn concentration nn of inpos these dt drugs nns
false	0	8	antiepileptic_drugs nn potential jj interactions nns between inpos trileptal nn and cc other jj aeds nns were vbd assessed vbn in inpos clinical jj studies nns
false	0	14	antiepileptic_drugs nn potential jj interactions nns between inpos trileptal jj and cc other jj aeds nn were vbd assessed vbn in inpos clinical jj studies nns
false	6	12	potential jj interactions nns between inpos trileptal nn and cc other jj aeds nn were vbd assessed vbn in inpos clinical jj studies nns
false	4	8	influence nn of inpos trileptal nn on inpos aed nn concentration nn
false	4	8	influence nn of inpos aed nn on inpos mhd nn concentration nn
false	38	54	num cd nc nn denotes vbz a dt mean jj change nn of inpos less jjr than inpos num cd num cd pediatrics nnp num cd mean nnp increase nn in inpos adults nns at inpos high jj trileptal nn doses nns in fw vivo fw the dt plasma nn levels nns of inpos phenytoin nn increased vbn by inpos up rb to topos num cd when wrb trileptal nnp was vbd given vbn at inpos doses nns above inpos num cd mg_day nn
mechanism	54	38	num cd nc nn denotes vbz a dt mean jj change nn of inpos less jjr than inpos num cd num cd pediatrics nnp num cd mean nnp increase nn in inpos adults nns at inpos high jj trileptal jj doses nns in fw vivo fw the dt plasma nn levels nns of inpos phenytoin nn increased vbn by inpos up rb to topos num cd when wrb trileptal nn was vbd given vbn at inpos doses nns above inpos num cd mg_day nn
advise	10	38	therefore rb when wrb using vbg doses nns of inpos trileptal nn greater jjr than inpos num cd mg_day nn during inpos adjunctive jj therapy nn a dt decrease nn in inpos the dt dose nn of inpos phenytoin nn may md be vb required vbn
mechanism	6	22	the dt increase nn of inpos phenobarbital nn level nn however rb is vbz small jj when wrb given vbn with inpos trileptal nn
false	10	30	strong jj inducers nns of inpos cytochrome nn p450 nn carbamazepine nn have vbp been vbn shown vbn to topos decrease vb the dt plasma nn levels nns of inpos mhd nn
false	10	30	strong jj inducers nns of inpos cytochrome nn p450 nn phenytoin nn have vbp been vbn shown vbn to topos decrease vb the dt plasma nn levels nns of inpos mhd nn
false	10	30	strong jj inducers nns of inpos cytochrome nn p450 nn phenobarbital nn have vbp been vbn shown vbn to topos decrease vb the dt plasma nn levels nns of inpos mhd nn
false	2	8	hormonal jj contraceptives nn co_administration nn of inpos trileptal nn with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
false	2	44	hormonal jj contraceptives nn co_administration nn of inpos trileptal nnp with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
false	2	48	hormonal jj contraceptives nn co_administration nn of inpos trileptal nnp with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
mechanism	8	2	hormonal jj contraceptives nns co_administration nn of inpos trileptal nn with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
false	8	44	hormonal jj contraceptives nns co_administration nn of inpos trileptal nn with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
false	8	48	hormonal jj contraceptives nns co_administration nn of inpos trileptal nn with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
false	2	44	hormonal jj contraceptives nns co_administration nn of inpos trileptal nnp with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
false	2	48	hormonal jj contraceptives nns co_administration nn of inpos trileptal nnp with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
false	44	48	hormonal jj contraceptives nns co_administration nn of inpos trileptal nnp with inpos an dt oral jj contraceptive nn has vbz been vbn shown vbn to topos influence vb the dt plasma nn concentrations nns of inpos the dt num cd hormonal jj components nns ethinylestradiol nn and cc levonorgestrel nn
effect	8	12	therefore rb concurrent jj use nn of inpos trileptal nn with inpos hormonal_contraceptives nn may md render vb these dt contraceptives nns less rbr effective jj
false	8	12	therefore rb concurrent jj use nn of inpos trileptal nn with inpos hormonal_contraceptives nns may md render vb these dt contraceptives nn less rbr effective jj
mechanism	8	16	after inpos repeated vbn co_administration nn of inpos trileptal nn the dt auc nn of inpos felodipine nn was vbd lowered vbn by inpos num cd lrb_num cd ci nn num cd
false	0	28	verapamil nn produced vbd a dt decrease nn of inpos num cd lrb_num cd ci nn num cd rrb_of inpos the dt plasma nn levels nns of inpos mhd nn
false	6	22	other jj drug nn interactions nns cimetidine nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos mhd nn
false	6	22	other jj drug nn interactions nns erythromycin nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos mhd nn
false	6	22	other jj drug nn interactions nns dextropropoxyphene nn had vbd no dt effect nn on inpos the dt pharmacokinetics nns of inpos mhd nn
false	4	30	results nns with inpos warfarin nn wshow vbp no dt evidence nn of inpos interaction nn with inpos either cc single jj or cc repeated vbn doses nns of inpos trileptal nn
false	18	22	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn
false	18	22	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn
false	18	22	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn lrb_ie fw taxol nn before inpos cisplatin nn
false	22	18	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn
false	22	18	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn lrb_ie fw taxol nn before inpos cisplatin nn
effect	18	22	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn
false	18	22	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn lrb_ie fw taxol nn before inpos cisplatin nn
false	22	18	in inpos a dt phase nn num cd trial nn using vbg escalating vbg doses nns of inpos taxol nn and cc cisplatin nn given vbn as inpos sequential jj infusions nns myelosuppression nn was vbd more rbr profound jj when wrb taxol nn was vbd given vbn after inpos cisplatin nn than inpos with inpos the dt alternate jj sequence nn lrb_ie fw taxol nn before inpos cisplatin nn
false	4	8	in inpos ie fw taxol nn before inpos cisplatin nn
false	18	30	pharmacokinetic jj data nns from inpos these dt patients nns demonstrated vbd a dt decrease nn in inpos paclitaxel nn clearance nn of inpos approximately rb num cd when wrb taxol nn was vbd administered vbn following vbg cisplatin nn
false	18	38	pharmacokinetic jj data nns from inpos these dt patients nns demonstrated vbd a dt decrease nn in inpos paclitaxel nn clearance nn of inpos approximately rb num cd when wrb taxol nn was vbd administered vbn following vbg cisplatin nn
mechanism	30	38	pharmacokinetic jj data nns from inpos these dt patients nns demonstrated vbd a dt decrease nn in inpos paclitaxel nn clearance nn of inpos approximately rb num cd when wrb taxol nn was vbd administered vbn following vbg cisplatin nn
false	6	18	potential jj interactions nns between inpos taxol nn a dt substrate nn of inpos cyp3a4 nn and cc protease_inhibitors nn which wdt are vbp substrates nns and_or cc inhibitors nns of inpos cyp3a4 nn have vbp not rb been vbn evaluated vbn in inpos clinical jj trials nns
false	6	18	potential jj interactions nns between inpos taxol nn a dt substrate nn of inpos cyp3a4 nn and cc ritonavir nn which wdt are vbp substrates nns and_or cc inhibitors nns of inpos cyp3a4 nn have vbp not rb been vbn evaluated vbn in inpos clinical jj trials nns
false	6	18	potential jj interactions nns between inpos taxol nn a dt substrate nn of inpos cyp3a4 nn and cc saquinavir nn which wdt are vbp substrates nns and_or cc inhibitors nns of inpos cyp3a4 nn have vbp not rb been vbn evaluated vbn in inpos clinical jj trials nns
false	6	18	potential jj interactions nns between inpos taxol nn a dt substrate nn of inpos cyp3a4 nn and cc indinavir nn which wdt are vbp substrates nns and_or cc inhibitors nns of inpos cyp3a4 nn have vbp not rb been vbn evaluated vbn in inpos clinical jj trials nns
false	6	18	potential jj interactions nns between inpos taxol nn a dt substrate nn of inpos cyp3a4 nn and cc nelfinavir nn which wdt are vbp substrates nns and_or cc inhibitors nns of inpos cyp3a4 nn have vbp not rb been vbn evaluated vbn in inpos clinical jj trials nns
false	18	28	reports nns in inpos the dt literature nn suggest vbp that inpos plasma nn levels nns of inpos doxorubicin nn may md be vb increased vbn when wrb paclitaxel nn and cc doxorubicin nn are vbp used vbn in inpos combination nn
false	28	38	reports nns in inpos the dt literature nn suggest vbp that inpos plasma nn levels nns of inpos doxorubicin nn lrb_and cc its prp active jj metabolite nn doxorubicinol nn rrb_may md be vb increased vbn when wrb paclitaxel nn and cc doxorubicin nn are vbp used vbn in inpos combination nn
mechanism	28	18	reports nns in inpos the dt literature nn suggest vbp that inpos plasma nn levels nns of inpos doxorubicin nn may md be vb increased vbn when wrb paclitaxel nn and cc doxorubicin nn are vbp used vbn in inpos combination nn
false	4	14	hypersensitivity nn eg fw cyclosporin nn for inpos injection nn concentrate nn and cc teniposide nn for inpos injection nn concentrate nn
advise	28	56	patients nns with inpos a dt history nn of inpos severe jj hypersensitivity nn reactions nns to topos products nns containing vbg cremophor nnp el nnp lrb_eg fw cyclosporin nn for inpos injection nn concentrate nn and cc teniposide nn for inpos injection nn concentrate nn rrb_should md not rb be vb treated vbn with inpos taxol nn
advise	38	56	patients nns with inpos a dt history nn of inpos severe jj hypersensitivity nn reactions nns to topos products nns containing vbg cremophor nnp el nnp lrb_eg fw cyclosporin nn for inpos injection nn concentrate nn and cc teniposide nn for inpos injection nn concentrate nn rrb_should md not rb be vb treated vbn with inpos taxol nn
false	28	38	in inpos order nn to topos avoid vb the dt occurrence nn of inpos severe jj hypersensitivity nn reactions nns all dt patients nns treated vbn with inpos taxol nn should md be vb premedicated vbn with inpos corticosteroids nns
false	28	38	in inpos order nn to topos avoid vb the dt occurrence nn of inpos severe jj hypersensitivity nn reactions nns all dt patients nns treated vbn with inpos taxol nn should md be vb premedicated vbn with inpos dexamethasone nns
false	28	38	in inpos order nn to topos avoid vb the dt occurrence nn of inpos severe jj hypersensitivity nn reactions nns all dt patients nns treated vbn with inpos taxol nn should md be vb premedicated vbn with inpos h2_antagonists nn
false	28	38	in inpos order nn to topos avoid vb the dt occurrence nn of inpos severe jj hypersensitivity nn reactions nns all dt patients nns treated vbn with inpos taxol nn should md be vb premedicated vbn with inpos cimetidine nn
false	28	38	in inpos order nn to topos avoid vb the dt occurrence nn of inpos severe jj hypersensitivity nn reactions nns all dt patients nns treated vbn with inpos taxol nn should md be vb premedicated vbn with inpos ranitidine nn
false	20	36	however rb severe jj reactions nns such jj as inpos hypotension nn requiring vbg treatment nn dyspnea nn requiring vbg bronchodilators nn angioedema nn generalized vbn urticaria nn require vbp immediate jj discontinuation nn of inpos taxol nn and cc aggressive jj symptomatic jj therapy nn
mechanism	4	48	treatment nn with inpos pegasys nn once rb weekly rb for inpos num cd weeks nns in inpos healthy jj subjects nns was vbd associated vbn with inpos an dt inhibition nn of inpos p450 nn 1a2 nn and cc a dt num cd increase nn in inpos theophylline nn auc nn
false	0	34	theophylline nn serum nn levels nns should md be vb monitored vbn and cc appropriate jj dose nn adjustments nns considered vbn for inpos patients nns given vbn both cc theophylline nn and cc pegasys nn
advise	0	34	theophylline nn serum nn levels nns should md be vb monitored vbn and cc appropriate jj dose nn adjustments nns considered vbn for inpos patients nns given vbn both cc theophylline nn and cc pegasys nn
false	16	24	in inpos patients nns with inpos chronic jj hepatitis nn c nn treated vbn with inpos pegasys nn in inpos combination nn with inpos copegus nn pegasys nn treatment nn did vbd not rb affect vb ribavirin nn distribution nn or cc clearance nn
false	16	36	in inpos patients nns with inpos chronic jj hepatitis nn c nn treated vbn with inpos pegasys nn in inpos combination nn with inpos copegus nn pegasys nn treatment nn did vbd not rb affect vb ribavirin nn distribution nn or cc clearance nn
false	24	16	in inpos patients nns with inpos chronic jj hepatitis nn c nn treated vbn with inpos pegasys nn in inpos combination nn with inpos copegus nn pegasys nn treatment nn did vbd not rb affect vb ribavirin nn distribution nn or cc clearance nn
false	24	36	in inpos patients nns with inpos chronic jj hepatitis nn c nn treated vbn with inpos pegasys nn in inpos combination nn with inpos copegus nn pegasys nn treatment nn did vbd not rb affect vb ribavirin nn distribution nn or cc clearance nn
false	16	36	in inpos patients nns with inpos chronic jj hepatitis nn c nn treated vbn with inpos pegasys nn in inpos combination nn with inpos copegus nn pegasys nn treatment nn did vbd not rb affect vb ribavirin nn distribution nn or cc clearance nn
false	4	10	nucleoside nn analogues vbz didanosine nn co_administration nn of inpos copegus nn and cc didanosine nn is vbz not rb recommended vbn
advise	10	4	nucleoside nn analogues nnp didanosine nnp co_administration nn of inpos copegus nn and cc didanosine nn is vbz not rb recommended vbn
false	0	4	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
false	0	6	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
false	0	4	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
false	4	6	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
false	4	0	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
effect	6	0	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
effect	6	4	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
false	0	4	stavudine nn and cc zidovudine nn ribavirin nn can md antagonize vb the dt in fw vitro fw antiviral jj activity nn of inpos stavudine nn and cc zidovudine nn against inpos hiv nn
false	10	14	the dt effect nn of inpos orally rb ingested vbn peginterferon nn or cc ribavirin nn from inpos breast nn milk nn on inpos the dt nursing nn infant nn has vbz not rb been vbn evaluated vbn
false	48	52	because inpos of inpos the dt potential nn for inpos adverse jj reactions nns from inpos the dt drugs nns in inpos nursing nn infants nns a dt decision nn must md be vb made vbn whether inpos to topos discontinue vb nursing nn or cc discontinue vb pegasys nn and cc copegus nn treatment nn
false	14	26	pediatric nnp use nnp the dt safety nn and cc effectiveness nn of inpos pegasys nn alone rb or cc in inpos combination nn with inpos copegus nn in inpos patients nns below inpos the dt age nn of inpos num cd years nns have vbp not rb been vbn established vbn
false	0	4	pegasys nn contains vbz benzyl_alcohol nn
false	6	18	clinical jj studies nns of inpos pegasys nn alone rb or cc in inpos combination nn with inpos copegus nn did vbd not rb include vb sufficient jj numbers nns of inpos subjects nns aged vbn num cd or cc over inpos to topos determine vb whether inpos they prp respond vbp differently rb from inpos younger jjr subjects nns
false	8	58	adverse jj reactions nns related vbn to topos ap_interferon nn s nns such jj as inpos cns nn cardiac jj and cc systemic jj effects nns may md be vb more rbr severe jj in inpos the dt elderly jj and cc caution nn should md be vb exercised vbn in inpos the dt use nn of inpos pegasys nn in inpos this dt population nn
false	0	4	pegasys nn and cc copegus nn are vbp excreted vbn by inpos the dt kidney nn and cc the dt risk nn of inpos toxic jj reactions nns to topos this dt therapy nn may md be vb greater jjr in inpos patients nns with inpos impaired jj renal jj function nn
false	0	28	pegasys nn should md be vb used vbn with inpos caution nn in inpos patients nns with inpos creatinine nn clearance nn num cd ml_min nn and cc copegus nn should md not rb be vb administered vbn to topos patients nns with inpos creatinine nn clearance nn num cd ml_min nn
effect	6	12	the dt mixing nn of inpos piperacillin nn with inpos an dt aminoglycoside nn in fw vitro fw can md result vb in inpos substantial jj inactivation nn of inpos the dt aminoglycoside nn
false	6	12	the dt mixing nn of inpos piperacillin nn with inpos an dt aminoglycoside nn in fw vitro fw can md result vb in inpos substantial jj inactivation nn of inpos the dt aminoglycoside nn
effect	12	36	when wrb used vbn in inpos the dt perioperative jj period nn piperacillin nn has vbz been vbn implicated vbn in inpos the dt prolongation nn of inpos the dt neuromuscular jj blockade nn of inpos vecuronium nn
effect	16	32	in inpos num cd controlled vbn clinical jj study nn the dt ureidopenicillins nns including vbg piperacillin nn were vbd reported vbn to topos prolong vb the dt action nn of inpos vecuronium nn
effect	38	54	due jj to topos their prp similar jj mechanism nn of inpos action nn it prp is vbz expected vbn that inpos the dt neuromuscular jj blockade nn produced vbn by inpos any dt of inpos the dt non_depolarizing_muscle_relaxants nn could md be vb prolonged vbn in inpos the dt presence nn of inpos piperacillin nn
mechanism	8	18	the dt oral jj combination nn of inpos probenecid nn before inpos intramuscular jj injection nn of inpos pipracil nn produces vbz an dt increase nn in inpos piperacillin nn peak nn serum nn level nn of inpos about inpos num cd
false	8	28	the dt oral jj combination nn of inpos probenecid nn before inpos intramuscular jj injection nn of inpos pipracil nn produces vbz an dt increase nn in inpos piperacillin nn peak nn serum nn level nn of inpos about inpos num cd
false	18	28	the dt oral jj combination nn of inpos probenecid nn before inpos intramuscular jj injection nn of inpos pipracil nn produces vbz an dt increase nn in inpos piperacillin nn peak nn serum nn level nn of inpos about inpos num cd
false	34	38	coagulation nn parameters nns should md be vb tested vbn more rbr frequently rb and cc monitored vbn regularly rb during inpos simultaneous jj administration nn of inpos high jj doses nns of inpos heparin nn oral jj anticoagulants nn other jj drugs nns that wdt may md affect vb the dt blood nn coagulation nn system nn or cc the dt thrombocyte nn function nn
mechanism	0	12	piperacillin_sodium nn may md reduce vb the dt excretion nn of inpos methotrexate nn
false	12	20	drug_laboratory nnp test nnp interactions nns as inpos with inpos other jj penicillins nn the dt administration nn of inpos pipracil nn may md result vb in inpos a dt false_positive jj reaction nn for inpos glucose nn in inpos the dt urine nn using vbg a dt copper_reduction nn method nn
false	0	4	phenothiazines nn hyph_taking vbg piperazine nn and cc a dt phenothiazine nn together rb may md increase vb the dt risk nn of inpos convulsions nns
effect	4	0	phenothiazines nns hyph_taking vbg piperazine nn and cc a dt phenothiazine nn together rb may md increase vb the dt risk nn of inpos convulsions nns
false	0	4	pyrantel nn hyph_taking vbg piperazine nn and cc pyrantel nn together rb may md decrease vb the dt effects nns of inpos piperazine nn
false	0	4	pyrantel nn hyph_taking vbg piperazine nn and cc pyrantel nn together rb may md decrease vb the dt effects nns of inpos piperazine nn
false	0	4	antiminth nn hyph_taking vbg piperazine nn and cc pyrantel nn together rb may md decrease vb the dt effects nns of inpos piperazine nn
false	0	8	antiminth nn hyph_taking vbg piperazine nn and cc pyrantel nn together rb may md decrease vb the dt effects nns of inpos piperazine nn
false	0	4	antiminth nn hyph_taking vbg piperazine nn and cc pyrantel nn together rb may md decrease vb the dt effects nns of inpos piperazine nn
effect	4	0	pyrantel nn hyph_taking vbg piperazine nn and cc pyrantel nn together rb may md decrease vb the dt effects nns of inpos piperazine nn
false	0	4	pyrantel nn hyph_taking vbg piperazine nn and cc pyrantel nn together rb may md decrease vb the dt effects nns of inpos piperazine nn
effect	6	20	reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos angiotensin_converting_enzyme_ace_inhibitors nn
false	26	32	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos num cd mg nn daily rb of inpos vioxx nn with inpos the dt ace_inhibitor nn benazepril nn num cd to topos num cd mg nn for inpos num cd weeks nns was vbd associated vbn with inpos an dt average jj increase nn in inpos mean jj arterial jj pressure nn of inpos about inpos num cd mm nn hg nn compared vbn to topos ace_inhibitor nn alone rb
effect	26	34	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos num cd mg nn daily rb of inpos vioxx nn with inpos the dt ace_inhibitor nn benazepril nn num cd to topos num cd mg nn for inpos num cd weeks nns was vbd associated vbn with inpos an dt average jj increase nn in inpos mean jj arterial jj pressure nn of inpos about inpos num cd mm nn hg nn compared vbn to topos ace_inhibitor nn alone rb
false	26	32	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos num cd mg nn daily rb of inpos vioxx nn with inpos the dt ace_inhibitor nn benazepril nn num cd to topos num cd mg nn for inpos num cd weeks nns was vbd associated vbn with inpos an dt average jj increase nn in inpos mean jj arterial jj pressure nn of inpos about inpos num cd mm nn hg nn compared vbn to topos ace_inhibitor nn alone rb
false	32	34	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos num cd mg nn daily rb of inpos vioxx nn with inpos the dt ace_inhibitor nn benazepril nn num cd to topos num cd mg nn for inpos num cd weeks nns was vbd associated vbn with inpos an dt average jj increase nn in inpos mean jj arterial jj pressure nn of inpos about inpos num cd mm nn hg nn compared vbn to topos ace_inhibitor nn alone rb
false	34	32	in inpos patients nns with inpos mild jj to topos moderate jj hypertension nn administration nn of inpos num cd mg nn daily rb of inpos vioxx nn with inpos the dt ace_inhibitor nn benazepril nn num cd to topos num cd mg nn for inpos num cd weeks nns was vbd associated vbn with inpos an dt average jj increase nn in inpos mean jj arterial jj pressure nn of inpos about inpos num cd mm nn hg nn compared vbn to topos ace_inhibitor nn alone rb
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg vioxx nn concomitantly rb with inpos ace_inhibitors nn
false	0	14	aspirin nn concomitant jj administration nn of inpos low_dose jj aspirin nn with inpos vioxx nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos vioxx nn alone rb
false	0	14	aspirin nn concomitant jj administration nn of inpos low_dose jj aspirin nn with inpos vioxx nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos vioxx nn alone rb
effect	8	12	concomitant jj administration nn of inpos low_dose jj aspirin nn with inpos vioxx nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos vioxx nn alone rb
false	8	12	concomitant jj administration nn of inpos low_dose jj aspirin nn with inpos vioxx nn may md result vb in inpos an dt increased vbn rate nn of inpos gi nn ulceration nn or cc other jj complications nns compared vbn to topos use nn of inpos vioxx nn alone rb
false	54	58	in inpos a dt num_week jj endoscopy nn study nn conducted vbn in inpos oa nn patients nns there ex was vbd no dt difference nn in inpos the dt cumulative jj incidence nn of inpos endoscopic jj gastroduodenal jj ulcers nns in inpos patients nns taking vbg low_dose jj enteric jj coated jj aspirin nn plus cc vioxx nn num cd mg nn daily rb as inpos compared vbn to topos those dt taking vbg ibuprofen nn num cd mg nn daily rb alone rb
false	54	76	in inpos a dt num_week jj endoscopy nn study nn conducted vbn in inpos oa nn patients nns there ex was vbd no dt difference nn in inpos the dt cumulative jj incidence nn of inpos endoscopic jj gastroduodenal jj ulcers nns in inpos patients nns taking vbg low_dose jj enteric jj coated jj aspirin nn plus cc vioxx nn num cd mg nn daily rb as inpos compared vbn to topos those dt taking vbg ibuprofen nn num cd mg nn daily rb alone rb
false	58	76	in inpos a dt num_week jj endoscopy nn study nn conducted vbn in inpos oa nn patients nns there ex was vbd no dt difference nn in inpos the dt cumulative jj incidence nn of inpos endoscopic jj gastroduodenal jj ulcers nns in inpos patients nns taking vbg low_dose jj enteric jj coated jj aspirin nn plus cc vioxx nn num cd mg nn daily rb as inpos compared vbn to topos those dt taking vbg ibuprofen nn num cd mg nn daily rb alone rb
false	6	10	patients nns taking vbg low_dose jj aspirin nn plus cc ibuprofen nn were vbd not rb studied vbn
false	6	34	at inpos steady jj state nn vioxx nn num cd mg nn once rb daily rb had vbd no dt effect nn on inpos the dt anti_platelet jj activity nn of inpos low_dose jj aspirin nn as inpos assessed vbn by inpos vivo fw platelet nn aggregation nn and cc serum nn txb2 nn generation nn in inpos clotting vbg blood nn
false	14	26	because inpos of inpos its prp lack nn of inpos platelet nn effects nns vioxx nn is vbz not rb a dt substitute nn for inpos aspirin nn for inpos cardiovascular jj prophylaxis nn
false	14	18	prospective jj long_term jj studies nns on inpos concomitant jj administration nn of inpos vioxx nn and cc aspirin nn have vbp not rb been vbn conducted vbn
false	0	30	cimetidine nn co_administration nn with inpos high jj doses nns of inpos cimetidine nn lrb_num cd mg nn twice rb daily rb rrb_increased vbd the dt cmax nn of inpos rofecoxib nn by inpos num cd the dt auc0_120hr nn by inpos num cd and cc the dt t1_num nn by inpos num cd
mechanism	10	28	co_administration nn with inpos high jj doses nns of inpos cimetidine nn lrb_num cd mg nn twice rb daily rb rrb_increased vbd the dt cmax nn of inpos rofecoxib nn by inpos num cd the dt auc0_120hr nn by inpos num cd and cc the dt t1_num nn by inpos num cd
false	0	38	rofecoxib nn num cd mg nn once rb daily rb for inpos num cd days nns does vbz not rb alter vb the dt plasma nn concentration nn profile nn or cc renal jj elimination nn of inpos digoxin nn after inpos a dt single jj float cd mg nn oral jj dose nn
false	0	22	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
effect	22	0	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
effect	22	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	0	30	ketoconazole nn num cd mg nn daily rb did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos rofecoxib nn
mechanism	0	14	nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
false	0	14	nsaids nn have vbp produced vbn an dt elevation nn of inpos plasma nn lithium nn levels nns and cc a dt reduction nn in inpos renal jj lithium nn clearance nn
advise	4	8	thus rb when wrb vioxx nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
false	4	8	thus rb when wrb vioxx nn and cc lithium nn are vbp administered vbn concurrently rb subjects nns should md be vb observed vbn carefully rb for inpos signs nns of inpos lithium nn toxicity nn
false	0	2	methotrexate nn vioxx nn float cd num cd num cd mg nn each dt dose nn administered vbn once rb daily rb for inpos num cd days nns had vbd no dt effect nn on inpos the dt plasma nn concentration nn of inpos methotrexate nn as inpos measured vbn by inpos auc0_24hr nn in inpos patients nns receiving vbg single jj weekly jj methotrexate nn doses nns of inpos float cd to topos num cd mg nn for inpos rheumatoid jj arthritis nn
false	2	0	methotrexate nn vioxx nn float cd num cd num cd mg nn each dt dose nn administered vbn once rb daily rb for inpos num cd days nns had vbd no dt effect nn on inpos the dt plasma nn concentration nn of inpos methotrexate nn as inpos measured vbn by inpos auc0_24hr nn in inpos patients nns receiving vbg single jj weekly jj methotrexate nn doses nns of inpos float cd to topos num cd mg nn for inpos rheumatoid jj arthritis nn
false	2	0	methotrexate nn vioxx nn float cd num cd num cd mg nn each dt dose nn administered vbn once rb daily rb for inpos num cd days nns had vbd no dt effect nn on inpos the dt plasma nn concentration nn of inpos methotrexate nn as inpos measured vbn by inpos auc0_24hr nn in inpos patients nns receiving vbg single jj weekly jj methotrexate nn doses nns of inpos float cd to topos num cd mg nn for inpos rheumatoid jj arthritis nn
mechanism	10	52	at inpos higher jjr than inpos recommended vbn doses nns vioxx nn num cd mg nn administered vbn once rb daily rb for inpos num cd days nns increased vbd plasma nn concentrations nns by inpos num cd as inpos measured vbn by inpos auc0_24hr nn in inpos patients nns receiving vbg methotrexate nn float cd to topos num cd mg_week nn for inpos rheumatoid jj arthritis nn
false	22	46	at inpos num cd hours nns postdose vbp a dt similar jj proportion nn of inpos patients nns treated vbn with inpos methotrexate nn alone rb and cc subsequently rb treated vbn with inpos methotrexate nn co_administered vbn with inpos num cd mg nn of inpos rofecoxib nn had vbd methotrexate nn plasma nn concentrations nns below inpos the dt measurable jj limit nn
mechanism	22	46	at inpos num cd hours nns postdose vbp a dt similar jj proportion nn of inpos patients nns treated vbn with inpos methotrexate nn alone rb and cc subsequently rb treated vbn with inpos methotrexate nn co_administered vbn with inpos num cd mg nn of inpos rofecoxib nn had vbd methotrexate nn plasma nn concentrations nns below inpos the dt measurable jj limit nn
false	46	22	at inpos num cd hours nns postdose vbp a dt similar jj proportion nn of inpos patients nns treated vbn with inpos methotrexate nn alone rb and cc subsequently rb treated vbn with inpos methotrexate nn co_administered vbn with inpos num cd mg nn of inpos rofecoxib nn had vbd methotrexate nn plasma nn concentrations nns below inpos the dt measurable jj limit nn
false	6	20	standard jj monitoring nn of inpos methotrexate nn related jj toxicity nn should md be vb continued vbn if inpos vioxx nn and cc methotrexate nn are vbp administered vbn concomitantly rb
advise	18	6	standard jj monitoring nn of inpos methotrexate_related jj toxicity nn should md be vb continued vbn if inpos vioxx nn and cc methotrexate nn are vbp administered vbn concomitantly rb
false	2	4	oral jj contraceptives nn rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn and cc norethindrone nn
false	2	28	oral jj contraceptives nn rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn and cc norethindrone nn
false	2	32	oral jj contraceptives nn rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn and cc norethindrone nn
false	4	28	oral jj contraceptives nns rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn and cc norethindrone nn
false	4	32	oral jj contraceptives nns rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn and cc norethindrone nn
false	28	32	oral jj contraceptives nnps rofecoxib nnp did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos ethinyl_estradiol nn and cc norethindrone nn
false	0	2	prednisone nn prednisolone nn
false	0	24	rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos prednisolone nn or cc prednisone nn
false	0	28	rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos prednisolone nn or cc prednisone nn
false	24	28	rofecoxib nn did vbd not rb have vb any dt clinically rb important jj effect nn on inpos the dt pharmacokinetics nns of inpos prednisolone nn or cc prednisone nn
false	0	6	rifampin nn co_administration nn of inpos vioxx nn with inpos rifampin nn num cd mg nn daily rb a dt potent jj inducer nn of inpos hepatic jj metabolism nn produced vbd an dt approximate jj num cd decrease nn in inpos rofecoxib nn plasma nn concentrations nns
false	0	42	rifampin nn co_administration nn of inpos vioxx nn with inpos rifampin nn num cd mg nn daily rb a dt potent jj inducer nn of inpos hepatic jj metabolism nn produced vbd an dt approximate jj num cd decrease nn in inpos rofecoxib nn plasma nn concentrations nns
mechanism	4	8	co_administration nn of inpos vioxx nn with inpos rifampin nn num cd mg nn daily rb a dt potent jj inducer nn of inpos hepatic jj metabolism nn produced vbd an dt approximate jj num cd decrease nn in inpos rofecoxib nn plasma nn concentrations nns
false	4	40	co_administration nn of inpos vioxx nn with inpos rifampin nn num cd mg nn daily rb a dt potent jj inducer nn of inpos hepatic jj metabolism nn produced vbd an dt approximate jj num cd decrease nn in inpos rofecoxib nn plasma nn concentrations nns
false	8	40	co_administration nn of inpos vioxx nn with inpos rifampin nn num cd mg nn daily rb a dt potent jj inducer nn of inpos hepatic jj metabolism nn produced vbd an dt approximate jj num cd decrease nn in inpos rofecoxib nn plasma nn concentrations nns
false	0	2	theophylline nn vioxx nn float cd num cd num cd mg nn administered vbn once rb daily rb for inpos num cd days nns increased vbd plasma nn theophylline nn concentrations nns rrb_by inpos num cd to topos num cd in inpos healthy jj subjects nns administered vbn a dt single jj num_mg jj dose nn of inpos theophylline nn
mechanism	2	0	theophylline nn vioxx nn float cd num cd num cd mg nn administered vbn once rb daily rb for inpos num cd days nns increased vbd plasma nn theophylline nn concentrations nns rrb_by inpos num cd to topos num cd in inpos healthy jj subjects nns administered vbn a dt single jj num_mg jj dose nn of inpos theophylline nn
false	2	0	theophylline nn vioxx nn float cd num cd num cd mg nn administered vbn once rb daily rb for inpos num cd days nns increased vbd plasma nn theophylline nn concentrations nns rrb_by inpos num cd to topos num cd in inpos healthy jj subjects nns administered vbn a dt single jj num_mg jj dose nn of inpos theophylline nn
false	6	24	adequate jj monitoring nn of inpos theophylline nn plasma nn concentrations nns should md be vb considered vbn when wrb therapy nn with inpos vioxx nn is vbz initiated vbn or cc changed vbn in inpos patients nns receiving vbg theophylline nn
advise	24	6	adequate jj monitoring nn of inpos theophylline nn plasma nn concentrations nns should md be vb considered vbn when wrb therapy nn with inpos vioxx nn is vbz initiated vbn or cc changed vbn in inpos patients nns receiving vbg theophylline nn
advise	30	40	anticoagulant jj activity nn should md be vb monitored vbn particularly rb in inpos the dt first jj few jj days nns after inpos initiating vbg or cc changing vbg vioxx nn therapy nn in inpos patients nns receiving vbg warfarin nn or cc similar jj agents nns since inpos these dt patients nns are vbp at inpos an dt increased vbn risk nn of inpos bleeding vbg complications nns
effect	22	26	in inpos single jj and cc multiple jj dose nn studies nns in inpos healthy jj subjects nns receiving vbg both cc warfarin nn and cc rofecoxib nn prothrombin nn time nn was vbd increased vbn by inpos approximately rb num cd to topos num cd
effect	44	50	in inpos post_marketing jj experience nn bleeding vbg events nns have vbp been vbn reported vbn predominantly rb in inpos the dt elderly jj in inpos association nn with inpos increases nns in inpos prothrombin nn time nn in inpos patients nns receiving vbg vioxx nn concurrently rb with inpos warfarin nn
false	18	22	several jj drug nn interaction nn studies nns have vbp been vbn completed vbn with inpos both cc invirase nn and cc fortovase nn
false	12	24	observations nns from inpos drug nn interaction nn studies nns with inpos fortovase nn may md not rb be vb predictive jj for inpos invirase nn
false	18	22	additional jj drugs nns that wdt are vbp not rb recommended vbn for inpos coadministration nn with inpos invirase nn and cc ritonavir nn are vbp included vbn below inpos
false	0	2	antiarrhythmics nn amiodarone nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns
false	0	2	antiarrhythmics nn bepridil nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns
false	0	2	antiarrhythmics nn flecainide nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns
false	0	2	antiarrhythmics nn propafenone nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns
false	0	2	antiarrhythmics nn quinidine nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns
false	0	2	antihistamines nn astemizole nn terfenadine_contraindicated vbn due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj cardiac jj arrhythmias nns
false	0	2	antihistamines nn astemizole_terfenadine nn contraindicated vbn due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj cardiac jj arrhythmias nns
false	2	4	antihistamines nns astemizole nn terfenadine nn contraindicated vbn due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj cardiac jj arrhythmias nns
false	0	2	ergot_derivatives nn dihydroergotamine nn contraindicated vbn due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	0	2	ergot_derivatives nn ergonovine nn contraindicated vbn due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	0	2	ergot_derivatives nn dihydroergotamine nn ergonovine jj ergotamine nn methylergonovine nn contraindicated vbn due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	0	8	ergot_derivatives nn dihydroergotamine nn ergonovine jj ergotamine nn methylergonovine nn contraindicated vbd due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	2	4	ergot_derivatives nns dihydroergotamine nn methylergonovine nn contraindicated vbd due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	2	0	ergot_derivatives nns ergonovine nn contraindicated vbn due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	2	8	ergot_derivatives nns dihydroergotamine nn ergonovine jj ergotamine nn methylergonovine nn contraindicated vbd due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	8	0	ergot_derivatives nns dihydroergotamine nn ergonovine jj ergotamine nn methylergonovine nn contraindicated vbd due jj to topos potential nn for inpos serious jj and cc life_threatening jj reactions nns such jj as inpos acute jj ergot nn toxicity nn characterized vbn by inpos peripheral jj vasospasm nn and cc ischemia nn of inpos the dt extremities nns and cc other jj tissues nns
false	0	2	antimycobacterial_agents nn rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral jj regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	0	20	antimycobacterial_agents nn rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral jj regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	0	26	antimycobacterial_agents nn rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral nn regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	0	20	antimycobacterial_agents nn rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral jj regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	2	20	antimycobacterial_agents nns rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral jj regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	2	26	antimycobacterial_agents nns rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral nn regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	2	20	antimycobacterial_agents nns rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral jj regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	20	26	antimycobacterial_agents nns rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral nn regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	26	20	antimycobacterial_agents nns rifampin nn contraindicated vbn since inpos the dt coadministration nn of inpos this dt product nn with inpos saquinavir nn in inpos an dt antiretroviral nn regimen nn reduces vbz the dt plasma nn concentrations nns of inpos saquinavir nn
false	20	28	garlic nnp capsules nnp garlic nnp capsules nns should md not rb be vb used vbn while inpos taking vbg saquinavir nn as inpos the dt sole jj protease_inhibitor nn due jj to topos the dt risk nn of inpos decreased vbn saquinavir nn plasma nn concentrations nns
false	20	28	garlic nnp capsules nnp garlic nnp capsules nns should md not rb be vb used vbn while inpos taking vbg fortovase nn as inpos the dt sole jj protease_inhibitor nn due jj to topos the dt risk nn of inpos decreased vbn saquinavir nn plasma nn concentrations nns
false	20	42	garlic nnp capsules nnp garlic nnp capsules nns should md not rb be vb used vbn while inpos taking vbg fortovase nn as inpos the dt sole jj protease_inhibitor nn due jj to topos the dt risk nn of inpos decreased vbn saquinavir nn plasma nn concentrations nns
false	28	20	garlic nnp capsules nnp garlic nnp capsules nns should md not rb be vb used vbn while inpos taking vbg saquinavir nn as inpos the dt sole jj protease_inhibitor nn due jj to topos the dt risk nn of inpos decreased vbn saquinavir nn plasma nn concentrations nns
false	0	2	hmg_coa_reductase_inhibitors nn lovastatin nn simvastatin nn warning nn potential nn for inpos serious jj reactions nns such jj as inpos risk nn of inpos myopathy nn including vbg rhabdomyolysis nn
false	0	4	hmg_coa_reductase_inhibitors nn lovastatin nn simvastatin nn warning nn potential nn for inpos serious jj reactions nns such jj as inpos risk nn of inpos myopathy nn including vbg rhabdomyolysis nn
false	2	4	hmg_coa_reductase_inhibitors nns lovastatin nn simvastatin nn warning nn potential nn for inpos serious jj reactions nns such jj as inpos risk nn of inpos myopathy nn including vbg rhabdomyolysis nn
false	0	2	sedatives nn hypnotics nn triazolam nn midazolam nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns such jj as inpos prolonged jj or cc increased vbn sedation nn or cc respiratory jj depression nn
false	0	4	sedatives nn hypnotics nns triazolam nn midazolam nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns such jj as inpos prolonged jj or cc increased vbn sedation nn or cc respiratory jj depression nn
false	0	6	sedatives nn hypnotics nns triazolam nn midazolam nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns such jj as inpos prolonged jj or cc increased vbn sedation nn or cc respiratory jj depression nn
false	2	4	sedatives nn hypnotics nn triazolam nn midazolam nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns such jj as inpos prolonged jj or cc increased vbn sedation nn or cc respiratory jj depression nn
false	2	6	sedatives nn hypnotics nn triazolam nn midazolam nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns such jj as inpos prolonged jj or cc increased vbn sedation nn or cc respiratory jj depression nn
false	2	4	sedatives_hypnotics nns triazolam nn midazolam nn contraindicated vbd due jj to topos potential nn for inpos serious jj and_or cc life_threatening jj reactions nns such jj as inpos prolonged jj or cc increased vbn sedation nn or cc respiratory jj depression nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos calcium_channel_blockers nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos dapsone nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos disopyramide nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos quinine nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos amiodarone nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos quinidine nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos warfarin nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos tacrolimus nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos cyclosporine nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos ergot_derivatives nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos pimozide nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos carbamazepine nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos fentanyl nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos alfentanyl nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos alprazolam nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
mechanism	30	48	although inpos specific jj studies nns have vbp not rb been vbn performed vbn coadministration nn with inpos drugs nns that wdt are vbp mainly rb metabolized vbn by inpos triazolam nn may md have vb elevated vbn plasma nn concentrations nns when wrb coadministered vbn with inpos saquinavir nn
advise	2	10	since inpos invirase nn is vbz coadministered vbn with inpos ritonavir nn the dt ritonavir nn label nn should md be vb reviewed vbn for inpos additional jj drugs nns that wdt should md not rb be vb coadministered vbn
false	2	10	since inpos invirase nn is vbz coadministered vbn with inpos ritonavir nn the dt ritonavir nn label nn should md be vb reviewed vbn for inpos additional jj drugs nns that wdt should md not rb be vb coadministered vbn
mechanism	16	32	coadministration nn with inpos compounds nns that wdt are vbp potent jj inducers nns of inpos phenobarbital nn may md result vb in inpos decreased vbn plasma nn levels nns of inpos saquinavir nn
mechanism	16	32	coadministration nn with inpos compounds nns that wdt are vbp potent jj inducers nns of inpos phenytoin nn may md result vb in inpos decreased vbn plasma nn levels nns of inpos saquinavir nn
mechanism	16	32	coadministration nn with inpos compounds nns that wdt are vbp potent jj inducers nns of inpos dexamethasone nn may md result vb in inpos decreased vbn plasma nn levels nns of inpos saquinavir nn
mechanism	16	32	coadministration nn with inpos compounds nns that wdt are vbp potent jj inducers nns of inpos carbamazepine nn may md result vb in inpos decreased vbn plasma nn levels nns of inpos saquinavir nn
int	0	10	sulfacetamide nn preparations nns are vbp incompatible jj with inpos silver nn preparations nns
int	0	16	sulfapyridine nn may md interact vb with inpos any dt of inpos the dt following vbg hyph_acetaminophen nn or cc
int	0	16	sulfapyridine nn may md interact vb with inpos any dt of inpos the dt following vbg hyph_tylenol nn or cc
false	2	6	hyph_oral jj contraceptives nn containing vbg estrogen nn or cc
false	0	6	hyph_valproic_acid nn use nn of inpos sulfapyridine nn with inpos these dt medicines nns may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn
false	0	6	hyph_depakene nn use nn of inpos sulfapyridine nn with inpos these dt medicines nns may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn
false	0	6	hyph_vitamin_k nn use nn of inpos sulfapyridine nn with inpos these dt medicines nns may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt blood nn
false	0	6	hyph_aquamephyton nn use nn of inpos sulfapyridine nn with inpos these dt medicines nns may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt blood nn
false	0	6	hyph_synkayvite nn use nn of inpos sulfapyridine nn with inpos these dt medicines nns may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt blood nn
false	0	6	hyph_mephenytoin nn use nn of inpos sulfapyridine nn with inpos these dt medicines nns may md increase vb the dt chance nn of inpos side jj effects nns of inpos these dt medicines nns
false	0	6	hyph_mesantoin nn use nn of inpos sulfapyridine nn with inpos these dt medicines nns may md increase vb the dt chance nn of inpos side jj effects nns of inpos these dt medicines nns
false	0	14	hyph_antidiabetics nn oral jj use nn of inpos oral jj antidiabetics nns with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt blood nn and_or cc the dt side nn effects nns or cc oral jj antidiabetics nns
effect	0	14	hyph_antidiabetics nnp oral jj use nn of inpos oral jj antidiabetics nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt blood nn and_or cc the dt side nn effects nns or cc oral jj antidiabetics nns
false	14	0	hyph_antidiabetics nnp oral jj use nn of inpos oral jj antidiabetics nns with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt blood nn and_or cc the dt side nn effects nns or cc oral jj antidiabetics nn
false	0	10	hyph_methotrexate nn use nn of inpos methotrexate nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos methotrexate nn
false	0	6	hyph_mexate nn use nn of inpos methotrexate nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos methotrexate nn
false	0	10	hyph_mexate nn use nn of inpos methotrexate nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos methotrexate nn
false	0	6	hyph_mexate nn use nn of inpos methotrexate nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos methotrexate nn
effect	0	10	hyph_methotrexate nnp use nnp of inpos methotrexate nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos methotrexate nn
false	10	0	hyph_methotrexate nnp use nnp of inpos methotrexate nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos methotrexate nn
false	0	10	hyph_methyldopa nn use nn of inpos methyldopa nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt blood nn
false	0	6	hyph_aldomet nn use nn of inpos methyldopa nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt blood nn
false	0	10	hyph_aldomet nn use nn of inpos methyldopa nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt blood nn
effect	0	10	hyph_methyldopa nnp use nnp of inpos methyldopa nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt blood nn
false	0	10	hyph_phenytoin nn use nn of inpos phenytoin nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos phenytoin nn
false	0	6	hyph_dilantin nn use nn of inpos phenytoin nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos phenytoin nn
false	0	10	hyph_dilantin nn use nn of inpos phenytoin nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos phenytoin nn
false	0	6	hyph_dilantin nn use nn of inpos phenytoin nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos phenytoin nn
effect	0	10	hyph_phenytoin nn use nn of inpos phenytoin nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos phenytoin nn
false	10	0	hyph_phenytoin nn use nn of inpos phenytoin nn with inpos sulfapyridine nn may md increase vb the dt chance nn of inpos side nn effects nns affecting vbg the dt liver nn and_or cc the dt side nn effects nns of inpos phenytoin nn
false	0	4	valproate nn and cc gabapentin nn are vbp not rb
false	0	16	gabitril nn is vbz considered vbn to topos be vb a dt non_enzyme jj inducing vbg aed nn
false	4	12	effects nns of inpos gabitril nn on inpos other jj antiepilepsy jj aeds nn phenytoin nn
false	4	14	effects nns of inpos gabitril nn on inpos other jj antiepilepsy nnp drugs nnp phenytoin nn
false	12	14	effects nns of inpos gabitril nn on inpos other jj antiepilepsy jj aeds nn phenytoin nn
false	0	20	tiagabine nn had vbd no dt effect nn on inpos the dt steady_state jj plasma nn concentrations nns of inpos phenytoin nn in inpos patients nns with inpos epilepsy nn
false	0	20	tiagabine nn had vbd no dt effect nn on inpos the dt steady_state jj plasma nn concentrations nns of inpos carbamazepine nn or cc its prp epoxide nn metabolite nn in inpos patients nns with inpos epilepsy nn
mechanism	0	14	tiagabine nn causes vbz a dt slight jj decrease nn in inpos steady_state jj valproate nn concentrations nns
false	0	4	phenobarbital nn or cc primidone nn
false	22	30	no dt formal jj pharmacokinetic jj studies nns have vbp been vbn performed vbn examining vbg the dt addition nn of inpos tiagabine nn to topos regimens nns containing vbg phenobarbital nn or cc primidone nn
false	22	34	no dt formal jj pharmacokinetic jj studies nns have vbp been vbn performed vbn examining vbg the dt addition nn of inpos tiagabine nn to topos regimens nns containing vbg phenobarbital nn or cc primidone nn
false	30	34	no dt formal jj pharmacokinetic jj studies nns have vbp been vbn performed vbn examining vbg the dt addition nn of inpos tiagabine nn to topos regimens nns containing vbg phenobarbital nn or cc primidone nn
false	6	38	the dt addition nn of inpos tiagabine nn in inpos a dt limited jj number nn of inpos patients nns in inpos num cd well_controlled jj studies nns caused vbd no dt systematic jj changes nns in inpos phenobarbital nn or cc primidone nn concentrations nns when wrb compared vbn to topos placebo nn
false	6	42	the dt addition nn of inpos tiagabine nn in inpos a dt limited jj number nn of inpos patients nns in inpos num cd well_controlled jj studies nns caused vbd no dt systematic jj changes nns in inpos phenobarbital nn or cc primidone nn concentrations nns when wrb compared vbn to topos placebo nn
false	38	42	the dt addition nn of inpos tiagabine nn in inpos a dt limited jj number nn of inpos patients nns in inpos num cd well_controlled jj studies nns caused vbd no dt systematic jj changes nns in inpos phenobarbital nn or cc primidone nn concentrations nns when wrb compared vbn to topos placebo nn
false	8	12	effects nns of inpos other jj antiepilepsy jj aeds nn on inpos gabitril nn carbamazepine nn
false	8	14	effects nns of inpos other jj antiepilepsy jj aeds nn on inpos gabitril nn carbamazepine nn
false	12	14	effects nns of inpos other jj antiepilepsy nnp drugs nns on inpos gabitril nn carbamazepine nn
mechanism	10	26	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg carbamazepine nn with inpos or cc without inpos other jj enzyme nn inducing vbg aeds nns
false	10	40	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg carbamazepine nn with inpos or cc without inpos other jj enzyme nn inducing vbg aeds nn
false	26	40	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg carbamazepine nn with inpos or cc without inpos other jj enzyme nn inducing vbg aeds nn
mechanism	10	26	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg phenytoin nn with inpos or cc without inpos other jj enzyme nn inducing vbg aeds nns
false	10	40	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg phenytoin nn with inpos or cc without inpos other jj enzyme nn inducing vbg aeds nn
false	26	40	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg phenytoin nn with inpos or cc without inpos other jj enzyme nn inducing vbg aeds nn
mechanism	10	26	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg phenobarbital nn with inpos or cc without inpos other jj enzyme_inducing jj aeds nns
mechanism	10	26	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg primidone nn with inpos or cc without inpos other jj enzyme_inducing jj aeds nns
false	10	38	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg phenobarbital nn with inpos or cc without inpos other jj enzyme_inducing jj aeds nn
false	26	38	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg phenobarbital nn with inpos or cc without inpos other jj enzyme_inducing jj aeds nn
false	26	38	population nn pharmacokinetic jj analyses nns indicate vbp that inpos tiagabine nn clearance nn is vbz num cd greater jjr in inpos patients nns taking vbg primidone nn with inpos or cc without inpos other jj enzyme_inducing jj aeds nn
false	6	14	the dt addition nn of inpos tiagabine nn to topos patients nns taking vbg valproate nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns but cc valproate nn significantly rb decreased vbd tiagabine nn binding nn in fw vitro fw from inpos float cd to topos float cd which wdt resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt free jj tiagabine nn concentration nn
false	6	14	the dt addition nn of inpos tiagabine nn to topos patients nns taking vbg valproate nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns but cc valproate nn significantly rb decreased vbd tiagabine nn binding nn in fw vitro fw from inpos float cd to topos float cd which wdt resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt free jj tiagabine nn concentration nn
false	14	6	the dt addition nn of inpos tiagabine nn to topos patients nns taking vbg valproate nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns but cc valproate nn significantly rb decreased vbd tiagabine nn binding nn in fw vitro fw from inpos float cd to topos float cd which wdt resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt free jj tiagabine nn concentration nn
false	14	6	the dt addition nn of inpos tiagabine nn to topos patients nns taking vbg valproate nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns but cc valproate nn significantly rb decreased vbd tiagabine nn binding nn in fw vitro fw from inpos float cd to topos float cd which wdt resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt free jj tiagabine nn concentration nn
false	6	14	the dt addition nn of inpos tiagabine nn to topos patients nns taking vbg valproate nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns but cc valproate nn significantly rb decreased vbd tiagabine nn binding nn in fw vitro fw from inpos float cd to topos float cd which wdt resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt free jj tiagabine nn concentration nn
mechanism	14	6	the dt addition nn of inpos tiagabine nn to topos patients nns taking vbg valproate nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns but cc valproate nn significantly rb decreased vbd tiagabine nn binding nn in fw vitro fw from inpos float cd to topos float cd which wdt resulted vbd in inpos an dt increase nn of inpos approximately rb num cd in inpos the dt free jj tiagabine nn concentration nn
false	4	12	interaction nn of inpos gabitril nn with inpos other jj drugs nns cimetidine nn
false	4	12	interaction nn of inpos gabitril nn with inpos other jj drugs nns cimetidine nn co_administration nn of inpos cimetidine nn to topos patients nns taking vbg tiagabine nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns
false	4	26	interaction nn of inpos gabitril nn with inpos other jj drugs nns cimetidine nn co_administration nn of inpos cimetidine nn to topos patients nns taking vbg tiagabine nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns
false	4	26	interaction nn of inpos gabitril nn with inpos other jj drugs nns cimetidine nn co_administration nn of inpos cimetidine nn to topos patients nns taking vbg tiagabine nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns
false	12	26	interaction nn of inpos gabitril nn with inpos other jj drugs nns cimetidine nn co_administration nn of inpos cimetidine nn to topos patients nns taking vbg tiagabine nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns
false	12	26	interaction nn of inpos gabitril nn with inpos other jj drugs nns cimetidine nn co_administration nn of inpos cimetidine nn to topos patients nns taking vbg tiagabine nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns
false	4	12	co_administration nn of inpos cimetidine nn to topos patients nns taking vbg tiagabine nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns
false	4	12	co_administration nn of inpos cimetidine nn to topos patients nns taking vbg tiagabine nn chronically rb had vbd no dt effect nn on inpos tiagabine nn pharmacokinetics nns
false	12	26	a dt single jj num cd mg nn dose nn of inpos tiagabine nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos theophylline nn at inpos steady jj state nn
false	20	24	no dt significant jj differences nns were vbd observed vbn in inpos the dt steady_state jj pharmacokinetics nns of inpos r_warfarin nn or cc s_warfarin nn with inpos the dt addition nn of inpos tiagabine nn given vbn as inpos a dt single jj dose nn
false	20	34	no dt significant jj differences nns were vbd observed vbn in inpos the dt steady_state jj pharmacokinetics nns of inpos r_warfarin nn or cc s_warfarin nn with inpos the dt addition nn of inpos tiagabine nn given vbn as inpos a dt single jj dose nn
false	24	34	no dt significant jj differences nns were vbd observed vbn in inpos the dt steady_state jj pharmacokinetics nns of inpos r_warfarin nn or cc s_warfarin nn with inpos the dt addition nn of inpos tiagabine nn given vbn as inpos a dt single jj dose nn
false	0	8	digoxin nn concomitant jj administration nn of inpos tiagabine nn did vbd not rb affect vb the dt steady_state jj pharmacokinetics nns of inpos digoxin nn or cc the dt mean jj daily jj trough nn serum nn level nn of inpos digoxin nn
false	6	22	concomitant jj administration nn of inpos tiagabine nn did vbd not rb affect vb the dt steady_state jj pharmacokinetics nns of inpos digoxin nn or cc the dt mean jj daily jj trough nn serum nn level nn of inpos digoxin nn
false	6	22	concomitant jj administration nn of inpos tiagabine nn did vbd not rb affect vb the dt steady_state jj pharmacokinetics nns of inpos digoxin nn or cc the dt mean jj daily jj trough nn serum nn level nn of inpos digoxin nn
false	0	4	ethanol nn or cc triazolam nn
false	18	22	no dt significant jj differences nns were vbd observed vbn in inpos the dt pharmacokinetics nns of inpos triazolam nn and cc tiagabine nn when wrb given vbn together rb as inpos a dt single jj dose nn
false	6	22	the dt pharmacokinetics nns of inpos ethanol nn were vbd not rb affected vbn by inpos multiple_dose jj administration nn of inpos tiagabine nn
false	0	30	tiagabine nn has vbz shown vbn no dt clinically rb important jj potentiation nn of inpos the dt pharmacodynamic jj effects nns of inpos triazo nn lam nn or cc alcohol nn
false	28	32	because inpos of inpos the dt possible jj additive jj effects nns of inpos drugs nns that wdt may md depress vb the dt nervous jj system nn ethanol nn or cc triazolam nn should md be vb used vbn cautiously rb in inpos combination nn with inpos tiagabine nn
advise	28	48	because inpos of inpos the dt possible jj additive jj effects nns of inpos drugs nns that wdt may md depress vb the dt nervous jj system nn ethanol nn or cc triazolam nn should md be vb used vbn cautiously rb in inpos combination nn with inpos tiagabine nn
advise	32	48	because inpos of inpos the dt possible jj additive jj effects nns of inpos drugs nns that wdt may md depress vb the dt nervous jj system nn ethanol nn or cc triazolam nn should md be vb used vbn cautiously rb in inpos combination nn with inpos tiagabine nn
false	8	24	multiple jj dose nn administration nn of inpos tiagabine nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos oral jj contraceptives nn in inpos healthy jj women nns of inpos childbearing vbg age nn
false	0	18	antipyrine nn pharmacokinetics nns were vbd not rb significantly rb different jj before inpos and cc after inpos tiagabine nn multiple_dose jj regimens nns
false	6	42	this dt indicates vbz that inpos tiagabine nn does vbz not rb cause vb induction nn or cc inhibition nn of inpos the dt hepatic jj microsomal jj enzyme nn systems nns responsible jj for inpos the dt metabolism nn of inpos antipyrine nn
false	0	12	aspirin nn concomitant jj administration nn of inpos aspirin nn with inpos valdecoxib nn may md result vb in inpos an dt increased vbn risk nn of inpos gi nn ulceration nn and cc complications nns compared vbn to topos valdecoxib vb alone rb
false	0	12	aspirin nn concomitant jj administration nn of inpos aspirin nn with inpos valdecoxib nn may md result vb in inpos an dt increased vbn risk nn of inpos gi nn ulceration nn and cc complications nns compared vbn to topos valdecoxib nn alone rb
effect	6	10	concomitant jj administration nn of inpos aspirin nn with inpos valdecoxib nn may md result vb in inpos an dt increased vbn risk nn of inpos gi nn ulceration nn and cc complications nns compared vbn to topos valdecoxib vb alone rb
false	6	10	concomitant jj administration nn of inpos aspirin nn with inpos valdecoxib nn may md result vb in inpos an dt increased vbn risk nn of inpos gi nn ulceration nn and cc complications nns compared vbn to topos valdecoxib nn alone rb
false	14	26	because inpos of inpos its prp lack nn of inpos anti_platelet jj effect nn valdecoxib nn is vbz not rb a dt substitute nn for inpos aspirin nn for inpos cardiovascular jj prophylaxis nn
false	26	54	in inpos a dt parallel jj group nn drug nn interaction nn study nn comparing vbg the dt intravenous jj prodrug nn form nn of inpos valdecoxib nn at inpos num cd mg nn bid nn vs inpos placebo nn valdecoxib nn had vbd no dt effect nn on inpos in fw vitro fw aspirin nn mediated jj inhibition nn of inpos arachidonate nn or cc collagen_stimulated jj platelet nn aggregation nn
false	26	54	in inpos a dt parallel jj group nn drug nn interaction nn study nn comparing vbg the dt intravenous jj prodrug nn form nn of inpos valdecoxib nn at inpos num cd mg nn bid nn vs inpos placebo nn valdecoxib nn had vbd no dt effect nn on inpos in fw vitro fw aspirin nn mediated jj inhibition nn of inpos arachidonate nn or cc collagen_stimulated jj platelet nn aggregation nn
false	0	32	valdecoxib_num_mg nn bid nn did vbd not rb show vb a dt significant jj effect nn on inpos the dt plasma nn exposure nn or cc renal jj clearance nn of inpos methotrexate nn
false	0	8	ace_inhibitors nn reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nns
effect	8	0	ace_inhibitors nns reports nns suggest vbp that inpos nsaids nn may md diminish vb the dt antihypertensive jj effect nn of inpos ace_inhibitors nn
advise	18	24	this dt interaction nn should md be vb given vbn consideration nn in inpos patients nns taking vbg bextra nn concomitantly rb with inpos ace_inhibitors nn
false	0	22	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
effect	22	0	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nns in inpos some dt patients nns
effect	22	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nn can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
false	0	40	furosemide nn clinical jj studies nns as rb well rb as inpos post_marketing jj observations nns have vbp shown vbn that inpos nsaids nns can md reduce vb the dt natriuretic jj effect nn of inpos furosemide nn and cc thiazides nn in inpos some dt patients nns
mechanism	10	32	steady jj state nn plasma nn exposure nn of inpos valdecoxib nn was vbd decreased vbn by inpos num cd when wrb co_administered vbn with inpos multiple jj doses nns of inpos phenytoin nn
advise	8	30	patients nns already rb stabilized vbn on inpos valdecoxib nn should md be vb closely rb monitored vbn for inpos loss nn of inpos symptom nn control nn with inpos phenytoin nn coadministration nn
false	0	24	valdecoxib nn did vbd not rb have vb a dt statistically rb significant jj effect nn on inpos the dt pharmacokinetics nns of inpos phenytoin nn
mechanism	4	18	coadministration nn with inpos valdecoxib nn resulted vbd in inpos a dt significant jj increase nn in inpos dextromethorphan nn plasma nn levels nns suggesting vbg that inpos at inpos these dt doses nns valdecoxib nn is vbz a dt weak jj inhibitor nn of inpos 2d6 nn
false	18	4	coadministration nn with inpos valdecoxib nn resulted vbd in inpos a dt significant jj increase nn in inpos dextromethorphan nn plasma nn levels nns suggesting vbg that inpos at inpos these dt doses nns valdecoxib nn is vbz a dt weak jj inhibitor nn of inpos 2d6 nn
mechanism	4	24	even rb so rb dextromethorphan nn plasma nn concentrations nns in inpos the dt presence nn of inpos high jj doses nns of inpos valdecoxib nn were vbd almost rb num_fold rb lower jjr than inpos those dt seen vbn in inpos cyp nn 2d6 nn poor jj metabolizers nns suggesting vbg that inpos dose nn adjustment nn is vbz not rb necessary jj
mechanism	0	22	valdecoxib nn num cd mg nn bid nn for inpos num cd days nns produced vbd significant jj decreases nns in inpos lithium nn serum nn clearance nn and cc renal jj clearance nn with inpos a dt num cd higher jjr serum nn exposure nn compared vbn to topos lithium nn alone rb
false	0	22	valdecoxib nn num cd mg nn bid nn for inpos num cd days nns produced vbd significant jj decreases nns in inpos lithium nn serum nn clearance nn and cc renal jj clearance nn with inpos a dt num cd higher jjr serum nn exposure nn compared vbn to topos lithium nn alone rb
false	0	26	lithium nn serum nn concentrations nns should md be vb monitored vbn closely rb when wrb initiating vbg or cc changing vbg therapy nn with inpos bextra nn in inpos patients nns receiving vbg lithium nn
advise	26	0	lithium nn serum nn concentrations nns should md be vb monitored vbn closely rb when wrb initiating vbg or cc changing vbg therapy nn with inpos bextra nn in inpos patients nns receiving vbg lithium nn
false	0	10	lithium_carbonate nn had vbd no dt effect nn on inpos valdecoxib nn pharmacokinetics nns
false	6	18	the dt effect nn of inpos valdecoxib nn on inpos the dt anticoagulant jj effect nn of inpos warfarin nn was vbd studied vbn in inpos healthy jj subjects nns by inpos coadministration nn of inpos bextra nn num cd mg nn bid nn for inpos num cd days nns
false	6	36	the dt effect nn of inpos valdecoxib nn on inpos the dt anticoagulant jj effect nn of inpos warfarin nn was vbd studied vbn in inpos healthy jj subjects nns by inpos coadministration nn of inpos bextra nn num cd mg nn bid nn for inpos num cd days nns
false	18	36	the dt effect nn of inpos valdecoxib nn on inpos the dt anticoagulant jj effect nn of inpos warfarin nn was vbd studied vbn in inpos healthy jj subjects nns by inpos coadministration nn of inpos bextra nn num cd mg nn bid nn for inpos num cd days nns
mechanism	0	20	valdecoxib nn caused vbd a dt statistically rb significant jj increase nn in inpos plasma nn exposures nns of inpos r_warfarin nn and cc s_warfarin nn and cc in inpos the dt pharmacodynamic jj effects nns of inpos warfarin nn
mechanism	0	24	valdecoxib nn caused vbd a dt statistically rb significant jj increase nn in inpos plasma nn exposures nns of inpos r_warfarin nn and cc s_warfarin nn and cc in inpos the dt pharmacodynamic jj effects nns of inpos warfarin nn
effect	0	20	valdecoxib nn caused vbd a dt statistically rb significant jj increase nn in inpos plasma nn exposures nns of inpos r_warfarin nn and cc s_warfarin nn and cc in inpos the dt pharmacodynamic jj effects nns of inpos warfarin nn
false	20	24	valdecoxib nn caused vbd a dt statistically rb significant jj increase nn in inpos plasma nn exposures nns of inpos r_warfarin nn and cc s_warfarin nn and cc in inpos the dt pharmacodynamic jj effects nns of inpos warfarin nn
false	0	30	anticoagulant nn therapy nn should md be vb monitored vbn particularly rb during inpos the dt first jj few jj weeks nns after inpos initiating vbg therapy nn with inpos bextra nn in inpos patients nns receiving vbg warfarin nn or cc similar jj agents nns
false	0	38	anticoagulant nn therapy nn should md be vb monitored vbn particularly rb during inpos the dt first jj few jj weeks nns after inpos initiating vbg therapy nn with inpos bextra nn in inpos patients nns receiving vbg warfarin nn or cc similar jj agents nns
advise	30	38	anticoagulant jj therapy nn should md be vb monitored vbn particularly rb during inpos the dt first jj few jj weeks nns after inpos initiating vbg therapy nn with inpos bextra nn in inpos patients nns receiving vbg warfarin nn or cc similar jj agents nns
false	0	4	fluconazole nn and cc ketoconazole nn
false	0	4	ketoconazole nn and cc fluconazole nn are vbp predominantly rb cyp nn 3a4 nn and cc 2c9 nn inhibitors nns respectively rb
mechanism	10	24	concomitant jj single jj dose nn administration nn of inpos valdecoxib nn num cd mg nn with inpos multiple jj doses nns of inpos ketoconazole nn and cc fluconazole nn produced vbd a dt significant jj increase nn in inpos exposure nn of inpos valdecoxib nn
mechanism	10	28	concomitant jj single jj dose nn administration nn of inpos valdecoxib nn num cd mg nn with inpos multiple jj doses nns of inpos ketoconazole nn and cc fluconazole nn produced vbd a dt significant jj increase nn in inpos exposure nn of inpos valdecoxib nn
false	24	28	concomitant jj single jj dose nn administration nn of inpos valdecoxib nn num cd mg nn with inpos multiple jj doses nns of inpos ketoconazole nn and cc fluconazole nn produced vbd a dt significant jj increase nn in inpos exposure nn of inpos valdecoxib nn
false	24	10	concomitant jj single jj dose nn administration nn of inpos valdecoxib nn num cd mg nn with inpos multiple jj doses nns of inpos ketoconazole nn and cc fluconazole nn produced vbd a dt significant jj increase nn in inpos exposure nn of inpos valdecoxib nn
false	28	10	concomitant jj single jj dose nn administration nn of inpos valdecoxib nn num cd mg nn with inpos multiple jj doses nns of inpos ketoconazole nn and cc fluconazole nn produced vbd a dt significant jj increase nn in inpos exposure nn of inpos valdecoxib nn
mechanism	6	20	plasma nn exposure nn to topos valdecoxib nn was vbd increased vbn num cd when wrb coadministered vbn with inpos fluconazole nn and cc num cd when wrb coadministered vbn with inpos ketoconazole nn
mechanism	6	32	plasma nn exposure nn to topos valdecoxib nn was vbd increased vbn num cd when wrb coadministered vbn with inpos fluconazole nn and cc num cd when wrb coadministered vbn with inpos ketoconazole nn
false	20	32	plasma nn exposure nn to topos valdecoxib nn was vbd increased vbn num cd when wrb coadministered vbn with inpos fluconazole nn and cc num cd when wrb coadministered vbn with inpos ketoconazole nn
false	4	8	coadministration nn of inpos valdecoxib nn with inpos glyburide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos glyburide nn
false	4	8	coadministration nn of inpos valdecoxib nn with inpos glyburide nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos glyburide nn
false	4	16	coadministration nn of inpos valdecoxib nn and cc num cd mg nn qd nn rrb_with inpos glyburide nn did vbd not rb affect vb either cc the dt pharmacokinetics nns or cc the dt pharmacodynamics nns of inpos glyburide nn
false	4	16	coadministration nn of inpos valdecoxib nn and cc num cd mg nn qd nn rrb_with inpos glyburide nn did vbd not rb affect vb either cc the dt pharmacokinetics nns or cc the dt pharmacodynamics nns of inpos glyburide nn
mechanism	4	16	coadministration nn of inpos valdecoxib nn and cc num cd mg nn qd nn rrb_with inpos glyburide nn resulted vbd in inpos num cd increase nn in inpos glyburide nn auc0_num nn and cc a dt num cd increase nn in inpos glyburide nn cmax nn leading vbg to topos a dt num cd decrease nn in inpos glucose nn auc0_num nn
false	4	16	coadministration nn of inpos valdecoxib nn and cc num cd mg nn qd nn rrb_with inpos glyburide nn lrb_num cd mg nn glyburide nn bid nn rrb_resulted vbd in inpos num cd increase nn in inpos glyburide nn auc0_num nn and cc a dt num cd increase nn in inpos glyburide nn cmax nn leading vbg to topos a dt num cd decrease nn in inpos glucose nn auc0_num nn
false	4	16	coadministration nn of inpos valdecoxib nn and cc num cd mg nn qd nn rrb_with inpos glyburide nn resulted vbd in inpos num cd increase nn in inpos glyburide nn auc0_num nn and cc a dt num cd increase nn in inpos glyburide nn cmax nn leading vbg to topos a dt num cd decrease nn in inpos glucose nn auc0_num nn
false	4	16	coadministration nn of inpos valdecoxib nn and cc num cd mg nn qd nn rrb_with inpos glyburide nn resulted vbd in inpos num cd increase nn in inpos glyburide nn auc0_num nn and cc a dt num cd increase nn in inpos glyburide nn cmax nn leading vbg to topos a dt num cd decrease nn in inpos glucose nn auc0_num nn
false	12	52	because inpos changes nns in inpos glucose nn concentrations nns with inpos valdecoxib nn coadministration nn were vbd within inpos the dt normal jj variability nn and cc individual jj glucose nn concentrations nns were vbd above inpos or cc near inpos num cd mg_dl nn dose nn adjustment nn for inpos glyburide nn with inpos valdecoxib nn coadministration nn is vbz not rb indicated vbn
advise	52	12	because inpos changes nns in inpos glucose nn concentrations nns with inpos valdecoxib nn coadministration nn were vbd within inpos the dt normal jj variability nn and cc individual jj glucose nn concentrations nns were vbd above inpos or cc near inpos num cd mg_dl nn dose nn adjustment nn for inpos glyburide nn with inpos valdecoxib nn coadministration nn is vbz not rb indicated vbn
false	4	18	coadministration nn of inpos glyburide nn with inpos doses nns higher jjr than inpos num cd mg nn valdecoxib nn have vbp not rb been vbn studied vbn
false	0	26	valdecoxib nn steady jj state nn plasma nn concentrations nns were vbd not rb affected vbn significantly rb with inpos multiple jj doses nns of inpos omeprazole nn
mechanism	4	12	coadministration nn with inpos valdecoxib nn increased vbd exposure nn of inpos omeprazole nn by inpos num cd
false	30	34	drugs nns whose wp absorption nn is vbz sensitive jj to topos ph nn may md be vb negatively rb impacted vbn by inpos concomitant jj administration nn of inpos omeprazole nn and cc valdecoxib nn
false	4	20	coadministration nn of inpos valdecoxib nn with inpos doses nns higher jjr than inpos num cd mg nn qd nn omeprazole nn has vbz not rb been vbn studied vbn
false	0	20	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive nn norethindrone nn
false	0	22	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive jj norethindrone nn
false	0	22	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive jj ethinyl_estradiol nn
false	0	34	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive jj norethindrone nn lrb_num cd mg nn num cd mcg nn combination nn ortho_novum nn num cd
false	20	22	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive nn norethindrone nn
false	20	22	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive nn ethinyl_estradiol nn
false	20	34	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive nn norethindrone nn lrb_num cd mg nn num cd mcg nn combination nn ortho_novum nn num cd
false	22	34	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive jj norethindrone nn lrb_num cd mg nn num cd mcg nn combination nn ortho_novum nn num cd
false	22	34	valdecoxib nn did vbd not rb induce vb the dt metabolism nn of inpos the dt combination nn oral jj contraceptive jj ethinyl_estradiol nn lrb_num cd mg nn num cd mcg nn combination nn ortho_novum nn num cd
mechanism	4	8	coadministration nn of inpos valdecoxib nn and cc ortho_novum nn num cd increased vbd the dt exposure nn of inpos norethindrone nn and cc ethinyl_estradiol nn by inpos num cd and cc num cd respectively rb
false	4	20	coadministration nn of inpos valdecoxib nn and cc ortho_novum nnp num cd increased vbd the dt exposure nn of inpos norethindrone nn and cc ethinyl_estradiol nn by inpos num cd and cc num cd respectively rb
false	4	24	coadministration nn of inpos valdecoxib nn and cc ortho_novum nnp num cd increased vbd the dt exposure nn of inpos norethindrone nn and cc ethinyl_estradiol nn by inpos num cd and cc num cd respectively rb
false	8	20	coadministration nn of inpos valdecoxib nn and cc ortho_novum nn num cd increased vbd the dt exposure nn of inpos norethindrone nn and cc ethinyl_estradiol nn by inpos num cd and cc num cd respectively rb
false	8	24	coadministration nn of inpos valdecoxib nn and cc ortho_novum nn num cd increased vbd the dt exposure nn of inpos norethindrone nn and cc ethinyl_estradiol nn by inpos num cd and cc num cd respectively rb
false	20	24	coadministration nn of inpos valdecoxib nn and cc ortho_novum nnp num cd increased vbd the dt exposure nn of inpos norethindrone nn and cc ethinyl_estradiol nn by inpos num cd and cc num cd respectively rb
false	8	12	these dt increased vbn exposures nns of inpos norethindrone nn and cc ethinyl_estradiol nn should md be vb taken vbn into inpos consideration nn when wrb selecting vbg an dt oral jj contraceptive nn for inpos women nns taking vbg valdecoxib nn
false	8	32	these dt increased vbn exposures nns of inpos norethindrone nn and cc ethinyl_estradiol nn should md be vb taken vbn into inpos consideration nn when wrb selecting vbg an dt oral jj contraceptive nn for inpos women nns taking vbg valdecoxib nn
false	8	40	these dt increased vbn exposures nns of inpos norethindrone nn and cc ethinyl_estradiol nn should md be vb taken vbn into inpos consideration nn when wrb selecting vbg an dt oral jj contraceptive nn for inpos women nns taking vbg valdecoxib nn
false	12	32	these dt increased vbn exposures nns of inpos norethindrone nn and cc ethinyl_estradiol nn should md be vb taken vbn into inpos consideration nn when wrb selecting vbg an dt oral jj contraceptive nn for inpos women nns taking vbg valdecoxib nn
false	12	40	these dt increased vbn exposures nns of inpos norethindrone nn and cc ethinyl_estradiol nn should md be vb taken vbn into inpos consideration nn when wrb selecting vbg an dt oral jj contraceptive nn for inpos women nns taking vbg valdecoxib nn
advise	32	40	these dt increased vbn exposures nns of inpos norethindrone nn and cc ethinyl_estradiol nn should md be vb taken vbn into inpos consideration nn when wrb selecting vbg an dt oral jj contraceptive nn for inpos women nns taking vbg valdecoxib nn
mechanism	6	22	plasma nn exposure nn of inpos diazepam nn was vbd increased vbn by inpos num cd following vbg administration nn of inpos valdecoxib nn for inpos num cd days nns while inpos plasma nn exposure nn of inpos valdecoxib nn was vbd not rb substantially rb increased vbn following vbg administration nn of inpos diazepam nn for inpos num cd days nns
false	6	22	plasma nn exposure nn of inpos diazepam nn was vbd increased vbn by inpos num cd following vbg administration nn of inpos valdecoxib nn for inpos num cd days nns while inpos plasma nn exposure nn of inpos valdecoxib nn was vbd not rb substantially rb increased vbn following vbg administration nn of inpos diazepam nn for inpos num cd days nns
false	22	6	plasma nn exposure nn of inpos diazepam nn was vbd increased vbn by inpos num cd following vbg administration nn of inpos valdecoxib nn for inpos num cd days nns while inpos plasma nn exposure nn of inpos valdecoxib nn was vbd not rb substantially rb increased vbn following vbg administration nn of inpos diazepam nn for inpos num cd days nns
false	22	6	plasma nn exposure nn of inpos diazepam nn was vbd increased vbn by inpos num cd following vbg administration nn of inpos valdecoxib nn for inpos num cd days nns while inpos plasma nn exposure nn of inpos valdecoxib nn was vbd not rb substantially rb increased vbn following vbg administration nn of inpos diazepam nn for inpos num cd days nns
false	12	24	although inpos the dt magnitude nn of inpos changes nns in inpos diazepam nn plasma nn exposure nn when wrb coadministered vbn with inpos valdecoxib nn were vbd not rb sufficient jj to topos warrant vb dosage nn adjustments nns patients nns may md experience vb enhanced vbn sedative jj side nn effects nns caused vbn by inpos increased vbn exposure nn of inpos diazepam nn under inpos this dt circumstance nn
effect	24	12	although inpos the dt magnitude nn of inpos changes nns in inpos diazepam nn plasma nn exposure nn when wrb coadministered vbn with inpos valdecoxib nn were vbd not rb sufficient jj to topos warrant vb dosage nn adjustments nns patients nns may md experience vb enhanced vbn sedative jj side nn effects nns caused vbn by inpos increased vbn exposure nn of inpos diazepam nn under inpos this dt circumstance nn
false	0	10	cimetidine nn had vbd no dt effect nn on inpos vardenafil nn bioavailability nn and cc maximum jj concentration nn of inpos vardenafil nn when wrb co_administered vbn with inpos num cd mg nn vardenafil nnp in inpos healthy jj volunteers nns
false	0	10	cimetidine nn had vbd no dt effect nn on inpos vardenafil nn bioavailability nn and cc maximum jj concentration nn of inpos vardenafil nn when wrb co_administered vbn with inpos num cd mg nn vardenafil nnp in inpos healthy jj volunteers nns
false	0	10	cimetidine nn had vbd no dt effect nn on inpos vardenafil nn bioavailability nn and cc maximum jj concentration nn of inpos vardenafil nn when wrb co_administered vbn with inpos num cd mg nn vardenafil nn in inpos healthy jj volunteers nns
mechanism	0	12	erythromycin nn produced vbd a dt num_fold jj increase nn in inpos vardenafil nn auc nn and cc a dt num_fold jj increase nn in inpos cmax nn when wrb co_administered vbn with inpos vardenafil nn num cd mg nn in inpos healthy jj volunteers nns
false	0	12	erythromycin nn produced vbd a dt num_fold jj increase nn in inpos vardenafil nn auc nn and cc a dt num_fold jj increase nn in inpos cmax nn when wrb co_administered vbn with inpos vardenafil nn num cd mg nn in inpos healthy jj volunteers nns
advise	24	44	it prp is vbz recommended vbn not rb to topos exceed vb a dt single jj num cd mg nn dose nn of inpos vardenafil nn in inpos a dt num_hour jj period nn when wrb used vbn in inpos combination nn with inpos erythromycin nn
mechanism	0	12	ketoconazole nn produced vbd a dt num_fold jj increase nn in inpos vardenafil nn auc nn and cc a dt num_fold jj increase nn in inpos cmax nn when wrb co_administered vbn with inpos vardenafil nn in inpos healthy jj volunteers nns
false	0	12	ketoconazole nn produced vbd a dt num_fold jj increase nn in inpos vardenafil nn auc nn and cc a dt num_fold jj increase nn in inpos cmax nn when wrb co_administered vbn with inpos vardenafil nn in inpos healthy jj volunteers nns
advise	4	34	a dt num_mg jj vardenafil nn dose nn should md not rb be vb exceeded vbn when wrb used vbn in inpos combination nn with inpos num cd mg nn once rb daily jj ketoconazole nn
false	8	40	since inpos higher jjr doses nns of inpos ketoconazole nn may md result vb in inpos higher jjr increases nns in inpos cmax nn and cc auc nn a dt single jj float cd mg nn dose nn of inpos vardenafil nn should md not rb be vb exceeded vbn in inpos a dt num_hour jj period nn when wrb used vbn in inpos combination nn with inpos ketoconazole nn num cd mg nn daily jj
advise	40	8	since inpos higher jjr doses nns of inpos ketoconazole nn may md result vb in inpos higher jjr increases nns in inpos cmax nn and cc auc nn a dt single jj float cd mg nn dose nn of inpos vardenafil nn should md not rb be vb exceeded vbn in inpos a dt num_hour jj period nn when wrb used vbn in inpos combination nn with inpos ketoconazole nn num cd mg nn daily jj
mechanism	0	6	indinavir nn co_administered vbn with inpos vardenafil nn num cd mg nn resulted vbd in inpos a dt num_fold jj increase nn in inpos vardenafil nn auc nn a dt num_fold jj increase nn in inpos vardenafil nn cmax nn and cc a dt num_fold jj increase nn in inpos vardenafil nn half_life nn
false	0	6	indinavir nn co_administered vbn with inpos vardenafil nn num cd mg nn resulted vbd in inpos a dt num_fold jj increase nn in inpos vardenafil nn auc nn a dt num_fold jj increase nn in inpos vardenafil nn cmax nn and cc a dt num_fold jj increase nn in inpos vardenafil nn half_life nn
false	0	6	indinavir nn co_administered vbn with inpos vardenafil nn num cd mg nn resulted vbd in inpos a dt num_fold jj increase nn in inpos vardenafil nn auc nn a dt num_fold jj increase nn in inpos vardenafil nn cmax nn and cc a dt num_fold jj increase nn in inpos vardenafil nn half_life nn
false	0	6	indinavir nn co_administered vbn with inpos vardenafil nn num cd mg nn resulted vbd in inpos a dt num_fold jj increase nn in inpos vardenafil nn auc nn a dt num_fold jj increase nn in inpos vardenafil nn cmax nn and cc a dt num_fold jj increase nn in inpos vardenafil nn half_life nn
advise	20	42	it prp is vbz recommended vbn not rb to topos exceed vb a dt single jj float cd mg nn vardenafil nn dose nn in inpos a dt num_hour jj period nn when wrb used vbn in inpos combination nn with inpos indinavir nn
mechanism	0	6	ritonavir nn co_administered vbn with inpos vardenafil nn num cd mg nn resulted vbd in inpos a dt num_fold jj increase nn in inpos vardenafil nn auc nn and cc a dt num_fold jj increase nn in inpos vardenafil nn cmax nn
false	0	6	ritonavir nn co_administered vbn with inpos vardenafil nn num cd mg nn resulted vbd in inpos a dt num_fold jj increase nn in inpos vardenafil nn auc nn and cc a dt num_fold jj increase nn in inpos vardenafil nn cmax nn
false	0	6	ritonavir nn co_administered vbn with inpos vardenafil nn num cd mg nn resulted vbd in inpos a dt num_fold jj increase nn in inpos vardenafil nn auc nn and cc a dt num_fold jj increase nn in inpos vardenafil nn cmax nn
mechanism	20	24	the dt interaction nn is vbz a dt consequence nn of inpos blocking vbg hepatic jj metabolism nn of inpos vardenafil nn by inpos ritonavir nn a dt highly rb potent jj cyp3a4 nn inhibitor nn which wdt also rb inhibits vbz cyp2c9 nn
mechanism	0	12	ritonavir nn significantly rb prolonged vbd the dt half_life nn of inpos vardenafil nn to topos num cd hours nns
advise	22	44	consequently rb it prp is vbz recommended vbn not rb to topos exceed vb a dt single jj float cd mg nn vardenafil nn dose nn in inpos a dt num_hour jj period nn when wrb used vbn in inpos combination nn with inpos ritonavir nn
false	12	22	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	12	24	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	12	26	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	12	22	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns maalox nn
false	12	32	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	22	24	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	22	26	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	22	32	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	24	26	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	24	32	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	26	32	no dt pharmacokinetic jj interactions nns were vbd observed vbn between inpos vardenafil nn and cc the dt following vbg drugs nns glyburide nn warfarin nn digoxin nn maalox nnp and cc ranitidine nn
false	4	8	in inpos the dt warfarin nn study nn vardenafil nn had vbd no dt effect nn on inpos the dt prothrombin nn time nn or cc other jj pharmacodynamic jj parameters nns
mechanism	14	28	the dt blood nn pressure nn lowering vbg effects nns of inpos sublingual jj nitrates nn taken vbn num cd and cc num cd hours nns after inpos vardenafil nn and cc increases nns in inpos heart nn rate nn when wrb taken vbn at inpos num cd num cd num cd hours nns were vbd potentiated vbn by inpos a dt num cd mg nn dose nn of inpos vardenafil nnp in inpos healthy jj middle_aged jj subjects nns
false	14	28	the dt blood nn pressure nn lowering vbg effects nns of inpos sublingual jj nitrates nn taken vbn num cd and cc num cd hours nns after inpos vardenafil nn and cc increases nns in inpos heart nn rate nn when wrb taken vbn at inpos num cd num cd num cd hours nns were vbd potentiated vbn by inpos a dt num cd mg nn dose nn of inpos vardenafil nn in inpos healthy jj middle_aged jj subjects nns
false	12	30	these dt effects nns were vbd not rb observed vbn when wrb vardenafil nn num cd mg nn was vbd taken vbn num cd hours nns before inpos the dt ntg nn
false	12	42	potentiation nn of inpos the dt hypotensive jj effects nns of inpos nitrates nn for inpos patients nns with inpos ischemic jj heart nn disease nn has vbz not rb been vbn evaluated vbn and cc concomitant jj use nn of inpos vardenafil nn and cc nitrates nns is vbz contraindicated vbn
advise	42	12	potentiation nn of inpos the dt hypotensive jj effects nns of inpos nitrates nns for inpos patients nns with inpos ischemic jj heart nn disease nn has vbz not rb been vbn evaluated vbn and cc concomitant jj use nn of inpos vardenafil nn and cc nitrates nn is vbz contraindicated vbn
false	0	2	nifedipine nn vardenafil nn num cd mg nn when wrb co_administered vbn with inpos slow_release jj nifedipine nn num cd mg nn or cc num cd mg nn once rb daily rb did vbd not rb affect vb the dt relative jj bioavailability nn or cc maximum jj concentration nn of inpos nifedipine nn a dt drug nn that wdt is vbz metabolized vbn via inpos cyp3a4 nn
false	2	0	nifedipine nn vardenafil nn num cd mg nn when wrb co_administered vbn with inpos slow_release nn nifedipine nn num cd mg nn or cc num cd mg nn once rb daily rb did vbd not rb affect vb the dt relative jj bioavailability nn or cc maximum jj concentration nn of inpos nifedipine nn a dt drug nn that wdt is vbz metabolized vbn via inpos cyp3a4 nn
false	2	0	nifedipine nn vardenafil nn num cd mg nn when wrb co_administered vbn with inpos slow_release jj nifedipine nn num cd mg nn or cc num cd mg nn once rb daily rb did vbd not rb affect vb the dt relative jj bioavailability nn or cc maximum jj concentration nn of inpos nifedipine nn a dt drug nn that wdt is vbz metabolized vbn via inpos cyp3a4 nn
false	0	16	nifedipine nn did vbd not rb alter vb the dt plasma nn levels nns of inpos vardenafil nn when wrb taken vbn in inpos combination nn
effect	16	18	in inpos these dt patients nns whose wp hypertension nn was vbd controlled vbn with inpos nifedipine nn vardenafil nn num cd mg nn produced vbd mean jj additional jj supine nn systolic jj blood nn pressure nn reductions nns of inpos num cd mm nn hg nn compared vbn to topos placebo nn
effect	2	44	when wrb vardenafil nn num cd or cc num cd mg nn was vbd given vbn to topos healthy jj volunteers nns either cc simultaneously rb or cc num cd hours nns after inpos a dt num cd mg nn dose nn of inpos terazosin nn significant jj hypotension nn developed vbn in inpos a dt substantial jj number nn of inpos subjects nns
effect	8	16	with inpos simultaneous jj dosing nn of inpos vardenafil nn num cd mg nn and cc terazosin nn num cd mg nn num cd of inpos num cd subjects nns experienced vbd a dt standing vbg systolic jj blood nn pressure nn of inpos less jjr than inpos num cd mm nn hg nn
effect	8	16	with inpos simultaneous jj dosing nn of inpos vardenafil nn num cd mg nn and cc terazosin nn num cd mg nn num cd of inpos num cd subjects nns experienced vbd a dt standing vbg systolic jj blood nn pressure nn of inpos less jjr than inpos num cd mm nn hg nn
effect	2	12	when wrb vardenafil nn dosing nn was vbd separated vbn from inpos terazosin nn num cd mg nn by inpos num cd hours nns num cd of inpos num cd subjects nns who wp received vbd num cd mg nn of inpos vardenafil nnp experienced vbd a dt decrease nn in inpos standing vbg systolic jj blood nn pressure nn below inpos num cd mm nn hg nn
false	12	2	when wrb vardenafil nnp dosing nn was vbd separated vbn from inpos terazosin nn num cd mg nn by inpos num cd hours nns num cd of inpos num cd subjects nns who wp received vbd num cd mg nn of inpos vardenafil nn experienced vbd a dt decrease nn in inpos standing vbg systolic jj blood nn pressure nn below inpos num cd mm nn hg nn
false	10	30	in inpos a dt similar jj study nn with inpos tamsulosin nn in inpos healthy jj volunteers nns num cd of inpos num cd subjects nns dosed vbn with inpos vardenafil nn num cd mg nn and cc tamsulosin nn float cd mg nn separated vbn by inpos num cd hours nns experienced vbd a dt standing vbg systolic jj blood nn pressure nn below inpos num cd mm nn hg nn
effect	30	10	in inpos a dt similar jj study nn with inpos tamsulosin nn in inpos healthy jj volunteers nns num cd of inpos num cd subjects nns dosed vbn with inpos vardenafil nn num cd mg nn and cc tamsulosin nn float cd mg nn separated vbn by inpos num cd hours nns experienced vbd a dt standing vbg systolic jj blood nn pressure nn below inpos num cd mm nn hg nn
effect	14	22	num cd of inpos num cd subjects nns dosed vbn simultaneously rb with inpos vardenafil nn num cd mg nn and cc tamsulosin nn float cd mg nn experienced vbd a dt standing vbg systolic jj blood nn pressure nn below inpos num cd mm nn hg nn
false	12	16	the dt administration nn of inpos lower jjr doses nns of inpos vardenafil nn with inpos ap_blockers nn has vbz not rb been vbn completely rb evaluated vbn to topos determine vb if inpos they prp can md be vb safely rb administered vbn together rb
advise	8	24	based vbn on inpos these dt data nns vardenafil nn should md not rb be vb used vbn in inpos patients nns on inpos ap_blocker nn therapy nn
false	0	4	ritonavir nn and cc indinavir nn
mechanism	14	24	upon inpos concomitant jj administration nn of inpos num cd mg nn of inpos vardenafil nn with inpos num cd mg nn bid nn ritonavir nn the dt cmax nn and cc auc nn of inpos ritonavir nn were vbd reduced vbn by inpos approximately rb num cd
false	14	24	upon inpos concomitant jj administration nn of inpos num cd mg nn of inpos vardenafil nn with inpos num cd mg nn bid nn ritonavir nn the dt cmax nn and cc auc nn of inpos ritonavir nn were vbd reduced vbn by inpos approximately rb num cd
mechanism	12	22	upon inpos administration nn of inpos num cd mg nn of inpos vardenafil nn with inpos num cd mg nn tid nn indinavir nn the dt cmax nn and cc auc nn of inpos indinavir nn were vbd reduced vbn by inpos num cd and cc num cd respectively rb
false	12	22	upon inpos administration nn of inpos num cd mg nn of inpos vardenafil nn with inpos num cd mg nn tid nn indinavir nn the dt cmax nn and cc auc nn of inpos indinavir nn were vbd reduced vbn by inpos num cd and cc num cd respectively rb
false	0	4	alcohol nn and cc vardenafil nn plasma nn levels nns were vbd not rb altered vbn when wrb dosed vbn simultaneously rb
false	0	16	vardenafil nn did vbd not rb potentiate vb the dt hypotensive jj effects nns of inpos alcohol nn during inpos the dt num_hour jj observation nn period nn in inpos healthy jj volunteers nns when wrb administered vbn with inpos alcohol nn
false	0	16	vardenafil nn did vbd not rb potentiate vb the dt hypotensive jj effects nns of inpos alcohol nn during inpos the dt num_hour jj observation nn period nn in inpos healthy jj volunteers nns when wrb administered vbn with inpos alcohol nn
false	0	22	vardenafil nn did vbd not rb potentiate vb the dt increase nn in inpos bleeding vbg time nn caused vbn by inpos aspirin nn
false	0	16	vardenafil nn had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos glyburide nn and cc warfarin nn
false	0	20	vardenafil nn had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos glyburide nn and cc warfarin nn
false	16	20	vardenafil nnp had vbd no dt effect nn on inpos the dt pharmacodynamics nns of inpos glyburide nn and cc warfarin nn
false	14	18	there ex is vbz no dt significant jj pharmacokinetic jj interaction nn between inpos zdv nn and cc zalcitabine nn which wdt has vbz been vbn confirmed vbn clinically rb
effect	0	22	zalcitabine nn also rb has vbz no dt significant jj effect nn on inpos the dt intracellular jj phosphorylation nn of inpos zdv nn as inpos shown vbn in fw vitro fw in inpos peripheral jj blood nn mononuclear jj cells nns or cc in inpos num cd other jj cell nn lines nns
false	16	20	in inpos the dt same jj study nn it prp was vbd shown vbn that inpos didanosine nn and cc stavudine nn had vbd no dt significant jj effect nn on inpos the dt intracellular jj phosphorylation nn of inpos zalcitabine nn in inpos peripheral jj blood nn mononuclear jj cells nns
false	16	40	in inpos the dt same jj study nn it prp was vbd shown vbn that inpos didanosine nn and cc stavudine nn had vbd no dt significant jj effect nn on inpos the dt intracellular jj phosphorylation nn of inpos zalcitabine nn in inpos peripheral jj blood nn mononuclear jj cells nns
false	20	40	in inpos the dt same jj study nn it prp was vbd shown vbn that inpos didanosine nn and cc stavudine nn had vbd no dt significant jj effect nn on inpos the dt intracellular jj phosphorylation nn of inpos zalcitabine nn in inpos peripheral jj blood nn mononuclear jj cells nns
effect	28	34	in fw vitro fw studies nns in inpos peripheral jj blood nn mononuclear jj cells nns u937 nn and cc molt_num nn cells nns revealed vbd that inpos lamivudine nn significantly rb inhibited vbd zalcitabine nn phosphorylation nn in inpos a dt dose nn dependent jj manner nn
effect	0	4	zalcitabine nn inhibited vbd lamivudine nn phosphorylation nn at inpos high jj concentration nn ratios nns
false	24	58	however rb it prp is vbz considered vbn to topos be vb unlikely jj that inpos this dt decrease nn of inpos phosphorylated vbn lamivudine nn concentration nn is vbz of inpos clinical jj significance nn as inpos lamivudine nn is vbz a dt more rbr efficient jj substrate nn for inpos deoxycytidine nn kinase nn than inpos zalcitabine nn
false	24	58	however rb it prp is vbz considered vbn to topos be vb unlikely jj that inpos this dt decrease nn of inpos phosphorylated vbn lamivudine nn concentration nn is vbz of inpos clinical jj significance nn as inpos lamivudine nn is vbz a dt more rbr efficient jj substrate nn for inpos deoxycytidine nn kinase nn than inpos zalcitabine nn
effect	18	22	these dt in fw vitro fw studies nns suggest vbp that inpos concomitant jj administration nn of inpos zalcitabine nn and cc lamivudine nn in inpos humans nns may md result vb in inpos sub_therapeutic jj concentrations nns of inpos active jj phosphorylated vbn zalcitabine nn which wdt may md lead vb to topos a dt decreased vbn antiretroviral jj effect nn of inpos zalcitabine nn
false	18	58	these dt in fw vitro fw studies nns suggest vbp that inpos concomitant jj administration nn of inpos zalcitabine nn and cc lamivudine nn in inpos humans nns may md result vb in inpos sub_therapeutic jj concentrations nns of inpos active jj phosphorylated vbn zalcitabine nn which wdt may md lead vb to topos a dt decreased vbn antiretroviral nn effect nn of inpos zalcitabine nn
false	22	18	these dt in fw vitro fw studies nns suggest vbp that inpos concomitant jj administration nn of inpos zalcitabine nn and cc lamivudine nn in inpos humans nns may md result vb in inpos sub_therapeutic jj concentrations nns of inpos active jj phosphorylated vbn zalcitabine nn which wdt may md lead vb to topos a dt decreased vbn antiretroviral jj effect nn of inpos zalcitabine nn
false	22	58	these dt in fw vitro fw studies nns suggest vbp that inpos concomitant jj administration nn of inpos zalcitabine nn and cc lamivudine nn in inpos humans nns may md result vb in inpos sub_therapeutic jj concentrations nns of inpos active jj phosphorylated vbn zalcitabine nn which wdt may md lead vb to topos a dt decreased vbn antiretroviral nn effect nn of inpos zalcitabine nn
false	22	18	these dt in fw vitro fw studies nns suggest vbp that inpos concomitant jj administration nn of inpos zalcitabine nn and cc lamivudine nn in inpos humans nns may md result vb in inpos sub_therapeutic jj concentrations nns of inpos active jj phosphorylated vbn zalcitabine nn which wdt may md lead vb to topos a dt decreased vbn antiretroviral jj effect nn of inpos zalcitabine nn
false	18	58	these dt in fw vitro fw studies nns suggest vbp that inpos concomitant jj administration nn of inpos zalcitabine nn and cc lamivudine nn in inpos humans nns may md result vb in inpos sub_therapeutic jj concentrations nns of inpos active jj phosphorylated vbn zalcitabine nn which wdt may md lead vb to topos a dt decreased vbn antiretroviral nn effect nn of inpos zalcitabine nn
false	58	18	these dt in fw vitro fw studies nns suggest vbp that inpos concomitant jj administration nn of inpos zalcitabine nn and cc lamivudine nn in inpos humans nns may md result vb in inpos sub_therapeutic jj concentrations nns of inpos active jj phosphorylated vbn zalcitabine nn which wdt may md lead vb to topos a dt decreased vbn antiretroviral nn effect nn of inpos zalcitabine nn
advise	6	10	concomitant jj use nn of inpos zalcitabine nn and cc lamivudine nn is vbz not rb recommended vbn
false	0	8	saquinavir nn the dt combination nn of inpos hivid nn has vbz been vbn studied vbn in inpos adults nns
false	0	8	saquinavir nn the dt combination nn of inpos zdv nn has vbz been vbn studied vbn in inpos adults nns
advise	6	10	concomitant jj use nn of inpos hivid nn with inpos didanosine nn is vbz not rb recommended vbn
false	2	8	intravenous jj pentamidine nn treatment nn with inpos hivid nn should md be vb interrupted vbn when wrb the dt use nn of inpos a dt drug nn that wdt has vbz the dt potential nn to topos cause vb pancreatitis nn is vbz required vbn
effect	18	22	death nn due inpos to topos fulminant jj pancreatitis nn possibly rb related jj to topos intravenous jj pentamidine nn and cc hivid nn has vbz been vbn reported vbn
advise	4	24	if inpos intravenous jj pentamidine nn is vbz required vbn to topos treat vb pneumocystis nnp carinii nn pneumonia nn treatment nn with inpos hivid nn should md be vb interrupted vbn
false	0	6	amphotericin nn foscarnet nnp and cc aminoglycosides nn drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	2	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos foscarnet nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	6	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos aminoglycosides nn may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	40	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid nn associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	60	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	8	foscarnet nnp drugs nns such jj as inpos amphotericin nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	8	foscarnet nnp drugs nns such jj as inpos aminoglycosides nn may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	34	foscarnet nnp drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid nn associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	54	foscarnet nnp drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	6	0	amphotericin nn foscarnet nnp and cc aminoglycosides nn drugs nns such jj as inpos amphotericin nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	6	2	amphotericin nn foscarnet nnp and cc aminoglycosides nn drugs nns such jj as inpos foscarnet nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	6	40	amphotericin nn foscarnet nnp and cc aminoglycosides nn drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid nn associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	6	60	amphotericin nn foscarnet nnp and cc aminoglycosides nn drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
effect	0	36	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos amphotericin nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid nn associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
mechanism	0	56	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos amphotericin nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
effect	2	36	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos foscarnet nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid nn associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
mechanism	2	56	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos foscarnet nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
effect	6	36	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos aminoglycosides nn may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid nn associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
mechanism	6	56	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos aminoglycosides nn may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid_associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	40	62	amphotericin nn foscarnet nnp and cc aminoglycosides nnp drugs nns such jj as inpos amphotericin nn foscarnet nn aminoglycosides nns may md increase vb the dt risk nn of inpos developing vbg peripheral jj neuropathy nn or cc other jj hivid nn associated jj adverse jj events nns by inpos interfering vbg with inpos the dt renal jj clearance nn of inpos zalcitabine nn
false	0	4	probenecid nn or cc cimetidine nn
false	0	4	probenecid nn or cc cimetidine nn concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	0	26	probenecid nn or cc cimetidine nn concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	0	26	probenecid nn or cc cimetidine nn concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	4	0	probenecid nn or cc cimetidine nn concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	4	26	probenecid nn or cc cimetidine nn concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	4	26	probenecid nn or cc cimetidine nn concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	6	10	concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
mechanism	6	20	concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	6	20	concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
mechanism	10	20	concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	10	20	concomitant jj administration nn of inpos probenecid nn or cc cimetidine nn decreases vbz the dt elimination nn of inpos zalcitabine nn most rbs likely rb by inpos inhibition nn of inpos renal jj tubular jj secretion nn of inpos zalcitabine nn
false	0	2	magnesium nn aluminum nn containing jj antacid_products nns
false	0	4	magnesium nn aluminum_containing jj antacid_products nn
false	0	10	magnesium nn aluminum_containing jj antacid_products nns absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos aluminum_containing jj antacid_products nns
false	0	2	magnesium nn aluminum_containing jj antacid_products nns absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos aluminum nn containing jj antacid_products nns
false	0	4	magnesium nn aluminum_containing jj antacid_products nns absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nn
false	2	6	magnesium nn aluminum nn containing jj antacid_products nn
false	2	12	magnesium nn aluminum nn containing jj antacid_products nns absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nns
false	2	0	magnesium nn aluminum nn containing jj antacid_products nns absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nns
false	2	6	magnesium nn aluminum nn containing jj antacid_products nns absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nn
false	2	8	magnesium_aluminum_containing jj antacid_products nn absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nns
false	2	0	magnesium_aluminum_containing jj antacid_products nn absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nns
false	2	0	magnesium_aluminum_containing jj antacid_products nn absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos aluminum nn containing jj antacid_products nns
false	4	18	absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nns
false	4	18	absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos aluminum nn containing jj antacid_products nns
false	4	20	absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nn
false	18	20	absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos magnesium nn antacid_products nn
false	18	22	absorption nn of inpos zalcitabine nn is vbz moderately rb reduced vbn when wrb coadministered vbn with inpos aluminum nn containing jj antacid_products nn
advise	20	38	the dt clinical jj significance nn of inpos this dt reduction nn is vbz not rb known vbn hence rb zalcitabine nn is vbz not rb recommended vbn to topos be vb ingested vbn simultaneously rb with inpos magnesium nn antacids nns
advise	20	38	the dt clinical jj significance nn of inpos this dt reduction nn is vbz not rb known vbn hence rb zalcitabine nn is vbz not rb recommended vbn to topos be vb ingested vbn simultaneously rb with inpos aluminum nn containing jj antacids nns
advise	20	40	the dt clinical jj significance nn of inpos this dt reduction nn is vbz not rb known vbn hence rb zalcitabine nn is vbz not rb recommended vbn to topos be vb ingested vbn simultaneously rb with inpos magnesium nn antacids nn
false	38	40	the dt clinical jj significance nn of inpos this dt reduction nn is vbz not rb known vbn hence rb zalcitabine nn is vbz not rb recommended vbn to topos be vb ingested vbn simultaneously rb with inpos magnesium nn antacids nn
false	38	42	the dt clinical jj significance nn of inpos this dt reduction nn is vbz not rb known vbn hence rb zalcitabine nn is vbz not rb recommended vbn to topos be vb ingested vbn simultaneously rb with inpos aluminum nn containing jj antacids nn
mechanism	10	14	bioavailability nn is vbz mildly rb reduced vbn when wrb zalcitabine nn and cc metoclopramide nn are vbp coadministered vbn
effect	0	10	doxorubicin nn caused vbd a dt decrease nn in inpos zalcitabine nn phosphorylation nn in inpos u937 nn num cd cells nns
effect	0	16	sonata nn num cd mg nn potentiated vbd the dt cns_impairing jj effects nns of inpos ethanol nn float cd g_kg nn on inpos balance nn testing nn and cc reaction nn time nn for inpos num cd hour nn after inpos ethanol nn administration nn and cc on inpos the dt digit nn symbol nn substitution nn test nn symbol nn copying nn test nn the dt variability nn component nn of inpos the dt divided vbn attention nn test nn for inpos float cd hours nns after inpos ethanol nn administration nn
false	0	16	sonata nn num cd mg nn potentiated vbd the dt cns_impairing jj effects nns of inpos ethanol nn float cd g_kg nn on inpos balance nn testing nn and cc reaction nn time nn for inpos num cd hour nn after inpos ethanol nn administration nn and cc on inpos the dt digit nn symbol nn substitution nn test nn symbol nn copying nn test nn the dt variability nn component nn of inpos the dt divided vbn attention nn test nn for inpos float cd hours nns after inpos ethanol nn administration nn
false	0	16	sonata nn num cd mg nn potentiated vbd the dt cns_impairing jj effects nns of inpos ethanol nn float cd g_kg nn on inpos balance nn testing nn and cc reaction nn time nn for inpos num cd hour nn after inpos ethanol nn administration nn and cc on inpos the dt digit nn symbol nn substitution nn test nn symbol nn copying nn test nn the dt variability nn component nn of inpos the dt divided vbn attention nn test nn for inpos float cd hours nns after inpos ethanol nn administration nn
false	0	14	zaleplon nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos ethanol nn
false	0	12	imipramine nn coadministration nn of inpos single jj doses nns of inpos sonata nn num cd mg nn and cc imipramine nn num cd mg nn produced vbd additive jj effects nns on inpos decreased vbn alertness nn and cc impaired jj psychomotor nn performance nn for inpos num cd to topos num cd hours nns after inpos administration nn
effect	10	18	coadministration nn of inpos single jj doses nns of inpos sonata nn num cd mg nn and cc imipramine nn num cd mg nn produced vbd additive jj effects nns on inpos decreased vbn alertness nn and cc impaired jj psychomotor nn performance nn for inpos num cd to topos num cd hours nns after inpos administration nn
false	0	14	paroxetine nn coadministration nn of inpos a dt single jj dose nn of inpos sonata nn num cd mg nn and cc paroxetine nn num cd mg nn daily rb for inpos num cd days nns did vbd not rb produce vb any dt interaction nn on inpos psychomotor nn performance nn
false	12	20	coadministration nn of inpos a dt single jj dose nn of inpos sonata nn num cd mg nn and cc paroxetine nn num cd mg nn daily rb for inpos num cd days nns did vbd not rb produce vb any dt interaction nn on inpos psychomotor nn performance nn
false	2	16	additionally rb paroxetine nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos sonata nn reflecting vbg the dt absence nn of inpos a dt role nn of inpos cyp2d6 nn in inpos zaleplon nn s nn metabolism nn
false	2	36	additionally rb paroxetine nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos sonata nnp reflecting vbg the dt absence nn of inpos a dt role nn of inpos cyp2d6 nn in inpos zaleplon nn s nn metabolism nn
false	16	36	additionally rb paroxetine nn did vbd not rb alter vb the dt pharmacokinetics nns of inpos sonata nn reflecting vbg the dt absence nn of inpos a dt role nn of inpos cyp2d6 nn in inpos zaleplon nn s nn metabolism nn
false	0	12	thioridazine nn coadministration nn of inpos single jj doses nns of inpos sonata nn num cd mg nn and cc thioridazine nn num cd mg nn produced vbd additive jj effects nns on inpos decreased vbn alertness nn and cc impaired jj psychomotor nn performance nn for inpos num cd to topos num cd hours nns after inpos administration nn
effect	10	18	coadministration nn of inpos single jj doses nns of inpos sonata nn num cd mg nn and cc thioridazine nn num cd mg nn produced vbd additive jj effects nns on inpos decreased vbn alertness nn and cc impaired jj psychomotor nn performance nn for inpos num cd to topos num cd hours nns after inpos administration nn
false	0	14	venlafaxine nn coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn num cd mg nn and cc multiple jj doses nns of inpos venlafaxine nn er nn num cd mg nn did vbd not rb result vb in inpos any dt significant jj changes nns in inpos the dt pharmacokinetics nns of inpos either cc zaleplon nn or cc venlafaxine nn
false	0	14	venlafaxine nn coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn num cd mg nn and cc multiple jj doses nns of inpos venlafaxine nn er nn num cd mg nn did vbd not rb result vb in inpos any dt significant jj changes nns in inpos the dt pharmacokinetics nns of inpos either cc zaleplon nn or cc venlafaxine nn
false	12	26	coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn num cd mg nn and cc multiple jj doses nns of inpos venlafaxine nn er nn num cd mg nn did vbd not rb result vb in inpos any dt significant jj changes nns in inpos the dt pharmacokinetics nns of inpos either cc zaleplon nn or cc venlafaxine nn
false	12	26	coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn num cd mg nn and cc multiple jj doses nns of inpos venlafaxine nn er nn num cd mg nn did vbd not rb result vb in inpos any dt significant jj changes nns in inpos the dt pharmacokinetics nns of inpos either cc zaleplon nn or cc venlafaxine nn
false	26	12	coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn num cd mg nn and cc multiple jj doses nns of inpos venlafaxine nn er nn num cd mg nn did vbd not rb result vb in inpos any dt significant jj changes nns in inpos the dt pharmacokinetics nns of inpos either cc zaleplon nn or cc venlafaxine nn
false	12	26	coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn num cd mg nn and cc multiple jj doses nns of inpos venlafaxine nn er nn num cd mg nn did vbd not rb result vb in inpos any dt significant jj changes nns in inpos the dt pharmacokinetics nns of inpos either cc zaleplon nn or cc venlafaxine nn
false	26	30	in inpos addition nn there ex was vbd no dt pharmacodynamic jj interaction nn as inpos a dt result nn of inpos coadministration nn of inpos zaleplon nn and cc venlafaxine nn er nn
false	0	14	promethazine nn coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn and cc promethazine nn resulted vbd in inpos a dt num cd decrease nn in inpos maximal jj plasma nn concentrations nns of inpos zaleplon nn but cc no dt change nn in inpos the dt area nn under inpos the dt plasma nn concentration_time nn curve nn
false	0	14	promethazine nn coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn and cc promethazine nn resulted vbd in inpos a dt num cd decrease nn in inpos maximal jj plasma nn concentrations nns of inpos zaleplon nn but cc no dt change nn in inpos the dt area nn under inpos the dt plasma nn concentration_time nn curve nn
mechanism	12	16	coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn and cc promethazine nn resulted vbd in inpos a dt num cd decrease nn in inpos maximal jj plasma nn concentrations nns of inpos zaleplon nn but cc no dt change nn in inpos the dt area nn under inpos the dt plasma nn concentration_time nn curve nn
false	16	12	coadministration nn of inpos a dt single jj dose nn of inpos zaleplon nn and cc promethazine nn resulted vbd in inpos a dt num cd decrease nn in inpos maximal jj plasma nn concentrations nns of inpos zaleplon nn but cc no dt change nn in inpos the dt area nn under inpos the dt plasma nn concentration_time nn curve nn
false	12	16	however rb the dt pharmacodynamics nns of inpos coadministration nn of inpos zaleplon nn and cc promethazine nn have vbp not rb been vbn evaluated vbn
mechanism	14	20	multiple_dose jj administration nn of inpos the dt potent jj cyp3a4 nn inducer nn rifampin nn however rb reduced vbd zaleplon nn cmax nn and cc auc nn by inpos approximately rb num cd
false	8	30	an dt alternative jj non_cyp3a4 jj substrate nn hypnotic_agent nn may md be vb considered vbn in inpos patients nns taking vbg cyp3a4 nn inducers nns such jj as inpos rifampin nn
false	8	30	an dt alternative jj non_cyp3a4 jj substrate nn hypnotic_agent nn may md be vb considered vbn in inpos patients nns taking vbg cyp3a4 nn inducers nns such jj as inpos phenytoin nn
false	8	30	an dt alternative jj non_cyp3a4 jj substrate nn hypnotic_agent nn may md be vb considered vbn in inpos patients nns taking vbg cyp3a4 nn inducers nns such jj as inpos carbamazepine nn
false	8	30	an dt alternative jj non_cyp3a4 jj substrate nn hypnotic_agent nn may md be vb considered vbn in inpos patients nns taking vbg cyp3a4 nn inducers nns such jj as inpos phenobarbital nn
mechanism	12	16	coadministration nn of inpos single jj oral jj doses nns of inpos zaleplon nn with inpos erythromycin nn a dt strong jj selective jj cyp3a4 nn inhibitor nn produced vbd a dt num cd increase nn in inpos zaleplons nns maximal jj plasma nn concentrations nns and cc a dt num cd increase nn in inpos the dt area nn under inpos the dt plasma nn concentration_time nn curve nn
false	16	12	coadministration nn of inpos single jj oral jj doses nns of inpos zaleplon nn with inpos erythromycin nn a dt strong jj selective jj cyp3a4 nn inhibitor nn produced vbd a dt num cd increase nn in inpos zaleplon nn s vbz maximal jj plasma nn concentrations nns and cc a dt num cd increase nn in inpos the dt area nn under inpos the dt plasma nn concentration_time nn curve nn
mechanism	14	34	other jj strong jj selective jj cyp3a4 nn inhibitors nns such jj as inpos ketoconazole nn can md also rb be vb expected vbn to topos increase vb the dt exposure nn of inpos zaleplon nn
false	12	16	there ex is vbz no dt pharmacokinetic jj interaction nn between inpos zaleplon nn and cc diphenhydramine nn following vbg the dt administration nn of inpos a dt single jj dose nn of inpos each dt drug nn
mechanism	0	30	cimetidine nn inhibits vbz both cc aldehyde nn oxidase nn and cc cyp3a4 nn the dt primary jj and cc secondary jj enzymes nns respectively rb responsible jj for inpos zaleplon nn metabolism nn
mechanism	6	10	concomitant jj administration nn of inpos sonata nn and cc cimetidine nn produced vbd an dt num cd increase nn in inpos the dt mean jj cmax nn and cc auc nn of inpos zaleplon nn
false	6	34	concomitant jj administration nn of inpos sonata nn and cc cimetidine nn produced vbd an dt num cd increase nn in inpos the dt mean jj cmax nn and cc auc nn of inpos zaleplon nn
false	10	34	concomitant jj administration nn of inpos sonata nnp and cc cimetidine nn produced vbd an dt num cd increase nn in inpos the dt mean jj cmax nn and cc auc nn of inpos zaleplon nn
false	0	20	sonata nn did vbd not rb affect vb the dt pharmacokinetic jj or cc pharmacodynamic jj profile nn of inpos digoxin nn
false	8	22	multiple jj oral jj doses nns of inpos sonata nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos warfarin nn hyph_enantiomers nns the dt pharmacodynamics nns following vbg a dt single jj num_mg nn oral jj dose nn of inpos warfarin nn
false	8	22	multiple jj oral jj doses nns of inpos sonata nn did vbd not rb affect vb the dt pharmacokinetics nns of inpos warfarin nn hyph_enantiomers nns the dt pharmacodynamics nns following vbg a dt single jj num_mg nn oral jj dose nn of inpos warfarin nn
false	14	18	there ex was vbd no dt apparent jj pharmacokinetic jj interaction nn between inpos zaleplon nn and cc ibuprofen nn following vbg single jj dose nn administration nn of inpos each dt drug nn
